PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Caccuri, AM; Antonini, G; Board, PG; Flanagan, J; Parker, MW; Paolesse, R; Turella, P; Federici, G; Lo Bello, M; Ricci, G				Caccuri, AM; Antonini, G; Board, PG; Flanagan, J; Parker, MW; Paolesse, R; Turella, P; Federici, G; Lo Bello, M; Ricci, G			Human glutathione transferase T2-2 discloses some evolutionary strategies for optimization of substrate binding to the active site of glutathione transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASES; MU-CLASS; CATALYTIC MECHANISM; PROTON RELEASE; ALPHA-CLASS; RESIDUES; THIOLATE; ENZYMES	Rapid kinetic, spectroscopic, and potentiometric studies have been performed on human Theta class glutathione transferase T2-2 to dissect the mechanism of interaction of this enzyme with its natural substrate GSH. Theta class glutathione transferases are considered to be older than Alpha, Pi, and Mu classes in the evolutionary pathway. As in the more recently evolved GSTs, the activation of GSH in the human Theta enzyme proceeds by a forced deprotonation of the sulfhydryl group (pK(alpha) = 6.1). The thiol proton is released quantitatively in solution, but above pH 6.5, a protein residue acts as an internal base. Unlike Alpha, Mu, and Pi class isoenzymes, the GSH-binding mechanism occurs via a simple bimolecular reaction with k(on) and k(off) values at least hundred times lower (k(on) = (2.7 +/- 0.8) x 10(4) M-1 s(-1) k(off) = 36 +/- 9 s(-1), at 37 degreesC). Replacement of Arg-107 by alanine, using site-directed mutagenesis, remarkably increases the pK alpha value of the bound GSH and modifies the substrate binding modality. Y107A mutant enzyme displays a mechanism and rate constants for GSH binding approaching those of Alpha, Mu, and Pi isoenzymes. Comparison of available crystallographic data for all these GSTs reveals an unexpected evolutionary trend in terms of flexibility, which provides a basis for understanding our experimental results.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Aquila, Dept Basic & Appl Biol, I-67010 Coppito, Italy; Univ Rome La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia; St Vincents Inst Med Res, Ian Potter Fdn Prot Crystallog Lab, Fitzroy, Vic 3065, Australia; Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Childrens Hosp IRCCS Bambin Gesu, I-00165 Rome, Italy	University of Rome Tor Vergata; University of L'Aquila; Sapienza University Rome; Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research; University of Rome Tor Vergata; IRCCS Bambino Gesu	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Biol, Viale Ric Sci, I-00133 Rome, Italy.		Parker, Michael W/F-9069-2013; Paolesse, Roberto/B-8966-2013; CACCURI, ANNA MARIA/AFU-2643-2022; Paolesse, Roberto/AAI-3182-2020	Parker, Michael W/0000-0002-3101-1138; Paolesse, Roberto/0000-0002-2380-1404; CACCURI, ANNA MARIA/0000-0002-3756-4163; Antonini, Giovanni/0000-0002-2115-8961; Ricci, Giorgio/0000-0002-7108-2846				Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; Board PG, 1997, BIOCHEM J, V328, P929; Caccuri AM, 1998, BIOCHEMISTRY-US, V37, P3028, DOI 10.1021/bi971903g; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; Caccuri AM, 1997, J BIOL CHEM, V272, P29681, DOI 10.1074/jbc.272.47.29681; CLAPP JJ, 1970, BIOCHEM J, V118, P765, DOI 10.1042/bj1180765; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Flanagan JU, 1999, PROTEIN SCI, V8, P2205, DOI 10.1110/ps.8.10.2205; Jemth P, 1999, BIOCHEMISTRY-US, V38, P9982, DOI 10.1021/bi983065b; Jemth P, 2000, J BIOL CHEM, V275, P8618, DOI 10.1074/jbc.275.12.8618; Patskovsky YV, 2000, J BIOL CHEM, V275, P3296, DOI 10.1074/jbc.275.5.3296; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; PETTERSSON G, 1989, EUR J BIOCHEM, V184, P561, DOI 10.1111/j.1432-1033.1989.tb15050.x; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; Salinas AE, 1999, CURR MED CHEM, V6, P279; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Tan KL, 1996, BIOCHEM J, V319, P315, DOI 10.1042/bj3190315; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	21	20	20	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5427	5431		10.1074/jbc.M002819200	http://dx.doi.org/10.1074/jbc.M002819200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11044442	hybrid			2022-12-27	WOS:000167115100004
J	Scott, EE; Gibson, QH; Olson, JS				Scott, EE; Gibson, QH; Olson, JS			Mapping the pathways for O-2 entry into and exit from myoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURES; CARBON-MONOXIDE; DISTAL HISTIDINE; PROTEIN DYNAMICS; X-RAY; PICOSECOND	The effects of mutagenesis on geminate and bimolecular O-2 rebinding to 90 mutants at 27 different positions were used to map pathways for ligand movement into and out of sperm whale myoglobin. By analogy to a baseball glove, the protein "catches" and then "holds" incoming ligand molecules long enough to allow bond formation with the iron atom. Opening of the glove occurs by outward movements of the distal histidine (His(64)), and the ligands are trapped in the interior "webbing" of the distal pocket, in the space surrounded by Ile(28), Leu(29), Leu(32), Val(68), and Ile(107). The size of this pocket is a major determinant of the rate of ligand entry into the protein. Immediately after photo- or thermal dissociation, O-2 moves away from the iron into this interior pocket. The majority of the dissociated ligands return to the active site and either rebind to the iron atom or escape through the His(64) gate. A fraction of the ligands migrate further away from the heme group into cavities that have been defined as Xe binding sites 4 and 1; however, most of these ligands also return to the distal pocket, and net escape through the interior of wildtype myoglobin is <20-25%.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA	Rice University; Rice University	Olson, JS (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS 140,6100 Main St, Houston, TX 77005 USA.	olson@rice.edu		Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM 35649, GM 08280, GM 14276] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; BOLOGNESI M, 1982, J MOL BIOL, V158, P305, DOI 10.1016/0022-2836(82)90435-1; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; Brunori M, 1999, TRENDS BIOCHEM SCI, V24, P253, DOI 10.1016/S0968-0004(99)01421-8; Carlson ML, 1996, BIOCHEMISTRY-US, V35, P1125, DOI 10.1021/bi951767k; CARLSON ML, 1994, BIOCHEMISTRY-US, V33, P10597, DOI 10.1021/bi00201a005; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CHATFIELD MD, 1990, J AM CHEM SOC, V112, P4680, DOI 10.1021/ja00168a009; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; EICH RF, 1997, THESIS RICE U HOUSTO; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GIBSON QH, 1993, J BIOL CHEM, V268, P16993; Gryczynski Z, 1998, BIOPHYS CHEM, V74, P187, DOI 10.1016/S0301-4622(98)00181-1; HARGROVE MS, 1994, BIOCHEMISTRY-US, V33, P11767, DOI 10.1021/bi00205a012; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HUANG XH, 1994, NAT STRUCT BIOL, V1, P226, DOI 10.1038/nsb0494-226; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; LAI HH, 1995, PROTEINS, V22, P322, DOI 10.1002/prot.340220404; LI HY, 1993, J BIOL CHEM, V268, P17908; LIONG EC, 1999, THESIS RICE U HOUSTO; LIONG EC, 2000, IN PRESS J BIOL CHEM; Luo YZ, 1997, NAT STRUCT BIOL, V4, P925, DOI 10.1038/nsb1197-925; Meller J, 1998, BIOPHYS J, V74, P789, DOI 10.1016/S0006-3495(98)74004-4; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; PERUTZ MF, 1966, J MOL BIOL, V21, P199, DOI 10.1016/0022-2836(66)90088-X; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; ROMO TD, 1995, PROTEINS, V22, P311, DOI 10.1002/prot.340220403; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 1998, THESIS RICE U HOUSTO; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; Teng TY, 1997, BIOCHEMISTRY-US, V36, P12087, DOI 10.1021/bi971140x; TIAN WD, 1993, J MOL BIOL, V233, P155, DOI 10.1006/jmbi.1993.1491; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TILTON RF, 1988, J MOL BIOL, V199, P195, DOI 10.1016/0022-2836(88)90389-0; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; WHITAKER TL, 1996, THESIS RICE U HOUSTO; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123	58	328	331	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5177	5188		10.1074/jbc.M008282200	http://dx.doi.org/10.1074/jbc.M008282200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11018046	hybrid			2022-12-27	WOS:000168484300087
J	Lutters, BCH; Meijers, JCM; Derksen, RHWM; Arnout, J; de Groot, PG				Lutters, BCH; Meijers, JCM; Derksen, RHWM; Arnout, J; de Groot, PG			Dimers of beta(2)-glycoprotein I mimic the in vitro effects of beta(2)-glycoprotein I-anti-beta(2)-glycoprotein I antibody complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-C; SYSTEMIC LUPUS-ERYTHEMATOSUS; BETA-2-GLYCOPROTEIN-I APOLIPOPROTEIN-H; AUTOIMMUNE ANTIPHOSPHOLIPID ANTIBODIES; AMINO-ACID-SEQUENCE; ANTICARDIOLIPIN ANTIBODIES; PHOSPHOLIPID-BINDING; ANTICOAGULANT ACTIVITY; ANTI-BETA(2)-GLYCOPROTEIN-I ANTIBODY; PROTHROMBINASE ACTIVITY	Anti-beta (2)-glycoprotein I antibodies are thought to cause lupus anticoagulant activity by forming bivalent complexes with beta (2)-glycoprotein I (beta (2)GPI). To test this hypothesis, chimeric fusion proteins were constructed of the dimerization domain (apple 4) of factor XI and beta (2)GPI. Both a covalent (apple 4-beta (2)GPI) and a noncovalent (apple 4-C321S-beta (2)GPI) chimer were constructed. As controls, apple 2-beta (2)GPI and apple 4-C321S-beta (2)GPI-W316S, in which beta (2)GPI-W316S is not able to bind to phospholipids, were made. In a phospholipid binding assay, apple 4-beta (2)GPI and apple 4-C321S-beta (2)GPI were able to bind to phospholipids with an affinity 35 times higher than that of plasma-derived beta (2)GPI and apple 2-beta (2)GPI. Apple 4-C321S-beta (2)GPI-W316S did not bind at all. Only apple 4-beta (2)GPI and apple 4-C321S-beta (2)GPI were able to bind to adhered platelets as shown by immunofluorescence. Using the prothrombin time, which was the most responsive coagulation assay, the clotting time was approximately doubled when 200 mug/ml apple 4-beta (2)GPI or apple 4-C321S-beta (2)GPI was added. Addition of 200 mug/ml plasma-derived beta (2)GPI, apple 2-beta (2)GPI, or apple 4-C321S-beta (2)GPI-W316S did not affect clotting time. Clotting time could be corrected with the addition of extra phospholipids, which is indicative for lupus anticoagulant activity. An additional increase in clotting times for apple 4-beta (2)GPI or apple 4-C321S-beta (2)GPI was achieved by the addition of monoclonal antibodies against beta (2)GPI. In conclusion, dimerization of beta (2)GPI explains the in vitro observed effects of beta (2)GPI-anti-beta (2)GPI antibody complexes.	Univ Utrecht, Med Ctr, Thrombosis & Haemostasis Lab, Dept Haematol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3508 TB Utrecht, Netherlands; Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands; Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	Utrecht University; Utrecht University; Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam; KU Leuven	Lutters, BCH (corresponding author), Univ Utrecht, Med Ctr, Thrombosis & Haemostasis Lab, Dept Haematol, G03-647,POB 85-500, NL-3508 GA Utrecht, Netherlands.		Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780				Arnout J, 1998, THROMB HAEMOSTASIS, V79, P79; Balasubramanian K, 1997, J BIOL CHEM, V272, P31113, DOI 10.1074/jbc.272.49.31113; BENDIXEN E, 1992, BIOCHEMISTRY-US, V31, P3611, DOI 10.1021/bi00129a009; BEVERS EM, 1991, THROMB HAEMOSTASIS, V66, P629; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; BRANDT JT, 1993, THROMB HAEMOSTASIS, V70, P598; BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185; BRUNNER J, 1976, BIOCHIM BIOPHYS ACTA, V455, P322, DOI 10.1016/0005-2736(76)90308-4; Chamley LW, 1999, CLIN EXP IMMUNOL, V115, P571; CHONN A, 1995, J BIOL CHEM, V270, P25845, DOI 10.1074/jbc.270.43.25845; DAHLBACK B, 1983, BLOOD, V62, P218; DEGROOT PG, 1993, BAILLIERE CLIN HAEM, V6, P691, DOI 10.1016/S0950-3536(05)80194-5; EXNER T, 1991, THROMB HAEMOSTASIS, V65, P320; Forastiero R, 1998, THROMB HAEMOSTASIS, V79, P42, DOI 10.1055/s-0037-1614216; Galazka M, 1999, APPL BIOCHEM BIOTECH, V76, P1, DOI 10.1385/ABAB:76:1:1; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1988, ANNU REV MED, V39, P261, DOI 10.1146/annurev.med.39.1.261; Hasunuma Y, 1997, CLIN EXP IMMUNOL, V107, P569, DOI 10.1046/j.1365-2249.1997.d01-948.x; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Horbach DA, 1998, THROMB HAEMOSTASIS, V80, P791; Horbach DA, 1996, THROMB HAEMOSTASIS, V76, P916; HUNT J, 1994, J IMMUNOL, V152, P653; HUNT JE, 1993, P NATL ACAD SCI USA, V90, P2141, DOI 10.1073/pnas.90.6.2141; ICHIKAWA K, 1994, ARTHRITIS RHEUM, V37, P1453, DOI 10.1002/art.1780371008; Ieko M, 1998, SEMIN THROMB HEMOST, V24, P211, DOI 10.1055/s-2007-995844; KATO H, 1991, BIOCHEMISTRY-US, V30, P11687, DOI 10.1021/bi00114a012; KEELING DM, 1993, J CLIN PATHOL, V46, P908, DOI 10.1136/jcp.46.10.908; KRISTENSEN T, 1991, FEBS LETT, V289, P183, DOI 10.1016/0014-5793(91)81065-G; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; MATSUDA J, 1995, AM J HEMATOL, V49, P89, DOI 10.1002/ajh.2830490116; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; Mehdi H, 2000, EUR J BIOCHEM, V267, P1770, DOI 10.1046/j.1432-1327.2000.01174.x; MEIJERS JC, 1992, BIOCHEMISTRY-US, V31, P4684; MEIJERS JCM, 1992, BLOOD, V79, P1435; Mori T, 1996, THROMB HAEMOSTASIS, V75, P49; NIMPF J, 1985, THROMB HAEMOSTASIS, V54, P397; NIMPF J, 1986, BIOCHIM BIOPHYS ACTA, V884, P142, DOI 10.1016/0304-4165(86)90237-0; OOSTING JD, 1992, THROMB HAEMOSTASIS, V67, P499; PENGO V, 1995, THROMB HAEMOSTASIS, V73, P29; PERMPIKUL P, 1994, BLOOD, V83, P2878, DOI 10.1182/blood.V83.10.2878.2878; ROUBEY RAS, 1994, BLOOD, V84, P2854; ROUBEY RAS, 1992, J CLIN INVEST, V90, P1100, DOI 10.1172/JCI115926; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHOUSBOE I, 1995, THROMB HAEMOSTASIS, V73, P798; SCHOUSBOE I, 1980, THROMB RES, V19, P225, DOI 10.1016/0049-3848(80)90421-1; SCHOUSBOE I, 1985, BLOOD, V66, P1086; Sheng YH, 1996, J IMMUNOL, V157, P3744; Sheng YH, 1998, J IMMUNOL, V161, P2038; SHI W, 1993, THROMB HAEMOSTASIS, V70, P342; SMIRNOV MD, 1995, J CLIN INVEST, V95, P309, DOI 10.1172/JCI117657; STEINKASSERER A, 1992, FEBS LETT, V313, P193, DOI 10.1016/0014-5793(92)81442-O; Takeya H, 1997, J CLIN INVEST, V99, P2260, DOI 10.1172/JCI119401; vanWijnen M, 1996, THROMB HAEMOSTASIS, V76, P397; vanZanten GH, 1996, BLOOD, V88, P3862, DOI 10.1182/blood.V88.10.3862.bloodjournal88103862; WAGENKNECHT DR, 1993, THROMB HAEMOSTASIS, V69, P361; Wang SX, 2000, BIOCHEM J, V348, P103, DOI 10.1042/0264-6021:3480103; Willems GM, 1996, BIOCHEMISTRY-US, V35, P13833, DOI 10.1021/bi960657q; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X	62	73	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3060	3067		10.1074/jbc.M008224200	http://dx.doi.org/10.1074/jbc.M008224200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11053420	hybrid			2022-12-27	WOS:000166784900014
J	Savouret, JF; Antenos, M; Quesne, M; Xu, J; Milgrom, E; Casper, RF				Savouret, JF; Antenos, M; Quesne, M; Xu, J; Milgrom, E; Casper, RF			7-ketocholesterol is an endogenous modulator for the arylhydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL OXIDATION-PRODUCTS; HUMAN MONOCYTE-MACROPHAGES; AH RECEPTOR; 7-ALPHA-HYDROXYCHOLESTEROL DEHYDROGENASE; ACTIVATION; OXYSTEROLS; TOXICITY; DIOXIN	We have identified 7-ketocholesterol (7-KC) as an endogenous modulator that inhibits transactivation by the arylhydrocarbon receptor (AhR) through competitive binding against xenobiotic ligands. 7-KC binds AhR and displaces labeled dioxin (2,3,7,8-tetrachlorodibenzo(p)dioxin (TCDD)). IC50 is 5 x 10(-7) M in vivo and 7 x 10(-6) M in vitro. These figures are consistent with its concentration in human blood plasma and tissues. Association with 7-KC prevents AhR binding to DNA. 7-KC blocks the TCDD-mediated transactivation of stably expressed reporter gene constructs in T47-D cells as well as the expression of the endogenous CYP 1A1 gene in HepG2 cells and in primary porcine aortic endothelial cells. Injection of 7-KC to rats blocks the induction of CYP 1A1 messenger RNA and protein in endothelial cells from myocardial blood vessels. The differential sensitivity of mammalian species to toxic effects of AhR ligands, especially dioxin (TCDD), correlates with the expression of 7-hydroxycholesterol dehydrogenase, which synthesizes 7-KC from 7-hydroxycholesterol. The documented involvement of AhR ligands in cardiovascular diseases through lipid peroxidation and endothelium dysfunction can now be examined in the context of displacement of this protective modulator.	CHU Niveau 3, INSERM, U135, Hop Bicetre, F-94270 Le Kremlin Bicetre, France; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Zool, Toronto, ON M5G 1A1, Canada	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Savouret, JF (corresponding author), CHU Niveau 3, INSERM, U135, Hop Bicetre, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France.		Casper, Robert F./E-3775-2013; Antenos, Monica/J-8985-2017	Casper, Robert F./0000-0002-6249-462X; Antenos, Monica/0000-0001-6350-2911				ADDIS PB, 1989, FREE RADICAL BIO MED, V7, P179, DOI 10.1016/0891-5849(89)90011-7; Alexander DL, 1998, J CELL SCI, V111, P3311; Bertazzi PA, 1998, ENVIRON HEALTH PERSP, V106, P625, DOI 10.2307/3433813; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brodie AE, 1997, TOXICOL LETT, V90, P91, DOI 10.1016/S0378-4274(96)03833-7; Casper RF, 1999, MOL PHARMACOL, V56, P784; CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452; CLARE K, 1995, ATHEROSCLEROSIS, V118, P67, DOI 10.1016/0021-9150(95)05594-M; Colles SM, 1996, J LIPID RES, V37, P2018; Crawford RB, 1997, MOL PHARMACOL, V52, P921, DOI 10.1124/mol.52.6.921; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; EBERHART DC, 1991, MOL PHARMACOL, V40, P859; Edwards PA, 1998, CURR OPIN LIPIDOL, V9, P433, DOI 10.1097/00041433-199810000-00007; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FLESCHJANYS D, 1995, AM J EPIDEMIOL, V142, P1165, DOI 10.1093/oxfordjournals.aje.a117575; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; Hardwick SJ, 1996, J PATHOL, V179, P294; Heath-Pagliuso S, 1998, BIOCHEMISTRY-US, V37, P11508, DOI 10.1021/bi980087p; Hengstler JG, 1999, DRUG METAB REV, V31, P917, DOI 10.1081/DMR-100101946; KANDUTSCH AA, 1975, J CELL PHYSIOL, V85, P415, DOI 10.1002/jcp.1040850408; KUCUK O, 1994, LIPIDS, V29, P657, DOI 10.1007/BF02536101; KUCUK O, 1992, CELL IMMUNOL, V139, P541, DOI 10.1016/0008-8749(92)90091-3; KURL RN, 1985, PHARMACOLOGY, V30, P241, DOI 10.1159/000138073; Lyons MA, 1999, INT J BIOCHEM CELL B, V31, P369, DOI 10.1016/S1357-2725(98)00123-X; MOOG C, 1989, INT J IMMUNOPHARMACO, V11, P559, DOI 10.1016/0192-0561(89)90186-0; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Phelan D, 1998, ARCH BIOCHEM BIOPHYS, V357, P155, DOI 10.1006/abbi.1998.0814; Schaldach CM, 1999, BIOCHEMISTRY-US, V38, P7594, DOI 10.1021/bi982861e; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Smith LL, 1996, LIPIDS, V31, P453, DOI 10.1007/BF02522641; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; Song W, 1996, ARCH BIOCHEM BIOPHYS, V328, P272, DOI 10.1006/abbi.1996.0173; SONG W, 1991, BIOCHEM PHARMACOL, V41, P1439, DOI 10.1016/0006-2952(91)90559-N; Song W, 1998, J BIOL CHEM, V273, P16223, DOI 10.1074/jbc.273.26.16223; Toborek M, 1995, J Biochem Toxicol, V10, P219, DOI 10.1002/jbt.2570100406; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Vena J, 1998, ENVIRON HEALTH PERSP, V106, P645, DOI 10.2307/3433815; WILHELMSSON A, 1994, J BIOL CHEM, V269, P19028	39	100	102	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3054	3059		10.1074/jbc.M005988200	http://dx.doi.org/10.1074/jbc.M005988200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042205	hybrid			2022-12-27	WOS:000166784900013
J	Gosslau, A; Ruoff, P; Mohsenzadeh, S; Hobohm, U; Rensing, L				Gosslau, A; Ruoff, P; Mohsenzadeh, S; Hobohm, U; Rensing, L			Heat shock and oxidative stress-induced exposure of hydrophobic protein domains as common signal in the induction of hsp68	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; IMMUNOSUPPRESSANT DEOXYSPERGUALIN; FACTOR-I; ACTIVATION; HSP70; EXPRESSION; INVOLVEMENT; CELLS; ACID	The hypothesis of a common signal for heat shock (HS) and oxidative stress (OS) was analyzed in C6 cells with regard to the induction of heat shock proteins (Hsps). The synthesis rate and level of the strictly inducible Hsp68 was significantly higher after HS (44 degreesC) compared with OS (2 mM H2O2). This difference corresponded to higher and lower activation of the heat shock factor (HSF) by HS and OS, respectively. OS, on the other hand, showed stronger cytotoxicity compared with HS as indicated by drastic lipid peroxidation and inhibition of protein synthesis as well as of mitochondrial and endocytotic activity. Lactic dehydrogenase also revealed stronger inhibition of enzyme activity by OS than by HS as shown in cells and in vitro experiments. Conformational analysis of lactic dehydrogenase by the fluorophore 1-anilinonaphtalene-8-sulfonic acid, however, showed stronger exposure of hydrophobic domains after HS than after OS which correlates positively with the Hsp68 response. Treatment of cells with deoxyspergualin, which exhibits high affinity to Hsps, the putative inhibitors of HSF, strongly increased only OS-induced hsp68 expression. In conclusion, the results suggest that exposure of hydrophobic domains of cytosolic proteins represents the common first signal in the multistep activation pathway of HSF.	Univ Bremen, Inst Cell Biol Biochem & Biotechnol, D-28334 Bremen, Germany; Stavanger Univ Coll, Sch Sci & Technol, N-4091 Stavanger, Norway	University of Bremen; Equinor; Universitetet i Stavanger	Rensing, L (corresponding author), Univ Bremen, Inst Cell Biol Biochem & Biotechnol, POB 33 04 40, D-28334 Bremen, Germany.	rensing@uni-bremen.de		Ruoff, Peter/0000-0003-4430-0382				ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; BABICH H, 1987, TOXICOL IN VITRO, V1, P3, DOI 10.1016/0887-2333(87)90031-2; Baler R, 1996, CELL STRESS CHAPERON, V1, P33, DOI 10.1379/1466-1268(1996)001<0033:EFAROH>2.3.CO;2; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BERG K, 1990, APMIS, V98, P156, DOI 10.1111/j.1699-0463.1990.tb01016.x; BERNHEIM F, 1948, J BIOL CHEM, V174, P257; BRUCE JL, 1993, CANCER RES, V53, P12; Burdon R H, 1987, Free Radic Res Commun, V3, P129, DOI 10.3109/10715768709069778; Chen HW, 1999, SHOCK, V12, P63, DOI 10.1097/00024382-199907000-00009; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; DAS DK, 1995, J MOL CELL CARDIOL, V27, P181, DOI 10.1016/S0022-2828(08)80017-X; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; Ding XZ, 1998, FASEB J, V12, P451, DOI 10.1096/fasebj.12.6.451; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; Freeman ML, 1999, FREE RADICAL BIO MED, V26, P737, DOI 10.1016/S0891-5849(98)00258-5; GOODSON ML, 1995, BIOCHEM BIOPH RES CO, V211, P943, DOI 10.1006/bbrc.1995.1903; Gosslau A, 2000, BRAIN RES, V864, P114, DOI 10.1016/S0006-8993(00)02195-8; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hatayama T, 1999, BIOCHEM BIOPH RES CO, V265, P763, DOI 10.1006/bbrc.1999.1751; Huang J, 1996, BRAIN RES, V711, P184, DOI 10.1016/0006-8993(95)01376-8; HUANG LE, 1994, J BIOL CHEM, V269, P30718; Hung JJ, 1998, J CELL BIOCHEM, V71, P21; JacquierSarlin MR, 1996, BIOCHEM J, V318, P187, DOI 10.1042/bj3180187; Jolly C, 1999, P NATL ACAD SCI USA, V96, P6769, DOI 10.1073/pnas.96.12.6769; JORNOT L, 1991, AM J RESP CELL MOL, V5, P265, DOI 10.1165/ajrcmb/5.3.265; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KEYSE SM, 1987, J BIOL CHEM, V262, P14821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; Liu HD, 1996, GENE DEV, V10, P592; Liu JK, 1997, ANAL BIOCHEM, V245, P161, DOI 10.1006/abio.1996.9990; Liu PCC, 1999, J BIOL CHEM, V274, P17219, DOI 10.1074/jbc.274.24.17219; LIU RY, 1995, MOL CELL BIOCHEM, V144, P27, DOI 10.1007/BF00926737; McDuffee AT, 1997, J CELL PHYSIOL, V171, P143, DOI 10.1002/(SICI)1097-4652(199705)171:2<143::AID-JCP4>3.0.CO;2-O; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; MUNRO S, 1985, NATURE, V317, P477, DOI 10.1038/317477a0; NADEAU K, 1994, BIOCHEMISTRY-US, V33, P2561, DOI 10.1021/bi00175a027; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; NEUHOFF V, 1979, H-S Z PHYSIOL CHEM, V360, P1657, DOI 10.1515/bchm2.1979.360.2.1657; Ohnishi K, 1999, MOL CELL BIOCHEM, V197, P129, DOI 10.1023/A:1006937513154; Ovelgonne JH, 1996, J MOL CELL CARDIOL, V28, P1617, DOI 10.1006/jmcc.1996.0152; PTISYN OB, 1990, FEBS LETT, V262, P20; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; RICHARME G, 1993, J BIOL CHEM, V268, P24074; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Senisterra GA, 1997, BIOCHEMISTRY-US, V36, P11002, DOI 10.1021/bi9711590; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Stephanou A, 1999, GENE EXPRESSION, V7, P311; Stuhlmeier KM, 2000, EUR J BIOCHEM, V267, P1161, DOI 10.1046/j.1432-1327.2000.01112.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; WEINER L, 1994, BIOCHEM BIOPH RES CO, V198, P915, DOI 10.1006/bbrc.1994.1130; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zhong M, 1999, J BIOL CHEM, V274, P3135, DOI 10.1074/jbc.274.5.3135; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	70	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1814	1821		10.1074/jbc.M008280200	http://dx.doi.org/10.1074/jbc.M008280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042186	hybrid			2022-12-27	WOS:000166528000024
J	Anfosso, F; Bardin, N; Vivier, E; Sabatier, F; Sampol, J; Dignat-George, F				Anfosso, F; Bardin, N; Vivier, E; Sabatier, F; Sampol, J; Dignat-George, F			Outside-in signaling pathway linked to CD146 engagement in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CAPACITATIVE CALCIUM-ENTRY; SMOOTH-MUSCLE CELLS; TYROSINE KINASE; PHOSPHOLIPASE-C; ACTIVATION; PHOSPHORYLATION; P130(CAS); SRC; PROTEIN	CD146 (S-Endo 1 Ag or MUC18) is a transmembrane glycoprotein expressed on endothelial cells on the whole vascular tree. CD146 is located at the intercellular junction where it plays a role in the cohesion of the endothelial monolayer, CD146 engagement initiates an outside-in signaling pathway involving the protein tyrosine kinases FYN and FAK as well as paxillin, Here we report that CD146 engagement by its specific monoclonal antibody in human umbilical vein endothelial cells induces a Ca2+ influx that is sensitive to thapsigargin and EGTA treatment, indicating that CD146 engagement initiates a store-operated calcium mobilization, In addition, biochemical and pharmacological analysis revealed that CD146 engagement initiates the tyrosine phosphorylation of phospholipase C-gamma, Pyk2, and p130(Cas). Pharmacological inhibition of Ca2+ flux with 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acetoxymethyl ester and EGTA indicated that an increase in Ca2+ is required for Pyk2 and p130(Cas) tyrosine phosphorylation. Moreover, a complex association was observed between Pyk2, p130(Cas), and paxillin. These results indicate that CD146 is coupled to a FYN-dependent pathway that triggers Ca2+ flux via phospholipase C-gamma activation leading subsequently to the tyrosine phosphorylation of downstream targets such as Pyk2, p130(Cas), FAK, and paxillin. In addition to its role in cell-cell adhesion, CD146 is a signaling molecule involved in the dynamics of actin cytoskeleton rearrangement.	Univ Mediterranee, EMI 0019, Lab Hematol Immunol, UFR Pharm, F-13385 Marseille 5, France; CNRS, INSERM, Ctr Immunol, Marseille, France; Inst Univ France, F-13276 Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Universitaire de France	Anfosso, F (corresponding author), Univ Mediterranee, EMI 0019, Lab Hematol Immunol, UFR Pharm, 27 Bd Jean Moulin, F-13385 Marseille 5, France.	anfosso@pharmacie.univ-mrs.fr	DIGNAT-GEORGE, Françoise/R-1129-2016; Vivier, Eric/F-8939-2010; Bardin, Nathalie/AAL-3663-2020	DIGNAT-GEORGE, Françoise/0000-0001-7006-4462; Vivier, Eric/0000-0001-7022-8287; Bardin, Nathalie/0000-0003-3680-082X				Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bardin N, 1996, BIOCHEM BIOPH RES CO, V218, P210, DOI 10.1006/bbrc.1996.0037; Bardin N, 1996, TISSUE ANTIGENS, V48, P531, DOI 10.1111/j.1399-0039.1996.tb02666.x; BENNETT J, 1986, BRIT MED BULL, V42, P385, DOI 10.1093/oxfordjournals.bmb.a072156; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DeLisser HM, 1997, TRENDS CARDIOVAS MED, V7, P203, DOI 10.1016/S1050-1738(97)00049-2; DHAR A, 1994, J BIOL CHEM, V269, P9123; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DONNADIEU E, 1994, J BIOL CHEM, V269, P32828; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gurubhagavatula I, 1998, J CLIN INVEST, V101, P212, DOI 10.1172/JCI269; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; HUANG AJ, 1993, J CELL BIOL, V120, P1371, DOI 10.1083/jcb.120.6.1371; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Johnson JP, 1997, INT J CANCER, V73, P769; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; LEHMANN JM, 1987, CANCER RES, V47, P841; LEHMANN JM, 1989, P NATL ACAD SCI USA, V96, P9691; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PATCH LA, 1995, J CELL SCI, V108, P1371; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PFAU S, 1995, J CELL BIOL, V128, P969, DOI 10.1083/jcb.128.5.969; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shih IM, 1998, J CELL SCI, V111, P2655; Shih IM, 1997, CANCER RES, V57, P3835; SHIH LE, 1999, J PATHOL, V189, P4; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Sun J, 2000, J CELL SCI, V113, P1459; Taira E, 1999, EXP CELL RES, V253, P697, DOI 10.1006/excr.1999.4713; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	62	113	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1564	1569		10.1074/jbc.M007065200	http://dx.doi.org/10.1074/jbc.M007065200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11036077	hybrid			2022-12-27	WOS:000166430900094
J	Fonteh, AN; LaPorte, T; Swan, D; McAlexander, MA				Fonteh, AN; LaPorte, T; Swan, D; McAlexander, MA			A decrease in remodeling accounts for the accumulation of arachidonic acid in murine mast cells undergoing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); PROSTAGLANDIN D-2 GENERATION; POLYUNSATURATED FATTY-ACIDS; A-INDEPENDENT TRANSACYLASE; ACYL-COA SYNTHETASE; C-KIT LIGAND; INDUCE APOPTOSIS; LIPID-PEROXIDATION; RELEASE; EXPRESSION	The goal of this study was to examine arachidonic acid (AA) metabolism by murine bone marrow-derived mast cells (BMMC) during apoptosis induced by cytokine depletion. BMMC deprived of cytokines for 12-48 h displayed apoptotic characteristics. During apoptosis, levels of AA, but not other unsaturated fatty acids, correlated with the percentage of apoptotic cells. A decrease in both cytosolic phospholipase A, expression and activity indicated that cytosolic phospholipase A, did not account for AA mobilization during apoptosis, Free AA accumulation is also unlikely to be due to decreases In 5-lipoxygenase and/or cyclooxygenase activities, since BMMC undergoing apoptosis produced similar amounts of leukotriene B-4 and significantly greater amounts of PGD(2) than control cells. Arachidonoyl-CoA synthetase and CoA-dependent transferase activities responsible for incorporating AA into phospholipids were not altered during apoptosis. However, there was an increase in arachidonate in phosphatidylcholine (PC) and neutral lipids concomitant with a 40.7 +/- 8.1% decrease in arachidonate content in phosphatidylethanolamine (PE), suggesting a diminished capacity of mast cells to remodel arachidonate from PC to PE pools. Further evidence of a decrease in AA remodeling was shown by a significant decrease in microsomal CoA-independent transacylase activity. Levels of lyse-PC and lyso-PE were not altered in cells undergoing apoptosis, suggesting that the accumulation of lysophospholipids did not account for the decrease in CoA-independent transacylase activity or the induction of apoptosis, Together, these data suggest that the mole quantities of free AA closely correlated with apoptosis and that the accumulation of AA in BMMC during apoptosis was mediated by a decreased capacity of these cells to remodel AA from PC to PE.	Wake Forest Univ, Sch Med, Dept Internal Med Pulm & Crit Care Med, Winston Salem, NC 27154 USA	Wake Forest University	Fonteh, AN (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med Pulm & Crit Care Med, Winston Salem, NC 27154 USA.	afonteh@wfubmc.edu			NIAID NIH HHS [AI 24985] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024985, R29AI024985] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adam-Klages S, 1998, J IMMUNOL, V161, P5687; Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; CHILTON FH, 1990, METHOD ENZYMOL, V187, P157; CHILTON FH, 1990, CHEM IMMUNOL, V49, P173; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; CHILTON FH, 1987, BIOCHEM BIOPH RES CO, V145, P1126, DOI 10.1016/0006-291X(87)91554-3; Costa JJ, 1997, JAMA-J AM MED ASSOC, V278, P1815, DOI 10.1001/jama.278.22.1815; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Das UN, 1999, PROSTAG LEUKOTR ESS, V61, P157, DOI 10.1054/plef.1999.0085; DAS UN, 1987, BIOCHEM BIOPH RES CO, V145, P15, DOI 10.1016/0006-291X(87)91281-2; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DVORAK AM, 1994, AM J PATHOL, V144, P160; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Elder DJE, 1998, NAT MED, V4, P392, DOI 10.1038/nm0498-392; Enari M, 1996, EUR J BIOCHEM, V236, P533, DOI 10.1111/j.1432-1033.1996.t01-1-00533.x; Fabisiak JP, 2000, BIOCHEMISTRY-US, V39, P127, DOI 10.1021/bi9912544; FONTEH AN, 1995, J CLIN INVEST, V96, P1432, DOI 10.1172/JCI118179; FONTEH AN, 1992, J IMMUNOL, V148, P1784; FONTEH AN, 1994, J IMMUNOL, V152, P5438; Fonteh AN, 2000, J IMMUNOL, V165, P2773, DOI 10.4049/jimmunol.165.5.2773; Fonteh AN, 1999, METH MOL B, V120, P77; FONTEH AN, 1993, J IMMUNOL, V150, P563; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Gerard-Monnier D, 1998, CHEM RES TOXICOL, V11, P1176, DOI 10.1021/tx9701790; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; Hara A, 1997, JPN J CANCER RES, V88, P600; Hundley TR, 1998, J PHARMACOL EXP THER, V284, P847; JAATTELA M, 1995, ONCOGENE, V10, P2297; Johnson MM, 1999, AM J RESP CELL MOL, V21, P253, DOI 10.1165/ajrcmb.21.2.3489; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; KRAMER RM, 1984, J BIOL CHEM, V259, P2403; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; LANDS WEM, 1982, J BIOL CHEM, V257, P4968; Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MACDONALD JIS, 1989, BIOCHIM BIOPHYS ACTA, V1004, P151, DOI 10.1016/0005-2760(89)90263-4; MEKORI YA, 1993, J IMMUNOL, V151, P3775; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; MORISAKI N, 1982, LIPIDS, V17, P893, DOI 10.1007/BF02534584; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NAKAGAWA Y, 1983, J LIPID RES, V24, P1268; NAKAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1085, P191, DOI 10.1016/0005-2760(91)90094-X; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OHISHI S, 1992, JPN J PHARMACOL, V59, P417, DOI 10.1254/jjp.59.417; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Sawaoka H, 1998, J CLIN GASTROENTEROL, V27, pS47, DOI 10.1097/00004836-199800001-00009; Schor NF, 1999, BRAIN RES, V831, P125, DOI 10.1016/S0006-8993(99)01414-6; Sheng HM, 1998, CANCER RES, V58, P362; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; SUGIURA T, 1984, FEBS LETT, V165, P273, DOI 10.1016/0014-5793(84)80184-2; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TRIGGIANI M, 1995, J EXP MED, V182, P1181, DOI 10.1084/jem.182.5.1181; Trimboli AJ, 1999, CANCER RES, V59, P6171; TSAI M, 1993, EUR J IMMUNOL, V23, P867, DOI 10.1002/eji.1830230415; Tsujimura T, 1997, AM J PATHOL, V151, P1043; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; WASSERMAN SI, 1994, AM J RESP CRIT CARE, V150, pS39, DOI 10.1164/ajrccm/150.5_Pt_2.S39; WILSON DB, 1982, J BIOL CHEM, V257, P3510; WINKLER JD, 1994, BBA-LIPID LIPID MET, V1215, P133, DOI 10.1016/0005-2760(94)90102-3; WINKLER JD, 1995, ADV PROSTAG THROMB L, V23, P89; Winkler JD, 1996, J PHARMACOL EXP THER, V279, P956; WINKLER JD, 1994, J LIPID MEDIAT CELL, V10, P315; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1	77	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1439	1449		10.1074/jbc.M006551200	http://dx.doi.org/10.1074/jbc.M006551200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11022038	hybrid			2022-12-27	WOS:000166430900078
J	Gurvitz, A; Hamilton, B; Ruis, H; Hartig, A				Gurvitz, A; Hamilton, B; Ruis, H; Hartig, A			Peroxisomal degradation of trans-unsaturated fatty acids in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS PIP2P; BETA-OXIDATION; DOUBLE-BONDS; OLEIC-ACID; 2,4-DIENOYL-COA REDUCTASE; DEPENDENT PATHWAY; COENZYME-A; GENE SPS19; PROLIFERATION; METABOLISM	Degradation of trans-unsaturated fatty acids was studied in the yeast Saccharomyces cerevisiae, Propagation of yeast cells on trans-9 elaidic acid medium resulted in transcriptional up-regulation of the SPS19 gene, whose promoter contains an oleate response element. This up-regulation depended on the Pip2p-Oaf1p transcription factor and was accompanied by induction of import-competent peroxisomes. Utilization of trans fatty acids as a single carbon and energy source was evaluated by monitoring the formation of clear zones around cell growth on turbid media containing fatty acids dispersed with Tween 80. For metabolizing odd-numbered trans double bonds, cells required the beta -oxidation auxiliary enzyme Delta (3)-Delta (2)-enoyl-CoA isomerase Eci1p, Metabolism of the corresponding even-numbered double bonds proceeded in the absence of Sps19p (2,4-dienoyl-CoA reductase) and Dci1p (Delta (3,5)-Delta (2,4)-dienoyl-CoA isomerase). trans-2,trans-4-Dienoyl-CoAs could enter beta -oxidation directly via Fox2p (2-enoyl-CoA hydratase 2 and D-specific 3-hydroxyacyl-CoA dehydrogenase) without the involvement of Sps19p, whereas trans-2,cis-4-dienoyl-CoAs could not. This reductase-independent metabolism of trans-2,trans-4-dienoyl-CoAs resembled the situation postulated for mammalian mitochondria in which oleic acid is degraded through a di-isomerase-dependent pathway. In this hypothetical process, trans-2,trans-4-dienoyl-CoA metabolites are generated by Delta (3)-Delta (2)-enoyl-CoA isomerase and Delta (3,5)-Delta (2,4)-dienoyl-CoA isomerase and are degraded by 8-enoyl-CoA hydratase 1 in the absence of 2,4-dienoyl-CoA reductase. Growth of a yeast fox2sps19 Delta mutant in which Fox2p was exchanged with rat peroxisomal multifunctional enzyme type 1 on trans-9,trans-12 linolelaidic acid medium gave credence to this theory. We propose an amendment to the current scheme of the carbon flux through beta -oxidation taking into account the dispensability of beta -oxidation auxiliary enzymes for metabolizing trans double bonds at even-numbered positions.	Vienna Bioctr, Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria; Univ Vienna, Inst Biochem & Mol Zellbiol, A-1030 Vienna, Austria	Ludwig Boltzmann Institute; Vienna Biocenter (VBC); University of Vienna	Gurvitz, A (corresponding author), Vienna Bioctr, Inst Biochem & Mol Zellbiol, Dr Bohrgasse 9, A-1030 Vienna, Austria.			Hartig, Andreas/0000-0003-3334-2763				CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; FILPPULA SA, 1995, J BIOL CHEM, V270, P27453, DOI 10.1074/jbc.270.46.27453; Geisbrecht BV, 1998, J BIOL CHEM, V273, P33184, DOI 10.1074/jbc.273.50.33184; Geisbrecht BV, 1999, BIOCHEM BIOPH RES CO, V260, P28, DOI 10.1006/bbrc.1999.0860; Gurvitz A, 1997, MOL MICROBIOL, V26, P675, DOI 10.1046/j.1365-2958.1997.5931969.x; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; Gurvitz A, 1999, J BIOL CHEM, V274, P24514, DOI 10.1074/jbc.274.35.24514; Gurvitz A, 1998, J BIOL CHEM, V273, P31366, DOI 10.1074/jbc.273.47.31366; Gurvitz A, 1999, BIOCHEM J, V344, P903, DOI 10.1042/0264-6021:3440903; Gurvitz A, 1999, MOL GEN GENET, V262, P481; Guzman M, 1999, LIPIDS, V34, P381, DOI 10.1007/s11745-999-0376-6; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; Hiltunen JK, 1996, ANN NY ACAD SCI, V804, P116, DOI 10.1111/j.1749-6632.1996.tb18612.x; IGUAL JC, 1991, YEAST, V7, P379, DOI 10.1002/yea.320070408; JONES EW, 1977, GENETICS, V85, P23; Karpichev IV, 2000, J CELL SCI, V113, P533; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Liang XQ, 1999, J BIOL CHEM, V274, P13830, DOI 10.1074/jbc.274.20.13830; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; MENSINK RP, 1992, J LIPID RES, V33, P1493; Qin YM, 1999, J BIOL CHEM, V274, P28619, DOI 10.1074/jbc.274.40.28619; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Sambrook J., 2002, MOL CLONING LAB MANU; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; SINCLAIR HM, 1990, BIOCHEM SOC T, V18, P756, DOI 10.1042/bst0180756; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; VOORNBROUWER T, 1993, BIOCHIM BIOPHYS ACTA, V1216, P325, DOI 10.1016/0167-4781(93)90166-B	36	18	18	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					895	903		10.1074/jbc.M003305200	http://dx.doi.org/10.1074/jbc.M003305200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032827	hybrid			2022-12-27	WOS:000166430900006
J	Jaffe, EK; Martins, J; Li, J; Kervinen, J; Dunbrack, RL				Jaffe, EK; Martins, J; Li, J; Kervinen, J; Dunbrack, RL			The molecular mechanism of lead inhibition of human porphobilinogen synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE DEHYDRATASE; ACID DEHYDRATASE; ESCHERICHIA-COLI; 5-AMINOLEVULINATE DEHYDRATASE; ACTIVE-SITE; ZINC; POLYMORPHISM; ISOZYMES; ZN(II); MG(II)	Human porphobilinogen synthase (PBGS) is a main target in lead poisoning. Human PBGS purifies with eight Zn(II) per homo-octamer; four ZnA have predominantly nonsulfur ligands, and four ZnB have predominantly sulfur ligands. Only four Zn(II) are required for activity. To better elucidate the roles of Zn(TI) and Pb(II), we produced human PBGS mutants that are designed to lack either the ZnA or ZnB sites. These proteins, MinusZnA (H131A, C223A) and MinusZnB (C122A, C124A, C132A), each become purified with four Zn(II) per octamer, thus confirming an asymmetry in the human PBGS structure. MinusZnA is fully active, whereas MinusZnB is far less active, verifying an important catalytic role for ZnB and the removed cysteine residues. Kinetic properties of the mutants and wild type proteins are described, Comparison of Pb(IT) inhibition of the mutants shows that ligands to both ZnA and ZnB interact with Pb(II). The ZnB ligands preferentially interact with Pb(II), At least one ZnA ligand is responsible for the slow tight binding behavior of Pb(II), The data support a novel model where a high affinity lead site is a hybrid of the ZnA and ZnB sites. We propose that the lone electron pair of Pb(IT) precludes Pb(II) to function in PBGS catalysis.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Jaffe, EK (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	EK_Jaffe@fccc.edu	Dunbrack, Roland/ABG-7141-2020	Dunbrack, Roland/0000-0001-7674-6667	NCI NIH HHS [CA06927] Funding Source: Medline; NIEHS NIH HHS [ES03654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASTRIN KH, 1987, ANN NY ACAD SCI, V514, P23; Bergdahl IA, 1997, PHARMACOL TOXICOL, V81, P153, DOI 10.1111/j.1600-0773.1997.tb02061.x; Bergdahl IA, 1997, ARCH ENVIRON HEALTH, V52, P91, DOI 10.1080/00039899709602870; BEVAN DR, 1980, J BIOL CHEM, V255, P2030; CHEH A, 1973, BIOCHEM BIOPH RES CO, V55, P1060, DOI 10.1016/S0006-291X(73)80002-6; DENT AJ, 1990, BIOCHEMISTRY-US, V29, P7822, DOI 10.1021/bi00486a007; DESPAUX N, 1979, BIOCHIMIE, V61, P1021; Erskine PT, 2000, ACTA CRYSTALLOGR D, V56, P421, DOI 10.1107/S0907444900000597; Erskine PT, 1997, NAT STRUCT BIOL, V4, P1025, DOI 10.1038/nsb1297-1025; Frankenberg N, 1999, J MOL BIOL, V289, P591, DOI 10.1006/jmbi.1999.2808; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13976, DOI 10.1021/bi9906470; GIBSON KD, 1955, BIOCHEM J, V61, P618, DOI 10.1042/bj0610618; HUCKEL D, 1979, ANAL BIOCHEM, V97, P277, DOI 10.1016/0003-2697(79)90072-1; JAFFE EK, 1995, BIOCHEMISTRY-US, V34, P244, DOI 10.1021/bi00001a029; JAFFE EK, 1986, J BIOL CHEM, V261, P9348; JAFFE EK, 1994, BIOCHEMISTRY-US, V33, P11554, DOI 10.1021/bi00204a018; Jaffe EK, 2000, ACTA CRYSTALLOGR D, V56, P115, DOI 10.1107/S0907444999014894; JAFFE EK, 1995, J BIOENERG BIOMEMBR, V27, P169, DOI 10.1007/BF02110032; JAFFE EK, 1984, J BIOL CHEM, V259, P5032; JAFFE EK, 1992, BIOCHEMISTRY-US, V31, P2113, DOI 10.1021/bi00122a032; JAFFE EK, 1991, BIOL TRACE ELEM RES, V28, P223, DOI 10.1007/BF02990469; Jaffe EK, 2000, J BIOL CHEM, V275, P2619, DOI 10.1074/jbc.275.4.2619; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRIGAN PJ, 1995, MT SINAI J MED, V62, P360; Matthews RG, 1997, CURR OPIN CHEM BIOL, V1, P332, DOI 10.1016/S1367-5931(97)80070-1; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MITCHELL LW, 1995, J BIOL CHEM, V270, P24054, DOI 10.1074/jbc.270.41.24054; MITCHELL LW, 1993, ARCH BIOCHEM BIOPHYS, V300, P169, DOI 10.1006/abbi.1993.1024; Petrovich RM, 1996, J BIOL CHEM, V271, P8692, DOI 10.1074/jbc.271.15.8692; Petrovich RM, 1997, BIOCHEMISTRY-US, V36, P13421, DOI 10.1021/bi971642a; SCHLOSSER M, 1987, BIOL CHEM H-S, V368, P1469, DOI 10.1515/bchm3.1987.368.2.1469; Senior NM, 1996, BIOCHEM J, V320, P401; Shimoni-Livny L, 1998, INORG CHEM, V37, P1853, DOI 10.1021/ic970909r; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Warren MJ, 1998, TRENDS BIOCHEM SCI, V23, P217, DOI 10.1016/S0968-0004(98)01219-5; WETMUR JG, 1991, ENVIRON RES, V56, P109, DOI 10.1016/S0013-9351(05)80001-5	37	86	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1531	1537		10.1074/jbc.M007663200	http://dx.doi.org/10.1074/jbc.M007663200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032836	hybrid			2022-12-27	WOS:000166430900090
J	Chen, XS; Funk, CD				Chen, XS; Funk, CD			The N-terminal "beta-barrel" domain of 5-lipoxygenase is essential for nuclear membrane translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLATELET 12-LIPOXYGENASE; CYTOSOLIC PHOSPHOLIPASE A(2); GENE CHROMOSOMAL ASSIGNMENT; CA2+-DEPENDENT TRANSLOCATION; LEUKOTRIENE PRODUCTION; FUNCTIONAL EXPRESSION; ALVEOLAR MACROPHAGES; MOLECULAR-CLONING; HUMAN-LEUKOCYTES; CDNA CLONING	5-Lipoxygenase is the key enzyme in the formation of leukotrienes, which are potent lipid mediators of asthma pathophysiology, This enzyme translocates to the nuclear envelope in a calcium-dependent manner for leukotriene biosynthesis, Eight green fluorescent protein (GFP)-lipoxygenase constructs, representing the major human and mouse enzymes within this family, were constructed and their cDNAs transfected into human embryonic kidney 293 cells. Of these eight lipoxygenases, only the B-lipoxygenase was clearly nuclear localized and translocated to the nuclear envelope upon stimulation with the calcium ionophore A23187. The N-terminal "beta -barrel" domain of 5-lipoxgenase, but not the catalytic domain, was necessary and sufficient for nuclear envelope translocation, The GFP-N-terminal 5-lipoxygenase domain translocated faster than GFP-5-lipoxygenase. beta -Barrel/catalytic domain chimeras with 12- and 15-lipoxygenase indicated that only the N-terminal domain of 5-lipoxygenase could carry out this translocation function. Mutations of iron atom binding ligands (His550 or deletion of C-terminal isoleucine) that disrupt nuclear localization do not alter translocation capacity indicating distinct determinants of nuclear localization and translocation. Moreover, data show that GFP-5-lipoxygenase beta -barrel containing constructs can translocate to the nuclear membrane whether cytoplasmic or nuclear localized. Thus, the predicted beta barrel domain of 5-lipoxygenase may function like the C2 domain within protein kinase C and cytosolic phospholipase A(2) with unique determinants that direct its localization to the nuclear envelope.	Univ Penn, Dept Pharmacol, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania	Funk, CD (corresponding author), Univ Penn, Dept Pharmacol, Ctr Expt Therapeut, 421 Curie Blvd,Rm 814, Philadelphia, PA 19104 USA.		Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058464] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58464] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABA A, 1989, J BIOL CHEM, V264, P15790; Battey, 1986, BASIC METHODS MOL BI; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Borngraber S, 1996, J MOL BIOL, V264, P1145, DOI 10.1006/jmbi.1996.0702; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Christmas P, 1999, J BIOL CHEM, V274, P25594, DOI 10.1074/jbc.274.36.25594; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COFFEY M, 1992, J BIOL CHEM, V267, P570; Funk CD, 1996, J BIOL CHEM, V271, P23338, DOI 10.1074/jbc.271.38.23338; FUNK CD, 1991, ADV PROSTAG THROMB L, V21, P33; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; HAGMANN W, 1995, PROSTAGLANDINS, V49, P49, DOI 10.1016/0090-6980(94)00005-H; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Healy AM, 1999, J BIOL CHEM, V274, P29812, DOI 10.1074/jbc.274.42.29812; HOGABOOM GK, 1986, MOL PHARMACOL, V30, P510; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287; Kinzig A, 1999, GENOMICS, V58, P158, DOI 10.1006/geno.1999.5816; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; May C, 2000, EUR J BIOCHEM, V267, P1100, DOI 10.1046/j.1432-1327.2000.01105.x; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Reddy KV, 2000, BIOCHEMISTRY-US, V39, P1840, DOI 10.1021/bi9919246; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P7505, DOI 10.1073/pnas.82.22.7505; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; Skorey KI, 1998, BIOCHEMISTRY-US, V37, P8027, DOI 10.1021/bi980371g; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; Sun DX, 1998, J BIOL CHEM, V273, P33540, DOI 10.1074/jbc.273.50.33540; UEDA N, 1986, J BIOL CHEM, V261, P7982; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018; WONG A, 1992, BIOCHEMISTRY-US, V31, P4046, DOI 10.1021/bi00131a021; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; Zhang YY, 2000, BIOCHEM J, V351, P697, DOI 10.1042/0264-6021:3510697	55	111	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					811	818		10.1074/jbc.M008203200	http://dx.doi.org/10.1074/jbc.M008203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11042185	hybrid			2022-12-27	WOS:000166280700109
J	Hajek, P; Villani, G; Attardi, G				Hajek, P; Villani, G; Attardi, G			Rate-limiting step preceding cytochrome c release in cells primed for Fas-mediated apoptosis revealed by analysis of cellular mosaicism of respiratory changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE ACTIVATION; JURKAT CELLS; IN-VIVO; MITOCHONDRIA; BCL-2; PHOSPHATIDYLSERINE; MEMBRANE; HOMEOSTASIS; OXIDASE; DEATH	In the present work, Jurkat cells undergoing anti-Pas antibody (anti-Fas)-triggered apoptosis exhibited in increasing proportion a massive release of cytochrome c from mitochondria, as revealed by double-labeling confocal immunofluorescence microscopy. The cytochrome c release was followed by a progressive reduction in the respiratory activity of the last respiratory enzyme, cytochrome c oxidase (COX), and with a little delay, by a decrease in overall endogenous respiration rate, as measured in vivo in the whole cell population. Furthermore, in vivo titration experiments showed that an similar to 30% excess of COX capacity over that required to support endogenous respiration, found in naive cells, was maintained in anti-Pas-treated cells having lost similar to 40% of their COX respiratory activity. This observation strongly suggested that only a subpopulation of anti-Pas-treated cells, which maintained the excess of COX capacity, respired. Fractionation of cells on annexin V-coated paramagnetic beads did indeed separate a subpopulation of annexin V-binding apoptotic cells with fully released cytochrome c and completely lacking respiration, and a nonbound cell subpopulation exhibiting nearly intact respiration and in their great majority preserving the mitochondrial cytochrome c localization. The above findings showed a cellular mosaicism in cytochrome c release and respiration loss, and revealed the occurrence of a rate-limiting step preceding cytochrome c release in the apoptotic cascade. Furthermore, the striking observation that controlled digitonin treatment caused a massive and very rapid release of cytochrome c and complete loss of respiration in the still respiring anti-Fas-treated cells, but not in naive cells, indicated that the cells responding to digitonin had already been primed for apoptosis, and that this treatment bypassed or accelerated the rate-limiting step most probably at the level of the mitochondrial outer membrane.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Bari, Dept Med Biochem & Biol, I-70124 Bari, Italy	California Institute of Technology; Universita degli Studi di Bari Aldo Moro	Attardi, G (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.				NIGMS NIH HHS [GM11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi S, 1998, J BIOL CHEM, V273, P19892, DOI 10.1074/jbc.273.31.19892; Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FADOK VA, 1992, J IMMUNOL, V148, P2207; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; JONES DP, 1979, BIOCHIM BIOPHYS ACTA, V576, P17, DOI 10.1016/0005-2795(79)90480-X; KENNEDY FG, 1986, AM J PHYSIOL, V250, pC374, DOI 10.1152/ajpcell.1986.250.3.C374; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linsinger G, 1999, MOL CELL BIOL, V19, P3299; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mannella CA, 1998, BIOFACTORS, V8, P225, DOI 10.1002/biof.5520080309; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	37	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					606	615		10.1074/jbc.M007871200	http://dx.doi.org/10.1074/jbc.M007871200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027691	hybrid, Green Accepted			2022-12-27	WOS:000166280700082
J	Jiang, Z; Guo, Z; Saad, FA; Ellis, J; Zacksenhaus, E				Jiang, Z; Guo, Z; Saad, FA; Ellis, J; Zacksenhaus, E			Retinoblastoma gene promoter directs transgene expression exclusively to the nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RB1 PROMOTER; DIFFERENTIATION; PROTEIN; SKELETAL; ELEMENTS; MOUSE; EMBRYOGENESIS; PROLIFERATION; MUTATIONS; REGION	In human, germ line mutations in the tumor suppressor retinoblastoma (Rb) predispose individuals to retinoblastoma, whereas somatic inactivation of Rb contributes to the progression of a large spectrum of cancers. In mice, Rb is highly expressed in restricted cell lineages including the neurogenic, myogenic, and hematopoietic systems, and disruption of the gene leads to specific embryonic defects in these tissues. The symmetry between Rb expression and the defects in mutant mice suggest that transcriptional control of Rb during embryogenesis is pivotal for normal development. We have initiated studies to dissect the mechanisms of transcriptional regulation of Rb during development by promoter lacZ transgenic analysis. DNA sequences up to 6 kilobase pairs upstream of the mouse Rb promoter, isolated from two different genomic libraries, directed transgene expression exclusively to the developing nervous system, excluding skeletal muscles and liver. Expression of the transgene in the central and peripheral nervous systems, including the retina, recapitulated the expression of endogenous Rb during embryogenesis, A promoter region spanning similar to 250 base pairs upstream of the transcriptional starting site was sufficient to confer expression in the central and peripheral nervous systems. To determine whether this expression pattern was conserved, we isolated the human Rb 5' genomic region and generated transgenic mice expressing lacZ under control of a 1.6-kilobase pair human Rb promoter. The human Rb promoter lacZ mice also expressed the transgene primarily in the nervous system in several independent lines. Thus, transgene expression directed by both the human and mouse Rb promoters is restricted to a subset of tissues in which Rb is normally expressed during embryogenesis. Our findings demonstrate that regulatory elements directing Bb expression to the nervous system are delineated within a well defined core promoter and are regionally separated from elements, yet to be identified, that are required for expression of Rb in the developing hematopoietic and skeletal muscle systems.	Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Dept Med, Toronto, ON M5G 2M1, Canada; Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Dept Med Biophys, Toronto, ON M5G 2M1, Canada; Univ Toronto, Hosp Sick Children, Dev Biol Program, Toronto, ON M5G, Canada; Univ Toronto, Hosp Sick Children, Canc & Blood Program, Toronto, ON M5G, Canada; Univ Toronto, Dept Med Genet, Toronto, ON M5G, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Zacksenhaus, E (corresponding author), Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Dept Med, 67 Coll St,Rm 407, Toronto, ON M5G 2M1, Canada.		Saad, Fawzy A/HHC-9993-2022; Ellis, James/F-4789-2011; Zacksenhaus, Eldad/AAD-3584-2020	Ellis, James/0000-0002-4400-0091; 				BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; Biben C, 1996, DEV BIOL, V173, P200, DOI 10.1006/dbio.1996.0017; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; JIANG Z, 2000, IN PRESS DEV BIOL; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lehman DA, 1999, DEVELOPMENT, V126, P1793; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLACK RS, 1993, ONCOGENE, V8, P1585; Sowa Y, 1997, CANCER RES, V57, P3145; Tamir A, 1999, MOL CELL BIOL, V19, P4452; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YULE L, 2000, IN PRESS ONCOGENE; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zacksenhaus E, 1999, BBA-MOL CELL RES, V1451, P288, DOI 10.1016/S0167-4889(99)00103-2; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	33	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					593	600		10.1074/jbc.M005474200	http://dx.doi.org/10.1074/jbc.M005474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016928	hybrid			2022-12-27	WOS:000166280700080
J	Prowse, CN; Lew, J				Prowse, CN; Lew, J			Mechanism of activation of ERK2 by dual phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; MAP; DIFFUSION; LIMITS	The mitogen-activated protein (MAP) kinases ape characterized by their requirement for dual phosphorylation at a conserved threonine and tyrosine residue for catalytic activation. The structural consequences of dual-phosphorylation in the MAP kinase ERK2 (extracellular signal-regulated kinase 2) include active site closure, alignment of key catalytic residues that interact with ATP, and remodeling of the activation loop. in this study, we report the specific effects of dual phosphorylation on the individual catalytic reaction steps in ERK2, Dual phosphorylation leads to an increase in overall catalytic efficiency and turnover rate of approximately 600,000- and 50,000-fold, respectively. Solvent viscosometric studies reveal moderate decreases in the equilibrium dissociation constants (K-d) for both ATP and myelin basic protein. However, the majority of the overall rate enhancement is due to an increase in the rate of the phosphoryl group transfer step by approximately 60,000-fold. By comparison, the rate of the same step in the ATPase reaction is enhanced only 2000-fold. This suggests that optimizing the position of the invariant residues Lys(52) and Glu(69), which stabilize the phosphates of ATP, accounts for only part of the enhanced rate of phosphoryl group transfer in the kinase reaction. Thus, significant stabilization of the protein phosphoacceptor group must also occur. Our results demonstrate similarities between the activation mechanisms of ERK2 and the cell cycle control enzyme, Cdk2 (cyclin-dependent kinase 2), Rather than dual phosphorylation, however, activation of the latter is controlled by cyclin binding followed by phosphorylation at Thr(160).	Univ Calif Santa Barbara, Interdepartmental Program Biochem & Mol Biol, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif San Diego, Grad Program Biomed Sci, La Jolla, CA 92093 USA	University of California System; University of California Santa Barbara; University of California System; University of California San Diego	Lew, J (corresponding author), Univ Calif Santa Barbara, Interdepartmental Program Biochem & Mol Biol, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.							ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKATANI H, 1979, J PHYS CHEM-US, V83, P2662, DOI 10.1021/j100483a023; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; ZHANG FM, 1993, J MOL BIOL, V233, P550, DOI 10.1006/jmbi.1993.1532; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	18	63	63	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					99	103		10.1074/jbc.M008137200	http://dx.doi.org/10.1074/jbc.M008137200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016942	hybrid			2022-12-27	WOS:000166280700015
J	Yu, AX; Malek, TR				Yu, AX; Malek, TR			The proteasome regulates receptor-mediated endocytosis of interleukin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; DOWN-REGULATION; GAMMA-CHAIN; BETA-CHAIN; UBIQUITIN; LIGAND; DEGRADATION; INTERNALIZATION; PROTEIN; SUBUNIT	Recent studies have increasingly implicated the proteasome in the regulation of cell surface receptors. In the present study, we investigated the role of the proteasome for ligand-dependent endocytosis and degradation of the interleukin-2 (IL-S)-interleukin-2 receptor (IL-BR) complex. Proteasome inhibitors impaired internalization of IL-2IL-2R and prevented the lysosomal degradation of this cytokine. Based on time-course studies, proteasome activity is primarily required after initial endocytosis of the IL-2 IL-2R. Proteasome function was also necessary for the lysosomal degradation of IL-2 internalized by IL-BR that were comprised of cytoplasmic tailless beta- or alpha -subunits, suggesting that the target protein for the proteasome is independent of either the cytoplasmic tail of the IL-BR beta- or gammac-subunits and their associated signaling components. Therefore, a functional proteasome is required for optimal endocytosis of the IL-SR/ligand complex and is essential for the subsequent lysosomal degradation of IL-2, possibly by regulating trafficking to the lysosome.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA	University of Miami	Malek, TR (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, 1600 NW 10th Ave, Miami, FL 33136 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040114, R56AI040114] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40114] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DUPREZ V, 1992, J BIOL CHEM, V267, P18639; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FURSE RK, 1993, EUR J IMMUNOL, V23, P3181, DOI 10.1002/eji.1830231221; He YW, 1998, CRIT REV IMMUNOL, V18, P503, DOI 10.1615/CritRevImmunol.v18.i6.20; HE YW, 1995, J IMMUNOL, V154, P1596; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Malek TR, 2000, J IMMUNOL, V164, P2905, DOI 10.4049/jimmunol.164.6.2905; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; Strous GJ, 1999, J CELL SCI, V112, P1417; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; SUBTIL A, 1994, J CELL SCI, V107, P3461; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; WEISSMAN AM, 1986, P NATL ACAD SCI USA, V83, P1463, DOI 10.1073/pnas.83.5.1463; YEE NS, 1994, J BIOL CHEM, V269, P31991; Yu AX, 2000, J IMMUNOL, V165, P2556, DOI 10.4049/jimmunol.165.5.2556; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017	29	86	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					381	385		10.1074/jbc.M007991200	http://dx.doi.org/10.1074/jbc.M007991200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11032838	hybrid			2022-12-27	WOS:000166280700052
J	Brown, K; Djinovic-Carugo, K; Haltia, T; Cabrito, I; Saraste, M; Moura, JJG; Moura, I; Tegoni, M; Cambillau, C				Brown, K; Djinovic-Carugo, K; Haltia, T; Cabrito, I; Saraste, M; Moura, JJG; Moura, I; Tegoni, M; Cambillau, C			Revisiting the catalytic CuZ cluster of nitrous oxide (N2O) reductase - Evidence of a bridging inorganic sulfur	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-STUTZERI; COPPER SITES	Nitrous-oxide reductases (N2OR) catalyze the two-electron reduction of N2O to N-2. The crystal structure of N(2)ORs from Pseudomonas nautica (Pn) and Paracoccus denitrificans (Pd) were solved at resolutions of 2.4 and 1.6 Angstrom respectively. The Pn N2OR structure revealed that the catalytic CuZ center belongs to a new type of metal cluster in which four copper ions are liganded by seven histidine residues. A bridging oxygen moiety and two other hydroxide ligands were proposed to complete the ligation scheme (Brown, K., Tegoni, RI., Prudencio, M., Pereira, A. S., Besson, S., Moura, J. J. G., Moura, I., and Cambillau, C, (2000) Nat. Struct Biol. 7, 191-195). However, in the CuZ cluster, inorganic sulfur chemical determination and the high resolution structure of Pd N2OR identified a bridging inorganic sulfur instead of an oxygen, This result reconciles the novel CuZ cluster with the hitherto puzzling spectroscopic data.	Architecture & Fonct Macromol Biol, UMR 6098, F-13402 Marseille 20, France; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, CQFB, P-2825114 Monte De Caparica, Portugal; Sincrotrone Trieste, Struct Biol Lab, I-34012 Bassovizza, TS, Italy; European Mol Biol Lab, D-69012 Heidelberg, Germany; Univ Helsinki, Helsinki Bioenerget Grp, Dept Med Chem, Inst Biomed Sci, FIN-00014 Helsinki, Finland	UDICE-French Research Universities; Aix-Marseille Universite; Universidade Nova de Lisboa; Elettra Sincrotrone Trieste; European Molecular Biology Laboratory (EMBL); University of Helsinki	Cambillau, C (corresponding author), Architecture & Fonct Macromol Biol, UMR 6098, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	cambillau@afmb.cnrs-mrs.fr	Moura, José J G/D-6426-2013; Djinovic-Carugo, Kristina/AAW-1167-2021; Moura, Isabel/D-6339-2013	Moura, José J G/0000-0002-4726-2388; Djinovic-Carugo, Kristina/0000-0003-0252-2972; Moura, Isabel/0000-0003-0971-4977				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Brown K, 2000, NAT STRUCT BIOL, V7, P191; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DOOLEY DM, 1987, J AM CHEM SOC, V109, P6730, DOI 10.1021/ja00256a029; DOOLEY DM, 1991, INORG CHEM, V30, P3006, DOI 10.1021/ic00015a013; Farrar JA, 1998, P NATL ACAD SCI USA, V95, P9891, DOI 10.1073/pnas.95.17.9891; FARRAR JA, 1991, FEBS LETT, V294, P11, DOI 10.1016/0014-5793(91)81331-2; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POILLON WN, 1963, BIOCHIM BIOPHYS ACTA, V77, P27, DOI 10.1016/0006-3002(63)90466-9; Prudencio M, 2000, BIOCHEMISTRY-US, V39, P3899, DOI 10.1021/bi9926328; Rasmussen T, 2000, BIOCHEMISTRY-US, V39, P12753, DOI 10.1021/bi001811i; RIESTER J, 1989, EUR J BIOCHEM, V178, P751, DOI 10.1111/j.1432-1033.1989.tb14506.x; Roussel A, 1991, SILICON GRAPHICS GEO, P81; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	19	160	161	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41133	41136		10.1074/jbc.M008617200	http://dx.doi.org/10.1074/jbc.M008617200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024061	hybrid			2022-12-27	WOS:000166114600064
J	Datta, SA; Rao, CM				Datta, SA; Rao, CM			Packing-induced conformational and functional changes in the subunits of alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK PROTEINS; NON-LENTICULAR TISSUES; HUMAN LENS CRYSTALLINS; B-CRYSTALLIN; A-CRYSTALLIN; QUATERNARY STRUCTURE; CELL-DIFFERENTIATION; MOLECULAR CHAPERONE; CIRCULAR-DICHROISM	The heteroaggregate alpha -crystallin and homoaggregates of its subunits, alphaA- and alphaB-crystallins, function like molecular chaperones and prevent the aggregation of several proteins. Although modulation of the chaperone-like activity of alpha -crystallin by both temperature and chaotropic agents has been demonstrated in vitro, the mechanism(s) of its regulation in vivo have not been elucidated. The subunits of alpha -crystallin exchange freely, resulting in its dynamic and variable quaternary structure. Mixed aggregates of the zeta -crystallins and other mammalian small heat shock proteins (sHSPs) have also been observed in vivo. We have investigated the time-dependent structural and functional changes during the course of heteroaggregate formation by the exchange of subunits between homoaggregates of alphaA- and alphaB-crystallins. Native isoelectric focusing was used to follow the time course of subunit exchange. Circular dichroism revealed large tertiary structural alterations in the subunits upon subunit exchange and packing into heteroaggregates, indicating specific homologous and heterologous interactions between the subunits. Subunit exchange also resulted in quaternary structural changes as demonstrated by gel filtration chromatography. Interestingly, we found time-dependent changes in chaperone-like activity against the dithiothreitol-induced aggregation of insulin, which correlated with subunit exchange and the resulting tertiary and quaternary structural changes. Heteroaggregates of varying subunit composition, as observed during eye lens epithelial cell differentiation, generated by subunit exchange displayed differential chaperone-like activity. It was possible to alter chaperone-like activity of preexisting oligomeric sHSPs by alteration of subunit composition by subunit exchange. Our results demonstrate that subunit exchange and the resulting structural and functional changes observed could constitute a mechanism of regulation of chaperone-like activity of alpha -crystallin (and possibly other mammalian sHSPs) in vivo.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Rao, CM (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.			Datta, Siddhartha/0000-0002-4098-7490				AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V102, P775; BINDELS JG, 1979, OPHTHALMIC RES, V11, P411; BLOEMENDAL B, 1981, MOL CELLULAR BIOL EY, P1; BLOEMENDAL H, 1962, EXP EYE RES, V1, P300, DOI 10.1016/S0014-4835(62)80015-3; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BRAHMA SK, 1987, CURR EYE RES, V6, P1291, DOI 10.3109/02713688708997554; CHIESA R, 1989, CURR EYE RES, V8, P151, DOI 10.3109/02713688908995186; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; CLAUWAERT J, 1989, CURR EYE RES, V8, P397, DOI 10.3109/02713688908996387; CLAYTON RM, 1974, EYE, V5, P399; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; DEBLOCK J, 1986, LENS RES, V3, P119; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1982, Z SAUGETIERKD, V47, P257; DELCOUR J, 1974, BIOCHEM BIOPH RES CO, V57, P134, DOI 10.1016/S0006-291X(74)80367-0; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Haley DA, 1999, EXP EYE RES, V68, P133, DOI 10.1006/exer.1998.0610; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JEDZINIAK JA, 1972, INVEST OPHTH VISUAL, V11, P905; KATO K, 1993, BIOCHIM BIOPHYS ACTA, V1175, P257, DOI 10.1016/0167-4889(93)90214-A; Kato K, 1997, CELL STRESS CHAPERON, V2, P199, DOI 10.1379/1466-1268(1997)002<0199:MOTAIE>2.3.CO;2; KATO K, 1992, J BIOL CHEM, V267, P7718; KELLEY MJ, 1993, J BIOL CHEM, V268, P18844; KLEMENZ R, 1994, VERH DEUT G, V78, P34; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KLEMENZ R, 1993, J CELL BIOL, V120, P103; LI LK, 1972, EXP EYE RES, V13, P110, DOI 10.1016/0014-4835(72)90023-1; LI LK, 1973, EXP EYE RES, V15, P179, DOI 10.1016/0014-4835(73)90117-6; LI LK, 1974, EXP EYE RES, V19, P49, DOI 10.1016/0014-4835(74)90071-2; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MCFALLNGAI MJ, 1985, EXP EYE RES, V41, P745, DOI 10.1016/0014-4835(85)90183-6; MITTEN KP, 1997, BIOCHEM BIOPH RES CO, V253, P69; NENE V, 1986, MOL BIOCHEM PARASIT, V21, P179, DOI 10.1016/0166-6851(86)90021-6; PURI N, 1983, EUR J BIOCHEM, V134, P321, DOI 10.1111/j.1432-1033.1983.tb07569.x; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; Rao CM, 1998, INT J BIOL MACROMOL, V22, P271; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; SIEZEN RJ, 1982, EXP EYE RES, V34, P969, DOI 10.1016/0014-4835(82)90077-X; SIEZEN RJ, 1978, EUR J BIOCHEM, V91, P387, DOI 10.1111/j.1432-1033.1978.tb12691.x; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SIEZEN RJ, 1979, EXP EYE RES, V28, P551, DOI 10.1016/0014-4835(79)90043-5; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V749, P227, DOI 10.1016/0167-4838(83)90229-7; SPECTOR A, 1974, INVEST OPHTH VISUAL, V13, P795; SPECTOR A, 1971, INVEST OPHTH VISUAL, V10, P677; SPECTOR A, 1973, EXP EYE RES, V16, P115, DOI 10.1016/0014-4835(73)90306-0; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Sun TX, 1998, FEBS LETT, V430, P401, DOI 10.1016/S0014-5793(98)00707-8; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1985, EXP EYE RES, V40, P393, DOI 10.1016/0014-4835(85)90152-6; THOMSON JA, 1989, BIOCHIM BIOPHYS ACTA, V994, P246, DOI 10.1016/0167-4838(89)90300-2; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; VANDENOETELAAR PJM, 1987, J CHROMATOGR, V398, P323, DOI 10.1016/S0021-9673(01)96520-3; VANDEROU.FJ, 1974, EUR J BIOCHEM, V49, P157; Vanhoudt J, 1998, INT J BIOL MACROMOL, V22, P229, DOI 10.1016/S0141-8130(98)00020-8; VANKAMP GJ, 1974, BIOCHIM BIOPHYS ACTA, V342, P89, DOI 10.1016/0005-2795(74)90109-3; VERETOUT F, 1989, J MOL BIOL, V205, P713, DOI 10.1016/0022-2836(89)90316-1; VERMORKEN AJM, 1978, NATURE, V271, P779, DOI 10.1038/271779a0; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZANTEMA A, 1989, J VIROL, V63, P3368, DOI 10.1128/JVI.63.8.3368-3375.1989	82	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41004	41010		10.1074/jbc.M007686200	http://dx.doi.org/10.1074/jbc.M007686200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024058	hybrid			2022-12-27	WOS:000166114600048
J	Zhang, H; Thomsen, JS; Johansson, L; Gustafsson, JA; Treuter, E				Zhang, H; Thomsen, JS; Johansson, L; Gustafsson, JA; Treuter, E			DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; LIGAND-BINDING; MOLECULAR-BASIS; N-COR; EXPRESSION; GENE; COACTIVATOR; ALPHA; BETA; DOMAIN	We have discovered that the orphan receptor DAX-1 (NROB1) interacts with the estrogen receptors ER alpha and ER beta. Interaction occurs with ligand-activated ERs in solution and on DNA and is mediated by the unique DAX-1 N-terminal repeat domain. Each of the three repeats contains a leucine-rich receptor-binding motif, known as the LXXLL motif, which is usually found in nuclear receptor coactivators. We have demonstrated that DAX-1 functions as an inhibitor of ER activation in mammalian cells and suggest a mechanism involving two sequential events, occupation of the ligand-induced coactivator-binding surface and subsequent recruitment of corepressors. Accordingly, we propose that DAX-1 itself acts as a corepressor for ERs. Because DAX-1 is coexpressed with ERs in reproductive tissues, these interactions could play significant roles by influencing estrogen signaling pathways. Our results point at functional similarities between DAX-1 and the orphan receptor SHP (NROB2) in that they have acquired features of transcriptional coregulators that are unique for members of the nuclear receptor family.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Karolinska Institutet	Treuter, E (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.	eckardt.treuter@cbt.ki.se		thomsen, jane/0000-0002-9336-5695; Treuter, Eckardt/0000-0002-4147-8989				Abe S, 1999, AM J MED GENET, V84, P87, DOI 10.1002/(SICI)1096-8628(19990521)84:2<87::AID-AJMG1>3.0.CO;2-7; Albrecht ED, 1999, ENDOCRINOLOGY, V140, P5953, DOI 10.1210/en.140.12.5953; Altincicek B, 2000, J BIOL CHEM, V275, P7662, DOI 10.1074/jbc.275.11.7662; Bae DS, 1996, ENDOCRINOLOGY, V137, P3921, DOI 10.1210/en.137.9.3921; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Glass CK, 2000, GENE DEV, V14, P121; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kawabe K, 1999, MOL ENDOCRINOL, V13, P1267, DOI 10.1210/me.13.8.1267; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lalli E, 1997, MOL ENDOCRINOL, V11, P1950, DOI 10.1210/me.11.13.1950; Lalli E, 1998, ENDOCRINOLOGY, V139, P4237, DOI 10.1210/en.139.10.4237; Lalli E, 2000, MOL CELL BIOL, V20, P4910, DOI 10.1128/MCB.20.13.4910-4921.2000; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Lemmen JG, 1999, MECH DEVELOP, V81, P163, DOI 10.1016/S0925-4773(98)00223-8; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Saunders PTK, 1997, J ENDOCRINOL, V154, pR13, DOI 10.1677/joe.0.154R013; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CA, 2000, J MOL ENDOCRINOL, V24, P23, DOI 10.1677/jme.0.0240023; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; Taylor AH, 2000, J MOL ENDOCRINOL, V24, P145, DOI 10.1677/jme.0.0240145; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; VANDERPELT AMM, 1999, ENDOCRINOLOGY, V140, P478; Yu RN, 1998, TRENDS ENDOCRIN MET, V9, P169, DOI 10.1016/S1043-2760(98)00048-4; Yu RN, 1998, NAT GENET, V20, P353, DOI 10.1038/3822; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899	50	147	153	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39855	39859		10.1074/jbc.C000567200	http://dx.doi.org/10.1074/jbc.C000567200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11053406	hybrid			2022-12-27	WOS:000166039500011
J	MacKeigan, JP; Collins, TS; Ting, JPY				MacKeigan, JP; Collins, TS; Ting, JPY			MEK inhibition enhances paclitaxel-induced tumor apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; INDUCED CELL-DEATH; C-JUN; SIGNAL-TRANSDUCTION; IN-VIVO; TAXOL; PATHWAY; PHOSPHORYLATION; BCL-2	The anti-cancer drug paclitaxel (Taxol) alters microtubule assembly and activates pro-apoptotic signaling pathways. Previously, we and others found that paclitaxel activates endogenous JNK in tumor cells, and the activation of JNK contributes to tumor cell apoptosis. Here we find that paclitaxel activates the prosurvival MEK/ERK pathway, which conversely may compromise the efficacy of paclitaxel. Hence, a combination treatment of paclitaxel and MER inhibitors was pursued to determine whether this treatment could lead to enhanced apoptosis. The inhibition of MEK/ERK with a pharmacologic inhibitor, U0126, together with paclitaxel resulted in a dramatic enhancement of apoptosis that is four times more than the additive value of the two drugs alone. Enhanced apoptosis was verified by the terminal transferase-mediated dUTP nick end labeling assay, by an enzyme-linked immunosorbent assay for histone-associated DNA fragments, and by flow cytometric analysis for DNA content. Specificity of the pharmacologic inhibitor was confirmed by the use of (a) a second MEK/ERK inhibitor and (b) a transdominant-negative MEK. Enhanced apoptosis was verified in breast, ovarian, and lung tumor cell lines, suggesting this effect is not cell type-specific. This is the first report of enhanced apoptosis detected in the presence of paclitaxel and MEK inhibition and suggests a new anticancer strategy.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ting, JPY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Campus BOx 7295, Chapel Hill, NC 27599 USA.			MacKeigan, Jeffrey/0000-0002-0198-5679	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045580] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45580, AI 41751] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amato SF, 1998, CANCER RES, V58, P241; Baselga J, 1998, CANCER RES, V58, P2825; BHALLA K, 1993, LEUKEMIA, V7, P563; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ETTINGER DS, 1993, J NATL CANC I MONOGR, V15, P177; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1997, CANCER RES, V57, P229; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SETH A, 1992, J BIOL CHEM, V267, P24796; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Torres K, 1998, CANCER RES, V58, P3620; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	34	206	216	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38953	38956		10.1074/jbc.C000684200	http://dx.doi.org/10.1074/jbc.C000684200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11038347	Green Published, hybrid			2022-12-27	WOS:000165953100002
J	Robert, V; Massimino, ML; Tosello, V; Marsault, R; Cantini, M; Sorrentino, V; Pozzan, T				Robert, V; Massimino, ML; Tosello, V; Marsault, R; Cantini, M; Sorrentino, V; Pozzan, T			Alteration in calcium handling at the subcellular level in mdx myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; ENDOPLASMIC-RETICULUM; DYSTROPHIC MDX; APOPTOSIS; HOMEOSTASIS; CHANNELS	In this study, we have tested the hypothesis that augmented [Ca2+] in subcellular regions or organelles, which are known to play a key role in cell survival, is the missing link between Ca2+ homeostasis alterations and muscular degeneration associated with muscular dystrophy. To this end, different targeted chimeras of the Ca2+-sensitive photoprotein aequorin have been transiently expressed in subcellular compartments of skeletal. myotubes of mdx: mice, the animal model of Duchenne muscular dystrophy. Direct measurements of the [Ca2+] in the sarcoplasmic reticulum, [Ca2+](sr), show a higher steady state level at rest and a larger drop after KCl-induced depolarization in mdx compared with control myotubes. The peaks in [Ca2+] occurring in the mitochondrial matrix of mdx myotubes are significantly larger than in controls upon KCl-induced depolarization or caffeine application. The augmented response of mitochondria precedes the alterations in the Ca2+ responses of the cytosol and of the cytoplasmic region beneath the membrane, which become significant only at a later stage of myotube differentiation. Taking into account the key role played by mitochondria Ca2+ handling in the control of cell death, our data suggest that mitochondria are potential targets of impaired Ca2+ homeostasis in muscular dystrophy.	Univ Padua, Dept Biomed Sci, CNR, Ctr Biomembranes, I-35121 Padua, Italy; Ist Sci San Raffaele, DIBIT, I-20132 Milan, Italy; Univ Siena, Dept Neurosci, Sect Mol Med, I-53100 Siena, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; Vita-Salute San Raffaele University; University of Siena	Robert, V (corresponding author), Univ Padua, Dept Biomed Sci, CNR, Ctr Biomembranes, Via G Colombo 3, I-35121 Padua, Italy.	pozzan@civ.bio.unipd.it	Sorrentino, Vincenzo/A-4793-2014; Massimino, Maria Lina/AAX-8773-2020; Tosello, Valeria/N-1010-2016	Sorrentino, Vincenzo/0000-0002-8573-8631; Tosello, Valeria/0000-0001-9560-340X; massimino, maria lina/0000-0002-1839-1404	Telethon [1226] Funding Source: Medline	Telethon(Fondazione Telethon)		BAKKER AJ, 1993, J PHYSIOL-LONDON, V460, P1; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 1997, MOL BIOL CELL, V8, P129, DOI 10.1091/mbc.8.1.129; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GAILLY P, 1993, CELL CALCIUM, V14, P473, DOI 10.1016/0143-4160(93)90006-R; HEAD SI, 1993, J PHYSIOL-LONDON, V469, P11, DOI 10.1113/jphysiol.1993.sp019801; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOLF FW, 1996, AM J PHYSIOL, V271, pC1325; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuznetsov AV, 1998, MOL CELL BIOCHEM, V183, P87, DOI 10.1023/A:1006868130002; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; PRESSMAR J, 1994, PFLUEGERS ARCH, V6, P499; RIVETBASTIDE M, 1993, CELL CALCIUM, V14, P563, DOI 10.1016/0143-4160(93)90077-J; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Robert V, 1998, J BIOL CHEM, V273, P30372, DOI 10.1074/jbc.273.46.30372; Sandri M, 1998, LAB INVEST, V78, P1005; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; TIDBALL JG, 1995, J CELL SCI, V108, P2197; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0	25	121	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4647	4651		10.1074/jbc.M006337200	http://dx.doi.org/10.1074/jbc.M006337200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11029464	hybrid			2022-12-27	WOS:000168484300018
J	Challet, C; Maechler, P; Wollheim, CB; Ruegg, UT				Challet, C; Maechler, P; Wollheim, CB; Ruegg, UT			Mitochondrial calcium oscillations in C2C12 myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CA2+ OSCILLATIONS; SKELETAL-MUSCLE MYOTUBES; MDX MOUSE; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; BETA-CELL; AEQUORIN; HOMEOSTASIS; RESPONSES; CHANNELS	Mitochondrial Ca2+ concentration ([Ca2+],) was monitored in C2C12 skeletal muscle cells stably expressing the Ca2+-sensitive photoprotein aequorin targeted to mitochondria. In myotubes, KCI-induced depolarization caused a peak of 3.03 +/- 0.14 muM [Ca2+], followed by an oscillatory second phase (5.1 +/- 0.1 per min). Chelation of extracellular Ca2+ or blockade of the voltage-operated Ca2+ channel attenuated both phases of the KCl response. The inhibitor of the sarcoplasmic reticulum Ca2+-ATPase, cyclopiazonic acid, reduced the amplitude of the KCl-induced [Ca2+](m) peak and prevented the oscillations, suggesting that these were generated intracellularly, No such [Ca2+](m) oscillations occurred with the nicotinic agonist carbachol, cyclopiazonic acid alone, or the purinergic agonist ATP. In contrast, caffeine produced an oscillatory behavior, indicating a role of ryanodine receptors as mediators of the oscillations. The [Ca2+](m) response was desensitized when cells were exposed to two consecutive challenges with KCl separated by a 5-min wash, whereas a second pulse of carbachol potentiated [Ca2+](m) indicating differences in intracellular Ca2+ redistribution. Cross-desensitization between KCl and carbachol and cross-potentiation between carbachol and KCl were observed. These results suggest that close contacts between mitochondria and sarcoplasmic reticulum exist permitting Ca2+ ex changes during KCl depolarization. These newly demonstrated dynamic changes in [Ca2+](m) in stimulated skeletal muscle cells might contribute to the understanding of physiological and pathological processes in muscular disorders.	Univ Lausanne, Pharmacol Grp, Sch Pharm, BEP, CH-1015 Lausanne, Switzerland; Univ Geneva, Med Ctr, Div Clin Biochem, Dept Internal Med, CH-1211 Geneva 4, Switzerland	University of Lausanne; University of Geneva	Ruegg, UT (corresponding author), Univ Lausanne, Pharmacol Grp, Sch Pharm, BEP, CH-1015 Lausanne, Switzerland.			Maechler, Pierre/0000-0002-2005-1433; RUEGG, Urs/0000-0001-6078-8280				Alderton JM, 2000, J BIOL CHEM, V275, P9452, DOI 10.1074/jbc.275.13.9452; ALLEN DG, 1978, NATURE, V273, P509, DOI 10.1038/273509a0; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 1997, MOL BIOL CELL, V8, P129, DOI 10.1091/mbc.8.1.129; Brini M, 2000, CELL MOL LIFE SCI, V57, P354, DOI 10.1007/PL00000698; COBBOLD PH, 1983, J CELL SCI, V61, P123; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; Engel AG, 1994, MYOLOGY BASIC CLIN, V2, P1133; GAILLY P, 1993, CELL CALCIUM, V14, P473, DOI 10.1016/0143-4160(93)90006-R; Gillis JM, 1999, J MUSCLE RES CELL M, V20, P605, DOI 10.1023/A:1005545325254; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAROOTUNIAN AT, 1991, CELL CALCIUM, V12, P153, DOI 10.1016/0143-4160(91)90017-9; Henning RH, 1996, BRIT J PHARMACOL, V117, P1785, DOI 10.1111/j.1476-5381.1996.tb15355.x; Hopf FW, 1996, AM J PHYSIOL-CELL PH, V271, pC1325, DOI 10.1152/ajpcell.1996.271.4.C1325; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; Jouaville LS, 1998, MOL CELL BIOCHEM, V184, P371, DOI 10.1023/A:1006850121769; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Leijendekker WJ, 1996, BRIT J PHARMACOL, V118, P611, DOI 10.1111/j.1476-5381.1996.tb15445.x; LUCASHERON B, 1994, NEUROSCI LETT, V169, P97, DOI 10.1016/0304-3940(94)90365-4; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; MCCORMACK JG, 1994, NEWS PHYSIOL SCI, V9, P71; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nakazaki M, 1998, DIABETOLOGIA, V41, P279, DOI 10.1007/s001250050904; Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046; Ogata T, 1997, ANAT REC, V248, P214; Pulido SM, 1998, FEBS LETT, V439, P357, DOI 10.1016/S0014-5793(98)01399-4; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robert V, 1998, J BIOL CHEM, V273, P30372, DOI 10.1074/jbc.273.46.30372; Ruegg Urs T., 1999, Trends in Pharmacological Sciences, V20, P351, DOI 10.1016/S0165-6147(99)01377-2; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Ward CW, 2000, J PHYSIOL-LONDON, V525, P91, DOI 10.1111/j.1469-7793.2000.t01-2-00091.x; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345	42	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3791	3797		10.1074/jbc.M006209200	http://dx.doi.org/10.1074/jbc.M006209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11036072	hybrid			2022-12-27	WOS:000166921200011
J	Salomons, FA; Faber, KN; Veenhuis, M; van der Klei, IJ				Salomons, FA; Faber, KN; Veenhuis, M; van der Klei, IJ			Peroxisomal remnant structures in Hansenula polymorpha pex5 cells can develop into normal peroxisomes upon induction of the PTS2 protein amine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEIN; SACCHAROMYCES-CEREVISIAE; METHANOL METABOLISM; TARGETING SIGNAL; PICHIA-PASTORIS; GENE ENCODES; BIOGENESIS; IMPORT; MUTANT; COMPLEMENTATION	have analyzed the properties of peroxisomal remnants in Hantsenula polymorpha pex5 cells. In such cells PTS1 matrix protein import is fully impaired. In H. polymorpha pex5 cells, grown on ethanol/ammonium sulfate, conditions that repressed the PTS2 protein amine oxidase (AMO), peroxisomal structures were below the limit of detection. In methanol/ammonium sulfate-grown cells, normal peroxisomes are absent, but a few small membranous structures were observed that apparently represented peroxisomal ghosts since they contained Pex14p. These structures were the target of a Pex10p.myc fusion protein that was produced in pex5 cells under the control of the homologous alcohol oxidase promoter (strain pex5::P-AOX.PEX10.MYC). Glycerol/methanol/ammonium sulfate-grown cells of this transformant were placed in fresh glucose/methylamine media, conditions that fully repress the synthesis of the Pex10p.myc fusion protein but induce the synthesis of AMO. Two hours after the shift Pex10p.myc-containing structures were detectable that had accumulated newly synthesized AMO protein and which during further cultivation developed in normal peroxisomes. Concurrently, the remaining portion of these structures was rapidly degraded. These findings indicate that peroxisomal remnants in pex5 cells can develop into peroxisomes. Also, as for normal peroxisomes in H. polymorpha, apparently a minor portion of these structures actually take part in the development of these organelles.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	University of Groningen	van der Klei, IJ (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.		van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679				Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; BRODSKY JL, 1998, PROTEIN TARGETING TR, P169; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; DOUMA AC, 1985, ARCH MICROBIOL, V143, P237, DOI 10.1007/BF00411242; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; FABER KN, 1994, P NATL ACAD SCI USA, V91, P12985, DOI 10.1073/pnas.91.26.12985; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; Gotte K, 1998, MOL CELL BIOL, V18, P616; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; HOVIUS R, 1998, PROTEIN TARGETING TR, P231; Kiel JAKW, 1999, YEAST, V15, P1059, DOI 10.1002/(SICI)1097-0061(199908)15:11<1059::AID-YEA434>3.0.CO;2-I; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Kragler F, 1998, P NATL ACAD SCI USA, V95, P13336, DOI 10.1073/pnas.95.22.13336; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; NUTTLEY WM, 1995, GENE, V160, P33, DOI 10.1016/0378-1119(95)00230-4; ROGGENKAMP R, 1989, MOL CELL BIOL, V9, P988, DOI 10.1128/MCB.9.3.988; ROGGENKAMP R, 1986, MOL GEN GENET, V202, P302, DOI 10.1007/BF00331655; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; van der Klei IJ, 1998, CURR GENET, V34, P1, DOI 10.1007/s002940050360; van der Klei IJ, 1998, EMBO J, V17, P3608, DOI 10.1093/emboj/17.13.3608; vanderKlei IJ, 1996, ANN NY ACAD SCI, V804, P47; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERKLEI IJ, 1991, ARCH MICROBIOL, V156, P15, DOI 10.1007/BF00418181; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; VEENHUIS M, 1981, ARCH MICROBIOL, V129, P35, DOI 10.1007/BF00417176; Veenhuis M, 1996, FEBS LETT, V383, P114, DOI 10.1016/0014-5793(96)00220-7; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; VEENHUIS M, 1989, ARCH MICROBIOL, V151, P105, DOI 10.1007/BF00414422; VEENHUIS M, 1987, PEROXISOMES BIOL MED, P436; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963; WATERHAM HR, 1993, EMBO J, V12, P4785, DOI 10.1002/j.1460-2075.1993.tb06167.x; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Yamasaki M, 1999, J BIOL CHEM, V274, P35293, DOI 10.1074/jbc.274.50.35293	48	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4190	4198		10.1074/jbc.M008476200	http://dx.doi.org/10.1074/jbc.M008476200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050097	hybrid, Green Published			2022-12-27	WOS:000166921200062
J	Dulhunty, A; Gage, P; Curtis, S; Chelvanayagam, G; Board, P				Dulhunty, A; Gage, P; Curtis, S; Chelvanayagam, G; Board, P			The glutathione transferase structural family includes a nuclear chloride channel and a ryanodine receptor calcium release channel modulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PROTEIN; LYMPHOCYTES; EXPRESSION; MUSCLE; ZETA; GENE; ADP	The ubiquitous glutathione transferases (GSTs) catalyze glutathione conjugation to many compounds and have other diverse functions that continue to, be discovered. We noticed sequence similarities between Omega class GSTs and a nuclear chloride channel, NCC27 (CLIC1), and show here that NCC27 belongs to the GST structural family. The structural homology prompted us to investigate whether the human Omega class glutathione transferase GSTO1-1 forms or modulates ion channels. We find that GSTO1-1 modulates ryanodine receptors (RyR), which are calcium channels in the endoplasmic reticulum of various cells. Cardiac RyR2 activity was inhibited by GSTO1-1, whereas skeletal muscle RyR1 activity was potentiated. An enzymatically active conformation of GSTO1-1 was required for inhibition of RyR2, and mutation of the active site cysteine (Cys-32 --> Ala) abolished the inhibitory activity. We propose a novel role for GSTO1-1 in protecting cells containing RyR2 from apoptosis induced by Ca2+ mobilization from intracellular stores.	Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research	Board, P (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, POB 334, Canberra, ACT 2601, Australia.		Dulhunty, Angela/AAO-5421-2020	Dulhunty, Angela/0000-0001-9493-4944				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; Fernandez-Canon JM, 1998, J BIOL CHEM, V273, P329, DOI 10.1074/jbc.273.1.329; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; Kermode H, 1998, BIOPHYS J, V74, P1296, DOI 10.1016/S0006-3495(98)77843-9; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; Laver DR, 1997, BIOPHYS J, V73, P1913, DOI 10.1016/S0006-3495(97)78222-5; LAVER DR, 1995, J MEMBRANE BIOL, V147, P7; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; Mariot P, 2000, PROSTATE, V43, P205; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MINIUM EW, 1993, STAT REASONING REASO; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Sei Y, 1999, J BIOL CHEM, V274, P5995, DOI 10.1074/jbc.274.9.5995; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tong Z, 1998, CHEM RES TOXICOL, V11, P1332, DOI 10.1021/tx980144f; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Villafania A, 2000, ANN CLIN LAB SCI, V30, P57; Whittington AT, 1999, BIOCHEM J, V337, P141, DOI 10.1042/0264-6021:3370141; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; Xu L, 1998, ANN NY ACAD SCI, V853, P130	28	222	231	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3319	3323		10.1074/jbc.M007874200	http://dx.doi.org/10.1074/jbc.M007874200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035031	hybrid			2022-12-27	WOS:000166784900045
J	Eisen, A; Utley, RT; Nourani, A; Allard, S; Schmidt, P; Lane, WS; Lucchesi, JC; Cote, J				Eisen, A; Utley, RT; Nourani, A; Allard, S; Schmidt, P; Lane, WS; Lucchesi, JC; Cote, J			The yeast NuA4 and Drosophila MSL complexes contain homologous subunits important for transcription regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE COMPLEXES; DOSAGE COMPENSATION; X-CHROMOSOME; SACCHAROMYCES-CEREVISIAE; ACTIVATION DOMAIN; PROTEIN DATABASE; MALELESS PROTEIN; IN-VIVO; CHROMATIN; GENE	In Drosophila, the MSL complex is required for the dosage compensation of X-linked genes in males and contains a histone acetyltransferase, MOF. A point mutation in the MOF acetyl-CoA-binding site results in male-specific lethality. Yeast Esa1p, a MOF homolog, is essential for cell cycle progression and is the catalytic subunit of the NuA4 acetyltransferase complex. Here we report that NuA4 purified from yeast with a point mutation in the acetyl-CoA-binding domain of Esa1p exhibits a strong decrease in histone acetyltransferase activity, yet has no effect on growth. We demonstrate that Eaf3p (Esa1p-associated factor-3 protein), a yeast protein homologous to the Drosophila dosage compensation protein MSL3, is also a stable component of the NuA4 complex. Unlike other subunits of the complex, it is not essential, and the deletion mutant has no growth phenotype. NuA4 purified from the mutant strain has a decreased apparent molecular mass, but retains wildtype levels of histone H4 acetyltransferase activity. The EAF3 deletion and the ESA1 mutation lead to a decrease in PHO5 gene expression; the EAF3 deletion also significantly reduces HIS4 and TRP4 expressions. These results, together with those previously obtained with both the MSL and NuA4 complexes, underscore the importance of targeted histone H4 acetylation for the gene-specific activation of transcription.	Univ Laval, Canc Res Ctr, Hotel Dieu Quebec, Ctr Hosp Univ Quebec, Quebec City, PQ G1R 2J6, Canada; Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA	Laval University; Emory University; Harvard University	Cote, J (corresponding author), Univ Laval, Canc Res Ctr, Hotel Dieu Quebec, Ctr Hosp Univ Quebec, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.		Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X				Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Ehrenstein D, 1998, SCIENCE, V279, P177, DOI 10.1126/science.279.5348.177; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Franke A, 1999, MOL CELL, V4, P117, DOI 10.1016/S1097-2765(00)80193-8; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Gu WG, 1998, DEV GENET, V22, P56, DOI 10.1002/(SICI)1520-6408(1998)22:1<56::AID-DVG6>3.0.CO;2-6; Harlow E., 1988, ANTIBODIES LAB MANUA; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jiang YW, 1996, GENE DEV, V10, P604, DOI 10.1101/gad.10.5.604; John S, 2000, GENE DEV, V14, P1196; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee CG, 1997, EMBO J, V16, P2671, DOI 10.1093/emboj/16.10.2671; Lennon JC, 1998, MOL CELL BIOL, V18, P5771, DOI 10.1128/MCB.18.10.5771; Lucchesi JC, 1996, BIOESSAYS, V18, P541, DOI 10.1002/bies.950180705; Lucchesi JC, 1998, CURR OPIN GENET DEV, V8, P179, DOI 10.1016/S0959-437X(98)80139-1; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Radcliffe P, 1998, MOL BIOL CELL, V9, P1757, DOI 10.1091/mbc.9.7.1757; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Scott MJ, 2000, EMBO J, V19, P144, DOI 10.1093/emboj/19.1.144; Sinclair DAR, 1998, GENETICS, V148, P211; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Stankunas K, 1998, DEVELOPMENT, V125, P4055; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	60	112	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3484	3491		10.1074/jbc.M008159200	http://dx.doi.org/10.1074/jbc.M008159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11036083	hybrid			2022-12-27	WOS:000166784900065
J	Kudlacek, O; Mitterauer, T; Nanoff, C; Hohenegger, M; Tang, WJ; Freissmuth, M; Kleuss, C				Kudlacek, O; Mitterauer, T; Nanoff, C; Hohenegger, M; Tang, WJ; Freissmuth, M; Kleuss, C			Inhibition of adenylyl and guanylyl cyclase isoforms by the antiviral drug foscarnet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; CATALYTIC ACTIVITY; SIGNAL-TRANSDUCTION; GS-ALPHA; PROTEIN; RECEPTOR; SUBUNITS; SUBSTITUTIONS; PURIFICATION; EXPRESSION	The pyrophosphate (PPi) analog foscarnet inhibits viral DNA-polymerases and is used to treat cytomegalovirus and human immunodeficiency vius infections. Nucleotide cyclases and DNA-polymerases catalyze analogous reactions, i.e. a phosphodiester bond formation, and have similar topologies in their active sites. Inhibition by foscarnet of adenylyl cyclase isoforms was therefore tested with (i) purified catalytic domains C1 and C2 of types I and VII (IC1 and VIIC1) and of type II (IIC2) and (ii) membrane-bound holoenzymes (from mammalian tissues and types I, II, and V heterologously expressed in Sf9 cell membranes). Foscarnet was more potent than PPi in suppressing forskolin-stimulated catalysis by both, IC1/IIC2 and VIIC1/IIC2. Stimulation of VIIC1/IIC2 by G alpha (s) relieved the inhibition by foscarnet but not that by PPi, The IC50 of foscarnet on membrane-bound adenylyl cyclases also depended on their mode of regulation. These findings predict that receptor-dependent cAMP formation is sensitive to inhibition by foscarnet in some, but not all, cells. This was verified with two cell lines; foscarnet blocked cAMP accumulation after A(2A)-adenosine receptor stimulation in PC12 but not in HEK-A(2A) cells. Foscarnet also inhibited soluble and, to a lesser extent, particulate guanylyl cylase, Thus, foscarnet interferes with the generation of cyclic nucleotides, an effect which may give rise to clinical side effects. The extent of inhibition varies with the enzyme isoform and with the regulatory input.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Free Univ Berlin, Inst Pharmacol, D-14195 Berlin, Germany	University of Vienna; University of Chicago; Free University of Berlin	Freissmuth, M (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@univie.ac.at	Hohenegger, Martin/AAF-6479-2020	Hohenegger, Martin/0000-0001-6537-9574; Kudlacek, Oliver/0000-0002-3086-8551; Tang, Wei-Jen/0000-0002-8267-8995; nanoff, christian/0000-0002-8857-2470; Freissmuth, Michael/0000-0001-9398-1765				Bayewitch ML, 1998, FASEB J, V12, P1019, DOI 10.1096/fasebj.12.11.1019; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; FREISSMUTH M, 1986, N-S ARCH PHARMACOL, V334, P56, DOI 10.1007/BF00498740; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; Harry A, 1997, J BIOL CHEM, V272, P19017, DOI 10.1074/jbc.272.30.19017; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; HAUSLEITHNER V, 1985, BIOCHEM J, V232, P501, DOI 10.1042/bj2320501; HELGSTRAND E, 1978, SCIENCE, V201, P819, DOI 10.1126/science.210500; HOCH BS, 1995, ANTIMICROB AGENTS CH, V39, P2008, DOI 10.1128/AAC.39.9.2008; Hohenegger M, 1996, MOL PHARMACOL, V49, P73; HOHENEGGER M, 1993, BIOCHEM J, V296, P303, DOI 10.1042/bj2960303; Hurley JH, 1999, J BIOL CHEM, V274, P7599, DOI 10.1074/jbc.274.12.7599; Ishikawa Y, 1997, CIRC RES, V80, P297, DOI 10.1161/01.RES.80.3.297; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; Mitterauer T, 1998, BIOCHEMISTRY-US, V37, P16183, DOI 10.1021/bi981441m; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Nanoff C, 1997, NEUROPHARMACOLOGY, V36, P1211, DOI 10.1016/S0028-3908(97)00135-4; NANOFF C, 1994, J BIOL CHEM, V269, P31999; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Segel I.H., 1975, ENZYME KINETICS; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Shoshani I, 1999, J BIOL CHEM, V274, P34742, DOI 10.1074/jbc.274.49.34742; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; VANSCOY M, 1988, AM J PHYSIOL, V255, pF984, DOI 10.1152/ajprenal.1988.255.5.F984; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WADSTAFF AJ, 1994, DRUGS, V48, P199; Weitmann S, 1999, BIOCHEMISTRY-US, V38, P3409, DOI 10.1021/bi982229l; WU ZL, 1993, J BIOL CHEM, V268, P23766	40	19	20	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3010	3016		10.1074/jbc.M007910200	http://dx.doi.org/10.1074/jbc.M007910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11050094	hybrid			2022-12-27	WOS:000166784900007
J	Baldursson, O; Ostedgaard, LS; Rokhlina, T; Cotten, JF; Welsh, MJ				Baldursson, O; Ostedgaard, LS; Rokhlina, T; Cotten, JF; Welsh, MJ			Cystic fibrosis transmembrane conductance regulator Cl- channels with R domain deletions and translocations show phosphorylation-dependent and -independent activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; CFTR; PROTEIN	Phosphorylation of the R domain regulates cystic fibrosis transmembrane conductance regulator Cl- channel activity. Earlier studies suggested that the R domain controls activity via more than one mechanism; a phosphorylated R domain may stimulate activity, and an unphosphorylated R domain may prevent constitutive activity, i.e, opening with ATP alone. However, the mechanisms responsible for these two regulatory properties are not understood. In this study we asked whether the two effects are dependent on its position in the protein and whether smaller regions from the R domain mediate the effects. We found that several portions of the R domain conferred phosphorylation-stimulated activity. This was true whether the R domain sequences were present in their normal location or were translocated to the C terminus. We also found that some parts of the R domain could be deleted without inducing constitutive activity. However, when residues 760-783 were deleted, channels opened without phosphorylation, Translocation of the R domain to the C terminus did not prevent constitutive activity, These results suggest that different parts of the phosphorylated R domain can stimulate activity and that their location within the protein is not critical. In contrast, prevention of constitutive activity required a short specific sequence that could not be moved to the C terminus. These results are consistent with a recent model of an R domain composed primarily of random coil in which more than one phosphorylation site is capable of stimulating channel activity, and net activity reflects interactions between multiple sites in the R domain and the rest of the channel.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, 500 EMRB, Iowa City, IA 52242 USA.			Ostedgaard, Lynda/0000-0001-7717-3442; Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL061234, R01HL058340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61234, HL58340] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldursson O, 2000, AM J PHYSIOL-LUNG C, V279, pL835, DOI 10.1152/ajplung.2000.279.5.L835; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DULHANTY AM, 1994, FEBS LETT, V343, P109, DOI 10.1016/0014-5793(94)80300-5; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Luo JX, 1998, AM J PHYSIOL-CELL PH, V274, pC1397, DOI 10.1152/ajpcell.1998.274.5.C1397; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; Ma JJ, 1997, J BIOL CHEM, V272, P28133, DOI 10.1074/jbc.272.44.28133; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Ostedgaard LS, 2000, P NATL ACAD SCI USA, V97, P5657, DOI 10.1073/pnas.100588797; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RICH DP, 1993, J BIOL CHEM, V268, P20259; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Travis SM, 1997, P NATL ACAD SCI USA, V94, P11055, DOI 10.1073/pnas.94.20.11055; Vankeerberghen A, 1999, BIOCHEMISTRY-US, V38, P14988, DOI 10.1021/bi991520d; Wilkinson DJ, 1997, AM J PHYSIOL-LUNG C, V273, pL127, DOI 10.1152/ajplung.1997.273.1.L127; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514; Xie JX, 2000, BIOPHYS J, V78, P1293, DOI 10.1016/S0006-3495(00)76685-9	25	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1904	1910		10.1074/jbc.M006934200	http://dx.doi.org/10.1074/jbc.M006934200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038358	hybrid			2022-12-27	WOS:000166528000036
J	Hayes, CS; Alarcon-Hernandez, E; Setlow, P				Hayes, CS; Alarcon-Hernandez, E; Setlow, P			N-terminal amino acid residues mediate protein-protein interactions between DNA-bound alpha/ss-type small, acid-soluble spore proteins from Bacillus species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS SPORES; IN-VITRO; BINDING; EXPRESSION; GENE; IDENTIFICATION; SPORULATION; RESISTANCE; CLONING	The binding of alpha/beta -type small, acid-soluble spore proteins (SASP) to DNA of spores of Bacillus species is the major determinant of DNA resistance to a variety of damaging treatments. The primary sequence of alpha/beta -type SASP is highly conserved; however, the N-terminal third of these proteins is less well conserved than the C-terminal two-thirds. To determine the functional importance of residues in the N-terminal region of alpha/beta -type SASP, variants of SspC (a minor alpha/beta -type SASP from Bacillus subtilis) with modified N termini were generated and their structural and DNA binding properties studied in vitro and in vivo. SspC variants with deletions of up to 14 residues (similar to 20% of SspC residues) were able to bind DNA in vitro and adopted similar conformations when bound to DNA, as determined by circular dichroism spectroscopy and protein-protein cross-linking. Progressive deletion of up to 11 N-terminal residues resulted in proteins with progressively lower DNA binding affinity. However, SspC(Delta 14) (in which 14 N-terminal residues have been deleted) showed significantly higher affinity for DNA than the larger proteins, SspC(Delta 10) and SspC(Delta 11). The affinity of these proteins for DNA was shown to be largely dependent upon the charge of the first few N-terminal residues. These results are interpreted in the context of a model for DNA-dependent alpha/beta -type SASP protein-protein interaction involving the N-terminal regions of these proteins.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Connecticut	Setlow, P (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA.	setlow@sun.uchc.edu	Hayes, Christopher/A-5505-2009		NIGMS NIH HHS [GM19698] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019698, R01GM019698] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Cantor C. R., 1980, BIOPHYSICAL CHEM 3; CONNORS MJ, 1985, J BACTERIOL, V161, P333, DOI 10.1128/JB.161.1.333-339.1985; DIXON HBF, 1964, BIOCHEM J, V92, P661, DOI 10.1042/bj0920661; Driks A, 2000, PROKARYOTIC DEVELOPMENT, P191; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; GOLDRICK S, 1983, J BACTERIOL, V155, P1459, DOI 10.1128/JB.155.3.1459-1462.1983; GRIFFITH J, 1994, P NATL ACAD SCI USA, V91, P8224, DOI 10.1073/pnas.91.17.8224; Hayes CS, 1998, J BIOL CHEM, V273, P17326, DOI 10.1074/jbc.273.28.17326; Hayes CS, 1997, J BACTERIOL, V179, P6020, DOI 10.1128/jb.179.19.6020-6027.1997; Hayes DS, 2000, J BIOL CHEM, V275, P35040, DOI 10.1074/jbc.M005669200; ILLADESAGUIAR B, 1994, J BACTERIOL, V176, P2788, DOI 10.1128/JB.176.10.2788-2795.1994; MASON JM, 1986, J BACTERIOL, V167, P174, DOI 10.1128/jb.167.1.174-178.1986; MASON JM, 1988, J BACTERIOL, V170, P239, DOI 10.1128/jb.170.1.239-244.1988; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MOHR SC, 1991, P NATL ACAD SCI USA, V88, P77, DOI 10.1073/pnas.88.1.77; NICHOLSON WL, 1990, J BACTERIOL, V172, P6900, DOI 10.1128/jb.172.12.6900-6906.1990; Nicholson WL., 1990, MOL BIOL METHODS BAC, P391, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X; POPHAM DL, 1995, APPL ENVIRON MICROB, V61, P3633, DOI 10.1128/AEM.61.10.3633-3638.1995; RAO H, 1992, FEBS LETT, V305, P115, DOI 10.1016/0014-5793(92)80876-I; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; SETLOW B, 1995, J BACTERIOL, V177, P4149, DOI 10.1128/jb.177.14.4149-4151.1995; SETLOW B, 1992, J BACTERIOL, V174, P2312, DOI 10.1128/JB.174.7.2312-2322.1992; SETLOW P, 1992, J BACTERIOL, V174, P2737, DOI 10.1128/JB.174.9.2737-2741.1992; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; TOVARROJO F, 1991, J BACTERIOL, V173, P4827, DOI 10.1128/jb.173.15.4827-4835.1991; VANHEYNINGEN S, 1967, BIOCH J, V104; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	33	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2267	2275		10.1074/jbc.M007858200	http://dx.doi.org/10.1074/jbc.M007858200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11044450	hybrid			2022-12-27	WOS:000166528000083
J	Kojima, K; Kitada, S; Ogishima, T; Ito, A				Kojima, K; Kitada, S; Ogishima, T; Ito, A			A proposed common structure of substrates bound to mitochondrial processing peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; PROTEIN IMPORT; ALPHA-SUBUNIT; BETA-SUBUNIT; ALDEHYDE DEHYDROGENASE; SYNTHETIC PEPTIDE; AMINO-ACIDS; RECOGNITION; CLEAVAGE; BINDING	Mitochondrial processing peptidase (MPP), a metalloendopeptidase consisting of alpha- and beta -subunits, specifically cleaves off the N-terminal presequence of the mitochondrial protein precursor. Structural information of the substrate bound to MPP was obtained using fluorescence resonance energy transfer (FRET) measurement. A series of the peptide substrates, which have distal arginine residues required for effective cleavage at positions -7, - 10, - 14, and -17 from the cleavage site, were synthesized and covalently labeled with 7-diethyl aminocoumarin-3-carboxylic acid at the N termini and N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa- 1,3-diazol-4-yl)ethylenediamine (IANBD) at position +4, as fluorescent donor and acceptor, respectively. When the peptides were bound to MPP, substantially the same distances were obtained between the two probes, irrespective of the length of the intervening sequence between the two probes. When 7-diethylamino-3-(4'-maleimidyl phenyl)-4-methyl coumarin was introduced into a single cysteine residue in beta -MPP as a donor and IANBD was coupled either at the N terminus or the +4 position of the peptide substrate as an acceptor, intermolecular FRET measurements also demonstrated that distances of the donor-acceptor pair were essentially the same among the peptides with different lengths of intervening sequences, The results indicate that the N-terminal portion and the portion around the cleavage site of the presequence interact with specific sites in the MPP molecule, irrespective of the length of the intervening sequence between the two portions, suggesting the structure of the intervening sequence is flexible when bound to the MPP.	Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan	Kyushu University	Ito, A (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan.							Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; GELI V, 1993, P NATL ACAD SCI USA, V90, P6247, DOI 10.1073/pnas.90.13.6247; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Ito A, 1999, BIOCHEM BIOPH RES CO, V265, P611, DOI 10.1006/bbrc.1999.1703; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; Kitada S, 1998, J BIOL CHEM, V273, P32547, DOI 10.1074/jbc.273.49.32547; Kojima K, 1998, J BIOL CHEM, V273, P32542, DOI 10.1074/jbc.273.49.32542; Makarova KS, 1999, PROTEIN SCI, V8, P2537; Moriwaki K, 1999, J BIOCHEM, V126, P874, DOI 10.1093/oxfordjournals.jbchem.a022529; Nagao Y, 2000, J BIOL CHEM, V275, P34552, DOI 10.1074/jbc.M003110200; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; Roise D, 1997, J BIOENERG BIOMEMBR, V29, P19, DOI 10.1023/A:1022403604273; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; Shimokata K, 1998, J BIOL CHEM, V273, P25158, DOI 10.1074/jbc.273.39.25158; Shimokata K, 1997, J BIOCHEM-TOKYO, V122, P1019; Song MC, 1996, J BIOCHEM-TOKYO, V120, P1163; Song MC, 1998, J BIOCHEM, V124, P1045, DOI 10.1093/oxfordjournals.jbchem.a022198; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	29	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2115	2121		10.1074/jbc.M003111200	http://dx.doi.org/10.1074/jbc.M003111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11031253	hybrid			2022-12-27	WOS:000166528000064
J	Toyofuku, T; Akamatsu, Y; Zhang, H; Kuzuya, T; Tada, M; Hori, M				Toyofuku, T; Akamatsu, Y; Zhang, H; Kuzuya, T; Tada, M; Hori, M			c-Src regulates the interaction between connexin-43 and ZO-1 in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP JUNCTION CHANNELS; ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; PDZ-DOMAIN; CELL COMMUNICATION; EPITHELIAL-CELLS; MOLECULAR-BASIS; EXPRESSION; HEART; PERMEABILITY	Connexin-43 is known to interact directly with ZO-1 in cardiac myocytes, but little is known about the role of ZO-1 in connexin 43 function. In cardiac myocytes, constitutively active c-Src inhibited endogenous interaction between connexin-43 and ZO-1 by binding to connexin-43, In HEK293 cells, by contrast, a connexin-43 mutant lacking the Src phosphorylation site (Tyr(265)) interacted with ZO-1 despite cotransfection of a constitutively active c-Src. Moreover, in vitro binding assays using recombinant proteins synthesized from regions of connexin-43 and ZO-1 showed that the tyrosine-phosphorylated C terminus of connexin-43 interacts with the c-Src SH2 domain in parallel with the loss of its interaction with ZO 1. Cell surface biotinylation revealed that, by phosphorylating Tyr(265), constitutively active c-Src reduces total and cell surface connexin-43 down to the levels seen in cells expressing a mutant connexin-43 lacking the ZO-1 binding domain. Finally, electrophysiological analysis showed that both the tyrosine phosphorylation site and the ZO-1-binding domain of connexin-43 were involved in the regulation of gap junctional function. We therefore conclude that c-Src regulates the interaction between connexin 43 and ZO-1 through tyrosine phosphorylation and through the binding of its SH2 domain to connexin-43.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Pathol & Pathophysiol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Toyofuku, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; Bennett M V, 1992, Semin Cell Biol, V3, P29; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DUNHAM B, 1992, CIRC RES, V70, P1233, DOI 10.1161/01.RES.70.6.1233; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FISHMAN GI, 1991, P NATL ACAD SCI USA, V88, P3525, DOI 10.1073/pnas.88.9.3525; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GUERRIER A, 1995, J CELL SCI, V108, P2609; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KWAK BR, 1995, EXP CELL RES, V220, P456, DOI 10.1006/excr.1995.1337; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; LAMPE PD, 1994, J CELL BIOL, V127, P1895, DOI 10.1083/jcb.127.6.1895; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; LUQUE EA, 1994, J MORPHOL, V222, P203, DOI 10.1002/jmor.1052220207; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MORENO AP, 1994, CIRC RES, V74, P1050, DOI 10.1161/01.RES.74.6.1050; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; OH SY, 1991, BIOCHIM BIOPHYS ACTA, V1094, P243, DOI 10.1016/0167-4889(91)90016-Q; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; Potts W M, 1988, Oncogene Res, V3, P343; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPRAY DC, 1994, BIOPHYS J, V67, P491, DOI 10.1016/S0006-3495(94)80510-7; SPRAY DC, 1990, AM J PHYSIOL, V258, P195; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Toyofuku T, 1999, CIRC RES, V85, P672, DOI 10.1161/01.RES.85.8.672; Toyofuku T, 1998, J BIOL CHEM, V273, P1519, DOI 10.1074/jbc.273.3.1519; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	48	173	178	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1780	1788		10.1074/jbc.M005826200	http://dx.doi.org/10.1074/jbc.M005826200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035005	hybrid			2022-12-27	WOS:000166528000019
J	Tsivkovskii, R; MacArthurs, BC; Lutsenko, S				Tsivkovskii, R; MacArthurs, BC; Lutsenko, S			The Lys(1010)-Lys(1325) fragment of the Wilson's disease protein binds nucleotides and interacts with the N-terminal domain of this protein in a copper-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; ESCHERICHIA-COLI; MENKES-DISEASE; FUNCTIONAL EXPRESSION; TRANSPORTING ATPASE; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC LOOP; CANDIDATE GENE; ATP7B; IDENTIFICATION	Wilson's disease, an autosomal disorder associated with vast accumulation of copper in tissues, is caused by mutations in a gene encoding a copper-transporting ATPase (Wilson's disease protein, WNDP), Numerous mutations have been identified throughout the WNDP sequence, particularly in the Lys(1010)-Lys(1325) segment; however, the biochemical properties and molecular mechanism of WNDP remain poorly characterized. Here, the Lys(1010)-Lys(1325) fragment of WNDP was overexpressed, purified, and shown to form an independently folded ATP-binding domain (ATP-BD). ATP-BD binds the fluorescent ATP analogue trinitrophenyl-ATP with high affinity, and ATP competes with trinitrophenyl-ATP for the binding site; ADP and AMP appear to bind to ATP-BD at the site separate from ATP. Purified ATP-BD hydrolyzes ATP and interacts specifically with the N-terminal copper-binding domain of WNDP (N-WNDP). Strikingly, copper binding to N-WNDP diminishes these interactions, suggesting that the copper-dependent change in domain-domain contact may represent the mechanism of WNDP regulation. In agreement with this hypothesis, N-WNDP induces conformational changes in ATP-BD as evidenced by the altered nucleotide binding properties of ATP-BD in the presence of N-WNDP, Significantly, the effects of copper-free and copper-bound N-WNDP on ATP-BD are not identical. The implications of these results for the WNDP function are discussed.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	lutsenko@ohsu.edu		MacArthur, Brian/0000-0003-1048-5243				Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; Harrison MD, 1999, BBA-MOL BASIS DIS, V1453, P254, DOI 10.1016/S0925-4439(98)00110-0; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Moncalian G, 1999, J BIOL CHEM, V274, P36117, DOI 10.1074/jbc.274.51.36117; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; Noll M, 1998, J BIOL CHEM, V273, P21393, DOI 10.1074/jbc.273.33.21393; Ogawa H, 2000, FEBS LETT, V471, P99, DOI 10.1016/S0014-5793(00)01374-0; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; Ralle M, 1998, J AM CHEM SOC, V120, P13525, DOI 10.1021/ja982990i; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Scheinberg IH, 1984, WILSONS DIS MAJOR PR, V23; Shah AB, 1997, AM J HUM GENET, V61, P317, DOI 10.1086/514864; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TSAI KJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P267, DOI 10.1006/abbi.1993.1421; VERGA V, 1991, AM J HUM GENET, V48, P1133; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; WylerDuda P, 1996, FEBS LETT, V399, P143, DOI 10.1016/S0014-5793(96)01306-3; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471	41	127	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2234	2242		10.1074/jbc.M003238200	http://dx.doi.org/10.1074/jbc.M003238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053407	hybrid			2022-12-27	WOS:000166528000078
J	Kozielski, F; Svergun, D; Zaccai, G; Wade, RH; Koch, MHJ				Kozielski, F; Svergun, D; Zaccai, G; Wade, RH; Koch, MHJ			The overall conformation of conventional kinesins studied by small angle X-ray and neutron scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN MOTOR DOMAIN; STIMULATED ATP HYDROLYSIS; PREDICTING COILED COILS; CRYSTAL-STRUCTURE; DIMERIC KINESIN; AXONAL-TRANSPORT; LIGHT-CHAIN; PROTEIN; MECHANISM; REVEALS	The quaternary structures of several monomeric and dimeric kinesin constructs from Homo sapiens and Drosophila melanogaster were analyzed using small angle K-ray and neutron scattering. The experimental scattering curves of these proteins were compared with simulated scattering curves calculated from available crystallographic coordinates. These comparisons indicate that the overall conformations of the solution structures of D. melanogaster and H. sapiens kinesin heavy chain dimers are compatible with the crystal structure of dimeric kinesin from Rattus norvegicus. This suggests that the unusual asymmetric conformation of dimeric kinesin in the microtubule-independent ADP state is likely to be a general feature of the kinesin heavy chain subfamily. An intermediate length Drosophila construct (365 residues) is mostly monomeric at low protein concentration whereas at higher concentrations it is dimeric with a tendency to form higher oligomers.	CNRS, CEA 47, Inst Biol Struct, Lab Microscop Elect Struct, F-38027 Grenoble 01, France; CNRS, CEA 47, Inst Biol Struct, Mol Biophys Lab, F-38027 Grenoble 01, France; DESY, Hamburg Outstn, EMBL, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 09, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; Institut Laue-Langevin (ILL)	Kozielski, F (corresponding author), CNRS, CEA 47, Inst Biol Struct, Lab Microscop Elect Struct, 41 Rue Jules Horowitz, F-38027 Grenoble 01, France.	kozielsk@lmes.ibs.fr		Svergun, Dmitri/0000-0003-0830-5696				BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BONNETE F, 1994, J MOL BIOL, V244, P436, DOI 10.1006/jmbi.1994.1741; BOULIN C, 1996, NUCL INSTRUM METHODS, V249, P399; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Brendza KM, 1999, J BIOL CHEM, V274, P31506, DOI 10.1074/jbc.274.44.31506; BUTTNER HG, 1997, YELLOW BOOK GUIDE NE; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Feigin L.A.S., 1987, STRUCTURE ANAL SMALL, V1st, P1; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; Gindhart JG, 1998, J CELL BIOL, V141, P443, DOI 10.1083/jcb.141.2.443; Gindhart JG, 1996, TRENDS BIOCHEM SCI, V21, P52, DOI 10.1016/0968-0004(96)80865-6; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; JACROT B, 1981, BIOPOLYMERS, V20, P2413, DOI 10.1002/bip.1981.360201110; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konig S, 1998, BIOCHEMISTRY-US, V37, P5329, DOI 10.1021/bi972125v; Kozielski F, 1999, STRUCTURE, V7, P1407, DOI 10.1016/S0969-2126(00)80030-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Marx A, 1998, EUR BIOPHYS J BIOPHY, V27, P455, DOI 10.1007/s002490050156; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rosenfeld SS, 1996, J BIOL CHEM, V271, P30212, DOI 10.1074/jbc.271.47.30212; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Schonbrunn E, 1998, EUR J BIOCHEM, V253, P406, DOI 10.1046/j.1432-1327.1998.2530406.x; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Stock MF, 1999, J BIOL CHEM, V274, P14617, DOI 10.1074/jbc.274.21.14617; Stone DB, 1999, BIOCHEMISTRY-US, V38, P4938, DOI 10.1021/bi982374z; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, PROTEINS, V27, P110; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; Svergun DI, 1998, P NATL ACAD SCI USA, V95, P2267, DOI 10.1073/pnas.95.5.2267; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsuruta H, 1998, J MOL BIOL, V284, P1439, DOI 10.1006/jmbi.1998.2231; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; ZACCAI G, 1983, ANNU REV BIOPHYS BIO, V12, P139, DOI 10.1146/annurev.bb.12.060183.001035	57	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1267	1275		10.1074/jbc.M007169200	http://dx.doi.org/10.1074/jbc.M007169200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11020387	hybrid			2022-12-27	WOS:000166430900056
J	Liu, Z; Peng, JB; Mo, R; Hui, CC; Huang, CH				Liu, Z; Peng, JB; Mo, R; Hui, CC; Huang, CH			Rh type B glycoprotein is a new member of the Rh superfamily and a putative ammonia transporter in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INSITU HYBRIDIZATION; MOLECULAR-CLONING; GENE FAMILY; PROTEIN; EXPRESSION; NH4+; DIFFERENTIATION; IDENTIFICATION; LOCALIZATION	Ammonium transporters play a key functional role in nitrogen uptake and assimilation in microorganisms and plants; however, little is known about their structural counterpart in mammals. Here, we report the molecular cloning and biochemical characterization of Rh type B glycoproteins, human RhBG and mouse Rhbg, two new members of the Rh family with distinct tissue specificities. The RhBG orthologues possess a conserved 12-transmembrane topology and most resemble bacterial and archaeal ammonium transporters. Human RHBG resides at chromosome 1q21,3, which harbors candidate genes for medullary cystic kidney disease, whereas mouse Rhbg is syntenic on chromosome 3. Northern blot and in situ hybridization revealed that RHBG and Rhbg are predominantly expressed in liver, kidney, and skin, the specialized organs involving ammonia genesis, excretion, or secretion. Confocal microscopy showed that RhBG is located in the plasma membrane and in some intracellular granules. Western blots of membrane proteins from stable HEK293 cells and from mouse kidney and liver confirmed this distribution. N-Glycanase digestion showed that RhBG/Rhbg has a carbohydrate moiety probably attached at the NHS motif on exoloop 1, Phylogenetic clustering, tissue-specific expression, and plasma membrane location suggest that RhBG homologous proteins are the long sought major ammonium transporters in mammalians.	New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Biochem & Mol Genet, New York, NY 10021 USA; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada	New York Blood Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Huang, CH (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Biochem & Mol Genet, 310 E 67th St, New York, NY 10021 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054459] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54459] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASKARI A, 1966, J GEN PHYSIOL, V49, P1147, DOI 10.1085/jgp.0491147; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; Bankir L, 2000, EXP PHYSIOL, V85, p243S, DOI 10.1111/j.1469-445X.2000.tb00029.x; CHERIFZAHAR B, 1991, HUM GENET, V86, P398, DOI 10.1007/BF00201843; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; Christodoulou K, 1998, HUM MOL GENET, V7, P905, DOI 10.1093/hmg/7.5.905; FONG AD, 1990, BIOCHIM BIOPHYS ACTA, V1022, P325, DOI 10.1016/0005-2736(90)90281-R; Gazzarrini S, 1999, PLANT CELL, V11, P937, DOI 10.1105/tpc.11.5.937; GOOD DW, 1985, AM J PHYSIOL, V248, pF459, DOI 10.1152/ajprenal.1985.248.4.F459; Harlow E., 1988, ANTIBODIES LAB MANUA; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HERMAND P, 1993, BLOOD, V82, P669; Huang CH, 2000, SEMIN HEMATOL, V37, P150, DOI 10.1016/S0037-1963(00)90040-4; Huang CH, 2000, J MOL EVOL, V51, P76, DOI 10.1007/s002390010068; Huang CH, 1998, J BIOL CHEM, V273, P2207, DOI 10.1074/jbc.273.4.2207; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; KLEINER D, 1981, BIOCHIM BIOPHYS ACTA, V639, P41, DOI 10.1016/0304-4173(81)90004-5; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KNEPPER MA, 1991, KIDNEY INT S, V40, P95; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LI Z, 1999, BIOCH GENET, V37, P119; Liu Z, 2000, J BIOL CHEM, V275, P25641, DOI 10.1074/jbc.M003353200; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Matassi G, 1999, J MOL EVOL, V48, P151, DOI 10.1007/PL00006453; Matassi G, 1998, GENOMICS, V47, P286, DOI 10.1006/geno.1997.5112; MCKUSIK VA, 1997, ONLINE MENDELIAN IN; Montesinos ML, 1998, J BIOL CHEM, V273, P31463, DOI 10.1074/jbc.273.47.31463; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; RIDGWELL K, 1994, J BIOL CHEM, V269, P6410; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Russo D, 2000, BLOOD, V96, P340, DOI 10.1182/blood.V96.1.340.013k45_340_346; Sambrook J., 2002, MOL CLONING LAB MANU; Seack J, 1997, IMMUNOGENETICS, V46, P493, DOI 10.1007/s002510050310; Soupene E, 1998, P NATL ACAD SCI USA, V95, P7030, DOI 10.1073/pnas.95.12.7030; Thomas GH, 2000, MOL MICROBIOL, V37, P331, DOI 10.1046/j.1365-2958.2000.01994.x; Thomason P, 1999, TRENDS GENET, V15, P15, DOI 10.1016/S0168-9525(98)01635-7; THORPE SJ, 1997, BIOTEST B, V5, P523; TIZIANELLO A, 1982, J CLIN INVEST, V69, P240, DOI 10.1172/JCI110436; Van Dommelen A, 1998, J BACTERIOL, V180, P2652, DOI 10.1128/JB.180.10.2652-2659.1998; von Wiren N, 2000, CURR OPIN PLANT BIOL, V3, P254, DOI 10.1016/S1369-5266(00)00073-X; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; [No title captured]	48	127	131	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1424	1433		10.1074/jbc.M007528200	http://dx.doi.org/10.1074/jbc.M007528200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11024028	hybrid			2022-12-27	WOS:000166430900076
J	Long, KE; Asou, H; Snider, MD; Lemmon, V				Long, KE; Asou, H; Snider, MD; Lemmon, V			The role of endocytosis in regulating L1-mediated adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; COATED VESICLE FORMATION; II PHOSPHORYLATION SITE; MOLECULE L1; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; CRASH SYNDROME	L1 is a neural cell adhesion molecule critical for neural development. Full-length L1 (L1(FL)) contains an alternatively spliced cytoplasmic sequence, RSLE, which is absent in L1 expressed in nonneuronal cells. The RSLE sequence follows a tyrosine, creating an endocytic motif that allows rapid internalization via clathrin-mediated endocytosis. We hypothesized that L1(FL) would internalize more rapidly than L1 lacking the RSLE sequence (L1(Delta RSLE)) and that internalization might regulate L1-mediated adhesion. L1 internalization was measured by immunofluorescence microscopy and by uptake of I-125-anti-rat-L1 antibody, demonstrating that L1(FL) is internalized 2-3 times faster than L1(Delta RSLE). Inhibition of clathrin-mediated endocytosis slowed internalization of L1(FL) but did not affect initial uptake of L1(Delta RSLE) To test whether L1 endocytosis regulates L1 adhesion, cell aggregation rates were tested. L1 Delta (RSLE) cells aggregated two times faster than L1(FL), cells. Inhibition of clathrin-mediated endocytosis increases the aggregation rate of the L1(Delta RSLE) cells. Our results demonstrate that rapid internalization of L1 dramatically affects L1 adhesion.	Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Tokyo Metropolitan Inst Gerontol, Dept Neurobiol, Itabashi Ku, Tokyo 1730015, Japan	Case Western Reserve University; Case Western Reserve University; Tokyo Metropolitan Institute of Gerontology	Lemmon, V (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, Rm E661,2109 Adelbert Rd, Cleveland, OH 44106 USA.		Lemmon, Vance/A-7410-2010; Lemmon, Vance/A-2565-2008	Lemmon, Vance/0000-0003-3550-7576; 	NATIONAL EYE INSTITUTE [P30EY011373, R01EY005285] Funding Source: NIH RePORTER; NEI NIH HHS [P30EY11373, R01 EY005285-23, EY-05285, P30 EY011373, R01 EY005285] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BARAMI K, 1994, NEURON, V13, P567, DOI 10.1016/0896-6273(94)90026-4; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Bradshaw JD, 1997, BIOCHEMISTRY-US, V36, P15975, DOI 10.1021/bi971762i; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; BRITTIS PA, 1995, MOL CELL NEUROSCI, V6, P433, DOI 10.1006/mcne.1995.1032; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; Burden-Gulley Susan M., 1995, Seminars in Developmental Biology, V6, P79, DOI 10.1016/S1044-5781(06)80017-4; CARPENTIER JL, 1989, J CELL PHYSIOL, V138, P519, DOI 10.1002/jcp.1041380311; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; CROWE DT, 1994, J BIOL CHEM, V269, P14411; DahlinHuppe K, 1997, MOL CELL NEUROSCI, V9, P144, DOI 10.1006/mcne.1997.0608; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DAVIS RJ, 1987, J BIOL CHEM, V262, P13126; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; FRANSEN E, 1995, EUR J HUM GENET, V3, P273; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; Holbrook MR, 1999, BIOCHEMISTRY-US, V38, P9348, DOI 10.1021/bi990195r; HORTSCH M, 1995, J BIOL CHEM, V270, P18809, DOI 10.1074/jbc.270.32.18809; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kamiguchi H, 1998, J NEUROSCI, V18, P3749, DOI 10.1523/jneurosci.18-10-03749.1998; KAMIGUCHI H, 2000, J ENUROSCI, V15, P3676; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MIURA M, 1992, J BIOL CHEM, V267, P10752; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHAEFER A, 1998, CELL ADHES COMMUN S, V6, P75; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; SCHMIDT CE, 1995, J NEUROSCI, V15, P3400; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; Takeda Y, 1996, J NEUROCHEM, V66, P2338; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wong EV, 1996, J NEUROCHEM, V66, P779; Wong EV, 1995, NEUROSCI LETT, V200, P155, DOI 10.1016/0304-3940(95)12100-I; Wong EV, 1996, J BIOL CHEM, V271, P18217, DOI 10.1074/jbc.271.30.18217; Yamasaki M, 1997, NEUROPEDIATRICS, V28, P175, DOI 10.1055/s-2007-973696	60	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1285	1290		10.1074/jbc.M006658200	http://dx.doi.org/10.1074/jbc.M006658200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035015	hybrid, Green Accepted			2022-12-27	WOS:000166430900058
J	Kruk, J; Strzalka, K				Kruk, J; Strzalka, K			Redox changes of cytochrome b(559) in the presence of plastoquinones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II REACTION CENTER; ALPHA-TOCOPHEROL QUINONE; ELECTRON-TRANSPORT PROPERTIES; CHARGE-TRANSFER COMPLEXES; PHOTOSYSTEM-II; OXYGEN EVOLUTION; PHOTOINHIBITION; PARTICLES; PLANTS	We have found that short chain plastoquinones effectively stimulated photoreduction of the low potential form of cytochrome b(559) and were also active in dark oxidation of this cytochrome under anaerobic conditions in Triton X-100-solubilized photosystem II (PSII) particles. It is also shown that molecular oxygen competes considerably with the prenylquinones in cytochrome b(559) oxidation under aerobic conditions, indicating that both molecular oxygen and plastoquinones could be electron accepters from cytochrome b(559) in PSII preparations. alpha -Tocopherol quinone was not active in the stimulation of cytochrome photoreduction but efficiently oxidized it in the dark. Both the observed photoreduction and dark oxidation of the cytochrome were not sensitive to 3-(3,4-dichlorophenyl)-1,1-dimethylurea. It was concluded that both quinone-binding sites responsible for the redox changes of cytochrome b(559) are different from either the Q(A) or Q(B) site in PSII and represent new quinone-binding sites in PSII.	Jagiellonian Univ, Jan Zurzycki Inst Mol Biol, Dept Plant Physiol & Biochem, PL-31120 Krakow, Poland	Jagiellonian University	Strzalka, K (corresponding author), Jagiellonian Univ, Jan Zurzycki Inst Mol Biol, Dept Plant Physiol & Biochem, Aleja Mickiewicza 3, PL-31120 Krakow, Poland.	strzalka@mol.uj.edu.pl						BARBER J, 1993, P NATL ACAD SCI USA, V90, P10942, DOI 10.1073/pnas.90.23.10942; Bendall DS, 1971, METHOD ENZYMOL, V23A, P327, DOI DOI 10.1016/S0076-6879(71)23109-8; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; CHAPMAN DJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P423, DOI 10.1016/0005-2728(88)90077-1; GOUNARIS K, 1988, FEBS LETT, V240, P143, DOI 10.1016/0014-5793(88)80356-9; GRUSZECKI WI, 1995, Z NATURFORSCH C, V50, P61; Hanley J, 1999, BIOCHEMISTRY-US, V38, P8189, DOI 10.1021/bi990633u; KRISHTALIK LI, 1993, BIOPHYS J, V65, P184, DOI 10.1016/S0006-3495(93)81050-6; KRUK J, 1992, BIOCHIM BIOPHYS ACTA, V1112, P19, DOI 10.1016/0005-2736(92)90248-K; KRUK J, 1988, BIOPHYS CHEM, V30, P143, DOI 10.1016/0301-4622(88)85011-7; KRUK J, 1995, J PLANT PHYSIOL, V145, P405, DOI 10.1016/S0176-1617(11)81762-1; Kruk J, 1997, Z NATURFORSCH C, V52, P766; Kruk J, 2000, PLANT PHYSIOL BIOCH, V38, P271, DOI 10.1016/S0981-9428(00)00747-6; Kruk J, 1999, PHOTOSYNTH RES, V62, P273, DOI 10.1023/A:1006374319191; MESSINGER J, 1993, BIOCHEMISTRY-US, V32, P7658, DOI 10.1021/bi00081a009; NAKANE H, 1991, PLANT CELL PHYSIOL, V32, P1165; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NEDBAL L, 1992, P NATL ACAD SCI USA, V89, P7929, DOI 10.1073/pnas.89.17.7929; OMATA T, 1984, BIOCHIM BIOPHYS ACTA, V765, P403, DOI 10.1016/0005-2728(84)90182-8; ORTEGA JM, 1988, EUR J BIOCHEM, V171, P449, DOI 10.1111/j.1432-1033.1988.tb13810.x; Ozawa S, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL I, P535; Patzlaff JS, 1996, BIOCHEMISTRY-US, V35, P7802, DOI 10.1021/bi960056z; POULSON M, 1995, BIOCHEMISTRY-US, V34, P10932, DOI 10.1021/bi00034a027; SATOH K, 1990, BIOCHIM BIOPHYS ACTA, V1016, P121, DOI 10.1016/0005-2728(90)90014-U; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; Stewart DH, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1113; TABATA K, 1985, PLANT CELL PHYSIOL, V26, P855; TANG XS, 1994, BIOCHEMISTRY-US, V33, P4594, DOI 10.1021/bi00181a021; TELFER A, 1994, PHOTOINHIBITION PHOT, P25; Whitmarsh J., 1994, PHOTOINHIBITION PHOT, P75; Whitmarsh J., 1996, OXYGENIC PHOTOSYNTHE, P249, DOI 10.1007/0-306-48127-8_13	31	71	72	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					86	91		10.1074/jbc.M003602200	http://dx.doi.org/10.1074/jbc.M003602200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022032	hybrid			2022-12-27	WOS:000166280700013
J	Solle, M; Labasi, J; Perregaux, DG; Stam, E; Petrushova, N; Koller, BH; Griffiths, RJ; Gabel, CA				Solle, M; Labasi, J; Perregaux, DG; Stam, E; Petrushova, N; Koller, BH; Griffiths, RJ; Gabel, CA			Altered cytokine production in mice lacking P2X(7) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; IL-1-BETA PRODUCTION; PURINERGIC RECEPTOR; NUCLEOTIDE RECEPTOR; P2Z PURINORECEPTOR; HUMAN MONOCYTES; INTERLEUKIN-1; MACROPHAGES; EXPRESSION; CELLS	The P2X(7) receptor (P2X(7)R) is an ATP-gated ion channel expressed by monocytes and macrophages, To directly address the role of this receptor in interleukin (IL)-1 beta post-translational processing, we have generated a P2X(7)R-deficient mouse line. P2X(7)R(-/-) macrophages respond to lipopolysaccharide and produce levels of cyclooxygenase-2 and pro-IL-1 beta comparable with those generated by wild-type cells. In response to ATP, however, pro-IL-1 beta produced by the P2X(7)R(-/-) cells is not externalized or activated by caspase-1, Nigericin, an alternate secretion stimulus, promotes release of 17-kDa IL-1 beta from P2X(7)R(-/-) macrophages. In response to in vivo lipopolysaccharide injection, both wild-type and P2X(7)R(-/-) animals display increases in peritoneal lavage IL-6 levels but no detectable IL-1. Subsequent ATP injection to wild-type animals promotes an increase in IL-1, which in turn leads to additional IL-6 production; similar increases did not occur in ATP-treated, LPS-primed P2X(7)R(-/-) animals. Absence of the P2X(7)R thus leads to an inability of peritoneal macrophages to release IL-1 in response to ATP. As a result of the IL-1 deficiency, in vivo cytokine signaling cascades are impaired in P2X(7)R-deficient animals. Together these results demonstrate that P2X(7)R activation can provide a signal that leads to maturation and release of IL-1 beta and initiation of a cytokine cascade.	Pfizer Inc, Dept Resp Allergy Immunol Inflammat & Infect Dis, Groton, CT 06340 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	Pfizer; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Gabel, CA (corresponding author), Pfizer Inc, Dept Resp Allergy Immunol Inflammat & Infect Dis, Groton, CT 06340 USA.	christopher_a_gabel@groton.pfizer.com						Allen M, 2000, J EXP MED, V191, P859, DOI 10.1084/jem.191.5.859; Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; AYALA JM, 1994, J IMMUNOL, V153, P2592; Balboa MA, 1999, J BIOL CHEM, V274, P36764, DOI 10.1074/jbc.274.51.36764; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BHAKDI S, 1990, J CLIN INVEST, V85, P1746, DOI 10.1172/JCI114631; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chessell IP, 1998, FEBS LETT, V439, P26, DOI 10.1016/S0014-5793(98)01332-5; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Flannery CR, 1999, MATRIX BIOL, V18, P225, DOI 10.1016/S0945-053X(99)00024-4; Foresta C, 1996, AM J PHYSIOL-CELL PH, V270, pC1709, DOI 10.1152/ajpcell.1996.270.6.C1709; GRAY PW, 1986, J IMMUNOL, V137, P3644; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRIFFITHS RJ, 1995, J IMMUNOL, V154, P2821; GUZN Z, 1998, J BIOL CHEM, V273, P28670; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; HICKMAN SE, 1994, BLOOD, V84, P2452; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Humphreys BD, 1998, MOL PHARMACOL, V54, P22, DOI 10.1124/mol.54.1.22; Humphreys BD, 1996, J IMMUNOL, V157, P5627; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALIBERTE R, 1994, J IMMUNOL, V153, P2168; Laliberte RE, 1999, J BIOL CHEM, V274, P36944, DOI 10.1074/jbc.274.52.36944; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; Michel AD, 1998, BRIT J PHARMACOL, V125, P1194, DOI 10.1038/sj.bjp.0702205; MILLER BE, 1995, J IMMUNOL, V154, P1331; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MOHN A, 1995, DNA CLONING 4; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; MURGIA M, 1992, BIOCHEM J, V288, P897, DOI 10.1042/bj2880897; Mutini C, 1999, J IMMUNOL, V163, P1958; North RA, 1996, CURR OPIN CELL BIOL, V8, P474, DOI 10.1016/S0955-0674(96)80023-8; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Perregaux DG, 1996, J IMMUNOL, V157, P57; PERREGAUX DG, 1999, AM J PHYSIOL, V275, pC1538; PETTIPHER ER, 1986, P NATL ACAD SCI USA, V83, P8749, DOI 10.1073/pnas.83.22.8749; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Rocca B, 1999, J IMMUNOL, V162, P4589; Sanz JM, 2000, J IMMUNOL, V164, P4893, DOI 10.4049/jimmunol.164.9.4893; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC766, DOI 10.1152/ajpcell.1999.277.4.C766; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SLACK J, 1993, J BIOL CHEM, V268, P2513; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEISMAN GA, 1984, J CELL PHYSIOL, V119, P211, DOI 10.1002/jcp.1041190211; WILEY JS, 1989, BLOOD, V73, P1316	64	744	772	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					125	132		10.1074/jbc.M006781200	http://dx.doi.org/10.1074/jbc.M006781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016935	Green Published, hybrid			2022-12-27	WOS:000166280700018
J	Trotti, D; Aoki, M; Pasinelli, P; Berger, UV; Danbolt, NC; Brown, RH; Hediger, MA				Trotti, D; Aoki, M; Pasinelli, P; Berger, UV; Danbolt, NC; Brown, RH; Hediger, MA			Amyotrophic lateral sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; RAT-BRAIN; REENTRANT LOOP; SPINAL-CORD; EXPRESSION; GLT-1; EAAT2; GENE; SUBSTRATE; GLYCOSYLATION	We have investigated the functional impact of a naturally occurring mutation of the human glutamate transporter GLT1 (EAAT2), which had been detected in a patient with sporadic amyotrophic lateral sclerosis, The mutation involves a substitution of the putative N-linked glycosylation site asparagine 206 by a serine residue (N206S) and results in reduced glycosylation of the transporter and decreased uptake activity. Electrophysiological analysis of N206S revealed a pronounced reduction in transport rate compared with wild-type, but there was no alteration in the apparent affinities for glutamate and sodium. In addition, no change in the sensitivity for the specific transport inhibitor dihydrokainate was observed, However, the decreased rate of transport was associated with a reduction of the N206S transporter in the plasma membrane. Under ionic conditions, which favor the reverse operation mode of the transporter, N206S exhibited an increased reverse transport capacity. Furthermore, if coexpressed in the same cell, N206S manifested a dominant negative effect on the wild-type GLT1 activity, whereas it did not affect wild-type EAAC1, These findings provide evidence for a role of the N-linked glycosylation in both cellular trafficking and transport function. The resulting alteration in glutamate clearance capacity likely contributes to excitotoxicity that participates in motor neuron degeneration in amyotrophic lateral sclerosis.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cecil B Day Lab Neuromuscular Res, Charlestown, MA 02129 USA; Univ Oslo, Inst Basic Med Sci, Dept Physiol, N-0337 Oslo, Norway	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Oslo	Hediger, MA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Membrane Biol Program, Harvard Inst Med Bldg,Rm 570,77 Ave Louis Pasteur, Boston, MA 02115 USA.	mhediger@rics.bwh.harvard.edu	Danbolt, Niels Christian/A-1907-2014	Danbolt, Niels Christian/0000-0003-4227-4520; Hediger, Matthias/0000-0003-1946-027X; Pasinelli, Piera/0000-0002-3385-2707; Trotti, Davide/0000-0001-6338-6404	NATIONAL INSTITUTE ON AGING [P01AG012992] Funding Source: NIH RePORTER; Fondazione Telethon Funding Source: Custom; AHRQ HHS [5F32HS10064] Funding Source: Medline; NIA NIH HHS [1PO1AG12992-04] Funding Source: Medline; Telethon [342/B] Funding Source: Medline; ONDIEH CDC HHS [1PO1ND31248-05] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Fondazione Telethon(Fondazione Telethon); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Telethon(Fondazione Telethon); ONDIEH CDC HHS		Aoki M, 1998, ANN NEUROL, V43, P645, DOI 10.1002/ana.410430514; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bergles DE, 1997, NEURON, V19, P1297, DOI 10.1016/S0896-6273(00)80420-1; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; CONRADT M, 1995, EUR J BIOCHEM, V229, P682, DOI 10.1111/j.1432-1033.1995.tb20514.x; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; Dehnes Y, 1998, J NEUROSCI, V18, P3606; Diamond JS, 1997, J NEUROSCI, V17, P4672; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Gaal L, 1998, J NEUROPHYSIOL, V79, P190, DOI 10.1152/jn.1998.79.1.190; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; HAYES G, 1994, J BIOL CHEM, V269, P24143; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kugler P, 1999, GLIA, V27, P129, DOI 10.1002/(SICI)1098-1136(199908)27:2<129::AID-GLIA3>3.0.CO;2-Y; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; Mennerick S, 1999, J NEUROSCI, V19, P9242; Meyer T, 1998, J NEUROL NEUROSUR PS, V65, P954, DOI 10.1136/jnnp.65.6.954; Meyer T, 1997, NEUROREPORT, V8, P775, DOI 10.1097/00001756-199702100-00039; Meyer T, 1996, ANN NEUROL, V40, P456, DOI 10.1002/ana.410400317; MEYER T, 1995, ANN NEUROL, V37, P817, DOI 10.1002/ana.410370618; Meyer T, 1998, NEUROSCI LETT, V241, P68, DOI 10.1016/S0304-3940(97)00973-7; Nagai M, 1998, NEUROSCI LETT, V244, P165, DOI 10.1016/S0304-3940(98)00158-X; Nguyen TT, 1996, J NEUROCHEM, V67, P645; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Rothstein JD, 1996, CLIN NEUROSCI, V3, P348; Roux MJ, 2000, NEURON, V25, P373, DOI 10.1016/S0896-6273(00)80901-0; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Trotti D, 1996, J BIOL CHEM, V271, P5976, DOI 10.1074/jbc.271.11.5976; Trotti D, 1999, NAT NEUROSCI, V2, P427, DOI 10.1038/8091; Trotti D, 1998, TRENDS PHARMACOL SCI, V19, P328, DOI 10.1016/S0165-6147(98)01230-9; Trotti D, 1997, EUR J NEUROSCI, V9, P2207, DOI 10.1111/j.1460-9568.1997.tb01388.x; Trotti D, 1997, EUR J NEUROSCI, V9, P1236, DOI 10.1111/j.1460-9568.1997.tb01478.x; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189, DOI 10.1124/mol.54.1.189; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	53	140	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					576	582		10.1074/jbc.M003779200	http://dx.doi.org/10.1074/jbc.M003779200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031254	hybrid			2022-12-27	WOS:000166280700078
J	Siskind, LJ; Colombini, M				Siskind, LJ; Colombini, M			The lipids C-2- and C-16-ceramide form large stable channels - Implications for apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; MEMBRANE-FUSION; CYTOCHROME-C; CERAMIDE; MITOCHONDRIAL; GENERATION; ACTIVATION; STABILITY; RELEASE	We report that physiological concentrations of both short- and long-chain ceramides, despite being lipids, form large stable pores in membranes. Some of these pores should be large enough to allow cytochrome c to permeate. Dihydroceramide differs from ceramide by the reduction of one double bond, and yet both its apoptogenic and channel-forming activities are greatly reduced. A structural model provides insight into how ceramides might form pores. According to a mathematical model, both the individual conductance of the channels and the overall membrane conductance are directly related to the overall concentration of ceramide in the membrane. Slight changes in concentration have dramatic effects on the size of the channels formed, providing an easy way for rapidly altering membrane permeability by changing the activity of local synthetic and catabolic enzymes. A possible role for these channels in apoptosis is discussed.	Univ Maryland, Dept Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Colombini, M (corresponding author), Univ Maryland, Dept Biol, College Pk, MD 20742 USA.	mc34@umail.umd.edu	Colombini, Marco/A-1540-2014	Siskind, Leah/0000-0001-5026-5187	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS042467] Funding Source: NIH RePORTER; NINDS NIH HHS [F31 NS042467, F31 NS042467-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ariga T, 1998, J LIPID RES, V39, P1; Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Castedo M, 1996, J IMMUNOL, V157, P512; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Huang HW, 1998, EUR BIOPHYS J BIOPHY, V27, P361, DOI 10.1007/s002490050143; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; PASCHER I, 1976, BIOCHIM BIOPHYS ACTA, V455, P433, DOI 10.1016/0005-2736(76)90316-3; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; RuizArguello MB, 1996, J BIOL CHEM, V271, P26616, DOI 10.1074/jbc.271.43.26616; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	33	231	237	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38640	38644		10.1074/jbc.C000587200	http://dx.doi.org/10.1074/jbc.C000587200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11027675	hybrid, Green Accepted			2022-12-27	WOS:000165739800068
J	O'Malley, KM; Cooperman, BS				O'Malley, KM; Cooperman, BS			Formation of the covalent chymotrypsin center dot antichymotrypsin complex involves no large-scale movement of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERPIN-PROTEINASE COMPLEX; REACTIVE CENTER LOOP; ALPHA-CHYMOTRYPSIN; CONFORMATIONAL-CHANGES; INHIBITION-MECHANISM; PROTEASE COMPLEXES; STRUCTURAL BASIS; ENERGY-TRANSFER; ACTIVE-SITE; BINDING	alpha (1)-Antichymotrypsin is a member of the serine proteinase inhibitor, or serpin, family that typically forms very long-lived, enzymatically inactive 1:1 complexes (denoted E*I*) with its target proteinases. Serpins share a conserved tertiary structure, in which an exposed region of amino acid residues (called the reactive center loop or RCL acts as bait for a target proteinase. Within E*'I*, the two proteins are linked covalently as a result of nucleophilic attack by Ser(195) of the serine proteinase on the P1 residue within the RCL of the serpin. This species is formally similar to the acyl enzyme species normally seen as an intermediate in serpin proteinase catalysis. However, its subsequent hydrolysis is extremely slow as a result of structural changes within the enzyme leading to distortion of the active site. There is at present an ongoing debate concerning the structure of the E*I* complex; in particular, as to whether the enzyme, bound to P1, maintains its original position at the top of the serpin molecule or instead translocates across the entire length of the serpin, with concomitant insertion of RCL residues P1-P14 within beta -sheet A and a large separation of the enzyme and RCL residue P1'. We report time-resolved fluorescence energy transfer and rapid mixing/quench studies that support the former model. Our results indicate that the distance between residue P1' in alpha (1)-antichymotrypsin and the amino terminus of chymotrypsin actually decreases on conversion of the encounter complex E.I to E*I*. These results led us to formulate a comprehensive mechanism that accounted both for our results and for those of others supporting the two different E*I* structures. In this mechanism, partial insertion of the RCL, with no large perturbation of the P1' enzyme distance, is followed by covalent acyl enzyme formation. Full insertion can subsequently take place, in a reversible fashion, with the position of equilibrium between the partially and fully inserted complexes depending on the particular serpin-proteinase pair under consideration.	Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	University of Pennsylvania	Cooperman, BS (corresponding author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.	cooprman@pobox.upenn.edu			NIA NIH HHS [AG 10599] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010599] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; BLEVINS RA, 1985, J BIOL CHEM, V260, P4264; BRUCH M, 1988, J BIOL CHEM, V263, P16626; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CONRAD RH, 1968, BIOCHEMISTRY-US, V7, P777, DOI 10.1021/bi00842a036; CORRIE JET, 1994, J CHEM SOC PERK T 1, P2975, DOI 10.1039/p19940002975; DIXON GH, 1957, J BIOL CHEM, V225, P1049; ENGH R, 1989, PROTEIN ENG, V2, P407, DOI 10.1093/protein/2.6.407; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; FINK AL, 1979, P NATL ACAD SCI USA, V76, P1566, DOI 10.1073/pnas.76.4.1566; FINK AL, 1976, BIOCHEMISTRY-US, V15, P1580, DOI 10.1021/bi00652a031; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; GROSSMAN SH, 1983, BIOCHEMISTRY-US, V22, P5369, DOI 10.1021/bi00292a018; HIRS CHW, 1956, J BIOL CHEM, V219, P611; HOANG DV, 1962, ARCH BIOCHEM BIOPH S, V1, P232; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KATZ DS, 1993, PROTEIN ENG, V6, P701, DOI 10.1093/protein/6.7.701; KELLA NKD, 1984, J BIOL CHEM, V259, P4777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; Luo Y, 1999, J BIOL CHEM, V274, P17733, DOI 10.1074/jbc.274.25.17733; MEEDOM B, 1956, ACTA CHEM SCAND, V10, P881, DOI 10.3891/acta.chem.scand.10-0881; Mellet P, 2000, J BIOL CHEM, V275, P10788, DOI 10.1074/jbc.275.15.10788; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Nash P, 2000, FEBS LETT, V475, P1, DOI 10.1016/S0014-5793(00)01620-3; OHLSSON K, 1976, CLIN SCI MOL MED, V51, P87, DOI 10.1042/cs0510087; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; Picard V, 1999, J BIOL CHEM, V274, P4586, DOI 10.1074/jbc.274.8.4586; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; RICHMOND V, 1966, BIOCHIM BIOPHYS ACTA, V127, P499, DOI 10.1016/0304-4165(66)90403-X; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHILLER PW, 1975, BIOCH FLUORESCENCE C, P285; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; Shrikumar A, 1998, J BIOL CHEM, V273, P17459, DOI 10.1074/jbc.273.28.17459; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Stone SR, 1997, ADV EXP MED BIOL, V425, P5; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; WACHSSTOCK DH, 1994, BIOPHYS J, V67, P1260, DOI 10.1016/S0006-3495(94)80598-3; Wells MJ, 1999, THROMB HAEMOSTASIS, V81, P325, DOI 10.1055/s-0037-1614472; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	53	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6631	6639		10.1074/jbc.M008478200	http://dx.doi.org/10.1074/jbc.M008478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11027695	hybrid			2022-12-27	WOS:000167261000074
J	Bell, AW; Ward, MA; Blackstock, WP; Freeman, HNM; Choudhary, JS; Lewis, AP; Chotai, D; Fazel, A; Gushue, JN; Paiement, J; Palcy, S; Chevet, E; Lafreniere-Roula, M; Solari, R; Thomas, DY; Rowley, A; Bergeron, JJM				Bell, AW; Ward, MA; Blackstock, WP; Freeman, HNM; Choudhary, JS; Lewis, AP; Chotai, D; Fazel, A; Gushue, JN; Paiement, J; Palcy, S; Chevet, E; Lafreniere-Roula, M; Solari, R; Thomas, DY; Rowley, A; Bergeron, JJM			Proteomics characterization of abundant Golgi membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE PROTEIN; ENDOPLASMIC-RETICULUM; BREFELDIN-A; VESICULAR TRANSPORT; VESICLE TRANSPORT; MASS-SPECTROMETRY; PLASMA-MEMBRANE; MEDIAL GOLGI; SEQUENCE; BINDING	A mass spectrometric analysis of proteins partitioning into Triton X-114 from purified hepatic Golgi apparatus (84% purity by morphometry, 122-fold enrichment over the homogenate for the Golgi marker galactosyl transferase) led to the unambiguous identification of 81 proteins including a novel Golgi-associated protein of 34 kDa (GPP34), The membrane protein complement was resolved by SDS-polyacrylamide gel electrophoresis and subjected to a hierarchical approach using delayed extraction matrix-assisted laser desorption ionization mass spectrometry characterization by peptide mass fingerprinting, tandem mass spectrometry to generate sequence tags, and Edman sequencing of proteins. Major membrane proteins corresponded to known Golgi residents, a Golgi lectin, anterograde cargo, and an abundance of trafficking proteins including KDEL receptors, p24 family members, SNAREs, Rabs, a single ARF-guanine nucleotide exchange factor, and two SCAMPs. Analytical fractionation and gold immunolabeling of proteins in the purified Golgi fraction were used to assess the intra-Golgi and total cellular distribution of GPP34, two SNAREs, SCAMPs, and the trafficking proteins GBF1, BAP31, and alpha (2)P24 identified by the proteomics approach as well as the endoplasmic reticulum contaminant calnexin, Although GPP34 has never previously been identified as a protein, the localization of GPP34 to the Golgi complex, the conservation of GPP34 from yeast to humans, and the cytosolically exposed location of GPP34 predict a role for a novel coat protein in Golgi trafficking.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England; Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3T 1J4, Canada	McGill University; GlaxoSmithKline; Universite de Montreal	Bergeron, JJM (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.	bergeron@med.mcgill.ca	Bergeron, John/AAW-1893-2021; chevet, eric/E-4992-2016; Lafreniere-Roula, Myriam/A-5443-2011; Choudhary, Jyoti/S-1232-2017; Thomas, David/M-7661-2017	chevet, eric/0000-0001-5855-4522; Choudhary, Jyoti/0000-0003-0881-5477; Thomas, David/0000-0002-8854-762X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Amshoff C, 1999, BIOL CHEM, V380, P669, DOI 10.1515/BC.1999.083; Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; ANTONY C, 1992, J CELL SCI, V103, P785; BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; Baranes D, 1996, P NATL ACAD SCI USA, V93, P4706, DOI 10.1073/pnas.93.10.4706; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; BAUDHUIN P, 1967, J CELL BIOL, V35, P631, DOI 10.1083/jcb.35.3.631; BEAUFAY H, 1964, BIOCHEM J, V92, P184, DOI 10.1042/bj0920184; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BONNER R, 1995, RAPID COMMUN MASS SP, V9, P1067, DOI 10.1002/rcm.1290091119; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Claude A, 1999, J CELL BIOL, V146, P71, DOI 10.1083/jcb.146.1.71; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Dominguez M, 1999, J CELL BIOL, V145, P673, DOI 10.1083/jcb.145.4.673; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; DUVE CD, 1971, J CELL BIOL, V50, pD20, DOI 10.1083/jcb.50.1.20d; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fiedler K, 1996, J CELL SCI, V109, P271; GOLGI C, 1898, ARCH ITAL BIOL, V30, P60; Gonatas JO, 1998, J CELL SCI, V111, P249; Harlow E., 1988, ANTIBODIES LAB MANUA; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jensen ON, 1997, ANAL CHEM, V69, P4741, DOI 10.1021/ac970896z; Kelner MJ, 2000, J BIOL CHEM, V275, P13000, DOI 10.1074/jbc.275.17.13000; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Lavoie C, 1999, J CELL BIOL, V146, P285, DOI 10.1083/jcb.146.2.285; Lin CC, 1999, J CELL BIOL, V147, P1457, DOI 10.1083/jcb.147.7.1457; Lippincott-Schwartz J, 1998, HISTOCHEM CELL BIOL, V109, P449, DOI 10.1007/s004180050247; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Mansour SJ, 1998, GENOMICS, V54, P323, DOI 10.1006/geno.1998.5563; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Paek I, 1997, J CELL BIOL, V137, P1017, DOI 10.1083/jcb.137.5.1017; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.3.CO;2-#; Schimmoller F, 1998, GENE, V216, P311, DOI 10.1016/S0378-1119(98)00349-7; SHEER DG, 1991, BIOTECHNIQUES, V11, P526; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; SINGERKRUGER B, 1993, J BIOL CHEM, V268, P14376; Singleton DR, 1997, J CELL SCI, V110, P2099; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Southern MR, 1998, BIOINFORMATICS, V14, P821, DOI 10.1093/bioinformatics/14.9.821; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; THORPE GHG, 1985, CLIN CHEM, V31, P1335; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEIBEL ER, 1979, STEREOLOGICAL METHOD, V1, P101; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Wilson AL, 1996, J BIOL CHEM, V271, P10932, DOI 10.1074/jbc.271.18.10932; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435	79	190	208	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5152	5165		10.1074/jbc.M006143200	http://dx.doi.org/10.1074/jbc.M006143200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11042173	hybrid			2022-12-27	WOS:000168484300085
J	Alberts, AS				Alberts, AS			Identification of a carboxyl-terminal diaphanous-related formin homology protein autoregulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CYTOSKELETON; SACCHAROMYCES-CEREVISIAE; RHO-FAMILY; FISSION YEAST; CELL-DIVISION; SRC KINASE; REORGANIZATION; CYTOKINESIS; ACTIVATION; DROSOPHILA	Mammalian and fungal Diaphanous-related formin homology (DRF) proteins contain several regions of conserved sequence homology. These include an amino-terminal GTPase binding domain (GBD) that interacts with activated Rho family members and formin homology domains that mediate targeting or interactions with signaling kinases and actin-binding proteins. DRFs also contain a conserved Dia-autoregulatory domain (DAD) in their carboxyl termini that binds the GBD. The GBD is a bifunctional autoinhibitory domain that is regulated by activated Rho. Expression of the isolated DAD in cells causes actin fiber formation and stimulates serum response factor-regulated gene expression. Inhibitor experiments show that the effects of exogenous DAD expression are dependent upon cellular Dia proteins. Alanine substitution of DAD consensus residues that disrupt GBD binding also eliminate DAD biological activity. Thus, DAD expression activates nuclear signaling and actin remodeling by mimicking activated Rho and unlatching the autoinhibited state of the cellular complement of Dia proteins.	Van Andel Res Inst, Lab Cell Struct & Signal Integrat, Grand Rapids, MI 49503 USA	Van Andel Institute	Alberts, AS (corresponding author), 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.							Afshar K, 2000, DEVELOPMENT, V127, P1887; Akada R, 1997, MOL GEN GENET, V254, P267, DOI 10.1007/s004380050415; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Chang F, 1997, J CELL BIOL, V137, P169, DOI 10.1083/jcb.137.1.169; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; FRAZIER JA, 1997, CURR BIOL, V7, P414; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harris SD, 1997, EMBO J, V16, P3474, DOI 10.1093/emboj/16.12.3474; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Kikyo M, 1999, ONCOGENE, V18, P7046, DOI 10.1038/sj.onc.1203184; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Suetsugu S, 1999, FEBS LETT, V457, P470, DOI 10.1016/S0014-5793(99)01086-8; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Uetz P, 1996, J BIOL CHEM, V271, P33525, DOI 10.1074/jbc.271.52.33525; Umikawa M, 1998, ONCOGENE, V16, P2011, DOI 10.1038/sj.onc.1201724; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Welch MD, 1999, TRENDS CELL BIOL, V9, P423, DOI 10.1016/S0962-8924(99)01651-7; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Zahner JE, 1996, MOL CELL BIOL, V16, P1857; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	42	263	271	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2824	2830		10.1074/jbc.M006205200	http://dx.doi.org/10.1074/jbc.M006205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035012	hybrid			2022-12-27	WOS:000166784800073
J	Aris, L; Gilchrist, A; Rens-Domiano, S; Meyer, C; Schatz, PJ; Dratz, EA; Hamm, HE				Aris, L; Gilchrist, A; Rens-Domiano, S; Meyer, C; Schatz, PJ; Dratz, EA; Hamm, HE			Structural Requirements for the Stabilization of metarhodopsin II by the C terminus of the alpha subunit of transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; 4TH CYTOPLASMIC LOOP; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; RHODOPSIN MUTANTS; LIGHT-SCATTERING; RECEPTOR-BINDING; AMINO-ACIDS; ACTIVATION; GTP	The retinal receptor rhodopsin undergoes a conformational change upon light excitation to form metarhodopsin II (Meta II), which allows interaction and activation of its cognate G protein, transducin (G(t)). A C-terminal Il-amino acid peptide from transducin, G(t alpha)-(340-350), has been shown to both bind and stabilize the Meta II conformation, mimicking heterotrimeric G,. Using a combinatorial library we identified analogs of G(t alpha)-(340-350) that bound light-activated rhodopsin with high affinity (Martin, E. L., Rens-Domiano, S., Schatz, P. J,, and Hamm, H. E. (1996) J. Biol. Chem. 271, 361-366). We have made peptides with key substitutions either on the background of the native G(t alpha)-(340-350) sequence or on the high affinity sequences and used the stabilization of Meta II as a tool to determine which amino acids are critical in G protein-rhodopsin interaction. Removal of the positive charge at the N termini by acylation or delocalization of the charge by K to R substitution enhances the affinity of the G(t alpha)-(340-350) peptides for Meta II, whereas a decrease was observed following C-terminal amidation. Cys-347, a residue conserved in pertussis toxin-sensitive G proteins, was shown to interact with a hydrophobic site in Meta II. These studies provide further insight into the mechanism of interaction between the G(t alpha) C terminus and light-activated rhodopsin.	Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Affymax Res Inst, Palo Alto, CA 94304 USA; Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA	Northwestern University; Montana State University System; Montana State University Bozeman	Aris, L (corresponding author), Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA.	heidi.hamm@mcmail.vanderbilt.edu	Gilchrist, Annette/I-4465-2014; Hamm, Heidi E/G-2374-2014	Gilchrist, Annette/0000-0003-2386-7646; 	NATIONAL EYE INSTITUTE [R01EY010291, R01EY006062] Funding Source: NIH RePORTER; NEI NIH HHS [EY10291, EY06062, EY06913] Funding Source: Medline; NHLBI NIH HHS [HL07829] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Arimoto R, 2000, BIOPHYS J, V78, p42A; Bae H, 1999, J BIOL CHEM, V274, P14963, DOI 10.1074/jbc.274.21.14963; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; DRATZ E, 1996, BIOPHYS J, V70, P16; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HAMM HE, 1989, J BIOL CHEM, V264, P11475; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HOFMANN KP, 1985, J BIOL CHEM, V260, P7990; IYENGAR R, 1980, J BIOL CHEM, V255, P312; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE CH, 1995, MOL PHARMACOL, V47, P218; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Marsh SR, 1998, MOL PHARMACOL, V53, P981; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; MIN KC, 1993, J BIOL CHEM, V268, P9400; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Natochin M, 1999, J BIOL CHEM, V274, P7865, DOI 10.1074/jbc.274.12.7865; Natochin M, 2000, J BIOL CHEM, V275, P2669, DOI 10.1074/jbc.275.4.2669; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PANICO J, 1990, J BIOL CHEM, V265, P18922; PFISTER C, 1983, EUR J BIOCHEM, V136, P489, DOI 10.1111/j.1432-1033.1983.tb07767.x; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1994, BIOCHEM J, V299, P351, DOI 10.1042/bj2990351; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; ROJAS FJ, 1985, J BIOL CHEM, V260, P7829; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STRYER L, 1983, METHOD ENZYMOL, V96, P617; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEST RE, 1985, J BIOL CHEM, V260, P4428; YAMAZAKI A, 1982, METHOD ENZYMOL, V81, P526	65	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2333	2339		10.1074/jbc.M002533200	http://dx.doi.org/10.1074/jbc.M002533200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11018024	hybrid			2022-12-27	WOS:000166784800007
J	Bjorkman, AM; Dunten, P; Sandgren, MOJ; Dwarakanath, VN; Mowbray, SL				Bjorkman, AM; Dunten, P; Sandgren, MOJ; Dwarakanath, VN; Mowbray, SL			Mutations that affect ligand binding to the Escherichia coli aspartate receptor - Implications for transmembrane signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS; SALMONELLA-TYPHIMURIUM; TAR CHEMORECEPTOR; SENSORY RECEPTOR; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL-CHANGES; MALTOSE CHEMOTAXIS; PROTEIN STRUCTURES; CROSS-LINKING; DOMAIN	Three arginine residues of the binding site of the Escherchia coli aspartate receptor contribute to its high affinity for aspartate (K-d similar to3 mum). Site-directed mutations at residue 64 had the greatest effect on aspartate binding. No residue could substitute for the native arginine; all changes resulted in an apparent K-d of similar to 35 mM. These mutations had little impact on maltose responses. At residue Arg-69, a lysine substitution was least disruptive, conferring an apparent K-d of 0.3 mM for aspartate, Results obtained for an alanine mutant were similar to those with cysteine and histidine mutants (K-d similar to5 mM) indicating that side chain size was not an important factor here. Proline and aspartate caused more severe defects, presumably for reasons related to conformation and charge. The impact of residue 69 mutations on the maltose response was small. Mutations at Arg-73 had similar effects on aspartate binding (K-d 0.3-7 mm) but more severe consequences for maltose responses. Larger side chains resulted in the best aspartate binding, implying steric considerations are important here. Signaling in the mutant proteins was surprisingly robust. Given aspartate binding, signaling occurred with essentially wild-type efficiency. These results were evaluated in the context of available structural data.	Swedish Univ Agr Sci, Dept Biol Mol, Ctr Biomed, S-75124 Uppsala, Sweden; Uppsala Univ, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Swedish University of Agricultural Sciences; Uppsala University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mowbray, SL (corresponding author), Swedish Univ Agr Sci, Dept Biol Mol, Ctr Biomed, Box 590, S-75124 Uppsala, Sweden.		Mowbray, Sherry L/D-2141-2013	Sandgren, Mats/0000-0002-2358-4534				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BOGONEZ E, 1985, P NATL ACAD SCI USA, V82, P4891, DOI 10.1073/pnas.82.15.4891; Bornhorst JA, 2000, BIOCHEMISTRY-US, V39, P9486, DOI 10.1021/bi0002737; BOWIE JU, 1995, ACTA CRYSTALLOGR D, V51, P145, DOI 10.1107/S0907444994010498; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Chi YI, 1997, FEBS LETT, V414, P327, DOI 10.1016/S0014-5793(97)01027-2; CLARKE S, 1979, J BIOL CHEM, V254, P9695; Djordjevic S, 1998, J STRUCT BIOL, V124, P189, DOI 10.1006/jsbi.1998.4034; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; GARDINA P, 1992, J BACTERIOL, V174, P1528, DOI 10.1128/jb.174.5.1528-1536.1992; Gardina PJ, 1998, MOL MICROBIOL, V29, P1147, DOI 10.1046/j.1365-2958.1998.00964.x; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HILL AV, 1910, J PHYSIOL-LONDON, V90, pR4; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KERMODE JC, 1989, BIOCHEM PHARMACOL, V38, P2053, DOI 10.1016/0006-2952(89)90057-9; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kolodziej AF, 1996, BIOCHEMISTRY-US, V35, P14782, DOI 10.1021/bi961481v; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MANSON MD, 1985, J BIOL CHEM, V260, P9727; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1993, J BIOL CHEM, V268, P19991; MIZUNO T, 1986, J BACTERIOL, V165, P890, DOI 10.1128/jb.165.3.890-895.1986; MOWBRAY SL, 1990, J BIOL CHEM, V265, P15638; Mowbray SL, 1998, J STRUCT BIOL, V124, P257, DOI 10.1006/jsbi.1998.4043; MOWBRAY SL, 1987, CELL, V50, P171, DOI 10.1016/0092-8674(87)90213-3; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Ottemann KM, 1998, BIOCHEMISTRY-US, V37, P7062, DOI 10.1021/bi980305e; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; SCOTT WG, 1994, STRUCTURE, V2, P877, DOI 10.1016/S0969-2126(94)00088-3; SHAKKED Z, 1994, NATURE, V368, P469, DOI 10.1038/368469a0; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; TERWILLIGER TC, 1983, J BIOL CHEM, V258, P9608; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; WOLFF C, 1983, THESIS U KONSTANZ GE; YEH JI, 1993, J BIOL CHEM, V268, P9787; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507; Zhang YH, 1999, P NATL ACAD SCI USA, V96, P939, DOI 10.1073/pnas.96.3.939; ZHANG YH, 1992, J BIOL CHEM, V267, P22813	53	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2808	2815		10.1074/jbc.M009593200	http://dx.doi.org/10.1074/jbc.M009593200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042221	hybrid			2022-12-27	WOS:000166784800071
J	Kobayashi, H; Suzuki, M; Tanaka, Y; Hirashima, Y; Terao, T				Kobayashi, H; Suzuki, M; Tanaka, Y; Hirashima, Y; Terao, T			Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL INVASION; LEWIS-LUNG-CARCINOMA; BREAST-CANCER CELLS; PLASMINOGEN-ACTIVATOR; GENE-EXPRESSION; DISTINCT FORMS; LINK PROTEIN; DOMAIN-II; METASTASIS; BINDING	Urinary trypsin inhibitor (UTI), a Kunitz-type protease inhibitor, interacts with cells as a negative modulator of the invasive cells, Human ovarian cancer cell line, HRA,was treated with phorbol ester (PMA) to evaluate the effect on expression of urokinase-type plasminogen activator (uPA), since the action of uPA has been implicated in matrix degradation and cell motility. Preincubation of the cells with UTI reduced the ability of PMA to trigger the uPA expression at the gene level and at the protein level. UTI-induced down-regulation of PMA-stimulated uPA expression is irreversible and is independent of a cytotoxic effect. Down-regulation of uPA by UTI is mediated by its binding to the cells. me next asked whether the mechanism of inhibition of uPA expression by UTI was due to interference with the protein kinase C second messenger system. An assay for PKC activity demonstrated that UTI does not directly inhibit the catalytic activity of PKC and that PIMA translocation of PKC from cytosol to membrane was inhibited by UTI, indicating that UTI inhibits the activation cascade of PKC. PMA could also activate a signaling pathway involving MEK1/ERK2/c-Jun-dependent uPA expression. When cells were preincubated with UTI, we could detect suppression of phosphorylation of these proteins. Like several types of PHC inhibitor, UTI inhibited PMA-stimulated invasiveness. We conclude that UTI markedly suppresses the cell motility possibly through negative regulation of PKC and MEK/ERK/c-Jun-dependent mechanisms, and that these changes in behavior are correlated with a coordinated down-regulation of uPA which is likely to contribute to the cell invasion processes.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Hamamatsu, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handacho 3600, Hamamatsu, Shizuoka 4313192, Japan.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DUBOIS P, 1988, BIOCHEM PHARMACOL, V37, P2139, DOI 10.1016/0006-2952(88)90572-2; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; FRIEDRICH B, 1988, IMMUNOBIOLOGY, V176, P465, DOI 10.1016/S0171-2985(88)80027-5; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; JOHNSON MD, 1993, CANCER RES, V53, P873; KIKUCHI Y, 1987, CANCER RES, V47, P592; Kobayashi H, 1999, ENDOCRINOLOGY, V140, P3835, DOI 10.1210/en.140.8.3835; Kobayashi H, 1996, EUR J CELL BIOL, V71, P380; KOBAYASHI H, 1995, CANCER RES, V55, P1847; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361; KOBAYASHI H, 1994, CLIN EXP METASTAS, V12, P117, DOI 10.1007/BF01753978; KOBAYASHI H, 1995, BRIT J CANCER, V72, P1131, DOI 10.1038/bjc.1995.476; KOBAYASHI H, 1995, INT J CANCER, V63, P455, DOI 10.1002/ijc.2910630326; Kobayashi H, 1998, EUR J BIOCHEM, V253, P817, DOI 10.1046/j.1432-1327.1998.2530817.x; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; KOBAYASHI H, 1994, CANCER RES, V54, P844; KOBAYASHI H, 1994, INT J CANCER, V57, P378, DOI 10.1002/ijc.2910570315; Kobayashi H, 1998, BBA-PROTEIN STRUCT M, V1383, P253, DOI 10.1016/S0167-4838(97)00215-X; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; MIZUNO K, 1995, FEBS LETT, V359, P259, DOI 10.1016/0014-5793(95)00042-8; NAGAMINE Y, 1995, FIBRINOLYSIS; NIIYA K, 1994, THROMB HAEMOSTASIS, V72, P92; Reuning U, 1998, INT J ONCOL, V13, P893; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; SAKSELA O, 1981, ANAL BIOCHEM, V111, P276, DOI 10.1016/0003-2697(81)90564-9; SEKIGUCHI K, 1987, BIOCHEM BIOPH RES CO, V145, P797, DOI 10.1016/0006-291X(87)91035-7; Sun GW, 1999, J HISTOCHEM CYTOCHEM, V47, P1433, DOI 10.1177/002215549904701109; WALTON GM, 1987, ANAL BIOCHEM, V161, P425, DOI 10.1016/0003-2697(87)90471-4; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Young SW, 1996, FEBS LETT, V384, P181, DOI 10.1016/0014-5793(96)00287-6	36	63	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2015	2022		10.1074/jbc.M007650200	http://dx.doi.org/10.1074/jbc.M007650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050091	hybrid			2022-12-27	WOS:000166528000051
J	Lien, E; Chow, JC; Hawkins, LD; McGuinness, PD; Miyake, K; Espevik, T; Gusovsky, F; Golenbock, DT				Lien, E; Chow, JC; Hawkins, LD; McGuinness, PD; Miyake, K; Espevik, T; Gusovsky, F; Golenbock, DT			A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/toll-like receptor 4 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE DIFFERENTIATION ANTIGEN; TUMOR-NECROSIS-FACTOR; CUTTING EDGE; SOLUBLE CD14; ENDOTOXIN; LPS; RECOGNITION; EXPRESSION; PROTEIN; RESPONSIVENESS	ER-112022 is a novel acyclic synthetic lipid A analog that contains six symmetrically organized fatty acids on a noncarbohydrate backbone. Chinese hamster ovary (CHO)-K1 fibroblasts and U373 human astrocytoma cells do not respond to lipopolysaccharide (LPS) in the absence of CD14. In contrast, exposure to ER-112022 effectively induced activation of CHO and U373 cells under serum-free conditions. Expression of CD14 was not necessary for cells to respond to ER-112022, although the presence of soluble CD14 enhanced the sensitivity of the response. Several lines of evidence suggested that ER-112022 stimulates cells via the LPS signal transduction pathway. First, the diglucosamine based LPS antagonists E5564 and E5531 blocked ER-112022-induced stimulation of CHO-RI, U373, and RAW264.7 cells. Second, ER-112022 was unable to activate C3H/HeJ mouse peritoneal macrophages, containing a mutation in Toll-like receptor (TLR) 4, as well as HEK293 cells, an epithelial cell line that does not express TLR4, Third, ER-112022 activated NF-KB in HEK293 cells transfected with TLR4/ MD-2. Finally, tumor necrosis factor release from primary human monocytes exposed to ER-112022 was blocked by TLR4 antibodies but not by TLR2 antibodies. Our results suggest that ER-112022 and the family of lipid A-like LPS antagonists can functionally associate with TLR4 in the absence of CD14. Synthetic molecules like ER-112022 may prove to be valuable tools to characterize elements in the LPS receptor complex, as well as to activate or inhibit the TLR4 signaling pathway for therapeutic purposes.	Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, Univ Med Ctr, N-7489 Trondheim, Norway; Boston Med Ctr, Evans Biomed Res Ctr, Boston, MA 02118 USA; Eisai Res Inst, Andover, MA 01810 USA; Saga Med Sch, Saga 8498501, Japan	Norwegian University of Science & Technology (NTNU); Boston Medical Center; Eisai Co Ltd; Saga University	Lien, E (corresponding author), Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, Univ Med Ctr, N-7489 Trondheim, Norway.	egil.lien@medisin.ntnu.no			NIAID NIH HHS [AI38515] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline; NIGMS NIH HHS [GM54060] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054060, R01GM054060] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; Delude RL, 1998, J IMMUNOL, V161, P3001; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; Flo TH, 2000, J IMMUNOL, V164, P2064, DOI 10.4049/jimmunol.164.4.2064; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; HAZIOT A, 1988, J IMMUNOL, V141, P547; Heine H, 1999, J IMMUNOL, V162, P6971; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoshino K, 1999, J IMMUNOL, V162, P3749; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Ingalls RR, 1997, J IMMUNOL, V159, P433; Ingalls RR, 1998, J IMMUNOL, V161, P5413; Ingalls RR, 1999, J BIOL CHEM, V274, P13993, DOI 10.1074/jbc.274.20.13993; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KOVACH NL, 1990, J EXP MED, V172, P77, DOI 10.1084/jem.172.1.77; Lien E, 1998, BLOOD, V92, P2084, DOI 10.1182/blood.V92.6.2084.418k26_2084_2092; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; LYNN WA, 1991, J IMMUNOL, V147, P3072; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MANTHEY CL, 1994, J IMMUNOL, V153, P2653; Means TK, 1999, J IMMUNOL, V163, P3920; Means TK, 1999, J IMMUNOL, V163, P6748; Ogata H, 2000, J EXP MED, V192, P23, DOI 10.1084/jem.192.1.23; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Rossignol DP, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P699; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SIMMONS DL, 1989, BLOOD, V73, P284; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J EXP MED, V186, P2051, DOI 10.1084/jem.186.12.2051; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4	52	70	103	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1873	1880		10.1074/jbc.M009040200	http://dx.doi.org/10.1074/jbc.M009040200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11032843	hybrid			2022-12-27	WOS:000166528000032
J	Sung, JS; Bennett, SE; Mosbaugh, DW				Sung, JS; Bennett, SE; Mosbaugh, DW			Fidelity of uracil-initiated base excision DNA repair in Escherichia coli cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASES; 5'-TERMINAL DEOXYRIBOSE-PHOSPHATE; GLYCOSYLASE; PROTEIN; RESIDUES; SITE; NUCLEOTIDE; SUBSTRATE; DEOXYRIBOPHOSPHODIESTERASE; 3,N-4-ETHENOCYTOSINE	The error frequency and mutational specificity associated with Escherichia coli uracil-initiated base excision repair were measured using an M13mp2 lacZ alpha DNA-based reversion assay. Repair was detected in cell-free extracts utilizing a form I DNA substrate containing a site-specific uracil residue. The rate and extent of complete uracil-DNA repair were measured using uracil-DNA glycosylase (Ung)- or double-strand uracil-DNA glycosylase (Dug)-proficient and -deficient isogenic E. coli cells. In reactions utilizing E. coli NR8051 (ung(+) dug(+)), similar to 80% of the uracil-DNA was repaired, whereas about 20% repair was observed using NR8052 (ung(-) dug(+)) cells, The Ung-deficient reaction was insensitive to inhibition by the PBS2 uracil-DNA glycosylase inhibitor protein, implying the involvement of Dug activity. Under both conditions, repaired form I DNA accumulated in conjunction with limited DNA synthesis associated with a repair patch size of 1-20 nucleotides. Reactions conducted with E. coli BH156 (ung(-) dug(+)), BH157 (ung(+) dug(-)), and BH158 (ung(-) dug(-)) cells provided direct evidence for the involvement of Dug in uracil-DNA repair. The rate of repair was B-fold greater in the Ung-proficient than in the Ung-deficient reactions, while repair was not detected in reactions deficient in both Ung and Dug. The base substitution reversion frequency associated with uracil-DNA repair was determined to be similar to5.5 x 10(-4) with transversion mutations dominating the mutational spectrum. In the presence of Dug, inactivation of Ung resulted in up to a 7.3-fold increase in mutation frequency without a dramatic change in mutational specificity.	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Oregon State Univ, Ctr Environm Hlth Sci, Corvallis, OR 97331 USA	Oregon State University; Oregon State University; Oregon State University	Mosbaugh, DW (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA.	mosbaugd@ucs.orst.edu			NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; GISH G, 1988, SCIENCE, V240, P1520, DOI 10.1126/science.2453926; GOSSARD F, 1978, EUR J BIOCHEM, V82, P321, DOI 10.1111/j.1432-1033.1978.tb12026.x; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; Lutsenko E, 1999, J BIOL CHEM, V274, P31034, DOI 10.1074/jbc.274.43.31034; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; Roy S, 1998, PROTEIN EXPRES PURIF, V13, P155, DOI 10.1006/prep.1998.0878; Sanderson RJ, 1996, J BIOL CHEM, V271, P29170, DOI 10.1074/jbc.271.46.29170; Sanderson RJ, 1998, J BIOL CHEM, V273, P24822, DOI 10.1074/jbc.273.38.24822; SANDERSON RJ, 2000, IN PRESS PROG NUCL A, V68; SANDERSON RJ, 1998, THESIS OREGON STATE; SANDIGURSKY M, 1992, NUCLEIC ACIDS RES, V20, P4699, DOI 10.1093/nar/20.18.4699; Sandigursky M, 1998, NUCLEIC ACIDS RES, V26, P1282, DOI 10.1093/nar/26.5.1282; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; Sung JS, 2000, BIOCHEMISTRY-US, V39, P10224, DOI 10.1021/bi0007066; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; TYE BK, 1978, P NATL ACAD SCI USA, V75, P233, DOI 10.1073/pnas.75.1.233; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776	41	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2276	2285		10.1074/jbc.M008147200	http://dx.doi.org/10.1074/jbc.M008147200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035036	hybrid			2022-12-27	WOS:000166528000084
J	Chen, VC; Chao, L; Pimenta, DC; Bledsoe, G; Juliano, L; Chao, J				Chen, VC; Chao, L; Pimenta, DC; Bledsoe, G; Juliano, L; Chao, J			Identification of a major heparin-binding site in kallistatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C INHIBITOR; ANTITHROMBIN-III-HEPARIN; COFACTOR-II; TISSUE KALLIKREIN; ACTIVATION; THROMBIN; GLYCOSAMINOGLYCANS; LOCALIZATION; SULFATE	Kallistatin is a heparin-binding serine proteinase inhibitor (serpin), which specifically inhibits human tissue kallikrein by forming a covalent complex. The inhibitory activity of kallistatin is blocked upon its binding to heparin, In this study we attempted to locate the heparin-binding site of kallistatin using synthetic peptides derived from its surface regions and by site-directed mutagenesis of basic residues in these surface regions. Two synthetic peptides, containing clusters of positive-charged residues, one derived from the F helix and the other from the region encompassing the H helix and C2 sheet of kallistatin, were used to assess their heparin binding activity. Competition assay analysis showed that the peptide derived from the Il helix and C2 sheet displayed higher and specific heparin binding activity. The basic residues in both regions were substituted to generate three kallistatin double mutants K187A/K188A (mutations in the F helix) and K307A/R308A and K312A/ K313A (mutations in the region between the H helix and Ca sheet), using a kallistatin P1Arg variant as a scaffold. Analysis of these mutants by heparin-affinity chromatography showed that the heparin binding capacity of the variant K187A/K188A was not altered, whereas the binding capacity of K307A/308A and K312A/K313A mutants was markedly reduced. Titration analysis with heparin showed that the K312A/K313A mutant has the highest dissociation constant. Like kallistatin, the binding activity of K187A/K188A to tissue kallikrein was blocked by heparin, whereas K307A/R308A and K312A/ K313A retained significant binding and inhibitory activities in the presence of heparin, These results indicate that the basic residues, particularly Lys(312)-Lys(313) in the region between the H helix and C2 sheet of kallistatin, comprise a major heparin-binding site responsible for its heparin-suppressed tissue kallikrein binding.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Escola Paulista Med, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Medical University of South Carolina; Universidade Federal de Sao Paulo (UNIFESP)	Chao, J (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.		Pimenta, Daniel C/B-4361-2008; Juliano, Luiz/D-7204-2012	Pimenta, Daniel C/0000-0003-2406-0860; Juliano, Luiz/0000-0002-5589-2822	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler A J, 1973, Methods Enzymol, V27, P675; Belzar KJ, 2000, J BIOL CHEM, V275, P8733, DOI 10.1074/jbc.275.12.8733; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chao JL, 1997, J CLIN INVEST, V100, P11, DOI 10.1172/JCI119502; Chen LM, 1997, HUM GENE THER, V8, P341, DOI 10.1089/hum.1997.8.3-341; CHEN VC, 2001, IN PRESS J BIOL CHEM, V276; CHEN VC, 2000, BIOCHIM BIOPHYS ACTA, V147, P237; Cooper ST, 1996, CLIN APPL THROMB-HEM, V2, P185, DOI 10.1177/107602969600200307; ECKE S, 1992, J BIOL CHEM, V267, P7048; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1992, J BIOL CHEM, V267, P8789; PRIGLINGER U, 1994, J BIOL CHEM, V269, P14705; SHIMAMOTO K, 1980, J CLIN ENDOCR METAB, V51, P840, DOI 10.1210/jcem-51-4-840; Shirk RA, 1996, ARTERIOSCL THROM VAS, V16, P1138, DOI 10.1161/01.ATV.16.9.1138; SHIRK RA, 1994, J BIOL CHEM, V269, P28690; SONJA E, 1997, EUR J BIOCHEM, V248, P475; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WHINNA HC, 1991, J BIOL CHEM, V266, P8129; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	30	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1276	1284		10.1074/jbc.M005791200	http://dx.doi.org/10.1074/jbc.M005791200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11016932	hybrid			2022-12-27	WOS:000166430900057
J	Kliger, Y; Gallo, SA; Peisajovich, SG; Munoz-Barroso, I; Avkin, S; Blumenthal, R; Shai, Y				Kliger, Y; Gallo, SA; Peisajovich, SG; Munoz-Barroso, I; Avkin, S; Blumenthal, R; Shai, Y			Mode of action of an antiviral peptide from HIV-1 - Inhibition at a post-lipid mixing stage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 ENVELOPE GLYCOPROTEIN; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; CRYSTAL-STRUCTURE; COILED-COIL; SIV GP41; PHOSPHOLIPID-MEMBRANES; TRANSMEMBRANE PROTEIN; CHEMOKINE RECEPTORS; CYTOPLASMIC TAIL	DP178, a synthetic peptide corresponding to a segment of the transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus, type 1 (HIV-l), is a potent inhibitor of viral infection and virus-mediated cell-cell fusion, Nevertheless, DP178 does not contain gp41 coiled-coil cavity binding residues postulated to be essential for inhibiting HIV-1 entry. We find that DP178 inhibits phospholipid redistribution mediated by the HIV-1 envelope glycoprotein at a concentration 8 times greater than that of solute redistribution (the IC,, values are 43 and 335 nM, respectively), In contrast, C34, a synthetic peptide which overlaps with DP178 but contains the cavity binding residues, did not show this phenomenon (11 and 25 nM, respectively). The ability of DP178 to inhibit membrane fusion at a post-lipid mixing stage correlates with its ability to bind and oligomerize on the surface of membranes. Furthermore, our results are consistent with a model in which DP178 inhibits the formation of gp41 viral hairpin structure at low affinity, whereas C34 inhibits its formation at high affinity: the failure to form the viral hairpin prevents both lipid and solute from redistributing between cells, However, our data also suggest an additional membrane-bound inhibitory site for DP178 in the ectodomain of gp41 within a region immediately adjacent to the membrane-spanning domain. By binding to this higher affinity site, DP178 inhibits the recruitment of several. gp41-membrane complexes, thus inhibiting fusion pore formation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; NCI, Lab Expt & Computat Biol, NIH, Frederick, MD 21702 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il	Peisajovich, Sergio/C-6641-2011	Gallo, Stephen/0000-0001-6043-2153				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; AROETI B, 1991, J BIOL CHEM, V266, P15845; Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 1999, PROTEIN SCI, V8, P1904, DOI 10.1110/ps.8.9.1904; Carr CM, 2000, NATURE, V404, P347, DOI 10.1038/35006200; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; CHERNOMORDIK L, 1994, J VIROL, V68, P7115, DOI 10.1128/JVI.68.11.7115-7123.1994; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; De Clercq E, 1999, Drugs R D, V2, P321, DOI 10.2165/00126839-199902050-00010; Delahunty MD, 1996, VIROLOGY, V218, P94, DOI 10.1006/viro.1996.0169; Doranz BJ, 1999, J VIROL, V73, P10346, DOI 10.1128/JVI.73.12.10346-10358.1999; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EISENBERG D, 1990, BIOPOLYMERS, V29, P171, DOI 10.1002/bip.360290122; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Fass D, 1995, CURR BIOL, V5, P1377, DOI 10.1016/S0960-9822(95)00275-2; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; FREY S, 1995, J VIROL, V69, P1462, DOI 10.1128/JVI.69.3.1462-1472.1995; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; FUJII G, 1992, PROTEIN SCI, V1, P1454, DOI 10.1002/pro.5560011107; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; GAWRISCH K, 1993, BIOCHEMISTRY-US, V32, P3112, DOI 10.1021/bi00063a024; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; HAFFAR OK, 1988, J CELL BIOL, V107, P1677, DOI 10.1083/jcb.107.5.1677; HAFFAR OK, 1991, VIROLOGY, V180, P439, DOI 10.1016/0042-6822(91)90054-F; JONAK ZL, 1993, AIDS RES HUM RETROV, V9, P23, DOI 10.1089/aid.1993.9.23; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kliger Y, 2000, J MOL BIOL, V301, P905, DOI 10.1006/jmbi.2000.4004; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Kliger Y, 1997, BIOCHEMISTRY-US, V36, P5157, DOI 10.1021/bi962935r; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Matsuzaki K, 1997, BIOPHYS J, V73, P831, DOI 10.1016/S0006-3495(97)78115-3; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MILLER MA, 1993, VIROLOGY, V196, P89, DOI 10.1006/viro.1993.1457; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Munoz-Barroso I, 1999, J VIROL, V73, P6089; Murphy PM, 2000, PHARMACOL REV, V52, P145; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Pilcher CD, 1999, AIDS, V13, P2171, DOI 10.1097/00002030-199910220-00024; RABENSTEIN M, 1995, BIOCHEMISTRY-US, V34, P13390, DOI 10.1021/bi00041a016; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Rizo J, 1998, NAT STRUCT BIOL, V5, P839, DOI 10.1038/2280; RIZZO V, 1987, BIOCHEMISTRY-US, V26, P2751, DOI 10.1021/bi00384a015; Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; SATTENTAU QJ, 1995, VIROLOGY, V206, P713, DOI 10.1016/S0042-6822(95)80094-8; SCHWARZ G, 1986, BIOCHIM BIOPHYS ACTA, V861, P141, DOI 10.1016/0005-2736(86)90412-8; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; Stephenson J, 1999, JAMA-J AM MED ASSOC, V282, P1994, DOI 10.1001/jama.282.21.1994; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; YANG CL, 1995, P NATL ACAD SCI USA, V92, P9871, DOI 10.1073/pnas.92.21.9871; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116	88	140	146	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1391	1397		10.1074/jbc.M004113200	http://dx.doi.org/10.1074/jbc.M004113200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11027678	hybrid			2022-12-27	WOS:000166430900072
J	Nilius, B; Vennekens, R; Prenen, J; Hoenderop, JGJ; Droogmans, G; Bindels, RJM				Nilius, B; Vennekens, R; Prenen, J; Hoenderop, JGJ; Droogmans, G; Bindels, RJM			The single pore residue Asp(542) determines Ca2+ permeation and Mg2+ block of the epithelial Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-IDENTIFICATION; CAPSAICIN-RECEPTOR; REABSORPTION; EXPRESSION; CALCIUM; CELLS; HEAT	The epithelial Ca2+ channel (ECaC), which was recently cloned from rabbit kidney, exhibits distinctive properties that support a facilitating role in transcellular Ca2+ (re)absorption, ECaC is structurally related to the family of six transmembrane-spanning ion channels with a pore-forming region between 55 and S6, Using point mutants of the conserved negatively charged amino acids present in the putative pore, we have identified a single aspartate residue that determines Ca2+ permeation of ECaC and modulation by extracellular Mg2+. Mutation of the aspartate residue, D542A, abolishes Ca2+ permeation and Ca2+ dependent current decay as well as block by extracellular Mg2+, whereas monovalent cations still permeate the mutant channel. Variation of the side chain length in mutations D542N, D542E, and D542M attenuated Ca2+ permeability and Ca2+-dependent current decay, Block of monovalent currents through ECaC by Mg2+ was decreased. Exchanging the aspartate residue for a positively charged amino acid, D542K, resulted in a nonfunctional channel, Mutations of two neighboring negatively charged residues, i,e. Glu(535) and Asp(550), had only minor effects on Ca2+ permeation properties.	Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium; Univ Nijmegen, Inst Cellular Signaling, Dept Cell Physiol, NL-6525 GA Nijmegen, Netherlands	KU Leuven; Radboud University Nijmegen	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Bindels, René JM/B-9824-2013; Hoenderop, Joost G.J./H-8047-2014; Vennekens, Rudi/AAQ-1664-2020	Bindels, René JM/0000-0003-1167-1339; Hoenderop, Joost G.J./0000-0002-1816-8544; Vennekens, Rudi/0000-0002-2564-5150				Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Hoenderop JGJ, 2000, AM J PHYSIOL-RENAL, V278, pF352, DOI 10.1152/ajprenal.2000.278.3.F352; Hoenderop JGJ, 1999, P NATL ACAD SCI USA, V96, P6084, DOI 10.1073/pnas.96.11.6084; Hoenderop JGJ, 1999, KIDNEY INT, V55, P225, DOI 10.1046/j.1523-1755.1999.00228.x; Hoenderop JGJ, 1999, BIOCHEM BIOPH RES CO, V261, P488, DOI 10.1006/bbrc.1999.1059; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Hoenderop JGJ, 2000, CURR OPIN NEPHROL HY, V9, P335, DOI 10.1097/00041552-200007000-00003; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; NILIUS B, 1994, J GEN PHYSIOL, V103, P787, DOI 10.1085/jgp.103.5.787; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; UGATE G, 1998, BIOL RES, V31, P17; Vennekens R, 1999, J PHYSIOL-LONDON, V515, P75, DOI 10.1111/j.1469-7793.1999.075ad.x; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211	17	138	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1020	1025		10.1074/jbc.M006184200	http://dx.doi.org/10.1074/jbc.M006184200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035011	Green Published, hybrid			2022-12-27	WOS:000166430900023
J	Hengst, U; Albrecht, H; Hess, D; Monard, D				Hengst, U; Albrecht, H; Hess, D; Monard, D			The phosphatidylethanolamine-binding protein is the prototype of a novel family of serine protease inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN CYTOSOL; AMINO-ACID-SEQUENCE; NEURITE OUTGROWTH; CRYSTAL-STRUCTURE; 21-KDA PROTEIN; MESSENGER-RNA; RAF KINASE; THROMBIN; PURIFICATION; HOMOLOGY	Serine proteases are involved in many processes in the nervous system and specific inhibitors tightly control their proteolytic activity. Thrombin is thought to play a role in tissue development and homeostasis. To date, protease nexin-l is the only known endogenous protease inhibitor that specifically interferes with thrombotic activity and is expressed in the brain. In this study, we report the detection of a novel thrombin inhibitory activity in the brain of protease nexin-1((-/-)) mice. Purification and subsequent analysis by tandem mass spectrometry identified this protein as the phosphatidylethanolamine-binding protein (PEBP), We demonstrate that PEEP exerts inhibitory activity against several serine proteases including thrombin, neuropsin, and chymotrypsin, whereas trypsin, tissue type plasminogen activator, and elastase are not affected. Since PEEP does not share significant homology with other serine protease inhibitors, our results define it as the prototype of a novel class of serine protease inhibitors. PEEP immunoreactivity is found on the surface of Rat-1 fibroblast cells and although its sequence contains no secretion signal, PEBP-H(6) can be purified from the conditioned medium upon recombinant expression.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Monard, D (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	monard@fmi.ch	Hengst, Ulrich/L-1413-2014; Albrecht, Hugo/F-9569-2011	Hengst, Ulrich/0000-0002-8061-2861; Albrecht, Hugo/0000-0002-3951-1866				Apostolidis A, 1997, CELL SIGNAL, V9, P439, DOI 10.1016/S0898-6568(97)00034-X; ARAKI Y, 1992, BIOL REPROD, V47, P832, DOI 10.1095/biolreprod47.5.832; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BERNIER I, 1986, BIOCHIM BIOPHYS ACTA, V871, P19, DOI 10.1016/0167-4838(86)90128-7; BERNIER I, 1984, BIOCHIM BIOPHYS ACTA, V790, P174, DOI 10.1016/0167-4838(84)90221-8; BOLLENGIER F, 1988, J NEUROCHEM, V50, P1210, DOI 10.1111/j.1471-4159.1988.tb10594.x; BOLLENGIER F, 1980, NEUROPEPTIDES, V1, P119, DOI 10.1016/0143-4179(80)90015-3; Bradley D, 1996, NATURE, V379, P791, DOI 10.1038/379791a0; Bruun AW, 1998, BIOCHEMISTRY-US, V37, P3351, DOI 10.1021/bi971286w; BUCQUOY S, 1994, EUR J BIOCHEM, V225, P1203, DOI 10.1111/j.1432-1033.1994.1203b.x; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; Davies BJ, 1998, J BIOL CHEM, V273, P23004, DOI 10.1074/jbc.273.36.23004; DAWES J, 1984, THROMB RES, V36, P397, DOI 10.1016/0049-3848(84)90296-2; Frayne J, 1999, CELL TISSUE RES, V298, P415, DOI 10.1007/s004419900113; GEMS D, 1995, J BIOL CHEM, V270, P18517, DOI 10.1074/jbc.270.31.18517; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; LOBOS E, 1990, MOL BIOCHEM PARASIT, V39, P135, DOI 10.1016/0166-6851(90)90016-F; Luthi A, 1997, J NEUROSCI, V17, P4688; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MONARD D, 1983, PROG BRAIN RES, V58, P359, DOI 10.1016/S0079-6123(08)60037-0; MORTENSEN UH, 1998, HDB PROTEOLYTIC ENZY, P389; Ohshima S, 1997, MOL GEN GENET, V254, P186, DOI 10.1007/s004380050407; Ojika K, 2000, PROG NEUROBIOL, V60, P37, DOI 10.1016/S0301-0082(99)00021-0; Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075; PERRY ACF, 1994, BIOCHEM J, V301, P235, DOI 10.1042/bj3010235; PIKIELNY CW, 1994, NEURON, V12, P35, DOI 10.1016/0896-6273(94)90150-3; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; SCHOENTGEN F, 1987, EUR J BIOCHEM, V166, P333, DOI 10.1111/j.1432-1033.1987.tb13519.x; SCHOENTGEN F, 1995, FEBS LETT, V369, P22, DOI 10.1016/0014-5793(95)00376-K; SEDDIQI N, 1994, J MOL EVOL, V39, P655, DOI 10.1007/BF00160411; Seeds NW, 1999, P NATL ACAD SCI USA, V96, P14118, DOI 10.1073/pnas.96.24.14118; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; TROTTEIN F, 1995, MOL BIOCHEM PARASIT, V70, P235, DOI 10.1016/0166-6851(95)00031-U; Tsirka SE, 1997, J NEUROSCI, V17, P543; Turgeon VL, 1997, BRAIN RES REV, V25, P85, DOI 10.1016/S0165-0173(97)00015-5; VANNOSTRAND WE, 1988, BIOCHEMISTRY-US, V27, P2176, DOI 10.1021/bi00406a054; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686	49	153	168	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					535	540		10.1074/jbc.M002524200	http://dx.doi.org/10.1074/jbc.M002524200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11034991	hybrid			2022-12-27	WOS:000166280700072
J	Lozano, J; Menendez, S; Morales, A; Ehleiter, D; Liao, WC; Wagman, R; Haimovitz-Friedman, A; Fuks, Z; Kolesnick, R				Lozano, J; Menendez, S; Morales, A; Ehleiter, D; Liao, WC; Wagman, R; Haimovitz-Friedman, A; Fuks, Z; Kolesnick, R			Cell autonomous apoptosis defects in acid sphingomyelinase knockout fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; EPSTEIN-BARR-VIRUS; STRESS-INDUCED APOPTOSIS; NIEMANN-PICK DISEASE; IONIZING-RADIATION; CERAMIDE FORMATION; DEFICIENT MICE; ACTIVATION; PROTEIN	A body of evidence suggests that stress-induced sphingomyelin hydrolysis to the second messenger ceramide initiates apoptosis in some cells. Although studies using lymphoblasts from Niemann-Pick disease patients or acid sphingomyelinase (ASMase)-deficient mice have provided genetic support for this hypothesis, these models have not been universally accepted as definitive. Here, we show that mouse embryonic fibroblasts (MEFs) prepared from osmose mice manifest cell autonomous defects in apoptosis in response to several stresses. In particular, asmase(-/-) MEFs failed to generate ceramide and were totally resistant to radiation-induced apoptosis but remained sensitive to staurosporine, which did not induce ceramide, asmase(-/-) MEFs were also partially resistant to tumor necrosis factor alpha/ actinomycin D and serum withdrawal. Thus, resistance to apoptosis in asmase(-/-) MEFs was not global but rather stress type specific. Most importantly, the sensitivity to stress could be restored in the asmase(-/-) MEFs by administration of natural ceramide, Overcoming apoptosis resistance by natural ceramide is evidence that it is the lack of ceramide, not ASMase, that determines apoptosis sensitivity. The ability to rescue the apoptotic phenotype without reversing the genotype by the product of the enzymatic deficiency provides proof that ceramide is obligate for apoptosis induction in response to some stresses.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.		Morales, Albert/E-2988-2013; Lozano, José/C-2760-2014	Morales, Albert/0000-0001-8702-2269; Lozano, José/0000-0002-8187-2833	NATIONAL CANCER INSTITUTE [R01CA085714] Funding Source: NIH RePORTER; NCI NIH HHS [CA85714, CA52462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bieberich E, 1999, J NEUROCHEM, V72, P1040, DOI 10.1046/j.1471-4159.1999.0721040.x; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bose R, 1998, J BIOL CHEM, V273, P28852, DOI 10.1074/jbc.273.44.28852; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Chmura SJ, 1997, CANCER RES, V57, P4340; Chmura SJ, 1997, CANCER RES, V57, P1270; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Khanna KK, 1997, J BIOL CHEM, V272, P9489; KIM MY, 1991, J BIOL CHEM, V266, P484; Kimura K, 1999, CANCER RES, V59, P1606; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Laethem RM, 1998, BLOOD, V91, P4350, DOI 10.1182/blood.V91.11.4350.411k27_4350_4360; LEIST M, 1994, J IMMUNOL, V153, P1778; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; Lin XH, 1998, J BIOL CHEM, V273, P14374, DOI 10.1074/jbc.273.23.14374; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LOZANO J, 2000, IN PRESS CELL DEATH; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Michael JM, 1997, CANCER RES, V57, P3600; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Moley KH, 1998, NAT MED, V4, P1421, DOI 10.1038/4013; Nix M, 2000, CELL DEATH DIFFER, V7, P413, DOI 10.1038/sj.cdd.4400666; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OMURA S, 1995, J ANTIBIOT, V48, P535, DOI 10.7164/antibiotics.48.535; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; Payne SG, 1999, J CELL PHYSIOL, V180, P263, DOI 10.1002/(SICI)1097-4652(199908)180:2<263::AID-JCP14>3.0.CO;2-H; Pena LA, 2000, CANCER RES, V60, P321; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shao RG, 1997, CANCER RES, V57, P4029; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Xing HR, 2000, J BIOL CHEM, V275, P17276, DOI 10.1074/jbc.C900989199; Xu Y, 1998, GASTROENTEROLOGY, V115, P1229, DOI 10.1016/S0016-5085(98)70095-2; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	58	77	78	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					442	448		10.1074/jbc.M006353200	http://dx.doi.org/10.1074/jbc.M006353200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031259	hybrid			2022-12-27	WOS:000166280700060
J	Maemura, K; de la Monte, SM; Chin, MT; Layne, MD; Hsieh, CM; Yet, SF; Perrella, MA; Lee, ME				Maemura, K; de la Monte, SM; Chin, MT; Layne, MD; Hsieh, CM; Yet, SF; Perrella, MA; Lee, ME			CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAS DOMAIN PROTEIN-1; RPER2 MESSENGER-RNA; SUPRACHIASMATIC NUCLEUS; MYOCARDIAL-INFARCTION; PERIPHERAL-TISSUES; DROSOPHILA PERIOD; ENDOTHELIAL-CELLS; CLOCK PROTEIN; TRANSCRIPTION; LOOP	The onset of myocardial infarction occurs frequently in the early morning, and it may partly result from circadian variation of fibrinolytic activity. Plasminogen activator inhibitor-1 activity shows a circadian oscillation and may account for the morning onset of myocardial infarction, However, the molecular mechanisms regulating this circadian oscillation remain unknown. Recent evidence indicates that basic helix-loop-helix (bHLH)/PAS domain transcription factors play a crucial role in controlling the biological clock that controls circadian rhythm. We isolated a novel bHLH/PAS protein, cycle-like factor (CLIF) rom human umbilical vein endothelial cells. CLIF shares high homology with Drosophila CYCLE, one of the essential transcriptional regulators of circadian rhythm. CLIF is expressed in endothelial cells and neurons in the brain, including the suprachiasmatic nucleus, the center of the circadian clock, In endothelial cells, CLIF forms a heterodimer with CLOCK and up-regulates the PAI-1 gene through E-box sites. Furthermore, Period2 and Cryptochrome1, whose expression show a circadian oscillation in peripheral tissues, inhibit the PAI-1 promoter activation by the CLOCK:CLIF heterodimer. These results suggest that CLIF regulates the circadian oscillation of PAI-1 gene expression in endothelial cells. In addition, the results potentially provide a molecular basis for the morning onset of myocardial infarction,	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care, Boston, MA 02115 USA; Brown Univ, Rhode Isl Hosp, Sch Med, Dept Pathol & Med, Providence, RI 02903 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Maemura, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan.		Yet, Shaw-Fang/B-1067-2010; Yet, Shaw-Fang/O-8583-2019; de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306; Layne, Matthew/0000-0003-0007-4870; Yet, Shaw-Fang/0000-0001-9097-3962	NHLBI NIH HHS [HL 60788, HL 10113, HL 03745] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788, F32HL010113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADREOTTI F, 1991, CHRONOBIOL INT, V8, P336; ANGLETON P, 1989, CIRCULATION, V79, P101, DOI 10.1161/01.CIR.79.1.101; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BRAUNWALD E, 1995, CIRCULATION, V91, P1604, DOI 10.1161/01.CIR.91.5.1604; Brown SA, 1999, CURR OPIN GENET DEV, V9, P588, DOI 10.1016/S0959-437X(99)00009-X; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; DelAMonte SM, 1997, MOL CHEM NEUROPATHOL, V30, P139, DOI 10.1007/BF02815155; DELAMONTE SM, 1995, AM J PATHOL, V147, P934; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Guney HZ, 1999, CHRONOBIOL INT, V16, P779, DOI 10.3109/07420529909016945; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Kurnik Peter B., 1996, Cardiology Clinics, V14, P251; Maemura K, 1999, J BIOL CHEM, V274, P31565, DOI 10.1074/jbc.274.44.31565; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; Oishi K, 1998, NEUROSCI LETT, V256, P117, DOI 10.1016/S0304-3940(98)00765-4; Oishi K, 1998, BIOCHEM BIOPH RES CO, V253, P199, DOI 10.1006/bbrc.1998.9779; Roest M, 2000, CIRCULATION, V101, P67, DOI 10.1161/01.CIR.101.1.67; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Sassone-Corsi P, 1998, NATURE, V392, P871, DOI 10.1038/31821; Schibler U, 2000, NATURE, V404, P25, DOI 10.1038/35003674; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	35	165	172	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36847	36851		10.1074/jbc.C000629200	http://dx.doi.org/10.1074/jbc.C000629200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11018023	hybrid			2022-12-27	WOS:000165577700058
J	Huai, JS; Drescher, U				Huai, JS; Drescher, U			An ephrin-A-dependent signaling pathway controls integrin function and is linked to the tyrosine phosphorylation of a 120-kDa protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; RECEPTOR; FAMILY; LIGANDS; KINASE; CAVEOLAE; REQUIRES; CELLS; ACTIVATION; DOMAINS	The Eph family of receptor tyrosine kinases and their ligands, the ephrins, have been implicated in the development of the retinotectal projection. Here, glycosylphosphatidylinositol-anchored A-ephrins are not only expressed in the tectum but also on retinal axons, raising the possibility that they function in this context as receptors. We now show that activation of ephrin-A2 or ephrin-A5 by one of their receptors, ephA3, results in a beta1-integrin-dependent increased adhesion of ephrin-A-expressing cells to laminin. In the search for an ephrin-A-dependent signaling pathway controlling integrin activation, we identified a 120-kDa raft membrane protein that is tyrosine-phosphorylated specifically after ephrin-A activation. Tyrosine phosphorylation of this protein is not seen after stimulating ephrin-A2-expressing cells with basic fibroblast growth factor, epidermal growth factor, insulin growth factor, or fetal calf serum containing a large set of different growth factors. The role of p120 as a mediator of an ephrin-A-integrin coupling is supported by the finding that inhibiting tyrosine phosphorylation of p120 correlates with an abolishment of the beta1-dependent cell adhesion.	Max Planck Dev Biol, Dept Phys Biol, D-72076 Tubingen, Germany	Max Planck Society	Drescher, U (corresponding author), Kings Coll London, MRC, Ctr Dev Neurobiol, 4th Floor,New Hunts House,Guys Campus, London SE1 1UL, England.	uwe.drescher@kcl.ac.uk	Drescher, Uwe/C-5438-2009	Drescher, Uwe/0000-0001-9725-7643				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; Ciossek T, 1998, EUR J NEUROSCI, V10, P1574, DOI 10.1046/j.1460-9568.1998.00180.x; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Davy A, 2000, J NEUROCHEM, V74, P676, DOI 10.1046/j.1471-4159.2000.740676.x; DOHERTY P, 1993, J CELL BIOL, V122, P181, DOI 10.1083/jcb.122.1.181; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; Dutting D, 1999, DEV BIOL, V216, P297, DOI 10.1006/dbio.1999.9489; ECONOMIDES AN, 1995, SCIENCE, V270, P1351, DOI 10.1126/science.270.5240.1351; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Massague J, 1996, NATURE, V382, P29, DOI 10.1038/382029a0; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; O'Leary DDM, 1999, CELL, V96, P255, DOI 10.1016/S0092-8674(00)80565-6; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	45	125	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6689	6694		10.1074/jbc.M008127200	http://dx.doi.org/10.1074/jbc.M008127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11053419	hybrid			2022-12-27	WOS:000167261000080
J	O'Handley, SF; Dunn, CA; Bessman, MJ				O'Handley, SF; Dunn, CA; Bessman, MJ			Orf135 from Escherichia coli is a nudix hydrolase specific for CTP, dCTP, and 5-methyl-dCTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSE PYROPHOSPHATASE; MUTT MOTIF FAMILY; SACCHAROMYCES-CEREVISIAE; CATALYTIC DOMAIN; SCHIZOSACCHAROMYCES-POMBE; STREPTOCOCCUS-PNEUMONIAE; BARTONELLA-BACILLIFORMIS; DNA 5-METHYLCYTOSINE; PROTEIN; CLONING	Orf135 from Escherichia coli is a new member of the Nudix (nucleoside diphosphate linked to some other moiety, x) hydrolase family of enzymes with substrate specificity for CTP, dCTP, and 5-methyl-dCTP. The gene has been cloned for overexpression, and the protein has been overproduced, purified, and characterized. Orf135 is most active on 5-methyl-dCTP (k(cat)/K-m = 301,000 m(-1) s(-1)), followed by CTP (k(cat)/K-m = 47,000 M-1 s(-1)) and dCTP (k(cat)/K-m = 18,000 M-1 s(-1)). Unlike other nucleoside triphosphate pyrophophohydrolases of the Nudix hydrolase family discovered thus far, Orf135 is highly specific for pyrimidine (deoxy)nucleoside triphosphates. Like other Nudix hydrolases, the enzyme cleaves its substrates to produce a nucleoside monophosphate and inorganic pyrophosphate, has an alkaline pH optimum, and requires a divalent metal cation for catalysis, with magnesium yielding optimal activity. Because of the nature of its substrate specificity, Orf135 may play a role in pyrimidine biosynthesis, lipid biosynthesis, and in controlling levels of 5-methyl-dCTP in the cell.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	O'Handley, SF (corresponding author), Univ Richmond, Dept Chem, Richmond, VA 23173 USA.	sohandle@richmond.edu		Dunn, Christopher/0000-0001-7899-0110; O'Handley, Suzanne/0000-0001-8373-0065	NIGMS NIH HHS [GM 18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BESSMAN MJ, 1958, P NATL ACAD SCI USA, V44, P633, DOI 10.1073/pnas.44.7.633; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; Cartwright JL, 1999, BIOCHEM BIOPH RES CO, V256, P474, DOI 10.1006/bbrc.1999.0354; Cleland W W, 1979, Methods Enzymol, V63, P103; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; CRONAN JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Hankin S, 1997, INT J BIOCHEM CELL B, V29, P317, DOI 10.1016/S1357-2725(96)00153-7; Hatch GM, 1996, J BIOL CHEM, V271, P25810, DOI 10.1074/jbc.271.42.25810; Ingram SW, 1999, BIOCHEMISTRY-US, V38, P3649, DOI 10.1021/bi982951j; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MATHEWS CK, 1964, J BIOL CHEM, V239, P2957; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; McLennan AG, 1999, INT J MOL MED, V4, P79; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; NEUHARD J, 1996, ESCHERICHIA COLI SAL, V1, P580; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; Raffaelli N, 1999, FEBS LETT, V444, P222, DOI 10.1016/S0014-5793(99)00068-X; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; Siegfried Z, 1997, CURR BIOL, V7, pR305, DOI 10.1016/S0960-9822(06)00144-8; VILPO JA, 1991, MUTAT RES, V256, P29, DOI 10.1016/0921-8734(91)90030-F; VILPO JA, 1993, MUTAT RES, V286, P217, DOI 10.1016/0027-5107(93)90186-J; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V696, P31, DOI 10.1016/0167-4781(82)90006-9; WEBER DJ, 1992, J BIOL CHEM, V267, P16939	44	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5421	5426		10.1074/jbc.M004100200	http://dx.doi.org/10.1074/jbc.M004100200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11053429	hybrid			2022-12-27	WOS:000167115100003
J	Hartford, OM; Wann, ER; Hook, M; Foster, TJ				Hartford, OM; Wann, ER; Hook, M; Foster, TJ			Identification of residues in the Staphylococcus aureus fibrinogen-binding MSCRAMM clumping factor A (ClfA) that are important for ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PROTEINS; NUCLEOTIDE-SEQUENCE; GAMMA-CHAIN; CELL-WALL; RECEPTOR; DOMAIN; FIBRONECTIN; PEPTIDES; ADHERENCE; CLEAVAGE	Clumping factor A (ClfA) is a cell surface-associated protein of Staphylococcus aureus that promotes binding of this pathogen to both soluble and immobilized fibrinogen (Fg), Previous studies have localized the Fg-binding activity of ClfA to residues 221-559 within the A region of this protein. In addition, the C-terminal part of the A region (residues 484-550) has been implicated as being important for Fg binding, In this study, we further investigate the involvement of this part of ClfA in the interaction of this protein with Fg, Polyclonal antibodies generated against a recombinant protein encompassing residues 500-559 of the A region inhibited the interaction of both S, aureus and recombinant ClfA with immobilized Fg in a dose-dependent manner. Using site-directed mutagenesis, two adjacent residues, Glu(526) and Val(527), were identified as being important for the activity of ClfA S. aureus expressing ClfA containing either the E526A or V5275 substitution exhibited a reduced ability to bind to soluble Fg and to adhere to immobilized Fg, Furthermore, bacteria expressing ClfA containing both substitutions were almost completely defective in Fg binding. The E526A and V527S substitutions were also introduced into recombinant ClfA (rClfA-(221-559)) expressed in Escherichia coli, The single mutant rClfA-(221-559) proteins showed a significant reduction in affinity for both immobilized Fg and a synthetic fluorescein-labeled C-terminal gamma -chain peptide compared with the wild-type protein, whereas the double mutant rClfA-(221-559) protein was almost completely defective in binding to either species. Substitution of Glu(526) and/or Val(527) did not appear to alter the secondary structure of rClfA-(221-559) as determined by far-UV circular dichroism spectroscopy. These data suggest that the C terminus of the A region may contain at least part of the Fg-binding site of ClfA and that Glu(526) and Val(527) may be involved in ligand recognition.	Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland; Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Dept Biochem & Biophys, Houston, TX 77030 USA	Trinity College Dublin; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Foster, TJ (corresponding author), Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland.	tfoster@tcd.ie			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGUSTIN J, 1990, FEMS MICROBIOL LETT, V66, P203, DOI 10.1016/0378-1097(90)90283-V; Deivanayagam CCS, 1999, ACTA CRYSTALLOGR D, V55, P554, DOI 10.1107/S0907444998012426; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Fa W., 1995, PRINCIPLES PRACTICES, V4, P1754; Foster TJ, 1998, METHOD MICROBIOL, V27, P433; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GULINO D, 1992, J BIOL CHEM, V267, P1001; Hartford O, 1999, MICROBIOL-SGM, V145, P2497, DOI 10.1099/00221287-145-9-2497; Hartford O, 1997, MOL MICROBIOL, V25, P1065, DOI 10.1046/j.1365-2958.1997.5291896.x; HAWIGER J, 1982, BIOCHEMISTRY-US, V21, P1407, DOI 10.1021/bi00535a047; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; JONSSON K, 1991, EUR J BIOCHEM, V202, P1041, DOI 10.1111/j.1432-1033.1991.tb16468.x; Josefsson E, 1998, MICROBIOL-UK, V144, P3387, DOI 10.1099/00221287-144-12-3387; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; McCrea KW, 2000, MICROBIOL-SGM, V146, P1535, DOI 10.1099/00221287-146-7-1535; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; OSKOUIAN B, 1990, J BACTERIOL, V172, P3804, DOI 10.1128/jb.172.7.3804-3812.1990; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SMITH JW, 1994, J BIOL CHEM, V269, P960; Spraggon G, 1998, P NATL ACAD SCI USA, V95, P9099, DOI 10.1073/pnas.95.16.9099; STRONG DD, 1982, BIOCHEMISTRY-US, V21, P1414, DOI 10.1021/bi00535a048; SWITALSKI LM, 1989, J BIOL CHEM, V264, P21080; Tung HS, 2000, BIOCHEM J, V345, P611, DOI 10.1042/0264-6021:3450611; VAUDAUX P, 1993, J INFECT DIS, V167, P633, DOI 10.1093/infdis/167.3.633; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863	39	56	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2466	2473		10.1074/jbc.M007979200	http://dx.doi.org/10.1074/jbc.M007979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11044451	Green Published, hybrid			2022-12-27	WOS:000166784800024
J	Lamb, TM; Xu, WJ; Diamond, A; Mitchell, AP				Lamb, TM; Xu, WJ; Diamond, A; Mitchell, AP			Alkaline response genes of Saccharomyces cerevisiae and their relationship to the RIM101 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER TRANSCRIPTION FACTOR; MEMBRANE H+-ATPASE; PH-REGULATED GENE; CANDIDA-ALBICANS; PLASMA-MEMBRANE; AMBIENT PH; PHOSPHATASE CALCINEURIN; BINDING-SITES; ENA1 GENE; YEAST	Environmental pH exerts broad control over growth and differentiation, but the molecular responses to external pH changes are poorly understood. Here we have used open reading frame macroarray hybridization to identify alkaline response genes in Saccharomyces cer evisiae. Northern or lacZ fusion assays confirmed the alkaline induction of two ion pump genes (ENA1 and VMA4), several ion limitation genes (CTR3, FRE1, PHO11/12, and PHO84), a siderophore-iron transporter gene (ARN4/ENB1), two transcription factor genes (NRG2 and TIS11), and two predicted membrane protein genes (YAR068W/YHR214W and YOL154W). Unlike ENA1 and SHC1, these new alkaline response genes are not induced by high salinity. The known pH-responsive genes in other fungi depend on the conserved PacC/Rim101p transcription factor, but induction of several of these new genes relied upon Rim101p-independent pH signaling mechanisms. Rim101p-dependent genes were also dependent on Rim13p, a protease required for Rim101p processing. The Rim101p-dependent gene VMA4 is required for growth in alkaline conditions, illustrating how Rim101p may control adaptation. Because Rim101p activates ion pump genes, we tested the role of RIM101 in ion homeostasis and found that RIM101 promotes resistance to elevated cation concentrations. Thus, gene expression surveys can reveal new functions for characterized transcription factors in addition to uncovering physiological responses to environmental conditions.	Columbia Univ, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Canc Res Inst, New York, NY 10032 USA; Columbia Univ, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Mitchell, AP (corresponding author), Columbia Univ, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.	apm4@columbia.edu	Xu, Wenjie/F-5453-2010	Mitchell, Aaron/0000-0002-0868-4000	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039531] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39531] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; Bearson S, 1997, FEMS MICROBIOL LETT, V147, P173, DOI 10.1016/S0378-1097(96)00503-4; Brink SJ, 1999, ACTA PAEDIATR, V88, P14, DOI 10.1111/j.1651-2227.1999.tb14335.x; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Davis D, 2000, MOL CELL BIOL, V20, P971, DOI 10.1128/MCB.20.3.971-978.2000; Davis D, 2000, INFECT IMMUN, V68, P5953, DOI 10.1128/IAI.68.10.5953-5959.2000; De Bernardis F, 1998, INFECT IMMUN, V66, P3317, DOI 10.1128/IAI.66.7.3317-3325.1998; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DESTEENSMA HY, 1989, CURR GENET, V16, P131, DOI 10.1007/BF00391468; El Barkani A, 2000, MOL CELL BIOL, V20, P4635, DOI 10.1128/MCB.20.13.4635-4647.2000; Espeso EA, 1996, J BIOL CHEM, V271, P28825, DOI 10.1074/jbc.271.46.28825; Falk GW, 1999, ENDOSCOPY, V31, P9, DOI 10.1055/s-1999-13643; FOURY F, 1990, J BIOL CHEM, V265, P18554; Futai E, 1999, MOL GEN GENET, V260, P559, DOI 10.1007/s004380050929; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; Gragnani A, 1998, THEOR POPUL BIOL, V54, P257, DOI 10.1006/tpbi.1997.1377; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; HO MN, 1993, J BIOL CHEM, V268, P221; Hong SK, 1999, BIOCHEM BIOPH RES CO, V255, P116, DOI 10.1006/bbrc.1999.0158; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kaiser C., 1994, METHODS YEAST GENETI; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; Lambert M, 1997, MOL CELL BIOL, V17, P3966, DOI 10.1128/MCB.17.7.3966; LI W, 1996, THESIS COLUMBIA U; Li WS, 1997, GENETICS, V145, P63; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Louden JD, 1999, KIDNEY INT, V56, pS85, DOI 10.1046/j.1523-1755.1999.07319.x; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Montecucco C, 1999, FEBS LETT, V452, P16, DOI 10.1016/S0014-5793(99)00652-3; Muhlschlegel FA, 1997, MOL CELL BIOL, V17, P5960; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Ogawa N, 1995, MOL GEN GENET, V249, P406, DOI 10.1007/BF00287102; OGAWA N, 1995, MOL CELL BIOL, V15, P997; OREJAS M, 1995, GENE DEV, V9, P1622, DOI 10.1101/gad.9.13.1622; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Porta A, 1999, J BACTERIOL, V181, P7516, DOI 10.1128/JB.181.24.7516-7523.1999; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Proft M, 1999, MOL CELL BIOL, V19, P537; Ramon AM, 1999, J BACTERIOL, V181, P7524, DOI 10.1128/JB.181.24.7524-7530.1999; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; Segurado M, 1999, INFECT IMMUN, V67, P2377, DOI 10.1128/IAI.67.5.2377-2382.1999; Sentandreu M, 1998, J BACTERIOL, V180, P282, DOI 10.1128/JB.180.2.282-289.1998; SMITH HE, 1989, MOL CELL BIOL, V9, P2142, DOI 10.1128/MCB.9.5.2142; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Suarez T, 1996, MOL MICROBIOL, V20, P529, DOI 10.1046/j.1365-2958.1996.5421065.x; Tenney KA, 1999, MOL CELL BIOCHEM, V191, P161, DOI 10.1023/A:1006893824947; TILBURN J, 1995, EMBO J, V14, P779, DOI 10.1002/j.1460-2075.1995.tb07056.x; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Treton B, 2000, MOL GEN GENET, V263, P505, DOI 10.1007/s004380051195; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VANDERREST ME, 1995, MICROBIOL REV, V59, P304, DOI 10.1128/MMBR.59.2.304-322.1995; Withee JL, 1998, GENETICS, V149, P865	59	196	204	2	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1850	1856		10.1074/jbc.M008381200	http://dx.doi.org/10.1074/jbc.M008381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050096	hybrid			2022-12-27	WOS:000166528000029
J	Quick, M; Loo, DDF; Wright, EM				Quick, M; Loo, DDF; Wright, EM			Neutralization of a conserved amino acid residue in the human Na+/glucose transporter (hSGLT1) generates a glucose-gated H+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; COTRANSPORTER SGLT1; NA+/PROLINE TRANSPORTER; ELECTROGENIC PROPERTIES; MEMBRANE TOPOLOGY; LACTOSE PERMEASE; PLASMA-MEMBRANE; SUGAR-TRANSPORT; NA+; BINDING	The role of conserved Asp(204) in the human high affinity Na+/glucose cotransporter (hSGLT1) was investigated by site-directed mutagenesis combined with functional assays exploiting the Xenopus oocyte expression system. Substitution of H+ for Na+ reduces the apparent affinity of hSGLT1 for glucose from 0.3 to 6 mM. The apparent affinity for H+ (7 muM) is about three orders of magnitude higher than for Na+ (6 mM). Cation/glucose cotransport exhibits a coupling ratio of 2 Na+ (or 2 H+):1. Pre-steady-state kinetics indicate that similar Na+- or H+-induced conformational changes are the basis for coupled transport. Replacing Asp204 with Glu increases the apparent affinity for H+ by >20-fold with little impact on the apparent Na+ affinity. This implies that the length of the carboxylate side chain is critical for cation selectivity. Neutralization of (Asp204 Asp --> Asn or Cys) reveals glucose evoked H+ currents that were one order of magnitude greater than Na+ currents. These phlorizin-sensitive H+ currents reverse and are enhanced by internal acidification of oocytes. Together with a H+ to sugar stoichiometry as high as 145:1, these results favor a glucose-gated H+ channel activity of the mutant. Our observations support the idea that cotransporters and channels share common features.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Quick, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.				NIDDK NIH HHS [DK19567] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ambroise Y, 2000, BIOCHEMISTRY-US, V39, P1338, DOI 10.1021/bi9916224; Chen XZ, 1997, BIOPHYS J, V73, P2503, DOI 10.1016/S0006-3495(97)78278-X; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; Cordat E, 2000, BIOCHEMISTRY-US, V39, P4493, DOI 10.1021/bi991852i; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Lam JT, 1999, BBA-MOL BASIS DIS, V1453, P297, DOI 10.1016/S0925-4439(98)00109-4; LEE JI, 1992, J BIOL CHEM, V267, P20758; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Loo DDF, 1999, J PHYSIOL-LONDON, V518, P195, DOI 10.1111/j.1469-7793.1999.0195r.x; Lostao MP, 1995, FEBS LETT, V377, P181, DOI 10.1016/0014-5793(95)01339-3; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; PanayotovaHeiermann M, 1997, J BIOL CHEM, V272, P20324, DOI 10.1074/jbc.272.33.20324; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Quick M, 1999, BIOCHEMISTRY-US, V38, P13523, DOI 10.1021/bi991256o; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; SAHINTOTH M, 1993, BIOCHEMISTRY-US, V32, P10027, DOI 10.1021/bi00089a019; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; WRIGHT EM, 1994, J EXP BIOL, V196, P197; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507	40	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1728	1734		10.1074/jbc.M005521200	http://dx.doi.org/10.1074/jbc.M005521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11024018	hybrid			2022-12-27	WOS:000166528000012
J	Brennan, P; Floettmann, JE; Mehl, A; Jones, M; Rowe, M				Brennan, P; Floettmann, JE; Mehl, A; Jones, M; Rowe, M			Mechanism of action of a novel latent membrane protein-1 dominant negative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; NF-KAPPA-B; C-TERMINUS; SIGNAL-TRANSDUCTION; DOWN-REGULATION; KINASE PATHWAY; STAT PROTEINS; BINDING-SITE; LMP1; ACTIVATION	Latent membrane protein-1 (LMP1) is a signaling molecule expressed by Epstein-Barr virus during latency. LMP1 is essential for B-cell immortalization by Epstein-Barr virus and transforms rodent fibroblasts. It activates many distinct signaling pathways including the transcription factors NF kappaB and AP1. We have generated a mutant of LMP1 with four point mutations; amino acids 204, 206, and 208 were mutated to alanine, and amino acid 384 was mutated to glycine. This mutant, termed LMP1(AAAG), is not only unable to activate nuclear signaling pathways, but also inhibits signaling from wild type LMP1, We have demonstrated the effectiveness, selectivity, and mechanism of this inhibitory molecule. It inhibits LMP1-stimulated NF kappaB, STAT, and Jun transcriptional activity. It is selective, as it does not inhibit TNF or interleukin-2 signaling. We have demonstrated that it does not sequester the downstream signaling molecule, TRAF2, but instead binds LMP1 and interferes with its ability to bind TRAF2. This demonstrates the importance of the interplay between the signaling domains of LMP1 and the oligomeric structure of LMP1 for effective signaling. It identifies a tool that will be useful to probe LMP1 function in disease.	Univ Wales Coll Cardiff, Coll Med, Dept Med, Cardiff CF14 4XX, S Glam, Wales	Cardiff University	Brennan, P (corresponding author), Univ Wales Coll Cardiff, Coll Med, Dept Med, Tenovus Bldg,Heath Pk, Cardiff CF14 4XX, S Glam, Wales.	brennanp@cardiff.ac.uk	Brennan, Paul/B-9210-2009; Brennan, Paul/ABB-9196-2021; Rowe, Martin/B-2880-2009	Brennan, Paul/0000-0001-8792-0499; Brennan, Paul/0000-0001-8792-0499; Rowe, Martin/0000-0003-4139-7326				ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Erickson KD, 2000, J VIROL, V74, P1057, DOI 10.1128/JVI.74.2.1057-1060.2000; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JL, 1998, ONCOGENE, V17, P2383, DOI 10.1038/sj.onc.1202144; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HORI T, 1987, BLOOD, V70, P1069; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1999, J VIROL, V73, P9908, DOI 10.1128/JVI.73.12.9908-9916.1999; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kim SH, 2000, BLOOD, V95, P294; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 2001, METHODS MOL BIOL EPS; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wang S, 1996, CANCER RES, V56, P4610; WeberNordt RM, 1996, BLOOD, V88, P809	46	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1195	1203		10.1074/jbc.M005461200	http://dx.doi.org/10.1074/jbc.M005461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11031256	hybrid			2022-12-27	WOS:000166430900047
J	Petersen, C; Moller, LB				Petersen, C; Moller, LB			The RihA, RihB, and RihC ribonucleoside hydrolases of Escherichia coli - Substrate specificity, gene expression and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRITHIDIA-FASCICULATA; NUCLEOSIDE HYDROLASE; ACTIVATOR PROTEIN; GUANOSINE KINASE; N-RIBOHYDROLASE; SEQUENCE; CLONING; SITE; IDENTIFICATION; MECHANISM	Pyrimidine-requiring cdd mutants of Escherichia coli deficient in cytidine deaminase utilize cytidine as a pyrimidine source by an alternative pathway. This has been presumed to involve phosphorylation of cytidine to CMP by cytidine/uridine kinase and subsequent hydrolysis of CMP to cytosine and ribose 8-phosphate by a putative CMP hydrolase, Here we show that cytidine, in cdd strains, is converted directly to cytosine and ribose by a ribonucleoside hydrolase encoded by the previously uncharacterized gene ybeK, which we have renamed rihA, The RihA enzyme is homologous to the products of two unlinked genes, yeiK and yaaF, which have been renamed rihB and rihC, respectively, The RihB enzyme was shown to be a pyrimidine-specific ribonucleoside hydrolase like RihA, whereas RihC hydrolyzed both pyrimidine and purine ribonucleosides, The physiological function of the ribonucleoside hydrolases in wild-type E, coli strains is enigmatic, as their activities are paralleled by the phosphorolytic activities of the nucleoside phosphorylases, and a triple mutant lacking all three hydrolytic activities grew normally. Furthermore, enzyme assays and lacZ gene fusion analysis indicated that rihB was essentially silent unless activated by mutation, whereas rihA and rihC were poorly expressed in glucose medium due to catabolite repression.	Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, DK-1307 Copenhagen K, Denmark; John F Kennedy Inst, DK-2600 Glostrup, Denmark	University of Copenhagen	Petersen, C (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Biol Chem, Solvgade 83H, DK-1307 Copenhagen K, Denmark.	carstenpt@mermaid.molbio.ku.dk		Moller, Lisbeth/0000-0002-9524-4301				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BECK CF, 1971, MOL GEN GENET, V111, P303, DOI 10.1007/BF00569782; BERG DE, 1980, J BACTERIOL, V142, P439, DOI 10.1128/JB.142.2.439-446.1980; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOUVIER J, 1984, J BIOL CHEM, V259, P4829; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; Degano M, 1998, BIOCHEMISTRY-US, V37, P6277, DOI 10.1021/bi973012e; Degano M, 1996, BIOCHEMISTRY-US, V35, P5971, DOI 10.1021/bi952999m; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; ESTUPINAN B, 1994, J BIOL CHEM, V269, P23068; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Gopaul DN, 1996, BIOCHEMISTRY-US, V35, P5963, DOI 10.1021/bi952998u; Hammer-Jespersen K., 1983, METABOLISM NUCLEOTID, P203; HAMMERJESPERSEN K, 1973, MOL GEN GENET, V126, P177, DOI 10.1007/BF00330992; HOVEJENSEN B, 1989, MOL MICROBIOL, V3, P1487, DOI 10.1111/j.1365-2958.1989.tb00134.x; HOVEJENSEN B, 1989, J GEN MICROBIOL, V135, P1263; KILSTRUP M, 1989, J BACTERIOL, V171, P2124, DOI 10.1128/jb.171.4.2124-2127.1989; KLECKNER N, 1991, METHOD ENZYMOL, V204, P139; KOSZALKA GW, 1979, J BIOL CHEM, V254, P8185; MAGNI G, 1975, J BIOL CHEM, V250, P9; Maniatis T., 1982, MOL CLONING; MELEFORS O, 1988, CELL, V52, P893, DOI 10.1016/0092-8674(88)90431-X; Miller J.H., 1972, EXPT MOL GENETICS; MILLER KW, 1987, J BIOL CHEM, V262, P7391; NEUHARD J, 1987, ESCHERICHIA COLI SAL, V1, P445; Neuhard J., 1983, METABOLISM NUCLEOTID, P95; NEUHARD J, 1996, ESCHERICHIA COLI SAL, V1, P580; PARKIN DW, 1991, J BIOL CHEM, V266, P20658; Pelle R, 1998, J BIOL CHEM, V273, P2118, DOI 10.1074/jbc.273.4.2118; Petersen C, 1999, J BIOL CHEM, V274, P5348, DOI 10.1074/jbc.274.9.5348; PETERSEN C, 1987, MOL GEN GENET, V209, P179, DOI 10.1007/BF00329856; PETERSEN C, 2001, IN PRESS GENE AMST; Saier MH, 1996, ESCHERICHIA COLI SAL, V1, P1325; Shi WX, 1999, J BIOL CHEM, V274, P21114, DOI 10.1074/jbc.274.30.21114; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valentin-Hansen P, 1978, Methods Enzymol, V51, P308; ValentinHansen P, 1996, MOL MICROBIOL, V20, P461, DOI 10.1046/j.1365-2958.1996.5341056.x; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; ZALKIN H, 1996, ESCHERICHIA COLI SAL, V1, P561	43	62	67	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					884	894		10.1074/jbc.M008300200	http://dx.doi.org/10.1074/jbc.M008300200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11027694	Green Submitted, hybrid			2022-12-27	WOS:000166430900005
J	Giannoni, F; Muller, HM; Vizioli, J; Catteruccia, F; Kafatos, FC; Crisanti, A				Giannoni, F; Muller, HM; Vizioli, J; Catteruccia, F; Kafatos, FC; Crisanti, A			Nuclear factors bind to a conserved DNA element that modulates transcription of Anopheles gambiae trypsin genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER; BLOOD MEAL; PROTEIN; GUT; EXPRESSION; GATA-1; CELLS; CLONING; FAMILY; HEART	The Anopheles gambiae trypsin family consists of seven genes that are transcribed in the gut of female mosquitoes in a temporal coordinated and mutually exclusive manner, suggesting the involvement of a complex transcription regulatory mechanism. We identified a highly conserved 12-nucleotide motif present in all A. gambiae and Anopheles stephensi trypsin promoters. We investigated the role of this putative trypsin regulatory element (PTRE) in controlling the transcription of the trypsin genes. Gel shift experiments demonstrated that nuclear proteins of A. gambiae cell lines formed two distinct complexes with probes encompassing the PTRE sequence. Mapping of the binding sites revealed that one of the complex has the specificity of a GATA transcription factor. Promoter constructs containing mutations in the PTRE sequence that selectively abolished the binding of either one or both complexes exerted opposite effects on the transcriptional activity of trypsin promoters in A. gambiae and Aedes aegypti cell lines. In addition, the expression of a novel GATA gene was highly enriched in A. gambiae guts. Taken together our data prove that factors binding to the PTRE region are key regulatory elements possibly involved in the blood meal-induced repression and activation of transcription in early and late trypsin genes.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 9AX, England; Univ Rome La Sapienza, Ist Parassitol, I-00185 Rome, Italy; European Mol Biol Lab, D-69117 Heidelberg, Germany	Imperial College London; Sapienza University Rome; European Molecular Biology Laboratory (EMBL)	Crisanti, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Imperial Coll Rd, London SW7 9AX, England.		Giannoni, Federico/A-6577-2013	Giannoni, Federico/0000-0001-5521-512X; Muller, Hans-Michael/0000-0002-2384-7285; Crisanti, Andrea/0000-0002-2406-4426; vizioli, jacopo/0000-0002-4310-8033; Catteruccia, Flaminia/0000-0003-3295-6683				AUSUBEL FM, 1992, SHORT MOL BIOL; BARILLASMURY C, 1994, INSECT BIOCHEM MOLEC, V25, P241; BILLINGSLEY PF, 1991, J MED ENTOMOL, V28, P865, DOI 10.1093/jmedent/28.6.865; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Catteruccia F, 2000, NATURE, V405, P959, DOI 10.1038/35016096; DREVET JR, 1994, J BIOL CHEM, V269, P10660; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; HOLMES DS, 1973, BIOCHEMISTRY-US, V12, P2330, DOI 10.1021/bi00736a023; Huggon IC, 1997, BBA-GENE STRUCT EXPR, V1353, P98, DOI 10.1016/S0167-4781(97)00049-3; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; Muller H.M., 1993, Parassitologia (Rome), V35, P73; Muller HM, 1995, EXP PARASITOL, V81, P371, DOI 10.1006/expr.1995.1128; Muller HM, 1999, J BIOL CHEM, V274, P11727, DOI 10.1074/jbc.274.17.11727; MULLER HM, 1993, EMBO J, V12, P2891, DOI 10.1002/j.1460-2075.1993.tb05951.x; ORKIN SH, 1992, BLOOD, V80, P575; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Shen ZC, 1998, INSECT BIOCHEM MOLEC, V28, P1007, DOI 10.1016/S0965-1748(98)00089-7; SKAVDIS G, 1996, EMBO J, V15, P334; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089	27	25	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					700	707		10.1074/jbc.M005540200	http://dx.doi.org/10.1074/jbc.M005540200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016929	hybrid			2022-12-27	WOS:000166280700094
J	Hagopian, JC; Kirtley, MP; Stevenson, LM; Gergis, RM; Russo, AA; Pavletich, NP; Parsons, SM; Lew, J				Hagopian, JC; Kirtley, MP; Stevenson, LM; Gergis, RM; Russo, AA; Pavletich, NP; Parsons, SM; Lew, J			Kinetic basis for activation of CDK2/clyclin A by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRUCTURAL BASIS; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; MECHANISM; YEAST; CAK	The activation of most protein kinases requires phosphorylation at a conserved site within a structurally defined segment termed the activation loop. A classic example is the regulation of the cell cycle central enzyme, CDK2/cyclin A, in which catalytic activation depends on phosphorylation at Thr(160) in CDK2, The structural consequences of phosphorylation have been revealed by x-ray crystallographic studies on CDE2-cyclin A and include changes in conformation, mainly of the activation loop. Here, we describe the kinetic basis for activation by phosphorylation in CDK2/cyclin A. Phosphorylation results in a 100,000-fold increase in catalytic efficiency and an approximate 1,000-fold increase in the overall turnover rate. The effects of phosphorylation on the individual steps in the catalytic reaction pathway were determined using solvent viscosometric techniques. It was found that the increase in catalytic power arises mainly from a 3,000-fold increase in the rate of the phosphoryl group transfer step with a more moderate increase in substrate binding affinity. In contrast, the rate of phosphoryl group transfer in the ATPase pathway was unaffected by phosphorylation, demonstrating that phosphorylation at Thr(160) does not serve to stabilize ATP in the ATPase reaction. Thus, we hypothesize that the role of phosphorylation in the kinase reaction may be to specifically stabilize the peptide phosphoacceptor group.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Interdept Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Calif Santa Barbara, Interdept Grad Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; University of California System; University of California Santa Barbara	Lew, J (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.			Parsons, Stanley/0000-0001-7097-8221				ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P683; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Cauthron RD, 1998, MOL CELL BIOL, V18, P1416, DOI 10.1128/MCB.18.3.1416; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; HACKNEY DD, 1990, ENZYMES, V19, P1; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Russo AA, 1997, METHOD ENZYMOL, V283, P3; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Saylor P, 1998, BIOCHEMISTRY-US, V37, P17875, DOI 10.1021/bi981775b	24	55	57	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					275	280		10.1074/jbc.M007337200	http://dx.doi.org/10.1074/jbc.M007337200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029468	hybrid			2022-12-27	WOS:000166280700038
J	Nakamura, T; Ohta, M; Sugiura, M; Sugita, M				Nakamura, T; Ohta, M; Sugiura, M; Sugita, M			Chloroplast ribonucleoproteins function as a stabilizing factor of ribosome-free mRNAs in the stroma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3 INVERTED REPEATS; BINDING PROTEINS; GENE-EXPRESSION; IMPORTANT DETERMINANTS; TOBACCO CHLOROPLASTS; PSBA; DEGRADATION; PHOSPHORYLATION; IDENTIFICATION; SEQUENCE	Post-transcriptional RNA processing is an important step in the regulation of chloroplast gene expression, and a number of chloroplast ribonucleoproteins (cpRNPs) are likely to be involved in this process, The major tobacco cpRNPs are composed of five species: cp28, cp29A, cp29B, cp31, and cp33 and these are divided into three groups (I, II, and III). By immunoprecipitation, gel filtration, and Western blot analysis, we demonstrated that these cpRNPs are abundant stromal proteins that exist as complexes with ribosome-free mRNAs. Many ribosome-free psbA mRNAs coprecipitate with cpRNPs, indicating that the majority of stromal psbA mRNAs are associated with cpRNPs, In addition, an In vitro mRNA degradation assay indicated that exogenous psbA mRNA is more rapidly degraded in cpRNP-depleted extracts than in nondepleted extracts. When the depleted extract was reconstituted with recombinant cpRNPs, the psbA mRNA in the extract was protected from degradation to a similar extent as the psbA mRNA in the nondepleted extract. Moreover, restoration of the stabilizing activity varied following addition of individual group-specific cpRNPs alone or in combination, When the five cpRNPs were supplemented in the depleted extract, full activity was restored. We propose that these cpRNPs act as stabilizing factors for nonribosome-bound mRNAs in the stroma.	Nagoya Univ, Ctr Gene Res, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Sch Human Informat, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Sugita, M (corresponding author), Nagoya Univ, Ctr Gene Res, Nagoya, Aichi 4648601, Japan.	sugita@info.human.nagoya-u.ac.jp						ADAMS CC, 1990, NUCLEIC ACIDS RES, V18, P6003, DOI 10.1093/nar/18.20.6003; Alexander C, 1998, NUCLEIC ACIDS RES, V26, P2265, DOI 10.1093/nar/26.10.2265; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; CHEN HC, 1991, MOL CELL BIOL, V11, P4380, DOI 10.1128/MCB.11.9.4380; CHEN QY, 1995, MOL CELL BIOL, V15, P2010; Churin Y, 1999, CURR GENET, V36, P173, DOI 10.1007/s002940050488; COOK WB, 1992, NUCLEIC ACIDS RES, V20, P359, DOI 10.1093/nar/20.2.359; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DEAN C, 1982, PLANT PHYSIOL, V69, P904, DOI 10.1104/pp.69.4.904; Drager RG, 1998, PLANT J, V13, P85, DOI 10.1046/j.1365-313X.1998.00016.x; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GRUISSEM W, 1988, TRENDS GENET, V4, P258, DOI 10.1016/0168-9525(88)90033-9; Hayes R, 1999, TRENDS BIOCHEM SCI, V24, P199, DOI 10.1016/S0968-0004(99)01388-2; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; HESS WR, 1994, PLANT CELL, V6, P1455, DOI 10.1105/tpc.6.10.1455; Hubschmann T, 1996, PLANT MOL BIOL, V30, P109, DOI 10.1007/BF00017806; Jenkins BD, 1997, PLANT CELL, V9, P283, DOI 10.1105/tpc.9.3.283; KIM J, 1994, PLANT MOL BIOL, V25, P459, DOI 10.1007/BF00043874; KIM MY, 1993, PLANT MOL BIOL, V22, P447, DOI 10.1007/BF00015975; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; Klaff P, 1995, NUCLEIC ACIDS RES, V23, P4885, DOI 10.1093/nar/23.23.4885; LI YQ, 1990, EMBO J, V9, P3059, DOI 10.1002/j.1460-2075.1990.tb07502.x; LI YQ, 1991, NUCLEIC ACIDS RES, V19, P2893, DOI 10.1093/nar/19.11.2893; Liere K, 1997, NUCLEIC ACIDS RES, V25, P2403, DOI 10.1093/nar/25.12.2403; LISITSKY I, 1995, NUCLEIC ACIDS RES, V23, P2506, DOI 10.1093/nar/23.13.2506; LISITSKY I, 1995, PLANT PHYSIOL, V107, P933, DOI 10.1104/pp.107.3.933; Memon AR, 1996, PLANT MOL BIOL, V30, P1195, DOI 10.1007/BF00019552; Meurer J, 1996, PLANT CELL, V8, P1193, DOI 10.1105/tpc.8.7.1193; MULLET JE, 1987, EMBO J, V6, P1571, DOI 10.1002/j.1460-2075.1987.tb02402.x; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; Nakamura T, 1999, FEBS LETT, V460, P437, DOI 10.1016/S0014-5793(99)01390-3; Nakamura T, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P2957; Nakano T, 1997, PLANT CELL, V9, P1673, DOI 10.1105/tpc.9.9.1673; NICKELSEN J, 1993, PLANT J, V3, P537, DOI 10.1046/j.1365-313X.1993.03040537.x; NICKELSEN J, 1994, EMBO J, V13, P3182, DOI 10.1002/j.1460-2075.1994.tb06617.x; Nickelsen J, 1999, PLANT CELL, V11, P957, DOI 10.1105/tpc.11.5.957; OHTA M, 1995, PLANT MOL BIOL, V27, P529, DOI 10.1007/BF00019319; RAPP JC, 1992, J BIOL CHEM, V267, P21404; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; Rochaix JD, 1995, ANNU REV GENET, V29, P209, DOI 10.1146/annurev.ge.29.120195.001233; Rott R, 1998, PLANT MOL BIOL, V36, P307, DOI 10.1023/A:1005943701253; Sakai A, 1998, PLANT CELL PHYSIOL, V39, P928, DOI 10.1093/oxfordjournals.pcp.a029456; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schuster G, 1999, PLANT PHYSIOL, V120, P937, DOI 10.1104/pp.120.4.937; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; STERN DB, 1989, J BIOL CHEM, V264, P18742; STERN DB, 1987, CELL, V51, P1145, DOI 10.1016/0092-8674(87)90600-3; STERN DB, 1991, PLANT CELL, V3, P285; Sugita M, 1996, PLANT MOL BIOL, V32, P315, DOI 10.1007/BF00039388; VERA A, 1994, EMBO J, V13, P2211, DOI 10.1002/j.1460-2075.1994.tb06498.x; Yang JJ, 1996, PLANT CELL, V8, P1409, DOI 10.1105/tpc.8.8.1409; YE LZ, 1991, NUCLEIC ACIDS RES, V19, P6485, DOI 10.1093/nar/19.23.6485; YE LZ, 1992, NUCLEIC ACIDS RES, V20, P6275, DOI 10.1093/nar/20.23.6275	54	65	67	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					147	152		10.1074/jbc.M008817200	http://dx.doi.org/10.1074/jbc.M008817200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11038367	hybrid			2022-12-27	WOS:000166280700021
J	Negulyaev, YA; Khaitlina, SY; Hinssen, H; Shumilina, EV; Vedernikova, EA				Negulyaev, YA; Khaitlina, SY; Hinssen, H; Shumilina, EV; Vedernikova, EA			Sodium channel activity in leukemia cells is directly controlled by actin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND DIVALENT-CATION; COLI A2 STRAIN; SELECTIVE CHANNELS; MEMBRANE PATCHES; NA+ CHANNELS; CYTOSKELETON; FILAMENTS; MUSCLE; LINE	The actin cytoskeleton has been shown to be involved in the regulation of sodium-selective channels in nonexcitable cells. However, the molecular mechanisms underlying the changes in channel function remain to be defined. In the present work, inside-out patch experiments were employed to elucidate the role of submembranous actin dynamics in the control of sodium channels in human myeloid leukemia K562 cells. We found that the application of cytochalasin D to the cytoplasmic surface of membrane fragments resulted in activation of non-voltage-gated sodium channels of 12 picosiemens conductance. Similar effects could be evoked by addition of the actin-severing protein gelsolin to the bath cytosol-like solution containing 1 muM [Ca2+](i). The sodium channel activity induced by disassembly of submembranous microfilaments with cytochalasin D or gelsolin could be abolished by intact actin added to the bath cytosol-like solution in the presence of 1 mM MgCl2, to induce actin polymerization, In the absence of MgCl2, addition of intact actin did not abolish the channel activity. Moreover, the sodium currents were unaffected by heat-inactivated actin or by actin whose polymerizability was strongly reduced by cleavage with specific Escherichia coli A2 protease ECP32, Thus, the inhibitory effect of actin on channel activity was observed only under conditions promoting rapid polymerization. Taken together, our data show that sodium channels are directly controlled by dynamic assembly and disassembly of submembranous F-actin.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; Univ Bielefeld, Dept Biochem Cell Biol, D-33501 Bielefeld, Germany	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; University of Bielefeld	Vedernikova, EA (corresponding author), Russian Acad Sci, Inst Cytol, 4 Tikhoretsky Ave, St Petersburg 194064, Russia.		Negulyaev, Yuri/N-6531-2015	Negulyaev, Yuri/0000-0002-1773-9798				BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; CANTIELLO HF, 1991, AM J PHYSIOL, V261, P882; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; HINSSEN H, 1984, FEBS LETT, V166, P90, DOI 10.1016/0014-5793(84)80051-4; HORBER JKH, 1995, BIOPHYS J, V68, P1687, DOI 10.1016/S0006-3495(95)80346-2; HUCKRIEDE A, 1988, EUR J CELL BIOL, V46, P506; HUCKRIEDE A, 1990, CELL MOTIL CYTOSKEL, V16, P229, DOI 10.1002/cm.970160403; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; KHAITLINA SY, 1993, EUR J BIOCHEM, V218, P911, DOI 10.1111/j.1432-1033.1993.tb18447.x; KHAITLINA SY, 1991, FEBS LETT, V279, P49, DOI 10.1016/0014-5793(91)80247-Z; Littlefield R, 1998, ANNU REV CELL DEV BI, V14, P487, DOI 10.1146/annurev.cellbio.14.1.487; Matveyev VV, 1996, BBA-PROTEIN STRUCT M, V1296, P55, DOI 10.1016/0167-4838(96)00053-2; Maximov AV, 1997, FEBS LETT, V412, P94, DOI 10.1016/S0014-5793(97)00754-0; Negulyaev YA, 1996, MOL BIOL CELL, V7, P1857, DOI 10.1091/mbc.7.12.1857; NEGULYAEV YA, 1994, BBA-BIOMEMBRANES, V1194, P171, DOI 10.1016/0005-2736(94)90217-8; Negulyaev YA, 1997, GEN PHYSIOL BIOPHYS, V16, P163; NEGULYAEV YA, 1994, J MEMBRANE BIOL, V138, P37; Parekh AB, 1996, J BIOL CHEM, V271, P23161, DOI 10.1074/jbc.271.38.23161; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; RUKNUDIN A, 1991, J CELL BIOL, V112, P125, DOI 10.1083/jcb.112.1.125; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; SELDEN LA, 1983, BIOCHEM BIOPH RES CO, V116, P478, DOI 10.1016/0006-291X(83)90548-X; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TUROVEROV KK, 1976, FEBS LETT, V62, P4, DOI 10.1016/0014-5793(76)80003-8; VANRENTERGHEM C, 1991, PFLUG ARCH EUR J PHY, V419, P401, DOI 10.1007/BF00371123	30	29	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40933	40937		10.1074/jbc.M008219200	http://dx.doi.org/10.1074/jbc.M008219200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016945	hybrid			2022-12-27	WOS:000166114600037
J	Bonini, JA; Jones, LK; Adham, N; Forray, C; Artymyshyn, R; Durkin, MM; Smith, KE; Tamm, JA; Boteju, LW; Lakhlani, PP; Raddatz, R; Yao, WJ; Ogozalek, KL; Boyle, N; Kouranova, EV; Quan, Y; Vaysse, PJ; Wetzel, JM; Branchek, TA; Gerald, C; Borowsky, B				Bonini, JA; Jones, LK; Adham, N; Forray, C; Artymyshyn, R; Durkin, MM; Smith, KE; Tamm, JA; Boteju, LW; Lakhlani, PP; Raddatz, R; Yao, WJ; Ogozalek, KL; Boyle, N; Kouranova, EV; Quan, Y; Vaysse, PJ; Wetzel, JM; Branchek, TA; Gerald, C; Borowsky, B			Identification and characterization of two G protein-coupled receptors for neuropeptide FF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SPINAL-CORD; MORPHINE-MODULATING PEPTIDE; PANCREATIC-POLYPEPTIDE; OPIOID RECEPTORS; ANALOGS; IMMUNOREACTIVITY; FLFQPQRFAMIDE; INHIBITION; BINDING; CLONING	The central nervous system octapeptide, neuropeptide FF (NPFF), is believed to play a role in pain modulation and opiate tolerance. Two G protein-coupled receptors, NPFF1 and NPFF2, were isolated from human and rat central nervous system tissues. NPFF specifically bound to NPFF1 (K-d = 1.13 nm) and NPFF2 (K-d = 0.37 nm), and both receptors were activated by NPFF in a variety of heterologous expression systems. The localization of mRNA and binding sites of these receptors in the dorsal horn of the spinal cord, the lateral hypothalamus, the spinal trigeminal nuclei, and the thalamic nuclei supports a role for NPFF in pain modulation. Among the receptors with the highest amino acid sequence homology to NPFF1 and NPFF2 are members of the orexin, NPY, and cholecystokinin families, which have been implicated in feeding. These similarities together with the finding that BIBP3226, an anorexigenic Y1 receptor ligand, also binds to NPFF1 suggest a potential role for NPFF1 in feeding. The identification of NPFF1 and NPFF2 will help delineate their roles in these and other physiological functions.	Synapt Pharmaceut Corp, Paramus, NJ 07652 USA		Bonini, JA (corresponding author), Synapt Pharmaceut Corp, 215 Coll Rd, Paramus, NJ 07652 USA.		Adham, Nika/N-4376-2017	Adham, Nika/0000-0002-2773-2522				ALLARD M, 1992, NEUROSCIENCE, V49, P101, DOI 10.1016/0306-4522(92)90078-G; ALLARD M, 1989, BRAIN RES, V500, P169, DOI 10.1016/0006-8993(89)90311-9; Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; BOEL E, 1984, EMBO J, V3, P909, DOI 10.1002/j.1460-2075.1984.tb01904.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cikos S, 1999, BIOCHEM BIOPH RES CO, V256, P352, DOI 10.1006/bbrc.1999.0332; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Doods HN, 1996, REGUL PEPTIDES, V65, P71, DOI 10.1016/0167-0115(96)00074-2; DUPUY V, 1996, PEPTIDES, V17, P399; DUPUY V, 1996, SYNAPSE, V24, P282; Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200; Gherardi N, 1997, PEPTIDES, V18, P577, DOI 10.1016/S0196-9781(97)00071-5; Gouarderes C, 1998, PEPTIDES, V19, P727, DOI 10.1016/S0196-9781(98)00015-1; Gouarderes C, 1997, BRAIN RES BULL, V42, P231, DOI 10.1016/S0361-9230(96)00261-4; Gouarderes C, 1996, BRIT J PHARMACOL, V117, P493, DOI 10.1111/j.1476-5381.1996.tb15217.x; Hoyle CHV, 1999, BRAIN RES, V848, P1, DOI 10.1016/S0006-8993(99)01975-7; Iyengar S, 1999, J PHARMACOL EXP THER, V289, P1031; KIVIPELTO L, 1991, J COMP NEUROL, V307, P107, DOI 10.1002/cne.903070110; KIVIPELTO L, 1989, J COMP NEUROL, V286, P269, DOI 10.1002/cne.902860211; KOHRI K, 1993, BIOCHIM BIOPHYS ACTA, V1173, P345, DOI 10.1016/0167-4781(93)90136-2; Kontinen VK, 1997, PEPTIDES, V18, P287, DOI 10.1016/S0196-9781(96)00287-2; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; MARCO N, 1995, NEUROSCIENCE, V64, P1035, DOI 10.1016/0306-4522(94)00383-G; Morgan DGA, 1998, REGUL PEPTIDES, V75-6, P377, DOI 10.1016/S0167-0115(98)00091-3; Murase T, 1996, PEPTIDES, V17, P353, DOI 10.1016/0196-9781(95)02137-X; Panula P, 1999, BRAIN RES, V848, P191, DOI 10.1016/S0006-8993(99)02044-2; Panula P, 1996, PROG NEUROBIOL, V48, P461, DOI 10.1016/0301-0082(96)00001-9; PAYZA K, 1993, J NEUROCHEM, V60, P1894, DOI 10.1111/j.1471-4159.1993.tb13417.x; PAYZA K, 1993, J PHARMACOL EXP THER, V267, P88; QUICK MW, 1994, J BIOL CHEM, V269, P30164; Roumy M, 1999, BRAIN RES, V845, P208, DOI 10.1016/S0006-8993(99)01965-4; Roumy M, 1998, EUR J PHARMACOL, V345, P1, DOI 10.1016/S0014-2999(97)01604-X; Smith KE, 1998, J BIOL CHEM, V273, P23321, DOI 10.1074/jbc.273.36.23321; TAKEUCHI T, 1986, J CLIN INVEST, V77, P1038, DOI 10.1172/JCI112357; Tan PPC, 1999, PEPTIDES, V20, P1211, DOI 10.1016/S0196-9781(99)00125-4; TANG J, 1984, P NATL ACAD SCI-BIOL, V81, P5002, DOI 10.1073/pnas.81.15.5002; VILIM ES, 1995, SOC NEUR ABSTR, V21, P760; Vilim FS, 1999, MOL PHARMACOL, V55, P804; Wraith A, 2000, GENOME RES, V10, P302, DOI 10.1101/gr.10.3.302; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	40	344	361	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39324	39331		10.1074/jbc.M004385200	http://dx.doi.org/10.1074/jbc.M004385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11024015	hybrid			2022-12-27	WOS:000165953100054
J	Radic, Z; Taylor, P				Radic, Z; Taylor, P			Interaction kinetics of reversible inhibitors and substrates with acetylcholinesterase and its fasciculin 2 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL SITE; CRYSTAL-STRUCTURE; ANIONIC SITE; ACTIVE-SITE; BINDING; LIGANDS; SPECIFICITY; CATALYSIS; ENZYME; CHOLINESTERASES	Fasciculin 2 (Fas2), a three-fingered peptide of 61 amino acids, binds tightly to the peripheral site of acetylcholinesterases (AChE; EC 3.1.1.7), occluding the entry portal into the active center gorge of the enzyme and inhibiting its catalytic activity. We investigated the mechanism of Fas2 inhibition by studying hydrolysis of cationic and neutral substrates and by determining the kinetics of interaction for fast equilibrating cationic and neutral reversible inhibitors with the AChE.Fas2 complex and free AChE. Catalytic parameters, derived by eliminating residual Fas2-resistant activity, reveal that Fas2 reduces k(cat)/K-m up to 10(6)-fold for cationic substrates and less than 10(3)-fold for neutral substrates. Rate constants for association of reversible inhibitors with the active center of the AChE.Fas2 complex were reduced about 10(4)-fold for both cationic and neutral inhibitors, while dissociation rate constants were reduced 10(2)-to 10(3)-fold, compared with AChE alone, Rates of ligand association with both AChE and AChE.Fas2 complex were dependent on the protonation state of ionizable ligands but were also markedly reduced by protonation of enzyme residue(s) with pK(a) of 6.1-6.2. Linear free energy relationships between the equilibrium constant and the kinetic constants show that Fas2, presumably through an allosteric influence, markedly alters the position of the transition state in the reaction pathway, Since Fas2 complexation introduces an energetic barrier for hydrolysis of substrates that exceeds that found for association of reversible ligands, Fas2 influences catalytic parameters by a more complex mechanism than simple restriction of diffusional entry and exit from the active center. Conformational flexibility appears critical for facilitating ligand passage in the narrow active center gorge for both AChE and the AChE Fas2 complex.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu			NIGMS NIH HHS [GM18360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRIDGE WN, 1972, FRONTIERS BIOL; ASHANI Y, 1994, MOL PHARMACOL, V45, P555; ASHANI Y, 1992, BIOCHEM BIOPH RES CO, V184, P719, DOI 10.1016/0006-291X(92)90649-6; BERMAN HA, 1991, CHOLINESTERASES STRU, P229; BOLGER MB, 1979, BIOCHEMISTRY-US, V18, P3622, DOI 10.1021/bi00583a029; Botti SA, 1999, BIOPHYS J, V77, P2430, DOI 10.1016/S0006-3495(99)77080-3; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Camps P, 2000, MOL PHARMACOL, V57, P409; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HODGE AS, 1992, MOL PHARMACOL, V41, P937; HOSEA NA, 1995, BIOCHEMISTRY-US, V34, P11528, DOI 10.1021/bi00036a028; Kryger G, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P323; Leffler J.E., 1963, RATES EQUILIBRIUM OR; Mallender WD, 1999, J BIOL CHEM, V274, P8491, DOI 10.1074/jbc.274.13.8491; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; Radic Z, 1997, J BIOL CHEM, V272, P23265, DOI 10.1074/jbc.272.37.23265; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Ravelli RBG, 1998, ACTA CRYSTALLOGR D, V54, P1359, DOI 10.1107/S0907444998005277; REINER E, 1967, BIOCHEM J, V105, P171, DOI 10.1042/bj1050171; Reiner E., 2000, CHOLINESTERASES CHOL, V3rd, P103; ROSENBERRY TL, 1971, BIOCHEMISTRY-US, V10, P4114, DOI 10.1021/bi00798a016; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3870, DOI 10.1021/bi00636a024; Rosenberry TL, 1996, BIOCHEMISTRY-US, V35, P685, DOI 10.1021/bi952431d; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14232, DOI 10.1021/bi961119g; SELWOOD T, 1993, J AM CHEM SOC, V115, P10477, DOI 10.1021/ja00076a002; Simeon-Rudolf V, 1999, CHEM-BIOL INTERACT, V119, P119, DOI 10.1016/S0009-2797(99)00020-4; Stojan J, 1998, FEBS LETT, V440, P85, DOI 10.1016/S0014-5793(98)01434-3; TAN RC, 1993, BIOCHEMISTRY-US, V32, P401, DOI 10.1021/bi00053a003; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; Zhou HX, 1998, P NATL ACAD SCI USA, V95, P9280, DOI 10.1073/pnas.95.16.9280	43	69	71	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4622	4633		10.1074/jbc.M006855200	http://dx.doi.org/10.1074/jbc.M006855200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11036076	hybrid			2022-12-27	WOS:000168484300015
J	Dode, L; Van Baelen, K; Wuytack, F; Dean, WL				Dode, L; Van Baelen, K; Wuytack, F; Dean, WL			Low temperature molecular adaptation of the skeletal muscle sarco(endo)plasmic reticulum Ca2+-ATPase 1 (SERCA 1) in the wood frog (Rana sylvatica)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM; ADENOSINE-TRIPHOSPHATASE; PLATELET MEMBRANES; MESSENGER-RNA; RABBIT; ATPASE; GENE; TRANSPORT; MECHANISM	We have compared the primary sequence and enzymatic properties of the sarcoplasmic reticulum Ca2+-ATPases from a cold-tolerant frog Rana sylvatica with those of a closely related cold-intolerant frog, Rana clamitans, Sarcoplasmic reticulum isolated from leg muscles of both species contains a major protein (similar to 100 kDa) that reacts with a monoclonal antibody against sarco(endo)plasmic reticulum Ca2+-ATPase type 1 (SERCA1). The apparent molecular mass of R. sylvatica SERCA1 is 115 kDa, whereas that of R. clamitans is 105 kDa. However, the deduced amino acid sequences obtained from cDNAs do not indicate a difference in molecular weight, thus suggesting post-translational protein modification of R. sylvatica SERCA1, Comparison of the temperature dependence of both ATP hydrolysis and Ca2+ transport indicates that R. sylvatica SERCA1 exhibits significantly lower activation energy below 20 degreesC and an similar to2-fold greater Ca2+-ATPase activity near 0 degreesC. Furthermore, R. sylvatica SERCA1 exhibits simple Michaelis-Menten kinetics with ATP and Ca2+ as opposed to the two-site ATP kinetics and positive cooperativity with Ca2+ observed for R. clamitans and mammalian SERCA1s. Cooperativity has been linked to protein-protein interaction in SERCA1, and this property may be altered in R. sylvatica SERCA1. Primary sequence comparison shows that R. sylvatica SERCA1 exhibits seven unique amino acid substitutions, three of which are in the ATP binding domain. We also report for the first time the presence of alternative splicing in the frog, resulting in isoforms SERCA1a and SERCA1b, Thus, it appears that the low temperature muscle contractility of R. sylvatica can be explained partially by significant functional and structural differences in SERCA1.	Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA	University of Louisville; KU Leuven; University of Louisville	Dean, WL (corresponding author), Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.	bill.dean@louisville.edu						BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CHINI EN, 1993, BIOCHEM J, V293, P469, DOI 10.1042/bj2930469; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONSTANZO JP, 1993, AM J PHYSIOL, V265, pR721; DALO NL, 1995, J EXP BIOL, V198, P1765; DEAMER DW, 1973, J BIOL CHEM, V248, P5477; DEAN WL, 1980, J BIOL CHEM, V255, P7514; DEAN WL, 1978, BIOCHEMISTRY-US, V17, P1683, DOI 10.1021/bi00602a016; DEAN WL, 1995, CELL CALCIUM, V17, P65, DOI 10.1016/0143-4160(95)90103-5; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V290, P178, DOI 10.1016/0005-2736(72)90062-4; ESCALANTE R, 1994, J BIOL CHEM, V269, P13005; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Hemmings SJ, 1996, CELL BIOCHEM FUNCT, V14, P139, DOI 10.1002/cbf.661; HEMMINGS SJ, 1996, CAN J PHYSL PHARM, V72, P1552; HESKETH TR, 1976, BIOCHEMISTRY-US, V15, P4145, DOI 10.1021/bi00664a002; INESI G, 1973, J MOL BIOL, V81, P483, DOI 10.1016/0022-2836(73)90518-4; Johnson JD, 1997, AM J PHYSIOL-CELL PH, V272, pC1437, DOI 10.1152/ajpcell.1997.272.5.C1437; KALABOKIS V, 1988, J BIOL CHEM, V263, P15184; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; KOSSLER F, 1987, BIOMED BIOCHIM ACTA, V46, P815; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AG, 1974, BIOCHEMISTRY-US, V13, P3699, DOI 10.1021/bi00715a013; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAGYAR A, 1995, BIOCHEM J, V310, P757, DOI 10.1042/bj3100757; Martonosi AN, 1996, BBA-BIOENERGETICS, V1275, P111, DOI 10.1016/0005-2728(96)00059-X; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOMMSEN TP, 1992, GEN COMP ENDOCR, V87, P44, DOI 10.1016/0016-6480(92)90148-D; NEET KE, 1977, ARCH BIOCHEM BIOPHYS, V178, P588, DOI 10.1016/0003-9861(77)90230-2; OGAWA Y, 1970, J BIOCHEM-TOKYO, V67, P667, DOI 10.1093/oxfordjournals.jbchem.a129295; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; STOREY KB, 1988, PHYSIOL REV, V68, P27, DOI 10.1152/physrev.1988.68.1.27; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VERJOVSKIALMEIDA S, 1981, J BIOL CHEM, V256, P2940; VILSEN B, 1992, FEBS LETT, V306, P213, DOI 10.1016/0014-5793(92)81003-5; VRBJAR N, 1990, BIOCHIM BIOPHYS ACTA, V1030, P94, DOI 10.1016/0005-2736(90)90243-H	43	17	17	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3911	3919		10.1074/jbc.M007719200	http://dx.doi.org/10.1074/jbc.M007719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11044449	hybrid			2022-12-27	WOS:000166921200027
J	Maurer, U; Jehan, F; Englert, C; Hubinger, G; Weidmann, E; DeLuca, HF; Bergmann, L				Maurer, U; Jehan, F; Englert, C; Hubinger, G; Weidmann, E; DeLuca, HF; Bergmann, L			The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D-3 by induction of the vitamin D receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR WT1; CD34(+) PROGENITORS; GROWTH-INHIBITION; MESSENGER-RNA; DIFFERENTIATION; EXPRESSION; APOPTOSIS; PROTEINS; PROMOTER; CELLS	The Wilms' tumor gene (wt1) encodes a transcription factor involved in urogenital development, in particular in renal differentiation, and in hematopoietic differentiation. Differentiation of a number of solid tumor and leukemic cells lines can be mediated by 1,25-dihydroxyvitamin D-3. This is predominantly mediated by the nuclear receptor for 1,25-dihydroxyvitamin D-3, the vitamin D receptor (VDR). In initial experiments addressing a possible link between WT1 and VDR, we observed a correlated expression of WT1 and VDR mRNA in samples from renal tissues. HT29 colon carcinoma cells, stably transfected to express WT1, exhibited elevated endogenous VDR levels compared with control cells transfected with a control construct. Elevated VDR expression was found in wt1-transfected human embryonic kidney 293 cells, as well. In transient cotransfection experiments, we observed an activation of a vdr promoter reporter by WT1 through a WT1 recognition element, indicating transcriptional regulation of the vdr gene expression by WT1. The responsive sequence element was specifically bound by wild-type, but not by mutated WT1, in electrophoretic mobility shift assays. HT29 colon carcinoma cells, which respond to 1,25-dihydroxyvitamin D, with slow induction of growth arrest, were investigated for the influence of WT1 on 1,25-dihydroxyvitamin D-3-mediated growth suppression. Although HT29 cells transfected with a control construct responded moderately to 1,25-dihydroxyvitamin Dar the response of HT29 cells expressing WT1 was strikingly enhanced, Stimulation with dihydroxyvitamin D, caused an up to 3-fold reduction in the growth rate of different HT29 clones expressing WT1 as compared with control cells lacking WT1 expression. Thus, induction of VDR by WT1 leads to an enhanced response to 1,25-dihydroxyvitamin D-3. We conclude that the vitamin D receptor gene is a target for transcriptional activation by WT1, suggesting a possible physiological role of this regulatory pathway.	Univ Ulm, Dept Internal Med 3, D-89081 Ulm, Germany; Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Univ Frankfurt, Dept Internal Med 3, D-60590 Frankfurt, Germany	Ulm University; University of Wisconsin System; University of Wisconsin Madison; Helmholtz Association; Karlsruhe Institute of Technology; Goethe University Frankfurt	Maurer, U (corresponding author), Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Jehan, Frederic/P-1568-2014	Jehan, Frederic/0000-0003-1271-6594; Englert, Christoph/0000-0002-5931-3189				Bergmann L, 1997, BLOOD, V90, P1217, DOI 10.1182/blood.V90.3.1217.1217_1217_1225; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Christakos S, 1996, BIOCHEM J, V316, P361, DOI 10.1042/bj3160361; Diaz GD, 2000, CANCER RES, V60, P2304; Elser B, 1997, J BIOL CHEM, V272, P27908, DOI 10.1074/jbc.272.44.27908; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Guan LS, 1998, J BIOL CHEM, V273, P27047, DOI 10.1074/jbc.273.42.27047; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hmama Z, 1999, J EXP MED, V190, P1583, DOI 10.1084/jem.190.11.1583; Jehan F, 2000, ARCH BIOCHEM BIOPHYS, V377, P273, DOI 10.1006/abbi.2000.1788; Jehan F, 1997, P NATL ACAD SCI USA, V94, P10138, DOI 10.1073/pnas.94.19.10138; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maurer U, 1997, BLOOD, V90, P4230, DOI 10.1182/blood.V90.10.4230; Maurer U, 1997, EXP HEMATOL, V25, P945; Maurer U., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P736; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; SHABAHANG M, 1994, CANCER RES, V54, P4057; Svedberg H, 1998, ONCOGENE, V16, P925, DOI 10.1038/sj.onc.1201613; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; WERNER H, 1995, MOL CELL BIOL, V15, P3516	29	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3727	3732		10.1074/jbc.M005292200	http://dx.doi.org/10.1074/jbc.M005292200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050081	hybrid			2022-12-27	WOS:000166921200003
J	Shiraishi, N; Natsume, A; Togayachi, A; Endo, T; Akashima, T; Yamada, Y; Imai, N; Nakagawa, S; Koizumi, S; Sekine, S; Narimatsu, H; Sasaki, K				Shiraishi, N; Natsume, A; Togayachi, A; Endo, T; Akashima, T; Yamada, Y; Imai, N; Nakagawa, S; Koizumi, S; Sekine, S; Narimatsu, H; Sasaki, K			Identification and characterization of three novel beta 1,3-N-acetylglucosaminyltransferases structurally related to the beta 1,3-galactosyltransferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; ALPHA-D-GALACTOSAMINE; HUMAN COLONIC ADENOCARCINOMA; SIALYL-LEWIS-X; BLOOD-GROUP-I; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; DEVELOPMENTALLY-REGULATED MEMBER; ELAM-1-DEPENDENT CELL-ADHESION; TUMOR-ASSOCIATED ANTIGEN; MOLECULAR-CLONING	We have isolated three types of cDNAs encoding novel beta1,3-N-acetylglucosaminyltransferases (designated beta 3Gn-T2, -T3, and -T4) from human gastric mucosa and the neuroblastoma cell Line SK-N-MC, These enzymes are predicted to be type 2 transmembrane proteins of 397, 372, and 378 amino acids, respectively, They share motifs conserved among members of the beta1,3-galactosyltransferase family and a beta1,3-N-acetylglucosaminyltransferase (designated beta 3Gn-T1), but show no structural similarity to another type of pl,3-N-acetylglucosaminyltransferase (iGnT). Each of the enzymes expressed by insect cells as a secreted protein fused to the FLAG peptide showed beta1,3N-acetylglucosaminyltransferase activity for type 2 oligosaccharides but not pl,3-galactosyltransferase activity. These enzymes exhibited different substrate specificity. Transfection of Namalwa KJM-1 cells with beta 3Gn-T2, -T3, or -T4 cDNA led to an increase in poly-N-acetyllactosamines recognized by an anti-i-antigen antibody or specific lectins, The expression profiles of these beta 3Gn-Ts were different among 35 human tissues, beta 3Gn-T2 was ubiquitously expressed, whereas expression of beta 3Gn-T3 and -T4 was relatively restricted. beta 3Gn-T3 was expressed in colon, jejunum, stomach, esophagus, placenta, and trachea beta 3Gn-T4 was mainly expressed in brain. These results have revealed that several beta1,3-N-acetylglucosaminyltransferases form a family with structural similarity to the pl,3-galactosyltransferase family. Considering the differences in substrate specificity and distribution, each pl,3-N-acetylglucosaminyltransferase may play different roles,	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 1948533, Japan; Soka Univ, Inst Life Sci, Div Cell Biol, Hachioji, Tokyo 1928577, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Bunkyo Ku, Tokyo 113, Japan; Tokyo Univ Agr, Fac Bioind, Lab Anim Resources, Abashiri, Hokkaido 0992422, Japan	Kyowa Kirin Ltd; Soka University; University of Tokyo; Tokyo University of Agriculture	Sasaki, K (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahi Machi, Machida, Tokyo 1948533, Japan.		Natsume, Atsushi/I-7364-2014	Natsume, Atsushi/0000-0002-9113-0470				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; BASU M, 1991, CARBOHYD RES, V209, P261, DOI 10.1016/0008-6215(91)80162-G; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; Fukumoto S, 1999, J BIOL CHEM, V274, P9271, DOI 10.1074/jbc.274.14.9271; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GU J, 1992, J BIOL CHEM, V267, P2994; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P14, DOI 10.1016/0003-9861(89)90410-4; HOLMES EH, 1988, ARCH BIOCHEM BIOPHYS, V260, P461, DOI 10.1016/0003-9861(88)90470-5; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; Ishii A, 1998, J BIOL CHEM, V273, P31652, DOI 10.1074/jbc.273.48.31652; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; KAWASHIMA H, 1990, GLYCOCONJUGATE J, V7, P323, DOI 10.1007/BF01073376; Kim YJ, 1996, BIOCHEM BIOPH RES CO, V228, P324, DOI 10.1006/bbrc.1996.1660; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; Kono M, 1996, J BIOL CHEM, V271, P29366, DOI 10.1074/jbc.271.46.29366; Kono M, 1998, BIOCHEM BIOPH RES CO, V253, P170, DOI 10.1006/bbrc.1998.9768; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; Kudo T, 1998, LAB INVEST, V78, P797; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE N, 1990, J BIOL CHEM, V265, P20476; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; LEE YC, 1994, J BIOL CHEM, V269, P10028; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LOWE BJ, 1994, MOL GLYCOBIOLOGY, P163; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAKAMORI S, 1993, CANCER RES, V53, P3632; Nakayama J, 1996, J BIOL CHEM, V271, P3684; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Okajima T, 2000, J BIOL CHEM, V275, P6717, DOI 10.1074/jbc.275.10.6717; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Okajima T, 1999, J BIOL CHEM, V274, P30557, DOI 10.1074/jbc.274.43.30557; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PILLER F, 1983, J BIOL CHEM, V258, P2293; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SASAKI K, 1994, Patent No. 0618759; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; Shinkai A, 1997, PROTEIN EXPRES PURIF, V10, P379, DOI 10.1006/prep.1997.0751; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; STROUD MR, 1991, J BIOL CHEM, V266, P8439; STULTS CLM, 1993, ARCH BIOCHEM BIOPHYS, V303, P125, DOI 10.1006/abbi.1993.1263; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Tsuji Y, 1996, BBA-GEN SUBJECTS, V1289, P115, DOI 10.1016/0304-4165(95)00130-1; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P16717, DOI 10.1074/jbc.274.24.16717; Ujita M, 1999, J BIOL CHEM, V274, P9296, DOI 10.1074/jbc.274.14.9296; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; WALTZ G, 1990, SCIENCE, V250, P1132; WEN DX, 1992, J BIOL CHEM, V267, P21011; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; White KE, 2000, GENE, V246, P347, DOI 10.1016/S0378-1119(00)00050-0; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	105	103	115	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3498	3507		10.1074/jbc.M004800200	http://dx.doi.org/10.1074/jbc.M004800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042166	hybrid			2022-12-27	WOS:000166784900067
J	Muller, JJ; Lapko, A; Bourenkov, G; Ruckpaul, K; Heinemann, U				Muller, JJ; Lapko, A; Bourenkov, G; Ruckpaul, K; Heinemann, U			Adrenodoxin reductase-adrenodoxin complex structure suggests electron transfer path in steroid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTATIONS; CROSS-LINKED COMPLEX; FERREDOXIN REDUCTASE; BOVINE ADRENODOXIN; CRYSTAL-STRUCTURE; CYTOCHROME-P-450SCC; IDENTIFICATION; ENZYMES; SYSTEMS; MODEL	The steroid hydroxylating system of adrenal cortex mitochondria consists of the membrane-attached NADPH-dependent adrenodoxin reductase (AR), the soluble one-electron transport protein adrenodoxin (Adx), and a membrane-integrated cytochrome P450 of the CYP11 family. In the 2.3-Angstrom resolution crystal structure of the Adx AR complex, 580 Angstrom (2) of partly polar surface are buried. Main interaction sites are centered around Asp(79), Asp(76), Asp(72), and Asp(39) Of Adx and around Arg(211), Arg(240), Arg(244) and Lys(27) Of AR, respectively. In particular, the region around Asp(39) defines a new protein interaction site for Adn, similar to those found in plant and bacterial ferredoxins. Additional contacts involve the electron transfer region between the redox centers of AR and Adx and C-terminal residues of Adx, The Adx residues Asp(113) to Arg(15) adopt 3(10)-helical conformation and engage in loose intermolecular contacts within a deep cleft of AR. Complex formation is accompanied by a slight domain rearrangement in AR. The [2Fe-2S] cluster of Adx and the isoalloxazine rings of FAD of AR are 10 Angstrom apart suggesting a possible electron transfer route between these redox centers. The AR . Adx complex represents the first structure of a biologically relevant complex between a ferredoxin and its reductase.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; DESY, MPG ASMB, D-22603 Hamburg, Germany; Free Univ Berlin, Inst Chem Kristallog, D-14195 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Free University of Berlin	Muller, JJ (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.		Heinemann, Udo/AAH-4766-2019; Bourenkov, Gleb P/C-7794-2017; Heinemann, Udo/S-3379-2016	Heinemann, Udo/0000-0002-8191-3850; Bourenkov, Gleb P/0000-0002-2617-5920; Heinemann, Udo/0000-0002-8191-3850				BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; Bernhardt R, 1996, REV PHYSIOL BIOCH P, V127, P137, DOI 10.1007/BFb0048267; BRANDT ME, 1993, J BIOL CHEM, V268, P17126; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; COGHLAN VM, 1992, J BIOL CHEM, V267, P8932; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Grinberg AV, 2000, PROTEINS, V40, P590, DOI 10.1002/1097-0134(20000901)40:4<590::AID-PROT50>3.0.CO;2-P; HANUKOGLU I, 1992, J STEROID BIOCHEM, V43, P779, DOI 10.1016/0960-0760(92)90307-5; HARA T, 1989, J BIOCHEM-TOKYO, V105, P594, DOI 10.1093/oxfordjournals.jbchem.a122710; HARA T, 1994, CYTOCHROME P450, P417; HARA T, 1991, J BIOCHEM-TOKYO, V110, P261, DOI 10.1093/oxfordjournals.jbchem.a123568; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P11100, DOI 10.1021/bi9709001; Ishimura K, 1997, MICROSC RES TECHNIQ, V36, P445, DOI 10.1002/(SICI)1097-0029(19970315)36:6<445::AID-JEMT2>3.0.CO;2-H; KIDO T, 1979, J BIOL CHEM, V254, P1806; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; LAMBETH JD, 1984, J BIOL CHEM, V259, P25; Lapko A, 1997, PROTEINS, V28, P289; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Muller A, 1998, STRUCTURE, V6, P269, DOI 10.1016/S0969-2126(98)00031-8; Muller JJ, 1999, J MOL BIOL, V294, P501, DOI 10.1006/jmbi.1999.3253; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Pikuleva IA, 2000, ARCH BIOCHEM BIOPHYS, V373, P44, DOI 10.1006/abbi.1999.1536; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; Vickery LE, 1997, STEROIDS, V62, P124, DOI 10.1016/S0039-128X(96)00170-5; Ziegler GA, 1999, J MOL BIOL, V289, P981, DOI 10.1006/jmbi.1999.2807	31	133	137	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2786	2789		10.1074/jbc.M008501200	http://dx.doi.org/10.1074/jbc.M008501200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053423	hybrid			2022-12-27	WOS:000166784800067
J	Guillard, C; Chretien, S; Jockers, R; Fichelson, S; Mayeux, P; Duprez, V				Guillard, C; Chretien, S; Jockers, R; Fichelson, S; Mayeux, P; Duprez, V			Coupling of heterotrimeric G(i) proteins to the erythropoietin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; NUCLEOTIDE-BINDING-PROTEINS; GROWTH-FACTOR RECEPTOR; SENSITIVE G-PROTEINS; DEPENDENT CELL-LINE; FACTOR-II RECEPTOR; TYROSINE PHOSPHORYLATION; PERTUSSIS-TOXIN; ADENYLATE-CYCLASE; RESPONSIVE CELLS	To identify new proteins involved in erythropoietin (Epo) signal transduction, we purified the entire set of proteins reactive with anti-phosphotyrosine antibodies from Epo-stimulated UT7 cells. Antisera generated against these proteins mere used to screen a lambda EXlox expression library. One of the isolated cDNAs encodes G beta (2), the beta (2) subunit of heterotrimeric GTP-binding proteins. G beta and G alpha (i) coprecipitated with the Epo receptor (EpoR) in extracts from human and murine cell Lines and from normal human erythroid progenitor cells. In addition, in vitro G beta associated with a fusion protein containing the intracellular domain of the EpoR. Using EpoR mutants, we found that the distal part of the EpoR (between amino acids 459-479) was required for G(i) binding. Epo activation of these cells induced the release of the G(i) protein from the EpoR. Moreover in isolated cell membranes, Epo treatment inhibited ADP-ribosylation of G(i) and increased the binding of GTP. Our results show that heterotrimeric G(i) proteins associate with the C-terminal end of the EpoR. Receptor activation leads to the activation and dissociation of G(i) from the receptor, suggesting a functional role of G(i) protein in Epo signal transduction.	INSERM, U363, F-75014 Paris, France; Inst Cochin Genet Mol, CNRS UPR 0415, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Duprez, V (corresponding author), Hop Cochin, INSERM U363, ICGM, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		Chretien, Stany/M-5166-2018; Jockers, Ralf/P-2272-2017; Jockers, Ralf/Q-2100-2019	Jockers, Ralf/0000-0002-4354-1750; Jockers, Ralf/0000-0002-4354-1750				AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; Beckman DL, 1999, BLOOD, V94, P2667, DOI 10.1182/blood.V94.8.2667.420k27_2667_2675; BILLAT C, 1991, BIOL NEONATE, V60, P371; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BONANOUTZEDAKI SA, 1986, EUR J BIOCHEM, V155, P363, DOI 10.1111/j.1432-1033.1986.tb09499.x; CENCIARELLI C, 1992, J BIOL CHEM, V267, P14527; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; Chretien S, 1997, ONCOGENE, V15, P1995, DOI 10.1038/sj.onc.1201364; CORRE I, 1995, BLOOD, V86, P1776, DOI 10.1182/blood.V86.5.1776.bloodjournal8651776; Corre I, 1999, ONCOGENE, V18, P6335, DOI 10.1038/sj.onc.1203010; Damen JE, 1996, EXP HEMATOL, V24, P1455; DAMEN JE, 1993, BLOOD, V82, P2296; Duprez V, 1998, J BIOL CHEM, V273, P33985, DOI 10.1074/jbc.273.51.33985; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Freyssinier JM, 1999, BRIT J HAEMATOL, V106, P912; Ghose S, 1999, J BIOL CHEM, V274, P12848, DOI 10.1074/jbc.274.18.12848; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GONG XH, 1995, SCIENCE, V269, P1718, DOI 10.1126/science.7569899; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; HANAZONO Y, 1993, BLOOD, V81, P3193; HE YX, 1988, BLOOD, V71, P1187; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; IMBODEN JB, 1986, P NATL ACAD SCI USA, V83, P5673, DOI 10.1073/pnas.83.15.5673; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; KITAMURA T, 1989, BLOOD, V73, P375; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; KOMATSU N, 1991, CANCER RES, V51, P341; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; LIANG M, 1991, J BIOL CHEM, V266, P13342; Lippert E, 1997, FEBS LETT, V417, P292, DOI 10.1016/S0014-5793(97)01308-2; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MCCOLL SR, 1989, BLOOD, V73, P588; MILLER BA, 1989, BLOOD, V73, P1188; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; Miller BA, 1996, J CLIN INVEST, V98, P1728, DOI 10.1172/JCI118971; MILLER BA, 1991, BLOOD, V77, P486; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; REN HY, 1994, J BIOL CHEM, V269, P19633; Roka F, 1999, MOL PHARMACOL, V56, P1014, DOI 10.1124/mol.56.5.1014; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TSAI SC, 1984, J BIOL CHEM, V259, P5320; TSUDA H, 1989, EXP HEMATOL, V17, P211; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; WILLIAMS AG, 1990, BLOOD, V76, P721; WINKELMANN JC, 1995, BLOOD, V85, P179, DOI 10.1182/blood.V85.1.179.bloodjournal851179; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YANG LJ, 1993, J BIOL CHEM, V268, P3739; ZUMBIHL R, 1995, J IMMUNOL, V155, P181	70	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2007	2014		10.1074/jbc.M003527200	http://dx.doi.org/10.1074/jbc.M003527200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053408	hybrid			2022-12-27	WOS:000166528000050
J	Leimkuhler, S; Rajagopalan, KV				Leimkuhler, S; Rajagopalan, KV			In vitro incorporation of nascent molybdenum cofactor into human sulfite oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STRUCTURAL-CHARACTERIZATION; NITRATE REDUCTASE; BIOSYNTHESIS; MOLYBDOPTERIN; IDENTIFICATION; MOLYBDATE; PURIFICATION; INVOLVEMENT; COMPONENT	We were able to reconstitute molybdopterin (MPT)free sulfite oxidase in vitro with the molybdenum cofactor (Moco) synthesized de novo from precursor Z and molybdate. MPT-free human sulfite oxidase apoprotein was obtained by heterologous expression in an Escherichia coli mutant with a defect in the early steps of MPT biosynthesis. In vitro reconstitution of the purified apoprotein was achieved using an incubation mixture containing purified precursor Z, purified MPT synthase, and sodium molybdate. In vitro synthesized MPT generated from precursor Z by MPT synthase remains bound to the synthase. Surprisingly, MPT synthase was found capable of donating bound MPT to MPT- free sulfite oxidase. MPT was not released from MPT synthase when either bovine serum albumin or Moco-containing sulfite oxidase was used in place of aposulfite oxidase. After the inclusion of sodium molybdate in the reconstitution mixture, active sulfite oxidase was obtained, revealing that in vitro MPT synthase and aposulfite oxidase are sufficient for the insertion of MPT into sulfite oxidase and the conversion of MPT into Moco in the presence of high concentrations of molybdate. The conversion of MPT into Moco by molybdate chelation apparently occurs concomitantly with the insertion of RIFT into sulfite oxidase.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu		Leimkuhler, Silke/0000-0003-3238-2122	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044283] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44283] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COHEN HJ, 1971, J BIOL CHEM, V246, P359; Grunden AM, 1997, ARCH MICROBIOL, V168, P345, DOI 10.1007/s002030050508; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON JL, 1997, INT PEDIAT, V12, P23; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JONES HP, 1977, J BIOL CHEM, V252, P4988; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Kozmin SG, 2000, J BACTERIOL, V182, P3361, DOI 10.1128/JB.182.12.3361-3367.2000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; Rajagopalan K.V., 1980, MOLYBDENUM MOLYBDENU, P241; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; RUDOLPH MJ, 2001, IN PRESS NAT STRUCT; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493	22	51	53	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1837	1844		10.1074/jbc.M007304200	http://dx.doi.org/10.1074/jbc.M007304200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042213	hybrid			2022-12-27	WOS:000166528000027
J	Li, GF; Bishop, KJ; Hall, TC				Li, GF; Bishop, KJ; Hall, TC			De novo activation of the beta-phaseolin promoter by phosphatase or protein synthesis inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID; MESSENGER-RNAS; C-FOS; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; OKADAIC ACID; HISTONE H3; CYCLOHEXIMIDE; KINASE; PHOSPHORYLATION	The promoter for the phaseolin (phas) bean seed protein gene adopts an inactive chromatin structure in leaves of transgenic tobacco. This repressive architecture, which confers stringent spatial regulation, is disrupted upon transcriptional activation during embryogenesis in a process that requires the presence of both a transcription factor (PvALF) and abscisic acid (ABA). Toward determining the need for de novo synthesis of proteins other than PvALF in transcriptional activation we explored the effect of several eukaryotic protein synthesis inhibitors. Surprisingly, cycloheximide (CHX), emetine, and verrucarin A were able to induce transcription from the phas promoter in tobacco and bean leaf tissue in the absence of either PVALF or ABA. This induction was decreased by the replication inhibitors hydroxyurea and aphidicolin but not by genistein or mimosine. Since protein phosphatases and kinases are essential components of the ABA signal transduction pathway, it is conceivable that CHX is also capable of inducing phosphorylation of proteins usually involved in ABA-mediated activation. Interestingly, okadaic acid, an inhibitor of serine/threonine phosphatase, also strongly activated transcription from the phas promoter. In contrast, the protein synthesis inhibitors anisomycin and puromycin did not activate transcription from the phas promoter, nor did the tyrosine phosphatase inhibitors phenylarsine oxide and sodium orthovanadate, These discrete but different results on transcriptional activation may reflect specific modes of action of the inhibitors, or they may reflect differential interactions of the inhibitors or of downstream events resulting from inhibitor activity with presently unknown components of the transcriptional activation system.	Texas A&M Univ, Inst Dev & Mol Biol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Hall, TC (corresponding author), Texas A&M Univ, Inst Dev & Mol Biol, College Stn, TX 77843 USA.	tim@idmb.tamu.edu						ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; ANTHONY JL, 1991, PLANT PHYSIOL, V97, P839, DOI 10.1104/pp.97.2.839; Berberich T, 1997, MOL GEN GENET, V254, P275, DOI 10.1007/s004380050416; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSTOS MM, 1989, PLANT CELL, V1, P839, DOI 10.1105/tpc.1.9.839; Cesari M, 1998, BIOCHEM J, V336, P619, DOI 10.1042/bj3360619; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EDWARDS Y, 1980, NATURE, V284, P511, DOI 10.1038/284511a0; Feldbrugge M, 1996, MOL GEN GENET, V251, P619, DOI 10.1007/s004380050210; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GUBLER F, 1995, PLANT CELL, V7, P1879, DOI 10.1105/tpc.7.11.1879; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; JEFFERSON RA, 1987, EMBO J, V6, P3901; Kalejta RF, 1997, EXP CELL RES, V231, P173, DOI 10.1006/excr.1996.3444; Kawagoe Y, 1996, PLANT SCI, V116, P47, DOI 10.1016/0168-9452(96)04366-X; KLIMCZAK LJ, 1992, PLANT CELL, V4, P87, DOI 10.1105/tpc.4.1.87; Knetsch MLW, 1996, PLANT CELL, V8, P1061, DOI 10.1105/tpc.8.6.1061; KOSHIBA T, 1995, J MOL BIOL, V253, P396, DOI 10.1006/jmbi.1995.0562; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; Li GF, 1998, P NATL ACAD SCI USA, V95, P4772, DOI 10.1073/pnas.95.8.4772; Li GF, 1999, P NATL ACAD SCI USA, V96, P7104, DOI 10.1073/pnas.96.12.7104; Li GF, 1999, PLANT J, V18, P633, DOI 10.1046/j.1365-313x.1999.00490.x; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MartinezGarcia M, 1996, MOL GEN GENET, V252, P587, DOI 10.1007/s004380050266; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; NUNBERG AN, 1994, PLANT CELL, V6, P473, DOI 10.1105/tpc.6.4.473; PONTECORVI A, 1988, EMBO J, V7, P1489, DOI 10.1002/j.1460-2075.1988.tb02967.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEFFENS WS, 1990, DEV GENET, V11, P65, DOI 10.1002/dvg.1020110108; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; SHEN QX, 1993, J BIOL CHEM, V268, P23652; SLIGHTOM JL, 1983, P NATL ACAD SCI-BIOL, V80, P1897, DOI 10.1073/pnas.80.7.1897; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; VANDERGEEST AHM, 1995, PLANT PHYSIOL, V109, P1151, DOI 10.1104/pp.109.4.1151; Wang P, 1998, GENE, V210, P79, DOI 10.1016/S0378-1119(98)00035-3; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Yakisich JS, 1999, EXP NEUROL, V159, P164, DOI 10.1006/exnr.1999.7121	43	11	12	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2062	2068		10.1074/jbc.M007504200	http://dx.doi.org/10.1074/jbc.M007504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11031270	hybrid			2022-12-27	WOS:000166528000057
J	Stewart, RS; Harris, DA				Stewart, RS; Harris, DA			Most pathogenic mutations do not alter the membrane topology of the prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-CELLS; ENDOPLASMIC-RETICULUM; BIOCHEMICAL-PROPERTIES; TERMINAL DOMAIN; PHOSPHOLIPASE-C; PRP 27-30; BIOGENESIS; DISEASES; MUTANT; FORM	The prion protein (PrP), a glycolipid-anchored membrane glycoprotein, contains a conserved hydrophobic sequence that can span the lipid bilayer in either direction, resulting in two transmembrane forms designated (PrP)-Pr-Ntm and (PrP)-Pr-Ctm. Previous studies have shown that the proportion of (PrP)-Pr-Ctm is increased by mutations in the membrane-spanning segment, and it has been hypothesized that (PrP)-Pr-Ctm represents a key intermediate in the pathway of prion-induced neurodegeneration, To further test this idea, we have surveyed a number of mutations associated with familial prion diseases to determine whether they alter the proportions of (PrP)-Pr-Ntm and (PrP)-Pr-Ctm produced in vitro, in transfected cells, and in transgenic mice. For the in vitro experiments, PrP mRNA was translated in the presence of murine thymoma microsomes which, in contrast to the canine pancreatic microsomes used in previous studies, are capable of efficient glycolipidation, We confirmed that mutations within or near the transmembrane domain enhance the formation of (PrP)-Pr-Ctm, and we demonstrate for the first time that this species contains a C-terminal glycolipid anchor, thus exhibiting an unusual, dual mode of membrane attachment. However, we find that pathogenic mutations in other regions of the molecule have no effect on the amounts of (PrP)-Pr-Ctm and (PrP)-Pr-Ntm, arguing against the proposition that transmembrane PrP plays an obligate role in the pathogenesis of prion diseases.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.			Harris, David/0000-0002-6985-5790	NINDS NIH HHS [T32 NS07129, R01 NS35496] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035496, T32NS007129] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chiesa R, 2000, J NEUROCHEM, V75, P72, DOI 10.1046/j.1471-4159.2000.0750072.x; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; DEFEA KA, 1994, J BIOL CHEM, V269, P16810; FASEL N, 1989, P NATL ACAD SCI USA, V86, P6858, DOI 10.1073/pnas.86.18.6858; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hegde RS, 1999, TRENDS CELL BIOL, V9, P132, DOI 10.1016/S0962-8924(99)01504-4; HITT AL, 1994, J CELL BIOL, V126, P1421, DOI 10.1083/jcb.126.6.1421; HOWELL S, 1994, J BIOL CHEM, V269, P16993; KOSTER B, 1994, ARCH BIOCHEM BIOPHYS, V310, P108, DOI 10.1006/abbi.1994.1146; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MASTRIANNI JA, 1995, NEUROLOGY, V45, P2042, DOI 10.1212/WNL.45.11.2042; Narwa R, 1999, BIOCHEMISTRY-US, V38, P8770, DOI 10.1021/bi990736c; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Priola SA, 1998, J BIOL CHEM, V273, P11980, DOI 10.1074/jbc.273.19.11980; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; PRUSINER SB, 1999, PRION BIOL DIS; ROSENBERRY TL, 1991, CELL BIOL INT REP, V15, P1133, DOI 10.1016/0309-1651(91)90060-V; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; Tateishi J, 1996, NEUROLOGY, V46, P532, DOI 10.1212/WNL.46.2.532; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; TRANCHANT C, 1992, J NEUROL NEUROSUR PS, V55, P185, DOI 10.1136/jnnp.55.3.185; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VIDUGIRIENE J, 1995, EMBO J, V14, P4686, DOI 10.1002/j.1460-2075.1995.tb00150.x; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; Young Katherine, 1999, P139	47	56	59	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2212	2220		10.1074/jbc.M006763200	http://dx.doi.org/10.1074/jbc.M006763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053411	hybrid			2022-12-27	WOS:000166528000075
J	Braun, FJ; Broad, LM; Armstrong, DL; Putney, JW				Braun, FJ; Broad, LM; Armstrong, DL; Putney, JW			Stable activation of single Ca2+ release-activated Ca2+ channels in divalent cation-free solutions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; JURKAT T-LYMPHOCYTES; STORE DEPLETION; MAST-CELLS; ANTIGEN	The regulation of store-operated, calcium-selective channels in the plasma membrane of rat basophilic leukemia cells (RBL-2H3 m1), an immortalized mucosal mast cell line, was studied at the single-channel level with the patch clamp technique by removing divalent cations from both sides of the membrane. The activity of the single channels in excised patches could be modulated by Ca2+, Mg2+, and pH. The maximal activation of these channels by divalent cation-free conditions occurred independently of depletion of intracellular Ca2+ stores, whether in excised patches or in whole cell mode. Yet, a number of points of evidence establish these single-channel openings as amplified store-operated channel events. Specifically, (i) the single channels are exquisitely sensitive to inhibition by intracellular Ca2+, and (ii) both the store-operated current and the single-channel openings are completely blocked by the capacitative calcium entry blocker, 2-aminoethoxydiphenyl borane, In addition, in Jurkat T cells single-channel openings with lower open probability have been observed in the whole cell mode with intracellular Mg2+ present (Kerschbaum, H. H., and Cahalan, M. D. (1999) Science 283, 836-839), and in RBL-2H3 m1 cells a current with similar properties is activated by store depletion.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Braun, FJ (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, ZIAES080043, Z01ES080043, Z01ES090087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; CHOI OH, 1993, J IMMUNOL, V151, P5586; Fierro L, 2000, PFLUG ARCH EUR J PHY, V440, P580, DOI 10.1007/s004240050009; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kerschbaum HH, 1998, J GEN PHYSIOL, V111, P521, DOI 10.1085/jgp.111.4.521; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov KI, 1999, PFLUG ARCH EUR J PHY, V437, P305, DOI 10.1007/s004240050784; Krause E, 1999, J BIOL CHEM, V274, P36957, DOI 10.1074/jbc.274.52.36957; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Zubov AI, 1999, J BIOL CHEM, V274, P25983, DOI 10.1074/jbc.274.37.25983; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	26	99	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1063	1070		10.1074/jbc.M008348200	http://dx.doi.org/10.1074/jbc.M008348200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042187	hybrid			2022-12-27	WOS:000166430900029
J	DeGregorio-Rocasolano, N; Gasull, T; Trullas, R				DeGregorio-Rocasolano, N; Gasull, T; Trullas, R			Overexpression of neuronal pentraxin 1 is involved in neuronal death evoked by low K+ in cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; DIFFERENTIAL DISPLAY; GROWTH-FACTOR; APOPTOSIS; SURVIVAL; EXCITOTOXICITY; DEPOLARIZATION; EXPRESSION; POTASSIUM	Mature cerebellar granule cells in culture die by a process that requires new RNA and protein synthesis when deprived of depolarizing concentrations of potassium. We investigated gene expression during the early phase of the cell death program evoked by potassium deprivation, Using a differential gene display technique, we isolated a cDNA that was increased by potassium deprivation. This cDNA was homologous to the 3' mRNA end of neuronal pentraxin 1 (NP1), a gene encoding a secreted glycoprotein whose expression is restricted to the nervous system. Reverse-Northern and Northern blot analyses confirmed that treatment with low potassium induces overexpression of NP1 mRNA, with a subsequent increase in NP1 protein levels. Time-course studies indicated that overexpression of NP1 protein reaches a maximum after 4 h of exposure to potassium deprivation and 4 h before significant cell death. Incubation of cerebellar granule cells with an antisense oligodeoxyribonucleotide directed against NP1 mRNA reduced low potassium-evoked NP1 protein levels by 60% and attenuated neuronal death by 50%, whereas incubation with the corresponding sense oligodeoxyribonucleotide was ineffective. Furthermore, acute treatment with lithium significantly inhibited both overexpression of NP1 and cell death evoked by low potassium. These results indicate that NP1 is part of the gene expression program of apoptotic cell death activated by nondepolarizing culture conditions in cerebellar granule cells.	CSIC, Inst Invest Biomed Barcelona, Neurobiol Unit, Inst Invest Biomed August Pi I Sunyer, Barcelona 08036, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Trullas, R (corresponding author), CSIC, Inst Invest Biomed Barcelona, Neurobiol Unit, Inst Invest Biomed August Pi I Sunyer, Rossello 161, Barcelona 08036, Spain.		Trullas, Ramon/D-2197-2016; De Gregorio - Rocasolano, Nuria/M-1523-2014	Trullas, Ramon/0000-0001-7951-9881; GASULL, TERESA/0000-0002-9321-1741; De Gregorio - Rocasolano, Nuria/0000-0001-5248-7525				Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Burek MJ, 1996, BRAIN PATHOL, V6, P427, DOI 10.1111/j.1750-3639.1996.tb00874.x; Catania MV, 1999, NEUROSCIENCE, V91, P1529, DOI 10.1016/S0306-4522(98)00544-2; Chang JY, 1997, NEUROCHEM RES, V22, P43, DOI 10.1023/A:1027373220133; Chen G, 1999, J NEUROCHEM, V72, P879, DOI 10.1046/j.1471-4159.1999.720879.x; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; D'MELLO SR, 1994, EXP CELL RES, V211, P332, DOI 10.1006/excr.1994.1095; D'Mello SR, 1997, J NEUROSCI, V17, P1548; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eldadah BA, 1997, J NEUROSCI, V17, P6105; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLO V, 1987, J NEUROSCI, V7, P2203; Goodman Adam R., 1996, Cytokine and Growth Factor Reviews, V7, P191, DOI 10.1016/1359-6101(96)00019-6; Ishitani R, 1997, MOL PHARMACOL, V51, P542, DOI 10.1124/mol.51.4.542; Kirkpatrick LL, 2000, J BIOL CHEM, V275, P17786, DOI 10.1074/jbc.M002254200; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Manji HK, 2000, J CLIN PSYCHIAT, V61, P82; Miller TM, 1996, J NEUROSCI, V16, P7487; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Nardi N, 1997, J NEUROCHEM, V68, P750; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; O'Brien RJ, 1999, NEURON, V23, P309, DOI 10.1016/S0896-6273(00)80782-5; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; Olmos G, 1999, BRIT J PHARMACOL, V127, P1317, DOI 10.1038/sj.bjp.0702679; Omeis IA, 1996, GENOMICS, V36, P543, DOI 10.1006/geno.1996.0503; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Rudolph JG, 1997, NEUROSCI LETT, V221, P149, DOI 10.1016/S0304-3940(96)13313-9; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; SUNAGA K, 1995, NEUROSCI LETT, V200, P133, DOI 10.1016/0304-3940(95)12098-O; Tsui CC, 1996, J NEUROSCI, V16, P2463; Viu E, 1998, J PHARMACOL EXP THER, V285, P527; Watson A, 1998, J NEUROSCI, V18, P751; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; Zhang H, 1996, NUCLEIC ACIDS RES, V24, P2454, DOI 10.1093/nar/24.12.2454	40	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					796	803		10.1074/jbc.M007967200	http://dx.doi.org/10.1074/jbc.M007967200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031272	hybrid			2022-12-27	WOS:000166280700107
J	Hammamieh, R; Yang, DCH				Hammamieh, R; Yang, DCH			Magnesium ion-mediated binding to tRNA by an amino-terminal peptide of a class II tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; PROTEIN-PROTEIN INTERACTIONS; ELONGATION-FACTOR 1-ALPHA; METHIONYL-TRANSFER-RNA; HIGH-MR COMPLEX; ESCHERICHIA-COLI; MULTISYNTHETASE COMPLEX; FUNCTIONAL-ANALYSIS; AMPHIPHILIC HELIX; RAT-LIVER	Aspartyl-tRNA synthetase is a class II tRNA synthetase and occurs in a multisynthetase complex in mammalian cells. Human Asp-tRNA synthetase contains a short 32-residue amino-terminal extension that can control the release of charged tRNA and its direct transfer to elongation factor 1 alpha; however, whether the extension binds to tRNA directly or interacts with the synthetase active site is not known. Full-length human AspRS, but not amino-terminal 32 residue-deleted, fully active As-pRS, was found to bind to noncognate tRNA(fMet) in the presence of Mg2+. Synthetic amino-terminal peptides bound similarly to tRNA(fMet), whereas little or no binding of polynucleotides, poly(dA-dT), or polyphosphate to the peptides was found. The apparent binding constants to tRNA by the peptide increased with increasing concentrations of Mg2+, suggesting Mg2+ mediates the binding as a new mode of RNA peptide interactions. The binding of tRNA(fMet), amino-terminal peptides was also observed using fluorescence-labeled tRNAs and circular dichroism. These results suggest that a small peptide can bind to tRNA selectively and that evolution of class II tRNA synthetases may involve structural changes of amino-terminal extensions for enhanced selective binding of tRNA.	Georgetown Univ, Dept Chem, Washington, DC 20057 USA	Georgetown University	Yang, DCH (corresponding author), Georgetown Univ, Dept Chem, Washington, DC 20057 USA.	yangdc@georgetown.edu	Yang, David/A-7294-2009	Hammamieh, Rasha/0000-0001-8643-6232				AGOU F, 1995, BIOCHEMISTRY-US, V34, P569, DOI 10.1021/bi00002a023; Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; BEC G, 1989, J BIOL CHEM, V264, P21138; BITTMAN R, 1969, J MOL BIOL, V46, P251, DOI 10.1016/0022-2836(69)90420-3; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CIRAKOGLU B, 1985, EUR J BIOCHEM, V151, P101, DOI 10.1111/j.1432-1033.1985.tb09074.x; de Pouplana LR, 1998, EMBO J, V17, P5449, DOI 10.1093/emboj/17.18.5449; ESCALANTE C, 1994, MOL CELL BIOCHEM, V140, P55, DOI 10.1007/BF00928366; ESCALANTE C, 1993, J BIOL CHEM, V268, P6014; FERGUSON BQ, 1986, BIOCHEMISTRY-US, V25, P2743, DOI 10.1021/bi00358a001; FERGUSON BQ, 1986, BIOCHEMISTRY-US, V25, P5298, DOI 10.1021/bi00366a046; FETT R, 1991, J BIOL CHEM, V266, P1448; Frugier M, 2000, EMBO J, V19, P2371, DOI 10.1093/emboj/19.10.2371; Glasfeld E, 1997, BIOCHEMISTRY-US, V36, P6739, DOI 10.1021/bi970151n; GODAR DE, 1988, BIOCHEMISTRY-US, V27, P6921, DOI 10.1021/bi00418a038; Grosshans H, 2000, J STRUCT BIOL, V129, P288, DOI 10.1006/jsbi.2000.4226; Hammamich R, 1997, FASEB J, V11, pA1024; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; HUANG CY, 1982, METHOD ENZYMOL, V87, P509; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; Job P, 1928, ANN CHIM FRANCE, V9, P113; JOHNSON DL, 1980, J BIOL CHEM, V255, P4362; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; MIRANDE M, 1992, EUR J BIOCHEM, V203, P459, DOI 10.1111/j.1432-1033.1992.tb16570.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1989, J BIOL CHEM, V264, P842; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; REED VS, 1994, J BIOL CHEM, V269, P32932; REED VS, 1994, J BIOL CHEM, V269, P32937; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Sauter C, 2000, J MOL BIOL, V299, P1313, DOI 10.1006/jmbi.2000.3791; SELLAMI M, 1985, GENE, V40, P349, DOI 10.1016/0378-1119(85)90060-5; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; STEIN A, 1976, BIOCHEMISTRY-US, V15, P157, DOI 10.1021/bi00646a024; TAO T, 1970, BIOCHEMISTRY-US, V9, P3514, DOI 10.1021/bi00820a004; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wang CC, 2000, J BIOL CHEM, V275, P17180, DOI 10.1074/jbc.M001057200; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	46	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					428	433		10.1074/jbc.M007570200	http://dx.doi.org/10.1074/jbc.M007570200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035022	hybrid			2022-12-27	WOS:000166280700058
J	Kobayashi, A; Miyake, T; Ohyama, Y; Kawaichi, M; Kokubo, T				Kobayashi, A; Miyake, T; Ohyama, Y; Kawaichi, M; Kokubo, T			Mutations in the TATA-binding protein, affecting transcriptional activation, show synthetic lethality with the TAF145 gene lacking the TAF N-terminal domain in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; IN-VIVO; BOX-BINDING; EUKARYOTIC TRANSCRIPTION; TBP BINDING; DNA-BINDING; PREINITIATION COMPLEX; BASAL TRANSCRIPTION; YEAST; PROMOTER	The general transcription factor TFIID, which is composed of the TATA box-binding protein (TBP) and a set of TBP-associated factors (TAFs), is crucial for both basal and regulated transcription by RNA polymerase II. The N-terminal small segment of yeast TAF145 (yTAF145) binds to TBP and thereby inhibits TBP function. To understand the physiological role of this inhibitory domain, which is designated as TAND (TAF N-terminal domain), we screened mutations, synthetically lethal with the TAF145 gene lacking TAND (taf145 Delta TAND), in Saccharomyces cerevisiae by exploiting a red/white colony-sectoring assay. Our screen yielded several recessive nsl (Delta TAND synthetic lethal) mutations, two of which, nsl1-1 and nsl1-2, define the same complementation group. The NSL1 gene was found to be identical to the SPT15 gene encoding TBP, Interestingly, both temperature-sensitive nsl1/spt15 alleles, which harbor the single amino acid substitutions, S118L and P65S, respectively, were defective in transcriptional activation in vivo. Several other previously characterized activation-deficient spt15 alleles arise displayed synthetic lethal interactions with taf145 Delta TAND, indicating that TAND and TBP carry an overlapping but as yet unidentified function that is specifically required for transcriptional regulation.	Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 6300101, Japan	Nara Institute of Science & Technology	Kokubo, T (corresponding author), Nara Inst Sci & Technol, Div Gene Funct Anim, 8916-5 Takayama, Nara 6300101, Japan.	kokubo@bs.aist-nara.ac.jp						Adams A, 1997, METHODS YEAST GENETI; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bagby S, 2000, FEBS LETT, V468, P149, DOI 10.1016/S0014-5793(00)01213-8; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Baker RE, 1998, GENETICS, V149, P73; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burley SK, 1998, CELL, V94, P551, DOI 10.1016/S0092-8674(00)81596-2; Cang Y, 1999, EMBO J, V18, P6662, DOI 10.1093/emboj/18.23.6662; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; Chen CY, 1998, GENETICS, V150, P577; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; Chicca JJ, 1998, MOL CELL BIOL, V18, P1701, DOI 10.1128/MCB.18.3.1701; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; Dorris DR, 2000, MOL CELL BIOL, V20, P4350, DOI 10.1128/MCB.20.12.4350-4358.2000; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; Knutson A, 2000, J BIOL CHEM, V275, P14190, DOI 10.1074/jbc.275.19.14190; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Kressler D, 1999, MOL CELL BIOL, V19, P8633; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; LEE M, 1995, MOL CELL BIOL, V15, P5461; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; LIEBERMAN P, 1994, MOL CELL BIOL, V14, P8365, DOI 10.1128/MCB.14.12.8365; Lieberman PM, 1997, MOL CELL BIOL, V17, P6624, DOI 10.1128/MCB.17.11.6624; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; LUNDBLACK V, 1998, CURRENT PROTOCOLS MO; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; Muldrow TA, 1999, MOL CELL BIOL, V19, P2835; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Stargell LA, 1996, MOL CELL BIOL, V16, P4456; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; Stargell LA, 2000, J BIOL CHEM, V275, P12374, DOI 10.1074/jbc.275.17.12374; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; Tsukihashi Y, 2000, MOL CELL BIOL, V20, P2385, DOI 10.1128/MCB.20.7.2385-2399.2000; vanderKnaap JA, 1997, P NATL ACAD SCI USA, V94, P11827, DOI 10.1073/pnas.94.22.11827; XIAO H, 1995, MOL CELL BIOL, V15, P5757; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; Zaman Z, 1998, COLD SPRING HARB SYM, V63, P167, DOI 10.1101/sqb.1998.63.167	85	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					395	405		10.1074/jbc.M008208200	http://dx.doi.org/10.1074/jbc.M008208200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035037	hybrid			2022-12-27	WOS:000166280700054
J	Cooper, CB; Arnot, MI; Feng, ZP; Jarvis, SE; Hamid, J; Zamponi, GW				Cooper, CB; Arnot, MI; Feng, ZP; Jarvis, SE; Hamid, J; Zamponi, GW			Cross-talk between G-protein and protein kinase C modulation of N-type calcium channels is dependent on the G-protein beta subunit isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; GAMMA-SUBUNITS; INHIBITION; FACILITATION; DETERMINANTS; CURRENTS; BINDING; NEURONS	The modulation of N-type calcium current by protein kinases and G-proteins is a factor in the fine tuning of neurotransmitter release. We have previously shown that phosphorylation of threonine 422 in the alpha (1B) calcium channel domain I-II linker region resulted in a dramatic reduction in somatostatin receptor-mediated G-protein inhibition of the channels and that the I-II linker consequently serves as an integration center for cross-talk between protein kinase C (PKC) and G-proteins (Hamid, J,, Nelson, D,, Spaetgens, R,, Dubel, S, J,, Snutch, T. P,, and Zamponi, G, W, (1999) J, Biol, Chem, 274, 6195-6202), Here we show that opioid receptor-mediated inhibition of N-type channels is affected to a lesser extent compared with that seen with somatostatin receptors, hinting at the possibility that PKC/G-protein cross-talk might be dependent on the G-protein subtype. To address this issue, we have examined the effects of four different types of G-protein beta subunits on both wild type and mutant alpha (1B) calcium channels in which residue 422 has been replaced by glutamate to mimic PKC-dependent phosphorylation and on channels that have been directly phosphorylated by protein kinase C, Our data show that phosphorylation or mutation of residue 422 antagonizes the effect of G beta (1) on channel activity, whereas G beta (2) G beta (3), and G beta (4) are not affected. Our data therefore suggest that the observed cross-talk between G-proteins and protein kinase C modulation of N-type channels is a selective feature of the G beta (1) subunit.	Univ Calgary, Dept Physiol & Biophys, Neurosci & Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Neurosci & Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; NeuroMed Technol Inc, Vancouver, BC, Canada	University of Calgary; University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Neurosci & Smooth Muscle Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Zamponi, Gerald W./0000-0002-0644-9066				Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; Barrett CF, 2000, J GEN PHYSIOL, V115, P277, DOI 10.1085/jgp.115.3.277; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bertram R, 1999, J COMPUT NEUROSCI, V7, P197, DOI 10.1023/A:1008976129832; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Brody DL, 2000, J NEUROSCI, V20, P889, DOI 10.1523/JNEUROSCI.20-03-00889.2000; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; Currie KPM, 1997, J NEUROSCI, V17, P4570; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; Garcia DE, 1998, J NEUROSCI, V18, P9163; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; STEFANI A, 1994, BRAIN RES, V642, P339, DOI 10.1016/0006-8993(94)90940-7; STUART GJ, 1991, NEUROSCI LETT, V126, P179, DOI 10.1016/0304-3940(91)90548-8; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	30	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40777	40781		10.1074/jbc.C000673200	http://dx.doi.org/10.1074/jbc.C000673200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11053424	hybrid			2022-12-27	WOS:000166114600017
J	Yamaguchi, S; Okamura, Y; Nagao, T; Adachi-Akahane, S				Yamaguchi, S; Okamura, Y; Nagao, T; Adachi-Akahane, S			Serine residue in the IIIS5-S6 linker of the L-type Ca2+ channel alpha(1C) subunit is the critical determinant of the action of dihydropyridine Ca2+ channel agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC CALCIUM CHANNELS; AMINO-ACID-RESIDUES; ALPHA-1 SUBUNIT; 1,4-DIHYDROPYRIDINE SENSITIVITY; MOLECULAR DETERMINANTS; FUNCTIONAL EXPRESSION; RADIOLIGAND BINDING; RECEPTOR-SITE; IDENTIFICATION; ANTAGONISTS	The dihydropyridine (DHP)-binding site has been identified within L-type Ca2+ channel alpha (1C) subunit. However, the molecular mechanism underlying modulation of Ca2+ channel gating by DHPs has not been clarified. To search for novel determinants of high affinity DHP binding, we introduced point mutations in the rat brain Ca2+ channel alpha (1C) subunit (rbCII or Ca(v)1.2c) based on the comparison of amino acid sequences between rbCII and the ascidian L-type Ca2+ channel alpha (1) subunit, which is insensitive to DHPs. The alpha (1C) mutants (S1115A, S1146A, and A1420S) and rbCII were transiently expressed in BHK6 cells with beta (1a) and alpha (2)/delta subunits. The mutation did not affect the electrophysiological properties of the Ca2+ channel, or the voltage- and concentration-dependent block of Ca2+ channel currents produced by diltiazem and verapamil. However, the S1115A channel was significantly less sensitive to DHP antagonists. Interestingly, in the S1115A channel, DHP agonists failed to enhance whole-cell Ca2+ channel currents and the prolongation of mean open time, as well as the increment of NPo. Responsiveness to the non-DHP agonist FPL-64176 was also markedly reduced in the S1115A channel. When S1115 was replaced by other amino acids (S1115D, S1115T, or S1115V), only S1115T was slightly sensitive to S-(-)-Bay K 8644. These results indicate that the hydroxyl group of Ser(1115) in IIIS5-S6 linker of the L-type Ca2+ channel alpha (1C) subunit plays a critical role in DHP binding and in the action of DHP Ca2+ channel agonists.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacaol & Toxicol, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Biosci & Human Technol, Dept Biomol Engn, Tsukuba, Ibaraki 3058566, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Adachi-Akahane, S (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacaol & Toxicol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	satomiaa@mol.f.u-tokyo.ac.jp						AdachiAkahane S, 1996, J GEN PHYSIOL, V108, P435, DOI 10.1085/jgp.108.5.435; BANGALORE R, 1994, MOL PHARMACOL, V46, P660; BEAN BP, 1984, P NATL ACAD SCI-BIOL, V81, P6388, DOI 10.1073/pnas.81.20.6388; BECHEM M, 1988, TRENDS PHARMACOL SCI, V9, P257, DOI 10.1016/0165-6147(88)90156-3; Bechem M, 1996, LIFE SCI, V60, P107, DOI 10.1016/S0024-3205(96)00600-5; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; He M, 1997, J BIOL CHEM, V272, P2629, DOI 10.1074/jbc.272.5.2629; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Jeziorski MC, 1998, J BIOL CHEM, V273, P22792, DOI 10.1074/jbc.273.35.22792; KALASZ H, 1993, FEBS LETT, V331, P177, DOI 10.1016/0014-5793(93)80321-K; KASS RS, 1989, J GEN PHYSIOL, V93, P1109, DOI 10.1085/jgp.93.6.1109; KASS RS, 1991, J GEN PHYSIOL, V98, P63, DOI 10.1085/jgp.98.1.63; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; Okamura Y, 1999, BIOPHYS J, V76, pA340; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; RAMPE D, 1991, J PHARMACOL EXP THER, V259, P982; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; STRUBING C, 1993, BRIT J PHARMACOL, V108, P884, DOI 10.1111/j.1476-5381.1993.tb13482.x; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TRIGGLE DJ, 1989, TRENDS PHARMACOL SCI, V10, P507, DOI 10.1016/0165-6147(89)90051-5; Wakamori M, 1998, J BIOL CHEM, V273, P34857, DOI 10.1074/jbc.273.52.34857; WANG ZY, 1995, J PHYSIOL-LONDON, V486, P131, DOI 10.1113/jphysiol.1995.sp020797; WEI XY, 1994, J BIOL CHEM, V269, P1635; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0; ZHENG W, 1991, MOL PHARMACOL, V40, P734	38	58	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41504	41511		10.1074/jbc.M007165200	http://dx.doi.org/10.1074/jbc.M007165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11022040	hybrid			2022-12-27	WOS:000166114600109
J	Farhang-Fallah, J; Yin, XH; Trentin, G; Cheng, AM; Rozakis-Adcock, M				Farhang-Fallah, J; Yin, XH; Trentin, G; Cheng, AM; Rozakis-Adcock, M			Cloning and characterization of PHIP, a novel insulin receptor substrate-1 pleckstrin homology domain interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAYS; IRS-1; RAS; PHOSPHORYLATION; SHC; ASSOCIATION; COMPLEXES; REGION; SYSTEM; CELLS	Insulin receptor substrate-1 (IRS-1) protein is a major substrate of the insulin receptor tyrosine kinase and is essential for transducing many of the biological effects of insulin including mitogenesis, gene expression, and glucose transport. The N terminus of IRS-1 contains a pleckstrin homology (PH) domain that is critical for recognition and subsequent phosphorylation of IRS-1 by the activated insulin receptor. Here we report the isolation of a novel protein, PHIP (PH-interacting protein), which selectively binds to the PH domain of IRS-1 in vitro and stably associates with IRS-1 in vivo, Importantly, mutants of the IRS-1 PH domain that disrupt the PH fold fail to bind to PHIP. Anti-phosphotyrosine immunoblots of PHIP revealed no discernible insulin receptor-regulated phosphorylation, suggesting that PHIP is not itself a substrate of the insulin receptor. In contrast to full-length PHIP, overexpression of the PH-binding region of PHIP has a pronounced inhibitory effect on insulin-induced IRS-1 tyrosine phosphorylation levels. Furthermore, expression of this dominant-negative PHIP mutant leads to a marked attenuation of insulin-stimulated mitogen-activated protein kinase activity. We conclude that PHIP represents a novel protein ligand of the IRS-1 PH domain that may serve to link IRS-1 to the insulin receptor.	Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada; Washington Univ, Sch Med, Dept Med & Pathol, St Louis, MO 63110 USA	McMaster University; McMaster University; McMaster University; Washington University (WUSTL)	Rozakis-Adcock, M (corresponding author), Hamilton Reg Canc Ctr, 699 Concess St, Hamilton, ON L8V 5C2, Canada.							Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; White MF, 1998, CURR TOP MICROBIOL, V228, P179; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yenush L, 1996, MOL CELL BIOL, V16, P2509	27	40	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40492	40497		10.1074/jbc.C000611200	http://dx.doi.org/10.1074/jbc.C000611200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11018022	hybrid			2022-12-27	WOS:000166039500093
J	Wang, GS; Peterkofsky, A; Clore, GM				Wang, GS; Peterkofsky, A; Clore, GM			A novel membrane anchor function for the N-terminal amphipathic sequence of the signal-transducing protein IIA(Glucose) of the Escherichia coli phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; SALMONELLA-TYPHIMURIUM; SECONDARY STRUCTURE; NMR-SPECTROSCOPY; SUGAR-TRANSPORT; IIIGLC; DOMAIN; IIA(GLC); PERMEASE; HELIX	Enzyme IIA(Glucose) (IIA(Glc)) is a signal-transducing protein in the phosphotransferase system of Escherichia coli. Structural studies of free IIA(Glc) and the HPr-IIA(Glc) complex have shown that IIA(Glc) comprises a globular P-sheet sandwich core (residues 19-168) and a disordered N-terminal tail (residues 1-18). Although the presence of the N-terminal tail is not required for IIA(Glc) to accept a phosphorus from the histidine phosphocarrier protein HPr, its presence is essential for effective phosphotransfer from IIA(Glc) to the membrane-bound IIBCGlc. The sequence of the N-terminal tail suggests that it has the potential to form an amphipathic helix. Using CD, we demonstrate that a peptide, corresponding to the N-terminal 18 residues of IIA(Glc), adopts a helical conformation in the presence of either the anionic lipid phosphatidylglycerol or a mixture of anionic E. coli lipids phosphatidylglycerol (25%) and phosphatidylethanolamine (75%), The peptide, however, is in a random coil state in the presence of the zwitterionic lipid phosphatidylcholine, indicating that electrostatic interactions play a role in the binding of the lipid to the peptide. In addition, we show that intact IIA(Glc) also interacts with anionic lipids, resulting in an increase in helicity, which can be directly attributed to the N-terminal segment. From these data we propose that IIA(Glc) comprises two functional domains: a folded domain containing the active site and capable of weakly interacting with the peripheral IIB domain of the membrane protein IIBCGlc; and the N-terminal tail, which interacts with the negatively charged E, coli membrane, thereby stabilizing the complex of IIA(Glc) with IIBCGlc. This stabilization is essential for the final step of the phosphoryl transfer cascade in the glucose transport pathway.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Rm B1-30I, Bethesda, MD 20892 USA.		Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000151] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Feese MD, 1997, BIOCHEMISTRY-US, V36, P16087, DOI 10.1021/bi971999e; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015; Huang K, 1998, STRUCTURE, V6, P697, DOI 10.1016/S0969-2126(98)00072-0; JACKSON RL, 1973, J BIOL CHEM, V248, P5218; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P9509, DOI 10.1021/bi980340l; Kadner R. J., 1996, ESCHERICHIA COLI SAL, P58; MCLACHLAN AD, 1977, NATURE, V267, P465, DOI 10.1038/267465a0; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1986, J BIOL CHEM, V261, P3504; NOVOTNY MJ, 1985, J BACTERIOL, V162, P810, DOI 10.1128/JB.162.2.810-816.1985; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; ROTTEM S, 1980, BIOCHIM BIOPHYS ACTA, V604, P65, DOI 10.1016/0005-2736(80)90585-4; SCHNETZ K, 1990, J BIOL CHEM, V265, P13464; SEGREST JP, 1992, J LIPID RES, V33, P141; Wang GS, 1996, BIOCHEMISTRY-US, V35, P10358, DOI 10.1021/bi960934t; Wang GS, 2000, J BIOL CHEM, V275, P16401, DOI 10.1074/jbc.C000167200; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; Wang GS, 1996, BBA-LIPID LIPID MET, V1301, P174, DOI 10.1016/0005-2760(96)00037-9; Wang GS, 1997, BIOCHEMISTRY-US, V36, P13657, DOI 10.1021/bi971151q; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	26	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39811	39814		10.1074/jbc.C000709200	http://dx.doi.org/10.1074/jbc.C000709200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11044440	hybrid			2022-12-27	WOS:000166039500003
J	Vandorpe, DH; Chernova, MN; Jiang, LW; Sellin, LK; Wilhelm, S; Stuart-Tilley, AK; Walz, G; Alper, SL				Vandorpe, DH; Chernova, MN; Jiang, LW; Sellin, LK; Wilhelm, S; Stuart-Tilley, AK; Walz, G; Alper, SL			The cytoplasmic C-terminal fragment of polycystin-1 regulates a Ca2+-permeable cation channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKD1 GENE-PRODUCT; KIDNEY-DISEASE; XENOPUS OOCYTES; IN-VITRO; PROTEIN; IDENTIFICATION; MEMBRANE; HOMOLOG; DOMAIN; PHOSPHORYLATION	The cytoplasmic C-terminal portion of the polycystin-1 polypeptide (PKD1(1-226)) regulates several important cell signaling pathways, and its deletion suffices to cause autosomal dominant polycystic kidney disease, However, a functional link between PKD1 and the ion transport processes required to drive renal cyst enlargement has remained elusive, We report here that expression at the Xenopus oocyte surface of a transmembrane fusion protein encoding the C-terminal portion of the PKD1 cytoplasmic tail, PKD1(115-226), but not the N-terminal portion, induced a large, Ca2+-permeable cation current, which shifted oocyte reversal potential (E-rev) by +33 mV, Whole cell currents were sensitive to inhibition by La3+, Gd3+, and Zn2+, and partially inhibited by SKF96365 and amiloride, Currents were not activated by bath hypertonicity, but were inhibited by acid pH, Outside-out patches pulled from PKD1(115-226)-expressing oocytes exhibited a 5.1-fold increased NP, of endogenous 20-picosiemens cation channels of linear conductance. PKD1(115-226)-injected oocytes also exhibited elevated NPo of unitary calcium currents in outside-out and cell-attached patches, and elevated calcium permeability documented by fluorescence ratio and Ca-45(2+) flux experiments. Both Ca2+ conductance and influx were inhibited by La3+, Mutation of candidate phosphorylation sites within PKD1(115-226) abolished the cation current. We conclude that the C-terminal cytoplasmic tail of PKD1 up-regulates inward current that includes a major contribution from Ca2+-permeable nonspecific cation channels. Dysregulation of these or similar channels in autosomal dominant polycystic kidney disease may contribute to cyst formation or expansion.	Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med & Cell Biol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Alper, SL (corresponding author), Beth Israel Deaconess Med Ctr, Mol Med Unit, 330 Brookline Ave, Boston, MA 02215 USA.				NHLBI NIH HHS [HL15157] Funding Source: Medline; NIDDK NIH HHS [DK34854, DK51059, DK52897] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052897, R01DK051059, P30DK034854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnould T, 1999, MOL CELL BIOL, V19, P3423; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Benzing T, 2000, J BIOL CHEM, V275, P28167; Bielfeld-Ackermann A, 1998, PFLUG ARCH EUR J PHY, V436, P329, DOI 10.1007/PL00008085; Bobanovic LK, 1999, BIOCHEM J, V340, P593, DOI 10.1042/0264-6021:3400593; Burckhardt BC, 1997, PFLUG ARCH EUR J PHY, V434, P306, DOI 10.1007/s004240050401; Busch AE, 1996, J PHYSIOL-LONDON, V491, P735, DOI 10.1113/jphysiol.1996.sp021253; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; Ebihara L, 1996, BIOPHYS J, V71, P742, DOI 10.1016/S0006-3495(96)79273-1; Harris PC, 1999, HUM MOL GENET, V8, P1861, DOI 10.1093/hmg/8.10.1861; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; HUMPHREYS BD, 1995, AM J PHYSIOL-CELL PH, V268, pC201, DOI 10.1152/ajpcell.1995.268.1.C201; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Koch JP, 1999, J MEMBRANE BIOL, V168, P131, DOI 10.1007/s002329900503; Li HP, 1999, BIOCHEM BIOPH RES CO, V259, P356, DOI 10.1006/bbrc.1999.0780; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Neophytou P, 1996, HUM GENET, V98, P437, DOI 10.1007/s004390050235; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Parnell SC, 1999, BIOCHEM BIOPH RES CO, V259, P539, DOI 10.1006/bbrc.1999.0810; Peral B, 1996, AM J HUM GENET, V58, P86; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROSETTI S, 1996, AM J MED GENET, V65, P155; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; Tomita Y, 1998, NEUROSCI LETT, V248, P195, DOI 10.1016/S0304-3940(98)00362-0; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; TSOKIAS L, 1997, P NATL ACAD SCI U S, V94, P6965; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; Wang XY, 1997, FEBS LETT, V409, P391, DOI 10.1016/S0014-5793(97)00559-0; Weber WM, 1999, J MEMBRANE BIOL, V170, P1, DOI 10.1007/s002329900532; Wilkinson NC, 1998, J MEMBRANE BIOL, V165, P161, DOI 10.1007/s002329900430; Wilson PD, 1999, LAB INVEST, V79, P1311; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703	47	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4093	4101		10.1074/jbc.M006252200	http://dx.doi.org/10.1074/jbc.M006252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11044446	hybrid			2022-12-27	WOS:000166921200050
J	Leonard, JL; Visser, TJ; Leonard, DM				Leonard, JL; Visser, TJ; Leonard, DM			Characterization of the subunit structure of the catalytically active type I iodothyronine deiodinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; RAT-LIVER; 5'-DEIODINASE ACTIVITY; THYROID-HORMONE; THYROXINE 5'-DEIODINASE; PLASMA-MEMBRANE; KIDNEY; IDENTIFICATION; SELENOCYSTEINE; PROPYLTHIOURACIL	Type I iodothyronine deiodinase is a similar to 50-kDa, integral membrane protein that catalyzes the outer ring deiodination of thyroxine, Despite the identification and cloning of a 27-kDa selenoprotein with the catalytic properties of the type I enzyme, the composition and the physical nature of the active deiodinase are unknown. In this report, we use a molecular approach to determine holoenzyme composition, the role of the membrane anchor on enzyme assembly, and the contribution of individual 27-kDa subunits to catalysis. Overexpression of an immunologically unique rat 27-kDa protein in LLC-PK1 cells that contain abundant catalytically active 27-kDa selenoprotein decreased deiodination by similar to 50%, and >95% of the LLC-PK1 derived 27-kDa selenoprotein was specifically immune precipitated by the anti-rat enzyme antibody. The hybrid enzyme had a molecular mass of 54 kDa and an s(20,w) of similar to3.5 S indicating that every native 27-kDa selenoprotein partnered with an inert rat 27-kDa subunit in a homodimer, Enzyme assembly did not depend on the presence of the N-terminal membrane anchor of the 27-kDa subunit, Direct visualization of the deiodinase dimer showed that the holoenzyme was sorted to the basolateral plasma membrane of the renal epithelial cell.	Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, Worcester, MA 01655 USA; Erasmus Univ, Sch Med, NL-3015 GD Rotterdam, Netherlands	University of Massachusetts System; University of Massachusetts Worcester; Erasmus University Rotterdam	Leonard, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.		Visser, Theo J/C-8059-2013	Visser, Theo J/0000-0002-6997-284X				BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1992, J BIOL CHEM, V267, P18055; Croteau W, 1998, J BIOL CHEM, V273, P25230, DOI 10.1074/jbc.273.39.25230; FEKKES D, 1982, FEBS LETT, V137, P40, DOI 10.1016/0014-5793(82)80310-4; FEKKES D, 1983, BIOCHIM BIOPHYS ACTA, V742, P324, DOI 10.1016/0167-4838(83)90318-7; FEKKES D, 1980, BIOCHIM BIOPHYS ACTA, V613, P41, DOI 10.1016/0005-2744(80)90190-4; GOSWAMI A, 1990, BIOCHEM BIOPH RES CO, V173, P6, DOI 10.1016/S0006-291X(05)81013-7; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; KOHRLE J, 1987, HORM RES, V26, P58, DOI 10.1159/000180686; KOHRLE J, 1990, J BIOL CHEM, V265, P6146; Larsen PR, 1997, BIOCHEM SOC T, V25, P588, DOI 10.1042/bst0250588; LARSEN PR, 1994, THYROID, V4, P357, DOI 10.1089/thy.1994.4.357; LEONARD JL, 1991, J BIOL CHEM, V266, P11262; LEONARD JL, 1981, BIOCHIM BIOPHYS ACTA, V659, P205, DOI 10.1016/0005-2744(81)90285-0; LEONARD JL, 1980, ENDOCRINOLOGY, V107, P1376, DOI 10.1210/endo-107-5-1376; LEONARD JL, 1984, BIOCHIM BIOPHYS ACTA, V787, P122, DOI 10.1016/0167-4838(84)90070-0; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P274, DOI 10.1210/endo-103-1-274; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P2137, DOI 10.1210/endo-103-6-2137; Leonard JL, 1986, THYROID HORMONE META, P189; MOL JA, 1984, BIOCHEM BIOPH RES CO, V120, P28, DOI 10.1016/0006-291X(84)91409-8; MOL JA, 1984, BIOCHEM BIOPH RES CO, V124, P475, DOI 10.1016/0006-291X(84)91578-X; Prabakaran D, 1999, J CELL SCI, V112, P1247; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; SAFRAN M, 1990, ENDOCRINOLOGY, V126, P826, DOI 10.1210/endo-126-2-826; Sanders JP, 1997, ENDOCRINOLOGY, V138, P5153, DOI 10.1210/en.138.12.5153; SCHONMAKERS CHH, 1992, BIOCHIM BIOPHYS ACTA, V1121, P160, DOI 10.1016/0167-4838(92)90349-I; Sun BC, 1997, ENDOCRINOLOGY, V138, P5452, DOI 10.1210/en.138.12.5452; TOYODA N, 1995, J BIOL CHEM, V270, P12310, DOI 10.1074/jbc.270.20.12310; TOYODA N, 1994, J BIOL CHEM, V269, P20329; Toyoda N, 1997, ENDOCRINOLOGY, V138, P213, DOI 10.1210/en.138.1.213; VISSER TJ, 1992, BIOCHEM BIOPH RES CO, V189, P1362, DOI 10.1016/0006-291X(92)90224-9; VISSER TJ, 1980, BIOCHIM BIOPHYS ACTA, V611, P371, DOI 10.1016/0005-2744(80)90074-1; Visser TJ, 1996, ACTA MED AUST, V23, P10	36	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2600	2607		10.1074/jbc.M006973200	http://dx.doi.org/10.1074/jbc.M006973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11044448	hybrid, Green Published			2022-12-27	WOS:000166784800043
J	Fewell, SW; Day, BW; Brodsky, JL				Fewell, SW; Day, BW; Brodsky, JL			Identification of an inhibitor of hsc70-mediated protein translocation and ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN-VIRUS-40 LARGE T; MOLECULAR CHAPERONE; J-DOMAIN; IMMUNOSUPPRESSANT DEOXYSPERGUALIN; POLYPEPTIDE TRANSLOCATION; QUALITY-CONTROL; HSP70; DNAJ; HSC70; 15-DEOXYSPERGUALIN	Members of the hsc70 family of molecular chaperones are critical players in the folding and quality control of cellular proteins, Because several human diseases arise from defects in protein folding, the activity of hsc70 chaperones is a potential therapeutic target for these disorders, By using a known hsc70 modulator, 15-deoxyspergualin, as a seed, we identified a novel inhibitor of hsc70 activity. This compound, R/1, inhibits the endogenous and DnaJ-stimulated ATPase activity of hsc70 by 48 and 51%, respectively, and blocks the hsc70-mediated translocation of a preprotein into yeast endoplasmic reticulum-derived microsomal vesicles. Biochemical studies demonstrate that WI most likely exerts these effects by altering the oligomeric state of hsc70.	Univ Pittsburgh, Dept Sci Biol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Brodsky, JL (corresponding author), Univ Pittsburgh, Dept Sci Biol, Pittsburgh, PA 15260 USA.	jbrodsky@pitt.edu		Day, Billy/0000-0001-6208-9950	NATIONAL CANCER INSTITUTE [P01CA078039, F32CA083270] Funding Source: NIH RePORTER; NCI NIH HHS [1 F32 CA83270-01, CA78039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; Becker J, 1996, MOL CELL BIOL, V16, P4378; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Brodsky JL, 1999, BIOCHEM PHARMACOL, V57, P877, DOI 10.1016/S0006-2952(98)00376-1; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CYR DM, 1992, J BIOL CHEM, V267, P20927; Davis JE, 1999, P NATL ACAD SCI USA, V96, P9269, DOI 10.1073/pnas.96.16.9269; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DURCHSCHLAG H, 1981, EUR J BIOCHEM, V114, P255, DOI 10.1111/j.1432-1033.1981.tb05144.x; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hughes SE, 1996, J CLIN PHARMACOL, V36, P1081, DOI 10.1002/j.1552-4604.1996.tb04160.x; JIANG C, 1998, AM J PHYSIOL, V275, P171; King C, 1999, BIOCHEMISTRY-US, V38, P12452, DOI 10.1021/bi9902788; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; Lebreton L, 1999, J MED CHEM, V42, P4749, DOI 10.1021/jm991043x; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McClellan AJ, 1998, MOL BIOL CELL, V9, P3533, DOI 10.1091/mbc.9.12.3533; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MUKAI H, 1997, GUIDEBOOK MOL CHAPER, P76; NADEAU K, 1994, BIOCHEMISTRY-US, V33, P2561, DOI 10.1021/bi00175a027; NADLER SG, 1995, THER DRUG MONIT, V17, P700, DOI 10.1097/00007691-199512000-00026; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; Rubenstein RC, 2000, AM J PHYSIOL-CELL PH, V278, pC259, DOI 10.1152/ajpcell.2000.278.2.C259; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	42	58	62	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					910	914		10.1074/jbc.M008535200	http://dx.doi.org/10.1074/jbc.M008535200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11036084	hybrid			2022-12-27	WOS:000166430900008
J	Bruno, S; Schiaretti, F; Burkhard, P; Kraus, JP; Janosik, M; Mozzarelli, A				Bruno, S; Schiaretti, F; Burkhard, P; Kraus, JP; Janosik, M; Mozzarelli, A			Functional properties of the active core of human cystathionine beta-synthase crystals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-ACETYLSERINE SULFHYDRYLASE; TRYPTOPHAN SYNTHASE; ALPHA(2)BETA(2) COMPLEX; SALMONELLA-TYPHIMURIUM; HEME PROTEIN; 3-DIMENSIONAL STRUCTURE; PYRIDOXAL 5'-PHOSPHATE; ENZYME; MICROSPECTROPHOTOMETRY; BINDING	Human cystathionine beta -synthase is a pyridoxal 5'-phosphate enzyme containing a heme binding domain and an S-adenosyl-L-methionine regulatory site. We have investigated by single crystal microspectrophotometry the functional properties of a mutant lacking the S-adenosyhmethionine binding domain. Polarized absorption spectra indicate that oxidized and reduced hemes are reversibly formed. Exposure of the reduced form of enzyme crystals to carbon monoxide led to the complete release of the heme moiety. This process, which takes place reversibly and without apparent crystal damage, facilitates the preparation of a heme-free human enzyme. The heme-free enzyme crystals exhibited polarized absorption spectra typical of a pyridoxal 5'-phosphate-dependent protein. The exposure of these crystals to increasing concentrations of the natural substrate L-serine readily led to the formation of the key catalytic intermediate alpha -aminoacrylate. The dissociation constant of L-serine was found to be 6 mM, close to that determined in solution. The amount of the alpha -aminoacrylate Schiff base formed in the presence of L-serine was pH independent between 6 and 9, However, the rate of the disappearance of the alpha -aminoacrylate, likely forming pyruvate and ammonia, was found to increase at pH values higher than 8, Finally, in the presence of homocysteine the alpha -aminoacrylate-enzyme absorption band readily disappears with the concomitant formation of the absorption band of the internal aldimine, indicating that cystathionine beta -synthase crystals catalyze both beta -elimination and beta -replacement reactions. Taken together, these findings demonstrate that the heme moiety is not directly involved in the condensation reaction catalyzed by cystathionine beta -synthase.	Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy; Univ Basel, Biozentrum, ME Muller Inst Struct Biol, CH-4056 Basel, Switzerland; Univ Colorado, Sch Med, Dept Pediat, Denver, CO 80262 USA	University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma; University of Basel; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Mozzarelli, A (corresponding author), Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy.	biochim@unipr.it	Mozzarelli, Andrea/C-3615-2014; Bruno, Stefano/A-4582-2011	Mozzarelli, Andrea/0000-0003-3762-0062; Bruno, Stefano/0000-0002-7890-2472				ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; DOUZOU P, 1984, ADV PROTEIN CHEM, V36, P245, DOI 10.1016/S0065-3233(08)60299-5; DRUMMOND JT, 1995, ANAL BIOCHEM, V228, P323, DOI 10.1006/abio.1995.1358; Eaton W A, 1981, Methods Enzymol, V76, P175; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JANOSIK M, 2000, IN PRESS ACTA CRYSTA; Jhee KH, 2000, J BIOL CHEM, V275, P11541, DOI 10.1074/jbc.C000056200; Jhee KH, 2000, BIOCHEMISTRY-US, V39, P10548, DOI 10.1021/bi001020g; Kery V, 1999, BIOCHEMISTRY-US, V38, P2716, DOI 10.1021/bi981808n; Kery V, 1998, ARCH BIOCHEM BIOPHYS, V355, P222, DOI 10.1006/abbi.1998.0723; KERY V, 1994, J BIOL CHEM, V269, P25283; MCPHERSON A, 1982, PREPARATION ANAL PRO, P94; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MOFFAT K, 1989, ANNU REV BIOPHYS BIO, V18, P309, DOI 10.1146/annurev.biophys.18.1.309; Mozzarelli A, 1998, J MOL BIOL, V283, P135, DOI 10.1006/jmbi.1998.2038; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; Mozzarelli A, 2000, J BIOL CHEM, V275, P6956, DOI 10.1074/jbc.275.10.6956; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; ROSSI GL, 1970, J MOL BIOL, V49, P85, DOI 10.1016/0022-2836(70)90377-3; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; Taoka S, 1999, BIOCHEMISTRY-US, V38, P2738, DOI 10.1021/bi9826052; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t	35	44	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					16	19		10.1074/jbc.C000588200	http://dx.doi.org/10.1074/jbc.C000588200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11042162	hybrid			2022-12-27	WOS:000166280700003
J	Maiti, D; Bhattacharyya, A; Basu, J				Maiti, D; Bhattacharyya, A; Basu, J			Lipoarabinomannan from Mycobacterium tuberculosis promotes macrophage survival by phosphorylating Bad through a phosphatidylinositol 3-kinase/Akt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; FORKHEAD TRANSCRIPTION FACTOR; NF-KAPPA-B; CELL-DEATH; GROWTH-FACTOR; ALVEOLAR MACROPHAGES; BH3 DOMAIN; AKT; ACTIVATION; APOPTOSIS	Efforts in prevention and control of tuberculosis suffer from the lack of detailed knowledge of the mechanisms used by pathogenic mycobacteria for survival within host cell macrophages, The exploitation of host cell signaling pathways to the benefit of the pathogen is a phenomenon that deserves to be looked into in detail, We have tested the hypothesis that lipoarabinomannan (LAM) from the virulent species of Mycobacterium tuberculosis possesses the ability to modulate signaling pathways linked to cell survival. The Bcl-2 family member Bad is a proapoptotic protein, Phosphorylation of Bad promotes cell survival in many cell types. We demonstrate that man-LAM stimulates Bad phosphorylation in a phosphatidylinositol 3-kinase (PI-3K)-dependent pathway in THP-1 cells. Man-LAM activated PI-BK, LAM-stimulated phosphorylation of Bad was abrogated in cells transfected with a dominant-negative mutant of PI-SK (Delta p85), indicating that activation of PI-3K is sufficient to trigger phosphorylation of Bad by LAM. Since phosphorylation of Bad occurred at serine 136, the target of the serine/threonine kinase Akt, the effect of LAM on Akt kinase activity was tested. Man-LAM could activate Akt as evidenced from phosphorylation of Akt at Thr(308) and by the phosphorylation of the exogenous substrate histone 2B, Akt activation was abrogated in cells transfected with Delta p85. The phosphorylation of Bad by man-LAM was abrogated in cells transfected with a kinase-dead mutant of Akt. These results establish that LAM-mediated Bad phosphorylation occurs in a PI-3K/ Akt-dependent manner. It is therefore the first demonstration of the ability of a mycobacterial virulence factor to up-regulate a signaling pathway involved in cell survival. This is likely to be one of a number of virulence-associated mechanisms by which bacilli control host cell apoptosis.	Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India	Department of Science & Technology (India); Bose Institute	Basu, J (corresponding author), Bose Inst, Dept Chem, 93-1 Acharya Prafulla Chandra Rd, Kolkata 700009, W Bengal, India.	joyoti@boseinst.ernet.in	Bhattacharyya, Asima/J-7423-2012	Bhattacharyya, Asima/0000-0001-7292-6644				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; BARNES PF, 1992, INFECT IMMUN, V60, P1441, DOI 10.1128/IAI.60.4.1441-1446.1992; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHAN AWE, 1992, LANGMUIR, V8, P1111, DOI 10.1021/la00040a017; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Fenton MJ, 1996, INFECT IMMUN, V64, P683, DOI 10.1128/IAI.64.3.683-690.1996; Fratazzi C, 1997, J IMMUNOL, V158, P4320; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; JACKETT PS, 1982, ADV EXP MED BIOL, V155, P687; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Keane J, 1997, INFECT IMMUN, V65, P298, DOI 10.1128/IAI.65.1.298-304.1997; Keane J, 2000, J IMMUNOL, V164, P2016, DOI 10.4049/jimmunol.164.4.2016; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Ozes ON, 1999, NATURE, V401, P82; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; ROACH TIA, 1993, J IMMUNOL, V150, P1886; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO R, 1996, J IMMUNOL, V156, P939; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	54	117	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					329	333		10.1074/jbc.M002650200	http://dx.doi.org/10.1074/jbc.M002650200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11020382	hybrid			2022-12-27	WOS:000166280700045
J	Servant, MJ; ten Oever, B; LePage, C; Conti, L; Gessani, S; Julkunen, I; Lin, RT; Hiscott, J				Servant, MJ; ten Oever, B; LePage, C; Conti, L; Gessani, S; Julkunen, I; Lin, RT; Hiscott, J			Identification of distinct signaling pathways leading to the phosphorylation of interferon regulatory factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CASCADES; KAPPA-B ACTIVATION; IKK-BETA SUBUNIT; GENE-EXPRESSION; VIRUS-INFECTION; GROWTH-FACTOR; IN-VITRO; TRANSCRIPTION; CELLS; INHIBITOR	Infection of host cells by viruses leads to the activation of multiple signaling pathways, resulting in the expression of host genes involved in the establishment of the antiviral state. Among the transcription factors mediating the immediate response to virus is interferon regulatory factor-3 (IRF-3) which is post-translationally modified as a result of virus infection. Phosphorylation of latent cytoplasmic IRF-3 on serine and threonine residues in the C-terminal region leads to dimerization, cytoplasmic to nuclear translocation, association with the p300/CBP coactivator, and stimulation of DNA binding and transcriptional activities. We now demonstrate that IRF-3 is a phosphoprotein that is uniquely activated via virus-dependent C-terminal phosphorylation. Paramyxoviridae including measles virus and rhabdoviridae, vesicular stomatitis virus, are potent inducers of a unique virus-activated kinase activity. In contrast, stress inducers, growth factors, DNA-damaging agents, and cytokines do not induce C-terminal IRF-3 phosphorylation, translocation or transactivation, but rather activate a MAPKKK-related signaling pathway that results in N-terminal IRF-3 phosphorylation, The failure of numerous well characterized pharmacological inhibitors to abrogate virus-induced IRF-3 phosphorylation suggests the involvement of a novel kinase activity in IRF-3 regulation by viruses.	McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Natl Publ Hlth Inst, Dept Virol, FIN-00300 Helsinki, Finland; Ist Super Sanita, I-00161 Rome, Italy	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; Finland National Institute for Health & Welfare; Istituto Superiore di Sanita (ISS)	Hiscott, J (corresponding author), McGill Univ, Lady Davis Inst Med Res, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mijh@musica.mcgill.ca	Lin, Rongtuan/A-1442-2008; Conti, Lucia/C-3159-2009; Le Page, Cecile/B-3215-2010; Conti, Lucia/K-2723-2016; Gessani, Sandra/K-5151-2016	Lin, Rongtuan/0000-0002-2238-3503; Le Page, Cecile/0000-0002-8020-1544; Conti, Lucia/0000-0001-9439-081X; Gessani, Sandra/0000-0002-8451-0758				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Azimi N, 2000, J VIROL, V74, P7338, DOI 10.1128/JVI.74.16.7338-7348.2000; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DeLuca C, 1998, VIROLOGY, V244, P27, DOI 10.1006/viro.1998.9085; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Genin P, 1995, NUCLEIC ACIDS RES, V23, P5055; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; Kim T, 2000, J BIOL CHEM, V275, P16910, DOI 10.1074/jbc.M000524200; Kim TK, 2000, CANCER RES, V60, P1153; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PATTERSON JL, 1990, REV INFECT DIS, V12, P1139; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; YANO H, 1993, J BIOL CHEM, V268, P25846; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	47	177	183	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					355	363		10.1074/jbc.M007790200	http://dx.doi.org/10.1074/jbc.M007790200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035028	hybrid			2022-12-27	WOS:000166280700049
J	Skinner, LM; Sudol, M; Harper, AL; Katzman, M				Skinner, LM; Sudol, M; Harper, AL; Katzman, M			Nucleophile selection for the endonuclease activities of human, ovine, and avian retroviral integrases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SITE-SPECIFIC HYDROLYSIS; VIRAL-DNA SPECIFICITY; STABLE COMPLEX; IN-VITRO; INTEGRATION; PROTEIN; SUBSTRATE; ALCOHOLYSIS; RECOGNITION	Retroviral integrases catalyze four endonuclease reactions (processing, joining, disintegration, and nonspecific alcoholysis) that differ in specificity for the attacking nucleophile and target DNA sites. To assess how the two substrates of this enzyme affect each other, we per formed quantitative analyses, in three retroviral systems, of the two reactions that use a variety of nucleophiles. The integrase proteins of human immunodeficiency virus type 1, visna virus, and Rous sarcoma virus exhibited distinct preferences for water or other nucleophiles during site-specific processing of viral DNA and during nonspecific alcoholysis of nonviral DNA. Although exogenous alcohols competed with water as the nucleophile for processing, the alcohols stimulated nicking of nonviral DNA Moreover, different nucleophiles were preferred when the various integrases acted on different DNA targets. In contrast, the nicking patterns were independent of whether integrase was catalyzing hydrolysis or alcoholysis and were not influenced by the particular exogenous alcohol. Thus, although the target DNA influenced the choice of nucleophile, the nucleophile did not affect the choice of target sites. These results indicate that interaction with target DNA is the critical step before catalysis and suggest that integrase does not reach an active conformation until target DNA has bound to the enzyme.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med,Dept Med, Div Infect Dis, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Katzman, M (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med,Dept Med, Div Infect Dis, POB 850,Mail Code H036, Hershey, PA 17033 USA.	mkatzman@psu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI047216] Funding Source: NIH RePORTER; NIAID NIH HHS [R21-AI47216] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; Asante-Appiah E, 1998, J BIOL CHEM, V273, P35078, DOI 10.1074/jbc.273.52.35078; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DONG JY, 1992, J VIROL, V66, P865, DOI 10.1128/JVI.66.2.865-874.1992; DOTAN I, 1995, J VIROL, V69, P456, DOI 10.1128/JVI.69.1.456-468.1995; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8; HAWKINS ME, 1995, NUCLEIC ACIDS RES, V23, P2872, DOI 10.1093/nar/23.15.2872; JONES KS, 1992, J BIOL CHEM, V267, P16037; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1991, P NATL ACAD SCI USA, V88, P4695, DOI 10.1073/pnas.88.11.4695; Katzman M, 1996, J VIROL, V70, P2598, DOI 10.1128/JVI.70.4.2598-2604.1996; Katzman M, 2000, VIRUS RES, V66, P87, DOI 10.1016/S0168-1702(99)00126-4; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Katzman M, 1999, ADV VIRUS RES, V52, P371, DOI 10.1016/S0065-3527(08)60307-3; KATZMAN M, 1995, J VIROL, V69, P5687, DOI 10.1128/JVI.69.9.5687-5696.1995; KATZMAN M, 1994, J VIROL, V68, P3558, DOI 10.1128/JVI.68.6.3558-3569.1994; Katzman M, 1998, J VIROL, V72, P1744, DOI 10.1128/JVI.72.3.1744-1753.1998; LAFEMINA RL, 1995, ANTIMICROB AGENTS CH, V39, P320, DOI 10.1128/AAC.39.2.320; LEE SP, 1995, BIOCHEMISTRY-US, V34, P10205, DOI 10.1021/bi00032a014; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; MAZUMDER A, 1994, NUCLEIC ACIDS RES, V22, P4441, DOI 10.1093/nar/22.21.4441; MILLER MD, 1995, CURR BIOL, V5, P1047, DOI 10.1016/S0960-9822(95)00209-0; Morgan AL, 2000, J GEN VIROL, V81, P839, DOI 10.1099/0022-1317-81-3-839; MULLER B, 1993, P NATL ACAD SCI USA, V90, P11633, DOI 10.1073/pnas.90.24.11633; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; TERRY R, 1988, J VIROL, V62, P2358, DOI 10.1128/JVI.62.7.2358-2365.1988; Tramontano E, 1998, BIOCHEMISTRY-US, V37, P7237, DOI 10.1021/bi972792o; VANGENT DC, 1993, NUCLEIC ACIDS RES, V21, P3373, DOI 10.1093/nar/21.15.3373; VINK C, 1994, NUCLEIC ACIDS RES, V22, P4103, DOI 10.1093/nar/22.20.4103; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VINK C, 1994, J VIROL, V68, P1468, DOI 10.1128/JVI.68.3.1468-1474.1994; VORA AC, 1990, J VIROL, V64, P5656, DOI 10.1128/JVI.64.11.5656-5659.1990; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n; YOSHINAGA T, 1994, J VIROL, V68, P5690, DOI 10.1128/JVI.68.9.5690-5697.1994	42	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					114	124		10.1074/jbc.M007032200	http://dx.doi.org/10.1074/jbc.M007032200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024025	hybrid			2022-12-27	WOS:000166280700017
J	Novitskaya, V; Grigorian, M; Kriajevska, M; Tarabykina, S; Bronstein, I; Berezin, V; Bock, E; Lukanidin, E				Novitskaya, V; Grigorian, M; Kriajevska, M; Tarabykina, S; Bronstein, I; Berezin, V; Bock, E; Lukanidin, E			Oligomeric forms of the metastasis-related Mts1 (S100A4) protein stimulate neuronal differentiation in cultures of rat hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; NEURITE OUTGROWTH; KINASE-C; NEUROTROPHIC FACTORS; IN-VITRO; ACTIVATION; CELLS; EXPRESSION; INHIBITOR; RECEPTOR	Neuronal differentiation and axonal growth are controlled by a variety of factors including neurotrophic factors; extracellular matrix components, and cell adhesion molecules. Here we describe a novel and very efficient neuritogenic factor, the metastasis-related Mts1 protein, belonging to the S100 protein family. The oligomeric but not the dimeric form of Mts1 strongly induces differentiation of cultured hippocampal neurons. A mutant with a single Y75F amino acid substitution, which stabilizes the dimeric form of Mts1, is unable to promote neurite extension. Disulfide bonds do not play an essential role in the Mts1 neuritogenic activity. Mts1-stimulated neurite outgrowth involves activation of phospholipase C and protein kinase C, depends on the intracellular level of Ca2+, and requires activation of the extracellular signal-regulated kinases (ERKs) 1 and 2.	Danish Canc Soc, Inst Mol Canc Biol, Dept Mol Canc Biol, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Inst Mol Pathol, Prot Lab, DK-2200 Copenhagen N, Denmark; Univ York, Dept Chem, Struct Biol Ctr, York YO1 5DD, N Yorkshire, England	Danish Cancer Society; University of Copenhagen; University of York - UK	Lukanidin, E (corresponding author), Danish Canc Soc, Inst Mol Canc Biol, Dept Mol Canc Biol, DK-2100 Copenhagen O, Denmark.	el@cancer.dk						Ambartsumian N, 1999, INVAS METAST, V18, P96; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Brewer GJ, 1999, EXP NEUROL, V159, P237, DOI 10.1006/exnr.1999.7123; Davies MPA, 1996, ONCOGENE, V13, P1631; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Duarte WR, 1999, BIOCHEM BIOPH RES CO, V255, P416, DOI 10.1006/bbrc.1999.0214; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; JARVIS WD, 1994, CANCER RES, V54, P1707; KAJI H, 1992, BIOCHEM BIOPH RES CO, V182, P1356, DOI 10.1016/0006-291X(92)91882-Q; Klingelhofer J, 1997, DEV DYNAM, V210, P87, DOI 10.1002/(SICI)1097-0177(199710)210:2<87::AID-AJA2>3.0.CO;2-5; Kolkova K, 2000, J NEUROSCI, V20, P2238; Kozlova EN, 1999, GLIA, V27, P249, DOI 10.1002/(SICI)1098-1136(199909)27:3<249::AID-GLIA6>3.3.CO;2-5; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Landar A, 1997, BBA-PROTEIN STRUCT M, V1343, P117, DOI 10.1016/S0167-4838(97)00126-X; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; Malcolm CS, 1996, J NEUROCHEM, V66, P2350; Matsumura H, 1998, STRUCTURE, V6, P233, DOI 10.1016/S0969-2126(98)00024-0; Mitsumoto H, 1999, MUSCLE NERVE, V22, P983, DOI 10.1002/(SICI)1097-4598(199908)22:8<983::AID-MUS1>3.0.CO;2-V; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pataky DM, 2000, EXP NEUROL, V163, P357, DOI 10.1006/exnr.2000.7365; PRONCE RJ, 1996, BIOCHEM PHARMACOL, V52, P613; *PROT SOL, 1998, SOFT MAN DYN VERS 4; Rammes A, 1997, J BIOL CHEM, V272, P9496; Ronn LCB, 1999, NAT BIOTECHNOL, V17, P1000, DOI 10.1038/13697; Ronn LCB, 2000, J NEUROSCI METH, V100, P25, DOI 10.1016/S0165-0270(00)00228-4; SACHS CW, 1995, J BIOL CHEM, V270, P26639, DOI 10.1074/jbc.270.44.26639; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Tarabykina S, 2000, FEBS LETT, V475, P187, DOI 10.1016/S0014-5793(00)01652-5; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TRIGGLE DJ, 1991, AM J HYPERTENS, V4, pS422, DOI 10.1093/ajh/4.7.422S; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VANELDIK LJ, 1988, CALCIUM CALCIUM BIND, P114; WALICKE PA, 1989, ANNU REV NEUROSCI, V12, P103, DOI 10.1146/annurev.neuro.12.1.103; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063	48	134	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41278	41286		10.1074/jbc.M007058200	http://dx.doi.org/10.1074/jbc.M007058200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018041	hybrid			2022-12-27	WOS:000166114600083
J	Weyand, M; Schlichting, I				Weyand, M; Schlichting, I			Structural basis for the impaired channeling and allosteric inter-subunit communication in the beta A169L/beta C170W mutant of tryptophan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; ALPHA(2)BETA(2) COMPLEX; 3-DIMENSIONAL STRUCTURE; SALMONELLA-TYPHIMURIUM; CATALYTIC ACTIVITY; BIENZYME COMPLEX; PROTEIN MODELS; SPECIFICITY; REFINEMENT; MECHANISM	We determined the 2.25 Angstrom resolution crystal structure of the beta A169L/beta C170W mutant form of the tryptophan synthase alpha (2)beta (2), complex from Salmonella typhimurium complexed:with the alpha -active site substrate analogue 5-fluoro-indole-propanol-phosphate to identify the structural basis for the changed kinetic properties of the mutant (Anderson, K. S., Kim, A. Y., Quillen, J. M., Sayers, E, Yang, X. J., and Miles, E. W. (1995) J. Biol. Chem, 270, 29936-29944), Comparison with the wild-type enzyme showed that the beta Trp(170) Side chain occludes the tunnel connecting the (alpha- and beta -active sites, explaining the accumulation of the intermediate indole during a single enzyme turnover. To prevent a steric clash between beta Leu(169) and beta Gly(135), located in the beta -sheet of the COMM (communication) domain (beta Gly(102)-beta Gly(189)), the latter reorganizes, The changed COMM domain conformation results in a loss of the hydrogen bonding networks between the alpha- and beta -active sites, explaining the poor activation of the alpha -reaction upon formation of the aminoacrylate complex at the beta -active site. The 100-fold reduced affinity for serine seems to result from a movement of beta Asp(305) away from the beta -active site so that it cannot interact with the hydroxyl group of a pyridoxal phosphate-bound serine, The proposed structural dissection:of the effects of each single mutation in the beta A169L/beta C170W mutant would explain the very different kinetics of this mutant and beta C170F.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany	Max Planck Society	Schlichting, I (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, Otto Hahn Str 11, D-44227 Dortmund, Germany.	ilme.schlichting@mpi-dortmund.mpg.de	Schlichting, Ilme/I-1339-2013					AHMED SA, 1991, J BIOL CHEM, V266, P21548; ANDERSON KS, 1995, J BIOL CHEM, V270, P29936; Anderson KS, 1999, METHOD ENZYMOL, V308, P111; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miles E W, 1995, Subcell Biochem, V24, P207; MILES EW, 1989, J BIOL CHEM, V264, P6280; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; RUVINOV SB, 1995, J BIOL CHEM, V270, P6357, DOI 10.1074/jbc.270.11.6357; SCHLICHTING I, 1994, J BIOL CHEM, V269, P26591; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; Weyand M, 1999, BIOCHEMISTRY-US, V38, P16469, DOI 10.1021/bi9920533	27	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41058	41063		10.1074/jbc.C000479200	http://dx.doi.org/10.1074/jbc.C000479200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11034989	hybrid			2022-12-27	WOS:000166114600054
J	Mohamed, AJ; Vargas, L; Nore, BF; Backesjo, CM; Christenssonn, B; Smith, CIE				Mohamed, AJ; Vargas, L; Nore, BF; Backesjo, CM; Christenssonn, B; Smith, CIE			Nucleocytoplasmic shuttling of Bruton's tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; X-LINKED AGAMMAGLOBULINEMIA; NUCLEAR EXPORT SIGNALS; SRC FAMILY; TEC FAMILY; ACTIVATION; CELLS; BTK; ASSOCIATION; EXPRESSION	Bruton's tyrosine kinase (Btk), a nonreceptor cytoplasmic tyrosine kinase belonging to the Tec family of kinases, has been shown to be critical for B cell proliferation, differentiation, and signaling. Loss-of-function mutations in the Btk gene lead to X-linked agammaglobulinemia (XLA), a primary immunodeficiency in humans, and the less severe condition xid in mice. Although Btk is mainly localized in the cytoplasm under steady state conditions, it translocates to the plasma membrane upon growth factor stimulation and crosslinking of the B cell receptor. Nevertheless, in ectopically as well as endogenously Btk-expressing cells, it can also translocate to the nucleus. Deletion of the pleckstrin homology (PH) domain (Delta PH1) leads, however, to an even redistribution of Btk within the nucleus and cytoplasm in the majority of transfected cells. In contrast, an SH3-deleted (Delta SH3) mutant of Btk has been found to be predominantly nuclear. We also demonstrate that the nuclear accumulation of Delta PH1 is dependent on Src expression. This nucleocytoplasmic shuttling is sensitive to the exportin 1/CRM1-inactivating drug, leptomycin B, indicating that Btk utilizes functional nuclear export signals. In addition, while the Delta PH1 mutant of Btk was found to be active and tyrosine-phosphorylated in vivo, Delta SH3 displayed decreased autokinase activity and was not phosphorylated. Our findings indicate that the nucleocytoplasmic shuttling of Btk has implications regarding potential targets inside the nucleus, which may be critical in gene regulation during B cell development and differentiation.	Karolinska Inst, Novum, Dept Biosci, Clin Res Ctr, S-14157 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Immunol Microbiol Pathol & Infect Dis, SE-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Mohamed, AJ (corresponding author), Karolinska Inst, Novum, Dept Biosci, Clin Res Ctr, S-14157 Huddinge, Sweden.		Nore, Beston F./N-9288-2016	Nore, Beston F./0000-0003-3865-2920; SMITH, C. I. Edvard/0000-0003-1907-3392				Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Ching KA, 1999, J IMMUNOL, V163, P6006; Conley ME, 1998, CURR OPIN IMMUNOL, V10, P399, DOI 10.1016/S0952-7915(98)80112-X; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P4421, DOI 10.1073/pnas.93.9.4421; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Hata D, 1998, J BIOL CHEM, V273, P10979, DOI 10.1074/jbc.273.18.10979; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Kashiwakura J, 1999, J EXP MED, V190, P1147, DOI 10.1084/jem.190.8.1147; Kitanaka A, 1998, BLOOD, V91, P940, DOI 10.1182/blood.V91.3.940.940_940_948; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mohamed AJ, 1999, SCAND J IMMUNOL, V49, P113; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SMITH CIE, 2001, IN PRESS BIOESSAYS; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 2001, ADV GENET, V43, P103, DOI 10.1016/S0065-2660(01)43005-7; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; Yamashita Y, 1996, JPN J CANCER RES, V87, P1106, DOI 10.1111/j.1349-7006.1996.tb03118.x; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832	38	63	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40614	40619		10.1074/jbc.M006952200	http://dx.doi.org/10.1074/jbc.M006952200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11016936	hybrid			2022-12-27	WOS:000166039500109
J	Molkentin, JD				Molkentin, JD			The zinc finger-containing transcription factors GATA-4,-5, and-6 - Ubiquitously expressed regulators of tissue-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							EMBRYONIC STEM-CELLS; HEAVY-CHAIN GENE; CONGENITAL HEART-DISEASE; NATRIURETIC-FACTOR GENE; GATA-BINDING-PROTEINS; TROPONIN-I GENE; CARDIAC-MUSCLE; ENDODERM DIFFERENTIATION; ACTIVATES TRANSCRIPTION; VENTRAL MORPHOGENESIS		Univ Cincinnati, Childrens Hosp, Med Ctr,Dept Pediat, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Molkentin, JD (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr,Dept Pediat, Div Mol Cardiovasc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Molkentin, Jeffery/0000-0002-3558-6529				Al-azzeh ED, 2000, BBA-GENE STRUCT EXPR, V1490, P324, DOI 10.1016/S0167-4781(00)00013-0; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Bhatia SN, 1999, PRENATAL DIAG, V19, P863; Bhavsar PK, 2000, J MOL CELL CARDIOL, V32, P95, DOI 10.1006/jmcc.1999.1058; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Bossard P, 1998, DEVELOPMENT, V125, P4909; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; Bruno MD, 2000, J BIOL CHEM, V275, P1043, DOI 10.1074/jbc.275.2.1043; Charron F, 1999, MOL CELL BIOL, V19, P4355; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Davis DL, 1996, MOL ENDOCRINOL, V10, P937, DOI 10.1210/me.10.8.937; Denson LA, 2000, GENE, V246, P311, DOI 10.1016/S0378-1119(00)00082-2; Di Lisi R, 1998, J BIOL CHEM, V273, P25371, DOI 10.1074/jbc.273.39.25371; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Gajewski K, 1999, DEVELOPMENT, V126, P5679; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; Hasegawa K, 1997, CIRCULATION, V96, P3943; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; Huggon IC, 1997, BBA-GENE STRUCT EXPR, V1353, P98, DOI 10.1016/S0167-4781(97)00049-3; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; KELLEY C, 1993, DEVELOPMENT, V118, P817; KO JL, 1993, MOL CELL BIOL, V13, P4011; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Kuo HC, 1999, DEVELOPMENT, V126, P4223; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lien CL, 1999, DEVELOPMENT, V126, P75; Lu JR, 1999, MOL CELL BIOL, V19, P4495; MacNeill C, 1997, J BIOL CHEM, V272, P8396, DOI 10.1074/jbc.272.13.8396; Mano T, 1999, CIRC RES, V84, P647, DOI 10.1161/01.RES.84.6.647; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Molkentin JD, 2000, MOL CELL BIOL, V20, P5256, DOI 10.1128/MCB.20.14.5256-5260.2000; Morimoto T, 1999, J BIOL CHEM, V274, P12811, DOI 10.1074/jbc.274.18.12811; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Murphy AM, 1997, BIOCHEM J, V322, P393, DOI 10.1042/bj3220393; Narita N, 1996, GENOMICS, V36, P345, DOI 10.1006/geno.1996.0472; Narita N, 1997, DEV BIOL, V189, P270, DOI 10.1006/dbio.1997.8684; Narita N, 1997, DEVELOPMENT, V124, P3755; Nicholas SB, 1999, AM J PHYSIOL-HEART C, V277, pH324, DOI 10.1152/ajpheart.1999.277.1.H324; Nishi T, 1997, J BIOCHEM, V121, P922; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; Orkin SH, 1998, INT J DEV BIOL, V42, P927; Pehlivan T, 1999, AM J MED GENET, V83, P201, DOI 10.1002/(SICI)1096-8628(19990319)83:3<201::AID-AJMG11>3.0.CO;2-V; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; Reiter JF, 1999, GENE DEV, V13, P2983, DOI 10.1101/gad.13.22.2983; Rivkees SA, 1999, J BIOL CHEM, V274, P14204, DOI 10.1074/jbc.274.20.14204; Rosoff ML, 1998, J BIOL CHEM, V273, P9124, DOI 10.1074/jbc.273.15.9124; Sakai Y, 1998, BIOCHEM BIOPH RES CO, V250, P682, DOI 10.1006/bbrc.1998.9374; Searcy RD, 1998, DEVELOPMENT, V125, P4461; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shaw-White JR, 1999, J BIOL CHEM, V274, P2658, DOI 10.1074/jbc.274.5.2658; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; Svensson EC, 2000, NAT GENET, V25, P353, DOI 10.1038/77146; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; TAMURA S, 1993, P NATL ACAD SCI USA, V90, P10876, DOI 10.1073/pnas.90.22.10876; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Viger RS, 1998, DEVELOPMENT, V125, P2665; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; Wada H, 2000, J BIOL CHEM, V275, P25330, DOI 10.1074/jbc.M000828200; Watanabe K, 2000, P NATL ACAD SCI USA, V97, P1624, DOI 10.1073/pnas.97.4.1624; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562	88	688	716	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38949	38952		10.1074/jbc.R000029200	http://dx.doi.org/10.1074/jbc.R000029200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11042222	hybrid			2022-12-27	WOS:000165953100001
J	Steensma, E; Gordon, E; Oster, LM; Ferguson, SJ; Hajdu, J				Steensma, E; Gordon, E; Oster, LM; Ferguson, SJ; Hajdu, J			Heme ligation and conformational plasticity in the isolated c domain of cytochrome cd(1) nitrite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-PANTOTROPHUS; LIGAND-EXCHANGE; YEAST ISO-1-CYTOCHROME-C; MAGNETIC-RESONANCE; CHEMICAL-SHIFTS; ACTIVE-SITES; SPECTROSCOPY; IDENTIFICATION; PROTEINS; COOA	The heme ligation in the isolated c domain of Paracoccus pantotrophus cytochrome ed, nitrite reductase has been characterized in both oxidation states in solution by NMR spectroscopy. In the reduced form, the heme ligands are His(69)-Met(106), and the tertiary structure around the c heme is similar to that found in reduced crystals of intact cytochrome ed, nitrite reductase. In the oxidized state, however, the structure of the isolated c domain is different from the structure seen in oxidized crystals of intact cytochrome ed,, where the c heme Ligands are His(69)-His(17). An equilibrium mixture of heme Ligands is present in isolated oxidized c domain. Two-dimensional exchange NMR spectroscopy shows that the dominant species has His69-Met106 ligation, similar to reduced c domains. This form is in equilibrium with a high-spin form in which Met(106) has Left the heme iron. Melting studies show that the midpoint of unfolding of the isolated c domain is 320.9 +/- 1.2 K in the oxidized and 357.7 +/- 0.6 K in the reduced form. The thermally denatured forms are high-spin in both oxidation states. The results reveal how redox changes modulate conformational plasticity around the c heme and show the first key steps in the mechanism that lead to ligand switching in the holoenzyme. This process is not solely a function of the properties of the c domain. The role of the d(1) heme in guiding His(17) to the c heme in the oxidized holoenzyme is discussed.	Uppsala Univ, Dept Biochem, S-75123 Uppsala, Sweden; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	Uppsala University; University of Oxford	Steensma, E (corresponding author), Uppsala Univ, Dept Biochem, Box 576, S-75123 Uppsala, Sweden.	elles@xray.bmc.uu.se						Adams P. A., 1996, CYTOCHROME C MULTIDI, P635; ANGSTROM J, 1982, BIOCHIM BIOPHYS ACTA, V703, P87, DOI 10.1016/0167-4838(82)90014-0; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 1999, COORDIN CHEM REV, V190, P267, DOI 10.1016/S0010-8545(99)00070-3; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BECKER ED, 1969, J AM CHEM SOC, V91, P7784, DOI 10.1021/ja50001a068; BERTINI I, 1989, METHOD ENZYMOL, V177, P246; BOYD J, 1984, J MAGN RESON, V58, P511, DOI 10.1016/0022-2364(84)90159-8; Colon W, 1997, BIOCHEMISTRY-US, V36, P12535, DOI 10.1021/bi971697c; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Feinberg BA, 1998, BIOCHEMISTRY-US, V37, P13091, DOI 10.1021/bi981037n; Fetrow JS, 1999, BIOCHEMISTRY-US, V38, P4480, DOI 10.1021/bi9827417; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; Giles PM, 1999, PURE APPL CHEM, V71, P587, DOI 10.1351/pac199971040587; Goldbeck RA, 1999, P NATL ACAD SCI USA, V96, P2782, DOI 10.1073/pnas.96.6.2782; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hammack B, 1998, J MOL BIOL, V275, P719, DOI 10.1006/jmbi.1997.1493; Jafferji A, 2000, J BIOL CHEM, V275, P25089, DOI 10.1074/jbc.M001377200; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kolczak U, 1997, J AM CHEM SOC, V119, P12643, DOI 10.1021/ja9722133; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; KOPPENHOFER A, 1998, THESIS U OXFORD OXFO; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Markley JL, 1998, J MOL BIOL, V280, P933, DOI 10.1006/jmbi.1998.1852; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moore GR, 1990, SPRINGER SERIES MOL; MOURA I, 1988, EUR J BIOCHEM, V177, P673, DOI 10.1111/j.1432-1033.1988.tb14422.x; Nakajima H, 1999, CHEM LETT, P1233, DOI 10.1246/cl.1999.1233; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nurizzo D, 1999, J BIOL CHEM, V274, P14997, DOI 10.1074/jbc.274.21.14997; Nurizzo D, 1997, STRUCTURE, V5, P1157, DOI 10.1016/S0969-2126(97)00267-0; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PAGE MD, 1989, MOL MICROBIOL, V3, P653, DOI 10.1111/j.1365-2958.1989.tb00213.x; PETTIGREW GW, 1987, SPRINGER SERIES MOL; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Rainey FA, 1999, INT J SYST BACTERIOL, V49, P645, DOI 10.1099/00207713-49-2-645; Ranghino G, 2000, BIOCHEMISTRY-US, V39, P10958, DOI 10.1021/bi000178y; Schejter A, 1996, J AM CHEM SOC, V118, P477, DOI 10.1021/ja9529448; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; Telford JR, 1999, BIOCHEMISTRY-US, V38, P1944, DOI 10.1021/bi981933z; Tezcan FA, 1998, J AM CHEM SOC, V120, P13383, DOI 10.1021/ja982536e; TIMKOVICH R, 1985, ARCH BIOCHEM BIOPHYS, V240, P689, DOI 10.1016/0003-9861(85)90077-3; TURNER DL, 1993, EUR J BIOCHEM, V211, P563, DOI 10.1111/j.1432-1033.1993.tb17583.x; UBBINK M, 1993, BIOCHEMISTRY-US, V32, P13893, DOI 10.1021/bi00213a019; Van Mierlo CPM, 1998, PROTEIN SCI, V7, P2331, DOI 10.1002/pro.5560071110; Wang L, 1998, PROTEINS, V30, P435, DOI 10.1002/(SICI)1097-0134(19980301)30:4<435::AID-PROT10>3.0.CO;2-J; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Winkler JR, 1997, P NATL ACAD SCI USA, V94, P4246, DOI 10.1073/pnas.94.9.4246; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xu YJ, 1998, NAT STRUCT BIOL, V5, P774, DOI 10.1038/1810; YAMANAKA T, 1963, BIOCHIM BIOPHYS ACTA, V67, P379; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51; Yeh SR, 1999, J BIOL CHEM, V274, P17853, DOI 10.1074/jbc.274.25.17853; Yeh SR, 1998, NAT STRUCT BIOL, V5, P222, DOI 10.1038/nsb0398-222	61	14	14	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5846	5855		10.1074/jbc.M007345200	http://dx.doi.org/10.1074/jbc.M007345200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11035020	hybrid			2022-12-27	WOS:000167115100061
J	Gotoh, I; Adachi, M; Nishida, E				Gotoh, I; Adachi, M; Nishida, E			Identification and characterization of a novel MAP kinase kinase kinase, MLTK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NUCLEAR EXPORT SIGNAL; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR; ACTIN CYTOSKELETON; CELL MORPHOLOGY; GENE-EXPRESSION; TRANSDUCTION; CASCADES; PATHWAY	The MAPK cascades regulate a wide variety of cellular functions, including cell proliferation, differentiation, and stress responses. Here we have identified a novel MAP kinase kinase kinase (MAPKKK), termed MLTK (for MLK-like mitogen-activated protein triple kinase), whose expression is increased by activation of the ERK/MAPK pathway. There are two alternatively spliced forms of MLTK, MLTK alpha and MLT beta. When overexpressed in cells, both MLTK alpha and MLTK beta are able to activate the ERK, JNK/SAPK p38, and ERK5 pathways. Moreover, both MTLK alpha and MLTK beta are activated in response to osmotic shock with hyperosmolar media through autophosphorylation. Remarkably, expression of MLTK alpha; but not MLTK beta, in Swiss 3T3 cells results in the disruption of actin stress fibers and dramatic morphological changes. A kinase-dead form of MLTK alpha does not cause these phenomena. Inhibition of the p38 pathway significantly blocks MTLK alpha -induced stress fiber disruption and morphological changes. These results suggest that MLTK is a stress-activated MAPKKK that may be involved in the regulation of actin organization.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.							Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; GOTOH Y, 1994, ONCOGENE, V9, P1891; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hout J, 1998, J CELL BIOL, V143, P1361; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VAN AL, 1997, GENE DEV, V11, P2295; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	44	88	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4276	4286		10.1074/jbc.M008595200	http://dx.doi.org/10.1074/jbc.M008595200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042189	hybrid			2022-12-27	WOS:000166921200073
J	van Kerkhof, P; Sachse, M; Klumperman, J; Strous, GJ				van Kerkhof, P; Sachse, M; Klumperman, J; Strous, GJ			Growth hormone receptor ubiquitination coincides with recruitment to clathrin-coated membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; MEDIATED INTERNALIZATION; POTASSIUM-DEPLETION; ENDOCYTOSIS; PROTEIN; SYSTEM; SIGNAL; MOTIF; IDENTIFICATION; ACIDIFICATION	Endocytosis of the growth hormone receptor (GHR) depends on a functional ubiquitin conjugation system, A 10-amino acid residue motif within the GHR cytosolic tail (the ubiquitin-dependent endocytosis motif) is involved in both GHR ubiquitination and endocytosis. As shown previously, ubiquitination of the receptor itself is not required. In this paper ubiquitination of the GHR was used as a tool to address the question of at which stage the ubiquitin conjugation system acts in the process of GHR endocytosis. If potassium depletion was used to interfere with early stages of coated pit formation, both GHR endocytosis and ubiquitination were inhibited. Treatment of cells with methyl-beta -cyclodextrin inhibited endocytosis at the stage of coated vesicle formation. Growth hormone addition to methyl-beta -cyclodextrin-treated cells resulted in an accumulation of ubiquitinated GHR at the cell surface. Using immunoelectron microscopy, the GHR was localized in flattened clathrin-coated membranes. In addition, when clathrin-mediated endocytosis was inhibited in HeLa cells expressing a temperature-sensitive dynamin mutant, ubiquitinated GHR accumulated at the cell surface. Together, these data show that the GHR is ubiquitinated at the plasma membrane, before endocytosis occurs, and indicate that the resident time of the GHR at the cell surface is regulated by the ubiquitin conjugation system together with the endocytic machinery.	Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Utrecht University	Strous, GJ (corresponding author), Univ Utrecht, Med Ctr, Dept Cell Biol, Heidelberglaan 100,AZU-G02-525, NL-3584 CX Utrecht, Netherlands.	strous@med.uu.nl	Sachse, Martin/W-7403-2019	van Kerkhof, Peter/0000-0002-8954-2230; Sachse, Martin/0000-0001-5981-9166				ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Benmerah A, 1999, J CELL SCI, V112, P1303; BENTHAM J, 1994, J HISTOCHEM CYTOCHEM, V42, P103, DOI 10.1177/42.1.8263321; Brown CM, 1999, BIOCHEM CELL BIOL, V77, P439; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; ILONDO MM, 1986, P NATL ACAD SCI USA, V83, P6460, DOI 10.1073/pnas.83.17.6460; ILONDO MM, 1991, ENDOCRINOLOGY, V128, P1597, DOI 10.1210/endo-128-3-1597; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Springael JY, 1999, BIOCHEM BIOPH RES CO, V257, P561, DOI 10.1006/bbrc.1999.0505; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strous GJ, 1999, J CELL SCI, V112, P1417; Strous GJ, 1997, J BIOL CHEM, V272, P40; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; Vleurick L, 1999, MOL ENDOCRINOL, V13, P1823, DOI 10.1210/me.13.11.1823	43	56	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3778	3784		10.1074/jbc.M007326200	http://dx.doi.org/10.1074/jbc.M007326200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042179	hybrid			2022-12-27	WOS:000166921200009
J	Hisamoto, K; Ohmichi, M; Kurachi, H; Hayakawa, J; Kanda, Y; Nishio, Y; Adachi, K; Tasaka, K; Miyoshi, E; Fujiwara, N; Taniguchi, N; Murata, Y				Hisamoto, K; Ohmichi, M; Kurachi, H; Hayakawa, J; Kanda, Y; Nishio, Y; Adachi, K; Tasaka, K; Miyoshi, E; Fujiwara, N; Taniguchi, N; Murata, Y			Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY HEART-DISEASE; PROTEIN-KINASE B/AKT; PHOSPHATIDYLINOSITOL 3-KINASE; POSTMENOPAUSAL WOMEN; GROWTH-FACTOR; BAD PHOSPHORYLATION; SIGNALING PATHWAY; RECEPTOR CDNA; RISK-FACTORS; FOLLOW-UP	Although estrogen is known to activate endothelial nitric oxide synthase (eNOS) in the vascular endothelium, the molecular mechanism responsible for this effect remains to be elucidated. In studies of both human umbilical vein endothelial cells (HUVECs) and simian virus 40-transformed rat lung vascular endothelial cells (TRLECs), 17 beta -estradiol (E2), but not 17 alpha -E2, caused acute activation of eNOS that was unaffected by actino-mycin D and was specifically blocked by the pure estrogen receptor antagonist ICI-182,780, Treatment of both TRLECs and HUVECs with 17 beta -E2 stimulated the activation of Akt, and the PI3K inhibitor wortmannin blocked the 17 beta -E2-induced activation of Akt, 17 beta -E2-induced Akt activation was also inhibited by ICI-182,780, but not by actinomycin D, Either treatment with wortmannin or exogenous expression of a dominant negative Akt in TRLECs decreased the 17 beta -E2-induced eNOS activation. Moreover, 17 beta -E2-induced Akt activation actually enhances the phosphorylation of eNOS, 17 beta -E2-induced Akt activation was dependent on both extracellular and intracellular Ca2+. We further examined the 17 beta -E2-induced Akt activity in Chinese hamster ovary (CHO) cells transiently transfected with cDNAs for estrogen receptor cw (ER alpha) or estrogen receptor beta (ER beta), 17 beta -E2 stimulated the activation of Akt in CHO cells expressing ERa but not in CHO cells expressing ERP, Our findings suggest that 17P-E2 induced eNOS activation through an Akt-dependent mechanism, which is mediated by ER alpha via a nongenomic mechanism.	Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Yamagata Univ, Sch Med, Dept Obstet & Gynecol, Yamagata 9909585, Japan	Osaka University; Osaka University; Yamagata University	Ohmichi, M (corresponding author), Osaka Univ, Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				ADAMS MR, 1987, ARTERIOSCLEROSIS, V7, P378, DOI 10.1161/01.ATV.7.4.378; ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1050; Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; BarrettConnor E, 1997, CIRCULATION, V95, P252, DOI 10.1161/01.CIR.95.1.252; Binko J, 1998, AM J PHYSIOL-HEART C, V274, pH853, DOI 10.1152/ajpheart.1998.274.3.H853; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CaulinGlaser T, 1997, CIRC RES, V81, P885; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; Chen SJ, 1996, CIRCULATION, V93, P577, DOI 10.1161/01.CIR.93.3.577; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DiDomenico M, 1996, CANCER RES, V56, P4516; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; Guetta V, 1997, CIRCULATION, V96, P2795, DOI 10.1161/01.CIR.96.9.2795; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hayakawa J, 2000, CANCER RES, V60, P5988; Homma H, 2000, J BIOL CHEM, V275, P11404, DOI 10.1074/jbc.275.15.11404; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; JACOBSSON J, 1992, J HEART LUNG TRANSPL, V11, P1188; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jiang BB, 1998, J CARDIOVASC PHARM, V31, pS142, DOI 10.1097/00005344-199800001-00042; Karas RH, 1999, P NATL ACAD SCI USA, V96, P15133, DOI 10.1073/pnas.96.26.15133; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kimura A, 2000, J BIOL CHEM, V275, P3667, DOI 10.1074/jbc.275.5.3667; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kubohara Y, 1999, BIOCHEM BIOPH RES CO, V263, P790, DOI 10.1006/bbrc.1999.1468; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; LANTINHERMOSO RL, 1997, AM J PHYSIOL, V273, P119; Levy H, 1936, J AMER MED ASSOC, V107, P97; Lindner V, 1998, CIRC RES, V83, P224, DOI 10.1161/01.RES.83.2.224; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; Naka M, 2000, BIOCHEM BIOPH RES CO, V270, P663, DOI 10.1006/bbrc.2000.2474; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PIETRAS RJ, 1979, J STEROID BIOCHEM, V11, P1471, DOI 10.1016/0022-4731(79)90124-9; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; REIS SE, 1994, CIRCULATION, V89, P52, DOI 10.1161/01.CIR.89.1.52; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SEO HG, 1994, J BIOCHEM-TOKYO, V115, P602, DOI 10.1093/oxfordjournals.jbchem.a124382; SEO HG, 1995, BIOCHEM BIOPH RES CO, V208, P10, DOI 10.1006/bbrc.1995.1298; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Taniguchi H, 1999, N-S ARCH PHARMACOL, V360, P69, DOI 10.1007/s002109900033; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yokoi T, 2000, J BIOL CHEM, V275, P21639, DOI 10.1074/jbc.M910252199; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539	81	308	315	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3459	3467		10.1074/jbc.M005036200	http://dx.doi.org/10.1074/jbc.M005036200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11044445	hybrid			2022-12-27	WOS:000166784900062
J	Hoegy, SE; Oh, HR; Corcoran, ML; Stetler-Stevenson, WG				Hoegy, SE; Oh, HR; Corcoran, ML; Stetler-Stevenson, WG			Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; FACTOR RECEPTOR; CELL-SURFACE; IN-VITRO; PROMOTING ACTIVITY; GELATINASE-A; MATRIX; INVASION; BINDING; PROLIFERATION	The tissue inhibitors of metalloproteinases (TIMPs) block matrix metalloproteinase (MMP)-mediated increases in cell proliferation, migration, and invasion that are associated with extracellular matrix (ECM) turnover. Here we demonstrate a direct role for TIMP-2 in regulating tyrosine kinase-type growth factor receptor activation. We show that TIMP-2 suppresses the mitogenic response to tyrosine kinase-type receptor growth factors in a fashion that is independent of MMP inhibition. The TIMP-2 suppression of mitogenesis is reversed by the adenylate cyclase inhibitor SQ22536, and implicates cAMP as the second messenger in these effects. TIMP-2 neither altered the release of transforming growth factor alpha from the cell surface, nor epidermal growth factor (EGF) binding to the cognate receptor, EGFR, TIMP-2 binds to the surface of AS49 cells in a specific and saturable fashion (K-d = 147 pM), that is not competed by the synthetic MMP inhibitor BB-94 and is independent of MT-1-MMP. TIMP-2 induces a decrease in phosphorylation of EGFR and a concomitant reduction in Grb-2 association. TIMP-2 prevents SH2-protein-tyrosine phosphatase-l (SHP-1) dissociation from immunoprecipitable EGFR complex and a selective increase in total SHP-1 activity. These studies represent a new functional paradigm for TIMP-2 in which TIMP suppresses EGF-mediated mitogenic signaling by short-circuiting EGFR activation.	NCI, Pathol Lab, Extracellular Matrix Pathol Sect, Div Clin Sci,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stetler-Stevenson, WG (corresponding author), NCI, Pathol Lab, Extracellular Matrix Pathol Sect, Div Clin Sci,NIH, Bldg 10,Room 2A33,MSC 1500, Bethesda, MD 20892 USA.		Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; BISSELL MJ, 1999, CANCER RES, V59, P1757; Blavier L, 1997, MOL BIOL CELL, V8, P1513, DOI 10.1091/mbc.8.8.1513; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; CARAGLIA M, 1993, CANCER IMMUNOL IMMUN, V37, P150, DOI 10.1007/BF01525428; Catalan RE, 1997, FEBS LETT, V400, P280, DOI 10.1016/S0014-5793(96)01405-6; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Codony-Servat J, 1999, CANCER RES, V59, P1196; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; DECLERCK YA, 1992, CANCER RES, V52, P701; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; Fabbri E, 1991, J Enzyme Inhib, V5, P87, DOI 10.3109/14756369109069062; Fedi P., 1997, CANC MED, P41; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Imren S, 1996, CANCER RES, V56, P2891; Itoh Y, 1998, J BIOL CHEM, V273, P24360, DOI 10.1074/jbc.273.38.24360; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; Lee YJ, 1999, J BIOL CHEM, V274, P22401, DOI 10.1074/jbc.274.32.22401; Li GY, 1999, CANCER RES, V59, P6267; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Martin DC, 1999, LAB INVEST, V79, P225; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NEMETH JA, 1993, EXP CELL RES, V207, P376, DOI 10.1006/excr.1993.1204; Nemeth JA, 1996, EXP CELL RES, V224, P110, DOI 10.1006/excr.1996.0117; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Sherr CJ, 2000, CANCER RES, V60, P3689; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WELGUS HG, 1982, J BIOL CHEM, V257, P1534; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Yamashita K, 1996, FEBS LETT, V396, P103, DOI 10.1016/0014-5793(96)01066-6; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	67	93	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3203	3214		10.1074/jbc.M008157200	http://dx.doi.org/10.1074/jbc.M008157200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042184	hybrid			2022-12-27	WOS:000166784900031
J	Pilot, G; Lacombe, B; Gaymard, F; Cherel, I; Boucherez, J; Thibaud, JB; Sentenac, H				Pilot, G; Lacombe, B; Gaymard, F; Cherel, I; Boucherez, J; Thibaud, JB; Sentenac, H			Guard cell inward K+ channel activity in Arabidopsis involves expression of the twin channel subunits KAT1 and KAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; PLANT POTASSIUM CHANNEL; XENOPUS-OOCYTES; TRANSLATIONAL REGULATION; ALPHA-SUBUNITS; ION CHANNELS; ATPASE GENE; THALIANA; DOMAIN; VOLTAGE	Stomatal opening, which controls gas exchanges between plants and the atmosphere, results from an increase in turgor of the two guard cells that surround the pore of the stoma, KAT1 was the only inward K+ channel shown to be expressed in Arabidopsis guard cells, where it was proposed to mediate a K+ influx that enables stomatal opening, We report that another Arabidopsis K+ channel, KAT2, is expressed in guard cells. More than KAT1, KAT2 displays functional features resembling those of native inward K+ channels in guard cells. Coexpression in Xenopus oocytes and two-hybrid experiments indicated that KAT1 and KAT2 can form heteromultimeric channels. The data indicate that KAT2 plays a crucial role in the stomatal opening machinery.	Univ Montpellier 2, INRA, CNRS, UMR 5004, F-34060 Montpellier 1, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier	Sentenac, H (corresponding author), Univ Montpellier 2, INRA, CNRS, UMR 5004, Pl Viala, F-34060 Montpellier 1, France.		Lacombe, Benoit/B-1202-2013	THIBAUD, Jean-Baptiste/0000-0002-0824-6465; Pilot, Guillaume/0000-0001-7520-1059; Sentenac, Herve/0000-0003-3641-4822; Lacombe, Benoit/0000-0001-9924-3093; Cherel, Isabelle/0000-0001-8007-7099				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Baizabal-Aguirre VM, 1999, J MEMBRANE BIOL, V167, P119, DOI 10.1007/s002329900476; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Bruggemann L, 1999, P NATL ACAD SCI USA, V96, P3298, DOI 10.1073/pnas.96.6.3298; Bruggemann L, 1999, PLANTA, V207, P370, DOI 10.1007/s004250050494; Butt AD, 1997, J PLANT PHYSIOL, V150, P652, DOI 10.1016/S0176-1617(97)80279-9; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DAMIANI RD, 1993, P NATL ACAD SCI USA, V90, P8244, DOI 10.1073/pnas.90.17.8244; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; Devic M, 1997, PLANT PHYSIOL BIOCH, V35, P331; Dreyer I, 1999, J EXP BOT, V50, P1073, DOI 10.1093/jexbot/50.suppl_1.1073; Dreyer I, 1997, BIOPHYS J, V72, P2143, DOI 10.1016/S0006-3495(97)78857-X; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; Ehrhardt T, 1997, FEBS LETT, V409, P166, DOI 10.1016/S0014-5793(97)00502-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gaymard F, 1998, CELL, V94, P647, DOI 10.1016/S0092-8674(00)81606-2; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HEDRICH R, 1995, EUR BIOPHYS J, V24, P107, DOI 10.1007/BF00211406; HILLE B, 1992, IONIC CHANNELS EXCIT, P272; HOFGEN R, 1988, NUCLEIC ACIDS RES, V16, P9877, DOI 10.1093/nar/16.20.9877; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; Hoth S, 1999, J BIOL CHEM, V274, P11599, DOI 10.1074/jbc.274.17.11599; Ichida AM, 1997, PLANT CELL, V9, P1843, DOI 10.1105/tpc.9.10.1843; Ichida AM, 1996, J MEMBRANE BIOL, V151, P53, DOI 10.1007/s002329900057; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lacombe B, 1998, J MEMBRANE BIOL, V166, P91, DOI 10.1007/s002329900451; Lacombe B, 2000, FEBS LETT, V466, P351, DOI 10.1016/S0014-5793(00)01093-0; Lacombe B, 2000, PLANT CELL, V12, P837, DOI 10.1105/tpc.12.6.837; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; LANG A, 1983, PLANT CELL ENVIRON, V6, P683, DOI 10.1111/j.1365-3040.1983.tb01186.x; Li JX, 1998, PLANT PHYSIOL, V116, P785, DOI 10.1104/pp.116.2.785; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LOBREAUX S, 1992, PLANT MOL BIOL, V19, P563, DOI 10.1007/BF00026783; Lukaszewicz M, 1998, PLANT J, V14, P413, DOI 10.1046/j.1365-313X.1998.00139.x; MacRobbie EAC, 1998, PHILOS T ROY SOC B, V353, P1475, DOI 10.1098/rstb.1998.0303; Marten I, 1999, P NATL ACAD SCI USA, V96, P7581, DOI 10.1073/pnas.96.13.7581; MENGEL K, 1977, PLANT PHYSIOL, V59, P282, DOI 10.1104/pp.59.2.282; MICHELET B, 1994, PLANT CELL, V6, P1375, DOI 10.1105/tpc.6.10.1375; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; Roelfsema MRG, 1998, PLANTA, V205, P100, DOI 10.1007/s004250050301; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; Tang HX, 1996, PLANT CELL, V8, P1545, DOI 10.1105/tpc.8.9.1545; VERY AA, 1994, PFLUG ARCH EUR J PHY, V428, P422, DOI 10.1007/BF00724528; VERY AA, 1995, PLANT J, V7, P321, DOI 10.1046/j.1365-313X.1995.7020321.x; Wang XQ, 1998, PLANT PHYSIOL, V118, P1421, DOI 10.1104/pp.118.4.1421; Zimmermann S, 1999, CURR OPIN PLANT BIOL, V2, P477, DOI 10.1016/S1369-5266(99)00020-5	52	171	197	3	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3215	3221		10.1074/jbc.M007303200	http://dx.doi.org/10.1074/jbc.M007303200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042178	Green Published, hybrid			2022-12-27	WOS:000166784900032
J	Otera, H; Nishimura, M; Setoguchi, K; Mori, T; Fujiki, Y				Otera, H; Nishimura, M; Setoguchi, K; Mori, T; Fujiki, Y			Biogenesis of nonspecific lipid transfer protein and sterol carrier protein x - Studies using peroxisome assembly-defective pex cell mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ACYL-COENZYME-A; RAT-LIVER; 3-KETOACYL-COA THIOLASE; TARGETING SIGNAL; FUNCTIONAL COMPLEMENTATION; ZELLWEGER-SYNDROME; NUCLEOTIDE-SEQUENCE; PTS1 RECEPTOR; CDNA CLONING	Nonspecific lipid transfer protein (nsLTP; also called sterol carrier protein 2) with a molecular mass of 13 kDa is synthesized as a larger 15-kDa precursor (pre-nsLTP) with an N-terminal IO-amino acid extension presequence, as well as with the peroxisome targeting signal type 1 (PTS1), Ala-Lys-Leu, at the C terminus. The precursor pre-nsLTP is processed to mature nsLTP by proteolytic removal of the presequence, most likely after being imported into peroxisomes. Sterol carrier protein x (SCPx), a 59-kDa branched-chain fatty acid thiolase of peroxisomes, contains the entire pre-nsLTP moiety at the C-terminal part and is converted to the 46-kDa form and nsLTP after the transport to peroxisomes. We investigated which of these two potential topogenic sequences functions in biogenesis of nsLTP and SCPx. Morphological and biochemical analyses, making use of Chinese hamster ovary cell per mutants such as the PTS1 receptor-impaired pex5 and PTS2 import-defective pex7, as well as green fluorescent protein chimeras, revealed that both pre-nsLTP and SCPx are imported into peroxisomes by the Pex5p-mediated PTS1 pathway. Nearly half of the pre-nsLTP remains in the cytosol, as assessed by subcellular fractionation of the wild-type Chinese hamster ovary cells. In an in vitro binding assay, only mature nsLTP, but not pre-nsLTP, from the cell lysates interacted with the Pex5p. It is likely, therefore, that modulation of the C-terminal PTS1 by the presequence gives rise to cytoplasmic localization of pre-nsLTP.	Kyushu Univ, Grad Sch, Fac Sci,Dept Biol, Higashi Ku, Fukuoka 8128581, Japan; Meiji Milk Prod Co, Odawara, Kanagawa 2500862, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1700013, Japan	Kyushu University; Meiji Holdings Co., Ltd.; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch, Fac Sci,Dept Biol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.			Miyata, Kiyoko/0000-0001-5303-6240				Antonenkov VD, 1997, J BIOL CHEM, V272, P26023, DOI 10.1074/jbc.272.41.26023; BunYa M, 1997, EUR J BIOCHEM, V245, P252, DOI 10.1111/j.1432-1033.1997.t01-1-00252.x; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Ferdinandusse S, 2000, J LIPID RES, V41, P336; FUJIKI Y, 1989, J BIOCHEM, V106, P1126, DOI 10.1093/oxfordjournals.jbchem.a122977; Ghaedi K, 1999, EXP CELL RES, V248, P489, DOI 10.1006/excr.1999.4413; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; KAWAJIRI K, 1977, J BIOCHEM, V82, P1403, DOI 10.1093/oxfordjournals.jbchem.a131828; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; Matsumura T, 2000, J BIOL CHEM, V275, P21715, DOI 10.1074/jbc.M000721200; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MONCECCHI D, 1991, J BIOL CHEM, V266, P9885; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; MOTLEY A, 1994, J CELL BIOL, V125, P755, DOI 10.1083/jcb.125.4.755; OHBA T, 1995, BIOCHEMISTRY-US, V34, P10660, DOI 10.1021/bi00033a042; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; OSSENDORP BC, 1991, EUR J BIOCHEM, V201, P233, DOI 10.1111/j.1432-1033.1991.tb16279.x; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Seedorf U, 2000, BBA-MOL CELL BIOL L, V1486, P45, DOI 10.1016/S1388-1981(00)00047-0; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; SEEDORF U, 1991, J BIOL CHEM, V266, P630; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; TRZECIAK WH, 1987, J BIOL CHEM, V262, P3713; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; TSUNEOKA M, 1988, J BIOCHEM-TOKYO, V104, P560, DOI 10.1093/oxfordjournals.jbchem.a122510; VANHEUSDEN GPH, 1990, J BIOL CHEM, V265, P4105; Wanders RJA, 1997, BIOCHEM BIOPH RES CO, V236, P565, DOI 10.1006/bbrc.1997.7007; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	41	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2858	2864		10.1074/jbc.M007730200	http://dx.doi.org/10.1074/jbc.M007730200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042217	hybrid			2022-12-27	WOS:000166784800077
J	Sai, KP; Jagannadham, MV; Vairamani, M; Raju, NP; Devi, AS; Nagaraj, R; Sitaram, N				Sai, KP; Jagannadham, MV; Vairamani, M; Raju, NP; Devi, AS; Nagaraj, R; Sitaram, N			Tigerinins: Novel antimicrobial peptides from the Indian frog Rana tigerina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPHIBIAN SKIN; ESCHERICHIA-COLI; OUTER-MEMBRANE; ANTIBIOTICS; MECHANISM; SEQUENCE; ANTIBACTERIAL; INDOLICIDIN; DEFENSINS; CELLS	Four broad-spectrum, 11 and 12 residue, novel antimicrobial peptides have been isolated from the adrenaline-stimulated skin secretions of the Indian frog Rana tigerina, Sequences of these peptides have been determined by automated Edman degradation, by mass spectral analysis and confirmed by chemical synthesis. These peptides, which we have named as tigerinins, are characterized by an intramolecular disulfide bridge between two cysteine residues forming a nonapeptide ring. This feature is not found in other amphibian peptides, Conformational analysis indicate that the peptides tend to form p-turn structures, The peptides are cationic and exert their activity by permeabilizing bacterial membranes. Tigerinins represent the smallest, nonhelical, cationic antimicrobial peptides from amphibians.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Indian Inst Chem Technol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT)	Sitaram, N (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.		Korrapati, Purna sai/ABC-6918-2020; Sitaram, Narasimhaiah/F-2211-2010; Jagannadham, Medicharla V. V./AAW-6773-2021; Sitaram, Narasimaiah/M-6309-2019; Korrapati, Purna sai/AAB-6375-2021	Sitaram, Narasimaiah/0000-0003-4179-1972; Vairamani, Mariappanadar/0000-0002-8356-6258				ALLEN G, 1981, LAB TECHNIQUES BIOCH, P17; Atherton E., 1990, SOLID PHASE PEPTIDE; BARRA D, 1995, TRENDS BIOTECHNOL, V13, P205, DOI 10.1016/S0167-7799(00)88947-7; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; CLARK DP, 1994, J BIOL CHEM, V269, P10849; Clarke BT, 1997, BIOL REV, V72, P365, DOI 10.1017/S0006323197005045; CSORDAS A, 1969, TOXICON, V7, P103, DOI 10.1016/0041-0101(69)90072-5; Dutta S.K., 1997, AMPHIBIANS INDIA SRI; Feder R, 2000, J BIOL CHEM, V275, P4230, DOI 10.1074/jbc.275.6.4230; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Ganz T, 1999, MOL MED TODAY, V5, P292, DOI 10.1016/S1357-4310(99)01490-2; Goraya J, 1999, PEPTIDES, V20, P159, DOI 10.1016/S0196-9781(98)00174-0; Goraya J, 2000, EUR J BIOCHEM, V267, P894, DOI 10.1046/j.1432-1327.2000.01074.x; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HAYASHI R, 1973, J BIOL CHEM, V218, P2236; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; Kim S, 1999, J BIOCHEM MOL BIOL, V32, P12; Kwon MY, 1998, BBA-PROTEIN STRUCT M, V1387, P239, DOI 10.1016/S0167-4838(98)00123-X; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; LONGKUMAR Y, 1992, INT C IUCN SSC ISRAG; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; Miller J.H., 1972, EXPT MOL GENETICS; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; MORIKAWA N, 1992, BIOCHEM BIOPH RES CO, V189, P184, DOI 10.1016/0006-291X(92)91542-X; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PARK JM, 1994, BIOCHEM BIOPH RES CO, V205, P948, DOI 10.1006/bbrc.1994.2757; PERCZEL A, 1991, J AM CHEM SOC, V113, P9772, DOI 10.1021/ja00026a010; Ponti D, 1999, EUR J BIOCHEM, V263, P921, DOI 10.1046/j.1432-1327.1999.00597.x; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SABERWAL G, 1994, BBA-REV BIOMEMBRANES, V1197, P109, DOI 10.1016/0304-4157(94)90002-7; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; Simmaco M, 1998, BIOPOLYMERS, V47, P435, DOI 10.1002/(SICI)1097-0282(1998)47:6<435::AID-BIP3>3.3.CO;2-#; SIMMACO M, 1994, J BIOL CHEM, V269, P11951; SITARAM N, 1990, J BIOL CHEM, V265, P10438; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; Subbalakshmi C, 1998, FEMS MICROBIOL LETT, V160, P91, DOI 10.1016/S0378-1097(98)00008-1; Subbalakshmi C, 1996, FEBS LETT, V395, P48, DOI 10.1016/0014-5793(96)00996-9; Suh JY, 1996, FEBS LETT, V392, P309, DOI 10.1016/0014-5793(96)00840-X; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; VEBER DF, 1972, J AM CHEM SOC, V94, P5456, DOI 10.1021/ja00770a600; Wu MH, 1999, J BIOL CHEM, V274, P29, DOI 10.1074/jbc.274.1.29; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	50	93	103	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2701	2707		10.1074/jbc.M006615200	http://dx.doi.org/10.1074/jbc.M006615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11031261	hybrid			2022-12-27	WOS:000166784800056
J	Territo, PR; French, SA; Dunleavy, MC; Evans, FJ; Balaban, RS				Territo, PR; French, SA; Dunleavy, MC; Evans, FJ; Balaban, RS			Calcium activation of heart mitochondrial oxidative phosphorylation - Rapid kinetics of m(V) over dot (O2), NADH, and light scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; RABBIT CARDIAC MYOCYTES; NUCLEAR-MAGNETIC-RESONANCE; PHOSPHATE ENERGY SHUTTLE; FREE CA2+ CONCENTRATION; ATP-ADP TRANSLOCASE; CREATINE-KINASE; MUSCLE-CELLS; INTRACELLULAR CALCIUM; INNER MEMBRANE	Parallel activation of heart mitochondria NADH and ATP production by Ca2+ has been shown to involve the Ca2+-sensitive dehydrogenases and the F0F1-ATPase, In the current study we hypothesize that the response time of Ca2+-activated ATP production is rapid enough to support step changes in myocardial workload (similar to 100 ms). To test this hypothesis, the rapid kinetics of Ca2+ activation of m(V)over dot (O2) [NADH], and light scattering were evaluated in isolated porcine heart mitochondria at 37 degreesC using a variety of optical techniques. The addition of Ca2+ was associated with an initial response time (IRT) of m(V)over dot (O2), that was dose-dependent with a minimum IRT of 0.27 +/- 0.02 a (n = 41) at 535 mM Ca2+. The IRTs for NADH fluorescence and light scattering in response to Ca2+ additions were similar to m(V)over dot (O2). The Ca2+ IRT for m(V)over dot(O2) was significantly shorter than 1.6 mM ADP (2.36 +/- 0.47 a; p less than or equal to 0.001, n = 13), 2.2 mM P-i (2.32 +/- 0.29,p less than or equal to 0.001, n = 13), or 10 mM creatine (15.6. +/- 1.18 s,p less than or equal to 0.001, n = 18) under similar experimental conditions. Calcium effects were inhibited with 8 muM ruthenium red (2.4 +/- 0.31 s;p less than or equal to 0.001, n = 16) and reversed with EG;TA (1.6 +/- 0.44;p less than or equal to 0.01, n = 6), Estimates of Ca2+ uptake into mitochondria using optical Ca2+ indicators trapped in the matrix revealed a sufficiently rapid uptake to cause the metabolic effects observed. These data are consistent with the notion that extramitochondrial Ca2+ can modify ATP production, via an increase in matrix Ca2+ content, rapidly enough to support cardiac work transitions in vivo.	NHLBI, Cardiac Energet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Territo, PR (corresponding author), NHLBI, Cardiac Energet Lab, NIH, Bldg 10,Rm B1D-400, Bethesda, MD 20892 USA.	territop@zeus.nhlbi.nih.gov	Balaban, Robert S/A-7459-2009	Balaban, Robert S/0000-0003-4086-0948	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004601, Z01HL004601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnold S, 1999, FEBS LETT, V443, P105, DOI 10.1016/S0014-5793(98)01694-9; Arnold S, 1997, EUR J BIOCHEM, V249, P350, DOI 10.1111/j.1432-1033.1997.t01-1-00350.x; AZZI A, 1966, BIOCHIM BIOPHYS ACTA, V120, P466, DOI 10.1016/0926-6585(66)90316-5; AZZI A, 1965, BIOCHIM BIOPHYS ACTA, V105, P265, DOI 10.1016/S0926-6593(65)80151-5; AZZI A, 1967, BIOCHIM BIOPHYS ACTA, V131, P468, DOI 10.1016/0005-2728(67)90006-0; AZZONE GF, 1965, P NATL ACAD SCI USA, V53, P1084, DOI 10.1073/pnas.53.5.1084; Balaban RS, 1996, ANAL BIOCHEM, V237, P274, DOI 10.1006/abio.1996.0239; BALABAN RS, 1981, AM J PHYSIOL, V240, pF337, DOI 10.1152/ajprenal.1981.240.4.F337; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BESSMAN SP, 1966, BIOCHEM BIOPH RES CO, V22, P597, DOI 10.1016/0006-291X(66)90317-2; BESSMAN SP, 1987, ANAL BIOCHEM, V161, P519, DOI 10.1016/0003-2697(87)90483-0; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BISHOP PD, 1984, ARCH BIOCHEM BIOPHYS, V230, P335, DOI 10.1016/0003-9861(84)90116-4; BROWN GC, 1992, BIOCHEM J, V284, P1; BUNGER R, 1984, AM J PHYSIOL, V247, pC45, DOI 10.1152/ajpcell.1984.247.1.C45; CARAFOLI E, 1988, METHOD ENZYMOL, V157, P3; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; Chacon E, 1996, FEBS LETT, V382, P31, DOI 10.1016/0014-5793(96)00138-X; CHACON E, 1994, BIOPHYS J, V66, P942, DOI 10.1016/S0006-3495(94)80904-X; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHAPPELL JB, 1968, BRIT MED BULL, V24, P150, DOI 10.1093/oxfordjournals.bmb.a070618; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; CORNISHBOWEN A, 1976, PRINCIPLES ENZYME KI; DAS AM, 1990, BIOCHEM SOC T, V18, P554, DOI 10.1042/bst0180554; DOELLER JE, 1990, AM J PHYSIOL, V259, pH1851, DOI 10.1152/ajpheart.1990.259.6.H1851; EISENHARDT RH, 1968, BIOCHEMISTRY-US, V7, P1327, DOI 10.1021/bi00844a012; ERICKSONVIITANEN S, 1982, J BIOL CHEM, V257, P4395; ERICKSONVIITANEN S, 1982, ADV EXP MED BIOL, V151, P115; ERICKSONVIITANEN S, 1982, J BIOL CHEM, V257, P4405; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLAHERTY JT, 1982, CIRCULATION, V65, P561, DOI 10.1161/01.CIR.65.3.561; FONT B, 1983, ARCH BIOCHEM BIOPHYS, V220, P541, DOI 10.1016/0003-9861(83)90445-9; French SA, 1998, AM J PHYSIOL-CELL PH, V275, pC900, DOI 10.1152/ajpcell.1998.275.3.C900; GARLID KD, 1985, J BIOL CHEM, V260, P3434; Gunter TE, 1998, BBA-BIOENERGETICS, V1366, P5, DOI 10.1016/S0005-2728(98)00117-0; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HALESTRAP AP, 1986, BIOCHEM J, V236, P779, DOI 10.1042/bj2360779; HALESTRAP AP, 1987, BIOCHEM J, V244, P159, DOI 10.1042/bj2440159; HANSFORD RG, 1989, ANN NY ACAD SCI, V573, P240, DOI 10.1111/j.1749-6632.1989.tb15001.x; HANSFORD RG, 1972, BIOCHEM J, V127, P271, DOI 10.1042/bj1270271; HANSFORD RG, 1982, J BIOENERG BIOMEMBR, V14, P361, DOI 10.1007/BF00743064; HANSFORD RG, 1975, BIOCHEM J, V146, P537, DOI 10.1042/bj1460537; Hansford RG, 1998, MOL CELL BIOCHEM, V184, P359, DOI 10.1023/A:1006893903113; HARRIS DA, 1991, BIOCHEM J, V280, P561, DOI 10.1042/bj2800561; Hasselbach W, 1998, ANN NY ACAD SCI, V853, P1, DOI 10.1111/j.1749-6632.1998.tb08251.x; HEINEMAN FW, 1990, J CLIN INVEST, V85, P843, DOI 10.1172/JCI114511; HELDT HW, 1967, EUR J BIOCHEM, V1, P199, DOI 10.1111/j.1432-1033.1967.tb00064.x; ISENBERG G, 1993, CARDIOVASC RES, V27, P1800, DOI 10.1093/cvr/27.10.1800; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; JACOBUS WE, 1986, J BIOL CHEM, V261, P6579; Jeneson JAL, 1996, J BIOL CHEM, V271, P27995, DOI 10.1074/jbc.271.45.27995; Jou MJ, 1996, J PHYSIOL-LONDON, V497, P299, DOI 10.1113/jphysiol.1996.sp021769; KAPLAN LJ, 1995, BIOCHIMIE, V77, P245, DOI 10.1016/0300-9084(96)88131-4; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; Kavanagh NI, 2000, BBA-BIOENERGETICS, V1457, P57, DOI 10.1016/S0005-2728(00)00054-2; KLINGENBERG M, 1966, REGULATION METABOLIC, P180; KORETSKY AP, 1987, BIOCHIM BIOPHYS ACTA, V893, P398, DOI 10.1016/0005-2728(87)90092-2; KUZNETSOV AV, 1989, ARCH BIOCHEM BIOPHYS, V268, P176, DOI 10.1016/0003-9861(89)90578-X; KUZNETSOV AV, 1986, BIOCHEM BIOPH RES CO, V134, P359, DOI 10.1016/0006-291X(86)90571-1; LEE HC, 1987, P NATL ACAD SCI USA, V84, P7793, DOI 10.1073/pnas.84.21.7793; LEISEY JR, 1993, AM J PHYSIOL, V265, pH1203; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCMURCHIE EJ, 1979, BIOCHIM BIOPHYS ACTA, V554, P364, DOI 10.1016/0005-2736(79)90377-8; MINKOV IB, 1979, BIOCHEM BIOPH RES CO, V89, P1300, DOI 10.1016/0006-291X(79)92150-8; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Mootha VK, 1997, AM J PHYSIOL-HEART C, V272, pH769, DOI 10.1152/ajpheart.1997.272.2.H769; MOREADITH RW, 1982, J BIOL CHEM, V257, P899; Napiwotzki J, 1998, BIOL CHEM, V379, P335, DOI 10.1515/bchm.1998.379.3.335; Ohata H, 1998, J BIOENERG BIOMEMBR, V30, P207, DOI 10.1023/A:1020588618496; POOL PE, 1966, CIRC RES, V19, P221, DOI 10.1161/01.RES.19.2.221; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Sahlin K, 1997, AM J PHYSIOL-CELL PH, V273, pC172, DOI 10.1152/ajpcell.1997.273.1.C172; SAKS VA, 1985, J BIOL CHEM, V260, P7757; SAKS VA, 1987, BIOCHIM BIOPHYS ACTA, V891, P138, DOI 10.1016/0005-2728(87)90005-3; SAKS VA, 1995, J MOL CELL CARDIOL, V27, P625, DOI 10.1016/S0022-2828(08)80056-9; SAKS VA, 1991, AM J PHYSIOL, V261, P30, DOI 10.1152/ajplung.1991.261.4.L30; SAKS VA, 1984, BIOCHIM BIOPHYS ACTA, V803, P254, DOI 10.1016/0167-4889(84)90115-0; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SAKS VA, 1980, J BIOL CHEM, V255, P755; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; SAKS VA, 1986, BIOCHEM BIOPH RES CO, V139, P1262, DOI 10.1016/S0006-291X(86)80314-X; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; STARNES JW, 1985, AM J PHYSIOL, V249, pH799, DOI 10.1152/ajpheart.1985.249.4.H799; SYROESHKIN AV, 1995, FEBS LETT, V366, P29, DOI 10.1016/0014-5793(95)00487-T; Territo PR, 2000, AM J PHYSIOL-CELL PH, V278, pC423, DOI 10.1152/ajpcell.2000.278.2.C423; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; Trollinger DR, 2000, BIOPHYS J, V79, P39, DOI 10.1016/S0006-3495(00)76272-2; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VIGNAIS P, 1976, CELL BIOL HDB, P159; Vinogradov AD, 2000, J EXP BIOL, V203, P41; Wier WG, 1999, CIRC RES, V85, P770, DOI 10.1161/01.RES.85.9.770; WIER WG, 1995, CIBA F SYMP, V188, P146; WILSON DF, 1988, J BIOL CHEM, V263, P2712; YOSHIKANE H, 1986, J SUBMICR CYTOL PATH, V18, P629; YUAN GX, 1992, BIOCHIM BIOPHYS ACTA, V1140, P78, DOI 10.1016/0005-2728(92)90022-T	100	120	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2586	2599		10.1074/jbc.M002923200	http://dx.doi.org/10.1074/jbc.M002923200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11029457	hybrid			2022-12-27	WOS:000166784800042
J	Torigoe, H; Hari, Y; Sekiguchi, M; Obika, S; Imanishi, T				Torigoe, H; Hari, Y; Sekiguchi, M; Obika, S; Imanishi, T			2 '-O,4 '-C-methylene bridged nucleic acid modification promotes pyrimidine motif tripler DNA formation at physiological pH - Thermodynamic and kinetic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX FORMATION; NUCLEOSIDE ANALOGS; OPTICAL BIOSENSOR; NEUTRAL PH; BASE-PAIRS; OLIGODEOXYNUCLEOTIDES; OLIGONUCLEOTIDES; RECOGNITION; STABILITY; BINDING	Extreme instability of pyrimidine motif tripler DNA at physiological pH severely limits its use in an artificial control of gene expression in vivo, Stabilization of the pyrimidine motif tripler at physiological pH is, therefore, crucial in improving its therapeutic potential. To this end, we have investigated the thermodynamic and kinetic effects of our previously reported chemical modification, 2'-O,4'-C-methylene bridged nucleic acid (2',4'-BNA) modification of tripler-forming oligonucleotide (TFO), on pyrimidine motif tripler formation at physiological pH, The thermodynamic analyses indicated that the 2',4'-BNA modification of TFO increased the binding constant of the pyrimidine motif tripler formation at neutral pH by similar to 20 times. The number and position of the 2',4'-BNA modification introduced into the TFO did not significantly affect the magnitude of the increase in the binding constant. The consideration of the observed thermodynamic parameters suggested that the increased rigidity itself of the 2',4'-BNA-modified TFO in the free state relative to the unmodified TFO may enable the significant increase in the binding constant at neutral pH, Kinetic data demonstrated that the observed increase in the binding constant at neutral pH by the 2',4'-BNA modification of TFO resulted from the considerable decrease in the dissociation rate constant. Our results certainly support the idea that the 2',4'-BNA modification of TFO could be a key chemical modification and may eventually lead to progress in therapeutic applications of the antigene strategy in vivo.	RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan	RIKEN; Osaka University	Torigoe, H (corresponding author), RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	torigoe@rtc.riken.go.jp		Hari, Yoshiyuki/0000-0002-3903-7340				BATES PJ, 1995, NUCLEIC ACIDS RES, V23, P3627, DOI 10.1093/nar/23.18.3627; Biltonen R L, 1979, Methods Enzymol, V61, P287; CHENG AJ, 1993, NUCLEIC ACIDS RES, V21, P5630, DOI 10.1093/nar/21.24.5630; CHENG YK, 1992, PROG BIOPHYS MOL BIO, V58, P225, DOI 10.1016/0079-6107(92)90007-S; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; Edelhoch H, 1976, Adv Protein Chem, V30, P183, DOI 10.1016/S0065-3233(08)60480-5; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRANKKAMENETSKII MD, 1992, METHOD ENZYMOL, V211, P180; HAMPEL KJ, 1991, BIOCHEMISTRY-US, V30, P4455, DOI 10.1021/bi00232a012; Imanishi T, 1999, J SYN ORG CHEM JPN, V57, P969, DOI 10.5059/yukigoseikyokaishi.57.969; JETTER MC, 1993, BIOCHEMISTRY-US, V32, P3249, DOI 10.1021/bi00064a006; JOHNSON KH, 1991, NUCLEIC ACIDS RES, V19, P2275, DOI 10.1093/nar/19.9.2275; Kamiya M, 1996, J AM CHEM SOC, V118, P4532, DOI 10.1021/ja952287j; KOH JS, 1992, J AM CHEM SOC, V114, P1470, DOI 10.1021/ja00030a050; Koshkin AA, 1998, TETRAHEDRON, V54, P3607, DOI 10.1016/S0040-4020(98)00094-5; KRAWCZYK SH, 1992, P NATL ACAD SCI USA, V89, P3761, DOI 10.1073/pnas.89.9.3761; Langerman N, 1979, Methods Enzymol, V61, P261; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MANZINI G, 1990, J MOL BIOL, V213, P833, DOI 10.1016/S0022-2836(05)80267-0; MILLIGAN JF, 1993, NUCLEIC ACIDS RES, V21, P327, DOI 10.1093/nar/21.2.327; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MOUSCADET JF, 1994, BIOCHEMISTRY-US, V33, P4187, DOI 10.1021/bi00180a011; Obika S, 1999, CHEM COMMUN, P2423, DOI 10.1039/a907218g; Obika S, 1999, BIOORG MED CHEM LETT, V9, P515, DOI 10.1016/S0960-894X(99)00028-1; Obika S, 1999, TETRAHEDRON LETT, V40, P6465, DOI 10.1016/S0040-4039(99)01324-6; Obika S, 1998, TETRAHEDRON LETT, V39, P5401, DOI 10.1016/S0040-4039(98)01084-3; Obika S, 1997, TETRAHEDRON LETT, V38, P8735, DOI 10.1016/S0040-4039(97)10322-7; Obika S, 2000, TETRAHEDRON LETT, V41, P221, DOI 10.1016/S0040-4039(99)02052-3; Obika S, 2000, TETRAHEDRON LETT, V41, P215, DOI 10.1016/S0040-4039(99)01998-X; ONO A, 1991, J AM CHEM SOC, V113, P4032, DOI 10.1021/ja00010a077; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021; Shafer RH, 1998, PROG NUCLEIC ACID RE, V59, P55; SHINDO H, 1993, BIOCHEMISTRY-US, V32, P8963, DOI 10.1021/bi00085a030; Singh SK, 1998, CHEM COMMUN, P455, DOI 10.1039/a708608c; SINGLETON SF, 1992, BIOCHEMISTRY-US, V31, P10995, DOI 10.1021/bi00160a008; Soyfer V.N., 1996, TRIPLE HELICAL NUCL; SUN JS, 1991, P NATL ACAD SCI USA, V88, P6023, DOI 10.1073/pnas.88.14.6023; SUN JS, 1993, CURR OPIN STRUC BIOL, V3, P345, DOI 10.1016/S0959-440X(05)80105-8; Sun JS, 1996, CURR OPIN STRUC BIOL, V6, P327, DOI 10.1016/S0959-440X(96)80051-0; Torigoe H, 1999, BIOCHEMISTRY-US, V38, P14653, DOI 10.1021/bi990832d; Torigoe H, 1999, J BIOL CHEM, V274, P6161, DOI 10.1074/jbc.274.10.6161; Torigoe H, 1999, NUCLEOS NUCLEOT, V18, P1655, DOI 10.1080/07328319908044812; Ueno Y, 1998, BIOCONJUGATE CHEM, V9, P33, DOI 10.1021/bc9701508; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625	47	124	125	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2354	2360		10.1074/jbc.M007783200	http://dx.doi.org/10.1074/jbc.M007783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035027	hybrid			2022-12-27	WOS:000166784800010
J	Weinreich, F; Jentsch, TJ				Weinreich, F; Jentsch, TJ			Pores formed by single subunits in mixed dimers of different CLC chloride channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO ELECTROPLAX; VOLTAGE; DEPENDENCE; RECONSTITUTION; STOICHIOMETRY; EXPRESSION; MUTATIONS; DOMINANT; MYOTONIA; REGIONS	CLC chloride channels comprise a gene family with nine mammalian members. Probably all CLC channels form homodimers, and some CLC proteins may also associate to heterodimers, ClC-0 and ClC-1, the only CLC channels investigated at the single-channel level, display two conductances of equal size which are thought to result from two separate pores, formed individually by the two monomers. We generated concatemeric channels containing one subunit of ClC-0 together with one subunit of ClC-1 or ClC-2, They should display two different conductances if one monomer were sufficient to form one pore. Indeed, we found a 8-picosiemens (pS) conductance (corresponding to ClC-0) that was associated with either a 1.8-pS (ClC-1) or a 2.8-pS (ClC-2) conductance, These conductances retained their typical gating, but the slow gating of ClC-0 that affects both pores simultaneously was lost. ClC-2 and ClC-0 current components were modified by point mutations in the corresponding subunit, The ClC-2 single pore of the mixed dimer was compared with the pores in the ClC-2 homodimer and found to be unaltered. We conclude that each monomer individually forms a gated pore. CLC dimers in general must be imagined as having two pores, as shown previously for ClC-0.	Univ Hamburg, ZMNH, Zentrum Mok Neurobiol Hamburg, D-20246 Hamburg, Germany	University of Hamburg	Jentsch, TJ (corresponding author), Univ Hamburg, ZMNH, Zentrum Mok Neurobiol Hamburg, Martinistr 85, D-20246 Hamburg, Germany.	jentsch@plexus.uke.uni-hamburg.de		Jentsch, Thomas/0000-0002-3509-2553				Akabas MH, 1997, J BIOENERG BIOMEMBR, V29, P453, DOI 10.1023/A:1022482923122; Astill DS, 1996, BBA-BIOMEMBRANES, V1280, P178, DOI 10.1016/0005-2736(95)00281-2; BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; BORMANN J, 1993, EMBO J, V12, P3729, DOI 10.1002/j.1460-2075.1993.tb06050.x; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HANKE W, 1983, J GEN PHYSIOL, V82, P25, DOI 10.1085/jgp.82.1.25; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Lin YW, 1999, J GEN PHYSIOL, V114, P1, DOI 10.1085/jgp.114.1.1; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Ludewig U, 1997, J GEN PHYSIOL, V110, P165, DOI 10.1085/jgp.110.2.165; Ludewig U, 1997, BIOPHYS J, V73, P789, DOI 10.1016/S0006-3495(97)78111-6; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Maduke M, 1999, J GEN PHYSIOL, V114, P713, DOI 10.1085/jgp.114.5.713; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; Purdy MD, 2000, FEBS LETT, V466, P26, DOI 10.1016/S0014-5793(99)01740-8; Pusch M, 1997, J GEN PHYSIOL, V109, P105, DOI 10.1085/jgp.109.1.105; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Pusch M, 1995, NEURON, V15, P1455, DOI 10.1016/0896-6273(95)90023-3; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; Sheppard David N., 1999, Physiological Reviews, V79, pS23; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0	29	121	123	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2347	2353		10.1074/jbc.M005733200	http://dx.doi.org/10.1074/jbc.M005733200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035003	hybrid			2022-12-27	WOS:000166784800009
J	Cornea, A; Janovick, DA; Maya-Nunez, G; Conn, PM				Cornea, A; Janovick, DA; Maya-Nunez, G; Conn, PM			Gonadotropin-releasing hormone receptor microaggregation - Rate monitored by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVING CELLS; DIMERIZATION; AGONIST; INTERNALIZATION; DESENSITIZATION; VISUALIZATION; ACTIVATION; LIGAND; DOMAIN	Gonadotropin-releasing hormone (GmRH) regulates pituitary gonadotropin release and is a therapeutic target for human and animal reproductive diseases, In the present study we have utilized the technique of fluorescence resonance energy transfer to monitor the rate of GnRH receptor-receptor interactions. This technique relies on the observation that the degree of physical intimacy of molecules can be assessed by the tendency of proximal fluorophores to exchange energy. Our data indicate that GnRH agonist, but not antagonist, occupancy of the GnRH receptor promotes physical intimacy (microaggregation) between receptors. The time course indicates that this occurs promptly (<1 min) after occupancy and persists for at least 80 min and within the physiologically relevant range of the releasing hormone. The process measured is not inhibited by 0.1 mM vinblastin, 2 <mu>M cytochalasin D, or 3 mM EGTA, an observation that distinguishes it from macroaggregation (patching, capping, and internalization). These observations, along with reports from other laboratories, are consonant with a growing body of evidence that indicates that microaggregation is an early event following agonist occupancy of the receptor and part of the mechanism by which effector regulation occurs.	Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA; Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University	Conn, PM (corresponding author), 505 NW 185th Ave, Beaverton, OR 97006 USA.				NCRR NIH HHS [RR00163] Funding Source: Medline; NICHD NIH HHS [HD18185, HD19899] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019899, R37HD019899] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Blakely BT, 2000, NAT BIOTECHNOL, V18, P218, DOI 10.1038/72686; BLUM JJ, 1982, P NATL ACAD SCI-BIOL, V79, P7307, DOI 10.1073/pnas.79.23.7307; BLUM JJ, 2000, AM J PHYSIOL, V2, pE263; CONN PM, 1984, MOL PHARMACOL, V25, P51; CONN PM, 1982, NATURE, V296, P653, DOI 10.1038/296653a0; CONN PM, 1982, ENDOCRINOLOGY, V111, P335, DOI 10.1210/endo-111-1-335; CONN PM, 1985, J CELL BIOCHEM, V7, P13; Cornea A, 1999, ENDOCRINOLOGY, V140, P4272, DOI 10.1210/en.140.9.4272; DOSREMEDIOS CG, 1995, J STRUCT BIOL, V115, P175, DOI 10.1006/jsbi.1995.1042; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GREGORY H, 1982, NATURE, V300, P269, DOI 10.1038/300269a0; GUO CM, 1995, J BIOL CHEM, V270, P27562, DOI 10.1074/jbc.270.46.27562; HARMATZ D, 1985, BIOCHEM BIOPH RES CO, V127, P687, DOI 10.1016/S0006-291X(85)80216-3; HAZUM E, 1980, P NATL ACAD SCI-BIOL, V77, P6692, DOI 10.1073/pnas.77.11.6692; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUCKLE WR, 1987, METHOD ENZYMOL, V141, P149; Janovick JA, 1996, ENDOCRINOLOGY, V137, P3602, DOI 10.1210/en.137.8.3602; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Lin XW, 1998, MOL CELL ENDOCRINOL, V146, P27, DOI 10.1016/S0303-7207(98)00204-4; MITRA BD, 1995, PROGR POL ALT I MOL, P13; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Pinter J H, 1999, Pituitary, V2, P181, DOI 10.1023/A:1009946807430; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; SMITH WA, 1984, ENDOCRINOLOGY, V114, P553, DOI 10.1210/endo-114-2-553; SMITH WA, 1983, ENDOCRINOLOGY, V112, P408, DOI 10.1210/endo-112-1-408; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818	30	112	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2153	2158		10.1074/jbc.M007850200	http://dx.doi.org/10.1074/jbc.M007850200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035030	hybrid			2022-12-27	WOS:000166528000068
J	Salero, E; Perez-Sen, R; Aruga, J; Gimenez, C; Zafra, F				Salero, E; Perez-Sen, R; Aruga, J; Gimenez, C; Zafra, F			Transcription factors Zic1 and Zic2 bind and transactivate the apolipoprotein E gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E MESSENGER-RNA; ALZHEIMERS-DISEASE; CHOLESTEROL TRANSPORT; REGULATORY REGION; DEFICIENT MICE; TYPE-4 ALLELE; CELL LINEAGE; APOE GENE; EPSILON 4; EXPRESSION	We have used the yeast one-hybrid system to identify transcription factors that bind to specific sequences in proximal regions of the apolipoprotein E gene promoter. The sequence between -163 and -124, that has been previously defined as a functional promoter element, was used as a bait to screen a human brain cDNA library. Ten cDNA clones that encoded portions of the human Zic1 (five clones) and Zic2 (five clones) transcription factors were isolated. Electrophoretic mobility shift assays confirmed the presence of a binding site for Zic1 and Zic2 in the -136/-125 region. Displacement of binding with oligonucleotides derived from adjacent sequences within the APOE promoter revealed the existence of two additional Zic-binding sequences in this promoter. These sequences were identified by electrophoretic mobility shift assays and mutational analysis in regions -65/-54 and -185/-174. Cotransfection of Zic1 and Zic2 expression vector and different APOE promoter-luciferase reporter constructs in U87 glioblastoma cell line showed that the three binding sites partially contributed to the trans-stimulation of the luciferase reporter. Ectopic expression of Zic1 and Zic2 in U87 cells also trans-stimulated the expression of the endogenous gene, increasing the amount of apolipopro tein E produced by glial cells. These data indicate that Zic proteins might contribute to the transcriptional activity of the apolipoprotein E gene and suggest that apolipoprotein E could mediate some of the developmental processes in which Zic proteins are involved.	Univ Autonoma Madrid, CSIC, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); RIKEN	Zafra, F (corresponding author), Univ Autonoma Madrid, CSIC, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	fzafra@cbm.uam.es	Aruga, Jun/H-5837-2011; Perez-Sen, Raquel/L-6975-2014; Gimenez, Cecilio/K-8027-2014; Zafra, Francisco/A-6121-2008	Aruga, Jun/0000-0001-7936-1375; Perez-Sen, Raquel/0000-0001-6213-3376; Gimenez, Cecilio/0000-0001-6726-8405; Zafra, Francisco/0000-0003-3801-3109				Allan CM, 1997, J BIOL CHEM, V272, P29113, DOI 10.1074/jbc.272.46.29113; Arendt T, 1997, J NEUROSCI, V17, P516; Artiga MJ, 1998, HUM MOL GENET, V7, P1887, DOI 10.1093/hmg/7.12.1887; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Aruga J, 1998, J NEUROSCI, V18, P284; ARUGA J, 1994, J NEUROCHEM, V63, P1880; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; Bachner D, 1999, BIOFACTORS, V9, P11; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BERG DT, 1995, J BIOL CHEM, V270, P15447, DOI 10.1074/jbc.270.26.15447; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69; Buttini M, 1999, J NEUROSCI, V19, P4867; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Garcia MA, 1996, J NEUROSCI, V16, P7550; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; JO DW, 1995, J BIOCHEM-TOKYO, V117, P915, DOI 10.1093/oxfordjournals.jbchem.a124796; KAYDEN HJ, 1985, ARCH BIOCHEM BIOPHYS, V239, P388, DOI 10.1016/0003-9861(85)90704-0; Kelley RI, 1996, AM J MED GENET, V66, P478, DOI 10.1002/(SICI)1096-8628(19961230)66:4<478::AID-AJMG22>3.0.CO;2-Q; KolfClauw M, 1996, TERATOLOGY, V54, P115, DOI 10.1002/(SICI)1096-9926(199609)54:3<115::AID-TERA1>3.0.CO;2-2; KOO C, 1985, J BIOL CHEM, V260, P1934; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Lanoue L, 1997, AM J MED GENET, V73, P24; LIAW GJ, 1994, BIOTECHNIQUES, V17, P668; LINLEE YC, 1981, BIOCHEMISTRY-US, V20, P6474, DOI 10.1021/bi00525a028; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Masliah E, 1997, BRAIN RES, V751, P307, DOI 10.1016/S0006-8993(96)01420-5; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; MULLER HW, 1985, SCIENCE, V228, P499, DOI 10.1126/science.3983637; Nagai T, 2000, P NATL ACAD SCI USA, V97, P1618, DOI 10.1073/pnas.97.4.1618; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nicoll JAR, 1996, ANN NEUROL, V39, P682, DOI 10.1002/ana.410390521; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAIK YK, 1988, J BIOL CHEM, V263, P13340; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; REUE KL, 1984, J BIOL CHEM, V259, P2100; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Shih SJ, 2000, J BIOL CHEM, V275, P31567, DOI 10.1074/jbc.M005468200; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; SMITH JD, 1988, J BIOL CHEM, V263, P8300; SNIPS GJ, 1986, P NATL ACAD SCI USA, V83, P1130, DOI 10.1073/pnas.83.4.1130; Srivastava RAK, 1996, BIOCHEM MOL BIOL INT, V38, P91; Stone DJ, 1997, EXP NEUROL, V143, P313, DOI 10.1006/exnr.1996.6360; Stone DJ, 1998, J NEUROSCI, V18, P3180; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Xu PT, 1998, NEUROSCI LETT, V246, P65, DOI 10.1016/S0304-3940(98)00247-X; Yokota N, 1996, CANCER RES, V56, P377	66	48	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1881	1888		10.1074/jbc.M007008200	http://dx.doi.org/10.1074/jbc.M007008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038359	hybrid			2022-12-27	WOS:000166528000033
J	Kim, YS; Cape, SP; Chi, E; Raffen, R; Wilkins-Stevens, P; Stevens, FJ; Manning, MC; Randolph, TW; Solomon, A; Carpenter, JF				Kim, YS; Cape, SP; Chi, E; Raffen, R; Wilkins-Stevens, P; Stevens, FJ; Manning, MC; Randolph, TW; Solomon, A; Carpenter, JF			Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREFERENTIAL HYDRATION; CHEMICAL CHAPERONES; PROTEIN-STRUCTURE; IN-VITRO; AGGREGATION; DISEASE; SCRAPIE; FIBRILLOGENESIS; TRANSTHYRETIN; CONSEQUENCES	In primary (light chain-associated) amyloidosis, immunoglobulin light chains deposit as amyloid fibrils in vital organs, especially the kidney. Because the kidney contains high concentrations of urea that can destabilize light chains as well as solutes such as betaine and sorbitol that serve as protein stabilizers, we investigated the effects of these solutes on in vitro amyloid fibril formation and thermodynamic stability of light chains, Two recombinant light chain proteins, one amyloidogenic and the other nonamyloidogenic, were used as models, For both light chains, urea enhanced fibril formation by reducing the nucleation lag time and diminished protein thermodynamic stability. Conversely, betaine or sorbitol increased thermodynamic stability of the proteins and partially inhibited fibril formation. These solutes also counteracted urea-induced reduction in protein thermodynamic stability and accelerated fibril formation. Betaine was more effective than sorbitol. A model is presented to explain how the thermodynamic effects of the solutes on protein state equilibria can alter nucleation lag time and, hence, fibril formation kinetics. Our results provide evidence that renal solutes control thermodynamic and kinetic stability of light chains and thus may modulate amyloid fibril formation in the kidney.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Dept Chem Engn, Boulder, CO 80309 USA; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA; Univ Tennessee, Human Immunol & Canc Program, Grad Sch Med, Knoxville, TN 37920 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder; United States Department of Energy (DOE); Argonne National Laboratory; University of Tennessee System; University of Tennessee Health Science Center	Carpenter, JF (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA.	John.Carpenter@uchsc.edu		Kim, Yong-Sung/0000-0003-2673-1509	NCI NIH HHS [CA10050] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKAWA T, 1983, ARCH BIOCHEM BIOPHYS, V224, P169, DOI 10.1016/0003-9861(83)90201-1; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Burg MB, 1998, AM J PHYSIOL-RENAL, V274, pF762, DOI 10.1152/ajprenal.1998.274.4.F762; Burg MB, 1996, KIDNEY INT, V50, pS100; Carpenter JF, 1999, METHOD ENZYMOL, V309, P236; COELHOSAMPAIO T, 1994, EUR J BIOCHEM, V221, P1103, DOI 10.1111/j.1432-1033.1994.tb18830.x; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; Davis DP, 2000, IMMUNITY, V13, P433, DOI 10.1016/S1074-7613(00)00043-1; Dhodapkar MV, 1997, HEMATOL ONCOL CLIN N, V11, P89, DOI 10.1016/S0889-8588(05)70417-2; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; Dong AC, 2000, J BIOL CHEM, V275, P27689; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P39, DOI 10.1093/oxfordjournals.jbchem.a133468; GLENNER GG, 1971, SCIENCE, V174, P712, DOI 10.1126/science.174.4010.712; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kim YS, 2000, J BIOL CHEM, V275, P1570, DOI 10.1074/jbc.275.3.1570; KYLE RA, 1995, SEMIN HEMATOL, V32, P45; KYLE RA, 1994, ANNU REV MED, V45, P71; MARSH DJ, 1992, RENAL PHYSL, P1317; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MYATT EA, 1994, P NATL ACAD SCI USA, V91, P3034, DOI 10.1073/pnas.91.8.3034; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Pace C N, 1986, Methods Enzymol, V131, P266; Raffen R, 1999, PROTEIN SCI, V8, P509; RONCO PM, 1997, DIS KIDNEY, V3, P2129; SANTORA MM, 1988, BIOCHEMISTRY-US, V27, P8603; SLUZKY V, 1991, P NATL ACAD SCI USA, V88, P9377, DOI 10.1073/pnas.88.21.9377; Solomon A, 1998, P NATL ACAD SCI USA, V95, P9547, DOI 10.1073/pnas.95.16.9547; STEVENS FJ, 1995, BIOCHEMISTRY-US, V34, P10697, DOI 10.1021/bi00034a001; STEVENS FJ, 1989, IMMUNOL TODAY, V20, P453; STEVENS PW, 1995, PROTEIN SCI, V4, P421; STRIKER LJM, 1994, RENAL PATHOLOGY, V2, P1442; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; Wall J, 1999, BIOCHEMISTRY-US, V38, P14101, DOI 10.1021/bi991131j; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; WELTZEL R, 1997, ADV PROTEIN CHEM, V50, P183; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Xie GF, 1997, PROTEIN SCI, V6, P211; YANCEY PH, 1979, BIOCHEM J, V183, P317, DOI 10.1042/bj1830317; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970	47	79	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1626	1633		10.1074/jbc.M007766200	http://dx.doi.org/10.1074/jbc.M007766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050093	hybrid			2022-12-27	WOS:000166430900102
J	Song, ES; Mukherjee, A; Juliano, MA; St Pyrek, J; Goodman, JP; Juliano, L; Hersh, LB				Song, ES; Mukherjee, A; Juliano, MA; St Pyrek, J; Goodman, JP; Juliano, L; Hersh, LB			Analysis of the subsite specificity of rat insulysin using fluorogenic peptide substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; DEGRADATION; IDENTIFICATION; PROTEIN	Recombinant rat insulysin was shown to cleave the internally quenched fluorogenic peptide 2-aminobenzyl-GGFLRKVGQ-ethylenediamine-2,4-dinitrophenol at the R-K bond, exhibiting a K-m of 13 muM and a V-max of 2.6 mu mol min(-1) mg(-1). Derivatives of this peptide in which the P-2 leucine or the P-2' valine were replaced with other residues were used to probe the subsite specificity of the enzyme. Varying the P-2 residue produced a l-fold range in K-m and a 7-fold range in k(cat). The nature of the P-2 residue had a significant effect on the site of cleavage. Leucine, isoleucine, valine, and aspartate produced cleavage at the R-K bond, Asparagine produced 36% cleavage at the N-R bond and 64% cleavage at the RK bond, whereas with alanine or serine the A-R and S-R bonds were the major cleavage sites. With tyrosine, phenylalanine, methionine, or histidine representing the varied residue X, cleavages at F-X, X-R, and RK were seen, whereas with tryptophan equal cleavage occurred at the F-W and W-R bonds. Variable P-2' residues produce less of a change in both K-m and k(cat) and have little influence on the cleavage site. Exceptions are phenylalanine, tyrosine, leucine, and isoleucine, which in addition to producing cleavage at the RK bond, produce significant cleavage at the GR bond. Alanine and tyrosine were unique in producing cleavage at the F-L bond. Taken together, these data suggest that insulysin specificity is directed toward the amino side of hydrophobic and basic residues and that the enzyme has an extended substrate binding site.	Univ Kentucky, Albert B Chandler Med Ctr, Coll Med, Dept Biochem, Lexington, KY 40536 USA; Univ Kentucky, Mass Spectrometry Facil, Lexington, KY 40506 USA; Escola Paulista Med, Dept Biophys, BR-04034 Sao Paulo, Brazil	University of Kentucky; University of Kentucky; Universidade Federal de Sao Paulo (UNIFESP)	Hersh, LB (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Coll Med, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.	lhersh@pop.uky.edu	Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822	NIDA NIH HHS [DA 07062, DA02243] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Authier F, 1996, CLIN INVEST MED, V19, P149; BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; CHAGAS JR, 1991, ANAL BIOCHEM, V192, P419, DOI 10.1016/0003-2697(91)90558-B; Cleland W W, 1979, Methods Enzymol, V63, P103; Csuhai E, 1999, ANAL BIOCHEM, V269, P149, DOI 10.1006/abio.1999.4033; DUCKWORTH WC, 1994, J BIOL CHEM, V269, P24575; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; GARCIA JV, 1989, J CELL BIOL, V109, P1301, DOI 10.1083/jcb.109.3.1301; GEHM BD, 1993, J BIOL CHEM, V268, P7943; Gershkovich A, 1996, J BIOCHEM BIOPH METH, V33, P135, DOI 10.1016/S0165-022X(96)00023-1; KUPFER SR, 1994, J BIOL CHEM, V269, P20622; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; MIRSKY A, 1949, ARCH BIOCHEM, V20, P1; Mukherjee A, 2000, J NEUROSCI, V20, P8745; MULLER D, 1992, BIOCHEMISTRY-US, V31, P11138; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; PERLMAN RK, 1994, J BIOL CHEM, V269, P33140; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROTH RA, 1984, ENDOCR RES, V10, P101, DOI 10.3109/07435808409035411; Safavi A, 1996, BIOCHEMISTRY-US, V35, P14318, DOI 10.1021/bi960582q; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEMPLE JW, 1989, J IMMUNOL, V142, P4184; Seta KA, 1997, BIOCHEM BIOPH RES CO, V231, P167, DOI 10.1006/bbrc.1997.6066; Vekrellis K, 2000, J NEUROSCI, V20, P1657	26	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1152	1155		10.1074/jbc.M008702200	http://dx.doi.org/10.1074/jbc.M008702200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042190	hybrid			2022-12-27	WOS:000166430900042
J	Takahashi, M; Takahashi, K; Hiratsuka, Y; Uchida, K; Yamagishi, A; Uyeda, TQP; Yazawa, M				Takahashi, M; Takahashi, K; Hiratsuka, Y; Uchida, K; Yamagishi, A; Uyeda, TQP; Yazawa, M			Functional characterization of vertebrate nonmuscle myosin IIB isoforms using Dictyostelium chimeric myosin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; HEAVY CHAIN-B; ACTIN-BINDING LOOP; MOTOR DOMAIN; ATPASE ACTIVITY; ADENOSINE-TRIPHOSPHATASE; MOLECULAR MOTOR; MESSENGER-RNAS; SURFACE LOOPS; SUBFRAGMENT-1	The alternatively spliced isoform of nonmuscle myosin II heavy chain B (MHC-IIB) with an insert of 21 amino acids in the actin-binding surface loop (loop 2), MHC-IIB(BE), is expressed specifically in the central nervous system of vertebrates. To examine the role of the B2 insert in the motor activity of the myosin II molecule, we expressed chimeric myosin heavy chain molecules using the Dictyostelium myosin II heavy chain as the backbone. We replaced the Dictyostelium native loop 2 with either the noninserted form of loop 2 from human MHC-IIB or the BE-inserted form of loop 2 from human MHC-IIB(BE), The transformant Dictyostelium cells expressing only the B2-inserted chimeric myosin formed unusual fruiting bodies. We then assessed the function of chimeric proteins, using an in vitro motility assay and by measuring ATPase activities and binding to F-actin, We demonstrate that the insertion of the B2 sequence reduces the motor activity of Dictyostelium myosin II, with reduction of the maximal actin-activated ATPase activity and a decrease in the affinity for actin, In addition, we demonstrate that the native loop 2 sequence of Dictyostelium myosin II is required for the regulation of the actin-activated ATPase activity by phosphorylation of the regulatory light chain.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan; Natl Inst Adv Interdisciplinary Res, Biomol Res Grp, Tsukuba, Ibaraki 3058562, Japan	Hokkaido University; Hokkaido University; National Institute of Advanced Industrial Science & Technology (AIST)	Takahashi, M (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan.	takahash@sci.hokudai.ac.jp	Takahashi, Masayuki/D-8079-2012	Takahashi, Masayuki/0000-0002-5923-2813; Hiratsuka, Yuichi/0000-0002-0237-081X				BALINT M, 1978, ARCH BIOCHEM BIOPHYS, V190, P793, DOI 10.1016/0003-9861(78)90339-9; Bernstein SI, 1997, J MOL BIOL, V271, P1, DOI 10.1006/jmbi.1997.1160; Bobkov AA, 1996, P NATL ACAD SCI USA, V93, P2285, DOI 10.1073/pnas.93.6.2285; BOTTS J, 1982, BIOCHEMISTRY-US, V21, P6903, DOI 10.1021/bi00269a043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUSSEPIED P, 1988, P NATL ACAD SCI USA, V85, P7471, DOI 10.1073/pnas.85.20.7471; COOK RK, 1993, J BIOL CHEM, V268, P2410; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EGELHOFF TT, 1990, DEV BIOL, V137, P359, DOI 10.1016/0012-1606(90)90260-P; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Giese KC, 1997, BIOCHEMISTRY-US, V36, P8465, DOI 10.1021/bi963141f; GONZALEZROMO P, 1992, ANAL BIOCHEM, V200, P235, DOI 10.1016/0003-2697(92)90458-J; Goodson HV, 1999, J MOL BIOL, V287, P173, DOI 10.1006/jmbi.1999.2565; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kawamoto S, 1996, J BIOL CHEM, V271, P17613; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Knetsch MLW, 1999, J BIOL CHEM, V274, P20133, DOI 10.1074/jbc.274.29.20133; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mendelson R, 1997, P NATL ACAD SCI USA, V94, P8533, DOI 10.1073/pnas.94.16.8533; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Miyazaki T, 2000, NEUROSCI RES, V37, P299, DOI 10.1016/S0168-0102(00)00130-9; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; MURAKAMI N, 1993, DEV BIOL, V157, P19, DOI 10.1006/dbio.1993.1108; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; NYITRAY L, 1994, P NATL ACAD SCI USA, V91, P12686, DOI 10.1073/pnas.91.26.12686; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Rovner AS, 1998, J BIOL CHEM, V273, P27939, DOI 10.1074/jbc.273.43.27939; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Smith JL, 1996, EMBO J, V15, P6075, DOI 10.1002/j.1460-2075.1996.tb00996.x; Spudich JA, 1995, COLD SPRING HARB SYM, V60, P783, DOI 10.1101/SQB.1995.060.01.084; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Takahashi M, 1999, BIOCHEM BIOPH RES CO, V259, P29, DOI 10.1006/bbrc.1999.0717; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; YAMAMOTO K, 1979, J BIOCHEM-TOKYO, V86, P1869, DOI 10.1093/oxfordjournals.jbchem.a132710; YAMAMOTO K, 1979, J BIOCHEM, V86, P1855, DOI 10.1093/oxfordjournals.jbchem.a132708; YAMAMOTO K, 1991, J MOL BIOL, V217, P229, DOI 10.1016/0022-2836(91)90535-E; YOUNT RG, 1995, BIOPHYS J S, V68, P44	62	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1034	1040		10.1074/jbc.M005370200	http://dx.doi.org/10.1074/jbc.M005370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042201	Green Submitted, hybrid			2022-12-27	WOS:000166430900025
J	Tangirala, RK; Pratico, D; FitzGerald, GA; Chun, S; Tsukamoto, K; Maugeais, C; Usher, DC; Pure, E; Rader, DJ				Tangirala, RK; Pratico, D; FitzGerald, GA; Chun, S; Tsukamoto, K; Maugeais, C; Usher, DC; Pure, E; Rader, DJ			Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOE-DEFICIENT MICE; HIGH-DENSITY-LIPOPROTEIN; DIRECTED GENE-TRANSFER; BONE-MARROW TRANSPLANTATION; LDL RECEPTOR-DEFICIENT; CHOLESTEROL EFFLUX; REDUCES ATHEROSCLEROSIS; REMNANT LIPOPROTEINS; A-I; PLASMA	Apolipoprotein E is a multifunctional protein synthesized by hepatocytes and macrophages. Plasma apoE is largely liver-derived and known to regulate lipoprotein metabolism. Macrophage-derived apoE has been shown to reduce the progression of atherosclerosis in mice. We tested the hypothesis that liver-derived apoE could directly induce regression of pre-existing advanced atherosclerotic lesions without reducing plasma cholesterol levels. Aged low density lipoprotein (LDL) receptor-deficient (LDLR-/-) mice were fed a western-type diet for 14 weeks to induce advanced atherosclerotic lesions. One group of mice was sacrificed for evaluation of atherosclerosis at base line, and two other groups were injected with a second generation adenoviruses encoding human apoE3 or a control empty virus. Hepatic apoE gene transfer increased plasma apoE levels by 4-fold at 1 week, and apoE levels remained at least S-fold higher than controls at 6 weeks. There were no significant changes in plasma total cholesterol levels or lipoprotein composition induced by expression of apoE, The liver-derived human apoE gained access to anal was retained in arterial wall. Compared with base-line mice, the control group demonstrated progression of atherosclerosis; in contrast, hepatic apoE expression induced highly significant regression of advanced atherosclerotic lesions. Regression of lesions was accompanied by the loss of macrophage-derived foam cells and a trend toward increase in extracellular matrix of lesions. As an index of in vivo oxidant stress, we quantitated the isoprostane iPF(2 alpha)-VI and found that expression of apoE markedly reduced urinary, LDL-associated, and arterial wall iPF(2 alpha)-VI levels. In summary, these results demonstrate that liver-derived apoE directly induced regression of advanced atherosclerosis and has anti-oxidant properties in vivo that may contribute to its anti-atherogenic effects.	Univ Penn, Med Ctr, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Delaware, Newark, DE 19711 USA; Wistar Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Delaware; The Wistar Institute	Rader, DJ (corresponding author), Univ Penn, Med Ctr, Sch Med, Dept Med, Rm 614 BRB II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.		FitzGerald, Garret A/A-4222-2010; Pratico, Domenico/ABA-9590-2020		NHLBI NIH HHS [HL-57811, HL-59407] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059407, R01HL057811] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; Dansky HM, 1999, CIRCULATION, V100, P1762, DOI 10.1161/01.CIR.100.17.1762; Desurmont C, 2000, ARTERIOSCL THROM VAS, V20, P435, DOI 10.1161/01.ATV.20.2.435; Fan JL, 1998, J CLIN INVEST, V101, P2151, DOI 10.1172/JCI1599; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; HARA H, 1991, J BIOL CHEM, V266, P3080; HUANG DY, 1995, EXP NEUROL, V136, P251, DOI 10.1006/exnr.1995.1101; Huang YD, 1997, ARTERIOSCL THROM VAS, V17, P2010, DOI 10.1161/01.ATV.17.10.2010; Huang YD, 1995, J CLIN INVEST, V96, P2693, DOI 10.1172/JCI118336; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; JI ZS, 1993, J BIOL CHEM, V268, P10160; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KELLY ME, 1994, CELL IMMUNOL, V159, P124, DOI 10.1006/cimm.1994.1302; Krimbou L, 1997, J LIPID RES, V38, P35; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Maugeais C, 2000, J LIPID RES, V41, P1673; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Osuga J, 1998, J CLIN INVEST, V102, P386, DOI 10.1172/JCI1124; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Tangirala RK, 1999, CIRCULATION, V100, P1816, DOI 10.1161/01.CIR.100.17.1816; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Thorngate FE, 2000, ARTERIOSCL THROM VAS, V20, P1939, DOI 10.1161/01.ATV.20.8.1939; Tsukamoto K, 1999, ARTERIOSCL THROM VAS, V19, P2162, DOI 10.1161/01.ATV.19.9.2162; Tsukamoto K, 2000, MOL THER, V1, P189, DOI 10.1006/mthe.2000.0028; Tsukamoto K, 2000, J LIPID RES, V41, P253; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; van Dijk KW, 1999, J LIPID RES, V40, P336; WILLNOW TE, 1995, J MOL MED, V73, P213; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; Woollett LA, 1995, P NATL ACAD SCI USA, V92, P12500, DOI 10.1073/pnas.92.26.12500; YAMADA N, 1992, J CLIN INVEST, V89, P706, DOI 10.1172/JCI115639; Zhang WY, 1996, J BIOL CHEM, V271, P28641, DOI 10.1074/jbc.271.45.28641; ZHONGSHEN J, 1998, J BIOL CHEM, V273, P13452; Zhu YH, 1998, P NATL ACAD SCI USA, V95, P7585, DOI 10.1073/pnas.95.13.7585	48	98	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					261	266		10.1074/jbc.M003324200	http://dx.doi.org/10.1074/jbc.M003324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024044	hybrid			2022-12-27	WOS:000166280700036
J	Cavadini, P; Adamec, J; Taroni, F; Gakh, O; Isaya, G				Cavadini, P; Adamec, J; Taroni, F; Gakh, O; Isaya, G			Two-step processing of human frataxin by mitochondrial processing peptidase - Precursor and intermediate forms are cleaved at different rates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEDREICHS-ATAXIA; IRON ACCUMULATION; YEAST FRATAXIN; PROTEINS; HOMOLOG; MATURATION; GENE; HOMEOSTASIS; MEMBRANES	We showed previously that maturation of the human frataxin precursor (p-fxn) involves two cleavages by the mitochondrial processing peptidase (MPP), This observation was not confirmed by another group, however, who reported only one cleavage. Here, we demonstrate conclusively that MPP cleaves p-fxn in two sequential steps, yielding a 18,826-Da intermediate (i-fxn) and a 17,255-Da mature (m-fxn) form, the latter corresponding to endogenous frataxin in human tissues. The two cleavages occur between residues 41-42 and 55-56, and both match the MPP consensus sequence RX down arrow (X/S). Recombinant rat and yeast MPP catalyze the p --> i step 4 and 40 times faster, respectively, than the i --> m step. In isolated rat mitochondria, p-fxn undergoes a sequence of cleavages, p --> i --> m --> d(1) --> d(2), with d(1) and d(2) representing two C-terminal fragments of m-Rm produced by an unknown protease, The i --> m step is limiting, and the overall rate of p --> i --> m does not exceed the rate of m --> d(1) --> d(2), such that the levels of m-fxn do not change during incubations as long as 3 h. Inhibition of the i --> m step by a disease-causing frataxin mutation (W173G) leads to nonspecific degradation of i-fxn, Thus, the second of the two processing steps catalyzed by MPP limits the levels of mature frataxin within mitochondria.	Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Ist Nazl Neurol Carlo Besta, Div Biochem & Genet, Milan, Italy; Acad Sci Czech Republic, Inst Microbiol, CR-14220 Prague, Czech Republic	Mayo Clinic; IRCCS Istituto Neurologico Besta; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Isaya, G (corresponding author), Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.	isaya@mayo.edu		cavadini, patrizia/0000-0002-1774-5290	NATIONAL INSTITUTE ON AGING [R01AG015709] Funding Source: NIH RePORTER; NIA NIH HHS [AG15709] Funding Source: Medline; Telethon [E.0514] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Telethon(Fondazione Telethon)		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Branda SS, 1999, HUM MOL GENET, V8, P1099, DOI 10.1093/hmg/8.6.1099; Branda SS, 1999, J BIOL CHEM, V274, P22763, DOI 10.1074/jbc.274.32.22763; BRANDA SS, 1995, J BIOL CHEM, V270, P27366, DOI 10.1074/jbc.270.45.27366; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Cavadini P, 2000, HUM MOL GENET, V9, P2523, DOI 10.1093/hmg/9.17.2523; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Cossee M, 1999, ANN NEUROL, V45, P200, DOI 10.1002/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U; FENTON WA, 1996, ADV MOL CEL, V17, P163; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GELI V, 1993, P NATL ACAD SCI USA, V90, P6247, DOI 10.1073/pnas.90.13.6247; Gordon DM, 1999, HUM MOL GENET, V8, P2255, DOI 10.1093/hmg/8.12.2255; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Koutnikova H, 1998, HUM MOL GENET, V7, P1485, DOI 10.1093/hmg/7.9.1485; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Puccio H, 2000, HUM MOL GENET, V9, P887, DOI 10.1093/hmg/9.6.887; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Villegas V, 1996, FOLD DES, V1, P29, DOI 10.1016/S1359-0278(96)00009-0; Voisine C, 2000, MOL CELL BIOL, V20, P3677, DOI 10.1128/MCB.20.10.3677-3684.2000	28	97	101	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41469	41475		10.1074/jbc.M006539200	http://dx.doi.org/10.1074/jbc.M006539200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11020385	Green Published, hybrid			2022-12-27	WOS:000166114600105
J	Pearson, G; Bumeister, R; Henry, DO; Cobb, MH; White, MA				Pearson, G; Bumeister, R; Henry, DO; Cobb, MH; White, MA			Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVATION; RIBOSOMAL S6 KINASE; KAPPA-B-ALPHA; SIGNAL-TRANSDUCTION; ONCOGENIC RAF-1; IN-VITRO; TRANSFORMATION; EXPRESSION; PATHWAY; CELLS	The Raf family of serine/threonine protein kinases is intimately involved in the transmission of cell regulatory signals controlling proliferation and differentiation. The best characterized Raf substrates are MEK1 and MEK2. The activation of MEK1/2 by Raf is required to mediate many of the cellular responses to Raf activation, suggesting that MEK1/2 are the dominant Raf effector proteins. However, accumulating evidence suggests that there are additional Raf substrates and that subsets of Raf-induced regulatory events are mediated independently of Raf activation of MEK1/2. To examine the possibility that there is bifurcation at the level of Raf in activation of MEK1/2-dependent and MEK1/2-independent cell regulatory events, we engineered a kinase-active Raf1 variant (RafBXB(T481A)) with an amino acid substitution that disrupts MEK1 binding. We find that disruption of MEK1/2 association uncouples Raf from activation of ERK1/2, induction of serum-response element-dependent gene expression, and induction of growth and morphological transformation. However, activation of NF-kappaB-dependent gene expression and induction of neurite differentiation were unimpaired. In addition, Raf-dependent activation of p90 ribosomal S6 kinase was only slightly impaired. These results support the hypothesis that Raf kinases utilize multiple downstream effectors to regulate distinct cellular activities.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	White, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NCI NIH HHS [CA71443] Funding Source: Medline; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; CHEN XR, 1995, J BIOL CHEM, V270, P18285, DOI 10.1074/jbc.270.31.18285; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Jette C, 2000, FEBS LETT, V467, P1, DOI 10.1016/S0014-5793(00)01114-5; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KHOSOUR SJ, 1995, SCIENCE, V13, P6443; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Lin JH, 1999, J BIOL CHEM, V274, P14706, DOI 10.1074/jbc.274.21.14706; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mineo C, 1997, J BIOL CHEM, V272, P10345; Naumann U, 1997, Recent Results Cancer Res, V143, P237; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052; Zuker CS, 1999, SCIENCE, V283, P650, DOI 10.1126/science.283.5402.650	35	65	66	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37303	37306		10.1074/jbc.C000570200	http://dx.doi.org/10.1074/jbc.C000570200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	11018021	hybrid			2022-12-27	WOS:000165618700001
J	Polyak, SW; Chapman-Smith, A; Mulhern, TD; Cronan, JE; Wallace, JC				Polyak, SW; Chapman-Smith, A; Mulhern, TD; Cronan, JE; Wallace, JC			Mutational analysis of protein substrate presentation in the post-translational attachment of biotin to biotin domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; DEHYDROGENASE MULTIENZYME COMPLEX; YEAST PYRUVATE-CARBOXYLASE; ESCHERICHIA-COLI; LIPOYL DOMAIN; PHAGE-DISPLAY; PROPIONIBACTERIUM-SHERMANII; EXCEPTIONAL SPECIFICITY; 3-DIMENSIONAL STRUCTURE; AZOTOBACTER-VINELANDII	Biotinylation in vivo is an extremely selective posttranslational event where the enzyme biotin protein ligase (BPL) catalyzes the covalent attachment of biotin to one specific and conserved lysine residue of biotin-dependent enzymes. The biotin-accepting lysine, present in a conserved Met-Lys-Met motif, resides in a structured domain that functions as the BPL substrate. We have employed phage display coupled with a genetic selection to identify determinants of the biotin domain (yPC-104) of yeast pyruvate carboxylase 1 (residues 1075-1178) required for interaction with BPL. Mutants isolated using this strategy were analyzed by in vivo biotinylation assays performed at both 30 degreesC and 37 degreesC, The temperature-sensitive substrates were reasoned to have structural mutations, leading to compromised conformations at the higher temperature. This interpretation was supplemented by molecular modeling of yPC-104, since these mutants mapped to residues involved in defining the structure of the biotin domain. In contrast, substitution of the Met residue N-terminal to the target lysine with either Val or Thr produced mutations that were temperature-insensitive in the in vivo assay. Furthermore, these two mutant proteins and wild-type yPC-104 showed identical susceptibility to trypsin, consistent with these substitutions having no structural effect. Kinetic analysis of enzymatic biotinylation using purified Met --> Thr/Val mutant proteins with both yeast and Escherichia coli BPLs revealed that these substitutions had a strong effect upon K-m values but not k(cat). The Met --> Thr mutant was a poor substrate for both BPLs, whereas the Met --> Val substitution was a poor substrate for bacterial BPL but had only at S-fold lower affinity for yeast BPL than the wild-type peptide. Our data suggest that substitution of Thr or Val for the Met N-terminal of the biotinyl-lys results in mutants specifically compromised in their interaction with BPL.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Adelaide; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Wallace, JC (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.	john.wallace@adelaide.edu.au	Polyak, Steven W/A-7488-2019; Mulhern, Terrence/A-1206-2007; Cronan, John/V-6626-2019; Polyak, Steven W./G-3185-2011; , John/AAP-5150-2020	Polyak, Steven W/0000-0002-8458-5194; Polyak, Steven W./0000-0002-8458-5194; Mulhern, Terrence/0000-0002-1609-7498				Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; Berg A, 1997, EUR J BIOCHEM, V244, P352, DOI 10.1111/j.1432-1033.1997.00352.x; Berg A, 1996, J MOL BIOL, V261, P432, DOI 10.1006/jmbi.1996.0474; BROCKLEHURST SM, 1993, PROTEIN SCI, V2, P626; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; Chapman-Smith A, 1999, J NUTR, V129, p477S, DOI 10.1093/jn/129.2.477S; Chapman-Smith A, 1999, J BIOL CHEM, V274, P1449, DOI 10.1074/jbc.274.3.1449; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; Demartis S, 1999, J MOL BIOL, V286, P617, DOI 10.1006/jmbi.1998.2476; DOWNER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127; Fischer D, 1996, PROTEIN SCI, V5, P947; GU HD, 1995, PROTEIN SCI, V4, P1108, DOI 10.1002/pro.5560040609; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Hudson PJ, 1998, CURR OPIN BIOTECH, V9, P395, DOI 10.1016/S0958-1669(98)80014-1; Jitrapakdee S, 1999, BIOCHEM J, V340, P1, DOI 10.1042/bj3400001; Katz BA, 1997, ANNU REV BIOPH BIOM, V26, P27, DOI 10.1146/annurev.biophys.26.1.27; KONDO H, 1984, INT J PEPT PROT RES, V23, P559; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LI SJ, 1992, J BIOL CHEM, V267, P855; LIM F, 1988, J BIOL CHEM, V263, P11493; Lucic MR, 1998, J BIOTECHNOL, V61, P95, DOI 10.1016/S0168-1656(98)00012-1; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Polyak SW, 1997, PROTEIN ENG, V10, P615, DOI 10.1093/protein/10.6.615; Polyak SW, 1999, J BIOL CHEM, V274, P32847, DOI 10.1074/jbc.274.46.32847; Reche P, 1998, BIOCHEM J, V329, P589, DOI 10.1042/bj3290589; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; Reddy DV, 1997, BIOCHEMISTRY-US, V36, P14676, DOI 10.1021/bi971674y; Reddy DV, 1998, PROTEIN SCI, V7, P2156, DOI 10.1002/pro.5560071013; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sharma RC, 1996, BIOTECHNIQUES, V20, P42; SHENOY BC, 1988, FASEB J, V2, P2396, DOI 10.1096/fasebj.2.8.3360240; SHENOY BC, 1992, J BIOL CHEM, V267, P18407; Stolz J, 1998, FEBS LETT, V440, P213, DOI 10.1016/S0014-5793(98)01454-9; Val DL, 1995, BIOCHEM J, V312, P817, DOI 10.1042/bj3120817; Wallis NG, 1996, J MOL BIOL, V263, P463, DOI 10.1006/jmbi.1996.0589; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; Xu Y, 1997, METHOD ENZYMOL, V279, P405; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f	48	34	37	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3037	3045		10.1074/jbc.M003968200	http://dx.doi.org/10.1074/jbc.M003968200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042165	hybrid			2022-12-27	WOS:000166784900011
J	Lopez, I; Mak, EC; Ding, JR; Hamm, HE; Lomasney, JW				Lopez, I; Mak, EC; Ding, JR; Hamm, HE; Lomasney, JW			A novel bifunctional phospholipase C that is regulated by G alpha(12) and stimulates the Ras/mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; RAS-BINDING DOMAIN; BASIC-AMINO-ACIDS; COUPLED RECEPTORS; ALPHA-SUBUNITS; P115 RHOGEF; CELLS; C-DELTA-1; IDENTIFICATION; HYDROLYSIS	Three families of phospholipase C (PI-PLC beta, gamma, and delta) are known to catalyze the hydrolysis of polyphosphoinositides such as phosphatidylinositol 4,5-bisphosphate (PIP2) to generate the second messengers inositol 1,4,5 trisphosphate and diacylglycerol, leading to a cascade of intracellular responses that result in cell growth, cell differentiation, and gene expression. Here we describe the founding member of a novel, structurally distinct fourth family of PI-PLC, PLC epsilon not only contains conserved catalytic (X and Y) and regulatory domains (C2) common to other eukaryotic PLCs, but also contains two Res-associating (RA) domains and a Ras guanine nucleotide exchange factor (RasGEF) motif. PLC epsilon hydrolyzes PIP2, and this activity is stimulated selectively by a constitutively active form of the heterotrimeric G protein Ga alpha (12). PLC epsilon and a mutant (H1144L) incapable of hydrolyzing phosphoinositides promote formation of GTP-Ras, Thus PLC epsilon is a RasGEF, PLCe, the mutant H1144L, and the isolated GEF domain activate the mitogen-activated protein kinase pathway in a manner dependent on Res but independent of PIP, hydrolysis, Our findings demonstrate that PLC epsilon is a novel bifunctional enzyme that is regulated by the heterotrimeric G protein Ga alpha (12), and activates the small G protein Ras/mitogen-activated protein kinase signaling pathway.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Feinberg Cardiovasc Res Inst, Chicago, IL 60611 USA; Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Lomasney, JW (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, Tarry Bldg 12-703,303 E Chicago Ave, Chicago, IL 60611 USA.		Hamm, Heidi E/G-2374-2014		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055591, R01HL055591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03836, HL55591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bokoch GM, 1996, FASEB J, V10, P1290, DOI 10.1096/fasebj.10.11.8836042; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; Cheng SD, 1995, MOL CRYST LIQ CRYS A, V270, P1, DOI 10.1080/10587259508031009; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Kim MJ, 1998, J BIOL CHEM, V273, P3618, DOI 10.1074/jbc.273.6.3618; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; Murai H, 1997, J BIOL CHEM, V272, P10483; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; WU DQ, 1993, J BIOL CHEM, V268, P3704; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287	35	210	223	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2758	2765		10.1074/jbc.M008119200	http://dx.doi.org/10.1074/jbc.M008119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11022047	hybrid			2022-12-27	WOS:000166784800063
J	Raspe, E; Duez, H; Gervois, P; Fievet, C; Fruchart, JC; Besnard, S; Mariani, J; Tedgui, A; Staels, B				Raspe, E; Duez, H; Gervois, P; Fievet, C; Fruchart, JC; Besnard, S; Mariani, J; Tedgui, A; Staels, B			Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor ROR alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; APO-CIII; A-I; APOCIII PROMOTER; DNA-BINDING; TRANSGENIC MICE; ACTIVATION; HORMONE; MODULATION; HYPERTRIGLYCERIDEMIA	Triglyceride-rich remnant lipoproteins are considered as major risk factors contributing to the pathogenesis of atherosclerosis. Because apolipoprotein (apo) C-III is a major determinant of plasma triglyceride and remnant lipoprotein metabolism, it is important to understand how the expression of this gene is regulated. In the present study, we identified the orphan nuclear receptor ROR alpha1 as a regulator of human and mouse apo C-III gene expression. Plasma triglyceride and apo C-III protein concentrations in staggerer (sg/sg) mice, homozygous for a deletion in the ROR alpha gene, were significantly lower than in wild type littermates. The lowered plasma apo C-III levels were associated with reduced apo C-III mRNA levels in liver and intestine of sg/sg mice. Transient transfection experiments in human hepatoma HepG2, human colonic CaCO2, and rabbit kidney RK13 cells demonstrated that overexpression of the human ROR alpha1 isoform specifically increases human apo C-III promoter activity, indicating that ROR alpha1 enhances human apo C-III gene transcription. ROR alpha1 response elements were mapped by promoter deletion analysis and gel shift experiments to two AGGTCA halfsites located at positions -83/-78 (within the C3P site) and -23/-18 (downstream of the TATA box) in the human apo C-III promoter, with the -23/-18 site exhibiting the highest binding affinity. Transfection of site-directed mutated constructs in HepG2 cells indicated that the ROR alpha1 effect is predominantly mediated by the -23/-18 site. This site is conserved in the mouse apo C-III gene promoter. Moreover, ROR alpha binds to the equivalent mouse site and activates constructs containing three copies of the mouse site cloned in front of an heterologous promoter. Taken together, our data identify ROR alpha as a transcriptional regulator of apo C-III gene expression, providing a novel, physiological role for ROR alpha1 in the regulation of genes controlling triglyceride metabolism.	Inst Pasteur, INSERM, U325, F-59019 Lille, France; INSERM, U141, F-75745 Paris 10, France; Univ Paris 06, CNRS, UMR 7624, F-75005 Paris, France; Ctr Rech & Dev, Grp Merck Lipha, F-69003 Lyon, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite de Lille - ISITE; Universite de Lille	Staels, B (corresponding author), Inst Pasteur, INSERM, U325, 1 Rue Calmette, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Duez, Helene/M-7609-2017; Duez, Helene/AAC-3217-2019; Staels, Bart/N-9497-2016	Duez, Helene/0000-0002-4130-7987; Staels, Bart/0000-0002-3784-1503; Mariani, Jean/0000-0002-2701-1581				AaltoSetala K, 1996, J LIPID RES, V37, P1802; AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Assmann G, 1998, EUR HEART J, V19, pA2; Austin S, 1998, CELL GROWTH DIFFER, V9, P267; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CHEN M, 1994, J LIPID RES, V35, P1918; CLAVEY V, 1995, ARTERIOSCL THROM VAS, V15, P963, DOI 10.1161/01.ATV.15.7.963; Davignon J, 1996, ATHEROSCLEROSIS, V124, pS57, DOI 10.1016/0021-9150(96)05858-3; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; Dussault I, 1998, MECH DEVELOP, V70, P147, DOI 10.1016/S0925-4773(97)00187-1; Ebara T, 1997, J CLIN INVEST, V99, P2672, DOI 10.1172/JCI119456; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Fraser JD, 1998, NUCLEIC ACIDS RES, V26, P2702, DOI 10.1093/nar/26.11.2702; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; Gotto AM, 1998, CIRCULATION, V97, P1027, DOI 10.1161/01.CIR.97.11.1027; Greiner EF, 1996, P NATL ACAD SCI USA, V93, P10105, DOI 10.1073/pnas.93.19.10105; GRUBER PJ, 1994, NUCLEIC ACIDS RES, V22, P2417, DOI 10.1093/nar/22.12.2417; Hadzopoulou-Cladaras M, 1998, BIOCHEMISTRY-US, V37, P14078, DOI 10.1021/bi9804176; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Harding HP, 1997, MOL ENDOCRINOL, V11, P1737, DOI 10.1210/me.11.11.1737; Haubenwallner S, 1995, J LIPID RES, V36, P2541; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; Hodis HN, 1999, CIRCULATION, V99, P2852, DOI 10.1161/01.CIR.99.22.2852; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JANUZZI JL, 1992, GENOMICS, V14, P1081, DOI 10.1016/S0888-7543(05)80133-8; Jong MC, 1999, ARTERIOSCL THROM VAS, V19, P472, DOI 10.1161/01.ATV.19.3.472; KINNUNEN PKJ, 1976, FEBS LETT, V65, P354, DOI 10.1016/0014-5793(76)80145-7; Krauss RM, 1998, AM J CARDIOL, V81, p13B, DOI 10.1016/S0002-9149(98)00032-0; Lacorte JM, 1997, J BIOL CHEM, V272, P23578, DOI 10.1074/jbc.272.38.23578; Lacorte JM, 1997, FEBS LETT, V415, P217, DOI 10.1016/S0014-5793(97)01127-7; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; LE NA, 1988, J LIPID RES, V29, P669; LEFF T, 1989, J BIOL CHEM, V264, P16132; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; LINLEE YC, 1993, J LIPID RES, V34, P249; MAEDA N, 1994, J BIOL CHEM, V269, P23610; MALMENDIER CL, 1989, ATHEROSCLEROSIS, V77, P139, DOI 10.1016/0021-9150(89)90075-0; Mamontova A, 1998, CIRCULATION, V98, P2738, DOI 10.1161/01.CIR.98.24.2738; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; Matsui T, 1996, BIOCHEM BIOPH RES CO, V220, P405, DOI 10.1006/bbrc.1996.0418; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; OGAMI K, 1990, J BIOL CHEM, V265, P9808; QUARFORDT SH, 1982, J BIOL CHEM, V257, P4642; Raspe E, 1999, J LIPID RES, V40, P2099; Schaeren-Wiemers N, 1997, EUR J NEUROSCI, V9, P2687, DOI 10.1111/j.1460-9568.1997.tb01698.x; SCHONFELD G, 1979, METABOLISM, V28, P1001, DOI 10.1016/0026-0495(79)90004-0; Schoonjans K, 1999, FEBS LETT, V452, P160, DOI 10.1016/S0014-5793(99)00632-8; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; STOCKS J, 1979, LANCET, V2, P667; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; Talmud PJ, 1997, CURR OPIN LIPIDOL, V8, P154, DOI 10.1097/00041433-199706000-00005; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; Vu-Dac N, 1998, J CLIN INVEST, V102, P625, DOI 10.1172/JCI1581; VuDac N, 1997, J BIOL CHEM, V272, P22401, DOI 10.1074/jbc.272.36.22401; VUDAC N, 1994, J BIOL CHEM, V269, P31012; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WINDLER E, 1980, J BIOL CHEM, V255, P8303	69	106	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2865	2871		10.1074/jbc.M004982200	http://dx.doi.org/10.1074/jbc.M004982200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053433	hybrid			2022-12-27	WOS:000166784800078
J	Krasel, C; Dammeier, S; Winstel, R; Brockmann, J; Mischak, H; Lohse, MJ				Krasel, C; Dammeier, S; Winstel, R; Brockmann, J; Mischak, H; Lohse, MJ			Phosphorylation of GRK2 by protein kinase C abolishes its inhibition by calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; LOCALIZATION; SUBSTRATE; RHODOPSIN; ISOZYMES; BINDING; DOMAIN; CELLS; RAF-1	G-protein-coupled receptor kinases (GRKs) are important regulators of G-protein-coupled receptor function. Two members of this family L, GRK2 and GRK5 L, have been shown to be substrates for protein kinase C (PKC). Whereas PRC-mediated phosphorylation results in inhibition of GRK5, it increases the activity of GRK2 toward its substrates probably through increased affinity for receptor-containing membranes. We show here that this increase in activity may be caused by relieving a tonic inhibition of GRK2 by calmodulin. In vitro, GRK2 was preferentially phosphorylated by PKC isoforms alpha, gamma, and delta, Two-dimensional peptide mapping of PHC alpha -phosphorylated GRK2 showed a single site of phosphorylation, which was identified as serine 29 by HPLC-MS. A S29A mutant of GRK2 was not phosphorylated by PKC in vitro and showed no phorbol ester-stimulated phosphorylation when transfected into human embryonic kidney (HEK)293 cells. Serine 29 is located in the calmodulinbinding region of GRK2, and binding of calmodulin to GRK2 results in inhibition of kinase activity. This inhibition was almost completely abolished in vitro when GRK2 was phosphorylated by PHC. These data suggest that calmodulin may be an inhibitor of GRK2 whose effects can be abolished with PKC-mediated phosphorylation of GRK2.	Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany; GSF, Forschungzentrum Umwelt & Gesundheit, Inst Klin Molkularbiol & Tumorgenet, D-81377 Munich, Germany; Med Hsch Hannover, Nephrol Abt, D-30526 Hannover, Germany	University of Wurzburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Hannover Medical School	Krasel, C (corresponding author), Inst Pharmakol & Toxikol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Mischak, Harald/E-8685-2011; Krasel, Cornelius/AAH-7074-2019; Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510; Mischak, Harald/0000-0003-0323-0306; Krasel, Cornelius/0000-0001-8309-8696				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; CULLEN B, 1987, METHOD ENZYMOL, V152, P687; Gan XQ, 2000, J BIOL CHEM, V275, P8469, DOI 10.1074/jbc.275.12.8469; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIM CM, 1993, RECEPTOR, V3, P39; KRASEL C, 1999, N-S ARCH PHARMACOL, V359, pR19; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Levay K, 1998, BIOCHEMISTRY-US, V37, P13650, DOI 10.1021/bi980998z; Lohse MJ, 1996, KIDNEY INT, V49, P1047, DOI 10.1038/ki.1996.153; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Mischak H, 1996, MOL CELL BIOL, V16, P5409; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; SOHLEMANN P, 1993, FEBS LETT, V324, P59, DOI 10.1016/0014-5793(93)81532-5; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; WINSTEL R, 1997, N-S ARCH PHARMACOL S, V355, pR50; Yu QM, 1999, J NEUROCHEM, V73, P1222, DOI 10.1046/j.1471-4159.1999.0731222.x	28	79	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1911	1915		10.1074/jbc.M008773200	http://dx.doi.org/10.1074/jbc.M008773200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042191	hybrid			2022-12-27	WOS:000166528000037
J	Scott, PH; Cairns, CA; Sutcliffe, JE; Alzuherri, HM; McLees, A; Winter, AG; White, RJ				Scott, PH; Cairns, CA; Sutcliffe, JE; Alzuherri, HM; McLees, A; Winter, AG; White, RJ			Regulation of RNA polymerase III transcription during cell cycle entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING-PROTEIN; RETINOBLASTOMA SUSCEPTIBILITY GENE; CASEIN KINASE-II; SIGNALING PATHWAY; EXPRESSION; GROWTH; DIFFERENTIATION; PHOSPHORYLATION; TFIIIB; D1	Increased rates of RNA polymerase (pol) III transcription constitute a central feature of the mitogenic response, but little is known about the mechanism(s) responsible. We demonstrate that the retinoblastoma protein RE plays a major role in suppressing pol III transcription in growth-arrested fibroblasts. RE knockout cells are compromised in their ability to down-regulate pol III following serum withdrawal. RE binds and represses the pol III-specific transcription factor TFIIIB during G(0) and early G(1), but this interaction decreases as cells approach S phase. Full induction of pol III coincides with mid- to late G(1) phase, when RE becomes phosphorylated by cyclin D- and E-dependent kinases, TFIIIB only associates with the underphosphorylated form of RE, and overexpression of cyclins D and E stimulates pol III transcription in vivo. The RE-related protein p130 also contributes to the repression of TFIIIB in growth-arrested fibroblasts, These observations provide insight into the mechanisms responsible for controlling pol III transcription during the switch between growth and quiescence.	Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	White, RJ (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.			Scott, Pam/0000-0001-5548-4039				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alzuherri HM, 1998, J BIOL CHEM, V273, P17166, DOI 10.1074/jbc.273.27.17166; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BOYIAN JF, 1999, EXP CELL RES, V248, P110; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ghavidel A, 1997, GENE DEV, V11, P2780, DOI 10.1101/gad.11.21.2780; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hockman DJ, 1996, MOL CELL BIOL, V16, P892; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHNSON LF, 1974, CELL, V1, P95, DOI 10.1016/0092-8674(74)90068-3; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LANIA L, 1987, FEBS LETT, V219, P400, DOI 10.1016/0014-5793(87)80260-0; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MAUCK JC, 1974, CELL, V3, P171, DOI 10.1016/0092-8674(74)90122-6; Mayol X, 1996, ONCOGENE, V13, P237; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; Nylandsted J, 1998, FEBS LETT, V436, P41, DOI 10.1016/S0014-5793(98)01089-8; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Shen YH, 1996, MOL CELL BIOL, V16, P4163; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TERASIMA T, 1966, EXP CELL RES, V44, P669, DOI 10.1016/0014-4827(66)90482-4; TOWER J, 1988, MOL CELL BIOL, V8, P1001, DOI 10.1128/MCB.8.2.1001; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; ZARKOWSKA T, 1997, J BIOL CHEM, V272, P1238	65	55	62	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1005	1014		10.1074/jbc.M005417200	http://dx.doi.org/10.1074/jbc.M005417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11024049	hybrid			2022-12-27	WOS:000166430900021
J	Harmon, FG; Kowalczykowski, SC				Harmon, FG; Kowalczykowski, SC			Biochemical characterization of the DNA helicase activity of the Escherichia coli RecQ helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME; ATP HYDROLYSIS; RECBCD ENZYME; CONJUGATIONAL RECOMBINATION; UNWINDING ACTIVITY; DEPENDENT ATPASE; SSB PROTEIN; BINDING	We demonstrate that RecQ helicase from Escherichia coli is a catalytic helicase whose activity depends on the concentration of ATP, free magnesium ion, and single-stranded DNA-binding (SSB) protein. Helicase activity is cooperative in ATP concentration, with an apparent S-0.5 value for ATP of 200 muM and a Hill coefficient of 3.3 +/- 0.3, Therefore, RecQ helicase utilizes multiple, interacting ATP-binding sites to mediate double-stranded DNA (dsDNA) unwinding, implicating a multimer of at least three subunits as the active unwinding species. Unwinding activity is independent of dsDNA ends, indicating that RecQ helicase can unwind from both internal regions and ends of dsDNA. The K-M for dsDNA is 0.5-0.9 mum base pairs; the K-cat for DNA unwinding is 2.3-2.7 base pairs/s/monomer of RecQ helicase; and unexpectedly, helicase activity is optimal at a free magnesium ion concentration of 0.05 mM. Omitting Escherichia coli SSB protein lowers the rate and extent of dsDNA unwinding, suggesting that RecQ helicase associates with the single-stranded DNA (ssDNA) product. In agreement, the ssDNA-dependent ATPase activity is reduced in proportion to the SSB protein concentration; in its absence, ATPase activity saturates at six nucleotides/RecQ helicase monomer and yields a k(cat) of 24 s(-1). Thus, we conclude that SSB protein stimulates RecQ helicase-mediated unwinding by both trapping the separated ssDNA strands after unwinding and preventing the formation of non-productive enzyme-ssDNA complexes.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, Hutchison Hall, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41347] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1998, J MOL BIOL, V282, P275, DOI 10.1006/jmbi.1998.2013; ARAI K, 1981, J BIOL CHEM, V256, P5253; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Cantor C., 1980, BIOPHYSICAL CHEM 3, P859; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; Eggleston AK, 1996, NUCLEIC ACIDS RES, V24, P1179, DOI 10.1093/nar/24.7.1179; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Fry M, 1998, NAT GENET, V19, P308, DOI 10.1038/1188; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; GUERRERO R, 1984, J GEN MICROBIOL, V130, P2247; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; IRINO N, 1986, MOL GEN GENET, V205, P298, DOI 10.1007/BF00430442; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kusano K, 1999, GENETICS, V151, P1027; LANZOV V, 1991, BIOCHIMIE, V73, P305, DOI 10.1016/0300-9084(91)90217-O; LEBOWITZ J, 1985, BIOCH MECH STRAND IN; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lindor NM, 2000, AM J MED GENET, V90, P223, DOI 10.1002/(SICI)1096-8628(20000131)90:3<223::AID-AJMG7>3.0.CO;2-Z; LLOYD RG, 1995, GENETICS, V139, P1123; LLOYD RG, 1984, MOL GEN GENET, V197, P328, DOI 10.1007/BF00330981; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Marrione PE, 1996, BIOCHEMISTRY-US, V35, P11228, DOI 10.1021/bi960316c; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MENDONCA VM, 1995, J BACTERIOL, V177, P1326, DOI 10.1128/jb.177.5.1326-1335.1995; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; RUYECHAN WT, 1976, BIOCHEMISTRY-US, V15, P5057, DOI 10.1021/bi00668a017; Sambrook J., 1989, MOL CLONING, pA1; Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Wong I, 1996, BIOCHEMISTRY-US, V35, P5726, DOI 10.1021/bi952959i; WOOD ER, 1987, J BIOL CHEM, V262, P15269; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zaitsev EN, 1998, NUCLEIC ACIDS RES, V26, P650, DOI 10.1093/nar/26.2.650	58	102	121	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					232	243		10.1074/jbc.M006555200	http://dx.doi.org/10.1074/jbc.M006555200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024023	hybrid			2022-12-27	WOS:000166280700033
J	Pinnix, I; Musunuru, U; Tun, H; Sridharan, A; Golde, T; Eckman, C; Ziani-Cherif, C; Onstead, L; Sambamurti, K				Pinnix, I; Musunuru, U; Tun, H; Sridharan, A; Golde, T; Eckman, C; Ziani-Cherif, C; Onstead, L; Sambamurti, K			A novel gamma-secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; IN-VIVO; CARBOXYL-TERMINUS; ANCHORED PROTEINS; CLEAVAGE SITE; PRESENILIN-1; PEPTIDE; CELLS; GENERATION; PATHOGENESIS	Alzheimer's disease is characterized by the deposits of the 4-kDa amyloid beta peptide (A beta). The A beta protein precursor (APP) is cleaved by beta -secretase to, generate a C-terminal fragment, CTF beta, which in turn is cleaved by gamma -secretase to generate A beta. Alternative cleavage of the APP by alpha -secretase at A beta 16/17 generates the C-terminal fragment, CTF alpha. In addition to AP, endoproteolytic cleavage of CTF alpha and CTF beta by gamma -secretase should yield a C-terminal fragment of 57-59 residues (CTF gamma), However, CTF gamma has not yet been reported in either brain or cell lysates, presumably due to its instability in vivo. We detected the in vitro generation of A beta as well as an similar to6-kDa fragment from guinea pig brain membranes. We have provided biochemical and pharmacological evidence that this 6-kDa fragment is the elusive CTF gamma, and we describe an in vitro assay for gamma -secretase activity. The fragment migrates with a synthetic peptide corresponding to the 57-residue CTF gamma fragment. Three cornpounds previously identified as gamma -secretase inhibitors, pepstatin-Al MG132, and a substrate-based dlifluoroketone (t-butoxycarbonyl-Val-Ile-(S)-4-amino-3-difluoropentanoyl-Val-Ile-OMe), reduced the yield of CTF gamma, providing additional evidence that the fragment arises from gamma -secretase cleavage. Consistent with reports that presenilins are the elusive gamma -secretases, subcellular fractionation studies showed that presenilin-1, CTF alpha, and CTF beta are enriched in the CTF gamma -generating fractions. The in vitro gamma -secretase assay described here will be useful for the detailed characterization of the enzyme and to screen for gamma -secretase inhibitors.	Mayo Clin, Jacksonville, FL 32224 USA	Mayo Clinic	Sambamurti, K (corresponding author), Mayo Clin, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	samba@mayo.edu	ziani-cherif, chewki/P-1556-2016; Sambamurti, Kumar/A-1620-2012	ziani-cherif, chewki/0000-0001-5759-8275; Sambamurti, Kumar/0000-0001-9507-9214				ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BARRET A, 1998, HDB PROTEOLYTIC ENZY, P405; Berger-Sweeney J, 1999, MOL BRAIN RES, V66, P150, DOI 10.1016/S0169-328X(99)00014-5; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BROWN D, 1994, BRAZ J MED BIOL RES, V27, P309; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHECLER F, 1995, J NEUROCHEM, V65, P1431; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; DICE JF, 1992, ANN NY ACAD SCI, V674, P58, DOI 10.1111/j.1749-6632.1992.tb27477.x; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; GANDY S, 1994, NEUROBIOL AGING, V15, P253, DOI 10.1016/0197-4580(94)90125-2; GERVAIS FG, 1999, NEUROREPORT, V10, P1035; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Koike H, 1999, J BIOCHEM-TOKYO, V126, P235, DOI 10.1093/oxfordjournals.jbchem.a022428; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Parkin ET, 1999, BIOCHEM J, V344, P23, DOI 10.1042/0264-6021:3440023; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2000, P NATL ACAD SCI USA, V97, P5690, DOI 10.1073/pnas.97.11.5690; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tjernberg LO, 1997, J BIOL CHEM, V272, P1870, DOI 10.1074/jbc.272.3.1870; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verdile G, 2000, J BIOL CHEM, V275, P20794, DOI 10.1074/jbc.C000208200; Waragai M, 1997, BIOCHEM BIOPH RES CO, V239, P480, DOI 10.1006/bbrc.1997.7488; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Younkin SG, 2000, J NEUROCHEM, V74, pS42; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	67	127	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					481	487		10.1074/jbc.M005968200	http://dx.doi.org/10.1074/jbc.M005968200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035007	hybrid			2022-12-27	WOS:000166280700065
J	Pomorski, T; Meyer, TF; Naumann, M				Pomorski, T; Meyer, TF; Naumann, M			Helicobacter pylori-induced prostaglandin E-2 synthesis involves activation of cytosolic phospholipase A(2) in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; PROTEIN-KINASE-C; HUMAN NEUTROPHILS; BINDING PROTEIN; HUMAN PLATELETS; ALPHA-SUBUNIT; HELA-CELLS; KAPPA-B; INHIBITION; PHOSPHORYLATION	Helicobacter pylori initiates an inflammatory response and gastric diseases, which are more common in patients infected with H. pylori strains carrying the pathogenicity island, by colonizing the gastric epithelium, In the present study we investigated the mechanism of prostaglandin E-2 (PGE(2)) synthesis in response to H, pylori infection. We demonstrate that H. pylori induces the synthesis of PGE(2) via release of arachidonic acid predominately from phosphatidylinositol. In contrast to H. pylori wild type, an isogenic H. pylori strain with a mutation in the pathogenicity island exerts only weak arachidonic acid and PGE(2) synthesis. The H. pylori-induced arachidonic acid release was abolished by phospholipase A(2) (PLA(2)) inhibitors and by pertussis toxin (affects the activity of G alpha (i)/G alpha (o)), The role of phospholipase C, diacylglycerol lipase, or phospholipase D was excluded by using specific inhibitors. An inhibitor of the stress-activated p38 kinase (SB202190), but neither inhibitors of protein kinase C nor an inhibitor of the extracellular-regulated kinase pathway (PD98059), decreased the H. pylori-induced arachidonic acid release. H. pylori-induced phosphorylation of p38 kinase and cytosolic PLA(2) was blocked by SB202190, These results indicate that H. pylori induces the release of PGE(2) from epithelial cells by cytosolic PLA(2) activation via G alpha (i)/G alpha (o) proteins and the p38 kinase pathway.	Max Planck Inst Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany	Max Planck Society	Naumann, M (corresponding author), Max Planck Inst Infekt Biol, Mol Biol Abt, Schumannstr 21-22, D-10117 Berlin, Germany.		Pomorski, Thomas Günther/G-4804-2014; Meyer, Thomas F. F/J-2485-2013; Naumann, Michael/B-5285-2011	Pomorski, Thomas Günther/0000-0002-4889-0829; Meyer, Thomas F. F/0000-0002-6120-8679; Naumann, Michael/0000-0002-8060-2313				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; BALSINDE J, 1991, J BIOL CHEM, V266, P15638; BLASER MJ, 1987, GASTROENTEROLOGY, V93, P371, DOI 10.1016/0016-5085(87)91028-6; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodger K, 1998, BRIT MED BULL, V54, P139; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; Borsch-Haubold AG, 1999, EUR J BIOCHEM, V265, P195, DOI 10.1046/j.1432-1327.1999.00722.x; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; Burke JR, 1997, BBA-PROTEIN STRUCT M, V1341, P223, DOI 10.1016/S0167-4838(97)00085-X; Buschbeck M, 1999, BIOCHEM J, V344, P359, DOI 10.1042/0264-6021:3440359; Chan EC, 1999, INT J MOL MED, V3, P421; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBERHART CE, 1995, GASTROENTEROLOGY, V109, P285, DOI 10.1016/0016-5085(95)90296-1; Eckmann L, 1997, J CLIN INVEST, V100, P296, DOI 10.1172/JCI119535; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; HII CST, 1989, FEBS LETT, V257, P35, DOI 10.1016/0014-5793(89)81779-X; HONG SL, 1981, J BIOL CHEM, V256, P5215; HUANG CF, 1990, J BIOL CHEM, V265, P14858; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Keates S, 1999, J IMMUNOL, V163, P5552; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; KOBAYASHI K., 1995, J CLIN GASTROENTE S1, V21, P12; LANGTON SR, 1992, J CLIN PATHOL, V45, P221, DOI 10.1136/jcp.45.3.221; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lin YL, 1998, FEBS LETT, V423, P249, DOI 10.1016/S0014-5793(98)00087-8; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; MURRAYWHELAN R, 1995, EUR J BIOCHEM, V230, P164, DOI 10.1111/j.1432-1033.1995.tb20547.x; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Nishio E, 1996, BIOCHEM BIOPH RES CO, V219, P277, DOI 10.1006/bbrc.1996.0223; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; OTTLECZ A, 1993, DIGEST DIS SCI, V38, P2071, DOI 10.1007/BF01297087; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PUCCIARELLI MG, 1995, FEMS MICROBIOL LETT, V129, P293, DOI 10.1016/0378-1097(95)00174-4; Romano M, 1998, J BIOL CHEM, V273, P28560, DOI 10.1074/jbc.273.44.28560; SAKURAI J, 1994, INFECT IMMUN, V62, P717, DOI 10.1128/IAI.62.2.717-721.1994; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Schulz A, 1999, MOL ENDOCRINOL, V13, P181, DOI 10.1210/me.13.2.181; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Syrbu SI, 1999, J IMMUNOL, V162, P2334; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; VISHWANATH BS, 1988, INFLAMMATION, V12, P549, DOI 10.1007/BF00914317; Wakabayashi H, 1998, J GASTROEN HEPATOL, V13, P566, DOI 10.1111/j.1440-1746.1998.tb00691.x; WALLACE JL, 1995, ALIMENT PHARM THERAP, V9, P227; WEITKAMP JH, 1993, ZBL BAKT-INT J MED M, V280, P11; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; WINITZ S, 1994, J BIOL CHEM, V269, P1889; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	62	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					804	810		10.1074/jbc.M003819200	http://dx.doi.org/10.1074/jbc.M003819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11034994	hybrid, Green Published			2022-12-27	WOS:000166280700108
J	Wei, CC; Wang, ZQ; Wang, Q; Meade, AL; Hemann, C; Hille, R; Stuehr, DJ				Wei, CC; Wang, ZQ; Wang, Q; Meade, AL; Hemann, C; Hille, R; Stuehr, DJ			Rapid kinetic studies link tetrahydrobiopterin radical formation to heme-dioxy reduction and arginine hydroxylation in inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE GENERATION; ELECTRON-TRANSFER; LOW-TEMPERATURE; COMPLEX; INTERMEDIATE; DOMAIN; PTERIN; INHIBITION; CATALYSIS; BINDING	To understand how heme and (6R)-5,6,7,8-tetrahydro-L-biopterin (H4B) participate in nitric-oxidle synthesis, we followed ferrous-dioxy heme ((FeO2)-O-II,) formation and disappearance, H4B radical formation, and Arg hydroxylation during a single catalytic turnover by the inducible nitric-oxide synthase oxygenase domain (iNOSoxy), In all cases, prereduced (ferrous) enzyme was rapidly mixed with an O-2-containing buffer to start the reaction, A ferrous-dioxy intermediate formed quickly (53 s(-1)) and then decayed with concurrent buildup of ferric iNOSoxy, The buildup of the ferrous-dioxy intermediate preceded both H4B radical formation and Arg hydroxylation, However, the rate of ferrous-dioxy decay (12 s(-1)) was equivalent to the rate of H4B radical formation and s(-1) ) and the rate of Arg hydroxylation (9 s(-1)). Practically all bound H4B was oxidized to a radical during the reaction and was associated with hydroxylation of 0.6 mol of Arg/mol of heme, In dihydrobiopterin-containing iN-OSoxy, ferrous-dioxy decay was much slower and was not associated with Arg hydroxylation. These results establish kinetic and quantitative links among ferrous-dioxy disappearance, H4B oxidation, and Arg hydroxylation and suggest a mechanism whereby H4B transfers an electron to the ferrous-dioxy intermediate to enable the formation of a heme-based oxidant that rapidly hydroxylates Arg.	Cleveland Clin Fdn, Dept Immunol NB3, Lerner Res Inst, Cleveland, OH 44195 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	Cleveland Clinic Foundation; University System of Ohio; Ohio State University	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Dept Immunol NB3, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org		Hemann, Craig/0000-0002-7380-4072; Wei, Chin-Chuan/0000-0001-6453-9409	NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM58481, GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491, R01GM058481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; Hemmens B, 1998, METH MOL B, V100, P1; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Iwanaga T, 1999, BIOCHEMISTRY-US, V38, P16629, DOI 10.1021/bi991277i; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Sagami I, 2000, J BIOL CHEM, V275, P26150, DOI 10.1074/jbc.M000534200; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736	26	129	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					315	319		10.1074/jbc.M008441200	http://dx.doi.org/10.1074/jbc.M008441200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11020389	hybrid			2022-12-27	WOS:000166280700043
J	Dowell, P; Flexner, C; Kwiterovich, PO; Lanes, MD				Dowell, P; Flexner, C; Kwiterovich, PO; Lanes, MD			Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; IMMUNODEFICIENCY-VIRUS INFECTION; RESPONSIVE GLUCOSE TRANSPORTER; FATTY-ACID SYNTHETASE; 3T3-L1 PREADIPOCYTES; GENE-EXPRESSION; CELL-DEATH; PPAR-GAMMA; TRANSCRIPTION; APOPTOSIS	Many human immunodeficiency virus (HIV)-infected patients taking combination antiretroviral therapy that includes HIV protease inhibitors experience atrophy of peripheral subcutaneous adipose tissue. We investigated the effects of HIV protease inhibitors on adipogenesis and adipocyte survival using the 3T3-L1 preadipocyte cell line. Several HIV protease inhibitors were found either to inhibit preadipocyte differentiation or to promote adipocyte cell death. One protease inhibitor, nelfinavir, elicited both of these effects strongly. When induced to differentiate in the presence of nelfinavir, 3T3-L1 preadipocytes failed to accumulate cytoplasmic triacylglycerol and failed to express normal levels of the adipogenic transcription factors CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. The level of the proteolytically processed, active 68-kDa form of sterol regulatory element-binding protein-1, a transcription factor known to promote lipogenic gene expression, also was reduced markedly in nelfinavir-treated cells, whereas the level of the 125-kDa precursor form of this protein was unaffected. The inhibitory effect of nelfinavir occurred subsequent to critical early events in preadipocyte differentiation, expression of CCAAT/enhancer-binding protein beta and completion of the mitotic clonal expansion phase, because these events were unaffected by nelfinavir treatment. In addition, nelfinavir treatment of fully differentiated 3T3-L1 adipocytes resulted in DNA strand cleavage and severe loss of cell viability. In contrast, cell proliferation and viability of preadipocytes were unaffected by nelfinavir treatment. Thus, molecular or cellular changes that occur during acquisition of the adipocyte phenotype promote susceptibility to nelfinavir-induced cell death. When considered together, these results suggest that nelfinavir may promote adipose tissue atrophy by compromising adipocyte viability and preventing replacement of lost adipocytes by inhibiting preadipocyte differentiation.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Dowell, P (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 509 WBSB,725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009894] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32DK09894] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; Beach JW, 1998, CLIN THER, V20, P2; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carr A, 2000, CLIN INFECT DIS, V30, pS135, DOI 10.1086/313854; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008; Dong Z, 1997, AM J PATHOL, V151, P1205; Dube MP, 1997, LANCET, V350, P713, DOI 10.1016/S0140-6736(05)63513-1; Eastone JA, 1997, ANN INTERN MED, V127, P948, DOI 10.7326/0003-4819-127-10-199711150-00017; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Gervasoni C, 1999, AIDS, V13, P465, DOI 10.1097/00002030-199903110-00004; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hengel RL, 1997, LANCET, V350, P1596, DOI 10.1016/S0140-6736(05)64011-1; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotler DP, 1999, J ACQ IMMUN DEF SYND, V20, P228, DOI 10.1097/00042560-199903010-00003; Lenhard JM, 2000, ANTIVIR RES, V47, P121, DOI 10.1016/S0166-3542(00)00102-9; Lenhard JM, 2000, BIOCHEM PHARMACOL, V59, P1063, DOI 10.1016/S0006-2952(00)00246-X; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Loftus TM, 1998, P NATL ACAD SCI USA, V95, P14168, DOI 10.1073/pnas.95.24.14168; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Madge S, 1999, AIDS, V13, P735, DOI 10.1097/00002030-199904160-00020; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Periard D, 1999, CIRCULATION, V100, P700, DOI 10.1161/01.CIR.100.7.700; Rosen ED, 2000, GENE DEV, V14, P1293; Roth VR, 1998, CLIN INFECT DIS, V27, P65, DOI 10.1086/514639; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Staiger H, 1998, EUR J CELL BIOL, V77, P220, DOI 10.1016/S0171-9335(98)80110-6; Stocker DN, 1998, LANCET, V352, P320, DOI 10.1016/S0140-6736(05)60295-4; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; WALKER PR, 1994, EXP CELL RES, V213, P100, DOI 10.1006/excr.1994.1178; Walli R, 1998, AIDS, V12, pF167, DOI 10.1097/00002030-199815000-00001; Wentworth JM, 2000, J ENDOCRINOL, V164, pR7, DOI 10.1677/joe.0.164R007; Yanovski JA, 1999, J CLIN ENDOCR METAB, V84, P1925, DOI 10.1210/jc.84.6.1925; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang B, 1999, J CLIN ENDOCR METAB, V84, P4274, DOI 10.1210/jc.84.11.4274; ZHU Y, 1995, P NATL ACAD SCI USA, V15, P7921	59	187	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41325	41332		10.1074/jbc.M006474200	http://dx.doi.org/10.1074/jbc.M006474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018036	hybrid			2022-12-27	WOS:000166114600088
J	Murat, A; Pellieux, C; Brunner, HR; Pedrazzini, T				Murat, A; Pellieux, C; Brunner, HR; Pedrazzini, T			Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ANGIOTENSIN-II; T-LYMPHOCYTES; MOLECULAR MECHANISMS; CYCLOSPORINE; MICE; MYOCYTES; JNK; TRANSCRIPTION; STIMULATION	Chronic stimulation of the renin-angiotensin system induces an elevation of blood pressure and the development of cardiac hypertrophy via the actions of its effector, angiotensin II. In cardiomyocytes, mitogen-activated protein kinases as well as protein kinase C isoforms have been shown to be important in the transduction of trophic signals. The Ca2+/calmodulin-dependent phosphatase calcineurin has also been suggested to play a role in cardiac growth. In the present report, we investigate possible cross-talks between calcineurin, protein kinase C, and mitogen-activated protein kinase pathways in controlling angiotensin II-induced hypertrophy. Angiotensin II-stimulated cardiomyocytes and mice with angiotensin II-dependent renovascular hypertension were treated with the calcineurin inhibitor cyclosporin A. Calcineurin, protein kinase C, and mitogen-activated protein kinase activations were determined. We show that cyclosporin A blocks angiotensin II-induced mitogen-activated protein kinase activation in cultured primary cardiomyocytes and in the heart of hypertensive mice. Cyclosporin A also inhibits specific protein kinase C isoforms. In vivo, cyclosporin A prevents the development of cardiac hypertrophy, and this effect appears to be independent of hemodynamic changes. These data suggest cross-talks between the calcineurin pathway, the protein kinase C, and the mitogen-activated protein kinase signaling cascades in transducing angiotensin II-mediated stimuli in cardiomyocytes and could provide the basis for an integrated model of cardiac hypertrophy.	Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland	University of Lausanne	Pedrazzini, T (corresponding author), Univ Lausanne, Sch Med, Div Hypertens, CH-1011 Lausanne, Switzerland.							ALEXANDER DR, 1990, BIOCHEM J, V268, P303, DOI 10.1042/bj2680303; Avraham A, 1998, EUR J IMMUNOL, V28, P2320, DOI 10.1002/(SICI)1521-4141(199808)28:08<2320::AID-IMMU2320>3.0.CO;2-K; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; DAHLOF B, 1995, J HUM HYPERTENS S5, V9, P37; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Ding B, 1999, CIRC RES, V84, P729, DOI 10.1161/01.RES.84.6.729; Dostal DE, 1997, J MOL CELL CARDIOL, V29, P2893, DOI 10.1006/jmcc.1997.0524; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Kanno T, 1996, J IMMUNOL, V157, P5277; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; Lee DBN, 1997, KIDNEY INT, V52, P248, DOI 10.1038/ki.1997.328; Luo ZY, 1998, NAT MED, V4, P1092, DOI 10.1038/2578; Meguro T, 1999, CIRC RES, V84, P735, DOI 10.1161/01.RES.84.6.735; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MULLER JG, 1998, SCIENCE, V282, P1007; Pellieux C, 2000, P NATL ACAD SCI USA, V97, P1595, DOI 10.1073/pnas.030533197; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Sealey JE, 1990, HYPERTENSION PATHOPH, P1287; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; THIEL G, 1986, CLIN NEPHROL S1, V25, P199; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wiesel P, 1997, HYPERTENSION, V29, P1025, DOI 10.1161/01.HYP.29.4.1025; Wiesner RJ, 1997, CIRCULATION, V95, P1253; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722	33	55	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40867	40873		10.1074/jbc.M008071200	http://dx.doi.org/10.1074/jbc.M008071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016940	hybrid			2022-12-27	WOS:000166114600028
J	Bjorbaek, C; Lavery, HJ; Bates, SH; Olson, RK; Davis, SM; Flier, JS; Myers, MG				Bjorbaek, C; Lavery, HJ; Bates, SH; Olson, RK; Davis, SM; Flier, JS; Myers, MG			SOCS3 mediates feedback inhibition of the leptin receptor via Tyr(985)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JANUS TYROSINE KINASE; SIGNAL-TRANSDUCTION; OB-R; CYTOKINE RECEPTORS; SH2 DOMAIN; ACTIVATION LOOP; BODY-WEIGHT; BOX MOTIF; PROTEINS; RESISTANCE	During leptin signaling, each of the phosphorylated tyrosine residues on the long form of the leptin receptor (LRb) mediates distinct signals. Phosphorylated Tyr(1138) binds STAT3 to mediate its tyrosine phosphorylation and transcriptional activation, while phosphorylated Tyr(985) binds the tyrosine phosphatase SHP-2 and reportedly mediates both activation of ERK kinases and inhibition of LRb-mediated STAT3 activation. We show here that although mutation of Tyr985 does not alter STAT3 signaling by erythropoietin receptor-LRb (ELR) chimeras in transfected 293 cells at short times of stimulation, this mutation enhances STAT3 signaling at longer times of stimulation (>6 h). These data suggest that Tyr(985) may mediate feedback inhibition of LRb signaling by an LRb-induced LRb inhibitor, such as SOCS3. Indeed, SOCS3 binds specifically to phosphorylated Tyr(985) Of LRb, and SOCS3 fails to inhibit transcription by ELR following mutation of Tyr985, suggesting that SOCS3 inhibits LRb signaling by binding to phosphorylated Tyr(985). Additionally, overexpression of SOCS3, but not SHP-2, impairs ELR signaling, and the overexpression of SHP-2 blunts SOCS3-mediated inhibition of ELR signaling. Thus, our data suggest that in addition to mediating SHP-2 binding and ERK activation during acute stimulation, Tyr985 Of LRb mediates feedback inhibition of LRb signaling by binding to LRb-induced SOCS3.	Joslin Diabet Ctr, Div Res, Sect Obes, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Myers, MG (corresponding author), Joslin Diabet Ctr, Div Res, Sect Obes, 1 Joslin Pl, Boston, MA 02215 USA.	Martin.myers@joslin.harvard.edu	Bjorbaek, Christian/S-4727-2019; Flier, jeffrey/AAG-6223-2019		NIDDK NIH HHS [DKR0156731, DKR3728082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082, R01DK056731] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1999, ENDOCRINOLOGY, V140, P2035, DOI 10.1210/en.140.5.2035; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Boden G, 1996, DIABETES CARE, V19, P394, DOI 10.2337/diacare.19.4.394; Bornstein SR, 1997, DIABETES, V46, P1235, DOI 10.2337/diabetes.46.7.1235; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Couce ME, 1997, NEUROENDOCRINOLOGY, V66, P145, DOI 10.1159/000127232; De Sepulveda P, 1999, EMBO J, V18, P904; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hinney A, 1997, INT J OBESITY, V21, P1190, DOI 10.1038/sj.ijo.0800534; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kim H, 1999, MOL CELL BIOL, V19, P5326; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Koistinen HA, 1998, EUR J CLIN INVEST, V28, P894; Krebs DL, 2000, J CELL SCI, V113, P2813; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Morton NM, 1999, J MOL ENDOCRINOL, V22, P173, DOI 10.1677/jme.0.0220173; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Novak U, 1999, GROWTH FACTORS, V16, P305, DOI 10.3109/08977199909069148; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Zamorano PL, 1997, NEUROENDOCRINOLOGY, V65, P223, DOI 10.1159/000127276; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	65	407	424	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40649	40657		10.1074/jbc.M007577200	http://dx.doi.org/10.1074/jbc.M007577200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11018044	hybrid			2022-12-27	WOS:000166039500114
J	Ball, SG; Baldock, C; Kielty, CM; Shuttleworth, CA				Ball, SG; Baldock, C; Kielty, CM; Shuttleworth, CA			The role of the C1 and C2 A-domains in type VI collagen assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; ALPHA-2(VI) CHAINS; CRYSTAL-STRUCTURE; GLOBULAR DOMAINS; PROTEIN VARIANTS; MESSENGER-RNA; PROCOLLAGEN; EXPRESSION; SEQUENCE; ALPHA-1(VI)	Constructs of each of the three chains of type VI collagen were generated and examined in an in vitro transcription/translation assay supplemented with semipermeabilized cells. Each of the constructs when used in the in vitro system was shown to be glycosylated and to undergo intracellular assembly, the extent of which was determined by the nature of the C-terminal globular domains. All three chains containing the C1 domain formed monomers; however, the C2 domain was required for dimer and tetramer formation. In the case of the full-length alpha2(VI) chain, monomers, dimers, and tetramers formed in a time-dependent manner. Although the splice variant alpha2(VI)C2a could form monomers, it was unable-to form dimers and tetramers. Similar results to the alpha2(VI) chain were found for the full-length alpha1(VI) chain, although assembly was at a slower rate. In the case: of the alpha3(VI) chain containing both C1 and C2 domains only monomers were observed. Addition of the C3, C4, and C5 did not change this pattern. Homology modeling suggested that a 10-amino acid insertion in the C2 domain of the alpha3(VI) chain may interfere with dimer formation. A near full-length construct of the alpha3(VI) chain only formed monomers but was shown to facilitate tetramer formation in cotranslation experiments.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Shuttleworth, CA (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford,Oxford Rd, Manchester M13 9PT, Lancs, England.	ashuttle@fs1.scg.man.ac.uk		Baldock, Clair/0000-0003-3497-1959				AYAD S, 1989, BIOCHEM J, V262, P753, DOI 10.1042/bj2620753; BIENKOWSKI RS, 1995, P SOC EXP BIOL MED, V209, P118; BONALDO P, 1990, MATRIX, V10, P139, DOI 10.1016/S0934-8832(11)80162-9; Bulleid NJ, 1996, SEMIN CELL DEV BIOL, V7, P667, DOI 10.1006/scdb.1996.0081; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; CARTER WG, 1984, J CELL BIOL, V99, P105, DOI 10.1083/jcb.99.1.105; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; COLOMBATTI A, 1992, EUR J BIOCHEM, V209, P785, DOI 10.1111/j.1432-1033.1992.tb17349.x; COLOMBATTI A, 1995, J BIOL CHEM, V270, P13105, DOI 10.1074/jbc.270.22.13105; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CRAWFORD SW, 1985, BIOCHEM J, V227, P491, DOI 10.1042/bj2270491; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Illidge C, 1998, J BIOL CHEM, V273, P22091, DOI 10.1074/jbc.273.34.22091; JANDER R, 1983, EUR J BIOCHEM, V133, P39, DOI 10.1111/j.1432-1033.1983.tb07427.x; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; KUO WW, 1979, J BIOL CHEM, V254, P2234; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamande SR, 1998, J BIOL CHEM, V273, P7423, DOI 10.1074/jbc.273.13.7423; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Rost B, 1996, METHOD ENZYMOL, V266, P525; SAITTA B, 1990, J BIOL CHEM, V265, P6473; STOKES DG, 1991, J BIOL CHEM, V266, P8626; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; TRUEB B, 1987, EUR J BIOCHEM, V166, P699, DOI 10.1111/j.1432-1033.1987.tb13568.x; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; ZANUSSI S, 1992, J BIOL CHEM, V267, P24082	32	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7422	7430		10.1074/jbc.M002816200	http://dx.doi.org/10.1074/jbc.M002816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11036066	hybrid			2022-12-27	WOS:000167442900078
J	Fridman, JS; Parsels, J; Rehemtulla, A; Maybaum, J				Fridman, JS; Parsels, J; Rehemtulla, A; Maybaum, J			Cytochrome c depletion upon expression of Bcl-XS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED-PROXIMITY MODEL; FAS-MEDIATED APOPTOSIS; PROGRAMMED CELL-DEATH; ISOLATED-MITOCHONDRIA; CASPASE ACTIVATION; BAX; BCL-X(L); PROTEINS; RELEASE; CHEMILUMINESCENCE	We have shown previously that Bcl-XS causes acute cell death in 3T3 cells without activating caspases (Fridman, J. S,, Benedict, M. k, and Maybaum, J. (1999) Cancer Res. 59, 5999-6004). In this study, we determined that the explanation for lack of caspase activation is the cellular depletion of cytochrome c. Electron microscopy revealed gross structural changes in the mitochondria of Bcl-XS-expressing cells; however, cytochrome c was not detected in cytosolic fractions from these cells. Surprisingly, it was determined that cellular cytochrome c levels decreased as Bcl-XS expression levels increased. Experiments performed to eliminate other possible explanations for the lack of caspase activation showed that these 3T3 cells have a functional cytoplasmic apoptosome, a complex of proteins that form a functional trigger capable of activating the proximal caspase in an apoptotic pathway Chinnaiyan, k M. (1999) Neoplasia 1, 5-15, as cytosolic extracts from these cells were capable of cleaving pro-caspase-9. These cells were also able to release cytochrome c from their mitochondria after appropriate stimulation, other than Bcl-XS expression (i.e. withdrawal from serum for 24 h), and initiate a cell death that is inhibited by a dominant negative caspase-9. We conclude that lack of caspase activation is due to a Bcl-XS-induced depletion of active cytochrome c, a phenomenon that represents an alternative cell death effector pathway and/or a novel mechanism for regulating caspase activation.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Maybaum, J (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.	maybaum@umich.edu			NATIONAL CANCER INSTITUTE [R01CA056663] Funding Source: NIH RePORTER; NCI NIH HHS [CA56663] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; BOYD JM, 1995, ONCOGENE, V11, P1921; Chinnaiyan Arul M., 1999, Neoplasia (New York), V1, P5; DORWARD DW, 1993, ANAL BIOCHEM, V209, P219, DOI 10.1006/abio.1993.1110; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fridman JS, 1999, CANCER RES, V59, P5999; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Munn EA, 1974, STRUCTURE MITOCHONDR; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SeminoMora C, 1997, LAB INVEST, V76, P487; SHEWACH DS, 1994, CANCER RES, V54, P3218; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	30	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4205	4210		10.1074/jbc.M008171200	http://dx.doi.org/10.1074/jbc.M008171200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11044452	hybrid			2022-12-27	WOS:000166921200064
J	Tchougounova, E; Forsberg, F; Angelborg, G; Kjellen, L; Pejler, G				Tchougounova, E; Forsberg, F; Angelborg, G; Kjellen, L; Pejler, G			Altered processing of fibronectin in mice lacking heparin - A role for heparin-dependent mast cell chymase in fibronectin degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULE PROTEASES; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; SERINE PROTEASES; CATHEPSIN-G; IN-VIVO; MOUSE; RAT; PROTEOGLYCAN	We have previously generated a mouse strain with a defect in its heparin biosynthesis by targeting the gene for N-deacetylase/N-sulfotransferase-2 (NDST-2). The NDST-2(-/-) mice show reduced levels of various mast cell mediators such as histamine and various heparin-binding mast cell proteases, including chymases, tryptases, and carboxypeptidase A In this work we have addressed the possible functional consequences of the lack of sulfated heparin. Peritoneal cells were harvested from normal and NDST-2(-/-) mice. After culturing the cells, conditioned media were collected and were subjected to SDS-polyacrylamide gel electrophoresis under reducing conditions. Several differences in the protein patterns were observed, including the presence of large amounts of a similar to 250-kDa protein in medium from NDST-2(-/-) mice that was absent in normal controls. Peptide microsequencing revealed identity of this protein with fibronectin. Western blot analysis showed the presence of fibronectin degradation products in cell cultures from normal mice, which were absent in cultures from NDST-2(-/-) animals. Further experiments showed that the degradation of fibronectin observed in cell cultures hom NDST-2(+/+) mice was catalyzed by mast cell chymase in a strongly heparin-dependent manner. This report thus indicates a biological function for chymase/heparin proteoglycan complexes in fibronectin turnover.	Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, S-75123 Uppsala, Sweden; Uppsala Univ, Dept Med Biochem & Microbiol, S-75124 Uppsala, Sweden	Swedish University of Agricultural Sciences; Uppsala University	Pejler, G (corresponding author), Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, Box 575, S-75123 Uppsala, Sweden.		Kjellen, Lena/F-1362-2011					ALITALO K, 1980, J EXP MED, V151, P602, DOI 10.1084/jem.151.3.602; BANOVAC K, 1993, P SOC EXP BIOL MED, V203, P221; Compton SJ, 1999, INT ARCH ALLERGY IMM, V118, P204, DOI 10.1159/000024068; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fang KC, 1997, J BIOL CHEM, V272, P25628, DOI 10.1074/jbc.272.41.25628; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GERVASONI JE, 1986, J IMMUNOL, V136, P285; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; He SH, 1997, J IMMUNOL, V159, P6216; He SH, 1998, BRIT J PHARMACOL, V125, P1491, DOI 10.1038/sj.bjp.0702223; He SH, 1998, EUR J PHARMACOL, V352, P91, DOI 10.1016/S0014-2999(98)00343-4; Homandberg Gene A., 1999, Frontiers in Bioscience, V4, pd713, DOI 10.2741/Homandberg; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Hynes RO, 1990, FIBRONECTINS SPRINGE; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; Kofford MW, 1997, J BIOL CHEM, V272, P7127, DOI 10.1074/jbc.272.11.7127; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Lindstedt L, 1996, J CLIN INVEST, V97, P2174, DOI 10.1172/JCI118658; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; MAIER M, 1983, J IMMUNOL, V130, P2352; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; Molinari JF, 1995, J APPL PHYSIOL, V79, P1966, DOI 10.1152/jappl.1995.79.6.1966; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nakano A, 1997, J IMMUNOL, V159, P1987; PEJIER G, 1994, J BIOL CHEM, V269, P14451; Pejler G, 1999, BIOCHEMISTRY-US, V38, P12187, DOI 10.1021/bi991046b; PEJLER G, 1995, EUR J BIOCHEM, V233, P192, DOI 10.1111/j.1432-1033.1995.192_1.x; PEJLER G, 1993, J BIOL CHEM, V268, P11817; PEJLER G, 1994, BIOCHEM J, V299, P507, DOI 10.1042/bj2990507; Pejler G, 1996, FEBS LETT, V383, P170, DOI 10.1016/0014-5793(96)00239-6; REILLY CF, 1985, BIOCHEM BIOPH RES CO, V127, P443, DOI 10.1016/S0006-291X(85)80180-7; REILLY CF, 1982, J BIOL CHEM, V257, P8619; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; STERK AR, 1982, J IMMUNOL, V128, P838; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; SUZUKI K, 1995, BIOCHEM J, V305, P301, DOI 10.1042/bj3050301; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; VARTIO T, 1981, J BIOL CHEM, V256, P471; WACHTFOGEL YT, 1988, J CLIN INVEST, V81, P1310, DOI 10.1172/JCI113456; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; XIE DL, 1993, BLOOD, V81, P186	52	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3772	3777		10.1074/jbc.M008434200	http://dx.doi.org/10.1074/jbc.M008434200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11035040	hybrid			2022-12-27	WOS:000166921200008
J	Koh, SS; Chen, DG; Lee, YH; Stallcup, MR				Koh, SS; Chen, DG; Lee, YH; Stallcup, MR			Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE N-METHYLTRANSFERASE; STEROID-HORMONE RECEPTORS; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; ANDROGEN RECEPTOR; TERMINAL DOMAIN; BINDING; MULTIPLE; TRANSACTIVATION	Nuclear receptors (NRs) activate gene transcription by binding to specific enhancer elements and recruiting coactivators of the p160 family to promoters of target genes. The p160 coactivators in turn enhance transcription by recruiting secondary coactivators, including histone acetyltransferases such as CREB-binding protein (CBP) and p300/CBP-associated factor (p/CAF), as well as the recently identified protein methyltransferase, coactivator-associated arginine methyltransferase 1 (CARM1), In the current study, protein arginine methyltransferase 1 (PRMT1), another arginine-specific protein methyltransferase that shares a region of high homology with CARM1, was also found to act as a coactivator for NRs, PRMT1, like CARM1, bound to the C-terminal AD2 activation domain of p160 coactivators and thereby enhanced the activity of NRs in transient transfection assays. The shape of the graphs of reporter gene activity versus the amounts of CARM1 or PRMT1 expression vector indicated a cooperative relationship between coactivator concentration and activity. Moreover, CARM1 and PRMT1 acted in a synergistic manner to enhance reporter gene activation by both hormone-dependent and orphan NRs, The synergy was most evident at low levels of transfected NR expression vectors, where activation of reporter genes was almost completely dependent on the presence of NR and all three exogenously supplied coactivators, i.e. GRIP1, CARM1, and PRMT1, In contrast, with the higher levels of NR expression vectors typically used in transient transfection assays, NR activity was much less dependent on the combination of coactivators, suggesting that target gene activation occurs by different mechanisms at high versus low cellular concentrations of NR, Because multiple coactivators are presumably required to mediate transcriptional activation of native genes in vivo, the low-NR conditions may provide a more physiologically relevant assay for coactivator function.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.		zhang, shijun/K-3688-2013; Lee, Young-Ho/G-2361-2014	Lee, Young-Ho/0000-0001-6415-4912	NIA NIH HHS [AG00093] Funding Source: Medline; NIDDK NIH HHS [DK55274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK055274, R01DK055274] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; ING NH, 1992, J BIOL CHEM, V267, P17617; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Ma H, 1999, MOL CELL BIOL, V19, P6164; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Westin S, 2000, ADV PHARMACOL, V47, P89; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	53	287	296	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1089	1098		10.1074/jbc.M004228200	http://dx.doi.org/10.1074/jbc.M004228200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050077	hybrid			2022-12-27	WOS:000166430900033
J	Torres, J; Pulido, R				Torres, J; Pulido, R			The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus - Implications for PTEN stability to proteasome-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; CASEIN KINASE-2; PHOSPHATASE; EXPRESSION; CELLS; GENE; ASSOCIATION; PTEN/MMAC1; SUBUNITS; PATHWAY	The tumor suppressor phosphatase PTEN regulates cell migration, growth, and survival by dephosphorylating phosphatidylinositol second messengers and signaling phosphoproteins, PTEN possesses a C-terminal noncatalytic regulatory domain that contains multiple putative phosphorylation sites, which could play an important role in the control of its biological activity. The protein kinase CK2 phosphorylated, in a constitutive manner, a cluster of Ser/Thr residues located at the PTEN C terminus, PTEN-phosphorylated defective mutants showed decreased stability in comparison with wild type PTEN and were more rapidly degraded by the proteasome, Inhibition of PTEN phosphorylation by the CK2 inhibitor 5,6-dichloro-1-beta -D-ribofuranosyl-benzimidazole also diminished the PTEN protein content. Our results support the notion that proper phosphorylation of PTEN by CK2 is important for PTEN protein stability to proteasome-mediated degradation.	Inst Invest Citol, Valencia 46010, Spain		Pulido, R (corresponding author), Inst Invest Citol, C Amadeo Saboya 4, Valencia 46010, Spain.		Torres, Josema/F-7070-2013	Torres, Josema/0000-0001-6906-7164; Pulido, Rafael/0000-0001-9100-248X				Adey NB, 2000, CANCER RES, V60, P35; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li DM, 1997, CANCER RES, V57, P2124; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LORENZ P, 1993, J BIOL CHEM, V268, P2733; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Torres J, 2001, EUR J CANCER, V37, P114, DOI 10.1016/S0959-8049(00)00366-X; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Zhang P, 2000, CANCER RES, V60, P1457	49	505	524	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					993	998		10.1074/jbc.M009134200	http://dx.doi.org/10.1074/jbc.M009134200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035045	hybrid, Green Published			2022-12-27	WOS:000166430900019
J	Wang, XQ; Rothnagel, JA				Wang, XQ; Rothnagel, JA			Post-transcriptional regulation of the GLI1 oncogene by the expression of alternative 5 ' untranslated regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL-CELL CARCINOMAS; PRE-MESSENGER-RNA; SONIC-HEDGEHOG; HUMAN HOMOLOG; TRANSCRIPTION FACTOR; GENE-EXPRESSION; KRUPPEL FAMILY; TRANSLATION; MUTATIONS; SEQUENCES	The oncogene GLI1 is involved in the formation of basal cell carcinoma and other tumor types as a result of the aberrant signaling of the Sonic hedgehog-Patched pathway. In this study, we have identified alternative GLI1 transcripts that differ in their 5' untranslated regions (UTRs) and are generated by exon skipping. These are denoted (alpha -UTR, beta -UTR, and gamma -UTR according to the number of noncoding exons possessed (three, two, and one, respectively). The alpha- and beta -UTR forms represent the major Gli1 transcripts expressed in mouse tissues, whereas the gamma -UTR is present at relatively low levels but is markedly induced in mouse skin treated with 12-O-tetradecanoylphorbol 13-acetate, Transcripts corresponding to the murine beta and gamma forms were identified in human tissues, but significantly, only the gamma -UTR form was present in basal cell carcinomas and in proliferating cultures of a keratinocyte cell line. Flow cytometry analysis determined that the gamma -UTR variant expresses a heterologous reporter gene 14-23-fold higher than the alpha -UTR and 5-13-fold higher than the beta -UTR in a variety of cell types. Because expression of the gamma -UTR variant correlates with proliferation, consistent with a role for GLI1 in growth promotion, up-regulation of GLI1 expression through skipping of 5' noncoding exons may be an important tumorigenic mechanism.	Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Rothnagel, JA (corresponding author), Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia.	josephr@biosci.uq.edu.au	Rothnagel, Joe/A-4874-2010; Wang, Xue-Qing/F-1758-2010	Rothnagel, Joe/0000-0002-6710-3165; 				Altaba ARI, 1999, NAT CELL BIOL, V1, pE147, DOI 10.1038/14099; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Darville MI, 1997, NUCLEIC ACIDS RES, V25, P2759, DOI 10.1093/nar/25.14.2759; Du KY, 1998, J BIOL CHEM, V273, P35208, DOI 10.1074/jbc.273.52.35208; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; FERRARI M, 1962, VIROLOGY, V16, P147; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Ghali L, 1999, J INVEST DERMATOL, V113, P595, DOI 10.1046/j.1523-1747.1999.00729.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Graves LE, 1999, NATURE, V399, P802, DOI 10.1038/21682; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HEYDEN A, 1994, DIFFERENTIATION, V57, P187, DOI 10.1046/j.1432-0436.1994.5730187.x; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jan E, 1997, EMBO J, V16, P6301, DOI 10.1093/emboj/16.20.6301; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lee J, 1997, DEVELOPMENT, V124, P2537; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Liu CZ, 1998, GENE, V209, P1, DOI 10.1016/S0378-1119(97)00668-9; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park HL, 2000, DEVELOPMENT, V127, P1593; Reifenberger J, 1998, CANCER RES, V58, P1798; ROBERTS WM, 1989, CANCER RES, V49, P5407; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Stein U, 1999, CANCER RES, V59, P1890; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	51	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1311	1316		10.1074/jbc.M005191200	http://dx.doi.org/10.1074/jbc.M005191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032829	hybrid			2022-12-27	WOS:000166430900062
J	Zhao, RB; Gao, F; Wang, YH; Diaz, GA; Gelb, BD; Goldman, ID				Zhao, RB; Gao, F; Wang, YH; Diaz, GA; Gelb, BD; Goldman, ID			Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHOTREXATE TRANSPORT-SYSTEM; MEGALOBLASTIC-ANEMIA SYNDROME; MEMBRANE-TRANSPORT; RESPONSIVE ANEMIA; PHOSPHATE-ESTERS; SMALL-INTESTINE; RAT; MONOPHOSPHATE; MUTATIONS; L1210-CELLS	The thiamin transporter encoded by SLC19A2 and the reduced folate carrier (RFC1) share 40% homology at the protein level, but the thiamin transporter does not mediate transport of folates, By using murine leukemia cell lines that express no, normal, or high levels of RFC1, we demonstrate that RFC1 does not mediate thiamin influx. However, high level RFC1 expression substantially reduced accumulation of the active thiamin coenzyme, thiamin pyrophosphate (TPP), This decreased level of TPP, synthesized intracellularly from imported thiamin, resulted from RFC1-mediated efflux of TPP, This conclusion was supported by the following observations. (i) Efflux of intracellular TPP was increased in cells with high expression of RFC1. (ii) Methotrexate inhibits TPP influx. (iii) TPP competitively inhibits methotrexate influx. (iv) Loading cells, which overexpress RFC1 to high levels of methotrexate to inhibit competitively RFC1-mediated TPP efflux, augment TPP accumulation. (v) There was an inverse correlation between thiamin accumulation and RFC1 activity in cells grown at a physiological concentration of thiamin. The modulation of thiamin accumulation by RFC1 in murine leukemia cells suggests that this carrier may play a role in thiamin homeostasis and could serve as a modifying factor in thiamin nutritional deficiency as well as when the high affinity thiamin transporter is mutated.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Comprehens Canc Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; CUNY Mt Sinai Sch Med, Dept Human Genet & Pediat, New York, NY 10029 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Goldman, ID (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Comprehens Canc Res Ctr, 1300 Morris Pk Ave,Chanin 2, Bronx, NY 10461 USA.	igoldman@aecom.yu.edu	Diaz, George/AAF-6199-2021		NCI NIH HHS [CA-39807, CA-82621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082621, R35CA039807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barile M, 1998, FEBS LETT, V435, P6, DOI 10.1016/S0014-5793(98)01007-2; BETTENDORFF L, 1995, NEUROCHEM INT, V26, P295, DOI 10.1016/0197-0186(94)00123-C; BOWEN D, 1979, J BIOL CHEM, V254, P5333; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Chiao JH, 1997, J BIOL CHEM, V272, P11165, DOI 10.1074/jbc.272.17.11165; CYBULSKI RL, 1982, BIOCHIM BIOPHYS ACTA, V714, P435, DOI 10.1016/0304-4165(82)90151-9; Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385; DIXON KH, 1994, J BIOL CHEM, V269, P17; Dutta B, 1999, J BIOL CHEM, V274, P31925, DOI 10.1074/jbc.274.45.31925; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; FRY DW, 1982, J BIOL CHEM, V257, P1890; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; HENDERSON GB, 1985, J MEMBRANE BIOL, V85, P263, DOI 10.1007/BF01871521; Kril JJ, 1996, METAB BRAIN DIS, V11, P9, DOI 10.1007/BF02080928; Kumar CK, 1998, AM J PHYSIOL-CELL PH, V274, pC289, DOI 10.1152/ajpcell.1998.274.1.C289; Labay V, 1999, NAT GENET, V22, P300, DOI 10.1038/10372; MANDEL H, 1984, NEW ENGL J MED, V311, P836, DOI 10.1056/NEJM198409273111307; MATSUDA T, 1981, ANAL BIOCHEM, V117, P203, DOI 10.1016/0003-2697(81)90711-9; MATSUDA T, 1978, J NUTR SCI VITAMINOL, V24, P123; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PATRINI C, 1988, J NEUROCHEM, V50, P90; Rindi G, 1997, METHOD ENZYMOL, V279, P118; RINDI G, 1995, ARCH PHYSIOL BIOCHEM, V103, P33, DOI 10.3109/13813459509007560; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SHANE B, 1989, VITAM HORM, V45, P263; Sierra EE, 1999, SEMIN ONCOL, V26, P11; Stagg AR, 1999, J CLIN INVEST, V103, P723, DOI 10.1172/JCI3895; Tallaksen CME, 1997, METHOD ENZYMOL, V279, P67; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067; Zhao R, 2000, CLIN CANCER RES, V6, P3304; Zhao RB, 2000, J BIOL CHEM, V275, P26599, DOI 10.1074/jbc.M002580200; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207	35	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1114	1118		10.1074/jbc.M007919200	http://dx.doi.org/10.1074/jbc.M007919200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038362	hybrid			2022-12-27	WOS:000166430900036
J	Kitada, T; Miyoshi, E; Noda, K; Higashiyama, S; Ihara, H; Matsuura, N; Hayashi, N; Kawata, S; Matsuzawa, Y; Taniguchi, N				Kitada, T; Miyoshi, E; Noda, K; Higashiyama, S; Ihara, H; Matsuura, N; Hayashi, N; Kawata, S; Matsuzawa, Y; Taniguchi, N			The addition of bisecting N-acetylglucosamine residues to E-cadherin down-regulates the tyrosine phosphorylation of beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; III GENE TRANSFECTION; CELL-CELL-ADHESION; HUMAN CANCER; ABERRANT GLYCOSYLATION; CYTOPLASMIC DOMAIN; EXPRESSION; OLIGOSACCHARIDES; BINDING; INVASIVENESS	The enzyme GnT-III (beta1,4-N-acetylglucosaminyltransferase III) catalyzes the addition of a bisecting N-acetylglucosamine (GlcNAc) residue on glycoproteins. Our previous study described that the transfection of GnT-lll into mouse melanoma cells results in the enhanced expression of E-cadherin, which in turn leads to, the suppression of lung metastasis. It has recently been proposed that the phosphorylation of a tyrosine residue of beta -catenin is associated with cell migration. The present study reports on the importance of bisecting GlcNAc residues by GnT-III on tyrosine phosphorylation of beta -catenin using three types of cancer cell lines. An addition of bisecting GlcNAc residues to E-cadherin leads to an alteration in cell morphology and the localization of beta -catenin after epidermal growth factor stimulation. These changes are the result of a down-regulation in the tyrosine phosphorylation of beta -catenin, In addition, tyrosine phosphorylation of beta -catenin by transfection of constitutively active c-src was suppressed in GnT-III transfectants as well as in the case of epidermal growth factor stimulation. Treatment with tunicamycin abolished any differences in beta -catenin phosphorylation for the mock vis a vis the GnT-III transfectants. Thus, the addition of a specific N-glycan structure, the bisecting GlcNAc to E-cadherin-beta -catenin complex, down-regulates the intracellular signaling pathway, suggesting its implication in cell motility and the suppression of cancer metastasis.	Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Mol Therapeut, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Med, Sch Allied Hlth Sci, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Med, Sch Allied Hlth Sci, Dept Pathol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University	Taniguchi, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Ihara, Hideyuki/0000-0003-0490-6355				BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Biscardi JS, 1999, ADV CANCER RES, V76, P61; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DORUDI S, 1993, AM J PATHOL, V142, P981; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; MAYER B, 1993, CANCER RES, V53, P1690; MIYOSHI E, 1993, CANCER RES, V53, P3899; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OYAMA T, 1994, CANCER RES, V54, P6282; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SOMMERS CL, 1994, CANCER RES, V54, P3544; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Taniguchi N, 1996, GLYCOBIOLOGY, V6, P691, DOI 10.1093/glycob/6.7.691; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; UMBAS R, 1992, CANCER RES, V52, P5104; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	35	82	87	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					475	480		10.1074/jbc.M006689200	http://dx.doi.org/10.1074/jbc.M006689200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024053	hybrid			2022-12-27	WOS:000166280700064
J	Mack, CP; Somlyo, AV; Hautmann, M; Somlyo, AP; Owens, GK				Mack, CP; Somlyo, AV; Hautmann, M; Somlyo, AP; Owens, GK			Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; TINMAN HOMOLOG NKX-2.5; HEAVY-CHAIN GENE; TRANSCRIPTIONAL ACTIVATION; FAMILY GTPASES; GROWTH-FACTOR; BINDING TARGETS; CALDESMON GENE; PROTEIN-KINASE; CELLS	complex array of local environmental cues, but the intracellular signaling pathways and the transcription mechanisms that regulate this process are largely unknown. We and others have shown that serum response factor (SRF) contributes to SMC-specific gene transcription, and because the small GTPase RhoA has been shown to regulate SRF, the goal of the present study was to test the hypothesis that RhoA signaling is a critical mechanism for regulating SMC differentiation. Coexpression of constitutively active RhoA in rat aortic SMC cultures significantly increased the activity of the SMC-specific promoters, SM22 and SM alpha -actin, whereas coexpression of C3 transferase abolished the activity of these promoters. Inhibition of either stress fiber formation with the Rho kinase inhibitor Y-27632 (10 muM) or actin polymerization with latrunculin B (0.5 muM) significantly decreased the activity of SM22 and SM alpha -actin promoters. In contrast, increasing actin polymerization with jasplakinolide (0.5 muM) increased SM22 and SM alpha -actin promoter activity by 22-fold and 13-fold, respectively. The above interventions had little or no effect on the transcription of an SRF-dependent c-fos promoter or on a minimal thymidine kinase promoter that is not SRF-dependent. Taken together, the results of these studies indicate that in SMC, RhoA-dependent regulation of the actin cytoskeleton selectively regulates SMC differentiation marker gene expression by modulating SRF-dependent transcription. The results also suggest that RhoA signaling may serve as a convergence point for the multiple signaling pathways that regulate SMC differentiation.	Univ Virginia, Ctr Hlth Sci, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany	University of Virginia	Owens, GK (corresponding author), Univ Virginia, Ctr Hlth Sci, Sch Med, Dept Mol Physiol & Biol Phys, Box 449, Charlottesville, VA 22908 USA.	gko@virginia.edu			NHLBI NIH HHS [R01 HL 19242, R01 HL 38854] Funding Source: Medline; PHS HHS [P01 19242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; BLANK RS, 1990, J CELL PHYSIOL, V142, P635, DOI 10.1002/jcp.1041420325; BLANK RS, 1992, J BIOL CHEM, V267, P984; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; Carson JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1624, DOI 10.1152/ajpcell.1996.270.6.C1624; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Groisman R, 1996, J BIOL CHEM, V271, P5258; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Kemp PR, 2000, BIOCHEM J, V345, P445, DOI 10.1042/0264-6021:3450445; Kim JH, 1997, BIOCHEM BIOPH RES CO, V232, P223, DOI 10.1006/bbrc.1997.6261; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; KOCHER O, 1991, LAB INVEST, V65, P459; KOCHER O, 1986, HUM PATHOL, V17, P875, DOI 10.1016/S0046-8177(86)80637-2; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Mack CP, 1999, CIRC RES, V84, P852; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; Miano JM, 2000, J BIOL CHEM, V275, P9814, DOI 10.1074/jbc.275.13.9814; Momiyama T, 1998, BIOCHEM BIOPH RES CO, V242, P429, DOI 10.1006/bbrc.1997.7959; Numaguchi K, 1999, CIRC RES, V85, P5; Owens GK, 1997, AGENT ACTION SUPPL, V48, P3; OWENS GK, 1995, PHYSIOL REV, V75, P487; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUNGGER D, 1979, NATURE, V282, P320, DOI 10.1038/282320a0; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Yamakawa T, 2000, HYPERTENSION, V35, P313, DOI 10.1161/01.HYP.35.1.313; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	62	325	340	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					341	347		10.1074/jbc.M005505200	http://dx.doi.org/10.1074/jbc.M005505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035001	hybrid			2022-12-27	WOS:000166280700047
J	McElhinny, AS; Kolmerer, B; Fowler, VM; Labeit, S; Gregorio, CC				McElhinny, AS; Kolmerer, B; Fowler, VM; Labeit, S; Gregorio, CC			The N-terminal end of nebulin interacts with tropomodulin at the pointed ends of the thin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPOMYOSIN-BINDING PROTEIN; SKELETAL-MUSCLE; ACTIN-FILAMENTS; STRIATED-MUSCLE; LENGTH; CAPS; IDENTIFICATION; MYOFIBRILS; NEBULETTE; SEQUENCE	Strict regulation of actin thin filament length is critical for the proper functioning of sarcomeres, the basic contractile units of myofibrils. It has been hypothesized that a molecular template works with actin filament capping proteins to regulate thin filament lengths. Nebulin is a giant protein (similar to 800 kDa) in skeletal muscle that has been proposed to act as a molecular ruler to specify the thin filament lengths characteristic of different muscles. Tropomodulin (Tmod), a pointed end thin filament capping protein, has been shown to maintain the final length of the thin filaments. Immunofluorescence microscopy revealed that the N-terminal end of nebulin colocalizes with Tmod at the pointed ends of thin filaments. The three extreme N-terminal modules (M1-M2-M3) of nebulin bind specifically to Tmod as demonstrated by blot overlay, bead binding, and solid phase binding assays. These data demonstrate that the N terminus of the nebulin molecule extends to the extreme end of the thin filament and also establish a novel biochemical function for this end. Two Tmod isoforms, erythrocyte Tmod (E-Tmod), expressed in embryonic and slow skeletal muscle, and skeletal Tmod (Sk-Tmod), expressed late in fast skeletal muscle differentiation, bind on overlapping sites to recombinant N-terminal nebulin fragments. Sk-Tmod binds nebulin with higher affinity than E-Tmod does, suggesting that the Tmod/ nebulin interaction exhibits isoform specificity.These data provide evidence that Tmod and nebulin may work together as a linked mechanism to control thin filament lengths in skeletal muscle.	Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ 85724 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; European Mol Biol Lab, D-69012 Heidelberg, Germany; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Arizona; University of Arizona; European Molecular Biology Laboratory (EMBL); Scripps Research Institute	Gregorio, CC (corresponding author), Univ Arizona, Dept Cell Biol & Anat, LSN455,1501 N Campbell Ave, Tucson, AZ 85724 USA.	gregorio@u.arizona.edu			NHLBI NIH HHS [HL57461, HL03985] Funding Source: Medline; NIGMS NIH HHS [GM3425] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057461, R29HL057461] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; Almenar-Queralt A, 1999, J CELL SCI, V112, P1111; AO XL, 1995, J CELL SCI, V108, P3397; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; BANG ML, 2000, IN PRESS MOL BIOL S; BROSCHAT KO, 1990, J BIOL CHEM, V265, P21323; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; CASELLA JF, 1986, J BIOL CHEM, V261, P915; Centner T, 2000, ADV EXP MED BIOL, V481, P35; CHEN MJG, 1993, J BIOL CHEM, V268, P20327; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Fowler VM, 1996, CURR OPIN CELL BIOL, V8, P86, DOI 10.1016/S0955-0674(96)80052-4; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; Fowler VM, 1997, SOC GEN PHY, V52, P79; Fuchs H, 1995, J IMMUNOL METHODS, V188, P197, DOI 10.1016/0022-1759(95)00202-2; GRANZIER HLM, 1993, ELECTROPHORESIS, V14, P56, DOI 10.1002/elps.1150140110; GRANZIER HLM, 1991, AM J PHYSIOL, V260, pC1060, DOI 10.1152/ajpcell.1991.260.5.C1060; GREGORIO CC, 1995, J CELL BIOL, V129, P683, DOI 10.1083/jcb.129.3.683; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; Gregorio CC, 1998, J CELL BIOL, V143, P1013, DOI 10.1083/jcb.143.4.1013; Herrera AH, 2000, CELL MOTIL CYTOSKEL, V45, P211, DOI 10.1002/(SICI)1097-0169(200003)45:3<211::AID-CM4>3.3.CO;2-P; Horowits R, 1996, ADV BIOPHYS, V33, P143; JIN JP, 1991, J BIOL CHEM, V266, P21215; KELLER CS, 1995, CURR OPIN CELL BIOL, V7, P32, DOI 10.1016/0955-0674(95)80042-5; KRUGER M, 1991, J CELL BIOL, V115, P97, DOI 10.1083/jcb.115.1.97; LABEIT S, 1991, FEBS LETT, V282, P313, DOI 10.1016/0014-5793(91)80503-U; Littlefield R, 1998, ANNU REV CELL DEV BI, V14, P487, DOI 10.1146/annurev.cellbio.14.1.487; Luo G, 1997, CELL MOTIL CYTOSKEL, V38, P75; MCLELLAN C, 2000, INPRESS MYOFIBRILLOG; Millevoi S, 1998, J MOL BIOL, V282, P111, DOI 10.1006/jmbi.1998.1999; Moncman CL, 2000, J MUSCLE RES CELL M, V21, P153, DOI 10.1023/A:1005697226465; Moncman CL, 1999, CELL MOTIL CYTOSKEL, V44, P1, DOI 10.1002/(SICI)1097-0169(199909)44:1<1::AID-CM1>3.0.CO;2-8; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; OHTSUKI I, 1979, J BIOCHEM-TOKYO, V85, P1377; Ojima K, 2000, J CELL BIOL, V150, P553, DOI 10.1083/jcb.150.3.553; PATEL K, 1988, J NEUROL SCI, V87, P315, DOI 10.1016/0022-510X(88)90256-0; Pelin K, 1999, P NATL ACAD SCI USA, V96, P2305, DOI 10.1073/pnas.96.5.2305; Pfuhl M, 1996, J MOL BIOL, V257, P367, DOI 10.1006/jmbi.1996.0169; PFUHL M, 1994, EMBO J, V13, P1782, DOI 10.1002/j.1460-2075.1994.tb06446.x; ROBINSON TF, 1979, J PHYSIOL-LONDON, V286, P607, DOI 10.1113/jphysiol.1979.sp012640; ROOT DD, 1994, BIOCHEMISTRY-US, V33, P12581, DOI 10.1021/bi00208a008; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHAFER DA, 1995, J CELL BIOL, V128, P61, DOI 10.1083/jcb.128.1.61; SCHAFER DA, 1995, ANNU REV CELL DEV BI, V12, P97; Shih CL, 1997, BIOCHEMISTRY-US, V36, P1814, DOI 10.1021/bi961236b; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SOSA H, 1994, BIOPHYS J, V67, P283, DOI 10.1016/S0006-3495(94)80479-5; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUNG LA, 1992, J BIOL CHEM, V267, P2616; Sussman MA, 1998, CIRC RES, V82, P94; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; TRINICK J, 1994, TRENDS BIOCHEM SCI, V19, P405, DOI 10.1016/0968-0004(94)90088-4; Wallgren-Pettersson C, 1999, NEUROMUSCULAR DISORD, V9, P564, DOI 10.1016/S0960-8966(99)00061-9; Wang K, 1996, J BIOL CHEM, V271, P4304; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199; Wang K, 1996, ADV BIOPHYS, V33, P123; Watakabe A, 1996, J CELL SCI, V109, P2299; Weber A, 1999, MOL CELL BIOCHEM, V190, P67, DOI 10.1023/A:1006984010267; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; WRIGHT J, 1993, J MUSCLE RES CELL M, V14, P476, DOI 10.1007/BF00297210; Zhukarev V, 1997, CELL MOTIL CYTOSKEL, V37, P363	65	96	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					583	592		10.1074/jbc.M005693200	http://dx.doi.org/10.1074/jbc.M005693200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016930	hybrid			2022-12-27	WOS:000166280700079
J	Shan, JG; Moran-Jones, K; Munro, TP; Kidd, GJ; Winzor, DJ; Hoek, KS; Smith, B				Shan, JG; Moran-Jones, K; Munro, TP; Kidd, GJ; Winzor, DJ; Hoek, KS; Smith, B			Binding of an RNA trafficking response element to heterogeneous nuclear ribonucleoproteins A1 and A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MESSENGER-RNA; HNRNP A1; CRYSTAL-STRUCTURE; U1A PROTEIN; ANGSTROM RESOLUTION; PREMESSENGER RNA; TELOMERIC DNA; DOMAINS; SEQUENCE; RECOGNITION	Heterogeneous nuclear ribonucleoprotein (hnRNP) A2 binds a 21-nucleotide myelin basic protein mRNA response element, the A2RE, and A2RE-like sequences in other localized mRNAs, and is a trans-acting factor in oligodendrocyte cytoplasmic RNA trafficking. Recombinant human hnRNPs A1 and A2 were used in a biosensor to explore interactions with A2RE and the cognate oligodeoxyribonucleotide. Both proteins have a single site that bound oligonucleotides with markedly different sequences but did not bind in the presence of heparin. Both also possess a second, specific site that bound only A2RE and was unaffected by heparin, hnRNP A2 bound A2RE in the latter site with a K-d near 50 nM, whereas the K-d for hnRNP A1 was above 10 muM. UV cross-linking assays led to a similar conclusion. Mutant A2RE sequences, that in earlier qualitative studies appeared not to bind hnRNP A2 or support RNA trafficking in oligodendrocytes, had dissociation constants above 5 muM for this protein. The two concatenated RNA recognition motifs (RRMs), but not the individual RRMs, mimicked the binding behavior of hnRNP A2. These data highlight the specificity of the interaction of A2RE with these hnRNPs and suggest that the sequence-specific A2RE-binding site on hnRNP A2 is formed by both RRMs acting in cis.	Univ Queensland, Dept Biochem, St Lucia, Qld 4072, Australia	University of Queensland	Smith, B (corresponding author), Univ Queensland, Dept Biochem, St Lucia, Qld 4072, Australia.		Munro, Trent/AAC-1129-2020; Munro, Trent/B-4856-2009	Munro, Trent/0000-0003-1987-2020; Kidd, Grahame/0000-0003-3956-2206				AbdulMana N, 1996, BIOCHEMISTRY-US, V35, P3545, DOI 10.1021/bi952298p; AbdulManan N, 1996, NUCLEIC ACIDS RES, V24, P4063, DOI 10.1093/nar/24.20.4063; Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; AMURUMARJEE S, 1993, J NEUROSCI RES, V36, P99, DOI 10.1002/jnr.490360111; Antson AA, 2000, CURR OPIN STRUC BIOL, V10, P87, DOI 10.1016/S0959-440X(99)00054-8; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; BARNETT SF, 1991, MOL CELL BIOL, V11, P864, DOI 10.1128/MCB.11.2.864; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; CASASFINET JR, 1993, J MOL BIOL, V229, P873, DOI 10.1006/jmbi.1993.1093; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; COBIANCHI F, 1988, J BIOL CHEM, V263, P1603; DAVIES RJ, 1994, TECHNIQUES PROTEIN C, V5; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Hall DR, 1997, ANAL BIOCHEM, V244, P152, DOI 10.1006/abio.1996.9867; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Howe PWA, 1998, J BIOMOL NMR, V11, P59, DOI 10.1023/A:1008297502874; HUANG M, 1994, MOL CELL BIOL, V14, P518, DOI 10.1128/MCB.14.1.518; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; KOZU T, 1995, GENOMICS, V25, P365, DOI 10.1016/0888-7543(95)80035-K; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; KUMAR A, 1986, J BIOL CHEM, V261, P1266; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P1212, DOI 10.1021/bi951974k; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P1387, DOI 10.1093/nar/20.6.1387; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; SCHENKEL J, 1988, EUR J BIOCHEM, V171, P565, DOI 10.1111/j.1432-1033.1988.tb13825.x; SCHUMACHER JM, 1995, J CELL BIOL, V129, P1023, DOI 10.1083/jcb.129.4.1023; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; SHAMOO Y, 1995, NUCLEIC ACIDS RES, V23, P725, DOI 10.1093/nar/23.5.725; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; WARD LD, 1995, BIOCHEMISTRY-US, V34, P2901, DOI 10.1021/bi00009a021; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; WILK HE, 1985, EUR J BIOCHEM, V146, P71, DOI 10.1111/j.1432-1033.1985.tb08621.x; Williams DJ, 1996, J MOL BIOL, V257, P265; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6	50	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38286	38295		10.1074/jbc.M007642200	http://dx.doi.org/10.1074/jbc.M007642200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11024030	hybrid			2022-12-27	WOS:000165739800023
J	Rae, TD; Torres, AS; Pufahl, RA; O'Halloran, TV				Rae, TD; Torres, AS; Pufahl, RA; O'Halloran, TV			Mechanism of Cu,Zn-superoxide dismutase activation by the human metallochaperone hCCS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MERCURIC ION REDUCTASE; HUMAN COPPER CHAPERONE; SUPEROXIDE-DISMUTASE; ATX1 METALLOCHAPERONE; CRYSTAL-STRUCTURE; ACTIVE-SITE; PROTEIN; DOMAIN; DETOXIFICATION; MUTAGENESIS	The mechanism for copper loading of the antioxidant enzyme copper, zinc superoxide dismutase (SOD1) by its partner metallochaperone protein is not well understood. Here we show the human copper chaperone for Cu,Zn-SOD1 (hCCS) activates either human or yeast enzymes in vitro by direct protein to protein transfer of the copper cofactor. Interestingly, when denatured with organic solvents, the ape-form of human SOD1 cannot be reactivated by added copper ion alone, suggesting an additional function of hCCS such as facilitation of an active folded state of the enzyme. While hCCS can bind several copper ions, metal binding studies in the presence of excess copper scavengers that mimic the intracellular chelation capacity indicate a limiting stoichiometry of one copper and one zinc per hCCS monomer. This protein is active and unlike the yeast protein, is a homodimer regardless of copper occupancy. Matrix-assisted laser desorption ionization-mass spectrometry and metal binding studies suggest that Cu(I) is bound by residues from the first and third domains and no bound copper is detected for the second domain of hCCS in either the full-length or truncated forms of the protein. Copper-induced conformational changes in the essential C-terminal peptide of hCCS are consistent with a "pivot, insert, and release" mechanism that is similar to one proposed for the well characterized metal handling enzyme, mercuric ion reductase.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.		O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NCRR NIH HHS [S10 RR11320, S10 RR13810] Funding Source: Medline; NIGMS NIH HHS [GM 19457, GM54111, R01 GM054111] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013810, S10RR011320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111, F32GM019457] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANCI L, 2001, IN PRESS J BIOL CHEM, V276; Blair D., 1961, TALANTA LONDON, V7, P163; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DISTEFANO MD, 1989, BIOCHEMISTRY-US, V28, P1168, DOI 10.1021/bi00429a035; Eisses JF, 2000, BIOCHEMISTRY-US, V39, P7337, DOI 10.1021/bi000690j; Engst S, 1999, BIOCHEMISTRY-US, V38, P3519, DOI 10.1021/bi982680c; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRIDOVICH I, 1985, CRC HDB METHODS OXYG, P213; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hall LT, 2000, BIOCHEMISTRY-US, V39, P3611, DOI 10.1021/bi992716g; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; HARTZ JW, 1972, J BIOL CHEM, V247, P7043; Hejtmancik JF, 1997, PROTEIN ENG, V10, P1347, DOI 10.1093/protein/10.11.1347; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; JABUSCH JR, 1980, BIOCHEMISTRY-US, V19, P2310, DOI 10.1021/bi00552a005; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P1589, DOI 10.1021/bi992822i; Lin SJ, 1997, J BIOL CHEM, V272, P9215; MILLER SM, 1989, BIOCHEMISTRY-US, V28, P1194, DOI 10.1021/bi00429a037; MOORE MJ, 1989, BIOCHEMISTRY-US, V28, P1183, DOI 10.1021/bi00429a036; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; STANSELL MJ, 1965, J BIOL CHEM, V240, P4306; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VALENTINE JS, 1982, COPPER PROTEINS, P292; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Zhu HN, 2000, BIOCHEMISTRY-US, V39, P5413, DOI 10.1021/bi992727+	36	93	94	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5166	5176		10.1074/jbc.M008005200	http://dx.doi.org/10.1074/jbc.M008005200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11018045	hybrid			2022-12-27	WOS:000168484300086
J	Ruttimann-Johnson, C; Rangaraj, P; Shah, VK; Ludden, PW				Ruttimann-Johnson, C; Rangaraj, P; Shah, VK; Ludden, PW			Requirement of homocitrate for the transfer of a V-49-labeled precursor of the iron-vanadium cofactor from VnfX to nif-apodinitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII; MOLYBDENUM COFACTOR; NUCLEOTIDE-SEQUENCE; MUTATIONAL ANALYSIS; INVITRO SYNTHESIS; STRUCTURAL GENES; NITROGENASE; DINITROGENASE; PROTEIN; PURIFICATION	A vanadium- and iron-containing cluster has been shown previously to accumulate on VnfX in the Azotobacter vinelandii mutant strain CA11.1 (Delta nifHDKvnfDGK::spc). In the present study, we show the homocitrate-dependent transfer of V-49 label from VnfX to nif-apodinitrogenase in vitro. This transfer of radiolabel correlates with acquisition of acetylene reduction activity. Acetylene is reduced both to ethylene and ethane by the hybrid holodinitrogenase so formed, a feature characteristic of alternative nitrogenases. Structural analogues of homocitrate prevent the acetylene reduction ability of the resulting dinitrogenase. Addition of NifB cofactor (-co) or a source of vanadium (Na3VO4 or VCl3) does not increase nitrogenase activity. Our results suggest that there is in vitro incorporation of homocitrate into the V-Fe-S cluster associated with VnfX and that the completed cluster can be inserted into nif-apodinitrogenase. The homocitrate incorporation react-ion and the insertion of the cluster into nif-apodinitrogenase (alpha (2)beta (2)gamma (2)) do not require MgATP. Attempts to achieve FeV-co synthesis using extracts of other FeV-co-negative mutants were unsuccessful, showing that earlier steps in FeV-co synthesis, such as the steps requiring VnfNE or VnfH do not occur in vitro.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; Bishop PE, 1992, BIOL NITROGEN FIXATI, P736; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; Chatterjee R, 1996, J BIOL CHEM, V271, P6819, DOI 10.1074/jbc.271.12.6819; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; DILWORTH MJ, 1988, BIOCHEM J, V249, P745, DOI 10.1042/bj2490745; Eady RR, 1996, CHEM REV, V96, P3013, DOI 10.1021/cr950057h; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KENNEDY C, 1992, MOL GEN GENET, V231, P494, DOI 10.1007/BF00292722; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LUQUE F, 1991, MOL GEN GENET, V227, P481, DOI 10.1007/BF00273941; Premakumar R, 1996, J BACTERIOL, V178, P691, DOI 10.1128/jb.178.3.691-696.1996; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; Ruttimann-Johnson C, 1999, J BIOL CHEM, V274, P18087, DOI 10.1074/jbc.274.25.18087; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1985, J BIOL CHEM, V260, P3891; SMITH BE, 1988, BIOCHEM J, V250, P299, DOI 10.1042/bj2500299; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995; WOLFINGER ED, 1991, J BACTERIOL, V173, P7565, DOI 10.1128/jb.173.23.7565-7572.1991; Zheng LM, 1997, J BACTERIOL, V179, P5963, DOI 10.1128/jb.179.18.5963-5966.1997	33	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4522	4526		10.1074/jbc.M007288200	http://dx.doi.org/10.1074/jbc.M007288200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053414	hybrid			2022-12-27	WOS:000166921200104
J	Samuel, D; Kumar, TKS; Balamurugan, K; Lin, WY; Chin, DH; Yu, C				Samuel, D; Kumar, TKS; Balamurugan, K; Lin, WY; Chin, DH; Yu, C			Structural events during the refolding of an all beta-sheet protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DIHYDROFOLATE-REDUCTASE; EARLY FOLDING INTERMEDIATE; FIBROBLAST-GROWTH-FACTOR; MUSCLE ACYLPHOSPHATASE; TRANSITION-STATE; KINETICS; STABILITY; MECHANISM; LYSOZYME; EXCHANGE	The refolding kinetics of the 140-residue, all beta -sheet, human fibroblast growth factor (hFGF-1) is studied using a variety of biophysical techniques such as stopped-flow fluorescence, stopped-flow circular dichroism, and quenched-flow hydrogen exchange in conjunction with multidimensional NMR spectroscopy. Urea-induced unfolding of hFGF-1 under equilibrium conditions reveals that the protein folds via a two-state (native <----> unfolded) mechanism without the accumulation of stable intermediates. However, measurement of the unfolding and refolding rates in various concentrations of urea shows that the refolding of hFGF-1 proceeds through accumulation of kinetic intermediates. Results of the quenched-flow hydrogen exchange experiments reveal that the hydrogen bonds linking the N- and C-terminal ends are the first to form during the refolding of hFGF-1. The basic beta -trefoil framework is provided by the simultaneous formation of beta -strands I, IV, IX, and X. The other beta -strands comprising the beta -barrel structure of hFGF-1 are formed relatively slowly with time constants ranging from 4 to 13 s.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 300, Taiwan; Natl Changhua Univ Educ, Dept Chem, Changhua 500, Taiwan; Natl Taiwan Univ, Dept Chem, Taipei 10764, Taiwan	National Tsing Hua University; National Changhua University of Education; National Taiwan University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu 300, Taiwan.	cyu@mx.nthu.edu.tw	KUMAR, P. SURESH/AAT-8951-2020; Kumar, Dr Suresh/HHZ-2615-2022; Kumar, Suresh Thallapuranam/R-5606-2016	KUMAR, P. SURESH/0000-0003-3222-2604; Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; Balamurugan, Prof. Dr. Krishnaswamy/0000-0001-9316-8141				BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURKE CJ, 1993, BIOCHEMISTRY-US, V32, P6419, DOI 10.1021/bi00076a015; Chiti F, 1998, BIOCHEMISTRY-US, V37, P1447, DOI 10.1021/bi971692f; Clementi C, 2000, P NATL ACAD SCI USA, V97, P5871, DOI 10.1073/pnas.100547897; Cota E, 2000, PROTEIN SCI, V9, P112; ENGELHARD M, 1995, PROTEIN SCI, V4, P1553, DOI 10.1002/pro.5560040813; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Finke JM, 2000, BIOCHEMISTRY-US, V39, P575, DOI 10.1021/bi991518m; Grantcharova VP, 1997, BIOCHEMISTRY-US, V36, P15685, DOI 10.1021/bi971786p; HAMMOND GS, 1955, J AM CHEM SOC, V77, P334, DOI 10.1021/ja01607a027; Heidary DK, 1997, NAT STRUCT BIOL, V4, P725, DOI 10.1038/nsb0997-725; Heidary DK, 2000, P NATL ACAD SCI USA, V97, P5866, DOI 10.1073/pnas.100547697; HOGAN SJ, 2000, J MOL BIOL, V297, P781; Ionescu RM, 2000, BIOCHEMISTRY-US, V39, P9540, DOI 10.1021/bi000511y; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; JACKSON SE, 1994, BIOCHEMISTRY-US, V30, P10436; JONES BE, 1994, BIOCHEMISTRY-US, V33, P15250, DOI 10.1021/bi00255a005; Jonsson T, 1996, BIOCHEMISTRY-US, V35, P4795, DOI 10.1021/bi953056s; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSZEWSKI J, 1994, PROTEIN SCI, V3, P1945, DOI 10.1002/pro.5560031106; Lozano RM, 2000, BIOCHEMISTRY-US, V39, P4982, DOI 10.1021/bi992544n; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; Main ERG, 1999, J MOL BIOL, V291, P429, DOI 10.1006/jmbi.1999.2941; MANN CJ, 1993, BIOCHEMISTRY-US, V32, P5282, DOI 10.1021/bi00071a002; Matagne A, 2000, J MOL BIOL, V297, P193, DOI 10.1006/jmbi.2000.3540; MATOUSCHEK A, 1994, PROTEIN ENG, V7, P1089, DOI 10.1093/protein/7.9.1089; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; Mirny LA, 1998, P NATL ACAD SCI USA, V95, P4976, DOI 10.1073/pnas.95.9.4976; Ogura K, 1999, J BIOMOL NMR, V13, P11, DOI 10.1023/A:1008330622467; Oliveberg M, 1998, J MOL BIOL, V277, P933, DOI 10.1006/jmbi.1997.1612; Otzen DE, 1999, BIOCHEMISTRY-US, V38, P6499, DOI 10.1021/bi982819j; Parker MJ, 1999, J MOL BIOL, V293, P1195, DOI 10.1006/jmbi.1999.3204; Plaxco KW, 1998, BIOCHEMISTRY-US, V37, P2529, DOI 10.1021/bi972075u; Ptitsyn Oleg B., 1992, P243; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; Ropson IJ, 1997, BIOCHEMISTRY-US, V36, P8594, DOI 10.1021/bi962983b; Schonbrunner N, 1997, J MOL BIOL, V268, P526, DOI 10.1006/jmbi.1997.0960; Shakhnovich E, 1996, NATURE, V379, P96, DOI 10.1038/379096a0; SHASTRY MCR, 1995, J MOL BIOL, V247, P1013, DOI 10.1006/jmbi.1994.0196; Silow M, 1999, BIOCHEMISTRY-US, V38, P13006, DOI 10.1021/bi9909997; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Sivaraman T, 1998, J BIOL CHEM, V273, P10181, DOI 10.1074/jbc.273.17.10181; Socci ND, 1998, PROTEINS, V32, P136, DOI 10.1002/(SICI)1097-0134(19980801)32:2<136::AID-PROT2>3.3.CO;2-5; Staniforth RA, 2000, P NATL ACAD SCI USA, V97, P5790, DOI 10.1073/pnas.97.11.5790; van Nuland NAJ, 1998, J MOL BIOL, V283, P883, DOI 10.1006/jmbi.1998.2009; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P2142, DOI 10.1021/bi00174a022; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	50	43	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4134	4141		10.1074/jbc.M005921200	http://dx.doi.org/10.1074/jbc.M005921200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11038349	Green Published, hybrid			2022-12-27	WOS:000166921200055
J	Yang, ZY; Li, H; Chai, ZL; Fullerton, MJ; Cao, Y; Toh, BH; Funder, JW; Liu, JP				Yang, ZY; Li, H; Chai, ZL; Fullerton, MJ; Cao, Y; Toh, BH; Funder, JW; Liu, JP			Dynamin II regulates hormone secretion in neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; SYNAPTIC VESICLE ENDOCYTOSIS; DISTINCT FUNCTIONS; MAMMALIAN-CELLS; PROTEIN; KINASE; DOMAIN; ALPHA; REDUNDANT; ISOFORMS	The dynamin family of GTP-binding proteins has been implicated as playing an important role in endocytosis. In Drosophila shibire, mutations of the single dynamin gene cause blockade of endocytosis and neurotransmitter release, manifest as temperature-sensitive neuromuscular paralysis. Mammals express three dynamin genes: the neural specific dynamin I, ubiquitous dynamin II, and predominantly testicular dynamin III. Mutations of dynamin I result in a blockade of synaptic vesicle recycling and receptor-mediated endocytosis. Here, we show that dynamin II plays a key role in controlling constitutive and regulated hormone secretion from mouse pituitary corticotrope (AtT20) cells. Dynamin II is preferentially localized to the Golgi apparatus where it interacts with G-protein py subunit and regulates secretory vesicle release. The presence of dynamin II at the Golgi apparatus and its interaction with the py subunit are mediated by the pleckstrin homology domain of the GTPase, Overexpression of the pleckstrin homology domain, or a dynamin II mutant lacking the C-terminal SH3-binding domain, induces translocation of endogenous dynamin II. from the Golgi apparatus to the plasma membrane and transformation of dynamin II from activity in the secretory pathway to receptor-mediated endocytosis. Thus, dynamin II regulates secretory vesicle formation from the Golgi apparatus and hormone release from mammalian neuroendocrine cells.	Monash Univ, Sch Med, Baker Med Res Inst, Prahran, Vic 3181, Australia; Monash Univ, Sch Med, Dept Pathol & Immunol, Prahran, Vic 3181, Australia	Baker Heart and Diabetes Institute; Monash University; Monash University	Liu, JP (corresponding author), Baker Med Res Inst, Mol Signalling Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.		CHAI, ZHONGLIN/X-1342-2019; Chai, Zhonglin/E-7482-2010	CHAI, ZHONGLIN/0000-0001-8182-8579; Liu, Jun-Ping/0000-0001-7442-2116				ALI SA, 1995, BIOTECHNIQUES, V18, P746; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; Austin CD, 1996, J CELL BIOL, V135, P1471, DOI 10.1083/jcb.135.6.1471; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Gleeson PA, 1996, J CELL SCI, V109, P2811; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kasai K, 1999, J BIOCHEM, V125, P780, DOI 10.1093/oxfordjournals.jbchem.a022349; Kelly RB, 1999, NAT CELL BIOL, V1, pE8, DOI 10.1038/8957; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li H, 1998, INT J BIOCHEM CELL B, V30, P1389, DOI 10.1016/S1357-2725(98)00093-4; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; LIU JP, 1990, J BIOL CHEM, V265, P14136; Liu JP, 1997, MOL CELL ENDOCRINOL, V132, P61, DOI 10.1016/S0303-7207(97)00120-2; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Shields D, 1999, CURR OPIN CELL BIOL, V11, P489, DOI 10.1016/S0955-0674(99)80070-2; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107	36	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4251	4260		10.1074/jbc.M006371200	http://dx.doi.org/10.1074/jbc.M006371200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11032832	hybrid			2022-12-27	WOS:000166921200070
J	Dash, C; Rao, M				Dash, C; Rao, M			Interactions of a novel inhibitor from an extremophilic Bacillus sp with HIV-1 protease - Implications for the mechanism of inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 PROTEASE; RETROVIRAL PROTEINASES; ASPARTIC PROTEINASES; CRYSTAL-STRUCTURE; RESISTANCE; RESOLUTION; DESIGN; AIDS; BINDING; MUTANTS	The active site cleft of the HIV-1 protease (PR) is bound by two identical conformationally mobile loops known as flaps, which are important for substrate binding and catalysis, The present article reports, for the first time, an HIV-1 PR inhibitor, ATBI, from an extremophilic Bacillus sp. The inhibitor is found to be a hydrophilic peptide with Mr of 1147, and an amino acid sequence of Ala-Gly-Lys-Lys-Asp-Asp-Asp-Asp-Pro-Pro-Glu, Sequence homology exhibited no similarity with the reported peptidic inhibitors of HIV-1 PR. Investigation of the kinetics of the enzyme-inhibitor interactions revealed that ATBI is a noncompetitive and tight binding inhibitor with the IC50 and K-i values 18.0 and 17.8 nM, respectively. The binding of the inhibitor with the enzyme and the subsequent induction of the localized conformational changes in the flap region of the HIV-1 PR were monitored by exploiting the intrinsic fluorescence of the surface exposed Trp-42 residues, which are present at the proximity of the flaps. We have demonstrated by fluorescence and circular dichroism studies that ATBI binds in the active site of the HIV-1 PR and thereby leads to the inactivation of the enzyme. Based on our results, we propose that the inactivation is due to the reorganization of the flaps impairing its flexibility leading toward inaccessibility of the substrate to the active site of the enzyme.	Natl Chem Lab, Div Biochem Sci, Pune 411008, Maharashtra, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL)	Rao, M (corresponding author), Natl Chem Lab, Div Biochem Sci, Pune 411008, Maharashtra, India.	malarao@dalton.ncl.res.in		Dash, Chandravanu/0000-0003-4466-8355				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; Bardi JS, 1997, BIOCHEMISTRY-US, V36, P6588, DOI 10.1021/bi9701742; *BIOS MOL SIM, 1995, INS 2; BLUNDELL T, 1989, NATURE, V337, P596, DOI 10.1038/337596a0; CHA S, 1976, BIOCHEM PHARMACOL, V25, P2695, DOI 10.1016/0006-2952(76)90259-8; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; DASH C, 1998, Patent No. 983560; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; Ermolieff J, 1997, BIOCHEMISTRY-US, V36, P12364, DOI 10.1021/bi971072e; GIGLI I, 1970, J IMMUNOL, V104, P574; GRIFFITHS JT, 1994, J BIOL CHEM, V269, P4787; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; LANG M, 1993, ARCH PHARM, V326, P921, DOI 10.1002/ardp.19933261202; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; Nair AC, 1998, BIOCHEM BIOPH RES CO, V242, P545, DOI 10.1006/bbrc.1997.8008; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PAWAR HS, 1988, J BIOSCIENCE, V3, P43; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; Pettit Steve C., 1993, Perspectives in Drug Discovery and Design, V1, P69, DOI 10.1007/BF02171656; PHYLIP LH, 1990, BIOCHEM BIOPH RES CO, V171, P439, DOI 10.1016/0006-291X(90)91412-L; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; RODRIGUEZ EJ, 1993, BIOCHEMISTRY-US, V32, P3557, DOI 10.1021/bi00065a006; RUTENBER E, 1993, J BIOL CHEM, V268, P15343; SARUBBI E, 1993, FEBS LETT, V319, P253, DOI 10.1016/0014-5793(93)80557-B; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TANG J, 1978, NATURE, V271, P618, DOI 10.1038/271618a0; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	43	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2487	2493		10.1074/jbc.M005662200	http://dx.doi.org/10.1074/jbc.M005662200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042202	hybrid, Green Submitted			2022-12-27	WOS:000166784800027
J	He, XY; Futterer, J; Hohn, T				He, XY; Futterer, J; Hohn, T			Sequence-specific and methylation-dependent and -independent binding of rice nuclear proteins to a rice tungro bacilliform virus vascular bundle expression element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BZIP TRANSCRIPTIONAL ACTIVATOR; IN-VITRO BINDING; DNA METHYLATION; CPG METHYLATION; CHROMOSOMAL-PROTEIN; BETA-GLUCURONIDASE; INHIBITS BINDING; GENE FUSION; PROMOTER; REPRESSION	Nuclear proteins from rice (Oryza sativa) were identified that bind specifically to a rice tungro bacilliform virus promoter region containing a vascular bundle expression element (VBE). One set of proteins of 29, 33, and 37 kDa, present in shoot and cell suspension extracts but hardly detectable in root extracts, bound to a site containing the sequence AGAAGGACCAGA within the VEE, which also contains two CpG and one CpNpG potential methylation motifs, Binding by these proteins was determined to be cytosine methylation-independent. However, a novel protein present in all analyzed extracts bound specifically to the methylated VEE. A region of at least 49 nucleotides overlapping the VEE and complete cytosine methylation of the three Cp(Np)G motifs was required for efficient binding of this methylated VBE-binding protein (MVBP).	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland	Friedrich Miescher Institute for Biomedical Research; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hohn, T (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	thomas.hohn@fmi.ch						Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; CHEN G, 1994, VIROLOGY, V204, P91, DOI 10.1006/viro.1994.1513; Chen G, 1996, J VIROL, V70, P8411, DOI 10.1128/JVI.70.12.8411-8421.1996; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; DATTA SK, 1990, BIO-TECHNOL, V8, P736, DOI 10.1038/nbt0890-736; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; Finnegan EJ, 2000, CURR OPIN GENET DEV, V10, P217, DOI 10.1016/S0959-437X(00)00061-7; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; Guilfoyle T. J., 1997, Genetic engineering: principles and methods. Volume 19., P15; HATTON D, 1995, PLANT J, V7, P859, DOI 10.1046/j.1365-313X.1995.07060859.x; HAUFFE KD, 1993, PLANT J, V4, P235, DOI 10.1046/j.1365-313X.1993.04020235.x; HE X, 2000, THESIS U BASE; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; INAMDAR NM, 1991, PLANT MOL BIOL, V17, P111, DOI 10.1007/BF00036811; Jackson S. P., 1993, Gene transcription: a practical approach., P189; JEFFERSON RA, 1987, EMBO J, V6, P3901; JOST JP, 1991, NUCLEIC ACIDS RES, V19, P5771, DOI 10.1093/nar/19.20.5771; Jost JP, 1997, PROG NUCLEIC ACID RE, V57, P217, DOI 10.1016/S0079-6603(08)60282-2; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KELLER B, 1989, EMBO J, V8, P1309, DOI 10.1002/j.1460-2075.1989.tb03510.x; Kloti A, 1999, PLANT MOL BIOL, V40, P249, DOI 10.1023/A:1006119517262; Kooter JM, 1999, TRENDS PLANT SCI, V4, P340, DOI 10.1016/S1360-1385(99)01467-3; KUNZE R, 1989, EMBO J, V8, P3177, DOI 10.1002/j.1460-2075.1989.tb08476.x; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Meisel L, 1997, Genet Eng (N Y), V19, P183; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Neustaedter DA, 1999, PLANT J, V18, P77, DOI 10.1046/j.1365-313X.1999.00430.x; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; PAUL AL, 1994, PLANT J, V5, P523, DOI 10.1046/j.1365-313X.1994.5040523.x; Radtke F, 1996, BIOL CHEM H-S, V377, P47, DOI 10.1515/bchm3.1996.377.1.47; Rossi V, 1997, J BIOL CHEM, V272, P13758, DOI 10.1074/jbc.272.21.13758; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; SHILLITO RD, 1985, BIO-TECHNOL, V3, P1099, DOI 10.1038/nbt1285-1099; STAIGER D, 1989, P NATL ACAD SCI USA, V86, P6930, DOI 10.1073/pnas.86.18.6930; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Thain A, 1996, J VIROL, V70, P7233, DOI 10.1128/JVI.70.10.7233-7235.1996; TorresSchumann S, 1996, PLANT J, V9, P283, DOI 10.1046/j.1365-313X.1996.09030283.x; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; WANG RYH, 1986, NUCLEIC ACIDS RES, V14, P1599, DOI 10.1093/nar/14.4.1599; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Yin YH, 1997, EMBO J, V16, P5247, DOI 10.1093/emboj/16.17.5247; Yin YH, 1997, PLANT J, V12, P1179, DOI 10.1046/j.1365-313X.1997.12051179.x; YIN YH, 1995, PLANT J, V7, P969, DOI 10.1046/j.1365-313X.1995.07060969.x; ZHANG DL, 1989, MOL CELL BIOL, V9, P1351, DOI 10.1128/MCB.9.3.1351; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387	53	8	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2644	2651		10.1074/jbc.M006653200	http://dx.doi.org/10.1074/jbc.M006653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11036074	hybrid			2022-12-27	WOS:000166784800049
J	Phylip, LH; Lees, WE; Brownsey, BG; Bur, D; Dunn, BM; Winther, JR; Gustchina, A; Li, M; Copeland, T; Wlodawer, A; Kay, J				Phylip, LH; Lees, WE; Brownsey, BG; Bur, D; Dunn, BM; Winther, JR; Gustchina, A; Li, M; Copeland, T; Wlodawer, A; Kay, J			The potency and specificity of the interaction between the IA(3) inhibitor and its target aspartic proteinase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-D; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURES; PORCINE PEPSIN; YEAST; PURIFICATION; RESOLUTION; EXPRESSION; CLONING; ENZYME	The yeast IA, polypeptide consists of only 68 residues, and the free inhibitor has little intrinsic secondary structure. IA, showed subnanomolar potency toward its target, proteinase A from Saccharomyces cerevisiae, and did not inhibit any of a large number of aspartic proteinases with similar sequences/structures from a wide variety of other species. Systematic truncation and mutagenesis of the IA, polypeptide revealed that the inhibitory activity is located in the N-terminal half of the sequence. Crystal structures of different forms of Lc, complexed with proteinase A showed that residues in the N-terminal half of the IA, sequence became ordered and formed an almost perfect cr-helix in the active site of the enzyme. This potent, specific interaction was directed primarily by hydrophobic interactions made by three key features in the inhibitory sequence. Whereas IA,was cut as a substrate by the nontarget aspartic proteinases, it mas not cleaved by proteinase A. The random coil IA, polypeptide escapes cleavage by being stabilized in a helical conformation upon interaction with the active site of proteinase A. This results, paradoxically, in potent selective inhibition of the target enzyme.	Cardiff Univ, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Wales, Coll Med, Dept Med, Cardiff CF14 4XN, S Glam, Wales; Hoffmann La Roche Ag, CH-4070 Basel, Switzerland; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Carlsberg Lab, Dept Yeast Genet, DK-2500 Copenhagen Valby, Denmark; NCI, Prot Struct Sect, Macromol Crystallog Lab, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, Frederick, MD 21702 USA; NCI, Program Core, DBS, Frederick, MD 21702 USA	Cardiff University; Cardiff University; Roche Holding; State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kay, J (corresponding author), Cardiff Univ, Sch Biosci, POB 911, Cardiff CF10 3US, S Glam, Wales.		Winther, Jakob R./K-4451-2014	Winther, Jakob R./0000-0001-6995-9154				Aguilar CF, 1997, J MOL BIOL, V267, P899, DOI 10.1006/jmbi.1996.0880; Arnold D, 1997, EUR J BIOCHEM, V249, P171, DOI 10.1111/j.1432-1033.1997.t01-1-00171.x; AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; BIEDERMANN K, 1980, CARLSBERG RES COMMUN, V45, P225, DOI 10.1007/BF02906176; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christeller JT, 1998, EUR J BIOCHEM, V254, P160, DOI 10.1046/j.1432-1327.1998.2540160.x; DREYER T, 1985, BIOCHEM J, V231, P777, DOI 10.1042/bj2310777; DREYER T, 1986, CARLSBERG RES COMMUN, V51, P27, DOI 10.1007/BF02907993; HILL J, 1994, FEBS LETT, V352, P155, DOI 10.1016/0014-5793(94)00940-6; Houston ME, 1998, J PEPT RES, V52, P81; Kageyama T, 1998, EUR J BIOCHEM, V253, P804, DOI 10.1046/j.1432-1327.1998.2530804.x; KAY J, 1983, PROTEINASE INHIBITOR, P201; Khan AR, 1998, PROTEIN SCI, V7, P815; Kreft S, 1997, PHYTOCHEMISTRY, V44, P1001, DOI 10.1016/S0031-9422(96)00668-1; Lenarcic B, 1999, J BIOL CHEM, V274, P563, DOI 10.1074/jbc.274.2.563; Li M, 2000, NAT STRUCT BIOL, V7, P113, DOI 10.1038/72378; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SAHEKI T, 1974, EUR J BIOCHEM, V47, P325, DOI 10.1111/j.1432-1033.1974.tb03697.x; SCHU P, 1991, FEBS LETT, V283, P78, DOI 10.1016/0014-5793(91)80558-K; Shintani T, 1997, J BIOL CHEM, V272, P18855, DOI 10.1074/jbc.272.30.18855; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; Takahashi S, 1999, J BIOCHEM-TOKYO, V125, P348, DOI 10.1093/oxfordjournals.jbchem.a022293; Tigue NJ, 1998, J BIOL CHEM, V273, P26441, DOI 10.1074/jbc.273.41.26441; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; White PC, 1999, J BIOL CHEM, V274, P16685, DOI 10.1074/jbc.274.24.16685	27	33	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2023	2030		10.1074/jbc.M008520200	http://dx.doi.org/10.1074/jbc.M008520200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042188	hybrid			2022-12-27	WOS:000166528000052
J	Schwer, B; Lehman, K; Saha, N; Shuman, S				Schwer, B; Lehman, K; Saha, N; Shuman, S			Characterization of the mRNA capping apparatus of Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; CAP METHYLTRANSFERASE; MUTATIONAL ANALYSIS; POLYMERASE-II; GUANYLYLTRANSFERASE COMPONENT; SCHIZOSACCHAROMYCES-POMBE; ENZYME BINDS; YEAST; TRIPHOSPHATASE; PHOSPHORYLATION	The mRNA capping apparatus of the pathogenic fungus Candida albicans consists of three components: a 520-amino acid RNA triphosphatase (CaCet1p), a 449-amino acid RNA guanylyltransferase (Cgt1p), and a 474-amino acid RNA (guanine-N7-)-methyltransferase (Ccm1p). The fungal guanylyltransferase and methyltransferase are structurally similar to their mammalian counterparts, whereas the fungal triphosphatase is mechanistically and structurally unrelated to the triphosphatase of mammals. Hence, the triphosphatase is an attractive antifungal target. Here we identify a biologically active C-terminal do main of CaCet1p from residues 202 to 520. We find that CaCet1p function in vivo requires the segment from residues 202 to 256 immediately flanking the catalytic domain from 257 to 520. Genetic suppression data implicate the essential flanking segment in the binding of CaCet1p to the fungal guanylyltransferase, Deletion analysis of the Candida guanylyltransferase demarcates an N-terminal domain, Cgt1(1-387)p, that suffices for catalytic activity in vitro and for cell growth, An even smaller domain, Cgt1(1-367)p, suffices for binding to the guanylyltransferase docking site on yeast RNA triphosphatase. Deletion analysis of the cap methyltransferase identifies a C-terminal domain, Ccm1(137-474)p, as being sufficient for cap methyltransferase function in vivo and in vitro. Ccm1(137-474)p binds in, vitro to synthetic peptides comprising the phosphorylated C-terminal domain of the largest subunit of RNA polymerase II, Binding is enhanced when the C-terminal domain is phosphorylated on both Ser-2 and Ser-5 of the YSPTSPS heptad repeat. We show that the entire three-component Saccharomyces cerevisiae capping apparatus can be replaced by C, albicans enzymes, Isogenic yeast cells expressing "all-Candida" versus "all-mammalian" capping components can be used to screen for cytotoxic agents that specifically target the fungal capping enzymes.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Janbon G, 1997, YEAST, V13, P985, DOI 10.1002/(SICI)1097-0061(199708)13:10<985::AID-YEA153>3.0.CO;2-T; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Mao XD, 1996, MOL CELL BIOL, V16, P475; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Schwer B, 2000, GENETICS, V155, P1561; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V251, P27, DOI 10.1006/bbrc.1998.9402; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yamada-Okabe T, 1999, MICROBIOL-UK, V145, P3023, DOI 10.1099/00221287-145-11-3023; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; YamadaOkabe T, 1996, MICROBIOL-UK, V142, P2515, DOI 10.1099/00221287-142-9-2515; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	36	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1857	1864		10.1074/jbc.M006072200	http://dx.doi.org/10.1074/jbc.M006072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035009	hybrid			2022-12-27	WOS:000166528000030
J	Escobar-Henriques, M; Daignan-Fornier, B				Escobar-Henriques, M; Daignan-Fornier, B			Transcriptional regulation of the yeast GMP synthesis pathway by its end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMP DEHYDROGENASE; INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE; HUMAN NORMAL LYMPHOCYTES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MYCOPHENOLATE MOFETIL; INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE; GENE-EXPRESSION; BETA-SUBUNIT; CELL LINES	AMP and GMP are synthesized from IMP by specific conserved pathways. In yeast, whereas IMP and AMP synthesis are coregulated, we found that the GMP synthesis pathway is specifically regulated. Transcription of the IMD genes, encoding the yeast homologs of IMP dehydrogenase, was repressed by extracellular guanine. Only this first step of GDP synthesis pathway is regulated, since the latter steps, encoded by the GUA1 and GUK1 genes, are guanine-insensitive. Use of mutants affecting GDP metabolism revealed that guanine had to be transformed into GDP to allow repression of the IMD genes. IMD gene transcription was also strongly activated by mycophenolic acid (MPA), a specific inhibitor of IMP dehydrogenase activity. Serial deletions of the IMD2 gene promoter revealed the presence of a negative cis-element, required for guanine regulation. Point mutations in this guanine response element strongly enhanced IMD2 expression, also making it insensitive to guanine and MPA. From these data, we propose that the guanine response element sequence mediates a repression process, which is enhanced by guanine addition, through GDP or a GDP derivative, and abolished in the presence of MPA.	CNRS UMR 5095, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Daignan-Fornier, B (corresponding author), CNRS UMR 5095, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	Daignan-Fornier@ibgc.u-bordeaux2.fr		Escobar-Henriques, Mafalda/0000-0002-0879-3119				ALLISON AC, 1975, LANCET, V2, P1179; ALLISON AC, 1994, TRANSPLANT P, V26, P3205; Barton AB, 1997, YEAST, V13, P1251; COLLART FR, 1990, BLOOD, V75, P570; COLLART FR, 1992, CANCER RES, V52, P5826; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; Denis V, 1998, MOL MICROBIOL, V30, P557, DOI 10.1046/j.1365-2958.1998.01087.x; DUJARDIN G, 1994, GENE, V139, P127, DOI 10.1016/0378-1119(94)90535-5; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; ELFORD HL, 1968, BIOCHEM BIOPH RES CO, V33, P129, DOI 10.1016/0006-291X(68)90266-0; FUKUCHI T, 1993, GENE, V129, P141; GILBERT HJ, 1979, BIOCHEM J, V183, P481, DOI 10.1042/bj1830481; GLESNE DA, 1991, MOL CELL BIOL, V11, P5417, DOI 10.1128/MCB.11.11.5417; Guetsova ML, 1997, GENETICS, V147, P383; HOLMES EW, 1974, BIOCHIM BIOPHYS ACTA, V364, P209, DOI 10.1016/0005-2744(74)90006-0; IKEGAMI T, 1987, LIFE SCI, V40, P2277, DOI 10.1016/0024-3205(87)90064-6; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; Jain A, 1999, SURG CLIN N AM, V79, P59, DOI 10.1016/S0039-6109(05)70007-4; KANZAKI N, 1990, NUCLEIC ACIDS RES, V18, P6710, DOI 10.1093/nar/18.22.6710; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; KONNO Y, 1991, J BIOL CHEM, V266, P506; KONRAD M, 1992, J BIOL CHEM, V267, P25652; Lecoq K, 2000, GENETICS, V156, P953; Liu YA, 1998, MOL BIOL CELL, V9, P15, DOI 10.1091/mbc.9.1.15; MENG LM, 1990, MOL MICROBIOL, V4, P2187, DOI 10.1111/j.1365-2958.1990.tb00580.x; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; MUKAI Y, 1991, MOL CELL BIOL, V11, P3773, DOI 10.1128/MCB.11.7.3773; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NAKAMURA H, 1992, LEUKEMIA RES, V16, P561, DOI 10.1016/0145-2126(92)90002-O; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NELSON PH, 1990, J MED CHEM, V33, P833, DOI 10.1021/jm00164a057; OKADA M, 1983, J BIOCHEM-TOKYO, V94, P1605; SHAW LM, 1995, THER DRUG MONIT, V17, P690, DOI 10.1097/00007691-199512000-00025; SIFRI CD, 1994, BBA-GENE STRUCT EXPR, V1217, P103; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; SOLLINGER HW, 1995, KIDNEY INT, V48, pS14; TIEDEMAN AA, 1991, GENE, V97, P289, DOI 10.1016/0378-1119(91)90065-J; TRICOT GJ, 1989, CANCER RES, V49, P3696; VITOLS E, 1970, BIOCHEM BIOPH RES CO, V41, P71, DOI 10.1016/0006-291X(70)90470-5; WENG ML, 1995, P NATL ACAD SCI USA, V92, P7455, DOI 10.1073/pnas.92.16.7455; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; WOODS RA, 1983, MOL GEN GENET, V191, P407, DOI 10.1007/BF00425755; ZHANG M, 1991, GENE, V97, P153, DOI 10.1016/0378-1119(91)90047-F; Zimmermann AG, 1998, PROG NUCLEIC ACID RE, V61, P181, DOI 10.1016/S0079-6603(08)60827-2	48	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1523	1530		10.1074/jbc.M007926200	http://dx.doi.org/10.1074/jbc.M007926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035032	hybrid			2022-12-27	WOS:000166430900089
J	Suzuki-Inoue, K; Ozaki, Y; Kainoh, M; Shin, YC; Wu, Y; Yatomi, Y; Ohmori, T; Tanaka, T; Satoh, K; Morita, T				Suzuki-Inoue, K; Ozaki, Y; Kainoh, M; Shin, YC; Wu, Y; Yatomi, Y; Ohmori, T; Tanaka, T; Satoh, K; Morita, T			Rhodocytin induces platelet aggregation by interacting with glycoprotein Ia/IIa (GPIa/IIa, integrin alpha(2)beta(1)) - Involvement of GPIa/IIa-associated Src and protein tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; RECEPTOR-GAMMA-CHAIN; COLLAGEN-STIMULATED ACTIVATION; SIGNAL-TRANSDUCTION PATHWAYS; MEDIATED CELL-ADHESION; VON-WILLEBRAND-FACTOR; C-TYPE LECTIN; PHOSPHOLIPASE C-GAMMA-2; SUBSTRATE P130(CAS); DEPENDENT ADHESION	Although glycoprotein Ia/IIa (GPIa/IIa, integrin alpha (2)beta (1)) has established its role as a collagen receptor, it remains unclear whether GPIa/IIa mediates activation signals. In this study, we show that rhodocytin, purified from the Calloselasma rhodostoma venom, induces platelet aggregation, which can be blocked by anti-GPIa monoclonal antibodies. Studies with rhodocytin-coupled beads and liposomes loaded with recombinant GPIa/IIa demonstrated that rhodocytin directly binds to GPIa/IIa independently of divalent cations, In vitro kinase assays and Western blotting of GPIa immunoprecipitates revealed that Src and Lyn constitutively associate with GPIa/IIa and that Src activity increases transiently after rhodocytin stimulation. Src specifically associates with p130 Crk-associated substrate (Cas) in a manner dependent upon Cas phosphorylation, suggesting that Src is responsible for Cas tyrosine phosphorylation. While all these phenomena occur early after rhodocytin stimulation in a cAMP-resistant manner, tyrosine phosphorylation of Syk and phospholipase C gamma2, intracellular Ca2+ mobilization, and platelet aggregation occur later in a cAMP-sensitive manner. Cytochalasin D, which interferes with actin polymerization and blocks receptor clustering, inhibits all the rhodocytin-mediated signals we examined in this study. We suggest that rhodocytin, by clustering GPIalIIa, activates GPIa/IIa-associated Src, which then mediates downstream activation signals.	Yamanashi Med Univ, Dept Clin Lab & Med, Yamanashi 4093898, Japan; Toray Ind Inc, Pharmaceut Res Labs, Kanagawa 2488555, Japan; Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan	University of Yamanashi; Toray Industries, Inc.; Meiji Pharmaceutical University	Ozaki, Y (corresponding author), Yamanashi Med Univ, Dept Clin Lab & Med, Shimokato 1110, Yamanashi 4093898, Japan.			Yatomi, Yutaka/0000-0003-1719-4297				ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; Asazuma N, 1996, THROMB HAEMOSTASIS, V75, P648; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; FUJII C, 1994, EUR J BIOCHEM, V226, P243, DOI 10.1111/j.1432-1033.1994.tb20047.x; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; HANDA M, 1995, THROMB HAEMOSTASIS, V73, P521; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HUANG TF, 1995, BIOCHEM J, V309, P1021, DOI 10.1042/bj3091021; Ichinohe T, 1997, J BIOL CHEM, V272, P63; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; Inoue K, 1999, BIOCHEM BIOPH RES CO, V256, P114, DOI 10.1006/bbrc.1999.0295; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Kamiguti AS, 1997, J BIOL CHEM, V272, P32599, DOI 10.1074/jbc.272.51.32599; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Kehrel B, 1998, BLOOD, V91, P491; KEHREL B, 1988, BLOOD, V71, P1074; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Manie SN, 1997, J BIOL CHEM, V272, P15636, DOI 10.1074/jbc.272.25.15636; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; NAKANO T, 1989, J BIOL CHEM, V264, P5400; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ohmori T, 2000, BIOCHEMISTRY-US, V39, P5797, DOI 10.1021/bi991849z; Ohmori T, 1999, THROMB RES, V93, P291, DOI 10.1016/S0049-3848(98)00188-1; PEERSCHKE EI, 1980, THROMB HAEMOSTASIS, V43, P58; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Shin Y, 1998, BIOCHEM BIOPH RES CO, V245, P741, DOI 10.1006/bbrc.1998.8516; SMITH JB, 1993, BIOCHEM BIOPH RES CO, V191, P695, DOI 10.1006/bbrc.1993.1273; SMITH JB, 1992, BIOCHEM J, V283, P889, DOI 10.1042/bj2830889; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Ueki K, 1998, FEBS LETT, V432, P197, DOI 10.1016/S0014-5793(98)00862-X; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Verkleij MW, 1998, BLOOD, V91, P3808; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang RH, 1999, BIOCHEMISTRY-US, V38, P7584, DOI 10.1021/bi982132z; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3	62	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1643	1652		10.1074/jbc.M006191200	http://dx.doi.org/10.1074/jbc.M006191200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038351	hybrid			2022-12-27	WOS:000166430900104
J	Fitzgerald, J; Morgelin, M; Selan, C; Wiberg, C; Keene, DR; Lamande, SR; Bateman, JF				Fitzgerald, J; Morgelin, M; Selan, C; Wiberg, C; Keene, DR; Lamande, SR; Bateman, JF			The N-terminal N5 subdomain of the alpha 3(VI) chain is important for collagen VI microfibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETHLEM MYOPATHY; VONWILLEBRAND-FACTOR; FILAMENTOUS NETWORK; MATRIX DEPOSITION; GLOBULAR DOMAINS; MESSENGER-RNA; HUMAN-SKIN; A-DOMAINS; PROTEIN; SECRETION	Collagen VI assembly is unique within the collagen superfamily in that the alpha1(VI), alpha2(VI), and alpha3(VI) chains associate intracellularly to form triple hlelical monomers, and then dimers and tetramers, which are secreted from the cell. Secreted tetramers associate end-to-end to form the distinctive extracellular microfibrils that are found in virtually all connective tissues. Although the precise protein interactions involved in this process are unknown, the N-terminal globular regions, which are composed of multiple copies elf von Willebrand factor type A-like domains, are likely to play a critical role in microfibril formation, because they are exposed at both ends of the tetramers. To explore the role of these subdomains in collagen VI intracellular and extracellular assembly, alpha3(VI) cDNA expression constructs with sequential N-terminal deletions were stably transfected into SaOS-2 cells, producing cell lines that express alpha3(VI) chains with N-terminal globular domains containing modules N9-N1, N6-N1, N5-N1, M4-N1, N3-N1, or N1, as well as the complete triple helix and C-terminal globular domain (C1-C5). All of these transfected alpha3(VI) chains were able to associate with endogenous (alpha1(VI) and alpha2(VI) to form collagen VI monomers, dimers, and tetramers, which were secreted. Importantly, cells that expressed alpha3(VI) chains containing the N5 subdomain, alpha3(VI) N9-C5, N6-C5, and N5-C5, formed microfibrils and deposited a collagen VI matrix. In contrast, cells that expressed the shorter alpha3(Vl) chains, N4-C5, N3-C5, and N1-C5, were severely compromised in their ability to form end-to-end tetramer assemblies and failed to deposit a collagen VI matrix. These data demonstrate that the alpha3(VI) N5 module is critical for microfibril formation, thus identifying a functional role for a specific type A subdomain in collagen VI assembly.	Univ Melbourne, Dept Paediat, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, S-22100 Lund, Sweden; Shriners Hosp Res Facil, Portland, OR 97201 USA	University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Lund University	Lamande, SR (corresponding author), Univ Melbourne, Dept Paediat, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia.			Lamande, Shireen/0000-0003-2938-2711; Bateman, John/0000-0001-8542-0730				BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BOHME K, 1995, DEV DYNAM, V204, P432; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; Chen Q, 1999, MOL BIOL CELL, V10, P2149, DOI 10.1091/mbc.10.7.2149; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; COLOMBATTI A, 1991, BLOOD, V77, P2305; COLOMBATTI A, 1987, J BIOL CHEM, V262, P14454; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; GERECKE DR, 1993, J BIOL CHEM, V268, P12177; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; Keene DR, 1997, MICROSC RES TECHNIQ, V38, P394, DOI 10.1002/(SICI)1097-0029(19970815)38:4<394::AID-JEMT7>3.0.CO;2-J; KUO HJ, 1989, BIOCHEMISTRY-US, V28, P3757, DOI 10.1021/bi00435a020; Lamande SR, 1998, J BIOL CHEM, V273, P7423, DOI 10.1074/jbc.273.13.7423; Lamande SR, 1999, J BIOL CHEM, V274, P21817, DOI 10.1074/jbc.274.31.21817; Lamande SR, 1998, HUM MOL GENET, V7, P981, DOI 10.1093/hmg/7.6.981; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Mazzucato M, 1999, J BIOL CHEM, V274, P3033, DOI 10.1074/jbc.274.5.3033; Pan TC, 1998, HUM MOL GENET, V7, P807, DOI 10.1093/hmg/7.5.807; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P43; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; STOKES DG, 1991, J BIOL CHEM, V266, P8626; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; ZANUSSI S, 1992, J BIOL CHEM, V267, P24082	32	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					187	193		10.1074/jbc.M008173200	http://dx.doi.org/10.1074/jbc.M008173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027693	hybrid			2022-12-27	WOS:000166280700027
J	Peri, R; Wible, BA; Brown, AM				Peri, R; Wible, BA; Brown, AM			Mutations in the Kv beta 2 binding site for NADPH and their effects on Kv1.4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL BETA-SUBUNIT; FUNCTIONAL EXPRESSION; K+ CHANNELS; INACTIVATION; CLONING	Kv beta2 enhances the rate of inactivation and level of expression of Kv1.4 currents. The crystal structure of Kv beta2 binds NADP(+), and it has been suggested that Kv beta2 is an oxidoreductase enzyme (1). To investigate how this function might relate to channel modulation, we made point mutations in Kv beta2 in either the NADPH docking or putative catalytic sites. Using the yeast two-hybrid system, we found that these mutations did not disrupt the interaction of Kv beta2 with Kv alpha1 channels. To characterize the Kv beta2 mutants functionally, we coinjected wild-type or mutant Kv beta2 cRNAs and Kv1.4 cRNA in Xenopus laevis oocytes. Kv beta2 increased both the amplitude and rate of inactivation of Kv1.4 currents. The cellular content of Kv1.4 protein was unchanged on Western blot, but the amount in the plasmalemma was increased. Mutations in either the orientation or putative catalytic sites for NADPH abolished the expression-enhancing effect on Kv1.4 current. Western blots showed that both types of mutation reduced Kv1.4 protein. Like the wild-type Kv beta2, both types of mutation increased the rate of inactivation of Kv1.4, confirming the physical association of mutant Kv beta2 subunits with Kv1.4, Thus, mutations that should interfere with NADPH function uncouple the expression-enhancing ef. feet of Kv beta2 on Kv1.4 currents from its effect on the rate of inactivation. These results suggest that the binding of NADPH and the putative oxidoreductase activity of Kv beta2 may play a role in the processing of Kv1.4.	Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Physiol & Biochem, Cleveland, OH 44109 USA	MetroHealth System; Case Western Reserve University	Peri, R (corresponding author), Rammelkamp Ctr Educ & Res, R301,MetroHlth Dr, Cleveland, OH 44109 USA.				NHLBI NIH HHS [HL60759, HL36930, HL55404] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930, R01HL055404, R01HL060759] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accili EA, 1998, J PHYSIOL-LONDON, V512, P325, DOI 10.1111/j.1469-7793.1998.325be.x; Accili EA, 1997, J BIOL CHEM, V272, P25824, DOI 10.1074/jbc.272.41.25824; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; Wang ZG, 1996, J BIOL CHEM, V271, P28311, DOI 10.1074/jbc.271.45.28311; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745	14	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					738	741		10.1074/jbc.M008445200	http://dx.doi.org/10.1074/jbc.M008445200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024060	hybrid			2022-12-27	WOS:000166280700099
J	Yang, Z; Champoux, JJ				Yang, Z; Champoux, JJ			The role of histidine 632 in catalysis by human topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SIMIAN VIRUS-40 DNA; EUKARYOTIC TOPOISOMERASE; VACCINIA TOPOISOMERASE; WHEAT-GERM; SV40 DNA; CAMPTOTHECIN; CLEAVAGE; SEQUENCE; IDENTIFICATION	Based on the crystal structure of human topoisomerase I, we hypothesized that hydrogen bonding between the side chain of the highly conserved His(632) and one of the nonbridging oxygens of the scissile phosphate contributes to catalysis by stabilizing the transition state. This hypothesis has been tested by examining the effects of changing His(632) to glutamine, asparagine, alanine, and tryptophan, The change to glutamine reduced both the relaxation activity and single-turnover cleavage activity by approximately 100-fold, whereas the same change at three other conserved histidines (positions 222, 387, and 406) had no significant effect on the relaxation activity. The properties of the mutant protein containing asparagine instead of histidine at position 632 were similar to those of the glutamine mutant, whereas mutations to alanine or tryptophan reduced the activity by approximately 4 orders of magnitude. The reduction in activity for the mutants was not due to alterations in substrate binding affinities or changes in the cleavage specificities of the proteins. The above results for the glutamine mutation in conjunction with the similar effects of pH on the wild type and the H632Q mutant enzyme rule out the possibility that His(632) acts as a general acid to protonate the leaving 5'-oxygen during the cleavage reaction, Taken together, these data strongly support the hypothesis that the only role for His632 is to stabilize the pentavalent transition state through hydrogen bonding to one of the nonbridging oxygens.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Champoux JJ, 1998, PROG NUCLEIC ACID RE, V60, P111, DOI 10.1016/S0079-6603(08)60891-0; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; CHENG C, 1997, J BIOL CHEM, V22, P8263; CHRISTIANSEN K, 1987, J MOL BIOL, V193, P517, DOI 10.1016/0022-2836(87)90264-6; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; FERST A, 1999, STRUCTURE MECH PROTE, P170; GOTO T, 1984, J BIOL CHEM, V259, P422; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Ireton GC, 2000, J BIOL CHEM, V275, P25820, DOI 10.1074/jbc.M002144200; Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371; KIKUCHI A, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P121; KIM RA, 1992, J BIOL CHEM, V267, P17178; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2000, BIOCHEMISTRY-US, V39, P6422, DOI 10.1021/bi000184u; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; MADDEN KR, 1992, CANCER RES, V52, P525; PARKER LH, 1993, J MOL BIOL, V231, P6, DOI 10.1006/jmbi.1993.1252; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; PORTER SE, 1989, MOL CELL BIOL, V9, P541, DOI 10.1128/MCB.9.2.541; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Redinbo Matthew R., 1999, Current Opinion in Structural Biology, V9, P29, DOI 10.1016/S0959-440X(99)80005-0; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; SHEN CC, 1990, J MOL BIOL, V212, P67, DOI 10.1016/0022-2836(90)90305-6; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	44	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					677	685		10.1074/jbc.M007593200	http://dx.doi.org/10.1074/jbc.M007593200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024057	hybrid			2022-12-27	WOS:000166280700091
J	Granovsky, AE; Artemyev, NO				Granovsky, AE; Artemyev, NO			Identification of the gamma subunit-interacting residues on photoreceptor cGMP phosphodiesterase, PDEG alpha '*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; CATALYTIC SUBUNITS; BINDING-SITES; VISUAL TRANSDUCTION; INHIBITORY SUBUNITS; AMINO-ACIDS; CDNA CLONE; DOMAIN; MUTAGENESIS	Photoreceptor cGMP phosphodiesterase (PDE6) is the effector enzyme in the G protein-mediated visual transduction cascade. In the dark, the activity of PDE6 is shut off by the inhibitory gamma subunit (P gamma), Chimeric proteins between cone PDE6 alpha' and cGMP-binding and cGMP-specific PDE (PDE5) have been constructed and expressed in Sf9 cells to study the mechanism of inhibition of PDE6 catalytic activity by P gamma. Substitution of the segment PDE5-(773-820) by the corresponding PDE6 alpha'-(737-784) sequence in the wild-type PDE5 or in a PDE5/PDE6 alpha' chimera containing the catalytic domain of PDE5 results in chimeric enzymes capable of inhibitory interaction with P gamma. The catalytic properties of the chimeric PDEs remained similar to those of PDE5. Ala-scanning mutational analysis of the P gamma -binding region, PDE6 alpha'-(750-760), revealed PDE6 alpha' residues essential for the interaction. The M758A mutation markedly impaired and the Q752A mutation moderately impaired the inhibition of chimeric PDE by P gamma. The analysis of the catalytic properties of mutant PDEs and a model of the PDE6 catalytic domain suggest that residues Met(758) and Gln(752) directly bind P gamma. A model of the PDE6 catalytic site shows that PDE6 alpha'-(750-760) forms a loop at the entrance to the cGMP-binding pocket. Binding of P gamma to Met(758) would effectively block access of cGMP to the catalytic cavity, providing a structural basis for the mechanism of PDE6 inhibition.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.		Alex, Granovsky/EUV-7323-2022	Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY10843] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; BAEHR W, 1979, J BIOL CHEM, V254, P1669; Ballard SA, 1998, J UROLOGY, V159, P2164, DOI 10.1016/S0022-5347(01)63299-3; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; Francis SH, 2000, BIOCHEMISTRY-US, V39, P9591, DOI 10.1021/bi000392m; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAMILTON SE, 1993, FEBS LETT, V318, P157, DOI 10.1016/0014-5793(93)80012-J; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; He F, 2000, J BIOL CHEM, V275, P20572, DOI 10.1074/jbc.M000440200; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Natochin M, 2000, METHOD ENZYMOL, V315, P539; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; QIN N, 1994, J BIOL CHEM, V269, P3265; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turko IV, 1999, MOL PHARMACOL, V56, P124, DOI 10.1124/mol.56.1.124; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; Turko IV, 1998, BIOCHEMISTRY-US, V37, P4200, DOI 10.1021/bi972448r; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	40	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41258	41262		10.1074/jbc.M008094200	http://dx.doi.org/10.1074/jbc.M008094200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024033	hybrid			2022-12-27	WOS:000166114600080
J	Llera, AS; Viedma, F; Sanchez-Madrid, F; Tormo, J				Llera, AS; Viedma, F; Sanchez-Madrid, F; Tormo, J			Crystal structure of the C-type lectin-like domain from the human hematopoietic cell receptor CD69	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION INDUCER MOLECULE; MHC CLASS-I; CARBOHYDRATE-RECOGNITION; GENE-COMPLEX; INHIBITORY RECEPTOR; ESCHERICHIA-COLI; HLA-E; EXPRESSION; PROTEIN; ANTIGEN	CD69,: one of the earliest specific antigens acquired during lymphoid activation, acts as a signal-transducing receptor,involved in cellular activation events, including proliferation and induction of specific genes. CD69 belongs:to a family of receptors that modulate the immune response and whose genes are clustered in the natural killer (NK) gene complex. The extracellular portion of these receptors represent a subfamily of C-type lectin-like domains (CTLDs), which are divergent from true C-type lectins and are referred to as NK-cell domains (NKDs). We have determined the three-dimensional:Structure of human CD69 NKD in two different crystal forms. CD69 NKD adopts the canonical CTLD fold but lacks:the features involved in Ca2+ and carbohydrate binding by C-type lectins. CD69 NKD dimerizes noncovalently, both in solution and in crystalline state. The dimer interface consists of a hydrophobic, loosely packed core,:surrounded by polar interactions, including an interdomain beta sheet. The intersubunit core shows certain structural plasticity that may facilitate conformational: rearrangements for binding to ligands. The surface equivalent to the binding site of other members of the CTLD superfamily reveals a hydrophobic patch surrounded by conserved charged residues that probably constitutes:the CD69 ligand-binding site.	Univ Autonoma Madrid, Natl Biotechnol Ctr, Dept Macromol Struct, E-28049 Madrid, Spain; Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Estudios Inmunidad Humoral, RA-1113 Buenos Aires, DF, Argentina; Univ Autonoma Madrid, Hosp Princesa, Serv Immunol, Madrid 28006, Spain	Autonomous University of Madrid; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Autonomous University of Madrid; Hospital de La Princesa	Tormo, J (corresponding author), Univ Autonoma Madrid, Natl Biotechnol Ctr, Dept Macromol Struct, E-28049 Madrid, Spain.	jtormo@cnb.uam.es	Sanchez-Madrid, Francisco/M-7889-2016; Llera, Andrea S/AAW-8116-2021	Sanchez-Madrid, Francisco/0000-0001-5303-0762; Llera, Andrea/0000-0002-0089-0061				BAJORATH J, 1994, J BIOL CHEM, V269, P32457; Bates EEM, 1999, J IMMUNOL, V163, P1973; Blery M, 2000, HUM IMMUNOL, V61, P51, DOI 10.1016/S0198-8859(99)00157-3; Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brown MG, 1997, IMMUNOL REV, V155, P53, DOI 10.1111/j.1600-065X.1997.tb00939.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CEBRIAN M, 1988, J EXP MED, V168, P1621, DOI 10.1084/jem.168.5.1621; Childs RA, 1999, BIOCHEM BIOPH RES CO, V266, P19, DOI 10.1006/bbrc.1999.1762; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DEMARIA R, 1994, J EXP MED, V180, P1999, DOI 10.1084/jem.180.5.1999; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HAMANN J, 1993, J IMMUNOL, V150, P4920; Hubbard S. J., 1993, NACCESS; Hubbard SJ, 1996, J MOL BIOL, V261, P289, DOI 10.1006/jmbi.1996.0460; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LANIER LL, 1988, J EXP MED, V167, P1572, DOI 10.1084/jem.167.5.1572; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauzurica P, 2000, BLOOD, V95, P2312, DOI 10.1182/blood.V95.7.2312.007k16_2312_2320; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Lopez-Botet M, 2000, SEMIN IMMUNOL, V12, P109, DOI 10.1006/smim.2000.0213; Lopez-Botet M, 1999, CURR OPIN IMMUNOL, V11, P301, DOI 10.1016/S0952-7915(99)80048-X; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; Marzio R, 1999, IMMUNOPHARM IMMUNOT, V21, P565, DOI 10.3109/08923979909007126; Masumoto M, 1999, J IMMUNOL, V163, P5039; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKAMURA S, 1989, J EXP MED, V169, P677, DOI 10.1084/jem.169.3.677; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SANCHEZMATEOS P, 1991, EUR J IMMUNOL, V21, P2317, DOI 10.1002/eji.1830211005; SANCHEZMATEOS P, 1989, IMMUNOLOGY, V68, P72; SANTIS AG, 1992, EUR J IMMUNOL, V22, P1253, DOI 10.1002/eji.1830220521; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Suzuki N, 1996, J IMMUNOL, V156, P128; TESTI R, 1988, J IMMUNOL, V141, P2557; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; TESTI R, 1989, J IMMUNOL, V143, P1123; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; Ugolini S, 2000, CURR OPIN IMMUNOL, V12, P295, DOI 10.1016/S0952-7915(00)00090-X; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; ZIEGLER SF, 1994, J IMMUNOL, V152, P1228; Zingoni A, 2000, EUR J IMMUNOL, V30, P644, DOI 10.1002/1521-4141(200002)30:2<644::AID-IMMU644>3.0.CO;2-H	60	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7312	7319		10.1074/jbc.M008573200	http://dx.doi.org/10.1074/jbc.M008573200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11036086	Green Published, hybrid			2022-12-27	WOS:000167442900063
J	Kobori, T; Sasaki, H; Lee, WC; Zenno, S; Saigo, K; Murphy, MEP; Tanokura, M				Kobori, T; Sasaki, H; Lee, WC; Zenno, S; Saigo, K; Murphy, MEP; Tanokura, M			Structure and site-directed mutagenesis of a flavoprotein from Escherichia coli that reduces nitrocompounds - Alteration of pyridine nucleotide binding by a single amino acid substitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; VIBRIO-HARVEYI; BIOLUMINESCENT BACTERIUM; MAJOR NITROREDUCTASE; SUBSTRATE-BINDING; FLAVIN REDUCTASE; OXIDOREDUCTASE; MUTAGENICITY; GENE; PURIFICATION	The crystal structure of a major oxygen-insensitive nitroreductase (NfsA) from Escherichia coli has been solved by the molecular replacement method at 1.7-Angstrom resolution. This enzyme is a homodimeric flavoprotein with one FMN cofactor per monomer and catalyzes reduction of nitrocompounds using NADPH. The structure exhibits an alpha + beta -fold, and is comprised of a central domain and an excursion domain. The overall structure of NfsA is similar to the NADPH-dependent flavin reductase of Vibrio harveyi, despite definite difference in the spatial arrangement of residues around the putative substrate-binding site. On the basis of the crystal structure of NfsA and its alignment with the V. harveyi flavin reductase and the NADPH-dependent nitro/flavin reductase of Bacillus subtilis, residues Arg(203) and Arg(208) Of the loop region between helices I and J in the vicinity of the calalytic center FMN is predicted as a determinant for NADPH binding. The R203A mutant results in a 33-fold increase in the K-m value for NADPH indicating that the side chain of Arg(203) plays a key role in binding NADPH possibly to interact with the 2'-phosphate group.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Biotechnol Res Ctr, Bunkyo Ku, Tokyo 1138657, Japan; Tokyo Univ Sci, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of Tokyo; University of Tokyo; University of Tokyo; Tokyo University of Science; University of British Columbia	Tanokura, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amtanok@mail.ecc.u-tokyo.ac.jp	Murphy, Michael/R-6805-2017	Murphy, Michael/0000-0003-2589-0014; Tanokura, Masaru/0000-0001-5072-2480				ADAMS MJ, 1994, STRUCTURE, V2, P651, DOI 10.1016/S0969-2126(00)00066-6; ASNIS RE, 1957, ARCH BIOCHEM BIOPHYS, V66, P208, DOI 10.1016/0003-9861(57)90551-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bell CE, 1997, PROTEIN SCI, V6, P2084; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYANT DW, 1981, CAN J MICROBIOL, V27, P81, DOI 10.1139/m81-013; Chung KT, 1996, ENVIRON MOL MUTAGEN, V27, P67, DOI 10.1002/(SICI)1098-2280(1996)27:1<67::AID-EM9>3.0.CO;2-B; Cleland W W, 1979, Methods Enzymol, V63, P103; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DeMarini DM, 1996, MUTAT RES-FUND MOL M, V349, P1, DOI 10.1016/0027-5107(95)00074-7; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; DRZYZGA O, 1995, APPL ENVIRON MICROB, V61, P3282, DOI 10.1128/AEM.61.9.3282-3287.1995; GRUNBERG E, 1973, ANNU REV MICROBIOL, V27, P317, DOI 10.1146/annurev.mi.27.100173.001533; HECHT HJ, 1995, NAT STRUCT BIOL, V2, P1109, DOI 10.1038/nsb1295-1109; JABLONSKI E, 1978, BIOCHEMISTRY-US, V17, P672, DOI 10.1021/bi00597a018; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; Kobori T, 1999, ACTA CRYSTALLOGR D, V55, P1901, DOI 10.1107/S0907444999008422; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR AN, 1991, J BIOSCIENCES, V16, P145, DOI 10.1007/BF02703367; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; MASON RP, 1975, BIOCHEM BIOPH RES CO, V67, P1267, DOI 10.1016/0006-291X(75)90163-1; MCCALLA DR, 1970, J BACTERIOL, V104, P1126, DOI 10.1128/JB.104.3.1126-1134.1970; MCCALLA DR, 1974, MUTAT RES, V26, P3, DOI 10.1016/S0027-5107(74)80065-5; MCCALLA DR, 1979, NITROFURANS; Murphy MEP, 1997, PROTEIN SCI, V6, P761; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETERSON FJ, 1979, J BIOL CHEM, V254, P4009; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REYES VM, 1995, BIOCHEMISTRY-US, V34, P2710, DOI 10.1021/bi00008a039; ROSENKRANZ HS, 1977, BIOCHEM PHARMACOL, V25, P1555; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPAIN JC, 1995, ANNU REV MICROBIOL, V49, P523, DOI 10.1146/annurev.mi.49.100195.002515; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; Tanner JJ, 1999, PROTEIN SCI, V8, P1725, DOI 10.1110/ps.8.9.1725; TAZIMA Y, 1975, MUTAT RES, V32, P55, DOI 10.1016/0165-1110(75)90011-1; THORN JM, 1995, J MOL BIOL, V249, P785, DOI 10.1006/jmbi.1995.0337; TOKIWA H, 1986, CRIT REV TOXICOL, V17, P23, DOI 10.3109/10408448609037070; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; Zenno S, 1998, BIOSCI BIOTECH BIOCH, V62, P1978, DOI 10.1271/bbb.62.1978; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994; Zenno S, 1996, J BIOCHEM-TOKYO, V120, P736; Zenno S, 1998, J BACTERIOL, V180, P422, DOI 10.1128/JB.180.2.422-425.1998; Zenno S, 1996, J BACTERIOL, V178, P4508, DOI 10.1128/jb.178.15.4508-4514.1996; Ziegler GA, 1999, J MOL BIOL, V289, P981, DOI 10.1006/jmbi.1999.2807	51	85	87	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2816	2823		10.1074/jbc.M002617200	http://dx.doi.org/10.1074/jbc.M002617200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11034992	hybrid			2022-12-27	WOS:000166784800072
J	Kutty, RK; Kutty, G; Samuel, W; Duncan, T; Bridges, CC; El-Sherbeeny, A; Nagineni, CN; Smith, SB; Wigger, B				Kutty, RK; Kutty, G; Samuel, W; Duncan, T; Bridges, CC; El-Sherbeeny, A; Nagineni, CN; Smith, SB; Wigger, B			Molecular characterization and developmental expression of NORPEG, a novel gene induced by retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; MESSENGER-RNA; ALTERNATIVE POLYADENYLATION; BINDING PROTEIN; MOUSE; RECEPTOR; COMPLEX; LINE; DIFFERENTIATION; TRANSCRIPTS	We have characterized NORPEG, a novel gene from human retinal pigment epithelial cells (ARPE-19), in which its expression is induced by all-trans-retinoic acid. Two transcripts (similar to3 and similar to5 kilobases in size) have been detected for this gene, which is localized to chromosome band 5p13.2-13.3. Placenta and testis showed the highest level of expression among various human tissues tested. Six ankyrin repeats and a long coiled-coil domain are present in the predicted sequence of the NORPEG protein, which contains 980 amino acid residues. This similar to 110-kDa protein was transiently expressed in COS-7 cells as a FLAG fusion protein and immunolocalized to the cytoplasm, Confocal microscopic analysis of the NORPEG protein in ARPE-19 cells showed threadlike projections in the cytoplasm reminiscent of the cytoskeleton, Consistent with this localization, the expressed NORPEG protein showed resistance to solubilization by Triton X-100 and KCl. An ortholog of NORPEG characterized from mouse encoded a protein that showed 91% sequence similarity to the human NORPEG protein. The expression of Norpeg mRNA was detected in mouse embryo at embryonic day 9.5 by in situ hybridization, and the expression appears to be developmentally regulated. In adult mouse, the highest level of expression was detected in the seminiferous tubules of testis.	NEI, LRCMB, NIH, Biochem Sect, Bethesda, MD 20892 USA; NEI, Immunol Lab, NIH, Immunol & Virol Sect, Bethesda, MD 20892 USA; Med Coll Georgia, Dept Cellular Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Anat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Kutty, RK (corresponding author), NEI, LRCMB, NIH, Biochem Sect, 6 Ctr Dr,Rm 338, Bethesda, MD 20892 USA.	krishnan@helix.nih.gov	El-Sherbeeny, Ahmed/ABC-7879-2020	Bridges, Christy/0000-0003-1603-1445	NEI NIH HHS [EY 13089] Funding Source: Medline; NATIONAL EYE INSTITUTE [R21EY013089] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; BOK D, 1993, J CELL SCI, P189; Chancy CD, 2000, J BIOL CHEM, V275, P20676, DOI 10.1074/jbc.M002328200; Chen F, 1999, P NATL ACAD SCI USA, V96, P15149, DOI 10.1073/pnas.96.26.15149; CONLON RA, 1995, TRENDS GENET, V11, P314, DOI 10.1016/S0168-9525(00)89089-7; Crouch RK, 1996, PHOTOCHEM PHOTOBIOL, V64, P613, DOI 10.1111/j.1751-1097.1996.tb03114.x; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Faber J.J., 1983, PLACENTAL PHYSL; Fawcett DW, 1975, HDB PHYSIOLOGY     7, VV, P21; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; FRANKE WW, 1981, J MOL BIOL, V153, P933, DOI 10.1016/0022-2836(81)90460-5; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Janssen JJM, 2000, NEUROREPORT, V11, P1571, DOI 10.1097/00001756-200005150-00040; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Komada M, 2000, GENE DEV, V14, P1332; Krebber H, 1996, GENE, V180, P7, DOI 10.1016/S0378-1119(96)00389-7; LU Y, 1994, GENE, V145, P261; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]; McCaffery P, 2000, CYTOKINE GROWTH F R, V11, P233, DOI 10.1016/S1359-6101(00)00002-2; McCaffery P, 1996, P NATL ACAD SCI USA, V93, P12570, DOI 10.1073/pnas.93.22.12570; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MISHIMA K, 1992, J BIOL CHEM, V267, P24109; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Rao NA, 2000, PROG RETIN EYE RES, V19, P41, DOI 10.1016/S1350-9462(99)00003-8; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Sapin V, 1997, DEV DYNAM, V208, P199, DOI 10.1002/(SICI)1097-0177(199702)208:2<199::AID-AJA7>3.0.CO;2-D; SCHMITT MC, 1993, BIOL REPROD, V49, P972, DOI 10.1095/biolreprod49.5.972; Sibley CP, 1998, FETAL NEONATAL PHYSL, P77; Sporn M.B., 1994, RETINOIDS BIOL CHEM; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANPELT AMM, 1991, ENDOCRINOLOGY, V128, P697, DOI 10.1210/endo-128-2-697; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; YAMAUCHITAKIHARA K, 1989, P NATL ACAD SCI USA, V86, P3504, DOI 10.1073/pnas.86.10.3504; YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1145/1165387.275645	52	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2831	2840		10.1074/jbc.M007421200	http://dx.doi.org/10.1074/jbc.M007421200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042181	hybrid			2022-12-27	WOS:000166784800074
J	Murakami, E; Deppenmeier, U; Ragsdale, SW				Murakami, E; Deppenmeier, U; Ragsdale, SW			Characterization of the intramolecular electron transfer pathway from 2-hydroxyphenazine to the heterodisulfide reductase from Methanosarcina thermophilo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; MAZEI GO1; OXIDOREDUCTASE SYSTEM; THIOREDOXIN REDUCTASE; F420H2 DEHYDROGENASE; METHANOGENIC ARCHAEA; ENERGY-CONSERVATION; SPINACH FERREDOXIN; PURIFICATION; COMPLEX	Heterodisulfide reductase (HDR) is a component of the energy-conserving electron transfer system in methanogens, HDR catalyzes the two-electron reduction of coenzyme B-S-S-coenzyme M (CoB-S-S-CoM), the heterodisulfide product of the methyl-CoM reductase reaction, to free thiols, HS-CoB and HS-CoM, HDR from Methanosarcina thermophila contains two b-hemes and two [Fe4S4] clusters. The physiological electron donor for HDR appears to be methanophenazine (MPhen), a membrane-bound cofactor, which can be replaced by a water-soluble analog, 2-hydroxyphenazine (HPhen), This report describes the electron transfer pathway from reduced HPhen (HPhenH(2)) to CoB-S-S-CoM. Steady-state kinetic studies indicate a ping-pong mechanism for heterodisulfide reduction by HPhenH(2) with the following values: k(cat) = 74 s(-1) at 25 degreesC, K-m (HPhenH(2)) = 92 muM, K-m (CoB-S-S-CoM) = 144 muM Rapid freeze-quench EPR and stopped-flow kinetic studies and inhibition experiments using CO and diphenylene iodonium indicate that only the low spin heme and the high potential FeS cluster are involved in CoB-S-S-CoM reduction by HPhenH(2). Fe-S cluster disruption by mersalyl acid inhibits heme reduction by HPhenH(2), suggesting that a 4Fe cluster is the initial electron acceptor from HPhenH(2). We propose the following electron transfer pathway: HPhenH(2) to the high potential 4Fe cluster, to the low potential heme, and finally, to CoB-S-S-CoM.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA; Univ Gottingen, Inst Mikrobiol, D-37077 Gottingen, Germany	University of Nebraska System; University of Nebraska Lincoln; University of Gottingen	Ragsdale, SW (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA.							Abken HJ, 1997, FEMS MICROBIOL LETT, V154, P231, DOI 10.1111/j.1574-6968.1997.tb12649.x; Abken HJ, 1998, J BACTERIOL, V180, P2027, DOI 10.1128/JB.180.8.2027-2032.1998; Baumer S, 1998, FEBS LETT, V428, P295, DOI 10.1016/S0014-5793(98)00555-9; BAUMER S, 2000, J BIOL CHEM; Becker DF, 1998, BIOCHEMISTRY-US, V37, P2639, DOI 10.1021/bi972145x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brodersen J, 1999, EUR J BIOCHEM, V259, P218, DOI 10.1046/j.1432-1327.1999.00017.x; Deppenmeier U, 1999, FEBS LETT, V457, P291, DOI 10.1016/S0014-5793(99)01026-1; DEPPENMEIER U, 1990, P NATL ACAD SCI USA, V87, P9449, DOI 10.1073/pnas.87.23.9449; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; ELLERMANN J, 1988, EUR J BIOCHEM, V172, P669, DOI 10.1111/j.1432-1033.1988.tb13941.x; ELLIOTT JI, 1982, J BACTERIOL, V151, P328, DOI 10.1128/JB.151.1.328-333.1982; GATLEY SJ, 1976, BIOCHEM J, V158, P307, DOI 10.1042/bj1580307; HAASE P, 1992, EUR J BIOCHEM, V203, P527, DOI 10.1111/j.1432-1033.1992.tb16579.x; Ide T, 1999, J BACTERIOL, V181, P4076, DOI 10.1128/JB.181.13.4076-4080.1999; KOWAL AT, 1995, BIOCHEMISTRY-US, V34, P12284, DOI 10.1021/bi00038a024; KUHN W, 1983, EUR J BIOCHEM, V135, P89, DOI 10.1111/j.1432-1033.1983.tb07621.x; Kunkel A, 1997, EUR J BIOCHEM, V244, P226, DOI 10.1111/j.1432-1033.1997.00226.x; KUNOW J, 1994, EUR J BIOCHEM, V223, P503, DOI 10.1111/j.1432-1033.1994.tb19019.x; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; Meuer J, 1999, EUR J BIOCHEM, V265, P325, DOI 10.1046/j.1432-1327.1999.00738.x; Muller V, 1999, J BIOENERG BIOMEMBR, V31, P15, DOI 10.1023/A:1005451311009; PEER CW, 1994, J BACTERIOL, V176, P6974, DOI 10.1128/JB.176.22.6974-6979.1994; RAGAN CI, 1977, BIOCHEM J, V163, P605, DOI 10.1042/bj1630605; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; Simianu M, 1998, BIOCHEMISTRY-US, V37, P10027, DOI 10.1021/bi9726483; SOWERS KR, 1984, CURR MICROBIOL, V11, P227, DOI 10.1007/BF01567165; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Staples CR, 1998, BIOCHEMISTRY-US, V37, P4612, DOI 10.1021/bi9729763; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H	30	24	28	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2432	2439		10.1074/jbc.M004809200	http://dx.doi.org/10.1074/jbc.M004809200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11034998	hybrid			2022-12-27	WOS:000166784800020
J	Shompole, S; Jasmer, DP				Shompole, S; Jasmer, DP			Cathepsin B-like cysteine proteases confer intestinal cysteine protease activity in Haemonchus contortus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; PROTECTIVE IMMUNITY; MOLECULAR-CLONING; ADULT WORMS; GUT; INHIBITORS; ANTIGENS; GENES; IMMUNIZATION; DEGRADATION	Cathepsin B-like cysteine protease genes (cbls) constitute large multigene families in parasitic and nonparasitic nematodes. Although expressed in the intestine of some nematodes, the biological and biochemical functions of the CBL proteins remain unresolved. Di- and tetra-oligopeptides were used as fluorogenic substrates and irreversible/competitive inhibitors to establish CBL functions in the intestine of the parasitic nematode Haemonchus contortus. Cysteine protease activity was detected against diverse substrates including the cathepsin Bn substrate FR, the caspase 1 substrate YVAD, the cathepsin B substrate RR, but not the CED-3 (caspase 3) substrate DEVD. The pH at which maximum activity was detected varied according to substrate and ranged from pH 5.0 to 7.0. Individual CBLs were affinity isolated using FA and YVAD substrates. pH influenced CBL affinity isolation in a substrate-specific manner that paralleled pH effects on individual substrates. N-terminal sequencing identified two isolated CBLs as H. contortus GCP-7 (33 kDa) and AC-4 (37 kDa). N termini of each began at a position consistent with proregion cleavage and protease activation. Isolation of the GCP-7 band by each peptide was preferentially inhibited when competed with a diazomethane-conjugated inhibitor, Z-FA-CHN2, demonstrating one functional difference among CBLs and among inhibitors. Substrate-based histological analysis placed CBLs on the intestinal microvilli. Data indicate that CBLs are responsible for cysteine protease activity described from H. contortus intestine. Results also support a role of CBLs in nutrient digestion.	Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA	Washington State University	Shompole, S (corresponding author), Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA.							Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Brindley PJ, 1997, MOL BIOCHEM PARASIT, V89, P1, DOI 10.1016/S0166-6851(97)00098-4; COX GN, 1990, MOL BIOCHEM PARASIT, V41, P25, DOI 10.1016/0166-6851(90)90093-2; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; GILMOR SA, 1997, PROTEIN SCI, V6, P1603; HARROP SA, 1995, TROP MED PARASITOL, V46, P119; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; HASNAIN S, 1993, J BIOL CHEM, V268, P235; HUGHES AL, 1994, MOL PHYLOGENET EVOL, V3, P310, DOI 10.1006/mpev.1994.1038; Jasmer DP, 2000, MOL BIOCHEM PARASIT, V105, P81, DOI 10.1016/S0166-6851(99)00169-3; JASMER DP, 1991, INFECT IMMUN, V59, P4412, DOI 10.1128/IAI.59.12.4412-4417.1991; JASMER DP, 1993, J IMMUNOL, V151, P5450; KARANU FN, 1993, EXP PARASITOL, V77, P362, DOI 10.1006/expr.1993.1093; Knox DP, 1999, PARASITE IMMUNOL, V21, P201, DOI 10.1046/j.1365-3024.1999.00220.x; Larminie CGC, 1996, DNA CELL BIOL, V15, P75, DOI 10.1089/dna.1996.15.75; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; PRATT D, 1992, MOL BIOCHEM PARASIT, V51, P209, DOI 10.1016/0166-6851(92)90071-Q; Rehman A, 1998, MOL BIOCHEM PARASIT, V97, P55, DOI 10.1016/S0166-6851(98)00132-7; Rehman A, 1999, MOL BIOCHEM PARASIT, V102, P297, DOI 10.1016/S0166-6851(99)00086-9; RHOADS ML, 1995, J PARASITOL, V81, P505, DOI 10.2307/3283844; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; SHAW E, 1986, BIOMED BIOCHIM ACTA, V45, P1397; Skuce PJ, 1999, PARASITOLOGY, V119, P405, DOI 10.1017/S0031182099004813; Smith SK, 1999, PARASITE IMMUNOL, V21, P187, DOI 10.1046/j.1365-3024.1999.00217.x; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; Vaux DL, 1997, MOL CELL BIOL, V17, P6502, DOI 10.1128/MCB.17.11.6502; Wasilewski MM, 1996, MOL BIOCHEM PARASIT, V81, P179, DOI 10.1016/0166-6851(96)02703-X; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	29	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2928	2934		10.1074/jbc.M007321200	http://dx.doi.org/10.1074/jbc.M007321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11032834	hybrid			2022-12-27	WOS:000166784800085
J	Petro, JB; Khan, WN				Petro, JB; Khan, WN			Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappa B signaling pathway in B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN-RECEPTOR; X-LINKED AGAMMAGLOBULINEMIA; SURFACE-IMMUNOGLOBULIN; C-REL; ACTIVATION; EXPRESSION; APOPTOSIS; MICE; PROLIFERATION; COMPLEX	Mutations in the gene encoding Bruton's tyrosine kinase (BTK) interfere with B cell proliferation and lead to an X-Linked immunodeficiency in mice characterized by reduced B cell numbers. Recent studies have established that BTK transmits signals from the B cell antigen receptor (BCR) to transcription factor NF-kappaB, which in turn reprograms a set of genes required for normal B cell growth. We now demonstrate that induction of NF-kappaB via this pathway requires the intermediate action of the -gamma2 isoform of phospholipase C (PLC-gamma2), a potential phosphorylation substrate of BTK. Specifically, pharmacologic agents that block the action of either PLC-gamma2 or its second messengers prevent BCR-induced activation of I kappaB kinase. Moreover, activation of NF-kappaB in response to BCR signaling is completely abolished in B cells deficient for PLC-gamma2. Taken together, these findings strongly suggest that PLC-gamma2 functions as an integral component of the BTK/NF-kappaB axis following BCR ligation. Interference with this NF-kappaB cascade may account for some of the B cell defects reported for plc-gamma2(-/-) mice, which develop an X-linked immunodeficiency-like phenotype.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Khan, WN (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA.							Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bendall HH, 1999, MOL IMMUNOL, V36, P187, DOI 10.1016/S0161-5890(99)00031-0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Chen CL, 1999, BIOCHEM BIOPH RES CO, V257, P798, DOI 10.1006/bbrc.1999.0548; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Ozes ON, 1999, NATURE, V401, P82; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Solvason N, 1998, J EXP MED, V187, P1081, DOI 10.1084/jem.187.7.1081; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VENKATARAMAN L, 1995, J EXP MED, V181, P1091, DOI 10.1084/jem.181.3.1091; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2; Zandi E, 1999, MOL CELL BIOL, V19, P4547	33	116	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1715	1719		10.1074/jbc.M009137200	http://dx.doi.org/10.1074/jbc.M009137200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042193	hybrid			2022-12-27	WOS:000166528000010
J	Weber, JT; Rzigalinski, BA; Ellis, EF				Weber, JT; Rzigalinski, BA; Ellis, EF			Traumatic injury of cortical neurons causes changes in intracellular calcium stores and capacitative calcium influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; OPERATED HTRP3 CHANNELS; STRETCH-INDUCED INJURY; CENTRAL-NERVOUS-SYSTEM; BRAIN INJURY; DELAYED DEPOLARIZATION; ENDOPLASMIC-RETICULUM; GLUTAMATE RECEPTORS; TRANSMITTER RELEASE; ARACHIDONIC-ACID	Using an in vitro traumatic injury model, we examined the effects of mechanical (stretch) injury on intracellular Ca2+ store-mediated signaling in cultured cortical neurons using fura-2. We previously found that elevation of [Ca2+](i) by the endoplasmic reticulum Ca2+-ATPase inhibitor, thapsigargin, was abolished 15 min post-injury. In the current studies, pre-injury inhibition of phospholipase C with neomycin sulfate maintained Ca2+-replete stores 15 min post-injury, suggesting that the initial injury-induced store depletion may be due to increased inositol trisphosphate production. Thapsigargin-stimulated elevation of [Ca2+], returned with time after injury and was potentiated at 3 h. Stimulation with thapsigargin in Ca2+-free media revealed that the size of the Ca2+ stores was normal at 3 h post-injury, However, Ca2+ influx triggered by depletion of intracellular Ca2+ stores (capacitative Ca2+ influx) was enhanced 3 h after injury. Enhancement was blocked by inhibitors of cytosolic phospholipase A, and cytochrome P450 epoxygenase. Since intracellular Ca2+ store-mediated signaling plays an important role in neuronal function, the observed changes may contribute to dysfunction produced by traumatic brain injury. Additionally, our results suggest that capacitative Ca2+ influx may be mediated by both conformational coupling and a diffusible messenger synthesized by the combined action of cytosolic PLA, and P450.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University	Rzigalinski, BA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Box 980613, Richmond, VA 23298 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57869] Funding Source: Medline; NINDS NIH HHS [NS-27214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AbdulGhani MA, 1996, J NEUROPHYSIOL, V76, P2691, DOI 10.1152/jn.1996.76.4.2691; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; BRORSON JR, 1991, J NEUROSCI, V11, P4024; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Budd SL, 1996, J NEUROCHEM, V67, P2282; Choi S, 1996, J NEUROSCI, V16, P36; DELAHUNTY TM, 1992, BRAIN RES, V594, P507; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Doutheil J, 1997, BRAIN RES, V775, P43, DOI 10.1016/S0006-8993(97)00899-8; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Fomina AF, 1999, J NEUROSCI, V19, P3711; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; Garaschuk O, 1997, J PHYSIOL-LONDON, V502, P13, DOI 10.1111/j.1469-7793.1997.013bl.x; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Jonas S, 1997, ANN NY ACAD SCI, V825, P389, DOI 10.1111/j.1749-6632.1997.tb48449.x; Kaftan EJ, 1997, J GEN PHYSIOL, V110, P529, DOI 10.1085/jgp.110.5.529; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kohn EC, 1996, CANCER RES, V56, P569; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LEI SHZ, 1992, BRAIN RES, V598, P196, DOI 10.1016/0006-8993(92)90183-A; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Ma L, 1998, J NEUROPHYSIOL, V79, P1183, DOI 10.1152/jn.1998.79.3.1183; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; McIntosh TK, 1996, LAB INVEST, V74, P315; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Picard L, 1998, CELL CALCIUM, V23, P339, DOI 10.1016/S0143-4160(98)90029-X; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PRASAD MR, 1994, J NEUROCHEM, V63, P773; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sakaki Y, 1997, J NEUROBIOL, V32, P62, DOI 10.1002/(SICI)1097-4695(199701)32:1<62::AID-NEU6>3.0.CO;2-C; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCHLAEPFER WW, 1985, PROG BRAIN RES, V63, P185; Scholz WK, 1998, J NEUROCHEM, V71, P580; SCHREIBER D, 1995, P 1995 INT RES C BIO; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; White RJ, 1996, J NEUROSCI, V16, P5688; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	70	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1800	1807		10.1074/jbc.M009209200	http://dx.doi.org/10.1074/jbc.M009209200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050103	hybrid			2022-12-27	WOS:000166528000022
J	Bernard, ML; Peterson, YK; Chung, P; Jourdan, J; Lanier, SM				Bernard, ML; Peterson, YK; Chung, P; Jourdan, J; Lanier, SM			Selective interaction of AGS3 with G-proteins and the influence of AGS3 on the activation state of G-proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; RECEPTOR; IDENTIFICATION; DIVISIONS; SITES	AGS3 (activator of G-protein Signaling 3) was isolated in a yeast-based functional screen for receptor-independent activators of heterotrimeric G-proteins, As an initial approach to define the role of AGS3 in mammalian signal processing, we defined the AGS3 subdomains involved in G-protein interaction, its selectivity for G-proteins, and its influence on the activation state of G-protein, Immunoblot analysis with AGS3 antisera indicated expression in rat brain, the neuronal-like cell lines PC12 and NG108-15, as well as the smooth muscle cell line DDT1-MF2, Immunofluorescence studies and confocal imaging indicated that AGS3 was predominantly cytoplasmic and enriched in microdomains of the cell. AGS3 coimmunoprecipitated with G alpha (i3) from cell and tissue lysates, indicating that a subpopulation of AGS3 and G alpha (1) exist as a complex in the cell. The coimmunoprecipitation of AGS3 and G alpha (i) was dependent upon the conformation of G alpha (i3) (GDP much greater than GTP gammaS (guanosine 5'-3-O-(thio)triphosphate)). The regions of AGS3 that bound G alpha (i) were localized to four amino acid repeats (G-protein regulatory motif (GPR)) in the carboxyl terminus (Pro(465)-Ser(650)), each of which were capable of binding G alpha (i). AGS3-GPR domains selectively interacted with G alpha (i) in tissue and cell lysates and with purified G alphai/G(alphat). Subsequent experiments with purified G alpha (i2) and G alpha (i3) indicated that the carboxyl-terminal region containing the four GPR motifs actually bound more than one G alpha (i) subunit at the same time. The AGS3GPR domains effectively competed with GP gamma for binding to G alpha (t(GDP)) and blocked GTP gammaS binding to G alpha (i). AGS3 and related proteins provide unexpected mechanisms for coordination of G-protein signaling pathways.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29403 USA	Medical University of South Carolina	Lanier, SM (corresponding author), Med Univ S Carolina, Dept Pharmacol, 173 Ashley Ave, Charleston, SC 29403 USA.	laniersm@musc.edu	Bernard, Michael/AAW-3944-2021	Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM08716] Funding Source: Medline; NIMH NIH HHS [MH5993] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; DUZIC E, 1992, J BIOL CHEM, V267, P24045; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GRABER SG, 1992, J BIOL CHEM, V267, P1271; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Makhlouf M, 1996, BBA-MOL CELL RES, V1312, P163, DOI 10.1016/0167-4889(96)00019-5; MIXON MB, 1996, SCIENCE, V270, P964; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; Rodbell M, 1996, MT SINAI J MED, V63, P381; ROSS EM, 1994, METHOD ENZYMOL, V237, P26; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	27	120	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1585	1593		10.1074/jbc.M005291200	http://dx.doi.org/10.1074/jbc.M005291200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042168	hybrid			2022-12-27	WOS:000166430900097
J	Masson, P; Andersson, O; Petersens, UM; Young, P				Masson, P; Andersson, O; Petersens, UM; Young, P			Identification and characterization of a Drosophila nuclear proteasome regulator - A homolog of human 11 S REG gamma (PA28 gamma)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PA28; MULTICATALYTIC PROTEASE; RECEPTOR FAMILY; 20S PROTEASOME; ALPHA-SUBUNIT; BETA-SUBUNIT; CELL-CYCLE; KI ANTIGEN; LOCALIZATION; EXPRESSION	We report the cloning and characterization of a Drosophila proteasome 11 S REG gamma (PA28) homolog. The 28-kDa protein shows 47% identity to the human REG gamma and strongly enhances the trypsin-like activities of both Drosophila and mammalian 20 S proteasomes. Surprisingly, the Drosophila REG was found to inhibit the proteasome's chymotrypsin-like activity against the fluorogenic peptide succinyl-LLVY-7-amino-4-methylcoumarin. Immunocytological analysis reveals that the Drosophila REG is localized to the nucleus but is distributed throughout the cell when nuclear envelope breakdown occurs during mitosis, Through site-directed mutagenesis studies, we have identified a functional nuclear localization signal present in the homolog-specific insert region. The Drosophila PA28 NLS is similar to the oncogene c-Myc nuclear localization motif. Comparison between uninduced and innate immune induced Drosophila cells suggests that the REG gamma proteasome activator has a role independent of the invertebrate immune system. Our results support the idea that gamma class proteasome activators have an ancient conserved function within metazoans and were present prior to the emergence of the (alpha and beta REG classes.	Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden	Stockholm University	Young, P (corresponding author), Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden.	patrick.young@molbio.su.se	Masson, Patrick/AAA-7213-2019	Masson, Patrick/0000-0002-7837-3662; Masson, Patrick/0000-0001-7646-0052				Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Covi JA, 1999, ARCH BIOCHEM BIOPHYS, V368, P85, DOI 10.1006/abbi.1999.1294; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; Fahmy O. G., 1958, DROS INFORM SERV, V32, P67; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Kandil E, 1997, IMMUNOGENETICS, V46, P337, DOI 10.1007/s002510050281; Kloetzel PM, 1999, BIOL CHEM, V380, P293, DOI 10.1515/BC.1999.040; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; Kohda K, 1998, J IMMUNOL, V160, P4923; Li J, 2000, J MOL BIOL, V299, P641, DOI 10.1006/jmbi.2000.3800; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MA CP, 1992, J BIOL CHEM, V267, P10515; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Murata S, 1999, J BIOL CHEM, V274, P38211, DOI 10.1074/jbc.274.53.38211; Murray BW, 2000, SCAND J IMMUNOL, V51, P571; NIKAIDO T, 1990, CLIN EXP IMMUNOL, V79, P209; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Paesen GC, 1996, BBA-GENE STRUCT EXPR, V1309, P9, DOI 10.1016/S0167-4781(96)00116-9; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; Sneath P.H.A., 1973, NUMERICAL TAXONOMY P; Soza A, 1997, FEBS LETT, V413, P27, DOI 10.1016/S0014-5793(97)00864-8; Stohwasser R, 2000, MOL IMMUNOL, V37, P13, DOI 10.1016/S0161-5890(00)00017-1; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; Tanaka K, 1998, IMMUNOL REV, V163, P161; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tojo T, 1981, Ryumachi, V21 Suppl, P129; Wojcik C, 1998, EUR J CELL BIOL, V77, P151, DOI 10.1016/S0171-9335(98)80083-6; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; Zhang ZG, 1998, J BIOL CHEM, V273, P9501, DOI 10.1074/jbc.273.16.9501; Zhang ZG, 1998, P NATL ACAD SCI USA, V95, P2807, DOI 10.1073/pnas.95.6.2807	50	39	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1383	1390		10.1074/jbc.M007379200	http://dx.doi.org/10.1074/jbc.M007379200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11027688	hybrid			2022-12-27	WOS:000166430900071
J	Nantes, IL; Zucchi, MR; Nascimento, OR; Faljoni-Alario, A				Nantes, IL; Zucchi, MR; Nascimento, OR; Faljoni-Alario, A			Effect of heme iron valence state on the conformation of cytochrome c and its association witt membrane interfaces - A CD and EPR investigation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM; CASPASE ACTIVATION; INDUCED APOPTOSIS; RELEASE; PEROXIDATION; CARDIOLIPIN; MECHANISM; OXIDATION	Recently cytochrome c has been mentioned as an important mediator in the events of cellular oxidative stress and apoptosis, To investigate the influence of charged interfaces on the conformation of cytochrome c, the CD and magnetic circular dichroic behavior of ferric and ferrous cytochrome c in homogeneous medium and in phosphatidylcholine/phosphatidylethanolamine/cardiolipin and dicetylphosphate liposomes was studied in the 300-600 and 200-320 nm wavelength region. EPR spectra demonstrate that the association of cytochrome c with membranes promotes alterations of the crystal field symmetry and spin state of the heme Fe3+. The studies also include the effect of P-i, NaCl, and CaCl2. Magnetic circular dichroism and CD results show that the interaction of both ferrous and ferric cytochrome c with charged interfaces promotes conformational changes in the cy-helix content, tertiary structure, and heme iron spin state. Moreover, the association of cytochrome c with different liposomes is sensitive to the heme iron valence state. The more effective association with membranes occurs with ferrous cytochrome c. Dicetylphosphate liposomes, as a negatively charged membrane model, promoted a more pronounced conformational modification in the cytochrome c structure. A decrease in the lipid/protein association is detected in the presence of increasing amounts of CaCl2, NaCl, and P-i, in response to the increase of the ionic strength.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil; UMC, Diretoria Pesquisa & Posgrad, CIIB, BR-08780911 Sao Paulo, Brazil; Univ Sao Paulo, Inst Fis Sao Carlos, Grp Biofis, BR-13560970 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Mogi das Cruzes; Universidade de Sao Paulo	Faljoni-Alario, A (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, CP 26077, BR-05513970 Sao Paulo, Brazil.		Nantes, Iseli Lourenço/B-9517-2012; DO ROSARIO ZUCCHI, MARIA/AAG-7660-2021	Nantes, Iseli Lourenço/0000-0003-1434-3154; 				Almeida AM, 1999, FREE RADICAL BIO MED, V27, P744, DOI 10.1016/S0891-5849(99)00136-7; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CILENTO G, 1995, FREE RADICAL BIO MED, V19, P103, DOI 10.1016/0891-5849(95)00002-F; Eaton W A, 1981, Methods Enzymol, V76, P175; GALLARDO H, 1984, BIOCHIM BIOPHYS ACTA, V789, P57, DOI 10.1016/0167-4838(84)90060-8; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Iwase H, 1996, BIOCHEM BIOPH RES CO, V222, P83, DOI 10.1006/bbrc.1996.0701; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; MORTARA RA, 1978, BIOCHEM BIOPH RES CO, V81, P1080, DOI 10.1016/0006-291X(78)91246-9; Nantes IL, 1998, FREE RADICAL BIO MED, V25, P546, DOI 10.1016/S0891-5849(98)00082-3; NANTES IL, 1995, PHOTOCHEM PHOTOBIOL, V62, P522, DOI 10.1111/j.1751-1097.1995.tb02378.x; Nantes IL, 2000, FREE RADICAL BIO MED, V28, P786, DOI 10.1016/S0891-5849(00)00170-2; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PINHEIRO TJT, 1994, BIOCHIMIE, V76, P489, DOI 10.1016/0300-9084(94)90173-2; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; SPECK SH, 1983, FEBS LETT, V164, P379, DOI 10.1016/0014-5793(83)80321-4; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STOREY BT, 1973, BIOCHIM BIOPHYS ACTA, V292, P554, DOI 10.1016/0005-2728(73)90004-2; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; VINCENT JS, 1987, BIOCHEMISTRY-US, V26, P2312, DOI 10.1021/bi00382a036; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	28	85	88	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					153	158		10.1074/jbc.M006338200	http://dx.doi.org/10.1074/jbc.M006338200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027687	hybrid			2022-12-27	WOS:000166280700022
J	Shao, J; Grammatikakis, N; Scroggins, BT; Uma, S; Huang, WJ; Chen, JJ; Hartson, SD; Matts, RL				Shao, J; Grammatikakis, N; Scroggins, BT; Uma, S; Huang, WJ; Chen, JJ; Hartson, SD; Matts, RL			Hsp90 regulates p50(cdc27) function during the biogenesis of the active conformation of the heme-regulated eIF2 alpha kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTE LYSATE; CYCLE CONTROL PROTEIN; HEAT-SHOCK PROTEIN; EIF-2-ALPHA KINASE; SIGNAL-TRANSDUCTION; MOLECULAR CHAPERONE; TERMINAL DOMAIN; BINDING-SITE; CDC37; COMPLEX	Recent studies indicate that p50(cdc37) facilitates Hsp90-mediated biogenesis of certain protein kinases. In this report, we examined whether p50(cdc37) is required for the biogenesis of the heme-regulated eIF2 alpha kinase (HRI) in reticulocyte lysate. p50cdc37 interacted with nascent HRI co-translationally and this interaction persisted during the maturation and activation of HRI, p50(cdc37) stimulated HRI's activation in response to heme deficiency, but did not activate HRI per se. p50cdc37 function was specific to immature and inactive forms of the kinase, Analysis of mutant Cdc37 gene products indicated that the N-terminal portion of p50(cdc37) interacted with immature HRI, but not with Hsp90, while the C-terminal portion of p50(cdc37) interacted with HspSO. The Hsp90-specific inhibitor geldanamycin disrupted the ability of both HspSO and p50(cdc37) to bind HRI and promote its activation, but did not disrupt the native association of p50(cdc37) With HsP90. A C-terminal truncated mutant of p50(cdc37) inhibited HRI's activation, prevented the interaction of HspSO with HRI, and bound to HRI irrespective of geldanamycin treatment. Additionally, native complexes of HRI with p50(cdc37) were detected in cultured K562 erythroleukemia cells. These results suggest that p50(cdc37) provides an activity essential to HRI biogenesis via a process regulated by nucleotide-mediated conformational switching of its partner HspSO.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Oklahoma State University System; Oklahoma State University - Stillwater; Jefferson University; Harvard University; Massachusetts Institute of Technology (MIT)	Matts, RL (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, 246 NRC, Stillwater, OK 74078 USA.	rmatts@biochem.okstate.edu			NIDDK NIH HHS [DK-53223, R01 DK016272] Funding Source: Medline; NIEHS NIH HHS [ES04299] Funding Source: Medline; NIGMS NIH HHS [GM15608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004299, R29ES004299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM015608] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1993, TRANSLATIONAL REGULA, V2, P349; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; Dey B, 1996, MOL BIOL CELL, V7, P1405, DOI 10.1091/mbc.7.9.1405; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; FERGUSON J, 1986, NUCLEIC ACIDS RES, V14, P6681, DOI 10.1093/nar/14.16.6681; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hartson SD, 1999, BIOCHEMISTRY-US, V38, P3837, DOI 10.1021/bi983027s; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; Hartson SD, 1998, J BIOL CHEM, V273, P8475, DOI 10.1074/jbc.273.14.8475; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Matsuda S, 1999, J BIOL CHEM, V274, P34515, DOI 10.1074/jbc.274.49.34515; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; O'Keeffe B, 2000, J BIOL CHEM, V275, P279, DOI 10.1074/jbc.275.1.279; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Thulasiraman V, 1998, EUR J BIOCHEM, V255, P552, DOI 10.1046/j.1432-1327.1998.2550552.x; Uma S, 1999, MOL CELL BIOL, V19, P5861; Uma S, 1997, J BIOL CHEM, V272, P11648; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu ZY, 1997, EUR J BIOCHEM, V246, P461, DOI 10.1111/j.1432-1033.1997.t01-1-00461.x	37	75	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					206	214		10.1074/jbc.M007583200	http://dx.doi.org/10.1074/jbc.M007583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11036079	hybrid			2022-12-27	WOS:000166280700030
J	Shi, XM; Bai, ST; Li, LN; Cao, X				Shi, XM; Bai, ST; Li, LN; Cao, X			Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; OSTEOGENIC PROTEIN-1; TUMOR-SUPPRESSOR; ACTS DOWNSTREAM; BONE-FORMATION; SMAD PROTEINS; TGF; BINDING; IDENTIFICATION; OSTEOCLASTS	Smad2 and Smad3 are downstream transforming growth factor-beta (TGF-beta) signaling molecules. Upon phosphorylation by its type I receptor, Smad2 or Smad3 forms a complex with Smad4 and translocates to the nucleus where the complex activates target gene transcription. In the present study, we report that Smad3 binds directly to the osteopontin (OPN) promoter and that Smad4 interacts with the Hox protein and displaces it from its cognate DNA binding site in response to TGF-beta stimulation. In gel shift assays, the glutathione S-transferase-Smad3 fusion protein was found to bind to a 50-base pair DNA element (-179 to -229) from the OPN promoter. Also, we found that both Hoxc-8 and Hoxa-9 bound to a Hox binding site adjacent to Smad3 binding sequence. Interestingly, Smad4, the common partner for both bone morphogenic protein and TGF-beta signaling pathways, inhibited the binding of Hox protein to DNA. FLAG-tagged Smad4 coimmunoprecipitated with HA-tagged Hoxa-9 from cotransfected COS-1 cells, demonstrating an interaction between Smad4 and Hoxa-9. Transfection studies showed that Hoxa-9 is a strong transcriptional repressor; it suppresses the transcription of the luciferase reporter gene driven by a 124-base pair OPN promoter fragment containing both Smad3 and Hox binding sites. Taken together, these data demonstrate a unique TGF-beta -induced transcription mechanism. Smad3 and Smad4 exhibit different functions in activation of OPN transcription. Smad4 binds directly to the OPN promoter as a sequence-specific activator, and Smad4 displaces the transcription repressor, Hoxa-9, by formation of Smad4/Hox complex as part of the transcription mechanism in response to TGF-beta stimulation.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Cao, X (corresponding author), Univ Alabama Birmingham, Dept Pathol, 1670 Univ Blvd,Volker Hall G002, Birmingham, AL 35294 USA.	cao@path.uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053757] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53757] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Candia AF, 1997, DEVELOPMENT, V124, P4467; CENTRELLA M, 1991, J BONE JOINT SURG AM, V73A, P1418, DOI 10.2106/00004623-199173090-00022; Cheifetz S, 1996, CONNECT TISSUE RES, V35, P71, DOI 10.3109/03008209609029176; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; GOTOH Y, 1990, EUR J BIOCHEM, V187, P49, DOI 10.1111/j.1432-1033.1990.tb15276.x; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MERRY K, 1993, J CELL SCI, V104, P1013; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakayama T, 1998, DEVELOPMENT, V125, P857; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; NODA M, 1989, CONNECT TISSUE RES, V21, P401, DOI 10.3109/03008208909049997; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	43	66	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					850	855		10.1074/jbc.M005955200	http://dx.doi.org/10.1074/jbc.M005955200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11042172	hybrid			2022-12-27	WOS:000166280700114
J	Liu, SH; Spinner, DS; Schmidt, MM; Danielsson, JA; Wang, SW; Schmidt, J				Liu, SH; Spinner, DS; Schmidt, MM; Danielsson, JA; Wang, SW; Schmidt, J			Interaction of MyoD family proteins with enhancers of acetylcholine receptor subunit genes in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CELL CULTURES; E-BOX ELEMENTS; ELECTRICAL-ACTIVITY; MYOGENIC FACTORS; SKELETAL-MUSCLE; DENERVATION SUPERSENSITIVITY; DEPENDENT EXPRESSION; EPSILON-SUBUNIT; TRANSGENIC MICE; BINDING-SITE	The myogenic determination factors (MDFs) are transcriptional activators that target E boxes in many muscle-specific promoters, including those of the genes coding for the subunits of the acetylcholine receptor. It is not known, however, if in vivo a given E box in a transcriptionally active gene is occupied, either uniquely by one MDF or randomly by all MDFs. We have analyzed expression of MDF and acetylcholine receptor subunits in cultured mouse muscle cells and, using chromatin immunoprecipitation, have determined which individual MDFs reside at promoters of several receptor subunit genes. We find that before fusion, C2C12 cells express myf-5, MyoD, and myogenin, all of which take up residence at promoters of all subunits except epsilon. At this stage, herculin is present in limited amounts and is detected mainly at the gamma and delta subunit genes. On myotube formation, herculin reaches high levels; concomitantly, the epsilon subunit gene becomes a common MDF target and beans to be expressed, In general, any MDF protein that is expressed also is present on transcriptionally active receptor genes; transcriptional activity of target genes correlates with occupancy by MDF, in particular, herculin.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Schmidt, J (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Life Sci Bldg,Rm 412, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020233] Funding Source: NIH RePORTER; NINDS NIH HHS [NS20233] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnold HH, 1996, INT J DEV BIOL, V40, P345; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLOCK NE, 1992, MOL CELL BIOL, V12, P2484, DOI 10.1128/MCB.12.6.2484; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BUONANNO A, 1992, NUCLEIC ACIDS RES, V20, P539, DOI 10.1093/nar/20.3.539; DAUBAS P, 1988, NUCLEIC ACIDS RES, V16, P1251, DOI 10.1093/nar/16.4.1251; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCLERT A, 1991, NEUROREPORT, V2, P25, DOI 10.1097/00001756-199101000-00006; DURR I, 1994, EUR J BIOCHEM, V224, P353, DOI 10.1111/j.1432-1033.1994.00353.x; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GUNDERSEN K, 1995, MOL CELL BIOL, V15, P7127; HAUSCHKA SD, 1994, MYOLOGY BASIC CLIN, V1, P3; Hughes SM, 1997, MECH DEVELOP, V61, P151, DOI 10.1016/S0925-4773(96)00631-4; JIA HT, 1992, CELL MOL NEUROBIOL, V12, P241, DOI 10.1007/BF00712929; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MONTARRAS D, 1991, NEW BIOL, V3, P592; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Neville C, 1996, DEV GENET, V19, P157, DOI 10.1002/(SICI)1520-6408(1996)19:2<157::AID-DVG7>3.0.CO;2-8; Neville CM, 1998, J BIOL CHEM, V273, P14046, DOI 10.1074/jbc.273.22.14046; NEVILLE CM, 1992, CELL MOL NEUROBIOL, V12, P511, DOI 10.1007/BF00711232; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1991, J BIOL CHEM, V266, P22588; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; SUNYER T, 1993, J NEUROSCI RES, V36, P224, DOI 10.1002/jnr.490360213; VOYTIK SL, 1993, DEV DYNAM, V198, P214, DOI 10.1002/aja.1001980307; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; WITZEMANN V, 1991, FEBS LETT, V282, P259, DOI 10.1016/0014-5793(91)80490-T; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	36	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41364	41368		10.1074/jbc.M004172200	http://dx.doi.org/10.1074/jbc.M004172200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024014	hybrid			2022-12-27	WOS:000166114600093
J	Richardson, A; Schwager, F; Landry, SJ; Georgopoulos, C				Richardson, A; Schwager, F; Landry, SJ; Georgopoulos, C			The importance of a mobile loop in regulating chaperonin/co-chaperonin interaction - Humans versus Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN MITOCHONDRIAL CHAPERONIN-60; CRYSTAL-STRUCTURE; IN-VIVO; ATP HYDROLYSIS; SINGLE-RING; PROTEIN; GROEL; PURIFICATION; POLYPEPTIDE; MUTATIONS	Chaperonins are universally conserved proteins that nonspecifically facilitate the folding of a wide spectrum of proteins. While bacterial GroEL is functionally promiscuous with various co-chaperonin partners, its human homologue, Hsp60 functions specifically with its co-chaperonin partner, Hsp10, and not with other co-chaperonins, such as the bacterial GroES or bacteriophage T4-encoded Gp31. Co-chaperonin interaction with chaperonin is mediated by the co-chaperonin mobile loop that folds into a beta -hairpin conformation upon binding to the chaperonin, A delicate balance of flexibility and conformational preferences of the mobile loop determines co-chaperonin affinity for chaperonin, Here, me show that the ability of Hsp10, but not GroES, to interact specifically with Hsp60 lies within the mobile loop sequence. Using mutational analysis, we show that three substitutions in the GroES mobile loop are necessary and sufficient to acquire Hsp10-like specificity. Two of these substitutions are predicted to preorganize the beta -hairpin turn and one to increase the hydrophobicity of the GroEL-binding site. Together, they result in a GroES that binds chaperonins with higher affinity, It seems likely that the single ring mitochondrial Hsp60 exhibits intrinsically lower affinity for the co-chaperonin that can be compensated for by a higher affinity mobile loop.	Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva, Switzerland; Tulane Univ, Sch Med, Dept Biochem, New Orleans, LA 70112 USA	University of Geneva; Tulane University	Georgopoulos, C (corresponding author), Ctr Med Univ Geneva, Dept Biochim Med, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.	Costa.Georgopoulos@medecine.unige.ch	Landry, Samuel/AAK-5778-2020	Landry, Samuel/0000-0002-4082-0543				Andreadis JD, 1998, J BIOL CHEM, V273, P34075, DOI 10.1074/jbc.273.51.34075; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CASTILLO CJ, 1978, J BIOL CHEM, V253, P2132; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DICKSON R, 1994, J BIOL CHEM, V269, P26858; Dubaquie Y, 1997, P NATL ACAD SCI USA, V94, P9011, DOI 10.1073/pnas.94.17.9011; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; Gething MJ., 1997, GUIDEBOOK MOL CHAPER; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HARTMAN DJ, 1993, BIOCHIM BIOPHYS ACTA, V1164, P219, DOI 10.1016/0167-4838(93)90251-L; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHFELD J, 1994, J CELL BIOL, V126, P305, DOI 10.1083/jcb.126.2.305; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; KOONIN EV, 1995, TRENDS BIOCHEM SCI, V20, P14, DOI 10.1016/S0968-0004(00)88941-0; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Landry S J, 1999, Pac Symp Biocomput, P520; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; Landry SJ, 1997, BIOCHEMISTRY-US, V36, P10975, DOI 10.1021/bi971141p; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; Nieba L, 1997, ANAL BIOCHEM, V252, P217, DOI 10.1006/abio.1997.2326; Nielsen KL, 1998, MOL CELL, V2, P93, DOI 10.1016/S1097-2765(00)80117-3; Nielsen KL, 1999, J BACTERIOL, V181, P5871, DOI 10.1128/JB.181.18.5871-5875.1999; *QIAG, 1998, QIAEXPR GUID HDB HIG; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Richardson A, 1999, GENETICS, V152, P1449; Richardson A, 1999, J BIOL CHEM, V274, P52, DOI 10.1074/jbc.274.1.52; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Saibil H, 1996, STRUCTURE, V4, P1, DOI 10.1016/S0969-2126(96)00002-0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; Viitanen PV, 1998, METHOD ENZYMOL, V290, P203, DOI 10.1016/S0076-6879(98)90020-9; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1997, GUIDEBOOK MOL CHAPER, P199; WANG Z, 1992, PROTEIN SCI, V1, P522; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WILSON GG, 1979, J MOL BIOL, V132, P471, DOI 10.1016/0022-2836(79)90270-5; Wimley WC, 1996, BIOCHEMISTRY-US, V35, P5109, DOI 10.1021/bi9600153; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993; ZeilstraRyalls J, 1996, FASEB J, V10, P148, DOI 10.1096/fasebj.10.1.8566535	57	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4981	4987		10.1074/jbc.M008628200	http://dx.doi.org/10.1074/jbc.M008628200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11050098	hybrid			2022-12-27	WOS:000168484300062
J	Alvarez, C; Garcia-Mata, R; Hauri, HP; Sztul, E				Alvarez, C; Garcia-Mata, R; Hauri, HP; Sztul, E			The p115-interactive proteins GM130 and giantin participate in endoplasmic reticulum-Golgi traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; MEMBRANE-PROTEIN; INTERMEDIATE COMPARTMENT; REQUIRES USO1P; MATRIX PROTEIN; COPI VESICLES; HELA-CELLS; COMPLEX; FUSION; APPARATUS	The transport factor p115 is essential for endoplasmic reticulum (ER) to Golgi traffic. P115 interacts with two Golgi proteins, GM130 and giantin, suggesting that they might also participate in ER-Golgi traffic. Here, we show that peptides containing the GM130 or the giantin p115 binding domain and anti-GM130 and anti-giantin antibodies inhibit transport of vesicular stomatitis virus (VSV)-G protein to a mannosidase II-containing Golgi compartment, To determine whether p115, GM130, and giantin act together or sequentially during transport, we compared kinetics of traffic inhibition, Anti-p115, anti-GM130, and anti-giantin antibodies inhibited transport at temporally distinct steps, with the p115-requiring step before the GM130-requiring stage, and both preceding the giantin-requiring stage. Examination of the distribution of the arrested VSV-G protein showed that anti-p115 antibodies inhibited transport at the level of vesicular-tubular clusters, whereas anti-GM130 and anti-giantin antibodies inhibited after the VSV-G protein moved to the Golgi complex. Our results provide the first evidence that GM130 and giantin are required for the delivery of a cargo protein to the mannosidase II-containing Golgi compartment, These data are most consistent with a model where transport from the ER to the cis/medial-Golgi compartments requires the action of p115, GM130, and giantin in a sequential rather than coordinate mechanism.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Basel, Biozentrum, Dept Pharmacol, CH-4056 Basel, Switzerland	University of Alabama System; University of Alabama Birmingham; University of Basel	Sztul, E (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, McCallum Bldg,Rm 668,1530 3rd Ave S, Birmingham, AL 35294 USA.	esztul@uab.edu		Fujita, Hideaki/0000-0002-4105-4430; Garcia-Mata, Rafael/0000-0002-7116-4411	PHS HHS [99508358] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Alvarez C, 1999, J CELL BIOL, V147, P1205, DOI 10.1083/jcb.147.6.1205; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DAVIDSON HW, 1992, METHOD ENZYMOL, V219, P261; Dirac-Svejstrup AB, 2000, J CELL BIOL, V150, P475, DOI 10.1083/jcb.150.3.475; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Lesa GM, 2000, J BIOL CHEM, V275, P2831, DOI 10.1074/jbc.275.4.2831; Linstedt AD, 2000, J BIOL CHEM, V275, P10196, DOI 10.1074/jbc.275.14.10196; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SCHWANINGER R, 1992, METHOD ENZYMOL, V219, P110; SEELIG HP, 1994, MOL CELL BIOL, V14, P2564, DOI 10.1128/MCB.14.4.2564; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Shorter J, 1999, J CELL BIOL, V146, P57, DOI 10.1083/jcb.146.1.57; SOHDA M, 1994, BIOCHEM BIOPH RES CO, V205, P1399, DOI 10.1006/bbrc.1994.2821; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157	49	103	106	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2693	2700		10.1074/jbc.M007957200	http://dx.doi.org/10.1074/jbc.M007957200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035033	hybrid			2022-12-27	WOS:000166784800055
J	Horie, S; Ishii, H; Matsumoto, F; Kusano, M; Kizaki, K; Matsuda, J; Kazama, M				Horie, S; Ishii, H; Matsumoto, F; Kusano, M; Kizaki, K; Matsuda, J; Kazama, M			Acceleration of thrombomodulin gene transcription by retinoic acid - Retinoic acid receptors and Sp1 regulate the promoter activity through interactions with two different sequences in the 5 '-flanking region of human gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; THROMBIN-CATALYZED ACTIVATION; DEPENDENT PROTEIN-KINASE; X-RECEPTOR; THYROID-HORMONE; TISSUE-FACTOR; NUCLEAR RECEPTORS; ANTICOAGULANT ACTIVITY; ESTROGEN-RECEPTOR	The interactions between retinoic acid- (RA)-dependent transcriptional regulatory sequences of the 5'-untranslated region of the thrombomodulin gene and nuclear RA-responsive proteins were studied using human pancreas BxPC-3 cells. Deletion mutants of pTM-CAT plasmid revealed the presence of distal and proximal RA-responsive regions containing direct repeat with 4 spaces (DR4) and three of four Spl sites, respectively. Cotransfection of a pTM-CAT plasmid with expression plasmids of RA receptors (RAR alpha, RAR beta, and RAR gamma) augmented the promoter activity under the condition of lower retinoid X receptor-alpha (RXR alpha) expression, whereas the activity was greatly diminished when RXR alpha was highly expressed. An electrophoretic mobility shift assay with cDNA containing the DR4 indicated that heterodimers of RAR and RXR alpha interacted with the DR4 site, although the interaction gradually disappeared with the increase in the ratio of RXR alpha /RAR. On the other hand, Spl protein interacted especially with the tandem Spl site corresponding to the first and second Spl sequences of the four Spl sites in the proximal RA-responsive region. The binding of Spl to Spl sites was independent of RAR-RXR heterodimer but increased with the increase in Spl concentration in the presence of unknown factor(s) of reticulocyte lysate, Upon treatment of the cells with RA, time-dependent increases in the ratio of RAR beta to RXR alpha and the phosphorylated form of Spl were observed. We concluded that two genomic DNA regions, the DR4 site (-1531 to -1516) and the first and second Spl-binding sites (-145 to -121), were involved in the RA-dependent augmentation of thrombomodulin gene expression through increased interactions of the two regions with heterodimer of RAR-RXR alpha and nuclear Spl, respectively.	Teikyo Univ, Fac Pharmaceut Sci, Dept Clin Biochem, Kanagawa 1990195, Japan; Showa Coll Pharmaceut Sci, Dept Publ Hlth, Tokyo 1948543, Japan	Teikyo University; Showa Pharmaceutical University	Horie, S (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Dept Clin Biochem, 1091-1 Suarashi, Kanagawa 1990195, Japan.							ARCHIPOFF G, 1991, BIOCHEM J, V273, P679, DOI 10.1042/bj2730679; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DITTMAN WA, 1990, BLOOD, V75, P329; DITTMAN WA, 1994, J BIOL CHEM, V269, P16925; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; Duprez E, 1996, ONCOGENE, V12, P2443; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMADA H, 1995, BLOOD, V86, P225, DOI 10.1182/blood.V86.1.225.bloodjournal861225; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; HORIE S, 1994, BIOCHEM J, V301, P683, DOI 10.1042/bj3010683; HORIE S, 1992, BIOCHEM J, V281, P149, DOI 10.1042/bj2810149; Hu ZZ, 1998, J BIOL CHEM, V273, P26225, DOI 10.1074/jbc.273.40.26225; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Ishii H, 1996, J BIOL CHEM, V271, P8458, DOI 10.1074/jbc.271.14.8458; ISHII H, 1990, THROMB RES, V59, P841, DOI 10.1016/0049-3848(90)90397-U; ISHII H, 1992, BLOOD, V80, P2556; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kang SH, 1996, J BIOL CHEM, V271, P7330, DOI 10.1074/jbc.271.13.7330; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOOISTRA T, 1995, EUR J BIOCHEM, V232, P425, DOI 10.1111/j.1432-1033.1995.425zz.x; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Rusten LS, 1996, BLOOD, V87, P1728; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Shibakura M, 1997, BLOOD, V90, P1545, DOI 10.1182/blood.V90.4.1545.1545_1545_1551; SHIRAI T, 1988, J BIOCHEM-TOKYO, V103, P281, DOI 10.1093/oxfordjournals.jbchem.a122261; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; TAZAWA R, 1993, J BIOCHEM-TOKYO, V113, P600, DOI 10.1093/oxfordjournals.jbchem.a124089; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; YU K, 1992, J BIOL CHEM, V267, P23237; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	73	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2440	2450		10.1074/jbc.M004942200	http://dx.doi.org/10.1074/jbc.M004942200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11036068	hybrid			2022-12-27	WOS:000166784800021
J	Han, SI; Oh, SY; Woo, SH; Kim, KH; Kim, JH; Kim, HD; Kang, HS				Han, SI; Oh, SY; Woo, SH; Kim, KH; Kim, JH; Kim, HD; Kang, HS			Implication of a small GTPase Rac1 in the activation of c-Jun N-terminal kinase and heat shock factor in response to heat shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR HSF1; STRESS-INDUCED APOPTOSIS; CELL-CYCLE PROGRESSION; PROTEIN-KINASE; BINDING PROTEIN; ACTIN POLYMERIZATION; MAMMALIAN-CELLS; CDC42 GTPASES; GROWTH-FACTOR; MAP KINASE	Heat shock induces c-Jun N-terminal kinase (JNK) activation as well as heat shock protein (HSP) expression through activation of the heat shock factor (HSP), but its signal pathway is not clearly understood. Since a small GTPase Rad has been suggested to participate in the cellular response to stresses, we examined whether Rad is involved in the heat shock response. Here we show that moderate heat shock (39-41 degreesC) induces membrane translocation of Rad and membrane ruffling in a Rad-dependent manner. In addition, Rac1N17, a dominant negative mutant of Rad, significantly inhibited JNK activation by heat shock. Since Rac1V12 was able to activate JNK, it is suggested that heat shock may activate JNK via Rad, Similar inhibition by Rac1N17 of HSP activation in response to heat shock was observed. However, inhibitory effects of Rac1N17 on heat shock-induced JNK and HSF activation were reduced as the heat shock temperature increased. Rac1N17 also inhibited HSF activation by L-azetidine-2-carboxylic acid, a proline analog, and heavy metals (CdCl2), suggesting that Rad may be linked to HSF activation by denaturation of polypeptides in response to various proteotoxic stresses. However, Rac1N17 did not prevent phosphorylation of HSF1 in response to these proteotoxic stresses. Interestingly, a constitutively active mutant Rac1V12 did not activate the HSF. Therefore, Rad activation may be necessary, but not sufficient, for heat shock-inducible HSF activation and HSP expression, or otherwise a signal pathway(s) involving Rad may be indirectly involved in the HSF activation. In sum, we suggest that Rad may play a critical role(s) in several aspects of the heat shock response.	Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 506712, South Korea	Pusan National University; Gwangju Institute of Science & Technology (GIST)	Kang, HS (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.	hspkang@hyowon.cc.pusan.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ANDERSON RL, 1982, INT J RADIAT BIOL, V42, P57, DOI 10.1080/09553008214550911; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; DEWEY WC, 1989, RADIAT RES, V120, P191, DOI 10.2307/3577707; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; Gorman AM, 1999, FEBS LETT, V445, P98, DOI 10.1016/S0014-5793(99)00094-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kim HR, 1999, IUBMB LIFE, V48, P429, DOI 10.1080/713803536; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Maroni P, 2000, CELL BIOL INT, V24, P145, DOI 10.1006/cbir.1999.0493; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; MurakamiMurofushi K, 1997, J BIOL CHEM, V272, P486; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ozaki M, 2000, J BIOL CHEM, V275, P35377, DOI 10.1074/jbc.M005287200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VAN AL, 1997, GENE DEV, V11, P2295; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; WELCH WJ, 1991, CURR TOP MICROBIOL, V167, P31; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu QB, 2000, CIRC RES, V86, P1122; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	50	50	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1889	1895		10.1074/jbc.M006042200	http://dx.doi.org/10.1074/jbc.M006042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050083	hybrid			2022-12-27	WOS:000166528000034
J	Leung, IWL; Lassam, N				Leung, IWL; Lassam, N			The kinase activation loop is the key to mixed lineage kinase-3 activation via both autophosphorylation and hematopoetic progenitor kinase 1 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-BEARING KINASE; PROTEIN-KINASE; MOLECULAR-CLONING; STRUCTURAL BASIS; SH3 DOMAIN; MAP KINASE; IDENTIFICATION; PATHWAY; FAMILY; MEMBER	We have demonstrated previously that Cdc42 induced MLK-3 homodimerization leads to both autophosphorylation and activation of MLK-3 and postulated that auto phosphorylation is an intermediate step of MLK-3 activation following its dimerization, In this report we sought to refine further the mechanism of MLK-3 activation and study the role of the putative kinase activation loop in MLK-3 activation. First we mutated the three potential phosphorylation sites in MLK-3 putative activation loop to alanine in an effort to abrogate MLK-3 autophosphorylation, Mutant T277A displayed almost no autophosphorylation activity and was nearly nonfunctional; mutant S281A, that displayed a low level of autophosphorylation, only slightly activated its downstream targets, whereas the T278A mutant, that exhibited autophosphorylation comparable to that of the wild type, was almost fully functional. Thus, these residues within the activation loop are critical for MLK-3 autophosphorylation and activation. In addition, when the Thr(277) and Ser(281) residues were mutated to negatively charged glutamic acid to mimic phosphorylated serine/threonine residues, the resulting mutants were fully functional, implying that these two residues may serve as the autophosphorylation sites. Interestingly, HPK1 also phosphorylated MLK-3 activation loop in vitro, and Ser281 was found to be the major phosphorylation site, indicating that HPK1 also activates MLK-3 via phosphorylation of the kinase activation loop.	Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Lab Med & Patholbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto	Leung, IWL (corresponding author), Univ Toronto, Dept Med Biophys, Rm 7360,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.							BOSSEMEYER D, 1995, FEBS LETT, V369, P57, DOI 10.1016/0014-5793(95)00580-3; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chiang GG, 2000, J BIOL CHEM, V275, P6055, DOI 10.1074/jbc.275.9.6055; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; EZOE K, 1994, ONCOGENE, V9, P935; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hehner SP, 2000, J IMMUNOL, V164, P3829, DOI 10.4049/jimmunol.164.7.3829; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; ING YL, 1994, ONCOGENE, V9, P1745; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; KATOH M, 1995, ONCOGENE, V10, P1447; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Matsui N, 1996, BIOCHEM BIOPH RES CO, V229, P571, DOI 10.1006/bbrc.1996.1845; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V205, P1494, DOI 10.1006/bbrc.1994.2834; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; SHOJI S, 1979, J BIOL CHEM, V254, P6211; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	38	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1961	1967		10.1074/jbc.M004092200	http://dx.doi.org/10.1074/jbc.M004092200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053428	hybrid			2022-12-27	WOS:000166528000044
J	Mizugishi, K; Aruga, J; Nakata, K; Mikoshiba, K				Mizugishi, K; Aruga, J; Nakata, K; Mikoshiba, K			Molecular properties of Zic proteins as transcriptional regulators and their relationship to GLI proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE CUBITUS-INTERRUPTUS; NEURAL CREST DEVELOPMENT; ZINC-FINGER PROTEIN; SONIC HEDGEHOG; BINDING-PROPERTIES; CELL LINEAGE; MOUSE ZIC1; IN-VITRO; DROSOPHILA; EXPRESSION	Zic family genes encode zinc finger proteins, which play important roles in vertebrate development. The zinc finger domains are highly conserved between Zic proteins and show a notable homology to those of Gli family proteins. In this study, we investigated the functional properties of Zic proteins and their relationship to the GLI proteins. We first established an optimal binding sequence for Zic1, Zic2, and Zic3 proteins by electrophoretic mobility shift assay based target selection and mutational analysis. The selected sequence was almost identical to the GLI binding sequence. However, the binding affinity was lower than that of GLI. Consistent results were obtained in reporter assays, in which transcriptional activation by Zic proteins was less dependent on the GLI binding sequence than GLI1. Moreover, Zic proteins activated a wide range of promoters irrespective of the presence of a GLI binding sequence. When Zic and GLI proteins were cotransfected into cultured cells, Zic proteins enhanced or suppressed sequence-dependent, GLI-mediated transactivation depending on cell type. Taken together, these results suggest that Zic proteins may act as transcriptional coactivators and that their function may be modulated by the GLI proteins and possibly by other cell type-specific cofactors.	RIKEN, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan; Univ Tokyo, Sch Med, Dept Pediat, Tokyo 1130033, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Tokyo 1088639, Japan	RIKEN; University of Tokyo; University of Tokyo	Aruga, J (corresponding author), RIKEN, Dev Neurobiol Lab, Brain Sci Inst, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Mikoshiba, Katsuhiko/N-7943-2015; Aruga, Jun/H-5837-2011	Aruga, Jun/0000-0001-7936-1375				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Aruga J, 1999, MECH DEVELOP, V89, P141, DOI 10.1016/S0925-4773(99)00220-8; Aruga J, 1998, J NEUROSCI, V18, P284; ARUGA J, 1994, J NEUROCHEM, V63, P1880; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; Aruga J, 2000, MOL BRAIN RES, V78, P15, DOI 10.1016/S0169-328X(00)00057-7; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; Brewster R, 1998, NATURE, V393, P579, DOI 10.1038/31242; BROWN S, 1995, AM J HUM GENET, V57, P859; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; CIMBORA DM, 1995, DEV BIOL, V169, P580, DOI 10.1006/dbio.1995.1171; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Feledy JA, 1999, NUCLEIC ACIDS RES, V27, P764, DOI 10.1093/nar/27.3.764; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Grinblat Y, 1998, DEVELOPMENT, V125, P4403; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Lee J, 1997, DEVELOPMENT, V124, P2537; Lin JC, 1998, J NEUROSCI, V18, P9342; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagai T, 2000, P NATL ACAD SCI USA, V97, P1618, DOI 10.1073/pnas.97.4.1618; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; Nakata K, 1998, MECH DEVELOP, V75, P43, DOI 10.1016/S0925-4773(98)00073-2; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Schubart DB, 1996, NUCLEIC ACIDS RES, V24, P1913, DOI 10.1093/nar/24.10.1913; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VORTKAMP A, 1995, DNA CELL BIOL, V14, P629, DOI 10.1089/dna.1995.14.629; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; WANANDI I, 1993, J BIOL CHEM, V268, P6629; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Yokota N, 1996, CANCER RES, V56, P377; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691	46	148	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2180	2188		10.1074/jbc.M004430200	http://dx.doi.org/10.1074/jbc.M004430200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053430	hybrid			2022-12-27	WOS:000166528000072
J	Taylor, WR; Schonthal, AH; Galante, J; Stark, GR				Taylor, WR; Schonthal, AH; Galante, J; Stark, GR			p130/E2F4 binds to and represses the cdc2 promoter in response to p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; TOPOISOMERASE II-ALPHA; DNA-DAMAGE CHECKPOINT; CELL-CYCLE; TRANSCRIPTION FACTOR; S-PHASE; G(2) CHECKPOINT; NUCLEAR-LOCALIZATION; HISTONE DEACETYLASE; IONIZING-RADIATION	p53 represses the transcription of cdc2 and cyclin B1, causing loss of Cdc2 activity and Cf, arrest. Here we show that the region -22 to -2 of the cdc2 promoter called the R box is required for repression by p53 but not for basal promoter activity. The R box confers p53-dependent repression on heterologous promoters and binds to p130/E2F4 in response to overexpression of p53. R box-dependent repression requires p21/waf1, and overexpression of p21/waf1 also represses the cdc2 promoter. These observations suggest that p53 represses the cdc2 promoter by inducing p21/waf1, which inhibits cyclin dependent kinase activity, enhancing the binding of p130 and E2F4, which together bind to and repress the cdc2 promoter.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44195 USA; Univ So Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA	Cleveland Clinic Foundation; University of Southern California; University of Southern California	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	starkg@ccf.org	Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653	NIGMS NIH HHS [GM 49345] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen X, 1999, MOL CELL BIOL, V19, P4695; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hughes TA, 1996, EXP CELL RES, V222, P275, DOI 10.1006/excr.1996.0035; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; KASTAN MB, 1991, CANCER RES, V51, P6304; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Massimi P, 1996, ONCOGENE, V12, P2325; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Olgiate J, 1999, VIROLOGY, V258, P257, DOI 10.1006/viro.1999.9755; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Philips A, 1999, ONCOGENE, V18, P6222, DOI 10.1038/sj.onc.1203017; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Reed SI, 1997, CANCER SURV, V29, P7; Rey O, 2000, VIROLOGY, V268, P372, DOI 10.1006/viro.1999.0175; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; SAMBROOK J., 1989, MOL CLONING LAB MANU, pB23; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; STEWART N, 1995, ONCOGENE, V10, P109; Stiegler P, 1998, J CELL BIOCHEM, P30; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	88	92	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1998	2006		10.1074/jbc.M005101200	http://dx.doi.org/10.1074/jbc.M005101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11032828	hybrid			2022-12-27	WOS:000166528000049
J	Grant, GA; Hu, ZQ; Xu, XL				Grant, GA; Hu, ZQ; Xu, XL			Specific interactions at the regulatory domain-substrate binding domain interface influence the cooperativity of inhibition and effector binding in Escherichia coli D-3-phosphoglycerate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOGLYCERATE DEHYDROGENASE; RESIDUES; ENZYME; SITE	The crystal structure of D-3-phosphoglycerate dehydrogenase reveals a limited number of contacts between the regulatory and substrate binding domains of each subunit in the tetrameric enzyme. These occur between the side chains of Arg-339, Arg-405, and Arg-407 in the regulatory domain and main chain carbonyls in the substrate binding domain. In addition, Arg-339 participates in a hydrogen bonding network within the regulatory domain involving Arg-338 and Tyr-410, the C-terminal residue of the enzyme subunit, Mutagenic analysis of these residues produce profound effects on the enzyme's sensitivity to serine, the cooperativity of serine inhibition, and in some cases, the apparent overall conformation of the enzyme. Mutations of Arg-405 and Arg-407, which span the interface where the two domains come together, reduce the cooperativity of inhibition and increase the sensitivity of the enzyme to serine concentration, Serine binding studies with Arg-407 converted to Ala demonstrate that cooperativity of serine binding is also significantly reduced in a manner similar to the reduction in the cooperativity of inhibition. Mutations of Tyr-410 and Arg-338 decrease the sensitivity to serine without an appreciable effect on the cooperativity of inhibition. In the case of Tyr-410, a deletion mutant demonstrates that this effect is due to the loss of the C-terminal carboxyl group rather than the tyrosine side chain. All mutations of Arg-339, with the exception of its conversion to Lys, had profound effects on the stability of the enzyme. In general, those mutants that decrease sensitivity to serine are those that participate mainly in intradomain interactions and may also directly affect the serine binding sites themselves. Those mutants that decrease cooperativity are those that participate in interdomain interaction within the subunit. The observation that the mutants that decrease cooperativity also increase sensitivity to serine suggests a potential separation of pathways between how the simple act of serine binding results in noncooperative active site inhibition in the first place and how serine binding also leads to cooperativity between sites in the native enzyme.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.				NIGMS NIH HHS [GM 56676] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056676] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlRabiee R, 1996, J BIOL CHEM, V271, P23235, DOI 10.1074/jbc.271.38.23235; BELL JE, 1988, PROTEINS ENZYMES, P465; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Grant GA, 2000, BIOCHEMISTRY-US, V39, P7316, DOI 10.1021/bi000218y; Grant GA, 1999, J BIOL CHEM, V274, P5357, DOI 10.1074/jbc.274.9.5357; Grant GA, 1999, PROTEIN SCI, V8, P2501; Grant GA, 1996, PROTEIN SCI, V5, P34; Grant GA, 1998, J BIOL CHEM, V273, P22389, DOI 10.1074/jbc.273.35.22389; HENDERSON PJF, 1992, ENZYME ASSAYS PRACTI, P284; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	16	21	27	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1078	1083		10.1074/jbc.M007512200	http://dx.doi.org/10.1074/jbc.M007512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050089	hybrid			2022-12-27	WOS:000166430900031
J	Hodel, MR; Corbett, AH; Hodel, AE				Hodel, MR; Corbett, AH; Hodel, AE			Dissection of a nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-T-ANTIGEN; KARYOPHERIN-ALPHA; IMPORTIN-ALPHA; ENHANCES RECOGNITION; PROTEIN IMPORT; SEQUENCE; TRANSPORT; BETA; SITE; DOMAIN	The regulated process of protein import into the nucleus of a eukaryotic cell is mediated by specific nuclear localization signals (NLSs) that are recognized by protein import receptors. This study seeks to decipher the energetic details of NLS recognition by the receptor importin alpha through quantitative analysis of variant NLSs. The relative importance of each residue in two monopartite NLS sequences was determined using an alanine scanning approach. These measurements yield an energetic definition of a monopartite NLS sequence where a required lysine residue is followed by two other basic residues in the sequence K(K/R)X(K/R). In addition, the energetic contributions of the second basic cluster in a bipartite NLS (similar to3 kcal/mol) as well as the energy of inhibition of the importin cu importin beta -binding domain (similar to3 kcal/mol) were also measured. These data allow the generation of an energetic scale of nuclear localization sequences based on a peptide's affinity for the importin alpha -importin beta complex. On this scale, a functional NLS has a binding constant of similar to 10 nra, whereas a nonfunctional NLS has a 100-fold weaker affinity of 1 muM. Further correlation between the current in vitro data and in vivo function will provide the foundation for a comprehensive quantitative model of protein import.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Hodel, AE (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd,Rm G234, Atlanta, GA 30322 USA.		Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058728] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-58728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISCHOFF FR, 1995, METHOD ENZYMOL, V257, P135; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Hood JK, 2000, BBA-REV CANCER, V1471, pM31, DOI 10.1016/S0304-419X(00)00018-4; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Johnson-Saliba M, 2000, FEBS LETT, V467, P169, DOI 10.1016/S0014-5793(00)01142-X; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Press W, 1992, NUMERICAL RECIPES C, P689; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Xiao CY, 1998, FEBS LETT, V440, P297, DOI 10.1016/S0014-5793(98)01478-1; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191	38	252	270	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1317	1325		10.1074/jbc.M008522200	http://dx.doi.org/10.1074/jbc.M008522200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038364	hybrid			2022-12-27	WOS:000166430900063
J	Van Putten, V; Refaat, Z; Dessev, C; Blaine, S; Wick, M; Butterfield, L; Han, SY; Heasley, LE; Nemenoff, RA				Van Putten, V; Refaat, Z; Dessev, C; Blaine, S; Wick, M; Butterfield, L; Han, SY; Heasley, LE; Nemenoff, RA			Induction of cytosolic phospholipase A(2) by oncogenic Ras is mediated through the JNK and ERK pathways in rat epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; SYNTHASE-2 GENE-EXPRESSION; PROTEIN-KINASE PATHWAY; SMOOTH-MUSCLE CELLS; LUNG-CANCER CELLS; C-JUN; GROWTH-FACTOR; TRANSCRIPTION FACTOR; CYTOKINE GENES; ALPHA-ACTIN	Mutations in ras genes have been detected with high frequency in nonsmall cell lung cancer cells (NSCLC) and contribute to transformed growth of these cells. It has previously been shown that expression of oncogenic forms of Ras in these cells is associated with elevated expression of cytosolic phospholipase A(2) (cPLA(2)) and cyclooxygenase-2 (COX-2), resulting in high constitutive levels of prostaglandin production. To determine whether expression of constitutively active Res is sufficient to induce expression of these enzymes in nontransformed cells, normal lung epithelial cells were transfected with H-Ras, Stable expression of H-Ras increased expression of cPLA(2) and COX-2 protein. Transient transfection with II-Pas increased promoter activity for both enzymes. H-Ras expression also activated all three families of MAP kinase: ERKs, JNKs, and p38 MAP kinase, Expression of constitutively active Raf did not increase either cPLA(2) or COX-2 promoter activity, but inhibition of the ERK pathway with pharmacological agents or expression of dominant negative ERK partially blocked the H-Ras-mediated induction of cPLA(2) promoter activity. Expression of dominant negative JNK kinases decreased cPLA(2) promoter activity in NSCLC cell lines and inhibited H-Ras-mediated induction in normal epithelial cells, whereas expression of constructs encoding constitutively active JNKs increased promoter activity. Inhibition of p38 MAP kinase or NF-KB had no effect on cPLA(2) expression. Truncational analysis revealed that the region of the cPLA(2) promoter from -58 to +12 contained sufficient elements to mediate H-Ras induction. We conclude that expression of oncogenic forms of Res directly increases cPLA(2) expression in normal epithelial cells through activation of the JNK and ERR pathways.	Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nemenoff, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, 4200 E 9th Ave,Box C-281, Denver, CO 80262 USA.				NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928, R01DK039902] Funding Source: NIH RePORTER; NCI NIH HHS [CA-58187] Funding Source: Medline; NIDDK NIH HHS [DK-39902, DK-19928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEBRAVO MG, 1991, LIPIDS, V26, P866, DOI 10.1007/BF02535969; DEMETRI GD, 1990, J CLIN INVEST, V86, P1261, DOI 10.1172/JCI114833; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DeWitt DL, 1993, AM J MED S2A, V95, P40, DOI DOI 10.1016/0002-9343(93)90396-7; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Giaccone G, 1996, CHEST, V109, pS130, DOI 10.1378/chest.109.5_Supplement.130S; GOPPELTSTRUEBE M, 1992, BIOCHIM BIOPHYS ACTA, V1127, P163, DOI 10.1016/0005-2760(92)90273-X; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; Guthridge CJ, 1995, ANTICANCER RES, V15, P1957; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; Hida T, 1998, ANTICANCER RES, V18, P775; Higashita R, 1997, J BIOL CHEM, V272, P25845, DOI 10.1074/jbc.272.41.25845; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HUANG M, 1995, CANCER RES, V55, P3847; HUBBARD WC, 1989, CANCER RES, V49, P826; HUBBARD WC, 1988, CANCER RES, V48, P4770; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; JAMES GL, 1994, J BIOL CHEM, V269, P27705; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li XM, 1997, BIOCHEM J, V327, P709, DOI 10.1042/bj3270709; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUNO K, 1994, JPN J CANCER RES, V85, P179, DOI 10.1111/j.1349-7006.1994.tb02080.x; ROBERTS PE, 1990, AM J PHYSIOL, V259, pL415, DOI 10.1152/ajplung.1990.259.6.L415; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Siebenlist U., 1997, BIOCHIMICA BIOPHYSIC, V1332, P7; TAY A, 1994, BBA-GENE STRUCT EXPR, V1217, P345, DOI 10.1016/0167-4781(94)90299-2; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wang JY, 1996, J INTERF CYTOK RES, V16, P53, DOI 10.1089/jir.1996.16.53; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	54	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1226	1232		10.1074/jbc.M003581200	http://dx.doi.org/10.1074/jbc.M003581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042196	hybrid			2022-12-27	WOS:000166430900051
J	Vogel, S; Mendelsohn, CL; Mertz, JR; Piantedosi, R; Waldburger, C; Gottesman, ME; Blaner, WS				Vogel, S; Mendelsohn, CL; Mertz, JR; Piantedosi, R; Waldburger, C; Gottesman, ME; Blaner, WS			Characterization of a new member of the fatty acid-binding protein family that binds all-trans-retinol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; CRYSTAL-STRUCTURES; VITAMIN-A; ADIPOCYTE; METABOLISM; PURIFICATION; SPECIFICITY; HYDROLYSIS; PATTERN; CELLS	Cellular retinol-binding protein, type I (CRBP-T) and type IT (CRBP-II) are the only members of the fatty acid-binding protein (FABP) family that process intracellular retinol. Heart and skeletal muscle take up postprandial retinol but express little or no CRBP-I or CRBP-II. We have identified an intracellular retinol-binding protein in these tissues. The 134-amino acid protein is encoded by a cDNA that is expressed primarily in heart, muscle and adipose tissue. It shares 57 and 56% sequence identity with CRBP-I and CRBP-II, respectively, but less than 40% with other members of the FABP family, In situ hybridization demonstrates that the protein is expressed at least as early as day 10 in developing heart and muscle tissue of the embryonic mouse. Fluorescence titrations of purified recombinant protein with retinol. isomers indicates binding to all-trans-, 13-cis-, and 9-cis-retinol, with respective K-d values of 109, 83, and 130 nM. Retinoic acids (all-trans-, 13-cis-, and 9-cis-), retinals (all-trans-, 13-cis-, and 9-cis-), fatty acids (laurate, myristate, palmitate, oleate, linoleate, arachidonate, and docosahexanoate), or fatty alcohols (palmityl, petrosenlinyl, and ricinolenyl) fail to bind. The distinct tissue expression pattern and binding specificity suggest that we have identified a novel FABP family member, cellular retinol-binding protein, type III.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; New England Coll Optometry, Dept Biol Sci, Boston, MA 02115 USA	Columbia University; Columbia University; Columbia University; Columbia University	Blaner, WS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 701 W 168th St, New York, NY 10032 USA.	WSB2@columbia.edu	Mendelsohn, Cathy/H-4280-2016	Mendelsohn, Cathy/0000-0002-4026-4073	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061459, R01DK052444, R56DK082963] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK061459-08, R01 DK061459-06, R01 DK061459, R01 DK061459-07S1, R01 DK061459-07, R01 DK061459-09, R01 DK52444, R56 DK082963-01, R56 DK082963] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BAXA CA, 1989, BIOCHEMISTRY-US, V28, P8683, DOI 10.1021/bi00448a003; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; Blaner W.S., 1999, HANDB EXP PHARM, P117; Blaner William S., 1994, P229; BLANER WS, 1987, J BIOL CHEM, V262, P53; BLANER WS, 1994, J BIOL CHEM, V269, P16559; CHENG L, 1991, J BIOL CHEM, V266, P24404; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DOLLE P, 1990, DEVELOPMENT, V110, P1133; ERIKSSON U, 1984, J BIOL CHEM, V259, P3464; FERRARA P, 1993, TECHNIQUES PROTEIN C, V4, P379; Furr Harold C., 1994, P179; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Glatz JFC, 1998, ADV EXP MED BIOL, V441, P207; Hausman GJ, 1985, NEW PERSPECTIVES ADI, P1; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; KATO M, 1984, J CELL BIOL, V98, P1696, DOI 10.1083/jcb.98.5.1696; KATO M, 1985, J BIOL CHEM, V260, P4832; KIRTLAND J, 1979, INT J OBESITY, V3, P15; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; MATARESE V, 1988, J BIOL CHEM, V263, P14544; Mendelsohn C, 1999, DEVELOPMENT, V126, P1139; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; NEWCOMER ME, 1995, FASEB J, V9, P229, DOI 10.1096/fasebj.9.2.7781925; Newcomer ME, 1998, SUB CELL BIOCHEM, V30, P53; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; NOY N, 1999, HANDB EXP PHARM, V139, P3; Ong David E., 1994, P283; ONG DE, 1982, J BIOL CHEM, V257, P13385; Palace VP, 1999, FREE RADICAL BIO MED, V26, P1501, DOI 10.1016/S0891-5849(99)00013-1; PEREZCASTRO AV, 1989, P NATL ACAD SCI USA, V86, P8813, DOI 10.1073/pnas.86.22.8813; RAJAN N, 1990, J LIPID RES, V31, P821; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; RODBELL M, 1964, J BIOL CHEM, V239, P375; STRUMP DG, 1991, J BIOL CHEM, V266, P4622; Subbarayan V, 2000, J CLIN INVEST, V105, P387, DOI 10.1172/JCI8150; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; UYEMURA K, 1984, NEUROCHEM RES, V28, P8683; van Bennekum AM, 1999, J LIPID RES, V40, P565; VEERKAMP JH, 1993, PROSTAG LEUKOTR ESS, V49, P887, DOI 10.1016/0952-3278(93)90174-U; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; VOGEL S, 1999, HANDB EXP PHARM, V139, P31; WILSON JG, 1949, AM J ANAT, V85, P113, DOI 10.1002/aja.1000850106; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; XU ZH, 1993, J BIOL CHEM, V268, P7874	52	94	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1353	1360		10.1074/jbc.M005118200	http://dx.doi.org/10.1074/jbc.M005118200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11022035	hybrid			2022-12-27	WOS:000166430900067
J	He, QF; Dolganov, N; Bjorkman, O; Grossman, AR				He, QF; Dolganov, N; Bjorkman, O; Grossman, AR			The high light-inducible polypeptides in Synechocystis PCC6803 - Expression and function in high light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON SUPEROXIDE-DISMUTASE; MEMBRANE-PROTEIN DAMAGE; PHOTOSYSTEM-II; XANTHOPHYLL CYCLE; IN-VIVO; CHLOROPLAST MEMBRANES; NUCLEOTIDE-SEQUENCE; EXCITATION-ENERGY; STRESS; PLANTS	There are five Synechocystis PCC6803 genes encoding polypeptides with similarity to the Lhc polypeptides of plants. Four of the polypeptides, designated HliA-D (Dolganov, N. A M., Bhaya, D., and Grossman, A. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 636-640) (corresponding to ScpC, ScpD, ScpB, and ScpE in Funk, C., and Vermaas, W. (1999) Biochemistry 38, 9397-9404) contain a single transmembrane domain. The fifth polypeptide (HemH) represents a fusion between a ferrochelatase and an Hli-like polypeptide. By using an epitope tag to identify specifically the different Hli polypeptides, the accumulation of each (excluding HemH) was examined under various environmental conditions. The levels of all of the Hli polypeptides were elevated in high light and during nitrogen limitation, whereas HliA, HliB, and HliC also accumulated to high levels following exposure to sulfur deprivation and low temperature. The temporal pattern of accumulation was significantly different among the different Hli polypeptides. HliC rapidly accumulated in high light, and its level remained high for at least 24 h. HliA and HliB also accumulated rapidly, but their levels began to decline 9-12 h following the imposition of high light. HliD was transiently expressed in high light and was not detected 24 h after the initiation of high light exposure. These results demonstrate that there is specificity to the accumulation of the Hli polypeptides under a diverse range of environmental conditions. Furthermore, mutants for the individual and combinations of the hli genes were evaluated for their fitness to grow in high light. Although all of the mutants grew as fast as wild-type cells in low light, strains inactivated for hliA or hliC/hliD were unable to compete with wild-type cells during co-cultivation in high light. A mutant lacking all four hli genes gradually lost its photosynthesis capacity and died in high light. Hence, the Hli polypeptides are critical for survival when Synechocystis PCC6803 is absorbing excess excitation energy and may allow the cells to cope more effectively with the production of reactive oxygen species.	Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Carnegie Institution for Science; Stanford University	He, QF (corresponding author), Carnegie Inst Sci, Dept Plant Biol, 290 Panama St, Stanford, CA 94305 USA.	qingfang@andrew2.stanford.edu	He, Qingfang/I-4181-2013					ADAMSKA I, 1993, J BIOL CHEM, V268, P5438; ADAMSKA I, 1995, PLANT PHYSIOL, V107, P1167, DOI 10.1104/pp.107.4.1167; Adamska I, 1997, PHYSIOL PLANTARUM, V100, P794, DOI 10.1034/j.1399-3054.1997.1000406.x; ADAMSKA I, 1992, J BIOL CHEM, V267, P24732; ADAMSKA I, 1992, P NATL ACAD SCI USA, V89, P2610, DOI 10.1073/pnas.89.7.2610; Allakhverdiev SI, 1997, BIOCHEMISTRY-US, V36, P4149, DOI 10.1021/bi962170n; ANDERSSON B, 1992, J PHOTOCH PHOTOBIO B, V15, P15, DOI 10.1016/1011-1344(92)87003-R; ARO EM, 1993, PLANT PHYSIOL, V103, P835, DOI 10.1104/pp.103.3.835; ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; ASADA K, 1992, PHOTOSYNTH RES, V34, P105; Banet G, 2000, PLANTA, V210, P947, DOI 10.1007/s004250050702; BARTLEY GE, 1995, PLANT CELL, V7, P1027, DOI 10.1105/tpc.7.7.1027; BIGGINS J, 1989, PHOTOSYNTH RES, V20, P1, DOI 10.1007/BF00028620; Boger P, 1996, J PESTIC SCI, V21, P473; BOWLER C, 1994, CRIT REV PLANT SCI, V13, P199, DOI 10.1080/713608062; BRAHAMSHA B, 1991, J BACTERIOL, V173, P2442, DOI 10.1128/jb.173.8.2442-2450.1991; COLLIER JL, 1992, J BACTERIOL, V174, P4718, DOI 10.1128/JB.174.14.4718-4726.1992; CRITCHLEY C, 1994, PHYSIOL PLANTARUM, V92, P188, DOI 10.1111/j.1399-3054.1994.tb06670.x; CROFTS J, 1991, BIOCHIM BIOPHYS ACTA, V1058, P187, DOI 10.1016/S0005-2728(05)80236-1; DELASRIVAS J, 1993, BIOCHIM BIOPHYS ACTA, V1142, P155, DOI 10.1016/0005-2728(93)90097-Y; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; Durnford DG, 1997, PHOTOSYNTH RES, V53, P229, DOI 10.1023/A:1005815725371; DUYSENS LNM, 1972, BIOPHYS J, V12, P858, DOI 10.1016/S0006-3495(72)86129-0; El Bissati K, 2000, BBA-BIOENERGETICS, V1457, P229, DOI 10.1016/S0005-2728(00)00104-3; FOYER CH, 1994, PLANT CELL ENVIRON, V17, P507, DOI 10.1111/j.1365-3040.1994.tb00146.x; Frank HA, 2000, BIOCHEMISTRY-US, V39, P2831, DOI 10.1021/bi9924664; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; Fujita Y, 1997, PHOTOSYNTH RES, V53, P83, DOI 10.1023/A:1005870301868; Funk C, 1999, BIOCHEMISTRY-US, V38, P9397, DOI 10.1021/bi990545+; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; GREEN BR, 1995, PHOTOSYNTH RES, V44, P139, DOI 10.1007/BF00018304; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; GRIMM B, 1987, EUR J CELL BIOL, V43, P21; Halliwell B., 1999, FREE RADICAL BIO MED, P1, DOI DOI 10.1093/ACPROF:OSO/9780198717478.001.0001; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; He QF, 1998, P NATL ACAD SCI USA, V95, P5830, DOI 10.1073/pnas.95.10.5830; Heddad M, 2000, P NATL ACAD SCI USA, V97, P3741, DOI 10.1073/pnas.050391397; HERBERT SK, 1992, P NATL ACAD SCI USA, V89, P8716, DOI 10.1073/pnas.89.18.8716; HERTWIG B, 1992, PLANT PHYSIOL, V100, P1547, DOI 10.1104/pp.100.3.1547; Holtman WL, 1998, J EXP BOT, V49, P1303, DOI 10.1093/jexbot/49.325.1303; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Hwang SY, 1999, PLANT GROWTH REGUL, V27, P167, DOI 10.1023/A:1006100508910; Iwasaki T, 1997, GENE, V185, P223, DOI 10.1016/S0378-1119(96)00646-4; Jansson S, 2000, PLANT MOL BIOL, V42, P345, DOI 10.1023/A:1006365213954; Kaneko T, 1997, PLANT CELL PHYSIOL, V38, P1171, DOI 10.1093/oxfordjournals.pcp.a029103; Kaneko T, 1996, DNA Res, V3, P109; Kloppstech K, 1997, PHYSIOL PLANTARUM, V100, P739, DOI 10.1034/j.1399-3054.1997.1000401.x; KOLANUS W, 1987, MOL GEN GENET, V209, P234, DOI 10.1007/BF00329648; KRUSE E, 1989, BIOL CHEM H-S, V370, P925; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; MAID U, 1992, PLANT MOL BIOL, V19, P1001, DOI 10.1007/BF00040531; Melis A, 1999, TRENDS PLANT SCI, V4, P130, DOI 10.1016/S1360-1385(99)01387-4; Montane MH, 1997, PLANTA, V202, P293, DOI 10.1007/s004250050131; Montane MH, 1999, PLANTA, V208, P519, DOI 10.1007/s004250050589; Neale AD, 2000, PLANT CELL ENVIRON, V23, P265, DOI 10.1046/j.1365-3040.2000.00548.x; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; OQUIST G, 1992, J BIOL CHEM, V267, P16745; Park YI, 1999, MOL MICROBIOL, V32, P123, DOI 10.1046/j.1365-2958.1999.01332.x; PETER GF, 1991, J BIOL CHEM, V266, P16745; Polivka T, 1999, P NATL ACAD SCI USA, V96, P4914, DOI 10.1073/pnas.96.9.4914; POTTER E, 1993, EUR J BIOCHEM, V214, P779, DOI 10.1111/j.1432-1033.1993.tb17980.x; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Ruban AV, 1999, PLANT PHYSIOL, V119, P531, DOI 10.1104/pp.119.2.531; RUBAN AV, 1995, PLANT PHYSIOL, V108, P721, DOI 10.1104/pp.108.2.721; RUBAN AV, 1994, BBA-BIOENERGETICS, V1186, P123, DOI 10.1016/0005-2728(94)90143-0; RUBAN AV, 1993, J PHOTOCH PHOTOBIO B, V21, P229, DOI 10.1016/1011-1344(93)80188-F; Schweitzer RH, 1997, BIOCHEMISTRY-US, V36, P11351, DOI 10.1021/bi9709203; Stirewalt VL, 1995, PLANT MOL BIOL REP, V13, P327, DOI 10.1007/BF02669186; Thomas DJ, 1998, PLANT PHYSIOL, V116, P1593, DOI 10.1104/pp.116.4.1593; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vonLintig J, 1997, PLANT J, V12, P625, DOI 10.1046/j.1365-313X.1997.00625.x; Windhovel U, 1997, PESTIC BIOCHEM PHYS, V57, P68, DOI 10.1006/pest.1997.2261; WOLFE GR, 1994, BBA-BIOENERGETICS, V1188, P357, DOI 10.1016/0005-2728(94)90056-6; Yamagata H, 1997, BIOSCI BIOTECH BIOCH, V61, P2143, DOI 10.1271/bbb.61.2143	79	174	183	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					306	314		10.1074/jbc.M008686200	http://dx.doi.org/10.1074/jbc.M008686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024039	hybrid			2022-12-27	WOS:000166280700042
J	Heller, R; Unbehaun, A; Schellenberg, B; Mayer, B; Werner-Felmayer, G; Werner, ER				Heller, R; Unbehaun, A; Schellenberg, B; Mayer, B; Werner-Felmayer, G; Werner, ER			L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-CYCLOHYDROLASE-I; PERFORMANCE LIQUID-CHROMATOGRAPHY; DEPENDENT VASODILATION; BIOSYNTHETIC ACTIVITIES; SUPEROXIDE GENERATION; SYNTHASE; DYSFUNCTION; CELLS; CYTOKINES; ENHANCEMENT	Ascorbic acid has been shown to stimulate endothelial nitric oxide (NO) synthesis in a time- and concentration-dependent fashion without affecting NO synthase (NOS) expression or L-arginine uptake. The present study investigates if the underlying mechanism is related to the NOS cofactor tetrahydrobiopterin, Pretreatment of human umbilical vein endothelial cells with ascorbate (1 muM to 1 mM, 24 h) led to an up to 3-fold increase of intracellular tetrahydrobiopterin levels that was concentration-dependent and saturable at 100 mum. Accordingly, the effect of ascorbic acid on Ca2+-dependent formation of citrulline (co-product of NO) and cGMP (product of the NO-activated soluble guanylate cyclase) was abolished when intracellular tetrahydrobiopterin levels were increased by coincubation of endothelial cells with sepiapterin (0.001-100 muM, 24 h), In contrast, ascorbic acid did not modify the pterin affinity of endothelial NOS, which was measured in assays with purified tetrahydrobiopterin-free enzyme. The ascorbate-induced increase of endothelial tetrahydrobiopterin was not due to an enhanced synthesis of the compound. Neither the mRNA expression of the rate-limiting enzyme in tetrahydrobiopterin biosynthesis, GTP cyclohydrolase I, nor the activities of either GTP cyclohydrolase I or 6-pyruvoyl-tetrahydropterin synthase, the second enzyme in the de novo synthesis pathway, were altered by ascorbate, Our data demonstrate that ascorbic acid leads to a chemical stabilization of tetrahydrobiopterin, This was evident as an increase in the half-life of tetrahydrobiopterin in aqueous solution. Furthermore, the increase of tetrahydrobiopterin levels in intact endothelial cells coincubated with cytokines and ascorbate was associated with a decrease of more oxidized biopterin derivatives (7,8-dihydrobiopterin and biopterin) in cells and cell supernatants, The present study suggests that saturated ascorbic acid levels in endothelial cells are necessary to protect tetrahydrobiopterin from oxidation and to provide optimal conditions for cellular NO synthesis.	Univ Jena, Ctr Vasc Biol & Med, D-99089 Erfurt, Germany; Karl Franzens Univ Graz, Inst Pharmacol & Toxicol, A-8010 Graz, Austria; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	Friedrich Schiller University of Jena; University of Graz; University of Innsbruck	Heller, R (corresponding author), Univ Jena, Ctr Vasc Biol & Med, Nordhauser Str 78, D-99089 Erfurt, Germany.	heller@zmkh.ef.uni-jena.de	Mayer, Bernd/B-9391-2008; Heller, Regine/AAC-9353-2019	Werner-Felmayer, Gabriele/0000-0002-2340-8063; Werner, Ernst R./0000-0003-1948-3391; Mayer, Bernd/0000-0002-2921-3494				Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Bult H, 1999, EUR J PHARMACOL, V375, P157, DOI 10.1016/S0014-2999(99)00328-3; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; EK A, 1995, BIOCHEM PHARMACOL, V50, P1339; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GAL EM, 1978, NEUROCHEM RES, V3, P69, DOI 10.1007/BF00964361; Gokce N, 1999, CIRCULATION, V99, P3234, DOI 10.1161/01.CIR.99.25.3234; Gorren ACF, 1998, BIOCHEMISTRY-MOSCOW+, V63, P734; Hattori Y, 1997, BBA-MOL CELL RES, V1358, P61, DOI 10.1016/S0167-4889(97)00052-9; Heitzer T, 2000, CIRC RES, V86, pE36, DOI 10.1161/01.RES.86.2.e36; Heitzer T, 1996, CIRCULATION, V94, P6, DOI 10.1161/01.CIR.94.1.6; Heller R, 1999, J BIOL CHEM, V274, P8254, DOI 10.1074/jbc.274.12.8254; Hornig B, 1998, CIRCULATION, V97, P363; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; HYLAND K, 1985, J CHROMATOGR, V343, P35, DOI 10.1016/S0378-4347(00)84565-X; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Katusic ZS, 1998, ARTERIOSCL THROM VAS, V18, P27, DOI 10.1161/01.ATV.18.1.27; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; Kinoshita H, 1997, AM J PHYSIOL-HEART C, V273, pH718, DOI 10.1152/ajpheart.1997.273.2.H718; Leber A, 1999, J BIOL CHEM, V274, P37658, DOI 10.1074/jbc.274.53.37658; Levine GN, 1996, CIRCULATION, V93, P1107, DOI 10.1161/01.CIR.93.6.1107; Linscheid P, 1998, CIRCULATION, V98, P1703, DOI 10.1161/01.CIR.98.17.1703; Maier W, 2000, J CARDIOVASC PHARM, V35, P173, DOI 10.1097/00005344-200002000-00001; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; Pieper GM, 1997, J CARDIOVASC PHARM, V29, P8, DOI 10.1097/00005344-199701000-00002; RAMIREZ J, 1980, AM J CLIN NUTR, V33, P2079, DOI 10.1093/ajcn/33.10.2079; Rosenblum WI, 1997, STROKE, V28, P186, DOI 10.1161/01.STR.28.1.186; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; SCHOEDON G, 1993, BIOCHEM BIOPH RES CO, V196, P1343, DOI 10.1006/bbrc.1993.2400; Solzbach U, 1997, CIRCULATION, V96, P1513, DOI 10.1161/01.CIR.96.5.1513; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; Tiefenbacher CP, 1996, CIRCULATION, V94, P1423, DOI 10.1161/01.CIR.94.6.1423; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Ting HH, 1997, CIRCULATION, V95, P2617, DOI 10.1161/01.CIR.95.12.2617; Tsutsui M, 1996, CIRC RES, V79, P336, DOI 10.1161/01.RES.79.2.336; Ueda S, 2000, J AM COLL CARDIOL, V35, P71, DOI 10.1016/S0735-1097(99)00523-9; VANAMSTERDAM JGC, 1992, EUR J PHARMACOL, V215, P349, DOI 10.1016/0014-2999(92)90056-A; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vita JA, 1998, J AM COLL CARDIOL, V31, P980, DOI 10.1016/S0735-1097(98)00059-X; WALTER R, 1994, BIOCHEM BIOPH RES CO, V203, P1522, DOI 10.1006/bbrc.1994.2358; Werner ER, 2000, BIOCHEM J, V348, P579, DOI 10.1042/0264-6021:3480579; WERNER ER, 1990, J BIOL CHEM, V265, P3189; Werner ER, 1997, METHOD ENZYMOL, V281, P53; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; Witteveen CFB, 1999, J BIOL CHEM, V274, P29755, DOI 10.1074/jbc.274.42.29755; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804	52	331	343	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					40	47		10.1074/jbc.M004392200	http://dx.doi.org/10.1074/jbc.M004392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022034	hybrid			2022-12-27	WOS:000166280700007
J	Honke, K; Tsuda, M; Koyota, S; Wada, Y; Iida-Tanaka, N; Ishizuka, I; Nakayama, J; Taniguchi, N				Honke, K; Tsuda, M; Koyota, S; Wada, Y; Iida-Tanaka, N; Ishizuka, I; Nakayama, J; Taniguchi, N			Molecular cloning and characterization of a human beta-gal-3 '-sulfotransferase that acts on both type 1 and type 2 (Gal beta 1-3/1-4GlcNAc-R) oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; O-GLYCAN BIOSYNTHESIS; SULFATED OLIGOSACCHARIDES; LEUKOCYTE ADHESION; COLON-CARCINOMA; L-SELECTIN; SULFOTRANSFERASE; EXPRESSION; CANCER; LIGANDS	A novel sulfotransferase gene (designated GP3ST) was identified on human chromosome 2q37.3 based on its similarity to the cerebroside 3'-sulfotransferase (CST) cDNA (Honke, K, Tsuda, M,, Hirahara, Y., Ishii, A., Makita, A., and Wade, Y, (1997) J. Biol. Chem, 272, 4864-4868), A full-length cDNA was obtained by reverse transcription-polymerase chain reaction and 5'- and 3'-rapid amplification of cDNA ends analyses of human colon mRNA, The isolated cDNA clone predicts that the protein is a type II transmembrane protein composed of 398 amino acid residues. The amino acid sequence indicates 33% identity to the human CST sequence. A recombinant protein that is expressed in COS-1 cells showed no CST activity, but did show sulfotransferase activities toward oligosaccharides containing nonreducing beta -galactosides such as N-acetyllactosamine, lactose, lacto-N-tetraose (Lc4), lacto-N-neotetraos (nLc4), and Gal beta1-3GalNAc alpha -benzyl (O-glycan core 1 oligosaccharide). To characterize the cloned sulfotransferase, at sulfotransferase assay method was developed that uses pyridylaminated (PA) Lc4 and nLc4 as enzyme substrates. The enzyme product using PA-Lc4 as an acceptor was identified as HSO3-3Gal beta1-3GlcNAc beta1-8Gal beta1-4Glc-PA by two-dimensional H-1 NMR, Kinetics studies suggested that GP3ST is able to act on both type 1 (Gal beta1-3Glc-NAc-R) and type 2 (Gal beta1-4GlcNAc-R) chains with a similar efficiency, In situ hybridization demonstrated that the GP3ST gene is expressed in epithelial cells lining the lower to middle layer of the crypts in colonic mucosa, hepatocytes surrounding the central vein of the liver, extravillous cytotrophoblasts in the basal plate and septum of the placenta, renal tubules of the kidney, and neuronal cells of the cerebral cortex. The results of this study indicate the existence of a never beta -Gal-3'-sulfotransferase gene family.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Mol Med, Izumi, Osaka 5941101, Japan; Teikyo Univ, Sch Med, Dept Biochem, Tokyo 1738605, Japan; Shinshu Univ, Grad Sch Med, Inst Organ Transplants REconstruct Med & Tissue E, Matsumoto, Nagano 3908621, Japan	Osaka University; Teikyo University; Shinshu University	Honke, K (corresponding author), Osaka Univ, Sch Med, Dept Biochem, Rm B1,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	khonke@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Brockhausen I, 1997, TRENDS GLYCOSCI GLYC, V9, P379, DOI 10.4052/tigg.9.379; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; Feizi T, 1999, TRENDS BIOCHEM SCI, V24, P369, DOI 10.1016/S0968-0004(99)01458-9; FILIPE MI, 1969, GUT, V10, P577, DOI 10.1136/gut.10.7.577; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HASE S, 1978, BIOCHEM BIOPH RES CO, V85, P257, DOI 10.1016/S0006-291X(78)80037-0; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HOKKE CH, 1994, EUR J BIOCHEM, V221, P491, DOI 10.1111/j.1432-1033.1994.tb18762.x; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; Honke K, 1996, J BIOCHEM-TOKYO, V119, P421; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Iida-Tanaka N, 2000, CARBOHYD RES, V324, P218, DOI 10.1016/S0008-6215(99)00291-8; IRIMURA T, 1991, CANCER RES, V51, P5728; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; KATO Y, 1989, J BIOL CHEM, V264, P3364; Kawakami M, 1997, CANCER RES, V57, P2321; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; MATSUBARA T, 1994, BBA-LIPID LIPID MET, V1214, P97, DOI 10.1016/0005-2760(94)90014-0; MAWHINNEY TP, 1987, J BIOL CHEM, V262, P2994; Murray J, 1999, GENOME RES, V9, P130; Namavar F, 1998, INFECT IMMUN, V66, P444, DOI 10.1128/IAI.66.2.444-447.1998; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; RAOUF AH, 1992, CLIN SCI, V83, P623, DOI 10.1042/cs0830623; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; STRECKER G, 1987, GLYCOCONJUGATE J, V4, P329, DOI 10.1007/BF01048366; Tadano-Aritomi K, 1998, GLYCOBIOLOGY, V8, P341, DOI 10.1093/glycob/8.4.341; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; VAVASSEUR F, 1994, EUR J BIOCHEM, V222, P415, DOI 10.1111/j.1432-1033.1994.tb18880.x; Yamamoto H, 1999, J BIOCHEM-TOKYO, V125, P923, DOI 10.1093/oxfordjournals.jbchem.a022370; YAMORI T, 1987, CANCER RES, V47, P2741; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; Zakrzewicz A, 1997, BLOOD, V89, P3228, DOI 10.1182/blood.V89.9.3228	48	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					267	274		10.1074/jbc.M005666200	http://dx.doi.org/10.1074/jbc.M005666200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029462	hybrid			2022-12-27	WOS:000166280700037
J	Kumar, A; Novoselov, V; Celeste, AJ; Wolfman, NM; ten Dijke, P; Kuehn, MR				Kumar, A; Novoselov, V; Celeste, AJ; Wolfman, NM; ten Dijke, P; Kuehn, MR			Nodal signaling uses activin and transforming growth factor-beta receptor-regulated smads	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY MOUSE EMBRYO; LEFT-RIGHT AXIS; TGF-BETA; MESODERM INDUCTION; TARGETED DISRUPTION; HEPG2 CELLS; GENE; EXPRESSION; XENOPUS; ACTIVATION	Nodal, a member of the transforming growth factor beta (TGF-beta) superfamily, is implicated in many events critical to the early vertebrate embryo, including mesoderm formation, anterior patterning, and left-right axis specification. Here we define the intracellular signaling pathway induced by recombinant nodal protein treatment of P19 embryonal carcinoma cells. Nodal signaling activates pAR3-Lux, a luciferase reporter previously shown to respond specifically to activin and TGF-beta. However, nodal is unable to induce pTlx2-Lux, a reporter specifically responsive to bone morphogenetic proteins. We also demonstrate that nodal induces p(CAGA)(12), a reporter previously shown to be specifically activated by Smad3. Expression of a dominant negative Smad2 significantly reduces the level of luciferase reporter activity induced by nodal treatment. Finally, we show that nodal signaling rapidly leads to the phosphorylation of Smad2. These results provide the first direct biochemical evidence that nodal signaling is mediated by both activin-TGF-beta pathway Smads, Smad2 and Smads. We also show here that the extracellular cripto protein is required for nodal signaling, making it distinct from activin or TGF-beta signaling.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Genet Inst, Cambridge, MA 02140 USA; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Netherlands Cancer Institute	Kuehn, MR (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10,Rm 4B-36,10 Ctr Dr, Bethesda, MD 20892 USA.		Kuehn, Michael R/A-4573-2014; Dijke, Peter ten/AAG-4660-2021	Kuehn, Michael R/0000-0002-7703-9160; Dijke, Peter ten/0000-0002-7234-342X				Chang CB, 1997, DEVELOPMENT, V124, P827; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; DONO R, 1993, DEVELOPMENT, V118, P1157; Dyson S, 1997, CURR BIOL, V7, P81, DOI 10.1016/S0960-9822(06)00030-3; Gaio U, 1999, CURR BIOL, V9, P1339, DOI 10.1016/S0960-9822(00)80059-7; GERMAIN P, 1993, ANTICANCER RES, V13, P1581; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Heyer J, 1999, P NATL ACAD SCI USA, V96, P12595, DOI 10.1073/pnas.96.22.12595; Hoodless PA, 1999, DEV BIOL, V207, P364, DOI 10.1006/dbio.1998.9168; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; JONES CM, 1995, DEVELOPMENT, V121, P3651; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kumar A, 1997, J LIPID RES, V38, P2240; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Pfendler KC, 2000, GENESIS, V28, P1, DOI 10.1002/1526-968X(200009)28:1<1::AID-GENE10>3.0.CO;2-X; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Saijoh Y, 2000, MOL CELL, V5, P35, DOI 10.1016/S1097-2765(00)80401-3; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; SCHLUNEGGER MP, 1992, FEBS LETT, V303, P91, DOI 10.1016/0014-5793(92)80484-X; Shen MM, 1997, DEVELOPMENT, V124, P429; Song JW, 1999, DEV BIOL, V213, P157, DOI 10.1006/dbio.1999.9370; Tang SJ, 1998, DEVELOPMENT, V125, P1877; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Weisberg E, 1998, MECH DEVELOP, V79, P17, DOI 10.1016/S0925-4773(98)00160-9; Xu CH, 1999, DEVELOPMENT, V126, P483; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yan YT, 1999, GENE DEV, V13, P2527, DOI 10.1101/gad.13.19.2527; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	46	94	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					656	661		10.1074/jbc.M004649200	http://dx.doi.org/10.1074/jbc.M004649200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024047	hybrid			2022-12-27	WOS:000166280700088
J	Pedraza-Alva, G; Sawasdikosol, S; Liu, YC; Merida, LB; Cruz-Munoz, ME; Oceguera-Yanez, F; Burakoff, SJ; Rosenstein, Y				Pedraza-Alva, G; Sawasdikosol, S; Liu, YC; Merida, LB; Cruz-Munoz, ME; Oceguera-Yanez, F; Burakoff, SJ; Rosenstein, Y			Regulation of Cbl molecular interactions by the co-receptor molecule CD43 in human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOTYROSINE-BINDING DOMAIN; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODY; NEGATIVE REGULATOR; ANTIGEN RECEPTOR; RING FINGER; DIFFERENTIAL REGULATION	CD43, one of the most abundant glycoproteins on the T cell surface, has been implicated in selection and maturation of thymocytes and migration, adhesion, and activation of mature T cells. The adapter molecule Cbl has been shown to be a negative regulator of Pas, Furthermore, it may also regulate intracellular signaling through the formation of several multi-molecular complexes. Here we investigated the role of Cbl in the CD43-mediated signaling pathway in human T cells. Unlike T cell receptor signaling, the interaction of the adapter protein Cbl with Vav and phosphatidylinositol 3-kinase, resulting from CD QS-specific signals, is independent of Cbl tyrosine phosphorylation, suggesting an alternative mechanism of interaction. CD43 signals induced a Cbl serine phosphorylation-dependent interaction with the tau -isoform of 14-3-3. protein. Protein kinase C-mediated Cbl serine phosphorylation was required for this interaction, because the PKC inhibitor RO-31-8220 prevented it, as well as 14-3-3 dimerization. Moreover, mutation of Cbl serine residues 619, 623, 639, and 642 abolished the interaction between Cbl and 14-3-3, Overexpression of Cbl in Jurkat cells inhibited the CD43-dependent activation of the mitogen-activated protein kinase (MAPK) pathway and AP-1 transcriptional activity, confirming nevertheless a negative role for Cbl in T cell signaling. However, under normal conditions, PKC activation resulting from CD43 engagement was required to activate the MAPK pathway, suggesting that phosphorylation of Cbl on serine residues by PKC and its association with 14-3-3 molecules may play a role in preventing the Cbl inhibitory effect on the Ras-MAPK pathway. These data suggest that by inducing its phosphorylation on serine residues, CD43-mediated signals may regulate the molecular associations and functions of the Cbl adapter protein.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca 62250, Morelos, Mexico; Dana Farber Canc Inst, Boston, MA 02115 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	Universidad Nacional Autonoma de Mexico; Harvard University; Dana-Farber Cancer Institute; La Jolla Institute for Immunology	Rosenstein, Y (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, APDO Postal 510-3, Cuernavaca 62250, Morelos, Mexico.	yvonne@ibt.unam.mx		LIU, YUN-CAI/0000-0002-0996-7109				AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; ALVARADO M, 1995, EUR J IMMUNOL, V25, P1051, DOI 10.1002/eji.1830250429; Anzai N, 1999, BLOOD, V93, P3317, DOI 10.1182/blood.V93.10.3317.410k12_3317_3326; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Corinti S, 1999, J IMMUNOL, V162, P6331; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Donda A, 1996, EUR J IMMUNOL, V26, P493, DOI 10.1002/eji.1830260232; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; ELLIES LG, 1994, GLYCOBIOLOGY, V4, P885, DOI 10.1093/glycob/4.6.885; FanalesBelasio E, 1997, ADV EXP MED BIOL, V417, P207; FanalesBelasio E, 1997, J IMMUNOL, V159, P2203; Fernandez B, 1999, J BIOL CHEM, V274, P20244, DOI 10.1074/jbc.274.29.20244; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Husson H, 1997, ONCOGENE, V14, P2331, DOI 10.1038/sj.onc.1201074; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson GG, 1999, J IMMUNOL, V163, P5678; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kanagasundaram V, 1996, BIOCHEM J, V320, P69, DOI 10.1042/bj3200069; Kishimoto H, 1999, J EXP MED, V190, P65, DOI 10.1084/jem.190.1.65; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Liu YH, 1999, J IMMUNOL, V162, P7095; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marengere LEM, 1997, J IMMUNOL, V159, P70; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Marshall CJ, 1998, NATURE, V392, P553, DOI 10.1038/33293; Matsuo T, 1996, FEBS LETT, V397, P113, DOI 10.1016/S0014-5793(96)01151-9; McEvoy LM, 1997, J EXP MED, V185, P1493, DOI 10.1084/jem.185.8.1493; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Musci MA, 1997, J IMMUNOL, V159, P1639; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; PADILLANORIEGA L, 1993, J CLIN MICROBIOL, V31, P622, DOI 10.1128/JCM.31.3.622-628.1993; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pedraza-Alva G, 1998, J BIOL CHEM, V273, P14218, DOI 10.1074/jbc.273.23.14218; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; PedrazaAlva G, 1996, J BIOL CHEM, V271, P27564, DOI 10.1074/jbc.271.44.27564; PEREZ L, 1993, P NATL ACAD SCI USA, V90, P8113, DOI 10.1073/pnas.90.17.8113; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PILLER F, 1988, J BIOL CHEM, V263, P15146; PINTADO CO, 1995, VET IMMUNOL IMMUNOP, V47, P333, DOI 10.1016/0165-2427(94)05403-F; PRATT JC, 1996, IMMUNOLOGIST, V4, P122; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROSENKRANZ AR, 1993, IMMUNOLOGY, V80, P431; SANCHEZMATEOS P, 1995, BLOOD, V86, P2228, DOI 10.1182/blood.V86.6.2228.bloodjournal8662228; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Scaife RM, 2000, J CELL SCI, V113, P215; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; Seveau S, 1997, J CELL SCI, V110, P1465; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; SPERLING AI, 1995, J EXP MED, V182, P139, DOI 10.1084/jem.182.1.139; Stockl J, 1996, J EXP MED, V184, P1769, DOI 10.1084/jem.184.5.1769; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Thien CBF, 1999, J IMMUNOL, V162, P7133; Thurman EC, 1998, INT IMMUNOL, V10, P691, DOI 10.1093/intimm/10.5.691; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yankee TM, 1999, J IMMUNOL, V163, P5827; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9; ZENNER G, 1995, BIOESSAYS, V17, P967, DOI 10.1002/bies.950171110	96	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					729	737		10.1074/jbc.M008494200	http://dx.doi.org/10.1074/jbc.M008494200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024037	hybrid			2022-12-27	WOS:000166280700098
J	Pernestig, AK; Melefors, O; Georgellis, D				Pernestig, AK; Melefors, O; Georgellis, D			Identification of UvrY as the cognate response regulator for the BarA sensor kinase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-FLUORESCENS; SIGNAL-TRANSDUCTION; ADAPTIVE RESPONSES; HOMOSERINE LACTONE; GLOBAL CONTROL; OMPC GENES; IN-VITRO; PROTEIN; PHOSPHORYLATION; GACA	BarA is a membrane-associated protein that belongs to a subclass of tripartite sensors of the two-component signal transduction system family, In this study, we report that UvrY is the cognate response regulator for BarA of Escherichia coli, This conclusion is based upon homologies with analogous two-component systems and demonstrated by both biochemical and genetic means. We show that the purified BarA protein is able to autophosphorylate when incubated with [gamma-P-32]ATP but not with [alpha-P-32]ATP or [gamma-P-32]GTP. Phosphorylated BarA, in turn, acts as an efficient phosphoryl group donor to UvrY but not to the non-cognate response regulators ArcA, PhoB, or CpxR. The specificity of the transphosphorylation reaction is further supported by the fact that UvrY can receive the phosphoryl group from BarA-P but not from the non-cognate tripartite sensor ArcB-P or ATP, In addition, genetic evidence that BarA and UvrY mediate the same signal transduction pathway is provided by the finding that both uvrY and barA mutant strains exhibit the same hydrogen peroxide hypersensitive phenotype, These results provide the first biochemical evidence as well as genetic support for a link between BarA and UvrY, suggesting that the two proteins constitute a new two-component system for gene regulation in Eschcrichia coli.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Karolinska Inst, Microbiol & Tumorbiol Ctr, SE-17177 Stockholm, Sweden	Harvard University; Harvard Medical School; Karolinska Institutet	Georgellis, D (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	dimitris_georgellis@hms.harvard.edu	Pernestig, Anna-Karin/X-8387-2018; Melefors, Öjar/N-6164-2015; Georgellis, Dimitris/U-2517-2017	Pernestig, Anna-Karin/0000-0003-4221-6013; Melefors, Öjar/0000-0003-4115-1190; Georgellis, Dimitris/0000-0002-6114-795X	NIGMS NIH HHS [GM-40993] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmer BMM, 1999, MOL MICROBIOL, V31, P971, DOI 10.1046/j.1365-2958.1999.01244.x; AIBA H, 1989, J BIOL CHEM, V264, P8563; Altier C, 2000, MOL MICROBIOL, V35, P635, DOI 10.1046/j.1365-2958.2000.01734.x; Bender CL, 1999, MICROBIOL MOL BIOL R, V63, P266, DOI 10.1128/MMBR.63.2.266-292.1999; Blumer C, 1999, P NATL ACAD SCI USA, V96, P14073, DOI 10.1073/pnas.96.24.14073; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Eriksson ARB, 1998, MOL PLANT MICROBE IN, V11, P743, DOI 10.1094/MPMI.1998.11.8.743; Fisher SL, 1996, BIOCHEMISTRY-US, V35, P4732, DOI 10.1021/bi9525435; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; Frederick RD, 1997, MOL PLANT MICROBE IN, V10, P407, DOI 10.1094/MPMI.1997.10.3.407; Georgellis D, 1999, J BIOL CHEM, V274, P35950, DOI 10.1074/jbc.274.50.35950; Georgellis D, 1998, J BIOL CHEM, V273, P32864, DOI 10.1074/jbc.273.49.32864; Georgellis D, 1997, J BACTERIOL, V179, P5429, DOI 10.1128/jb.179.17.5429-5435.1997; Hengge-Aronis R, 2000, BACTERIAL STRESS RESPONSES, P161; Hoch JA, 1995, 2 COMPONENT SIGNAL T; HRABAK EM, 1993, MOL PLANT MICROBE IN, V6, P368, DOI 10.1094/MPMI-6-368; IGO MM, 1989, GENE DEV, V3, P598, DOI 10.1101/gad.3.5.598; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; JIN SG, 1990, J BACTERIOL, V172, P4945, DOI 10.1128/jb.172.9.4945-4950.1990; Johnston C, 1996, MOL MICROBIOL, V22, P715, DOI 10.1046/j.1365-2958.1996.d01-1719.x; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; Kinscherf TG, 1999, J BACTERIOL, V181, P4133, DOI 10.1128/JB.181.13.4133-4136.1999; Kitten T, 1998, MOL MICROBIOL, V28, P917, DOI 10.1046/j.1365-2958.1998.00842.x; LAVILLE J, 1992, P NATL ACAD SCI USA, V89, P1562, DOI 10.1073/pnas.89.5.1562; Liao CH, 1996, CAN J MICROBIOL, V42, P177, DOI 10.1139/m96-026; Liao CH, 1997, CAN J MICROBIOL, V43, P425, DOI 10.1139/m97-060; LIN ECC, 1996, REGULATION GENE EXPR; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; MOOLENAAR GF, 1987, NUCLEIC ACIDS RES, V15, P4273, DOI 10.1093/nar/15.10.4273; Mukhopadhyay S, 2000, MOL MICROBIOL, V37, P371, DOI 10.1046/j.1365-2958.2000.01999.x; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; OBERHANSLI T, 1991, J GEN MICROBIOL, V137, P2273, DOI 10.1099/00221287-137-10-2273; Ogino T, 1998, MOL MICROBIOL, V27, P573, DOI 10.1046/j.1365-2958.1998.00703.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; Reimmann C, 1997, MOL MICROBIOL, V24, P309, DOI 10.1046/j.1365-2958.1997.3291701.x; RICH JJ, 1994, J BACTERIOL, V176, P7468, DOI 10.1128/JB.176.24.7468-7475.1994; SACHERER P, 1994, FEMS MICROBIOL LETT, V116, P155, DOI 10.1111/j.1574-6968.1994.tb06694.x; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; Uhl MA, 1996, J BIOL CHEM, V271, P33176, DOI 10.1074/jbc.271.52.33176; Whistler CA, 1998, J BACTERIOL, V180, P6635, DOI 10.1128/JB.180.24.6635-6641.1998; Wong SM, 1998, INFECT IMMUN, V66, P5854, DOI 10.1128/IAI.66.12.5854-5861.1998; Zhang JP, 1996, SCIENCE, V273, P1234, DOI 10.1126/science.273.5279.1234	47	123	128	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					225	231		10.1074/jbc.M001550200	http://dx.doi.org/10.1074/jbc.M001550200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022030	hybrid			2022-12-27	WOS:000166280700032
J	Russo, LA; Calabro, SP; Filler, TA; Carey, DJ; Gardner, RM				Russo, LA; Calabro, SP; Filler, TA; Carey, DJ; Gardner, RM			In vivo regulation of syndecan-3 expression in the rat uterus by 17 beta-estradiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; MESSENGER-RIBONUCLEIC-ACID; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; N-SYNDECAN; LUMINAL EPITHELIUM; ESTROGEN-RECEPTORS; FIBROBLAST GROWTH; INVIVO REGULATION; OVARIAN HORMONES	The immature rat uterus has been extensively used as an in vivo model system to study the molecular mechanisms of steroid hormone actions. In this study, we demonstrated the regulated expression of syndecan-3 in the rat uterus by the steroid hormone 17 beta -estradiol. Administration of a single physiological dose of 17 beta -estradiol (40 mug/kg) to ovariectomized immature animals induced a rapid and transient increase in uterine syndecan-3 mRNA Transcript levels reached a peak elevation of 3-fold above saline control tissues 4 h after hormone administration. Inhibition of message up-regulation by actinomycin D but not cycloheximide indicated a hormone response dependent on RNA transcription but not new protein synthesis. The estrogenic ligands estriol and tamoxifen were also effective at raising syndecan-3 mRNA levels; however, nonestrogenic ligands, including progesterone, 5 alpha -dihydrotestosterone, and dexamethasone, failed to stimulate a change in mRNA levels. Hormone-induced changes in mRNA led to transient changes in syndecan-3 protein content and significant alteration in the temporal and spatial expression in endometrial epithelial cells. Collectively, these data show that the steroid hormone 17 beta -estradiol, regulates transcription of the syndecan-3 gene in the uterus via an estrogen receptor-dependent mechanism. This estrogen-regulated expression of syndecan-3 may play an important role in changes in tissue ultrastructure crucial for proper uterine growth.	Villanova Univ, Dept Biol, Villanova, PA 19085 USA; Penn State Univ, Coll Med, Weis Ctr Res, Danville, PA 17822 USA	Villanova University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Russo, LA (corresponding author), Villanova Univ, Dept Biol, Mendel Hall,800 Lancaster Ave, Villanova, PA 19085 USA.	louise.russo@villanova.edu						ANDERSON JN, 1972, BIOCHEM BIOPH RES CO, V48, P1460, DOI 10.1016/0006-291X(72)90878-9; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BAKER HJ, 1978, J BIOL CHEM, V253, P4521; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; Carey DJ, 1997, J BIOL CHEM, V272, P2873, DOI 10.1074/jbc.272.5.2873; Carey DJ, 1997, BIOCHEM J, V327, P1; Chernousov MA, 1996, J BIOL CHEM, V271, P13844, DOI 10.1074/jbc.271.23.13844; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P53; CIZMECISMITH G, 1993, J BIOL CHEM, V268, P18740; CizmeciSmith G, 1997, ARTERIOSCL THROM VAS, V17, P172, DOI 10.1161/01.ATV.17.1.172; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DAUVOIS S, 1993, STEROID HORMONE ACTI, P166; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; FREYSCHUSS B, 1994, J ENDOCRINOL, V142, P285, DOI 10.1677/joe.0.1420285; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; IKEDA K, 1989, J BIOL CHEM, V264, P15743; KAYE AM, 1972, BIOCHIM BIOPHYS ACTA, V261, P475, DOI 10.1016/0304-4165(72)90072-4; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KLANGKALYA B, 1988, LIFE SCI, V42, P2307, DOI 10.1016/0024-3205(88)90183-X; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LOOSEMITCHELL DS, 1988, MOL ENDOCRINOL, V2, P946, DOI 10.1210/mend-2-10-946; MORRIS JE, 1988, J BIOL CHEM, V263, P4712; MUKKU VR, 1985, J BIOL CHEM, V260, P9820; MURPHY CR, 1981, CELL BIOPHYS, V3, P305, DOI 10.1007/BF02785116; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1882, DOI 10.1210/endo-120-5-1882; MYERS MJ, 1986, LIFE SCI, V39, P313, DOI 10.1016/0024-3205(86)90649-1; PASTORE GN, 1992, BIOL REPROD, V47, P83, DOI 10.1095/biolreprod47.1.83; POTTER SW, 1992, ANAT REC, V234, P383, DOI 10.1002/ar.1092340308; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHLAFKE S, 1985, ANAT REC, V212, P47, DOI 10.1002/ar.1092120107; STACK G, 1985, ENDOCRINOLOGY, V117, P2024, DOI 10.1210/endo-117-5-2024; SUVA LJ, 1991, MOL ENDOCRINOL, V5, P829, DOI 10.1210/mend-5-6-829; THIEDE MA, 1991, ENDOCRINOLOGY, V128, P2317, DOI 10.1210/endo-128-5-2317; THURESSONKLEIN A, 1985, AM J OBSTET GYNECOL, V151, P506, DOI 10.1016/0002-9378(85)90279-0; WEBB DK, 1990, BIOCHEM BIOPH RES CO, V168, P721, DOI 10.1016/0006-291X(90)92381-9; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183	46	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					686	692		10.1074/jbc.M004106200	http://dx.doi.org/10.1074/jbc.M004106200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024013	hybrid			2022-12-27	WOS:000166280700092
J	Zheng, M; Zhang, SJ; Zhu, WZ; Ziman, B; Kobilka, BK; Xiao, RP				Zheng, M; Zhang, SJ; Zhu, WZ; Ziman, B; Kobilka, BK; Xiao, RP			beta(2)-adrenergic receptor-induced p38 MAPK activation is mediated by protein kinase A rather than by G(i) or G beta gamma in adult mouse cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASES; TYROSINE KINASE; CARDIAC-HYPERTROPHY; STRESS; STIMULATION; MYOCYTES; HEART; PHOSPHORYLATION; SPECIFICITY; INVOLVEMENT	Increasing evidence shows that stimulation of p-adrenergic receptor (AR) activates mitogen-activated protein kinases (MAPKs), in addition to the classical G(s) adenylyl cyclase-cAMP-dependent protein kinase (PKA) signaling cascade. In the present study, we demonstrate a novel beta (2)-AR-mediated cross-talk between PKA and p38 MAPK in adult mouse cardiac myocytes expressing beta (2)-AR, with a null background of beta (1)beta (2)-AR double knockout. beta (2)-AR stimulation by isoproterenol increased p38 MARK activity in a time- and dose-dependent manner. Inhibiting G(i) with pertussis toxin or scavenging G beta gamma with beta ARK-ct overexpression could not prevent beta (2)-AR-induced p38 MAPK activation. In contrast, a specific peptide inhibitor of PKA, PKI (5 muM), completely abolished the stimulatory effect of beta (2)-AR, suggesting that beta (2)-AR-induced p38 MAPK activation is mediated via a PKA-dependent mechanism, rather than by G(i) or G beta gamma. This conclusion was further supported by the ability of forskolin (10 muM), an adenylyl cyclase activator, to elevate p38 MAPK activity in a PKI-sensitive manner. Furthermore, inhibition of p38 MAPK with SB203580 (10 muM) markedly enhanced the beta (2)-AR-mediated contractile response, without altering base-line contractility. These results provide the first evidence that cardiac beta (2)-AR activates p38 MAPK via a PKA-dependent signaling pathway, rather than by G(i) or G beta gamma, and reveal a novel role of p38 MAPK in regulating cardiac contractility.	NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA; Stanford Univ, Med Ctr, Howard Hughes Med Inst, Stanford, CA 94305 USA; Peking Univ, Hosp 3, Sch Med, Inst Vasc Med, Beijing 100083, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Howard Hughes Medical Institute; Stanford University; Peking University	Xiao, RP (corresponding author), NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	xiaor@grc.nia.nih.gov	Yimei, Wang/AAE-4083-2019; Xiao, Rui-Ping/AAE-2629-2019		NATIONAL INSTITUTE ON AGING [ZIAAG000287, Z01AG000855, Z01AG000287] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; Kuschel M, 1999, CIRCULATION, V99, P2458, DOI 10.1161/01.CIR.99.18.2458; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lim R, 1996, J BIOL CHEM, V271, P22953, DOI 10.1074/jbc.271.38.22953; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Skeberdis VA, 1997, J PHARMACOL EXP THER, V283, P452; VAN BT, 1995, NATURE, V376, P781; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xiao RP, 1999, CIRC RES, V85, P1092; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429; Zhou YY, 1997, AM J PHYSIOL-HEART C, V273, pH1611, DOI 10.1152/ajpheart.1997.273.3.H1611	35	103	106	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40635	40640		10.1074/jbc.M006325200	http://dx.doi.org/10.1074/jbc.M006325200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11018034	hybrid			2022-12-27	WOS:000166039500112
J	Xu, DL; Joglekar, AP; Williams, AL; Hay, JC				Xu, DL; Joglekar, AP; Williams, AL; Hay, JC			Subunit structure of a mammalian ER/Golgi SNARE complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; ENDOPLASMIC-RETICULUM; MEMBRANE-FUSION; TRANSPORT VESICLES; GOLGI-APPARATUS; V-SNARES; T-SNARES; PROTEIN; BOS1P; ER	SNAP receptor (SNARE) complexes bridge opposing membranes to promote membrane fusion within the secretory and endosomal pathways. Because only the exocytic SNARE complexes have been characterized in detail, the structural features shared by SNARE complexes from different fusion steps are not known. We now describe the subunit structure, assembly, and regulation of a quaternary SNARE complex, which appears to mediate an early step in endoplasmic reticulum (ER) to Golgi transport. Purified recombinant syntaxin 5, membrin, and rbet1, three Q-SNAREs, assemble cooperatively to create a high affinity binding site for sec22b, an R-SNARE. The syntaxin 5 amino-terminal domain potently inhibits SNARE complex assembly. The ER/Golgi quaternary complex is remarkably similar to the synaptic complex, suggesting that a common pattern is followed at all transport steps, where three Q-helices assemble to form a high affinity binding site for a fourth R-helix on an opposing membrane. Interestingly, although sec22b binds to the combination of syntaxin 5, membrin, and rbet1, it can only bind if it is present while the others assemble; sec22b cannot bind to a pre-assembled ternary complex of syntaxin 5, membrin, and rbet1. Finally, we demonstrate that the quaternary complex containing sec22b is not an in vitro entity only, but is a bona fide species in living cells.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Biomed Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hay, JC (corresponding author), Univ Michigan, Dept Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.		Williams, Antionette/GQP-2255-2022		NIGMS NIH HHS [T32 GM007315, GM59378] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059378, T32GM007315] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; Sacher M, 1997, J BIOL CHEM, V272, P17134, DOI 10.1074/jbc.272.27.17134; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Stone S, 1997, MOL BIOL CELL, V8, P1175, DOI 10.1091/mbc.8.7.1175; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435	37	93	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39631	39639		10.1074/jbc.M007684200	http://dx.doi.org/10.1074/jbc.M007684200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11035026	hybrid			2022-12-27	WOS:000165953100090
J	van Adelsberg, J; Sehgal, S; Kukes, A; Brady, C; Barasch, J; Yang, J; Huan, YH				van Adelsberg, J; Sehgal, S; Kukes, A; Brady, C; Barasch, J; Yang, J; Huan, YH			Activation of hepatocyte growth factor (HGF) by endogenous HGF activator is required for metanephric kidney morphogenesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE INHIBITOR; FACTOR SCATTER FACTOR; MET TYROSINE KINASE; PLASMINOGEN ACTIVATORS; FACTOR/SCATTER FACTOR; MOLECULAR-CLONING; GENE-EXPRESSION; RECEPTOR; BINDING; PROTHROMBIN	The interaction of hepatocyte growth factor (HGF) with c-Met has been implicated in morphogenesis of the kidney, lung, mammary gland, liver, placenta, and limb bud. HGF is secreted as an inactive zymogen and must be cleaved by a serine protease to initiate Met signaling. We show here that a serine protease specific for HGF, HGF activator (HGFA), is expressed and activated by the ureteric bud of the developing kidney in vivo and in vitro. Inhibition of HGFA activity with serine protease inhibitors reduced ureteric bud branching and inhibited glomerulogenesis and nephrogenesis. Activated HGF rescued developing kidneys from the effects of inhibitors. HGFA was localized around the tips of the ureteric bud in developing kidneys, while HGF was expressed diffusely throughout the mesenchyme. These data show that expression of HGF is not sufficient for development, but that its activation is also required. The localization of HCFA to the ureteric bud and the mesenchyme immediately adjacent to it suggests that HGFA creates a gradient of HGF activity in the developing kidney. The creation and shape of gradients of activated HGF by the localized secretion of HGF activators could play an important role in pattern formation by HGF responsive tissues.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	van Adelsberg, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barasch J, 1996, AM J PHYSIOL-RENAL, V271, pF50, DOI 10.1152/ajprenal.1996.271.1.F50; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; ChoiMiura NH, 1996, J BIOCHEM, V119, P1157; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; Grover PK, 2000, EUR J BIOCHEM, V267, P61, DOI 10.1046/j.1432-1327.2000.00954.x; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; LIJNEN HR, 1986, J BIOL CHEM, V261, P1253; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MARS WM, 1993, AM J PATHOL, V143, P949; Matsubara Y, 1998, BIOCHEM BIOPH RES CO, V253, P477, DOI 10.1006/bbrc.1998.9808; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; Ohmichi H, 1998, DEVELOPMENT, V125, P1315; Piepenhagen PA, 1995, AM J PHYSIOL-CELL PH, V269, pC1417, DOI 10.1152/ajpcell.1995.269.6.C1417; Sakata H, 1997, J BIOL CHEM, V272, P9457; Sakurai H, 1997, P NATL ACAD SCI USA, V94, P6279, DOI 10.1073/pnas.94.12.6279; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; Scaal M, 1999, DEVELOPMENT, V126, P4885; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Stapleton AMF, 1998, BRIT J UROL, V81, P666; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Sumiya J, 1997, J BIOCHEM-TOKYO, V122, P983; Suzuki K, 1999, J AM SOC NEPHROL, V10, pS408; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171	39	43	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15099	15106		10.1074/jbc.M006634200	http://dx.doi.org/10.1074/jbc.M006634200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11032833	hybrid			2022-12-27	WOS:000168528800077
J	Dallongeville, J; Bauge, E; Tailleux, A; Peters, JM; Gonzalez, FJ; Fruchart, JC; Staels, B				Dallongeville, J; Bauge, E; Tailleux, A; Peters, JM; Gonzalez, FJ; Fruchart, JC; Staels, B			Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; POLYUNSATURATED FATTY-ACIDS; HIGH-DENSITY-LIPOPROTEINS; MESSENGER-RNA ABUNDANCE; ELEMENT-BINDING PROTEIN; S14 GENE-TRANSCRIPTION; EICOSAPENTAENOIC ACID; ACYL-COENZYME; DIETARY-FAT; C-III	Similar to fibrate hypolipidemic drugs, long chain polyunsaturated fatty acids contained in fish oil are activators of peroxisome proliferator-activated receptor alpha (PPAR alpha), The goal of this study was to assess the contribution of PPAR alpha in mediating the effect of fish oil on plasma lipid, lipoprotein, and apolipoprotein levels. To this end, PPAR alpha -deficient mice and wild-type littermates were fed isocaloric fish oil or coconut oil diets, the content of which varied reciprocally between 0, 3, 7, and 10% for 1 week. In both wild-type and PPAR alpha -deficient mice, fish oil feeding was associated with a dose-dependent decrease in triglycerides, cholesterol, and phospholipids associated with lower levels of very low density lipoprotein (VLDL) triglycerides and high density lipoprotein (HDL) cholesterol, The lowering of triglycerides and VLDL triglycerides was associated with a significant decrease of plasma apoC-III in both genotypes, Fish oil treatment did not influence hepatic apoC-III mRNA levels in either genotype indicating that apoC-III is not under transcriptional control by fish oil. The lowering of HDL cholesterol observed in both genotypes was associated with reduced plasma apoA-II without changes in liver apoA-II mRNA levels. In contrast, plasma apoA-I and liver apoA-I mRNA levels were decreased in wild-type but not in PPAR alpha -deficient mice after fish oil feeding indicating that PPAR alpha contributes to the effect of fish oil on apoA-I gene expression. In conclusion, PPAR alpha is not rate-limiting for fish oil to exert its triglyceride- and HDL-lowering action. Furthermore, PPAR alpha mediates, at least partly, the decrease of apoA-I after fish oil treatment, whereas apoC-III and apoA-II levels are affected in a PPAR alpha -independent manner. Altogether, these results show major molecular differences in action between fibrates and fish oil providing a molecular rationale for combination treatment with these compounds.	Inst Pasteur, Dept Atherosclerose, F-59019 Lille, France; Inst Pasteur, INSERM, U508, F-59019 Lille, France; Inst Pasteur, INSERM, U325, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59000 Lille, France; Penn State Univ, Ctr Mol Toxicol, University Pk, PA 16802 USA; NCI, Mol Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dallongeville, J (corresponding author), Inst Pasteur, Dept Atherosclerose, 1 Rue Professeur Calmette, F-59019 Lille, France.		TAILLEUX, Anne/R-5530-2018; Staels, Bart/N-9497-2016; Peters, Jeffrey/D-8847-2011; Bauge, Eric/R-6522-2018	TAILLEUX, Anne/0000-0003-1430-2627; Staels, Bart/0000-0002-3784-1503; Peters, Jeffrey/0000-0003-2782-2998; Bauge, Eric/0000-0001-9994-8667				AHN YS, 1994, J NUTR, V124, P2147, DOI 10.1093/jn/124.11.2147; Andersson Y, 1999, ARTERIOSCL THROM VAS, V19, P115, DOI 10.1161/01.ATV.19.1.115; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; BERTHOU L, 1995, EUR J BIOCHEM, V232, P179, DOI 10.1111/j.1432-1033.1995.tb20797.x; BOCOS C, 1995, J STEROID BIOCHEM, V53, P467, DOI 10.1016/0960-0760(95)00093-F; BROUSSEAU ME, 1995, J NUTR, V125, P425; BROUSSEAU ME, 1995, ATHEROSCLEROSIS, V115, P107, DOI 10.1016/0021-9150(94)05505-D; BURGAYA F, 1989, BIOCHEM J, V259, P159, DOI 10.1042/bj2590159; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECRAEMER D, 1994, J LIPID RES, V35, P1241; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GRONN M, 1992, BIOCHIM BIOPHYS ACTA, V1125, P35, DOI 10.1016/0005-2760(92)90152-L; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HALMINSKI MA, 1991, J NUTR, V121, P1554, DOI 10.1093/jn/121.10.1554; Harris WS, 1997, AM J CLIN NUTR, V65, P1611; Harris WS, 1997, AM J CLIN NUTR, V65, P1645, DOI 10.1093/ajcn/65.5.1645S; HARRIS WS, 1989, J LIPID RES, V30, P785; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KUSHWAHA RS, 1991, J LIPID RES, V32, P1929; LEACH AB, 1984, LIPIDS, V19, P25, DOI 10.1007/BF02534604; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; NOSSEN JO, 1986, BIOCHIM BIOPHYS ACTA, V879, P56, DOI 10.1016/0005-2760(86)90266-3; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Power GW, 1997, J NUTR, V127, P2142, DOI 10.1093/jn/127.11.2142; QUARFORDT SH, 1982, J BIOL CHEM, V257, P4642; RAMIREZ I, 1985, BIOCHEM J, V232, P229, DOI 10.1042/bj2320229; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; RUSTAN AC, 1988, J LIPID RES, V29, P1417; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Schoonjans K, 1996, J LIPID RES, V37, P907; SHEPHERD J, 1978, J CLIN INVEST, V61, P1582, DOI 10.1172/JCI109078; SORCITHOMAS M, 1992, J LIPID RES, V33, P1147; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; STAELS B, 1989, J LIPID RES, V30, P1137; STUCCHI AF, 1991, ARTERIOSCLER THROMB, V11, P1719, DOI 10.1161/01.ATV.11.6.1719; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WILLUMSEN N, 1993, LIPIDS, V28, P683, DOI 10.1007/BF02535987; WINDLER E, 1980, J BIOL CHEM, V255, P8303; WONG S, 1985, METABOLISM, V34, P900, DOI 10.1016/0026-0495(85)90135-0; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577	57	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4634	4639		10.1074/jbc.M008809200	http://dx.doi.org/10.1074/jbc.M008809200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11050100	hybrid			2022-12-27	WOS:000168484300016
J	Joel, PB; Trybus, KM; Sweeney, HL				Joel, PB; Trybus, KM; Sweeney, HL			Two conserved lysines at the 50/20-kDa junction of myosin are necessary for triggering actin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; ACTOMYOSIN INTERACTIONS; ATPASE ACTIVITY; MOTOR DOMAIN; CHIMERIC SUBSTITUTIONS; CHARGED RESIDUES; BINDING SITES; HEAVY-CHAIN; N-TERMINUS; SUBFRAGMENT-1	Actin stimulates myosin's activity by inducing structural alterations that correlate with the transition from a weakly to a strongly bound state, during which time inorganic phosphate (P-i) is released from myosin's active site. The surface loop at the 50/20-kDa junction of myosin (loop 2) is part of the actin interface. Here we demonstrate that elimination of two highly conserved lysines at the C-terminal end of loop 2 specifically blocks the ability of heavy meromyosin to undergo a weak to strong binding transition with actin in the presence of ATP, Removal of these lysines has no effect on strong binding in the absence of nucleotide, on the rate of ADP binding or release, or on the basal ATPase activity. We further show that the 16 amino acids of loop 2 preceding the lysine-rich region are not essential for actin activation, although they do modulate myosin's affinity for actin in the presence of ATP. We conclude that interaction of the conserved lysines with acidic residues in subdomain I of actin either triggers a structural change or stabilizes a conformation that is necessary for actin-activated release of P-i and completion of the ATPase cycle.	Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Vermont; University of Pennsylvania	Trybus, KM (corresponding author), Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Given Bldg E205, Burlington, VT 05405 USA.	trybus@salus.med.uvm.edu	Sweeney, H Lee/F-1862-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035661] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54568] Funding Source: Medline; NIAMS NIH HHS [AR35661] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHAUSSEPIED P, 1983, FEBS LETT, V161, P84, DOI 10.1016/0014-5793(83)80735-2; CHAUSSEPIED P, 1988, P NATL ACAD SCI USA, V85, P7471, DOI 10.1073/pnas.85.20.7471; CHEUNG P, 1992, BIOCHEM BIOPH RES CO, V189, P1143, DOI 10.1016/0006-291X(92)92323-P; COOK RK, 1993, J BIOL CHEM, V268, P2410; DASGUPTA G, 1992, BIOCHEMISTRY-US, V31, P1836, DOI 10.1021/bi00121a036; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GEEVES MA, 1991, BIOCHEM J, V274, P1; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; Knetsch MLW, 1999, J BIOL CHEM, V274, P20133, DOI 10.1074/jbc.274.29.20133; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER CJ, 1995, BIOCHEMISTRY-US, V34, P2694, DOI 10.1021/bi00008a037; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rovner AS, 1998, J BIOL CHEM, V273, P27939, DOI 10.1074/jbc.273.43.27939; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; Wong WNW, 1999, BIOCHEMISTRY-US, V38, P1365, DOI 10.1021/bi982467g; YAMAMOTO K, 1990, BIOCHEMISTRY-US, V29, P844, DOI 10.1021/bi00455a035; YAMAMOTO K, 1991, J MOL BIOL, V217, P229, DOI 10.1016/0022-2836(91)90535-E	36	63	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					2998	3003		10.1074/jbc.M006930200	http://dx.doi.org/10.1074/jbc.M006930200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042210	hybrid			2022-12-27	WOS:000166784900005
J	Rumenapp, U; Asmus, M; Schablowski, H; Woznicki, M; Han, L; Jakobs, KH; Fahimi-Vahid, M; Michalek, C; Wieland, T; Schmidt, M				Rumenapp, U; Asmus, M; Schablowski, H; Woznicki, M; Han, L; Jakobs, KH; Fahimi-Vahid, M; Michalek, C; Wieland, T; Schmidt, M			The M-3 muscarinic acetylcholine receptor expressed in HEK-293 cells signals to phospholipase D via G(12) but not G(q)-type G proteins - Regulators of G proteins as tools to dissect pertussis toxin-resistant G proteins in receptor-effector coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; HETEROTRIMERIC G-PROTEINS; ADP-RIBOSYLATION-FACTOR; SERUM RESPONSE FACTOR; SMOOTH-MUSCLE CELLS; ALPHA-SUBUNITS; RGS PROTEINS; DEPENDENT ACTIVATION; TRANSITION-STATE; ANGIOTENSIN-II	The M-3 muscarinic acetylcholine receptor (mAChR) expressed in HEK-293 cells couples to G(q) and G(12) proteins and stimulates phospholipase C (PLC) and phospholipase D (PLD) in a pertussis toxin-insensitive manner. To determine the type of G protein mediating M-3 mAChR-PLD coupling in comparison to M-3 mAChR-PLC coupling, we expressed various G alpha proteins and regulators of the G protein signaling (RGS), which act as GTPase-activating proteins for G(q)- or G(12)-type G proteins. PLD stimulation by the M-3 mAChR was enhanced by the overexpression of G alpha (12), and G alpha (13), whereas the overexpression of G alpha (q) strongly increased PLC activity without affecting PLD activity. Expression of the RGS homology domain of Lsc, which acts specifically on G alpha (12) and G alpha (13), blunted the M-3 mAChR-induced PLD stimulation without affecting PLC stimulation. On the other hand, overexpression of RGS4, which acts on G alpha (q)- but not G alpha (12)-type G proteins, suppressed the M-3 mAChR-induced PLC stimulation without altering PLD stimulation. We conclude that the M-3 mAChR in HEK-293 cells apparently signals to PLD via G alpha (q)- but not G alpha (12)-type G proteins and that G protein subtype-selective RGS proteins can be used as powerful tools to dissect the pertussis toxin-resistant G proteins and their role in receptor-effector coupling.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany; Univ Hamburg, Krankenhaus Eppendorf, Inst Expt & Klin Pharmakol & Toxicol, D-20246 Hamburg, Germany	University of Duisburg Essen; University of Hamburg	Rumenapp, U (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.		Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012; Schmidt, Martina/C-5339-2018	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261; Schmidt, Martina/0000-0003-3075-0630				Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gsell S, 2000, FASEB J, V14, P17, DOI 10.1096/fasebj.14.1.17; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rumenapp U, 1997, EUR J BIOCHEM, V248, P407, DOI 10.1111/j.1432-1033.1997.00407.x; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; Schurmann A, 1999, J BIOL CHEM, V274, P9744, DOI 10.1074/jbc.274.14.9744; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Ushio-Fukai M, 1999, MOL PHARMACOL, V55, P142, DOI 10.1124/mol.55.1.142; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; WIELAND T, 1993, J BIOL CHEM, V268, P18111; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924	45	73	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2474	2479		10.1074/jbc.M004957200	http://dx.doi.org/10.1074/jbc.M004957200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11036069	hybrid			2022-12-27	WOS:000166784800025
J	Song, C; Hu, CD; Masago, M; Kariya, K; Yamawaki-Kataoka, Y; Shibatohge, M; Wu, DM; Satoh, T; Kataoka, T				Song, C; Hu, CD; Masago, M; Kariya, K; Yamawaki-Kataoka, Y; Shibatohge, M; Wu, DM; Satoh, T; Kataoka, T			Regulation of a novel human phospholipase C, PLC epsilon, through membrane targeting by Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISSOCIATION STIMULATOR; ADENYLYL-CYCLASE; GOLGI-COMPLEX; MAP KINASE; ACTIVATION; PROTEIN; EFFECTOR; RAP1; TRANSFORMATION; IDENTIFICATION	Phosphoinositide-specific phospholipase C (PI-PLG) plays a pivotal role in regulation of intracellular signal transduction from various receptor molecules. More than 10 members of human PI-PLG isoforms have been identified and classified into three classes beta, gamma, and delta, which are regulated by distinct mechanisms. Here we report identification of a novel class of human PI-PLG, named PLG epsilon, which is characterized by the presence of a Res-associating domain at its C terminus and a CDC25-like domain at its N terminus. The Res-associating domain of PLGe specifically binds to the GTP-bound forms of Ha-Ras and Rap1A. The dissociation constant for Ha-Ras is estimated to be approximately 40 nM, comparable with those of other Res effecters. Co-expression of an activated Ha-Res mutant with PLGe induces its translocation from the cytosol to the plasma membrane. Upon stimulation with epidermal growth factor, similar translocation of ectopically expressed PLGe is observed, which is inhibited by co-expression of dominant-negative Ha-Res. Furthermore, using a liposome-based reconstitution assay, it is shown that the phosphatidylinositol 4,5-bisphosphate-hydrolyzing activity of PLC epsilon is stimulated in vitro by Ha-Ras in a GTP-dependent manner. These results indicate that Res directly regulates phosphoinositide breakdown through membrane targeting of PLCe.	Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Univ Ryukyus, Sch Med, Dept Biochem 2, Okinawa 9030215, Japan	Kobe University; University of the Ryukyus	Kataoka, T (corresponding author), Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp	Satoh, Takaya/K-2628-2014; song, chunhua/K-7882-2016; song, chunhua/K-7882-2016	song, chunhua/0000-0001-7563-0339; song, chunhua/0000-0002-4081-2543				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HOMMA Y, 1997, SIGNALING INOSITIDES, P99; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; MINATO T, 1994, J BIOL CHEM, V269, P20845; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Watari Y, 1998, GENE, V224, P53, DOI 10.1016/S0378-1119(98)00527-7; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	38	262	287	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2752	2757		10.1074/jbc.M008324200	http://dx.doi.org/10.1074/jbc.M008324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11022048	hybrid			2022-12-27	WOS:000166784800062
J	Songyang, Z; Yamanashi, Y; Liu, D; Baltimore, D				Songyang, Z; Yamanashi, Y; Liu, D; Baltimore, D			Domain-dependent function of the rasGAP-binding protein p62Dok in cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEIN; V-SRC; TYROSINE PHOSPHORYLATION; DOCKING PROTEIN; PTB DOMAIN; C-SRC; DOK-R; RECEPTOR; FAMILY	p62Dok, the rasGAP-binding protein, is a common target of protein-tyrosine kinases. It is one of the major tyrosine-phosphorylated molecules in v-Src-transformed cells. Dok consists of an amino-terminal Pleckstrin homology domain, a putative phosphotyrosine binding domain, and a carboxyl-terminal tail containing multiple tyrosine phosphorylation sites. The importance and function of these sequences in Dok signaling remain largely unknown. We have demonstrated here that the expression of Dok can inhibit cellular transformation by the Src tyrosine kinase, Both the phosphotyrosine binding domain and the carboxyl-terminal tail of Dok tin particular residues 336-363) are necessary for such activity. Using a combinatorial peptide library approach, we have shown that the Dok phosphotyrosine binding domain binds phosphopeptides with the consensus motif of Y/MXXNXL-phosphotyrosine. Furthermore, Dok can homodimerize through its phosphotyrosine binding domain and Tyr(146) at the amino-terminal region. Mutations of this domain or Tyr(146) that block homodimerization significantly reduce the ability of Dok to inhibit Src transformation. Our results suggest that Dok oligomerization through its multiple domains plays a critical role in Dok signaling in response to tyrosine kinase activation.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 108, Japan; CALTECH, Pasadena, CA 91125 USA	Baylor College of Medicine; University of Tokyo; California Institute of Technology	Songyang, Z (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	songyang@cbcm.tmc.edu						Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; Cong F, 1999, MOL CELL BIOL, V19, P8314; DARBY C, 1994, J IMMUNOL, V152, P5429; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Dunant NM, 2000, CELL SIGNAL, V12, P317, DOI 10.1016/S0898-6568(00)00073-5; ELLIS C, 1991, ONCOGENE, V6, P895; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAWLEY RG, 1994, GENE THER, V1, P136; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Jones N, 1999, CURR BIOL, V9, P1057, DOI 10.1016/S0960-9822(99)80458-8; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; NEET K, 1995, MOL CELL BIOL, V15, P4908; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; OKADA M, 1991, J BIOL CHEM, V266, P24249; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Shoelson SE, 1997, CURR OPIN CHEM BIOL, V1, P227, DOI 10.1016/S1367-5931(97)80014-2; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhou SY, 1999, PROG BIOPHYS MOL BIO, V71, P359, DOI 10.1016/S0079-6107(98)00045-5	36	64	64	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2459	2465		10.1074/jbc.M005504200	http://dx.doi.org/10.1074/jbc.M005504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042170	Green Accepted, hybrid			2022-12-27	WOS:000166784800023
J	Waidner, LA; Flynn, EK; Wu, M; Li, X; Karpel, RL				Waidner, LA; Flynn, EK; Wu, M; Li, X; Karpel, RL			Domain effects on the DNA-interactive properties of bacteriophage T4 gene 32 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BINDING-SITE; NUCLEIC-ACID; T4-GENE 32-PROTEIN; COOPERATIVITY DOMAIN; MELTING PROTEINS; REPLICATION; PURIFICATION; RECOMBINATION; FLUORESCENCE; ASSOCIATION	Bacteriophage T4 gene 32 protein, a model for single-strand specific nucleic acid-binding proteins, consists of three structurally and functionally distinct domains. We have studied the effects of the N and C domains on the protein structure and its nucleic acid-interactive properties. Although the presence of the C domain decreases the proteolytic susceptibility of the core (central) domain, quenching of the core tryptophan fluorescence by iodide is unaltered by the presence of the terminal domains. These results suggest that the overall conformation of the core domain remains largely independent of the flanking domains. Removal of the N or the C terminus does not abolish the DNA renaturation activity of the protein. However, intact protein and its three truncated forms differ in DNA helix-destabilizing activity. The C domain alone is responsible for the kinetic barrier to natural DNA helix destabilization seen with intact protein. Intact protein and core domain potentiate the DNA helix-destabilizing activity of truncated protein lacking only the C domain (*I), enhancing the observed hyperchromicity while increasing the melting temperature. Proteolysis experiments suggest that the affinity of core domain for single-stranded DNA is increased in the presence of *I. We propose that *I can "mingle" with intact protein or core domain while bound to single-stranded DNA.	Univ Maryland Baltimore Cty, Dept Chem & Biochem, Baltimore, MD 21250 USA	University System of Maryland; University of Maryland Baltimore County	Karpel, RL (corresponding author), Univ Maryland Baltimore Cty, Dept Chem & Biochem, Baltimore, MD 21250 USA.		Waidner, Lisa/F-8573-2010; Li, Xing/D-3852-2009; Waidner, Lisa/L-8921-2019	Waidner, Lisa/0000-0003-0117-665X	NIGMS NIH HHS [1R01GM52530] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BITTNER M, 1979, J BIOL CHEM, V254, P9565; CASASFINET JR, 1992, P NATL ACAD SCI USA, V89, P1050, DOI 10.1073/pnas.89.3.1050; CASASFINET JR, 1993, J MOL BIOL, V229, P873, DOI 10.1006/jmbi.1993.1093; CASASFINET JR, 1993, BIOCHEMISTRY-US, V32, P9735, DOI 10.1021/bi00088a028; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; HOSODA J, 1978, J BIOL CHEM, V253, P7547; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KARPEL RL, 1987, J BIOL CHEM, V262, P9359; KELLY RC, 1976, J BIOL CHEM, V251, P7229; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; VILLEMAIN JL, 1993, BIOCHEMISTRY-US, V32, P11235, DOI 10.1021/bi00092a038; Villemain JL, 1996, J BIOL CHEM, V271, P27623, DOI 10.1074/jbc.271.44.27623; Wheeler LJ, 1996, J BIOL CHEM, V271, P11156, DOI 10.1074/jbc.271.19.11156; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; Wu M, 1999, J MOL BIOL, V286, P1107, DOI 10.1006/jmbi.1999.2541	25	23	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2509	2516		10.1074/jbc.M007778200	http://dx.doi.org/10.1074/jbc.M007778200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053417	hybrid			2022-12-27	WOS:000166784800030
J	Watt, WC; Storm, DR				Watt, WC; Storm, DR			Odorants stimulate the ERK/mitogen-activated protein kinase pathway and activate cAMP-response element-mediated transcription in olfactory sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE ADENYLATE-CYCLASE; NUCLEOTIDE-GATED CHANNELS; MAP KINASE; GENE-EXPRESSION; RECEPTOR-CELLS; PHOSPHORYLATION; INHIBITION; CREB; CASCADE; BINDING	Olfactory sensory neurons (OSNs) respond acutely to volatile molecules and exhibit adaptive responses including desensitization to odorant exposure. Although mechanisms for short term adaptation have been described, there is little evidence that odorants cause long lasting, transcription-dependent changes in OSNs. Here we report that odorants stimulate cAMP-response element (CRE)-mediated transcription in OSNs through Ca2+ activation of the ERK/MAPK/p90(rsh) pathway, Odorant stimulation of ERK phosphorylation was ablated by inhibition of calmodulin-dependent protein kinase II suggesting that odorant activation of ERK is mediated through this kinase. Moreover, a brief exposure in vivo to an odorant in vapor phase stimulated CRE-mediated gene transcription in discrete populations of OSNs. These data suggest that like central nervous system neurons, OSNs may undergo long term adaptive changes mediated through CRE-mediated transcription.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Storm, DR (corresponding author), Univ Washington, Dept Pharmacol, Mail Box 357280,Hlth Sci Bldg, Seattle, WA 98195 USA.	dstorm@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004156] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC04156] Funding Source: Medline; NIGMS NIH HHS [GM07270] Funding Source: Medline; NINDS NIH HHS [NS357056] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraham ST, 1997, CIRC RES, V81, P575, DOI 10.1161/01.RES.81.4.575; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Barth AL, 2000, J NEUROSCI, V20, P4206; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Blum S, 1999, J NEUROSCI, V19, P3535; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BORISY FF, 1992, J NEUROSCI, V12, P915; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; Dittman AH, 1997, NEURON, V19, P381, DOI 10.1016/S0896-6273(00)80947-2; Duchamp-Viret P, 1999, SCIENCE, V284, P2171, DOI 10.1126/science.284.5423.2171; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRINGS S, 1991, J GEN PHYSIOL, V97, P725, DOI 10.1085/jgp.97.4.725; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREVAL SS, 2000, J BIOL CHEM, V275, P3722; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hirotsu T, 2000, NATURE, V404, P289, DOI 10.1038/35005101; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; Kurahashi T, 1997, NATURE, V385, P725, DOI 10.1038/385725a0; LeindersZufall T, 1997, J NEUROSCI, V17, P4136; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Lindstrom L, 1999, CLIN PHYSIOL, V19, P1, DOI 10.1046/j.1365-2281.1999.00137.x; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1989, P NATL ACAD SCI USA, V86, P5641, DOI 10.1073/pnas.86.14.5641; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Moon C, 1999, P NATL ACAD SCI USA, V96, P14605, DOI 10.1073/pnas.96.25.14605; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Obrietan K, 1999, J BIOL CHEM, V274, P17748, DOI 10.1074/jbc.274.25.17748; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; Pham TA, 1999, NEURON, V22, P63, DOI 10.1016/S0896-6273(00)80679-0; RONNETT GV, 1991, P NATL ACAD SCI USA, V88, P2366, DOI 10.1073/pnas.88.6.2366; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tully T, 1998, NAT NEUROSCI, V1, P543, DOI 10.1038/2780; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WANG HW, 1993, SCIENCE, V260, P998, DOI 10.1126/science.8493539; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Wei J, 1998, NEURON, V21, P495, DOI 10.1016/S0896-6273(00)80561-9; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZUFALL F, 1991, P ROY SOC B-BIOL SCI, V246, P225, DOI 10.1098/rspb.1991.0148; ZUFALL F, 1991, J NEUROSCI, V11, P3573	63	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2047	2052		10.1074/jbc.M006703200	http://dx.doi.org/10.1074/jbc.M006703200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042208	hybrid			2022-12-27	WOS:000166528000055
J	Berman, Y; Mzhavia, N; Polonskaia, A; Devi, LA				Berman, Y; Mzhavia, N; Polonskaia, A; Devi, LA			Impaired prohormone convertases in Cpe(fat)/Cpe(fat) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN REGIONS; PRODYNORPHIN-DERIVED PEPTIDES; CHRONIC FOOD RESTRICTION; MESSENGER-RNA LEVELS; CARBOXYPEPTIDASE-E; PROPROTEIN CONVERTASES; BASIC RESIDUES; FAT MUTATION; PROOPIOMELANOCORTIN; PC2	A spontaneous point mutation in the coding region of the carboxypeptidase E (CPE) gene results in a loss of CPE activity that correlates with the development of late onset obesity (Nagert, J, K,, Fricker, L. D., Varlamov, O,, Nishina, P. M,, Rouille, Y., Steiner, D. F., Carroll, R, J., Paigen, B. J,, and Leiter, E, H. (1995) Not. Genet. 10, 135-142), Examination of the level of neuropeptides in these mice showed a decrease in mature bioactive peptides as a result of a decrease in both carboxypeptidase and prohormone convertase activities. A defect in CPE is not expected to affect endoproteolytic processing. In this report we have addressed the mechanism of this unexpected finding by directly examining the expression of the major precursor processing endoproteases, prohormone convertases. PC1 and PC2 in Cpe(fat) mice. We found that the levels of PC1 and PC2 are differentially altered in a number of brain regions and in the pituitary. Since these enzymes have been implicated in the generation of neuroendocrine peptides dynorphin A-17, beta -endorphin, and (alpha- melanocyte-stimulating hormone) involved in the control of feeding behavior and body weight, we compared the levels of these peptides in Cpe(fat) and wild type animals. We found a marked increase in the level of dynorphin A-17, a decrease in the level of alpha -melanocyte-stimulating hormone, and an alteration in the level of C-terminally processed beta -endorphhin. These results suggest that the impairment in the level of these and other peptides involved in body weight regulation is mainly due to an alteration in carboxypeptidase and prohormone convertase activities and that this may lead to the development of obesity in these animals.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Berman, Y (corresponding author), NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA.		Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776; Mzhavia, Nino/0000-0001-8602-9987	NIDA NIH HHS [DA00342, DA00458] Funding Source: Medline; NINDS NIH HHS [NS26880] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026880, R01NS026880] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahima RS, 1999, ENDOCRINOLOGY, V140, P4923, DOI 10.1210/en.140.11.4923; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; Berman Y, 1997, MOL BRAIN RES, V46, P25, DOI 10.1016/S0169-328X(96)00175-1; BERMAN Y, 1994, BRAIN RES, V664, P49, DOI 10.1016/0006-8993(94)91952-6; Berman Y, 2000, J NEUROCHEM, V75, P1763, DOI 10.1046/j.1471-4159.2000.0751763.x; BERMAN Y, 1995, BRAIN RES, V685, P129, DOI 10.1016/0006-8993(95)00419-Q; BRAY GA, 1989, AM J CLIN NUTR, V50, P891, DOI 10.1093/ajcn/50.5.891; Bruzzaniti A, 1999, J BIOL CHEM, V274, P24703, DOI 10.1074/jbc.274.35.24703; Cain BM, 1997, ENDOCRINOLOGY, V138, P4034, DOI 10.1210/en.138.9.4034; Castro MG, 1997, CRIT REV NEUROBIOL, V11, P35; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DOUGLASS J, 1989, MOL ENDOCRINOL, V3, P2070, DOI 10.1210/mend-3-12-2070; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; Fisher SL, 1999, J RECEPT SIGNAL TR R, V19, P203, DOI 10.3109/10799899909036646; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; FUKUSHIMA M, 1993, INT J OBESITY, V17, P337; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Inui A, 2000, PHARMACOL REV, V52, P35; JAFFE SB, 1994, BRAIN RES, V648, P24, DOI 10.1016/0006-8993(94)91900-3; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; KRUMLAUF R, 1996, BASIC DNA RNA PROTOC, P116; Lacourse KA, 1997, FEBS LETT, V416, P45, DOI 10.1016/S0014-5793(97)01164-2; Lamango NS, 1999, ARCH BIOCHEM BIOPHYS, V362, P275, DOI 10.1006/abbi.1998.1033; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P263, DOI 10.1006/mcne.1994.1030; LOW MJ, 1993, J BIOL CHEM, V268, P24967; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; Mountjoy KG, 1997, MOL CELL ENDOCRINOL, V128, P171, DOI 10.1016/S0303-7207(96)04017-8; NAGERT JK, 1995, NAT GENET, V10, P135; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; Shen FS, 1997, P NATL ACAD SCI USA, V94, P5314, DOI 10.1073/pnas.94.10.5314; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SMYTH DG, 1989, J NEUROCHEM, V53, P489, DOI 10.1111/j.1471-4159.1989.tb07360.x; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Udupi V, 1997, ENDOCRINOLOGY, V138, P1959, DOI 10.1210/en.138.5.1959; UHLER M, 1983, J BIOL CHEM, V258, P257; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919	48	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1466	1473		10.1074/jbc.M008499200	http://dx.doi.org/10.1074/jbc.M008499200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038363	hybrid			2022-12-27	WOS:000166430900081
J	Hirsch, DS; Pirone, DM; Burbelo, PD				Hirsch, DS; Pirone, DM; Burbelo, PD			A new family of Cdc42 effector proteins, CEPs, function in fibroblast and epithelial cell shape changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-BINDING DOMAIN; P21-ACTIVATED KINASE; FILOPODIUM FORMATION; ACTIN-CYTOSKELETON; MDCK CELLS; N-WASP; RHO; RAC1; POLARIZATION; EXPRESSION	Cdc42, a Rho GTPase, regulates the organization of the actin cytoskeleton by its interaction with several distinct families of downstream effector proteins. Here, we report the identification of four new Cdc42-binding proteins that, along with MSE55, constitute a new family of effector proteins. These molecules, designated CEPs, contain three regions of homology, including a Cdc42 binding domain acid two unique domains called CI and CII. Experimentally, we have verified that CEP2 and CEP5 bind Cdc42. Expression of CEP2, CEP3, CEP4, and CEP5 in NIH-3T3 fibroblasts induced pseudopodia formation. Fibroblasts coexpressing dominant negative Cdc42 with CEP2 or expressing a Cdc42/Rac interactive binding domain mutant of CEP2 did not induce pseudopodia formation. In primary keratinocytes, CEP2-and CEP5-expressing cells showed reduced F-actin localization at the adherens junctions with an increase in thin stress fibers that extended the length of the cell body. Keratinocytes expressing CEPs also showed an altered vinculin distribution and a loss of E-cadherin from adherens junctions. Similar effects were observed in keratinocytes expressing constitutively active Cdc42, but were not seen with a Cdc42/Rac interactive binding domain mutant of CEP2. These results suggest that CEPs act downstream of Cdc42 to induce actin filament assembly leading to cell shape changes.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Burbelo, PD (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Oncol, Rm EG16,New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	burbelpd@gunet.georgetown.edu	Burbelo, Peter D./B-1027-2009		NATIONAL CANCER INSTITUTE [R29CA077459] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA77459-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; BAHOU WF, 1992, J BIOL CHEM, V267, P13986; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Burbelo PD, 1999, P NATL ACAD SCI USA, V96, P9083, DOI 10.1073/pnas.96.16.9083; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; Clayton L, 1999, DEV BIOL, V205, P322, DOI 10.1006/dbio.1998.9117; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Dutartre H, 1996, J CELL SCI, V109, P367; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Pirone DM, 2000, J BIOL CHEM, V275, P22650, DOI 10.1074/jbc.M002832200; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Stoffler HE, 1998, J CELL SCI, V111, P2779; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	48	73	81	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					875	883		10.1074/jbc.M007039200	http://dx.doi.org/10.1074/jbc.M007039200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035016	hybrid			2022-12-27	WOS:000166430900004
J	Ho, HH; Ganeshalingam, N; Rosenhouse-Dantsker, A; Osman, R; Gershengorn, MC				Ho, HH; Ganeshalingam, N; Rosenhouse-Dantsker, A; Osman, R; Gershengorn, MC			Charged residues at the intracellular boundary of transmembrane helices 2 and 3 independently affect constitutive activity of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; ALPHA(1B)-ADRENERGIC RECEPTOR; ACTIVATION; RHODOPSIN; ONCOGENE; MUTATION; LYMPHOMA; HELIX-6	Because charged residues at the intracellular ends of transmembrane helix (TMH) 2 and TMH3 of G protein-coupled receptors (GPCRs) affect signaling, we performed mutational analysis of these residues in the constitutively signaling Kaposi's sarcoma-associated herpesvirus GPCR (KSNV-GPCR), KSHV-GPCR contains the amino acid sequence Val-Arg-Tyr rather than the Asp/Glu-Arg-Tyr ((D/ E)RY) moth at the intracellular end of TMH3, Mutation of Arg-143 to Ala (R143A) or Gln (R143Q) abolished constitutive signaling whereas R143K exhibited 50% of the basal activity of RSHV-GPCR, R143A was not stimulated by agonist, whereas R143Q was stimulated by growth-related oncogene-cu, and R143K, similar to KSHV-GPCR, was stimulated further. These findings show that Arg-143 is critical for signal generation in KSHV-GPCR In other GPCRs, Arg in this position may act as a signaling switch by movement of its sidechain from a hydrophilic pocket in the TMH bundle to a position outside the bundle. In rhodopsin, the Arg of Glu-Arg-Tyr interacts with the adjacent Asp to constrain Arg outside the TMH bundle. V142D was 70% more active than KSHV-GPCR, suggesting that an Arg residue, which is constrained outside the bundle by interacting with Asp-142, leads to a receptor that signals more actively, Because the usually conserved Asp in the middle of TMH2 is not present in KSHV-GPCR, we tested whether Asp-83 at the intracellular end of TMH2 was involved in signaling. D83N and D83A were 110 and 190% more active than KSHV-GPCR, respectively. The double mutant D83A/V142D was 510% more active than KSHV-GPCR That is, cosubstitutions of Asp-83 by Ala and Val-142 by Asp act synergistically to increase basal signaling. A model of RSHV-GPCR predicts that Arg-143 interacts with residues in the TMH bundle and that the sidechain of Asp-83 does not interact with Arg-143, These data are consistent with the hypothesis that Arg-143 and Asp-83 independently affect the signaling activity of KSHV-GPCR.	Cornell Univ, Weill Med Coll, Dept Med, Div Mol Med, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Cornell University; Cornell University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Gershengorn, MC (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Mol Med, 1300 York Ave,Rm A328, New York, NY 10021 USA.							Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Arvanitakis L, 1998, TRENDS ENDOCRIN MET, V9, P27, DOI 10.1016/S1043-2760(98)00007-1; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Burger M, 1999, J IMMUNOL, V163, P2017; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Colson AO, 1998, MOL PHARMACOL, V54, P968, DOI 10.1124/mol.54.6.968; Donohue PJ, 1999, BIOCHEMISTRY-US, V38, P9366, DOI 10.1021/bi990544h; Fanelli F, 1999, MOL PHARMACOL, V56, P214, DOI 10.1124/mol.56.1.214; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; IMAI A, 1987, METHOD ENZYMOL, V141, P100; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Offermann MK, 1996, TRENDS MICROBIOL, V4, P419, DOI 10.1016/0966-842X(96)84953-5; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PERLMAN JH, 1995, MOL PHARMACOL, V47, P480; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; Porter JE, 1999, J BIOL CHEM, V274, P34535, DOI 10.1074/jbc.274.49.34535; Rhee MH, 2000, FEBS LETT, V466, P300, DOI 10.1016/S0014-5793(00)01094-2; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Scheer A, 2000, MOL PHARMACOL, V57, P219; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	35	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1376	1382		10.1074/jbc.M007885200	http://dx.doi.org/10.1074/jbc.M007885200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11031271	hybrid			2022-12-27	WOS:000166430900070
J	Myohanen, S; Baylin, SB				Myohanen, S; Baylin, SB			Sequence-specific DNA binding activity of RNA helicase A to the p16(INK4a) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APRT GENE PROMOTER; CPG ISLAND; HISTONE DEACETYLASE; DOSAGE COMPENSATION; MALELESS PROTEIN; POLYMERASE-II; SP1; METHYLATION; P16; TRICHOSTATIN	p16(INK4a) is frequently altered in human cancer, often through epigenetically mediated transcriptional silencing. However, little is known about the transcriptional regulation of this gene. To learn more about such control, we initiated studies of proteins that bind to the promoter in cancer cells that do, and do not, express the gene. We identify RNA helicase A (RHA) as a protein that binds much better to the p16(INK4a) promoter in the expressing cells. RHA has not previously been characterized to manifest sequence-specific DNA interaction but does so to the sequence 5' CGG ACC GCG TGC GC 3' in the p16(INK4a) promoter. The Drosophila homologue to RHA, maleless (Mle), functions in the fly for a-fold activation of male X-chromosome genes. In our experimental setting, RHA induces a similar modest up-regulation of the p16(INK4a) promoter that is dependent upon its sequence-specific interaction. Mle colocalizes with hyperacetylated H4Ac16 on the X-chromosome and some autosomal loci. The decreased binding of RHA to p16(INK4a) in our cells, where the gene is transcriptionally inactive, is associated with decreased amounts of RHA that immunoprecipitate with acetylated lysine antibodies. Finally, we show RHA to be a cellular substrate for caspase-3, which decreases its sequence-specific binding to p16(INK4a) by cleavage of the N terminus. Thus, we have identified a new protein interaction with the p16(INK4a) promoter that involves an important protein for transcriptional modulation. This interaction is decreased in cancer cells, where this gene is aberrantly transcriptionally silent.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Baylin, SB (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.	sbaylin@jhmi.edu			NCI NIH HHS [R01 CA43318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bashaw GJ, 1996, CURR OPIN GENET DEV, V6, P496, DOI 10.1016/S0959-437X(96)80073-6; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Hara E, 1996, MOL CELL BIOL, V16, P859; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; LI Y, 1994, CANCER RES, V54, P6078; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Medina V, 1997, CANCER RES, V57, P3697; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Tang H, 1999, MOL CELL BIOL, V19, P3540; Wong DJ, 1999, MOL CELL BIOL, V19, P5642; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016; ZHANG SS, 1995, J BIOL CHEM, V270, P16422, DOI 10.1074/jbc.270.27.16422; Zhang SS, 1997, J BIOL CHEM, V272, P11487	33	64	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1634	1642		10.1074/jbc.M004481200	http://dx.doi.org/10.1074/jbc.M004481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038348	hybrid			2022-12-27	WOS:000166430900103
J	Parks, IK; Klug, CA; Li, KJ; Jerabek, L; Li, LH; Nanamori, M; Neubig, RR; Hood, L; Weissman, IL; Clarke, MF				Parks, IK; Klug, CA; Li, KJ; Jerabek, L; Li, LH; Nanamori, M; Neubig, RR; Hood, L; Weissman, IL; Clarke, MF			Molecular cloning and characterization of a novel regulator of G-protein signaling from mouse hematopoietic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RGS PROTEIN; MESSENGER-RNA; CORE DOMAIN; CHEMOATTRACTANT RECEPTORS; SACCHAROMYCES-CEREVISIAE; MEMBRANE ASSOCIATION; MEDIATED MODULATION; KINASE ACTIVATION; PHOSPHOLIPASE-C	A novel regulator of G-protein signaling (RGS) has been isolated from a highly purified population of mouse long-term hematopoietic stem cells, and designated RGS18. It has 234 amino acids consisting of a central RGS box and short divergent NH2 and COOH termini, The calculated molecular weight of RGS18 is 27,610 and the isoelectric point is 8.63. Mouse RGS18 is expressed from a single gene and shows tissue specific distribution. It is most highly expressed in bone marrow followed by fetal liver, spleen, and then lung. In bone marrow, RGS18 level is highest in long-term and short-term hematopoietic stem cells, and is decreased as they differentiate into more committed multiple progenitors. The human RGS18 ortholog has a tissue-specific expression pattern similar to that of mouse RGS18. Purified RGS18 interacts with the alpha subunit of both G(i) and G(q) subfamilies. The results of in vitro GTPase single-turnover assays using G alpha (i) indicated that RGS18 accelerates the intrinsic GTPase activity of G alpha (i). Transient overexpression of RGS18 attenuated inositol phosphates production via angiotensin receptor and transcriptional activation through cAMP-responsive element via M1 muscarinic receptor. This suggests RGS18 can act on G(q)-mediated signaling pathways in vivo.	Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Stanford University; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan	Clarke, MF (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol & Oncol, CCGC 4431,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.			Neubig, Richard/0000-0003-0501-0008	NIDDK NIH HHS [DK53074-04] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; Beadling C, 1999, J IMMUNOL, V162, P2677; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BLUM S, 1990, DNA CELL BIOL, V9, P589, DOI 10.1089/dna.1990.9.589; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; Denecke B, 1999, J BIOL CHEM, V274, P26860, DOI 10.1074/jbc.274.38.26860; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; Granderath S, 1999, DEVELOPMENT, V126, P1781; Grant SL, 2000, MOL PHARMACOL, V57, P460, DOI 10.1124/mol.57.3.460; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, DNA CELL BIOL, V16, P589, DOI 10.1089/dna.1997.16.589; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HONG JX, 1993, J IMMUNOL, V150, P3895; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Maniatis T., 1989, MOL CLONING LAB MANU; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Moratz C, 2000, J IMMUNOL, V164, P1829, DOI 10.4049/jimmunol.164.4.1829; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; Natochin M, 1998, J BIOL CHEM, V273, P4300, DOI 10.1074/jbc.273.8.4300; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nomoto S, 1997, BIOCHEM BIOPH RES CO, V241, P281, DOI 10.1006/bbrc.1997.7802; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Thomas EA, 1998, J NEUROSCI RES, V52, P118, DOI 10.1002/(SICI)1097-4547(19980401)52:1<118::AID-JNR11>3.0.CO;2-6; Thompson JB, 1998, J PHARMACOL EXP THER, V285, P216; Versele M, 1999, EMBO J, V18, P5577, DOI 10.1093/emboj/18.20.5577; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WU HK, 1995, LEUKEMIA, V9, P1291; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851	67	45	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					915	923		10.1074/jbc.M005947200	http://dx.doi.org/10.1074/jbc.M005947200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042171	hybrid			2022-12-27	WOS:000166430900009
J	Schaenman, JM; Gilchrist, CA; Mann, BJ; Petri, WA				Schaenman, JM; Gilchrist, CA; Mann, BJ; Petri, WA			Identification of two Entamoeba histolytica sequence-specific URE4 enhancer-binding proteins with homology to the RNA-binding motif RRM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT MUTANT; LECTIN GENE; TRANSCRIPTIONAL ANALYSIS; CRYSTAL-STRUCTURE; ALPHA-AMANITIN; POLYMERASE-II; CODING GENES; EXPRESSION; PROMOTER; DOMAIN	To study transcriptional regulation in the lower branching eukaryote Entamoeba histolytica, we have identified two sequence-specific DNA-binding proteins that recognize the upstream regulatory element URE4, an enhancer that regulates expression of the Gal/GalNAc lectin heavy subunit gene hgl5, A chromatographic purification of E, histolytica nuclear extracts by gel filtration, cation exchange, and sequence-specific DNA affinity chromatography led to a 700-fold increase in URE4 binding activity and the appearance of two dominant protein species with molecular masses of 28 and 18 kDa, These proteins, termed E, histolytica enhancer-binding proteins 1 and 2 (EhEBP1 and EhEBP2), were sequenced by tandem mass spectroscopy and their corresponding cDNA clones identified. Recombinant EhEBP1 and EhEBPB were able to bind double-stranded oligonucleotides bearing the URE4 motif in a sequence-specific manner, and antibodies raised against EhEBP1 were able to interfere with the formation of URE4-protein complexes in crude nuclear extracts, Overexpression of EhEBP1 in E, histolytica trophozoites resulted in a 7-fold drop in promoter activity in transiently transfected reporter gene constructs when the URE4 motif was present, confirming its ability to specifically recognize the URE4 motif and suggesting that additional cofactors may be required for transcriptional activation by URE4, Further characterization and identification of binding partners for EhEBP1 and EhEBP2, the first proteins with demonstrated sequence-specific DNA binding activity to be identified in E, histolytica, should provide new insights into transcriptional regulation in this protozoan parasite.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Petri, WA (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, MR4 Bldg,Rm 2115,300 Pk Pl, Charlottesville, VA 22908 USA.		Petri, William A./D-3639-2019; Petri, William/AAL-3642-2020	Petri, William/0000-0002-7268-1218	NIAID NIH HHS [AI 37941] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037941] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRUCHHAUS I, 1993, DNA CELL BIOL, V12, P925, DOI 10.1089/dna.1993.12.925; BUSS H, 1995, MOL BIOCHEM PARASIT, V72, P1, DOI 10.1016/0166-6851(95)00060-E; DEANGELO DJ, 1995, MOL CELL BIOL, V15, P1254; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Gilchrist CA, 1995, MOL BIOCHEM PARASIT, V74, P1, DOI 10.1016/0166-6851(95)02474-3; Gilchrist CA, 1998, INFECT IMMUN, V66, P2383, DOI 10.1128/IAI.66.5.2383-2386.1998; Gomez C, 1998, J BIOL CHEM, V273, P7277, DOI 10.1074/jbc.273.13.7277; HOLBERTON DV, 1995, NUCLEIC ACIDS RES, V23, P2945, DOI 10.1093/nar/23.15.2945; Huang WB, 1997, J BIOL CHEM, V272, P3852, DOI 10.1074/jbc.272.6.3852; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LIOUTAS C, 1995, MOL BIOCHEM PARASIT, V73, P259, DOI 10.1016/0166-6851(95)00101-6; Liston DR, 1999, MOL CELL BIOL, V19, P2380; LIU F, 1992, GENE, V120, P143, DOI 10.1016/0378-1119(92)90087-6; Luna-Arias JP, 1999, MICROBIOL-SGM, V145, P33, DOI 10.1099/13500872-145-1-33; Maxson JM, 1996, PLANT MOL BIOL, V31, P751, DOI 10.1007/BF00019463; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; ORTNER S, 1995, MOL BIOCHEM PARASIT, V73, P189, DOI 10.1016/0166-6851(95)00115-H; Perez DG, 1998, J BIOL CHEM, V273, P7285, DOI 10.1074/jbc.273.13.7285; Purdy JE, 1996, MOL BIOCHEM PARASIT, V78, P91, DOI 10.1016/S0166-6851(96)02614-X; PURDY JE, 1994, P NATL ACAD SCI USA, V91, P7099, DOI 10.1073/pnas.91.15.7099; Quon DVK, 1996, J MOL EVOL, V43, P253, DOI 10.1007/PL00006084; Ramakrishnan G, 1997, MOL BIOCHEM PARASIT, V84, P93, DOI 10.1016/S0166-6851(96)02784-3; Schaenman JM, 1998, MOL BIOCHEM PARASIT, V94, P309, DOI 10.1016/S0166-6851(98)00081-4; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; Singh U, 1997, P NATL ACAD SCI USA, V94, P8812, DOI 10.1073/pnas.94.16.8812; Vines RR, 1998, MOL BIOL CELL, V9, P2069, DOI 10.1091/mbc.9.8.2069; VIONES RR, 1995, MOL BIOCHEM PARASIT, P265	30	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1602	1609		10.1074/jbc.M006866200	http://dx.doi.org/10.1074/jbc.M006866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038357	hybrid			2022-12-27	WOS:000166430900099
J	Andres, G; Alejo, A; Simon-Mateo, C; Salas, ML				Andres, G; Alejo, A; Simon-Mateo, C; Salas, ML			African swine fever virus protease, a new viral member of the SUMO-1-specific protease family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADENOVIRUS PROTEINASE; VACCINIA VIRUS; SEQUENCE; POLYPROTEIN; EXPRESSION; CLEAVAGE; GENE; MORPHOGENESIS; POLYMERASE; PEPTIDE	African swine fever virus (ASFV) is a complex DNA virus that employs polyprotein processing at Gly-Gly-Xaa sites as a strategy to produce several major core components of the viral particle. The virus gene S273R encodes a 31-kDa protein that contains a "core domain" with the conserved catalytic residues characteristic of SUMO-l-specific proteases and the adenovirus protease. Using a COS cell expression system, it was found that protein pS273R is capable of cleaving the viral polyproteins pp62 and pp220 in a specific way giving rise to the same intermediates and mature products as those produced in ASFV-infected cells. Furthermore, protein pS273R, like adenovirus protease and SUMO-1-specific enzymes, is a cysteine protease, because its activity is abolished by mutation of the predicted catalytic histidine and cysteine residues and is inhibited by sulfhydryl-blocking reagents. Protein pS273R is expressed late after infection and is localized in the cytoplasmic viral factories, where it is found associated with virus precursors and mature virions. In the virions, the protein is present in the core shell, a domain where the products of the viral polyproteins are also located. The identification of the ASFV protease will allow a better understanding of the role of polyprotein processing in virus assembly and may contribute to our knowledge of the emerging family of SUMO-1-specific proteases.	UAM, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, ML (corresponding author), UAM, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.		Alejo, Ali/AAF-1477-2020; Andres, German/E-2632-2016; Simon Mateo, Carmen/D-4878-2013	Alejo, Ali/0000-0002-1613-6063; Andres, German/0000-0003-0265-5409; Simon Mateo, Carmen/0000-0002-4251-0821				ALMAZAN F, 1992, J VIROL, V66, P6655; ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; Andres G, 1997, J VIROL, V71, P2331; Andres G, 1998, J VIROL, V72, P8988; CARRASCOSA AL, 1985, J VIROL, V54, P337, DOI 10.1128/JVI.54.2.337-344.1985; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COTTEN M, 1995, VIROLOGY, V213, P494, DOI 10.1006/viro.1995.0022; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; ENJUANES L, 1976, J GEN VIROL, V32, P471, DOI 10.1099/0022-1317-32-3-471; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GARCIABEATO R, 1992, VIROLOGY, V188, P938, DOI 10.1016/0042-6822(92)90558-7; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gorbalenya AE, 1996, PERSPECT DRUG DISCOV, V6, P64, DOI 10.1007/BF02174046; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KANE EM, 1993, J VIROL, V67, P2689, DOI 10.1128/JVI.67.5.2689-2698.1993; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LEE PY, 1994, J BIOL CHEM, V269, P8616; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; LOPEZOTIN C, 1989, J BIOL CHEM, V264, P9107; Mangel WF, 1996, J BIOL CHEM, V271, P536, DOI 10.1074/jbc.271.1.536; MOSS B, 1973, J MOL BIOL, V81, P267, DOI 10.1016/0022-2836(73)90195-2; SALAS ML, 1986, VIROLOGY, V152, P228, DOI 10.1016/0042-6822(86)90387-9; Sambrook J., 2002, MOL CLONING LAB MANU; SANZ A, 1985, J VIROL, V54, P199, DOI 10.1128/JVI.54.1.199-206.1985; Simon-Mateo C, 1997, J VIROL, V71, P5799; SIMONMATEO C, 1993, EMBO J, V12, P2977, DOI 10.1002/j.1460-2075.1993.tb05960.x; Sircar S, 1998, ANTIVIR RES, V40, P45, DOI 10.1016/S0166-3542(98)00040-0; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; TIHANYI K, 1993, J BIOL CHEM, V268, P1780; VANSLYKE JK, 1991, VIROLOGY, V183, P467, DOI 10.1016/0042-6822(91)90976-I; VINUELA E, 1985, CURR TOP MICROBIOL, V116, P151; WEBER J, 1976, J VIROL, V17, P462, DOI 10.1128/JVI.17.2.462-471.1976; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; YANEZ RJ, 1993, J GEN VIROL, V74, P1633, DOI 10.1099/0022-1317-74-8-1633; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	42	79	88	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					780	787		10.1074/jbc.M006844200	http://dx.doi.org/10.1074/jbc.M006844200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031264	Green Published, hybrid			2022-12-27	WOS:000166280700105
J	Delgado, M; Ganea, D				Delgado, M; Ganea, D			Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; IN-VITRO; C-JUN; MEDIATED TRANSCRIPTION; SIGNAL-TRANSDUCTION; CYTOKINE PRODUCTION; MURINE MACROPHAGES; KINASE PATHWAYS	The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) suppress monocyte/macrophage production of proinflammatory agents. The transcription factor NF-KB regulates the transcription of most agents. VIP/ PACAP inhibit NF-KB transactivation in the lipopolysaccharide-stimulated human monocytic cell line THP-1 at multiple levels. First, VIP/PACAP inhibit p65 nuclear translocation and NF-KB DNA binding by stabilizing the inhibitor IKB alpha. Second, VIP/PACAP induce phosphorylation of the CRE-binding protein (CREB) and its binding to the CREB-binding protein (CBP). This results in a decrease in p65 CBP complexes, which further reduces NF-KB transactivation. Third, VIP and PACAP reduce the phosphorylation of the TATA box-binding protein (TBP), resulting in a reduction in TBP binding to both p65 and the TATA box. All these effects are mediated through the specific receptor VPAC1. The cAMP/cAMP-dependent protein kinase pathway mediates the effects on CBP and TBP, whereas a cAMP-independent pathway is the major transducer for the effects on p65 nuclear translocation. Since NF-KB represents a focal point for various stimuli and induces the expression of many proinflammatory genes, its targeting by VIP and PACAP positions them as important anti-inflammatory agents. The VIP/PACAP inhibition of NF-KB at various levels and through different transduction pathways could offer a significant advantage over other anti-inflammatory agents.	Rutgers State Univ, Dept Sci Biol, Newark, NJ 07102 USA; Univ Complutense Madrid, Dept Biol Celular, Fac Biol, Madrid 28040, Spain	Rutgers State University Newark; Rutgers State University New Brunswick; Complutense University of Madrid	Ganea, D (corresponding author), Rutgers State Univ, Dept Sci Biol, Newark, NJ 07102 USA.		Delgado, Mario/P-1524-2016	Delgado, Mario/0000-0003-1893-5982	NIAID NIH HHS [AI 041786-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041786, R21AI041786] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; CHEDEVILLE A, 1993, FEBS LETT, V319, P171, DOI 10.1016/0014-5793(93)80061-X; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; Delgado M, 1999, J BIOL CHEM, V274, P31930, DOI 10.1074/jbc.274.45.31930; Delgado M, 1999, ANN NY ACAD SCI, V897, P401, DOI 10.1111/j.1749-6632.1999.tb07909.x; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; Delgado M, 1999, J IMMUNOL, V162, P4685; Delgado M, 1999, J IMMUNOL, V163, P4213; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 1999, J IMMUNOL, V162, P1707; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dewit D, 1998, IMMUNOL LETT, V60, P57, DOI 10.1016/S0165-2478(97)00129-6; Ganea D, 1996, ADV NEUROIMMUNOL, V6, P61, DOI 10.1016/S0960-5428(96)00007-1; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LALLI E, 1994, J BIOL CHEM, V269, P17359; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martinez C, 1998, J LEUKOCYTE BIOL, V63, P591, DOI 10.1002/jlb.63.5.591; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Parry GCN, 1997, J IMMUNOL, V159, P5450; Pozo D, 2000, IMMUNOL TODAY, V21, P7, DOI 10.1016/S0167-5699(99)01525-X; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TREDE NS, 1995, J IMMUNOL, V155, P902; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang HY, 1999, REGUL PEPTIDES, V84, P55, DOI 10.1016/S0167-0115(99)00068-3; Xin ZC, 1998, J NEUROIMMUNOL, V89, P206, DOI 10.1016/S0165-5728(98)00140-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	53	92	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					369	380		10.1074/jbc.M006923200	http://dx.doi.org/10.1074/jbc.M006923200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029467	hybrid			2022-12-27	WOS:000166280700051
J	Pise-Masison, CA; Mahieux, R; Radonovich, M; Jiang, H; Brady, JN				Pise-Masison, CA; Mahieux, R; Radonovich, M; Jiang, H; Brady, JN			Human T-lymphotropic virus type I tax protein utilizes distinct pathways for p53 inhibition that are cell type-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; NF-KAPPA-B; TRANSFORMS RAT FIBROBLASTS; LEUKEMIA-VIRUS; HTLV-I; DNA-DAMAGE; TUMOR-SUPPRESSOR; BINDING-PROTEIN; LYMPHOCYTES; GENE	p53 plays a pivotal role in transmitting signals from many forms of genotoxic stress to genes and factors that control the cell cycle and apoptosis, We have previously shown that the human T-lymphotropic virus type I Tax protein can inhibit p53 function. Recently we reported that Tax inhibits p53 function in Jurkat cells and mouse embryo fibroblasts through a mechanism involving the nuclear factor kappaB pathway and correlates with phosphorylation on serines 15 and 392 of p53, However, several groups have also observed a mechanism that correlates with p300 binding of Tax. To address this controversy and to determine the mechanism by which Tax inhibits p53 function, we examined the activation functions of Tax required for p53 inhibition. In HeLa and H1299 cells the cAMP-response element-binding protein/activating transcription factor activation function is essential, as demonstrated by the Tax mutants M47 and K88k In addition, expression of exogenous p300 in H1299 cells allows full recovery of p53 transactivation in the presence of Tax. Consistent with p300 being a limiting factor in H1299, Saos-2, and HeLa cells, we found that the level of endogenous p300 is relatively low in these cells compared with Jurkat cells or the human T-lymphotropic virus type I-infected C81 and MT2 cells. Thus our data suggests that Tax utilizes distinct mechanisms to inhibit p53 function that are cell type-dependent.	NCI, Basic Res Lab, Virus Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brady, JN (corresponding author), NCI, Basic Res Lab, Virus Tumor Biol Sect, NIH, Bldg 41-B201, Bethesda, MD 20892 USA.			mahieux, renaud/0000-0002-5129-6804				Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Anderson CW, 1998, J PROTEIN CHEM, V17, P527; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GESSAIN A, 1985, LANCET, V2, P407; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; KASHANCHI F, 1999, PERSISTENT VIRAL INF, P47; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Liu L, 1999, MOL CELL BIOL, V19, P1202; Manteuffel-Cymborowska M, 1999, ACTA BIOCHIM POL, V46, P77, DOI 10.18388/abp.1999_4185; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OSAME M, 1986, LANCET, V1, P1031; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; REID RL, 1993, ONCOGENE, V8, P3029; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tsai HL, 1996, J BIOL CHEM, V271, P3534; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	52	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					200	205		10.1074/jbc.M005601200	http://dx.doi.org/10.1074/jbc.M005601200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11036071	hybrid			2022-12-27	WOS:000166280700029
J	Abrecht, H; Goormaghtigh, E; Ruysschaert, JM; Homble, F				Abrecht, H; Goormaghtigh, E; Ruysschaert, JM; Homble, F			Structure and orientation of two voltage-dependent anion-selective channel isoforms - An attenuated total reflection Fourier-transform infrared spectroscopy study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; SECONDARY STRUCTURE; NEUROSPORA-CRASSA; DICHROIC RATIOS; VDAC CHANNELS; CYTOCHROME-C; PORIN; PROTEINS; EXPRESSION; EXCHANGE	Two VDAC (voltage-dependent anion-selective channel) isoforms were purified from seed cotyledons of Phaseolus vulgaris by chromatofocusing chromatography. Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy was used to study the structural properties of the two isoforms reconstituted in a mixture of asolectin and 5% stigmasterol. The IR spectra of the two VDAC isoforms were highly similar indicating 50 to 53% anti-parallel beta -sheet. The orientation of the beta -strands relative to the barrel axis was calculated from the experimentally obtained dichroic ratios of the amide I beta -sheet component and the amide II band. Comparing the IR spectra of the reconstituted VDAC isoforms with the IR spectra of the bacterial porin OmpF, for which a high resolution structure is available, provided evidence for a general structural organization of the VDAC isoforms similar to that of bacterial porins. Hydrogen-deuterium exchange measurements indicated that the exchange of the amide protons occurs to a higher extent in the two VDAC isoforms than in the OmpF porin.	Free Univ Brussels, Lab Physiol Vegetale, Fac Sci, B-1050 Brussels, Belgium; Free Univ Brussels, Fac Sci, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Homble, F (corresponding author), Free Univ Brussels, Lab Physiol Vegetale, Fac Sci, CP 206-2,Bld Triomphe, B-1050 Brussels, Belgium.		Homble, Fabrice/AAH-3780-2020	Homble, Fabrice/0000-0001-6031-136X; Goormaghtigh, Erik/0000-0002-2071-2262				Abrecht H, 2000, PLANT PHYSIOL, V124, P1181, DOI 10.1104/pp.124.3.1181; ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; Bechinger B, 1999, BIOPHYS J, V76, P552, DOI 10.1016/S0006-3495(99)77223-1; BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P311, DOI 10.1016/0005-2736(90)90279-W; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Cabiaux V, 1997, BIOPHYS J, V73, P406, DOI 10.1016/S0006-3495(97)78080-9; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEJONGH HHJ, 1995, BIOCHEMISTRY-US, V34, P172, DOI 10.1021/bi00001a021; DEPINTO V, 1989, EUR J BIOCHEM, V183, P179; Dolder M, 1999, J STRUCT BIOL, V127, P64, DOI 10.1006/jsbi.1999.4141; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; Elkeles A, 1997, J BIOL CHEM, V272, P6252, DOI 10.1074/jbc.272.10.6252; FORTE M, 1987, J BIOENERG BIOMEMBR, V19, P341, DOI 10.1007/BF00768537; FREITAG H, 1982, FEBS LETT, V145, P72, DOI 10.1016/0014-5793(82)81209-X; Fringeli U P, 1981, Mol Biol Biochem Biophys, V31, P270; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GUO XW, 1995, J STRUCT BIOL, V114, P41, DOI 10.1006/jsbi.1995.1004; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HAUSER H, 1988, BIOCHEMISTRY-US, V27, P9166, DOI 10.1021/bi00426a014; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KLEFFEL B, 1985, EMBO J, V4, P1589, DOI 10.1002/j.1460-2075.1985.tb03821.x; Koppel DA, 1998, J BIOL CHEM, V273, P13794, DOI 10.1074/jbc.273.22.13794; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; Mannella CA, 1997, J BIOENERG BIOMEMBR, V29, P525, DOI 10.1023/A:1022489832594; Marsh D, 2000, J MOL BIOL, V297, P803, DOI 10.1006/jmbi.2000.3557; Marsh D, 1998, BIOPHYS J, V75, P354, DOI 10.1016/S0006-3495(98)77519-8; Marsh D, 1997, BIOPHYS J, V72, P2710, DOI 10.1016/S0006-3495(97)78914-8; MURZIN AG, 1994, J MOL BIOL, V236, P1369, DOI 10.1016/0022-2836(94)90064-7; NABEDRYK E, 1988, BIOPHYS J, V53, P671, DOI 10.1016/S0006-3495(88)83148-5; PFALLER R, 1990, EXPERIENTIA, V46, P153, DOI 10.1007/BF02027311; POPP B, 1995, BIOCHEMISTRY-US, V34, P3352, DOI 10.1021/bi00010a026; RAUCH G, 1994, BIOCHEM BIOPH RES CO, V200, P908, DOI 10.1006/bbrc.1994.1536; Roosens N, 2000, BBA-BIOMEMBRANES, V1463, P470, DOI 10.1016/S0005-2736(99)00246-1; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Shao L, 1996, BIOPHYS J, V71, P778, DOI 10.1016/S0006-3495(96)79277-9; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Tatulian SA, 1998, FEBS LETT, V423, P205, DOI 10.1016/S0014-5793(98)00091-X; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; Xu X, 1999, J MEMBRANE BIOL, V170, P89, DOI 10.1007/s002329900540	49	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40992	40999		10.1074/jbc.M006437200	http://dx.doi.org/10.1074/jbc.M006437200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018035	hybrid			2022-12-27	WOS:000166114600046
J	Cornea, RL; Autry, JM; Chen, ZH; Jones, LR				Cornea, RL; Autry, JM; Chen, ZH; Jones, LR			Reexamination of the role of the leucine/isoleucine zipper residues of phospholamban in inhibition of the Ca2+ pump of cardiac sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE; LIPID BILAYERS; CALCIUM-PUMP; PHOSPHORYLATION; CA2+-ATPASE; DOMAIN; FORMS; DEPOLYMERIZATION; COEXPRESSION; ACTIVATION	Phospholamban is a small phosphoprotein inhibitor of the Ca2+-pump in cardiac sarcoplasmic reticulum, which shows a distinct oligomeric distribution between monomers and homopentamers that are stabilized through Leu/Ile zipper interactions. A two-faced model of phospholamban inhibition of the Ca2+-pump was proposed, in which the Leu/Ile zipper residues located on one face of the transmembrane alpha -helix regulate the pentamer to monomer equilibrium, whereas residues on the other face of the helix bind to and inhibit the pump, Here we tested this two-faced model of phospholamban action by analyzing the functional effects of a new series of Leu/Ile zipper mutants. Pentameric stabilities of the mutants were quantified at different SDS concentrations. We show that several phospholamban mutants with hydrophobic amino acid substitutions at the Leu/Ile zipper region retain the ability to form pentamers but at the same time give the same or even stronger (i.e. L37I-PLB) inhibition of the Ca2+-pump than do mutants that are more completely monomeric. Steric constraints prevent the Leu/Ile zipper residues sequestered in the interior of the phospholamban pentamer from binding to the Ca2+-pump, leading. to the conclusion that the zipper residues access the pump from the phospholamban monomer, which is the active inhibitory species. A modified model of phospholamban transmembrane domain action is proposed, in which the membrane span of the phospholamban monomer maintains contacts with the Ca2+-pump around most of its circumference, including residues located in the Leu/Ile zipper region.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Jones, LR (corresponding author), Indiana Univ, Sch Med, Krannert Inst Cardiol, 1111 W 10th St, Indianapolis, IN 46202 USA.	lrjones@iupui.edu	Autry, Joseph M./X-6839-2019	Autry, Joseph M./0000-0002-1144-725X; Cornea, Razvan/0000-0001-5739-0992	NHLBI NIH HHS [HL49428] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049428, R37HL049428] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antipenko AY, 1997, BIOCHEMISTRY-US, V36, P12903, DOI 10.1021/bi971109v; Asahi M, 1999, J BIOL CHEM, V274, P32855, DOI 10.1074/jbc.274.46.32855; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Autry JM, 1998, ANN NY ACAD SCI, V853, P92, DOI 10.1111/j.1749-6632.1998.tb08259.x; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; Chu GX, 1998, J BIOL CHEM, V273, P33674, DOI 10.1074/jbc.273.50.33674; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; FUJII J, 1989, J BIOL CHEM, V264, P12950; JONES LR, 1979, BIOCHIM BIOPHYS ACTA, V557, P230, DOI 10.1016/0005-2736(79)90105-6; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahaney J, 1999, ARCH BIOCHEM BIOPHYS, V372, P408, DOI 10.1006/abbi.1999.1524; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; Reddy LG, 1999, BIOCHEMISTRY-US, V38, P3954, DOI 10.1021/bi981795d; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; TADA M, 1975, J BIOL CHEM, V250, P2640; Torres J, 2000, J MOL BIOL, V300, P677, DOI 10.1006/jmbi.2000.3885; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538	25	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41487	41494		10.1074/jbc.M008195200	http://dx.doi.org/10.1074/jbc.M008195200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016944	hybrid			2022-12-27	WOS:000166114600107
J	Li, JH; Yen, TY; Allende, ML; Joshi, RK; Cai, J; Pierce, WM; Jaskiewicz, E; Darling, DS; Macher, BA; Young, WW				Li, JH; Yen, TY; Allende, ML; Joshi, RK; Cai, J; Pierce, WM; Jaskiewicz, E; Darling, DS; Macher, BA; Young, WW			Disulfide bonds of GM2 synthase homodimers - Antiparallel orientation of the catalytic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; GROWTH FACTOR-BB; COMPLEX GANGLIOSIDES; MEMBRANE-PROTEIN; ESCHERICHIA-COLI; GOLGI MEMBRANES; UDP-GALNAC; GLYCOSYLATION; EXPRESSION; ENZYME	GM2 synthase is a homodimer in which the subunits are joined by lumenal domain disulfide bond(s). To define the disulfide bond pattern of this enzyme, we analyzed a soluble form by chemical fragmentation, enzymatic digestion, and mass spectrometry and a full-length:form by site-directed mutagenesis. All Cys residues of the lumenal domain of GM2 synthase are disulfide bonded with Cys(429) and Cys(476) forming a disulfide-bonded pair while Cys(80) and Cys(82) are disulfide bonded in combination with Cys(412) and Cys(529). Partial reduction to produce monomers converted Cys(80) and Cys(82) to free thiols while the Cys(429) to Cys(476) disulfide remained intact. CNBr cleavage at amino acid 330 produced a monomer-sized band under nonreducing conditions which was converted upon reduction to a 40-kDa fragment and a 24-kDa myc-positive fragment. Double mutation of Cys(80) and Cys(82) to Ser produced monomers but not: dimers, In summary these results demonstrate that Cys(429) and Cys(476) form an intrasubunit disulfide while the intersubunit disulfides formed by both Cys(80) and Cys(82) with Cys(412) and Cys(529) are responsible for formation of the homodimer. This disulfide bond arrangement results in an antiparallel orientation of the catalytic domains of the GM2 synthase homodimer.	Univ Louisville, Sch Dent, Dept Mol Cellular & Craniofacial Biol, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Univ Louisville, Dept Pharmacol, Louisville, KY 40292 USA; San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA	University of Louisville; University of Louisville; University of Louisville; California State University System; San Francisco State University	Young, WW (corresponding author), Univ Louisville, Sch Dent, Dept Mol Cellular & Craniofacial Biol, 501 S Preston St, Louisville, KY 40292 USA.		Darling, Douglas S/D-4573-2009	Darling, Douglas/0000-0002-9039-1169	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042698] Funding Source: NIH RePORTER; NCRR NIH HHS [5P20RR11805] Funding Source: Medline; NIGMS NIH HHS [R01GM42698] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allende ML, 2000, GLYCOBIOLOGY, V10, P1025, DOI 10.1093/glycob/10.10.1025; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; ASPRAY TE, 1979, J BIOL CHEM, V254, P1576; BERNINSONE P, 1995, J BIOL CHEM, V270, P14564, DOI 10.1074/jbc.270.24.14564; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Birkle S, 1999, J NEUROCHEM, V72, P954, DOI 10.1046/j.1471-4159.1999.0720954.x; Borsig L, 1998, GLYCOBIOLOGY, V8, P259, DOI 10.1093/glycob/8.3.259; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Chen C, 2000, J BIOL CHEM, V275, P13819, DOI 10.1074/jbc.275.18.13819; Chen X, 2000, J BIOL CHEM, V275, P31594, DOI 10.1074/jbc.M004005200; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2413; Dan N, 1997, J BIOL CHEM, V272, P14214, DOI 10.1074/jbc.272.22.14214; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P1; Fritz VMR, 1997, BBA-GENE STRUCT EXPR, V1354, P153, DOI 10.1016/S0167-4781(97)00117-6; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Hakomori S, 1996, CANCER RES, V56, P5309; HANIU M, 1993, BIOCHEMISTRY-US, V32, P2431, DOI 10.1021/bi00060a039; HARAGUCHI M, 1995, BIOCHEM J, V312, P273, DOI 10.1042/bj3120273; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; Holmes EH, 2000, J BIOL CHEM, V275, P24237, DOI 10.1074/jbc.M000888200; Imberty A, 1997, PROTEIN ENG, V10, P1353, DOI 10.1093/protein/10.12.1353; Jaskiewicz E, 1996, GLYCOCONJUGATE J, V13, P213, DOI 10.1007/BF00731496; Jaskiewicz E, 1996, J BIOL CHEM, V271, P26395, DOI 10.1074/jbc.271.42.26395; Jensen ON, 1999, METH MOL B, V112, P513; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Leal WS, 1999, FEBS LETT, V464, P85, DOI 10.1016/S0014-5793(99)01683-X; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; MANDON E, 1994, J BIOL CHEM, V269, P11729; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MINAMITAKE Y, 1990, J BIOCHEM-TOKYO, V107, P292, DOI 10.1093/oxfordjournals.jbchem.a123041; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAVARATNAM N, 1988, EUR J BIOCHEM, V171, P623, DOI 10.1111/j.1432-1033.1988.tb13833.x; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; Ouzzine M, 2000, J BIOL CHEM, V275, P28254; PATTERSON SD, 1994, ANAL CHEM, V66, P3727, DOI 10.1021/ac00093a030; PROUDFOOT AEI, 1991, FEBS LETT, V283, P61, DOI 10.1016/0014-5793(91)80553-F; Schutte CG, 1998, PROTEIN SCI, V7, P1039; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; Shen GJ, 1999, J BIOL CHEM, V274, P35139, DOI 10.1074/jbc.274.49.35139; SMITH PL, 1994, J BIOL CHEM, V269, P15162; Takamiya K, 1998, P NATL ACAD SCI USA, V95, P12147, DOI 10.1073/pnas.95.21.12147; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTENDECKER.G, 1998, COMPREHENSIVE NATURA, V3, P87; VILLA S, 1989, ANAL BIOCHEM, V177, P161, DOI 10.1016/0003-2697(89)90032-8; Volchkova VA, 1998, VIROLOGY, V250, P408, DOI 10.1006/viro.1998.9389; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; Yen TY, 2000, J MASS SPECTROM, V35, P990, DOI 10.1002/1096-9888(200008)35:8<990::AID-JMS27>3.0.CO;2-K; Zhu GF, 1998, GLYCOBIOLOGY, V8, P831, DOI 10.1093/glycob/8.8.831	55	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41476	41486		10.1074/jbc.M007480200	http://dx.doi.org/10.1074/jbc.M007480200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018043	hybrid			2022-12-27	WOS:000166114600106
J	Misenheimer, TM; Huwiler, KG; Annis, DS; Mosher, DF				Misenheimer, TM; Huwiler, KG; Annis, DS; Mosher, DF			Physical characterization of the procollagen module of human thrombospondin 1 expressed in insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; PREDICTING COILED COILS; CYSTEINE-RICH DOMAIN; TISSUE GROWTH-FACTOR; AMYLOID-P COMPONENT; C-REACTIVE PROTEIN; LAMININ G-LIKE; VONWILLEBRAND-FACTOR; CIRCULAR-DICHROISM; ENDOTHELIAL-CELLS	Thrombospondin 1 (TSP1) is a homotrimeric glycoprotein composed of 150-kDa subunits connected by disulfide bridges. The procollagen module of thrombospondin 1 has been implicated in antiangiogenic activity. Procollagen modules are found in a number of extracellular proteins and are identifiable by 10 cysteines with characteristic spacing. We expressed and studied the procollagen module (C) of human TSP1, both by itself and in the context of the adjoining oligomerization sequence (o) and N-terminal module (N). The coding sequences were introduced into baculoviruses along with an N-terminal signal sequence and C-terminal poly-histidine tag. Proteins were purified from conditioned medium of infected insect cells by nickel-chelate chromatography. NoC is a disulfide bonded trimer and cleaves readily at a site of preferential proteolysis to yield monomeric N and trimeric oC. These are known properties of full-length TSP1. Mass spectroscopy indicated that C is N-glycosylated, and all 10 cysteine residues of C are in disulfides. By equilibrium ultracentrifugation, C is a monomer in physiological salt solution. Circular dichroism, intrinsic fluorescence, and differential scanning calorimetry experiments suggest that the stability of C is determined by the disulfides. The two tryptophans of C are in a polar, exposed environment as assessed by iodide fluorescence quenching and solvent perturbation. The oC far UV circular dichroism spectrum could be modeled as the sum of C and a coiled-coil oligomerization domain. The results indicate that the recombinant C folds autonomously into its native structure, and trimerization of the modules in TSP1 does not perturb their structures.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Misenheimer, TM (corresponding author), Univ Wisconsin, Dept Med, 1300 Univ Ave, Madison, WI 53706 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BALE MD, 1986, J BIOL CHEM, V261, P862; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; ENGEL J, 1977, BIOCHEMISTRY-US, V16, P4026, DOI 10.1021/bi00637a014; FOUSER L, 1991, P NATL ACAD SCI USA, V88, P10158, DOI 10.1073/pnas.88.22.10158; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Herskovits TT, 1967, METHOD ENZYMOL, V11, P748; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HUNT LT, 1987, BIOCHEM BIOPH RES CO, V144, P876, DOI 10.1016/S0006-291X(87)80046-3; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Kanda S, 1999, EXP CELL RES, V252, P262, DOI 10.1006/excr.1999.4622; LAHAV J, 1998, BIOCHIM BIOPHYS ACTA, P1; Lakowicz J. R., 1983, PRINCIPLES FLUORESCE, P305; Larrain J, 2000, DEVELOPMENT, V127, P821; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER JW, 1981, THROMB RES, V22, P267, DOI 10.1016/0049-3848(81)90119-5; Lehrer S S, 1978, Methods Enzymol, V49, P222; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MIYAZAWA K, 1990, J IMMUNOL, V145, P650; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1985, BLOOD, V66, P1098; NELSON RE, 1994, EMBO J, V13, P3438, DOI 10.1002/j.1460-2075.1994.tb06649.x; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; Panetti TS, 2000, ARTERIOSCL THROM VAS, V20, P1013, DOI 10.1161/01.ATV.20.4.1013; Rademaker G J, 1996, Methods Mol Biol, V61, P231; RYAN MC, 1990, J BIOL CHEM, V265, P10334; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schmid F. Z., 1997, PROTEIN STRUCTURE PR, P261; SCHONBAUM CP, 1992, DEV BIOL, V151, P431, DOI 10.1016/0012-1606(92)90183-H; SMITH KF, 1991, BIOCHEMISTRY-US, V30, P8000, DOI 10.1021/bi00246a018; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TROMP G, 1988, BIOCHEM J, V253, P919, DOI 10.1042/bj2530919; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WADA Y, 1996, PROTEIN PEPTIDE ANAL, P101; WOLF FW, 1990, GENOMICS, V6, P685, DOI 10.1016/0888-7543(90)90505-O; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; WU CH, 1986, J BIOL CHEM, V261, P482; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	66	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40938	40945		10.1074/jbc.M007022200	http://dx.doi.org/10.1074/jbc.M007022200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016937	hybrid			2022-12-27	WOS:000166114600038
J	Ranganathan, G; Li, CL; Kern, PA				Ranganathan, G; Li, CL; Kern, PA			The translational regulation of lipoprotein lipase in diabetic rats involves the 3 '-untranslated region of the lipoprotein lipase mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADIPOSE-TISSUE; SUBUNIT MESSENGER-RNAS; GENE-EXPRESSION; THYROID-HORMONE; HEAVY-SUBUNIT; ADIPOCYTES; PROTEIN; FERRITIN; SEQUENCE; EPINEPHRINE	Adipose tissue:lipoprotein lipase (LPL) activity is decreased in patients with poorly controlled diabetes, and this contributes to the dyslipidemia of diabetes. To study the mechanism of this decrease in LPL, we studied adipose tissue LPL expression in male rats with streptozotocin-induced diabetes. Heparin releasable and extractable LPL activity in the epididymal fat decreased by 75-80% in the diabetic group and treatment of the rats with insulin prior to sacrifice reversed this effect, Northern blot analysis indicated no corresponding change in LPL mRNA levels. However, LPL synthetic rate, measured using [S-35]methionine pulse labeling, was decreased by 75% in the diabetic adipocytes, and insulin treatment reversed this effect. These results suggested regulation of LPL at the level of translation, Diabetic adipocytes demonstrated no change in the distribution of LPL mRNA associated with polysomes, suggesting no inhibition of translation initiation. Addition of cytoplasmic extracts from control and diabetic adipocytes to a reticulocyte lysate system demonstrated the inhibition of LPL translation in vitro. Using different LPL mRNA transcripts in this in vitro translation assay, we found that the 3'-untranslated region (UTR) of the LPL mRNA was important in controlling translation inhibition by the cytoplasmic extracts, To identify the specific region involved, gel shift analysis was performed. A specific shift in mobility was observed when diabetic cytoplasmic extract was added to a transcript containing nucleotides 1818-2000 of the LPL 3'-UTR, Thus, inhibition of translation is the predominant mechanism for the decreased adipose tissue LPL in this insulin-deficient model of diabetes. Translation inhibition involves the interaction of a cytoplasmic factor, probably an RNA-binding protein, with specific sequences of the LPL 3'-UTR.	Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Div Endocrinol, Dept Med, Little Rock, AR 72205 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of Arkansas System; University of Arkansas Medical Sciences	Kern, PA (corresponding author), Cent Arkansas Vet Healthcare Syst 151LR, 4300 W 7th St, Little Rock, AR 72205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039176, R01DK039176, R29DK039176] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39176] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHNG JL, 1990, SCIENCE, V245, P1003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGIROLAMO M, 1971, AM J PHYSIOL, V221, P850, DOI 10.1152/ajplegacy.1971.221.3.850; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; ENERBACK S, 1988, GENE, V64, P97, DOI 10.1016/0378-1119(88)90484-2; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; KERN PA, 1985, J CLIN INVEST, V75, P199, DOI 10.1172/JCI111675; Kern PA, 1996, J LIPID RES, V37, P2332; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Mead JR, 1999, FEBS LETT, V462, P1, DOI 10.1016/S0014-5793(99)01495-7; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; ONG JM, 1989, J CLIN INVEST, V84, P305, DOI 10.1172/JCI114155; ONG JM, 1988, J BIOL CHEM, V263, P12933; ONG JM, 1992, MOL ENDOCRINOL, V6, P61, DOI 10.1210/me.6.1.61; ONG JM, 1994, J LIPID RES, V35, P1542; PFEIFER MA, 1983, DIABETES, V32, P525, DOI 10.2337/diabetes.32.6.525; PYKALISTO OJ, 1975, J CLIN INVEST, V56, P1108, DOI 10.1172/JCI108185; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; Ranganathan G, 1999, J BIOL CHEM, V274, P9122, DOI 10.1074/jbc.274.13.9122; RANGANATHAN G, 1995, J BIOL CHEM, V270, P7149, DOI 10.1074/jbc.270.13.7149; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; SAFFARI B, 1992, J LIPID RES, V33, P241; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SIMSOLO RB, 1992, J LIPID RES, V33, P89; TASKINEN M-R, 1987, Diabetes Metabolism Reviews, V3, P551; TASKINEN MR, 1979, DIABETOLOGIA, V17, P351, DOI 10.1007/BF01236268; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WORMINGTON M, 1994, BIOESSAYS, V16, P533, DOI 10.1002/bies.950160804; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	38	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40986	40991		10.1074/jbc.M008775200	http://dx.doi.org/10.1074/jbc.M008775200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024042	hybrid			2022-12-27	WOS:000166114600045
J	Schmidt, M; Goebeler, M; Posern, G; Feller, SM; Seitz, CS; Brocker, EB; Rapp, UR; Ludwig, S				Schmidt, M; Goebeler, M; Posern, G; Feller, SM; Seitz, CS; Brocker, EB; Rapp, UR; Ludwig, S			Ras-independent activation of the Raf/MEK/ERK pathway upon calcium-induced differentiation of keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-REGULATED KINASE; NERVE GROWTH-FACTOR; EXTRACELLULAR CALCIUM; TYROSINE KINASE; EPIDERMAL DIFFERENTIATION; TERMINAL DIFFERENTIATION; RAF-1 KINASE; IN-VITRO; CELLS	MAPKs are crucially involved in the regulation of growth and differentiation of a variety of cells. To elucidate the role of MAPKs in keratinocyte differentiation, activation of ERK, JNK, and p38 in response to stimulation with extracellular calcium was analyzed. We provide evidence that calcium-induced differentiation of keratinocytes is associated with rapid and transient activation of the Raf/MEK/ERK pathway. Stimulation of keratinocytes with extracellular calcium resulted in activation of Raf isozymes and their downstream effector ERK within 10-15 min, but did not increase JNK or p38 activity. Calcium-induced ERK activation differed in kinetics from mitogenic ERK activation by epidermal growth factor and could be modulated by alterations of intracellular calcium levels. Interestingly, calcium stimulation led to down-regulation of Ras activity at the same time that ERK activation was initiated. Expression of a dominant-negative mutant of Ras also did not significantly impair calcium-induced ERK activation, indicating that calcium-mediated ERK activation does not require active Ras, Despite the transient nature of ERK activation, calcium-induced expression of the cyclin-dependent kinase inhibitor p21/Cip1 and the differentiation marker involucrin was sensitive to MEK inhibition, which suggests a role for the Raf/MEK/ERK pathway in early stages of keratinocyte differentiation.	Univ Wurzburg, MSZ, D-97080 Wurzburg, Germany; Univ Wurzburg, Klin & Poliklin Haut & Geschlechtskrankheiten, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Ludwig, S (corresponding author), Univ Wurzburg, MSZ, Versbacher Str 5, D-97080 Wurzburg, Germany.	s.ludwig@mail.uni-wuerzburg.de	Schmidt, Marc/E-8821-2010; Goebeler, Matthias/P-3612-2019; Goebeler, Matthias/F-7118-2013	Schmidt, Marc/0000-0002-8643-1615; Ludwig, Stephan/0000-0003-4490-3052				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bikle DD, 1996, J CLIN INVEST, V97, P1085, DOI 10.1172/JCI118501; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Dotto Paolo, 1998, Frontiers in Bioscience, V3, pD502; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; Forslind B, 1997, MICROSC RES TECHNIQ, V38, P373, DOI 10.1002/(SICI)1097-0029(19970815)38:4<373::AID-JEMT5>3.0.CO;2-K; FUCHS E, 1993, J CELL SCI, P197; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Haase I, 1997, J INVEST DERMATOL, V108, P748, DOI 10.1111/1523-1747.ep12292135; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LI LW, 1995, J CELL PHYSIOL, V163, P105, DOI 10.1002/jcp.1041630112; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; MEDEMA JP, 1994, MOL CELL BIOL, V14, P7078, DOI 10.1128/MCB.14.11.7078; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Oda Y, 2000, J BIOL CHEM, V275, P1183, DOI 10.1074/jbc.275.2.1183; Puri PL, 2000, GENE DEV, V14, P574; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; REISS M, 1991, J CELL PHYSIOL, V147, P281, DOI 10.1002/jcp.1041470213; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Sharma SV, 1997, ONCOGENE, V14, P2641, DOI 10.1038/sj.onc.1201115; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STACEY DW, 1991, ONCOGENE, V6, P2297; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Todd C, 1998, AM J PATHOL, V153, P39, DOI 10.1016/S0002-9440(10)65543-5; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	54	87	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41011	41017		10.1074/jbc.M003716200	http://dx.doi.org/10.1074/jbc.M003716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018025	hybrid			2022-12-27	WOS:000166114600049
J	Volynski, KE; Meunier, FA; Lelianova, VG; Dudina, EE; Volkova, TM; Rahman, MA; Manser, C; Grishin, EV; Dolly, JO; Ashley, RH; Ushkaryov, YA				Volynski, KE; Meunier, FA; Lelianova, VG; Dudina, EE; Volkova, TM; Rahman, MA; Manser, C; Grishin, EV; Dolly, JO; Ashley, RH; Ushkaryov, YA			Latrophilin, neurexin, and their signaling-deficient mutants facilitate alpha-latrotoxin insertion into membranes but are not involved in pore formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDOW SPIDER VENOM; ADRENAL CHROMAFFIN CELLS; CALCIUM-INDEPENDENT RECEPTOR; TRANSMITTER RELEASE; BRAIN SYNAPTOSOMES; SYNAPTIC VESICLES; QUANTAL RELEASE; NERVE-TERMINALS; STORED CA2+; I-ALPHA	Pure alpha -latrotoxin is very inefficient at forming channels/pores in artificial lipid bilayers or in the plasma membrane of non-secretory cells. However, the toxin induces pores efficiently in COS-7 cells transfected with the heptahelical receptor latrophilin or the monotopic receptor neurexin. Signaling-deficient (truncated) mutants of latrophilin and latrophilin-neurexin hybrids also facilitate pore induction, which correlates with toxin binding irrespective of receptor structure. This rules out the involvement of signaling in pore formation. With any receptor, the alpha -latrotoxin pores are permeable to Ca2+ and small molecules including fluorescein isothiocyanate and norepinephrine. Bound alpha -latrotoxin remains on the cell surface without penetrating completely into the cytosol. Higher temperatures facilitate insertion of the toxin into the plasma membrane, where it co-localizes with latrophilin (under all conditions) and with neurexin tin the presence of Ca2+). Interestingly, on subsequent removal of Ca2+, alpha -latrotoxin dissociates from neurexin but remains in the membrane and continues to form pores. These receptor-independent pores are inhibited by anti-alpha -latrotoxin antibodies. Our results indicate that (i) c alpha -latrotoxin is a pore-forming toxin, (ii) receptors that bind alpha -latrotoxin facilitate its insertion into the membrane, (iii) the receptors are not physically involved in the pore structure, (iv) alpha -latrotoxin pores may be independent of the receptors, and (v) pore formation does not require alpha -latrotoxin interaction with other neuronal proteins.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Univ Edinburgh, Dept Biomed Sci, Edinburgh EH8 9XD, Midlothian, Scotland; Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117871, Russia	Imperial College London; University of Edinburgh; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Ushkaryov, YA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England.		Meunier, Frederic A/C-8161-2009; Dolly, Oliver/ABH-6677-2020; Ushkaryov, Yuri/AAQ-2985-2020; Dolly, Oliver/G-1532-2012	Meunier, Frederic A/0000-0001-6400-1107; Dolly, Oliver/0000-0002-0861-5320; Ushkaryov, Yuri/0000-0002-5712-8297; Dolly, Oliver/0000-0002-0861-5320; Volynski, Kirill/0000-0001-8208-1905				Ashley RH, 1995, ESSAYS BIOCHEM, V30, P97; Ashton AC, 2000, BIOCHIMIE, V82, P453, DOI 10.1016/S0300-9084(00)00199-1; Barnett DW, 1996, PFLUG ARCH EUR J PHY, V432, P1039, DOI 10.1007/s004240050232; Bittner MA, 1998, J NEUROSCI, V18, P2914; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; DePotter WP, 1997, SYNAPSE, V25, P44, DOI 10.1002/(SICI)1098-2396(199701)25:1<44::AID-SYN6>3.0.CO;2-F; DERI Z, 1993, J NEUROCHEM, V60, P1065, DOI 10.1111/j.1471-4159.1993.tb03255.x; FILIPPOV AK, 1994, NEUROSCIENCE, V61, P179, DOI 10.1016/0306-4522(94)90070-1; FINKELSTEIN A, 1976, SCIENCE, V193, P1009, DOI 10.1126/science.948756; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; GORIO A, 1978, J CELL BIOL, V78, P716, DOI 10.1083/jcb.78.3.716; GORIO A, 1978, J NEUROCYTOL, V7, P193, DOI 10.1007/BF01217918; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; Hlubek MD, 2000, MOL PHARMACOL, V57, P519, DOI 10.1124/mol.57.3.519; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; Ichtchenko K, 1998, EMBO J, V17, P6188, DOI 10.1093/emboj/17.21.6188; KOBAYASHI H, 1986, NEUROSCI LETT, V65, P114, DOI 10.1016/0304-3940(86)90130-8; KRASILNIKOV OV, 1992, BIOCHIM BIOPHYS ACTA, V1112, P124, DOI 10.1016/0005-2736(92)90262-K; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1998, J NEUROSCI, V18, P6113; Liu J, 1998, BRAIN RES, V799, P55, DOI 10.1016/S0006-8993(98)00467-3; MAGAZANIK LG, 1992, NEUROSCIENCE, V46, P181, DOI 10.1016/0306-4522(92)90017-V; Mathi SK, 1997, MOL ENDOCRINOL, V11, P424, DOI 10.1210/me.11.4.424; MCMAHON HT, 1990, J NEUROCHEM, V55, P2039, DOI 10.1111/j.1471-4159.1990.tb05793.x; MELDOLESI J, 1982, J NEUROCHEM, V38, P1559, DOI 10.1111/j.1471-4159.1982.tb06633.x; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; Meunier FA, 1997, NEUROSCIENCE, V78, P883, DOI 10.1016/S0306-4522(96)00568-4; MIRONOV SL, 1986, BIOCHIM BIOPHYS ACTA, V862, P185, DOI 10.1016/0005-2736(86)90482-7; NICHOLLS DG, 1982, P NATL ACAD SCI-BIOL, V79, P7924, DOI 10.1073/pnas.79.24.7924; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Rahman MA, 1999, PHILOS T ROY SOC B, V354, P379, DOI 10.1098/rstb.1999.0390; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Rucklidge GJ, 1996, ANAL BIOCHEM, V243, P158, DOI 10.1006/abio.1996.0495; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Tse FW, 1999, ENDOCRINOLOGY, V140, P3025, DOI 10.1210/en.140.7.3025; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1986, BIOORG KHIM+, V12, P71; Van Renterghem C, 2000, EUR J NEUROSCI, V12, P3953, DOI 10.1046/j.1460-9568.2000.00282.x; VICENTINI LM, 1984, BIOCHEM BIOPH RES CO, V121, P538, DOI 10.1016/0006-291X(84)90215-8; WANKE E, 1986, BIOCHEM BIOPH RES CO, V134, P320, DOI 10.1016/0006-291X(86)90565-6; WESS J, 1995, LIFE SCI, V56, P915, DOI 10.1016/0024-3205(95)00028-5; Williams A. J., 1995, ION CHANNELS PRACTIC, P43	51	39	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41175	41183		10.1074/jbc.M005857200	http://dx.doi.org/10.1074/jbc.M005857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024019	hybrid			2022-12-27	WOS:000166114600070
J	Newey, SE; Howman, EV; Ponting, CP; Benson, MA; Nawrotzki, R; Loh, NY; Davies, KE; Blake, DJ				Newey, SE; Howman, EV; Ponting, CP; Benson, MA; Nawrotzki, R; Loh, NY; Davies, KE; Blake, DJ			Syncoilin, a novel member of the intermediate filament superfamily that interacts with alpha-dystrobrevin in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; MUSCULAR-DYSTROPHY; GLYCOPROTEIN COMPLEX; CELL-LINES; EXPRESSION; UTROPHIN; GENE; TORPEDO; LOCALIZATION; SYNTROPHIN	Dystrophin coordinates the assembly of a complex of structural and signaling proteins that are required for normal muscle function. A key component of the dystrophin protein complex is alpha -dystrobrevin, a dystrophin-associated protein whose absence results in neuromuscular junction defects and muscular dystrophy. To gain further insights into the role of alpha -dystrobrevin in skeletal muscle, we used the yeast two-hybrid system to identify a novel alpha -dystrobrevin-binding partner called syncoilin. Syncoilin is a new member of the intermediate filament superfamily and is highly expressed in skeletal and cardiac muscle. In normal skeletal muscle, syn coilin is concentrated at the neuromuscular junction, where it colocalizes and coimmunoprecipitates with alpha -dystrobrevin-1. Expression studies in mammalian cells demonstrate that, while alpha -dystrobrevin and syncoilin associate directly, overexpression of syncoilin does not result in the self-assembly of intermediate filaments. Finally, unlike many components of the dystrophin protein complex, we show that syncoiIin expression is upregulated in dystrophin-deficient muscle. These data suggest that alpha -dystrobrevin provides a link between the dystrophin protein complex and the intermediate filament network at the neuromuscular junction, which may be important for the maintenance and maturation of the synapse.	Univ Oxford, Dept Human Anat & Genet, MRC, Funct Genet Unit, Oxford OX1 3QX, England	University of Oxford	Davies, KE (corresponding author), Univ Oxford, Dept Human Anat & Genet, MRC, Funct Genet Unit, S Parks Rd, Oxford OX1 3QX, England.	kay.davies@anat.ox.ac.uk	Ponting, Chris/AAV-2621-2021	Ponting, Chris/0000-0003-0202-7816; Benson, Matthew/0000-0003-4459-0439				AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ambrose HJ, 1997, GENOMICS, V39, P359, DOI 10.1006/geno.1996.4515; Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; ASKANAS V, 1990, NEUROLOGY, V40, P949, DOI 10.1212/WNL.40.6.949; Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493; BILAK M, 1994, SYNAPSE, V16, P280, DOI 10.1002/syn.890160405; Bilak SR, 1998, ARCH BIOCHEM BIOPHYS, V355, P63, DOI 10.1006/abbi.1998.0702; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; BLAKE DJ, 1997, PROTEIN DYSFUNCTION, P219; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Bowe MA, 2000, J CELL BIOL, V148, P801, DOI 10.1083/jcb.148.4.801; Bredt DS, 1999, NAT CELL BIOL, V1, pE89, DOI 10.1038/12085; BROWN SC, 1993, BIOESSAYS, V15, P413, DOI 10.1002/bies.950150608; Corman B, 1999, AM J HUM GENET, V64, P126, DOI 10.1086/302206; Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; Ehlers MD, 1998, J NEUROSCI, V18, P720; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Flaherty L, 1998, MAMM GENOME, V9, P417, DOI 10.1007/s003359900788; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Loh NY, 2000, J CELL SCI, V113, P2715; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; Mitsui T, 2000, J CELL BIOCHEM, V77, P584, DOI 10.1002/(SICI)1097-4644(20000615)77:4<584::AID-JCB6>3.0.CO;2-U; MIZUNO Y, 1993, J NEUROL SCI, V119, P43, DOI 10.1016/0022-510X(93)90190-A; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Nawrotzki R, 1998, J CELL SCI, V111, P2595; Newey SE, 2000, CURR BIOL, V10, P1295, DOI 10.1016/S0960-9822(00)00760-0; Newey SE, 2001, MOL CELL NEUROSCI, V17, P127, DOI 10.1006/mcne.2000.0918; NGUYEN TM, 1992, BIOCHEM J, V288, P663, DOI 10.1042/bj2880663; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; Peters MF, 1998, J CELL BIOL, V142, P1269, DOI 10.1083/jcb.142.5.1269; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; SANTAVUORI P, 1989, BRAIN DEV-JPN, V11, P147, DOI 10.1016/S0387-7604(89)80088-9; SEALOCK R, 1989, SYNAPSE, V3, P315, DOI 10.1002/syn.890030404; Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Tews DS, 1997, EXP NEUROL, V146, P125, DOI 10.1006/exnr.1997.6512; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Vaittinen S, 1999, AM J PATHOL, V154, P591, DOI 10.1016/S0002-9440(10)65304-7; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; Wilson KL, 2000, TRENDS CELL BIOL, V10, P125, DOI 10.1016/S0962-8924(99)01708-0; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	61	103	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6645	6655		10.1074/jbc.M008305200	http://dx.doi.org/10.1074/jbc.M008305200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11053421	Green Accepted, hybrid			2022-12-27	WOS:000167261000076
J	Tyagi, M; Rusnati, M; Presta, M; Giacca, M				Tyagi, M; Rusnati, M; Presta, M; Giacca, M			Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH-FACTOR; NF-KAPPA-B; CARBOXY-TERMINAL DOMAIN; RNA-POLYMERASE-II; TYPE-1 TAT; BASIC DOMAIN; T-CELLS; ENDOTHELIAL-CELLS; IN-VIVO	Tat, the transactivator protein of human immunodeficiency virus-1, has the unusual capacity of being internalized by cells when present in the extracellular milieu. This property can be exploited for the cellular delivery of heterologous proteins fused to Tat both in cell culture and in living animals. Here we provide genetic and biochemical evidence that cell membrane heparan sulfate (HS) proteoglycans act as receptors for extracellular Tat uptake. Cells genetically defective in the biosynthesis of fully sulfated HS are selectively impaired in the internalization of recombinant Tat fused to the green fluorescent protein, as evaluated by both flow cytometry and functional assays. In wild type cells, Tat uptake is competitively inhibited by soluble heparin and by treatment with glycosaminoglycan lyases specifically degrading HS chains. Cell surface HS proteoglycans also mediate physiological internalization of Tat green fluorescent protein released from neighboring producing cells. In contrast to extracellular Tat uptake, both wild type cells and cells genetically impaired in proteoglycan synthesis are equally proficient in the extracellular release of Tat, thus indicating that proteoglycans are not required for this process. The ubiquitous distribution of HS proteoglycans is consistent with the efficient intracellular delivery of heterologous proteins fused with Tat to different mammalian cell types.	Int Ctr Genet Engn & Biotechnol, Mol Med Lab, I-34012 Trieste, Italy; Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Scuola Normale Super Pisa, I-56126 Pisa, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Brescia; Scuola Normale Superiore di Pisa	Giacca, M (corresponding author), Int Ctr Genet Engn & Biotechnol, Mol Med Lab, Padriciano 99, I-34012 Trieste, Italy.	giacca@icgeb.trieste.it	Rusnati, Marco/F-1168-2010; Giacca, Mauro/J-9287-2016; Presta, Marco/B-4345-2010	Rusnati, Marco/0000-0001-9968-5908; Giacca, Mauro/0000-0003-2927-7225; PRESTA, Marco/0000-0002-4398-8376				ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BISWAS DK, 1995, J VIROL, V69, P7437, DOI 10.1128/JVI.69.12.7437-7444.1995; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; CHIRMULE N, 1995, J VIROL, V69, P492, DOI 10.1128/JVI.69.1.492-498.1995; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FURLINI MCRG, 1995, J ACQ IMMUN DEF SYND, V10, P408, DOI 10.1097/00042560-199512000-00003; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HELLAND DE, 1991, J VIROL, V65, P4547, DOI 10.1128/JVI.65.8.4547-4549.1991; HOFMAN FM, 1994, J NEUROIMMUNOL, V54, P19, DOI 10.1016/0165-5728(94)90226-7; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Lafrenie RM, 1997, J IMMUNOL, V159, P4077; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; OPALENIK SR, 1995, J BIOL CHEM, V270, P17457, DOI 10.1074/jbc.270.29.17457; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; POCSIK E, 1992, LYMPHOKINE CYTOK RES, V11, P317; PURI RK, 1992, CANCER RES, V52, P3787; PURVIS SF, 1992, CELL IMMUNOL, V144, P32, DOI 10.1016/0008-8749(92)90223-C; Rostand KS, 1997, INFECT IMMUN, V65, P1; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sosnowski BA, 1996, J BIOL CHEM, V271, P33647, DOI 10.1074/jbc.271.52.33647; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; THOMAS CA, 1994, J IMMUNOL, V153, P3831; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; ZAULI G, 1993, CANCER RES, V53, P4481; ZAULI G, 1992, BLOOD, V80, P3036; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	71	595	626	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3254	3261		10.1074/jbc.M006701200	http://dx.doi.org/10.1074/jbc.M006701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11024024	hybrid			2022-12-27	WOS:000166784900037
J	Burritt, JB; DeLeo, FR; McDonald, CL; Prigge, JR; Dinauer, MC; Nakamura, M; Nauseef, WM; Jesaitis, AJ				Burritt, JB; DeLeo, FR; McDonald, CL; Prigge, JR; Dinauer, MC; Nakamura, M; Nauseef, WM; Jesaitis, AJ			Phage display epitope mapping of human neutrophil flavocytochrome b(558) - Identification of two juxtaposed extracellular domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PHAGOCYTE NADPH OXIDASE; SRC HOMOLOGY-3 DOMAINS; CYTOCHROME-B; MONOCLONAL-ANTIBODIES; BINDING-SITE; MATURATION; MEMBRANE; CARRIER; FEMALE	Despite extensive experimental and clinical evidence demonstrating the critical role of flavocytochrome b(558) (Cyt b) in the NADPH-dependent oxidase, there is paucity of direct structural data defining its topology in the phagocyte membrane. Unlike other Cyt b-specific monoclonal antibodies, 7D5 binds exclusively to an extracellular domain, and identification of its epitope should provide novel insight into the membrane topology of Cyt b. To that end, we examined biochemical features of 7D5-Cyt b binding and used the J404 phage display nonapeptide library to identify the bound epitope. 7D5 precipitated only heterodimeric gp91-p22(phox) and not individual or denatured Cyt b subunits from detergent extracts of human neutrophils and promyelocytic leukemia cells (gp91-PLB). Moreover, 7D5 precipitated precursor gp65-p22(phox) complexes from detergent extracts of the biosynthetically active gp91-PLB cells, demonstrating that complex carbohydrates were not required for epitope recognition. Epitope mimetics selected from the J404 phage display library by 7D5 demonstrated that (226)RIVRG(230) and (IKNP163)-I-160 regions of gp91(phox) were both bound by 7D5, These studies reveal specific information about Cyt b membrane topology and structure, namely that gp91(phox) residues (226)RIVRG(230) and (IKNP163)-I-160 closely juxtaposed on extracytoplasmic domains and that predicted helices containing residues Gly(165)-Ile(190) and Ser(200)-Glu(226) are adjacent to each other in the membrane.	Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA; Vet Affairs Med Ctr, Inflammat Program, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Iowa City, IA 52242 USA; Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Inst Trop Med, Nagasaki 8528523, Japan	Montana State University System; Montana State University Bozeman; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Jesaitis, AJ (corresponding author), Montana State Univ, Dept Microbiol, 109 Lewis Hall, Bozeman, MT 59717 USA.	umbaj@gemini.oscs.montana.edu		DeLeo, Frank/0000-0003-3150-2516; Jesaitis, Algirdas/0000-0001-9001-5617; Nauseef, William/0000-0003-4032-757X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635, R01HL053592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026711, R01AI034879] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53592, HL 45635] Funding Source: Medline; NIAID NIH HHS [R01 AI 34879, R01 AI 26711] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; BATOT G, 1995, EUR J BIOCHEM, V234, P208, DOI 10.1111/j.1432-1033.1995.208_c.x; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Burritt JB, 1998, J BIOL CHEM, V273, P24847, DOI 10.1074/jbc.273.38.24847; Burritt JB, 1996, ANAL BIOCHEM, V238, P1, DOI 10.1006/abio.1996.0241; Burritt JB, 2000, EUR J HAEMATOL, V65, P407, DOI 10.1034/j.1600-0609.2000.065006407.x; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DUSI S, 1990, ACTA HAEMATOL-BASEL, V84, P49; EMMENDORFFER A, 1994, CYTOMETRY, V18, P147, DOI 10.1002/cyto.990180306; Faizunnessa NN, 1997, HUM GENET, V99, P469, DOI 10.1007/PL00008702; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; GUILLET V, 1993, STRUCTURE, V1, P165, DOI 10.1016/0969-2126(93)90018-C; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; INGERSLEV J, 1989, CLIN GENET, V35, P41; JESAITIS AJ, 1995, J IMMUNOL, V155, P3286; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; KALADHAR RB, 1984, HUM GENET, V67, P460; KURIBAYASHI F, 1995, BIOCHEM BIOPH RES CO, V209, P146, DOI 10.1006/bbrc.1995.1482; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; MARCUS S, 1992, HUM GENET, V89, P395; MIZUNO Y, 1988, J PEDIATR-US, V113, P458, DOI 10.1016/S0022-3476(88)80628-0; MOSER H, 1974, CLIN GENET, V5, P271; NAKAMURA M, 1987, BLOOD, V69, P1404; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; PARK MY, 1994, BIOCHEM BIOPH RES CO, V204, P924, DOI 10.1006/bbrc.1994.2548; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1992, MOL BASIS OXIDATIVE; Roos D, 1996, BLOOD, V87, P1663; ROPERS HH, 1977, AM J HUM GENET, V29, P361; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TAYLOR SAM, 1991, P NATL ACAD SCI USA, V88, P39, DOI 10.1073/pnas.88.1.39; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	60	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2053	2061		10.1074/jbc.M006236200	http://dx.doi.org/10.1074/jbc.M006236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11027685	hybrid			2022-12-27	WOS:000166528000056
J	Frickel, EM; Jemth, P; Widersten, M; Mannervik, B				Frickel, EM; Jemth, P; Widersten, M; Mannervik, B			Yeast glyoxalase I is a monomeric enzyme with two active sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUCRASE-ISOMALTASE; GENE DUPLICATION; PROTEIN; METHYLGLYOXAL; MECHANISM; ISOMERASE; SEGMENTS; MEMBRANE; MAMMALS	The tertiary structure of the monomeric yeast glyoxalase I has been modeled based on the crystal structure of the dimeric human glyoxalase I and a sequence alignment of the two enzymes, The model suggests that yeast glyoxalase I has two active sites contained in a single polypeptide, To investigate this, a recombinant expression clone of yeast glyoxalase I was constructed for overproduction of the enzyme in Escherichia coli. Each putative active site was inactivated by site-directed mutagenesis. According to the alignment, glutamate 163 and glutamate 318 in yeast glyoxalase I correspond to glutamate 172 in human glyoxalase I, a Zn(II) ligand and proposed general base in the catalytic mechanism. The residues were each replaced by glutamine and a double mutant containing both mutations was also constructed. Steady-state kinetics and metal analyses of the recombinant enzymes corroborate that yeast glyoxalase I has two functional active sites. The activities of the catalytic sites seem to be somewhat different, The metal ions bound in the active sites are probably one Fe(II) and one Zn(II), but Mn(II) may replace Zn(II). Yeast glyoxalase I appears to be one of the few enzymes that are present as a single polypeptide with two active sites that catalyze the same reaction.	Uppsala Univ, Ctr Biomed, Dept Biochem, SE-75123 Uppsala, Sweden	Uppsala University	Mannervik, B (corresponding author), Uppsala Univ, Ctr Biomed, Dept Biochem, Box 576, SE-75123 Uppsala, Sweden.	Bengt.Mannervik@biokem.uu.se	Widersten, Mikael/O-2565-2015					ARONSSON AC, 1978, BIOCHEM BIOPH RES CO, V81, P1235, DOI 10.1016/0006-291X(78)91268-8; BARDSLEY WG, 1995, COMPUT CHEM, V19, P75, DOI 10.1016/0097-8485(95)00007-F; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BJORNESTEDT R, 1992, BIOCHEM J, V282, P505; Cameron AD, 1997, EMBO J, V16, P3386, DOI 10.1093/emboj/16.12.3386; Cameron AD, 1999, BIOCHEMISTRY-US, V38, P13480, DOI 10.1021/bi990696c; Clugston SL, 1997, GENE, V186, P103, DOI 10.1016/S0378-1119(96)00691-9; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; IYENGAR R, 1981, BIOCHEMISTRY-US, V20, P1229, DOI 10.1021/bi00508a027; JAGT DLV, 1973, BIOCHEMISTRY-US, V12, P5161, DOI 10.1021/bi00749a022; JONES TA, 1991, O MANUAL; KALAPOS MP, 1994, TOXICOL LETT, V73, P3, DOI 10.1016/0378-4274(94)90184-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LO TWC, 1994, J BIOL CHEM, V269, P32299; MARMSTAL E, 1979, BIOCHEM J, V183, P23, DOI 10.1042/bj1830023; MARMSTAL E, 1978, FEBS LETT, V85, P275, DOI 10.1016/0014-5793(78)80472-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitsuhashi S, 2000, J BIOL CHEM, V275, P5521, DOI 10.1074/jbc.275.8.5521; RACKER E, 1951, J BIOL CHEM, V190, P685; Ridderstrom M, 1998, J BIOL CHEM, V273, P21623, DOI 10.1074/jbc.273.34.21623; Ridderstrom M, 1996, BIOCHEM J, V316, P1005, DOI 10.1042/bj3161005; Ridderstrom M, 1997, BIOCHEM J, V328, P231, DOI 10.1042/bj3280231; SELLIN S, 1984, J BIOL CHEM, V259, P1426; SJOSTROM H, 1980, J BIOL CHEM, V255, P1332; VACA CE, 1994, CARCINOGENESIS, V15, P1887, DOI 10.1093/carcin/15.9.1887; VANDERJAGT DL, 1972, BIOCHEMISTRY-US, V11, P3735, DOI 10.1021/bi00770a011; VANDERJAGT DL, 1989, GLUTATHIONE CHEM B A, P597; WACKER H, 1984, J BIOL CHEM, V259, P4878	30	42	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1845	1849		10.1074/jbc.M005760200	http://dx.doi.org/10.1074/jbc.M005760200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050082	hybrid			2022-12-27	WOS:000166528000028
J	Van Lenten, BJ; Wagner, AC; Navab, M; Fogelman, AM				Van Lenten, BJ; Wagner, AC; Navab, M; Fogelman, AM			Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; LOW-DENSITY-LIPOPROTEIN; ACUTE-PHASE RESPONSE; MESSENGER-RNA LEVELS; APOLIPOPROTEIN-J; SERUM; CYTOKINES; ACTIVATION; EXPRESSION; CLUSTERIN	In this study, we tested if interleukin-6 (IL-6) plays a role in mediating the effects of oxidized phospholipids (OXPL). Treatment of HepG2 cells with oxidized 1-palmitoyl-2-arachidonyl-sn-gIycero-3-phosphoryl choline (OX-PAPC), or biologically active lipids present in mildly oxidized low density lipoprotein, increased apo lipoprotein J (apoJ), and decreased paraoxonase (PON) mRNA levels. Antibodies to IL-6 blocked these changes. IL-6 treatment in the absence of OXPL produced the same pattern of mRNA changes observed with OXPL treatment alone. In vivo, OX-PAPC injected into C57BL/6J mice resulted in a marked reduction in PON activity and an increase in apoJ levels in plasma after 16 h. Injection of OX-PAPC into IL-6-deficient C57BL/6J mice (IL-6 -/-) did not alter either PON activity or apoJ levels. We then tested if other mechanisms involved in fatty streak formation depended upon IL-6. Antibody to IL-6 had no effect on OX-PAPC-induced secretion of MCP-1 by endothelial cells nor on MCP-1 mRNA expression in HepG2 cells. C57BL/6J and IL-6 -/- mice fed an atherogenic diet both demonstrated markedly reduced plasma PON activities and the IL-6 -/- mice developed fatty streaks to a greater degree than wild-type mice. We conclude that IL-6 is critical to short term but not long term regulation of PON and that IL-6 is not required for OXPL regulation of MCP-1.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Van Lenten, BJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	bvalent@mednet.ucla.edu			NCRR NIH HHS [5M01RR00865-25] Funding Source: Medline; NHLBI NIH HHS [HL 30568] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT CA, 1995, ARTERIOSCL THROM VAS, V15, P1812, DOI 10.1161/01.ATV.15.11.1812; Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461; ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; Biasucci LM, 1996, CIRCULATION, V94, P874, DOI 10.1161/01.CIR.94.5.874; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; Dahmen H, 1998, BIOCHEM J, V331, P695, DOI 10.1042/bj3310695; EUGUI EM, 1994, INT IMMUNOL, V6, P409, DOI 10.1093/intimm/6.3.409; Feingold KR, 1998, ATHEROSCLEROSIS, V139, P307, DOI 10.1016/S0021-9150(98)00084-7; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Grayston JT, 1998, CIRCULATION, V97, P1669, DOI 10.1161/01.CIR.97.17.1669; HARDARDOTTIR I, 1994, J CLIN INVEST, V94, P1304, DOI 10.1172/JCI117449; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; Herbelin C, 1998, EUR CYTOKINE NETW, V9, P57; Huang JYH, 1999, J INTERF CYTOK RES, V19, P1403, DOI 10.1089/107999099312867; Huber SA, 1999, ARTERIOSCL THROM VAS, V19, P2364, DOI 10.1161/01.ATV.19.10.2364; KELSO GJ, 1994, BIOCHEMISTRY-US, V33, P832, DOI 10.1021/bi00169a026; Khovidhunkit W, 2000, J INFECT DIS, V181, pS462, DOI 10.1086/315611; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; Kumon Y, 1998, SCAND J IMMUNOL, V48, P419; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LIAO F, 1991, J CLIN INVEST, V87, P2253, DOI 10.1172/JCI115261; MACKNESS MI, 1995, LANCET, V346, P856, DOI 10.1016/S0140-6736(95)92702-6; MCELVEEN J, 1986, CLIN CHEM, V32, P671; Meier CR, 1998, LANCET, V351, P1467, DOI 10.1016/S0140-6736(97)11084-4; Memon RA, 1998, ARTERIOSCL THROM VAS, V18, P1257, DOI 10.1161/01.ATV.18.8.1257; MULLEN PG, 1995, J SURG RES, V58, P124, DOI 10.1006/jsre.1995.1020; Navab M, 1997, J CLIN INVEST, V99, P2005, DOI 10.1172/JCI119369; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Orus J, 2000, J HEART LUNG TRANSPL, V19, P419, DOI 10.1016/S1053-2498(00)00083-8; Robak T, 1998, MEDIAT INFLAMM, V7, P347, DOI 10.1080/09629359890875; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Song H, 1998, CYTOKINE, V10, P275, DOI 10.1006/cyto.1997.0291; Sukovich DA, 1999, CIRCULATION, V100, P43; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; TSCHOPP J, 1997, CLIN EXP IMMUNOL S2, V2, P11; van Deuren M, 1998, CYTOKINE, V10, P897, DOI 10.1006/cyto.1998.0367; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359	43	107	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1923	1929		10.1074/jbc.M004074200	http://dx.doi.org/10.1074/jbc.M004074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11034996	hybrid			2022-12-27	WOS:000166528000039
J	Doostzadeh-Cizeron, J; Terry, NHA; Goodrich, DW				Doostzadeh-Cizeron, J; Terry, NHA; Goodrich, DW			The nuclear death domain protein p84N5 activates a G(2)/M cell cycle checkpoint prior to the onset of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; RETINOBLASTOMA PROTEIN; MAMMALIAN-CELLS; FAMILY-MEMBERS; P53; GENE; INHIBITION; INDUCTION; LIFE	In contrast to extracellular signals, the mechanisms utilized to transduce nuclear apoptotic signals are not well understood. Characterizing these mechanisms is important for predicting how tumors will respond to genotoxic radiation or chemotherapy. The retinoblastoma (Rb) tumor suppressor protein can regulate apoptosis triggered by DNA damage through an unknown mechanism. The nuclear death domain-containing protein p84N5 can induce apoptosis that is inhibited by association with Rb, The pattern of caspase and NF-kappaB activation during p84N5-induced apoptosis is similar to p53-independent cellular responses to DNA damage. One hallmark of this response is the activation of a G(2)/M cell cycle checkpoint. In this report, we characterize the effects of p84N5 on the cell cycle. Expression of p84N5 induces changes in cell cycle distribution and kinetics that are consistent with the activation of a G(2)/M cell cycle checkpoint. Like the radiation-induced checkpoint, caffeine blocks p84N5-induced G(2)/M arrest but not subsequent apoptotic cell death, The p84N5-induced checkpoint is functional in ataxia telangiectasia-mutated kinase-deficient cells. We conclude that p84N5 induces an ataxia telangiectasia-mutated kinase (ATM)independent, caffeine-sensitive G(2)/dM cell cycle arrest prior to the onset of apoptosis. This conclusion is consistent with the hypotheses that p84N5 functions in an Rb-regulated cellular response that is similar to that triggered by DNA damage.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Goodrich, DW (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.	goodrich@odin.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA070292, P01CA006294] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672, CA-06294, CA-70292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Bracey TS, 1997, CLIN CANCER RES, V3, P1371; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Darbon JM, 2000, J BIOL CHEM, V275, P15363, DOI 10.1074/jbc.275.20.15363; Doostzadeh-Cizeron J, 2000, J BIOL CHEM, V275, P25336, DOI 10.1074/jbc.M000793200; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Haimovitz-Friedman A, 1998, RADIAT RES, V150, pS102, DOI 10.2307/3579812; HARRIS AL, 1985, CANCER SURV, V4, P601; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hong FD, 1999, CARCINOGENESIS, V20, P1161, DOI 10.1093/carcin/20.7.1161; HUYGHE BG, 1995, HUM GENE THER, V6, P1403, DOI 10.1089/hum.1995.6.11-1403; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; Rotman G, 1997, CANCER SURV, V29, P285; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; TERRY NH, 1996, CLIN IMMUNOL NEWS, V16, P46; TERRY NHA, 1991, CYTOMETRY, V12, P234, DOI 10.1002/cyto.990120305; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WHITE RA, 1990, CYTOMETRY, V11, P314, DOI 10.1002/cyto.990110214; WHITE RA, 1990, CELL TISSUE KINET, V23, P561, DOI 10.1111/j.1365-2184.1990.tb01346.x; White RA, 2000, CYTOMETRY, V41, P1; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yin SM, 2000, CANCER GENE THER, V7, P985, DOI 10.1038/sj.cgt.7700194; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	37	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1127	1132		10.1074/jbc.M006944200	http://dx.doi.org/10.1074/jbc.M006944200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050087	hybrid			2022-12-27	WOS:000166430900038
J	Shiose, A; Kuroda, J; Tsuruya, K; Hirai, M; Hirakata, H; Naito, S; Hattori, M; Sakaki, Y; Sumimoto, H				Shiose, A; Kuroda, J; Tsuruya, K; Hirai, M; Hirakata, H; Naito, S; Hattori, M; Sakaki, Y; Sumimoto, H			A novel superoxide-producing NAD(P)H oxidase in kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; SRC HOMOLOGY-3 DOMAINS; NADH/NADPH OXIDASE; ACTIVATION; BINDING; CYTOCHROME-B558; COMPONENT; SYSTEM; CELLS; GENE	During phagocytosis, gp91(phox), th, catalytic subunit of the phagocyte NADPH oxidase, becomes activated to produce superoxide, a precursor of microbicidal oxidants. Currently increasing evidence suggests that nonphagocytic cells contain similar superoxide-producing oxidases, which are proposed to play crucial roles in various events such as cell proliferation and oxygen sensing for erythropoiesis. Here we describe the cloning of human cDNA that encodes a novel NAD(P)H oxidase, designated NOX4. The NOX4 protein of 578 amino acids exhibits 39% identity to gp91(Phox) with special conservation in membrane-spanning regions and binding sites for heme, FAD, and NAD(P)H, indicative of its function as a superoxide-producing NAD(P)H oxidase. The membrane fraction of kidney derived human embryonic kidney (HEK) 293 cells, expressing NOX4, exhibits NADH-and NADPH-dependent superoxide-producing activities, both of which are inhibited by diphenylene iodonium, an agent known to block oxygen sensing, and decreased in cells expressing antisense NOX4 mRNA. The human NOX4 gene, comprising 18 exons, is located on chromosome 11q14.2-q21, and its expression is almost exclusively restricted to adult and fetal kidneys. in human renal cortex, high amounts of the NOX4 protein are present in distal tubular cells, which reside near erythropoietin-producing cells. In addition, overexpression of NOX4 in cultured cells leads to increased superoxide production and decreased rate of growth. The present findings thus suggest that the novel NAD(P)H oxidase NOX4 may serve as an oxygen sensor and/or a regulator of cell growth in kidney.	Kyushu Univ, Grad Sch Med Sci, Dept Mol & Struct Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Urol, Higashi Ku, Fukuoka 8128582, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Tokyo 1130033, Japan; RIKEN, Genom Sci Ctr, Sagamihara, Kanagawa 2288555, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 1088639, Japan	Kyushu University; Kyushu University; Kyushu University; University of Tokyo; RIKEN; University of Tokyo	Sumimoto, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol & Struct Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Bunn HF, 1998, J EXP BIOL, V201, P1197; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Ebert BL, 1999, BLOOD, V94, P1864; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Griendling KK, 1997, TRENDS CARDIOVAS MED, V7, P301, DOI 10.1016/S1050-1738(97)00088-1; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; MEYER JW, 1990, FEBS LETT, V472, P1; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAITO S, 1982, J UROLOGY, V128, P1117, DOI 10.1016/S0022-5347(17)53357-1; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; SMITH RM, 1991, BLOOD, V77, P673; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUMIMOTO H, 1989, BIOCHEM BIOPH RES CO, V165, P902, DOI 10.1016/S0006-291X(89)80051-8; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TAMAKI K, 1994, KIDNEY INT, V45, P525, DOI 10.1038/ki.1994.68; Ueda N, 2000, AM J MED, V108, P403, DOI 10.1016/S0002-9343(00)00311-9; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Vasserman NN, 1999, HUM HERED, V49, P129, DOI 10.1159/000022859; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	38	418	439	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1417	1423		10.1074/jbc.M007597200	http://dx.doi.org/10.1074/jbc.M007597200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032835	hybrid			2022-12-27	WOS:000166430900075
J	Johnson, C; Glover, G; Arias, J				Johnson, C; Glover, G; Arias, J			Regulation of DNA binding and trans-activation by a xenobiotic stress-activated plant transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; TISSUE-SPECIFIC EXPRESSION; SALICYLIC-ACID; INTRAMOLECULAR INHIBITION; GENE PROMOTER; FACTOR ASF-1; OCS-ELEMENT; AUXIN; INDUCTION; PROTEIN	As-1-type cis-elements augment transcription of both nuclear and pathogen genes in response to stress and defense cues in plants. Basic/leucine zipper proteins termed "TGA factors" that specifically bind as-1 elements are likely candidates for mediating these transcription activities. Our earlier work has shown that 2,4-dichlorophenoxyacetic acid-induced xenobiotic stress enhances trans-activation by a chimeric fusion protein of the yeast Gal4 binding domain and TGA1a, a TGA factor of tobacco. Here we demonstrate that xenobiotic stress also enhances the ability of native TGA1a to bind as-1 and activate transcription of a known target gene. In addition, the previously identified xenobiotic stress-responsive domain of TGA1a was found to inhibit this factor's trans-activation potential by a mechanism that appears to involve stimulus-reversible interactions with a nuclear repressor protein. Results from these and other studies can now be placed in the context of a working model to explain basal and xenobiotic stress-induced activities of TGA1a through its cognate cis-acting element.	Univ Maryland, Inst Biotechnol, Ctr Agr Biotechnol, College Pk, MD 20742 USA; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	University System of Maryland; University of Maryland Baltimore; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Arias, J (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Agr Biotechnol, 5115 Plant Sci Bldg, College Pk, MD 20742 USA.	arias@umbi.umd.edu						AN GH, 1990, PLANT CELL, V2, P225, DOI 10.1105/tpc.2.3.225; Angerer ND, 1999, J BIOL CHEM, V274, P4147, DOI 10.1074/jbc.274.7.4147; ARIAS JA, 1993, PLANT CELL, V5, P485, DOI 10.1105/tpc.5.4.485; BENFEY PN, 1990, EMBO J, V9, P1677, DOI 10.1002/j.1460-2075.1990.tb08291.x; BOUCHEZ D, 1989, EMBO J, V8, P4197, DOI 10.1002/j.1460-2075.1989.tb08605.x; Chen WQ, 1996, PLANT J, V10, P955, DOI 10.1046/j.1365-313X.1996.10060955.x; Chen WQ, 1999, PLANT J, V19, P667, DOI 10.1046/j.1365-313x.1999.00560.x; Despres C, 2000, PLANT CELL, V12, P279, DOI 10.1105/tpc.12.2.279; DrogeLaser W, 1997, EMBO J, V16, P726, DOI 10.1093/emboj/16.4.726; Droog F, 1995, PLANT MOL BIOL, V29, P413, DOI 10.1007/BF00020974; Harlow E., 1988, ANTIBODIES LAB MANUA; KATAGIRI F, 1992, MOL CELL BIOL, V12, P4809, DOI 10.1128/MCB.12.11.4809; KIM YH, 1994, PLANT MOL BIOL, V24, P105, DOI 10.1007/BF00040578; Klinedinst S, 2000, PLANT MOL BIOL, V42, P679, DOI 10.1023/A:1006332708388; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Koehler SM, 1996, PLANT MOL BIOL, V31, P595, DOI 10.1007/BF00042232; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; LAWTON MA, 1987, MOL CELL BIOL, V7, P335, DOI 10.1128/MCB.7.1.335; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU XJ, 1994, J BIOL CHEM, V269, P668; MAUCH F, 1993, PLANT PHYSIOL, V102, P1193, DOI 10.1104/pp.102.4.1193; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; NEUHAUS G, 1994, PLANT CELL, V6, P827, DOI 10.1105/tpc.6.6.827; Niggeweg R, 2000, J BIOL CHEM, V275, P19897, DOI 10.1074/jbc.M909267199; Pascuzzi P, 1998, J BIOL CHEM, V273, P26631, DOI 10.1074/jbc.273.41.26631; Sano Y, 1998, J BIOL CHEM, V273, P29098, DOI 10.1074/jbc.273.44.29098; ULMASOV T, 1995, PLANT PHYSIOL, V108, P919, DOI 10.1104/pp.108.3.919; Xiang CB, 1998, PLANT CELL, V10, P1539, DOI 10.1105/tpc.10.9.1539; Xiang CB, 1996, PLANT MOL BIOL, V32, P415, DOI 10.1007/BF00019093; YAMAZAKI K, 1990, P NATL ACAD SCI USA, V87, P7035, DOI 10.1073/pnas.87.18.7035; Zhang B, 1995, PLANT CELL, V7, P2241, DOI 10.1105/tpc.7.12.2241; Zhang YL, 1999, P NATL ACAD SCI USA, V96, P6523, DOI 10.1073/pnas.96.11.6523; Zhou JM, 2000, MOL PLANT MICROBE IN, V13, P191, DOI 10.1094/MPMI.2000.13.2.191	33	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					172	178		10.1074/jbc.M005143200	http://dx.doi.org/10.1074/jbc.M005143200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11034999	hybrid			2022-12-27	WOS:000166280700025
J	Zhang, YH; Heulsmann, A; Tondravi, MM; Mukherjee, A; Abu-Amer, Y				Zhang, YH; Heulsmann, A; Tondravi, MM; Mukherjee, A; Abu-Amer, Y			Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RHEUMATOID-ARTHRITIS; OSTEOPROTEGERIN LIGAND; THERAPEUTIC TARGET; KEY REGULATOR; ACTIVATION; BONE; CYTOKINE; KINASE; CELLS	Tumor necrosis factor-cw (TNF) and the ligand for receptor activator of NF-KB (RANKL) are abundant in sites of inflammatory bone erosion. Because these cytokines are potent osteoclastogenic factors and because their signaling pathways are considerably overlapping, we postulated that under pro-inflammatory conditions RANKL and TNF might synergistically orchestrate enhanced osteoclastogenesis via cooperative mechanisms. We found TNF, via TNF type 1 receptor (TNFr1), prompts robust osteoclastogenesis by osteoclast precursors pretreated with RANKL, and deletion of TNFrl abrogates this response. Enhanced osteoclastogenesis is associated with high expression of otherwise TNF and RANKL-induced mediators, including c-Src, TRAF2, TRAF6, and MEKK-1, levels of which were notably reduced in TNFrl knockouts. Recruitment of TRAFs and MEKK1 leads to activation of downstream pathways, primarily I kappaB/NF-kappaB, ERKs, and cJun/AP-1. Consistent with impaired osteoclastogenesis and reduced expression of TRAFs and MEKK1, we found that phosphorylation and activation of I kappaB, NF-kappaB, ERKs, and cJun/AP-1 are severely reduced in RANKL-treated TNFr1-null osteoclast precursors compared with wild type counterparts. Finally, we found that TNF and RANKL synergistically up-regulate RANK expression in wild type precursors, whereas basal and stimulated levels of RANK are significantly lower in TNFrl knockout cells. Our data suggest that exuberant TNF-induced osteoclastogensis is the result of coupling between RANK and TNFrl and is dependent upon signals transmitted by the latter receptor.	Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Orthopaed Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Pathol, St Louis, MO 63110 USA; Amer Red Cross, Dept Hematopoiesis, Rockville, MD 20855 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); American Red Cross	Abu-Amer, Y (corresponding author), Washington Univ, Sch Med, Dept Orthopaed Surg, 1 Barnes Hosp Plaza,11300 W Pavil,Campus Box 8233, St Louis, MO 63110 USA.	abuamery@msnotes.wustl.edu			NIDCR NIH HHS [DE 13754-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013754] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abu-Amer Y, 2000, J BIOL CHEM, V275, P27307; Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; AbuAmer Y, 1997, NAT MED, V3, P1189, DOI 10.1038/nm1197-1189; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Allen JE, 1997, IMMUNOL TODAY, V18, P387, DOI 10.1016/S0167-5699(97)01102-X; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; CLOHISY DR, 1989, J BIOL CHEM, V264, P5370; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DROUET C, 1991, J IMMUNOL, V147, P1694; DUFF GW, 1994, SCAND J RHEUMATOL, P9; Feldmann M, 1995, ANN NY ACAD SCI, V766, P272, DOI 10.1111/j.1749-6632.1995.tb26675.x; Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HARRIS WH, 1995, CLIN ORTHOP RELAT R, P46; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Isomaki P, 1997, ANN MED, V29, P499, DOI 10.3109/07853899709007474; JIRANEK WA, 1993, J BONE JOINT SURG AM, V75A, P863, DOI 10.2106/00004623-199306000-00007; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li J, 1999, J BONE MINER RES, V14, pS149; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; MUNDY GR, 1993, J CELL BIOCHEM, V53, P296, DOI 10.1002/jcb.240530405; MUNDY GR, 1993, J BONE MINER RES, V8, pS505, DOI 10.1002/jbmr.5650081315; Schlaak JF, 1996, CLIN EXP RHEUMATOL, V14, P155; Takayanagi H, 2000, ARTHRITIS RHEUM-US, V43, P259, DOI 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W; Tetsuka T, 1996, BIOCHEM BIOPH RES CO, V218, P808, DOI 10.1006/bbrc.1996.0144; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; ULFGREN AK, 1995, ANN RHEUM DIS, V54, P654, DOI 10.1136/ard.54.8.654; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VILCEK J, 1991, J BIOL CHEM, V266, P7313; Wagner S, 1997, RHEUMATOL INT, V16, P191, DOI 10.1007/BF01330295; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355	43	384	420	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					563	568		10.1074/jbc.M008198200	http://dx.doi.org/10.1074/jbc.M008198200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11032840	hybrid			2022-12-27	WOS:000166280700076
J	Kutay, U; Hartmann, E; Treichel, N; Calado, A; Carmo-Fonseca, M; Prehn, S; Kraft, R; Gorlich, D; Bischoff, FR				Kutay, U; Hartmann, E; Treichel, N; Calado, A; Carmo-Fonseca, M; Prehn, S; Kraft, R; Gorlich, D; Bischoff, FR			Identification of two novel RanGTP-binding proteins belonging to the importin beta superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSPORT FACTOR; EXPORT RECEPTOR; KARYOPHERIN-BETA; PORE COMPLEX; TRANSFER-RNA; RANBP1; CRM1; NUCLEOPORINS; DISSOCIATION; ASSOCIATION	Nucleo-cytoplasmic transport comprises a large number of distinct pathways, many of which are defined by members of the importin beta superfamily of nuclear transport receptors. These transport receptors all directly interact with RanGTP to modulate the compartment-specific binding of their transport substrates. To identify new members of the importin beta family, we used affinity chromatography on immobilized RanGTP and isolated Ran-binding protein (RanBP) 16 from HeLa cell extracts. RanBP16 and its close human homologue, RanBP17, are distant members of the importin beta family. Like the other members of the transport receptor superfamily, RanBP16 interacts with the nuclear pore complex and is able to enter the nucleus independent of energy and additional nuclear transport receptors.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland; Univ Gottingen, Dept Biochem 2, D-37073 Gottingen, Germany; Univ Lisbon, Inst Histol & Embryol, P-1649028 Lisbon, Portugal; Humboldt Univ, Charite, Inst Biochem, D-10115 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Mol Biol Mitosis, D-69120 Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Gottingen; Universidade de Lisboa; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Kutay, U (corresponding author), Swiss Fed Inst Technol, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.		Görlich, Dirk/B-8296-2017; Calado, Ângelo Miguel Silva/Y-2296-2019; Hartmann, Enno/C-5687-2013	Görlich, Dirk/0000-0002-4343-5210; Calado, Ângelo Miguel Silva/0000-0003-0182-2615; Carmo-Fonseca, Maria/0000-0002-3402-7143				Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Deane R, 1997, MOL CELL BIOL, V17, P5087, DOI 10.1128/MCB.17.9.5087; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Morgenstern B, 1998, BIOINFORMATICS, V14, P290, DOI 10.1093/bioinformatics/14.3.290; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Sambrook J., 2002, MOL CLONING LAB MANU; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181	38	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40163	40168		10.1074/jbc.M006242200	http://dx.doi.org/10.1074/jbc.M006242200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11024021	hybrid, Green Published			2022-12-27	WOS:000166039500051
J	Smith, L; Chen, L; Reyland, ME; DeVries, TA; Talanian, RV; Omura, S; Smith, JB				Smith, L; Chen, L; Reyland, ME; DeVries, TA; Talanian, RV; Omura, S; Smith, JB			Activation of atypical protein kinase C zeta by caspase processing and degradation by the ubiquitin-proteasome system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; DRUG-INDUCED APOPTOSIS; DEPENDENT DEGRADATION; LEUKEMIA-CELLS; BETA-TRCP; IN-VITRO; CLEAVAGE; PHOSPHORYLATION; INHIBITION; GROWTH	Atypical protein kinase C zeta (PKC zeta) is known to transduce signals that influence cell proliferation and survival. Here we show that recombinant human caspases can process PKC zeta at three sites in the hinge region between the regulatory and catalytic domains. Caspase-3, -6, -7, and -8 chiefly cleaved human PKC zeta at EETD down arrow G, and caspase-3 and -7 also cleaved PKC zeta at DGMD down arrow G and DSED down arrow L, respectively. Processing of PKC zeta expressed in transfected cells occurred chiefly at EETD down arrow G and DGMD down arrow G and produced carboxyl-terminal polypeptides that contained the catalytic domain. Epitope-tagged PKC zeta that lacked the regulatory domain was catalytically active following expression in HeLa cells. Induction of apoptosis in HeLa cells by tumor necrosis factor cu plus cycloheximide evoked the conversion of full-length epitope-tagged PKC zeta to two catalytic domain polypeptides and increased PKC zeta activity. A caspase inhibitor, zVAD-fmk, prevented epitope-tagged PKC zeta processing and activation following the induction of apoptosis. Induction of apoptosis in rat parotid C5 cells produced catalytic domain polypeptides of endogenous PKC zeta and increased PKC zeta activity. Caspase inhibitors prevented the increase in PKC zeta activity and production of the catalytic domain polypeptides. Treatment with lactacystin, a selective inhibitor of the proteasome, caused polyubiquitin-PKC zeta conjugates to accumulate in cells transfected with the catalytic domain or full-length PKC alpha, or with a PKC zeta mutant that was resistant to caspase processing. We conclude that caspases process PKC zeta to carboxyl-terminal fragments that are catalytically active and that are degraded by the ubiquitin-proteasome pathway.	Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Colorado, Hlth Sci Ctr, Sch Dent, Dept Basic Sci & Oral Res, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cell & Struct Biol, Denver, CO 80262 USA; BASF AG, Biores Corp, Worcester, MA 01605 USA; Kitasato Inst, Minato Ku, Tokyo 108, Japan	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; BASF	Smith, JB (corresponding author), Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Volker Hall G133E,1670 Univ Bldg, Birmingham, AL 35294 USA.				NIDDK NIH HHS [DK50690] Funding Source: Medline; NIGMS NIH HHS [GM60383] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060383] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Chen L, 2000, ARCH BIOCHEM BIOPHYS, V374, P306, DOI 10.1006/abbi.1999.1603; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; KUO JF, 1994, PROTEIN KINASE C, P1; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HW, 1997, MOL PHARMACOL, V51, P439; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; PETERS JM, 1998, UBIQUITIN BIOL CELL, P1; PONGRACZ J, 1995, EXP CELL RES, V218, P430, DOI 10.1006/excr.1995.1176; Quissell DO, 1998, IN VITRO CELL DEV-AN, V34, P58; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VAN AD, 1996, SCIENCE, V274, P787; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	50	72	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40620	40627		10.1074/jbc.M908517199	http://dx.doi.org/10.1074/jbc.M908517199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11016947	hybrid			2022-12-27	WOS:000166039500110
J	Cai, L; Klein, JB; Kang, YJ				Cai, L; Klein, JB; Kang, YJ			Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; LIPID-PEROXIDATION; SUPEROXIDE; CELLS; ACTIVATION; OXIDATION; MEMBRANE; RADICALS; TOXICITY; HEART	Previous studies have demonstrated that metallothionein functions as an antioxidant that protects against oxidative DNA, protein, and lipid damage induced by superoxide anion, hydrogen peroxide, hydroxyl radical, and nitric oxide. The present study was undertaken to test the hypothesis that metallothionein also protects from DNA and lipoprotein damage induced by peroxynitrite, an important reactive nitrogen species that causes a diversity of pathological processes. A cell-free system was used. DNA damage was detected by the mobility of plasmid DNA in electrophoresis. Oxidation of low density lipoprotein was measured by a thiobarbituric acid-reactive substance, which was confirmed by lipid hydroperoxide assay. Plasmid DNA damage and low density lipoprotein oxidation were induced by 3-morpholinosydnomine, which produces peroxynitrite through the reaction between nitric oxide and superoxide anion or by synthesized peroxynitrite directly. DNA damage by 3-morpholinosydnomine was prevented by both metallothionein and superoxide dismutase, whereas the damage caused by peroxynitrite was prevented by metallothionein only. The oxidation of low density lipoprotein by 3-morpholinosydnomine and peroxynitrite was also significantly inhibited by metallothionein. This study thus demonstrates that metallothionein may react directly with peroxynitrite to prevent DNA and lipoprotein damage induced by this pathological reactive nitrogen species.	Univ Louisville, Sch Med, Dept Med, Louisville, KY 40202 USA; Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40292 USA; Jewish Hosp Heart & Lung Inst, Louisville, KY 40292 USA	University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Kang, YJ (corresponding author), Univ Louisville, Sch Med, Dept Med, 511 S Sloyd St,MDR 530, Louisville, KY 40202 USA.		Cai, Lu/A-6024-2008; Klein, Jon/B-9833-2013	Cai, Lu/0000-0003-3048-1135; 	NCI NIH HHS [CA68125] Funding Source: Medline; NHLBI NIH HHS [HL59225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068125] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059225] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Borutaite V, 1999, BBA-MOL BASIS DIS, V1453, P41, DOI 10.1016/S0925-4439(98)00082-9; Cai L, 1999, TOXICOLOGY, V132, P85, DOI 10.1016/S0300-483X(98)00150-4; CAI L, 1995, CHEM-BIOL INTERACT, V96, P143, DOI 10.1016/0009-2797(94)03585-V; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Gadelha FR, 1997, ARCH BIOCHEM BIOPHYS, V345, P243, DOI 10.1006/abbi.1997.0259; Grace SC, 1998, FEBS LETT, V426, P24, DOI 10.1016/S0014-5793(98)00298-1; Gutteridge JMC, 2000, ANN NY ACAD SCI, V899, P136, DOI 10.1111/j.1749-6632.2000.tb06182.x; Hermann M, 1999, FEBS LETT, V445, P212, DOI 10.1016/S0014-5793(99)00043-5; Jope RS, 2000, ARCH BIOCHEM BIOPHYS, V376, P365, DOI 10.1006/abbi.2000.1728; Kang YJ, 1999, P SOC EXP BIOL MED, V222, P263, DOI 10.1046/j.1525-1373.1999.d01-143.x; Kang YJ, 2000, J BIOL CHEM, V275, P13690, DOI 10.1074/jbc.275.18.13690; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6; Misra RR, 1996, CHEM RES TOXICOL, V9, P326, DOI 10.1021/tx950109y; Miura T, 1997, LIFE SCI, V60, P301; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Quesada AR, 1996, ARCH BIOCHEM BIOPHYS, V334, P241, DOI 10.1006/abbi.1996.0452; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; Spector A, 2000, J OCUL PHARMACOL TH, V16, P193, DOI 10.1089/jop.2000.16.193; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; Wang GW, 1999, AM J PHYSIOL-HEART C, V276, pH167, DOI 10.1152/ajpheart.1999.276.1.H167; Weinstein DM, 2000, J PHARMACOL EXP THER, V294, P396	26	132	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38957	38960		10.1074/jbc.C000593200	http://dx.doi.org/10.1074/jbc.C000593200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11042194	hybrid			2022-12-27	WOS:000165953100003
J	Narvaez, CJ; Welsh, J				Narvaez, CJ; Welsh, J			Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; D ANALOG; BAX; DEATH; BCL-2; ACTIVATION; CLEAVAGE; EB1089	Vitamin D-3 compounds are currently in clinical trials for human breast cancer and offer an alternative approach to anti-hormonal therapies for this disease. 1 alpha ,25-Dihydroxyvitamin D-3 (1 alpha ,25(OH)(2)D-3), the active form of vitamin D-3, induces apoptosis in breast cancer cells and tumors, but the underlying mechanisms are poorly characterized. In these studies, we focused on the role of caspase activation and mitochondrial disruption in 1 alpha ,25(OH)(2)D-3-mediated apoptosis in breast cancer cells (MCF-7) in vitro. The effect of 1 alpha ,25(OH)(2)D-3 on MCF-7 cells was compared with that of tumor necrosis factor alpha, which induces apoptosis via a caspase-dependent pathway. Our major findings are that 1 alpha ,25(OH)(2)D-3 induces apoptosis in MCF-7 cells by disruption of mitochondrial function, which is associated with Bax translocation to mitochondria, cytochrome c release, and production of reactive oxygen species. Moreover, we show that Bax translocation and mitochondrial disruption do not occur after 1 alpha ,25(OH)(2)D-3 treatment of a MCF-7 cell clone selected for resistance to 1 alpha ,25(OH)(2)D-3-mediated apoptosis. These mitochondrial effects of 1 alpha ,25(OH)(2)D-3 do not require caspase activation, since they are not blocked by the cell-permeable caspase inhibitor z-Val-Ala-Asp-fluoromethylketone. Although caspase inhibition blocks 1 alpha ,25(OH)(2)D-3-mediated events downstream of mitochondria such as poly(ADP-ribose) polymerase cleavage, external display of phosphatidylserine, and DNA fragmentation, MCF-7 cells still execute apoptosis in the presence of z-Val-Ala-Asp-fluoromethylketone, indicating that the commitment to 1 alpha ,25(OH)(2)D-3-mediated cell death is caspase-independent.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	University of Notre Dame	Welsh, J (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.				NCI NIH HHS [CA69700] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069700] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Blutt SE, 2000, ENDOCRINOLOGY, V141, P10, DOI 10.1210/en.141.1.10; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fitch ME, 2000, CELL DEATH DIFFER, V7, P338, DOI 10.1038/sj.cdd.4400659; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gulliford T, 1998, BRIT J CANCER, V78, P6, DOI 10.1038/bjc.1998.434; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JAMES SY, 1995, J MOL ENDOCRINOL, V14, P391, DOI 10.1677/jme.0.0140391; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Mathiasen IS, 1999, CANCER RES, V59, P4848; Miyashita T, 1998, CELL DEATH DIFFER, V5, P1034, DOI 10.1038/sj.cdd.4400442; Narvaez CJ, 1996, ENDOCRINOLOGY, V137, P400, DOI 10.1210/en.137.2.400; Narvaez CJ, 1997, ENDOCRINOLOGY, V138, P4690, DOI 10.1210/en.138.11.4690; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; SimboliCampbell M, 1997, BREAST CANCER RES TR, V42, P31, DOI 10.1023/A:1005772432465; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; VanWeelden K, 1998, ENDOCRINOLOGY, V139, P2102, DOI 10.1210/en.139.4.2102; Welsh J, 1998, SUB CELL BIOCHEM, V30, P245; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	33	156	156	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9101	9107		10.1074/jbc.M006876200	http://dx.doi.org/10.1074/jbc.M006876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11053435	hybrid			2022-12-27	WOS:000167607700066
J	Li, CQ; Vindigni, A; Sadler, JE; Wardell, MR				Li, CQ; Vindigni, A; Sadler, JE; Wardell, MR			Platelet glycoprotein Ib alpha binds to thrombin anion-binding exosite II inducing allosteric changes in the activity of thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; GLA DOMAIN; PROCOAGULANT ACTIVITY; ANTITHROMBIN-III; MEMBRANE-BINDING; LIGAND-BINDING; IX COMPLEX; FACTOR-X; RECEPTOR; HEPARIN	The glycoprotein (GP) Ib-IX complex is a platelet surface receptor that binds thrombin as one of its ligands, although the biological significance of thrombin interaction remains unclear. In this study we have used several approaches to investigate the GPIb alpha -thrombin interaction in more detail and to study its effect on the thrombin-induced elaboration of fibrin. We found that both glycocalicin and the amino terminal fragment of GPIb alpha reduced the release of fibrinopeptide A from fibrinogen by about 50% by a noncompetitive allosteric mechanism. Similarly, GPIb alpha caused in thrombin an allosteric reduction in the rate of turnover of the small peptide substrate D-Phe-Pro-Arg-pNA. The K-d for the glycocalicin-thrombin interaction was 1 muM at physio logical ionic strength but was highly salt-dependent, decreasing to 0.19 muM at 100 mM NaCl (Gamma (salt) = -4.2). The salt dependence was characteristic of other thrombin ligands that bind to exosite II of this enzyme, and we confirmed this as the GPIb alpha -binding site on thrombin by using thrombin mutants and by competition binding studies. R68E or R70E mutations in exosite I of thrombin had little effect on its interaction with GPIb alpha. Both the allosteric inhibition of fibrinogen turnover caused by GPIb alpha binding to these mutants, and the K-d values for their interactions with GPIb alpha were similar to those of wild type thrombin. In contrast, R89E and K248E mutations in exosite II of thrombin markedly increased the K-d values for the interactions of these thrombin mutants with GPIb alpha by 10- and 25-fold, respectively. Finally, me demonstrated that low molecular weight heparin (which binds to thrombin exosite II) but not hirugen (residues 54-65 of hirudin, which binds to exosite I of thrombin) inhibited thrombin binding to GPIb alpha. These data demonstrate that GPIb alpha binds to thrombin exosite II and in so doing causes a conformational change in the active site of thrombin by an allosteric mechanism that alters the accessibility of both its natural substrate, fibrinogen, and the small peptidyl substrate D-Phe-Pro-Arg-pNA.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Wardell, MR (corresponding author), New Century Pharmaceut Inc, 895 Martin Rd, Huntsville, AL 35824 USA.	mwardell@newcenturypharm.com	Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060617] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60617] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNDT MC, 1986, ANN NY ACAD SCI, V485, P374, DOI 10.1111/j.1749-6632.1986.tb34598.x; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DANG QD, 1994, J PROTEIN CHEM, V13, P367, DOI 10.1007/BF01901692; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; De Candia E, 1999, CIRCULATION, V99, P3308, DOI 10.1161/01.CIR.99.25.3308; de Cristofaro R, 1998, BIOCHEM J, V332, P643, DOI 10.1042/bj3320643; De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887; DeCandia E, 1997, THROMB HAEMOSTASIS, V77, P735; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 1997, BLOOD, V89, P4355, DOI 10.1182/blood.V89.12.4355; Dormann D, 2000, BLOOD, V96, P2469, DOI 10.1182/blood.V96.7.2469.h8002469_2469_2478; ENDO T, 1981, J BIOL CHEM, V256, P2485; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GANGULY P, 1979, BRIT J HAEMATOL, V42, P137, DOI 10.1111/j.1365-2141.1979.tb03706.x; GRALNICK HR, 1994, P NATL ACAD SCI USA, V91, P6334, DOI 10.1073/pnas.91.14.6334; HARMON JT, 1986, J BIOL CHEM, V261, P3224; HESS D, 1991, EUR J BIOCHEM, V199, P389, DOI 10.1111/j.1432-1033.1991.tb16135.x; HOPFNER KP, 1993, BIOCHEMISTRY-US, V32, P2947, DOI 10.1021/bi00063a004; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; JANDROTPERRUS M, 1992, BLOOD, V80, P2781; JANDROTPERRUS M, 1991, THROMB HAEMOSTASIS, V66, P300; JandrotPerrus M, 1996, SEMIN THROMB HEMOST, V22, P151, DOI 10.1055/s-2007-999003; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; LARSEN NE, 1981, BIOCHEMISTRY-US, V20, P4141, DOI 10.1021/bi00517a030; Li CQ, 2000, BLOOD, V95, P205, DOI 10.1182/blood.V95.1.205.001k14_205_211; LI CQ, 1995, J BIOL CHEM, V270, P16302, DOI 10.1074/jbc.270.27.16302; Li CQ, 1997, BLOOD, V90, P1911; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; Mazzucato M, 1998, J BIOL CHEM, V273, P1880, DOI 10.1074/jbc.273.4.1880; McGee MP, 1998, BIOCHEM J, V330, P533; MILETICH JP, 1977, P NATL ACAD SCI USA, V74, P4033, DOI 10.1073/pnas.74.9.4033; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Smith RD, 1999, BIOCHEMISTRY-US, V38, P8936, DOI 10.1021/bi9827518; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STONE SR, 1989, BIOCHEMISTRY-US, V28, P6857, DOI 10.1021/bi00443a012; STONE SR, 1987, EUR J BIOCHEM, V169, P373, DOI 10.1111/j.1432-1033.1987.tb13622.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS HJ, 1975, NEW ENGL J MED, V293, P531, DOI 10.1056/NEJM197509112931105; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	64	57	62	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6161	6168		10.1074/jbc.M004164200	http://dx.doi.org/10.1074/jbc.M004164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11024046	hybrid			2022-12-27	WOS:000167261000016
J	Li, Y; Baldauf, S; Lim, EK; Bowles, DJ				Li, Y; Baldauf, S; Lim, EK; Bowles, DJ			Phylogenetic analysis of the UDP-glycosyltransferase multigene family of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PROTEINS; ENDOPLASMIC-RETICULUM; PETUNIA-HYBRIDA; BIOCHEMICAL-CHARACTERIZATION; GLUCOSE GLUCOSYLTRANSFERASE; HETEROLOGOUS EXPRESSION; O-GLUCOSYLTRANSFERASE; AMINO-ACID; RAT-LIVER; ZEA-MAYS	A class of UDP-glycosyltransferases (UGTs) defined by the presence of a C-terminal consensus sequence is found throughout the plant and animal kingdoms. Whereas mammalian enzymes use UDP-glucuronic acid, the plant enzymes typically use UDP-glucose in the transfer reactions. A diverse array of aglycones can be glucosylated by these UGTs. In plants, the aglycones include plant hormones, secondary metabolites involved in stress and defense responses, and xenobiotics such as herbicides. Glycosylation is known to regulate many properties of the aglycones such as their bioactivity, their solubility, and their transport properties within the cell and throughout the plant. As a means of providing a framework to start to understand the substrate specificities and structure-function relationships of plant UGTs, we have now applied a molecular phylogenetic analysis to the multigene family of 99 UGT sequences in Arabidopsis. We have determined the overall organization and evolutionary relationships among individual members with a surprisingly high degree of confidence. Through constructing a composite phylogenetic tree that also includes all of the additional plant UGTs with known catalytic activities, we can start to predict both the evolutionary history and substrate specificities of new sequences as they are identified. The tree already suggests that while the activities of some subgroups of the UGT family are highly conserved among different plant species, others subgroups shift substrate specificity with relative ease.	Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England	University of York - UK	Bowles, DJ (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5DD, N Yorkshire, England.			Baldauf, Sandra/0000-0003-4485-6671				Bak S, 1998, PLANT MOL BIOL, V38, P725, DOI 10.1023/A:1006064202774; BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; BRUGLIERA F, 1994, PLANT J, V5, P81, DOI 10.1046/j.1365-313X.1994.5010081.x; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; de Wildt SN, 1999, CLIN PHARMACOKINET, V36, P439, DOI 10.2165/00003088-199936060-00005; Edwards R, 2000, TRENDS PLANT SCI, V5, P193, DOI 10.1016/S1360-1385(00)01601-0; FEDOROFF NV, 1984, P NATL ACAD SCI USA, V81, P3829; Ford CM, 1998, J BIOL CHEM, V273, P9224, DOI 10.1074/jbc.273.15.9224; Fraissinet-Tachet L, 1998, FEBS LETT, V437, P319, DOI 10.1016/S0014-5793(98)01257-5; FURTEK D, 1988, PLANT MOL BIOL, V11, P473, DOI 10.1007/BF00039028; Halkier BA, 1999, NATURALLY OCCURRING GLYCOSIDES, P193; Hostel W., 1981, BIOCH PLANTS, V7, P725; HUGHES J, 1994, DNA SEQUENCE, V5, P41, DOI 10.3109/10425179409039703; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Jackson RG, 2001, J BIOL CHEM, V276, P4350, DOI 10.1074/jbc.M006185200; Jones PR, 1999, J BIOL CHEM, V274, P35483, DOI 10.1074/jbc.274.50.35483; KLECZKOWSKI K, 1995, CRIT REV PLANT SCI, V14, P283, DOI 10.1080/07352689509382361; Kranz HD, 1998, PLANT J, V16, P263, DOI 10.1046/j.1365-313x.1998.00278.x; KROON J, 1994, PLANT J, V5, P69, DOI 10.1046/j.1365-313X.1994.5010069.x; Lee H, 1999, J BIOL CHEM, V274, P36637, DOI 10.1074/jbc.274.51.36637; Lim EK, 2001, J BIOL CHEM, V276, P4344, DOI 10.1074/jbc.M007263200; MACKENZIE PI, 1984, BIOCHEM BIOPH RES CO, V122, P1441, DOI 10.1016/0006-291X(84)91252-X; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MACKENZIE PI, 1990, FRONTIERS BIOTRANSFO, V2, P211; Martin RC, 1999, P NATL ACAD SCI USA, V96, P284, DOI 10.1073/pnas.96.1.284; Martin RC, 1999, PLANT PHYSIOL, V120, P553, DOI 10.1104/pp.120.2.553; Meech R, 1996, DNA CELL BIOL, V15, P489, DOI 10.1089/dna.1996.15.489; Miller KD, 1999, J BIOL CHEM, V274, P34011, DOI 10.1074/jbc.274.48.34011; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; Moehs CP, 1997, PLANT J, V11, P227, DOI 10.1046/j.1365-313X.1997.11020227.x; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; O'Donnell PJ, 1998, PLANT J, V14, P137, DOI 10.1046/j.1365-313X.1998.00110.x; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; PATTHY L, 1991, BIOESSAYS, V13, P187, DOI 10.1002/bies.950130408; Radominska-Pandya A, 1999, DRUG METAB REV, V31, P817, DOI 10.1081/DMR-100101944; ROGERS JH, 1990, FEBS LETT, V268, P339, DOI 10.1016/0014-5793(90)81282-S; Sambrook J., 2002, MOL CLONING LAB MANU; SEMBDNER G, 1994, PLANT MOL BIOL, V26, P1459, DOI 10.1007/BF00016485; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; Tanaka Y, 1996, PLANT CELL PHYSIOL, V37, P711, DOI 10.1093/oxfordjournals.pcp.a029004; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Truesdale M. R., 1996, PLANT PHYSIOL, V112, P446; Vogt T, 1999, PLANT J, V19, P509, DOI 10.1046/j.1365-313X.1999.00540.x; Yamazaki M, 1999, J BIOL CHEM, V274, P7405, DOI 10.1074/jbc.274.11.7405; YOKOTA H, 1992, J BIOCHEM, V112, P192, DOI 10.1093/oxfordjournals.jbchem.a123876; 1997, Patent No. 9716559	49	311	483	16	112	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4338	4343		10.1074/jbc.M007447200	http://dx.doi.org/10.1074/jbc.M007447200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042215	hybrid			2022-12-27	WOS:000166921200081
J	Nechiporuk, T; Urness, LD; Keating, MT				Nechiporuk, T; Urness, LD; Keating, MT			ETL, a novel seven-transmembrane receptor that is Developmentally regulated in the heart - ETL is a member of the secretin family and belongs to the epidermal growth factor seven-transmembrane subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GENE-EXPRESSION; POSTNATAL-DEVELOPMENT; EXTRACELLULAR DOMAIN; VENTRICULAR MYOCYTES; LINKED RECEPTORS; DOWN-REGULATION; RAT; ACTIVATION; CALCIUM	Using differential display of rat fetal and postnatal cardiomyocytes, we have identified a novel seven-trans-membrane receptor, ETL. The cDNA-predicted amino acid sequence of ETL indicated that it encodes a 738-aa protein composed of a large extracellular domain with epidermal growth factor (EGF)-like repeats, a seven-transmembrane domain, and a short cytoplasmic tail. ETL belongs to the secretin family of G-protein-coupled peptide hormone receptors and the EGF-TM7 subfamily of receptors. The latter are characterized by a variable number of extracellular EGF and cell surface domains and conserved seven transmembrane-spanning regions. ETL mRNA expression is up-regulated in the adult rat and human heart. In situ hybridization analyses revealed expression in rat cardiomyocytes and abundant expression in vascular and bronchiolar smooth muscle cells. In COS-7 cells transfected with Myc-tagged rat ETL, rat ETL exists as a stable dimer and undergoes endoproteolytic cleavage of the extracellular domain. The proteolytic activity can be abolished by a specific mutation, T455A, in this domain. In transfected mammalian cells, ETL is associated with cell membranes and is also observed in cytoplasmic: vesicles. ETL is the first seven-transmembrane receptor containing EGF-like repeats that is developmentally regulated in the heart.	Univ Utah, Eccles Inst Human Genet, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Inst Human Genet, Dept Internal Med, Div Cardiol, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Inst Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Keating, MT (corresponding author), Univ Utah, Eccles Inst Human Genet, Dept Human Genet, Salt Lake City, UT 84112 USA.	mkeating@genetics.med.harvard.edu						Abe J, 1999, J BIOL CHEM, V274, P19957, DOI 10.1074/jbc.274.28.19957; ANVERSA P, 1980, CIRC RES, V46, P495, DOI 10.1161/01.RES.46.4.495; Ayad S, 1998, EXTRACELLULAR MATRIX; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; BrayWard P, 1996, GENOMICS, V32, P1, DOI 10.1006/geno.1996.0070; CHENG W, 1995, LAB INVEST, V72, P646; Durocher D, 1998, RECENT PROG HORM RES, V53, P7; ENGELMANN GL, 1993, CARDIOVASC RES, V27, P1598, DOI 10.1093/cvr/27.9.1598; Engelmann GL, 1996, MOL CELL BIOCHEM, V164, P47, DOI 10.1007/BF00408640; Hadjantonakis AK, 1997, GENOMICS, V45, P97, DOI 10.1006/geno.1997.4892; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hamann J, 1998, EUR J IMMUNOL, V28, P1701, DOI 10.1002/(SICI)1521-4141(199805)28:05<1701::AID-IMMU1701>3.0.CO;2-2; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; Hlubek MD, 2000, MOL PHARMACOL, V57, P519, DOI 10.1124/mol.57.3.519; Hughes J, 1999, HUM MOL GENET, V8, P543, DOI 10.1093/hmg/8.3.543; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OZEKI Y, 1991, BIOCHEMISTRY-US, V30, P2391, DOI 10.1021/bi00223a014; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; RONDEAU E, 1995, NEPHROLOGIE, V16, P338; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schoneberg T, 1999, MOL CELL ENDOCRINOL, V151, P181, DOI 10.1016/S0303-7207(99)00017-9; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; Sheikh F, 1997, MOL CELL BIOCHEM, V176, P89, DOI 10.1023/A:1006879029333; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; WATSON S, 1994, G PROTEIN LINKED REC, P1; ZAK R, 1984, GROWTH HEART HLTH DI, P140; Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261; Zhu XL, 1996, DEV DYNAM, V207, P429, DOI 10.1002/(SICI)1097-0177(199612)207:4<429::AID-AJA7>3.0.CO;2-J	42	82	87	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4150	4157		10.1074/jbc.M004814200	http://dx.doi.org/10.1074/jbc.M004814200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050079	hybrid			2022-12-27	WOS:000166921200057
J	Wang, JY; Miller, SJ; Falls, DL				Wang, JY; Miller, SJ; Falls, DL			The N-terminal region of neuregulin isoforms determines the accumulation of cell surface and released neuregulin ectodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR-ALPHA; SCHWANN-CELLS; NEUROMUSCULAR-JUNCTIONS; NEURITE OUTGROWTH; CYTOPLASMIC TAIL; PROTGF-ALPHA; EXPRESSION; MEMBRANE; ARIA	Two neuregulin-1 isoforms highly expressed in the nervous system are the type III neuregulin III-beta 1a and the type I neuregulin I-beta 1a The sequence of these two isoforms differs only in the region that is N-terminal of the bioactive epidermal growth factor-like domain. While the biosynthetic processing of the I-beta 1a isoform has been well characterized, the processing of III-beta 1a has not been reported. In this study, we compared III-beta 1a and I-beta 1a processing. Both III-beta 1a and I-beta 1a were synthesized as transmembrane proproteins that were proteolytically cleaved to produce an N-terminal fragment containing the bioactive epidermal growth factor-like domain. For I-beta 1a, this product was released into the medium. However, for III-beta 1a, this product was a transmembrane protein. In cultures of cells expressing III-beta 1a, the amount of neuregulin at the cell surface was much greater, and the amount in the medium was much less than in cultures expressing I-beta 1a Phorbol eater treatment and truncation of the cytoplasmic tail had markedly different effects on III-beta 1a and I-beta 1a processing. These results demonstrate an important role for the N-terminal region in determining neuregulin biosynthetic processing and show that a major product of III-beta 1a processing is a tethered ligand that may act as a cell surface signaling molecule.	Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	Emory University; University System of Ohio; University of Cincinnati	Falls, DL (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.				NIGMS NIH HHS [GM 56337] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM056337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Bermingham-McDonogh O, 1997, MOL CELL NEUROSCI, V10, P184, DOI 10.1006/mcne.1997.0654; BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; BURRY RW, 1993, J NEUROSCI RES, V36, P241, DOI 10.1002/jnr.490360302; Carroll SL, 1997, J NEUROSCI, V17, P1642; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; Han B, 1999, J BIOL CHEM, V274, P26407, DOI 10.1074/jbc.274.37.26407; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Liu XF, 1998, P NATL ACAD SCI USA, V95, P13024, DOI 10.1073/pnas.95.22.13024; Loeb JA, 1998, MOL CELL NEUROSCI, V11, P77, DOI 10.1006/mcne.1998.0676; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; Maurel P, 2000, J NEUROSCI, V20, P4635, DOI 10.1523/JNEUROSCI.20-12-04635.2000; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; Meyer D, 1997, DEVELOPMENT, V124, P3575; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Moore DD, 1995, GLOB MOB SURV; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; Osheroff PL, 1999, GROWTH FACTORS, V16, P241, DOI 10.3109/08977199909002133; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Rimer M, 1998, MOL CELL NEUROSCI, V12, P1, DOI 10.1006/mcne.1998.0695; Rosenbaum C, 1997, EXP NEUROL, V148, P604, DOI 10.1006/exnr.1997.6696; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; Sambrook J., 2002, MOL CLONING LAB MANU; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; SANDROCK AW, 1995, J NEUROSCI, V15, P6124; Schroering A, 1998, J BIOL CHEM, V273, P30643, DOI 10.1074/jbc.273.46.30643; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Urena JM, 1999, J CELL SCI, V112, P773; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Wang JY, 1998, J BIOL CHEM, V273, P20525, DOI 10.1074/jbc.273.32.20525; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Wolpowitz D, 2000, NEURON, V25, P79, DOI 10.1016/S0896-6273(00)80873-9; WOOD PM, 1975, NATURE, V256, P662, DOI 10.1038/256662a0; Yang JF, 1999, MOL CELL NEUROSCI, V13, P415, DOI 10.1006/mcne.1999.0759; Yang X, 1998, NEURON, V20, P255, DOI 10.1016/S0896-6273(00)80454-7	55	103	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2841	2851		10.1074/jbc.M005700200	http://dx.doi.org/10.1074/jbc.M005700200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042203	hybrid			2022-12-27	WOS:000166784800075
J	Lochowska, A; Iwanicka-Nowicka, R; Plochocka, D; Hryniewicz, MM				Lochowska, A; Iwanicka-Nowicka, R; Plochocka, D; Hryniewicz, MM			Functional dissection of the LysR-type CysB transcriptional regulator - Regions important for DNA binding, inducer response, oligomerization, and positive control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO INTERACTIONS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; MUTATIONAL ANALYSIS; PROMOTER REGIONS; CYSJIH PROMOTER; PLASMID VECTORS; GENE-CLUSTER; PROTEIN; ACTIVATOR	CysB is a tetrameric LysR-type transcriptional regulator that acts as an activator of cys regulon genes and as an autorepressor. Positive control of cys genes requires the presence of the inducer N-acetylserine. Following random and site directed mutagenesis of the cysB gene, 20 CysB variants were isolated. Six single amino acid substitutions within the N terminus of CysB abolished the DNA-binding ability of the protein. Seven mutations in the central region of CysB affected its response to the inducer. Four of these CysB mutants retained repressing activity, but lost their activating function in vivo. Their DNA binding characteristics were consistent with an inability to respond to acetylserine by a qualitative change in the DNA-protein interaction. Three of the single residue substitutions resulted in constitutive activity of CysB. The electrophoretic mobility of the complex formed by one of the CysB(c) variants with the cysP promoter suggested a dimeric state of this protein. Characteristics of six truncated CysB variants lacking 5-30 C-terminal residues indicated the involvement of the C terminus in the DNA binding, oligomerization, and stability of CysB. The single substitution Y27G resulted in the CysB(Pc) variant, able to bind DNA and to respond to the inducer by a qualitative change in the DNA-protein complex, but defective in the positive control of the cysP promoter.	Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland	Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Hryniewicz, MM (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Pawinskiego 5A, PL-02106 Warsaw, Poland.	monikah@ibbrain.ibb.waw.pl	Iwanicka-Nowicka, Roksana/M-4910-2019					AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARTOWSKY E, 1991, MOL MICROBIOL, V5, P1715, DOI 10.1111/j.1365-2958.1991.tb01920.x; Cebolla A, 1997, J BIOL CHEM, V272, P3986, DOI 10.1074/jbc.272.7.3986; COLYER TE, 1994, MOL MICROBIOL, V13, P797, DOI 10.1111/j.1365-2958.1994.tb00472.x; Colyer TE, 1996, MOL MICROBIOL, V21, P247, DOI 10.1046/j.1365-2958.1996.6301347.x; FIJALKOWSKA IJ, 1995, J BACTERIOL, V177, P5979, DOI 10.1128/jb.177.20.5979-5986.1995; GIFFARD PM, 1988, MOL GEN GENET, V214, P148, DOI 10.1007/BF00340193; GOETHALS K, 1992, P NATL ACAD SCI USA, V89, P1646, DOI 10.1073/pnas.89.5.1646; Gosink KK, 1996, J BACTERIOL, V178, P5182, DOI 10.1128/jb.178.17.5182-5187.1996; Grob P, 1997, J BACTERIOL, V179, P5398, DOI 10.1128/jb.179.17.5398-5406.1997; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HRYNIEWICZ M, 1988, J GEN MICROBIOL, V134, P763; HRYNIEWICZ MM, 1991, J BACTERIOL, V173, P5876, DOI 10.1128/jb.173.18.5876-5886.1991; HRYNIEWICZ MM, 1994, J BACTERIOL, V176, P3673, DOI 10.1128/JB.176.12.3673-3682.1994; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; IWANICKANOWICKA R, 1995, GENE, V166, P11, DOI 10.1016/0378-1119(95)00606-8; JAGURA-BURDZY G, 1981, J BACTERIOL, V147, P744, DOI 10.1128/JB.147.3.744-751.1981; Jorgensen C, 1999, J BACTERIOL, V181, P4397; Jourdan AD, 1998, J BACTERIOL, V180, P4865, DOI 10.1128/JB.180.18.4865-4871.1998; KREDICH NM, 1992, MOL MICROBIOL, V6, P2747, DOI 10.1111/j.1365-2958.1992.tb01453.x; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P514; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; KULLIK I, 1995, J BACTERIOL, V177, P1285, DOI 10.1128/jb.177.5.1285-1291.1995; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MILLER BE, 1987, J BIOL CHEM, V262, P6006; MILLER JH, 1992, SHORT COURSE BACTERI, P268; MINTON NP, 1984, GENE, V31, P269, DOI 10.1016/0378-1119(84)90220-8; MONROE RS, 1990, J BACTERIOL, V172, P6919, DOI 10.1128/jb.172.12.6919-6929.1990; Muse WB, 1999, J BACTERIOL, V181, P934, DOI 10.1128/JB.181.3.934-940.1999; OSTROWSKI J, 1990, J BACTERIOL, V172, P779, DOI 10.1128/jb.172.2.779-785.1990; OSTROWSKI J, 1987, J BIOL CHEM, V262, P5999; OSTROWSKI J, 1991, J BACTERIOL, V173, P2212, DOI 10.1128/JB.173.7.2212-2218.1991; PEREZRUEDA E, 2000, NUCLEIC ACIDS RES, V285, P1838; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SCHELL MA, 1990, J BIOL CHEM, V265, P3844; SHAMAH SM, 1995, METHOD ENZYMOL, V254, P565; SIKORSKI R S, 1991, P302; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; Tyrrell R, 1997, STRUCTURE, V5, P1017, DOI 10.1016/S0969-2126(97)00254-2; van der Ploeg JR, 1999, J BIOL CHEM, V274, P29358, DOI 10.1074/jbc.274.41.29358; vanderPloeg JR, 1996, J BACTERIOL, V178, P5438, DOI 10.1128/jb.178.18.5438-5446.1996; vanderPloeg JR, 1997, J BACTERIOL, V179, P7671, DOI 10.1128/jb.179.24.7671-7678.1997; Whipple FW, 1997, J MOL BIOL, V265, P261, DOI 10.1006/jmbi.1996.0735	45	80	86	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2098	2107		10.1074/jbc.M007192200	http://dx.doi.org/10.1074/jbc.M007192200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038360	hybrid			2022-12-27	WOS:000166528000062
J	Kapur, R; Zhang, L				Kapur, R; Zhang, L			A novel mechanism of cooperation between c-Kit and erythropoietin receptor - Stem cell factor induces the expression of Stat5 and erythropoietin receptor, resulting in efficient proliferation and survival by erythropoietin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; ERYTHROID-DIFFERENTIATION; SEQUENCE SIMILARITY; HEMATOPOIETIC-CELLS; S-PHASE; GENE; TRANSCRIPTION; APOPTOSIS; GATA-1; DEATH	Optimal production of red cells in vivo requires collaboration between c-Kit, erythropoietin receptor (Epo-R), and GATA-1. However, the mechanism(s) of collaboration remain unclear. Utilizing an embryonic stem cell-derived erythroid progenitor cell line from mice deficient in GATA-1, we have examined the role of c-Kit and Epo-R in erythroid cell proliferation, survival, and differentiation. In the absence of GATA-1, we demonstrate an essential role for c-Kit in survival and proliferation of erythroid progenitors via the regulation of Bcl-2 expression. In addition, we demonstrate that Epo-R and Stat5 are regulated by a second, novel mechanism. We demonstrate that c-Kit stimulation by stem cell factor is essential for the maintenance of Epo-R and Stat5 protein expression, which results in significantly enhanced Bcl-x(L) induction and survival of erythroid progenitors in response to Epo stimulation Restoration of GATA-1 function results in terminal erythroid maturation and up-regulation of Epo-R and Bcl-K, expression, leading also to significantly enhanced survival of terminally differentiating erythroid progenitors in the presence of only Epo, These results demonstrate that c-Kit and Epo-R have unique role(s) during distinct phases of erythroid maturation, and both stem cell factor and Epo contribute to the regulation of the Epo-R-Stat5-Bcl-x(L) pathway to ensure optimal survival, proliferation, and differentiation of erythroid progenitors.	Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Dept Pediat,Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Kapur, R (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Inst Canc Res, 1044 W Walnut St,Rm 425, Indianapolis, IN 46202 USA.	rkapur@iupui.edu						Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043; Kapur R, 1998, BLOOD, V91, P879, DOI 10.1182/blood.V91.3.879.879_879_889; Kapur R, 1999, BLOOD, V94, P1915; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KELLEY LL, 1993, BLOOD, V82, P2340; KOURY MJ, 1994, ANN NY ACAD SCI, V718, P259; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lacronique V, 1997, BLOOD, V90, P3050, DOI 10.1182/blood.V90.8.3050; LANDSCHULZ KT, 1992, BLOOD, V79, P2749; LIN EY, 1993, J IMMUNOL, V151, P1979; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sato T, 1998, J BIOL CHEM, V273, P16921, DOI 10.1074/jbc.273.27.16921; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; SPIVAK JL, 1991, BLOOD, V77, P1228; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YU H, 1993, BLOOD, V81, P373; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	41	60	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1099	1106		10.1074/jbc.M007442200	http://dx.doi.org/10.1074/jbc.M007442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042182	hybrid			2022-12-27	WOS:000166430900034
J	Wei, HJ; Ashby, DG; Moreno, CS; Ogris, E; Yeong, FM; Corbett, AH; Pallas, DC				Wei, HJ; Ashby, DG; Moreno, CS; Ogris, E; Yeong, FM; Corbett, AH; Pallas, DC			Carboxymethylation of the PP2A catalytic subunit in Saccharomyces cerevisiae is required for efficient interaction with the B-type subunits CDC55p and RTS1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; SMALL-T ANTIGEN; REGULATORY SUBUNIT; TYROSINE PHOSPHORYLATION; OKADAIC ACID; BOVINE BRAIN; CELL-GROWTH; MIDDLE-T; YEAST; FORMS	Protein phosphatase 2A (PP2A) is an essential eukaryotic serine/threonine phosphatase known to play important roles in cell cycle regulation. Association of different B-type targeting subunits with the heterodimeric core (A/C) enzyme is known to be an important mechanism of regulating PP2A activity, substrate specificity, and localization. However, how the binding of these targeting subunits to the A/C heterodimer might be regulated is unknown. We have used the budding yeast Saccharomyces cerevisiae as a model system to investigate the hypothesis that covalent modification of the C subunit (Pph21p/Pph22p) carboxyl terminus modulates PP2A complex formation. Two approaches were taken. First, S, cerevisiae cells were generated whose survival depended on the expression of different carboxyl-terminal Pph21p mutants. Second, the major S, cerevisiae methyltransferase (Ppm1p) that catalyzes the methylation of the PH)2A C subunit carboxyl-terminal leucine was identified, and cells deleted for this methyltransferase were utilized for our studies. Our results demonstrate that binding of the yeast B subunit, Cdc55p, to Pph21p was disrupted by either acidic substitution of potential carboxyl-terminal phosphorylation sites on Pph21p or by deletion of the gene for Ppm1p, Loss of Cdc55p association was accompanied in each case by a large reduction in binding of the yeast A subunit, Tpd3p, to Pph21p, Moreover, decreased Cdc55p and Tpd3p binding invariably resulted in nocodazole sensitivity, a known phenotype of CDC55 or TPD3 deletion. Furthermore, loss of methylation also greatly reduced the association of another yeast B-type subunit, Rts1p, Thus, methylation of Pph21p is important for formation of PPSA trimeric and dimeric complexes, and consequently, for PP2A function. Taken together, our results indicate that methylation and phosphorylation may be mechanisms by which the cell dynamically regulates PP2A complex formation and function.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Univ Vienna, Inst Mol Biol, Vienna Bioctr, A-1030 Vienna, Austria	Emory University; Emory University; University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Pallas, DC (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.		yeong, foong m/J-7832-2012; Corbett, Anita/AAH-6106-2021; Moreno, Carlos S/B-3863-2009	yeong, foong m/0000-0002-5641-6588; Corbett, Anita/0000-0002-0461-6895; Moreno, Carlos S/0000-0002-5582-0028; Ogris, Egon/0000-0001-5950-9264	NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NCI NIH HHS [CA57327, R01 CA057327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams A, 1997, METHODS YEAST GENETI; Ayyavoo V, 1997, J LEUKOCYTE BIOL, V62, P93, DOI 10.1002/jlb.62.1.93; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CAYLA X, 1993, EUR J BIOCHEM, V214, P281, DOI 10.1111/j.1432-1033.1993.tb17922.x; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CLOTET J, 1995, EUR J BIOCHEM, V229, P207, DOI 10.1111/j.1432-1033.1995.tb20457.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; De Baere I, 1999, BIOCHEMISTRY-US, V38, P16539, DOI 10.1021/bi991646a; FAVRE B, 1994, J BIOL CHEM, V269, P16311; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HOPKIN K, 1995, J NIH RES, V7, P27; Hrimech M, 2000, EMBO J, V19, P3956, DOI 10.1093/emboj/19.15.3956; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kowluru A, 1996, ENDOCRINOLOGY, V137, P2315, DOI 10.1210/en.137.6.2315; LEE J, 1993, J BIOL CHEM, V268, P19192; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; LI M, 1994, BIOCHEM BIOPH RES CO, V202, P1023, DOI 10.1006/bbrc.1994.2031; Masuda M, 2000, J VIROL, V74, P2636, DOI 10.1128/JVI.74.6.2636-2646.2000; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SHU YM, 1995, MOL CELL BIOL, V15, P5618; Shu YM, 1997, MOL CELL BIOL, V17, P3242, DOI 10.1128/MCB.17.6.3242; SIKORSKI RS, 1989, GENETICS, V122, P19; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; USUI H, 1988, J BIOL CHEM, V263, P3752; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; WANG Y, 1997, MOL CELL BIOL, V17, P6220; XIE HY, 1994, J BIOL CHEM, V269, P1981; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	46	97	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1570	1577		10.1074/jbc.M008694200	http://dx.doi.org/10.1074/jbc.M008694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038366	Green Accepted, hybrid			2022-12-27	WOS:000166430900095
J	Zhang, YJ; Kornfeld, H; Cruikshank, WW; Kim, S; Reardon, CC; Center, DM				Zhang, YJ; Kornfeld, H; Cruikshank, WW; Kim, S; Reardon, CC; Center, DM			Nuclear Translocation of the N-terminal prodomain of interleukin-16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ-DOMAIN; PROTEIN-INTERACTION; IL-16; EXPRESSION; LOCALIZATION; LIM-KINASE-1; SEQUENCE; KINASES; FAMILY; CELLS	Interleukin-18 (IL-16) is a pleiotropic cytokine that functions as a chemoattractant factor, a modulator of T cell activation, and an inhibitor of human immunodeficiency virus (HIV) replication. These diverse functions are exclusively attributed to the secreted C-terminal peptide of 121 amino acids (mature IL 16), which is cleaved from the precursor protein (pro-IL-16) by caspase-3, Human pro-IL-16 is comprised of 631 amino acids with three PDZ domains, one of which is present in secreted mature IL-16, No cellular localization or biologic functions have been ascribed to the unusually large and highly conserved N-terminal prodomain formed as a result of proteolytic release of the third PDZ domain of pro-IL-16, Here we show that the N-terminal prodomain of pro-IL-16 translocates into the nucleus following cleavage of the C-terminal segment. The nuclear localization signal of pro-IL-16 consists of a classical bipartite nuclear targeting motif, We also show that the nuclear targeting of the IL-16 prodomain induces a G(0)/G(1) arrest in the cell cycle. Taken together, the high degree of conservation of the prodomain among species, the presence of two PDZ motifs, and the nuclear localization and subsequent inhibitory effect on cell cycle progression suggest that pro-IL-16 is cleaved into two functional proteins, a C-terminal-secreted cytokine and an N-terminal product, which affects the cell. cycle.	Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA	Boston University	Zhang, YJ (corresponding author), Boston Univ, Sch Med, Ctr Pulm, R-304,80 E Concord St, Boston, MA 02118 USA.		Kornfeld, Hardy/AAS-2903-2021	Center, David/0000-0002-5879-7978; Reardon, Christine/0000-0002-3709-8342	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032802] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32802] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baier M, 1997, P NATL ACAD SCI USA, V94, P5273, DOI 10.1073/pnas.94.10.5273; BALER M, 1995, NATURE, V378, P563; CENTER DM, 1982, J IMMUNOL, V128, P2562; CRUIKSHANK W, 1982, J IMMUNOL, V128, P2569; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P47; Keane J, 1998, J IMMUNOL, V160, P5945; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Maciaszek JW, 1997, J IMMUNOL, V158, P5; Osada H, 1996, BIOCHEM BIOPH RES CO, V229, P582, DOI 10.1006/bbrc.1996.1847; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Stevenson FT, 1997, P NATL ACAD SCI USA, V94, P508, DOI 10.1073/pnas.94.2.508; Theodore AC, 1996, J IMMUNOL, V157, P1958; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144; Zhou P, 1997, NAT MED, V3, P659, DOI 10.1038/nm0697-659	22	46	53	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1299	1303		10.1074/jbc.M008513200	http://dx.doi.org/10.1074/jbc.M008513200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032842	hybrid			2022-12-27	WOS:000166430900060
J	Zhang, YQ; Yin, LY; Hillgartner, FB				Zhang, YQ; Yin, LY; Hillgartner, FB			Thyroid hormone stimulates acetyl-CoA carboxylase-alpha transcription in hepatocytes by modulating the composition of nuclear receptor complexes bound to a thyroid hormone response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; CHICKEN MALIC ENZYME; GENE-EXPRESSION; MESSENGER-RNA; IN-VIVO; ACID; ACTIVATION; LXR; COACTIVATOR; PROMOTER	Triiodothyronine (T3) stimulates a 7-fold increase in transcription of the acetyl-CoA carboxylase-alpha (ACC alpha) gene in chick embryo hepatocytes, Here, we characterized an ACC alpha T3 response element (ACC alpha -T3RE) with unique functional and protein binding properties. ACCa-T3RE activated transcription both in the absence and presence of T3, with a greater activation observed in the presence of T3. In nuclear extracts from hepatocytes incubated in the absence of T3, ACC alpha -T3RE bound protein complexes (complexes 1 and 2) containing the liver X receptor (LXR) and the retinoid X receptor (RXR). In nuclear extracts from hepatocytes incubated in the presence of T3 for 24 h, ACC alpha -T3RE bound a different set of complexes. One complex contained LXR and RXR (complex 3) and another contained the nuclear T3 receptor (TR) and RXR (complex 4). Mutations of ACC alpha -T3RE that inhibited the binding of complexes 1 and 2 decreased transcriptional activation in the absence of T3, and mutations of ACC alpha -T3RE that inhibited the binding of complexes 3 and 4 decreased transcriptional activation in the presence of T3. The stimulation of ACC alpha transcription caused by T3 was closely associated with changes in the binding of complexes 1-4 to ACC alpha -T3RE, These data suggest that T3 regulates ACC alpha transcription by a novel mechanism involving changes in the composition of nuclear receptor complexes bound to ACC alpha -T3RE. We propose that complexes containing LXR/RXR ensure a basal level of ACC alpha expression for the synthesis of structural lipids in cell membranes and that complexes containing LXR/RXR and TR/RXR mediate the stimulation of ACC alpha expression caused by T3.	W Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA	West Virginia University	Hillgartner, FB (corresponding author), W Virginia Univ, Sch Med, Dept Biochem, POB 9142, Morgantown, WV 26506 USA.	fbhillgartner@hsc.wvu.edu						Anderson GW, 1998, J BIOL CHEM, V273, P16391, DOI 10.1074/jbc.273.26.16391; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; BAILLIE RA, 1993, J NUTR BIOCHEM, V4, P431, DOI 10.1016/0955-2863(93)90074-7; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; Costet P, 2000, J BIOL CHEM, V275, P28240; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESVERGNE B, 1994, MOL CELL ENDOCRINOL, V100, P125, DOI 10.1016/0303-7207(94)90291-7; Desvergne B, 1997, NUCLEIC ACIDS RES, V25, P1774, DOI 10.1093/nar/25.9.1774; ElKhadirMounier C, 1996, BIOCHEM J, V314, P613; Fang XX, 2000, MOL CELL ENDOCRINOL, V164, P41, DOI 10.1016/S0303-7207(00)00238-0; FISCHER PWF, 1978, ARCH BIOCHEM BIOPHYS, V190, P332, DOI 10.1016/0003-9861(78)90283-7; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Glass CK, 2000, GENE DEV, V14, P121; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1924; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; Harbers M, 1996, NUCLEIC ACIDS RES, V24, P2252, DOI 10.1093/nar/24.12.2252; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; HILLGARTNER FB, 1992, J BIOL CHEM, V267, P12299; Hillgartner FB, 1996, BIOCHEM J, V319, P263, DOI 10.1042/bj3190263; Hillgartner FB, 1997, ARCH BIOCHEM BIOPHYS, V337, P159, DOI 10.1006/abbi.1996.9776; Hodnett DW, 1996, ARCH BIOCHEM BIOPHYS, V334, P309, DOI 10.1006/abbi.1996.0460; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; Kim TS, 1996, J NUTR, V126, P611, DOI 10.1093/jn/126.3.611; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1994, J BIOL CHEM, V269, P31436; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; LOPEZCASILLAS F, 1992, METABOLISM, V41, P201, DOI 10.1016/0026-0495(92)90154-3; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Moore DD, 1995, GLOB MOB SURV; Olson DP, 1998, J BIOL CHEM, V273, P3375, DOI 10.1074/jbc.273.6.3375; ONATE SA, 1995, SCIENCE, V270, P1354; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SAMUELS HH, 1989, ANNU REV PHYSIOL, V51, P623, DOI 10.1146/annurev.ph.51.030189.003203; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Takeshita A, 1998, J BIOL CHEM, V273, P21554, DOI 10.1074/jbc.273.34.21554; Taylor AH, 1996, BIOCHEMISTRY-US, V35, P8281, DOI 10.1021/bi960269o; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Thurmond DC, 1998, J BIOL CHEM, V273, P1613, DOI 10.1074/jbc.273.3.1613; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	63	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					974	983		10.1074/jbc.M005894200	http://dx.doi.org/10.1074/jbc.M005894200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11027684	Green Published, hybrid			2022-12-27	WOS:000166430900017
J	Basar, T; Havlicek, V; Bezouskova, S; Hackett, M; Sebo, P				Basar, T; Havlicek, V; Bezouskova, S; Hackett, M; Sebo, P			Acylation of lysine 983 is sufficient for toxin activity of Bordetella pertussis adenylate cyclase - Substitutions of alanine 140 modulate acylation site selectivity of the toxin acyltransferase CyaC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL PROTEIN ACYLTRANSFERASE; ESCHERICHIA-COLI HEMOLYSIN; CELL-INVASIVE ACTIVITY; FATTY-ACYLATION; DIRECTED MUTAGENESIS; ENZYMATIC-ACTIVITY; IN-VIVO; CHEMICAL MODIFICATION; ACTIVATION; HLYC	The capacity of adenylate cyclase toxin (ACT) to penetrate into target cells depends on post-translational fatty-acylation by the acyltransferase CyaC, which can palmitoylate the conserved lysines 983 and 860 of ACT. Here, the in vivo acylating capacity of a set of mutated CyaC acyltransferases was characterized by two-dimensional gel electrophoresis and mass spectrometric analyses of the ACT product. Substitutions of the potentially catalytic serine 20 and histidine 33 residues ablated acylating activity of CyaC, Conservative replacements of alanine 140 by glycine (A140G) and valine (A140V) residues, however, affected selectivity of CyaC for the two acylation sites on ACT. Activation by the A140G variant of CyaC generated a mixture of bi- and monoacylated ACT molecules, modified either at both Lys-860 and Lys-983, or only at Lys-860, respectively. In contrast, the A140V CyaC produced a nearly 1:1 mixture of nonacylated pro-ACT with ACT monoacylated almost exclusively at Lys-983, The respective proportion of toxin molecules acylated at Lye-983 correlated well with the cell-invasive activity of both ACT mixtures, which was about half of that of ACT fully acylated on Lys-983 by intact CyaC, These results show that acylation of Lys-860 alone does not confer cell-invasive activity on ACT, whereas acylation of Lys-983 is necessary and sufficient.	CAS, Inst Microbiol, CZ-14220 Prague 4, Czech Republic; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Washington; University of Washington Seattle	Sebo, P (corresponding author), CAS, Inst Microbiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.		SEBO, Peter/F-7423-2011; SEBO, Peter/N-2043-2019; Havlicek, Vladimir/H-2626-2014; Basar, Tamer/V-6613-2019	SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; Havlicek, Vladimir/0000-0002-8614-7059; 	NCRR NIH HHS [S10 RR12939-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012939] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1995, INFECT IMMUN, V63, P3309, DOI 10.1128/IAI.63.9.3309-3315.1995; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; Dadaglio G, 2000, INFECT IMMUN, V68, P3867, DOI 10.1128/IAI.68.7.3867-3872.2000; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; Fayolle C, 1996, J IMMUNOL, V156, P4697; Fayolle C, 1999, J IMMUNOL, V162, P4157; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; Gueirard P, 1998, INFECT IMMUN, V66, P1718, DOI 10.1128/IAI.66.4.1718-1725.1998; GuzmanVerri C, 1997, J BACTERIOL, V179, P5959, DOI 10.1128/jb.179.18.5959-5962.1997; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HAVLICEK V, 2001, IN PRESS J MASS SPEC, V36; HEWLETT EL, 1984, ANN INTERN MED, V101, P5526; Hormozi K, 1999, Dev Biol Stand, V101, P147; Hormozi K, 1999, FEMS IMMUNOL MED MIC, V23, P273, DOI 10.1016/S0928-8244(98)00146-1; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; KHELEF N, 1992, MICROB PATHOGENESIS, V12, P227, DOI 10.1016/0882-4010(92)90057-U; KHELEF N, 1993, INFECT IMMUN, V61, P4064, DOI 10.1128/IAI.61.10.4064-4071.1993; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; LEPAGE G, 1986, J LIPID RES, V27, P114; Lim KB, 2000, J BIOL CHEM, V275, P36698, DOI 10.1074/jbc.C000544200; Ludwig A, 1996, J BACTERIOL, V178, P5422, DOI 10.1128/jb.178.18.5422-5430.1996; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ROGEL A, 1991, J BIOL CHEM, V266, P3154; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; Saron MF, 1997, P NATL ACAD SCI USA, V94, P3314, DOI 10.1073/pnas.94.7.3314; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Stanley P, 1999, MOL MICROBIOL, V34, P887, DOI 10.1046/j.1365-2958.1999.01648.x; SZABO G, 1994, J BIOL CHEM, V269, P22496; Trent MS, 1999, BIOCHEMISTRY-US, V38, P9541, DOI 10.1021/bi9905617; Trent MS, 1999, BIOCHEMISTRY-US, V38, P3433, DOI 10.1021/bi982491u; Trent MS, 1998, BIOCHEMISTRY-US, V37, P4644, DOI 10.1021/bi971588y; Trent MS, 1999, BIOCHEMISTRY-US, V38, P8831, DOI 10.1021/bi990138y; Wang HL, 1997, ANAL BIOCHEM, V250, P162, DOI 10.1006/abio.1997.2214; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	46	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					348	354		10.1074/jbc.M006463200	http://dx.doi.org/10.1074/jbc.M006463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031260	hybrid			2022-12-27	WOS:000166280700048
J	Ellsworth, D; Finnen, RL; Flint, SJ				Ellsworth, D; Finnen, RL; Flint, SJ			Superimposed promoter sequences of the adenoviral E2 early RNA polymerase III and RNA polymerase II transcription units	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 FUNCTIONAL COMPONENTS; C-MYC GENE; CONTROL REGIONS; VAI RNA; ELEMENTS; CELLS; E1A; TRANSACTIVATION; REQUIREMENTS; TRANSLATION	The human adenovirus type 2 E2 early (E2E) transcriptional control region contains an efficient RNA polymerase III promoter, in addition to the well characterized promoter for RNA polymerase II. To determine whether this promoter includes intragenic sequences, we examined the effects of precise substitutions introduced between positions +2 and +62 on E2E transcription in an RNA polymerase III-specific, in vitro system. Two noncontiguous sequences within this region were necessary for efficient or accurate transcription by this enzyme. The sequence and properties of the functional element proximal to the sites of initiation identified it as an A box. Although a B box sequence could not be unambiguously located, substitutions between positions +42 and +62 that severely impaired transcription also inhibited binding of the human general initiation protein TFIIIC, Thus, this region of the RNA polymerase III E2E promoter contains a B box sequence. We also identified previously unrecognized intragenic sequences of the E2E RNA polymerase II promoter. In conjunction with our previous observations, these data establish that RNA polymerase II and RNA polymerase III promoter sequences are superimposed from approximately positions -30 to +20 of the complex E2E transcriptional control region. The alterations in transcription induced by certain mutations suggest that components of the RNA polymerase II and RNA polymerase III transcriptional machines compete for access to overlapping binding sites in the E2E template.	Princeton Univ, Dept Biol Mol, Princeton, NJ 08544 USA	Princeton University	Flint, SJ (corresponding author), Princeton Univ, Dept Biol Mol, Princeton, NJ 08544 USA.	sjflint@molbio.princeton.edu						BAKER CC, 1979, COLD SPRING HARB SYM, V44, P415, DOI 10.1101/SQB.1980.044.01.045; BENTLEY DL, 1989, GENE DEV, V3, P1179, DOI 10.1101/gad.3.8.1179; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BHAT RA, 1984, NUCLEIC ACIDS RES, V12, P7377, DOI 10.1093/nar/12.19.7377; Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; CANNON RE, 1986, P NATL ACAD SCI USA, V83, P1285, DOI 10.1073/pnas.83.5.1285; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CHEN HJ, 1992, J BIOL CHEM, V267, P25457; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DINGERMANN T, 1983, J BIOL CHEM, V258, P395; FLINT SJ, 1986, ADV VIRUS RES, V31, P169, DOI 10.1016/S0065-3527(08)60264-X; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Gunnery S, 1999, J MOL BIOL, V286, P745, DOI 10.1006/jmbi.1998.2518; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; HOWE JG, 1988, J VIROL, V62, P2790, DOI 10.1128/JVI.62.8.2790-2798.1988; HOWE JG, 1993, MOL CELL BIOL, V13, P2655, DOI 10.1128/MCB.13.5.2655; HUANG WL, 1994, P NATL ACAD SCI USA, V91, P1265, DOI 10.1073/pnas.91.4.1265; HULL MW, 1994, MOL CELL BIOL, V14, P1266, DOI 10.1128/MCB.14.2.1266; KASAI Y, 1992, MOL CELL BIOL, V12, P2884, DOI 10.1128/MCB.12.6.2884; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; LEONG K, 1984, J BIOL CHEM, V259, P1527; MANOHAR CF, 1990, J VIROL, V64, P2457, DOI 10.1128/JVI.64.6.2457-2466.1990; MARTINEZ E, 1994, J BIOL CHEM, V269, P25692; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MATHEWS MB, 1996, TRANSLATIONAL CONTRO, P505; PRUZAN R, 1992, NUCLEIC ACIDS RES, V20, P5705, DOI 10.1093/nar/20.21.5705; RAILEY JF, 1988, MOL CELL BIOL, V8, P1147, DOI 10.1128/MCB.8.3.1147; Roeder R.G., 1976, RNA POLYMERASE, P285; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; Shenk T, 1981, Curr Top Microbiol Immunol, V93, P25; SHENK T, 1991, ADV CANCER RES, V57, P47; SHENK T, 1996, VIROLOGY, P2111; SODERLUND H, 1976, CELL, V7, P585, DOI 10.1016/0092-8674(76)90209-9; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; STEINBERG TH, 1992, J BIOL CHEM, V267, P20204; SUSSMAN DJ, 1991, NUCLEIC ACIDS RES, V19, P5045, DOI 10.1093/nar/19.18.5045; Swaminathan S, 1996, J MOL BIOL, V258, P736, DOI 10.1006/jmbi.1996.0283; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; TRIBOULEY C, 1994, J VIROL, V68, P4450, DOI 10.1128/JVI.68.7.4450-4457.1994; Wang ZX, 1996, MOL CELL BIOL, V16, P6841; Wang ZX, 1997, GENE DEV, V11, P2371, DOI 10.1101/gad.11.18.2371; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585	56	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					827	834		10.1074/jbc.M007036200	http://dx.doi.org/10.1074/jbc.M007036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031267	hybrid			2022-12-27	WOS:000166280700111
J	Datta, R; Yoshinaga, K; Kaneki, M; Pandey, P; Kufe, D				Datta, R; Yoshinaga, K; Kaneki, M; Pandey, P; Kufe, D			Phorbol ester-induced generation of reactive oxygen species is protein kinase C beta-dependent and required for SAPK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; HUMAN-IMMUNODEFICIENCY-VIRUS; LEUKEMIA-CELL-LINE; MONOCYTIC DIFFERENTIATION; MACROPHAGE DIFFERENTIATION; JUN KINASES; EXPRESSION; STRESS; TRANSCRIPTION; PROLIFERATION	Treatment of human U-937 myeloid leukemia cells with 12 O-tetradecanoylphorbol-13-acetate (TPA) is associated with protein kinase C (PKC) beta II-mediated activation of the stress-activated protein kinase (SAPK) pathway. The present studies demonstrate that the TPA response of U-937 cells includes the generation of reactive oxygen species (ROS), By contrast, the TPA-resistant U-937 cell variant (TUR), which is deficient in PKC beta II expression, failed to respond to TPA with the induction of ROS. Moreover, we show that TPA-induced ROS production is restored in TUR cells stably transfected to express PKC beta II, The results also demonstrate that TPA-induced ROS production is required for activation of the MEK kinase-1 (MEKI-1)--> SAPK pathway. In concert with this observation, treatment of U-937 with H2O2 as a source of ROS is associated with activation of the MEKK-1-->SAPK cascade. These findings indicate that PKC beta II is required for TPA-induced ROS production and that the MEKK-1-->SAPK pathway is activated by a ROS-mediated mechanism.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Datta, R (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.				NCI NIH HHS [CA42802] Funding Source: Medline; NIGMS NIH HHS [GM58200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLLINS SJ, 1987, BLOOD, V70, P1233; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Kaneki M, 1999, MOL CELL BIOL, V19, P461; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P221; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NISHIKAWA M, 1990, CANCER RES, V50, P621; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; Pongracz J, 1996, LEUKEMIA RES, V20, P319, DOI 10.1016/0145-2126(95)00074-7; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; YANG KD, 1994, BLOOD, V83, P490	31	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41000	41003		10.1074/jbc.M009322200	http://dx.doi.org/10.1074/jbc.M009322200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11042219	hybrid			2022-12-27	WOS:000166114600047
J	Oshiro, J; Rangaswamy, S; Chen, XM; Han, GS; Quinn, JE; Carman, GM				Oshiro, J; Rangaswamy, S; Chen, XM; Han, GS; Quinn, JE; Carman, GM			Regulation of the DPP1-encoded diacylglycerol pyrophosphate (DGPP) phosphatase by inositol and growth phase - Inhibition of DGPP phosphatase activity by CDP-diacylglycerol and activation of phosphatidylserine synthase activity by DGPP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE METHYLATION PATHWAY; AFFECTING MITOCHONDRIAL DEVELOPMENT; YEAST SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID BIOSYNTHESIS; TRANSFER PROTEIN; PHOSPHATIDYLGLYCEROLPHOSPHATE SYNTHASE; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; PHOSPHATIDYLINOSITOL SYNTHASE; FUNCTIONAL-CHARACTERIZATION; COORDINATE REGULATION	The regulation of the Saccharomyces cerevisiae DPP1-encoded diacylglycerol pyrophosphate (DGPP) phosphatase by inositol supplementation and growth phase was examined. Addition of inositol to the growth medium resulted in a dose-dependent increase in the level of DGPP phosphatase activity in both exponential and stationary phase cells. Activity was greater in stationary phase cells when compared with exponential phase cells, and the inositol- and growth phase-dependent regulations of DGPP phosphatase were additive. Analyses of DG;PP phosphatase mRNA and protein levels, and expression of beta -galactosidase activity driven by a P-DPP1-lacZ reporter gene, indicated that a transcriptional mechanism was responsible for this regulation. Regulation of DGPP phosphatase by inositol and growth phase occurred in a manner that was opposite that of many phospholipid biosynthetic enzymes. Regulation of DGPP phosphatase expression by inositol supplementation, but not growth phase, was altered in opi1 Delta, ino2 Delta, and ino4 Delta phospholipid synthesis regulatory mutants. CDP-diacylglycerol, a phospholipid pathway intermediate used for the synthesis of phosphatidylserine and phosphatidylinositol, inhibited DGPP phosphatase activity by a mixed mechanism that caused an increase in K-m and a decrease in V-max. DGPP stimulated the activity of pure phosphatidylserine synthase by a mechanism that increased the affinity of the enzyme for its substrate CDP-diacylglycerol, Phospholipid composition analysis of a dpp1 Delta mutant showed that DGPP phosphatase played a role in the regulation of phospholipid metabolism by inositol, as well as regulating the cellular levels of phosphatidylinositol.	Rutgers State Univ, New Jersey Agr Expt Stn, Cook Coll, Dept Food Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, New Jersey Agr Expt Stn, Cook Coll, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.		Oshiro, June/ACF-4163-2022	Oshiro, June/0000-0003-1134-5023	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAELEE M, 1990, J BIOL CHEM, V265, P7221; BAELEE MS, 1984, J BIOL CHEM, V259, P857; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; Balboa MA, 1999, J BIOL CHEM, V274, P522, DOI 10.1074/jbc.274.1.522; BECKER GW, 1977, J BIOL CHEM, V252, P8684; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; CULBERTSON MR, 1976, J BACTERIOL, V126, P232, DOI 10.1128/JB.126.1.232-242.1976; CULBERTSON MR, 1976, J BACTERIOL, V126, P243, DOI 10.1128/JB.126.1.243-250.1976; CULBERTSON MR, 1975, GENETICS, V80, P23; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; Furneisen JM, 2000, BBA-MOL CELL BIOL L, V1484, P71, DOI 10.1016/S1388-1981(99)00202-4; GAYNOR PM, 1991, J BACTERIOL, V173, P6124, DOI 10.1128/jb.173.19.6124-6131.1991; Graves JA, 2000, GENETICS, V154, P1485; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GREENBERG ML, 1982, MOL GEN GENET, V186, P157, DOI 10.1007/BF00331845; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; HAID A, 1983, METHOD ENZYMOL, V96, P192; HAMAMATSU S, 1994, FEBS LETT, V348, P33, DOI 10.1016/0014-5793(94)00576-1; Harlow E., 1988, ANTIBODIES LAB MANUA; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOMANN MJ, 1987, J BACTERIOL, V169, P3276, DOI 10.1128/jb.169.7.3276-3280.1987; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kim KS, 1999, J BIOL CHEM, V274, P14857, DOI 10.1074/jbc.274.21.14857; KLIG LS, 1984, P NATL ACAD SCI-BIOL, V81, P3816, DOI 10.1073/pnas.81.12.3816; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KODAKI T, 1989, EUR J BIOCHEM, V185, P243, DOI 10.1111/j.1432-1033.1989.tb15109.x; KODAKI T, 1991, J BACTERIOL, V173, P7992, DOI 10.1128/jb.173.24.7992-7995.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; Munnik T, 2000, PLANT J, V22, P147, DOI 10.1046/j.1365-313x.2000.00725.x; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; Murray M, 1997, MOL MICROBIOL, V25, P541, DOI 10.1046/j.1365-2958.1997.4881840.x; Murray M, 2000, MOL MICROBIOL, V36, P651, DOI 10.1046/j.1365-2958.2000.01886.x; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; Pical C, 1999, J BIOL CHEM, V274, P38232, DOI 10.1074/jbc.274.53.38232; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; Riedel B, 1997, PLANT SCI, V128, P1, DOI 10.1016/S0168-9452(97)00120-9; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Segel IH, 1975, ENZYME KINETICS BEHA; Shen HF, 1998, J BIOL CHEM, V273, P11638, DOI 10.1074/jbc.273.19.11638; SUMMERS EF, 1988, GENETICS, V120, P909; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; Toke DA, 1999, BIOCHEMISTRY-US, V38, P14606, DOI 10.1021/bi991472x; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; WHITE MJ, 1991, J BIOL CHEM, V266, P863; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	95	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40887	40896		10.1074/jbc.M008144200	http://dx.doi.org/10.1074/jbc.M008144200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016943	hybrid			2022-12-27	WOS:000166114600031
J	Cebo, C; Dambrouck, T; Maes, E; Laden, C; Strecker, G; Michalski, JC; Zanetta, JP				Cebo, C; Dambrouck, T; Maes, E; Laden, C; Strecker, G; Michalski, JC; Zanetta, JP			Recombinant human interleukins IL-1 alpha, IL-1 beta, IL-4, IL-6, and IL-7 show different and specific calcium-independent carbohydrate-binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; REDUCTIVE BETA-ELIMINATION; N-LINKED OLIGOSACCHARIDES; HEPTAFLUOROBUTYRATE DERIVATIVES; MONOCLONAL-ANTIBODIES; NITROCELLULOSE SHEETS; MASS-SPECTROMETRY; OVIDUCAL MUCINS; RAT-BRAIN; RECEPTOR	A method was developed for the determination of putative lectin activities of cytokines, It involved the immunoblotting measurement of the quantity of these cytokines unbound to a series of different immobilized glycoconjugates and displacement of the bound cytokines with oligosaccharides of known structures. This method allows demonstrating that the following interleukins specifically recognize different oligosaccharide structures in a calcium-independent mechanism: interleukin lcr binds to the biantennary disialylated N-glycan completed with two Neu5Ac alpha2-3 residues; interleukin-1 beta to a GM, sialylated glycolipid Neu5Ac alpha2-3Gal beta1-Cer having very long and unusual long-chain bases; interleukin-4 to the 1,7 intramolecular lactone of N-acetyl-neuraminic acid; interleukin-6 to compounds having N-linked and O-linked HNK-1-like epitopes; and interleukin-7 to the sialyl-Tn antigen. Because the glycan ligands are rare structures in human circulating cells, it is suggested that such activities could be essential for providing specific signaling systems to cells having both the receptors and the oligosaccharide ligands of the interleukin at their cell surface.	Univ Sci & Tech Lille Flandres Artois, Chim Biol Lab, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Zanetta, JP (corresponding author), Univ Sci & Tech Lille Flandres Artois, Chim Biol Lab, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France.							BABA H, 1986, J NEUROIMMUNOL, V13, P89, DOI 10.1016/0165-5728(86)90052-4; BADACHE A, 1992, DEV NEUROSCI-BASEL, V14, P342, DOI 10.1159/000111681; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; CLARKE D, 1995, CYTOKINE, V7, P325, DOI 10.1006/cyto.1995.0041; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; Florea D, 1997, CARBOHYD RES, V302, P179, DOI 10.1016/S0008-6215(97)00129-8; FU DT, 1994, CARBOHYD RES, V261, P173, DOI 10.1016/0008-6215(94)84015-6; Fukushima K, 1997, J BIOL CHEM, V272, P10579; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; GLASS WF, 1981, ANAL BIOCHEM, V115, P219, DOI 10.1016/0003-2697(81)90549-2; Guttman A, 1997, ELECTROPHORESIS, V18, P1136, DOI 10.1002/elps.1150180719; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; KAPLAN D, 1995, FASEB J, V9, P1096, DOI 10.1096/fasebj.9.11.7649410; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KITAMURA K, 1976, BIOCHIM BIOPHYS ACTA, V455, P606; KJELDSEN T, 1988, CANCER RES, V48, P2214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON G, 1986, ARCH BIOCHEM BIOPHYS, V246, P531, DOI 10.1016/0003-9861(86)90308-5; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; Licinio J, 1996, NAT MED, V2, P1314, DOI 10.1038/nm1296-1314; Maes E, 1999, ANAL BIOCHEM, V267, P300, DOI 10.1006/abio.1998.2967; MIRESLUIS A, 1995, BLOOD, V86, P2679; MONSIGNY M, 1988, ANAL BIOCHEM, V175, P525, DOI 10.1016/0003-2697(88)90578-7; Morelle W, 1997, GLYCOBIOLOGY, V7, P1129, DOI 10.1093/glycob/7.8.1129; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; OZAKI K, 1995, GLYCOCONJUGATE J, V12, P268, DOI 10.1007/BF00731329; OZAWA H, 1993, J BIOCHEM-TOKYO, V114, P5, DOI 10.1093/oxfordjournals.jbchem.a124138; Ozbek S, 1998, J BIOL CHEM, V273, P21374, DOI 10.1074/jbc.273.33.21374; PAGE TH, 1995, EUR J IMMUNOL, V25, P2956, DOI 10.1002/eji.1830251036; Pons A, 2000, ANAL BIOCHEM, V284, P201, DOI 10.1006/abio.2000.4686; QUARLES RH, 1983, BIOCHIM BIOPHYS ACTA, V757, P140, DOI 10.1016/0304-4165(83)90162-9; SCHAUER R, 1997, GLYCOPROTEINS 2 B, V29, P243; SHERBLOM AP, 1989, J IMMUNOL, V143, P939; SHERBLOM AP, 1988, J BIOL CHEM, V263, P5418; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; SPIK G, 1995, METHODS GLYCOCONJUGA, P41; STECK A, 1988, NEUROLOGY, V33, P19; STRECKER G, 1977, EUR J BIOCHEM, V75, P391, DOI 10.1111/j.1432-1033.1977.tb11540.x; Tandai-Hiruma M, 1999, J BIOL CHEM, V274, P4459, DOI 10.1074/jbc.274.7.4459; TETTAMANTI G, 1968, ARCH BIOCHEM BIOPHYS, V124, P41, DOI 10.1016/0003-9861(68)90301-9; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TOMOZAWA Y, 1995, NEUROSCI LETT, V195, P57, DOI 10.1016/0304-3940(95)11781-Q; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENKITARAMAN AR, 1994, EUR J IMMUNOL, V24, P2168, DOI 10.1002/eji.1830240935; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; WATANABE K, 1981, J LIPID RES, V22, P1020; Zanetta JP, 1999, GLYCOBIOLOGY, V9, P255, DOI 10.1093/glycob/9.3.255; ZANETTA JP, 1980, LIPIDS, V15, P1055, DOI 10.1007/BF02534323; ZANETTA JP, 1975, BRAIN RES, V83, P337, DOI 10.1016/0006-8993(75)90940-3; Zanetta JP, 1998, GLYCOBIOLOGY, V8, P221, DOI 10.1093/glycob/8.3.221; Zanetta JP, 1996, BIOCHEM J, V318, P49, DOI 10.1042/bj3180049; ZANETTA JP, 1993, LECTINS GLYCOBIOLOGY, P182	54	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5685	5691		10.1074/jbc.M008662200	http://dx.doi.org/10.1074/jbc.M008662200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11050099	hybrid			2022-12-27	WOS:000167115100039
J	Alpy, F; Stoeckel, ME; Dierich, A; Escola, JM; Wendling, C; Chenard, MP; Vanier, MT; Gruenberg, J; Tomasetto, C; Rio, MC				Alpy, F; Stoeckel, ME; Dierich, A; Escola, JM; Wendling, C; Chenard, MP; Vanier, MT; Gruenberg, J; Tomasetto, C; Rio, MC			The steroidogenic acute regulatory protein homolog MLN64, a late endosomal cholesterol-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICK-C-DISEASE; BREAST-CANCER; STAR; TRANSPORT; ONCOGENE; PATHWAY; CELLS; IDENTIFICATION; CHROMOSOME-17; AMPLIFICATION	MLN64 is a transmembrane protein that shares homology with the cholesterol binding domain (START domain) of the steroidogenic acute regulatory protein. The steroidogenic acute regulatory protein is located in the inner membrane of mitochondria, where it facilitates cholesterol import into the mitochondria, Crystallographic analysis showed that the START domain of MLN64 is a cholesterol-binding domain, The present work was undertaken to determine which step of the intracellular cholesterol pathway ML64 participates in. Using immunocytofluorescence, MLN64 colocalizes with LBPA, a lipid found specifically in late endosomes. Electron microscopy indicates that MLN64 is restricted to the limiting membrane of late endosomes. Microinjection or endocytosis of specific antibodies shows that the START domain of MLN64 is cytoplasmic, Deletion and mutagenesis experiments demonstrate that the aminoterminal part of MLN64 is responsible for its addressing. Although this domain does not contain conventional dileucine- or tyrosine-based targeting signals, we show that a dileucine motif (Leu(66)-Leu(67)) and a tyrosine residue (Tyr(89)) are critical for the targeting or the proper folding of the molecule, Finally, MLN64 colocalizes with cholesterol and Niemann Pick CI protein in late endosomes. However, complementation assays show that MLN64 is not involved in the Niemann Pick C2 disease which, results in cholesterol lysosomal accumulation. Together, our results show that MLN64 plays a role at the surface of the late endosomes, where it might shuttle cholesterol from the limiting membrane to cytoplasmic acceptor(s).	Univ Strasbourg 1, INSERM, U184, CNRS,UPR 6520,IGBMC, F-67404 Illkirch, France; CU Strasbourg, Strasbourg, France; Univ Strasbourg 1, CNRS, URA 1446, Lab Physiol Gen, F-67084 Strasbourg, France; Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland; CHU Hautepierre, Serv Anat Pathol Gen, F-67098 Strasbourg, France; Fac Med & Ctr Hosp Lyon Sud, Fdn Gillet Merieux, INSERM, U189, F-69921 Oullins, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Geneva; CHU Strasbourg; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Tomasetto, C (corresponding author), Univ Strasbourg 1, INSERM, U184, CNRS,UPR 6520,IGBMC, 1 Rue Laurent Fries,BP163, F-67404 Illkirch, France.		Chenard, Marie-Pierre/O-2373-2016; Tomasetto, Catherine Laure/J-2783-2014; Alpy, Fabien/ABD-5893-2020; Alpy, Fabien/H-8941-2016	Tomasetto, Catherine Laure/0000-0002-1811-5848; Alpy, Fabien/0000-0002-0526-0720; Alpy, Fabien/0000-0002-0526-0720				Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bieche I, 1996, CANCER RES, V56, P3886; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; DIERICH A, 1987, EMBO J, V6, P2305, DOI 10.1002/j.1460-2075.1987.tb02505.x; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Holtta-Vuori M, 2000, CURR BIOL, V10, P95, DOI 10.1016/S0960-9822(99)99991-8; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Laurent-Matha V, 1998, J CELL SCI, V111, P2539; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Rochefort H, 2000, CLIN CHIM ACTA, V291, P157, DOI 10.1016/S0009-8981(99)00226-0; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STEINBERG SJ, 1994, J MED GENET, V31, P317, DOI 10.1136/jmg.31.4.317; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Strauss JF, 1999, RECENT PROG HORM RES, V54, P369; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Vanier MT, 1996, AM J HUM GENET, V58, P118; Vanier MT, 1998, BRAIN PATHOL, V8, P163; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462	42	132	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4261	4269		10.1074/jbc.M006279200	http://dx.doi.org/10.1074/jbc.M006279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053434	Green Published, hybrid			2022-12-27	WOS:000166921200071
J	Holtmann, H; Enninga, J; Kalble, S; Thiefes, A; Dorrie, A; Broemer, M; Winzen, R; Wilhelm, A; Ninomiya-Tsuji, J; Matsumoto, K; Resch, K; Kracht, M				Holtmann, H; Enninga, J; Kalble, S; Thiefes, A; Dorrie, A; Broemer, M; Winzen, R; Wilhelm, A; Ninomiya-Tsuji, J; Matsumoto, K; Resch, K; Kracht, M			The MAPK kinase kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms of gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; BETA SIGNAL-TRANSDUCTION; TERMINAL KINASE; TGF-BETA; (JNK)-BINDING PROTEIN; SCAFFOLD PROTEINS; RABBIT LIVER; MEK KINASE-1; JNK PATHWAY	Mechanisms of fulminant gene induction during an inflammatory response were investigated using expression of the chemoattractant cytokine interleukin-8 (IL-8) as a model. Recently we found that coordinate activation ofNF-kappaB and c-Jun N-terminal protein kinase (JNK) is required for strong IL-8 transcription, whereas the p38 MAP kinase (MAPK) pathway stabilizes the IL-8 mRNA It is unclear how these pathways are coupled to the receptor for IL-1, an important physiological inducer of IL-8. Expression of the MAP kinase kinase kinase (MAPKKK) TAK1 together with its coactivator TAB1 in HeLa cells activated all three pathways and was sufficient to induce IL-8 formation, NF-kappaB + JNK2-mediated transcription from a minimal IL-8 promoter, and p38 MAPK-mediated stabilization of a reporter mRNA containing IL-8-derived regulatory mRNA sequences. Expression of a kinase-inactive mutant of TAK1 largely blocked IL-1-induced transcription and mRNA stabilization, as well as formation of endogenous IL-8. Truncated TAB1, lacking the TAK1 binding domain, or a TAK1-derived peptide containing a TAK1 autoinhibitory domain were also efficient in inhibition. These data indicate that the previously described three-pathway model of IL-8 induction is operative in response to a physiological stimulus, IL-1, and that the MAPKKK TAK1 couples the IL-1 receptor to both transcriptional and RNA-targeted mechanisms mediated by the three pathways.	Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan	Hannover Medical School; Nagoya University	Kracht, M (corresponding author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kracht.Michael@MH-Hannover.de		Kracht, Michael/0000-0002-8501-043X; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito M, 1999, MOL CELL BIOL, V19, P7539; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Koyano S, 1999, FEBS LETT, V457, P385, DOI 10.1016/S0014-5793(99)01084-4; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Martin MU, 1997, EUR CYTOKINE NETW, V8, P5; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	44	79	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3508	3516		10.1074/jbc.M004376200	http://dx.doi.org/10.1074/jbc.M004376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11050078	hybrid			2022-12-27	WOS:000166784900068
J	Zalevsky, J; Grigorova, I; Mullins, RD				Zalevsky, J; Grigorova, I; Mullins, RD			Activation of the Arp2/3 complex by the Listeria ActA protein - ActA binds two actin monomers and three subunits of the Arp2/3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; ACANTHAMOEBA-CASTELLANII; L-MONOCYTOGENES; N-WASP; PROFILIN; POLYMERIZATION; FILAMENTS; MOTILITY; NUCLEATION; FAMILY	ActA is a bacterially encoded protein that enables Listeria monocytogenes to hijack the host cell actin cytoskeleton. It promotes Arp2/3-dependent actin nucleation, but its interactions with cellular components of the nucleation machinery are not well understood. Here we show that two domains of ActA (residues 85-104 and 121-138) with sequence similarity to WASP homology 2 domains bind two actin monomers with submicromolar affinity. ActA binds Arp2/3 with a K-d of 0.6 muM and competes for binding with the WASP family proteins N-WASP and Scar1. By chemical cross-linking, ActA, N-WASP, and Scar1 contact the same three subunits of the Arp2/3 complex, p40, Arp2, and Arp3. Interestingly, profilin competes with ActA for binding of Arp2/3, but actophorin (cofilin) does not. The minimal Arp2/3-binding site of ActA (residues 144-170) is C-terminal to both actin-binding sites and shares sequence homology with Arp2/3-binding regions of WASP family proteins. The maximal activity at saturating concentrations of ActA is identical to the most active domains of the WASP family proteins. We propose that ActA and endogenous WASP family proteins promote Arp2/3-dependent nucleation by similar mechanisms and require simultaneous binding of Arp2 and Arp3.	Univ Calif San Francisco, Sch Med, Dept Mol & Cellular Pharmacol, San Francisco, CA 94129 USA	University of California System; University of California San Francisco	Mullins, RD (corresponding author), Univ Calif San Francisco, Sch Med, Dept Mol & Cellular Pharmacol, 513 Parnassus Ave, San Francisco, CA 94129 USA.		Grigorova, Irina/AAR-8795-2020	Grigorova, Irina/0000-0002-4963-7403	NIGMS NIH HHS [GM61010-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; Cicchetti G, 1999, J BIOL CHEM, V274, P33616, DOI 10.1074/jbc.274.47.33616; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; GIULIANO KA, 1988, BIOCHEMISTRY-US, V27, P8931, DOI 10.1021/bi00425a009; GORDON DJ, 1976, J BIOL CHEM, V251, P4778; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kaiser DA, 1999, J CELL SCI, V112, P3779; Kelleher JF, 1998, METHOD ENZYMOL, V298, P42, DOI 10.1016/S0076-6879(98)98007-7; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1996, TRENDS CELL BIOL, V6, P208, DOI 10.1016/0962-8924(96)20017-0; Mullins RD, 1999, CURR BIOL, V9, P405, DOI 10.1016/S0960-9822(99)80187-0; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; Mullins RD, 1999, CURR OPIN STRUC BIOL, V9, P244; Otto IM, 2000, CURR BIOL, V10, P345, DOI 10.1016/S0960-9822(00)00388-2; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Skoble J, 2000, J CELL BIOL, V150, P527, DOI 10.1083/jcb.150.3.527; SMITH GA, 1995, MOL MICROBIOL, V17, P945, DOI 10.1111/j.1365-2958.1995.mmi_17050945.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	44	97	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3468	3475		10.1074/jbc.M006407200	http://dx.doi.org/10.1074/jbc.M006407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11029465	hybrid			2022-12-27	WOS:000166784900063
J	Bielli, P; Bellenchi, GC; Calabrese, L				Bielli, P; Bellenchi, GC; Calabrese, L			Site-directed mutagenesis of human ceruloplasmin - Production of a proteolytically stable protein and structure-activity relationships of type 1 sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER SITES; FET3 PROTEIN; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; OXIDASE; IRON; FERROXIDASE; YEAST; MODEL; GENE	A fully active recombinant human ceruloplasmin was obtained, and it was mutated to produce a ceruloplasmin stable to proteolysis. The stable ceruloplasmin was further mutated to perturb the environment of copper at the type 1 copper sites in two different domains. The wild type and the mutated ceruloplasmin were produced in the yeast Pichia pastoris and characterized. The mutations R481A, R701A, and K887A were at the proteolytic sites, did not alter the enzymatic activity, and were all necessary to protect ceruloplasmin from degradation. The mutation L329M was at the tricoordinate type 1 site of the domain 2 and was ineffective to induce modifications of the spectroscopic and catalytic properties of ceruloplasmin, supporting the hypothesis that this site is reduced and locked in a rigid frame. In contrast the mutation C1021S at the type 1 site of domain 6 substantially altered the molecular properties of the protein, leaving a small fraction endowed with oxidase activity. This result, while indicating the importance of this site in stabilizing the overall protein structure, suggests that another type 1 site is competent for dioxygen reduction. During the expression of ceruloplasmin, the yeast maintained a high level of Fet3 that was released from membranes of yeast not harboring the ceruloplasmin gene. This indicates that expression of ceruloplasmin induces a state of iron deficiency in yeast because the ferric iron produced in the medium by its ferroxidase activity is not available for the uptake.	Univ Roma Tre, Dept Biol, I-00146 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy	Roma Tre University; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Bielli, P (corresponding author), Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, Dr Bohrgasse 9-4, A-1030 Vienna, Austria.	pamela@gem.univie.ac.at	Bielli, Pamela/K-1208-2018	Bielli, Pamela/0000-0003-3347-8345; BELLENCHI, GIANCARLO/0000-0002-9302-0021				AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Bianchini A, 1999, J BIOL CHEM, V274, P20265, DOI 10.1074/jbc.274.29.20265; Blackburn NJ, 2000, BIOCHEMISTRY-US, V39, P2316, DOI 10.1021/bi992334a; Bonomi F, 1996, J BIOL INORG CHEM, V1, P67, DOI 10.1007/s007750050024; Calabrese L., 1997, MULTICOPPER OXIDASES, P307; CANTERS GW, 1993, FEBS LETT, V325, P39, DOI 10.1016/0014-5793(93)81410-2; Cha MK, 1999, BIOCHEMISTRY-US, V38, P12104, DOI 10.1021/bi990444b; CHIDAMBARAM MV, 1983, FEBS LETT, V159, P137, DOI 10.1016/0014-5793(83)80432-3; deSilva D, 1997, J BIOL CHEM, V272, P14208, DOI 10.1074/jbc.272.22.14208; di Patti MCB, 1999, ARCH BIOCHEM BIOPHYS, V372, P295, DOI 10.1006/abbi.1999.1493; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Farver O, 1999, J BIOL CHEM, V274, P26135, DOI 10.1074/jbc.274.37.26135; FRIEDEN E, 1976, ADV ENZYMOL RAMB, V44, P187; Gitlin JD, 1998, PEDIATR RES, V44, P271, DOI 10.1203/00006450-199809000-00001; GUTTERIDGE JMC, 1983, FEBS LETT, V157, P37, DOI 10.1016/0014-5793(83)81111-9; Hall JF, 1999, BIOCHEMISTRY-US, V38, P12675, DOI 10.1021/bi990983g; Harris E D, 1993, Prog Clin Biol Res, V380, P163; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Libeu CAP, 1997, BIOCHEMISTRY-US, V36, P13160, DOI 10.1021/bi9704111; Lindley PF, 1997, J BIOL INORG CHEM, V2, P454, DOI 10.1007/s007750050156; Machonkin TE, 1998, BIOCHEMISTRY-US, V37, P9570, DOI 10.1021/bi980434v; MALMSTROM BG, 1982, ANNU REV BIOCHEM, V51, P21, DOI 10.1146/annurev.bi.51.070182.000321; Malmstrom BG, 1998, CURR OPIN CHEM BIOL, V2, P286, DOI 10.1016/S1367-5931(98)80071-9; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Miyajima H, 1996, FREE RADICAL BIO MED, V20, P757, DOI 10.1016/0891-5849(95)02178-7; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; MUSCI G, 1993, J BIOL CHEM, V268, P13388; MUSCI G, 1990, ARCH BIOCHEM BIOPHYS, V279, P8, DOI 10.1016/0003-9861(90)90455-8; Musci G, 1999, ADV EXP MED BIOL, V448, P175; MUSCI G, 1993, ARCH BIOCHEM BIOPHYS, V306, P111, DOI 10.1006/abbi.1993.1487; Musci G, 1999, J BIOL INORG CHEM, V4, P441, DOI 10.1007/s007750050330; MUSCI G, 1995, J PROTEIN CHEM, V14, P611, DOI 10.1007/BF01886887; Olsson MHM, 1999, J BIOL INORG CHEM, V4, P654, DOI 10.1007/s007750050389; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; OSAKI S, 1966, J BIOL CHEM, V241, P5053; OSAKI S, 1966, J BIOL CHEM, V241, P2746; Rafiq M, 1997, FEBS LETT, V407, P132, DOI 10.1016/S0014-5793(97)00325-6; ROMERO A, 1993, J MOL BIOL, V229, P1007, DOI 10.1006/jmbi.1993.1101; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SATO M, 1991, J BIOL CHEM, V266, P5128; Shimizu A, 1999, BIOCHEMISTRY-US, V38, P3034, DOI 10.1021/bi9819531; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; SWAIN J, 1995, FEBS LETT, V368, P513, DOI 10.1016/0014-5793(95)00726-P; Wittung-Stafshede P, 1998, J BIOL INORG CHEM, V3, P367, DOI 10.1007/s007750050246; Xu F, 1999, J BIOL CHEM, V274, P12372, DOI 10.1074/jbc.274.18.12372; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zaitsev VN, 1999, J BIOL INORG CHEM, V4, P579, DOI 10.1007/s007750050380; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	55	19	20	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2678	2685		10.1074/jbc.M007176200	http://dx.doi.org/10.1074/jbc.M007176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042176	hybrid			2022-12-27	WOS:000166784800053
J	Kumar, A; Eby, MT; Sinha, S; Jasmin, A; Chaudhary, PM				Kumar, A; Eby, MT; Sinha, S; Jasmin, A; Chaudhary, PM			The ectodermal dysplasia receptor activates the nuclear factor-kappa B, JNK, and cell death pathways and binds to ectodysplasin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE; EDA GENE; APOPTOSIS; DOMAIN; HOMOLOG; INDUCTION; MEMBRANE; ALPHA; BETA	The ectodermal dysplasia receptor (EDAR) is a recently isolated member of the tumor necrosis factor receptor family that has been shown to play a key role in the process of ectodermal differentiation. We present evidence that EDAR is capable of activating the nuclear factor-kappaB, JNK and caspase-independent cell death pathways and that these activities are impaired in mutants lacking its death domain or those associated with anhidrotic ectodermal dysplasia and the downless phenotype, Although EDAR possesses a death domain, it did not interact with the death domain-containing adaptor proteins TRADD and FADD, EDAR successfully interacted with various TRAP family members; however, a dominant-negative mutant of TRAF2 was incapable of blocking EDAR-induced nuclear factor-kappaB or JNK activation. Collectively, the above results suggest that EDAR utilizes a novel signal transduction pathway. Finally, ectodysplasin A can physically interact with the extracellular domain of EDAR and thus represents its biological ligand.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Chaudhary, Preet/E-1970-2018; Kumar, Arvind/B-6094-2009		NIAMS NIH HHS [P30 AR41940-09] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1996, ONCOGENE, V12, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Ezer S, 1997, HUM MOL GENET, V6, P1581, DOI 10.1093/hmg/6.9.1581; Ezer S, 1999, HUM MOL GENET, V8, P2079, DOI 10.1093/hmg/8.11.2079; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Ferguson BM, 1997, HUM MOL GENET, V6, P1589, DOI 10.1093/hmg/6.9.1589; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Frade JM, 1996, NATURE, V383, P166; Freire-Maia N, 1984, ECTODERMAL DYSPLASIA; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Kojima T, 2000, J BIOL CHEM, V275, P20742, DOI 10.1074/jbc.M002691200; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	47	136	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2668	2677		10.1074/jbc.M008356200	http://dx.doi.org/10.1074/jbc.M008356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035039	hybrid			2022-12-27	WOS:000166784800052
J	Vargo, MA; Colman, RF				Vargo, MA; Colman, RF			Affinity labeling of rat glutathione S-transferase isozyme 1-1 by 17 beta-iodoacetoxy-estradiol-3-sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; BINDING SITE; ACTIVE-SITE; COMPLEX; EVOLUTION; ACID; DRUG	Rat liver glutathione S-transferase, isozyme 1-1, catalyzes the glutathione dependent isomerization of Delta (5)-androstene-3,17-dione and also binds steroid sulfates at a nonsubstrate inhibitory steroid site. 17 beta -dodoacetoxyestradiol-3-sulfate, a reactive steroid analogue, produces a time-dependent inactivation of this glutathione S-transferase to a limit of 60% residual activity. The rate constant for inactivation (k(obs)) exhibits a nonlinear dependence on reagent concentration with K-I = 71 muM and k(max) = 0.0133 min(-1), Complete protection against inactivation is provided by 17 beta -estradiol-3,17-disulfate, whereas Delta (5)-androstene-3,17-dione and S-methylglutathhione have little effect on k(obs). These results indicate that 17 beta -iodoacetoxy-estradiol-3-sulfate reacts as an affinity label of the nonsubstrate steroid site rather than of the substrate sites occupied by Delta (5)-androstene-3,17-dione or glutathione. Loss of activity occurs concomitant with incorporation of about I mol C-14-labeled reagent/mol enzyme dimer when the enzyme is maximally inactivated, Isolation of the labeled peptide from the chymotryptic digest shows that Cys(17) is the only enzymic amino acid modified. Covalent modification of Cys(17) by 17 beta -iodoacetoxy-estradiol-3-sulfate on subunit A prevents reaction of the steroid analogue with subunit B, These results and examination of the crystal structure of the enzyme suggest that the interaction between the two subunits of glutathione S-transferase 1-1, and the electrostatic attraction between the 3-sulfate of the reagent and Arg(14) of subunit B, are important in binding steroid sulfates at the nonsubstrate steroid binding site and in determining the specificity of this affinity label.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	rfcolman@chem.udel.edu			NATIONAL CANCER INSTITUTE [R01CA066561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008550] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 66561] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08550] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Barycki JJ, 1997, ARCH BIOCHEM BIOPHYS, V345, P16, DOI 10.1006/abbi.1997.0244; BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLMAN RF, 1997, PROTEIN FUNCTION, P155; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hu LQ, 1997, BIOCHEMISTRY-US, V36, P1635, DOI 10.1021/bi962119j; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; Ji XH, 1997, BIOCHEMISTRY-US, V36, P9690, DOI 10.1021/bi970805s; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; LISTOWSKY I, 1998, STRUCTURE FUNCTION G, P199; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; McHugh TE, 1996, J BIOL CHEM, V271, P27470, DOI 10.1074/jbc.271.44.27470; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; Oakley AJ, 1997, BIOCHEMISTRY-US, V36, P576, DOI 10.1021/bi962316i; Penefsky H S, 1979, Methods Enzymol, V56, P527; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PONS M, 1973, FEBS LETT, V36, P23, DOI 10.1016/0014-5793(73)80328-X; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SCHRAMM VL, 1984, J BIOL CHEM, V259, P714; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Vargo MA, 2000, BIOCHEMISTRY-US, V39, P1544; Wang JB, 1996, PROTEIN SCI, V5, P1032; Wang JB, 2000, J BIOL CHEM, V275, P5493, DOI 10.1074/jbc.275.8.5493; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; Wilchek M, 1977, Methods Enzymol, V46, P153	29	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2031	2036		10.1074/jbc.M008212200	http://dx.doi.org/10.1074/jbc.M008212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11031273	hybrid			2022-12-27	WOS:000166528000053
J	Areida, SK; Reinhardt, DP; Muller, PK; Fietzek, PP; Kowitz, J; Marinkovich, MP; Notbohm, H				Areida, SK; Reinhardt, DP; Muller, PK; Fietzek, PP; Kowitz, J; Marinkovich, MP; Notbohm, H			Properties of the collagen type XVII ectodomain - Evidence for N- to C-terminal triple helix folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLOUS PEMPHIGOID ANTIGEN; MOLECULAR RECOGNITION; CYTOPLASMIC DOMAIN; BP180 ECTODOMAIN; TRIMER FORMATION; PROCOLLAGEN; HEMIDESMOSOMES; PROTEIN; CELLS; CLEAVAGE	Collagen XVII is a transmembrane component of hemidesmosomal cells with important functions in epithelial-basement membrane interactions. Here we report on properties of the extracellular ectodomain of collagen XVII, which harbors multiple collagenous stretches. We have recombinantly produced subdomains of the collagen XVII ectodomain in a mammalian expression system. rColXVII-A spans the entire ectodomain from delta NC16a to NC1, rColXVII-B is similar but lacks the NC1 domain, a small N-terminal polypeptide rColXVII-C encompasses domains delta NC16a to C15, and a small C-terminal polypeptide rColXVII-D comprises domains NC6 to NC1, Amino acid analysis of rColXVII-A and -C demonstrated prolyl and lysyl hydroxylation with ratios for hydroxyproline/proline of 0.4 and for hydroxylysine/lysine of 0,5, A small proportion of the hydroxylysyl residues in rColXVII-C (similar to3.3%) was glycosylated. Limited pepsin and trypsin degradation assays and analyses of circular dichroism spectra clearly demonstrated a triple-helical conformation for rColXVII-A, -B, and -C, whereas the C-terminal rColXVII-D did not adopt a triple-helical fold. These results were further substantiated by electron microscope analyses, which revealed extended molecules for rColXVII-A and -C, whereas rColXVII-D appeared globular, Thermal denaturation experiments revealed melting temperatures of 41 degreesC (rCol/XVII-A), 39 degreesC (rColXVII-B), and 35 degreesC (rColXVII-C), In summary, our data suggest that triple helix formation in the ectodomain of ColXVII occurs with an N- to C-terminal directionality.	Med Univ Lubeck, Inst Mol Sci Med, D-23538 Lubeck, Germany; Vet Affairs Palo Alto Hlth Care Syst, Dermatol Serv, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Univ Rostock, Orthopad Klin, D-18057 Rostock, Germany	University of Lubeck; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of Rostock	Notbohm, H (corresponding author), Med Univ Lubeck, Inst Mol Sci Med, Ratzeburger Allee 160, D-23538 Lubeck, Germany.		Reinhardt, Dieter P/A-3102-2008	Reinhardt, Dieter P/0000-0001-6535-9872	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044012] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR 44012] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balding SD, 1997, BIOCHEMISTRY-US, V36, P8821, DOI 10.1021/bi970675n; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; Borradori L, 1997, J CELL BIOL, V136, P1333, DOI 10.1083/jcb.136.6.1333; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BRUCKNERTUDERMA.L, 2000, CONNECTIVE TISSUE IT; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FIETZEK PP, 1972, EUR J BIOCHEM, V30, P163, DOI 10.1111/j.1432-1033.1972.tb02083.x; GIUDICE GJ, 1993, J IMMUNOL, V151, P5742; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Hirako Y, 1998, J BIOL CHEM, V273, P9711, DOI 10.1074/jbc.273.16.9711; Hirako Y, 1996, J BIOL CHEM, V271, P13739, DOI 10.1074/jbc.271.23.13739; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAZZORANA M, 1995, MATRIX BIOL, V14, P583, DOI 10.1016/S0945-053X(05)80007-1; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; OLSEN BR, 1976, ARCH BIOCHEM BIOPHYS, V175, P341, DOI 10.1016/0003-9861(76)90516-6; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Schumann H, 2000, AM J PATHOL, V156, P685, DOI 10.1016/S0002-9440(10)64772-4; Tasanen K, 2000, J BIOL CHEM, V275, P3093, DOI 10.1074/jbc.275.5.3093	28	51	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1594	1601		10.1074/jbc.M008709200	http://dx.doi.org/10.1074/jbc.M008709200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042218	hybrid			2022-12-27	WOS:000166430900098
J	Bonicalzi, ME; Groulx, I; de Paulsen, N; Lee, S				Bonicalzi, ME; Groulx, I; de Paulsen, N; Lee, S			Role of exon 2-encoded beta-domain of the von Hippel-Lindau tumor suppressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27(KIP1); INDUCIBLE FACTOR 1-ALPHA; UBIQUITIN-LIKE PROTEIN; GENE-PRODUCT; NUCLEOCYTOPLASMIC TRANSPORT; RENAL-CARCINOMA; NUCLEAR EXPORT; MESSENGER-RNA; HUMAN TISSUES; GROWTH-FACTOR	Sporadic clear cell renal carcinomas frequently harbor inactivating mutations in exon 2 of the von Hippel-Lindau (VHL) tumor suppressor gene. Here, we examine the effect of the loss of exon 2-encoded beta -domain function on VHL biochemical properties. Exon 2-encoded residues are required for VHL-mediated NEDD8 conjugation on cullin-2 and assembly with hypoxia-inducible factor alpha (HIF alpha) and fibronectin. These residues are not essential for VHL ability to assemble with elongin BC/cullin-2, to display E3 ubiquitin ligase activity in vitro and to confer energy-dependent nuclear import properties to a reporter protein. Localization studies in)HIF-1 alpha -null embryonic cells suggest that exon 2-encoded beta -domain mediates transcription-dependent nuclear/cytoplasmic shuttling of VHL independently of assembly with HIF-1 alpha and oxygen concentration. Exon 2-encoded alpha -helical domain is required for VHL complex formation with BC/cullin-2 and E3 ubiquitin ligase activity, for binding to HIF alpha /fibronectin, but this domain is not essential for transcription-dependent nuclear/cytoplasmic trafficking. VHL-/- renal carcinoma cells expressing beta -domain mutants failed to produce an extracellular fibronectin matrix and to degrade HIF alpha which accumulated exclusively in the nucleus of normorric cells. These results demonstrate that exon 2-encoded residues are involved in two independent functions: substrate protein recognition and transcription-dependent nuclear/cytoplasmic trafficking. They also suggest that beta -domain mutations inactivate VHL function differently than alpha -domain mutations, potentially providing an explanation for the relationship between different mutations of the VHL gene and clinical outcome.	Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Kidney Res Ctr, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Lee, S (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	slee@uottawa.ca						Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Chen LN, 1996, SOMAT CELL MOLEC GEN, V22, P477, DOI 10.1007/BF02369439; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Groulx I, 2000, J BIOL CHEM, V275, P8991, DOI 10.1074/jbc.275.12.8991; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; KISHIDA T, 1995, CANCER RES, V55, P4544; Knebelmann B, 1998, CANCER RES, V58, P226; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Los M, 1996, LAB INVEST, V75, P231; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Ryan HE, 2000, CANCER RES, V60, P4010; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Scheffner M, 1999, NATURE, V398, P103, DOI 10.1038/18105; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Siemeister G, 1996, CANCER RES, V56, P2299; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsuchiya H, 1996, CANCER RES, V56, P2881; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	52	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1407	1416		10.1074/jbc.M008295200	http://dx.doi.org/10.1074/jbc.M008295200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11024059	hybrid			2022-12-27	WOS:000166430900074
J	Galan, A; Sot, B; Llorca, O; Carrascosa, JL; Valpuesta, JM; Muga, A				Galan, A; Sot, B; Llorca, O; Carrascosa, JL; Valpuesta, JM; Muga, A			Excluded volume effects on the refolding and assembly of an oligomeric protein - GroEL, a case study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; CHAPERONIN GROEL; MACROMOLECULAR STRUCTURE; MOLECULAR CHAPERONE; SELF-ASSOCIATION; LOW-TEMPERATURE; IN-VITRO; CYTOPLASM	We have studied the effect of macromolecular crowding reagents, such as polysaccharides and bovine serum albumin, on the refolding of tetradecameric GroEL from urea-denatured protein monomers, The results show that productive refolding and assembly strongly depends on the presence of nucleotides (ATP or ADP) and background macromolecules. Nucleotides are required to generate an assembly-competent monomeric conformation, suggesting that proper folding of the equatorial domain of the protein subunits into a native-like structure is essential for productive assembly. Crowding modulates GroEL oligomerization in two different ways. First, it increases the tendency of refolded, monomeric GroEL to undergo self-association at equilibrium. Second, crowding can modify the relative rates of the two competing self-association reactions, namely, productive assembly into a native tetradecameric structure and unproductive aggregation, This kinetic effect is most likely exerted by modifications of the diffusion coefficient of the refolded monomers, which in turn determine the conformational properties of the interacting subunits, If they are allowed to become assembly-competent before self-association, productive oligomerization occurs; otherwise, unproductive aggregation takes place. Our data demonstrate that the spontaneous refolding and assembly of homo-oligomeric proteins, such as GroEL, can occur efficiently (70%) under crowding conditions similar to those expected in vivo.	Univ Basque Country, Consejo Super Invest Cientificas, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Muga, A (corresponding author), Univ Basque Country, Consejo Super Invest Cientificas, Unidad Biofis, E-48080 Bilbao, Spain.	gbpmuvia@lg.ehu.es	Sot, Begoña/H-2882-2015; Llorca, Oscar/P-2784-2019; Llorca, Oscar/K-1144-2014; Valpuesta, José M/T-1977-2017; Valpuesta, Jose M/AAA-6002-2019; Muga, Arturo/N-1174-2014	Sot, Begoña/0000-0001-8763-0651; Llorca, Oscar/0000-0001-5705-0699; Llorca, Oscar/0000-0001-5705-0699; Valpuesta, José M/0000-0001-7468-8053; Muga, Arturo/0000-0003-0345-6882				ARRONDO JLR, 1994, BIOCHEMISTRY-US, V33, P11650, DOI 10.1021/bi00204a029; BELNNOW A, 1995, BIOCHIM BIOPHYS ACTA, V1252, P68; BRAIG K, 1994, NATURE, V37, P1578; BURNETT BP, 1994, J BACTERIOL, V176, P6980, DOI 10.1128/JB.176.22.6980-6985.1994; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Chen JW, 2000, BIOCHEMISTRY-US, V39, P4250, DOI 10.1021/bi992619n; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; ELLIS RJ, 1997, CURR BIOL, V7, P531; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FABIAN H, 1995, BIOCHEMISTRY-US, V34, P13651, DOI 10.1021/bi00041a046; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Galan A, 1999, EUR J BIOCHEM, V259, P347, DOI 10.1046/j.1432-1327.1999.00045.x; Golbik R, 1998, J MOL BIOL, V276, P505, DOI 10.1006/jmbi.1997.1538; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; Kumar S, 2000, PROTEIN SCI, V9, P10; LINDNER R, 1995, BIOPHYS CHEM, V57, P15, DOI 10.1016/0301-4622(95)00063-4; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; Llorca O, 1998, J BIOL CHEM, V273, P32587, DOI 10.1074/jbc.273.49.32587; Llorca O, 1997, J BIOL CHEM, V272, P32925, DOI 10.1074/jbc.272.52.32925; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Llorca O, 1997, J STRUCT BIOL, V118, P31, DOI 10.1006/jsbi.1996.3832; LUBYPHELPS K, 1994, CURR OPIN CELL BIOL, V6, P3, DOI 10.1016/0955-0674(94)90109-0; LUBYPHELPS K, 1987, P NATL ACAD SCI USA, V84, P4910, DOI 10.1073/pnas.84.14.4910; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1995, BBA-PROTEIN STRUCT M, V1247, P209, DOI 10.1016/0167-4838(94)00231-5; MENDOZA JA, 1994, J BIOL CHEM, V269, P25963; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; Minton AP, 1997, CURR OPIN BIOTECH, V8, P65, DOI 10.1016/S0958-1669(97)80159-0; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; MINTON AP, 1981, BIOPOLYMERS, V20, P2093, DOI 10.1002/bip.1981.360201006; Minton AP, 2000, CURR BIOL, V10, pR97, DOI 10.1016/S0960-9822(00)00301-8; MINTON AP, 1992, BIOPHYS J, V63, P1090, DOI 10.1016/S0006-3495(92)81663-6; MINTON KW, 1982, P NATL ACAD SCI-BIOL, V79, P7107, DOI 10.1073/pnas.79.23.7107; MUGA A, 1991, BIOCHEMISTRY-US, V30, P2629, DOI 10.1021/bi00224a010; Rivas G, 1999, BIOCHEMISTRY-US, V38, P9379, DOI 10.1021/bi990355z; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Surin AK, 1997, FEBS LETT, V405, P260, DOI 10.1016/S0014-5793(97)00199-3; TIMASHEFF SN, 1998, PROTEIN STRUCTURE PR, P331; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Todd MJ, 1998, METHOD ENZYMOL, V290, P135, DOI 10.1016/S0076-6879(98)90012-X; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; WHITE ZW, 1995, J BIOL CHEM, V270, P20404, DOI 10.1074/jbc.270.35.20404; YBARRA J, 1995, J BIOL CHEM, V270, P22113, DOI 10.1074/jbc.270.38.22113; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	54	42	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					957	964		10.1074/jbc.M006861200	http://dx.doi.org/10.1074/jbc.M006861200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11020386	hybrid			2022-12-27	WOS:000166430900015
J	Dwyer, TM; Rao, KS; Westover, JB; Kim, JJP; Frerman, FE				Dwyer, TM; Rao, KS; Westover, JB; Kim, JJP; Frerman, FE			The function of Arg-94 in the oxidation and decarboxylation of glutaryl-CoA by human glutaryl-CoA dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE ACTIVE-SITE; COENZYME-A DEHYDROGENASE; ARACHIDONIC-ACID; PIG-KIDNEY; ACYL; INHIBITORS; MECHANISM; SUBSTRATE; LIVER; ARGININE-120	Glutaryl-CoA dehydrogenase catalyzes the oxidation and decarboxylation of glutaryl-CoA to crotonyl-CoA and CO2. Inherited defects in the protein cause glutaric acidemia type I, a fatal neurologic disease. Glutaryl-CoA dehydrogenase is the only member of the acyl-CoA dehydrogenase family with a cationic residue, Arg-94, situated in the binding site of the acyl moiety of the substrate. Crystallographic investigations suggest that Argc94 is within hydrogen bonding distance of the gamma -carboxylate of glutaryl-CoA Substitution of Arg-94 by glycine, a disease-causing mutation, and by glutamine, which is sterically more closely related to arginine, reduced K-cat of the mutant dehydrogenases to 2-3% of k(ca)t of the wild type enzyme. K-m of these mutant dehydrogenases for glutaryl-CoA increases 10- to 16-fold. The steady-state kinetic constants of alternative substrates, hexanoyl-CoA and glutaramyl-CoA, which are not decarboxylated, are modestly affected by the mutations. The latter changes are probably due to steric and polar effects. The dissociation constants of the non-oxidizable substrate analogs, 3-thiaglutaryl-CoA and acetoacetyl-CoA, are not altered by the mutations. However, abstraction of a cy-proton from 3-thiaglutaryl-CoA, to yield a charge transfer complex with the oxidized flavin, is severely limited. In contrast, abstraction of the alpha -proton of acetoacetyl-CoA by Arg-94 --> Gin mutant dehydrogenase is unaffected, and the resulting enolate forms a charge transfer complex with the oxidized flavin, These experiments indicate that Arg-94 does not make a major contribution to glutaryl-CoA binding. However, the electric field of Arg-94 may stabilize the dianions resulting from abstraction of the alpha -proton of glutaryl-CoA and 3-thiaglutaryl-CoA, both of which contain gamma -carbaxylates. It is also possible that Arg-94 may orient glutaryl-CoA and 3-thiaglutaryl-CoA for abstraction of an alpha -proton.	Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Medical College of Wisconsin	Frerman, FE (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pediat, Box C233,4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [GM29076] Funding Source: Medline; NINDS NIH HHS [NS39339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039339] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNERT JT, 1977, J BIOL CHEM, V252, P6736; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BYRON CM, 1990, BIOCHEMISTRY-US, V29, P3691, DOI 10.1021/bi00467a015; Dwyer TM, 2000, BIOCHEMISTRY-US, V39, P11488, DOI 10.1021/bi000700g; FRERMAN FE, 1980, J BIOL CHEM, V255, P2195; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; Garavito RM, 1999, BBA-MOL CELL BIOL L, V1441, P278, DOI 10.1016/S1388-1981(99)00147-X; GATENBY AA, 1992, PLANT MOL BIOL, V19, P677, DOI 10.1007/BF00026793; GHISLA S, 1997, FLAVINS FLAVOPROTEIN, P629; GOMES B, 1981, BIOCHEMISTRY-US, V20, P1481, DOI 10.1021/bi00509a012; GOODMAN SI, 1995, HUM MOL GENET, V4, P1493; Goodman SI, 1998, HUM MUTAT, V12, P141, DOI 10.1002/(SICI)1098-1004(1998)12:3<141::AID-HUMU1>3.0.CO;2-K; GOODMAN SI, 1995, METABOLIC MOL BASIS, V1, P1451; JEFFERY GH, 1934, J CHEM SOC, P101; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KIM JJP, 1999, FLAVINS FLAVOPROTEIN, P539; KUMAR NR, 1997, FLAVINS FLAVOPROTEIN, P633; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAU SM, 1986, BIOCHEMISTRY-US, V25, P4184, DOI 10.1021/bi00363a003; LAU SM, 1988, BIOCHEMISTRY-US, V27, P5089, DOI 10.1021/bi00414a021; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LENICH AC, 1986, J BIOL CHEM, V261, P4090; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; MARQUEZ VE, 1980, J ORG CHEM, V45, P5308, DOI 10.1021/jo01314a018; MCKEAN MC, 1983, J BIOL CHEM, V258, P1866; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Tamaoki H, 1999, J BIOCHEM, V125, P285, DOI 10.1093/oxfordjournals.jbchem.a022285; Telford EAR, 1999, BBA-GENE STRUCT EXPR, V1446, P371, DOI 10.1016/S0167-4781(99)00102-5; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; Vock P, 1998, BIOCHEMISTRY-US, V37, P1848, DOI 10.1021/bi971827h; Zschocke J, 2000, J MED GENET, V37, P177, DOI 10.1136/jmg.37.3.177	33	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					133	138		10.1074/jbc.M007672200	http://dx.doi.org/10.1074/jbc.M007672200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024031	hybrid			2022-12-27	WOS:000166280700019
J	Krnajski, Z; Gilberger, TW; Walter, RD; Muller, S				Krnajski, Z; Gilberger, TW; Walter, RD; Muller, S			Intersubunit interactions in Plasmodium falciparum thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI GLUTATHIONE-REDUCTASE; MERCURIC ION REDUCTASE; ENGINEERING SURFACE-CHARGE; ESCHERICHIA-COLI; ACTIVE-SITE; NADH OXIDASE; SELENOCYSTEINE; MECHANISM; CATALYSIS; SEQUENCE	The thioredoxin redox system is composed of the NADPH-dependent homodimeric flavoprotein thioredoxin reductase (TrxR) and the 12-kDa protein thioredoxin, It is responsible for the reduction of disulfide bridges in proteins such as ribonucleotide reductase and several transcription factors. Furthermore, thioredoxin is involved in the detoxification of hydrogen peroxide and protects the cell against oxidative damage. There exist two classes of TrxRs: the high M-r and the low IM,proteins, The well characterized Escherichia coli TrxR represents a member of the low IM, class of proteins, whereas the mammalian, Caenorhabditis elegans, and Plasmodium falciparum proteins belong to the family of high M-r proteins. The primary structure of these proteins is very similar to that of glutathione reductase and lipoamide dehydrogenase. However, the high M-r TrxRs possess, in addition to their redox active N-terminal pair of cysteines, a pair of cysteine residues or a selenenylsulfide; motif at their C terminus. These residues have been shown to be crucial for the reduction of thioredoxin, In this study we address the question whether the active site residues of P, falciparum TrxR are provided by one or both subunits. Differentially tagged wild-type and PfTrxR mutants were co-expressed in E, coli and the recombinant protein species were purified by affinity chromatography specific for the respective tags of the recombinant proteins. Co-expression of PfTrxR wild-type and mutant proteins resulted in the formation of three different protein species: homodimeric PfTrxR wild-type proteins, homodimeric mutant proteins, and heterodimers composed of one PfTrxR wild-type subunit and one PfTrxR mutant subunit. Go-expression of the double mutant PfTrxRC88AC535A with PfTxR wild-type generated an inactive heterodimer, which indicates that PfTrxR possesses intersubunit active sites. In addition, the data presented possibly imply a coopertive interaction between both active sites of PfTrxR.	Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin	Muller, S (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Dundee DDE1 5EH, Scotland.			Gilberger, Tim-Wolf/0000-0002-7965-8272				Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buettner C, 1999, J BIOL CHEM, V274, P21598, DOI 10.1074/jbc.274.31.21598; DEONARAIN MP, 1992, BIOCHEMISTRY-US, V31, P1491, DOI 10.1021/bi00120a028; DEONARAIN MP, 1992, BIOCHEMISTRY-US, V31, P1498, DOI 10.1021/bi00120a029; DISTEFANO MD, 1990, BIOCHEMISTRY-US, V29, P2703, DOI 10.1021/bi00463a013; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gilberger TW, 1997, J BIOL CHEM, V272, P29584, DOI 10.1074/jbc.272.47.29584; Gilberger TW, 1998, FEBS LETT, V425, P407, DOI 10.1016/S0014-5793(98)00270-1; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Luba J, 1999, BIOCHEMISTRY-US, V38, P2725, DOI 10.1021/bi9825899; Mallett TC, 1998, BIOCHEMISTRY-US, V37, P8790, DOI 10.1021/bi9803630; Mallett TC, 1999, BIOCHEMISTRY-US, V38, P3000, DOI 10.1021/bi9817717; MILLER SM, 1991, BIOCHEMISTRY-US, V30, P2600, DOI 10.1021/bi00224a006; MOORE MJ, 1992, BIOCHEMISTRY-US, V31, P1677, DOI 10.1021/bi00121a015; MOORE MJ, 1989, BIOCHEMISTRY-US, V28, P1183, DOI 10.1021/bi00429a036; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; NORDHOFF A, 1993, BIOCHEMISTRY-US, V32, P4060, DOI 10.1021/bi00066a029; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; Sambrook J., 2002, MOL CLONING LAB MANU; SCRUTTON NS, 1990, P ROY SOC B-BIOL SCI, V242, P217, DOI 10.1098/rspb.1990.0127; THIEME R, 1981, J MOL BIOL, V152, P763, DOI 10.1016/0022-2836(81)90126-1; Wang PF, 1999, BIOCHEMISTRY-US, V38, P3187, DOI 10.1021/bi982674g; WANG PF, 1999, FLAVINS FLAVOPROTEIN, P695; WILLIAMS CH, 1995, FASEB J, V9, P1267, DOI 10.1096/fasebj.9.13.7557016; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	30	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40874	40878		10.1074/jbc.M008443200	http://dx.doi.org/10.1074/jbc.M008443200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11022050	hybrid			2022-12-27	WOS:000166114600029
J	Tachiki, H; Kato, R; Kuramitsu, S				Tachiki, H; Kato, R; Kuramitsu, S			DNA binding and protein-protein interaction sites in MutS, a mismatched DNA recognition protein from Thermus thermophilus HB8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ATPASE ACTIVITY; ASPARTATE-AMINOTRANSFERASE; TRANSLOCATION MECHANISM; HETERODUPLEX DNA; REPAIR PROTEIN; HMUTS-ALPHA; BACTERIUM; HETERODIMER; CELLS	The mismatch repair system repairs mismatched base pairs, which are caused by either DNA replication errors, DNA damage, or genetic recombination. Mismatch repair begins with the recognition of mismatched base pairs in DNA by MutS. Protein denaturation and limited proteolysis experiments suggest that Thermus thermophilus MutS can be divided into three structural domains as follows: A (N-terminal domain), B (central domain), and C (C-terminal domain) (Tachiki, H., Kato, R., Masui, R., Hasegawa, K., Itakura, H., Fukuyama, K., and Kuramitsu, S, (1998) Nucleic Acids Res. 26, 4153-4159). To investigate the functions of each domain in detail, truncated genes corresponding to the domains were designed. The gene products were overproduced in Escherichia coli, purified, and assayed for various activities. The MutS-MutS protein interaction site was determined by size-exclusion chromatography to be located in the B domain. The B domain was also found to possess nonspecific double-stranded DNA-binding ability. The C domain, which contains a Walker's A-type nucleotide-binding motif, demonstrated ATPase activity and specific DNA recognition of mismatched base pairs. These ATPase and specific DNA binding activities were found to be dependent upon C domain dimerization.	Osaka Univ, Dept Biol, Grad Sch Sci, Toyonaka, Osaka 5600043, Japan	Osaka University	Kuramitsu, S (corresponding author), Osaka Univ, Dept Biol, Grad Sch Sci, 1-1 Machikaneyama Cho, Toyonaka, Osaka 5600043, Japan.	kuramitu@bio.sci.osaka-u.ac.jp		Kato, Ryuichi/0000-0003-2087-2896				Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; Biswas I, 1999, J BIOL CHEM, V274, P23673, DOI 10.1074/jbc.274.33.23673; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; CHI NW, 1994, J BIOL CHEM, V269, P29984; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Kaplan W, 1997, PROTEIN SCI, V6, P399; Kato R, 1999, EUR J BIOCHEM, V259, P592, DOI 10.1046/j.1432-1327.1999.00044.x; Kato R, 1997, J BACTERIOL, V179, P6499, DOI 10.1128/jb.179.20.6499-6503.1997; Kato R, 1996, J BIOL CHEM, V271, P9612, DOI 10.1074/jbc.271.16.9612; KEVIN MC, 1997, PLANT PHYSIOL, V115, P833; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Maniatis T., 1989, MOL CLONING LAB MAN; Mikawa T, 1998, NUCLEIC ACIDS RES, V26, P903, DOI 10.1093/nar/26.4.903; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Okamoto A, 1996, J BIOCHEM-TOKYO, V119, P135; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; ROVERT K, 1997, J IMMUNOL METHODS, V200, P121; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Tachiki H, 1998, NUCLEIC ACIDS RES, V26, P4153, DOI 10.1093/nar/26.18.4153; Takamatsu S, 1996, NUCLEIC ACIDS RES, V24, P640, DOI 10.1093/nar/24.4.640; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Whitehouse A, 1997, BIOCHEM BIOPH RES CO, V232, P10, DOI 10.1006/bbrc.1997.6211; Wu TH, 1999, J BIOL CHEM, V274, P5948, DOI 10.1074/jbc.274.9.5948; Yamamoto N, 1996, GENE, V171, P103, DOI 10.1016/0378-1119(96)00052-2	41	13	13	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40703	40709		10.1074/jbc.M007124200	http://dx.doi.org/10.1074/jbc.M007124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024056	hybrid			2022-12-27	WOS:000166114600008
J	Terzano, S; Flora, A; Clementi, F; Fornasari, D				Terzano, S; Flora, A; Clementi, F; Fornasari, D			The minimal promoter of the human alpha(3) nicotinic receptor subunit gene - Molecular and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; RESTRICTIVE SILENCER FACTOR; BOX-BINDING-PROTEINS; DNA-BINDING; NEGATIVE REGULATION; MESSENGER-RNA; SP1; ACTIVATION; EXPRESSION; CLONING	The minimal promoter of the human alpha (3) nicotinic receptor subunit gene has been mapped to a region of 60 base pairs and found to contain two Spl sites, one of which is essential for promoter activity, DNase footprinting has revealed the presence of another region of interaction with nuclear factors (named F2) immediately downstream of the Spl sites. This region has been found to be functional since it is capable of stimulating the minimal promoter. The F2 protection is completely and specifically competed by an AP2 consensus oligonucleotide that has been proved to bind AP2 alpha exclusively. However, the AP2 alpha recombinant protein was unable to bind the F2 region directly, thus suggesting that AP2 alpha may participate in F2 protection by protein-protein interactions with other nuclear factors, The minimal promoter has been shown to be stimulated by two additional regions, one located downstream of F2 and the other upstream of the minimal promoter itself. In neuronal cells, the combined stimulatory activities of these three regions have synergistic effects, whereas in nonneuronal cells, there is a negative interference between the upstream and downstream regions, These opposite transcriptional effects may account for at least part of the neuro-specific expression profile of the alpha (3) gene.	Univ Milan, CNR, Cellular & Mol Pharmacol Ctr, Dept Med Pharmacol, I-20129 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan	Fornasari, D (corresponding author), Univ Milan, CNR, Cellular & Mol Pharmacol Ctr, Dept Med Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.		Flora, Adriano/A-9663-2008	Fornasari, Diego/0000-0002-9668-3103				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; Battaglioli E, 1998, J NEUROCHEM, V71, P1261; BERG DK, 2000, HANDB EXP PHARM, V144, P247; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; BESSIS A, 1995, NEUROSCIENCE, V69, P807, DOI 10.1016/0306-4522(95)00303-Z; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; Campos-Caro A, 1999, J BIOL CHEM, V274, P4693, DOI 10.1074/jbc.274.8.4693; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CIMINO M, 1992, NEUROSCIENCE, V51, P77, DOI 10.1016/0306-4522(92)90472-E; Clementi F., 2000, Neuronal nicotinic receptors, V144, P13, DOI 10.1007/978-3-642-57079-7_2; DENERIS ES, 2000, HANDB EXP PHARM, V144, P57; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FISHER KD, 1993, J BIOL CHEM, V268, P23915; Flora A, 2000, J NEUROCHEM, V75, P18, DOI 10.1046/j.1471-4159.2000.0750018.x; FORNASARI D, 1997, MOL PHARMACOL, V51, P251; FORNASARI D, 1999, NEURONAL NICOTINIC R, P25; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gotti C, 1997, PROG NEUROBIOL, V53, P199, DOI 10.1016/S0301-0082(97)00034-8; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Johnson W, 1997, J BIOL CHEM, V272, P15405, DOI 10.1074/jbc.272.24.15405; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KRADY JK, 1995, MOL CELL BIOL, V15, P524, DOI 10.1128/MCB.15.1.524; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LINDSTROM J, 2000, HANDB EXP PHARM, V144, P101; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; MATTER JM, 2000, HANDB EXP PHARM, V144, P33; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Noti JD, 1996, MOL CELL BIOL, V16, P2940; PARK K, 1993, J BIOL CHEM, V268, P17811; Pena P, 1999, MOL ENDOCRINOL, V13, P1402, DOI 10.1210/me.13.8.1402; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Roztocil T, 1998, J BIOL CHEM, V273, P15131, DOI 10.1074/jbc.273.24.15131; SARGENT PB, 2000, HANDB EXP PHARM, V144, P163; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; Skak K, 1999, GENE, V236, P231, DOI 10.1016/S0378-1119(99)00286-3; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yajima S, 1998, DNA CELL BIOL, V17, P471, DOI 10.1089/dna.1998.17.471; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514	61	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41495	41503		10.1074/jbc.M006197200	http://dx.doi.org/10.1074/jbc.M006197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018033	hybrid			2022-12-27	WOS:000166114600108
J	Yuan, LW; Gambee, JE				Yuan, LW; Gambee, JE			Phosphorylation of p300 at serine 89 by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASES; TRANSCRIPTIONAL COACTIVATOR; MEDIATED TRANSCRIPTION; ESTROGEN-RECEPTOR; ONCOPROTEIN E1A; CELL-CYCLE; CBP; ACETYLATION; ACTIVATION; SEQUENCE	CREB-binding protein (CBP)/p300 plays an important role in the connection of many different signal transduction pathways and the promotion of certain differentiation and proliferation processes. This role depends upon the ability of CBP/p300 to serve as coactivator for transcription factors. It has been suggested that CBP/p300 is regulated by phosphorylation, but the nature of the phosphorylation, the responsible kinase in vivo, and its physiological significance are still unclear. Here, we demonstrate the first identification of an in vivo phosphorylation site, conserved serine 89, in p300. Signal-dependent protein kinase C is able to phosphorylate serine 89 and mediates this phosphorylation event in vivo. Different from other phosphorylation observed so far in CBP/p300, this serine 89-specific phosphorylation represses the transcriptional activity of p300. This phosphorylation-mediated regulation of p300 function represents a previously unrecognized signal transduction pathway for protein kinase C to regulate cell growth and differentiation.	Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Shriners Hosp Children, Prot Struct Facil, Portland, OR 97201 USA	Oregon Health & Science University	Yuan, LW (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.	yuanlw@uswest.net						ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Johnson JE, 1997, J BIOL CHEM, V272, P30787, DOI 10.1074/jbc.272.49.30787; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kung AL, 2000, GENE DEV, V14, P272; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Muraoka M, 1996, ONCOGENE, V12, P1565; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Xu JH, 1997, J CELL BIOL, V136, P473, DOI 10.1083/jcb.136.2.473; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	54	100	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40946	40951		10.1074/jbc.M007832200	http://dx.doi.org/10.1074/jbc.M007832200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11020388	hybrid			2022-12-27	WOS:000166114600039
J	Lamberty, M; Zachary, D; Lanot, R; Bordereau, C; Robert, A; Hoffmann, JA; Bulet, P				Lamberty, M; Zachary, D; Lanot, R; Bordereau, C; Robert, A; Hoffmann, JA; Bulet, P			Insect immunity - Constitutive expression of a cysteine-rich antifungal and a linear antibacterial peptide in a termite insect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSESHOE-CRAB HEMOCYTES; ANTIMICROBIAL PEPTIDES; SEQUENCE HOMOLOGY; AEDES-AEGYPTI; CDNA CLONING; DROSOPHILA; DEFENSIN; INVERTEBRATES; DROSOMYCIN; CECROPIN	Two novel antimicrobial peptides, which we propose to name termicin and spinigerin, have been isolated from the fungus-growing termite Pseudacanthotermes spiniger (heterometabole insect, Isoptera). Termicin is a 36-amino acid residue antifungal peptide, with six cysteines arranged in a disulfide array similar to that of insect defensins. In contrast to most insect defensins, termicin is C-terminally amidated. Spinigerin consists of 25 amino acids and is devoid of cysteines. It is active against bacteria and fungi, Termicin and spinigerin show no obvious sequence similarities with other peptides. Termicin is constitutively present in hemocyte granules and in salivary glands. The presence of termicin and spinigerin in unchallenged termites contrasts with observations in evolutionary recent insects or insects undergoing complete metamorphosis, in which antimicrobial peptides are induced in the fat body and released into the hemolymph after septic injury.	CNRS, Inst Biol Mol & Cellulaire, Unite Propre Rech 9022, F-67084 Strasbourg, France; Univ Bourgogne, Zool Lab, CNRS, Unite Mixte Rech 5548, F-21000 Dijon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne	Bulet, P (corresponding author), CNRS, Inst Biol Mol & Cellulaire, Unite Propre Rech 9022, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	P.Bulet@ibmc.u-strasbg.fr	BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; Ekengren S, 1999, INSECT BIOCHEM MOLEC, V29, P965, DOI 10.1016/S0965-1748(99)00071-5; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; Ferrandon D, 1998, EMBO J, V17, P1217, DOI 10.1093/emboj/17.5.1217; HAN SH, 1992, SOCIOBIOLOGY, V20, P219; Hetru C, 1997, Methods Mol Biol, V78, P35; Hetru Charles, 1998, P40; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; Lowenberger C, 1999, J BIOL CHEM, V274, P20092, DOI 10.1074/jbc.274.29.20092; LOWENBERGER C, 1995, INSECT BIOCHEM MOLEC, V25, P867, DOI 10.1016/0965-1748(95)00043-U; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; Michaut L, 1996, FEBS LETT, V395, P6, DOI 10.1016/0014-5793(96)00992-1; Mitta G, 1999, J CELL SCI, V112, P4233; Mitta G, 1999, EUR J BIOCHEM, V265, P71, DOI 10.1046/j.1432-1327.1999.00654.x; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; Qiu P, 1998, DEVELOPMENT, V125, P1909; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SHIGENAGA T, 1990, J BIOL CHEM, V265, P21350; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; UttenweilerJoseph S, 1997, ANAL BIOCHEM, V247, P366, DOI 10.1006/abio.1997.2083; YAMADA K, 1993, BIOCHEM J, V291, P275, DOI 10.1042/bj2910275	32	204	252	4	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4085	4092		10.1074/jbc.M002998200	http://dx.doi.org/10.1074/jbc.M002998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053427	hybrid, Green Published			2022-12-27	WOS:000166921200049
J	Ohgami, N; Nagai, R; Ikemoto, M; Arai, H; Kuniyasu, A; Horiuchi, S; Nakayama, H				Ohgami, N; Nagai, R; Ikemoto, M; Arai, H; Kuniyasu, A; Horiuchi, S; Nakayama, H			CD36, a member of the class B scavenger receptor family, as a receptor for advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEMODIALYSIS-ASSOCIATED AMYLOIDOSIS; HUMAN ATHEROSCLEROTIC LESIONS; HUMAN MONOCYTE CHEMOTAXIS; GLUCOSE-MODIFIED PROTEINS; NECROSIS-FACTOR-ALPHA; GLYCOPROTEIN-IV CD36; INDUCED DIABETIC RAT; ADVANCED GLYCOSYLATION; IMMUNOCHEMICAL DETECTION	Interaction of advanced glycation end products (AGE) with AGE receptors induces several cellular phenomena potentially relating to diabetic complications. Five AGE receptors identified so far are RAGE (receptor for AGE), galectin-3, 80K-H, OST-48, and SRA (macrophage Scavenger receptor class A types I and II). Since SRA is known to belong to the class A scavenger receptor family, and the scavenger receptor collectively represents a family of multiligand lipoprotein receptors, it is possible that CD36, although belonging to the class B scavenger receptor family, can recognize AGE proteins as ligands. This was tested at the cellular level in this study using Chinese hamster ovary (CHO) cells overexpressing hu man CD36 (CD36-CHO cells). Cellular expression of CD36 was confirmed by immunoblotting and immunofluorescent microscopy using anti-CD36 antibody; Upon incubation at 37 degreesC, I-125-AGE-bovine serum albumin (AGE-BSA) and I-125-oxidized low density lipoprotein (LDL), an authentic ligand for CD36, were endocytosed in a dose-dependent fashion and underwent lysosomal degradation by CD36-CHO cells, but not wildtype CHO cells. In binding experiments at 4 degreesC, I-125-AGE-BSA exhibited specific and saturable binding to CD36-CHO cells (K-d = 5.6 mug/ml). The endocytic uptake of I-125-AGE-BSA by these cells was inhibited by 50% by oxidized LDL and by 60% by FA6-152, an anti-CD36 antibody inhibiting cellular binding of oxidized LDL. Our results indicate that CD36 expressed by these cells mediates the endocytic uptake and subsequent intracellular degradation of AGE proteins. Since CD36 is one of the major oxidized LDL receptors and is up-regulated in macrophage- and smooth muscle cell-derived foam cells in human atherosclerotic lesions, these results suggest that, like oxidized LDL, AGE proteins generated in situ are recognized by CD36, which might contribute to the pathogenesis of diabetic macrovascular complications.	Kumamoto Univ, Sch Med, Dept Biochem, Kumamoto 8600811, Japan; Kumamoto Univ, Fac Pharmaceut Sci, Dept Biofunct Chem, Kumamoto 8620973, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Lab Cellular Biochem, Wako, Saitama 3510198, Japan	Kumamoto University; Kumamoto University; University of Tokyo; RIKEN	Horiuchi, S (corresponding author), Kumamoto Univ, Sch Med, Dept Biochem, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Ohgami, Nobutaka/I-4572-2014					Abumrad N, 1999, BBA-MOL CELL BIOL L, V1441, P4, DOI 10.1016/S1388-1981(99)00137-7; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; ARAKI N, 1992, J BIOL CHEM, V267, P10211; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Calvo D, 1998, J LIPID RES, V39, P777; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; DOI T, 1993, J BIOL CHEM, V268, P2126; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Finot P. A., 1982, Advances in Chemistry Series, V198, P91; Gotoda T, 1999, NAT GENET, V22, P226, DOI 10.1038/10285; GREENWALT DE, 1992, BLOOD, V80, P1105; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Huh HY, 1996, BLOOD, V87, P2020; Iwashima Y, 1999, BIOCHEM BIOPH RES CO, V264, P441, DOI 10.1006/bbrc.1999.1539; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KUME S, 1995, AM J PATHOL, V147, P654; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; Lipsky RH, 1997, RECEPT SIGNAL TRANS, V7, P1; MAILLARD LC, 1992, C R ACAD SCI PARIS 3, V154, P66; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; Matsumoto K, 2000, ARTERIOSCL THROM VAS, V20, P1027, DOI 10.1161/01.ATV.20.4.1027; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MITSUHASHI T, 1993, DIABETES, V42, P826, DOI 10.2337/diabetes.42.6.826; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MIYATA T, 1994, J CLIN INVEST, V93, P521, DOI 10.1172/JCI117002; Nagai R, 2000, DIABETES, V49, P1714, DOI 10.2337/diabetes.49.10.1714; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NAITO M, 1992, AM J PATHOL, V141, P591; NAKAMURA Y, 1993, AM J PATHOL, V143, P1649; Nakata A, 1999, ARTERIOSCL THROM VAS, V19, P1333, DOI 10.1161/01.ATV.19.5.1333; NAKAYAMA H, 1993, DIABETES, V42, P345, DOI 10.2337/diabetes.42.2.345; Navazo MDP, 1996, ARTERIOSCL THROM VAS, V16, P1033, DOI 10.1161/01.ATV.16.8.1033; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; SAKAI M, 1994, J BIOL CHEM, V269, P31430; Sakata N, 1999, ATHEROSCLEROSIS, V142, P67, DOI 10.1016/S0021-9150(98)00192-0; Sakata N, 1998, ATHEROSCLEROSIS, V141, P61, DOI 10.1016/S0021-9150(98)00149-X; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1993, J CLIN INVEST, V91, P2155, DOI 10.1172/JCI116442; Sfeir Z, 1999, MOL CELL BIOCHEM, V192, P3, DOI 10.1023/A:1006811300125; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SKOLNIK EY, 1991, J EXP MED, V174, P931, DOI 10.1084/jem.174.4.931; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TAKATA K, 1988, J BIOL CHEM, V263, P14819; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TEZUKA M, 1993, BIOCHEM BIOPH RES CO, V193, P674, DOI 10.1006/bbrc.1993.1677; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Uchida K, 1997, FEBS LETT, V410, P313, DOI 10.1016/S0014-5793(97)00610-8; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; VLASSARA H, 1994, LAB INVEST, V70, P138; YAMADA K, 1994, CLIN NEPHROL, V42, P354; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YUI S, 1994, J IMMUNOL, V152, P1943	73	189	200	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3195	3202		10.1074/jbc.M006545200	http://dx.doi.org/10.1074/jbc.M006545200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035013	hybrid			2022-12-27	WOS:000166784900030
J	Aurrand-Lions, M; Duncan, L; Ballestrem, C; Imhof, BA				Aurrand-Lions, M; Duncan, L; Ballestrem, C; Imhof, BA			JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION STRANDS; ADHESION MOLECULE; VASCULAR-PERMEABILITY; INTERCELLULAR-JUNCTIONS; ADHERENS JUNCTIONS; PROTEINS; OCCLUDIN; IDENTIFICATION; FAMILY; DISORGANIZATION	Cell-cell contacts are essential for morphogenesis and tissue function and play a vital role in mediating endothelial cohesion within the vascular system during vessel growth and organization. We identified a never junctional adhesion molecule, named JAM-2, by a selective RNA display method, which allowed identification of transcripts encoding immunoglobulin superfamily molecules regulated during coculture of endothelial cells with tumor cells. The JAM-2 transcript is highly expressed during embryogenesis and is detected in lymph node and Peyer's patches RNA of adult mice. Accordingly, antibodies specific for JAM-a stain high endothelial venules and lymphatic vessels in lymphoid organs, and vascular structures in the kidney. Using real time video microscopy, we show that JAM-2 is localized within minutes to the newly formed cell-cell contact, The role of the protein in the sealing of cell-cell contact is further suggested by the reduced paracellular permeability of cell monolayer transfected with JAM-2 cDNA, and by the localization of JAM-2 to tight junctional complexes of polarized cells. Taken together, our results suggest that JAM-2 is a novel vascular molecule, which participates in interendothelial junctional complexes.	Ctr Med Univ, Dept Pathol, CH-1211 Geneva, Switzerland	University of Geneva	Aurrand-Lions, M (corresponding author), Ctr Med Univ, Dept Pathol, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.		Aurrand-Lions, Michel/O-9953-2016	Aurrand-Lions, Michel/0000-0002-8361-3034; Ballestrem, Christoph/0000-0002-5375-7985				Allport JR, 1997, J EXP MED, V186, P517, DOI 10.1084/jem.186.4.517; Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; AurrandLions M, 1996, IMMUNITY, V5, P391, DOI 10.1016/S1074-7613(00)80496-3; AurrandLions M, 1997, CELL IMMUNOL, V176, P173, DOI 10.1006/cimm.1996.1073; Ballestrem C, 1998, J CELL SCI, V111, P1649; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Dejana E, 1996, J CLIN INVEST, V98, P1949, DOI 10.1172/JCI118997; Dejana E, 1996, HAEMOSTASIS, V26, P210; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Du Pasquier L, 1999, EUR J IMMUNOL, V29, P1729, DOI 10.1002/(SICI)1521-4141(199905)29:05<1729::AID-IMMU1729>3.0.CO;2-K; Ebnet K, 2000, J BIOL CHEM, V275, P27979; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gow A, 1999, CELL, V99, P649, DOI 10.1016/S0092-8674(00)81553-6; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARDER R, 1991, EXP CELL RES, V197, P259, DOI 10.1016/0014-4827(91)90431-S; Hirase T, 1997, J CELL SCI, V110, P1603; IMHOF BA, 1983, CELL, V35, P667, DOI 10.1016/0092-8674(83)90099-5; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; KRAMER RH, 1984, J CELL BIOL, V99, P692, DOI 10.1083/jcb.99.2.692; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MIKATA A, 1971, EXP MOL PATHOL, V14, P289, DOI 10.1016/0014-4800(71)90002-5; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; NAGY Z, 1991, ANN NY ACAD SCI, V633, P395; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PIALI L, 1995, J EXP MED, V181, P811, DOI 10.1084/jem.181.2.811; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; SIMIONESCU M, 1975, J CELL BIOL, V67, P863, DOI 10.1083/jcb.67.3.863; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Telo P, 1997, THERAPIE, V52, P395; VANDEURS B, 1975, LAB INVEST, V32, P201; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Wiedle G, 1999, CANCER RES, V59, P5255; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; WOLBURG H, 1994, J CELL SCI, V107, P1347	51	186	198	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2733	2741		10.1074/jbc.M005458200	http://dx.doi.org/10.1074/jbc.M005458200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053409	hybrid			2022-12-27	WOS:000166784800060
J	Levy, R; Wiedmann, M; Kreibich, G				Levy, R; Wiedmann, M; Kreibich, G			In vitro binding of ribosomes to the beta subunit of the Sec61p protein translocation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PARTICLE; MICROSOMAL-MEMBRANES; SECRETORY PROTEIN; ER MEMBRANE; BOUND RIBOSOMES; TRANSPORT; COMPONENTS; RECEPTOR; IDENTIFICATION	The Sec61p complex forms the core element of the protein translocation complex (translocon) in the rough endoplasmic reticulum trough ER) membrane. Translating or nontranslating ribosomes bind with high affinity to ER membranes that have been stripped of ribosomes or to liposomes containing purified Sec61p, Here we present evidence that the beta subunit of the complex (Sec61 beta) makes contact with nontranslating ribosomes, A fusion protein containing the Sec61 beta cytoplasmic domain (Sec61 beta (c)) prevents the binding of ribosomes to stripped ER-derived membranes and also binds to ribosomes directly with an affinity close to the affinity of ribosomes for stripped ER-derived membranes. The ribosome binding activity of Sec61 beta (c), like that of native ER membranes, is sensitive to high salt concentrations and is not based on an unspecific charge-dependent interaction of the relatively basic Sec61 beta (c) domain with ribosomal RNA. Like stripped ER membranes, the Sec61 beta (c) sequence binds to large ribosomal subunits in preference over small subunits, Previous studies have shown that Sec61 beta is inessential for ribosome binding and protein translocation, but translocation is impaired by the absence of Sec61 beta (c) and it has been proposed that Sec61 beta assists in the insertion of nascent proteins into the translocation pore. Our results suggest a physical interaction of the ribosome itself with Sec61 beta; this may normally occur alongside interactions between the ribosome and other elements of Sec61p, or it may represent one stage in a temporal sequence of binding.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	New York University; Memorial Sloan Kettering Cancer Center	Kreibich, G (corresponding author), NYU, Sch Med, Dept Cell Biol, 550 1St Ave, New York, NY 10016 USA.	kreibg01@-mcrcr.med.nyu.edu						ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; KISILEVSKY R, 1987, BIOCHIM BIOPHYS ACTA, V910, P282, DOI 10.1016/0167-4781(87)90121-7; KUHLBRANDT W, 1982, J MOL BIOL, V156, P431, DOI 10.1016/0022-2836(82)90259-5; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LEWIS JA, 1977, J BIOL CHEM, V252, P5547; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; Raden D, 2000, J CELL BIOL, V150, P53, DOI 10.1083/jcb.150.1.53; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Song WQ, 2000, CELL, V100, P333, DOI 10.1016/S0092-8674(00)80669-8; TASHIRO Y, 1965, J MOL BIOL, V11, P149, DOI 10.1016/S0022-2836(65)80047-X; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; UNWIN PNT, 1977, NATURE, V269, P118, DOI 10.1038/269118a0; UNWIN PNT, 1979, J MOL BIOL, V132, P69, DOI 10.1016/0022-2836(79)90496-0; UNWIN PNT, 1977, J MOL BIOL, V114, P491, DOI 10.1016/0022-2836(77)90174-7; Valcarcel R, 1999, J CELL SCI, V112, P4389; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; YOSHIDA H, 1987, BIOCHEM J, V245, P811, DOI 10.1042/bj2450811	48	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2340	2346		10.1074/jbc.M004867200	http://dx.doi.org/10.1074/jbc.M004867200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11036067	hybrid			2022-12-27	WOS:000166784800008
J	Tisdale, EJ				Tisdale, EJ			Glyceraldehyde-3-phosphate dehydrogenase is required for vesicular transport in the early secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BREFELDIN-A; TRANSMEMBRANE PROTEINS; MEMBRANE-TRANSPORT; ADP-RIBOSYLATION; GOLGI-APPARATUS; IDENTIFICATION; RAB2; ER; PHOSPHORYLATION	Protein transport in the early secretory pathway requires Rab2 GTPase, This protein promotes the recruitment of soluble components that participate in protein sorting and recycling from pre-Golgi intermediates (vesicular tubular clusters (VTCs)), We previously reported that a constitutively activated form of Rab2 (Q65L) as well as Rab2 wild type promoted vesicle formation from VTCs, These vesicles contained Rab2, P-COP, p53/gp58, and protein kinase C iota/lambda but lacked anterograde-directed cargo. To identify other candidate Rab2 effecters, the polypeptide composition of the vesicles was further analyzed. We found that vesicles released in response to Rab2 also contained the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), To study the relationship of this enzyme to Rab2 function, we performed a quantitative binding assay to measure recruitment of GAPDH to membrane when incubated with Rab2, Rab2-treated microsomes showed a 5-10-fold increase in the level of membrane-associated GAPDH. We generated an affinity-purified anti-GAPDH polyclonal to study the biochemical role of GAPDH in the early secretory pathway. The antibody arrests transport of a reporter molecule in an assay that reconstitutes ER to Golgi traffic. Furthermore, the affinity-purified antibody blocked the ability of Rab2 to recruit GAPDH to membrane. However, the antibody did not interfere with Rab2 stimulated vesicle release. These data suggest that GAPDH is required for ER to Golgi transport. We propose that membranes incubated with anti-GAPDH and Rab2 form "dead end" vesicles that are unable to transport and fuse with the acceptor compartment.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.	etisdale@med.wayne.edu						ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BECKERS CJ, 1989, CELL, V50, P523; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; Grigorieva JA, 1999, ARCH BIOCHEM BIOPHYS, V369, P252, DOI 10.1006/abbi.1999.1341; Han XL, 1998, BBA-BIOMEMBRANES, V1414, P95, DOI 10.1016/S0005-2736(98)00154-0; Harris J.I., 1976, ENZYMES, VXIII; Hessler RJ, 1998, J LEUKOCYTE BIOL, V63, P331, DOI 10.1002/jlb.63.3.331; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KUMAGAI H, 1983, J BIOCHEM-TOKYO, V93, P1259, DOI 10.1093/oxfordjournals.jbchem.a134260; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Reiss N, 1996, BIOCHEM MOL BIOL INT, V40, P1191; ROBBINS AR, 1995, J CELL BIOL, V130, P1093, DOI 10.1083/jcb.130.5.1093; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Tisdale EJ, 2000, TRAFFIC, V1, P702, DOI 10.1034/j.1600-0854.2000.010903.x; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; VINALS AEL, 1987, BIOCHEM BIOPH RES CO, V143, P403, DOI 10.1016/0006-291X(87)90680-2; VOLKER KW, 1995, COMP BIOCHEM PHYS B, V112, P503, DOI 10.1016/0305-0491(95)00096-8; Weigert R, 1997, J BIOL CHEM, V272, P14200, DOI 10.1074/jbc.272.22.14200	34	108	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2480	2486		10.1074/jbc.M007567200	http://dx.doi.org/10.1074/jbc.M007567200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035021	hybrid			2022-12-27	WOS:000166784800026
J	Kanipes, MI; Lin, SH; Cotter, RJ; Raetz, CRH				Kanipes, MI; Lin, SH; Cotter, RJ; Raetz, CRH			Ca2+-induced phosphoethanolamine transfer to the outer 3-deoxy-D-manno-octulosonic acid moiety of Escherichia coli lipopolysaccharide - A novel membrane enzyme dependent upon phosphatidylethanolamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; LIPID-A; VIRULENCE GENE; BIOSYNTHESIS; PURIFICATION; MUTANT; ENDOTOXINS; BACTERIAL	Certain strains of Escherichia coli and Salmonella contain lipopolysaccharide (LPS) modified with a phosphoethanolamine (pEtN) group at position 7 of the outer 3-deoxy-D-manno-octulosonic acid (Kdo) residue. Using the heptose-deficient E, coli mutant WBB06 (Brabetz, W,, Muller-Loennies, S., Hoist, O, and Brade, H. (1997) Eur. J. Biochem. 247, 716-724), we now demonstrate that the critical parameter determining the presence or absence of pEtN is the concentration of CaCl2 in the medium. As judged by mass spectrometry, half the LPS in WBB06, grown on nutrient broth with 5 mM CaCl2, is derivatized with a pEtN group, whereas LPS from WBB06 grown without supplemental CaCl2 is not. Membranes from E, coli WBB06 or wild-type W3110 grown on 5-50 mM CaCl2 contain a novel pEtN transferase that uses the precursor Kdo(2)-[4'-P-32]lipid IVA as an acceptor. Transferase is not present in membranes of E. coli grown with 5 mM MgCl2, BaCl2, or ZnCl2, Hydrolysis of the in vitro reaction product, pEtN-Kdo(2)-[4'-P-32]lipid IVA, at pH 4.5 shows that the pEtN substituent is located on the outer Kdo moiety, Membranes from an E, coli pss knockout mutant grown on 50 mM CaCl2, which lack phosphatidylethanolamine, do not contain measurable transferase activity unless exogenous phosphatidylethanolamine is added back to the assay system. The induction of the pEtN transferase by 5-50 mM CaCl2 suggests possible role(s) in establishing transformation competence or resisting environmental stress, and represents the first example of a regulated covalent modification of the inner core of E. coli LPS.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NIGMS NIH HHS [GM-54882, GM-51310] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; BERGMANS HEN, 1981, J BACTERIOL, V146, P564, DOI 10.1128/JB.146.2.564-570.1981; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Brade H., 1999, ENDOTOXIN HLTH DIS; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; Clementz T, 1997, J BIOL CHEM, V272, P10353; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Ferguson AD, 2000, STRUCTURE, V8, P585; Groisman EA, 1998, BIOESSAYS, V20, P96, DOI 10.1002/(SICI)1521-1878(199801)20:1<96::AID-BIES13>3.0.CO;2-3; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HASIN M, 1982, J BIOL CHEM, V257, P2475; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; Miller J.H., 1972, EXPT MOL GENETICS; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; QURESHI N, 1988, J BIOL CHEM, V263, P11971; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; STRAIN SM, 1983, J BIOL CHEM, V258, P3466; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; Yethon JA, 1998, J BIOL CHEM, V273, P26310, DOI 10.1074/jbc.273.41.26310; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	34	68	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1156	1163		10.1074/jbc.M009019200	http://dx.doi.org/10.1074/jbc.M009019200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042192	hybrid			2022-12-27	WOS:000166430900043
J	Liu, XQ; Wang, CC				Liu, XQ; Wang, CC			Disulfide-dependent folding and export of Escherichia coli DsbC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; BOND FORMATION; PERIPLASMIC PROTEIN; ISOMERASE; THIOREDOXIN; GENE; ELECTRONS; ENCODES; BINDING; FAMILY	DsbC, a member of the Dsb family in the periplasm of Gram-negative bacteria, is not only a disulfide isomerase but also a chaperone. Five DsbC mutants with Cys in the active site sequence of Cys(98)-Gly-Tyr-Cys(101) and the nonactive site disulfide Cys(141)-Cys(163) replaced by Ser have been studied. The results show that the active site Cys residues are necessary for enzyme activities but not required for chaperone activity, while the lack of the nonactive site disulfide results in a decreased chaperone activity in assisting the reactivation of denatured D-glyceraldehyde-3-phosphate dehydrogenase but has no effect on enzyme activities. Wild-type DsbC was overexpressed and correctly processed as a soluble periplasmic protein. Mutation in one of these Cys residues results in aggregation or extracellular/membrane locations, but does not affect the proper processing. DsbC mutated in either Cys residue of nonactive site disulfide shows higher sensitivity to unfolding by guanidine hydrochloride and slower refolding compared with wild-type DsbC and the active site Cys mutants. The above results provide experimental evidence for structural role of the nonactive site disulfide in folding and biological activities of DsbC.	Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, CC (corresponding author), Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.							AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; Betton JM, 1996, J BIOL CHEM, V271, P8046, DOI 10.1074/jbc.271.14.8046; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1994, J BIOL CHEM, V269, P24550; CARTER P, 1987, METHOD ENZYMOL, V154, P383; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; Chung J, 2000, MOL MICROBIOL, V35, P1099, DOI 10.1046/j.1365-2958.2000.01778.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frishman D, 1996, BIOCHEM BIOPH RES CO, V219, P686, DOI 10.1006/bbrc.1996.0295; GALISTEO EM, 1993, BIOCHIMIE, V75, P803; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Liu XQ, 1999, PROTEIN SCI, V8, P2085, DOI 10.1110/ps.8.10.2085; MCMARTHY AA, 2000, NAT STRUCT BIOL, V7, P196; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; OLIVE C, 1967, BIOCHEMISTRY-US, V6, P730, DOI 10.1021/bi00855a012; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; SAMUNI A, 1975, ANAL BIOCHEM, V63, P17, DOI 10.1016/0003-2697(75)90185-2; Shao F, 2000, J BIOL CHEM, V275, P13349, DOI 10.1074/jbc.275.18.13349; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; STADER JA, 1990, METHOD ENZYMOL, V185, P167; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; STRAATEN M, 1998, FEBS LETT, V428, P255; Thomas JG, 1997, APPL BIOCHEM BIOTECH, V66, P197, DOI 10.1007/BF02785589; Thorstenson YR, 1997, J BACTERIOL, V179, P5333, DOI 10.1128/jb.179.17.5333-5339.1997; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; Zheng WD, 1997, ARCH BIOCHEM BIOPHYS, V337, P326, DOI 10.1006/abbi.1996.9783	34	34	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1146	1151		10.1074/jbc.M004929200	http://dx.doi.org/10.1074/jbc.M004929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042167	hybrid			2022-12-27	WOS:000166430900041
J	Mehl, AM; Floettmann, JE; Jones, M; Brennan, P; Rowe, M				Mehl, AM; Floettmann, JE; Jones, M; Brennan, P; Rowe, M			Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways that cooperate with nuclear factor kappa B to activate transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA STABILIZATION; PHORBOL-MYRISTATE ACETATE; INTERFERON-GAMMA; GENE-EXPRESSION; C-TERMINUS; INFLAMMATORY CYTOKINES; SIGNAL-TRANSDUCTION; ESSENTIAL ROLES; LYMPHOCYTES-B	The latent membrane protein-1 (LMP1) of Epstein-Barr virus induces gene transcription, phenotypic changes, and oncogenic transformation. One cellular gene induced by LMP1 is that for intercellular adhesion molecule-1 (ICAM-1), which participates in a wide range of inflammatory and immune responses. ICAM-1 may enhance the immune recognition of cells transformed by Epstein-Barr virus, and thus combat development of malignancy. Despite growing understanding of the various signaling functions of LMP1, the molecular mechanisms by which LMP1 induces ICAM-1 are not understood. Here, we demonstrate that transcriptional activation by LMP1 is absolutely dependent upon a variant NF-kappaB motif within the tumor necrosis factor alpha (TNF alpha) response element of the ICAM-1 promoter. Although the TNF alpha response element is sufficient for TNF alpha induction of the ICAM-1 promoter, LMP1 also required the cooperation of additional upstream sequences for optimal induction, inhibitor studies of known LMP1-induced signaling pathways ruled out the involvement of c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase, and the Janus-activating tyrosine kinase 3 (JAK3), and confirmed NF-kappaB as a critical factor for induction of ICAM-1. However, although constitutive activation of NF-kappaB efficiently induced promoter activity, it was not sufficient to induce either ICAM-1 mRNA or ICAM-1 protein. Using signaling defective LMP1 mutants and deacetylation inhibitors, we showed that the C-terminal activator region 1 of LMP1 delivers a new cooperating signal to induce ICAM-1 mRNA.	Univ Wales, Coll Med, Dept Med, Cardiff CF14 4XX, S Glam, Wales	Cardiff University	Rowe, M (corresponding author), Univ Wales, Coll Med, Dept Med, Tenovus Bldg, Cardiff CF14 4XX, S Glam, Wales.		Rowe, Martin/B-2880-2009; Brennan, Paul/ABB-9196-2021; Brennan, Paul/B-9210-2009	Rowe, Martin/0000-0003-4139-7326; Brennan, Paul/0000-0001-8792-0499; Brennan, Paul/0000-0001-8792-0499				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; Chini BA, 1998, J VIROL, V72, P1623, DOI 10.1128/JVI.72.2.1623-1626.1998; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Dhanasekaran N, 1998, ONCOGENE, V17, P1329, DOI 10.1038/sj.onc.1202170; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Floettmann JL, 1998, ONCOGENE, V17, P2383, DOI 10.1038/sj.onc.1202144; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Goodman PA, 1998, J BIOL CHEM, V273, P17742, DOI 10.1074/jbc.273.28.17742; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; JAHNKE A, 1995, EUR J BIOCHEM, V228, P439; JAHNKE A, 1995, IMMUNOBIOLOGY, V193, P305, DOI 10.1016/S0171-2985(11)80559-0; JONES M, 2001, METHODS MOL BIOL EPS, V174; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Koyama Y, 2000, BLOOD, V96, P1490, DOI 10.1182/blood.V96.4.1490.h8001490_1490_1495; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Liljeholm S, 1998, J GEN VIROL, V79, P2117, DOI 10.1099/0022-1317-79-9-2117; Magnaghi-Jaulin L, 2000, Prog Cell Cycle Res, V4, P41; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OHH M, 1994, J BIOL CHEM, V269, P30117; OHH M, 1994, BLOOD, V84, P2632; Papi A, 1999, J BIOL CHEM, V274, P30041, DOI 10.1074/jbc.274.42.30041; Paxton LLL, 1997, J BIOL CHEM, V272, P15928, DOI 10.1074/jbc.272.25.15928; Puls A, 1999, J CELL SCI, V112, P2983; RICKINSON A, 1996, FIELDS VIROLOGY, V2, P2397; Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wang S, 1996, CANCER RES, V56, P4610; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6	59	32	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					984	992		10.1074/jbc.M003758200	http://dx.doi.org/10.1074/jbc.M003758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11034993	hybrid			2022-12-27	WOS:000166430900018
J	Scott, RP; Ibanez, CF				Scott, RP; Ibanez, CF			Determinants of ligand binding specificity in the glial cell line-derived neurotrophic factor family receptor alpha s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-RET PROTOONCOGENE; NERVE GROWTH-FACTOR; TYROSINE KINASE; CRYSTAL-STRUCTURE; GDNF; ACTIVATION; COMPLEX; PROTEIN; EXPRESSION; MECHANISMS	The glial cell line-derived neurotrophic factor (GDNF) family comprise a subclass of cystine-knot superfamily ligands that interact with a multisubunit receptor complex formed by the c-Ret tyrosine kinase and a cystine-rich glycosyl phosphatidylinositol-anchored binding subunit called GDNF family receptor alpha (GFR alpha). All four GDNF family ligands utilize c-Ret as a common signaling receptor, whereas specificity is conferred by differential binding to four distinct GFR alpha homologues. To understand how the different GFR alphas discriminate ligands, we have constructed a large set of chimeric and truncated receptors and analyzed their ligand binding and signaling capabilities. The major determinant of ligand binding was found in the most conserved region of the molecule, a central domain predicted to contain four conserved alpha helices and two beta strands. Distinct hydrophobic and positively charged residues in this central region were required for binding of GFR alpha1 to GDNF. Interaction of GFR alpha1 and GFR alpha2 with GDNF and neurturin required distinct subsegments within this central domain, which allowed the construction of chimeric receptors that responded equally well to both ligands, C-terminal segments adjacent to the central domain are necessary and have modulatory function in ligand binding. In contrast, the N-terminal domain was dispensable without compromising ligand binding specificity. Ligand-independent interaction with c-Ret also resides in the central domain of GFR alpha1, albeit within a distinct and smaller region than that required for ligand binding. Our results indicate that the central region of this class of receptors constitutes a novel binding domain for cystine-knot superfamily ligands.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, Berzelius Vag 1, S-17177 Stockholm, Sweden.		Scott, Rizaldy/Y-7584-2019; Scott, Rizaldy/AAC-5264-2020	Scott, Rizaldy/0000-0002-0288-8862; 				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Baloh RH, 2000, J BIOL CHEM, V275, P3412, DOI 10.1074/jbc.275.5.3412; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; ILAG LL, 1994, J BIOL CHEM, V269, P19941; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lindahl M, 2000, MOL CELL NEUROSCI, V15, P522, DOI 10.1006/mcne.2000.0845; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; Masure S, 2000, J BIOL CHEM, V275, P39427, DOI 10.1074/jbc.M003867200; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; MURRAYRUST J, 1993, STRUCTURE, V1, P153, DOI 10.1016/0969-2126(93)90029-G; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Rosenblad C, 2000, MOL CELL NEUROSCI, V15, P199, DOI 10.1006/mcne.1999.0817; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Sariola H, 1999, INT J DEV BIOL, V43, P413; Thompson J, 1998, MOL CELL NEUROSCI, V11, P117, DOI 10.1006/mcne.1998.0682; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Trupp M, 1997, J NEUROSCI, V17, P3554; Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; Urfer R, 1997, BIOCHEMISTRY-US, V36, P4775, DOI 10.1021/bi962877+; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wong YW, 1998, NEUROREPORT, V9, P3767, DOI 10.1097/00001756-199812010-00002; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619; Yu T, 1998, J NEUROSCI, V18, P4684	41	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1450	1458		10.1074/jbc.M006157200	http://dx.doi.org/10.1074/jbc.M006157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11018032	hybrid			2022-12-27	WOS:000166430900079
J	Emanuelli, M; Carnevali, F; Saccucci, F; Pierella, F; Amici, A; Raffaelli, N; Magni, G				Emanuelli, M; Carnevali, F; Saccucci, F; Pierella, F; Amici, A; Raffaelli, N; Magni, G			Molecular cloning, chromosomal localization, tissue mRNA levels, bacterial expression, and enzymatic properties of human NMN adenylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE MONONUCLEOTIDE ADENYLYLTRANSFERASE; NAD BIOSYNTHESIS; CDNA SEQUENCE; PROTEIN; PURIFICATION; TIAZOFURIN; METABOLISM; BINDING; GENE	A 1329-base pair clone isolated from a human placenta cDNA library contains a full-length 837-base pair coding region for a 31.9-kDa protein whose deduced primary structure exhibits high homology to consensus sequences found in other NMN adenylyltransferases. Northern blotting detected a major 3.1-kilobase mRNA transcript as well as a minor 4.1-kilobase transcript in all human tissues examined. In several cancer cell lines, lower levels of mRNA expression were clearly evident. The gene encoding the human enzyme was mapped to chromosome band 1p32-35. High efficiency bacterial expression yielded 1.5 mg of recombinant enzyme/liter of culture medium. The molecular and kinetic properties of recombinant human NMR adenylyltransferase provide new directions for investigating metabolic pathways involving this enzyme.	Univ Ancona, Fac Med & Chirurg, Ist Biochim, I-60100 Ancona, Italy; Univ Ancona, Fac Med & Chirurg, Ist Biol & Genet, I-60100 Ancona, Italy	Marche Polytechnic University; Marche Polytechnic University	Magni, G (corresponding author), Univ Ancona, Fac Med & Chirurg, Ist Biochim, Via Ranieri, I-60100 Ancona, Italy.		Amici, Adolfo/C-5342-2012	Amici, Adolfo/0000-0002-1081-7749; Saccucci, Franca/0000-0002-8407-2516				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALDUCCI E, 1995, ANAL BIOCHEM, V228, P64, DOI 10.1006/abio.1995.1315; BALDUCCI E, 1995, BIOCHEM J, V310, P395, DOI 10.1042/bj3100395; BORK P, 1995, PROTEINS, V22, P259, DOI 10.1002/prot.340220306; Boulton S, 1997, BRIT J CANCER, V76, P845, DOI 10.1038/bjc.1997.473; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Emanuelli M, 1999, FEBS LETT, V455, P13, DOI 10.1016/S0014-5793(99)00852-2; EMANUELLI M, 1992, ARCH BIOCHEM BIOPHYS, V298, P29, DOI 10.1016/0003-9861(92)90089-F; EMANUELLI M, 1995, BIOCHEM PHARMACOL, V49, P575, DOI 10.1016/0006-2952(94)00478-5; FUNAKOSHI I, 1992, ARCH BIOCHEM BIOPHYS, V295, P180, DOI 10.1016/0003-9861(92)90504-P; GREENBAUM AL, 1968, BIOCHEM J, V107, P63, DOI 10.1042/bj1070063; HELMANN U, 1995, ANAL BIOCHEM, V224, P451; HOGEBOOM GH, 1952, J BIOL CHEM, V197, P611; HUGHES KT, 1983, J BACTERIOL, V155, P213, DOI 10.1128/JB.155.1.213-221.1983; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Jacobson EL, 1999, MOL CELL BIOCHEM, V193, P69, DOI 10.1023/A:1006960126369; JAYARAM HN, 1986, BIOCHEM PHARMACOL, V35, P587, DOI 10.1016/0006-2952(86)90352-7; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; MORTON RK, 1971, NATURE, V181, P540; NATALINI P, 1986, BIOCHEMISTRY-US, V25, P3725, DOI 10.1021/bi00360a037; Raffaelli N, 1997, J BACTERIOL, V179, P7718, DOI 10.1128/jb.179.24.7718-7723.1997; Raffaelli N, 1999, FEBS LETT, V444, P222, DOI 10.1016/S0014-5793(99)00068-X; Raffaelli N, 1999, J BACTERIOL, V181, P5509, DOI 10.1128/JB.181.17.5509-5511.1999; RAFFAELLI N, 2001, IN PRESS METHODS ENZ, V331; SOLAO PB, 1971, EXP CELL RES, V69, P295, DOI 10.1016/0014-4827(71)90227-8; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1986, J MOL BIOL, V189, P435; WILLIAMS SR, 1984, NUCLEIC ACIDS RES, V12, P5779, DOI 10.1093/nar/12.14.5779	33	116	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					406	412		10.1074/jbc.M008700200	http://dx.doi.org/10.1074/jbc.M008700200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027696	hybrid			2022-12-27	WOS:000166280700055
J	Boule, JB; Rougeon, F; Papanicolaou, C				Boule, JB; Rougeon, F; Papanicolaou, C			Comparison of the two murine terminal deoxynucleotidyltransferase isoforms. A 20-amino acid insertion in the highly conserved carboxyl-terminal region modifies the thermosensitivity but not the catalytic activity (vol 275, pg 28984, 2000)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction													Boulé, Jean-Baptiste/M-8200-2017	Boulé, Jean-Baptiste/0000-0002-0994-5831				Boule JB, 2000, J BIOL CHEM, V275, P28984, DOI 10.1074/jbc.M005544200	1	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33184	33184						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	11032847				2022-12-27	WOS:000090003800109
J	Ding, XQ; Dolu, V; Hadac, EM; Holicky, EL; Pinon, DI; Lybrand, TP; Miller, LJ				Ding, XQ; Dolu, V; Hadac, EM; Holicky, EL; Pinon, DI; Lybrand, TP; Miller, LJ			Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminaI probe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BINDING-SITE; A RECEPTOR; DIRECT IDENTIFICATION; CCKA RECEPTOR; AFFINITY; GLYCOSYLATION; PEPTIDE; PANCREOZYMIN; INTERACT	Affinity labeling is a powerful tool to establish spatial approximations between photolabile residues within a ligand and its receptor. Here, we have utilized a cholecystokinin (CCK) analogue with a photolabile benzoylphenylalanine (Bpa) sited in position 24, adjacent to the pharmacophoric domain of this hormone (positions 27-33). This probe was a fully efficacious agonist that bound to the CCK receptor saturably and with high affinity (K-i = 8.9 +/- 1.1 nM). It covalently labeled the CCK receptor either within the amino terminus (between Asn(10) and Lys(37)) or within the third extracellular loop (Glu(345)), as demonstrated by proteolytic peptide mapping, deglycosylation, micropurification, and Edman degradation sequencing. Truncation of the receptor to eliminate residues 1-30 had no detrimental effect on CCK binding, stimulated signaling, or affinity labeling through a residue within the pharmacophore (Bpa(29)) but resulted in elimination of the covalent attachment of the Bpa(24) probe to the receptor, Thus, the distal amino terminus of the CCK: receptor resides above the docked ligand, compressing the portion of the peptide extending beyond its pharmacophore toward the receptor core. Exposure of wild type and truncated receptor constructs to extracellular trypsin damaged the truncated construct but not the wild type receptor, suggesting that this domain also may play a protective role. Use of these additional insights into molecular approximations provided key constraints for molecular modeling of the peptide-receptor complex, supporting the counterclockwise organization of the transmembrane helical domains.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA; Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37235 USA	Mayo Clinic; Vanderbilt University; Vanderbilt University	Miller, LJ (corresponding author), Mayo Clin, Ctr Basic Res Digest Dis, Guggenheim 17, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033290] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32878] Funding Source: Medline; NINDS NIH HHS [NS33290] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BODANSZKY M, 1980, INT J PEPT PROT RES, V16, P402; Dong MQ, 1999, J BIOL CHEM, V274, P4778, DOI 10.1074/jbc.274.8.4778; FOURNIEZALUSKI MC, 1986, BIOCHEMISTRY-US, V25, P3778, DOI 10.1021/bi00361a008; Gigoux V, 1999, PROTEIN SCI, V8, P2347; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; Gouldson P, 2000, EUR J PHARMACOL, V389, P115, DOI 10.1016/S0014-2999(99)00894-8; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Hadac EM, 1999, J MED CHEM, V42, P2105, DOI 10.1021/jm980732q; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Ho HH, 1999, BIOCHEMISTRY-US, V38, P1866, DOI 10.1021/bi981195e; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG SC, 1989, PEPTIDES, V10, P785, DOI 10.1016/0196-9781(89)90114-9; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; Keire DA, 1999, BIOCHEM BIOPH RES CO, V266, P400, DOI 10.1006/bbrc.1999.1825; KENNEDY K, 1995, BIOCHEM BIOPH RES CO, V213, P845, DOI 10.1006/bbrc.1995.2206; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; KLUEPPELBERG UG, 1989, BIOCHEMISTRY-US, V28, P3463, DOI 10.1021/bi00434a047; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUTT V, 1980, COMPREHENSIVE ENDOCR, P169; ONDETTI MA, 1970, AM J DIG DIS, V15, P149, DOI 10.1007/BF02235646; Pang RTK, 1999, ENDOCRINOLOGY, V140, P5102, DOI 10.1210/en.140.11.5102; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PEARSON RK, 1987, BIOCHEM BIOPH RES CO, V147, P346, DOI 10.1016/S0006-291X(87)80128-6; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEARSON RK, 1987, J BIOL CHEM, V262, P869; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; POWERS SP, 1988, J BIOL CHEM, V263, P5295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Smeets RLL, 1997, EUR J PHARMACOL, V325, P93, DOI 10.1016/S0014-2999(97)00106-4; SWANSON E, 1995, PSSHOW 4D VERSION; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316	38	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4236	4244		10.1074/jbc.M003798200	http://dx.doi.org/10.1074/jbc.M003798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050076	hybrid			2022-12-27	WOS:000166921200068
J	Bond, CS; White, MF; Hunter, WN				Bond, CS; White, MF; Hunter, WN			High resolution structure of the phosphohistidine-activated form of Escherichia coli cofactor-dependent phosphoglycerate mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN; MECHANISM; DATABASE; SUBUNIT; PROGRAM; COMPLEX; YEAST	The active conformation of the dimeric cofactor-dependent phosphoglycerate mutase (dPGM) from Escherichia coli has been elucidated by crystallographic methods to a resolution of 1.25 Angstrom (R-factor 0.121; R-free 0.168), The active site residue His(10), central in the catalytic mechanism of dPGM, is present as a phosphohistidine with occupancy of 0.28, The structural changes on histidine phosphorylation highlight various features that are significant in the catalytic mechanism, The C-terminal 10-residue tail, which is not observed in previous dPGM structures, is well ordered and interacts with residues implicated in substrate binding; the displacement of a loop adjacent to the active histidine brings previously overlooked residues into positions where they may directly influence catalysis. E. coli dPGM, like the mammalian dPGMs, is a dimer, whereas previous structural work has concentrated on monomeric and tetrameric yeast forms. We can now analyze the sequence differences that cause this variation of quaternary structure.	Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Hunter, WN (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	W.N.Hunter@dundee.ac.uk	Hunter, William/AAE-3947-2019; Bond, Charles S/B-4094-2011; White, Malcolm F/A-6055-2010; Bond, Charles/AAF-9608-2020	Bond, Charles S/0000-0002-9584-6783; White, Malcolm F/0000-0003-1543-9342; Bond, Charles/0000-0002-9584-6783				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BEARD LN, 1968, ACTA CRYSTALL B-STRU, VB 24, P1529, DOI 10.1107/S0567740868004590; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CAMPBELL JW, 1974, NATURE, V250, P301, DOI 10.1038/250301a0; Crowhurst GS, 1999, ACTA CRYSTALLOGR D, V55, P1822, DOI 10.1107/S0907444999009944; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fletcher DA, 1996, J CHEM INF COMP SCI, V36, P746, DOI 10.1021/ci960015+; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; Fraser HI, 1999, FEBS LETT, V455, P344, DOI 10.1016/S0014-5793(99)00910-2; Fraser ME, 1999, J MOL BIOL, V285, P1633, DOI 10.1006/jmbi.1998.2324; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jedrzejas MJ, 2000, J BIOL CHEM, V275, P23146, DOI 10.1074/jbc.M002544200; Jedrzejas MJ, 2000, EMBO J, V19, P1419, DOI 10.1093/emboj/19.7.1419; Jones BE, 1997, PROTEIN SCI, V6, P2107; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McEvoy MM, 1997, CURR OPIN STRUC BIOL, V7, P793, DOI 10.1016/S0959-440X(97)80148-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAIRN J, 1995, FEBS LETT, V359, P192, DOI 10.1016/0014-5793(95)00044-A; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rigden DJ, 1999, J MOL BIOL, V289, P691, DOI 10.1006/jmbi.1999.2848; Rigden DJ, 1998, J MOL BIOL, V276, P449, DOI 10.1006/jmbi.1997.1554; Rigden DJ, 1999, J MOL BIOL, V286, P1507, DOI 10.1006/jmbi.1999.2566; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Uhrinova S, 1997, J BIOMOL NMR, V10, P309, DOI 10.1023/A:1018307210607; Walter RA, 1999, BIOCHEM J, V337, P89, DOI 10.1042/0264-6021:3370089; WHITE MF, 1993, BIOCHEM J, V295, P743, DOI 10.1042/bj2950743	37	65	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3247	3253		10.1074/jbc.M007318200	http://dx.doi.org/10.1074/jbc.M007318200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11038361	hybrid			2022-12-27	WOS:000166784900036
J	Murray, JM; Johnson, DI				Murray, JM; Johnson, DI			The Cdc42p GTPase and its regulators Nrf1p and Scd1p are involved in endocytic trafficking in the fission yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; TRANSPORT; FUSION; GROWTH; CELLS	Nrf1p was first identified in a screen for negative regulators of the Cdc42p GTPase. Overexpression of Nrf1p resulted in dose-dependent lethality, with cells exhibiting an ellipsoidal morphology and abnormal vacuolar phenotypes including an increase in vacuolar fusion. Green fluorescent protein (GFP)-Cdc42p and GFP-Nrf1p colocalized to vacuolar membranes and GFP-Nrf1p vacuolar localization depended on Scd1p, the Schizosaccharomyces pombe homolog of the Cdc24p guanine nucleotide exchange factor. In this study, site-directed mutagenesis was conducted on Nrf1p to determine its functional domains. Mutations in the three putative transmembrane domains resulted in mislocalization of GFP-Nrf1p and an inability to induce lethality, suggesting a loss of function. Mutations in the second extramembranous loop of Nrf1p also resulted in a loss of function and altered the ability of GFP-Nrf1p to localize to vacuolar membranes. Analysis of Delta nrf1 and Delta scd1 mutants revealed defects in endocytosis. In addition, overexpression of constitutively active Cdc42(GI2V)p re suited in an increase in endocytosis and an ability to rescue the endocytic defects in Delta nrf1 and Delta scd1 cells. These data are consistent with Nrf1p and Scd1p being necessary for efficient endocytosis, possibly through the regulation of Cdc42p.	Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; Univ Vermont, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Johnson, DI (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, 202B Stafford Hall, Burlington, VT 05405 USA.	dijohnso@zoo.uvm.edu						Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Bone N, 1998, CURR BIOL, V8, P135, DOI 10.1016/S0960-9822(98)00060-8; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Cohen A, 1999, J BIOL CHEM, V274, P26885, DOI 10.1074/jbc.274.38.26885; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Garrett WS, 2000, CELL, V102, P325, DOI 10.1016/S0092-8674(00)00038-6; GOODE NT, 1994, MOL BIOL CELL, V5, P907, DOI 10.1091/mbc.5.8.907; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murray JM, 2000, GENETICS, V154, P155; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sherman F., 1986, METHODS YEAST GENETI; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Toda T, 1996, MOL CELL BIOL, V16, P6752; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WHITNEY JA, 1995, CELL, V83, P703; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; ZIMAN M, 1994, YEAST, V10, P463, DOI 10.1002/yea.320100405	25	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3004	3009		10.1074/jbc.M007389200	http://dx.doi.org/10.1074/jbc.M007389200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042180	hybrid			2022-12-27	WOS:000166784900006
J	Ohkubo, N; Mitsuda, N; Tamatani, M; Yamaguchi, A; Lee, YD; Ogihara, T; Vitek, MP; Tohyama, M				Ohkubo, N; Mitsuda, N; Tamatani, M; Yamaguchi, A; Lee, YD; Ogihara, T; Vitek, MP; Tohyama, M			Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PRIMARY HIPPOCAMPAL-NEURONS; THROMBIN-CLEAVAGE FRAGMENT; SYNAPTIC PLASTICITY; TYPE-4 ALLELE; EXPRESSION; GENE; CREB; CALCIUM; PHOSPHORYLATION	Inheritance of the epsilon4 allele of the apolipoprotein E gene (APOE4) is a major risk factor for the development of Alzheimer's disease (AD). Although the association between APOE4 and AD is well documented, the mechanism by which apolipoprotein E exerts an isoform-specific effect on neurons in disease is unknown. In this report, we demonstrate that apoE4 stimulates the transcriptional activity of cAMP-response element-binding protein (CREB) by activating the extracellular signal-regulated kinase (ERK) cascade in rat primary hippocampal neurons. In contrast, apoE3 was unable to stimulate CREB transcriptional activity and unable to activate the ERK pathway. Elevation of intracellular Ca2+ levels are also involved because treatment with receptor-associated protein, nifedipine, MK801, removal of Ca2+ from the medium and dantrolene all served to inhibit calcium elevation and attenuate the activation of CREB, Treatment with an apoE peptide was also found to facilitate transcription of the CREB-dependent genes, c-fos and Bcl-2. In contrast to treatment with apoE3, our findings suggest apoE4 and apoE-peptide induce a novel signaling pathway.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Geriatr Med, Suita, Osaka 5650871, Japan; CREST Japan Sci & Technol, Yokohama, Kanagawa, Japan; Ajou Univ, Sch Med, Dept Anat, Suwon 442749, South Korea; Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA	Osaka University; Osaka University; Japan Science & Technology Agency (JST); Ajou University; Duke University	Mitsuda, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Vitek, Michael/0000-0001-8140-8048				Bortolotto ZA, 1999, NATURE, V402, P297, DOI 10.1038/46290; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLAY MA, 1995, BIOCHEMISTRY-US, V34, P11142, DOI 10.1021/bi00035a020; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Jordan J, 1998, J NEUROSCI, V18, P195; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Marques MA, 1996, NEUROREPORT, V7, P2529, DOI 10.1097/00001756-199611040-00025; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Moulder KL, 1999, J NEUROCHEM, V72, P1069, DOI 10.1046/j.1471-4159.1999.0721069.x; Poirier J, 1995, ANN MED, V27, P663, DOI 10.3109/07853899509019253; Rajadhyaksha A, 1999, J NEUROSCI, V19, P6348; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun YL, 1998, J NEUROSCI, V18, P3261; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tolar M, 1997, J NEUROSCI, V17, P5678; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Wang XS, 1997, J CELL PHYSIOL, V173, P73, DOI 10.1002/(SICI)1097-4652(199710)173:1<73::AID-JCP9>3.3.CO;2-B; Weisskopf MG, 1999, J NEUROSCI, V19, P10512	34	81	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3046	3053		10.1074/jbc.M005070200	http://dx.doi.org/10.1074/jbc.M005070200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042199	Green Published, hybrid			2022-12-27	WOS:000166784900012
J	Peters, MF; Ross, CA				Peters, MF; Ross, CA			Isolation of a 40-kDa Huntingtin-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE GENE-PRODUCT; NUCLEAR-LOCALIZATION; SUBCELLULAR-LOCALIZATION; EMBRYONIC LETHALITY; GLUTAMINE REPEATS; MUTANT HUNTINGTIN; INTERACTS; POLYGLUTAMINE; APOPTOSIS; INCLUSIONS	Huntington's disease is caused by an expanded CAG trinucleotide repeat coding for a polyglutamine stretch within the huntingtin protein. Currently, the function of normal huntingtin and the mechanism by which expanded huntingtin causes selective neurotoxicity remain unknown. Clues may come from the identification of huntingtin-associated proteins (HAPs). Here, we show that huntingtin copurifies with a single novel 40-kDa protein termed HAP40. HAP40 is encoded by the open reading frame factor VIII-associated gene A (F8A) located within intron 22 of the factor VIII gene. In transfected cell extracts, HAP40 coimmunoprecipitates with full-length huntingtin but not with an N-terminal huntingtin fragment. Recombinant HAP40 is cytoplasmic in the presence of huntingtin but is actively targeted to the nucleus in the absence of huntingtin. These data indicate that HAP40 is likely to contribute to the function of normal huntingtin and is a candidate for involvement in the aberrant nuclear localization of mutant huntingtin found in degenerating neurons in Huntington's disease.	Johns Hopkins Univ, Sch Med, Dept Psychiat, Mol Neurobiol Lab,Div Neurobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Program Cellular Mol Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Peters, MF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Mol Neurobiol Lab,Div Neurobiol, Ross 618,720 Rutland Ave, Baltimore, MD 21205 USA.	mfpeters@jhmi.edu; caross@jhu.edu	Ross, Christopher A/H-8395-2013		NINDS NIH HHS [NS38144, NS16375, NS34172] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034172, P50NS016375, R01NS038144, P01NS016375] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Bao J, 1996, P NATL ACAD SCI USA, V93, P5037, DOI 10.1073/pnas.93.10.5037; BESSERT DA, 1995, MOL BRAIN RES, V33, P165, DOI 10.1016/0169-328X(95)00124-B; Boutell JM, 1998, HUM MOL GENET, V7, P371, DOI 10.1093/hmg/7.3.371; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; DeRooij KE, 1996, HUM MOL GENET, V5, P1093, DOI 10.1093/hmg/5.8.1093; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Gusella JF, 2000, NEUROSCIENCE NEWS, V3, P15; Harlow E., 1999, USING ANTIBODIES LAB; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Jones L., 2000, NEUROSCIENCE NEWS, V3, P55; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; LEVINSON B, 1992, GENOMICS, V13, P862, DOI 10.1016/0888-7543(92)90170-W; Li H, 2000, NAT GENET, V25, P385, DOI 10.1038/78054; Li H, 1999, HUM MOL GENET, V8, P1227, DOI 10.1093/hmg/8.7.1227; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; NAYLOR JA, 1995, HUM MOL GENET, V4, P1217, DOI 10.1093/hmg/4.7.1217; NUCIFORA FC, 2000, SOC NEUR ABSTR, V26, pS1030; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; PERUTZ MF, 1995, MOL MED, V1, P718, DOI 10.1007/BF03401886; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Singaraja RR, 1999, AM J HUM GENET, V65, pA112; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wells R.D., 1998, GENETIC INSTABILITIE; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; Wood JD, 1996, HUM MOL GENET, V5, P481, DOI 10.1093/hmg/5.4.481; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	49	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3188	3194		10.1074/jbc.M008099200	http://dx.doi.org/10.1074/jbc.M008099200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035034	hybrid			2022-12-27	WOS:000166784900029
J	Taboy, CH; Vaughan, KG; Mietzner, TA; Aisen, P; Crumbliss, AL				Taboy, CH; Vaughan, KG; Mietzner, TA; Aisen, P; Crumbliss, AL			Fe3+ coordination and redox properties of a bacterial transferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-BINDING PROTEIN; SPECTROELECTROCHEMICAL METHOD; PATHOGENIC NEISSERIA; SERUM TRANSFERRIN; ACTIVE-SITE; C-LOBE; N-LOBE; HEMOGLOBINS; RESOLUTION; TRANSPORT	The Fe3+ binding site of recombinant nFbp, a ferric-binding protein found in the periplasmic space of pathogenic Neisseria, has been characterized by physicochemical techniques. An effective Fe3+ binding constant in the presence of 350 muM phosphate at pH 6.5 and 25 degreesC was determined as 2.4 x 10(18) M-1. EPR spectra for the recombinant Fe3+ nFbp gave g' = 4.3 and 9 signals characteristic of high spin Fe3+ in a strong ligand field of low (orthorhombic) symmetry. P-31 NMR experiments demonstrated the presence of bound phosphate in the hole form of nFbp and showed that phosphate can be dialyzed away in the absence of Fe3+ in apo-nFbp, Finally, an uncorrected Fe3+/2+ redox potential for Fe-nFbp was determined to be -290 mV (NHE) at pH 6.5, 20 degreesC, Whereas our findings show that nFbp and mammalian transferrin have similar Fe3+ binding constants and EPR spectra, they differ greatly in their redox potentials. This has implications for the mechanism of Fe transport across the periplasmic space of Gram-negative bacteria.	Duke Univ, Dept Chem, Durham, NC 27708 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yeshiva University; Albert Einstein College of Medicine	Crumbliss, AL (corresponding author), Duke Univ, Dept Chem, Durham, NC 27708 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015056] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL58248] Funding Source: Medline; NIAID NIH HHS [1 R29 AI32226] Funding Source: Medline; NIDDK NIH HHS [2 RO1 DK15056] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AASA R, 1963, BIOCHIM BIOPHYS ACTA, V75, P203, DOI 10.1016/0006-3002(63)90599-7; AASA R, 1967, J BIOL CHEM, V243, P2399; AISEN P, 1978, J BIOL CHEM, V253, P1930; AISEN P, 1994, IRON METABOLISM HLTH, P1; Albrecht-Gary AM, 1998, MET IONS BIOL SYST, V35, P239; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BERISH SA, 1990, J EXP MED, V171, P1535, DOI 10.1084/jem.171.5.1535; Braun V, 1997, BIOL CHEM, V378, P779; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; CHEN CY, 1993, MOL MICROBIOL, V10, P311, DOI 10.1111/j.1365-2958.1993.tb01957.x; CRICHTON RR, 1991, INORGANIC BIOCH IRON, P29; FAULKNER KM, 1994, INORG CHIM ACTA, V226, P187, DOI 10.1016/0020-1693(94)04086-9; FAULKNER KM, 1995, J BIOL CHEM, V270, P13604, DOI 10.1074/jbc.270.23.13604; FERGUSON SJ, 1991, PROKARYOTIC STRUCTUR, P311; FILATOVA LN, 1966, ZH NEORG KHIM, V11, P1662; HARRIS DC, 1985, BIOCHIM BIOPHYS ACTA, V838, P295, DOI 10.1016/0304-4165(85)90226-0; HARRIS WR, 1986, J INORG BIOCHEM, V27, P41, DOI 10.1016/0162-0134(86)80107-6; KRAGTEN J, 1978, ATLAS METAL LIGAND E, P284; Kraiter DC, 1998, INORG CHEM, V37, P964, DOI 10.1021/ic970644g; KRETCHMAR SA, 1988, BIOCHIM BIOPHYS ACTA, V956, P85, DOI 10.1016/0167-4838(88)90301-9; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; MCREE DE, IN PRESS; MIETZNER TA, 1987, J EXP MED, V165, P1041, DOI 10.1084/jem.165.4.1041; Mietzner TA, 1998, CURR TOP MICROBIOL, V225, P113; MORSE S, 1988, REV INFECT DIS S, V10, P306; NOWALK AJ, 1994, BIOCHEMISTRY-US, V33, P12769, DOI 10.1021/bi00209a007; SCHWARZENBACH G, 1963, HELV CHIM ACTA, V46, P1390, DOI 10.1002/hlca.19630460434; Taboy CH, 1999, BIOELECTROCH BIOENER, V48, P79, DOI 10.1016/S0302-4598(98)00236-0; Wilkins R.G., 1991, KINETICS MECH REACTI, DOI 10.1002/bbpc.19920960429; Zak O, 1997, BIOCHEMISTRY-US, V36, P11036, DOI 10.1021/bi970628v; ZAK O, 1983, BIOCHIM BIOPHYS ACTA, V742, P490, DOI 10.1016/0167-4838(83)90266-2; ZAK O, 1985, BIOCHIM BIOPHYS ACTA, V829, P348, DOI 10.1016/0167-4838(85)90243-2; [No title captured]	35	63	64	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2719	2724		10.1074/jbc.M004763200	http://dx.doi.org/10.1074/jbc.M004763200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11029460	hybrid			2022-12-27	WOS:000166784800058
J	Yang, BX; Gillespie, A; Carlson, EJ; Epstein, CJ; Verkman, AS				Yang, BX; Gillespie, A; Carlson, EJ; Epstein, CJ; Verkman, AS			Neonatal mortality in an aquaporin-2 knock-in mouse model of recessive nephrogenic diabetes insipidus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSENSITIVE WATER CHANNEL; COLLECTING DUCT; HEART-FAILURE; UP-REGULATION; RAT-KIDNEY; EXPRESSION; GENE; TRAFFICKING; MUTATIONS; MEMBRANE	Hereditary non-X-linked nephrogenic diabetes insipidus (NDI) is caused by mutations in the aquaporin-2 (AQP2) water channel. In transfected cells, the human disease-causing mutant AQP2-T126M is retained at the endoplasmic reticulum (ER) where it is functional and targetable to the plasma membrane with chemical chaperones. A mouse knock-in model of NDI was generated by targeted gene replacement using a Cre-loxP strategy. Along with T126M, mutations H122S, N124S, and A125T were introduced to preserve the consensus sequence for N-linked glycosylation found in human AQP2. Breeding of heterozygous mice yielded the expected Mendelian distribution with 26 homozygous mutant offspring of 99 live births. The mutant mice appeared normal at 2-3 days after birth but failed to thrive and generally died by day 6 if not given supplemental fluid. Urine/serum analysis showed a urinary concentrating defect with serum hyperosmolality and low urine osmolality that was not increased by a V2 vasopressin agonist, Northern blot analysis showed up-regulated AQP2-T126M transcripts of identical size to wild-type AQP2, Immunoblots showed complex glycosylation of wild-type AQP2 but mainly endoglycosidase H-sensitive core glycosylation of AQP2-T126M indicating ER-retention, Biochemical analysis revealed that the AQP2-T126M protein was resistant to detergent solubilization, Kidneys from mutant mice showed collecting duct dilatation, papillary atrophy, and unexpectedly, some plasma membrane AQP2 staining. The severe phenotype of the AQP2 mutant mice compared with that of mice lacking kidney water channels AQP1, AQP3, and AQP4 indicates a critical role for AQP2 in neonatal renal function in mice. Our results establish a mouse model of human autosomal NDI and provide the first in vivo biochemical data on a disease-causing AQP2 mutant.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288, R01HL051854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51854, HL58198, HL60288] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bichet DG, 1998, AM J MED, V105, P431, DOI 10.1016/S0002-9343(98)00301-5; Brown D, 1998, AM J PHYSIOL-RENAL, V275, pF328, DOI 10.1152/ajprenal.1998.275.3.F328; Chou CL, 1998, AM J PHYSIOL-CELL PH, V274, pC549, DOI 10.1152/ajpcell.1998.274.2.C549; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Devuyst O, 1996, AM J PHYSIOL-RENAL, V271, pF169, DOI 10.1152/ajprenal.1996.271.1.F169; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HAYASHI M, 1994, J CLIN INVEST, V94, P1778, DOI 10.1172/JCI117525; Hozawa S, 1996, AM J PHYSIOL-CELL PH, V270, pC1695, DOI 10.1152/ajpcell.1996.270.6.C1695; Lewandoski M, 1997, NAT GENET, V17, P223, DOI 10.1038/ng1097-223; MA T, 1998, AM J PHYSIOL, V273, P4296; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Marples D, 1998, P ASSOC AM PHYSICIAN, V110, P401; Marples D, 1999, AM J PHYSIOL-RENAL, V276, pF331, DOI 10.1152/ajprenal.1999.276.3.F331; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Nielsen S, 1997, P NATL ACAD SCI USA, V94, P5450, DOI 10.1073/pnas.94.10.5450; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Nielsen S, 1999, J AM SOC NEPHROL, V10, P647; Promeneur D, 2000, AM J PHYSIOL-RENAL, V279, pF370, DOI 10.1152/ajprenal.2000.279.2.F370; Saito T, 1999, AM J PHYSIOL-REG I, V277, pR427, DOI 10.1152/ajpregu.1999.277.2.R427; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Terris J, 1996, AM J PHYSIOL-RENAL, V271, pF414, DOI 10.1152/ajprenal.1996.271.2.F414; VANLIEBURG AF, 1994, AM J HUM GENET, V55, P648; Verkman AS, 2000, CURR OPIN NEPHROL HY, V9, P517, DOI 10.1097/00041552-200009000-00010; Ward DT, 1999, ANNU REV PHYSIOL, V61, P683, DOI 10.1146/annurev.physiol.61.1.683; Xu DL, 1997, J CLIN INVEST, V99, P1500, DOI 10.1172/JCI119312; YAMAMOTO T, 1995, EXP NEPHROL, V3, P193; Yamamoto T, 1998, KIDNEY INT, V54, P1041, DOI 10.1046/j.1523-1755.1998.00123.x; Yang Baoxue, 2000, Current Genomics, V1, P91, DOI 10.2174/1389202003351832; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200; Yang BX, 1999, GENOMICS, V57, P79, DOI 10.1006/geno.1999.5759; YUN J, 2000, J CLIN INVEST, V276, P624	35	115	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2775	2779		10.1074/jbc.M008216200	http://dx.doi.org/10.1074/jbc.M008216200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035038	hybrid			2022-12-27	WOS:000166784800065
J	Anflous, K; Armstrong, DD; Craigen, WJ				Anflous, K; Armstrong, DD; Craigen, WJ			Altered mitochondrial sensitivity for ADP and maintenance of creatine-stimulated respiration in oxidative striated muscles from VDAC1-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; ADENINE-NUCLEOTIDE TRANSLOCATOR; RAT-HEART MITOCHONDRIA; OUTER-MEMBRANE; SKELETAL-MUSCLE; IN-VIVO; ENERGY-TRANSPORT; KINASE; ISOFORMS; PORIN	Voltage-dependent anion channels (VDACs) form the main pathway for metabolites across the mitochondrial outer membrane. The mouse vdac1 gene has been disrupted by gene targeting, and the resulting mutant mice have been examined for defects in muscle physiology, To test the hypothesis that VDAC1 constitutes a pathway for ADP translocation into mitochondria, the apparent mitochondrial sensitivity for ADP (k(m(ADP))) and the calculated rate of respiration in the presence of the maximal ADP concentration (V-max) have been assessed using skinned fibers prepared from two oxidative muscles (ventricle and soleus) and a glycolytic muscle (gastrocnemius) in control and vdac1(-/-) mice. We observed a significant increase in the apparent K-m(ADP) in heart and gastrocnemius, whereas the V-max remained unchanged in both muscles. In contrast, a significant decrease in both the apparent K-m(ADP) and V-max was observed in soleus, To test whether VDAC1 is required for creatine stimulation of mitochondrial respiration in oxidative muscles, the apparent K-m(ADP) and V-max were determined in the presence of 25 mM creatine. The creatine effect on mitochondrial respiration was unchanged in both heart and soleus, These data, together with the significant increase in citrate synthase activity in heart, but not in soleus and gastrocnemius, suggest that distinct metabolic responses to altered mitochondrial outer membrane permeability occur in these different striated muscle types.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Craigen, WJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Rm S821,1 Baylor Plaza, Houston, TX 77030 USA.	wcraigen@bcm.tmc.edu			NIGMS NIH HHS [R01 GM055713-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055713] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anflous K, 1998, BBA-GENE STRUCT EXPR, V1399, P47, DOI 10.1016/S0167-4781(98)00088-8; Anflous K, 1997, BIOCHEM J, V322, P73, DOI 10.1042/bj3220073; BABEL D, 1991, BIOL CHEM H-S, V372, P1027, DOI 10.1515/bchm3.1991.372.2.1027; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BESSMAN SP, 1966, BIOCHEM BIOPH RES CO, V22, P597, DOI 10.1016/0006-291X(66)90317-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; BRDICZKA D, 1994, MOL CELL BIOCHEM, V133, P892; CLARK JF, 1994, BIOCHEM J, V300, P211, DOI 10.1042/bj3000211; COGSWELL AM, 1993, AM J PHYSIOL, V264, pC383, DOI 10.1152/ajpcell.1993.264.2.C383; CORNELIO F, 1985, J NEUROL, V232, P329, DOI 10.1007/BF00313831; Decker WK, 2000, MOL GENET METAB, V70, P69, DOI 10.1006/mgme.2000.2987; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DORING C, 1985, J MEMBRANE BIOL, V83, P81, DOI 10.1007/BF01868740; GELLERICH F, 1982, BIOCHEM BIOPH RES CO, V105, P1473, DOI 10.1016/0006-291X(82)90954-8; GELLERICH FN, 1983, BIOCHIM BIOPHYS ACTA, V722, P381, DOI 10.1016/0005-2728(83)90086-5; GOSALVEZ M, 1974, EUR J BIOCHEM, V46, P133, DOI 10.1111/j.1432-1033.1974.tb03605.x; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; Huizing M, 1996, PEDIATR RES, V39, P760, DOI 10.1203/00006450-199605000-00003; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; Kay L, 1997, BBA-BIOENERGETICS, V1322, P41, DOI 10.1016/S0005-2728(97)00071-6; Kuznetsov AV, 1996, EUR J BIOCHEM, V241, P909, DOI 10.1111/j.1432-1033.1996.00909.x; Lee AC, 1998, J MEMBRANE BIOL, V161, P173, DOI 10.1007/s002329900324; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; Ogata T, 1997, ANAT REC, V248, P214; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; PHILIPPI M, 1994, J EXP BIOL, V189, P1; Rahmani Z, 1998, EUR J HUM GENET, V6, P337, DOI 10.1038/sj.ejhg.5200198; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; SAKS V, 1995, BIOCHEM BIOPH RES CO, V208, P919, DOI 10.1006/bbrc.1995.1422; SAKS VA, 1995, J MOL CELL CARDIOL, V27, P625, DOI 10.1016/S0022-2828(08)80056-9; SAKS VA, 1975, EUR J BIOCHEM, V57, P273, DOI 10.1111/j.1432-1033.1975.tb02299.x; SAKS VA, 1980, J BIOL CHEM, V255, P755; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; Saks VA, 1996, MOL CELL BIOCHEM, V161, P195, DOI 10.1007/BF00240050; SAKS VA, 1991, BIOCHIM BIOPHYS ACTA, V1074, P302, DOI 10.1016/0304-4165(91)90168-G; Sampson MJ, 1996, GENOMICS, V36, P192, DOI 10.1006/geno.1996.0445; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Sampson MJ, 1996, GENOMICS, V33, P283, DOI 10.1006/geno.1996.0193; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SENGERS RCA, 1984, EUR J PEDIATR, V141, P192, DOI 10.1007/BF00572761; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; VEKSLER VI, 1987, BIOCHIM BIOPHYS ACTA, V892, P191, DOI 10.1016/0005-2728(87)90174-5; Wallimann T, 1998, BIOFACTORS, V8, P229, DOI 10.1002/biof.5520080310; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Xu X, 1999, J MEMBRANE BIOL, V170, P89, DOI 10.1007/s002329900540	51	105	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1954	1960		10.1074/jbc.M006587200	http://dx.doi.org/10.1074/jbc.M006587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11044447	hybrid			2022-12-27	WOS:000166528000043
J	Rodney, GG; Moore, CP; Williams, BY; Zhang, JZ; Krol, J; Pedersen, SE; Hamilton, SL				Rodney, GG; Moore, CP; Williams, BY; Zhang, JZ; Krol, J; Pedersen, SE; Hamilton, SL			Calcium binding to calmodulin leads to an N-terminal shift in its binding site on the ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; SKELETAL-MUSCLE; PROTEIN; APOCALMODULIN; COMPLEXES; DOMAINS; MUTANTS	The skeletal muscle calcium release channel, ryanodine receptor, is activated by calcium-free calmodulin and inhibited by calcium-bound calmodulin, Previous biochemical studies from our laboratory have shown that calcium-free calmodulin and calcium bound calmodulin protect sites at amino acids 3630 and 3637 from trypsin cleavage (Moore, C. P., Rodney, G,, Zhang, J. Z., Santacruz-Toloza, L,, Strasburg, G,, and Hamilton, S, L, (1999) Biochemistry 38, 8532-8537), We now demonstrate that both calcium-free calmodulin and calcium-bound calmodulin bind with nanomolar affinity to a synthetic peptide matching amino acids 3614-3643 of the ryanodine receptor, Deletion of the last nine amino acids (3635-3643) destroys the ability of the peptide to bind calcium-free calmodulin, but not calcium-bound calmodulin, We propose a novel mechanism for calmodulin's interaction with a target protein. Our data suggest that the binding sites for calcium-free calmodulin and calcium-bound calmodulin are overlapping and, when calcium binds to calmodulin, the calmodulin molecule shifts to a more N-terminal location on the ryanodine receptor converting it from an activator to an inhibitor of the channel, This region of the ryanodine receptor has previously been identified as a site of intersubunit contact, suggesting the possibility that calmodulin regulates ryanodine receptor activity by regulating subunit-subunit interactions.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.			Pedersen, Steen E./0000-0001-8755-8899; Hamilton, Susan/0000-0003-0241-9369	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041802, R01AR044864] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41802, AR44864] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Gomes AV, 2000, ARCH BIOCHEM BIOPHYS, V379, P28, DOI 10.1006/abbi.2000.1827; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Moore CP, 1999, J BIOL CHEM, V274, P36831, DOI 10.1074/jbc.274.52.36831; Mukherjea P, 1996, PROTEIN SCI, V5, P468; MUKHERJEA P, 1993, BIOCHEM MOL BIOL INT, V29, P555; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; Weljie AM, 2000, PROTEIN ENG, V13, P59, DOI 10.1093/protein/13.1.59; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; Yuan T, 1998, BIOCHEMISTRY-US, V37, P3187, DOI 10.1021/bi9716579; Zhang JZ, 1999, AM J PHYSIOL-CELL PH, V276, pC46	23	110	110	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2069	2074		10.1074/jbc.M008891200	http://dx.doi.org/10.1074/jbc.M008891200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035044	hybrid			2022-12-27	WOS:000166528000058
J	Chowdhury, S; Thomas, MG; Escalante-Semerena, JC; Banerjee, R				Chowdhury, S; Thomas, MG; Escalante-Semerena, JC; Banerjee, R			The coenzyme B-12 analog 5 '-deoxyadenosylcobinamide-GDP supports catalysis by methylmalonyl-CoA mutase in the absence of trans-ligand coordination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALT-CARBON BOND; X-RAY STRUCTURE; METHIONINE SYNTHASE; GLUTAMATE MUTASE; ESCHERICHIA-COLI; CLOSTRIDIUM-TETANOMORPHUM; DISSOCIATION ENERGY; HISTIDINE RESIDUE; DIOL DEHYDRATASE; NUCLEOTIDE LOOP	Methylmalonyl-CoA mutase is an 5'-adenosylcobalamin (AdoCbl)-dependent enzyme that catalyzes the rearrangement of methylmalonyl-CoA to succinyl-CoA The crystal structure of this protein revealed that binding of the cofactor is accompanied by a significant conformational change in which dimethylbenzimidazole, the lower axial ligand to cobalt in solution, is replaced by His(610) donated by the active site. The role of the lower axial ligand in the trillion fold labilization of the upper axial cobalt-carbon bond has been the subject of enduring debate in the model inorganic literature. In this study, we have used a cofactor analog, 5'deoxyadenosylcobinamide GDP (AdoCbi-GDP), which reconstitutes the enzyme in a "histidine-off' form and which allows us to evaluate the contribution of the lower axial ligand to catalysis, The k(cat) for the enzyme in the presence of AdoCbi-GDP is reduced by a factor of 4 compared with the native cofactor AdoCbl, The overall deuterium isotope effect in the presence of AdoCbi-GDP (V-D = 7.2 +/- 0.8) is comparable with that observed in the presence of AdoCbl (5.0 +/- 0.6) and indicates that the hydrogen transfer steps in this reaction are not significantly affected by the change in coordination state of the bound cofactor. These surprising results are in marked contrast to the effects ascribed to the corresponding lower axial histidine ligands in the cobalamin-dependent enzymes glutamate mutase and methionine synthase.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Nebraska System; University of Nebraska Lincoln; University of Wisconsin System; University of Wisconsin Madison	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, N133 Beadle Ctr, Lincoln, NE 68588 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045776, R01DK045776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040313, R37GM040313] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45776] Funding Source: Medline; NIGMS NIH HHS [GM40313, R01 GM040313] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1976, ACCOUNTS CHEM RES, V9, P114, DOI 10.1021/ar50099a006; Abend A, 1999, ARCH BIOCHEM BIOPHYS, V370, P138, DOI 10.1006/abbi.1999.1382; Amaratunga M, 1996, BIOCHEMISTRY-US, V35, P2453, DOI 10.1021/bi952388u; BABIOR BM, 1975, ACCOUNTS CHEM RES, V8, P376, DOI 10.1021/ar50095a003; Banerjee R, 1997, CHEM BIOL, V4, P175, DOI 10.1016/S1074-5521(97)90286-6; Banerjee R., 1999, CHEM BIOCH B 12; BROWN KL, 1991, INORG CHEM, V30, P3420, DOI 10.1021/ic00018a011; CHEMALY SM, 1980, J CHEM SOC DALTON, P2274, DOI 10.1039/dt9800002274; Chen HP, 1997, BIOCHEMISTRY-US, V36, P7884, DOI 10.1021/bi970169y; Chowdhury S, 2000, J AM CHEM SOC, V122, P5417, DOI 10.1021/ja994302g; Chowdhury S, 2000, BIOCHEMISTRY-US, V39, P7998, DOI 10.1021/bi992535e; Chowdhury S, 1999, BIOCHEMISTRY-US, V38, P15287, DOI 10.1021/bi9914762; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Garr CD, 1996, INORG CHEM, V35, P5912, DOI 10.1021/ic951272j; GENO MK, 1987, J AM CHEM SOC, V109, P1238, DOI 10.1021/ja00238a039; GRATE JH, 1979, J AM CHEM SOC, V101, P4601, DOI 10.1021/ja00510a027; HALPERN J, 1984, J AM CHEM SOC, V106, P8317, DOI 10.1021/ja00338a065; HAY BP, 1987, J AM CHEM SOC, V109, P8012, DOI 10.1021/ja00260a011; Hoover DM, 1997, BIOCHEMISTRY-US, V36, P127, DOI 10.1021/bi961693s; Jarrett JT, 1998, BIOCHEMISTRY-US, V37, P5372, DOI 10.1021/bi9730893; Jarrett JT, 1996, BIOCHEMISTRY-US, V35, P2464, DOI 10.1021/bi952389m; Ke SC, 1999, BIOCHEMISTRY-US, V38, P12681, DOI 10.1021/bi983067w; Lawrence CC, 1999, J BIOL CHEM, V274, P7039, DOI 10.1074/jbc.274.11.7039; LENHERT PG, 1961, NATURE, V192, P937, DOI 10.1038/192937a0; Maggio-Hall LA, 1999, P NATL ACAD SCI USA, V96, P11798, DOI 10.1073/pnas.96.21.11798; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; MARZILLI LG, 1979, J AM CHEM SOC, V101, P6754, DOI 10.1021/ja00516a049; MCKIE N, 1990, BIOCHEM J, V269, P293, DOI 10.1042/bj2690293; MICHENFELDER M, 1987, EUR J BIOCHEM, V168, P659, DOI 10.1111/j.1432-1033.1987.tb13467.x; NG FTT, 1982, J AM CHEM SOC, V104, P621, DOI 10.1021/ja00366a045; OTOOLE GA, 1995, J BIOL CHEM, V270, P23560, DOI 10.1074/jbc.270.40.23560; PADMAKUMAR R, 1995, J BIOL CHEM, V270, P9295, DOI 10.1074/jbc.270.16.9295; Padmakumar R, 1997, BIOCHEMISTRY-US, V36, P3713, DOI 10.1021/bi962503g; PADMAKUMAR R, 1995, J AM CHEM SOC, V117, P7033, DOI 10.1021/ja00131a039; Padmakumar R, 1997, METHOD ENZYMOL, V279, P220; PILBROW JR, 1982, B12; Poppe L, 1997, EUR J BIOCHEM, V250, P303, DOI 10.1111/j.1432-1033.1997.0303a.x; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; RANDACCIO L, 1980, J AM CHEM SOC, V102, P7373; Reitzer R, 1999, STRUCTURE, V7, P891, DOI 10.1016/S0969-2126(99)80116-6; Shibata N, 1999, STRUCTURE, V7, P997, DOI 10.1016/S0969-2126(99)80126-9; Sirovatka JM, 1997, J AM CHEM SOC, V119, P3057, DOI 10.1021/ja963380q; STUPPERICH E, 1990, EUR J BIOCHEM, V193, P105, DOI 10.1111/j.1432-1033.1990.tb19310.x; SUMMERS MF, 1983, J AM CHEM SOC, V105, P6259, DOI 10.1021/ja00358a012; TAOKA S, 1994, J BIOL CHEM, V269, P31630; Tollinger M, 1998, STRUCTURE, V6, P1021, DOI 10.1016/S0969-2126(98)00103-8; WADDINGTON MD, 1993, J AM CHEM SOC, V115, P4629, DOI 10.1021/ja00064a026; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008; ZELDER O, 1995, FEBS LETT, V369, P252, DOI 10.1016/0014-5793(95)00762-X; [No title captured]	51	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1015	1019		10.1074/jbc.M006842200	http://dx.doi.org/10.1074/jbc.M006842200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11031263	hybrid			2022-12-27	WOS:000166430900022
J	Liang, FQ; Schaufele, F; Gardner, DG				Liang, FQ; Schaufele, F; Gardner, DG			Functional interaction of NF-Y and Sp1 is required for type a natriuretic peptide receptor gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING PROTEIN; SMOOTH-MUSCLE CELLS; SEQUENCE IDENTITY; MICE LACKING; DNA COMPLEX; YEAST HAP2; B-SUBUNIT; CLASS-II; CBF-B; PROMOTER	The vasorelaxant and anti-mitogenic activities of the atrial and brain natriuretic peptides depend upon their binding to the type A natriuretic peptide receptor (NPR-A) expressed on the surface of vascular cells. Intervention strategies aimed at controlling NPR-A expression are limited by the paucity of studies in this area. Here we identify a sequence CCAAT between -141 and -137 of the NPR-A promoter that, when mutated, reduces promoter activity by 90% in rat aortic smooth muscle (RASM) cells. Protein/DNA cross-linking and immunoperturbation of electrophoretically shifted complexes formed between RASM nuclear extracts and an oligonucleotide surrounding the CCAAT sequence indicates that the heterotrimeric transcription factor NF-Y binds specifically to the wild-type, but not mutated, CCAAT element. Cotransfection of a dominant negative mutant of the NF-YA subunit results in a concentration-dependent decrease in the activity of the NPR-A promoter in RASM cells confirming that endogenous NF-Y is an activator of the promoter. Mutation of the CCAAT element, in conjunction with mutation of all three Spl sites previously shown to be involved in NPR-A promoter regulation, virtually eliminates NPR-A promoter activity in RASM cells. Coexpression of all three NF-Y subunits together with Spl in Drosophila cells deficient in these factors indicates that NF-Y and Spl act synergistically to reconstitute NPR-A promoter activity. A direct physical association between NF-Y and Spl can be demonstrated both in vitro by glutathione S-transferase pull-down assay and in the intact cell by coimmunoprecipitation and functional studies. Together, these studies show that NPR-A promoter activity is dominantly regulated through functional, and possibly physical, interactions of NF-Y and Spl.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DG (corresponding author), Univ Calif San Francisco, Metab Res Unit, 1109 HSW, San Francisco, CA 94143 USA.				NHLBI NIH HHS [HL45637] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045637] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; GOOD L, 1995, J CELL PHYSIOL, V163, P636, DOI 10.1002/jcp.1041630326; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Levin ER, 1998, NEW ENGL J MED, V339, P321; Liang FQ, 1999, ENDOCRINOLOGY, V140, P1695, DOI 10.1210/en.140.4.1695; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Osada S, 1996, J BIOL CHEM, V271, P3891; Schaufele F, 1996, J BIOL CHEM, V271, P21484, DOI 10.1074/jbc.271.35.21484; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; Schwartzbauer G, 1998, J BIOL CHEM, V273, P24760, DOI 10.1074/jbc.273.38.24760; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; YAMAGUCHI M, 1990, J BIOL CHEM, V265, P20414; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	41	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1516	1522		10.1074/jbc.M006350200	http://dx.doi.org/10.1074/jbc.M006350200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11022037	hybrid			2022-12-27	WOS:000166430900088
J	Otero, DC; Omori, SA; Rickert, RC				Otero, DC; Omori, SA; Rickert, RC			CD19-dependent activation of Akt kinase in B-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR COMPLEX; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; INOSITOL 5'-PHOSPHATASE; CA2+ MOBILIZATION; SYNTHASE KINASE-3; CD19 RECEPTOR; ASSOCIATION	CD19 is rapidly phosphorylated upon B-cell antigen receptor (BCR) cross-linking, leading to the recruitment of downstream signaling intermediates. A prominent feature of CD19 signaling is the binding and activation of phosphoinositide S-kinase (PI3K), which accounts for the majority of PI3K activity induced by BCR ligation. Recent findings have implicated activation of the serine/threonine kinase Akt as imparting survival signals in a PI3K-dependent fashion. Using CD19-deficient B-lymphhoma cells and mouse splenic B-cells, we show that CD19 is necessary for efficient activation of Akt following cross-linking of surface immunoglobulin or Ig beta, In the absence of CD19, Akt kinase activity is reduced and transient. In addition, coligation of CD19 with surface immunoglobulin leads to augmented Akt activity in a dose-dependent manner. Thus, CD19 is a key regulator of Akt activity in B-cells; as such it may contribute to pre-BCR or BCR-mediated cell survival in vivo.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Rickert, RC (corresponding author), 9500 Gilman Dr,0322, La Jolla, CA 92093 USA.	rrickert@ucsd.edu		Fitzpatrick, Sidne/0000-0002-5245-4624	NATIONAL CANCER INSTITUTE [T32CA009345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041649] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09345] Funding Source: Medline; NIAID NIH HHS [AI41649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Carter RH, 1997, J IMMUNOL, V158, P3062; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gold MR, 1999, J IMMUNOL, V163, P1894; Gupta N, 1999, J BIOL CHEM, V274, P7489, DOI 10.1074/jbc.274.11.7489; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Kitanaka A, 1997, J IMMUNOL, V159, P184; Li HL, 1999, P NATL ACAD SCI USA, V96, P6890, DOI 10.1073/pnas.96.12.6890; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; Xiao J, 1996, J BIOL CHEM, V271, P7659, DOI 10.1074/jbc.271.13.7659	24	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1474	1478		10.1074/jbc.M003918200	http://dx.doi.org/10.1074/jbc.M003918200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042164	hybrid			2022-12-27	WOS:000166430900082
J	Westmark, CJ; Malter, JS				Westmark, CJ; Malter, JS			Up-regulation of nucleolin mRNA and protein in peripheral blood mononuclear cells by extracellular-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-CLEAVING ACTIVITY; HEAT-SHOCK PROTEIN-70; RNA-BINDING-PROTEIN; PRE-RIBOSOMAL-RNA; MESSENGER-RNA; GLYCINE-RICH; 3'-UNTRANSLATED REGION; COMPLEX-FORMATION; PHOSPHORYLATION; IDENTIFICATION	The signal transduction pathways regulating nucleolin mRNA and protein production have yet to be elucidated. Peripheral blood mononuclear cells treated with phorbol 12-myristate 13-acetate showed steady state levels of nucleolin mRNA that were 2-2.5-fold greater than untreated control cells. The up-regulation of nucleolin mRNA was substantially repressed by U0126, a specific inhibitor that blocks phosphorylation of extracellular-regulated kinase (ERK), Calcium ionophores A23187 and ionomycin also activated ERK and substantially elevated nucleolin mRNA levels, demonstrating phorbol 12-myristate 13-acetate and calcium signaling converge on ERK, Drugs that affected protein kinase C, protein kinase A, and phospholipase C signal transduction pathways did not alter nucleolin mRNA levels significantly. The half-life of nucleolin mRNA increased from 1.8 h in resting cells to 3.2 h with phorbol ester activation, suggesting ERK-mediated posttranscriptional regulation. Concomitantly, full-length nucleolin protein was increased. The higher levels of nucleolin protein were accompanied by increased binding of a 70-kDa nucleolin fragment to the 29-base instability element in the 3'-untranslated region of amyloid precursor protein (APP) mRNA in gel mobility shift assays. Supplementation of rabbit reticulocyte lysate with nucleolin decreased APP mRNA stability and protein production. These data suggest ERK up-regulates nucleolin posttranscriptionally thereby controlling APP production.	Univ Wisconsin, Sch Med, Inst Aging, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Malter, JS (corresponding author), Univ Wisconsin Hosp & Clin, Rm K4-812,600 Highland Ave, Madison, WI 53792 USA.		Westmark, Cara J/L-4647-2019; Westmark, Cara/AAX-4408-2020		NATIONAL INSTITUTE ON AGING [R01AG010675] Funding Source: NIH RePORTER; NIA NIH HHS [AG00213, R01AG10675] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOURBON HM, 1983, MOL BIOL REP, V9, P39, DOI 10.1007/BF00777472; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; CSERMELY P, 1993, J BIOL CHEM, V268, P9747; DERENZINI M, 1995, LAB INVEST, V73, P497; EGYHAZI E, 1988, EXP CELL RES, V178, P264, DOI 10.1016/0014-4827(88)90397-7; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; FUKUDA H, 1994, NEUROCHEM INT, V25, P567, DOI 10.1016/0197-0186(94)90155-4; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Herblot S, 1999, J IMMUNOL, V162, P3280; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; KIBBEY MC, 1995, J NEUROSCI RES, V42, P314, DOI 10.1002/jnr.490420305; KONISHI T, 1995, J BIOCHEM-TOKYO, V117, P1170, DOI 10.1093/oxfordjournals.jbchem.a124840; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; Larrucea S, 1998, J BIOL CHEM, V273, P31718, DOI 10.1074/jbc.273.48.31718; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; LISCHWE MA, 1981, EXP CELL RES, V136, P101, DOI 10.1016/0014-4827(81)90041-0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MEHES G, 1995, CELL PROLIFERAT, V28, P329, DOI 10.1111/j.1365-2184.1995.tb00074.x; MEYUHAS O, 1990, BIOCHIM BIOPHYS ACTA, V1049, P38, DOI 10.1016/0167-4781(90)90082-D; MURAKAMI T, 1991, J BIOCHEM-TOKYO, V110, P146, DOI 10.1093/oxfordjournals.jbchem.a123533; OHMORI H, 1990, EXP CELL RES, V189, P227, DOI 10.1016/0014-4827(90)90240-B; OLSON MOJ, 1990, BIOCHEMISTRY-US, V29, P5682, DOI 10.1021/bi00476a006; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Rajagopalan LE, 1998, NUCLEIC ACIDS RES, V26, P3418, DOI 10.1093/nar/26.14.3418; Reddy PMS, 1996, AM J RESP CELL MOL, V15, P398, DOI 10.1165/ajrcmb.15.3.8810645; SCHNEIDER HR, 1989, BIOCHIM BIOPHYS ACTA, V1014, P98, DOI 10.1016/0167-4889(89)90246-2; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; Waggoner S, 1998, J VIROL, V72, P6699, DOI 10.1128/JVI.72.8.6699-6709.1998; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; Yurkova MS, 1997, J BIOL CHEM, V272, P10870; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292	53	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1119	1126		10.1074/jbc.M009435200	http://dx.doi.org/10.1074/jbc.M009435200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042220	hybrid			2022-12-27	WOS:000166430900037
J	Carneiro, FA; Ferradosa, AS; Da Poian, AT				Carneiro, FA; Ferradosa, AS; Da Poian, AT			Low pH-induced conformational changes in vesicular stomatitis virus glycoprotein involve dramatic structure reorganization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI-FOREST VIRUS; MEMBRANE-FUSION ACTIVITY; ENVELOPED VIRUSES; VIRAL FUSION; CELL-FUSION; G-PROTEIN; DOMAIN; FLUORESCENCE; INFLUENZA; MUTATIONS	Membrane fusion is the key step in the entry of enveloped animal viruses into their host cells. Fusion of vesicular stomatitis virus with membranes occurs at acidic pH and is mediated by its envelope glycoprotein, the G protein. To study the structural transitions induced by acidic pH on cr protein, we have extracted the protein from purified virus by incubation with nonionic detergent, At pH 6.0, purified G protein was able to mediate fusion of either phospholipid vesicles or Vero cells in culture. Intrinsic fluorescence studies revealed that changes in the environment of Trp residues occurred as pH decreases. In the absence of lipidic membranes, acidification led to G protein aggregation, whereas protein-protein interactions were substituted bg protein-lipid interactions in the presence of liposomes, 1,1'-Bis(4-aniline-5-naphthalene sulfonate) (bis-ANS) binding was utilized to probe the degree of exposure of hydrophobic regions of G protein during acidification. Bis-ANS binding was maximal at pH 6.2, suggesting that a hydrophobic segment is exposed to the medium at this pH, At pH 6.0, a dramatic decrease in bis-ANS binding was observed, probably due to loss of tridimensional structure during the conformational rearrangement. This hypothesis was confirmed by circular dichroism analysis at different pH values, which showed a great decrease in cu-helix content at pH values close to 6.0, suggesting that a reorganization of G protein secondary structure occurs during the fusion reaction. Our results indicate that G protein undergoes dramatic structural changes at acidic pH and acquires a conformational state able to interact with the target membrane.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Da Poian, AT (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.		CARNEIRO, FABIANA A/S-4525-2018; Da Poian, Andrea T./V-1699-2019; Carneiro, Fabiana/GVS-8458-2022	Da Poian, Andrea/0000-0002-3969-704X; Carneiro, Fabiana/0000-0002-6584-4875				BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Cantor C.R., 1980, BIOPHYSICAL CHEM 2, P838; Cleverley DZ, 1998, P NATL ACAD SCI USA, V95, P3425, DOI 10.1073/pnas.95.7.3425; Da Poian AT, 1998, J VIROL METHODS, V70, P45, DOI 10.1016/S0166-0934(97)00166-3; DaPoian AT, 1996, P NATL ACAD SCI USA, V93, P8268, DOI 10.1073/pnas.93.16.8268; DAPOIAN AT, 1994, BIOCHEMISTRY-US, V33, P8339, DOI 10.1021/bi00193a022; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; EIDELMAN O, 1984, J BIOL CHEM, V259, P4622; FREDERICKSEN BL, 1995, J VIROL, V69, P1435, DOI 10.1128/JVI.69.3.1435-1443.1995; Freire E, 2000, J BIOL CHEM, V275, P817, DOI 10.1074/jbc.275.2.817; FULLER SD, 1995, CELL, V81, P715, DOI 10.1016/0092-8674(95)90533-2; GAUDIN Y, 1991, J VIROL, V65, P4853, DOI 10.1128/JVI.65.9.4853-4859.1991; GAUDIN Y, 1995, J GEN VIROL, V76, P1541, DOI 10.1099/0022-1317-76-7-1541; Hall MP, 1998, BBA-BIOMEMBRANES, V1415, P101, DOI 10.1016/S0005-2736(98)00186-2; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HUANG RTC, 1981, VIROLOGY, V110, P243, DOI 10.1016/0042-6822(81)90030-1; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; JUSTMAN J, 1993, J VIROL, V67, P7597, DOI 10.1128/JVI.67.12.7597-7607.1993; LANZREIN M, 1994, BIOCHEM J, V302, P313, DOI 10.1042/bj3020313; Nandi PK, 1999, ARCH VIROL, V144, P1751, DOI 10.1007/s007050050702; NEWCOMB WW, 1981, J VIROL, V39, P295, DOI 10.1128/JVI.39.1.295-299.1981; Odell D, 1997, J VIROL, V71, P7996, DOI 10.1128/JVI.71.10.7996-8000.1997; Pak CC, 1997, BIOCHEMISTRY-US, V36, P8890, DOI 10.1021/bi9702851; PAL R, 1988, BIOCHEMISTRY-US, V27, P30, DOI 10.1021/bi00401a006; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Shokralla S, 1998, VIROLOGY, V242, P39, DOI 10.1006/viro.1997.8986; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; WAHLBERG JM, 1992, J CELL BIOL, V116, P339, DOI 10.1083/jcb.116.2.339; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; ZHANG L, 1994, J VIROL, V68, P2186, DOI 10.1128/JVI.68.4.2186-2193.1994	32	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					62	67		10.1074/jbc.M008753200	http://dx.doi.org/10.1074/jbc.M008753200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024041	hybrid			2022-12-27	WOS:000166280700010
J	Cieslewicz, MJ; Kasper, DL; Wang, Y; Wessels, MR				Cieslewicz, MJ; Kasper, DL; Wang, Y; Wessels, MR			Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE; ESCHERICHIA-COLI; IMMUNOCHEMICAL CHARACTERIZATION; MOLECULAR CHARACTERIZATION; PNEUMONIAE SEROTYPE-14; OVERLAP EXTENSION; ACID CAPSULE; EXPRESSION; IDENTIFICATION; BIOSYNTHESIS	Several species of streptococci produce extracellular polysaccharides in the form of secreted exopolysaccharides or cell-associated capsules. Although the biological properties and repeating unit structures of these polysaccharides are diverse, sequence analysis of the genes required for their production has revealed a surprising degree of conservation among five genes found in the capsule gene cluster of each of several polysaccharide-producing streptococci. To determine the function of these conserved genes, we characterized a series of isogenic mutants derived from a wild-type strain of type Is group B Streptococcus by selectively inactivating each gene. Inactivation of cpsIaE resulted in an aeapsular phenotype, consistent with previous work that identified the cpsIaE product as the glycosyltransferase that initiates synthesis of the polysaccharide repeating unit. Mutants in cpsIaA, cpsIaB, cpsIaC, or cpsIaD produced type Is capsular polysaccharide, but in reduced amounts compared with the wild type. Analysis of the mutant polysaccharides and of capsule gene transcription in the mutant strains provided evidence that cpsIaA encodes a transcriptional activator that regulates expression of the capsule gene operon. Mutants in cpsIaC or cpsIaD produced polysaccharide of reduced molecular size but with an identical repeating unit structure as the wild-type strain. We conclude that CpsA to -D are not required for polysaccharide repeating unit biosynthesis but rather that they direct the coordinated polymerization and export of high molecular weight polysaccharide.	Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Wessels, MR (corresponding author), Harvard Univ, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	mwessels@channing.harvard.edu			NIAID NIH HHS [AI42940, AI07061] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042940, R21AI042940] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberti S, 1998, MOL MICROBIOL, V28, P343, DOI 10.1046/j.1365-2958.1998.00800.x; BATCHELOR RA, 1991, J BACTERIOL, V173, P5699, DOI 10.1128/jb.173.18.5699-5704.1991; BECKER PT, 1995, RES NURS HEALTH, V18, P191, DOI 10.1002/nur.4770180302; DIFABIO JL, 1989, CAN J CHEM, V67, P877; GARCIA E, 1993, MOL GEN GENET, V239, P188; GUIDOLIN A, 1994, INFECT IMMUN, V62, P5384, DOI 10.1128/IAI.62.12.5384-5396.1994; Guttormsen HK, 1996, J INFECT DIS, V173, P142, DOI 10.1093/infdis/173.1.142; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JENNINGS HJ, 1990, CURR TOP MICROBIOL, V150, P97; JENNINGS HJ, 1983, BIOCHEMISTRY-US, V22, P1258, DOI 10.1021/bi00274a042; JENNINGS HJ, 1981, BIOCHEMISTRY-US, V20, P4511, DOI 10.1021/bi00519a001; KOGAN G, 1995, CARBOHYD RES, V277, P1, DOI 10.1016/0008-6215(95)00195-Y; Kogan G, 1996, J BIOL CHEM, V271, P8786, DOI 10.1074/jbc.271.15.8786; Kolkman MAB, 1998, J BIOCHEM, V123, P937; Kolkman MAB, 1997, J BIOL CHEM, V272, P19502, DOI 10.1074/jbc.272.31.19502; Kolkman MAB, 1996, J BACTERIOL, V178, P3736, DOI 10.1128/jb.178.13.3736-3741.1996; Koskiniemi S, 1998, FEMS IMMUNOL MED MIC, V21, P159, DOI 10.1111/j.1574-695X.1998.tb01162.x; LAZAREVIC V, 1992, J GEN MICROBIOL, V138, P1949, DOI 10.1099/00221287-138-9-1949; Morona JK, 2000, MOL MICROBIOL, V35, P1431, DOI 10.1046/j.1365-2958.2000.01808.x; OCONNOR SP, 1987, J INFECT DIS, V156, P495, DOI 10.1093/infdis/156.3.495; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; Paoletti LC, 1996, INFECT IMMUN, V64, P1220, DOI 10.1128/IAI.64.4.1220-1226.1996; PEREZCASAL J, 1993, MOL MICROBIOL, V8, P809, DOI 10.1111/j.1365-2958.1993.tb01628.x; RUBENS CE, 1987, P NATL ACAD SCI USA, V84, P7208, DOI 10.1073/pnas.84.20.7208; RUBENS CE, 1993, MOL MICROBIOL, V8, P843, DOI 10.1111/j.1365-2958.1993.tb01631.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sau S, 1997, MICROBIOL-UK, V143, P2395, DOI 10.1099/00221287-143-7-2395; Smith HE, 1999, INFECT IMMUN, V67, P1750; Stingele F, 1996, J BACTERIOL, V178, P1680, DOI 10.1128/jb.178.6.1680-1690.1996; vanKranenburg R, 1997, MOL MICROBIOL, V24, P387, DOI 10.1046/j.1365-2958.1997.3521720.x; VIMR E, 1995, J IND MICROBIOL, V15, P352, DOI 10.1007/BF01569991; VONHUNOLSTEIN C, 1993, INFECT IMMUN, V61, P1272, DOI 10.1128/IAI.61.4.1272-1280.1993; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WESSELS MR, 1991, J BIOL CHEM, V266, P6714; WESSELS MR, 1993, INFECT IMMUN, V61, P4760, DOI 10.1128/IAI.61.11.4760-4766.1993; WESSELS MR, 1987, J BIOL CHEM, V262, P8262; Yamamoto S, 1999, J BACTERIOL, V181, P5176, DOI 10.1128/JB.181.17.5176-5184.1999; Yim HH, 1997, BIOTECHNIQUES, V23, P229, DOI 10.2144/97232bm11	39	128	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					139	146		10.1074/jbc.M005702200	http://dx.doi.org/10.1074/jbc.M005702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027683	hybrid			2022-12-27	WOS:000166280700020
J	Lee, MS; Zhu, YL; Chang, JE; Dannies, PS				Lee, MS; Zhu, YL; Chang, JE; Dannies, PS			Acquisition of Lubrol insolubility, a common step for growth hormone and prolactin in the secretory pathway of neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; SITE-DIRECTED MUTAGENESIS; GRANULE CONTENT PROTEINS; GH4C1 CELLS; CARBOXYPEPTIDASE-E; MOLECULAR-ORGANIZATION; MEMBRANE-PROTEINS; REGULATED PATHWAY; SECRETOGRANIN-II; GH(4)C(1) CELLS	Rat prolactin in the dense cores of secretory granules of the pituitary gland is a Lubrol-insoluble aggregate. In GH(4)C(1) cells, newly synthesized rat prolactin and growth hormone were soluble, but after 30 min about 40% converted to a Lubrol-insoluble form. Transport from the endoplasmic reticulum is necessary for conversion to Lubrol insolubility, since incubating cells with brefeldin A or at 15 degreesC reduced formation of insoluble rat S-35-prolactin, Formation of Lubrol-insoluble aggregates has protein and cell specificity; newly synthesized human growth hormone expressed in AtT20 cells underwent a 40% conversion to Lubrol insolubility with time, but albumin did not, and human growth hormone expressed in COS cells underwent less than 10% conversion to Lubrol insolubility. del32-46 growth hormone, a naturally occurring form of growth hormone, and P89L growth hormone underwent conversion, although they were secreted more slowly, indicating that there is some tolerance in structural requirements for aggregation. An intracellular compartment with an acidic pH is not necessary for conversion to Lubrol insolubility, because incubation with chloroquine or bafilomycin slowed, but did not prevent, the conversion. GH(4)G(1) cells treated with estradiol, insulin, and epidermal growth factor accumulate more secretory granules and store more prolactin, but not more growth hormone, than untreated cells; Lubrol-insoluble aggregates of prolactin and growth hormone formed to the same extent in hormone-treated or untreated GH(4)C(1) cells, but prolactin was retained longer in hormone-treated cells. These findings indicate that aggregation alone is not sufficient to cause retention of secretory granule proteins, and there is an additional selective process.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Dannies, PS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.				NIDDK NIH HHS [DK 46807] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046807] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIZAWA T, 1985, ENDOCRINOLOGY, V116, P909, DOI 10.1210/endo-116-3-909; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BAUMANN G, 1991, ENDOCR REV, V12, P424, DOI 10.1210/edrv-12-4-424; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; DELBEKE D, 1985, MOL CELL ENDOCRINOL, V43, P15, DOI 10.1016/0303-7207(85)90037-1; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUQUESNOY P, 1998, END SOC 80 ANN M JUN; FARQUHAR MG, 1978, ENDOCRINOLOGY, V102, P296, DOI 10.1210/endo-102-1-296; FARQUHAR MG, 1974, COMP ENDOCRINOLOGY P; FREEDMAN SD, 1993, BIOCHEM BIOPH RES CO, V197, P992, DOI 10.1006/bbrc.1993.2577; FRICKER LD, 1990, NEUROENDOCRINOLOGY, V51, P658, DOI 10.1159/000125407; GIANNATTASIO G, 1975, J CELL BIOL, V64, P246, DOI 10.1083/jcb.64.1.246; Gorr SU, 1996, J BIOL CHEM, V271, P3575; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HINKLE PM, 1992, ENDOCRINOLOGY, V130, P3503, DOI 10.1210/en.130.6.3503; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEBLOND FA, 1993, BIOCHEM J, V291, P289, DOI 10.1042/bj2910289; Lee MS, 2000, ENDOCRINOLOGY, V141, P883, DOI 10.1210/en.141.3.883; Lee MS, 2000, ENDOCRINOLOGY, V141, P3485, DOI 10.1210/en.141.9.3485; Lee MS, 1998, ENDOCRINOLOGY, V139, P2727, DOI 10.1210/en.139.6.2727; MAINS RE, 1988, J BIOL CHEM, V263, P7887; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; RAMBOURG A, 1992, ANAT RECORD, V232, P169, DOI 10.1002/ar.1092320202; REAVES BJ, 1990, MOL ENDOCRINOL, V4, P1017, DOI 10.1210/mend-4-7-1017; Rindler MJ, 1998, J BIOL CHEM, V273, P31180, DOI 10.1074/jbc.273.47.31180; SARASTE J, 1991, J CELL SCI, V100, P415; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; Song LX, 1997, BIOCHEM J, V323, P265, DOI 10.1042/bj3230265; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; SOSSIN WS, 1990, P NATL ACAD SCI USA, V87, P4845, DOI 10.1073/pnas.87.12.4845; STOLLER TJ, 1989, J BIOL CHEM, V264, P6922; Sun ZY, 1996, MOL ENDOCRINOL, V10, P265, DOI 10.1210/me.10.3.265; THOMPSON ME, 1992, ENDOCRINOLOGY, V131, P318, DOI 10.1210/en.131.1.318; Wada M, 1998, MOL ENDOCRINOL, V12, P146, DOI 10.1210/mend.12.1.0054; ZANINI A, 1980, J CELL BIOL, V86, P260, DOI 10.1083/jcb.86.1.260	46	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					715	721		10.1074/jbc.M008530200	http://dx.doi.org/10.1074/jbc.M008530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024038	hybrid			2022-12-27	WOS:000166280700096
J	Pohjanjoki, P; Fabrichniy, IP; Kasho, VN; Cooperman, BS; Goldman, A; Baykov, AA; Lahti, R				Pohjanjoki, P; Fabrichniy, IP; Kasho, VN; Cooperman, BS; Goldman, A; Baykov, AA; Lahti, R			Probing essential water in yeast pyrophosphatase by directed mutagenesis and fluoride inhibition measurements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INORGANIC PYROPHOSPHATASE; ESCHERICHIA-COLI; ACTIVE-SITE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ORTHO-PHOSPHATE; CATALYSIS; HYDROLYSIS; SUBSTITUTION	The pattern of yeast pyrophosphatase (Y-PPase) inhibition by fluoride suggests that it replaces active site Mg2+-bound nucleophilic water, for which two different locations were proposed previously. To localize the bound fluoride, we investigate here the effects of mutating Tyr(93) and five dicarboxylic amino acid residues forming two metal binding sites in Y-PPase on its inhibition by fluoride and its five catalytic functions (steady-state PPi hydrolysis and synthesis, formation of enzyme-bound PPi at equilibrium, phosphate-water oxygen exchange, and Mg2+ binding). D117E substitution had the largest effect on fluoride binding and made the P-O bond cleavage step rate-limiting in the catalytic cycle, consistent with the mechanism in which the nucleophile is coordinated by two metal ions and Asp(117). The effects of the mutations on PPi hydrolysis (as characterized by the catalytic constant and the net rate constant for P-O bond cleavage) were in general larger than on PPi synthesis (as characterized by the net rate constant for PPi release from active site). The effects of fluoride on the Y-PPase variants confirmed that PPase catalysis involves two enzyme PPi intermediates, which bind fluoride with greatly different rates (Baykov, A. A., Fabrichniy, I. P., Pobjanjoki, P., Zyryanov, A. B., and Lahti, R. (2000) Biochemistry 39, 11989-11947). A mechanism for the structural changes underlying the interconversion of the enzyme PPi intermediates is proposed.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Moscow MV Lomonosov State Univ, Sch Chem, Moscow 119899, Russia; Univ Turku, Dept Biochem, FIN-20014 Turku, Finland; Univ Calif Los Angeles, Dept Med, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	Lomonosov Moscow State University; Lomonosov Moscow State University; Finland National Institute for Health & Welfare; University of Turku; University of California System; University of California Los Angeles; University of Pennsylvania; University of Helsinki	Baykov, AA (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia.		Baykov, Alexander A/C-7981-2012; Baykov, Alexander/AAH-5301-2021	Baykov, Alexander/0000-0002-2495-8200				Avaeva S, 1996, FEBS LETT, V399, P99, DOI 10.1016/S0014-5793(96)01296-3; Avaeva SM, 1998, BIOCHEMISTRY-MOSCOW+, V63, P671; BAYKOV AA, 1973, EUR J BIOCHEM, V32, P136, DOI 10.1111/j.1432-1033.1973.tb02589.x; BAYKOV AA, 1992, EUR J BIOCHEM, V206, P463, DOI 10.1111/j.1432-1033.1992.tb16947.x; Baykov AA, 2000, BIOCHEMISTRY-US, V39, P11939, DOI 10.1021/bi000627u; BAYKOV AA, 1977, BIOCHIM BIOPHYS ACTA, V481, P184, DOI 10.1016/0005-2744(77)90150-4; BAYKOV AA, 1979, BIOCHIM BIOPHYS ACTA, V569, P228, DOI 10.1016/0005-2744(79)90058-5; Baykov AA, 1996, BIOCHEMISTRY-US, V35, P4655, DOI 10.1021/bi952635u; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; Belogurov GA, 2000, BIOCHEMISTRY-US, V39, P13931, DOI 10.1021/bi000895s; Chen GJ, 1997, BIOCHEMISTRY-US, V36, P4278, DOI 10.1021/bi9618676; DALEY LA, 1986, ANAL BIOCHEM, V157, P385, DOI 10.1016/0003-2697(86)90642-1; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; EMSLEY J, 1977, J CHEM SOC PERK T 2, P2079, DOI 10.1039/p29770002079; Fabrichniy IP, 1997, BIOCHEMISTRY-US, V36, P7746, DOI 10.1021/bi9629844; GONZALEZ MA, 1984, BIOCHEMISTRY-US, V23, P797, DOI 10.1021/bi00300a002; HACKNEY DD, 1980, J BIOL CHEM, V255, P5320; Harutyunyan EH, 1997, BIOCHEMISTRY-US, V36, P7754, DOI 10.1021/bi962637u; Harutyunyan EH, 1996, EUR J BIOCHEM, V239, P220, DOI 10.1111/j.1432-1033.1996.0220u.x; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Heikinheimo P, 1996, EUR J BIOCHEM, V239, P138, DOI 10.1111/j.1432-1033.1996.0138u.x; JANSON CA, 1979, J BIOL CHEM, V254, P3743; Kaminskaia NV, 2000, J AM CHEM SOC, V122, P6411, DOI 10.1021/ja993704l; KAPYLA J, 1995, BIOCHEMISTRY-US, V34, P792, DOI 10.1021/bi00003a012; KOLAKOWSKI LF, 1988, NUCLEIC ACIDS RES, V16, P10441, DOI 10.1093/nar/16.22.10441; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; LEBIODA L, 1993, PROTEINS, V16, P219, DOI 10.1002/prot.340160302; NYREN P, 1985, ANAL BIOCHEM, V151, P504, DOI 10.1016/0003-2697(85)90211-8; Pinkse MWH, 1999, BIOCHEMISTRY-US, V38, P9926, DOI 10.1021/bi990446w; Pohjanjoki P, 1998, BIOCHEMISTRY-US, V37, P1754, DOI 10.1021/bi971771r; SALMINEN T, 1995, BIOCHEMISTRY-US, V34, P782, DOI 10.1021/bi00003a011; SMIRNOVA I N, 1983, Biokhimiya, V48, P1643; SPRINGS B, 1981, BIOCHEMISTRY-US, V20, P6384, DOI 10.1021/bi00525a016; Todd MJ, 2000, BIOCHEMISTRY-US, V39, P5389, DOI 10.1021/bi992287m; Tuominen V, 1998, J MOL BIOL, V284, P1565, DOI 10.1006/jmbi.1998.2266; Volk SE, 1996, BIOCHEMISTRY-US, V35, P4662, DOI 10.1021/bi952636m; WEDEKIND JE, 1994, BIOCHEMISTRY-US, V33, P9333, DOI 10.1021/bi00197a038; WELSH KM, 1983, BIOCHEMISTRY-US, V22, P2243, DOI 10.1021/bi00278a029	38	18	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					434	441		10.1074/jbc.M007360200	http://dx.doi.org/10.1074/jbc.M007360200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031269	hybrid			2022-12-27	WOS:000166280700059
J	Schwarz, K; Walther, M; Anton, M; Gerth, C; Feussner, I; Kuhn, H				Schwarz, K; Walther, M; Anton, M; Gerth, C; Feussner, I; Kuhn, H			Structural basis for lipoxygenase specificity - Conversion of the human leukocyte 5-lipoxygenase to a 15-lipoxygenating enzyme species by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIONAL SPECIFICITY; PRIMARY DETERMINANT; GENE-EXPRESSION; 12/15-LIPOXYGENASE; INDUCTION; ASTHMA; ACID; INTERLEUKIN-13; INVOLVEMENT; SUBSTRATE	Mammalian lipoxygenases constitute a heterogeneous family of lipid-peroxidizing enzymes, and the various isoforms are categorized with respect to their positional specificity of arachidonic acid oxygenation into 5-, 8-, 12-, and 15-lipoxygenases, Structural modeling suggested that the substrate binding pocket of the human 5-lipoxygenase is 20% bigger than that of the reticulocyte-type 15-lipoxygenase; thus, reduction of the activesite volume was suggested to convert a 5-lipoxygenase to a 15-lipoxygenating enzyme species. To test this "spacebased" hypothesis of the positional specificity, the volume of the 5-lipoxygenase substrate binding pocket was reduced by introducing space-filling amino acids at critical positions, which have previously been identified as sequence determinants for the positional specificity of other lipoxygenase isoforms. We found that single point mutants of the recombinant human 5-lipoxygenase exhibited a similar specificity as the wild-type enzyme but double, triple, and quadruple mutations led to a gradual alteration of the positional specificity from 55- via 8S-toward 15S-lipoxygenation, The quadruple mutant F359W/A424I\N425M/A603I exhibited a major 15S-lipoxygenase activity (85-95%), with (8S,5Z,9E,11Z,14Z)-8-hydroperoxyeicosa-5,9,11,14-tetraenoic acid being a minor side product. These data indicate the principle possibility of interconverting 5- and 15-lipoxygenases by site-directed mutagenesis and appear to support the space-based hypothesis of positional specificity.	Humboldt Univ, Inst Biochem, Clin Charite, D-10115 Berlin, Germany; Inst Plant Biochem, D-06120 Halle, Germany	Humboldt University of Berlin; Leibniz Institut fur Pflanzenbiochemie	Kuhn, H (corresponding author), Humboldt Univ, Inst Biochem, Clin Charite, Hess Str 3-4, D-10115 Berlin, Germany.		Feussner, Ivo/H-9320-2013	Feussner, Ivo/0000-0002-9888-7003				Borngraber S, 1996, J MOL BIOL, V264, P1145, DOI 10.1006/jmbi.1996.0702; Borngraber S, 1999, J BIOL CHEM, V274, P37345, DOI 10.1074/jbc.274.52.37345; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Browner MF, 1998, NAT STRUCT BIOL, V5, P179, DOI 10.1038/nsb0398-179; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Funk CD, 1997, NAT STRUCT BIOL, V4, P966, DOI 10.1038/nsb1297-966; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; GEERTS A, 1994, PLANT PHYSIOL, V105, P269, DOI 10.1104/pp.105.1.269; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; Heydeck D, 1998, BLOOD, V92, P2503, DOI 10.1182/blood.V92.7.2503.2503_2503_2510; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; OByrne PM, 1997, ANN INTERN MED, V127, P472, DOI 10.7326/0003-4819-127-6-199709150-00009; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Prigge ST, 1998, NAT STRUCT BIOL, V5, P178, DOI 10.1038/nsb0398-178; RAPOPORT SM, 1990, BLOOD CELL BIOCH, V1, P151; ROUZER CA, 1991, METHOD ENZYMOL, V187, P312; Roy B, 1998, J BIOL CHEM, V273, P32023, DOI 10.1074/jbc.273.48.32023; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; SUZUKI H, 1994, BBA-LIPID LIPID MET, V1210, P308, DOI 10.1016/0005-2760(94)90234-8; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Wenzel SE, 1996, ANN PHARMACOTHER, V30, P858, DOI 10.1177/106002809603000725; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	37	78	81	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					773	779		10.1074/jbc.M005114200	http://dx.doi.org/10.1074/jbc.M005114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027682	hybrid			2022-12-27	WOS:000166280700104
J	Liu, K; Li, LM; Nisson, PE; Gruber, C; Jessee, J; Cohen, SN				Liu, K; Li, LM; Nisson, PE; Gruber, C; Jessee, J; Cohen, SN			Neoplastic transformation and tumorigenesis associated with Sam68 protein deficiency in cultured murine fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; FAMILY TYROSINE KINASES; TUMOR-SUPPRESSOR GENES; RNA-BINDING PROTEIN; CANCER CELL-LINES; KH-DOMAIN; DEPENDENT DEGRADATION; SIGNAL-TRANSDUCTION; GSG DOMAIN; GERM-LINE	Sam68 is a multimeric 68-kDa RNA-binding nuclear protein of unknown function that interacts with, and is tyrosine-phosphorylated by, the oncogenic protein Src during mitosis. Random homozygous knock-out (RHKO) is a retroviral-based antisense RNA strategy that can identify chromosomal genes whose functional disablement leads to reversible tumorigenic capabilities. Here we report that RHKO-induced Sam68 deficiency results in neoplastic transformation of murine NIH3T3 fibroblasts. Whereas simple haploinsufficiency of Sam68 produced by insertion mutagenesis in a single chromosomal allele did not detectably affect cell growth, reduction of Sam68 protein to <25% of the wild type level was associated with anchorage-independent growth, defective contact inhibition, and the ability to form metastatic tumors in nude mice. These properties were reversed by cessation of RHKO inactivation. Our findings, which indicate that the Sam68 protein level can prominently affect cell proliferation, implicate Sam68 function in tumorigenesis. Consistent with these results is evidence that cells undergoing mitosis show a dramatic reduction in the level of Sam68 protein.	Stanford Univ, Sch Med, Med Ctr, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Sch Med, Dept Med, Stanford, CA 94305 USA; Life Technol Inc, Rockville, MD 20850 USA	Stanford University; Stanford University; Thermo Fisher Scientific	Cohen, SN (corresponding author), Stanford Univ, Sch Med, Med Ctr, Dept Genet, Rm M320, Stanford, CA 94305 USA.				NCI NIH HHS [CA09302] Funding Source: Medline; NHGRI NIH HHS [HG00044-04] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Crooke ST, 1999, BBA-GENE STRUCT EXPR, V1489, P31, DOI 10.1016/S0167-4781(99)00148-7; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Di Fruscio M, 1998, J BIOL CHEM, V273, P30122, DOI 10.1074/jbc.273.46.30122; Dilworth S M, 1990, Semin Cancer Biol, V1, P407; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Frisch SM, 1996, MUTAT RES-FUND MOL M, V350, P261, DOI 10.1016/0027-5107(95)00103-4; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; Jabado N, 1998, J IMMUNOL, V161, P2798; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Karras JG, 2000, MOL PHARMACOL, V58, P380, DOI 10.1124/mol.58.2.380; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1989, INT S PRINCESS TAKAM, V20, P221; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Liu KY, 1999, MOL CELL BIOL, V19, P3696; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAA MC, 1994, MOL CELL BIOL, V14, P5466, DOI 10.1128/MCB.14.8.5466; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; NOWELL PC, 1986, CANCER RES, V46, P2203; Oka K, 1999, GENE CHROMOSOME CANC, V26, P47, DOI 10.1002/(SICI)1098-2264(199909)26:1<47::AID-GCC7>3.0.CO;2-8; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Sanchez-Margalet V, 1999, FEBS LETT, V455, P307, DOI 10.1016/S0014-5793(99)00887-X; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHALLOWAY D, 1992, CIBA F SYMP, V170, P248; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Sierakowska H, 1999, RNA, V5, P369, DOI 10.1017/S135583829998130X; Sierakowska H, 2000, METHOD ENZYMOL, V313, P506; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Yamashita A, 1999, ONCOGENE, V18, P4777, DOI 10.1038/sj.onc.1202852	69	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40195	40201		10.1074/jbc.M006194200	http://dx.doi.org/10.1074/jbc.M006194200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11032831	hybrid			2022-12-27	WOS:000166039500056
J	Fingerhut, A; von Figura, K; Honing, S				Fingerhut, A; von Figura, K; Honing, S			Binding of AP2 to sorting signals is modulated by AP2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; LYSOSOMAL ACID-PHOSPHATASE; MEDIATED ENDOCYTOSIS; UNCOATING ATPASE; ARRESTIN/CLATHRIN INTERACTION; ASSEMBLY POLYPEPTIDES; CYTOPLASMIC DOMAIN; KINASE-ACTIVITIES; INVITRO BINDING; TERMINAL DOMAIN	The two clathrin-associated adaptor complexes API and AP2 are known to participate in the formation of clathrin-coated vesicles at the trans-Golgi network and at the plasma membrane. During this process adaptors are involved in the sequestration of vesicle cargo by binding to the sorting signals within the cytoplasmic domains of the cargo proteins and in the recruitment of the clathrin coat. After budding of the clathrin-coated vesicles, the clathrin and adaptors dissociate from the vesicles. Here we show that in vitro binding of AP2 to sorting signals, which is one of the initial steps in receptor-mediated endocytosis, is modulated by adaptor phosphorylation. AP2 was phosphorylated by incubating purified AP2 in the presence of ATP and dephosphorylated by incubation with alkaline phosphatase. Affinity for tyrosine-, leucine-based and noncanonical sorting motifs was 15-33 times higher for phosphorylated than for dephosphorylated AP2. Also the binding of AP2 to membranes was regulated by adaptor phosphorylation/dephosphorylation and was about 8-fold higher for phosphorylated than for dephosphorylated AP2. Moreover, AP2 isolated from cytosol is higher phosphorylated than membrane-extracted and exhibits a B-fold higher binding affinity than AP2 extracted from membranes. Taken together these data point to a cycle of phosphorylation/dephosphorylation as a mechanism for regulating the reversible association of AP2 with membranes and sorting signals during the process of recptor-mediated endocytosis.	Univ Gottingen, Inst Biochem 2, D-37073 Gottingen, Germany	University of Gottingen	Honing, S (corresponding author), Univ Gottingen, Inst Biochem 2, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.		Fingerhut, Abe/AAE-6424-2022	Fingerhut, Abe/0000-0003-4243-9196				BARZVI D, 1988, J BIOL CHEM, V263, P4408; BARZVI D, 1986, J BIOL CHEM, V261, P9614; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; Hannan LA, 1998, MOL BIOL CELL, V9, P2217, DOI 10.1091/mbc.9.8.2217; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HILL BL, 1988, J BIOL CHEM, V263, P5499; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; HONING S, 1994, J CELL SCI, V107, P1185; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; Iannolo G, 1997, CANCER RES, V57, P240; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Lauritsen JPH, 2000, BBA-MOL CELL RES, V1497, P297, DOI 10.1016/S0167-4889(00)00065-3; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PAULOIN A, 1993, BIOCHEM J, V296, P409, DOI 10.1042/bj2960409; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHMID SL, 1984, NATURE, V311, P228, DOI 10.1038/311228a0; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SOSA MA, 1993, J BIOL CHEM, V268, P12537; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	44	61	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5476	5482		10.1074/jbc.M009516200	http://dx.doi.org/10.1074/jbc.M009516200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11044456	hybrid			2022-12-27	WOS:000167115100011
J	Chan, JYH; Lee-Prudhoe, JE; Jorgensen, B; Ihrke, G; Doyonnas, R; Zannettino, ACW; Buckle, VJ; Ward, CJ; Simmons, PJ; Watt, SM				Chan, JYH; Lee-Prudhoe, JE; Jorgensen, B; Ihrke, G; Doyonnas, R; Zannettino, ACW; Buckle, VJ; Ward, CJ; Simmons, PJ; Watt, SM			Relationship between novel isoforms, functionally important domains, and subcellular distribution of CD164/endolyn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEMATOPOIETIC PROGENITORS; SINGLE-STEP METHOD; MESSENGER-RNA; CELL-ADHESION; CD164; SIALOMUCIN; CD34(+); TRANSCRIPTION; EXPRESSION; CLATHRIN	Functional analyses have indicated that the human CD164 sialomucin may play a key role in hematopoiesis by facilitating the adhesion of human CD34(+) cells to the stroma and by negatively regulating CD34(+)CD38(lo/-) cell proliferation. We have identified three novel human CD164 variants derived by alternative splicing of bona fide exons from a single genomic transcription unit. The predominant CD164(E1-6) isoform, encoded by six exons, is a type I transmembrane protein containing two extracellular mucin domains (I and II) interrupted by a cysteine-rich non-mucin domain, The 103B2/9E10 and 105A5 epitopes, which specify ligand binding characteristics, are located on the exon 1-encoded mucin domain I. Three human CD164(E1-6) mRNA species, exhibiting differential polyadenylation site usage, are differentially expressed in hematopoietic and non-hematopoietic tissues. This study provides additional evidence that human CD164(E1-6) represents the ortholog of murine MGC-24v and rat endolyn. Comparative analysis of murine MGC-24v/CD164(E1-6) with human CD164(E1-6) revealed two potential splice variants and a similar genomic structure. Whereas the human CD164 gene is located on chromosome 6q21, the mouse gene occurs in a syntenic region on chromosome 10B1-B2. By confocal microscopy, human CD164 in CD34(+)CD38(+) hematopoietic progenitor (KG1B) and epithelial cell lines appears to be localized primarily in endosomes and lysosomes, with low concentrations at the cell surface. However, in a minority of KG1B cells, CD164 is more prominently expressed at the plasma membrane and in the recycling endosomes, suggesting that its distribution is regulated in cells of hematopoietic origin.	Inst Mol Med, MRC, Mol Hematol Unit, Oxford OX3 9DS, England; Univ Cambridge, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge CB2 2XY, England; Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2XY, England; Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia	University of Oxford; University of Cambridge; University of Cambridge; Institute Medical & Veterinary Science Australia; Peter Maccallum Cancer Center	Watt, SM (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC, Oxford OX3 9DS, England.	Swatt@molbiol.ox.ac.uk		Zannettino, Andrew/0000-0002-6646-6167; Doyonnas, Regis/0000-0002-3818-0807; Ihrke, Gudrun/0000-0003-4604-735X				Almeida-Porada G, 1999, BLOOD, V94, p462A; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Bazil V, 1996, BLOOD, V87, P1272, DOI 10.1182/blood.V87.4.1272.bloodjournal8741272; Bazil V, 1997, STEM CELLS, V15, P13, DOI 10.1002/stem.5530150804; BUCKLE VJ, 1993, HUMAN GENETIC DISEAS, V2, P59; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; CROZE E, 1989, J CELL BIOL, V108, P1597, DOI 10.1083/jcb.108.5.1597; Doyonnas R, 2000, J IMMUNOL, V165, P840, DOI 10.4049/jimmunol.165.2.840; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; FACKLER MJ, 1995, BLOOD, V85, P3040, DOI 10.1182/blood.V85.11.3040.bloodjournal85113040; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Hinds KA, 1999, BLOOD, V94, p44A; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HIRST MC, 1992, TRENDS GENET, V8, P6, DOI 10.1016/0168-9525(92)90005-O; Ihrke G, 2000, BIOCHEM J, V345, P287, DOI 10.1042/0264-6021:3450287; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kurosawa N, 1999, EUR J BIOCHEM, V265, P466, DOI 10.1046/j.1432-1327.1999.00777.x; Levesque JP, 1999, IMMUNITY, V11, P369, DOI 10.1016/S1074-7613(00)80112-0; MASUZAWA Y, 1992, J BIOCHEM-TOKYO, V112, P609, DOI 10.1093/oxfordjournals.jbchem.a123948; MILANESI L, 2001, IN PRESS BIOINFORMAT; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Miyamoto S, 1996, BIOCHEM J, V315, P791, DOI 10.1042/bj3150791; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TRIMAN KL, 1975, CYTOGENET CELL GENET, V15, P166, DOI 10.1159/000130515; Verfaillie CM, 1998, BLOOD, V92, P2609, DOI 10.1182/blood.V92.8.2609; Watt SM, 1998, BLOOD, V92, P849, DOI 10.1182/blood.V92.3.849.415k21_849_866; Watt SM, 2000, LEUKEMIA LYMPHOMA, V37, P1, DOI 10.3109/10428190009057625; Watt SM, 2000, BLOOD, V95, P3113; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Whetton AD, 1999, TRENDS CELL BIOL, V9, P233, DOI 10.1016/S0962-8924(99)01559-7; Zannettino ACW, 1998, BLOOD, V92, P2613, DOI 10.1182/blood.V92.8.2613.420k15_2613_2628	39	34	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2139	2152		10.1074/jbc.M007965200	http://dx.doi.org/10.1074/jbc.M007965200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11027692	Green Published, hybrid			2022-12-27	WOS:000166528000067
J	Fahlke, C; Desai, RR; Gillani, N; George, AL				Fahlke, C; Desai, RR; Gillani, N; George, AL			Residues lining the inner pore vestibule of human muscle chloride channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT MYOTONIA-CONGENITA; K+ CHANNEL; POTASSIUM CHANNELS; TETRAETHYLAMMONIUM ION; TORPEDO ELECTROPLAX; SELECTIVITY FILTER; PEPTIDE INHIBITOR; MOLECULAR-BASIS; ARCHITECTURE; PERMEATION	Chloride channels belonging to the ClC family are ubiquitous and participate in a wide variety of physiological and pathophysiological processes. To define sequence segments in ClC channels that contribute to the formation of their ion conduction pathway, we employed a combination of site-directed mutagenesis, heterologous expression, patch clamp recordings, and chemical modification of the human muscle ClC isoform, hClC-1. We demonstrate that a highly conserved 8-amino acid motif (P3) located in the linker between transmembrane domains D2 and D3 contributes to the formation of a wide pore vestibule facing the cell interior. Similar to a previously defined pore region (P1 region), this segment functionally interacts with the corresponding segment of the contralateral subunit. The use of cysteine-specific reagents of different size revealed marked differences in the diameter of pore-forming regions implying that ClC channels exhibit a pore architecture quite similar to that of certain cation channels, in which a narrow constriction containing major structural determinants of ion selectivity is neighbored by wide vestibules on both sides of the membrane.	Rhein Westfal TH Aachen, Inst Physiol, D-52057 Aachen, Germany; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Ctr Estudios Cient, Valdivia, Chile	RWTH Aachen University; Vanderbilt University; Vanderbilt University	Fahlke, C (corresponding author), Rhein Westfal TH Aachen, Inst Physiol, Pauwelsstr 30, D-52074 Aachen, Germany.	chfahlke@physiology.rwth-aachen.de	Fahlke, Christoph/G-3635-2013	Fahlke, Christoph/0000-0001-8602-9952	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044506] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44506] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ANDERSEN OS, 1992, PHYSIOL REV, V72, P78; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; CECCHI X, 1987, BIOPHYS J, V52, P707, DOI 10.1016/S0006-3495(87)83265-4; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Dang TX, 1998, J GEN PHYSIOL, V111, P185, DOI 10.1085/jgp.111.2.185; EIGEN M, 1991, NEUROSCI RES PROGRAM, V9, P330; Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; Fahlke C, 1997, J GEN PHYSIOL, V110, P551, DOI 10.1085/jgp.110.5.551; Fahlke C, 1996, BIOPHYS J, V71, P695, DOI 10.1016/S0006-3495(96)79269-X; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Fahlke C, 2000, KIDNEY INT, V57, P780, DOI 10.1046/j.1523-1755.2000.00915.x; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Holmgren M, 1997, J GEN PHYSIOL, V109, P527, DOI 10.1085/jgp.109.5.527; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Lu T, 1999, NEURON, V22, P571, DOI 10.1016/S0896-6273(00)80711-4; Ludewig U, 1997, J PHYSIOL-LONDON, V498, P691, DOI 10.1113/jphysiol.1997.sp021893; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; MILLER C, 1990, VOLTAGE DEPENDENT CH, P383; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rychkov GY, 1998, J GEN PHYSIOL, V111, P653, DOI 10.1085/jgp.111.5.653; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Vergara C, 1999, J GEN PHYSIOL, V114, P365, DOI 10.1085/jgp.114.3.365; Wollnik B, 1997, HUM MOL GENET, V6, P805, DOI 10.1093/hmg/6.5.805	42	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1759	1765		10.1074/jbc.M007649200	http://dx.doi.org/10.1074/jbc.M007649200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035024	hybrid			2022-12-27	WOS:000166528000016
J	Chen, GX; Hohmeier, HE; Newgard, CB				Chen, GX; Hohmeier, HE; Newgard, CB			Expression of the transcription factor STAT-1 alpha in insulinoma cells protects against cytotoxic effects of multiple cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED TRANSFER; NITRIC-OXIDE SYNTHASE; BETA-CELLS; RECOMBINANT ADENOVIRUS; INTERFERON-GAMMA; GENE-THERAPY; ISLETS; DESTRUCTION; REPLACEMENT; LANGERHANS	Destruction of pancreatic islet beta -cells in type 1 diabetes appears to result from direct contact with infiltrating T-cells and macrophages and exposure to inflammatory cytokines such as interferon (IFN)-gamma interleukin (IL)-1 beta, and tumor necrosis factor TNF-alpha that such cells produce. We recently reported on a method for selection of insulinoma cells that are resistant to the cytotoxic effects of inflammatory cytokines (INS-1(res)), involving their growth in progressively increasing concentrations of IL-1 beta plus IFN-gamma, and selection of surviving cells. In the current study, we have investigated the molecular mechanism of cytokine resistance in INS-1(res) cells. By focusing on the known components of the IFN-gamma receptor signaling pathway, we have discovered that expression levels of signal transducer and activator of transcription (STAT)-1 alpha are closely correlated with the cytokine-resistant and -sensitive phenotypes, That STAT-1 alpha is directly involved in development of cytokine resistance is demonstrated by an increase of viability from 10 +/- 2% in control cells to 50 +/- 6% in cells with adenovirus-mediated overexpression of STAT-1 alpha (p < 0.001) after culture of both cell groups in the presence of 100 units/ml IFN-<gamma> plus 10 ng/ml IL-1 beta for 48 h. The resistance to IL-1 beta plus IFN-gamma in STAT-1 alpha -expressing cells is due in part to interference with IL-1 beta -mediated stimulation of inducible nitric-oxide synthase expression and nitric oxide production. Furthermore, overexpression of STAT-1 alpha does not impair robust glucose-stimulated insulin secretion in the INS-1-derived cell line 832/13. We conclude that expression of STAT-1 alpha may be a means of protecting insulin-producing cell lines from cytokine damage, which, in conjunction with appropriate cell-impermeant macroencapsulation devices, may allow such cells to be used for insulin replacement in type 1 diabetes.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; BetaGene Inc, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, 5323 Harry Hines Blvd,Room Y8-212, Dallas, TX 75235 USA.				NIDDK NIH HHS [DK-55188] Funding Source: Medline; NIGMS NIH HHS [T32 GM08203] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Brendel M, 1999, INT ISLET TRANSPLANT, P1; Chen GX, 2000, DIABETES, V49, P562, DOI 10.2337/diabetes.49.4.562; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; Dupraz P, 1999, GENE THER, V6, P1160, DOI 10.1038/sj.gt.3300922; Efrat Shimon, 1996, P438; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Heitmeier MR, 1999, J BIOL CHEM, V274, P29266, DOI 10.1074/jbc.274.41.29266; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hohmeier HE, 1998, J CLIN INVEST, V101, P1811, DOI 10.1172/JCI1489; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Levine F, 1997, DIABETES METAB REV, V13, P209; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NEWGARD CB, 1994, DIABETES, V43, P341, DOI 10.2337/diabetes.43.3.341; NEWGARD CB, 1997, DIABETOLOGIA, V40, P42; NEWGARD CB, 1999, CAN J DIABETES CARC, V23, P52; Rabinovitch A, 1999, DIABETES, V48, P1223, DOI 10.2337/diabetes.48.6.1223; RABINOVITCH A, 1993, DIABETES REV, V1, P215; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Sutherland DER, 1996, DIABETES METAB REV, V12, P137; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Zhou YP, 2000, AM J PHYSIOL-ENDOC M, V278, pE340, DOI 10.1152/ajpendo.2000.278.2.E340	32	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					766	772		10.1074/jbc.M008330200	http://dx.doi.org/10.1074/jbc.M008330200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024034	hybrid			2022-12-27	WOS:000166280700103
J	Kataoka, K; Yoshitomo-Nakagawa, K; Shioda, S; Nishizawa, M				Kataoka, K; Yoshitomo-Nakagawa, K; Shioda, S; Nishizawa, M			A set of Hox proteins interact with the Maf oncoprotein to inhibit its DNA binding, transactivation, and transforming activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOGENOUS LEUKEMIA; A-CRYSTALLIN GENE; TRANSCRIPTION FACTOR; C-MAF; HOMEOBOX GENE; V-MAF; ALVEOLAR RHABDOMYOSARCOMA; HOMEODOMAIN PROTEINS; NUCLEAR ONCOPROTEIN; MYELOID-LEUKEMIA	Maf oncoprotein is a basic-leucine zipper (bZip) type of transcriptional activator, Since many transcription factors are known to form functional complexes, we searched for proteins that interact with the DNA-binding domain of Maf using the phage display method and identified two homeodomain-containing proteins, Hoxd12 and MHox/Prx1/Phox1/Pmx1. Studies with mutants of Hox and Maf proteins showed that they associate through their DNA-binding domains; the homeodomain of Hox and the bZip domain of Maf, respectively. Reflecting the high similarity of the bZip domain, all other Maf family members tested (c-/v-Maf, MafB, MafK, MafF, and MafG) also associated with the Hox proteins. Pax6, whose homeodomain is relatively similar to MHox, also could interact with Maf, However, two other bZip oncoproteins, Fos and Jun, failed to associate with the Hox proteins, while a distantly related Hox family member, Meis1, could not interact with Maf. Through interactions with the bZip domain, the Hox proteins inhibited the DNA binding activity of Maf, whereas the binding of Hox proteins to their recognition sequences was not abrogated by Maf. We further showed that coexpression of the Hox proteins repressed transcriptional activation and transforming activity of Maf. These results suggested that the interaction of a set of Hox proteins with Maf family members may interfere not only with their oncogenicity but also with their physiological roles.	Univ Tokyo, Inst Med Sci, Dept Virol, Minato Ku, Tokyo 1088639, Japan; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University of Tokyo; Scripps Research Institute	Kataoka, K (corresponding author), Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	kkataoka@bio.titech.ac.jp						ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BENBROOK DM, 1990, ONCOGENE, V5, P295; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; CVEKL A, 1995, MOL CELL BIOL, V15, P653; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; DAVIS RJ, 1994, CANCER RES, V54, P2869; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HEDGE SP, 1999, BLOOD, V94, P1578; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 1996, ONCOGENE, V12, P53; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; Li MF, 1999, J VIROL, V73, P9178, DOI 10.1128/JVI.73.11.9178-9186.1999; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Moens CB, 1998, DEVELOPMENT, V125, P381; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Nakamura T, 1999, BLOOD, V94, P741, DOI 10.1182/blood.V94.2.741.414k04_741_747; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; NOHNO T, 1993, DEV BIOL, V158, P254, DOI 10.1006/dbio.1993.1184; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Sharon-Friling R, 1998, MOL CELL BIOL, V18, P2067, DOI 10.1128/MCB.18.4.2067; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	57	56	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					819	826		10.1074/jbc.M007643200	http://dx.doi.org/10.1074/jbc.M007643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11036080	hybrid			2022-12-27	WOS:000166280700110
J	Ko, JL; Loh, HH				Ko, JL; Loh, HH			Single-stranded DNA-binding complex involved in transcriptional regulation of mouse mu-opioid receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-K; MORPHINE-INDUCED ANALGESIA; PROTEIN PUR-ALPHA; MESSENGER-RNA; MOLECULAR-CLONING; TFIID COMPLEX; RAS PROMOTER; MICE LACKING; EXPRESSION; SEQUENCES	Previously, we reported the presence of dual (distal and proximal) promoters in mouse mu -opioid receptor (mor) gene, with mar transcription in mouse brain predominantly initiated by the proximal promoter. Sp factors, bound to double-stranded (ds) cis-regulatory elements, are critical for proximal promoter activity. Here, we further report that a single-stranded (ss) cis-regulatory element and trans-acting protein factor are also important for proximal promoter activity. A 26-bp mar polypyrimidine/polypurine region (PPy/u) can adopt ss DNA conformation, as demonstrated by S1 nuclease sensitivity. Using electrophoretic mobility shift analysis with nuclear extracts from mor-expressing SH-SY5Y cells, we demonstrate that the sense strand of PPy/u interacts with a major nuclear protein, termed mor polypyrimidine-binding protein (mPy), which is not related to Sp factors. Southwestern blot analysis indicated that mPy protein is similar to 25 kDa in size. Functional analysis suggests that mPy protein can trans-activate mar promoter as well as a heterologous promoter. Moreover, combinatorial activation of ss (mPy) and ds (Sps) DNA binding factors, interacting with an overlapping DNA (PPy/u) region, is necessary for proximal promoter activation. Thus our results suggest that transcription of mouse mar gene is regulated by an interplay of se and ds DNA binding factors.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Ko, JL (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	koxxx001@maroon.tc.umn.edu			NIDA NIH HHS [DA-05695, DA-01583, DA-00546] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA001583, R37DA001583, P01DA005695] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BACOLLA A, 1995, J BIOL CHEM, V270, P24556, DOI 10.1074/jbc.270.41.24556; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; Basbaum A.I., 1984, ANALGESICS NEUROCHEM, P97; BEHE MJ, 1987, BIOCHEMISTRY-US, V26, P7870, DOI 10.1021/bi00398a050; BIRNBOIM HC, 1978, J MOL BIOL, V121, P541, DOI 10.1016/0022-2836(78)90399-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CLARK SP, 1990, NUCLEIC ACIDS RES, V18, P5119, DOI 10.1093/nar/18.17.5119; DELFS JM, 1994, J NEUROCHEM, V63, P777; DELFS JM, 1994, J COMP NEUROL, V345, P46, DOI 10.1002/cne.903450104; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; Di Matteo G, 1998, J BIOL CHEM, V273, P495, DOI 10.1074/jbc.273.1.495; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Duncan R, 1996, MOL CELL BIOL, V16, P2274; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; Hyman SE, 1996, SCIENCE, V273, P611, DOI 10.1126/science.273.5275.611; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P190; Jurk M, 1996, NUCLEIC ACIDS RES, V24, P2799, DOI 10.1093/nar/24.14.2799; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Ko JL, 1998, J BIOL CHEM, V273, P27678, DOI 10.1074/jbc.273.42.27678; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; KOHWI Y, 1993, J MOL BIOL, V231, P1090, DOI 10.1006/jmbi.1993.1354; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; KRAUS J, 1995, BIOCHEM BIOPH RES CO, V215, P591, DOI 10.1006/bbrc.1995.2505; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; Liang YB, 1997, BRAIN RES, V769, P372, DOI 10.1016/S0006-8993(97)00854-8; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Menon RK, 1997, MOL ENDOCRINOL, V11, P1291, DOI 10.1210/me.11.9.1291; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; NESTLER EJ, 1994, BRAIN RES BULL, V35, P521, DOI 10.1016/0361-9230(94)90166-X; Pan YX, 1999, MOL PHARMACOL, V56, P396, DOI 10.1124/mol.56.2.396; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; Phillips BW, 1999, J BIOL CHEM, V274, P22197, DOI 10.1074/jbc.274.32.22197; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Solecki D, 1997, J BIOL CHEM, V272, P5579, DOI 10.1074/jbc.272.9.5579; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; Wendel B, 1998, J MOL MED-JMM, V76, P525, DOI 10.1007/s001090050246; Wood P. L., 1988, OPIATE RECEPTORS, P307; Xu G, 1996, J BIOL CHEM, V271, P16008, DOI 10.1074/jbc.271.27.16008	67	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					788	795		10.1074/jbc.M004279200	http://dx.doi.org/10.1074/jbc.M004279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027679	hybrid			2022-12-27	WOS:000166280700106
J	Schulte, V; Snell, D; Bergmeier, W; Zirngibl, H; Watson, SP; Nieswandt, B				Schulte, V; Snell, D; Bergmeier, W; Zirngibl, H; Watson, SP; Nieswandt, B			Evidence for two distinct epitopes within collagen for activation of murine platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; GLYCOPROTEIN-VI; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-2; INTEGRIN ALPHA(2)BETA(1); SYK; ASSOCIATION; AGGREGATION; CONVULXIN; ADHESION	It has recently been shown that the monoclonal antibody JAQ1 to murine glycoprotein VI (GPVI) can cause aggregation of mouse platelets upon antibody crosslinking and that collagen-induced platelet aggregation can be inhibited by preincubation of platelets with JAQ1 in the absence of cross-linking (Nieswandt, B,, Bergmeier, W,, Schulte, V,, Rackebrandt, K,, Gessner, J, E,, and Zirngibl, H, (2000) J. Biol, Chem, 275, 23998-24002), In the present study, we have shown that crosslinking of GPVI by JAQ1 results in tyrosine phosphorylation of the same profile of proteins as that induced by collagen, including the Fc receptor (FcR) gamma -chain, Syk, LAT, SLP-76, and phospholipase C gamma2. In contrast, platelet aggregation and tyrosine phosphorylation of these proteins were inhibited when mouse platelets were preincubated with JAQ1 in the absence of cross-linking and were subsequently stimulated with a collagen-related peptide (CRP) that is specific for GPVI and low concentrations of collagen. However, at higher concentrations of collagen, but not CRP, aggregation of platelets and tyrosine phosphorylation of the above proteins (except for the adapter LAT) is re-established despite the presence of JAQ1, These observations suggest that a second activatory binding site, which is distinct from the CRP binding site on GPVI on mouse platelets, is occupied in the presence of high concentrations of collagen. Although this could be a second site on GPVI that is activated by a novel motif within the collagen molecule, the absence of LAT phosphorylation in response to collagen in the presence of JAQ1 suggests that this is more likely to be caused by activation of a second receptor that is also coupled to the FcR gamma -chain. The possibility that this response is mediated by a receptor that is not coupled to FcR gamma -chain is excluded on the grounds that aggregation is absent in platelets from FcR gamma -chain-deficient mice.	Berg Univ Gesamthsch Wuppertal, Ferdinand SauerBruch Klinikum, Dept Mol Oncol, D-42117 Wuppertal, Germany; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Wuppertal; University of Oxford	Nieswandt, B (corresponding author), Berg Univ Gesamthsch Wuppertal, Ferdinand SauerBruch Klinikum, Dept Mol Oncol, ArrenbergerStr 20,Haus 10, D-42117 Wuppertal, Germany.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423				Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Gross BS, 1999, EUR J BIOCHEM, V263, P612, DOI 10.1046/j.1432-1327.1999.00560.x; Ichinohe T, 1997, J BIOL CHEM, V272, P63; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; SUGIYAMA T, 1987, BLOOD, V69, P1712; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528	20	34	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					364	368		10.1074/jbc.M007536200	http://dx.doi.org/10.1074/jbc.M007536200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11036078	hybrid			2022-12-27	WOS:000166280700050
J	Lutz, LB; Kim, B; Jahani, D; Hammes, SR				Lutz, LB; Kim, B; Jahani, D; Hammes, SR			G protein beta gamma subunits inhibit nongenomic progesterone-induced signaling and maturation in Xenopus laevis oocytes - Evidence for a release of inhibition mechanism for cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; NITRIC-OXIDE SYNTHASE; NUCLEOTIDE REGULATORY PROTEIN; ACTIVATED K+ CHANNEL; MAP KINASE; ADENYLATE-CYCLASE; PERTUSSIS TOXIN; MEIOTIC MATURATION; STARFISH OOCYTE; VITAMIN-D3 METABOLITES	Progesterone-induced maturation of Xenopus oocytes is a well known example of nongenomic signaling by steroids; however, little is known about the early signaling events involved in this process. Previous work has suggested that G proteins and G protein-coupled receptors may be involved in progesterone-mediated oocyte maturation as well as in other nongenomic steroid-induced signaling events. To investigate the role of G proteins in nongenomic signaling by progesterone, the effects of modulating G alpha and G beta gamma levels in Xenopus oocytes on progesterone-induced signaling and maturation were examined. Our results demonstrate that G beta gamma subunits, rather than G alpha, are the principal mediators of progesterone action in this system. We show that overexpression of G beta gamma inhibits both progesterone-induced maturation and activation of the MAPK pathway, whereas sequestration of endogenous G beta gamma subunits enhances: progesterone-mediated signaling and maturation. These data are consistent with a model whereby endogenous free Xenopus G beta gamma subunits constitutively inhibit oocyte maturation. Progesterone may induce maturation by antagonizing this inhibition and therefore allowing cell cycle progression to occur. These studies offer new insight into the early signaling events mediated by progesterone and may be useful in characterizing and identifying the membrane progesterone receptor in oocytes.	Univ Texas, SW Med Sch, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hammes, SR (corresponding author), Univ Texas, SW Med Sch, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	stephen.hammes@email.swmed.edu						BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLONDEAU JP, 1984, BIOCHEM J, V219, P785, DOI 10.1042/bj2190785; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CHEN Y, 1994, J BIOL CHEM, V269, P7839; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; CHIBA K, 1995, DEV BIOL, V169, P415, DOI 10.1006/dbio.1995.1157; CHIBA K, 1993, MOL BIOL CELL, V4, P1027, DOI 10.1091/mbc.4.10.1027; Chiba K, 1995, Prog Cell Cycle Res, V1, P255; CHRIST M, 1995, HYPERTENSION, V25, P117, DOI 10.1161/01.HYP.25.1.117; CHRIST M, 1993, J CLIN ENDOCR METAB, V77, P1452, DOI 10.1210/jc.77.6.1452; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; GODEAU JF, 1978, P NATL ACAD SCI USA, V75, P2353, DOI 10.1073/pnas.75.5.2353; GOODHARDT M, 1984, EMBO J, V3, P2653, DOI 10.1002/j.1460-2075.1984.tb02189.x; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; Kirsch EA, 1999, AM J RESP CELL MOL, V20, P658, DOI 10.1165/ajrcmb.20.4.3241; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1994, J CELL SCI, P115; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; LIU ZM, 1993, BIOL REPROD, V49, P980, DOI 10.1095/biolreprod49.5.980; Luchian T, 1997, J PHYSIOL-LONDON, V505, P13, DOI 10.1111/j.1469-7793.1997.013bc.x; MAGUIRE ME, 1976, MOL PHARMACOL, V12, P335; Maller J L, 1980, Curr Top Cell Regul, V16, P271; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Meier CA, 1997, J RECEPT SIGNAL TR R, V17, P319, DOI 10.3109/10799899709036612; Miller BA, 1996, J CLIN INVEST, V98, P1728, DOI 10.1172/JCI118971; MULNER O, 1985, FEBS LETT, V181, P397, DOI 10.1016/0014-5793(85)80300-8; Nagahama Y, 1997, STEROIDS, V62, P190, DOI 10.1016/S0039-128X(96)00180-8; NAGAHAMA Y, 1995, CURR TOP DEV BIOL, V30, P103, DOI 10.1016/S0070-2153(08)60565-7; Norman AW, 1996, J STEROID BIOCHEM, V56, P13, DOI 10.1016/0960-0760(95)00219-7; OLATE J, 1990, FEBS LETT, V268, P27, DOI 10.1016/0014-5793(90)80964-K; OLATE J, 1984, FEBS LETT, V175, P25; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SADLER SE, 1984, MOL PHARMACOL, V26, P526; SADLER SE, 1985, ADV CYCLIC NUCL PROT, V19, P179; SADLER SE, 1983, J BIOL CHEM, V258, P7935; SADLER SE, 1981, J BIOL CHEM, V256, P6368; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Schneider M, 1997, AM J PHYSIOL-ENDOC M, V272, pE616, DOI 10.1152/ajpendo.1997.272.4.E616; Shaul PW, 1999, STEROIDS, V64, P28, DOI 10.1016/S0039-128X(98)00105-6; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; Shibuya EK, 1996, CELL GROWTH DIFFER, V7, P235; SHILLING F, 1989, DEV BIOL, V133, P605, DOI 10.1016/0012-1606(89)90063-8; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SMITH LD, 1969, DEV BIOL, V19, P281, DOI 10.1016/0012-1606(69)90065-7; TADENUMA H, 1992, BIOCHEM BIOPH RES CO, V186, P114, DOI 10.1016/S0006-291X(05)80782-X; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEHLING M, 1992, MOL CELL ENDOCRINOL, V90, pC5, DOI 10.1016/0303-7207(92)90092-K; WEHLING M, 1994, BIOCHEM BIOPH RES CO, V204, P475, DOI 10.1006/bbrc.1994.2484; WEHLING M, 1995, CIRC RES, V76, P973, DOI 10.1161/01.RES.76.6.973; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939	67	84	89	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41512	41520		10.1074/jbc.M006757200	http://dx.doi.org/10.1074/jbc.M006757200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018039	hybrid			2022-12-27	WOS:000166114600110
J	Zhang, W; Efanov, A; Yang, SN; Fried, G; Kolare, S; Brown, H; Zaitsev, S; Berggren, PO; Meister, B				Zhang, W; Efanov, A; Yang, SN; Fried, G; Kolare, S; Brown, H; Zaitsev, S; Berggren, PO; Meister, B			Munc-18 associates with syntaxin and serves as a negative regulator of exocytosis in the pancreatic beta-cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNC-18 GENE ENCODES; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; SEC1 HOMOLOG; CAENORHABDITIS-ELEGANS; CHROMAFFIN GRANULES; SECRETORY PATHWAY; 3T3-L1 ADIPOCYTES; CALCIUM CHANNELS; MEMBRANE-FUSION		Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden; Karolinska Inst, Rolf Luft Ctr Diabet Res, Dept Mol Med, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Women & Childrens Hlth, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Meister, B (corresponding author), Karolinska Inst, Dept Neurosci, Berzelius Vag 1,5th Floor,Rm 5D 07, SE-17177 Stockholm, Sweden.		Tuluc, Petronel/C-2527-2011; Efanov, Alexander/R-3630-2019	Efanov, Alexander/0000-0002-8630-1503; Kolare Jeffrey, Susanne/0000-0003-3370-1965; Berggren, Per-Olof/0000-0001-8991-413X				AAITO MK, 1993, EMBO J, V12, P4095; AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BROADIE KS, 1995, J PHYSIOLOGY-PARIS, V89, P59, DOI 10.1016/0928-4257(96)80552-3; BUCHAN AMJ, 1985, HISTOCHEMISTRY, V83, P175, DOI 10.1007/BF00495150; Dresbach T, 1998, J NEUROSCI, V18, P2923; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GengyoAndo K, 1996, J NEUROSCI, V16, P6695; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; Halachmi N, 1996, J NEUROCHEM, V66, P889; Hames BD., 1990, GEL ELECTROPHORESIS, P1; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Haynes LP, 1999, BIOCHEM J, V342, P707, DOI 10.1042/0264-6021:3420707; HILL RS, 1985, DIABETES, V34, P115, DOI 10.2337/diabetes.34.2.115; HODEL A, 1994, J BIOL CHEM, V269, P8623; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN F, 1995, DIABETOLOGIA, V38, P860, DOI 10.1007/s001250050364; Martin F, 1996, BIOCHEM J, V320, P201, DOI 10.1042/bj3200201; Matsuo N, 1997, J BIOL CHEM, V272, P16438, DOI 10.1074/jbc.272.26.16438; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; Pelham HRB, 1997, EUR J CELL BIOL, V74, P311; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; Riento K, 1996, EUR J BIOCHEM, V239, P638, DOI 10.1111/j.1432-1033.1996.0638u.x; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164	62	73	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41521	41527		10.1074/jbc.M005479200	http://dx.doi.org/10.1074/jbc.M005479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024017	hybrid			2022-12-27	WOS:000166114600111
J	Cook, TA; Ghomashchi, F; Gelb, MH; Florio, SK; Beavo, JA				Cook, TA; Ghomashchi, F; Gelb, MH; Florio, SK; Beavo, JA			The delta subunit of type 6 phosphodiesterase reduces light-induced cGMP hydrolysis in rod outer segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; RETINAL RODS; PHOTORECEPTOR PHOSPHODIESTERASE; DARK-ADAPTATION; VERTEBRATE PHOTORECEPTORS; GUANYLATE-CYCLASE; GTPASE ACTIVITY; PDE-DELTA; G-PROTEIN; BINDING	The delta subunit of the rod photoreceptor PDE has previously been shown to copurify with the soluble form of the enzyme and to solubilize the membrane-bound form (1), To determine the physiological effect of the delta subunit on the light response of bovine rod outer segments, we measured the real time accumulation of the products of cGMP hydrolysis in a preparation of permeablized rod outer segments. The addition of delta subunit GST fusion protein (delta -GST) to this preparation caused a reduction in the maximal rate of cGMP hydrolysis in response to light. The maximal reduction of the light response was about 80%, and the half-maximal effect occurred at 385 nM delta subunit, Several experiments suggest that this effect was not due to the effects of delta -GST on transducin or rhodopsin kinase. Immunoblots demonstrated that exogenous delta -GST solubilized the majority of the PDE in ROS but did not affect the solubility of transducin. Therefore, changes in the solubility of transducin cannot account for the effects of delta -GST in the pH assay. The reduction in cGMP hydrolysis was independent of ATP, which indicates that it was not due to effects of delta -GST on rhodopsin kinase. In addition to the effect on cGMP hydrolysis, the delta -GST fusion protein slowed the turn-off of the system. This is probably due, at least in part, to an observed reduction in the GTPase rate of transducin in the presence of delta -GST. These results demonstrate that delta -GST can modify the activity of the phototransduction cascade in preparations of broken rod outer segments, probably due to a functional uncoupling of the transducin to PDE step of the signal transduction cascade and suggest that the delta subunit may play a similar role in the intact outer segment.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Beavo, JA (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.			gelb, michael/0000-0001-7000-5219	NEI NIH HHS [EY01730, 2T32 EY07031-21, EY08197] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007031, R01EY008197, P30EY001730] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; BELLJE, 1988, PROTEINS ENZYMES, P317; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTY P, 1992, J BIOL CHEM, V267, P19489; Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l; CORNWALL MC, 1990, J GEN PHYSIOL, V96, P345, DOI 10.1085/jgp.96.2.345; Detwiler PB, 1996, CURR OPIN NEUROBIOL, V6, P440, DOI 10.1016/S0959-4388(96)80047-X; Fain GL, 1996, TRENDS NEUROSCI, V19, P502, DOI 10.1016/S0166-2236(96)10056-4; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GrayKeller MP, 1996, NEURON, V17, P323, DOI 10.1016/S0896-6273(00)80163-4; JONES GJ, 1995, J PHYSIOL-LONDON, V487, P441, DOI 10.1113/jphysiol.1995.sp020891; KAPLAN MW, 1993, METH NEUROSCI, V15, P205; KAWAMURA S, 1989, J GEN PHYSIOL, V94, P649, DOI 10.1085/jgp.94.4.649; KOCH KW, 1992, TRENDS BIOCHEM SCI, V17, P307, DOI 10.1016/0968-0004(92)90442-C; KONDO H, 1988, P NATL ACAD SCI USA, V85, P1322, DOI 10.1073/pnas.85.4.1322; LAGNADO L, 1994, NATURE, V367, P273, DOI 10.1038/367273a0; LEIBROCK CS, 1994, VISION RES, V34, P2787, DOI 10.1016/0042-6989(94)90048-5; Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139; Li N, 1998, GENOMICS, V49, P76, DOI 10.1006/geno.1998.5210; Li N, 1998, FEBS LETT, V440, P454, DOI 10.1016/S0014-5793(98)01501-4; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; Linari M, 1999, P NATL ACAD SCI USA, V96, P1315, DOI 10.1073/pnas.96.4.1315; Linari M, 1999, FEBS LETT, V458, P55, DOI 10.1016/S0014-5793(99)01117-5; LIU L, 1995, METHOD ENZYMOL, V250, P189; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; Marzesco AM, 1998, J BIOL CHEM, V273, P22340, DOI 10.1074/jbc.273.35.22340; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; MIKI N, 1975, J BIOL CHEM, V250, P6320; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PEPPERBERG DR, 1994, VISUAL NEUROSCI, V11, P53, DOI 10.1017/S095252380001110X; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; QIN N, 1992, J BIOL CHEM, V267, P8458; QIN N, 1994, J BIOL CHEM, V269, P3265; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TYMINSKI PN, 1984, BIOCHEMISTRY-US, V23, P3986, DOI 10.1021/bi00312a028	42	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5248	5255		10.1074/jbc.M004690200	http://dx.doi.org/10.1074/jbc.M004690200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11053432	hybrid			2022-12-27	WOS:000168484300096
J	Kasahara, H; Usheva, A; Ueyama, T; Aoki, H; Horikoshi, N; Izumo, S				Kasahara, H; Usheva, A; Ueyama, T; Aoki, H; Horikoshi, N; Izumo, S			Characterization of homo- and heterodimerization of cardiac Csx/Nkx2.5 homeoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL HEART-DISEASE; TINMAN-RELATED GENES; DNA-BINDING TARGETS; CASEIN KINASE-II; HOMEODOMAIN PROTEINS; VND/NK-2 HOMEODOMAIN; CRYSTAL-STRUCTURE; HOMEOBOX GENES; DROSOPHILA; TRANSCRIPTION	Csx/Nkx2.5 is an evolutionarily conserved homeodomain (HD)-containing transcription factor that is essential for early cardiac development. We found that the HD of Csx/Nkx2.5 binds as a monomer as well as a dimer to its DNA binding sites in the promoter of the atrial natriuretic factor (ANF) gene, an in vivo target gene of Csx/Nkx2.5. Csx/Nkx2.5 physically interacts with each other in vitro as well as in cells, and the HD is critical for homodimerization. Lys(193) and Arg(194), located at the COOH-terminal end of HD, are essential for dimerization. Lys193 is also required for a specific interaction with the zinc finger transcription factor GATA4. Csx/ Nkx2.5 can heterodimerize with other NK2 homeodomain proteins, Nkx2.3 and Nkx2.6/Tix, with different affinities. A single missense mutation, Ile(183) to Pro in the HD of Csx/Nkx2.5, preserved homodimerization function, but totally abolished DNA binding. Ile(183) --> Pro mutant acts in an inhibitory manner on wild type Csx/ Nkx2.5 transcriptional activity through the ANF promoter in 10T1/2 cells. However, Ile(183) --> Pro mutant does not inhibit wild type Csx/Nkx2.5 function on the ANF promoter in cultured neonatal cardiac myocytes, possibly due to failure of dimerization in the presence of the target DNA. These results suggest that complex protein-protein interactions of Csx/Nkx2.5 play a role in its transcriptional regulatory function.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Cardiovasc Div, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02215 USA; Washington Univ, Sch Med, Radiat Oncol Ctr, Sect Canc Biol, St Louis, MO 63108 USA; Yamaguchi Univ, Sch Med, Dept Mol Cardiovasc Biol, Ube, Yamaguchi 7558505, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Washington University (WUSTL); Yamaguchi University	Kasahara, H (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Cardiovasc Div, 330 Brookline Ave,SL201, Boston, MA 02215 USA.		Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178	NHLBI NIH HHS [R01-HL61036, R01-HL51253] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051253, P50HL061036] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Biben C, 1998, MECH DEVELOP, V73, P125, DOI 10.1016/S0925-4773(98)00037-9; Biggin MD, 1997, DEVELOPMENT, V124, P4425; BODMER R, 1993, DEVELOPMENT, V118, P719; Brand T, 1997, MECH DEVELOP, V64, P53, DOI 10.1016/S0925-4773(97)00044-0; Buchberger A, 1996, MECH DEVELOP, V56, P151, DOI 10.1016/0925-4773(96)00521-7; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen JN, 1996, DEVELOPMENT, V122, P3809; Chin JW, 1999, CURR BIOL, V9, pR929, DOI 10.1016/S0960-9822(00)80107-4; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DUBOULE D, 1994, GUIDBOOK HOMEOBOX GE; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; EVANS SM, 1995, DEVELOPMENT, V121, P3889; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; GAY NJ, 1988, NUCLEIC ACIDS RES, V16, P6637, DOI 10.1093/nar/16.14.6637; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; Grow MW, 1998, DEV BIOL, V204, P187, DOI 10.1006/dbio.1998.9080; Gruschus JM, 1999, J MOL BIOL, V289, P529, DOI 10.1006/jmbi.1999.2774; Gruschus JM, 1997, BIOCHEMISTRY-US, V36, P5372, DOI 10.1021/bi9620060; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; Kasahara H, 1999, MOL CELL BIOL, V19, P526; Kasahara H, 2000, J CLIN INVEST, V106, P299, DOI 10.1172/JCI9860; Kasahara H, 1998, CIRC RES, V82, P936, DOI 10.1161/01.RES.82.9.936; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; Kohler JJ, 1999, P NATL ACAD SCI USA, V96, P11735, DOI 10.1073/pnas.96.21.11735; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Lee KH, 1996, DEV BIOL, V180, P722, DOI 10.1006/dbio.1996.0341; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; Mead PE, 1996, NATURE, V382, P357, DOI 10.1038/382357a0; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; Newman CS, 1998, DEV GENET, V22, P230; Pabst O, 1997, DEV DYNAM, V209, P29; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Tanaka M, 1999, DEVELOPMENT, V126, P1269; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014; Weiss JB, 1998, GENE DEV, V12, P3591, DOI 10.1101/gad.12.22.3591; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WILSON DS, 1995, CURR BIOL, V5, P32, DOI 10.1016/S0960-9822(95)00010-8	63	78	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4570	4580		10.1074/jbc.M004995200	http://dx.doi.org/10.1074/jbc.M004995200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11042197	hybrid			2022-12-27	WOS:000168484300009
J	Jackson, RG; Lim, EK; Li, Y; Kowalczyk, M; Sandberg, G; Hoggett, J; Ashford, DA; Bowles, DJ				Jackson, RG; Lim, EK; Li, Y; Kowalczyk, M; Sandberg, G; Hoggett, J; Ashford, DA; Bowles, DJ			Identification and biochemical characterization of an Arabidopsis indole-3-acetic acid glucosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-GLUCOSYL; ZEA-MAYS-L; ENZYMATIC-SYNTHESIS; ENZYMIC-SYNTHESIS; O-GLUCOSYLTRANSFERASE; LIQUID-CHROMATOGRAPHY; PHASEOLUS-LUNATUS; METABOLISM; GENE; INDOL-3-YLACETYL-MYO-INOSITOL	Biochemical characterization of recombinant gene products following a phylogenetic analysis of the UDP-glucosyltransferase (UGT) multigene family of Arabidopsis has identified one enzyme (UGT84B1) with high activity toward the plant hormone indole-3-acetic acid (IAA) and three related enzymes (UGT84B2, UGT75B1, and UGT75B2) with trace activities. The identity of the IAA conjugate has been confirmed to be 1-O-indole acetyl glucose ester. A sequence annotated as a UDP-glucose:IAA glucosyltransferase (IAA-UGT) in the Arabidopsis genome and expressed sequence tag data bases given its similarity to the maize iaglu gene sequence showed no activity toward IAA This study describes the first biochemical analysis of a recombinant IAA-UGT and provides the foundation for future genetic approaches to understand the role of 1-O-indole acetyl glucose ester in Arabidopsis.	Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England; Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, S-90183 Umea, Sweden	University of York - UK; Swedish University of Agricultural Sciences	Bowles, DJ (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5DD, N Yorkshire, England.		Kowalczyk, Mariusz/ABD-2910-2020	Kowalczyk, Mariusz/0000-0001-7454-4762				Bandurski Robert S., 1995, P39; Bartel Bonnie, 1997, Annu Rev Plant Physiol Plant Mol Biol, V48, P51, DOI 10.1146/annurev.arplant.48.1.51; BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; COHEN JD, 1982, ANNU REV PLANT PHYS, V33, P403, DOI 10.1146/annurev.pp.33.060182.002155; CORCUERA LJ, 1982, BIOCHEM J, V207, P283, DOI 10.1042/bj2070283; DIXON SC, 1989, PLANT PHYSIOL, V90, P1316, DOI 10.1104/pp.90.4.1316; EHMANN A, 1974, CARBOHYD RES, V34, P99, DOI 10.1016/S0008-6215(00)80374-2; ENTSCH B, 1979, BIOCHIM BIOPHYS ACTA, V570, P124, DOI 10.1016/0005-2744(79)90207-9; EPSTEIN E, 1980, PLANT PHYSIOL, V65, P415, DOI 10.1104/pp.65.3.415; EPSTEIN E, 1993, PHYSIOL PLANTARUM, V88, P382, DOI 10.1111/j.1399-3054.1993.tb05513.x; Graham Richard, 1997, Plant Physiology (Rockville), V113, P1004; Hostel W., 1981, BIOCH PLANTS, V7, P725; HUGHES J, 1994, DNA SEQUENCE, V5, P41, DOI 10.3109/10425179409039703; JAKAS A, 1993, J LABELLED COMPD RAD, V33, P933, DOI 10.1002/jlcr.2580331007; KLECZKOWSKI K, 1995, CRIT REV PLANT SCI, V14, P283, DOI 10.1080/07352689509382361; KOWALCZYK S, 1991, BIOCHEM J, V279, P509, DOI 10.1042/bj2790509; KOWALCZYK S, 1990, PLANT PHYSIOL, V94, P4, DOI 10.1104/pp.94.1.4; LETHAM DS, 1983, ANNU REV PLANT PHYS, V34, P163, DOI 10.1146/annurev.pp.34.060183.001115; LEZNICKI AJ, 1988, PLANT PHYSIOL, V88, P1481, DOI 10.1104/pp.88.4.1481; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 1998, J BIOL CHEM, V273, P34920, DOI 10.1074/jbc.273.52.34920; Lim EK, 2001, J BIOL CHEM, V276, P4344, DOI 10.1074/jbc.M007263200; LUDWIGMULLER J, 1993, PLANT GROWTH REGUL, V13, P189, DOI 10.1007/BF00024261; Martin RC, 1999, P NATL ACAD SCI USA, V96, P284, DOI 10.1073/pnas.96.1.284; Martin RC, 1999, PLANT PHYSIOL, V120, P553, DOI 10.1104/pp.120.2.553; MICHALCZUK L, 1982, BIOCHEM J, V207, P273, DOI 10.1042/bj2070273; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; NOWACKI J, 1980, PLANT PHYSIOL, V65, P422, DOI 10.1104/pp.65.3.422; Ostin A, 1998, PLANT PHYSIOL, V118, P285, DOI 10.1104/pp.118.1.285; Pflugmacher S, 1998, PHYTOCHEMISTRY, V49, P507, DOI 10.1016/S0031-9422(98)00139-3; PIERS KL, 1993, GENE, V134, P7, DOI 10.1016/0378-1119(93)90168-3; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT R, 1985, PESTIC BIOCHEM PHYS, V24, P77, DOI 10.1016/0048-3575(85)90116-6; SCHMITT R, 1982, Z NATURFORSCH C, V37, P772; SCHNEIDER G, 1994, PLANT GROWTH REGUL, V15, P247, DOI 10.1007/BF00029898; SEMBDNER G, 1985, BIOL PLANTARUM, V27, P231, DOI 10.1007/BF02902167; SEMBDNER G, 1994, PLANT MOL BIOL, V26, P1459, DOI 10.1007/BF00016485; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; Tam YY, 2000, PLANT PHYSIOL, V123, P589, DOI 10.1104/pp.123.2.589; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362	41	206	223	4	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4350	4356		10.1074/jbc.M006185200	http://dx.doi.org/10.1074/jbc.M006185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042207	hybrid			2022-12-27	WOS:000166921200083
J	Gomez, A; Wellbrock, C; Gutbrod, H; Dimitrijevic, N; Schartl, M				Gomez, A; Wellbrock, C; Gutbrod, H; Dimitrijevic, N; Schartl, M			Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; XIPHOPHORUS MELANOMA-CELLS; TYROSINE KINASE-ACTIVITY; NEOPLASIA TYPE 2B; EGF-RECEPTOR; DISULFIDE BOND; POINT MUTATION; RET PROTOONCOGENE; GENE; BINDING	Overexpression of the oncogenic receptor tyrosine kinase ONC-Xmrk is the first step in the development of hereditary malignant melanoma in the fish Xiphophorus. However, overexpression of its proto-oncogene counterpart (INV-Xmrk) is not sufficient for the oncogenic function of the receptor. Compared with INV-Xmrk, the ONC-Xmrk receptor displays 14 amino acid changes, suggesting the presence of activating mutations. To identify such activating mutations, a series of chimeric and mutant receptors were studied. None of the mutations present in the intracellular domain was found to be involved in receptor activation. In the extracellular domain, we found two mutations responsible for activation of the receptor. One is the substitution of a conserved cysteine (C578S) involved in intramolecular disulfide bonding. The other is a glycine to arginine exchange (G359R) in subdomain III. Either mutation leads to constitutive dimer formation and thereby to activation of the ONC-Xmrk receptor. Besides, the presence of these mutations slows down the processing of the Xmrk receptor in the endoplasmic reticulum; which is apparent as an incomplete glycosylation.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany	University of Wurzburg	Schartl, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, Hubland, D-97074 Wurzburg, Germany.		Gómez, Ana/K-6998-2014	Gómez, Ana/0000-0003-4714-8064; Wellbrock, Claudia/0000-0002-3825-6381; Schartl, Manfred/0000-0001-9882-5948				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bongarzone I, 1999, ONCOGENE, V18, P4833, DOI 10.1038/sj.onc.1202848; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CAO HN, 1992, J BIOL CHEM, V267, P20489; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Collesi C, 1996, MOL CELL BIOL, V16, P5518; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Dimitrijevic N, 1998, ONCOGENE, V16, P1681, DOI 10.1038/sj.onc.1201693; FENDLY BM, 1990, CANCER RES, V50, P1550; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; Katz WS, 1996, MOL CELL BIOL, V16, P529; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; Lorenzi MV, 1997, ONCOGENE, V15, P817, DOI 10.1038/sj.onc.1201242; MALITSCHEK B, 1994, J BIOL CHEM, V269, P10423; Nanda I, 2000, CHROMOSOMA, V109, P173, DOI 10.1007/s004120050425; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P55, DOI 10.1073/pnas.90.1.55; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHARTL M, 1995, TRENDS GENET, V11, P185, DOI 10.1016/S0168-9525(00)89041-1; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Tessitore A, 1999, J CLIN ENDOCR METAB, V84, P3522, DOI 10.1210/jc.84.10.3522; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Weis S, 1998, GENETICS, V149, P1909; Wellbrock C, 1999, EUR J BIOCHEM, V260, P275, DOI 10.1046/j.1432-1327.1999.00180.x; Wellbrock C, 1998, ONCOGENE, V16, P3047, DOI 10.1038/sj.onc.1201844; Wellbrock C, 1998, INT J CANCER, V76, P437, DOI 10.1002/(SICI)1097-0215(19980504)76:3<437::AID-IJC24>3.0.CO;2-6; WINKLER C, 1994, ONCOGENE, V9, P1517; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0	55	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3333	3340		10.1074/jbc.M006574200	http://dx.doi.org/10.1074/jbc.M006574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11038352	hybrid			2022-12-27	WOS:000166784900047
J	Wells, KM; Rao, R				Wells, KM; Rao, R			The yeast Na+/H+ exchanger Nhx1 is an N-linked glycoprotein - Topological implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; GROWTH; ANTIPORTER; DOMAIN; PROTEINS; ATPASE	Nkx1, the endosomal Na+/H+ exchanger of Saccharomyces cerevisiae represents the founding member of a newly emerging subfamily of intracellular Na+/H+ exchangers. These proteins share significantly greater sequence homology to one another than to members of the mammalian Na+/H+ exchanger (NHE) family encoding plasma membrane Na+/H+ exchangers. Members of both subtypes are predicted to share a common organization, with an N-terminal transporter domain of transmembrane helices followed by a C-terminal hydrophilic tail. In the present study, we show that Nhx1 is an asparagine-linked glycoprotein and that the sites of glycosylation map to two residues within the C-terminal stretch of the polypeptide, This is the first evidence, to date, for glycosylation of the C-terminal region of any known NHE isoform, Importantly, the mapping of N-linked glycosylation to the C-terminal domain of Nhx1 is indicative of an unexpected membrane topology, particularly with regard to the orientation of the tail region. Although one recent study demonstrated that certain epitopes in the C-terminal domain of NHE3 were accessible from the exoplasmic side of the plasma membrane (Biemesderfer, D., DeGray, B,, and Aronson, P. S. (1998) J, Biol, Chem. 273, 12391-12396), numerous other studies implicate a cytosolic disposition for the hydrophilic C-terminal tail of plasma membrane NHE isoforms, Our analysis of the glycosylation of Nhx1 is strongly indicative of residence of at least some portion of the hydrophilic tail domain within the endosomal lumen, These findings imply that the organization of the tail domain may be more complex than previously assumed.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Rao, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	rrao@jhmi.edu			NIDDK NIH HHS [DK54214] Funding Source: Medline; NIGMS NIH HHS [GM52414] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052414] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderie I, 1996, J MEMBRANE BIOL, V152, P195, DOI 10.1007/s002329900097; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; DUSKIN D, 1982, J BIOL CHEM, V257, P3105; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILDEN SA, 1990, AM J PHYSIOL, V258, pF1311; KEPES F, 1988, J BIOL CHEM, V263, P9155; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; Nass R, 1999, MICROBIOL-SGM, V145, P3221, DOI 10.1099/00221287-145-11-3221; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Quintero FJ, 2000, FEBS LETT, V471, P224, DOI 10.1016/S0014-5793(00)01412-5; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sorin A, 1997, J BIOL CHEM, V272, P9895; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TSE CM, 1994, BIOCHEMISTRY-US, V33, P12954, DOI 10.1021/bi00248a003; VANDYKE RW, 1995, AM J PHYSIOL-CELL PH, V269, pC943, DOI 10.1152/ajpcell.1995.269.4.C943; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51	34	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3401	3407		10.1074/jbc.M001688200	http://dx.doi.org/10.1074/jbc.M001688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11036065	hybrid			2022-12-27	WOS:000166784900055
J	Xia, ZF; Morales, JC; Dunphy, WG; Carpenter, PB				Xia, ZF; Morales, JC; Dunphy, WG; Carpenter, PB			Negative cell cycle regulation and DNA damage-inducible phosphorylation of the BRCT protein 53BP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; FISSION YEAST; CHECKPOINT PATHWAY; S-PHASE; TRANSCRIPTIONAL ACTIVATION; MIDBLASTULA TRANSITION; IONIZING-RADIATION; BUDDING YEAST	In a screen designed to discover suppressors of mitotic catastrophe, we identified the Xenopus ortholog of 53BP1 (X53BP1), a BRCT protein previously identified in humans through its ability to bind the p53 tumor suppressor. X53BP1 transcripts are highly expressed in ovaries, and the protein interacts with Xp53 throughout the cell cycle in embryonic extracts. However, no interaction between X53BP1 and Xp53 can be detected in somatic cells, suggesting that the association between the two proteins may be developmentally regulated. X53BP1 is modified via phosphorylation in a DNA damage-dependent manner that correlates with the dispersal of X53BP1 into multiple foci throughout the nucleus in somatic cells. Thus, X53BP1 can be classified as a novel participant in the DNA damage response pathway. We demonstrate that X53BP1 and its human ortholog can serve as good substrates in vitro as well as in vivo for the ATM kinase. Collectively, our results reveal that 53BP1 plays an important role in the checkpoint response to DNA damage, possibly in collaboration with ATM.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Program Canc Biol, Houston, TX 77030 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Carpenter, PB (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.			Morales, Julio/0000-0002-0854-7866				ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; Anderson JA, 1997, MOL BIOL CELL, V8, P1195, DOI 10.1091/mbc.8.7.1195; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carpenter PB, 1998, J BIOL CHEM, V273, P24891, DOI 10.1074/jbc.273.38.24891; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Clute P, 1997, DEV BIOL, V185, P1, DOI 10.1006/dbio.1997.8540; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; COX LS, 1994, ONCOGENE, V9, P2951; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; HALAZONETIS TD, 1999, BIOCHIM BIOPHYS ACTA, V1424, P45; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOEVER M, 1994, ONCOGENE, V9, P109; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu QH, 2000, GENE DEV, V14, P1448; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shieh SY, 2000, GENE DEV, V14, P289; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; SMITH JC, 1991, METHOD CELL BIOL, V36, P636; SOUSSI T, 1987, ONCOGENE, V1, P71; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wang H, 1999, P NATL ACAD SCI USA, V96, P3824, DOI 10.1073/pnas.96.7.3824; Wang Y, 2000, GENE DEV, V14, P927; WANG Y, 1995, ONCOGENE, V10, P779; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang SS, 1997, J CELL BIOL, V136, P345, DOI 10.1083/jcb.136.2.345; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	81	80	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2708	2718		10.1074/jbc.M007665200	http://dx.doi.org/10.1074/jbc.M007665200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11042216	Green Accepted, hybrid			2022-12-27	WOS:000166784800057
J	Burks, EA; Bezerra, PP; Le, H; Gallie, DR; Browning, KS				Burks, EA; Bezerra, PP; Le, H; Gallie, DR; Browning, KS			Plant initiation factor 3 subunit composition resembles mammalian initiation factor 3 and has a novel subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; FACTOR 3 EIF3; TEMPERATURE-SENSITIVE MUTANTS; MAMMARY-TUMOR VIRUS; FACTOR 4G EIF4G; TRANSLATION INITIATION; WHEAT-GERM; RNA-BINDING; FACTOR-III; CELL-PROLIFERATION	Eukaryotic initiation factor 3 (eIF3) is a multisubunit complex that is required for binding of mRNA to 40 S ribosomal subunits, stabilization of ternary complex binding to 40 S subunits, and dissociation of 40 and 60 S subunits. These functions and the complex nature of eIF3 suggest multiple interactions with many components of the translational machinery. Recently, the subunits of mammalian and Saccharomyces cerevisiae eIF3 were identified, and substantial differences in the subunit composition of mammalian and S. cerevisiae were observed. Mammalian eIF3 consists of 11 nonidentical subunits, whereas S. cerevisiae eIF3 consists of up to eight nonidentical subunits. Only five of the subunits of mammalian and S. cerevisiae are shared in common, and these five subunits comprise a "core" complex in S. cerevisiae. eIF3 from wheat consists of at least 10 subunits, but their relationship to either the mammalian or S. cerevisiae eIF3 subunits is unknown. Peptide sequences derived from purified wheat eIF3 subunits were used to correlate each subunit with mammalian and/or S. cerevisiae subunits. The peptide sequences were also used to identify Arabidopsis thaliana cDNAs for each of the eIF3 subunits. We report seven new cDNAs for A. thaliana eIF3 subunits. A. thaliana eIF3 was purified and characterized to confirm that the subunit composition and activity of wheat and A. thaliana eIF3 were similar. We report that plant eIF3 closely resembles the subunit composition of mammalian eIF3, having 10 out of 11 subunits in common. Further, we find a novel subunit in the plant eIF3 complex not present in either mammalian or S. cerevisiae eIF3. These results suggest that plant and mammalian eIF3 evolved similarly, whereas S. cerevisiae has diverged.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of California System; University of California Riverside	Browning, KS (corresponding author), Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA.	kbrowning@mail.utexas.edu						Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1985, PLANT PHYSIOL, V77, P370, DOI 10.1104/pp.77.2.370; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; CEGLARZ E, 1980, BIOCHIM BIOPHYS ACTA, V610, P181, DOI 10.1016/0005-2787(80)90068-4; CHANDHURI J, 1999, J BIOL CHEM, V274, P17975; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; CHECKLEY JW, 1981, J BIOL CHEM, V256, P1582; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DUMAS LB, 1982, MOL GEN GENET, V187, P42, DOI 10.1007/BF00384381; Fulop V, 1999, CURR OPIN STRUC BIOL, V9, P715, DOI 10.1016/S0959-440X(99)00035-4; Gallie DR, 1998, PLANT J, V14, P715, DOI 10.1046/j.1365-313x.1998.00175.x; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; Hanachi P, 1999, J BIOL CHEM, V274, P8546, DOI 10.1074/jbc.274.13.8546; HANICJOYCE PJ, 1987, EXP CELL RES, V172, P134, DOI 10.1016/0014-4827(87)90100-5; HANICJOYCE PJ, 1985, GENETICS, V110, P591; HARTWELL LH, 1968, J BACTERIOL, V96, P1664, DOI 10.1128/JB.96.5.1664-1671.1968; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; HEUFLER C, 1988, BIOCHIM BIOPHYS ACTA, V951, P182, DOI 10.1016/0167-4781(88)90039-5; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; Karniol B, 1998, FEBS LETT, V439, P173, DOI 10.1016/S0014-5793(98)01367-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAUER SJ, 1985, BIOCHEMISTRY-US, V24, P2928, DOI 10.1021/bi00333a017; LAUER SJ, 1985, BIOCHEMISTRY-US, V24, P2924, DOI 10.1021/bi00333a016; LAX SR, 1986, METHOD ENZYMOL, V118, P109; Linder P, 1999, YEAST, V15, P865; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Metz AM, 1999, BIOCHEM BIOPH RES CO, V266, P314, DOI 10.1006/bbrc.1999.1814; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; NYGARD O, 1982, BIOCHIM BIOPHYS ACTA, V697, P263, DOI 10.1016/0167-4781(82)90088-4; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEAL SN, 1983, J BIOL CHEM, V258, P866; Shen WH, 1999, PLANT SCI, V143, P45, DOI 10.1016/S0168-9452(99)00017-5; TAKADA Y, 1994, RAPID COMMUN MASS SP, V8, P695, DOI 10.1002/rcm.1290080906; van Buuren ML, 1999, MOL PLANT MICROBE IN, V12, P171, DOI 10.1094/MPMI.1999.12.3.171; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200	72	73	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2122	2131		10.1074/jbc.M007236200	http://dx.doi.org/10.1074/jbc.M007236200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042177	hybrid			2022-12-27	WOS:000166528000065
J	Piekielko, A; Drung, A; Rogalla, P; Schwanbeck, R; Heyduk, T; Gerharz, M; Bullerdiek, J; Wisniewski, JR				Piekielko, A; Drung, A; Rogalla, P; Schwanbeck, R; Heyduk, T; Gerharz, M; Bullerdiek, J; Wisniewski, JR			Distinct organization of DNA complexes of various HMGI/Y family proteins and their modulation upon mitotic phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; 4-WAY JUNCTION DNA; IFN-BETA GENE; PULMONARY CHONDROID HAMARTOMAS; GROUP CHROMOSOMAL-PROTEINS; MOBILITY GROUP PROTEINS; COLI RNA-POLYMERASE; NEOPLASTIC TRANSFORMATION; ARCHITECTURAL FACTOR; BINDING PROPERTIES	High mobility group (HMG) proteins HMGI, HMGY, HMGI-C, and Chironomus HMGI are DNA-binding proteins thought to modulate the assembly and the function of transcriptional complexes. Each of these proteins contains three DNA-binding domains (DBD), properties of which appear to be regulated by phosphorylation. High levels of these proteins are characteristic for rapidly dividing cells in embryonic tissues and tumors. On the basis of their occurrence, specific functions for each of these proteins have been postulated. In this study we demonstrate differences in the nature of contacts of these proteins with promoter region of the interferon-p gene. We show that HMGI and HMGY interact with this DNA via three DBDs, whereas HMGI-C and Chironomus HMGI bind to this DNA using only two domains. Phosphorylation of HMGY protein by Cdc2 kinase leads to impairing of contacts between the N-terminally located DBD and a single promoter element. The perturbations in the architecture of the protein DNA complexes involve changes in the degree of unbending of the intrinsically bent TFN beta promoter. Our results provide first insights into the molecular basis of functional specificity of proteins of the HMGI/Y family and their regulation by phosphorylation.	Univ Gottingen, Zool Inst Entwicklungsbiol 3, D-37073 Gottingen, Germany; Univ Bremen, Zentrum Humangenetik & Genet Beratung, ZHG, D-28359 Bremen, Germany; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	University of Gottingen; University of Bremen; Saint Louis University	Wisniewski, JR (corresponding author), Univ Gottingen, Zool Inst Entwicklungsbiol 3, D-37073 Gottingen, Germany.		Schwanbeck, Ralf/A-2648-2008; Piekielko-Witkowska, Agnieszka/V-1011-2019	Schwanbeck, Ralf/0000-0003-0925-929X; Piekielko-Witkowska, Agnieszka/0000-0002-5348-0760				ASHAR HR, 1995, CELL, V82, P57; Banks GC, 2000, BIOCHEMISTRY-US, V39, P8333, DOI 10.1021/bi000378+; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; Blank C, 2000, CANCER GENET CYTOGEN, V121, P172, DOI 10.1016/S0165-4608(00)00249-1; Bol S, 1996, CANCER GENET CYTOGEN, V90, P88, DOI 10.1016/0165-4608(96)00062-3; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CARREY J, 1988, P NATL ACAD SCI USA, V85, P975; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CLAUS P, 1994, J BIOL CHEM, V269, P33042; Cmarik JL, 1998, ONCOGENE, V16, P3387, DOI 10.1038/sj.onc.1201888; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fedele M, 1996, CANCER RES, V56, P1896; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Frank O, 1998, J BIOL CHEM, V273, P20015, DOI 10.1074/jbc.273.32.20015; Giannini G, 1999, CANCER RES, V59, P2484; Heyduk E, 1997, ANAL BIOCHEM, V248, P216, DOI 10.1006/abio.1997.2148; Heyduk E, 1999, J BIOL CHEM, V274, P3315, DOI 10.1074/jbc.274.6.3315; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; Heyduk E, 1998, P SOC PHOTO-OPT INS, V3256, P218, DOI 10.1117/12.307063; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KAZMIERCZAK B, 1995, CANCER RES, V55, P6038; Kazmierczak B, 1996, ONCOGENE, V12, P515; Kazmierczak B, 1996, J NATL CANCER I, V88, P1234, DOI 10.1093/jnci/88.17.1234; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Maxam A M, 1980, Methods Enzymol, V65, P499; MUJUMDAR RB, 1993, BIOCONJUGATE CHEM, V4, P105, DOI 10.1021/bc00020a001; Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; Rogalla P, 1997, MOL CARCINOGEN, V19, P153, DOI 10.1002/(SICI)1098-2744(199707)19:3<153::AID-MC2>3.0.CO;2-F; Rommel B, 1997, LEUKEMIA LYMPHOMA, V26, P603, DOI 10.3109/10428199709050896; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Schwanbeck R, 2000, J BIOL CHEM, V275, P1793, DOI 10.1074/jbc.275.3.1793; Schwanbeck R, 1997, J BIOL CHEM, V272, P27476, DOI 10.1074/jbc.272.43.27476; Schwanbeck R, 2000, BIOCHEMISTRY-US, V39, P14419, DOI 10.1021/bi0011274; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SELVIN PR, 1994, P NATL ACAD SCI USA, V91, P10024, DOI 10.1073/pnas.91.21.10024; SELVIN PR, 1994, J AM CHEM SOC, V116, P6029, DOI 10.1021/ja00092a088; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; SELVIN PR, 1996, IEEE J SEL TOP QUANT, V2, P1; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; Tamimi Y, 1996, BRIT J CANCER, V74, P573, DOI 10.1038/bjc.1996.403; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; WANG DZ, 1995, J BIOL CHEM, V270, P22924, DOI 10.1074/jbc.270.39.22924; Williams AJ, 1997, AM J PATHOL, V150, P911; Wisniewski JR, 1999, BBA-GENE STRUCT EXPR, V1447, P25, DOI 10.1016/S0167-4781(99)00123-2; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 2000, INT J MOL MED, V6, P409; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; Xiao DM, 2000, J NEUROCHEM, V74, P392, DOI 10.1046/j.1471-4159.2000.0740392.x; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	69	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1984	1992		10.1074/jbc.M004065200	http://dx.doi.org/10.1074/jbc.M004065200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11034995	hybrid			2022-12-27	WOS:000166528000047
J	Barbera, MJ; Schluter, A; Pedraza, N; Iglesias, P; Villarroya, F; Giralt, M				Barbera, MJ; Schluter, A; Pedraza, N; Iglesias, P; Villarroya, F; Giralt, M			Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene - A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID TRANSPORT PROTEIN; PPAR-GAMMA ACTIVATORS; ADIPOSE-TISSUE; ADIPOCYTE DIFFERENTIATION; 5'-FLANKING REGION; NUCLEAR RECEPTOR; RETINOIC ACID; EXPRESSION; RAT; BETA	High expression of the peroxisome proliferator-activated receptor alpha (PPAR alpha) differentiates brown fat from white, and is related to its high capacity of lipid oxidation, We analyzed the effects of PPAR alpha activation on expression of the brown fat-specific uncoupling protein-1 (ucp-1) gene. Activators of PPAR alpha increased UCP-1 mRNA levels severalfold both in primary brown adipocytes and in brown fat in vivo. Transient transfection assays indicated that the (-4551)UCP1-CAT construct, containing the 5'-regulatory region of the rat ucp-1 gene, was activated by PPAR alpha co-transfection in a dose-dependent manner and this activation was potentiated by Wy 14,643 and retinoid X receptor alpha, The coactivators CBP and PPAR gamma -coactivator-1 (PGC-1), which is highly expressed in brown fat, also enhanced the PPAR alpha -dependent regulation of the ucp-1 gene. Deletion and point-mutation mapping analysis indicated that the PPAR alpha -responsive element was located in the upstream enhancer region of the ucp-1 gene. This -2485/-2458 element bound PPAR alpha and PPAR gamma from brown fat nuclei. Moreover, this element behaved as a promiscuous responsive site to either PPAR alpha or PPAR gamma activation, and we propose that it mediates ucp-1 gene up-regulation associated with adipogenic differentiation (via PPAR gamma) or in coordination with gene expression for the fatty acid oxidation machinery required for active thermogenesis (via PPAR alpha).	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain	University of Barcelona	Giralt, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Giralt, Marta/A-4756-2013; Iglesias, Roser/C-5561-2017; Schlüter, Agatha/N-4097-2014; Iglesias, P/AAU-1011-2020; Schluter, Agatha/AAA-9665-2021; Pedraza González, Neus/C-6390-2011; Villarroya, Francesc/K-4357-2014	Giralt, Marta/0000-0001-7968-4190; Iglesias, Roser/0000-0002-7107-8097; Schlüter, Agatha/0000-0001-6732-1528; Iglesias, P/0000-0003-0126-1985; Pedraza González, Neus/0000-0003-4749-5111; Villarroya, Francesc/0000-0003-1266-9142				ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; Alvarez R, 2000, BIOCHEM J, V345, P91, DOI 10.1042/0264-6021:3450091; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; BOUILLAUD F, 1985, P NATL ACAD SCI USA, V82, P445, DOI 10.1073/pnas.82.2.445; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CassardDoulcier AM, 1996, INT J OBESITY, V20, P278; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frohnert BI, 1999, J BIOL CHEM, V274, P3970, DOI 10.1074/jbc.274.7.3970; GIRALT M, 1990, BIOCHIM BIOPHYS ACTA, V1048, P270, DOI 10.1016/0167-4781(90)90066-B; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; Guardiola-Diaz HM, 1999, J BIOL CHEM, V274, P23368, DOI 10.1074/jbc.274.33.23368; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lindquist JM, 1998, J BIOL CHEM, V273, P30147, DOI 10.1074/jbc.273.46.30147; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; MARTIN I, 1989, BIOCHEM J, V263, P965, DOI 10.1042/bj2630965; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; NICHOLLS DG, 1986, BROWN ADIPOSE TISSUE, P52; Pedraza N, 2000, DIABETES, V49, P1224, DOI 10.2337/diabetes.49.7.1224; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Tai TAC, 1996, J BIOL CHEM, V271, P29909, DOI 10.1074/jbc.271.47.29909; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Valmaseda A, 1999, MOL CELL ENDOCRINOL, V154, P101, DOI 10.1016/S0303-7207(99)00081-7; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yubero P, 1998, MOL ENDOCRINOL, V12, P1023, DOI 10.1210/me.12.7.1023; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	55	263	273	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1486	1493		10.1074/jbc.M006246200	http://dx.doi.org/10.1074/jbc.M006246200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050084	hybrid			2022-12-27	WOS:000166430900084
J	McLarrent, FW; Theriault, FM; Stifani, S				McLarrent, FW; Theriault, FM; Stifani, S			Association with the nuclear matrix and interaction with Groucho and RUNX proteins regulate the transcription repression activity of the basic helix loop helix factor Hes1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUCHO/TRANSDUCIN-LIKE ENHANCER; DROSOPHILA-ENHANCER; SENSORY NEURONS; TERMINAL DOMAIN; NERVOUS-SYSTEM; SPLIT COMPLEX; WRPW MOTIF; GENE; EXPRESSION; FAMILY	Hairy/Enhancer of split 1 (Hes1) is a mammalian transcriptional repressor that plays crucial roles in the regulation of several developmental processes, including neuronal differentiation. The aim of this study was to elucidate the molecular mechanisms that regulate the transcription repression activity of Hes1, It is shown here that Heel associates with the nuclear matrix, the ribonucleoprotein network of the nucleus that plays important roles in transcriptional regulation. Nuclear matrix binding is mediated by the same Hes1 C-terminal domain that is also required for transcriptional repression. This domain contains the WRPW motif that acts as a binding site for the transcriptional corepressor Groucho, which also localizes to the nuclear matrix. Both the nuclear matrix association and transcription repression activity of Heel are inhibited by deletion of the WRPW motif, indicating that Groucho acts as a transcriptional corepressor for Hes1. This corepressor role is not modulated by the Groucho-related gene product Grg5, In contrast, the Bunt-related protein RUNX2, which localizes to the nuclear matrix and interacts with Groucho and Hes1, can inhibit both the Groucho(.)Hes1 interaction and the transcription repression ability of Hes1, Together, these observations suggest that transcriptional repression by Hes1 requires interactions with Groucho at the nuclear matrix and that RUNX proteins act as negative regulators of the repressive activity of Groucho(.)Hes1 complexes.	McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada	McGill University	Stifani, S (corresponding author), McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	mdst@musica.mcgill.ca		Stifani, Stefano/0000-0002-2376-7701				Allen T, 1999, CELL MOL BIOL, V45, P687; Anderson DJ, 1999, CURR OPIN NEUROBIOL, V9, P517, DOI 10.1016/S0959-4388(99)00015-X; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; DEHNI G, 1995, MECH DEVELOP, V53, P269; DELIDAKIS C, 1991, GENETICS, V129, P803; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Fode C, 1998, NEURON, V20, P483, DOI 10.1016/S0896-6273(00)80989-7; Grbavec D, 1999, BIOCHEM J, V337, P13, DOI 10.1042/0264-6021:3370013; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Heitzler P, 1996, DEVELOPMENT, V122, P161; HUSAIN J, 1996, BIOCHEM J, V317, P323; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Javed A, 2000, J CELL SCI, V113, P2221; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; KNUST E, 1992, GENETICS, V132, P505; Koop KE, 1996, MECH DEVELOP, V59, P73, DOI 10.1016/0925-4773(96)00582-5; Kramer SG, 1999, DEVELOPMENT, V126, P191; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; Matsue M, 1997, BONE, V20, P329, DOI 10.1016/S8756-3282(97)00005-7; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MIYASAKA H, 1993, EUR J BIOCHEM, V216, P343, DOI 10.1111/j.1432-1033.1993.tb18151.x; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pinto M, 1996, J BIOL CHEM, V271, P33026, DOI 10.1074/jbc.271.51.33026; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Stein GS, 1999, CRIT REV EUKAR GENE, V9, P183, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.30; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Yao J, 1998, DEV GROWTH DIFFER, V40, P133; Yao J, 2000, MECH DEVELOP, V93, P105, DOI 10.1016/S0925-4773(00)00278-1; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746	53	73	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1578	1584		10.1074/jbc.M007629200	http://dx.doi.org/10.1074/jbc.M007629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035023	hybrid			2022-12-27	WOS:000166430900096
J	Sayama, K; Hanakawa, Y; Shirakata, Y; Yamasaki, K; Sawada, Y; Sun, L; Yamanishi, K; Ichijo, H; Hashimoto, K				Sayama, K; Hanakawa, Y; Shirakata, Y; Yamasaki, K; Sawada, Y; Sun, L; Yamanishi, K; Ichijo, H; Hashimoto, K			Apoptosis signal-regulating kinase 1 (ASK1) is an intracellular inducer of keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; HUMAN INVOLUCRIN PROMOTER; TERMINAL DIFFERENTIATION; MOLECULAR-CLONING; MAP KINASE; CELLS; EXPRESSION; GROWTH; SKIN; TRANSGLUTAMINASE	Cells differentiate in response to various extracellular stimuli. This cellular response requires intracellular signaling pathways. The mitogen-activated protein (MAP) kinase cascade is a core signal transduction pathway that determines the fate of many kinds of cell. MAP kinase kinase kinase activates MAP kinase kinase, which in turn activates MAP kinase. Apoptosis signal-regulating kinase (ASK1) was Identified as a MAP kinase kinase kinase involved in the stress-induced apoptosis-signaling cascade that activates the SEK1-JNK and MKK3/MKK6-p38 MAP kinase cascades. Expression of the constitutively active form of ASK1 (ASK1-DeltaN) in keratinocytes induced significant morphological changes and differentiation markers, transglutaminase-1, loricrin, and involucrin, A transient increase in p21(Cip1/WAF1) reduced DNA synthesis, and cell cycle analysis verified the differentiation. p38 MAP kinase inhibitors, SB202190 and SB203580, abolished the induction of differentiation markers, transglutaminase-l, loricrin, and involucrin. In turn, the induction of differentiation with ceramide in keratinocytes caused an increase in ASK1 expression and activity. Furthermore, normal human skin expresses ASK1 protein in the upper epidermis, implicating ASK1 in in vivo keratinocyte differentiation. We propose that the ASK1-p38 MAP kinase cascade is a new intracellular regulator of keratinocyte differentiation.	Ehime Univ, Dept Dermatol, Sch Med, Shigenobucho, Ehime 7910295, Japan; Tokyo Med & Dent Univ, Grad Sch, Lab Cell Signalling, Tokyo 1138519, Japan; Dalian Med Univ, Affiliated Hosp 2, Dept Dermatol, Dalian, Peoples R China; Kyoto Prefectural Univ Med, Dept Dermatol, Kyoto 6020841, Japan	Ehime University; Tokyo Medical & Dental University (TMDU); Dalian Medical University; Kyoto Prefectural University of Medicine	Sayama, K (corresponding author), Ehime Univ, Dept Dermatol, Sch Med, Shigenobucho, Ehime 7910295, Japan.		Yamasaki, Kenshi/C-8905-2018; Yamanishi, Kiyofumi/R-2200-2019; Sawada, Yasuhiro/H-8044-2012	Yamasaki, Kenshi/0000-0002-5495-4956; Yamanishi, Kiyofumi/0000-0003-0484-2320; Sawada, Yasuhiro/0000-0003-0625-3335; Ichijo, Hidenori/0000-0002-5005-6438				CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DIUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; GHERZI R, 1992, BIOCHEM BIOPH RES CO, V184, P283, DOI 10.1016/0006-291X(92)91190-2; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUI MS, 1992, J INVEST DERMATOL, V99, P565, DOI 10.1111/1523-1747.ep12667411; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OKUMURA H, 1991, EXP CELL RES, V192, P647, DOI 10.1016/0014-4827(91)90089-D; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; PITTELKOW MR, 1986, J INVEST DERMATOL, V86, P410, DOI 10.1111/1523-1747.ep12285684; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sayama K, 1999, J CELL PHYSIOL, V179, P40, DOI 10.1002/(SICI)1097-4652(199904)179:1<40::AID-JCP5>3.0.CO;2-Z; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; VANERP PEJ, 1989, AM J PATHOL, V135, P865; WAKITA H, 1994, ARCH DERMATOL RES, V286, P350, DOI 10.1007/BF00402228; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YAMANISHI K, 1991, BIOCHEM BIOPH RES CO, V175, P906, DOI 10.1016/0006-291X(91)91651-R; YUSPA SH, 1982, CANCER RES, V42, P2344	39	111	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					999	1004		10.1074/jbc.M003425200	http://dx.doi.org/10.1074/jbc.M003425200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11029458	hybrid			2022-12-27	WOS:000166430900020
J	Yan, ZF; Deng, XB; Friedman, E				Yan, ZF; Deng, XB; Friedman, E			Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; MEMBRANE PROTEOGLYCAN; DISEASE PROGRESSION; POTENTIAL MEDIATOR; EXPRESSION CLONING; TRANSGENIC MICE	Transforming growth factor-beta1 (TGF-beta1) can act as a tumor suppressor or a tumor promoter depending on the characteristics of the malignant cell. Each of three Ki-ras(G12V) transfectants of HD6-4 colon cancer cells had been shown to be more aggressive in vivo than controls in earlier studies (Yan, Z,, Chen, M,, Perucho, M., and Friedman, E. (1997) J, Biob. Chem. 272, 30928-30936). We now show that stable expression of oncogenic Ki-ras(G12V) converts the HD6-4 colon cancer cell line from insensitive to TGF-beta1 to growth-promoted by TGF-beta1, Each of three Ki-ras(G12V) transfectants responded to TGF-beta1 by an increase in proliferation and by decreasing the abundance of the Cdk inhibitor p21 and the tumor suppressor PTEN, whereas each of three wild-type Ki-ras transfectants remained unresponsive to TG-F-beta1. The wildtype Ki-ras transfectants lack functional TGF-beta receptors, whereas all three Ki-rasG12V transfectants expressed functional TGF-beta receptors that bound I-125-TGF-beta1. The previous studies showed that in cells with wild-type Ki-ras, TGF-beta receptors were not mutated, and receptor proteins were transported to the cell surface, but post-translational modification of TGF-beta receptor ill (T beta RIII) was incomplete. We now show that the betaglycan form of T beta RIII is highly modified following translation when transiently expressed in Ki-ras(G12V) cells, whereas no such post-translational modification of T beta RIII occurs in control cells. Antisense oligonucleotides directed to Ki-Ras decreased both T beta RIII posttranslational modification in Ki-ras(G12V) cells and TGF-beta1 down-regulation of p21, demonstrating the direct effect of mutant Res. Therefore, one mechanism by which mutant Ki-Ras confers a more aggressive tumor phenotype is by enhancing T beta RIII post-translational modification.	SUNY, Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College	Friedman, E (corresponding author), SUNY, Upstate Med Univ, Dept Pathol, Rm 2305,Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.				NATIONAL CANCER INSTITUTE [R01CA075708] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA75708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; Barrack ER, 1997, PROSTATE, V31, P61; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; CUI W, 1996, GROWTH FACTORS CYTOK; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; EASTON EW, 1991, J BIOL CHEM, V266, P21674; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; Factor VM, 1997, CANCER RES, V57, P2089; Farina AR, 1998, INT J CANCER, V75, P721; FILMUS J, 1992, ONCOGENE, V7, P521; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARPER JW, 1993, CELL, V75, P805; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOUCK KA, 1989, ONCOGENE, V4, P19; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; HUANG F, 1994, ONCOGENE, V9, P3701; HUANG F, 1995, CELL GROWTH DIFFER, V6, P1635; Kansra S, 2000, INT J CANCER, V87, P373, DOI 10.1002/1097-0215(20000801)87:3<373::AID-IJC10>3.0.CO;2-X; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Li DM, 1997, CANCER RES, V57, P2124; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; LONGSTREET M, 1992, ONCOGENE, V7, P1549; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Riggins GJ, 1997, CANCER RES, V57, P2578; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Robson H, 1996, BRIT J CANCER, V74, P753, DOI 10.1038/bjc.1996.432; SCHROY P, 1990, CANCER RES, V50, P261; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shim KS, 1999, CANCER-AM CANCER SOC, V85, P554, DOI 10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X; SIPES NJ, 1990, MOL CARCINOGEN, V3, P12, DOI 10.1002/mc.2940030106; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Tsushima H, 1996, GASTROENTEROLOGY, V110, P375, DOI 10.1053/gast.1996.v110.pm8566583; Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197; Ventura F, 1996, J BIOL CHEM, V271, P13931, DOI 10.1074/jbc.271.24.13931; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yan ZF, 1997, J BIOL CHEM, V272, P27902, DOI 10.1074/jbc.272.44.27902; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YAN ZF, 1992, ONCOGENE, V7, P801; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; ZHAO J, 1995, CANCER RES, V55, P6181	79	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1555	1563		10.1074/jbc.M004553200	http://dx.doi.org/10.1074/jbc.M004553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11029459	hybrid			2022-12-27	WOS:000166430900093
J	Harrington, RH; Sharma, A				Harrington, RH; Sharma, A			Transcription factors recognizing overlapping C1-A2 binding sites positively regulate insulin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL LINE; NF-KAPPA-B; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; II GENE; PANCREATIC MESENCHYME; GLUCOSE-CONCENTRATION; CHRONIC EXPOSURE; CONTROL ELEMENT; ISLET CELLS	Transcription factors binding the insulin enhancer region, RIPE3b, mediate beta -cell type-specific and glucose-responsive expression of the insulin gene. Earlier studies demonstrate that activator present in the beta -cell-specific RIPE3b1-binding complex is critical for these actions. The DNA binding activity of the RIPE3b1 activator is induced in response to glucose stimulation and is inhibited under glucotoxic conditions. The C1 element within the RIPE3b region has been implicated as the binding site for RIPE3b1 activator. The RTPE3b region also contains an additional element, A2, which shares homology with the A elements in the insulin enhancer. Transcription factors (PDX-1 and HNF-1 alpha) binding to A elements are critical regulators of insulin gene expression and/or pancreatic development. Hence, to understand the roles of C1 and A2 elements in regulating insulin gene expression, we have systematically mutated the RIPE3b region and analyzed the effect of these mutations on gene expression. Our results demonstrate that both C1 and A2 elements together constitute the binding site for the RIPE3b1 activator, In addition to C1-A2 (RIPE3b) binding complexes, three binding complexes that specifically recognize A2 elements are found in nuclear extracts from insulinoma cell lines; the A2.2 complex is detected only in insulin-producing cell lines. Furthermore, two base pairs in the A2 element were critical for binding of both RIPE3b1 and A2.2 activators. Transient transfection results indicate that both C1-A2 and A2-specific binding activators cooperatively activate insulin gene expression. In addition, RIPE3b1- and A2-specific activators respond differently to glucose, suggesting that their overlapping binding specificity and functional cooperation may play an important role in regulating insulin gene expression.	Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Sharma, A (corresponding author), Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, 1 Joslin Pl, Boston, MA 02215 USA.				NIDDK NIH HHS [DK-36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Bennett BL, 1997, J BIOL CHEM, V272, P10212; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFRAT S, 1991, J BIOL CHEM, V266, P11141; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Lu M, 1997, J BIOL CHEM, V272, P28349, DOI 10.1074/jbc.272.45.28349; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Matsukura S, 1999, J IMMUNOL, V163, P6876; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Odagiri H, 1996, J BIOL CHEM, V271, P1909, DOI 10.1074/jbc.271.4.1909; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PEYTON M, 1994, J BIOL CHEM, V269, P25936; PLLIZZARI L, 1997, FEBS LETT, V407, P320; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; Raychowdhury R, 1999, J BIOL CHEM, V274, P20961, DOI 10.1074/jbc.274.30.20961; ROBINSON GLWG, 1994, J BIOL CHEM, V269, P2452; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sharma A, 1999, DIABETES, V48, P507, DOI 10.2337/diabetes.48.3.507; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1468, DOI 10.1210/me.9.11.1468; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; SHIEH SY, 1995, J BIOL CHEM, V270, P21503, DOI 10.1074/jbc.270.37.21503; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; STEIN R, 1993, TRENDS ENDOCRIN MET, V4, P96, DOI 10.1016/1043-2760(93)90086-T; Stellrecht CMM, 1997, J BIOL CHEM, V272, P3567, DOI 10.1074/jbc.272.6.3567; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; Tomonari A, 1996, DIABETOLOGIA, V39, P1462, DOI 10.1007/s001250050599; Weiler S, 1998, J BIOL CHEM, V273, P10994, DOI 10.1074/jbc.273.18.10994; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532	67	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					104	113		10.1074/jbc.M008415200	http://dx.doi.org/10.1074/jbc.M008415200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024035	hybrid			2022-12-27	WOS:000166280700016
J	Haurie, V; Perrot, M; Mini, T; Jeno, P; Sagliocco, F; Boucherie, H				Haurie, V; Perrot, M; Mini, T; Jeno, P; Sagliocco, F; Boucherie, H			The transcriptional activator Cat8p provides a major contribution to the reprogramming of carbon metabolism during the diauxic shift in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA; GLUCONEOGENIC ENZYMES; PROTEIN-SYNTHESIS; GENE-EXPRESSION; HEAT-SHOCK; YEAST; IDENTIFICATION; DEREPRESSION; TRANSPORTER; REPRESSION	In yeast, the transition between the fermentative and the oxidative metabolism, called the diauxic shift, is associated with major changes in gene expression and protein synthesis. The zinc cluster protein Cat8p is required for the derepression of nine genes under nonfermentative growth conditions (ACS1, FBP1, ICL1, IDP2, JEN1, MLS1, PCK1, SFCI, and SIP4). To investigate whether the transcriptional control mediated by Cat8p can be extended to other genes and whether this control is the main control for the changes in the synthesis of the respective proteins during the adaptation to growth on ethanol, we analyzed the transcriptome and the proteome of a cat8 Delta strain during the diauxic shift. In this report, we demonstrate that, in addition to the nine genes known as Cat8p-dependent, there are 25 other genes or open reading frames whose expression at the diauxic shift is altered in the absence of Cat8p, For all of the genes characterized here, the Cat8p-dependent control results in a parallel alteration in mRNA and protein synthesis. It appears that the biochemical functions of the proteins encoded by Cat8p-dependent genes are essentially related to the first steps of ethanol utilization, the glyogylate cycle, and gluconeogenesis. Interestingly, no function involved in the tricarboxylic cycle and the oxidative phosphorylation seems to be controlled by Cat8p.	Inst Biochim & Genet Cellulaires, UMR 5095, Bordeaux, France; Univ Basel, Biozentrum, Dept Biochem, CH-4056 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; University of Basel	Sagliocco, F (corresponding author), Inst Biochim & Genet Cellulaires, UMR 5095, Bordeaux, France.							BATAILLE N, 1991, YEAST, V7, P367, DOI 10.1002/yea.320070407; Bojunga N, 1998, MOL GEN GENET, V260, P453, DOI 10.1007/s004380050916; Bojunga N, 1999, MOL GEN GENET, V262, P869, DOI 10.1007/s004380051152; BOUCHERIE H, 1995, YEAST, V11, P601, DOI 10.1002/yea.320110702; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BoyMarcotte E, 1996, MICROBIOL-UK, V142, P459, DOI 10.1099/13500872-142-3-459; Carlson M, 1998, CURR OPIN GENET DEV, V8, P560, DOI 10.1016/S0959-437X(98)80011-7; Casal M, 1999, J BACTERIOL, V181, P2620, DOI 10.1128/JB.181.8.2620-2623.1999; Caspary F, 1997, MOL GEN GENET, V255, P619, DOI 10.1007/s004380050536; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; ENTIAN KD, 1997, YEAST SUGAR METABOLI, P409; FERNANDEZ M, 1994, MOL GEN GENET, V242, P727; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; HEDGES D, 1995, MOL CELL BIOL, V15, P1915; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; Kratzer S, 1997, MOL MICROBIOL, V26, P631, DOI 10.1046/j.1365-2958.1997.5611937.x; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; Lodi T, 1999, MOL GEN GENET, V262, P623, DOI 10.1007/s004380051125; MILLER MJ, 1979, P NATL ACAD SCI USA, V76, P5222, DOI 10.1073/pnas.76.10.5222; Palmieri L, 1999, FEBS LETT, V462, P472, DOI 10.1016/S0014-5793(99)01555-0; Perrot M, 1999, ELECTROPHORESIS, V20, P2280, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2280::AID-ELPS2280>3.3.CO;2-H; Rahner A, 1999, MOL MICROBIOL, V34, P146, DOI 10.1046/j.1365-2958.1999.01588.x; Rahner A, 1996, NUCLEIC ACIDS RES, V24, P2331, DOI 10.1093/nar/24.12.2331; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMALIX W, 1993, J BIOL CHEM, V268, P27428; TU J, 1995, EMBO J, V14, P6789; Tzschoppe K, 1999, YEAST, V15, P1645, DOI 10.1002/(SICI)1097-0061(199911)15:15<1645::AID-YEA491>3.0.CO;2-G; van Roermund CWT, 1999, EMBO J, V18, P5843, DOI 10.1093/emboj/18.21.5843; Vincent O, 1998, EMBO J, V17, P7002, DOI 10.1093/emboj/17.23.7002; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C	36	121	124	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					76	85		10.1074/jbc.M008752200	http://dx.doi.org/10.1074/jbc.M008752200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024040	hybrid			2022-12-27	WOS:000166280700012
J	Sasai, K; Ikeda, Y; Tsuda, T; Ihara, H; Korekane, H; Shiota, K; Taniguchi, N				Sasai, K; Ikeda, Y; Tsuda, T; Ihara, H; Korekane, H; Shiota, K; Taniguchi, N			The critical role of the stem region as a functional domain responsible for the oligomerization and Golgi localization of N-acetylglucosaminyltransferase V - The involvement of a domain homophilic interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; SECONDARY-STRUCTURE; CDNA CLONING; TRANSFERASE TRANSPEPTIDASE; KIN RECOGNITION; HELA-CELLS; PROTEIN; EXPRESSION; SEQUENCE; OLIGOSACCHARIDES	We demonstrated that a region in the stem of N-acetyl- glucosaminyltransferase V (GnT-V), a Golgi resident protein, is not required for enzyme activity but serves as functional domain, responsible for intracellular localization. Deletion of the domain led to complete retention of the kinetic properties but resulted in the cell surface localization of the enzyme as well as its efficient secretion into the medium. The lack of this domain concomitantly abolished the disulfide-mediated oligomerization of GnT-V, which appears to confer the Golgi retention. When the domain was inserted into the stem region of a cell surface-localized type II membrane protein, the resulting chimeric protein was substantially oligomerized and predominantly localized in the intracellular organelle, Furthermore, it was found that the presence of this domain is exclusively responsible for homo-oligomer formation. This homophilic interaction appears to involve a hydrophobic cluster of residues in the alpha -helix of the domain, as indicated by secondary structure predictions. These findings suggest that the domain specifically participates in the Golgi retention of GnT-V, probably via inducing homo-oligomer formation, and would also provide a possible mechanism for the oligomerization, which is critical for localization in the Golgi.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Univ Tokyo, Dept Anim Resource Sci, Lab Cellular Biochem, Bunkyo Ku, Tokyo 1138657, Japan	Osaka University; University of Tokyo	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Sasai, Kazumi/GLV-2527-2022; Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Ihara, Hideyuki/0000-0003-0490-6355				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen C, 2000, J BIOL CHEM, V275, P13819, DOI 10.1074/jbc.275.18.13819; CHEN L, 1995, GLYCOCONJUGATE J, V12, P813, DOI 10.1007/BF00731243; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, CANCER RES, V49, P945; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; GARDELL SJ, 1979, J BIOL CHEM, V254, P4942; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; IKEDA Y, 1993, J BIOL CHEM, V268, P3980; IKEDA Y, 1995, J BIOL CHEM, V270, P22223, DOI 10.1074/jbc.270.38.22223; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LUTHY R, 1991, PROTEINS, V10, P229, DOI 10.1002/prot.340100307; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; Nagai K, 1997, GLYCOBIOLOGY, V7, P769, DOI 10.1093/glycob/7.6.769; NASH B, 1982, J BIOL CHEM, V257, P585; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; PIERCE M, 1987, BIOCHEM BIOPH RES CO, V146, P679, DOI 10.1016/0006-291X(87)90582-1; Pierce M, 1997, GLYCOCONJUGATE J, V14, P623, DOI 10.1023/A:1018592627696; Poumbourios P, 1997, J VIROL, V71, P2041, DOI 10.1128/JVI.71.3.2041-2049.1997; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; Seberger PJ, 1999, GLYCOBIOLOGY, V9, P235, DOI 10.1093/glycob/9.3.235; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; Taniguchi N, 1999, BBA-MOL BASIS DIS, V1455, P287, DOI 10.1016/S0925-4439(99)00066-6; TANIGUCHI N, 1985, CANCER RES, V45, P5835; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580	37	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					759	765		10.1074/jbc.M004972200	http://dx.doi.org/10.1074/jbc.M004972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024048	hybrid			2022-12-27	WOS:000166280700102
J	Pleschke, JM; Kleczkowska, HE; Strohm, M; Althaus, FR				Pleschke, JM; Kleczkowska, HE; Strohm, M; Althaus, FR			Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CYCLIN-DEPENDENT KINASES; BASE EXCISION-REPAIR; MAMMALIAN-CELLS; KU AUTOANTIGEN; XRCC1 PROTEIN; POLYMERASE; P21; APOPTOSIS; INHIBITOR	Poly(ADP-ribose) is formed in possibly all multicellular organisms by a familiy of poly(ADP-ribose) polymerases (PARPs). PARP-1, the best understood and until recently the only known member of this family, is a DNA damage signal protein catalyzing its automodification with multiple, variably sized ADP-ribose polymers that may contain up to 200 residues and several branching points. Through these polymers, PARP-1 can interact noncovalently with other proteins and alter their functions. Here we report the discovery of a poly(ADP-ribose)-binding sequence motif in several important DNA damage checkpoint proteins. The 20-amino acid motif contains two conserved regions: (i) a cluster rich in basic amino acids and (ii) a pattern of hydrophobic amino acids interspersed with basic residues. Using a combination of alanine scanning, polymer blot analysis, and photoaffinity labeling, we have identified poly(ADP-ribose)-binding sites in the following proteins: p53, p21(CIP1/WAF1) xeroderma pigmentosum group A complementing protein, MSH6, DNA ligase III, XRCC1, DNA polymerase epsilon, DNA-PKCS, Ku70, NF-kappaB, inducible nitric-oxide synthase , caspase-activated DNase, and telomerase. The poly(ADP-ribose)-binding motif was found to overlap with five important functional domains responsible for (i) protein-protein interactions, (ii) DNA binding, (iii) nuclear localization, (iv) nuclear export, and (v) protein degradation. Thus, PARPs may target specific signal network proteins via poly(ADP-ribose) and regulate their domain functions.	Univ Zurich, Inst Pharmacol & Toxicol, Tierspital, CH-8057 Zurich, Switzerland	University of Zurich	Althaus, FR (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Tierspital, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	fra@vetpharm.unizh.ch						Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Greider CW, 1999, TRENDS GENET, V15, P109, DOI 10.1016/S0168-9525(98)01681-3; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; HARPER JW, 1993, CELL, V75, P805; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; HAUSCHILDT S, 1992, BIOCHEM J, V288, P255, DOI 10.1042/bj2880255; HUPPI K, 1994, ONCOGENE, V9, P3017; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Jacobson MK, 1999, TRENDS BIOCHEM SCI, V24, P415, DOI 10.1016/S0968-0004(99)01481-4; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kickhoefer VA, 1996, TRENDS CELL BIOL, V6, P174, DOI 10.1016/0962-8924(96)10014-3; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; KIEHLBAUCH CC, 1993, ANAL BIOCHEM, V208, P26, DOI 10.1006/abio.1993.1004; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Malanga M, 1998, BBA-GENE STRUCT EXPR, V1399, P154, DOI 10.1016/S0167-4781(98)00110-9; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MASUTANI M, 1995, BIOCHIMIE, V77, P462, DOI 10.1016/0300-9084(96)88161-2; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Oei SL, 2000, J BIOL CHEM, V275, P23234, DOI 10.1074/jbc.M002429200; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PANZETER PL, 1993, J BIOL CHEM, V268, P17662; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SATOH MS, 1993, J BIOL CHEM, V268, P5480; Schmitz AAP, 1998, BIOCHEMISTRY-US, V37, P9520, DOI 10.1021/bi973063b; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; Wu XT, 1996, MOL CELL BIOL, V16, P5186; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	61	426	441	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40974	40980		10.1074/jbc.M006520200	http://dx.doi.org/10.1074/jbc.M006520200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016934	hybrid			2022-12-27	WOS:000166114600043
J	Shen, Q; Subauste, JS				Shen, Q; Subauste, JS			Dimerization interfaces of v-ErbA homodimers and heterodimers with retinoid X receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; DOMINANT-NEGATIVE ACTIVITY; AVIAN ERYTHROBLASTOSIS VIRUS; DNA-BINDING SPECIFICITY; DIRECT REPEATS; LIGAND-BINDING; TARGET GENES; RXR; ACID; DOMAIN	The oncoprotein v-ErbA, a member of the zinc finger transcription factor superfamily, is a mutated version of thyroid hormone receptor al that is virtually incapable of binding T3. v-ErbA and other members of this family can bind as homodimers and heterodimers with retinoid X receptors to specific DNA sequences arranged as direct, inverted, or everted repeats. At least two regions in the C-terminal domain, the I box (10 and 11 helices in v-ErbA and thyroid hormone receptors) and the 20-amino acid region are involved in dimerization. However, it has not been entirely understood how these receptors dimerize on differently oriented core motifs and whether the domain(s) responsible for homodimerization and heterodimerization are identical. Therefore, deletions of the entire 20-amino acid region, the 10 helix, the 11 helix, and point mutations within these regions of v-ErbA were made by site-directed mutagenesis. The mutant proteins were tested for their ability to form v-ErbA homodimers and heterodimers with retinoid X receptor Lu on differently oriented core motifs by electrophoretic mobility shift assay. Transient transfections were performed to determine the dominant negative activity of the v-ErbA mutants. The data indicate that different dimerization interfaces are used for v-ErbA homodimerization and heterodimerization with retinoid X receptor alpha, and different dimerization interfaces are used on differently oriented core motifs. The data are of:general interest because the information improves our understanding of the role of these dimerization interfaces in the mechanism of action not only of v-ErbA but also of other members of the superfamily.	GV Montgomery Vet Adm Med Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Div Endocrinol & Metab, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Subauste, JS (corresponding author), GV Montgomery Vet Adm Med Ctr, R&E Bldg,Rm 422,1500 E Woodrow Wilson Blvd, Jackson, MS 39216 USA.							AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Busch K, 2000, MOL ENDOCRINOL, V14, P201, DOI 10.1210/me.14.2.201; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; Hadzic E, 1998, J BIOL CHEM, V273, P10270, DOI 10.1074/jbc.273.17.10270; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; PROST E, 1988, NUCLEIC ACIDS RES, V16, P6248, DOI 10.1093/nar/16.13.6248; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Reginato MJ, 1996, J BIOL CHEM, V271, P28199, DOI 10.1074/jbc.271.45.28199; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; SUBAUSTE JS, 1994, J BIOL CHEM, V269, P30232; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Yang YZ, 1996, J BIOL CHEM, V271, P28235, DOI 10.1074/jbc.271.45.28235; YEN PM, 1994, J BIOL CHEM, V269, P903; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457	42	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41018	41027		10.1074/jbc.M006111200	http://dx.doi.org/10.1074/jbc.M006111200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018031	hybrid			2022-12-27	WOS:000166114600050
J	Suzuma, K; Naruse, K; Suzuma, I; Takahara, N; Ueki, K; Aiello, LP; King, GL				Suzuma, K; Naruse, K; Suzuma, I; Takahara, N; Ueki, K; Aiello, LP; King, GL			Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-Akt-dependent pathways in retinal vascular cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FACTOR GENE-EXPRESSION; ANGIOGENESIS IN-VIVO; GLUCOSE-TRANSPORT; INSULIN STIMULATION; RECOMBINANT ADENOVIRUSES; DIABETIC-RETINOPATHY; FLK-1/KDR ACTIVATION; SIGNAL-TRANSDUCTION; TYROSINE KINASE	Fibroblastic proliferation accompanies many angiogenesis-related retinal and systemic diseases. Since connective tissue growth factor (CTGF) is a potent mitogen for fibrosis, extracellular matrix production, and angiogenesis, we have studied the effects and mechanism by which vascular endothelial growth factor (VEGF) regulates CTGF gene expression in retinal capillary cells. In our study, VEGF increased CTGF mRNA levels in a time and concentration-dependent manner in bovine retinal endothelial cells and pericytes, without the need of new protein synthesis and without altering mRNA stability. VEGF activated the tyrosine receptor phosphorylation of KDR and Flt1 and increased the binding of phosphatidylinositol 3-kinase (PIS-kinase) p85 subunit to KDR and Flt1, both of which could mediate CTGF gene induction. VEGF-induced CTGF expression was mediated primarily by PI3-kinase activation, whereas PKC and ERK pathways made only minimal contributions. Furthermore, overexpression of constitutive active Akt was sufficient to induce CTGF gene expression, and inhibition of Akt activation by overexpressing dominant negative mutant of Akt abolished the VEGF-induced CTGF expression. These data suggest that VEGF can increase CTGF gene expression in bovine retinal capillary cells via KDR or Fit receptors and the activation of PI3-kinase-Akt pathway independently of PKC or Ras-ERK pathway, possibly inducing the fibrosis observed in retinal neovascular diseases.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	King, GL (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.		Sokabe, Masahiro/I-1565-2012		NEI NIH HHS [EY5110] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Boes M, 1999, ENDOCRINOLOGY, V140, P1575, DOI 10.1210/en.140.4.1575; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Dammeier J, 1998, J BIOL CHEM, V273, P18185, DOI 10.1074/jbc.273.29.18185; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Firestein GS, 1999, J CLIN INVEST, V103, P3, DOI 10.1172/JCI5929; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Joukov V, 1996, EMBO J, V15, P290; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; NAYAK RC, 1988, J EXP MED, V167, P1003, DOI 10.1084/jem.167.3.1003; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Oemar BS, 1997, CIRCULATION, V95, P831; PARK JE, 1994, J BIOL CHEM, V269, P25646; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Ricupero DA, 2000, J BIOL CHEM, V275, P12475, DOI 10.1074/jbc.275.17.12475; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006	65	204	223	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40725	40731		10.1074/jbc.M006509200	http://dx.doi.org/10.1074/jbc.M006509200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018037	Green Published, hybrid			2022-12-27	WOS:000166114600011
J	van Breukelen, B; Kanellopoulos, PN; Tucker, PA; van der Vliet, PC				van Breukelen, B; Kanellopoulos, PN; Tucker, PA; van der Vliet, PC			The formation of a flexible DNA-binding protein chain is required for efficient DNA unwinding and adenovirus DNA chain elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; HELIX-DESTABILIZING PROPERTIES; STRANDED-DNA; REPLICATION INVITRO; COMPLEX; POLYMERASE; INITIATION; MECHANISM; VITRO; DISSOCIATION	The adenovirus DNA-binding protein (DBP) binds co-operatively to single-stranded DNA (ssDNA) and stimulates both initiation and elongation of DNA replication. DBP consists of a globular core domain and a C-terminal arm that hooks onto a neighboring DBP molecule to form a stable protein chain with the DNA bound to the internal surface of the chain. This multimerization is the driving force for ATP-independent DNA unwinding by DBP during elongation. As shown by x-ray diffraction of different crystal forms of the C-terminal domain, the C-terminal arm can adopt different conformations, leading to flexibility in the protein chain. This flexibility is a function of the hinge region, the part of the protein joining the C-terminal arm to the protein core. To investigate the function of the flexibility, proline residues were introduced in the hinge region, and the proteins were purified to homogeneity after baculovirus expression. The mutant proteins were still able to bind ss- and double-stranded DNA with approximately the same affinity as wild type, and the binding to ssDNA was found to be cooperative. All mutant proteins were able to stimulate the initiation of DNA replication to near wild type levels. However, the proline mutants could not support elongation of DNA replication efficiently. Even the elongation up to 26 nucleotides was severely impaired. This defect was also seen when DNA unwinding was studied. Binding studies of DBP to homo-oligonucleotides showed an inability of the proline mutants to bind to poly(dA)(40), indicating an inability to adapt to specific DNA conformations. Our data suggest that the flexibility of the protein chain formed by DBP is important in binding and unwinding of DNA during adenovirus DNA replication. A model explaining the need for flexibility of the C-terminal arm is proposed.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; DESY, European Mol Biol Lab, D-22603 Hamburg, Germany	Utrecht University; Utrecht University; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	van der Vliet, PC (corresponding author), Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	p.c.vandervliet@med.uu.nl						ANDERSON CW, 1983, J VIROL, V48, P31, DOI 10.1128/JVI.48.1.31-39.1983; ARIGA H, 1980, VIROLOGY, V101, P307, DOI 10.1016/0042-6822(80)90510-3; BOSHER J, 1990, New Biologist, V2, P1083; CHEN M, 1990, J BIOL CHEM, V265, P18634; CLEAT PH, 1989, EMBO J, V8, P1841, DOI 10.1002/j.1460-2075.1989.tb03579.x; CLEGHON V, 1989, J VIROL, V63, P2289, DOI 10.1128/JVI.63.5.2289-2299.1989; COENJAERTS FEJ, 1994, NUCLEIC ACIDS RES, V22, P5235, DOI 10.1093/nar/22.24.5235; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; Dekker J, 1997, EMBO J, V16, P1455, DOI 10.1093/emboj/16.6.1455; Dekker J, 1996, MOL CELL BIOL, V16, P4073; Dekker J, 1998, J MOL BIOL, V277, P825, DOI 10.1006/jmbi.1998.1652; Dekker Joe, 1996, P269; FRIEFELD BR, 1983, VIROLOGY, V124, P380, DOI 10.1016/0042-6822(83)90354-9; Harfst E, 1999, VIRUS GENES, V18, P97, DOI 10.1023/A:1008009630695; Hay R T, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P31; KANELLOPOULOS PN, 1995, J STRUCT BIOL, V115, P113, DOI 10.1006/jsbi.1995.1035; Kanellopoulos PN, 1996, J MOL BIOL, V257, P1, DOI 10.1006/jmbi.1996.0141; KING AJ, 1994, EMBO J, V13, P5786, DOI 10.1002/j.1460-2075.1994.tb06917.x; King AJ, 1997, J BIOL CHEM, V272, P24617, DOI 10.1074/jbc.272.39.24617; KUIL ME, 1989, BIOCHEMISTRY-US, V28, P9795, DOI 10.1021/bi00451a038; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; MONAGHAN A, 1994, NUCLEIC ACIDS RES, V22, P742, DOI 10.1093/nar/22.5.742; MUL YM, 1993, NUCLEIC ACIDS RES, V21, P641, DOI 10.1093/nar/21.3.641; NICOLAS JC, 1983, VIROLOGY, V126, P228, DOI 10.1016/0042-6822(83)90474-9; PRONK R, 1994, FEBS LETT, V337, P33, DOI 10.1016/0014-5793(94)80624-1; RUBENSTEIN FE, 1974, INTERVIROLOGY, V3, P170, DOI 10.1159/000149753; STUIVER MH, 1990, J VIROL, V64, P379, DOI 10.1128/JVI.64.1.379-386.1990; TSERNOGLOU D, 1985, FEBS LETT, V188, P248, DOI 10.1016/0014-5793(85)80381-1; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; Van der Vliet P C, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P1; VANAMERONGEN H, 1987, BIOCHEMISTRY-US, V26, P4646, DOI 10.1021/bi00389a009; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; ZIJDERVELD DC, 1994, J VIROL, V68, P8288, DOI 10.1128/JVI.68.12.8288-8295.1994; ZIJDERVELD DC, 1993, NUCLEIC ACIDS RES, V21, P2591, DOI 10.1093/nar/21.11.2591; ZIJDERVELD DC, 1994, J VIROL, V68, P1158, DOI 10.1128/JVI.68.2.1158-1164.1994	35	16	16	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40897	40903		10.1074/jbc.M005745200	http://dx.doi.org/10.1074/jbc.M005745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11016931	hybrid			2022-12-27	WOS:000166114600032
J	Jakubowiak, A; Pouponnot, C; Berguido, F; Frank, R; Mao, SF; Massague, J; Nimer, SD				Jakubowiak, A; Pouponnot, C; Berguido, F; Frank, R; Mao, SF; Massague, J; Nimer, SD			Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE CHROMOSOMAL TRANSLOCATIONS; TGF-BETA; FUNCTIONAL COOPERATION; TUMOR-SUPPRESSOR; SMAD PROTEINS; GENE; TRANSCRIPTION; PROMOTER; DNA; REPRESSION	The t(8;21) translocation, found in adult acute myelogenous leukemia, results in the formation of an AML1/ETO chimeric transcription factor. AML1/ETO expression leads to alterations in hematopoietic progenitor cell differentiation, although its role in leukemic transformation is not clear. The N-terminal portion of AML1, which is retained in AML1/ETO, contains a region of homology to the FAST proteins, which cooperate with Smads to regulate transforming growth factor beta1 (TGF-beta1) target genes. We have demonstrated the physical association of Smad proteins with AML1 and AML1/ETO by immunoprecipitation and have mapped the region of interaction to the rant homology domain in these AML1 proteins. Using confocal microscopy, we demonstrated that AML1, and ETO and/or AML1/ETO, colocalize with Smads in the nucleus of t(8;21)-positive Kasumi-1 cells, in the presence but not the absence of TGF-beta1. Using transient transfection assays and a reporter gene construct that contains both Smad and AML1 consensus binding sequences, we demonstrated that overexpression of AML1B cooperates with TGF-beta1 in stimulating reporter gene activity, whereas AML1/ETO represses basal promoter activity and blocks the response to TGF-beta1. Considering the critical role of TGF-beta1 in the growth and differentiation of hematopoietic cells, interference with TGF-beta1 signaling by AML1/ETO may contribute to leukemogenesis.	Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Div Hematol Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, 1275 York Ave,Box 575, New York, NY 10021 USA.	s-nimer@mskcc.org		Massague, Joan/0000-0001-9324-8408	NIDDK NIH HHS [DK43025] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Germain S, 2000, GENE DEV, V14, P435; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Im YH, 2000, CANCER RES, V60, P1536; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Nagarajan RP, 1999, J BIOL CHEM, V274, P31229, DOI 10.1074/jbc.274.44.31229; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shi MJ, 1998, J IMMUNOL, V161, P6751; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	48	74	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40282	40287		10.1074/jbc.C000485200	http://dx.doi.org/10.1074/jbc.C000485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11032826	hybrid			2022-12-27	WOS:000166039500067
J	Hou, YM; Azpiazu, I; Smrcka, A; Gautam, N				Hou, YM; Azpiazu, I; Smrcka, A; Gautam, N			Selective role of G protein gamma subunits in receptor interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MUSCARINIC RECEPTORS; COUPLED RECEPTORS; RECONSTITUTION; CELLS; PURIFICATION; MEMBRANES; GTPASE	Receptor stimulation of nucleotide exchange in a heterotrimeric G protein (alpha beta gamma) is the primary event-modulating signaling by G proteins, The molecular mechanisms at the basis of this event and the role of the G protein subunits, especially the py complex, in receptor activation are unclear. In a reconstituted system, a purified muscarinic receptor, M2, activates G protein heterotrimers alpha i2 beta1 gamma5 and alpha i2 beta1 gamma7 with equal efficacy. However, when the ct subunit type is substituted with alphao, alphao beta1 gamma7 shows a 100% increase in M2-stimulated GTP hydrolysis compared with alphao beta1 gamma5, Using a sensitive assay based on py complex stimulation of phospholipase C activity, we show that both beta1 gamma5 and beta1 gamma7 form heterotrimers equally well with alphao and alphai, These results indicate that the gamma subunit interaction with a receptor is critical for modulating nucleotide exchange and is influenced by the subunit-type composition of the heterotrimer.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	Washington University (WUSTL); Washington University (WUSTL); University of Rochester	Gautam, N (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054, St Louis, MO 63110 USA.				NIGMS NIH HHS [R01 GM053536, GM46963, R01 GM046963, GM53536] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; FUNG BKK, 1983, J BIOL CHEM, V258, P495; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Hayashi MK, 1996, J BIOCHEM, V120, P1232; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Kostenis E, 1999, LIFE SCI, V64, P355, DOI 10.1016/S0024-3205(98)00574-8; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; Nathanson NM, 2000, P NATL ACAD SCI USA, V97, P6245, DOI 10.1073/pnas.97.12.6245; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PARKER EM, 1991, J BIOL CHEM, V266, P519; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; SHINOZAWA T, 1980, P NATL ACAD SCI-BIOL, V77, P1408, DOI 10.1073/pnas.77.3.1408; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588	22	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38961	38964		10.1074/jbc.C000604200	http://dx.doi.org/10.1074/jbc.C000604200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11042163	hybrid			2022-12-27	WOS:000165953100004
J	Mahalingam, S; Chaudhri, G; Tan, CL; John, A; Foster, PS; Karupiah, G				Mahalingam, S; Chaudhri, G; Tan, CL; John, A; Foster, PS; Karupiah, G			Transcription of the interferon gamma (IFN-gamma)-inducible chemokine Mig in IFN-gamma-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; BINDING PROTEIN GENE; RESPONSE ELEMENT; IN-VIVO; KAPPA-B; ACTIVATION; PROMOTER; EXPRESSION; INDUCTION; CYTOKINES	MuMig or Mig (murine monokine induced by interferon gamma) is a CXC chemokine whose induction is thought to be strictly dependent on interferon gamma (IFN-gamma). Here we have: studied the expression of this chemokine gene in various organs of mice infected with vaccinia virus. We have employed animals deficient in either IFN-gamma (IFN-/-), or receptors for IFN-alpha/beta, IFN-gamma, or both IFN-alpha/beta gamma and IFN-gamma (DR-/-) to dissect out the role of interferons in the: induction of Mig during the host response to virus infection. Our data show that Mig mRNA and protein are expressed in organs of vaccinia virus-infected IFN-gamma (-/-) mice,albeit at lower levels compared with infected, wild-type animals. In the DR-/- mice and in IFN-gamma (-/-) mice:treated:with a neutralizing antibody to IFN-alpha/beta, Mig mRNA transcripts were completely absent. Our data indicate that, in vaccinia virus-infected IFN-gamma (-/-) mice, Mg mRNA expression is mediated through the interaction between IFN-gamma responsive element 1 (gamma RE-1) and IFN-alpha/beta -induced STAT-1 complex referred to as IFN-y response factor 2 (gamma RF-2). Further, our findings support the view that gamma RF-2 is the IFN-alpha/beta induced STAT-1 complex,: IFN-alpha -activated factor. We have found that, in the absence of IFN-gamma, IFN-alpha/beta are able to induce Mig in response to a viral infection in vivo.	Univ Sydney, Dept Pathol, Host Def Grp, Div Fac Med, Sydney, NSW 2006, Australia; Australian Natl Univ, Sch Human & Biomed Sci, Div Sci & Design, Canberra, ACT 2601, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Cell Biol, Viral Engn & Cytokines Grp, Canberra, ACT 2601, Australia; Australian Natl Univ, John Curtin Sch Med Res, Med Mol Biol Grp, Canberra, ACT 2601, Australia; Australian Natl Univ, John Curtin Sch Med Res, Leukocyte Signalling & Regulat Grp, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia	University of Sydney; Australian National University; Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research	Karupiah, G (corresponding author), Univ Sydney, Dept Pathol, Host Def Grp, Div Fac Med, Blackburn Bldg,D06, Sydney, NSW 2006, Australia.		Foster, Paul/G-5057-2013; Chaudhri, Geeta/K-3290-2013; Karupiah, Gunasegaran/J-4707-2013	Chaudhri, Geeta/0000-0003-3388-2102; Karupiah, Gunasegaran/0000-0001-6306-4405				Amichay D, 1996, J IMMUNOL, V157, P4511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; COLONNO RJ, 1982, J BIOL CHEM, V257, P9234; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESPOSITO JJ, 1978, VIROLOGY, V89, P53, DOI 10.1016/0042-6822(78)90039-9; FARBER JM, 1993, BIOCHEM BIOPH RES CO, V192, P223, DOI 10.1006/bbrc.1993.1403; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GUYER NB, 1995, J IMMUNOL, V155, P3472; KARUPIAH G, 1993, J VIROL, V67, P4214, DOI 10.1128/JVI.67.7.4214-4226.1993; KARUPIAH G, 1990, J IMMUNOL, V144, P290; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIAO F, 1995, J EXP MED, V182, P1301, DOI 10.1084/jem.182.5.1301; Mahalingam S, 1999, J VIROL, V73, P1479, DOI 10.1128/JVI.73.2.1479-1491.1999; Mahalingam S, 1999, IMMUNOL CELL BIOL, V77, P469, DOI 10.1046/j.1440-1711.1999.00858.x; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Ohmori Y, 1998, J BIOL CHEM, V273, P29202, DOI 10.1074/jbc.273.44.29202; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SVETIC A, 1991, J IMMUNOL, V147, P2391; VANDENBROEK MF, 1995, J VIROL, V69, P4792, DOI 10.1128/JVI.69.8.4792-4796.1995; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; WRIGHT TM, 1991, J EXP MED, V173, P417, DOI 10.1084/jem.173.2.417; WYNN TA, 1993, J IMMUNOL, V151, P1430	42	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7568	7574		10.1074/jbc.M005773200	http://dx.doi.org/10.1074/jbc.M005773200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11024052	hybrid			2022-12-27	WOS:000167442900096
J	Zhang, W; Neer, EJ				Zhang, W; Neer, EJ			Reassembly of phospholipase C-beta(2) from separated domains - Analysis of basal and G protein-stimulated activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PLECKSTRIN HOMOLOGY DOMAINS; MEMBRANE-BINDING PROPERTIES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; C BETA-2; ACTIVATION; IDENTIFICATION; ASSOCIATION; INTERACTS; REGION	Phosphatidylinositol-specific phospholipase C-betas (PLC-betas) are the only PLC isoforms that are regulated by G; protein subunits, To further understand the regulation of PLC-beta (2) by G proteins and the functional roles of PLC-beta (2) structural domains, we tested whether the separately expressed amino and carboxyl halves of PLC-beta (2) could associate to form catalytically active enzymes as two polypeptides, and we explored how the complexes thus formed would be regulated by G protein py subunits (G beta gamma), We expressed cDNA constructs encoding PLC-beta (2), fragments of different lengths in COS-7 cells and demonstrated by coimmunoprecipitation that the coexpressed fragments could assemble and functionally reconstitute an active PLC-beta (2). The pleckstrin homology domain of PLC-beta (2) was required for its targeting to the membrane and for substrate hydrolysis, Reconstituted enzymes that contained the linker region that joins the two catalytic domains were as active or more active than the wild-type PLC-beta (2), When the linker region was removed, basal PLC-beta (2) enzymatic activity was increased further, suggesting that the linker region exerts an inhibitory effect on basal PLC-P, activity. The reconstituted enzymes, like wild-type PLC-beta (2), were activated by G beta gamma; when the C-terminal region was present in these constructs, they were also activated by G alpha (q). G beta gamma and G alpha (q) activated these PLC-beta (2) constructs equally in the presence or absence of the linker region. We conclude that the linker region is an inhibitory element in PLC-beta (2) and that G beta gamma and G alpha (q) do not stimulate PLC-beta (2) through easing the inhibition of enzymatic activity by the linker region.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Zhang, W (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.							Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Exton JH, 1997, ADV EXP MED BIOL, V400, P3; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HORTSMAN DA, 1996, P NATL ACAD SCI USA, V93, P7518; Irvine R, 1996, NATURE, V380, P581, DOI 10.1038/380581a0; Jenco JM, 1997, BIOCHEM J, V327, P431; JHON DY, 1993, J BIOL CHEM, V268, P6654; JIANG HP, 1994, J BIOL CHEM, V269, P7593; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LEE SB, 1993, J BIOL CHEM, V268, P25952; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; PARK DG, 1993, J BIOL CHEM, V268, P3710; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Schnabel P, 1998, BIOCHEM J, V330, P461, DOI 10.1042/bj3300461; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; WU DQ, 1993, J BIOL CHEM, V268, P3704	34	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2503	2508		10.1074/jbc.M003562200	http://dx.doi.org/10.1074/jbc.M003562200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11044443	hybrid			2022-12-27	WOS:000166784800029
J	Mejillano, M; Yamamoto, M; Rozelle, AL; Sun, HQ; Wang, XD; Yin, HL				Mejillano, M; Yamamoto, M; Rozelle, AL; Sun, HQ; Wang, XD; Yin, HL			Regulation of apoptosis by phosphatidylinositol 4,5-bisphosphate inhibition of caspases, and caspase inactivation of phosphatidylinositol phosphate 5-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID KINASE FAMILY; CYTOCHROME-C; PHOSPHOLIPASE-C; IN-VIVO; GELSOLIN; BINDING; PHOSPHORYLATION; ACTIVATION; SPECIFICITY; PROTEASES	Phosphoinositides such as phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-bisphosphate promote cell survival and protect against apoptosis by activating Akt/PKB, which phosphorylates components of the apoptotic machinery. We now report that another phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2) is a direct inhibitor of initiator caspases 8 and 9, and their common effector caspase 3, PIP, inhibited procaspase 9 processing in cell extracts and in a reconstituted procaspase 9/Apaf1 apoptosome system. It inhibited purified caspase 3 and 8 activity, at physiologically attainable PIP, levels in mixed Lipid vesicles. Caspase 3 binding to PIP, was confirmed by cosedimentation with mixed lipid vesicles. Overexpression of phosphatidylinositol phosphate 5-kinase alpha (PIP5KI alpha), which synthesizes PIP2, suppressed apoptosis, whereas a kinase-deficient mutant did not. Protection by the wild-type PIP5KI alpha was accompanied by decreases in the generation of activated caspases and of caspase 3-cleaved PARP, Protection was not mediated through PIP3 or Akt activation. An anti-apoptotic role for PIP2 is further substantiated by our finding that PIP5KI alpha was cleaved by caspase 3 during apoptosis, and cleavage inactivated PIP5KI alpha in vitro. Mutation of the P-4 position (D279A) of the PIP5KI alpha caspase 3 cleavage consensus prevented cleavage in vitro, and during apoptosis in vivo. Significantly, the caspase 3-resistant PIP5KI alpha mutant was more effective in suppressing apoptosis than the wild-type kinase. These results show that PIP2 is a direct regulator of apical and effector caspases in the death receptor and mitochondrial pathways, and that PIP5KI alpha inactivation contributes to the progres sion of apoptosis, This novel feedforward amplification mechanism for maintaining the balance between life and death of a cell works through phosphoinositide regulation of caspases and caspase regulation of phosphoinositide synthesis.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yin, HL (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA.				NIAMS NIH HHS [AR41940] Funding Source: Medline; NIGMS NIH HHS [GM61203] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061203] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Ma L, 1998, J CELL BIOL, V140, P1125; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Yin HL, 1999, J BIOL CHEM, V274, P32529, DOI 10.1074/jbc.274.46.32529; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	69	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1865	1872		10.1074/jbc.M007271200	http://dx.doi.org/10.1074/jbc.M007271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042212	hybrid			2022-12-27	WOS:000166528000031
J	Orre, RS; Cotter, MA; Subramanian, C; Robertson, ES				Orre, RS; Cotter, MA; Subramanian, C; Robertson, ES			Prothymosin alpha functions as a cellular oncoprotein by inducing transformation of rodent fibroblasts in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F TRANSCRIPTION FACTOR; C-MYC; HL-60 CELLS; LIVER-REGENERATION; NUCLEAR-PROTEIN; LYMPHOCYTES-T; GENE-PRODUCT; HISTONE H1; IN-VITRO; EXPRESSION	Prothymosin alpha (ProT alpha), a cellular molecule known to be associated with cell proliferation, is transcriptionally up-regulated on expression of c-myc and interacts with histones in vitro and associates with histone H1 in cells. Previous studies have also shown that ProT alpha is involved in chromatin remodeling. Recent studies have shown that ProT alpha interacts with the acetyl transferase p300 and an essential Epstein-Barr virus protein, EBNA3C, involved in regulation of viral and cellular transcription. These studies suggest a potential involvement in regulation of histone acetylation through the association with these cellular and viral factors. In the current studies, we show that heterologous expression of ProTa! in the Rat-1 rodent fibroblast cell line results in increased proliferation, loss of contact inhibition, anchorage-independent growth, and decreased serum dependence, These phenotypic changes seen in transfected Rat-1 cells are similar to those observed with a known oncoprotein, Ras, expressed under the control of a heterologous promoter and are characteristic oncogenic growth properties. These results demonstrate that the ProTa gene may function as an oncogene when stably expressed in Rat-1 cells and may be an important downstream cellular target for inducers of cellular transformation, which may include Epstein-Barr virus and c-myc.	Univ Michigan, Dept Microbiol & Immunol, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Cellular & Mol Biol Grad Program, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Robertson, ES (corresponding author), Univ Michigan, Dept Microbiol & Immunol, Sch Med, 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA07215-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aster JC, 1997, J BIOL CHEM, V272, P11336; BARCIA MG, 1992, FEBS LETT, V312, P152, DOI 10.1016/0014-5793(92)80924-6; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; Castro JM, 1996, BIOCHEM BIOPH RES CO, V224, P140, DOI 10.1006/bbrc.1996.0997; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; DOMINGUEZ F, 1993, EUR J CANCER, V29A, P893, DOI 10.1016/S0959-8049(05)80433-2; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Gomez-Marquez J, 1998, BIOCHEM J, V333, P1; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; Kinoshita T, 1997, VIROLOGY, V232, P53, DOI 10.1006/viro.1997.8536; Loidi L, 1997, CLIN CHEM, V43, P59; Lutz W, 1996, ONCOGENE, V13, P803; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MAKAROVA T, 1989, FEBS LETT, V257, P247, DOI 10.1016/0014-5793(89)81544-3; MANROW RE, 1991, J BIOL CHEM, V266, P3916; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; NEVINS JR, 1992, SCIENCE, V258, P424; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; Parker GA, 1996, ONCOGENE, V13, P2541; Rodriguez P, 1999, CELL DEATH DIFFER, V6, P3, DOI 10.1038/sj.cdd.4400450; Rodriguez P, 1998, BIOCHEM J, V331, P753, DOI 10.1042/bj3310753; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SCHMIDT G, 1991, BIOCHIM BIOPHYS ACTA, V1088, P442, DOI 10.1016/0167-4781(91)90141-8; SILVERMAN AL, 1994, ALCOHOL CLIN EXP RES, V18, P616, DOI 10.1111/j.1530-0277.1994.tb00919.x; SMITH MR, 1993, BLOOD, V82, P1127; SZABO P, 1992, BIOCHEM BIOPH RES CO, V185, P953, DOI 10.1016/0006-291X(92)91719-7; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; TSITSILONI OE, 1993, P NATL ACAD SCI USA, V90, P9504, DOI 10.1073/pnas.90.20.9504; VARELI K, 1995, FEBS LETT, V371, P337, DOI 10.1016/0014-5793(95)00938-6; Vareli K, 1996, EUR J BIOCHEM, V238, P799, DOI 10.1111/j.1432-1033.1996.0799w.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6; Wu CG, 1997, BIOCHEM BIOPH RES CO, V232, P817, DOI 10.1006/bbrc.1997.6377; Wu CL, 1997, LIFE SCI, V61, P2091, DOI 10.1016/S0024-3205(97)00882-5	52	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1794	1799		10.1074/jbc.M008560200	http://dx.doi.org/10.1074/jbc.M008560200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11036085	hybrid			2022-12-27	WOS:000166528000021
J	Gaubert, F; Escaffit, F; Bertrand, C; Korc, M; Pradayrol, L; Clemente, F; Estival, A				Gaubert, F; Escaffit, F; Bertrand, C; Korc, M; Pradayrol, L; Clemente, F; Estival, A			Expression of the high molecular weight fibroblast growth factor-2 isoform of 210 amino acids is associated with modulation of protein kinases C delta and epsilon and ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; ENDOTHELIAL-CELLS; DIFFERENTIAL REGULATION; SELECTIVE INHIBITOR; MESSENGER-RNA; SIGNAL; BFGF; TRANSLATION; ISOZYMES; FORMS	The high molecular weight (HMW) fibroblast growth factor (FGF)-2 isoform of 210 amino acids initiated at a CUG start codon possesses a nuclear localization sequence and is not secreted, In contrast, the low molecular weight (LMW) isoform of 155 amino acids initiated at the AUG start codon can be secreted and activates the cell surface FGF receptors, The two isoforms possess different biological properties; however, little is known about the intracrine regulatory mechanisms involved in the biological effects of the HMW FGF-2 isoform, Using pancreatic cells stably transfected with cDNAs leading to the expression of either the HMW FGF-2 (A3 cells) or the LMW form (A5 cells), we provide evidence that the two FGF-2 isoforms differentially modulate PKC levels. The LMW FGF-2 up-regulated the PKC epsilon levels by 1.6-fold; by contrast the HMW isoform down-regulated the level of this PKC isotype by about 3-fold and increased the amount of PKC delta by 1.7-fold. PKC mRNAs were also modified, suggesting that PKC expression was regulated at a pretranslational level. Additionally, expression of different levels of the HMW FGF-2 with an inducible expression system confirmed the role of this isoform on PKC delta and epsilon expressions. Increased activation of ERK-1 and -2 was also observed in cells expressing the HMW FGF-2, By using different PKC inhibitors and a dominant negative PKC delta, it was found that ERK activation was PKC delta -dependent. These data indicate that expression of HMW FGF-2 can modify PKC levels by acting at the intracellular level and that the overexpression of PKC delta induces ERK-1/2 activation. The expression of a dominant negative FGFR1 did not reduce ERK-1/2 activation by the HMW FGF-2, suggesting that ERK activation does not require FGFR activity. The signaling cascade downstream of ERK might be involved in the known mitogenic effect exerted by this FGF-2 isoform.	CHU Rangueil, INSERM U531, ILB, F-31054 Toulouse, France; Univ Calif Irvine, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California Irvine	Clemente, F (corresponding author), CHU Rangueil, INSERM U531, ILB, Bat L3, F-31054 Toulouse, France.		ESCAFFIT, Fabrice/AAE-4832-2021					Arnaud E, 1999, MOL CELL BIOL, V19, P505; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BORNER C, 1992, J BIOL CHEM, V267, P12892; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Delrieu I, 1999, BIOCHEM J, V340, P201, DOI 10.1042/0264-6021:3400201; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; Escaffit F, 2000, INT J CANCER, V85, P555, DOI 10.1002/(SICI)1097-0215(20000215)85:4<555::AID-IJC18>3.0.CO;2-H; Estival A, 1996, J BIOL CHEM, V271, P5663, DOI 10.1074/jbc.271.10.5663; ESTIVAL A, 1993, CANCER RES, V53, P1182; Estival A, 1996, BIOCHEM J, V315, P619, DOI 10.1042/bj3150619; ESTIVAL A, 1992, GASTROENTEROLOGY, V103, P1851, DOI 10.1016/0016-5085(92)91444-9; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; Gualandris A, 1999, J CELL PHYSIOL, V181, P273, DOI 10.1002/(SICI)1097-4652(199911)181:2<273::AID-JCP9>3.0.CO;2-#; Hrzenjak M, 1997, RECEPT SIGNAL TRANS, V7, P207; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Klein S, 1996, J BIOL CHEM, V271, P22583, DOI 10.1074/jbc.271.37.22583; Lengye E, 1995, ONCOGENE, V11, P2639; Lim YP, 1999, J BIOL CHEM, V274, P19025, DOI 10.1074/jbc.274.27.19025; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Monzat V, 1996, EUR J CELL BIOL, V69, P316; Peters CA, 1999, J BIOL CHEM, V274, P37499, DOI 10.1074/jbc.274.52.37499; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SHERMAN L, 1993, DEVELOPMENT, V118, P1313; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Stachowiak MK, 1997, MOL NEUROBIOL, V15, P257, DOI 10.1007/BF02740663; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Wagner M, 1998, GASTROENTEROLOGY, V114, P798, DOI 10.1016/S0016-5085(98)70594-3; YAMANAKA Y, 1993, CANCER RES, V53, P5289; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	51	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1545	1554		10.1074/jbc.M001184200	http://dx.doi.org/10.1074/jbc.M001184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11031252	hybrid			2022-12-27	WOS:000166430900092
J	Croniger, CM; Millward, C; Yang, JQ; Kawai, Y; Arinze, IJ; Liu, S; Harada-Shiba, M; Chakravarty, K; Friedman, JE; Poli, V; Hanson, RW				Croniger, CM; Millward, C; Yang, JQ; Kawai, Y; Arinze, IJ; Liu, S; Harada-Shiba, M; Chakravarty, K; Friedman, JE; Poli, V; Hanson, RW			Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta have an attenuated response to cAMP and impaired carbohydrate metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; KINASE SUBUNITS; RAT; EXPRESSION; TRANSCRIPTION; LIVER; IDENTIFICATION; HYPOGLYCEMIA; SENSITIVITY	Fifty percent of the mice homozygous for a deletion in the gene for CCAAT/enhancer-binding protein beta (C/ EBP beta-/- mice; B phenotype) die within 1 to 2 h after birth of hypoglycemia. They do not mobilize their hepatic glycogen or induce the cytosolic form of phosphoenolpyruvate carboxykinase (PEPCK). Administration of cAMP resulted in mobilization of glycogen, induction of PEPCK mRNA, and a normal blood glucose; these mice survived beyond 2 h postpartum. Adult C/EBP beta-/- mice (A phenotype) also had difficulty in maintaining blood glucose levels during starvation. Fasting these mice for 16 or 30 h resulted in lower levels of hepatic PEPCK mRNA, blood glucose, beta -hydroxybutyrate, blood urea nitrogen, and gluconeogenesis when compared with control mice. The concentration of hepatic cAMP in these mice was 50% of controls, but injection of theophylline, together with glucagon, resulted in a normal cAMP levels. Agonists (glucagon, epinephrine, and isoproterenol) and other effecters of activation of adenylyl cyclase were the same in liver membranes isolated from C/EBP beta-/- mice and littermates, The hepatic activity of cAMP-dependent protein kinase was 80% of wild type mice. There was a 79% increase in the concentration of RI alpha and 27% increase in RII alpha in the particulate fraction of the livers of C/EBP beta-/- mice relative to wild type mice, with no change in the catalytic subunit (C alpha). Thus, a 45% increase in hepatic cAMP (relative to the wild type) would be required in C/EBP beta-/- mice to activate protein kinase A by 50%. In addition, the total activity of phosphodiesterase in the livers of C/EBP beta-/- mice, as well as the concentration of mRNA for phosphodiesterase 3A (PDE3A) and PDE3B was approximately 25% higher than in control animals, suggesting accelerated degradation of cAMP. C/EBP beta influences the regulation of carbohydrate metabolism by altering the level of hepatic cAMP and the activity of protein kinase A.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA; Univ Dundee, Dept Mol Biol, Dundee DD1 4HN, Scotland	Case Western Reserve University; Case Western Reserve University; Meharry Medical College; University of Dundee	Croniger, CM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	cmc6@po.cwru.edu	Poli, Valeria/A-9215-2012	Poli, Valeria/0000-0002-3739-3966	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050272, R01DK025541] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25541, DK-50272, DK-07319] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1999, J IMMUNOL, V162, P4864; Arizmendi C, 1999, J BIOL CHEM, V274, P13033, DOI 10.1074/jbc.274.19.13033; BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; CADD GG, 1990, J BIOL CHEM, V265, P19502; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; EKANGER R, 1989, J BIOL CHEM, V264, P4374; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HETENYI G, 1974, FED PROC, V33, P1841; HOUGE G, 1990, MOL ENDOCRINOL, V4, P481, DOI 10.1210/mend-4-3-481; KAWAI Y, 1993, MOL CELL ENDOCRINOL, V90, P203, DOI 10.1016/0303-7207(93)90153-B; KAWAI Y, 1981, JBC, V26, P853; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; Kimura T, 1998, J BIOL CHEM, V273, P27505, DOI 10.1074/jbc.273.42.27505; Kun E, 1974, METHOD ENZYMAT AN, P1801; LIU JS, 1991, J BIOL CHEM, V266, P19095; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; LO S, 1970, J APPL PHYSIOL, V28, P234, DOI 10.1152/jappl.1970.28.2.234; LOOSE DS, 1986, P NATL ACAD SCI USA, V83, P5184, DOI 10.1073/pnas.83.14.5184; Lopez HW, 1998, J NUTR, V128, P1487, DOI 10.1093/jn/128.9.1487; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; O'Brien LJ, 1998, J NUTR, V128, P927, DOI 10.1093/jn/128.6.927; Owen O.E., 1976, GLUCONEOGENESIS ITS, P533; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1993, J BIOL CHEM, V268, P613; PARRILLA R, 1978, PFLUG ARCH EUR J PHY, V374, P9, DOI 10.1007/BF00585691; PARRILLA R, 1978, PFLUG ARCH EUR J PHY, V374, P3, DOI 10.1007/BF00585690; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shahid M, 1995, Methods Mol Biol, V41, P129; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; Wang LQ, 2000, J BIOL CHEM, V275, P14173, DOI 10.1074/jbc.M000764200; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; YOOWARREN H, 1981, J BIOL CHEM, V256, P224	46	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					629	638		10.1074/jbc.M007576200	http://dx.doi.org/10.1074/jbc.M007576200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024029	hybrid			2022-12-27	WOS:000166280700085
J	Hawley, SB; Tamura, T; Miles, LA				Hawley, SB; Tamura, T; Miles, LA			Purification, cloning, and characterization of a profibrinolytic plasminogen-binding protein, TIP49a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUVB-LIKE PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; STRUCTURAL PROTEINS; DNA HELICASE; TUMOR-CELLS; EXPRESSION; ACTIVATION; RECEPTOR; SURFACE; UROKINASE	The plasminogen receptors responsible for enhancing cell surface-dependent plasminogen activation expose COOH-terminal lysines on the cell surface and are sensitive to proteolysis by carboxypeptidase B (CpB). We treated U937 cells with CpB, then subjected membrane fractions to two-dimensional gel electrophoresis followed by ligand blotting with I-125-plasminogen. A 54-kDa protein lost the ability to bind I-125-plasminogen after treatment of intact cells and was purified by two-dimensional gel electrophoresis and then sequenced by mass spectrometry. Two separate amino acid sequences were obtained and were identical to sequences contained within human and rat TIP49a. The cDNA for the 54-kDa protein matched the human TIP49a sequence, and encoded a COOH-terminal lysine, consistent with susceptibility to CpB. Antibodies against rat TIP49a recognized the plasminogen-binding protein on two-dimensional Western blots of U937 cell membranes. Human I-125-Glu-plasminogen bound specifically to TIP49a protein, and binding was inhibited by epsilon -aminocaproic acid. A single class of binding sites was detected, and a K-d of 0.57 +/- 0.14 muM was determined. TIP49a enhanced plasminogen activation 8-fold compared with the BSA control, and this was equivalent to the enhancement mediated by plasmin-treated fibrinogen. These results suggest that TIP49a is a previously unrecognized plasminogen-binding protein on the U937 cell surface.	Scripps Res Inst, Dept Vasc Biol CVN 26, La Jolla, CA 92037 USA; Chiba Univ, Chiba 2638522, Japan	Scripps Research Institute; Chiba University	Miles, LA (corresponding author), Scripps Res Inst, Dept Vasc Biol CVN 26, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038272, R29HL038272, R01HL045934, P01HL031950] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31950, HL45934, HL38272] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1995, NATURE, V377, P3; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; CAMACHO M, 1989, FEBS LETT, V245, P21, DOI 10.1016/0014-5793(89)80183-8; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Dudani AK, 1996, BRIT J HAEMATOL, V95, P168, DOI 10.1046/j.1365-2141.1996.7482367.x; ELLIS V, 1991, J BIOL CHEM, V266, P12752; FELEZ J, 1993, THROMB HAEMOSTASIS, V69, P1232; Felez J, 1996, THROMB HAEMOSTASIS, V76, P577; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Gase K, 1996, EUR J BIOCHEM, V239, P42, DOI 10.1111/j.1432-1033.1996.0042u.x; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; HEYDORN WE, 1985, J NEUROCHEM, V44, P201, DOI 10.1111/j.1471-4159.1985.tb07131.x; Holzmann K, 1998, BIOCHEM BIOPH RES CO, V252, P39, DOI 10.1006/bbrc.1998.9604; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; Kanemaki M, 1997, BIOCHEM BIOPH RES CO, V235, P64, DOI 10.1006/bbrc.1997.6729; KATO K, 1983, CLIN CHIM ACTA, V127, P353, DOI 10.1016/0009-8981(83)90162-6; Kim SO, 1996, J BIOL CHEM, V271, P23761, DOI 10.1074/jbc.271.39.23761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUBE RE, 1986, DIFFERENTIATION, V33, P69, DOI 10.1111/j.1432-0436.1986.tb00412.x; LIEPKALNS VA, 1990, J RECEPTOR RES, V10, P333, DOI 10.3109/10799899009064674; Makino Y, 1998, BIOCHEM BIOPH RES CO, V245, P819, DOI 10.1006/bbrc.1998.8504; Makino Y, 1999, J BIOL CHEM, V274, P15329, DOI 10.1074/jbc.274.22.15329; MILES LA, 1985, J BIOL CHEM, V260, P4303; MILES LA, 1989, BIOCHEMISTRY-US, V28, P9337, DOI 10.1021/bi00450a014; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MILES LA, 1988, J BIOL CHEM, V263, P11928; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NAMIRANIAN S, 1995, BIOCHEM J, V309, P977, DOI 10.1042/bj3090977; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; PLOW EF, 1990, CELL DIFFER DEV, V32, P293, DOI 10.1016/0922-3371(90)90042-U; Qiu XB, 1998, J BIOL CHEM, V273, P27786, DOI 10.1074/jbc.273.43.27786; REDLITZ A, 1995, EUR J BIOCHEM, V227, P407, DOI 10.1111/j.1432-1033.1995.tb20403.x; Salzer U, 1999, BBA-GENE STRUCT EXPR, V1446, P365, DOI 10.1016/S0167-4781(99)00104-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WALLEN P, 1970, BIOCHIM BIOPHYS ACTA, V221, P20, DOI 10.1016/0005-2795(70)90194-7; Winram SB, 1996, MICROBIOL-SGM, V142, P2311, DOI 10.1099/13500872-142-8-2311; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669	44	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					179	186		10.1074/jbc.M004919200	http://dx.doi.org/10.1074/jbc.M004919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027681	hybrid			2022-12-27	WOS:000166280700026
J	Nagata, D; Suzuki, E; Nishimatsu, H; Satonaka, H; Goto, A; Omata, M; Hirata, Y				Nagata, D; Suzuki, E; Nishimatsu, H; Satonaka, H; Goto, A; Omata, M; Hirata, Y			Transcriptional activation of the cyclin D1 gene is mediated by multiple cis-elements, including SP1 sites and a cAMP-responsive element in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; SIGNAL-REGULATED KINASE; RIBOSOMAL S6 KINASE; GROWTH-FACTOR GENE; DOWN-REGULATION; DNA-BINDING; PROMOTER; PROTEIN; EXPRESSION; INDUCTION	In an attempt to examine the mechanisms by which transcriptional activity of the cyclin D1 promoter is regulated in vascular endothelial cells (EC), we examined the cis-elements in the human cyclin D1 promoter, which are required for transcriptional activation of the gene. The results of luciferase assays showed that transcriptional activity of the cyclin D1 promoter was largely mediated by SP1 sites and a cARIP-responsive element (CRE), DNA binding activity at the SP1 sites, which was analyzed by electrophoretic mobility shift assays, was significantly increased in the early to mid G(1) phase, whereas DNA binding activity at CRE did not change significantly. Furthermore, Induction of the cyclin D1 promoter activity in the early to mid G(1) phase depended largely on the promoter fragment containing the SP1 sites, whereas the proximal fragment containing CRE but not the SP1 sites was constitutively active. Finally, the increase in DNA binding and promoter activities via the SP1 sites was mediated by the Ras-dependent pathway. The results suggested that the activation of the cyclin D1 gene in vascular ECs was regulated by a dual system; one was inducible in the G(1) phase, and the other was constitutively active.	Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, Tokyo 1338655, Japan; Univ Tokyo, Fac Med, Dept Urol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo	Suzuki, E (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1338655, Japan.	suzuki-2im@h.u-tokyo.ac.jp						Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hinz M, 1999, MOL CELL BIOL, V19, P2690; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kanno T, 1996, J IMMUNOL, V157, P5277; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUZUKI E, 1995, MOL CELL BIOL, V15, P3415; Suzuki E, 1999, CIRC RES, V84, P611, DOI 10.1161/01.RES.84.5.611; Suzuki E, 2000, J BIOL CHEM, V275, P3637, DOI 10.1074/jbc.275.5.3637; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; Wang ZY, 1999, BLOOD, V93, P4208, DOI 10.1182/blood.V93.12.4208.412k17_4208_4221; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan GZ, 1997, J NEUROSCI, V17, P6122; Ye JP, 1996, MOL CELL BIOL, V16, P6178	45	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					662	669		10.1074/jbc.M005522200	http://dx.doi.org/10.1074/jbc.M005522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024050	hybrid			2022-12-27	WOS:000166280700089
J	Rusche, KM; Marletta, MA				Rusche, KM; Marletta, MA			Reconstitution of pterin-free inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; MACROPHAGE NO SYNTHASE; TETRAHYDROBIOPTERIN-BINDING; ESCHERICHIA-COLI; DIMERIC ENZYME; HEME; BRAIN; PURIFICATION; SUBSTRATE; CATALYSIS	Inducible nitric-oxide synthase (NOS) was expressed and purified in the absence of 6(R)-tetrahydro-L-biopterin (H4B). Pterin-free NOS exhibits a Soret band (416-420 nm) characteristic of predominantly low spin heme and does not catalyze the formation of nitric oxide (. NO) (Rusche, K. M., Spiering, M. M., and Marletta, M. A. (1998) Biochemistry 37, 15503-15512). Reconstitution of pterin-free NOS with H4B was monitored by a shift in the Soret band to 396-400 nm, the recovery of . NO-forming activity, and the measurement of H4B bound to the enzyme. As assessed by these properties, H4B binding was not rapid and required the presence of a reduced thiol. Spectral changes and recovery of activity were incomplete in the absence of reduced thiol. Full reconstitution of holoenzyme activity and stoichiometric H4B binding was achieved in the presence of 5 mM glutathione (GSH). Preincubation with GSH before the addition of H4B decreased, whereas lower concentrations of GSH extended, the time required for reconstitution. Six protected cysteine residues in pterin-free NOS were identified by labeling of NOS with cysteine-directed reagents before and after reduction with GSH. Heme and metal content of pterin-free and H4B-reconstituted NOS were also measured and were found to be independent of H4B content. Additionally, pterin-free NOS was reconstituted with 6-methylpterin analogs, including redox-stable deazapterins. Reconstitution with the redox-stable pterin analogs was neither time- nor thiol-dependent, Apparent binding constants were determined for the 6-methyl- (50 muM) and 6-ethoxymethyl (200 muM) deazapterins. The redox-stable pterin analogs appear to bind to NOS in a different manner than H4B.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Div Med Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Marletta, MA (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.				PHS HHS [50414] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRENNEMAN AR, 1965, J BIOL CHEM, V240, P3617; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Clague MJ, 1997, BIOCHEMISTRY-US, V36, P14465, DOI 10.1021/bi971024u; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; Gorren ACF, 1997, BIOCHEMISTRY-US, V36, P4360, DOI 10.1021/bi962381s; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; HOWELLS DW, 1986, J CHROMATOGR, V381, P285, DOI 10.1016/S0378-4347(00)83594-X; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MOAD G, 1979, J AM CHEM SOC, V101, P6068, DOI 10.1021/ja00514a033; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; PFLEIDERER W, 1985, FOLATES PTERINS, V2, P43; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; PUFAHL RA, 1992, BIOCHEMISTRY-US, V31, P6822, DOI 10.1021/bi00144a024; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rodriguez-Crespo I, 1999, J BIOL CHEM, V274, P21617, DOI 10.1074/jbc.274.31.21617; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; RUSCHE KM, 1995, FASEB J, V1381, pA1495; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SCHMIDT HHW, 1991, BIOCHEM BIOPH RES CO, V181, P1372, DOI 10.1016/0006-291X(91)92090-7; Sono M, 1999, BIOCHEMISTRY-US, V38, P15853, DOI 10.1021/bi991580j; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WHITE KA, 1994, THESIS U MICHIGAN AN	52	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					421	427		10.1074/jbc.M006860200	http://dx.doi.org/10.1074/jbc.M006860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022039	hybrid			2022-12-27	WOS:000166280700057
J	Wu, F; Lee, AS				Wu, F; Lee, AS			YY1 as a regulator of replication-dependent hamster histone H3.2 promoter and an interactive partner of AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YY1; GROWTH-REGULATION; GENE-EXPRESSION; BINDING; ELEMENT; PROTEIN; IDENTIFICATION; SEQUENCES; DOMAIN; ACTIN	In analyzing cia-regulatory elements important for cell cycle control of the replication-dependent hamster histone H3.2 gene, we discovered a binding site for the transcription factor YY1 embedded within GC-rich sequences between the two tandem CCAAT repeats proximal to the TATA element. Base mutations that specifically eliminated YY1 binding resulted in suppression of the S phase induction of the H3.2 promoter. In addition, we discovered that YY1 is an interactive partner of AP-2, which also binds the H3.2 promoter and regulates its cell cycle-dependent expression. The critical domains for YY1 and AP-2A interaction are mapped, revealing that the N-terminal portion of YY1 (amino acids 1500) and the DNA-binding/dimerization region of AP-2A are required. Our results suggest that YY1, acting as a transcription factor binding to its site on the promoter, or through protein-protein interaction with AP-2, may be part of a regulatory network including key cell cycle regulators such as c-Myc and Rb in controlling growth- and differentiation-regulated gene expression.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.			Lee, Amy/0000-0002-0378-5443	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031138] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31138] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARTISHEVSKY A, 1987, NATURE, V328, P823, DOI 10.1038/328823a0; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Eliassen KA, 1998, MOL CELL BIOL, V18, P7106, DOI 10.1128/MCB.18.12.7106; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FLANAGAN JR, 1995, CELL GROWTH DIFFER, V6, P185; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Kaludov NK, 1996, P NATL ACAD SCI USA, V93, P4465, DOI 10.1073/pnas.93.9.4465; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Last TJ, 1999, J CELL BIOCHEM, V72, P507, DOI 10.1002/(SICI)1097-4644(19990315)72:4<507::AID-JCB6>3.0.CO;2-5; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1994, ONCOGENE, V9, P1047; Lee TC, 1998, NUCLEIC ACIDS RES, V26, P3215, DOI 10.1093/nar/26.13.3215; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; NAEVE GS, 1995, NUCLEIC ACIDS RES, V23, P475, DOI 10.1093/nar/23.3.475; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Wu F, 1998, NUCLEIC ACIDS RES, V26, P4837, DOI 10.1093/nar/26.21.4837; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	30	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					28	34		10.1074/jbc.M006074200	http://dx.doi.org/10.1074/jbc.M006074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11018030	hybrid			2022-12-27	WOS:000166280700005
J	Zucker, WR; Kerentseva, TA; Lawson, CL; Barbour, AG				Zucker, WR; Kerentseva, TA; Lawson, CL; Barbour, AG			Structural conservation of neurotropism-associated VspA within the variable Borrelia Vsp-OspC lipoprotein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYME-DISEASE SPIROCHETE; MEMBRANE PROTEIN P66; SURFACE PROTEIN; RELAPSING FEVER; ANTIGENIC VARIATION; TRYPANOSOMA-BRUCEI; MOUSE MODEL; BURGDORFERI; HERMSII; TURICATAE	Vsp surface lipoproteins are serotype-defining antigens of relapsing fever spirochetes that undergo multiphasic antigenic variation to avoid the immune response. One of these proteins, VspA of Borrelia turicatae, is also associated with neurotropism in infected mice. Vsp proteins are highly polymorphic in sequence, which may relate to their specific antibody reactivities and host cell interactions. To determine whether sequence variations affect protein structure, we compared B. turicatae VspA with three related proteins: VspB of B. turicatae, Vsp26 of the relapsing fever agent Borrelia hermsii, and OspC of the Lyme disease spirochete Borrelia burgdorferi. Recombinant mon-lipidated proteins were purified by affinity or ion exchange chromatography. Circular dichroism spectra revealed similar, highly alpha -helical secondary structures for all four proteins. In vitro assays demonstrated protease-resistant, thermostable Vsp cores starting at, a conserved serine at position 34 (Ser(34)). All proteins aggregate as dimers in solution. In situ trypsin treatment and surface protein cross-linking showed that the native lipoproteins also form protease-resistant dimers. These findings indicate that Vsp proteins have a common compact fold and that their established functions are based on localized polymorphisms. Two forms of VspA crystals suitable for structure determination by x-ray diffraction methods have been obtained.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Med, Irvine, CA 92697 USA; Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Rutgers State University New Brunswick	Zucker, WR (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.		Barbour, Alan/B-3160-2009	Barbour, Alan/0000-0002-0719-5248; Lawson, Catherine/0000-0002-3261-7035	NIAID NIH HHS [AI24424] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024424, R01AI024424] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARBOUR AG, 1982, J EXP MED, V156, P1312, DOI 10.1084/jem.156.5.1312; Barbour AG, 2000, EMERG INFECT DIS, V6, P449, DOI 10.3201/eid0605.000502; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BARBOUR AG, 1984, INFECT IMMUN, V45, P94, DOI 10.1128/IAI.45.1.94-100.1984; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARBOUR AG, 1990, ANNU REV MICROBIOL, V44, P155, DOI 10.1146/annurev.mi.44.100190.001103; Beermann C, 2000, BIOCHEM BIOPH RES CO, V267, P897, DOI 10.1006/bbrc.1999.2057; BRANDT ME, 1990, INFECT IMMUN, V58, P983, DOI 10.1128/IAI.58.4.983-991.1990; Bunikis J, 1999, INFECT IMMUN, V67, P2874, DOI 10.1128/IAI.67.6.2874-2883.1999; Bunikis J, 1998, J BACTERIOL, V180, P1618, DOI 10.1128/JB.180.7.1618-1623.1998; CADAVID D, 1994, J EXP MED, V179, P631, DOI 10.1084/jem.179.2.631; Cadavid D, 1997, INFECT IMMUN, V65, P3352, DOI 10.1128/IAI.65.8.3352-3360.1997; CADAVID D, 1993, J INFECT DIS, V168, P143, DOI 10.1093/infdis/168.1.143; Carrington M, 1998, MOL BIOCHEM PARASIT, V91, P153, DOI 10.1016/S0166-6851(97)00190-4; Casjens S, 2000, MOL MICROBIOL, V35, P490, DOI 10.1046/j.1365-2958.2000.01698.x; Coleman JL, 1999, INFECT IMMUN, V67, P3929, DOI 10.1128/IAI.67.8.3929-3936.1999; Coleman JL, 1997, CELL, V89, P1111, DOI 10.1016/S0092-8674(00)80298-6; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; DELBECQ F, 1993, LANGMUIR, V9, P197, DOI 10.1021/la00025a039; DIMENT S, 1990, J IMMUNOL, V145, P417; Ding W, 2000, J MOL BIOL, V302, P1153, DOI 10.1006/jmbi.2000.4119; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; Dunn J J, 1990, Protein Expr Purif, V1, P159, DOI 10.1016/1046-5928(90)90011-M; ERDILE LF, 1993, INFECT IMMUN, V61, P81, DOI 10.1128/IAI.61.1.81-90.1993; Fairlie DP, 2000, J MED CHEM, V43, P1271, DOI 10.1021/jm990315t; Fehr T, 1997, J EXP MED, V185, P1785, DOI 10.1084/jem.185.10.1785; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; FUNG BP, 1994, INFECT IMMUN, V62, P3213, DOI 10.1128/IAI.62.8.3213-3221.1994; Gebbia JA, 1999, J CLIN INVEST, V103, P81, DOI 10.1172/JCI5171; Guo BP, 1998, MOL MICROBIOL, V30, P711, DOI 10.1046/j.1365-2958.1998.01103.x; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; Hinnebusch BJ, 1998, INFECT IMMUN, V66, P432, DOI 10.1128/IAI.66.2.432-440.1998; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOWE TR, 1985, SCIENCE, V227, P645, DOI 10.1126/science.3969554; Huang XL, 1999, J BIOMOL NMR, V14, P283, DOI 10.1023/A:1008398527355; JAURISHEIPKE S, 1993, MED MICROBIOL IMMUN, V182, P37; KERLIN RL, 1992, MED VET ENTOMOL, V6, P121, DOI 10.1111/j.1365-2915.1992.tb00587.x; Li H, 1995, J STRUCT BIOL, V115, P335, DOI 10.1006/jsbi.1995.1058; Li H, 1997, P NATL ACAD SCI USA, V94, P3584, DOI 10.1073/pnas.94.8.3584; LIVEY I, 1995, MOL MICROBIOL, V18, P257, DOI 10.1111/j.1365-2958.1995.mmi_18020257.x; Magoun L, 2000, MOL MICROBIOL, V36, P886, DOI 10.1046/j.1365-2958.2000.01906.x; McKisic MD, 2000, INFECT IMMUN, V68, P5190, DOI 10.1128/IAI.68.9.5190-5197.2000; Mendiola J, 1996, EXP PARASITOL, V82, P27, DOI 10.1006/expr.1996.0004; NEWMAN K, 1984, INFECT IMMUN, V45, P572, DOI 10.1128/IAI.45.3.572-576.1984; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pennington PM, 1999, MOL MICROBIOL, V34, P1120, DOI 10.1046/j.1365-2958.1999.01675.x; Pennington PM, 1997, INFECT IMMUN, V65, P285, DOI 10.1128/IAI.65.1.285-292.1997; Pennington PM, 1999, INFECT IMMUN, V67, P4637, DOI 10.1128/IAI.67.9.4637-4645.1999; Probert WS, 1998, MOL MICROBIOL, V30, P1003, DOI 10.1046/j.1365-2958.1998.01127.x; Ras NM, 2000, RES MICROBIOL, V151, P5, DOI 10.1016/S0923-2508(00)00133-9; RESTREPO BI, 1992, MOL MICROBIOL, V6, P3299, DOI 10.1111/j.1365-2958.1992.tb02198.x; RESTREPO BI, 1994, CELL, V78, P867, DOI 10.1016/S0092-8674(94)90642-4; Riese RJ, 2000, CURR OPIN IMMUNOL, V12, P107, DOI 10.1016/S0952-7915(99)00058-8; SADZIENE A, 1993, INFECT IMMUN, V61, P2192, DOI 10.1128/IAI.61.5.2192-2195.1993; Sambrook J., 2002, MOL CLONING LAB MANU; SELA M, 1972, P NATL ACAD SCI USA, V69, P2696, DOI 10.1073/pnas.69.9.2696; Shamaei-Tousi A, 1999, J INFECT DIS, V180, P1929, DOI 10.1086/315118; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STULTZ CM, 1997, PROTEIN STRUCTURAL B, V22; THOMAS DD, 1994, J INFECT DIS, V169, P445, DOI 10.1093/infdis/169.2.445; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VATSN, 2000, ARCH ORAL BIOL, V45, P305; Vidal V, 1998, NAT MED, V4, P1416, DOI 10.1038/4007; Wang IN, 1999, GENETICS, V151, P15; Zinkernagel RM, 1997, BIOL CHEM, V378, P725; Zuckert WR, 1999, INFECT IMMUN, V67, P3257; 1999, EUR J BIOCH, V264, P610	71	39	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					457	463		10.1074/jbc.M008449200	http://dx.doi.org/10.1074/jbc.M008449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11018048	hybrid			2022-12-27	WOS:000166280700062
J	Kuboki, Y; Ito, M; Takamatsu, N; Yamamoto, K; Shiba, T; Yoshioka, K				Kuboki, Y; Ito, M; Takamatsu, N; Yamamoto, K; Shiba, T; Yoshioka, K			A scaffold protein in the c-Jun NH2-terminal kinase signaling pathways suppresses the extracellular signal-regulated kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; MITOGEN; ACTIVATION; TRANSDUCTION; INFLAMMATION; CASCADES; STRESS; YEAST; JNK	We previously reported that c-Jun NH2-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 (JSAP1) functions as a putative scaffold factor in the JNK mitogen-activated protein kinase (MAPK) cascades. In that study we also found MEK1 and Raf-1, which are involved in the extracellular signal-regulated kinase (ERK) MAPK cascades, bind to JSAP1. Here we have defined the regions of JSAP1 responsible for the interactions with MEK1 and Raf-1. Both of the binding regions were mapped to the COOH-terminal region (residues 1054-1305) of JSAP1. We next examined the effect of overexpressing JSAP1 on the activation of ERK by phorbol 12-myristate 13-acetate in transfected COS-7 cells and found that JSAP1 inhibits ERK's activation and that the COOH-terminal region of JSAP1 was required for the inhibition. Finally, we investigated the molecular mechanism of JSAP1's inhibitory function and showed that JSAP1 prevents MEK1 phosphorylation and activation by Raf-1, resulting in the suppression of the activation of ERK. Taken together, these results suggest that JSAP1 is involved both in the JNK cascades, as a scaffolding factor, and the ERK cascades, as a suppressor.	Kanazawa Univ, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan; Kitasato Univ, Sch Sci, Dept Biosci, Kanagawa 2288555, Japan	Kanazawa University; Kitasato University	Yoshioka, K (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Pathol, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.							CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; HANCOCK JF, 1988, ONCOGENE, V3, P187; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Onishi I, 1997, FEBS LETT, V420, P201, DOI 10.1016/S0014-5793(97)01517-2; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000	19	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39815	39818		10.1074/jbc.C000403200	http://dx.doi.org/10.1074/jbc.C000403200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11044439	hybrid			2022-12-27	WOS:000166039500004
J	Bortner, CD; Gomez-Angelats, M; Cidlowski, JA				Bortner, CD; Gomez-Angelats, M; Cidlowski, JA			Plasma membrane depolarization without repolarization is an early molecular event in anti-Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTWARD POTASSIUM CURRENT; PROGRAMMED CELL-DEATH; HUMAN LYMPHOCYTE-T; GATED K+ CHANNELS; PERMEABILITY TRANSITION; NEURONAL APOPTOSIS; FLOW-CYTOMETRY; AMINO-ACIDS; ION-CHANNEL; X-RAY	The movement of intracellular monovalent cations has previously been shown to play a critical role in events leading to the characteristics associated with apoptosis. A loss of intracellular potassium and sodium occurs during apoptotic cell shrinkage establishing an intracellular environment favorable for nuclease activity and caspase activation. We have now investigated the potential movement of monovalent ions in Jurkat cells that occur prior to cell shrinkage following the induction of apoptosis. A rapid increase in intracellular sodium occurs early after apoptotic stimuli suggesting that the normal negative plasma membrane potential may change during cell death, We report here that diverse apoptotic stimuli caused a rapid cellular depolarization of Jurkat T-cells that occurs prior to and after cell shrinkage. In addition to the early increase in intracellular Na+, Rb-86(+) studies reveal a rapid inhibition of K+ uptake in response to anti-Fas. These effects on Na+ and K+ ions were accounted far by the inactivation of the Na+/K+-ATPase protein and its activity. Furthermore, ouabain, a cardiac glycoside inhibitor of the Na+/K+-ATPase, potentiated anti-Fas-induced apoptosis. Finally, activation of an anti-apoptotic signal, i.e. protein kinase C, prevented both cellular depolarization in response to anti-Pas and all downstream characteristics associated with apoptosis. Thus cellular depolarization is an important early event in anti-Pas-induced apoptosis, and the inability of cells to repolarize via inhibition of the Na+/K+-ATPase is a likely regulatory component of the death process.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516				ADEBODUN F, 1993, J CELL PHYSIOL, V154, P199, DOI 10.1002/jcp.1041540123; Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Bilney AJ, 1998, FEBS LETT, V424, P221, DOI 10.1016/S0014-5793(98)00172-0; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; Dallaporta B, 1998, J IMMUNOL, V160, P5605; DECKERS CLP, 1993, EXP CELL RES, V208, P362, DOI 10.1006/excr.1993.1257; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DUPRAT F, 1995, P NATL ACAD SCI USA, V92, P11796, DOI 10.1073/pnas.92.25.11796; Ferlini C, 1999, EXP CELL RES, V247, P160, DOI 10.1006/excr.1998.4343; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; Gilbert MS, 1996, J CELL PHYSIOL, V168, P114; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; HACKING C, 1981, BIOCHEM J, V194, P415, DOI 10.1042/bj1940415; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Inai Y, 1997, CELL STRUCT FUNCT, V22, P555, DOI 10.1247/csf.22.555; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JONAS D, 1994, INFECT IMMUN, V62, P1304, DOI 10.1128/IAI.62.4.1304-1312.1994; JONES GS, 1981, J CELL PHYSIOL, V106, P75, DOI 10.1002/jcp.1041060109; KALLEN RG, 1993, MOL NEUROBIOL, V7, P383, DOI 10.1007/BF02769184; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LONGO N, 1991, AM J PHYSIOL, V260, pC1341; Marakhova II, 1998, BBA-BIOMEMBRANES, V1368, P61, DOI 10.1016/S0005-2736(97)00164-8; McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; PHILO RD, 1978, BIOCHEM J, V174, P801, DOI 10.1042/bj1740801; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SENN N, 1989, AM J PHYSIOL, V257, pC12, DOI 10.1152/ajpcell.1989.257.1.C12; Szabo I, 1997, PFLUG ARCH EUR J PHY, V433, P626, DOI 10.1007/s004240050323; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; WILLMAN CL, 1989, SEMIN DIAGN PATHOL, V6, P3; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Yu SP, 1998, NEUROBIOL DIS, V5, P81, DOI 10.1006/nbdi.1998.0186; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	48	141	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4304	4314		10.1074/jbc.M005171200	http://dx.doi.org/10.1074/jbc.M005171200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050080	hybrid			2022-12-27	WOS:000166921200077
J	Ammanamanchi, S; Brattain, MG				Ammanamanchi, S; Brattain, MG			Sp3 is a transcriptional repressor of transforming growth factor-beta receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; HUMAN GASTRIC-CANCER; TGF-BETA; II RECEPTOR; MCF-7 CELLS; SP-FAMILY; EXPRESSION; ACTIVATION; RESISTANCE; PROMOTER	MCF-7E breast cancer cells express transforming growth factor-beta (TGF-beta) receptors RI and RII in comparison to MCF-7L cells. We present data showing that Sp3 acts as a transcriptional repressor of RI and RII in MCF-7L cells and GEO colon cancer cells. MCF-7L and GEO cells express high levels of Sp3 protein. Gel shift analysis indicated enhanced binding of Sp3 from MCF-7L cells to a consensus Spl oligonucleotide. Southwestern data indicated increased binding of Sp3 to RI and RII promoters in MCF-7L cells, suggesting a correlation between Sp3 binding and reduced expression of TGF-P receptors in MCF-7L cells. Cotransfection of CMV-Sp3 cDNA with RI and RII promoter-luciferase reporter constructs decreased RI and RII promoter activities by 70% in MCF-7E and GEO cells. Southwestern analysis detected the binding of transiently expressed Sp3 to RI and RII promoters in MCF-7E cells. Significantly, ectopic Sp3 expression led to repression of RI and RII transcripts in MCF-7E cells. This report demonstrates that inappropriate overexpression of Sp3 is a mechanism that contributes to repression of TGF-beta receptors.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Brattain, MG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NATIONAL CANCER INSTITUTE [R37CA038173, R01CA072001, R01CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72001, CA 38173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kim DH, 1997, J BIOL CHEM, V272, P688; Ko Y, 1998, J CELL PHYSIOL, V176, P424, DOI 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.3.CO;2-N; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	29	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3348	3352		10.1074/jbc.M002462200	http://dx.doi.org/10.1074/jbc.M002462200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11027677	hybrid			2022-12-27	WOS:000166784900049
J	Kasof, GM; Gomes, BC				Kasof, GM; Gomes, BC			Livin, a novel inhibitor of apoptosis protein family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH; BACULOVIRAL-INHIBITOR; SURVIVIN; IAP; CASPASES; GENE; CANCER; XIAP; EXPRESSION	A novel human inhibitor of apoptosis protein (IAP) family member termed Livin was identified, containing a single baculoviral IAP repeat (BIR) domain and a COOH-terminal RING finger domain. The mRNA for livin was not detectable by Northern blot in most normal adult tissues with the exception of the placenta, but was present in developmental tissues and in several cancer cell lines. Highest levels were observed in two melanoma-derived cell lines, G361 and SK-Me129, Transfection of livin in HeLa cells resulted in protection from apoptosis induced by expression of FADD, Bax, RIP, RIP3, and DR6. Similar to other IAP family members, the anti-apoptotic activity of Livin was dependent on the BIR domain, Livin was also capable of inhibiting DEVD-like caspase activity triggered by tumor necrosis factor-cy, In vitro binding studies demonstrated a direct interaction between Livin and the active form of the downstream caspases, caspase-3 and -7, that was dependent on the BIR domain of Livin, In addition, the unprocessed and cleaved forms of caspase-9 co-immuno-precipitated with Livin in vivo, and recombinant Livin could inhibit the activation of caspase-9 induced by Apaf-1, cytochrome c, and dATP, The subcellular distribution of the transfected Livin was analyzed by immunofluorescence. Both Livin and Survivin were expressed in the nucleus and in a filamentous pattern throughout the cytoplasm. In contrast to the apoptotic activity, the COOH-terminal RING domain mediated its subcellular localization patterning. Further studies found that transfection of an antisense construct against livin could trigger apoptosis specifically in cell lines expressing livin mRNA, This was associated with an increase in DNA fragmentation and in DEVD-like caspase activity. Thus, disruption of Livin may provide a strategy to induce apoptosis in certain cancer cells.	AstraZeneca Pharmaceut, Enabling Sci & Technol, Wilmington, DE 19803 USA	AstraZeneca	Gomes, BC (corresponding author), AstraZeneca Pharmaceut, Enabling Sci & Technol, CRDL 145,1800 Concord Pike, Wilmington, DE 19803 USA.							Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Barks JH, 1997, GENE CHROMOSOME CANC, V19, P278, DOI 10.1002/(SICI)1098-2264(199708)19:4<278::AID-GCC11>3.3.CO;2-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grossman D, 1999, LAB INVEST, V79, P1121; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Kasof GM, 2000, FEBS LETT, V473, P285, DOI 10.1016/S0014-5793(00)01473-3; Kawasaki H, 1998, CANCER RES, V58, P5071; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lu CD, 1998, CANCER RES, V58, P1808; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Olie RA, 2000, CANCER RES, V60, P2805; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Saitoh Y, 1999, INT J ONCOL, V15, P137; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tamm I, 1998, CANCER RES, V58, P5315; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yu PW, 1999, CURR BIOL, V9, P539, DOI 10.1016/S0960-9822(99)80239-5	47	375	539	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3238	3246		10.1074/jbc.M003670200	http://dx.doi.org/10.1074/jbc.M003670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11024045	hybrid			2022-12-27	WOS:000166784900035
J	Galanis, A; Yang, SH; Sharrocks, AD				Galanis, A; Yang, SH; Sharrocks, AD			Selective targeting of MAPKs to the ETS domain transcription factor SAP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; C-JUN; MAMMALIAN-CELLS; CELLULAR STRESSES; DOCKING SITES; SPECIFICITY; CYTOKINES; PATHWAYS; ELK-1; MKK6	MAPK pathways play important roles in regulating the key cellular processes of proliferation, differentiation, and apoptosis, There are multiple MAPK pathways, which are subject to different regulatory cues. It is important that these pathways maintain specificity in sig naling to elicit the activation of a specific program of gene expression. MAPK-docking domains in several transcription factors have been shown to play important roles in determining the specificity and efficiency of their phosphorylation by MAPKs. Here we investigate the mechanisms by which MAPKs are targeted to the ETS domain transcription factor SAP-I. We demonstrate that SAP-1 contains two different domains that are required for its efficient phosphorylation in vitro and activation in vivo by ERK2 and a subset of p38 MAPKs. The D-domain is closely related to other MAPK-docking domains, but exhibits a novel specificity and serves to promote selective targeting of ERK2, p38 alpha, and p38 beta (2) to SAP-1. A second important region, the FXF motif, also plays an important role in directing MAPKs to phosphorylate SAP-1. The FXF motif promotes targeting by ERK2 and, to a lesser extent, p38 alpha, but not p38 beta (2). Our data therefore demonstrate that a modular system of motifs is responsible for directing specific MAPK subtypes to SAP-1, but also point to important distinctions in the mechanism of action of the D-domain and FXF motif.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Newcastle Upon Tyne, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Manchester; Newcastle University - UK	Sharrocks, AD (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Blvd,Oxford Rd, Manchester M13 9PT, Lancs, England.		Galanis, Alex/ABF-4762-2020	Galanis, Alex/0000-0001-9991-3173				Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAI TN, 1995, ONCOGENE, V10, P849; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Pawson T, 2000, GENE DEV, V14, P1027; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SETH A, 1992, J BIOL CHEM, V267, P24796; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; WHITMARSH AJ, 1998, SCIENCE, V17, P2360; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; YANG SH, 1999, GENE THER MOL BIOL, V3, P355	35	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					965	973		10.1074/jbc.M007697200	http://dx.doi.org/10.1074/jbc.M007697200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11029469	hybrid			2022-12-27	WOS:000166430900016
J	Li, M; Shillinglaw, W; Henzel, WJ; Beg, AA				Li, M; Shillinglaw, W; Henzel, WJ; Beg, AA			The RelA(p65) subunit of NF-kappa B is essential for inhibiting double-stranded RNA-induced cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DEPENDENT PROTEIN-KINASE; INDUCED CELL-DEATH; INDUCED APOPTOSIS; EMBRYONIC LETHALITY; FACTOR RECEPTOR; CD95 FAS/APO-1; CASPASES; ACTIVATION; VIRUS	Double-stranded RNA (dsRNA) molecules generated during virus infection can initiate a host antiviral response to limit further infection. Such a response involves induction of antiviral gene expression by the dsRNA-activated protein kinase (PKR) and the NF-kappaB transcription factor. In addition, dsRNA can also induce apoptosis by an incompletely understood mechanism that may servo to further limit viral replication. Here we demonstrate a novel role for the RelA subunit of NF-KB in inhibiting dsRNA-induced cell death, dsRNA treatment resulted in caspase 3 activation and apoptotic morphological transformations in mouse embryonic fibroblasts (MEFs) derived from RelA-/- mice but not from RelA+/- mice. Such dsRNA-induced killing could be inhibited by expression of either a dominant-negative mutant of PKR or wild-type RelA Interestingly, caspase 3 activated following dsRNA treatment of RelA-/- MEFs was essential for apoptotic nuclear changes but dispensable for cytotoxicity. A broader specificity caspase inhibitor was also unable to inhibit dsRNA-induced cytotoxicity, suggesting that caspase activation is not essential for the induction of cell death by dsRNA in MEFs. However, combined inhibition of caspase 3 and reactive oxygen species production resulted in complete inhibition of dsRNA-induced cytotoxicity. These results demonstrate an essential role for NF-kappaB in protecting cells from dsRNA-induced apoptosis and suggest that NF-kappaB may inhibit both caspase-dependent and reactive oxygen species-dependent cytotoxic pathways.	Columbia Univ, Dept Biol Sci, Fairchild Ctr 1110, New York, NY 10027 USA; Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA	Columbia University; Roche Holding; Genentech	Beg, AA (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild Ctr 1110, 1212 Amsterdam Ave, New York, NY 10027 USA.			Henzel, William/0000-0003-2940-3797; li, ming/0000-0002-1383-0535	NCI NIH HHS [R01 CA074892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074892] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADERKA D, 1985, CELL IMMUNOL, V92, P218, DOI 10.1016/0008-8749(85)90003-6; Aranda M, 1998, VIROLOGY, V243, P261, DOI 10.1006/viro.1998.9032; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gil J, 1999, MOL CELL BIOL, V19, P4653; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Li M, 2000, J VIROL, V74, P7470, DOI 10.1128/JVI.74.16.7470-7477.2000; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MIURA M, 1992, P NATL ACAD SCI USA, V92, P8218; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Schwarz EM, 1998, J VIROL, V72, P5654, DOI 10.1128/JVI.72.7.5654-5660.1998; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAN AD, 1996, SCIENCE, V274, P787; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	61	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1185	1194		10.1074/jbc.M006647200	http://dx.doi.org/10.1074/jbc.M006647200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035014	hybrid			2022-12-27	WOS:000166430900046
J	Olin, AI; Morgelin, M; Sasaki, T; Timpl, R; Heinegard, D; Aspberg, A				Olin, AI; Morgelin, M; Sasaki, T; Timpl, R; Heinegard, D; Aspberg, A			The proteoglycans aggrecan and versican form networks with fibulin-2 through their lectin domain binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX PROTEINS; ELECTRON-MICROSCOPY; CALCIUM-BINDING; CARTILAGE PROTEOGLYCANS; CELL-ADHESION; TENASCIN-R; EXPRESSION; BRAIN; MOUSE	Aggrecan, versican, neurocan, and brevican are important components of the extracellular matrix in various tissues. Their amino-terminal globular domains bind to hyaluronan, but the function of their carboxyl-terminal globular domains has long remained elusive. A picture is now emerging where the C-type lectin motif of this domain mediates binding to other extracellular matrix proteins. We here demonstrate that aggrecan, versican, and brevican lectin domains bind fibulin-2, whereas neurocan does not. As expected for a C-type lectin, the interactions are calcium-dependent, with K-D values in the nanomolar range as measured by surface plasmon resonance. Solid phase competition assays with previously identified ligands demonstrated that fibulin-2 and tenascin-a bind the same site on the proteoglycan lectin domains. Fibulin-1 has affinity for the common site on versican but may bind to a different site on the aggrecan lectin domain, By using deletion mutants, the interaction sites for aggrecan and versican lectin domains were mapped to epidermal growth factor-like repeats in domain II of fibulin-2. Affinity chromatography and solid phase assays confirmed that also native full-length aggrecan and versican bind the lectin domain ligands, Electron microscopy confirmed the mapping and demonstrated that hyaluronan-aggrecan complexes can be cross-linked by the fibulins.	Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, SE-22184 Lund, Sweden; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Lund University; Max Planck Society	Aspberg, A (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, BMC Plan C12, SE-22184 Lund, Sweden.			Aspberg, Anders/0000-0002-6588-6944				ASHER R, 1991, J NEUROSCI RES, V28, P410, DOI 10.1002/jnr.490280314; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; DOEGE K, 1987, J BIOL CHEM, V262, P17757; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; FALTZ LL, 1979, J BIOL CHEM, V254, P1375; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; Henderson DJ, 1998, CIRC RES, V83, P523, DOI 10.1161/01.RES.83.5.523; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KLUGE M, 1990, EUR J BIOCHEM, V193, P651, DOI 10.1111/j.1432-1033.1990.tb19383.x; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Maroudas A, 1979, ADULT ARTICULAR CART, P215; Miosge N, 1998, CELL MOL LIFE SCI, V54, P606, DOI 10.1007/s000180050188; Miosge N, 1996, HISTOCHEM J, V28, P109, DOI 10.1007/BF02331415; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; RAUCH U, 1992, J BIOL CHEM, V267, P19536; Rauch U, 1997, J BIOL CHEM, V272, P26905, DOI 10.1074/jbc.272.43.26905; RAUCH U, 1991, J BIOL CHEM, V266, P14785; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sasaki T, 1996, J CELL SCI, V109, P2895; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Sasaki T, 1997, EMBO J, V16, P3035, DOI 10.1093/emboj/16.11.3035; SPENCE SG, 1992, DEV BIOL, V151, P473, DOI 10.1016/0012-1606(92)90186-K; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamaguchi Y, 1996, PERSPECT DEV NEUROBI, V3, P307; Yamamura H, 1997, DEV BIOL, V186, P58, DOI 10.1006/dbio.1997.8559; Zhang HY, 1996, DEV DYNAM, V205, P348, DOI 10.1002/(SICI)1097-0177(199603)205:3<348::AID-AJA13>3.0.CO;2-0; ZHANG HY, 1995, DEV BIOL, V167, P18, DOI 10.1006/dbio.1995.1003; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	48	166	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1253	1261		10.1074/jbc.M006783200	http://dx.doi.org/10.1074/jbc.M006783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038354	hybrid			2022-12-27	WOS:000166430900054
J	Santolini, J; Adak, S; Curran, CML; Stuehr, DJ				Santolini, J; Adak, S; Curran, CML; Stuehr, DJ			A kinetic simulation model that describes catalysis and regulation in nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOPPED-FLOW ANALYSIS; L-ARGININE; ELECTRON-TRANSFER; NO SYNTHASE; SUPEROXIDE GENERATION; FEEDBACK INHIBITION; LOW-TEMPERATURE; HEME; SUBSTRATE; TETRAHYDROBIOPTERIN	After initiating NO synthesis a majority of neuronal NO synthase (nNOS) quickly partitions into a ferrous heme-NO complex. This down-regulates activity and increases enzyme K-m,K-O2. To understand this process, we developed a 10-step kinetic model in which the ferric heme-NO enzyme forms as the immediate product of catalysis, and then partitions between NO dissociation versus reduction to a ferrous heme-NO complex. Rate constants used for the model were derived from recent literature or were determined here. Computer simulations of the model precisely described both pre-steady and steady-state features of nNOS catalysis, including NADPH consumption and NO production, buildup of a heme-NO complex, changes between pre-steady and steady-state rates, and the change in enzyme K-m,K-O2 in the presence or absence of NO synthesis. The model also correctly simulated the catalytic features of nNOS mutants W409F and W409Y, which are hyperactive and display less heme-NO complex formation in the steady state. Model simulations showed how the rate of heme reduction influences several features of nNOS catalysis, including populations of NO-bound versus NO-free enzyme in the steady state and the rate of NO synthesis. The simulation predicts that there is an optimum rate of heme reduction that is close to the measured rate in nNOS, Ratio between NADPH consumption and NO synthesis is also predicted to increase with faster heme reduction. Our kinetic model is an accurate and versatile tool for understanding catalytic behavior and will provide new perspectives on NOS regulation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Santolini, Jerome/0000-0001-8919-112X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 1999, BIOCHEMISTRY-US, V38, P12446, DOI 10.1021/bi990698x; Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; ADAK S, 2001, J BIOL CHEM, V276, P10118; Andersen JF, 2000, BIOCHEMISTRY-US, V39, P10118, DOI 10.1021/bi000766b; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Berka V, 1996, J BIOL CHEM, V271, P33293, DOI 10.1074/jbc.271.52.33293; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FREY C, 1994, J BIOL CHEM, V269, P26083; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gorren ACF, 2000, BIOCHEM J, V347, P475, DOI 10.1042/0264-6021:3470475; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEMMENS B, 1997, METHOD MOL BIOL, V100, P1; HEVEL JM, 1993, ADV EXP MED BIOL, V338, P285; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; Iwanaga T, 1999, BIOCHEMISTRY-US, V38, P16629, DOI 10.1021/bi991277i; Kominami S, 1999, J BIOCHEM-TOKYO, V126, P756, DOI 10.1093/oxfordjournals.jbchem.a022513; LINCOLN J, 1997, NITRIC OXIDE HLTH DI, P27; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Nishimura JS, 1999, J BIOL CHEM, V274, P5399, DOI 10.1074/jbc.274.9.5399; POU S, 1992, J BIOL CHEM, V267, P24173; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Rengasamy A, 1996, J PHARMACOL EXP THER, V276, P30; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Scheele JS, 1999, J BIOL CHEM, V274, P13105, DOI 10.1074/jbc.274.19.13105; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1999, BIOCHIM BIOPHYS ACTA, V1411, P2146; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; WANG J, 1994, J BIOL CHEM, V268, P22255; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705	63	81	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1233	1243		10.1074/jbc.M006858200	http://dx.doi.org/10.1074/jbc.M006858200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038356	hybrid			2022-12-27	WOS:000166430900052
J	Smith, JJ; Rachubinski, RA				Smith, JJ; Rachubinski, RA			A role for the peroxin Pex8p in Pex20p-dependent thiolase import into peroxisomes of the yeast Yarrowia lipolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; MATRIX PROTEIN; PTS1 RECEPTOR; MEMBRANE; GENE; BIOGENESIS; ENCODES; IDENTIFICATION; PROLIFERATION	Peroxins are proteins required for peroxisome assembly. The cytosolic peroxin Pex20p binds directly to the beta -oxidation enzyme thiolase and is necessary for its dimerization and peroxisomal targeting. The intraperoxisomal peroxin Pex8p has a role in the import of peroxisomal matrix proteins, including thiolase. We report the results of yeast two-hybrid analyses with various peroxins of the yeast Yarrowia lipolytica and characterize more fully the interaction between Pex8p and Pex20p. Coimmunoprecipitation showed that Pex8p and Pex20p form a complex, while in vitro binding studies demonstrated that the interaction between Pex8p and Pex20p is specific, direct, and autonomous. Pex8p fractionates with peroxisomes in cells of a PEX20 disruption strain, indicating that Pex20p is not necessary for the targeting of Pex8p to peroxisomes. In cells of a PEX8 disruption strain, thiolase is mostly cytosolic, while Pex20p and a small amount of thiolase associate with peroxisomes, suggesting the involvement of Pex8p in the import of thiolase after docking of the Pex20p-thiolase complex to the membrane. In the absence of Pex8p, peroxisomal thiolase and Pex20p are protected from the action of externally added protease. This finding, together with the fact that Pex8p is intraperoxisomal, suggests that Pex20p may accompany thiolase into peroxisomes during import.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, 5-14 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	rick.rachubinski@ualberta.ca						Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Ausubel FM, 1988, MOL REPROD DEV; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; DEVORE JL, 1987, PROBABILITY STAT ENG, P340; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Eitzen GA, 1996, J BIOL CHEM, V271, P20300, DOI 10.1074/jbc.271.34.20300; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; EITZEN GA, 1995, J BIOL CHEM, V270, P1429, DOI 10.1074/jbc.270.3.1429; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; Gotte K, 1998, MOL CELL BIOL, V18, P616; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LIU H, 1995, J BIOL CHEM, V270, P10940, DOI 10.1074/jbc.270.18.10940; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; NUTTLEY WM, 1994, J BIOL CHEM, V269, P556; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; Smith JJ, 1997, MOL CELL BIOL, V17, P2511, DOI 10.1128/MCB.17.5.2511; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; Titorenko VI, 1997, MOL CELL BIOL, V17, P5210, DOI 10.1128/MCB.17.9.5210; Titorenko VI, 1996, J BIOL CHEM, V271, P20307, DOI 10.1074/jbc.271.34.20307; Titorenko VI, 1998, J CELL BIOL, V142, P403, DOI 10.1083/jcb.142.2.403; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737	34	35	36	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1618	1625		10.1074/jbc.M005072200	http://dx.doi.org/10.1074/jbc.M005072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042200	hybrid			2022-12-27	WOS:000166430900101
J	Chen, CH; Tsai, WY; Chen, HR; Wang, CH; Cheng, SC				Chen, CH; Tsai, WY; Chen, HR; Wang, CH; Cheng, SC			Identification and characterization of two novel components of the prp19p-associated complex, Ntc30p and Ntc20p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNWINDS RNA DUPLEXES; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; PREMESSENGER RNA; IN-VITRO; PROTEIN; YEAST; SPLICEOSOME; PRP19; U4	The yeast Saccharomyces cerevisiae Prp19p protein is an essential splicing factor and a spliceosomal component. It is not tightly associated with small nuclear RNAs (snRNAs) but is associated with a protein complex consisting of at least eight proteins. We have identified two novel components of the Prp19p-associated complex, Ntc30p and Ntc20p, Like other identified components of the complex, both Ntc30p and Ntc20p are associated with the spliceosome in the same manner as Prp19p immediately after or concurrently with dissociation of U4, indicating that the entire complex may bind to the spliceosome as an intact form. Neither Ntc30p nor Ntc20p directly interacts with Prp19p, but both interact with another component of the complex, Ntc85p. Immunoprecipitation analysis revealed an ordered interactions of these components in formation of the Prp19-passociated complex. Although null mutants of NTC30 or NTC20 showed no obvious growth phenotype, deletion of both genes impaired yeast growth resulting in accumulation of precursor mRNA Extracts prepared from such a strain were defective in pre-mRNA splicing in vitro, but the splicing activity could be restored upon addition of the purified Prp19p-associated complex. These results indicate that Ntc30p and Ntc20p are auxiliary splicing factors the functions of which may be modulating the function of the Prp19p-associated complex.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai 112, Taiwan; Acad Sinica, Inst Mol Biol, Nankang 115, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Cheng, SC (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai 112, Taiwan.		Chen, Chun-Hong/E-3990-2010	CHEN, CHUN-HONG/0000-0002-3028-5508				BEGGS JD, 1993, MOL BIOL REP, V18, P99, DOI 10.1007/BF00986763; Chen HR, 1999, P NATL ACAD SCI USA, V96, P5406, DOI 10.1073/pnas.96.10.5406; Chen HR, 1998, MOL CELL BIOL, V18, P2196, DOI 10.1128/MCB.18.4.2196; Dix I, 1999, RNA, V5, P360, DOI 10.1017/S1355838299981396; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Laggerbauer B, 1998, P NATL ACAD SCI USA, V95, P4188, DOI 10.1073/pnas.95.8.4188; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; Moore M., 1993, RNA WORLD, P303; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; TARN WY, 1993, MOL CELL BIOL, V13, P1883, DOI 10.1128/MCB.13.3.1883; TARN WY, 1994, EMBO J, V13, P2421, DOI 10.1002/j.1460-2075.1994.tb06527.x; Tsai WY, 1999, J BIOL CHEM, V274, P9455, DOI 10.1074/jbc.274.14.9455; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; XU Y, 1990, MOL CELL BIOL, V10, P1217, DOI 10.1128/MCB.10.3.1217	23	35	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					488	494		10.1074/jbc.M006958200	http://dx.doi.org/10.1074/jbc.M006958200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11018040	hybrid			2022-12-27	WOS:000166280700066
J	Cho, H; Nam, GB; Lee, SH; Earm, YE; Ho, WK				Cho, H; Nam, GB; Lee, SH; Earm, YE; Ho, WK			Phosphatidylinositol 4,5-bisphosphate is acting as a signal molecule in alpha(1)-adrenergic pathway via the modulation of acetylcholine-activated K+ channels in mouse atrial myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED PHOSPHORYLATION; TONIC VAGAL-STIMULATION; G-BETA-GAMMA; MUSCARINIC RECEPTORS; POTASSIUM CHANNELS; ATP CHANNELS; CELLS; DESENSITIZATION; PIP2; MEMBRANE	We have investigated the effect of alpha (1)-adrenergic agonist phenylephrine (PE) on acetylcholine-activated K+ currents (I-KACh). I-KACh was recorded in mouse atrial myocytes using the patch clamp technique. I-KACh was activated by 10 muM ACh and the current decreased by 44.27 +/- 2.38% (n = 12) during 4 min due to ACh-induced desensitization. When PE was applied with ACh, the extent of desensitization was markedly increased to 69.34 +/- 2.22% (n = 9), indicating the presence of PE-induced desensitization, I-KACh was fully recovered from desensitization after a 6-min washout. PE-induced desensitization of I-KACh was not affected by protein kinase C inhibitor, calphostin C, but abolished by phospholipase C (PLC) inhibitor, neomycin, When phophatidylinositol 4,5-bisphosphate (PIP2) replenishment was blocked by wortmannin (an inhibitor of phophatidylinositol 3-kinase and phophatidylinositol 4-kinase), desensitization of I,,, in the presence of PE was further increased (97.25 +/- 7.63%, n = 6), Furthermore, the recovery from PE-induced desensitization was inhibited, and the amplitude of I,, at the second exposure after washout was reduced to 19.65 +/- 2.61% (n = 6) of the preceding level. These data suggest that the K-ACh, channel is modulated by PE through PLC stimulation and depletion of PIP2.	Seoul Natl Univ, Coll Med, Dept Physiol & Biophys, Chongno Ku, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Natl Res Lab Cellular Signalling, Seoul 110799, South Korea; Asan Med Ctr, Dept Internal Med, Seoul 138140, South Korea	Seoul National University (SNU); Seoul National University (SNU); University of Ulsan; Asan Medical Center	Ho, WK (corresponding author), Seoul Natl Univ, Coll Med, Dept Physiol & Biophys, Chongno Ku, 28 Yonkeun Dong, Seoul 110799, South Korea.		Ho, Won-Kyung/J-2798-2012; Lee, Suk-Ho/D-6344-2012	Lee, Suk-Ho/0000-0003-4117-5619				Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BOYETT MR, 1987, J PHYSIOL-LONDON, V393, P171, DOI 10.1113/jphysiol.1987.sp016818; BOYETT MR, 1988, J PHYSIOL-LONDON, V404, P613, DOI 10.1113/jphysiol.1988.sp017309; BRAUN AP, 1992, PFLUG ARCH EUR J PHY, V421, P431, DOI 10.1007/BF00370253; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CARMELIET E, 1986, J PHYSIOL-LONDON, V371, P239, DOI 10.1113/jphysiol.1986.sp015971; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; HARRISON SM, 1992, J PHYSIOL-LONDON, V449, P517, DOI 10.1113/jphysiol.1992.sp019100; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; HONJO H, 1992, AM J PHYSIOL, V263, pH1779, DOI 10.1152/ajpheart.1992.263.6.H1779; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; JENKINSON S, 1994, MOL PHARMACOL, V46, P1138; Kim D, 1999, J PHYSIOL-LONDON, V517, P59, DOI 10.1111/j.1469-7793.1999.0059z.x; Kobrinsky E, 1999, BIOPHYS J, V76, pA411; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KURACHI Y, 1986, AM J PHYSIOL, V251, pH681, DOI 10.1152/ajpheart.1986.251.3.H681; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; Logothetis DE, 1999, J PHYSIOL-LONDON, V520, P630, DOI 10.1111/j.1469-7793.1999.00630.x; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; MARTIN P, 1983, J PHYSIOL-LONDON, V245, pH584; MARTIN P, 1982, J PHYSIOL-LONDON, V243, pH219; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SHUI Z, 1995, J PHYSIOL-LONDON, V487, P359, DOI 10.1113/jphysiol.1995.sp020885; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; SIMMONS MA, 1987, PFLUG ARCH EUR J PHY, V409, P454, DOI 10.1007/BF00583801; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Vorobiov D, 1998, PFLUG ARCH EUR J PHY, V436, P56, DOI 10.1007/s004240050604; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292; Yamaguchi H, 1997, AM J PHYSIOL-HEART C, V273, pH1745, DOI 10.1152/ajpheart.1997.273.4.H1745; Zhainazarov AB, 1999, J NEUROSCI, V19, P2929; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	39	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					159	164		10.1074/jbc.M004826200	http://dx.doi.org/10.1074/jbc.M004826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029461	hybrid			2022-12-27	WOS:000166280700023
J	Katsel, PL; Greenstein, RJ				Katsel, PL; Greenstein, RJ			Identification of overlapping AP-2/NF-kappa B-responsive elements on the rat cholecystokinin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MESSENGER-RNA EXPRESSION; CARCINOMA CELL-LINE; PROTEIN-KINASE C; TRANSCRIPTION FACTOR; DIFFERENTIAL EXPRESSION; GLUCOCORTICOID RECEPTOR; IMMUNOREACTIVE CCK; BRAIN; SITE	In this study we evaluate both proximal and more distal transcriptional regulation of the 5' flanking region of the rat cholecystokinin gene in transfected GH3 (rat pituitary tumor) cells. Transcriptional activity was measured on the intact (-400 to +73) 5' flanking region of cholecystokinin (CCK), as well as with DNA constructs, which were deleted in both the conventional 5' to 3', as well as an unconventional 3' to 5' direction. Our in vivo studies indicate complex phorbol ester and forskolin interactions in the 10-base pair region between - 130 and -140. We conclude, there are at least two transcriptional factors involved in regulation of the rat CCK transcription in this region. In vitro studies utilizing heterologous nuclear (HeLa) extract, as well as purified transcription factors AP-2 and NF-KB, identify overlapped AP-2- and NF-KB-responsive elements within the 17-base pair sequence between -149 and -134 of the distal 5' flanking region. In this region complex transcriptional regulation occurs, which indicates inhibition of AP-2 CCK promoter complexing by NF-KB. Six-point mutations introduced into this sequence prevent AP-2 and NF-KB binding to CCK promoter, as well as its transcriptional activation by phorbol ester and forskolin in GH3 cells.	VAMC, Bronx, NY 10468 USA; CUNY Mt Sinai Sch Med, Dept Anesthesiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Katsel, PL (corresponding author), VAMC, 151,Res Bldg,Rm 2F-30,130 W Kingsbridge Rd, Bronx, NY 10468 USA.							AGNATI LF, 1985, ANN NY ACAD SCI, V448, P315, DOI 10.1111/j.1749-6632.1985.tb29927.x; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEINFELD MC, 1992, NEUROPEPTIDES, V22, P213, DOI 10.1016/0143-4179(92)90048-2; BEINFELD MC, 1992, PEPTIDES, V13, P545, DOI 10.1016/0196-9781(92)90087-J; BRUNVAND MW, 1993, NUCLEIC ACIDS RES, V21, P4824, DOI 10.1093/nar/21.20.4824; Ciaccio PJ, 1996, BIOCHEM BIOPH RES CO, V228, P524, DOI 10.1006/bbrc.1996.1693; DESCHENES RJ, 1984, P NATL ACAD SCI-BIOL, V81, P726, DOI 10.1073/pnas.81.3.726; DOCKRAY GJ, 1976, NATURE, V264, P568, DOI 10.1038/264568a0; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; FONG CLW, 1995, BIOCHEM BIOPH RES CO, V212, P879, DOI 10.1006/bbrc.1995.2051; FRIEDMAN J, 1985, P NATL ACAD SCI USA, V82, P5593, DOI 10.1073/pnas.82.17.5593; GREENSTEIN RJ, 1992, J SURG RES, V53, P12, DOI 10.1016/0022-4804(92)90005-K; Hansen TV, 1999, MOL ENDOCRINOL, V13, P466, DOI 10.1210/me.13.3.466; HAUN RS, 1990, J BIOL CHEM, V265, P15455; ICHIHARA K, 1983, BIOCHEM BIOPH RES CO, V112, P891, DOI 10.1016/0006-291X(83)91701-1; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Ivy AC, 1928, AM J PHYSIOL, V86, P599, DOI 10.1152/ajplegacy.1928.86.3.599; JUNCOSAGINESTA M, 1994, BIOTECHNIQUES, V16, P820; Katsel PL, 1997, DNA CELL BIOL, V16, P1013, DOI 10.1089/dna.1997.16.1013; KONINGS PNM, 1993, NEUROPEPTIDES, V25, P19, DOI 10.1016/0143-4179(93)90064-H; Li JJ, 1997, CANCER RES, V57, P3569; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; MONSTEIN HJ, 1993, NEUROREPORT, V4, P195, DOI 10.1097/00001756-199302000-00020; MONSTEIN HJ, 1991, FEBS LETT, V293, P145, DOI 10.1016/0014-5793(91)81172-5; MONSTEIN HJ, 1993, NEUROREPORT, V4, P1167; MULLER JE, 1977, P NATL ACAD SCI USA, V74, P3035, DOI 10.1073/pnas.74.7.3035; Nielsen FC, 1996, DNA CELL BIOL, V15, P53, DOI 10.1089/dna.1996.15.53; ODUM L, 1995, NEUROPEPTIDES, V29, P45, DOI 10.1016/0143-4179(95)90055-1; Ratineau C, 1996, J ENDOCRINOL, V151, P137, DOI 10.1677/joe.0.1510137; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIMERLY RB, 1987, P NATL ACAD SCI USA, V84, P2087, DOI 10.1073/pnas.84.7.2087; TAKAHASHI Y, 1986, GENE, V50, P353; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; VANDERHAEGHEN JJ, 1975, NATURE, V257, P604, DOI 10.1038/257604a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VITALE M, 1991, NUCLEIC ACIDS RES, V19, P169, DOI 10.1093/nar/19.1.169; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	42	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					752	758		10.1074/jbc.M007553200	http://dx.doi.org/10.1074/jbc.M007553200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022044	hybrid			2022-12-27	WOS:000166280700101
J	Vishnivetskiy, SA; Schubert, C; Climaco, GC; Gurevich, YV; Velez, MG; Gurevich, VV				Vishnivetskiy, SA; Schubert, C; Climaco, GC; Gurevich, YV; Velez, MG; Gurevich, VV			An additional phosphate-binding element in arrestin molecule - Implications for the mechanism of arrestin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; VISUAL ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHORYLATION-RECOGNITION; CRYSTAL-STRUCTURE; 48-KDA PROTEIN; RHODOPSIN; DEPHOSPHORYLATION; SELECTIVITY; PHOSPHORHODOPSIN	Arrestins quench the signaling of a wide variety of G protein-coupled receptors by virtue of high-affinity binding to phosphorylated activated receptors, The high selectivity of arrestins for this particular functional form of receptor ensures their timely binding and dissociation. In a continuing effort to elucidate the molecular mechanisms responsible for arrestin's selectivity, we used the visual arrestin model to probe the functions of its N-terminal beta -strand I comprising the highly conserved hydrophobic element Val-Ile-Phe (residues 11-13) and the adjacent positively charged Lys(14) and Lys(15). Charge elimination and reversal in positions 14 and 15 dramatically reduce arrestin binding to phosphorylated light-activated rhodopsin (P-Rh*). The same mutations in the context of various constitutively active arrestin mutants (which bind to P-Rh*, dark phosphorylated rhodopsin (P-Rh), and unphosphorylated light-activated rhodopsin (Rh*)) have minimum impact on P-Rh* and Rh* binding and virtually eliminate P-Rh binding. These results suggest that the two lysines "guide" receptor-attached phosphates toward the phosphorylation-sensitive trigger Arg(175) and participate in phosphate binding in the active state of arrestin, The elimination of the hydrophobic side chains of residues 11-13 (triple mutation V11A, I12A, and F13A) moderately enhances arrestin binding to P-Rh and Rh*, The effects of triple mutation V11A, I12A, and F13A in the context of phosphorylation-independent mutants suggest that residues 11-13 play a dual role. They stabilize arrestin's basal conformation via interaction with hydrophobic elements in arrestin's C-tail and alpha -helix I as well as its active state by interactions with alternative partners. In the context of the recently solved crystal structure of arrestin's basal state, these findings allow us to propose a model of initial phosphate-driven structural rearrangements in arrestin that ultimately result in its transition into the active receptor-binding state.	Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85372 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA	Banner Research; Banner Health; Banner Sun Health Research Institute; Howard Hughes Medical Institute; Yale University; Yale University	Gurevich, VV (corresponding author), Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, 10515 W Santa Fe Dr, Sun City, AZ 85372 USA.		Vishnivetskiy, Sergey/AAJ-8661-2020; Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [EY11500] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P319; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451	35	137	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41049	41057		10.1074/jbc.M007159200	http://dx.doi.org/10.1074/jbc.M007159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024026	hybrid			2022-12-27	WOS:000166114600053
J	Ono, S; McGough, A; Pope, BJ; Tolbert, VT; Bui, A; Pohl, J; Benian, GM; Gernert, KM; Weeds, AG				Ono, S; McGough, A; Pope, BJ; Tolbert, VT; Bui, A; Pohl, J; Benian, GM; Gernert, KM; Weeds, AG			The C-terminal tail of UNC-60B (actin depolymerizing factor/cofilin) is critical for maintaining its stable association with F-actin and is implicated in the second actin-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; FILAMENT TURNOVER; FACTOR ADF/COFILIN; FACTOR COFILIN; YEAST COFILIN; SUBDOMAIN 2; PROTEIN; GELSOLIN; ADF; ACTOPHORIN	Actin depolymerizing factor (ADF)/cofilin changes the twist of actin filaments by binding two longitudinally associated actin subunits, In the absence of an atomic model of the ADF/cofilin-F-actin complex, we have identified residues in ADF/cofilin that are essential for filament binding. Here, we have characterized the C-terminal tail of UNC-60B (a nematode ADF/cofilin isoform) as a novel determinant for its association with F-actin, Removal of the C-terminal isoleucine (Ile(152)) by carboxypeptidase A or truncation by mutagenesis eliminated F-actin binding activity but strongly enhanced actin depolymerizing activity, Replacement of Ile(152) by Ala had a similar but less marked effect; F-actin binding was weakened and depolymerizing activity slightly enhanced. Truncation of both Arg(151) and Ile(152) or replacement of Arg(151) with Ala also abolished F-actin binding and enhanced depolymerizing activity. Loss of F-actin binding in these mutants was accompanied by loss or greatly decreased severing activity. All of the variants of UNC-60B interacted with G-actin in an indistinguishable manner from wild type. Cryoelectron microscopy showed that UNC-60B changed the twist of F-actin to a similar extent to vertebrate ADF/cofilins. Helical reconstruction and structural modeling of UNC-60B-F-actin complex reveal how the C terminus of UNC-60B might be involved in one of the two actin-binding sites.	Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Purdue Univ, Dept Sci Biol, W Lafayette, IN 47907 USA; Emory Univ, Winship Canc Inst, Microchem Facil, Atlanta, GA 30322 USA; Frederick Douglas High Sch, Decatur, GA 30030 USA; Emory Univ, BIMCORE, Atlanta, GA 30322 USA	Emory University; MRC Laboratory Molecular Biology; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Emory University; Emory University	Ono, S (corresponding author), Emory Univ, Dept Pathol, 1639 Pierce Dr,Woodruff Mem Bldg,Rm 7109C, Atlanta, GA 30322 USA.	ono@bimcore.emory.edu	Ono, Shoichiro/A-6475-2015	Ono, Shoichiro/0000-0002-4763-0398	NCRR NIH HHS [RR13948, RR12878] Funding Source: Medline; NIGMS NIH HHS [GM59677] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012878, S10RR013948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059677] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; Du JY, 1998, BIOCHEMISTRY-US, V37, P13276, DOI 10.1021/bi981117r; Fedorov AA, 1997, NAT STRUCT BIOL, V4, P366, DOI 10.1038/nsb0597-366; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; Ichetovkin I, 2000, CELL MOTIL CYTOSKEL, V45, P293, DOI 10.1002/(SICI)1097-0169(200004)45:4<293::AID-CM5>3.0.CO;2-1; Jiang CJ, 1997, P NATL ACAD SCI USA, V94, P9973, DOI 10.1073/pnas.94.18.9973; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim E, 1995, BIOPHYS J, V69, P2024, DOI 10.1016/S0006-3495(95)80072-X; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Leonard SA, 1997, NAT STRUCT BIOL, V4, P369, DOI 10.1038/nsb0597-369; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; Maciver SK, 1998, EUR J BIOCHEM, V256, P388, DOI 10.1046/j.1432-1327.1998.2560388.x; McGough A, 1999, J MOL BIOL, V291, P513, DOI 10.1006/jmbi.1999.2968; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Moraczewska J, 1996, BIOCHEM J, V317, P605, DOI 10.1042/bj3170605; Moriyama K, 1999, EMBO J, V18, P6752, DOI 10.1093/emboj/18.23.6752; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; Ono S, 1999, J CELL BIOL, V145, P491, DOI 10.1083/jcb.145.3.491; Ono S, 1999, CELL MOTIL CYTOSKEL, V43, P128, DOI 10.1002/(SICI)1097-0169(1999)43:2&lt;128::AID-CM4&gt;3.0.CO;2-C; Ono S, 1998, J BIOL CHEM, V273, P3778, DOI 10.1074/jbc.273.6.3778; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pope BJ, 2000, J MOL BIOL, V298, P649, DOI 10.1006/jmbi.2000.3688; Ressad F, 1999, J BIOL CHEM, V274, P20970, DOI 10.1074/jbc.274.30.20970; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; SAFER D, 1989, ANAL BIOCHEM, V178, P32, DOI 10.1016/0003-2697(89)90351-5; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; Smertenko AP, 1998, PLANT J, V14, P187, DOI 10.1046/j.1365-313X.1998.00107.x; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Van Troys M, 1997, J BIOL CHEM, V272, P32750, DOI 10.1074/jbc.272.52.32750; WHITTAKER M, 1995, ULTRAMICROSCOPY, V58, P245, DOI 10.1016/0304-3991(95)00057-8; Wriggers W, 1998, J MOL BIOL, V282, P921, DOI 10.1006/jmbi.1998.2048; Yeoh S, 1999, MOL BIOL CELL, V10, p156A; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485; Zhou ZH, 1996, J STRUCT BIOL, V116, P216, DOI 10.1006/jsbi.1996.0033	55	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5952	5958		10.1074/jbc.M007563200	http://dx.doi.org/10.1074/jbc.M007563200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11050090	hybrid			2022-12-27	WOS:000167115100073
J	Lim, EK; Li, Y; Parr, A; Jackson, R; Ashford, DA; Bowles, DJ				Lim, EK; Li, Y; Parr, A; Jackson, R; Ashford, DA; Bowles, DJ			Identification of glucosyltransferase genes involved in sinapate metabolism and lignin synthesis in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCOSE GLUCOSYLTRANSFERASE; BIOCHEMICAL-CHARACTERIZATION; O-GLUCOSYLTRANSFERASE; SALICYLIC-ACID; EXPRESSION; CLONING; PURIFICATION; 5-O-GLUCOSYLTRANSFERASE; FERULATE-5-HYDROXYLASE; ANTHOCYANIN	Sinapic acid is a major phenylpropanoid in Brassicaceae providing intermediates in two distinct metabolic pathways leading to sinapoyl esters and lignin synthesis. Glucosyltransferases play key roles in the formation of these intermediates, either through the production of the high energy compound 1-O-sinapoyl-glucose leading to sinapoylmalate and sinapoylcholine or through the production of sinapyl alcohol-4-O-glucoside, potentially leading to the syringyl units found in lignins. While the importance of these glucosyltransferases has been recognized for more than 20 years, their corresponding genes have not been identified. Combining sequence information in the Arabidopsis genomic data base with biochemical data from screening the activity of recombinant proteins in vitro, we have now identified five gene sequences encoding enzymes that can glucosylate sinapic acid, sinapyl alcohol, and their related phenylpropanoids. The data provide a foundation for future understanding and manipulation of sinapate metabolism and lignin biology in Arabidopsis.	Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England; Inst Food Res, Norwich NR4 7UA, Norfolk, England	University of York - UK; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Bowles, DJ (corresponding author), Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England.	djb32@york.ac.uk						BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; CHAPPLE CCS, 1992, PLANT CELL, V4, P1413, DOI 10.1105/tpc.4.11.1413; DHARMAWARDHANA DP, 1995, PLANT PHYSIOL, V107, P331, DOI 10.1104/pp.107.2.331; Ford CM, 1998, J BIOL CHEM, V273, P9224, DOI 10.1074/jbc.273.15.9224; Fraissinet-Tachet L, 1998, FEBS LETT, V437, P319, DOI 10.1016/S0014-5793(98)01257-5; Gorinova N, 1999, BIOTECHNOL BIOTEC EQ, V13, P13, DOI 10.1080/13102818.1999.10819011; Hostel W., 1981, BIOCH PLANTS, V7, P725; HUGHES J, 1994, DNA SEQUENCE, V5, P41, DOI 10.3109/10425179409039703; Ibrahim RK, 1998, PLANT MOL BIOL, V36, P1, DOI 10.1023/A:1005939803300; IBRAHIM RK, 1976, ARCH BIOCHEM BIOPHYS, V176, P700, DOI 10.1016/0003-9861(76)90214-9; ISHIMARU K, 1990, PHYTOCHEMISTRY, V29, P3823, DOI 10.1016/0031-9422(90)85340-L; Jones PR, 1999, J BIOL CHEM, V274, P35483, DOI 10.1074/jbc.274.50.35483; LANDRY LG, 1995, PLANT PHYSIOL, V109, P1159, DOI 10.1104/pp.109.4.1159; Lee H, 1999, J BIOL CHEM, V274, P36637, DOI 10.1074/jbc.274.51.36637; LEE HI, 1995, P NATL ACAD SCI USA, V92, P4076, DOI 10.1073/pnas.92.10.4076; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 1998, J BIOL CHEM, V273, P34920, DOI 10.1074/jbc.273.52.34920; Lorenzen M, 1996, PLANT PHYSIOL, V112, P1625, DOI 10.1104/pp.112.4.1625; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Martin RC, 1999, P NATL ACAD SCI USA, V96, P284, DOI 10.1073/pnas.96.1.284; Meyer K, 1996, P NATL ACAD SCI USA, V93, P6869, DOI 10.1073/pnas.93.14.6869; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; Moehs CP, 1997, PLANT J, V11, P227, DOI 10.1046/j.1365-313X.1997.11020227.x; O'Donnell PJ, 1998, PLANT J, V14, P137, DOI 10.1046/j.1365-313X.1998.00110.x; PIERS KL, 1993, GENE, V134, P7, DOI 10.1016/0378-1119(93)90168-3; Ruegger M, 1999, PLANT PHYSIOL, V119, P101, DOI 10.1104/pp.119.1.101; SAMBROOK J, 1989, MOL CLONING LAB MANU, V18, P47; SHARMA V, 1985, PLANTA, V163, P563, DOI 10.1007/BF00392714; Solecka D, 1997, ACTA PHYSIOL PLANT, V19, P257, DOI 10.1007/s11738-997-0001-1; STRACK D, 1983, Z NATURFORSCH C, V38, P21; STRACK D, 1977, Z PFLANZENPHYSIOL, V84, P139, DOI 10.1016/S0044-328X(77)80186-4; SUGIYAMA M, 1993, PHYTOCHEMISTRY, V33, P1215, DOI 10.1016/0031-9422(93)85052-S; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; Tanaka Y, 1996, PLANT CELL PHYSIOL, V37, P711, DOI 10.1093/oxfordjournals.pcp.a029004; Truesdale M. R., 1996, PLANT PHYSIOL, V112, P446; VANCE CP, 1980, ANNU REV PHYTOPATHOL, V18, P259, DOI 10.1146/annurev.py.18.090180.001355; Vogt T, 1999, PLANT J, V19, P509, DOI 10.1046/j.1365-313X.1999.00540.x; Warnecke DC, 1997, PLANT MOL BIOL, V35, P597, DOI 10.1023/A:1005806119807; Whetten RW, 1998, ANNU REV PLANT PHYS, V49, P585, DOI 10.1146/annurev.arplant.49.1.585; Winkel-Shirley B, 1999, PHYSIOL PLANTARUM, V107, P142, DOI 10.1034/j.1399-3054.1999.100119.x; Yamazaki M, 1999, J BIOL CHEM, V274, P7405, DOI 10.1074/jbc.274.11.7405	41	158	182	6	39	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4344	4349		10.1074/jbc.M007263200	http://dx.doi.org/10.1074/jbc.M007263200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042211	hybrid			2022-12-27	WOS:000166921200082
J	Benedict, CA; Norris, PS; Prigozy, TI; Bodmer, JL; Mahr, JA; Garnett, CT; Martinon, F; Tschopp, J; Gooding, LR; Ware, CF				Benedict, CA; Norris, PS; Prigozy, TI; Bodmer, JL; Mahr, JA; Garnett, CT; Martinon, F; Tschopp, J; Gooding, LR; Ware, CF			Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LYMPHOTOXIN-BETA-RECEPTOR; GROWTH-FACTOR RECEPTOR; FADD-DEPENDENT APOPTOSIS; REGION E3; MEDIATED APOPTOSIS; RETROVIRAL VECTORS; MEMBRANE-PROTEIN; DEATH; TRAIL	Adenovirus encodes multiple gene products that regulate proapoptotic cellular responses to viral infection mediated by both the innate and adaptive immune systems. The E3-10.4K and 14.5K gene products are known to modulate the death receptor Fas. In this study, we demonstrate that an additional viral E3 protein, 6.7K, functions in the specific modulation of the two death receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), The 6.7K protein is expressed on the cell surface and forms a complex with the 10.4K and 14.5K proteins, and this complex is sufficient to induce down-modulation of TRAIL receptor-1 and -2 from the cell surface and reverse the sensitivity of infected cells to TRAIL-mediated apoptosis. Down-modulation of TRAIL-R2 by the E3 complex is dependent on the cytoplasmic tail of the receptor, but the death domain alone is not sufficient. These results identify a mechanism for viral modulation of TRAIL receptor-mediated apoptosis and suggest the E3 protein complex has evolved to regulate the signaling of selected cytokine receptors.	La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, Div Dev Immunol, San Diego, CA 92121 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	La Jolla Institute for Immunology; La Jolla Institute for Immunology; Emory University; University of Lausanne	Ware, CF (corresponding author), La Jolla Inst Allergy & Immunol, Div Mol Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	carl_ware@liai.org	Martinon, Fabio/A-5575-2009	Martinon, Fabio/0000-0002-6969-822X	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000252] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA69381] Funding Source: Medline; NIAID NIH HHS [AI03368] Funding Source: Medline; NIA NIH HHS [T32AG00252] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Benedict CA, 1999, J IMMUNOL, V162, P6967; Benedict CA, 1999, HUM GENE THER, V10, P545, DOI 10.1089/10430349950018625; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; BRADY HA, 1987, NUCLEIC ACIDS RES, V15, P9397, DOI 10.1093/nar/15.22.9397; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; CARLIN CR, 1989, CELL, V57, P135, DOI 10.1016/0092-8674(89)90179-7; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CLADARAS C, 1985, VIROLOGY, V140, P44, DOI 10.1016/0042-6822(85)90444-1; Cook JL, 1996, ONCOGENE, V13, P833; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Elsing A, 1998, P NATL ACAD SCI USA, V95, P10072, DOI 10.1073/pnas.95.17.10072; Force WR, 2000, J BIOL CHEM, V275, P11121, DOI 10.1074/jbc.275.15.11121; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1999, J IMMUNOL, V162, P2597; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HOFFMAN P, 1992, J BIOL CHEM, V267, P13480; Johnsen AC, 1999, CYTOKINE, V11, P664, DOI 10.1006/cyto.1999.0489; Kayagaki N, 1999, J IMMUNOL, V162, P2639; Klefstrom J, 1999, ONCOGENE, V18, P2181, DOI 10.1038/sj.onc.1202546; KRAJCSI P, 1992, VIROLOGY, V187, P131, DOI 10.1016/0042-6822(92)90302-6; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Mahr JA, 1999, IMMUNOL REV, V168, P121, DOI 10.1111/j.1600-065X.1999.tb01287.x; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Rooney IA, 2000, J BIOL CHEM, V275, P14307, DOI 10.1074/jbc.275.19.14307; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shisler J, 1997, J VIROL, V71, P8299, DOI 10.1128/JVI.71.11.8299-8306.1997; Shisler JL, 1998, TRENDS MICROBIOL, V6, P337, DOI 10.1016/S0966-842X(98)01342-0; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Sparer TE, 1996, J VIROL, V70, P2431, DOI 10.1128/JVI.70.4.2431-2439.1996; STEWART AR, 1995, J VIROL, V69, P172, DOI 10.1128/JVI.69.1.172-181.1995; Thomas WD, 1998, J IMMUNOL, V161, P2195; TOLLEFSON AE, 1991, J VIROL, V65, P3095, DOI 10.1128/JVI.65.6.3095-3105.1991; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WILSONRAWLS J, 1993, VIROLOGY, V195, P6, DOI 10.1006/viro.1993.1341; WILSONRAWLS J, 1990, VIROLOGY, V178, P204, DOI 10.1016/0042-6822(90)90395-8; WOLD WSM, 1986, VIROLOGY, V148, P168, DOI 10.1016/0042-6822(86)90412-5; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961	47	111	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3270	3278		10.1074/jbc.M008218200	http://dx.doi.org/10.1074/jbc.M008218200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11050095	hybrid			2022-12-27	WOS:000166784900039
J	Rane, MJ; Coxon, PY; Powell, DW; Webster, R; Klein, JB; Pierce, W; Ping, PP; McLeish, KR				Rane, MJ; Coxon, PY; Powell, DW; Webster, R; Klein, JB; Pierce, W; Ping, PP; McLeish, KR			p38 kinase-dependent MAPKAPK-2 activation functions as 3-phosphoinositide-dependent kinase-2 for Akt in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYL PEPTIDE RECEPTORS; HEAT-SHOCK PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PHOSPHORYLATION; PATHWAYS; CASCADES; BINDING	Akt activation requires phosphorylation of Thr(308) and Ser(473) by 3-phosphoinositide-dependent kinase-1 and a (PDK1 and PDK2), respectively. While PDK1 has been cloned and sequenced, PDK2 has yet to be identified. The present study shows that phosphatidyl inositol 3-kinase-dependent p38 kinase activation regulates Akt phosphorylation and activity in human neutrophils, Inhibition of p38 kinase activity with SB203580 inhibited Akt Ser473 phosphorylation following neutrophil stimulation with formyl-methionyl-leucyl phenylalanine, Fc gammaR cross-linking, or phosphatidylinositol 3,4,5-trisphosphate. Concentration inhibition studies showed that Ser473 phosphorylation was inhibited by 0.3 muM SB203580, while inhibition of Thr(308) phosphorylation required 10 muM SB203580. Transient transfection of HEK293 cells with adenoviruses containing constitutively active MKK3 or MKK6 resulted in activation of both p38 kinase and Akt, Immunoprecipitation and glutathione S-transferase (GST) pull-down studies showed that Akt was associated with p38 kinase, MK2, and Hsp27 in neutrophils, and Hsp27 dissociated from the complex upon activation. Active recombinant MK2 phosphorylated recombinant Akt and Akt in anti-Akt, anti-MK2, anti-p38, and anti-Hsp27 immunoprecipitates, and this was inhibited by an MK2 inhibitory peptide. We conclude that Akt exists in a signaling complex containing p38 kinase, MK2, and Hsp27 and that p38-dependent MK2 activation functions as PDK2 in human neutrophils.	Univ Louisville, Mol Signalling Grp, Kidney Dis Program, Hlth Sci Ctr,Dept Med, Louisville, KY 40202 USA; Univ Louisville, Hlth Sci Ctr, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Hlth Sci Ctr, Dept Physiol & Biophys, Louisville, KY 40202 USA; Univ Louisville, Hlth Sci Ctr, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Rane, MJ (corresponding author), Univ Louisville, Mol Signalling Grp, Kidney Dis Program, Hlth Sci Ctr,Dept Med, 615 S Preston St, Louisville, KY 40202 USA.		Klein, Jon/B-9833-2013; McLeish, Kenneth R./B-9819-2013; Powell, David W/E-9288-2013	McLeish, Kenneth R./0000-0002-7816-3286; 	NCRR NIH HHS [1S10RR11368-01A1] Funding Source: Medline; NHLBI NIH HHS [HL63901] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011368] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063901, R37HL063901] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Coxon PY, 2000, J IMMUNOL, V164, P6530, DOI 10.4049/jimmunol.164.12.6530; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; DOOLEY DC, 1982, EXP HEMATOL, V10, P591; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Jensen ON, 1999, METH MOL B, V112, P513; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P835, DOI 10.1002/jlb.64.6.835; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151; Rane MJ, 1997, J IMMUNOL, V159, P5070; Rane MJ, 1998, J BIOL CHEM, V273, P20916, DOI 10.1074/jbc.273.33.20916; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287; ZU YL, 1992, J BIOL CHEM, V267, P20181	40	224	232	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3517	3523		10.1074/jbc.M005953200	http://dx.doi.org/10.1074/jbc.M005953200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11042204	hybrid			2022-12-27	WOS:000166784900069
J	Avdi, NJ; Nick, JA; Whitlock, BB; Billstrom, MA; Henson, PM; Johnson, GL; Worthen, GS				Avdi, NJ; Nick, JA; Whitlock, BB; Billstrom, MA; Henson, PM; Johnson, GL; Worthen, GS			Tumor necrosis factor-alpha activation of the c-Jun N-terminal kinase pathway in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; KAPPA-B ACTIVATION; MAP KINASE; SIGNAL-TRANSDUCTION; RESPIRATORY BURST; NH2-TERMINAL KINASE; TNF-ALPHA; MECHANICAL-PROPERTIES; MOLECULAR-CLONING	The intensity and duration of an inflammatory response depends on the balance of factors that favor perpetuation versus resolution. At sites of inflammation, neutrophils adherent to other cells or matrix components are exposed to tumor necrosis factor-alpha (TNF alpha), Although TNF alpha has been implicated in induction of pro-inflammatory responses, it may also inhibit the intensity of neutrophilic inflammation by promoting apoptosis, Since TNF alpha is not only an important activator of the stress-induced pathways leading to p38 MAPk and c-Jun N-terminal kinase (JNK) but also a potent effector of apoptosis, we investigated the effects of TNF alpha on the JNK pathway in adherent human neutrophils and the potential involvement of this pathway in neutrophil apoptosis. Stimulation with TNF alpha was found to result in beta (2) integrin-mediated activation of the cytoplasmic tyrosine kinases Pyk2 and Syk, and activation of a three-part MAPk module composed of MEKK1, MKK7, and/or MKK4 and JNK1. JNK activation was attenuated by blocking antibodies to beta (2) integrins, the tyrosine kinase inhibitors, genistein, and tyrphostin A9, a Pyk2-specific inhibitor, and piceatannol, a Syk-specific inhibitor, Exposure of adherent neutrophils to TNF alpha led to the rapid onset of apoptosis that was demonstrated by augmented annexin V binding and caspase-3 cleavage. TNF alpha -induced increases in annexin V binding to neutrophils were attenuated by blocking antibodies to beta (2) integrins, and the caspase-3 cleavage was attenuated by tyrphostin A9. Hence, exposure of adherent neutrophils to TNF alpha leads to utilization of the JNK-signaling pathways that may contribute to diverse functional responses including induction of apoptosis and subsequent resolution of the inflammatory response.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Cell Biol Program, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Med, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Worthen, GS (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061407, P50HL040784] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61407, HL40784, HL13403] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM E, 1995, J EXP MED, V181, P569, DOI 10.1084/jem.181.2.569; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; Astier A, 1997, J BIOL CHEM, V272, P228; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Berton G, 1996, INT J CLIN LAB RES, V26, P160, DOI 10.1007/BF02592978; Berton G, 1999, CELL SIGNAL, V11, P621, DOI 10.1016/S0898-6568(99)00003-0; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Coffer PJ, 1997, IMMUNOL LETT, V57, P27, DOI 10.1016/S0165-2478(97)00067-9; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; DAPINO P, 1993, CLIN EXP IMMUNOL, V94, P533; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ERZURUM SC, 1991, AM J RESP CELL MOL, V5, P230, DOI 10.1165/ajrcmb/5.3.230; ERZURUM SC, 1992, J IMMUNOL, V149, P154; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Gavin AC, 1997, MOL REPROD DEV, V46, P383, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;383::AID-MRD18&gt;3.0.CO;2-#; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; HENSON PM, 1988, HUMAN INFLAMMATORY D, V1, P69; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LLOYDS D, 1995, IMMUNOLOGY, V84, P220; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Meszaros AJ, 2000, J IMMUNOL, V165, P435, DOI 10.4049/jimmunol.165.1.435; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Mori L, 1996, J IMMUNOL, V157, P3178; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; NATHAN C, 1990, J CELL BIOL, V111, P2171, DOI 10.1083/jcb.111.5.2171; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1989, BLOOD, V73, P301; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; OTTONELLO L, 1994, AGENTS ACTIONS, V41, P57, DOI 10.1007/BF01986395; PARSONS PE, 1992, AM REV RESPIR DIS, V146, P694, DOI 10.1164/ajrccm/146.3.694; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Walzog B, 1997, FASEB J, V11, P1177, DOI 10.1096/fasebj.11.13.9367353; WINDSOR ACJ, 1994, ARCH SURG-CHICAGO, V129, P80; WINDSOR ACJ, 1993, J CLIN INVEST, V91, P1459, DOI 10.1172/JCI116351; Winston BW, 1997, J IMMUNOL, V159, P4491; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WORTHEN GS, 1989, SCIENCE, V245, P183, DOI 10.1126/science.2749255; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; Yan SR, 1999, FEBS LETT, V451, P33, DOI 10.1016/S0014-5793(99)00539-6; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	95	94	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2189	2199		10.1074/jbc.M007527200	http://dx.doi.org/10.1074/jbc.M007527200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11053415	hybrid			2022-12-27	WOS:000166528000073
J	Gong, F; Yanofsky, C				Gong, F; Yanofsky, C			Reproducing tna operon regulation in vitro in an S-30 system - Tryptophan induction inhibits cleavage of TnaC peptidyl-RNA?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTION TERMINATION; ESCHERICHIA-COLI; LEADER PEPTIDE; NUCLEOTIDE-SEQUENCE; EXPRESSION; RHO; RELEASE; BICYCLOMYCIN; TRANSLATION; ATTENUATION	Expression of the tryptophanase (tna) operon of Escherichia coli is regulated by catabolite repression and tryptophan-induced transcription antitermination, Catabolite repression regulates transcription initiation, whereas excess tryptophan induces antitermination at Rho factor-dependent termination sites in the leader region of the operon, Synthesis of the leader peptide, TnaC, is essential for antitermination. BoxA and rut sites in the immediate vicinity of the tnaC stop codon are required for termination. In this paper we use an in vitro S-30 cell-free system to analyze the features of tna operon regulation. We show that transcription initiation is cyclic AMP (cAMP)-dependent and is not influenced by tryptophan, Continuation of transcription beyond the leader region requires the presence of inducing levels of tryptophan and synthesis of the TnaC leader peptide. Using a tnaA'-'trpE fusion, we demonstrate that induction results in a 15-20-fold increase in synthesis of the tryptophan-free TnaA-TrpE fusion protein. Replacing Trp codon 12 of tnaC by an Arg codon, or changing the tnaC start codon to a stop codon, eliminates induction. Addition of bicyclomycin, a specific inhibitor of Rho factor action, substantially increases basal level expression. Analyses of tna mRNA synthesis in vitro demonstrate that, in the absence of inducer transcription is terminated and the terminated transcripts are degraded, In the presence of inducer, antitermination increases the synthesis of the read-through transcript. TnaC synthesis is observed in the cell-free system. However, in the presence of tryptophan, a peptidyl-tRNA also appears, TnaC-tRNA(Pro). Our findings suggest that inducer acts by preventing cleavage of TnaC peptidyl-tRNA The ribosome associated with this newly synthesized peptidyl-tRNA presumably stalls at the tnaC stop codon, blocking Rho's access to the BoxA and rut sites, thereby preventing termination. 1-Methyltryptophan also is an effective inducer in vitro, This tryptophan analog is not incorporated into TnaC.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Yanofsky, C (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	yanofsky@cmgm.stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM009738, R37GM009738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM09738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BILEZIKIAN JP, 1967, J MOL BIOL, V27, P495, DOI 10.1016/0022-2836(67)90054-X; BOTSFORD JL, 1971, J BACTERIOL, V105, P303, DOI 10.1128/JB.105.1.303-312.1971; CAO JH, 1995, J VIROL, V69, P1030, DOI 10.1128/JVI.69.2.1030-1036.1995; Cao JH, 1996, MOL CELL BIOL, V16, P7109; Cao JH, 1998, RNA, V4, P181; DEELEY MC, 1981, J BACTERIOL, V147, P787, DOI 10.1128/JB.147.3.787-796.1981; EDWARDS RM, 1982, BIOCHEM J, V204, P617, DOI 10.1042/bj2040617; GISH K, 1995, J BACTERIOL, V177, P7245, DOI 10.1128/jb.177.24.7245-7254.1995; GOLLNICK P, 1990, J BACTERIOL, V172, P3100, DOI 10.1128/jb.172.6.3100-3107.1990; Hopkins FG, 1903, J PHYSIOL-LONDON, V29, P451; KAMATH AV, 1992, J BIOL CHEM, V267, P19978; KAZARINOFF MN, 1977, J BIOL CHEM, V252, P7598; Konan KV, 1997, J BACTERIOL, V179, P1774, DOI 10.1128/jb.179.5.1774-1779.1997; Konan KV, 1999, J BACTERIOL, V181, P1530, DOI 10.1128/JB.181.5.1530-1536.1999; Konan KV, 2000, J BACTERIOL, V182, P3981, DOI 10.1128/JB.182.14.3981-3988.2000; Lesley S A, 1995, Methods Mol Biol, V37, P265; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; NEWTON WA, 1964, P NATL ACAD SCI USA, V51, P382, DOI 10.1073/pnas.51.3.382; PARK HG, 1995, ARCH BIOCHEM BIOPHYS, V323, P447, DOI 10.1006/abbi.1995.0066; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SQUIRES CL, 1973, NATURE-NEW BIOL, V245, P131, DOI 10.1038/newbio245131a0; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; STEWART V, 1986, J BACTERIOL, V167, P383, DOI 10.1128/jb.167.1.383-386.1986; STEWART V, 1985, J BACTERIOL, V164, P731, DOI 10.1128/JB.164.2.731-740.1985; WATANABE T, 1972, P NATL ACAD SCI USA, V69, P1086, DOI 10.1073/pnas.69.5.1086; WINKLER ME, 1981, BIOCHEMISTRY-US, V20, P3738, DOI 10.1021/bi00516a011; YANOFSKY C, 1995, J BACTERIOL, V177, P4451, DOI 10.1128/jb.177.15.4451-4456.1995; YANOFSKY C, 1994, J BACTERIOL, V176, P6245, DOI 10.1128/jb.176.20.6245-6254.1994; Yanofsky C, 1996, BIOCHIMIE, V78, P1017, DOI 10.1016/S0300-9084(97)86725-9; Yanofsky C, 1996, J BACTERIOL, V178, P3755, DOI 10.1128/jb.178.13.3755-3762.1996; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991; YANOFSKY C, 1999, ENCY MOL BIOL, V4, P2676; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411; ZWIEFKA A, 1993, BIOCHEMISTRY-US, V32, P3564, DOI 10.1021/bi00065a007	36	52	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1974	1983		10.1074/jbc.M008892200	http://dx.doi.org/10.1074/jbc.M008892200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050101	hybrid			2022-12-27	WOS:000166528000046
J	Heldermon, C; DeAngelis, PL; Weigel, PH				Heldermon, C; DeAngelis, PL; Weigel, PH			Topological organization of the hyaluronan synthase from Streptococcus pyogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; INTEGRAL MEMBRANE-PROTEINS; LAC CARRIER PROTEIN; AMINO-ACID-RESIDUES; ESCHERICHIA-COLI; MOLECULAR-CLONING; SYNTHESIZE HYALURONAN; SECONDARY-STRUCTURE; GLOBULAR PROTEINS; GENE FUSIONS	Since we first reported (DeAngelis, P, L,, Papaconstantinou, J,, and Weigel, P, H. (1993) J, Biol. Chem. 268, 19181-19184) the cloning of the hyaluronan (HA) synthase from Streptococcus pyogenes (spHAS), numerous membrane-bound HA synthases have been discovered in both prokaryotes and eukaryotes. The HASs are unique among enzymes studied to date because they mediate 6-7 discrete functions in order to assemble a polysaccharide containing hetero-disaccharide units and simultaneously effect translocation of the growing HA chain through the plasma membrane. To understand how the relatively small spHAS performs these various functions, we investigated the topological organization of the protein utilizing fusion analysis with two reporter enzymes, alkaline phosphatase and beta -galactosidase, as well as several other approaches. From these studies, we conclude that the NH2 terminus and the COOH terminus, as well as the major portion of a large central domain are localized intracellularly, The first two predicted membrane domains were confirmed to be transmembrane domains and give rise to a very small extracellular loop that is inaccessible to proteases, Several regions of the large internal central domain appear to be associated with, but do not traverse, the membrane. Following the central domain, there are two additional transmembrane domains connected by a second small extracellular loop that also is inaccessible to proteases, The COOH-terminal similar to 25% of spHAS also contains a membrane domain that does not traverse the membrane and may contain extensive re-entrant loops or amphipathic helices, Numerous membrane associations of this latter COOH-terminal region and the central domain may be required to create a pore-like structure through which a growing HA chain can be extruded to the cell exterior. Based on the high degree of similarity among Class I HAS family members, these enzymes may have a similar topological organization for their spHAS-related domains.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@OUHSC.edu		Heldermon, Coy/0000-0002-2148-2868	NIGMS NIH HHS [GM35978, GM56497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978, R01GM056497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EVERED D, 1989, CIBA F SYMP, V143, P1; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; FISCHBARG J, 1994, MOL CELL BIOCHEM, V140, P147, DOI 10.1007/BF00926753; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Geller D, 1996, J BIOL CHEM, V271, P13746, DOI 10.1074/jbc.271.23.13746; GOLDKORN T, 1983, P NATL ACAD SCI-BIOL, V80, P3322, DOI 10.1073/pnas.80.11.3322; Haardt M, 1996, J BACTERIOL, V178, P5370, DOI 10.1128/jb.178.18.5370-5381.1996; HERZLINGER D, 1984, BIOCHEMISTRY-US, V23, P3688, DOI 10.1021/bi00311a018; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Huber F, 1996, EUR J BIOCHEM, V239, P810, DOI 10.1111/j.1432-1033.1996.0810u.x; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; Jung H, 1998, J BIOL CHEM, V273, P26400, DOI 10.1074/jbc.273.41.26400; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1967, ACTA OTOLARYNGOL, V442, P7; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; Meyer K, 1934, J BIOL CHEM, V107, P629; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J. H ., 1971, EXPT MOL GENETICS; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; PAGE MGP, 1988, J BIOL CHEM, V263, P15906; Rockey DC, 1998, HEPATOLOGY, V27, P86, DOI 10.1002/hep.510270115; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; ROSE GD, 1978, NATURE, V272, P586, DOI 10.1038/272586a0; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; WHITNACK E, 1981, INFECT IMMUN, V31, P985, DOI 10.1128/IAI.31.3.985-991.1981; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; YUN CH, 1991, J BIOL CHEM, V266, P10967	72	69	79	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2037	2046		10.1074/jbc.M002276200	http://dx.doi.org/10.1074/jbc.M002276200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11024012	hybrid			2022-12-27	WOS:000166528000054
J	Martinez-Maza, R; Poyatos, I; Lopez-Corcuera, B; Nunez, E; Gimenez, C; Zafra, F; Aragon, C				Martinez-Maza, R; Poyatos, I; Lopez-Corcuera, B; Nunez, E; Gimenez, C; Zafra, F; Aragon, C			The role of N-glycosylation in transport to the plasma membrane and sorting of the neuronal glycine transporter GLYT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; CANINE KIDNEY-CELLS; EPITHELIAL-CELLS; RAT-BRAIN; NOREPINEPHRINE TRANSPORTER; SEROTONIN TRANSPORTER; LINKED GLYCOSYLATION; GOLGI-NETWORK; SPINAL-CORD; MOUSE-BRAIN	Glycine transporter GLYT2 is an axonal glycoprotein involved in the removal of glycine from the synaptic cleft. To elucidate the role of the carbohydrate moiety on GLYT2 function, we analyzed the effect of the disruption of the putative N-glycosylation sites on the transport activity, intracellular traffic in COS cells, and asymmetrical distribution of this protein in polarized Madin-Darby canine kidney (MDCK) cells. Transport activity was reduced by 35-40% after enzymatic deglycosylation of the transporter reconstituted into liposomes, Site-directed mutagenesis of the four glycosylation sites (Asn-345, Asn-355, Asn-360, and Asn-366), located in the large extracellular loop of GLYT2, produced an inactive protein that was retained in intracellular compartments when transiently transfected in COS cells or in nonpolarized MDCK cells. When expressed in polarized MDCK cells, wild type GLYT2 localizes in the apical surface as assessed by transport and biotinylation assays. However, a partially unglycosylated mutant (triple mutant) was distributed in a nonpolarized manner in MDCK cells. The apical localization of GLYT2 occurred by a glycolipid rafts independent pathway.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Aragon, C (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain.	caragon@cbm.uam.es	Aragon, Carmen/K-9783-2014; Gimenez, Cecilio/K-8027-2014; Zafra, Francisco/A-6121-2008; Corcuera, Beatriz López/D-5188-2009	Aragon, Carmen/0000-0001-8287-9386; Gimenez, Cecilio/0000-0001-6726-8405; Zafra, Francisco/0000-0003-3801-3109; Corcuera, Beatriz López/0000-0002-0383-4241				Alonso MA, 1997, J BIOL CHEM, V272, P30748, DOI 10.1074/jbc.272.49.30748; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Asano S, 2000, J BIOL CHEM, V275, P8324, DOI 10.1074/jbc.275.12.8324; Bergeron R, 1998, P NATL ACAD SCI USA, V95, P15730, DOI 10.1073/pnas.95.26.15730; BOROWSKY B, 1993, NEURON, V10, P851, DOI 10.1016/0896-6273(93)90201-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CASADO M, 1993, J BIOL CHEM, V268, P27313; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Gahmberg CG, 1996, TRENDS BIOCHEM SCI, V21, P308, DOI 10.1016/0968-0004(96)10034-7; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HAYES G, 1994, J BIOL CHEM, V269, P24143; HIGUCHI E, 1990, PCR PROTOCOLS, P177; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; Jursky F, 1996, J NEUROCHEM, V67, P336; KIM KM, 1994, MOL PHARMACOL, V45, P608; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOPEZCORCUERA B, 1991, J BIOL CHEM, V266, P24809; LOPEZCORCUERA B, 1989, EUR J BIOCHEM, V181, P519, DOI 10.1111/j.1432-1033.1989.tb14754.x; LUQUE JM, 1995, NEUROSCIENCE, V64, P525, DOI 10.1016/0306-4522(94)00404-S; Melikian HE, 1996, MOL PHARMACOL, V50, P266; MINELLI A, 1995, J NEUROSCI, V15, P7734, DOI 10.1523/jneurosci.15-11-07734.1995; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; Nguyen TT, 1996, J NEUROCHEM, V67, P645; Nirenberg MJ, 1997, J NEUROSCI, V17, P6899; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; Ponce J, 1998, NEUROSCI LETT, V242, P25, DOI 10.1016/S0304-3940(98)00037-8; Poyatos I, 2000, MOL CELL NEUROSCI, V15, P99, DOI 10.1006/mcne.1999.0807; Puertollano R, 1999, J CELL BIOL, V145, P141, DOI 10.1083/jcb.145.1.141; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; Spike RC, 1997, NEUROSCIENCE, V77, P543, DOI 10.1016/S0306-4522(96)00501-5; Supplisson S, 1997, J NEUROSCI, V17, P4580; Sur C, 1996, NEUROSCIENCE, V73, P217, DOI 10.1016/0306-4522(96)00030-9; TATE CG, 1994, J BIOL CHEM, V269, P26303; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197; ZAFRA F, 1995, EUR J NEUROSCI, V7, P1342, DOI 10.1111/j.1460-9568.1995.tb01125.x; ZAFRA F, 1995, J NEUROSCI, V15, P3952; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596	53	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2168	2173		10.1074/jbc.M006774200	http://dx.doi.org/10.1074/jbc.M006774200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11036075	hybrid			2022-12-27	WOS:000166528000070
J	Yan, B; Heus, J; Lu, N; Nichols, RC; Raben, N; Plotz, PH				Yan, B; Heus, J; Lu, N; Nichols, RC; Raben, N; Plotz, PH			Transcriptional regulation of the human acid alpha-glucosidase gene - Identification of a repressor element and its transcription factors Hes-1 and YY1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX FACTORS; ACHAETE-SCUTE HOMOLOG-1; CELL FATE; MAMMALIAN HAIRY; NERVOUS-SYSTEM; DROSOPHILA; ENHANCER; SPLIT; DIFFERENTIATION; NOTCH	Acid alpha -glucosidase, the product of a housekeeping gene, is a lysosomal enzyme that degrades glycogen. A deficiency of this enzyme is responsible for a recessively inherited myopathy and cardiomyopathy, glycogenesis type II. We have previously demonstrated that the human acid alpha -glucosidase gene expression is regulated by a silencer within intron 1, which is located in the 5'-untranslated region. In this study, we have used deletion analysis, electrophoretic mobility shift assay, and footprint analysis to further localize the silencer to a 25-base pair element, The repressive effect on the TK promoter was about 50% in both orientations in expression plasmid, and two transcriptional factors were identified with antibodies binding specifically to the element. Mutagenesis and functional analyses of the element demonstrated that the mammalian homologue 1 of Drosophila hairy and Enhancer of split (Hes-l) binding to an E box (CACGCG) and global transcription factor-YY1 binding to its core site function as a transcriptional repressor, Furthermore, the overexpression of Hes-l significantly enhanced the repressive effect of the silencer element. The data should be helpful in understanding the expression and regulation of the human acid alpha -glucosidase gene as well as other lysosomal enzyme genes.	NIAMS, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA; Pharming Technol BV, NL-2333 CA Leiden, Netherlands; Dartmouth Med Sch, Lebanon, NH 03756 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Dartmouth College	Plotz, PH (corresponding author), NIAMS, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA.	plotzp@mail.nih.gov						Antoine M, 1998, BIOCHEM J, V336, P327, DOI 10.1042/bj3360327; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Barolo S, 1997, EMBO J, V16, P2883, DOI 10.1093/emboj/16.10.2883; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HERS HG, 1963, BIOCHEM J, V86, P11, DOI 10.1042/bj0860011; HOEFSLOOT LH, 1990, BIOCHEM J, V272, P493, DOI 10.1042/bj2720493; HUIE ML, 1994, HUM MOL GENET, V3, P2231; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JEFFREY PL, 1970, BIOCHEMISTRY-US, V9, P1403, DOI 10.1021/bi00808a015; JEFFREY PL, 1970, BIOCHEMISTRY-US, V9, P1416, DOI 10.1021/bi00808a016; Jennings BH, 1999, MOL CELL BIOL, V19, P4600; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; LEBLANC B, 1994, DNA PROTEIN INTERACT, P1; MARTINIUK F, 1991, DNA CELL BIOL, V10, P283, DOI 10.1089/dna.1991.10.283; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ponce E, 1999, AM J PATHOL, V154, P1089, DOI 10.1016/S0002-9440(10)65361-8; Raben N, 1996, HUM MOL GENET, V5, P995, DOI 10.1093/hmg/5.7.995; Robey E, 1999, ANNU REV IMMUNOL, V17, P283, DOI 10.1146/annurev.immunol.17.1.283; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; TAYLOR JD, 1994, DNA PROTEIN INTERACT, P263; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729	33	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1789	1793		10.1074/jbc.M005959200	http://dx.doi.org/10.1074/jbc.M005959200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038350	hybrid			2022-12-27	WOS:000166528000020
J	Gijsbers, R; Ceulemans, H; Stalmans, W; Bollen, M				Gijsbers, R; Ceulemans, H; Stalmans, W; Bollen, M			Structural and catalytic similarities between nucleotide pyrophosphatases/phosphodiesterases and alkaline phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; FIBROBLAST GROWTH-FACTOR; MOTILITY-STIMULATING PROTEIN; MEMBRANE GLYCOPROTEIN PC-1; ACTIVE-SITE; 5'-NUCLEOTIDE PHOSPHODIESTERASE; PHOSPHOGLYCERATE MUTASE; CRYSTAL-STRUCTURE; ZINC-BINDING; CELLS	Nucleotide pyrophosphatases/phosphodiesterases (NPPs) generate nucleoside 5'-monophosphates from a variety of nucleotides and their derivatives. Here we show by data base analysis that these enzymes are conserved from eubacteria to higher eukaryotes, We also provide evidence for the existence of two additional members of the mammalian family of ecto-NPPs, Homology searches and alignment-assisted mutagenesis revealed that the catalytic core of NPPs assumes a fold similar to that of a superfamily of phospho-/sulfo-coordinating metalloenzymes comprising alkaline phosphatases, phosphoglycerate mutases, and arysulfatases. Mutation of mouse NPP1 in some of its predicted metal-coordinating residues (D358N or H362Q) or in the catalytic site threonine (T238S) resulted in an enzyme that could still form the nucleotidylated catalytic intermediate but was hampered in the second step of catalysis, We also obtained data indicating that the ability of some mammalian NPPs to auto(de)phosphorylate is due to an intrinsic phosphatase activity, whereby the enzyme phosphorylated on 'Thr-238 represents the covalent intermediate of the phosphatase reaction. The results of site-directed mutagenesis suggested that the nucleotide pyrophosphatase/phosphodiesterase and the phosphatase activities of NPPs are mediated by a single catalytic site.	Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium	KU Leuven	Bollen, M (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	mathieu.bollen@med.kuleuven.ac.be		Ceulemans, Hugo/0000-0002-7059-4399				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andoh K, 1999, BBA-GENE STRUCT EXPR, V1446, P213, DOI 10.1016/S0167-4781(99)00090-1; Belfiore A, 1996, MOL ENDOCRINOL, V10, P1318, DOI 10.1210/me.10.11.1318; BELLI SI, 1993, EUR J BIOCHEM, V217, P421, DOI 10.1111/j.1432-1033.1993.tb18261.x; BELLI SI, 1995, EUR J BIOCHEM, V228, P669, DOI 10.1111/j.1432-1033.1995.tb20308.x; BLYTT HJ, 1985, ANAL BIOCHEM, V147, P517, DOI 10.1016/0003-2697(85)90307-0; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; CULP JS, 1985, J BIOL CHEM, V260, P8320; Deissler H, 1999, FASEB J, V13, P657, DOI 10.1096/fasebj.13.6.657; Galperin MY, 1998, PROTEIN SCI, V7, P1829, DOI 10.1002/pro.5560070819; Goding JW, 2000, J LEUKOCYTE BIOL, V67, P285, DOI 10.1002/jlb.67.3.285; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; GRANA X, 1992, J BIOL CHEM, V267, P12797; GRUPE A, 1995, J BIOL CHEM, V270, P22085, DOI 10.1074/jbc.270.38.22085; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Holtz KM, 1999, J BIOL CHEM, V274, P8351, DOI 10.1074/jbc.274.13.8351; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; Hosoda N, 1999, EUR J BIOCHEM, V265, P763, DOI 10.1046/j.1432-1327.1999.00779.x; Jedrzejas MJ, 2000, EMBO J, V19, P1419, DOI 10.1093/emboj/19.7.1419; Johnson K, 1999, ARTHRITIS RHEUM-US, V42, P1986, DOI 10.1002/1529-0131(199909)42:9<1986::AID-ANR26>3.0.CO;2-O; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; King RD, 2000, PROTEIN ENG, V13, P15, DOI 10.1093/protein/13.1.15; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Lopez-Gomez J, 1998, FEBS LETT, V421, P77, DOI 10.1016/S0014-5793(97)01536-6; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Ma L, 1996, BIOCHEMISTRY-US, V35, P2394, DOI 10.1021/bi9523421; Martin DC, 1999, PROTEIN SCI, V8, P1152, DOI 10.1110/ps.8.5.1152; Meerson NR, 1998, HEPATOLOGY, V27, P563, DOI 10.1002/hep.510270234; MURATA J, 1994, J BIOL CHEM, V269, P30479; Murphy JE, 1997, NAT STRUCT BIOL, V4, P618, DOI 10.1038/nsb0897-618; Nakamura I, 1999, HUM GENET, V104, P492, DOI 10.1007/s004390050993; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; ODA Y, 1993, J BIOL CHEM, V268, P27318; Ouali M, 2000, PROTEIN SCI, V9, P1162, DOI 10.1110/ps.9.6.1162; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; REBBE NF, 1993, MOL IMMUNOL, V30, P87, DOI 10.1016/0161-5890(93)90429-F; Recksiek R, 1998, J BIOL CHEM, V273, P6096, DOI 10.1074/jbc.273.11.6096; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Stec B, 1998, J MOL BIOL, V277, P647, DOI 10.1006/jmbi.1998.1635; Stefan C, 1996, EUR J BIOCHEM, V241, P338, DOI 10.1111/j.1432-1033.1996.00338.x; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TAN AWH, 1979, BIOCHIM BIOPHYS ACTA, V582, P543, DOI 10.1016/0304-4165(79)90146-6; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Tibbitts TT, 1996, J MOL BIOL, V257, P700, DOI 10.1006/jmbi.1996.0195; TIBBITTS TT, 1994, PROTEIN SCI, V3, P2005, DOI 10.1002/pro.5560031113; URIARTE M, 1995, BIOCHEM J, V306, P271, DOI 10.1042/bj3060271; URIARTE M, 1993, BIOCHEM J, V293, P93, DOI 10.1042/bj2930093; XU X, 1992, J BIOL CHEM, V267, P16244; Zimmermann H., 2000, ECTO ATPASES RELATED, P1	58	134	142	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1361	1368		10.1074/jbc.M007552200	http://dx.doi.org/10.1074/jbc.M007552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11027689	hybrid			2022-12-27	WOS:000166430900068
J	Li, J; Saxena, S; Pain, D; Dancis, A				Li, J; Saxena, S; Pain, D; Dancis, A			Adrenodoxin reductase homolog (Arh1p) of yeast mitochondria required for iron homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SULFUR CLUSTER; MOLECULAR-BIOLOGY; ESSENTIAL GENE; PROTEIN; FRATAXIN; DEFICIENCY; ACONITASE; SYSTEM; CODES	Arh1p is an essential mitochondrial protein of yeast with reductase activity. Here we show that this protein is involved in iron metabolism. A yeast strain was constructed in which the open reading frame was placed under the control of a galactose-regulated promoter. Protein expression was induced by galactose and repressed to undetectable levels in the absence of galactose, although cells grew quite well in the absence of inducer. Under noninducing conditions, cellular iron uptake was dysregulated, exhibiting a failure to repress in response to medium iron. Iron trafficking within the cell was also disturbed. Exposure of Arh1p-depleted cells to increasing iron concentrations during growth led to drastic increases in mitochondrial iron, indicating a loss of homeostatic control. Activity of aconitase, a prototype Fe-S protein, was deficient at all concentrations of mitochondrial iron, although the protein level was unaltered, Heme protein deficiencies were exacerbated in the iron-loaded mitochondria, suggesting a toxic side effect of accumulated iron. Finally, a time course correlated the cellular depletion of Arh1p with the coordinated appearance of various mutant phenotypes including dysregulated cellular iron uptake, deficiency of Fe-S protein activities in mitochondria and cytoplasm, and deficiency of hemoproteins. Thus, Arh1p is required for control of cellular and mitochondrial iron levels and for the activities of Fe-S cluster proteins.	Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Dancis, A (corresponding author), Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.	adancis@mail.med.upenn.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053953, R01DK053953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057067] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53953] Funding Source: Medline; NIGMS NIH HHS [GM57067] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Barros MH, 1999, GENE, V233, P197, DOI 10.1016/S0378-1119(99)00137-7; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Brittenham GM, 2000, HEMATOLOGY BASIC PRI, P397; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Freeman MR, 1999, DEVELOPMENT, V126, P4591; Halliwell B., 1991, FREE RADICALS BIOL M; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; KOHLHAW GB, 1988, METHOD ENZYMOL, V166, P423; Lacour T, 1998, J BIOL CHEM, V273, P23984, DOI 10.1074/jbc.273.37.23984; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Manzella L, 1998, YEAST, V14, P839, DOI 10.1002/(SICI)1097-0061(19980630)14:9<839::AID-YEA283>3.0.CO;2-A; Martin H, 1998, ANAL BIOCHEM, V265, P123, DOI 10.1006/abio.1998.2863; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Oyedotun KS, 1999, FEBS LETT, V442, P203, DOI 10.1016/S0014-5793(98)01657-3; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; SIKORSKI RS, 1989, GENETICS, V122, P19; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; Vickery LE, 1997, STEROIDS, V62, P124, DOI 10.1016/S0039-128X(96)00170-5; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	39	101	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1503	1509		10.1074/jbc.M007198200	http://dx.doi.org/10.1074/jbc.M007198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035018	hybrid			2022-12-27	WOS:000166430900086
J	Qin, CL; Cook, RG; Orkiszewski, RS; Butler, WT				Qin, CL; Cook, RG; Orkiszewski, RS; Butler, WT			Identification and characterization of the carboxyl-terminal region of rat dentin sialoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALOPHOSPHOPROTEIN DSPP GENE; IMPERFECTA TYPE-II; SEQUENCE DETERMINATION; MATRIX PROTEINS; PHOSPHOPROTEIN; PHOSPHOPHORYN; ENAMELYSIN; CLEAVAGE; DOMAIN; BONE	Two acidic proteins, dentin sialoprotein (DSP) and dentin phosphoprotein (DPP), are present in the extracellular matrix of dentin but not in bone. These two proteins are expressed in odontoblasts and preameloblasts as a single cDNA transcript coding a large precursor protein termed dentin sialophosphoprotein (DSPP). DSPP is specifically cleaved into two unique proteins, DSP and DPP, However, the cleavage site(s) of DSPP and the mechanisms for regulating the cleavages are unknown. To identify the specific site(s) of DSPP that are cleaved when the initial translation product is converted to DSP and DPP, we performed a detailed analysis (Edman degradation and mass spectrometry) on selected tryptic peptides of a size originating from the COOH-terminal region of rat DSP, After cleavage with trypsin, the DSP fragments were separated by a two-dimensional method (size-exclusion chromatography followed by reversed phase high performance liquid chromatography). We characterized 13 peptides from various regions of DSP, The analyses showed that peptide Il(409)-Tyr(421) was the major COOH-terminal fragment, ending at Tyr(421) only 9 residues from the NH, terminus of DPP, Peptide Gln(385)-His(406) represented a second, minor COOH-terminal peptide that terminated at His(406), Both of these residues are well beyond the COOH terminus predicted previously by two independent studies estimating that rat DSP contained 360-370 amino acids. Careful studies on two peptides showed that, among 9 potential casein kinase II phosphorylation sites, 2 serines were phosphorylated, We found that rat DSP was heterogeneous with respect to phosphorylation, because this same peptide sequence eluted in two discrete peaks, one with 2 phosphoserines and the other having 1. The finding that 3 lysines just preceding the COOH termini were modified by a 43-Da substituent (possibly a carbamoyl substituent) suggests that the lysines in this region were particularly susceptible to attachment of this substituent.	Univ Texas, Hlth Sci Ctr, Dept Basic Sci, Dent Branch, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Prot Chem Core Lab, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine	Qin, CL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Basic Sci, Dent Branch, 6516 John Freeman Ave,DBB,Rm 4-133, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE005092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE005092] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE05092] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		APLIN HM, 1995, GENOMICS, V30, P347, DOI 10.1006/geno.1995.9867; Bartlett JD, 1999, CRIT REV ORAL BIOL M, V10, P425, DOI 10.1177/10454411990100040101; BARTLETT JD, 1996, GENE AMST, V183, P13; Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909-8836.1998.eos106510.x; Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P254, DOI 10.1111/j.1600-0722.1998.tb02184.x; Butler W T, 1995, Connect Tissue Res, V33, P59, DOI 10.3109/03008209509016983; BUTLER WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P178, DOI 10.1016/0003-9861(83)90021-8; BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934-8832(11)80030-2; BUTLER WT, 1995, INT J DEV BIOL, V39, P169; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; BUTLER WT, 1987, METHOD ENZYMOL, V145, P290; Chang SR, 1996, CALCIFIED TISSUE INT, V59, P149, DOI 10.1007/s002239900101; Crosby AH, 1996, MAMM GENOME, V7, P149, DOI 10.1007/s003359900037; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; FUJISAWA R, 1993, J DENT RES, V72, P1222, DOI 10.1177/00220345930720081001; George A, 1998, EUR J ORAL SCI, V106, P221, DOI 10.1111/j.1600-0722.1998.tb02179.x; George A, 1996, J BIOL CHEM, V271, P32869, DOI 10.1074/jbc.271.51.32869; Gu K, 2000, EUR J ORAL SCI, V108, P35, DOI 10.1034/j.1600-0722.2000.00765.x; Li W, 1999, EUR J ORAL SCI, V107, P352, DOI 10.1046/j.0909-8836.1999.eos107506.x; Linde Anders, 1993, Critical Reviews in Oral Biology and Medicine, V4, P679; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1998, EUR J ORAL SCI, V106, P227, DOI 10.1111/j.1600-0722.1998.tb02180.x; Neame PJ, 1996, CONNECT TISSUE RES, V35, P145, DOI 10.3109/03008209609029185; Ritchie HH, 1998, EUR J ORAL SCI, V106, P211, DOI 10.1111/j.1600-0722.1998.tb02178.x; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Ritchie HH, 1996, J BIOL CHEM, V271, P21695, DOI 10.1074/jbc.271.36.21695; Ryu OH, 1999, J DENT RES, V78, P743, DOI 10.1177/00220345990780030601; VEIS A, 1993, J BONE MINER RES, V8, P5493	28	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					904	909		10.1074/jbc.M006271200	http://dx.doi.org/10.1074/jbc.M006271200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042175	hybrid			2022-12-27	WOS:000166430900007
J	Glover, KE; Spencer, DF; Gray, MW				Glover, KE; Spencer, DF; Gray, MW			Identification and structural characterization of nucleus-encoded transfer RNAs imported into wheat mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVERWORT MARCHANTIA-POLYMORPHA; NUCLEOTIDE-SEQUENCE; PLANT-MITOCHONDRIA; PHASEOLUS-VULGARIS; TRANSFER RNAHIS; TRANSFER RNATYR; GENES; DNA; GENOME; ORGANIZATION	Despite its large size (200-2400 kilobase pairs), the mitochondrial genome of angiosperms does not encode the minimal set of tRNAs required to support mitochondrial protein synthesis. Here we report the identification of cytosolic-like tRNAs in wheat mitochondria using a method involving quantitative hybridization to distinguish among three tRNA classes: (i) those encoded by mitochondrial DNA (mtDNA) and localized in mitochondria, (ii) those encoded by nuclear DNA and located in the cytosol, and (iii) those encoded by nuclear DNA and found in both the cytosol and mitochondria. The latter class comprises tRNA species that are considered to be imported into mitochondria to compensate for the deficiency of mtDNA-encoded tRNAs, In a comprehensive survey of the wheat mitochondrial tRNA population, we identified 14 such imported tRNAs, the structural characterization of which is presented here. These imported tRNAs complement 16 mtDNA-encoded tRNAs, for a total of at least 30 distinct tRNA species in wheat mitochondria. Considering differences in the set of mtDNA-encoded and imported tRNAs in the mitochondria of various land plants, the import system must be able to adapt relatively rapidly over evolutionary time with regard to the particular cytosolic-like tRNA that are brought into mitochondria.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Gray, MW (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.			Gray, Michael/0000-0001-7125-2625				Akashi K, 1996, CURR GENET, V30, P181, DOI 10.1007/s002940050118; Akashi K, 1998, NUCLEIC ACIDS RES, V26, P2168, DOI 10.1093/nar/26.9.2168; Akashi K, 1997, BBA-GENE STRUCT EXPR, V1350, P262, DOI 10.1016/S0167-4781(96)00239-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARCISZEWSKA M, 1988, NUCLEIC ACIDS RES, V16, P8175, DOI 10.1093/nar/16.16.8175; BARCISZEWSKA M, 1987, NUCLEIC ACIDS RES, V15, P1333, DOI 10.1093/nar/15.3.1333; BARCISZEWSKA MZ, 1986, BIOCHIMIE, V68, P319, DOI 10.1016/S0300-9084(86)80029-3; BARCISZEWSKA MZ, 1986, PLANT SCI, V47, P103, DOI 10.1016/0168-9452(86)90056-7; Baum M, 1998, NUCLEIC ACIDS RES, V26, P1390, DOI 10.1093/nar/26.6.1390; BEIER H, 1984, EMBO J, V3, P351, DOI 10.1002/j.1460-2075.1984.tb01810.x; BINDER S, 1990, CURR GENET, V17, P353, DOI 10.1007/BF00314884; BONEN L, 1980, NUCLEIC ACIDS RES, V8, P319, DOI 10.1093/nar/8.2.319; BURKARD G, 1982, METHODS CHLOROPLAST, P347; Ceci LR, 1996, DNA SEQUENCE, V6, P159, DOI 10.3109/10425179609010203; CECI LR, 1989, PLANT SCI, V61, P219, DOI 10.1016/0168-9452(89)90228-8; CHANG SH, 1973, BIOCHEM BIOPH RES CO, V51, P951, DOI 10.1016/0006-291X(73)90019-3; Chen HC, 1997, BIOCHEM BIOPH RES CO, V237, P432, DOI 10.1006/bbrc.1997.7138; deBarros JPP, 1996, NUCLEIC ACIDS RES, V24, P1489; DIETRICH A, 1992, ANNU REV CELL BIOL, V8, P115, DOI 10.1146/annurev.cb.08.110192.000555; DUDOCK BS, 1969, J BIOL CHEM, V244, P3069; GAILLARD C, 1990, NUCLEIC ACIDS RES, V18, P378, DOI 10.1093/nar/18.2.378; GELIEBTER J, 1987, FOCUS, V9, P5; GLOVER K, 1995, THESIS DALHOUSIE U H; Gray MW, 1998, NUCLEIC ACIDS RES, V26, P865, DOI 10.1093/nar/26.4.865; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; GREEN GA, 1987, PLANT MOL BIOL, V10, P13, DOI 10.1007/BF00014182; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; IAMS K P, 1985, Plant Molecular Biology, V4, P225, DOI 10.1007/BF02418240; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; JOYCE PBM, 1988, PLANT MOL BIOL, V10, P251, DOI 10.1007/BF00027402; JOYCE PBM, 1989, NUCLEIC ACIDS RES, V17, P7865, DOI 10.1093/nar/17.19.7865; JOYCE PBM, 1989, NUCLEIC ACIDS RES, V17, P5461, DOI 10.1093/nar/17.14.5461; JOYCE PBM, 1989, THESIS DALHOUSIE U H; JUKES TH, 1990, EXPERIENTIA, V46, P1117, DOI 10.1007/BF01936921; Kanno A, 1997, PLANT MOL BIOL, V34, P353, DOI 10.1023/A:1005828728036; Kumar R, 1996, MOL GEN GENET, V252, P404, DOI 10.1007/BF02173005; KUSAMAEGUCHI K, 1991, BIOCHEM BIOPH RES CO, V177, P745, DOI 10.1016/0006-291X(91)91851-3; MARCU K, 1978, NUCLEIC ACIDS RES, V5, P1075, DOI 10.1093/nar/5.4.1075; MARCU KB, 1977, BIOCHEMISTRY-US, V16, P797, DOI 10.1021/bi00623a036; MARECHAL L, 1985, PLANT MOL BIOL, V5, P347, DOI 10.1007/BF00037555; MarechalDrouard L, 1995, METHOD ENZYMOL, V260, P310, DOI 10.1016/0076-6879(95)60148-1; MARECHALDROUARD L, 1988, NUCLEIC ACIDS RES, V16, P4777, DOI 10.1093/nar/16.11.4777; MARECHALDROUARD L, 1990, NUCLEIC ACIDS RES, V18, P3689, DOI 10.1093/nar/18.13.3689; MARECHALDROUARD L, 1993, ANNU REV PLANT PHYS, V44, P13, DOI 10.1146/annurev.pp.44.060193.000305; MARTIN RP, 1990, BIOCHEMISTRY-US, V29, P956, DOI 10.1021/bi00456a016; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; ODA K, 1992, NUCLEIC ACIDS RES, V20, P3773, DOI 10.1093/nar/20.14.3773; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PFITZINGER H, 1990, PLANT MOL BIOL, V14, P805, DOI 10.1007/BF00016513; SANGARE A, 1990, MOL GEN GENET, V223, P224, DOI 10.1007/BF00265058; SCHNARE MN, 1985, CURR GENET, V9, P389, DOI 10.1007/BF00421610; SPENCER DF, 1992, MOD METHOD PLANT, V14, P347; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57; WATANABE N, 1994, CURR GENET, V26, P512, DOI 10.1007/BF00309942; WEBERLOTFI F, 1993, PLANT MOL BIOL, V21, P403, DOI 10.1007/BF00019957; ZEFF RA, 1987, FOCUS, V9, P1	57	48	50	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					639	648		10.1074/jbc.M007708200	http://dx.doi.org/10.1074/jbc.M007708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11027690	hybrid			2022-12-27	WOS:000166280700086
J	Wu, WI; Schwindinger, WF; Aparicio, LF; Levine, MA				Wu, WI; Schwindinger, WF; Aparicio, LF; Levine, MA			Selective resistance to parathyroid hormone caused by a novel uncoupling mutation in the carboxyl terminus of G alpha(s) - A cause of pseudohypoparathyroidism type Ib	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALBRIGHT-HEREDITARY-OSTEODYSTROPHY; GRADIENT GEL-ELECTROPHORESIS; STIMULATORY G-PROTEIN; (PTH)/PTH-RELATED PEPTIDE RECEPTOR; NUCLEOTIDE-BINDING-PROTEIN; HUMAN GNAS1 GENE; ADENYLYL-CYCLASE; ALPHA-SUBUNIT; DEOXYRIBONUCLEIC-ACID; PARENTAL ORIGIN	G(s) is a heterotrimeric (alpha, beta, and gamma chains) G protein that couples heptahelical plasma membrane receptors to stimulation of adenylyl cyclase, Inactivation of one GNAS1 gene allele encoding the a chain of G(s) (G alpha (s)) causes pseudohypoparathyroidism type Ia. Affected subjects have resistance to parathyroid hormone (PTH) and other hormones that activate adenylyl cyclase plus somatic features termed Albright hereditary ostesdystrophy. By contrast, subjects with pseudohspoparathyroidism type Ib have hormone resistance that is limited to PTH and lack Albright hereditary osteodystrophy, The molecular basis for pseudohypoparathyroidism type Ib is unknown. We analyzed the GNAS1 gene for mutations using polymerase chain reaction to amplify genomic DNA from three brothers with pseudohypoparathyroidism type Ib. We identified a novel heterozygous 3-base pair deletion causing loss of isoleucine 382 in the three affected boys and their clinically unaffected mother and maternal grandfather, This mutation was absent in other family members and 15 additional unrelated subjects with pseudohypoparathyroidism type Ib. To characterize the signaling properties of the mutant G alpha (s), we used site-directed mutagenesis to introduce the isoleucine 382 deletion into a wild type G alpha (s) cDNA, transfected HEK293 cells with either wild type or mutant G alpha (s) cDNA, plus cDNAs encoding heptahelical receptors for PTH, thyrotropic hormone, or luteinizing hormone, and we measured cAMP production in response to hormone stimulation. The mutant G alpha (s) protein was unable to interact with the receptor for PTH but showed normal coupling to the other coexpressed heptahelical receptors, These results provide evidence of selective uncoupling of the mutant G alpha (s) from PTH receptors and explain PTH-specific hormone resistance in these three brothers with pseudohypoparathyroidism type Ib. The absence of PTH resistance in the mother and maternal grandfather who carry the same mutation is consistent with current models of paternal imprinting of time GNAS1 gene.	Johns Hopkins Univ, Sch Med, Div Pediat Endocrinol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Ilyssa Ctr Mol & Cellular Endocrinol, Dept Pediat, Baltimore, MD 21287 USA; Metab Dis Associates, Erie, PA 16507 USA	Johns Hopkins University; Johns Hopkins University	Levine, MA (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Endocrinol, Pk Bldg,Rm 211,600 N Wolfe St, Baltimore, MD 21287 USA.			Levine, Michael/0000-0003-0036-7809	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034281] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0035] Funding Source: Medline; NIDDK NIH HHS [DK34281] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS AE, 1995, BIOCHEMISTRY-US, V34, P10553, DOI 10.1021/bi00033a030; ALBRIGHT F, 1952, T ASSOC AM PHYSICIAN, V65, P337; Albright F, 1942, ENDOCRINOLOGY, V30, P922; ALLEN DB, 1988, AM J MED GENET, V31, P153, DOI 10.1002/ajmg.1320310118; Bettoun JD, 1997, J CLIN ENDOCR METAB, V82, P1031, DOI 10.1210/jc.82.4.1031; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BURNSTEIN MI, 1985, RADIOLOGY, V155, P351, DOI 10.1148/radiology.155.2.3983385; CAIN CD, 1987, J BONE MINER RES, V2, P437; CAMPBELL R, 1994, J MED GENET, V31, P607, DOI 10.1136/jmg.31.8.607; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Conklin BR, 1996, MOL PHARMACOL, V50, P885; DAVIES SJ, 1993, J MED GENET, V30, P101, DOI 10.1136/jmg.30.2.101; DEBEUR SMJ, 1998, P END SOC ANN M ABST, P62; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; Fukumoto S, 1996, J CLIN ENDOCR METAB, V81, P2554, DOI 10.1210/jc.81.7.2554; GEJMAN PV, 1991, GENOMICS, V9, P782, DOI 10.1016/0888-7543(91)90377-Q; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P15475, DOI 10.1073/pnas.95.26.15475; Hayward BE, 1998, P NATL ACAD SCI USA, V95, P10038, DOI 10.1073/pnas.95.17.10038; Jobert AS, 1998, J CLIN INVEST, V102, P34, DOI 10.1172/JCI2918; Juppner H, 1998, P NATL ACAD SCI USA, V95, P11798, DOI 10.1073/pnas.95.20.11798; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEVINE MA, 1986, J CLIN ENDOCR METAB, V62, P497, DOI 10.1210/jcem-62-3-497; LEVINE MA, 1983, J CLIN INVEST, V72, P316, DOI 10.1172/JCI110971; Levine MA, 1999, J BONE MINER RES, V14, P1255, DOI 10.1359/jbmr.1999.14.8.1255; LEVINE MA, 1983, AM J MED, V74, P545, DOI 10.1016/0002-9343(83)91008-2; Levine MA, 2000, ENDOCRINOLOGY, P1133; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; Liu J, 2000, MOL CELL BIOL, V20, P5808, DOI 10.1128/MCB.20.16.5808-5817.2000; MIRIC A, 1993, J CLIN ENDOCR METAB, V76, P1560, DOI 10.1210/jc.76.6.1560; MURRAY TM, 1993, J BONE MINER RES, V8, P83; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3111, DOI 10.1093/nar/13.9.3111; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; Nakamoto JM, 1998, AM J MED GENET, V77, P261; Namnoum AB, 1998, J CLIN ENDOCR METAB, V83, P824, DOI 10.1210/jc.83.3.824; NUSYNOWITZ ML, 1976, MEDICINE, V55, P105, DOI 10.1097/00005792-197603000-00001; PANTALONI C, 1993, J RECEPTOR RES, V13, P591, DOI 10.3109/10799899309073681; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PATTEN JL, 1990, J CLIN ENDOCR METAB, V71, P1208, DOI 10.1210/jcem-71-5-1208; RALL T, 1987, FEBS LETT, V224, P365, DOI 10.1016/0014-5793(87)80486-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHIPANI E, 1995, J CLIN ENDOCR METAB, V80, P1611, DOI 10.1210/jc.80.5.1611; SCHWINDINGER WF, 1994, J BIOL CHEM, V269, P25387; SCHWINDINGER WF, 1998, P 80 ANN M END SOC N, P480; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; Spiegel A M, 1990, Biochem Soc Symp, V56, P61; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; SWAROOP A, 1991, NUCLEIC ACIDS RES, V19, P4725, DOI 10.1093/nar/19.17.4725; Warner DR, 1998, J BIOL CHEM, V273, P23976, DOI 10.1074/jbc.273.37.23976; Warner DR, 1997, MOL ENDOCRINOL, V11, P1718, DOI 10.1210/me.11.11.1718; Weinstein LS, 2000, AM J PHYSIOL-RENAL, V278, pF507, DOI 10.1152/ajprenal.2000.278.4.F507; WILSON LC, 1994, J MED GENET, V31, P835, DOI 10.1136/jmg.31.11.835; WINTER JSD, 1980, CAN MED ASSOC J, V123, P26; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715	58	49	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					165	171		10.1074/jbc.M006032200	http://dx.doi.org/10.1074/jbc.M006032200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029463	hybrid			2022-12-27	WOS:000166280700024
J	Hill-Kapturczak, N; Truong, L; Thamilselvan, V; Visner, GA; Nick, HS; Agarwal, A				Hill-Kapturczak, N; Truong, L; Thamilselvan, V; Visner, GA; Nick, HS; Agarwal, A			Smad7-dependent regulation of heme oxygenase-1 by transforming growth factor-beta in human renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; CARBON-MONOXIDE PRODUCTION; NF-KAPPA-B; TGF-BETA; ENDOTHELIAL-CELLS; GENE-EXPRESSION; TUMOR-SUPPRESSOR; MESSENGER-RNA; OXIDATIVE STRESS; PROTEIN	Heme oxygenase-l (HO-1), a 32-kDa microsomal enzyme, is induced as a beneficial and adaptive response in cells/tissues exposed to oxidative stress. Transforming growth factor-beta1 (TGF-beta1) is a regulatory cytokine that has been implicated in a variety of renal diseases where it promotes extracellular matrix deposition and proinflammatory events. We hypothesize that the release of TGF-beta1 via autocrine and/or paracrine pathways may induce HO-1 and serve as a protective response lin renal injury. To understand the molecular mechanism of HO-1 induction by TGF-beta1, we exposed confluent human renal proximal tubule cells to TGF-beta1 and observed a significant induction of HO-1 mRNA at 4 h with a maximal induction at 8 h. This induction was accompanied by increased expression of HO-1 protein. TGF-beta1 treatment in conjunction with actinomycin D or cycloheximide demonstrated that induction of HO-1 mRNA requires de novo transcription and, in part, protein synthesis. Exposure to TGF-beta1 resulted in marked induction of Smad7 mRNA with no effect on Smad6 expression. Overexpression of Smad7, but not Smad6, inhibited TGF-beta1-mediated induction of endogenous HO-1 gene expression. We speculate that the induction of HO-1 in the kidney is an adaptive response to the inflammatory effects of TGF-beta1 and manipulations of the Smad pathway to alter HO-1 expression may serve as a potential therapeutic target.	Univ Florida, Div Nephrol Hypertens & Transplantat, JHMHC, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Div Nephrol Hypertens & Transplantat, Dept Pediat, Gainesville, FL 32610 USA; Univ Florida, Div Nephrol Hypertens & Transplantat, Dept Neurosci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Agarwal, A (corresponding author), Univ Florida, Div Nephrol Hypertens & Transplantat, JHMHC, Dept Med, Box 100224,1600 SW Archer Rd, Gainesville, FL 32610 USA.	agarwal@nersp.nerdc.ufl.edu	Hill-Kapturczak, Nathalie/A-4106-2009		NHLBI NIH HHS [HL39593] Funding Source: Medline; NIDDK NIH HHS [R03DK56279, K08DK02446] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK056279, K08DK002446] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Agarwal A, 1998, J AM SOC NEPHROL, V9, P1990; Agarwal A, 1996, AM J PHYSIOL-RENAL, V271, pF814, DOI 10.1152/ajprenal.1996.271.4.F814; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; BALLA G, 1991, LAB INVEST, V64, P648; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Bitzer M, 2000, GENE DEV, V14, P187; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dechend R, 1999, CIRCULATION, V100, P1369, DOI 10.1161/01.CIR.100.13.1369; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Durante W, 1999, ARTERIOSCL THROM VAS, V19, P2666, DOI 10.1161/01.ATV.19.11.2666; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Engel ME, 1998, J CELL BIOCHEM, P111; Fogg S, 1999, AM J RESP CELL MOL, V20, P797, DOI 10.1165/ajrcmb.20.4.3477; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Han DC, 1999, J AM SOC NEPHROL, V10, P1891; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kays S E, 1996, J Biochem Toxicol, V11, P79; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KUTTY RK, 1994, J CELL PHYSIOL, V159, P371; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Nath KA, 1998, KIDNEY INT, V53, P100, DOI 10.1046/j.1523-1755.1998.00731.x; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Pellacani A, 1998, CIRC RES, V83, P396, DOI 10.1161/01.RES.83.4.396; PHILLIPS AO, 1995, AM J PATHOL, V147, P362; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; Sharma VK, 1996, KIDNEY INT, V49, P1297, DOI 10.1038/ki.1996.185; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Terry CM, 1999, AM J PHYSIOL-HEART C, V276, pH1493, DOI 10.1152/ajpheart.1999.276.5.H1493; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wagner CT, 1997, J CLIN INVEST, V100, P589, DOI 10.1172/JCI119569; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto T, 1996, KIDNEY INT, V49, P461, DOI 10.1038/ki.1996.65; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258	68	82	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40904	40909		10.1074/jbc.M006621200	http://dx.doi.org/10.1074/jbc.M006621200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018038	hybrid			2022-12-27	WOS:000166114600033
J	Biederer, T; Sudhof, TC				Biederer, T; Sudhof, TC			Mints as adaptors - Direct binding to neurexins and recruitment of Munc18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; SYNAPTIC VESICLE EXOCYTOSIS; CELL-SURFACE PROTEINS; EPITHELIAL-CELLS; RECEPTOR; GENE; LOCALIZATION; ADHESION; COMPLEX; DOMAINS	Mint1 (X11/human Lin-10) and Mint2 are neuronal adaptor proteins that bind to Munc18-1 (n/rb-sec1), a protein essential for synaptic vesicle exocytosis. Mint1 has previously been characterized in a complex with CASK, another adaptor protein that in turn interacts with neurexins. Neurexins are neuron-specific cell surface proteins that act as receptors for the excitatory neurotoxin cw-latrotoxin. Hence, one possible function for Mint1 is to mediate the recruitment of Munc18 to neurexins. In agreement with this hypothesis, we now show that the cytoplasmic tail of neurexins captures Munc18 via a multiprotein complex that involves Mint1. Furthermore, we demonstrate that both Mint1 and Mint2 can directly bind to neurexins in a PDZ domain-mediated interaction. Various Mint and/or CASK-containing complexes can be assembled on neurexins, and we demonstrate that Mint1 can bind to Munc18 and CASK simultaneously. Our data support a model whereby one of the functions of Mints is to localize the vesicle fusion protein Munc18 to those sites at the plasma membrane that are defined by neurexins, presumably in the vicinity of points of exocytosis.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Biederer, T (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Biederer, Thomas/AAZ-6133-2021	Biederer, Thomas/0000-0003-0912-1514				Blanco G, 1998, MAMM GENOME, V9, P473, DOI 10.1007/s003359900800; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cowburn D, 1997, CURR OPIN STRUC BIOL, V7, P835, DOI 10.1016/S0959-440X(97)80155-8; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; Hata Y, 1996, J NEUROSCI, V16, P2488; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Okamoto M, 2000, EUR J NEUROSCI, V12, P3067, DOI 10.1046/j.1460-9568.2000.00200.x; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Okamoto M, 1998, EUR J CELL BIOL, V77, P161, DOI 10.1016/S0171-9335(98)80103-9; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V255, P663, DOI 10.1006/bbrc.1999.0265; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087	22	182	190	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39803	39806		10.1074/jbc.C000656200	http://dx.doi.org/10.1074/jbc.C000656200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11036064	hybrid			2022-12-27	WOS:000166039500001
J	Dean, G; Young, DA; Edwards, DR; Clark, IM				Dean, G; Young, DA; Edwards, DR; Clark, IM			The human tissue inhibitor of metalloproteinases (TIMP)-1 gene contains repressive elements within the promoter and intron 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; TRANSCRIPTION FACTORS; BINDING-SITE; SP-FAMILY; EXPRESSION; FIBROBLASTS; ACTIVATION; DOMAINS; TIMP-1	Expression of the TIMP-1 (tissue inhibitor of metalloproteinases-l) gene is tightly controlled during embryonic development and in the adult animal, Previous studies have focused on elements within the gene promoter which activate transcription of the gene. Here, we identify two regions of the gene which repress transcription: An element upstream of the basal gene promoter at -1718/-1458, represses expression of a reporter gene by approximately 50%; addition of the first intron to any promoter-reporter construct also strongly represses gene expression. The TIMP-1 gene has a short first exon which is transcribed but not translated, with the translation start site located in exon 2, Deletion analysis through intron 1 reveals a number of potential regions which might mediate its effect. Protein binding studies and mutational analyses reveal that a repressive element at +684/+748 binds Sp1, Sp3, and an unidentified Ets-related factor to suppress transcription.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Clark, IM (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	i.clark@uea.ac.uk	Edwards, Dylan R/B-4734-2009; Clark, Ian M/D-1920-2009; Young, David/GOV-5677-2022	Edwards, Dylan R/0000-0002-3292-2064; Young, David/0000-0002-7078-6745				Bornstein P, 1996, MATRIX BIOL, V15, P3, DOI 10.1016/S0945-053X(96)90121-3; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Edwards DR, 2000, CANC DRUG DISC DEV, P67; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KRISTIE TM, 1986, P NATL ACAD SCI USA, V83, P4700, DOI 10.1073/pnas.83.13.4700; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LOTZ M, 1991, J BIOL CHEM, V266, P2017; MAIER R, 1993, J BIOL CHEM, V268, P21527; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; SATO T, 1990, BIOCHEM BIOPH RES CO, V170, P824, DOI 10.1016/0006-291X(90)92165-V; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; VANSANT G, 1995, P NATL ACAD SCI USA, V92, P8229, DOI 10.1073/pnas.92.18.8229; Woessner JF, 1999, ANN NY ACAD SCI, V878, P388, DOI 10.1111/j.1749-6632.1999.tb07697.x	23	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32664	32671		10.1074/jbc.275.42.32664	http://dx.doi.org/10.1074/jbc.275.42.32664			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	11032844	hybrid			2022-12-27	WOS:000090003800041
J	Mercuri, FA; Maciewicz, RA; Tart, J; Last, K; Fosang, AJ				Mercuri, FA; Maciewicz, RA; Tart, J; Last, K; Fosang, AJ			Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns - Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL COLLAGENASE MMP-8; HUMAN ARTICULAR-CARTILAGE; ANTIGEN-INDUCED ARTHRITIS; HUMAN SYNOVIAL-FLUID; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; TERMINAL DOMAIN; ADAMTS FAMILY; CATHEPSIN-B; DEGRADATION	We have expressed G1-G2 mutants with amino acid changes at the DIPEN(341)down arrow (342)FFGVG and ITEGE(373)down arrow (374)-ARGSV cleavage sites, in order to investigate the relationship between matrix metalloproteinase (MMP) and aggrecanase activities in the interglobular domain (IGD) of aggrecan. The mutation DIPEN341 to DIGSA(341) partially blocked cleavage by MMP-13 and MMP-8 at the MMP site, while the mutation (342)FFGVG to (342)GTRVG; completely blocked cleavage at this site by MMP-1, -2, -3, -7, -8, -9, -13, -14. Each of the MMP cleavage site mutants, including a four-amino acid deletion mutant lacking residues ENFF343, were efficiently cleaved by aggrecanase, suggesting that the primary sequence at the MMP site had no effect on aggrecanase activity in the IGD. The mutation (374)ARGSV to (NVYSV)-N-374 completely blocked cleavage at the aggrecanase site by aggrecanase, MMP-8 and atrolysin C but had no effect on the ability of MMP-8 and MMP-13 to cleave at the Asn(341)down arrow Phe bond. Susceptibility to atrolysin C cleavage at the MMP site was conferred in the DIGSA(341) mutant but absent in the wildtype, (342)GTRVG, (NVYSV)-N-374, and deletion mutants. To further explore the relationship between MMP and aggrecanase activities, sequential digest experiments were done in which MMP degradation products were subsequently digested with aggrecanase and vice versa. Aggrecanase-derived G1 domains with ITEGE(373) C termini were viable substrates for MMPs; however, MMP-derived G2 fragments were resistant to cleavage by aggrecanase. A 10-mer peptide FVDIPENFFG, which is a substrate analogue for the MMP cleavage site, inhibited aggrecanase cleavage at the Glu(373)down arrow Ala bond. This study demonstrates that MMPs and aggrecanase have unique substrate recognition in the IGD of aggrecan and suggests that sequences at the C terminus of the DIPEN341 G1 domain may be important for regulating aggrecanase cleavage.	Univ Melbourne, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; AstraZeneca, Resp & Inflammat Res Dept, Macclesfield SK10 4TG, Cheshire, England	University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; AstraZeneca	Fosang, AJ (corresponding author), Univ Melbourne, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia.	fosang@cryptic.rch.unimelb.edu.au		Last, Karena/0000-0002-4396-8404; Fosang, Amanda/0000-0002-5523-5427; Mercuri, Francesca/0000-0003-1026-2672				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 1999, ANN NY ACAD SCI, V878, P92, DOI 10.1111/j.1749-6632.1999.tb07676.x; Arner EC, 1997, J BIOL CHEM, V272, P9294; Dodge GR, 1998, ARTHRITIS RHEUM-US, V41, P274; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; Fosang AJ, 2000, J BIOL CHEM, V275, P33027, DOI 10.1074/jbc.M910207199; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; FOSANG AJ, 1998, T ORTHOP RES SOC, V23, P3; FOSANG AJ, 1999, METALLOPROTEINS TARG; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; ILIC MZ, 1995, ARCH BIOCHEM BIOPHYS, V322, P22, DOI 10.1006/abbi.1995.1431; Ilic MZ, 1998, J BIOL CHEM, V273, P17451, DOI 10.1074/jbc.273.28.17451; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Lark MW, 1995, ACTA ORTHOP SCAND, V66, P92, DOI 10.3109/17453679509157660; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; Lohmander LS, 1995, ACTA ORTHOP SCAND, V66, P84; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Mercuri FA, 1999, J BIOL CHEM, V274, P32387, DOI 10.1074/jbc.274.45.32387; Mort JS, 1998, BIOCHEM J, V335, P491, DOI 10.1042/bj3350491; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olszewski J, 1996, ARTHRITIS RHEUM, V39, P1234, DOI 10.1002/art.1780390724; Parks WC, 1998, BIOL EXTRAC, P263; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Singer II, 1997, OSTEOARTHR CARTILAGE, V5, P407, DOI 10.1016/S1063-4584(97)80045-3; SINGER II, 1995, J CLIN INVEST, V95, P2178, DOI 10.1172/JCI117907; Sztrolovics R, 1997, BIOCHEM J, V326, P235, DOI 10.1042/bj3260235; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Tortorella MD, 1998, J BIOL CHEM, V273, P5846, DOI 10.1074/jbc.273.10.5846; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; van Meurs J, 1999, ARTHRITIS RHEUM-US, V42, P2074, DOI 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5; van Meurs JBJ, 1998, ARTHRITIS RHEUM, V41, P647, DOI 10.1002/1529-0131(199804)41:4<647::AID-ART11>3.0.CO;2-T; van Meurs JBJ, 1999, ANN RHEUM DIS, V58, P350, DOI 10.1136/ard.58.6.350; van Meurs JBJ, 1999, ARTHRITIS RHEUM, V42, P1128, DOI 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179	55	43	46	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					33038	33045		10.1074/jbc.275.42.33038	http://dx.doi.org/10.1074/jbc.275.42.33038			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	11032846	hybrid			2022-12-27	WOS:000090003800090
J	Price, AC; Choi, KH; Heath, RJ; Li, ZM; White, SW; Rock, CO				Price, AC; Choi, KH; Heath, RJ; Li, ZM; White, SW; Rock, CO			Inhibition of beta-ketoacyl-acyl carrier protein syntheses by thiolactomycin and cerulenin - Structure and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHESIS; SYNTHASE III FABH; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ANTIBIOTIC CERULENIN; THERMAL REGULATION; CONDENSING ENZYMES; TARGET; OVERPRODUCTION; BINDING	The beta -ketoacyl-acyl carrier protein (ACP) synthases are key regulators of type II fatty acid synthesis and are the targets for two natural products, thiolactomycin (TLM) and cerulenin. The high resolution structures of the FabB-TLM and FabB-cerulenin binary complexes were determined. TLM mimics malonyl-ACP in the FabB active site. It forms strong hydrogen bond interactions with the two catalytic histidines, and the unsaturated alkyl side chain interaction with a small hydrophobic pocket is stabilized by pi stacking interactions. Cerulenin binding mimics the condensation transition state. The subtle differences between the FabB-cerulenin and FabF-cerulenin (Moche, M., Schneider, G., Edwards, P., Dehesh, K., and Lindqvist, Y. (1999) J. Biol. Chem. 244, 6031-6034) structures explain the differences in the sensitivity of the two enzymes to the antibiotic and may reflect the distinct substrate specificities that differentiate the two enzymes. The FabB[H333N] protein was prepared to convert the FabB His-His Cys active site triad into the FabH His-Asn-Cys configuration to test the importance of the two His residues in TLM and cerulenin binding. FabB[H333N] was significantly more resistant to both antibiotics than FabB and had an affinity for TLM an order of magnitude less than the wild-type enzyme, illustrating that the two-histidine active site architecture is critical to protein-antibiotic interaction. These data provide a structural framework for understanding antibiotic sensitivity within this group of enzymes.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	charles.rock@stjude.org	White, Stephen W/N-8164-2018	Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM44973, GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P1604, DOI 10.1021/bi00405a032; ARIMURA N, 1993, ARCH MICROBIOL, V160, P158, DOI 10.1007/BF00288719; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; BUTTKE TM, 1978, BIOCHEMISTRY-US, V17, P5282, DOI 10.1021/bi00617a031; Choi KH, 2000, J BIOL CHEM, V275, P28201; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Cronan J.E., 1996, BIOSYNTHESIS MEMBRAN, V2nd, P612; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DAGNOLO G, 1975, J BIOL CHEM, V250, P5289; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; DEMENDOZA D, 1983, TRENDS BIOCHEM SCI, V8, P49, DOI 10.1016/0968-0004(83)90388-2; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; HAMADA S, 1990, ORAL MICROBIOL IMMUN, V5, P340, DOI 10.1111/j.1399-302X.1990.tb00438.x; HAYASHI T, 1984, J ANTIBIOT, V37, P1456, DOI 10.7164/antibiotics.37.1456; HAYASHI T, 1983, BIOCHEM BIOPH RES CO, V115, P1108, DOI 10.1016/S0006-291X(83)80050-3; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; Jones AL, 2000, BIOCHEM J, V347, P205, DOI 10.1042/0264-6021:3470205; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KAWAGUCHI A, 1982, J BIOCHEM-TOKYO, V92, P7, DOI 10.1093/oxfordjournals.jbchem.a133933; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MIYAKAWA S, 1982, J ANTIBIOT, V35, P411, DOI 10.7164/antibiotics.35.411; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Morita YS, 2000, SCIENCE, V288, P140, DOI 10.1126/science.288.5463.140; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NOTO T, 1982, J ANTIBIOT, V35, P401, DOI 10.7164/antibiotics.35.401; Olsen JG, 1999, FEBS LETT, V460, P46, DOI 10.1016/S0014-5793(99)01303-4; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; Omura S, 1981, Methods Enzymol, V72, P520; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; Rock C O, 1981, Methods Enzymol, V72, P397; ROCK CO, 1979, J BIOL CHEM, V254, P7123; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; ROSENFELD IS, 1973, J BIOL CHEM, V248, P2452; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Subrahmanyam S, 1998, J BACTERIOL, V180, P4596, DOI 10.1128/JB.180.17.4596-4602.1998; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; TSAY JT, 1992, J BIOL CHEM, V267, P6807; Val D, 2000, STRUCT FOLD DES, V8, P565, DOI 10.1016/S0969-2126(00)00146-5; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352	59	281	292	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6551	6559		10.1074/jbc.M007101200	http://dx.doi.org/10.1074/jbc.M007101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11050088	hybrid			2022-12-27	WOS:000167261000065
J	Qiu, JZ; Li, XW; Frank, G; Shen, BH				Qiu, JZ; Li, XW; Frank, G; Shen, BH			Cell cycle-dependent and DNA damage-inducible nuclear localization of FEN-1 nuclease is consistent with its dual functions in DNA replication and repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FLAP ENDONUCLEASE-1; NUCLEOTIDE EXCISION-REPAIR; B TRANSCRIPTION FACTOR; STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; TARGETING SEQUENCES; PROTEIN-TRANSPORT; IN-VITRO	Flap endonuclease-1 (FEN-1), a 43-kDa protein, is a structure-specific and multifunctional nuclease. It plays important roles in RNA primer removal of Okazaki fragments during DNA replication, DNA base excision repair, and maintenance of genome stability. Three functional motifs of the enzyme were proposed to be responsible for its nuclease activities, interaction with proliferating cell nuclear antigen, and nuclear localization. In this study, we demonstrate in HeLa cells that a signal located at the C terminus (the nuclear localization signal (NLS) motif) facilitates nuclear localization of the enzyme during S phase of the cell cycle and in response to DNA damage. Truncation of the NLS motif prevents migration of the protein from the cytoplasm to the nucleus, while having no effect on the nuclease activities and its proliferating cell nuclear antigen interaction capability. Site-directed mutagenesis further revealed that a mutation of the KRK cluster to three alanine residues completely blocked the localization of FEN-1 into the nucleus, whereas mutagenesis of the KKK cluster led to a partial defect of nuclear localization in HeLa cells without observable phenotype in yeast. Therefore, the KRKXYXXYXYXKKK motif may be a bipartite NLS driving the protein into nuclei. Yeast RAD27 Delta cells transformed with human mutant M-krk survived poorly upon methyl methanesulfonate treatment or when they were incubated at an elevated temperature.	City Hope Natl Med Ctr, Dept Cell & Tumor Biol, Duarte, CA 91010 USA	City of Hope	Shen, BH (corresponding author), City Hope Natl Med Ctr, Dept Cell & Tumor Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.			Shen, Binghui/0000-0002-4408-407X	NCI NIH HHS [CA 73764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073764, R01CA073764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN J, 1996, GENE TRANSCRIPTION D, P140; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Boulikas T, 1997, ANTICANCER RES, V17, P843; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Frank G, 1998, J BIOL CHEM, V273, P33064, DOI 10.1074/jbc.273.49.33064; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRIEDBERG EC, 1992, TRENDS BIOCHEM SCI, V17, P347, DOI 10.1016/0968-0004(92)90312-W; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Knauf JA, 1996, MUTAT RES-DNA REPAIR, V363, P67, DOI 10.1016/0921-8777(95)00062-3; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; PETERSEN LN, 1995, MOL CELL BIOL, V15, P3731; Qiu JZ, 1999, MOL CELL BIOL, V19, P8361, DOI 10.1128/mcb.19.12.8361; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Sherman F., 1986, METHODS YEAST GENETI; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TISHKOFF DX, 1997, CELL, V88, P263; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WHITESIDE ST, 1993, J CELL SCI, V104, P949; Yoneda Y, 1997, J BIOCHEM, V121, P811	53	55	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4901	4908		10.1074/jbc.M007825200	http://dx.doi.org/10.1074/jbc.M007825200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11053418	hybrid			2022-12-27	WOS:000168484300052
J	Palacios, S; Lalioti, V; Martinez-Arca, S; Chattopadhyay, S; Sandoval, IV				Palacios, S; Lalioti, V; Martinez-Arca, S; Chattopadhyay, S; Sandoval, IV			Recycling of the insulin-sensitive glucose transporter GLUT4 - Access of surface internalized GLUT4 molecules to the perinuclear storage compartment is mediated by the Phe(5)-Gln(6)-Gln(7)-Ile(8) MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR TRAFFICKING KINETICS; INTEGRAL MEMBRANE-PROTEINS; GTP-BINDING-PROTEINS; RAT SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; TRANSFERRIN RECEPTOR; GOLGI-APPARATUS; CELLS; LOCALIZATION; TRANSLOCATION	The insulin-sensitive glucose transporter GLUT4 is translocated to the plasma membrane in response to insulin and recycled back to the intracellular store(s) after removal of the hormone. We have used clonal 3T3-L1 fibroblasts and adipocyte-like cells stably expressing wild-type GLUT4 to characterize (a) the intracellular compartment where the bulk of GLUT4 is intracellularly stored and (b) the mechanisms involved in the recycling of endocytosed GLUT4 to the store compartment. Surface internalized GLUT4 is targeted to a large, flat, fenestrated saccular structure resistant to brefeldin A that localized to the vicinity of the Golgi complex is sealed to endocytosed transferrin (GLUT4 storage compartment). Recycling of endocytosed GLUT4 was studied by comparing the cellular distributions of anti-body/biotin tagged GLUT4 and GLUT4(Ser(5)), a mutant with the Phe(5)-Gln(6)-Gln(7)-Ile(8) inactivated by the substitution of Ser for Phe(5). Ablation of the Phe(5)-Gln(6)-Gln(7)-Ile(8) inhibits the recycling of endocytosed GLUT4 to the GLUT4 store compartment and results in its transport to late endosomes/lysosomes where it is rapidly degraded.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Sandoval, IV (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Mol Biol, E-28049 Madrid, Spain.			LALIOTI, VASILIKI/0000-0002-4273-6126				ALCALDE J, 1992, J CELL BIOL, V116, P69, DOI 10.1083/jcb.116.1.69; ALEDO JC, 1995, BIOCHEM BIOPH RES CO, V215, P321, DOI 10.1006/bbrc.1995.2469; Apelt J, 1999, J NEUROSCI RES, V57, P693, DOI 10.1002/(SICI)1097-4547(19990901)57:5<693::AID-JNR11>3.0.CO;2-X; Araki S, 1996, BIOCHEM J, V315, P153, DOI 10.1042/bj3150153; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Cormont M, 1996, MOL CELL BIOL, V16, P6879; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; Courtoy P J, 1988, Prog Clin Biol Res, V270, P169; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; El Messari S, 1998, J COMP NEUROL, V399, P492, DOI 10.1002/(SICI)1096-9861(19981005)399:4<492::AID-CNE4>3.0.CO;2-X; El-Jack AK, 1999, MOL BIOL CELL, V10, P1581, DOI 10.1091/mbc.10.5.1581; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HUDSON AW, 1993, J CELL BIOL, V122, P579, DOI 10.1083/jcb.122.3.579; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; Kobayashi M, 1996, NEUROSCI LETT, V213, P103, DOI 10.1016/0304-3940(96)12845-7; Koumanov F, 1998, BIOCHEM J, V330, P1209, DOI 10.1042/bj3301209; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; Leloup C, 1996, MOL BRAIN RES, V38, P45, DOI 10.1016/0169-328X(95)00306-D; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; McCall AL, 1997, BRAIN RES, V744, P318, DOI 10.1016/S0006-8993(96)01122-5; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; Ralston E, 1996, J CELL SCI, V109, P2967; RAMBOURG A, 1986, AM J ANAT, V176, P393, DOI 10.1002/aja.1001760403; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Thurmond DC, 2000, EMBO J, V19, P3565, DOI 10.1093/emboj/19.14.3565; UPHUES I, 1994, BIOCHEM J, V301, P177, DOI 10.1042/bj3010177; Vannucci SJ, 1998, BRAIN RES, V797, P1, DOI 10.1016/S0006-8993(98)00103-6; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Vollenweider P, 1997, ENDOCRINOLOGY, V138, P4941, DOI 10.1210/en.138.11.4941; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; YANG J, 1993, J BIOL CHEM, V268, P4600; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	59	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3371	3383		10.1074/jbc.M006739200	http://dx.doi.org/10.1074/jbc.M006739200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11031262	hybrid			2022-12-27	WOS:000166784900052
J	Zhang, M; Dwyer, NK; Neufeld, EB; Love, DC; Cooney, A; Comly, M; Patel, S; Watari, H; Strauss, JF; Pentchev, PG; Hanover, JA; Blanchette-Mackie, EJ				Zhang, M; Dwyer, NK; Neufeld, EB; Love, DC; Cooney, A; Comly, M; Patel, S; Watari, H; Strauss, JF; Pentchev, PG; Hanover, JA; Blanchette-Mackie, EJ			Sterol-modulated glycolipid sorting occurs in Niemann-Pick C1 late endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MANNOSE 6-PHOSPHATE RECEPTOR; CHOLESTEROL STORAGE; PRELYSOSOMAL COMPARTMENT; ENDOCYTIC PATHWAY; ONE SET; DISEASE; TRANSPORT; ACCUMULATION; FIBROBLASTS	The Niemann-Pick C1 (NPC1) protein and endocytosed low density lipoprotein (LDL)-derived cholesterol were shown to enrich separate subsets of vesicles containing lysosomal associated membrane protein 2, Localization of Rab7 in the NPC1-containing vesicles and enrichment of lysosomal hydrolases in the cholesterol-containing vesicles confirmed that these organelles were late endosomes and lysosomes, respectively. Lyso-bisphosphatidic acid, a lipid marker of the late endosomal pathway, was found in the cholesterol-enriched lysosomes, Recruitment of NPC1 to Rab7 compartments was stimulated by cellular uptake of cholesterol, The NPC1 compartment was shown to be enriched ill glyco lipids, and internalization of GalNAc beta1-4[NeuAc alpha2-3]Gal beta1-4Glc beta1-1'-ceramide (G(M2)) into endocytic vesicles depends on the presence of NPC1 protein. The glycolipid profiles of the NPC1 compartment could be modulated by LDL uptake and accumulation of lysosomal cholesterol, Expression in cells of biologically active NPC1 protein fused to green fluorescent protein revealed rapidly moving and flexible tubular extensions emanating from the NPC1-containing vesicles. We conclude that the NPC1 compartment is a dynamic, sterol-modulated sorting organelle involved in the trafficking of plasma membrane-derived glycolipids as well as plasma membrane and endocytosed LDL cholesterol,	NINDK, Lipid Cell Biol Sect, NIH, Bethesda, MD 20892 USA; NINDK, Cell Biochem Sect, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA; NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA; Vet Affairs Med Ctr, Neurol Res Lab, Newington, CT 06111 USA; Univ Penn, Ctr Res & Reprod & Womens Hlth, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Pennsylvania; Pennsylvania Medicine	Blanchette-Mackie, EJ (corresponding author), NINDK, Lipid Cell Biol Sect, NIH, Bldg 8,Rm 427,MSC 0850, Bethesda, MD 20892 USA.		Neufeld, Edward/R-3819-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060003, Z01DK060000, Z01DK060001, ZIADK060003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANSAL R, 1992, J NEUROSCI RES, V32, P309, DOI 10.1002/jnr.490320303; Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; Blanchette-Mackie EJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P53; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; CARSTEA ED, 1997, SCIENCE, V277, P288; COXEY RA, 1993, J LIPID RES, V34, P1165; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FISHMAN PH, 1977, BIOCHEMISTRY-US, V16, P1871, DOI 10.1021/bi00628a017; GHOSH RN, 1994, J CELL SCI, V107, P2177; GRIFFITHS G, 1990, J CELL SCI, V95, P441; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Hirst J, 1998, MOL BIOL CELL, V9, P809, DOI 10.1091/mbc.9.4.809; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KOTANI M, 1992, BIOCHIM BIOPHYS ACTA, V1117, P97, DOI 10.1016/0304-4165(92)90168-T; KOTANI M, 1994, ARCH BIOCHEM BIOPHYS, V310, P89, DOI 10.1006/abbi.1994.1144; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Patel RC, 1997, PROTEIN ENG, V10, P621, DOI 10.1093/protein/10.6.621; PATERSON MC, 2001, METABOLIC MOL BASIS, P3611; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; PROIA RL, 1988, P NATL ACAD SCI USA, V85, P1883, DOI 10.1073/pnas.85.6.1883; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SOKOL J, 1988, J BIOL CHEM, V263, P3411; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Suresh S, 1998, J NEUROCHEM, V70, P242; Vanier MT, 1996, AM J HUM GENET, V58, P118; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; Watari H, 1999, J BIOL CHEM, V274, P21861, DOI 10.1074/jbc.274.31.21861	34	92	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3417	3425		10.1074/jbc.M005393200	http://dx.doi.org/10.1074/jbc.M005393200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11032830	hybrid			2022-12-27	WOS:000166784900057
J	Mehrani, T; Wu, KC; Morasso, MI; Bryan, JT; Marekov, LN; Parry, DAD; Steinert, PM				Mehrani, T; Wu, KC; Morasso, MI; Bryan, JT; Marekov, LN; Parry, DAD; Steinert, PM			Residues in the 1A rod domain segment and the linker L2 are required for stabilizing the A(11) molecular alignment mode in keratin intermediate filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL; CROSS-LINKING; II KERATINS; EXPRESSION; DISEASE; HETERODIMER; MECHANISM; DISTINCT; PROTEINS; INVITRO	Both analyses of x-ray diffraction patterns of well oriented specimens of trichocyte keratin intermediate filaments (IF) and in vitro cross-linking experiments on several types of IF have documented that there are three modes of alignment of pairs of antiparallel molecules in all IF: A(11), A(22), and A(12), based on which parts of the major rod domain segments are overlapped. Here we have examined which residues may be important for stabilizing the A(11) mode. Using the K5/R14 system, we have made point mutations of charged residues along the chains and examined the propensities of equimolar mixtures of wild type and mutant chains to reassemble using as criteria: the formation (or not) of IF in vitro or in vivo; and stabilities of one- and two-molecule assemblies. We identified that the conserved residue Arg(10) of the 1A rod domain, and the conserved residues Glu(4) and Glu(6) of the linker L2, were essential for stability. Additionally, conserved residues Lys(31) of 1A and Asp(1) of 2A and non-conserved residues Asp/Asn(9) of 1A, Asp/Asn(3) of 2A, and Asp(7) of L2 are important for stability. Notably, these groups of residues lie close to each other when two antiparallel molecules are aligned in the A(11) mode, and are located toward the ends of the overlap region. Although other sets of residues might theoretically also contribute, we conclude that these residues in particular engage in favorable intermolecular ionic and/or H-bonding interactions and thereby may play a role in stabilizing the A(11) mode of alignment in keratin IF.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Massey University	Steinert, PM (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 6,Rm 425, Bethesda, MD 20892 USA.			Bryan, Janine/0000-0002-4923-6247	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041084] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; Candi E, 1998, P NATL ACAD SCI USA, V95, P2067, DOI 10.1073/pnas.95.5.2067; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; Fradette J, 1998, J BIOL CHEM, V273, P35176, DOI 10.1074/jbc.273.52.35176; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; Parry DAD, 1999, Q REV BIOPHYS, V32, P99, DOI 10.1017/S0033583500003516; PARRY DAD, 1995, INTERMEDIATE FILAMEM; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1993, BIOCHEMISTRY-US, V32, P10046, DOI 10.1021/bi00089a021; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; Steinert PM, 1999, J BIOL CHEM, V274, P1657, DOI 10.1074/jbc.274.3.1657; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1991, J STRUCT BIOL, V107, P157, DOI 10.1016/1047-8477(91)90019-S; STEINERT PM, 1998, MOL BIOL CELL, V11, P3539; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; Wang H, 1999, J INVEST DERMATOL, V112, P619; Wawersik M, 1997, J BIOL CHEM, V272, P32557, DOI 10.1074/jbc.272.51.32557; Windoffer R, 1999, J CELL SCI, V112, P4521	23	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2088	2097		10.1074/jbc.M007260200	http://dx.doi.org/10.1074/jbc.M007260200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11022041	hybrid			2022-12-27	WOS:000166528000061
J	Remy, JJ; Nespoulous, C; Grosclaude, J; Grebert, D; Couture, L; Pajot, E; Salesse, R				Remy, JJ; Nespoulous, C; Grosclaude, J; Grebert, D; Couture, L; Pajot, E; Salesse, R			Purification and structural analysis of a soluble human chorionogonadotropin hormone-receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HIGH-LEVEL EXPRESSION; LEUCINE-RICH REPEATS; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; LH RECEPTOR; PROTEIN; BINDING; CHORIOGONADOTROPIN; CELLS	Receptors for the luteotropin/human chorionogonadotropin hormone belong to the G-protein-coupled receptor family by their membrane-anchoring domains. They also possess a large extracellular domain (ECD) responsible for most of the hormone-receptor interactions. Structure-function studies identified several contacts between hormone and receptor ECD, but the precise topology of the complex is still unknown because of the lack of suitable heterologous expression means. Receptor ECDs exhibit leucine repeats and have been modelized on the basis of the three-dimensional structure of the porcine ribonuclease inhibitor, the first structurally known leucine-rich repeats protein. Here we report overexpression (up to 20 mg per liter) and purification to homogeneity of a soluble human chorionogonadotropin-ECD receptor complex secreted by stably cotransfected Chinese hamster ovary cells. Biochemical analysis and surface plasmon resonance data were in favor of a unique dimer with a 1:1 ligand-receptor stoichiometry. Immunopurified complex was submitted to circular dichroism characterization; CD spectra deconvolution indicated more than 25% alpha helices contributed by the receptor, in agreement with the porcine ribonuclease inhibitor-based modelization.	INRA, F-78352 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Remy, JJ (corresponding author), INRA, F-78352 Jouy En Josas, France.	remy@biotec.jouy.inra.fr						Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BIDART JM, 1987, J BIOL CHEM, V262, P15483; BOZON V, 1995, J MOL ENDOCRINOL, V14, P277, DOI 10.1677/jme.0.0140277; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; Couture L, 1996, J MOL ENDOCRINOL, V16, P15, DOI 10.1677/jme.0.0160015; Da Costa CR, 1998, J BIOL CHEM, V273, P11874, DOI 10.1074/jbc.273.19.11874; ElTayar N, 1996, MOL CELL ENDOCRINOL, V125, P65; Emsley P, 1996, NATURE, V381, P90, DOI 10.1038/381090a0; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Helman D, 1998, J BIOL CHEM, V273, P16067, DOI 10.1074/jbc.273.26.16067; Hong SH, 1999, MOL ENDOCRINOL, V13, P1285, DOI 10.1210/me.13.8.1285; HUET JC, 1992, PHYTOCHEMISTRY, V31, P1471, DOI 10.1016/0031-9422(92)83089-H; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAJOTAUGY E, 1995, J MOL ENDOCRINOL, V14, P51, DOI 10.1677/jme.0.0140051; PANTEL J, 1993, BIOCHEM BIOPH RES CO, V195, P588, DOI 10.1006/bbrc.1993.2086; Puett D, 1996, MOL CELL ENDOCRINOL, V125, P55, DOI 10.1016/S0303-7207(96)03954-8; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; ROBERT P, 1994, MOL CELL ENDOCRINOL, V101, P11, DOI 10.1016/0303-7207(94)90214-3; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; Simoni M, 1998, STEROIDS, V63, P288, DOI 10.1016/S0039-128X(98)00008-7; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VUHAILUUTHI MT, 1990, ENDOCRINOLOGY, V127, P2090, DOI 10.1210/endo-127-5-2090; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; XIE YB, 1990, J BIOL CHEM, V265, P21411; YANG JT, 1986, METHOD ENZYMOL, V130, P208	38	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1681	1687		10.1074/jbc.M005206200	http://dx.doi.org/10.1074/jbc.M005206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11018026	Green Published, hybrid			2022-12-27	WOS:000166528000005
J	Chuang, LC; Yew, PR				Chuang, LC; Yew, PR			Regulation of nuclear transport and degradation of the Xenopus cyclin-dependent kinase inhibitor, p27(Xic1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED DEGRADATION; CELL-CYCLE; DNA-REPLICATION; CDK INHIBITOR; P27(KIP1); PHOSPHORYLATION; PROTEOLYSIS; INITIATION; COMPLEX; PHASE	The regulation of the vertebrate cell cycle is controlled by the function of cyclin-dependent kinases (CDKs), cyclins, and CDK inhibitors. The Xenopus Laevis kinase inhibitor, p27(Xic1) (Xic1) is a member of the p21(Cip1)/p27(Kip1)/p57(Kip2) CDK inhibitor family and inhibits CDK2-cyclin E in vitro as well as DNA replication in Xenopus egg extracts. Xic1 is targeted for degradation in interphase extracts in a manner dependent on both the ubiquitin conjugating enzyme, Cdc34, and nuclei. Here we show that ubiquitination of Xic1 occurs exclusively in the nucleus and that nuclear localization of Xic1 is necessary for its degradation. We find that Xic1 nuclear localization is independently mediated by binding to CDK2-cyclin E and by nuclear localization sequences within the C terminus of Xic1, Our results also indicate that binding of Xic1 to CDK2-cyclin E is dispensable for Xic1 ubiquitination and degradation. Moreover, Re show that amino acids 180-183 of Xic1 are critical determinants of Xic1 degradation. This region of Xic1 may define a motif of Xic1 essential for recognition by the ubiquitin conjugation machinery or for binding an alternate protein required for degradation.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Yew, PR (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	yew@uthscsa.edu						Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; GOEHL MG, 1988, SCIENCE, V241, P1331; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; KAEPP DM, 1999, CELL, V97, P491; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koff A, 1995, Prog Cell Cycle Res, V1, P141; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Laskey RA, 1996, EXP CELL RES, V229, P204, DOI 10.1006/excr.1996.0361; LASKEY RA, 1990, TRENDS GENET, V6, P406, DOI 10.1016/0168-9525(90)90301-L; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Scheffner M, 1999, NATURE, V398, P103, DOI 10.1038/18105; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Willems AR, 1999, PHILOS T ROY SOC B, V354, P1533, DOI 10.1098/rstb.1999.0497; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	50	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1610	1617		10.1074/jbc.M008896200	http://dx.doi.org/10.1074/jbc.M008896200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11044455	hybrid			2022-12-27	WOS:000166430900100
J	Andric, SA; Kostic, TS; Tomic, M; Koshimizu, T; Stojilkovic, SS				Andric, SA; Kostic, TS; Tomic, M; Koshimizu, T; Stojilkovic, SS			Dependence of soluble guanylyl cyclase activity on calcium signaling in pituitary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE SECRETION; NITRIC-OXIDE SYNTHASES; PROTEIN-KINASE-A; CA2+ OSCILLATIONS; INTRACELLULAR CALCIUM; GH(3) CELLS; SELECTIVE-INHIBITION; PROLACTIN-RELEASE; RAT SOMATOTROPHS; MECHANISM	The role of nitric oxide (NO) in the stimulation of soluble guanylyl cyclase (sGC) is well established, but the mechanism by which the enzyme is inactivated during the prolonged NO stimulation has not been characterized. In this paper we studied the interactions between NO and intracellular Ca2+ in the control of sGC in rat anterior pituitary cells. Experiments were done in cultured cells, which expressed neuronal and endothelial NO synthases, and in cells with elevated NO levels induced by the expression of inducible NO synthase and by the addition of several NO donors. Basal sGC-dependent cGMP production was stimulated by the increase in NO levels in a time-dependent manner. In contrast, depolarization of cells by high K+ and Bay K 8644, an L-type Ca2+ channel agonist, inhibited sGC activity. Depolarization-induced down-regulation of sGC activity was also observed in cells with inhibited cGMP-dependent phosphodiesterases but not in cells bathed in Ca2+ deficient medium. This inhibition was independent from the pattern of Ca2+ signaling (oscillatory versus nonoscillatory) and NO levels, and was determined by averaged concentration of intracellular Ca2+. These results indicate that inactivation of sGC by intracellular Ca2+ serves as a negative feedback to break the stimulatory action of NO on enzyme activity in intact pituitary cells.	NICHD, Sect Cellular Signalling, ERRB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHD, Sect Cellular Signalling, ERRB, NIH, Bldg 49,Room 6A-36,49 Convent Dr, Bethesda, MD 20892 USA.		Koshimizu, Taka-aki/G-2740-2015; Tomic, Melanija/C-3371-2016; Kostic, Tatjana S/H-4038-2012	Andric, Silvana/0000-0002-2908-8136; Kostic, Tatjana/0000-0003-3440-8998; Koshimizu, Taka-aki/0000-0001-5292-7535	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Cataldi M, 1999, BBA-MOL CELL RES, V1449, P186, DOI 10.1016/S0167-4889(99)00013-0; Charles A, 1999, NAT CELL BIOL, V1, pE193, DOI 10.1038/70221; Charles AC, 1999, J BIOL CHEM, V274, P7508, DOI 10.1074/jbc.274.11.7508; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; DUVILANSKI BH, 1995, P NATL ACAD SCI USA, V92, P170, DOI 10.1073/pnas.92.1.170; Feelisch M, 1998, N-S ARCH PHARMACOL, V358, P113, DOI 10.1007/PL00005231; Fiekers JF, 1996, CELL CALCIUM, V19, P327, DOI 10.1016/S0143-4160(96)90073-1; GARBERS DL, 1992, CELL, V71, P1; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HARTT DJ, 1995, BIOCHEM BIOPH RES CO, V214, P918, DOI 10.1006/bbrc.1995.2374; HERRINGTON J, 1994, ENDOCRINOLOGY, V135, P1100, DOI 10.1210/en.135.3.1100; HOLL RW, 1988, J BIOL CHEM, V263, P9682; KATO M, 1992, ENDOCRINOLOGY, V131, P2133, DOI 10.1210/en.131.5.2133; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KURYSHEV YA, 1995, ENDOCRINOLOGY, V136, P3925, DOI 10.1210/en.136.9.3925; Kwiecien R, 1997, J PHYSIOL-LONDON, V499, P613, DOI 10.1113/jphysiol.1997.sp021954; Kwiecien R, 1998, NEUROENDOCRINOLOGY, V68, P135, DOI 10.1159/000054360; Lozach A, 1998, MOL CELL ENDOCRINOL, V143, P43, DOI 10.1016/S0303-7207(98)00135-X; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P592, DOI 10.1210/endo-128-1-592; Mayer B, 1998, N-S ARCH PHARMACOL, V358, P127, DOI 10.1007/PL00005233; Olesen SP, 1998, BRIT J PHARMACOL, V123, P299, DOI 10.1038/sj.bjp.0701603; Parkinson SJ, 1999, BIOCHEMISTRY-US, V38, P6441, DOI 10.1021/bi990154v; Patel S, 1999, NAT CELL BIOL, V1, P467, DOI 10.1038/70249; Pinilla L, 1998, NEUROENDOCRINOLOGY, V68, P180, DOI 10.1159/000054364; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; Tomic M, 1999, J NEUROSCI, V19, P7721; Tomic M, 1999, J BIOL CHEM, V274, P35693, DOI 10.1074/jbc.274.50.35693; Tsumori W, 1999, J NEUROENDOCRINOL, V11, P451; VANCELECOM H, 1997, J HISTOCHEM CYTOCHEM, V45, P847; Vitalis EA, 2000, P NATL ACAD SCI USA, V97, P1861, DOI 10.1073/pnas.040545197; WAGNER KA, 1993, BIOCHEM J, V292, P175, DOI 10.1042/bj2920175; Wei JY, 1998, PROG NEUROBIOL, V56, P37, DOI 10.1016/S0301-0082(98)00029-X; Willmott NJ, 2000, J NEUROSCI, V20, P1767; Wolbring G, 1996, BIOCHEMISTRY-US, V35, P11013, DOI 10.1021/bi960699e; WOLFF D, 1992, BIOCHEM J, V128, P201; YAMAMOTO T, 1983, J BIOL CHEM, V258, P4173; Yermolaieva O, 2000, P NATL ACAD SCI USA, V97, P448, DOI 10.1073/pnas.97.1.448; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	47	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					844	849		10.1074/jbc.M004406200	http://dx.doi.org/10.1074/jbc.M004406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031255	hybrid			2022-12-27	WOS:000166280700113
J	Galli, A; Pinaire, J; Fischer, M; Dorris, R; Crabb, DW				Galli, A; Pinaire, J; Fischer, M; Dorris, R; Crabb, DW			The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism - A novel mechanism for the development of ethanol-induced fatty liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC ALCOHOL-CONSUMPTION; RAT HEPATOCYTE COUPLETS; BETA-OXIDATION; LIPID-PEROXIDATION; NUCLEAR RECEPTORS; MAMMALIAN-CELLS; PROTEIN ADDUCTS; ACYL-COENZYME; ACETALDEHYDE; GENE	Fatty acids are ligands for the peroxisome proliferator-activated receptor a (PPAR alpha). Fatty acid levels are increased in liver during the metabolism of ethanol and might be expected to activate PPAR alpha. However, ethanol inhibited PPAR alpha activation of a reporter gene in H4IIEC3 hepatoma cells expressing alcohol-metabolizing enzymes but not in CV-1 cells, which lack these enzymes. Ethanol also reduced the ability of the PPAR alpha ligand WY14,643 to activate reporter constructs in the hepatoma cells or cultured rat hepatocytes, This effect of ethanol was abolished by the alcohol dehydrogenase inhibitor 4-methylpyrazole and augmented by the aldehyde dehydrogenase inhibitor cyanamide, indicating that acetaldehyde was responsible for the action of ethanol. PPAR alpha /retinoid X receptor extracted from hepatoma cells exposed to ethanol or acetaldehyde bound poorly to an oligonucleotide containing peroxisome proliferator response elements. This effect was also blocked by 4-methylpyrazole and augmented by cyanamide. Furthermore, in vitro translated PPAR alpha exposed to acetaldehyde failed to bind DNA. Thus, ethanol metabolism blocks transcriptional activation by PPARa, in part due to impairment of its ability to bind DNA. This effect of ethanol may promote the development of alcoholic fatty liver and other hepatic consequences of alcohol abuse.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Univ Florence, Dept Clin Pathophysiol, Florence, Italy	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Florence	Crabb, DW (corresponding author), Emerson Hall 312,545 Barnhill Dr, Indianapolis, IN 46202 USA.	dcrabb@iupui.edu	Galli, Andrea/AAC-1623-2019	Galli, Andrea/0000-0001-5416-6290	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007462, P50AA007611, R37AA006434, R01AA006434] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06434, P50 AA07611, T32 AA07462] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEHRENS UJ, 1988, BIOCHEM BIOPH RES CO, V154, P584, DOI 10.1016/0006-291X(88)90180-5; Berson A, 1998, GASTROENTEROLOGY, V114, P764, DOI 10.1016/S0016-5085(98)70590-6; BOCOS C, 1995, J STEROID BIOCHEM, V53, P1; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CASINI A, 1993, J HEPATOL, V19, P385, DOI 10.1016/S0168-8278(05)80547-1; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; Crabb DW, 1995, ALCOHOL CLIN EXP RES, V19, P1414, DOI 10.1111/j.1530-0277.1995.tb01000.x; DeCraemer D, 1996, ALCOHOL CLIN EXP RES, V20, P908; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Everett LM, 1999, J STEROID BIOCHEM, V70, P197, DOI 10.1016/S0960-0760(99)00109-0; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FROMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101, DOI 10.1016/0163-7258(95)00012-6; Galli A, 2000, HEPATOLOGY, V31, P101, DOI 10.1002/hep.510310117; Galli A, 1998, ARCH BIOCHEM BIOPHYS, V354, P288, DOI 10.1006/abbi.1997.0701; GAUTAM A, 1987, HEPATOLOGY, V7, P216, DOI 10.1002/hep.1840070203; GEARING KL, 1994, J NUTR, V124, pS1284, DOI 10.1093/jn/124.suppl_8.1284S; GINOT F, 1989, EUR J BIOCHEM, V180, P289, DOI 10.1111/j.1432-1033.1989.tb14646.x; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAF J, 1984, P NATL ACAD SCI-BIOL, V81, P6516, DOI 10.1073/pnas.81.20.6516; GRUNNET N, 1986, ALCOHOL CLIN EXP RES, V10, pS64, DOI 10.1111/j.1530-0277.1986.tb05182.x; Grunnet N, 1987, Alcohol Alcohol Suppl, V1, P257; JENNETT RB, 1987, ARCH BIOCHEM BIOPHYS, V256, P10, DOI 10.1016/0003-9861(87)90420-6; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Li CJ, 1997, HEPATOLOGY, V26, P650, DOI 10.1002/hep.510260317; LIEBER CS, 1965, J CLIN INVEST, V44, P1009, DOI 10.1172/JCI105200; LIN RC, 1988, J CLIN INVEST, V81, P615, DOI 10.1172/JCI113362; MA XL, 1993, HEPATOLOGY, V18, P1247; Masuda N, 1998, GENE, V221, P225, DOI 10.1016/S0378-1119(98)00461-2; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; NOMURA F, 1981, BIOCHEM BIOPH RES CO, V100, P131, DOI 10.1016/S0006-291X(81)80073-3; NUUTINEN HU, 1984, EUR J CLIN INVEST, V14, P306, DOI 10.1111/j.1365-2362.1984.tb01186.x; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; PANCHENKO LF, 1987, EXPERIENTIA, V43, P580, DOI 10.1007/BF02143593; PIGNON JP, 1987, HEPATOLOGY, V7, P865, DOI 10.1002/hep.1840070512; Polavarapu R, 1998, HEPATOLOGY, V27, P1317, DOI 10.1002/hep.510270518; RABINOWITZ JL, 1991, ALCOHOL, V8, P241, DOI 10.1016/0741-8329(91)90289-9; Rakic V, 1998, ATHEROSCLEROSIS, V137, P243, DOI 10.1016/S0021-9150(97)00269-4; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SALASPURO MP, 1981, HEPATOLOGY, V1, P33, DOI 10.1002/hep.1840010106; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SMITH SL, 1989, J CLIN INVEST, V84, P337, DOI 10.1172/JCI114159; Stewart MJ, 1998, BBA-GENE STRUCT EXPR, V1399, P181, DOI 10.1016/S0167-4781(98)00115-8; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; Tuma DJ, 1996, HEPATOLOGY, V23, P872, DOI 10.1002/hep.510230431; WAN YJY, 1994, LIFE SCI, V56, P307, DOI 10.1016/0024-3205(94)00953-8; WOLFLA CE, 1988, ARCH BIOCHEM BIOPHYS, V263, P69, DOI 10.1016/0003-9861(88)90614-5; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	55	155	167	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					68	75		10.1074/jbc.M008791200	http://dx.doi.org/10.1074/jbc.M008791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022051	hybrid			2022-12-27	WOS:000166280700011
J	Nakazawa, T; Komai, S; Tezuka, T; Hisatsune, C; Umemori, H; Semba, K; Mishina, M; Manabe, T; Yamamoto, T				Nakazawa, T; Komai, S; Tezuka, T; Hisatsune, C; Umemori, H; Semba, K; Mishina, M; Manabe, T; Yamamoto, T			Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; POSTSYNAPTIC DENSITY FRACTION; EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; NMDA-RECEPTOR; SYNAPTIC TRANSMISSION; GLUTAMATE RECEPTORS; MUTANT MICE; 2B SUBUNIT	The N-methyl-D-aspartate (NMDA) receptors play critical roles in synaptic plasticity, neuronal development, and excitotoxicity, Tyrosine phosphorylation of NMDA receptors by Src-family tyrosine kinases such as Fyn is implicated in synaptic plasticity. To precisely address the roles of NMDA receptor tyrosine phosphorylation, we identified Fyn-mediated phosphorylation sites on the GluR epsilon2 (NR2B) subunit of NMDA receptors, Seven out of 25 tyrosine residues in the C-terminal cytoplasmic region of GluR epsilon2 were phosphorylated by Fyn in vitro. Of these 7 residues, Tyr-1252, Tyr-1336, and Tyr-1472 in GluR epsilon2 were phosphorylated in human embryonic kidney fibroblasts when co-expressed with active Fyn, and Tyr-1472 was the major phosphorylation site in this system. We then generated rabbit polyclonal antibodies specific to Tyr-1472-phosphorylated GluR epsilon2 and showed that Tyr-1472 of GluR epsilon2 was indeed phosphorylated in murine brain using the antibodies. Importantly Tyr-1472 phosphorylation was greatly reduced in fyn mutant mice. Moreover, Tyr-1472 phosphorylation became evident when hippocampal long term potentiation started to be observed, and its magnitude became larger in murine brain. Finally, Tyr-1472 phosphorylation was significantly enhanced after induction of long term potentiation in the hippocampal CA1 region. These data suggest that Tyr-1472 phosphorylation of GluR epsilon2 is important for synaptic plasticity.	Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan; Kobe Univ, Sch Med, Dept Physiol, Kobe, Hyogo 6500017, Japan; Univ Tokyo, Sch Med, Dept Mol Neurobiol & Pharmacol, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; Kobe University; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp	Nakazawa, Takanobu/E-1012-2014; Hisatsune, Chihiro/C-6661-2017; Komai, Shoji/L-9273-2018	Nakazawa, Takanobu/0000-0002-5049-9140; Hisatsune, Chihiro/0000-0001-7811-7784; Komai, Shoji/0000-0002-8474-7800; NAKAZAWA, Takanobu/0000-0003-4863-1277; Umemori, Hisashi/0000-0001-7198-2062				Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Dunah AW, 1998, J NEUROCHEM, V71, P1926; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Gurd JW, 1997, J NEUROCHEM, V69, P623; Hisatsune C, 1999, GENES CELLS, V4, P657, DOI 10.1046/j.1365-2443.1999.00287.x; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; Liao DZ, 1996, LEARN MEMORY, V3, P138, DOI 10.1101/lm.3.2-3.138; Lin SY, 1999, MOL BRAIN RES, V70, P18, DOI 10.1016/S0169-328X(99)00122-9; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Manabe T, 2000, J NEUROSCI, V20, P2504; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; Mori H, 1998, NEURON, V21, P571, DOI 10.1016/S0896-6273(00)80567-X; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Okabe S, 1998, J NEUROSCI, V18, P4177; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rosenblum K, 1997, J NEUROSCI, V17, P5129; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhao WQ, 2000, P NATL ACAD SCI USA, V97, P8098, DOI 10.1073/pnas.97.14.8098	56	377	393	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					693	699		10.1074/jbc.M008085200	http://dx.doi.org/10.1074/jbc.M008085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024032	hybrid			2022-12-27	WOS:000166280700093
J	Pariyarath, R; Wang, HX; Aitchison, JD; Ginsberg, HN; Welch, WJ; Johnson, AE; Fisher, EA				Pariyarath, R; Wang, HX; Aitchison, JD; Ginsberg, HN; Welch, WJ; Johnson, AE; Fisher, EA			Co-translational interactions of apoprotein B with the ribosome and translocon during lipoprotein assembly or targeting to the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; SECRETORY PROTEINS; NASCENT POLYPEPTIDES; MOLECULAR CHAPERONES; MEMBRANE-PROTEIN; PAUSE TRANSFER	Hepatic lipoprotein assembly and secretion can be regulated by proteasomal degradation of newly synthesized apoB, especially if lipid synthesis or lipid transfer is low. Our previous studies in HepG2 cells showed that, under these conditions, newly synthesized apoB remains stably associated with the endoplasmic reticulum (ER) membrane (Mitchell, D. M., Zhou, M., Pariyarath, R., Wang, H., Aitchison, J. D., Ginsberg, T-I. N., and Fisher, E. A (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 14733-14738). We now show that independent of lipid synthesis, apoB chains that appear full-length are, in fact, incompletely translated polypeptides still engaged by the ribosome and associated with the ER translocon. In the presence of active lipid synthesis and transfer, translation and lipoprotein assembly are completed, and the complexes exit the ER. Upon omitting fatty acids from, or adding a microsomal triglyceride transfer protein inhibitor to, culture media to reduce lipid synthesis or transfer, respectively, apoB was degraded while it remained associated with the ER and complexed with cytosolic hsp70 and proteasomes. Thus, unlike other ER substrates of the proteasome, such as major histocompatibility complex class I molecules, apoB does not fully retrotranslocate to the cytosol before entering the ubiquitin-proteasome pathway. Although, upon immunofluorescence, apoB in proteasome-inhibited cells accumulated in punctate structures similar in appearance to aggresomes (cytosolic structures containing molecules irreversibly lost from the secretory pathway), these apoB molecules could be secreted when lipid synthesis was stimulated. The results suggest a model in which 1) apoB translation does not complete until lipoprotein assembly terminates, and 2) assembly with lipids or entry into the ubiquitin-proteasome pathway occurs while apoB polypeptides remain associated with the translocon and attached to the ribosome.	CUNY Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Cell Biol & Anat, New York, NY 10029 USA; Univ Alberta, Dept Anat & Cell Biol, Edmonton, AB T6G 2H7, Canada; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Texas A&M Univ, Dept Med Biochem, College Stn, TX 77843 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Alberta; Columbia University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Texas A&M University System; Texas A&M University College Station	Fisher, EA (corresponding author), CUNY Mt Sinai Sch Med, Cardiovasc Inst, 1 Gustave Levy Pl,POB 1269, New York, NY 10029 USA.	edmd-phd.fisher@mssm.edu	Adiels, Martin/C-9278-2011; Johnson, Arthur E/G-3457-2012	Fisher, Edward/0000-0001-9802-143X	NHLBI NIH HHS [HL 58541, HL 55683] Funding Source: Medline; NIGMS NIH HHS [GM 26494] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Benoist F, 1996, EUR J BIOCHEM, V240, P713, DOI 10.1111/j.1432-1033.1996.0713h.x; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Eggers DK, 1997, MOL BIOL CELL, V8, P1559, DOI 10.1091/mbc.8.8.1559; Eleuteri AM, 1997, J BIOL CHEM, V272, P11824, DOI 10.1074/jbc.272.18.11824; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HALL MN, 1982, ANN INST PASTEUR MIC, VA133, P123; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; Huang XF, 1999, J LIPID RES, V40, P2212; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Johnson CH, 1999, YEAST, V15, P799, DOI 10.1002/(SICI)1097-0061(19990630)15:9&lt;799::AID-YEA419&gt;3.0.CO;2-N; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kivlen MH, 1997, J LIPID RES, V38, P1149; Kuehn DL, 1999, MOL BIOL CELL, V10, p213A; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; Leiper JM, 1996, J LIPID RES, V37, P2215; Liang JS, 1998, J BIOL CHEM, V273, P35216, DOI 10.1074/jbc.273.52.35216; Liang JS, 2000, J BIOL CHEM, V275, P32003, DOI 10.1074/jbc.M004646200; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; WETTERAU JR, 1992, SCIENCE, V258, P999; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wigley WC, 1999, J CELL BIOL, V145, P481; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	56	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					541	550		10.1074/jbc.M007944200	http://dx.doi.org/10.1074/jbc.M007944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022045	hybrid			2022-12-27	WOS:000166280700073
J	Yang, BX; Ma, TH; Verkman, KS				Yang, BX; Ma, TH; Verkman, KS			Erythrocyte water permeability and renal function in double knockout mice lacking aquaporin-1 and aquaporin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UREA TRANSPORTERS; NULL MICE; CHANNEL; LOCALIZATION; PROTEIN; CHIP28; KIDNEY; CELLS	Aquaporin (AQP) water channel AQP3 has been proposed to be the major glycerol and non-AQP1 water transporter in erythrocytes, AQP1 and AQP3 are also expressed in the kidney where their deletion in mice produces distinct forms of nephrogenic diabetes insipidus. Here AQP1/AQP3 double knockout mice were generated and analyzed to investigate the functional role of AQP3 in erythrocytes and kidneys. 53 double knockout mice were born out of 756 pups from breeding double heterozygous mice. The double knockout mice had reduced survival and impaired growth compared with the single knockout mice. Erythrocyte water permeability was 7-fold reduced by AQP1 deletion but not further reduced in AQP1/AQP3 null mice. AQP3 deletion did not affect erythrocyte glycerol permeability or its inhibition by phloretin, Daily urine output in AQP1/AQP3 double knockout mice (15 ml) was 9-fold greater than in wildtype mice, and urine osmolality (194 mosM) was 8.4-fold reduced. The mice remained polyuric after DDAVP administration or water deprivation. The renal medulla in most AQP1/AQP3 null mice by age 4 weeks was atrophic and fluid-filled due to the severe polyuria and hydronephrosis. Our data provide direct evidence that AQP3 is not functionally important in erythrocyte water or glycerol permeability, The renal function studies indicate independent roles of AQP1 and AQP3 in countercurrent exchange and collecting duct osmotic equilibration, respectively.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, KS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Ma, Tonghui/0000-0001-9338-1030	NHLBI NIH HHS [HL60288, HL59198] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; FISCHBARG J, 1989, P NATL ACAD SCI USA, V86, P8397, DOI 10.1073/pnas.86.21.8397; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 2001, AM J PHYSIOL-CELL PH, V280, pC126; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; MACEY RI, 1970, BIOCHIM BIOPHYS ACTA, V211, P104, DOI 10.1016/0005-2736(70)90130-6; MACEY RI, 1996, J BIOL CHEM, V271, P1309; Meinild AK, 2000, AM J PHYSIOL-RENAL, V278, pF777, DOI 10.1152/ajprenal.2000.278.5.F777; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; Pallone TL, 2000, J CLIN INVEST, V105, P215, DOI 10.1172/JCI8214; Ramirez-Lorca R, 1999, PFLUG ARCH EUR J PHY, V438, P94, DOI 10.1007/s004240050884; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; Sands JM, 1999, J AM SOC NEPHROL, V10, P635; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; Sidoux-Walter F, 1999, J BIOL CHEM, V274, P30228, DOI 10.1074/jbc.274.42.30228; Silberstein C, 1999, BRAZ J MED BIOL RES, V32, P1303, DOI 10.1590/S0100-879X1999001000018; Song LL, 2000, J GEN PHYSIOL, V115, P17, DOI 10.1085/jgp.115.1.17; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Trinh-Trang-Tan MM, 1998, EXP NEPHROL, V6, P471; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; Verkman AS, 2000, AM J PHYSIOL-LUNG C, V278, pL867, DOI 10.1152/ajplung.2000.278.5.L867; Yang BX, 1998, J BIOL CHEM, V273, P9369, DOI 10.1074/jbc.273.16.9369	27	89	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					624	628		10.1074/jbc.M008664200	http://dx.doi.org/10.1074/jbc.M008664200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035042	hybrid			2022-12-27	WOS:000166280700084
J	Zhang, CL; McKinsey, TA; Lu, JR; Olson, EN				Zhang, CL; McKinsey, TA; Lu, JR; Olson, EN			Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; INTERACTS; IDENTIFICATION; EXPRESSION; CLONING; DOMAIN; COREPRESSORS; FAMILY	The class II histone deacetylases (HDACs) 4, 5, and 7 share a common structural organization, with a carboxyl-terminal catalytic domain and an amino-terminal extension that mediates interactions with members of the myocyte enhancer factor-2 (MEF2) family of transcription factors. Association of these HDACs with MEF2 factors represses transcription of MEF2 target genes. MEF2-interacting transcription repressor (MITR) shares homology with the amino-terminal extensions of class II HDACs and also acts as a transcriptional repressor, but lacks a histone deacetylase catalytic domain. This suggests that MITR represses transcription by recruiting other corepressors. We show that the amino-terminal regions of MITR and class II HDACs interact with the transcriptional corepressor, COOH-terminal-binding protein (CtBP), through a CtBP-binding motif (P-X-D-L-R) conserved in MITR and HDACs 4, 5, and 7. Mutation of this sequence in MITR abolishes interaction with CtBP and impairs, but does not eliminate, the ability of MITR to inhibit MEF2-dependent transcription. The residual repressive activity of MITR mutants that fail to bind CtBP can be attributed to association with other HDAC family members. These findings reveal CtBP-dependent and -independent mechanisms for transcriptional repression by MITR and show that MITR represses MEF2 activity through recruitment of multi-component corepressor complexes that include CtBP and HDACs.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA.	eolson@hamon.swmed.edu	Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040				Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Huang EY, 2000, GENE DEV, V14, P45; Kao HY, 2000, GENE DEV, V14, P55; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	35	158	165	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					35	39		10.1074/jbc.M007364200	http://dx.doi.org/10.1074/jbc.M007364200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022042	hybrid			2022-12-27	WOS:000166280700006
J	Korneeva, NL; Lamphear, BJ; Hennigan, FLC; Rhoads, RE				Korneeva, NL; Lamphear, BJ; Hennigan, FLC; Rhoads, RE			Mutually cooperative binding of eukaryotic translation initiation factor (eIF) 3 and eIF4A to human eIF4G-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 4G EIF4G; CAP-DEPENDENT TRANSLATION; PROTEIN-SYNTHESIS; MESSENGER-RNA; WHEAT-GERM; POLY(A)-BINDING PROTEIN; FUNCTIONAL DOMAINS; RIBOSOMAL-SUBUNIT; CROSS-LINKING; FACTOR EIF-3	Eukaryotic translation initiation factor 4G-1 (eIF4G) plays a critical role in the recruitment of mRNA to the 43 S preinitiation complex. The central region of eIF4G binds the ATP-dependent RNA helicase eIF4A, the 40 S binding factor eIF3, and RNA. In the present work, we have further characterized the binding properties of the central region of human eIF4G, Both titration and competition experiments were consistent with a 1:1 stoichiometry for eIF3 binding. Surface plasmon resonance studies showed that three recombinant eIF4G fragments corresponding to amino acids 642-1560, 613-1078, and 975-1078 bound eIF3 with similar kinetics. A dissociation equilibrium constant of similar to 42 nM was derived from an association rate constant of 3.9 x 10(4) M-1 s(-1) and dissociation rate constant of 1.5 x 10(-3) s(-1). Thus, the eIF3-binding region is included within amino acid residues 975-1078. This region does not overlap with the RNA-binding site, which suggests that eIF3 binds eIF4G directly and not through an RNA bridge, or the central eIF4A-binding site. Surprisingly, the binding of eIF3 and eIF4A to the central region was mutually cooperative; eIF3 binding to eIF4G: increased 4-fold in the presence of eIF4A, and conversely, eIF4A binding to the central (but not COOH-terminal) region of eIF4G increased 2.4-fold in the presence of eIF3.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Rhoads, RE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	rrhoad@lsuhsc.edu			NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; BENNE R, 1978, J BIOL CHEM, V253, P3078; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P6977, DOI 10.1021/bi00242a024; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; De Gregorio E, 1999, EMBO J, V18, P4865, DOI 10.1093/emboj/18.17.4865; Dominguez D, 1999, J BIOL CHEM, V274, P26720, DOI 10.1074/jbc.274.38.26720; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Keiper BD, 1999, INT J BIOCHEM CELL B, V31, P37, DOI 10.1016/S1357-2725(98)00130-7; Kolupaeva VG, 1998, J BIOL CHEM, V273, P18599, DOI 10.1074/jbc.273.29.18599; KORNEEVA NL, 2001, IN PRESS J BIOL CHEM, V276; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamphear BJ, 1996, BIOCHEMISTRY-US, V35, P15726, DOI 10.1021/bi961864t; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; MADER S, 1995, MOL CELL BIOL, V15, P4990; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; Neff CL, 1999, MOL CELL BIOL, V19, P5557; NYGARD O, 1982, NUCLEIC ACIDS RES, V10, P1327, DOI 10.1093/nar/10.4.1327; Odreman-Macchioli FE, 2000, NUCLEIC ACIDS RES, V28, P875, DOI 10.1093/nar/28.4.875; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEAL SN, 1986, ARCH BIOCHEM BIOPHYS, V246, P710, DOI 10.1016/0003-9861(86)90327-9; SETYONO B, 1984, BIOCHIM BIOPHYS ACTA, V782, P242, DOI 10.1016/0167-4781(84)90058-7; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TOLAN DR, 1983, BIOCHIMIE, V65, P427, DOI 10.1016/S0300-9084(83)80062-5; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; WESTERMANN P, 1984, NUCLEIC ACIDS RES, V12, P8887, DOI 10.1093/nar/12.23.8887; WESTERMANN P, 1986, FEBS LETT, V205, P171, DOI 10.1016/0014-5793(86)80891-2; YODERHILL J, 1993, J BIOL CHEM, V268, P5566	53	89	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41369	41376		10.1074/jbc.M007525200	http://dx.doi.org/10.1074/jbc.M007525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11022043	hybrid			2022-12-27	WOS:000166114600094
J	Natochin, M; Lester, B; Peterson, YK; Bernard, ML; Lanier, SM; Artemyev, NO				Natochin, M; Lester, B; Peterson, YK; Bernard, ML; Lanier, SM; Artemyev, NO			AGS3 inhibits GDP dissociation from G alpha subunits of the G(i) family and rhodopsin-dependent activation of transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE BINDING; G-PROTEINS; EXCHANGE FACTOR; RGS; CHROMATOGRAPHY; PURIFICATION; G-ALPHA(O); GTP	A number of recently discovered proteins that interact with the alpha subunits of G(i)-like G proteins contain homologous repeated sequences named G protein regulatory (GPR) motifs, Activator of G: protein signaling 3 (AGS3), identified as an activator of the yeast pheromone pathway in the absence of the pheromone receptor, has a domain with four such repeats. To elucidate the potential mechanisms of regulation of G protein signaling by proteins containing GPR motifs, we examined the effects of the AGS3 GPR domain on the kinetics of guanine nucleotide exchange and GTP hydrolysis by G(i)alpha (1) and transducin-alpha (G(t)alpha). The AGS3 GPR domain markedly inhibited the rates of spontaneous guanosine 5'-O-(3-thiotriphosphate) (GTP gammaS) binding to G(i)alpha and rhodopsin-stimulated GTP gammaS binding to G(i)alpha The full-length AGS3 GPR domain, AGS3-(463-650), was similar to 30-fold more potent than AGS3-(572-629), containing two AGS3 GPR motifs, The IC50 values for the AGS3-(463-650) inhibitory effects on G(i)alpha and transducin were 0.12 and 0.15 muM, respectively. Furthermore, AGS3-(463-650) and AGS3-(572-629) effectively blocked the GDP release from G(i)alpha and rhodopsin-induced dissociation of GDP from G(i)alpha The potencies of AGS3-(572-629) and AGS3(463-650) to suppress the GDP dissociation rates correlated with their ability to inhibit the rates of GTP gammaS binding. Consistent with the inhibition of nucleotide exchange, the AGS3 GPR domain slowed the rate of steady-state GTP hydrolysis by G(i)alpha The catalytic rate of G(i)alpha GTP hydrolysis, measured under single turnover conditions, remained unchanged with the addition of AGS3-(463-650). Altogether, our results suggest that proteins containing GPR motifs, in addition to their potential role as G protein-coupled receptor-independent activators of G beta gamma signaling pathways, act as GDP dissociation inhibitors and negatively regulate the activation of a G protein by a G protein-coupled receptor.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29403 USA	University of Iowa; Medical University of South Carolina	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.		Bernard, Michael/AAW-3944-2021	Artemyev, Nikolai/0000-0002-5266-6854; Lanier, Stephen/0000-0002-2740-7607	NATIONAL EYE INSTITUTE [R01EY012682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY12682] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Granderath S, 1999, DEVELOPMENT, V126, P1781; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702	24	90	91	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40981	40985		10.1074/jbc.M006478200	http://dx.doi.org/10.1074/jbc.M006478200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024022	hybrid			2022-12-27	WOS:000166114600044
J	Ensor, E; Smith, MD; Latchman, DS				Ensor, E; Smith, MD; Latchman, DS			The BRN-3A transcription factor protects sensory but not sympathetic neurons from programmed cell death/apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MOTOR-NEURONS; CANCER CELLS; FAMILY; DOMAIN; DIFFERENTIATION; SURVIVAL; ACTIVATION; MOTONEURONS; OUTGROWTH	Inactivation of the gene encoding the POU domain transcription factor BRN-3A results in the absence of specific neurons in knockout mice. Here we demonstrate for the first time a direct effect of BRN-3A on the survival of neuronal cells. Specifically, overexpression of BRN-3A in cultured trigeminal ganglion or dorsal root ganglion sensory neurons enhanced their survival following the withdrawal of nerve growth factor. Moreover, reduction of BRN-3A levels impaired the survival of these neurons, The survival of sympathetic neurons was not affected by either approach. Similarly, overexpression of BRN-3A activated the endogenous Bcl-2 gene in trigeminal neurons, but not in sympathetic neurons. The protective effect of BRN-3A on trigeminal neuron survival following nerve growth factor withdrawal significantly increased during embryonic development. In contrast, overexpression of the related factor BRN-3B enhanced survival of trigeminal neurons only at an early stage of embryonic development. Thus, BRN-3A (and in some circumstances, BRN-3B) can promote the survival of nerve growth factor-dependent sensory but not sympathetic neurons, allowing it to play a direct role in the survival of some (but not all) neuronal populations in the developing and adult nervous systems.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England	University of London; University College London	Latchman, DS (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	d.latchman@ich.ucl.ac.uk			MRC [G9901318] Funding Source: UKRI; Medical Research Council [G9901318] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; Athlan ES, 1997, J NEUROSCI RES, V47, P300; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; CAMU W, 1992, J NEUROSCI METH, V44, P59, DOI 10.1016/0165-0270(92)90114-S; Coffin RS, 1996, GENE THER, V3, P886; Davies A. M., 1995, NEURAL CELL CULTURE, P153; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DUPREY P, 1995, INT J DEV BIOL, V39, P443; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; Huang EJ, 1999, DEVELOPMENT, V126, P2869; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; Latchman DS, 1996, PHILOS T R SOC B, V351, P511, DOI 10.1098/rstb.1996.0049; Latchman DS, 1997, INT J ONCOL, V10, P1133; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; McQuillin A, 1997, NEUROREPORT, V8, P1481, DOI 10.1097/00001756-199704140-00031; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Smith MD, 1997, J BIOL CHEM, V272, P21325, DOI 10.1074/jbc.272.34.21325; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VAHAUA O, 1954, SCIENCE, V279, P1950; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; Wyatt S, 1998, MOL BRAIN RES, V55, P254, DOI 10.1016/S0169-328X(98)00006-0; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIANG M, 1955, P NATL ACAD SCI USA, V93, P11950	40	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5204	5212		10.1074/jbc.M007068200	http://dx.doi.org/10.1074/jbc.M007068200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11053412	hybrid			2022-12-27	WOS:000168484300090
J	Wang, JY; Arbuzova, A; Hangyas-Mihalyne, G; McLaughlin, S				Wang, JY; Arbuzova, A; Hangyas-Mihalyne, G; McLaughlin, S			The effector domain of myristoylated alanine-rich C kinase substrate binds strongly to phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MONOLAYER SURFACE PRESSURE; BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; INOSITOL TRISPHOSPHATE; MEMBRANE-BINDING; HIGH-AFFINITY; ELECTROSTATIC PROPERTIES; BASIC PEPTIDES; ACIDIC LIPIDS	Both the myristoylated alanine-rich protein kinase C substrate protein (MARCKS) and a peptide corresponding to its basic effector domain, MARCKS-(151-175), inhibit phosphoinositide-specific phospholipase C (PLC)catalyzed hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP,) in vesicles (Glaser, M., Wanaski, S., Buser, C. A., Boguslavsky, V., Rashidzada, W., Morris, k, Rebecchi, M., Scarlata, S. F., Runnels, L. W., Prestwich, G. D., Chen, J., Aderem, A., Ahn, J., and McLaughlin, S. (1996) J. Biol. Chem. 271, 26187-26193). We report here that adding 10-100 nM MARCRS-(151-175) to a subphase containing either PLC-delta or -beta inhibits hydrolysis of PIP, in a monolayer and that this inhibition is due to the strong binding of the peptide to PIP2. Two direct binding measurements, based on centrifugation and fluorescence, show that approximate to 10 nM PIP2, in the form of vesicles containing 0.01%, 0.1%, or 1% PIP2, binds 50% of MARCKS-(151-175). Both electrophoretic mobility measurements and competition experiments suggest that MARCKS-(151-175) forms an electroneutral complex with approximate to4 PIP2. MARCKS-(151-175) binds equally well to PI(4,5)P-2 and PI(3,4)P-2. Local electrostatic interactions of PIP2 with MARCKS-(151-175) contribute to the binding energy because increasing the salt concentration from 100 to 500 mM decreases the binding 100-fold. We hypothesize that the effector domain of MARCKS can bind a significant fraction of the PIP2 in the plasma membrane, and release the bound PIP2 upon interaction with Ca2+/calmodulin or phosphorylation by protein kinase C.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	McLaughlin, S (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	smcl@epo.som.sunysb.edu		Arbuzova, Anna/0000-0003-2462-147X	NIGMS NIH HHS [GM24971, GM43422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043422, R37GM024971, R01GM043422, R01GM024971] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; Arbuzova A, 2000, BBA-BIOMEMBRANES, V1464, P35, DOI 10.1016/S0005-2736(99)00243-6; Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Arbuzova A, 1998, BBA-REV BIOMEMBRANES, V1376, P369, DOI 10.1016/S0304-4157(98)00011-2; BenTal N, 1997, BIOPHYS J, V73, P1717, DOI 10.1016/S0006-3495(97)78203-1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; Buser CA, 1998, METH MOL B, V84, P267; CAFISO D, 1989, METHOD ENZYMOL, V171, P342; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Denisov G, 1998, BIOPHYS J, V74, P731, DOI 10.1016/S0006-3495(98)73998-0; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Flanagan LA, 2000, FR MOLEC B, V27, P166; FROMHERZ P, 1975, REV SCI INSTRUM, V46, P1380, DOI 10.1063/1.1134025; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUNTER RJ, 1981, ZETA POTNTIAL COLLOI; James SR, 1997, BIOCHEMISTRY-US, V36, P848, DOI 10.1021/bi962108q; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; May S, 2000, BIOPHYS J, V79, P1747, DOI 10.1016/S0006-3495(00)76427-7; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MORRIS AJ, 1995, MOL PHARMACOL, V48, P532; Murray D, 1999, BIOPHYS J, V77, P3176, DOI 10.1016/S0006-3495(99)77148-1; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Newton AC, 2000, PRINCIPLES OF MOLECULAR REGULATION, P205; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; Rhee SG, 2000, FR MOLEC B, V27, P1; Roy MO, 2000, BIOCHEMISTRY-US, V39, P8298, DOI 10.1021/bi000512q; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Sciorra VA, 2000, FR MOLEC B, V27, P268; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Tall EG, 2000, CURR BIOL, V10, P743, DOI 10.1016/S0960-9822(00)00541-8; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; Tolias KF, 2000, FR MOLEC B, V27, P109; TONER M, 1988, BIOCHEMISTRY-US, V27, P7435, DOI 10.1021/bi00419a039; VANPARIDON PA, 1986, BIOCHIM BIOPHYS ACTA, V877, P216, DOI 10.1016/0005-2760(86)90137-2; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; Wang LP, 1996, J BIOL CHEM, V271, P24505, DOI 10.1074/jbc.271.40.24505; Yamaga M, 1999, J BIOL CHEM, V274, P28537, DOI 10.1074/jbc.274.40.28537; YANG L, 1995, BIOCHEMISTRY-US, V34, P1500, DOI 10.1021/bi00005a005	69	146	147	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5012	5019		10.1074/jbc.M008355200	http://dx.doi.org/10.1074/jbc.M008355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11053422	hybrid			2022-12-27	WOS:000168484300066
J	Bittova, L; Stahelin, RV; Cho, W				Bittova, L; Stahelin, RV; Cho, W			Roles of ionic residues of the C1 domain in protein kinase C-alpha activation and the origin of phosphatidylserine specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; CYSTEINE-RICH DOMAINS; MEMBRANE-BINDING; MONOLAYERS; DIACYLGLYCEROL; CA2+; COMPLEX	On the basis of extensive structure-function studies of protein kinase C-Cy (PRC-OL), We have proposed an activation mechanism for conventional PKCs in which the C2 domain and the C1 domain interact sequentially with membranes (Medkova, M., and Cho, W. (1999) J. Biol Chem. 274, 19852-19881), To further elucidate the interactions between the C1 and C2 domains during PKC activation and the origin of phosphatidylserine specificity, we mutated several charged residues in two CI domains (Cla and Gib) of PHC-alpha. We then measured the membrane binding affinities, activities, and monolayer penetration of these mutants. Results indicate that cationic residues of the C1a domain, most notably Arg(77), interact nonspecifically with anionic phospholipids prior to the membrane penetration of hydrophobic residues. The mutation of a single aspartate (Asp(55)) in the C1a domain to Ala or Lys resulted in dramatically reduced phosphatidylserine specificity in vesicle binding, activity, and monolayer penetration. In particular, D55A showed much higher vesicle affinity, activity, and monolayer penetration power than wild type under nonactivating conditions, i.e. with phosphatidylglycerol and in the absence of Ca2+, indicating that Asp(55) in involved in the tethering of the Cia domain to another part of PKC-alpha, which keeps it in an inactive conformation at the resting state, Based on these results, we propose a refined model for the activation of conventional PKC, in which phosphatidylserine specifically disrupts the C1a domain tethering by competing with Asp(55), which then leads to membrane penetration and diacylglycerol binding of the Cia domain and PKC activation.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem, M-C 111, Chicago, IL 60607 USA.		Bittova, Lenka/K-4375-2015; Stahelin, Robert/L-3567-2019	Bittova, Lenka/0000-0002-3556-5234; Stahelin, Robert/0000-0001-5443-7863	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53987] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; HANNUN YA, 1985, J BIOL CHEM, V260, P39; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; Pepio AM, 1998, BIOCHEMISTRY-US, V37, P1256, DOI 10.1021/bi971841u; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Slater SJ, 1996, J BIOL CHEM, V271, P4627; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	35	107	108	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4218	4226		10.1074/jbc.M008491200	http://dx.doi.org/10.1074/jbc.M008491200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11029472	hybrid			2022-12-27	WOS:000166921200066
J	Free, A; Wakefield, RID; Smith, BO; Dryden, DTF; Barlow, PN; Bird, AP				Free, A; Wakefield, RID; Smith, BO; Dryden, DTF; Barlow, PN; Bird, AP			DNA recognition by the methyl-CpG binding domain of MeCP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETT-SYNDROME; TRANSCRIPTIONAL REPRESSION; MUTATION TYPE; SELECTIVITY; DYNAMICS	The methyl-CpG binding domain (MBD) of the transcriptional repressor MeCP2 has been proposed to recognize a single symmetrically methylated CpG base pair via hydrophobic patches on an otherwise positively charged DNA binding surface. We have tested this binding model by analysis of mutant derivatives of the MeCP2 MBD in electrophoretic mobility shift assays complemented by NMR structural analysis. Exposed arginine side chains on the binding face, in particular Arg-lll, were found to be critical for binding. Arg-111 was found to interact with the conserved aspartate side chain Asp-121, which is proposed to orientate the arginine side chain to allow specific contacts with the DNA. The conformational flexibility of the disordered B-C loop region, which forms part of the binding face, was also shown to be important. In contrast, mutation off the exposed hydrophobic side chains had a less severe effect on DNA binding. This suggests that the Arg-lll side chain may contribute to sequence-specific recognition of the CpG site rather than simply making nonspecific contacts with the phosphate backbone. The majority of missense mutations within the MBD found in the human genetic disorder Rett syndrome were shown or predicted to affect folding of the domain rather than the DNA recognition event directly.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Edinburgh, Edinburgh Ctr Prot Technol, Edinburgh EH9 3JJ, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Free, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Swann Bldg,Kings Bldgs,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.	andrew.free@ed.ac.uk	Smith, Brian O/J-1899-2015; Free, Andrew/AAX-2632-2020; Barlow, Paul N/G-2853-2011; Smith, Brian/AAJ-9393-2020	Smith, Brian O/0000-0003-3363-4168; Smith, Brian/0000-0003-3363-4168; Free, Andrew/0000-0002-1787-4965; Bird, Adrian/0000-0002-8600-0372				Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Amir RE, 2000, ANN NEUROL, V47, P670, DOI 10.1002/1531-8249(200005)47:5<670::AID-ANA20>3.3.CO;2-6; Ballestar E, 2000, BIOCHEMISTRY-US, V39, P7100, DOI 10.1021/bi0001271; Bienvenu T, 2000, HUM MOL GENET, V9, P1377, DOI 10.1093/hmg/9.9.1377; Cheadle JP, 2000, HUM MOL GENET, V9, P1119, DOI 10.1093/hmg/9.7.1119; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Elrod-Erickson M, 1999, J BIOL CHEM, V274, P19281, DOI 10.1074/jbc.274.27.19281; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2000, CURR BIOL, V10, pR60, DOI 10.1016/S0960-9822(00)00286-4; Huppke P, 2000, HUM MOL GENET, V9, P1369, DOI 10.1093/hmg/9.9.1369; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Ohki I, 1999, EMBO J, V18, P6653, DOI 10.1093/emboj/18.23.6653; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Wan MM, 1999, AM J HUM GENET, V65, P1520, DOI 10.1086/302690; Xiang FQ, 2000, J MED GENET, V37, P250, DOI 10.1136/jmg.37.4.250; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	26	78	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3353	3360		10.1074/jbc.M007224200	http://dx.doi.org/10.1074/jbc.M007224200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035019	hybrid			2022-12-27	WOS:000166784900050
J	Maes, K; Missiaen, L; Parys, JB; De Smet, P; Sienaert, I; Waelkens, E; Callewaert, G; De Smedt, H				Maes, K; Missiaen, L; Parys, JB; De Smet, P; Sienaert, I; Waelkens, E; Callewaert, G; De Smedt, H			Mapping of the ATP-binding sites on inositol 1,4,5-trisphosphate receptor type 1 and type 3 homotetramers by controlled proteolysis and photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; CALCIUM-RELEASE; TRISPHOSPHATE RECEPTOR; ADENINE-NUCLEOTIDES; LIGAND-BINDING; EPITHELIAL-CELLS; SMOOTH-MUSCLE; CA2+ SIGNALS; PROTEIN; PURIFICATION	Submillimolar ATP concentrations strongly enhance the inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release, by binding specifically to ATP-binding sites on the IP3, receptor (IP3R). To locate those ATP-binding sites on IP(3)R1 and IP(3)R3, both proteins were expressed in Sf9 insect cells and covalently labeled with 8-azido-[alpha -32P]ATP. IP(3)R1 and IP(3)R3 were then purified and subjected to a controlled proteolysis, and the labeled proteolytic fragments were identified by site-specific antibodies. Two fragments of IP(3)R1 were labeled, each containing one of the previously proposed ATP-binding sites with amino acid sequence GXGXXG (amino acids 1773-1780 and 2016-2021, respectively). In IP(3)R3, only one fragment was labeled. This fragment contained the GXGXXG sequence (amino acids 1920-1925), which is conserved in the three IP3R isoforms, The presence of multiple interaction sites for ATP was also evident from the IP3-induced Ca2+ release in permeabilized A7r5 cells, which depended on ATP over a very broad concentration range from micromolar to millimolar.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Biochem Lab, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Maes, K (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Karlien.Maes@med.kuleuven.ac.be		Parys, Jan/0000-0002-3591-4967				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; DeSmedt H, 1997, BIOCHEM J, V322, P575; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GUILLEMETTE G, 1987, J BIOL CHEM, V262, P1010; GUILLEMETTE G, 1989, MOL PHARMACOL, V35, P339; Hagar RE, 2000, BIOPHYS J, V79, P271, DOI 10.1016/S0006-3495(00)76289-8; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Kaplin AI, 1996, J NEUROSCI, V16, P2002; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; Maes K, 1999, CELL CALCIUM, V25, P143, DOI 10.1054/ceca.1998.0011; Maes K, 2000, CELL CALCIUM, V27, P257, DOI 10.1054/ceca.2000.0121; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Missiaen L, 1997, BIOCHEM J, V325, P661, DOI 10.1042/bj3250661; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Nucifora FC, 1996, MOL BIOL CELL, V7, P949, DOI 10.1091/mbc.7.6.949; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; Sienaert I, 1998, PFLUG ARCH EUR J PHY, V436, P40, DOI 10.1007/s004240050602; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; Sipma H, 1999, J BIOL CHEM, V274, P12157, DOI 10.1074/jbc.274.17.12157; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Vanlingen S, 1997, CELL CALCIUM, V22, P475, DOI 10.1016/S0143-4160(97)90075-0; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WILLCOCKS AL, 1987, BIOCHEM BIOPH RES CO, V146, P1071, DOI 10.1016/0006-291X(87)90756-X; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316	50	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3492	3497		10.1074/jbc.M006082200	http://dx.doi.org/10.1074/jbc.M006082200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035010	hybrid			2022-12-27	WOS:000166784900066
J	Hoshino, R; Tanimura, S; Watanabe, K; Kataoka, T; Kohno, M				Hoshino, R; Tanimura, S; Watanabe, K; Kataoka, T; Kohno, M			Blockade of the extracellular signal-regulated kinase pathway induces marked G(1) cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated - Up-regulation of p27(Kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; INDEPENDENT MECHANISMS; MAMMALIAN-CELLS; GROWTH; DEATH; EXPRESSION; INHIBITOR; DNA; TRANSFORMATION; FRAGMENTATION	Constitutive activation of the ERK pathway is associated with the neoplastic phenotype of a relatively large number of human tumor cells. Blockade of the ERK pathway by treatment with PD98059, a specific inhibitor of mitogen-activated protein (MAP) kinase/ERK kinase (MEK), completely suppressed the growth of tumor cells in which the pathway is constitutively activated (RPMI-SE and HT1080 cells). Consistent with its prominent antiproliferative effect, PD98059 induced a remarkable G(1) cell cycle arrest, followed by a modest apoptotic response, in these tumor cells. Selective up-regulation of p27(Kip1) was observed after PD98059 treatment of RPMI-SE and HT1080 cells. Overexpression in RPMI-SE cells of either a kinase-negative form of MEK1 or wild-type MAP kinase phosphatase-3 also induced up-regulation of p27(Kip1), The up-regulation of p27(Kip1) correlated with increased association of p27(Kip1) With cyclin E-cyclin-dependent kinase (CDK) 2 complexes, a concomitant inhibition of cyclin E-CDK2 kinase activity, and a consequent decrease in the phosphorylation state of retinoblastoma protein, which would culminate in the marked G(1), cell cycle arrest observed in these tumor cells. These results suggest that the complete growth suppression that follows specific blockade of the ERK pathway in tumor cells in which the pathway is constitutively activated is mediated by up-regulation of p27(Kip1).	Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, Nagasaki 8528131, Japan; Gifu Pharmaceut Univ, Gifu 5028585, Japan	Nagasaki University; Gifu Pharmaceutical University	Kohno, M (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, 1-14 Bunkyo Machi, Nagasaki 8528131, Japan.		Kohno, Michiaki/R-6532-2019	Kohno, Michiaki/0000-0002-7644-0059				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P421; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gioeli D, 1999, CANCER RES, V59, P279; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Katayose Y, 1997, CANCER RES, V57, P5441; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Muda M, 1996, J BIOL CHEM, V271, P4319; NAKATSU Y, 1985, COLD SPRING HARB SYM, V51, P1001; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OKA H, 1995, CANCER RES, V55, P4182; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335	33	120	133	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2686	2692		10.1074/jbc.M006132200	http://dx.doi.org/10.1074/jbc.M006132200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11031257	hybrid			2022-12-27	WOS:000166784800054
J	Ritzel, MWL; Ng, AML; Yao, SYM; Graham, K; Loewen, SK; Smith, KN; Ritzel, RG; Mowles, DA; Carpenter, P; Chen, XZ; Karpinski, E; Hyde, RJ; Baldwin, SA; Cass, CE; Young, JD				Ritzel, MWL; Ng, AML; Yao, SYM; Graham, K; Loewen, SK; Smith, KN; Ritzel, RG; Mowles, DA; Carpenter, P; Chen, XZ; Karpinski, E; Hyde, RJ; Baldwin, SA; Cass, CE; Young, JD			Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; XENOPUS-LAEVIS OOCYTES; FUNCTIONAL EXPRESSION; TRANSPORT-SYSTEM; SODIUM/NUCLEOSIDE COTRANSPORTERS; HL-60 CELLS; CLONING; ADENOSINE; EI; DIFFERENTIATION	The human concentrative (Na+-linked) plasma membrane transport proteins hCNT1 and hCNT2 are selective for pyrimidine nucleosides (system cit) and purine nucleosides (system cif), respectively. Both have homologs in other mammalian species and belong to a gene family (CNT) that also includes hfCNT, a newly identified broad specificity pyrimidine and purine Na+-nucleoside symporter (system cib) from the ancient marine vertebrate, the Pacific hagfish (Eptatretus stouti). We now report the cDNA cloning and characterization of cib homologs of hfCNT from human mammary gland, differentiated human myeloid HL-60 cells, and mouse liver. The 691- and 703-residue human and mouse proteins, designated hCNT3 and mCNT3, respectively, were 79% identical in amino acid sequence and contained 13 putative transmembrane helices. hCNT3 was 48, 47, and 57% identical to hCNT1, hCNT2, and hfCNT, respectively. When produced in Xenopus oocytes, both proteins exhibited Na+-dependent cib-type functional activities. hCNT3 was electrogenic, and a sigmoidal dependence of uridine influx on Na+ concentration indicated a Na+: uridine coupling ratio of at least 2:1 for both hCNT3 and mCNT3 (cf 1:1 for hCNT1/2). Phorbol myristate acetate-induced differentiation of HL-60 cells led to the parallel appearance of cib-type activity and hCNT3 mRNA. Tissues containing hCNT3 transcripts included pancreas, bone marrow, trachea, mammary gland, liver, prostrate, and regions of intestine, brain, and heart. The hCNT3 gene mapped to chromosome 9q22.2 and included an upstream phorbol myristate acetate response element.	Univ Alberta, Dept Physiol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2H7, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Transport Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.		Cass, Carol E/F-5861-2010					Anderson CM, 1996, MOL BRAIN RES, V42, P358, DOI 10.1016/S0169-328X(96)00244-6; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BELT J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P20; BELT JA, 1993, ADV ENZYME REGUL, V33, P235; Boleti H, 1997, NEUROPHARMACOLOGY, V36, P1167, DOI 10.1016/S0028-3908(97)00136-6; CASS CE, 1995, DRUG TRANSPORT ANTIM, P404; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Chen XZ, 1999, J BIOL CHEM, V274, P2773, DOI 10.1074/jbc.274.5.2773; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; Fang X, 1996, BIOCHEM J, V317, P457, DOI 10.1042/bj3170457; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; FREDHOLM BB, 1997, CURR MED CHEM, V4, P35; Graham KA, 2000, NUCLEOS NUCLEOT NUCL, V19, P415, DOI 10.1080/15257770008033018; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HANDSCHUMACHER RE, 1993, CANC METABOLISM, P712; Hong M, 2000, J PHARMACOL EXP THER, V292, P366; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; Lee Chee-Wee, 1994, In Vivo (Attiki), V8, P795; LEE CW, 1991, BIOCHEM J, V274, P85, DOI 10.1042/bj2740085; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; Mackey JR, 1998, CANCER RES, V58, P4349; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; Mackey JR, 1999, JNCI-J NATL CANCER I, V91, P1876, DOI 10.1093/jnci/91.21.1876; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; Paterson AR, 1993, P AM ASSOC CANC RES, V34, pA84; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; Roy L, 1996, INT J RADIAT BIOL, V70, P665, DOI 10.1080/095530096144545; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wang J, 1997, J BIOL CHEM, V272, P28845, DOI 10.1074/jbc.272.46.28845; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; WU XC, 1992, J BIOL CHEM, V267, P8813; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	53	292	304	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2914	2927		10.1074/jbc.M007746200	http://dx.doi.org/10.1074/jbc.M007746200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11032837	hybrid			2022-12-27	WOS:000166784800084
J	Miranda, KM; Espey, MG; Yamada, K; Krishna, M; Ludwick, N; Kim, S; Jourd'heuil, D; Grisham, MB; Feelisch, M; Fukuto, JM; Wink, DA				Miranda, KM; Espey, MG; Yamada, K; Krishna, M; Ludwick, N; Kim, S; Jourd'heuil, D; Grisham, MB; Feelisch, M; Fukuto, JM; Wink, DA			Unique oxidative mechanisms for the reactive nitrogen oxide species, nitroxyl anion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXYNITRITE-MEDIATED OXIDATION; FREE NITRIC-OXIDE; CARBON-DIOXIDE; SUPEROXIDE-DISMUTASE; BIOLOGICAL-ACTIVITY; HYDROGEN-PEROXIDE; NITROSYL HYDRIDE; NO; NITRATION; DIHYDRORHODAMINE-123	The nitroxyl anion (NO-) is a highly reactive molecule that may be involved in pathophysiological actions associated with increased formation of reactive nitrogen oxide species. Angeli's salt (Na2N2O3; AS) is a NO- donor that has been shown to exert marked cytotoxicity. However, its decomposition intermediates have not been well characterized. In this study, the chemical reactivity of AS was examined and compared with that of peroxynitrite (ONOO-) and NO/N2O3. Under aerobic conditions, AS and ONOO- exhibited similar and considerably higher affinities for dihydrorhodamine (DHR) than NO/N2O3. Quenching of DHR oxidation by azide and nitrosation of diaminonaphthalene were exclusively observed with NO/N2O3. Additional comparison of ONOO- and AS chemistry demonstrated that ONOO- was a far more potent one-electron oxidant and nitrating agent of hydroxyphenylacetic acid than was AS. However, AS was more effective at hydroxylating benzoic acid than was ONOO-. Taken together, these data indicate that neither NO/N2O3 nor ONOO- is an intermediate of AS decomposition. Evaluation of the stoichiometry of AS decomposition and O-2 consumption revealed a 1:1 molar ratio. Indeed, oxidation of DHR mediated by AS proved to be oxygen dependent. Analysis of the end products of AS decomposition demonstrated formation of NO2- and NO3- in approximately stoichiometric ratios. Several mechanisms are proposed for O-2 adduct formation followed by decomposition to NO3- or by oxidation of an HN2O3- molecule to form NO2-. Given that the cytotoxicity of AS is far greater than that of either NO/N2O3 or NO + O-2(-) this study provides important new insights into the implications of the potential endogenous formation of NO- under inflammatory conditions in vivo.	NCI, Tumor Biol Sect, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Dept Mol Pharmacol, Los Angeles, CA 90269 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Los Angeles; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Miranda, KM (corresponding author), NCI, Tumor Biol Sect, Radiat Biol Branch, NIH, Bldg 10,Rm B3-B69, Bethesda, MD 20892 USA.		Yamada, Ken-ichi/E-6318-2012; Miranda, Katrina M/B-7823-2009; Cook, Natalie Mikki/J-5401-2019; Feelisch, Martin/C-3042-2008	Yamada, Ken-ichi/0000-0003-2100-8477; Feelisch, Martin/0000-0003-2320-1158; Azad, Mahan/0000-0002-8633-3513; Jourd'heuil, David/0000-0002-6555-5061; Wink, David/0000-0002-5652-7480				ADAK S, 2000, IN PRESS J BIOL CHEM; AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; Bonner F.T., 2010, CHEMINFORM, V28, DOI [10.1002/chin.199715245, DOI 10.1002/CHIN.199715245]; BONNER FT, 1978, INORG CHEM, V17, P2487, DOI 10.1021/ic50187a030; Briviba K, 1998, BIOCHEM PHARMACOL, V55, P817, DOI 10.1016/S0006-2952(97)00542-X; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; DONALD CE, 1986, INORG CHEM, V25, P2676, DOI 10.1021/ic00236a004; DOYLE MP, 1988, J AM CHEM SOC, V110, P593, DOI 10.1021/ja00210a047; Feelisch M., 1996, METHODS NITRIC OXIDE, P71; Forstner H., 1983, POLAROGRAPHIC OXYGEN, P321, DOI [10.1007/978-3-642-81863-9_28, DOI 10.1007/978-3-642-81863-9_28]; FUKUTO JM, 1993, BIOCHEM BIOPH RES CO, V196, P707, DOI 10.1006/bbrc.1993.2307; GALLUP GA, 1975, INORG CHEM, V14, P563, DOI 10.1021/ic50145a023; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P1003; HOBBS AJ, 1994, P NATL ACAD SCI USA, V91, P10992, DOI 10.1073/pnas.91.23.10992; HUGHES MN, 1968, J CHEM SOC A, P451; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; Ischiropoulos H, 1996, FREE RADICAL BIO MED, V20, P373, DOI 10.1016/0891-5849(95)02098-5; ISHAWATA T, 1974, CHEM PHYS LETT, V27, P260; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Khan AU, 2000, P NATL ACAD SCI USA, V97, P2984, DOI 10.1073/pnas.050587297; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Lemercier JN, 1997, ARCH BIOCHEM BIOPHYS, V345, P160, DOI 10.1006/abbi.1997.0240; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; ROBINSON J, 1970, ANAL BIOCHEM, V33, P390, DOI 10.1016/0003-2697(70)90310-6; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; WILLIAMS DLH, 1988, NITROSATION, P179; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; Wink DA, 1997, J BIOL CHEM, V272, P11147; Wink DA, 1996, ARCH BIOCHEM BIOPHYS, V331, P241, DOI 10.1006/abbi.1996.0304; WINK DA, 1996, METHODS NITRIC OXIDE, P403; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g	43	122	124	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1720	1727		10.1074/jbc.M006174200	http://dx.doi.org/10.1074/jbc.M006174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042174	hybrid			2022-12-27	WOS:000166528000011
J	van Bennekum, AM; Wei, SH; Gamble, MV; Vogel, S; Piantedosi, R; Gottesman, M; Episkopou, V; Blaner, WS				van Bennekum, AM; Wei, SH; Gamble, MV; Vogel, S; Piantedosi, R; Gottesman, M; Episkopou, V; Blaner, WS			Biochemical basis for depressed serum retinol levels in transthyretin-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEIN; ACUTE-RENAL-FAILURE; PLASMA RETINOL; ENDOPLASMIC-RETICULUM; HELA-CELLS; METABOLISM; RAT; COMPLEX; INTERNALIZATION; EXPRESSION	Transthyretin (TTR) acts physiologically in the transport of retinol in the circulation. We previously reported the generation and partial characterization of TTR-deficient (TTR-) mice. TTR- mice have very low circulating levels of retinol and its specific transport protein, retinol-binding protein (RBP). We have examined the biochemical basis for the low plasma retinol-RBP levels. Cultured primary hepatocytes isolated from wild type (WT) and TTR- mice accumulated REP in their media to an identical degree, suggesting that REP was being secreted from the hepatocytes at the same rate, In vivo experiments support; this conclusion. For the first 11 h after complete nephrectomy, the levels retinol and REP rose in the circulations of WT and TTR- mice at nearly identical rates. However, human retinol-RBP injected intravenously was more rapidly cleared from the circulation (t(1/2) = 0.5 h for TTR- versus t(1/2) > 6 h for WT) and accumulated faster in the kidneys of TTR- compared with WT mice. The rate of infiltration of the retinol-RBP complex from the circulation to tissue interstitial fluids was identical in both strains. Taken together, these data indicate that low circulating retinol-RBP levels in TTRmice arise from increased renal filtration of the retinol-RBP complex.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Inst Canc Res, New York, NY 10032 USA; Hammersmith Hosp, MRC, London W12 0NN, England	Columbia University; Columbia University; Columbia University; Columbia University; Imperial College London	Blaner, WS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, Hammer Hlth Sci Bldg,Rm 502,701 W 168th St, New York, NY 10032 USA.		Episkopou, Vasso/E-2952-2010		Medical Research Council [MC_U120074332] Funding Source: Medline; NEI NIH HHS [EY12858] Funding Source: Medline; NIDDK NIH HHS [DK52444] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052444] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bellovino D, 1996, EXP CELL RES, V222, P77, DOI 10.1006/excr.1996.0010; Blaner William S., 1994, P229; BLANER WS, 1990, METHOD ENZYMOL, V189, P270; BLANER WS, 1990, METHOD ENZYMOL, V189, P193; BRONZERT TJ, 1977, CLIN CHEM, V23, P2089; BROUWER A, 1988, CHEM-BIOL INTERACT, V68, P203, DOI 10.1016/0009-2797(88)90017-8; Cooper AD, 1997, J LIPID RES, V38, P2173; DIVINO CM, 1990, J BIOL CHEM, V265, P1425; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; GERLACH TH, 1990, FASEB J, V4, P2511, DOI 10.1096/fasebj.4.8.2335274; GERLACH TH, 1991, J LIPID RES, V32, P515; GOODMAN DS, 1965, J LIPID RES, V6, P390; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; KATO M, 1985, J BIOL CHEM, V260, P4832; KRASINSKI SD, 1990, METABOLISM, V39, P357, DOI 10.1016/0026-0495(90)90249-C; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MELHUS H, 1992, J BIOL CHEM, V267, P12036; MELHUS H, 1991, EXP CELL RES, V197, P119, DOI 10.1016/0014-4827(91)90488-G; RITTER SJ, 1995, J NUTR BIOCHEM, V6, P689, DOI 10.1016/0955-2863(95)00149-2; SCHINDLER R, 1986, INT J VITAM NUTR RES, V56, P21; SENOO H, 1990, J LIPID RES, V31, P1229; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; van Bennekum AM, 1999, J LIPID RES, V40, P565; VOGEL S, 1999, HANDB EXP PHARM, V139, P31; Waynforth H, 1992, EXPT SURG TECHNIQUE, P274; WEI SH, 1995, J BIOL CHEM, V270, P866, DOI 10.1074/jbc.270.2.866	28	95	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1107	1113		10.1074/jbc.M008091200	http://dx.doi.org/10.1074/jbc.M008091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11036082	hybrid			2022-12-27	WOS:000166430900035
J	Deng, L; Lin-Lee, YC; Claret, FX; Kuo, MT				Deng, L; Lin-Lee, YC; Claret, FX; Kuo, MT			2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MULTIDRUG RESISTANCE-1 GENE; P-GLYCOPROTEIN; CELL-PROLIFERATION; TRANSCRIPTIONAL ACTIVITY; HEPATOCYTE CULTURES; OXIDATIVE STRESS; BINDING-SITE; INDUCTION; LIVER	Overexpression of multidrug resistance genes and their encoded P-glycoproteins is a major mechanism for the development of multidrug resistance in cancer cells, The hepatocarcinogen 2-acetylaminofluorene (2-AAF) efficiently activates rat mdr1b expression. However, the underlying mechanisms are largely unknown. In this study, we demonstrated that a NF-kappaB site on the mdr1b promoter was required for this induction. Overexpression of antisense p65 and I kappaB alpha partially abolished the induction. We then delineated the pathway through which 2-AAF activates NF-kappaB. 2-AAF treatment led to the increase of intracellular reactive oxygen species (ROS) which causes activation of IKK kinases, degradation of I kappaB beta (but not I kappaB alpha), and increase in NF-kappaB DNA binding activity. Consistent with the idea that ROS may participate in mdr1b regulation, antioxidant N-acetylcysteine inhibited the induction of mdr1b by 2-AAF. Overproduction of a physiological antioxidant glutathione (GSH) blocked the activation of IKK kinase complex and NF-kappaB DNA binding. Based on these results, we conclude that 2-AAF up-regulates mdr1b through the generation of ROS, activation of IKK kinase, degradation of I kappaB beta, and subsequent activation of NF-kappaB. This is the first report that reveals the specific cis-elements and signaling pathway responsible for the induction of mdr1b by the chemical carcinogen 2-AAF.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuo, MT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.		Claret, Francois X/R-2104-2016	Claret, Francois X/0000-0003-4629-6495	NATIONAL CANCER INSTITUTE [R01CA079085, R01CA072404, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 79085, CA 72404, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balansky R, 1996, CANCER RES, V56, P1642; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Chen F, 1999, J BIOL CHEM, V274, P20307, DOI 10.1074/jbc.274.29.20307; Christman JW, 1998, INTENS CARE MED, V24, P1131, DOI 10.1007/s001340050735; Christman JW, 2000, BRAIN PATHOL, V10, P153; COGSWELL JP, 1994, J IMMUNOL, V153, P712; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; Hirsch-Ernst KI, 1998, J CELL PHYSIOL, V176, P506, DOI 10.1002/(SICI)1097-4652(199809)176:3<506::AID-JCP7>3.0.CO;2-S; Huang RP, 1999, CARCINOGENESIS, V20, P485, DOI 10.1093/carcin/20.3.485; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lin Jen-Kun, 1999, Proceedings of the National Science Council Republic of China Part B Life Sciences, V23, P99; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MEHTA R, 1995, CANCER LETT, V93, P85, DOI 10.1016/0304-3835(95)03790-4; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; Ng IOL, 2000, AM J CLIN PATHOL, V113, P355, DOI 10.1309/AC1M-4TY4-U0TN-EN7T; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; POIRIER MC, 1991, CARCINOGENESIS, V12, P895, DOI 10.1093/carcin/12.5.895; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; SILVERMAN JA, 1995, MOL CARCINOGEN, V13, P50, DOI 10.1002/mc.2940130109; Soini Y, 1996, J CLIN PATHOL, V49, P470, DOI 10.1136/jcp.49.6.470; TEETER LD, 1993, MOL CARCINOGEN, V8, P67, DOI 10.1002/mc.2940080202; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; UMEMURA T, 1993, CANCER LETT, V73, P1, DOI 10.1016/0304-3835(93)90181-8; Utsunomiya Y, 1997, LEUKEMIA, V11, P894, DOI 10.1038/sj.leu.2400663; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Verna L, 1996, PHARMACOL THERAPEUT, V71, P83, DOI 10.1016/0163-7258(96)00063-0; VOLM M, 1990, CARCINOGENESIS, V11, P169, DOI 10.1093/carcin/11.1.169; Yamane Y, 1998, J BIOL CHEM, V273, P31075, DOI 10.1074/jbc.273.47.31075; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhou G, 1998, J BIOL CHEM, V273, P15387, DOI 10.1074/jbc.273.25.15387; Zhou G, 1996, CELL GROWTH DIFFER, V7, P1369	43	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					413	420		10.1074/jbc.M004551200	http://dx.doi.org/10.1074/jbc.M004551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11020383	hybrid			2022-12-27	WOS:000166280700056
J	Gustafson, MP; Thomas, CF; Rusnak, F; Limper, AH; Leof, EB				Gustafson, MP; Thomas, CF; Rusnak, F; Limper, AH; Leof, EB			Differential regulation of growth and checkpoint control mediated by a Cdc25 mitotic phosphatase from Pneumocystis carinii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; REPLICATION CHECKPOINT; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; ACTIVATION; PNEUMONIA; PARASITE; CDS1; IDENTIFICATION; CONTAINS	Pneumocystis carinii is an opportunistic fungal pathogen phylogenetically related to the fission yeast Schizosaccharomyces pombe. P. carinii causes severe pneumonia in immunocompromised patients with AIDS and malignancies. Although the life cycle of P, carinii remains poorly characterized, morphologic studies of infected lung tissue indicate that P. carinii alternates between numerous small trophic forms and fewer large cystic forms. To understand further the molecular mechanisms that regulate progression of the cell cycle of P, carinii, we have sought to identify and characterize genes in P. carinii that are important regulators of eukaryotic cell cycle progression. In this study, we have isolated a cDNA from P. carinii that exhibits significant homology, but unique functional characteristics, to the mitotic phosphatase Cdc25 found in S. pombe. P. carinii Cdc25 was shown to rescue growth of the temperature-sensitive S. pombe cdc25-22 strain and thus provides an additional tool to investigate the unique P.. carinii life cycle. Although P. carinii Cdc25 could also restore the DNA damage checkpoint in cdc25-22 cells, it was unable to restore fully the DNA replication checkpoint. The dissociation of checkpoint control at the level of Cdc25 indicates that Cdc25 may be under distinct regulatory control in mediating checkpoint signaling.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Thorac Dis Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Pulm Crit Care & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Hematol Res Sect, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Leof, EB (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Guggenheim 642C, Rochester, MN 55905 USA.	leof.edward@mayo.edu	Gustafson, Michael P./H-4056-2011	Gustafson, Michael P./0000-0002-5514-7072	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057125, R01HL062150, R01HL055934] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL55934, R01 HL 57125, R01 HL 62150] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baber-Furnari BA, 2000, MOL BIOL CELL, V11, P1; BARTLETT MS, 1988, J CLIN MICROBIOL, V26, P1100, DOI 10.1128/JCM.26.6.1100-1102.1988; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Bruns TD, 1992, MOL PHYLOGENET EVOL, V1, P231, DOI 10.1016/1055-7903(92)90020-H; CUSHION MT, 1993, J CLIN MICROBIOL, V31, P1217, DOI 10.1128/JCM.31.5.1217-1223.1993; CUSHION MT, 1993, INFECT IMMUN, V61, P4801, DOI 10.1128/IAI.61.11.4801-4813.1993; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Eckstein JW, 1996, PROTEIN SCI, V5, P5; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; Fleig U N, 1991, Semin Cell Biol, V2, P195; FLETCHER LD, 1993, GENE, V129, P307, DOI 10.1016/0378-1119(93)90285-B; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; Haase G, 1997, INFECT IMMUN, V65, P4365, DOI 10.1128/IAI.65.10.4365-4366.1997; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HONG ST, 1990, J CLIN MICROBIOL, V28, P1785, DOI 10.1128/JCM.28.8.1785-1795.1990; Honigberg SM, 1993, CURR OPIN CELL BIOL, V5, P219, DOI 10.1016/0955-0674(93)90106-Z; IINO Y, 1995, GENETICS, V140, P1235; Kottom TJ, 1999, J EUKARYOT MICROBIOL, V46, p131S; Kottom TJ, 2000, AM J RESP CELL MOL, V22, P722, DOI 10.1165/ajrcmb.22.6.3838; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; Kovelman R, 1996, MOL CELL BIOL, V16, P86; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; Limper A. H., 1995, Journal of Investigative Medicine, V43, p466A; LIMPER AH, 1990, J CLIN INVEST, V85, P391, DOI 10.1172/JCI114451; LIMPER AH, 1989, AM REV RESPIR DIS, V140, P1204, DOI 10.1164/ajrccm/140.5.1204; Limper AH, 1997, J LAB CLIN MED, V130, P132, DOI 10.1016/S0022-2143(97)90089-5; LONG EG, 1986, LAB INVEST, V54, P609; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MACNEILL SA, 1993, CELL CYCLE PRACTICAL, P106; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Merali S, 1999, P NATL ACAD SCI USA, V96, P2402, DOI 10.1073/pnas.96.5.2402; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1993, CELL CYCLE INTRO, P42; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Raleigh JM, 2000, J CELL SCI, V113, P1727; Rhind N, 1998, MOL CELL BIOL, V18, P3782, DOI 10.1128/MCB.18.7.3782; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; RUFFOLO JJ, 1994, PNEUMOCYSTIS CARINII, P25; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Safrin S, 1993, Semin Respir Infect, V8, P96; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCHMATZ DM, 1990, P NATL ACAD SCI USA, V87, P5950, DOI 10.1073/pnas.87.15.5950; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Thomas CF, 1998, AM J PHYSIOL-LUNG C, V275, pL193, DOI 10.1152/ajplung.1998.275.1.L193; Thomas CF, 1998, AM J RESP CELL MOL, V18, P297, DOI 10.1165/ajrcmb.18.3.3122; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	59	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					835	843		10.1074/jbc.M007814200	http://dx.doi.org/10.1074/jbc.M007814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029470	hybrid			2022-12-27	WOS:000166280700112
J	Shen, AL; Kasper, CB				Shen, AL; Kasper, CB			Differential contributions of NADPH-cytochrome P450 oxidoreductase FAD binding site residues to flavin binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-450 REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; DIRECTED MUTAGENESIS; CODING NUCLEOTIDE; DOMAINS; FMN; ACID; IDENTIFICATION; PROTOTYPE; SEQUENCE	Transfer of reducing equivalents from NADPH to the cytochromes P450 is mediated by NADPH-cytochrome P450 oxidoreductase, which contains stoichiometric amounts of tightly bound FMN and FAD. Hydrogen bonding and van der Waals interactions between FAD and amino acid residues in the FAD binding site of the reductase serve to regulate both flavin binding and reactivity. The precise orientation of key residues (Arg(454), Tyr(456), Cys(472), Gly(488), Thr(491), and Trp(677)) has been defined by x-ray crystallography (Wang, M., Roberts, D. L., Paschke, R., Shea, T. M., Masters, B. S., Kim, J.-J. P. (1997) Proc. Natl. Acad Sci. U.S. A. 94, 8411-8416). The current study examines the relative contributions of these residues to FAD binding and catalysis by site-directed mutagenesis and kinetic analysis. Mutation of either Tyr(456), which makes van der Waals contact with the FAD isoalloxazine ring and also hydrogen-bonds to the ribityl 4'-hydroxyl, or Arg(454), which bonds to the FAD pyrophosphate, decreases the affinity for FAD 8000- and 25,000-fold, respectively, with corresponding decreases in cytochrome c reductase activity. In contrast, substitution of Thr(491), which also interacts with the pyrophosphate grouping, had a relatively modest effect on both FAD binding (100-fold decrease) and catalytic activity (2-fold decrease), while the G488L mutant exhibited, respectively, 800- and 50-fold decreases in FAD binding and catalytic activity. Enzymic activity of each of these mutants could be restored by addition of FAD. Kinetic properties and the FMN content of these mutants were not affected by these substitutions, with the exception of a 3-fold increase in Y456S K-m(cyt c) and a 70% decrease in R454E FMN content, suggesting that the FMN- and FAD-binding domains are largely, but not completely, independent, Even though Trp(677) iS stacked against the re-face of FAD, suggesting an important role in FAD binding, deletion of both Trp(677) and the carboxyl-terminal Ser(678) decreased catalytic activity 50-fold without affecting FAD content.	Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Shen, AL (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.				NATIONAL CANCER INSTITUTE [P01CA022484, K04CA000920] Funding Source: NIH RePORTER; NCI NIH HHS [CA22484, CA0920] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barsukov I, 1997, J BIOMOL NMR, V10, P63, DOI 10.1023/A:1018313830207; BLACK SD, 1982, J BIOL CHEM, V257, P5929; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CALCATERRA NB, 1995, BIOCHEMISTRY-US, V34, P12842, DOI 10.1021/bi00039a045; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Dwyer TM, 1999, BIOCHEMISTRY-US, V38, P9735, DOI 10.1021/bi9903906; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; GUEX N, 1997, PROTEIN DATA BANK Q, V77, P7; Hodgson AV, 1996, ARCH BIOCHEM BIOPHYS, V325, P99, DOI 10.1006/abbi.1996.0012; HUBBARD PA, 1999, FLAVINS FLAVOPROTEIN, P159; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; KURZBAN GP, 1990, J BIOL CHEM, V265, P12272; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; NARAYANASAMI R, 1995, ARCH BIOCHEM BIOPHYS, V316, P267, DOI 10.1006/abbi.1995.1037; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; SEM DS, 1994, BIOCHEMISTRY-US, V33, P12012, DOI 10.1021/bi00206a002; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; SHEN AL, 1993, HDB EXPT PHARM, V105, P35; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411	29	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41087	41091		10.1074/jbc.M008380200	http://dx.doi.org/10.1074/jbc.M008380200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11022049	hybrid			2022-12-27	WOS:000166114600058
J	Caccuri, AM; Antonini, G; Board, PG; Flanagan, J; Parker, MW; Paolesse, R; Turella, P; Chelvanayagam, G; Ricci, G				Caccuri, AM; Antonini, G; Board, PG; Flanagan, J; Parker, MW; Paolesse, R; Turella, P; Chelvanayagam, G; Ricci, G			Human glutathione transferase T2-2 discloses some evolutionary strategies for optimization of the catalytic activity of glutathione transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; S-TRANSFERASES; BIOCHEMICAL PATHWAYS; KINETIC-ANALYSIS; PROTON RELEASE; HELIX 2; P1-1; MECHANISM; BINDING; FLEXIBILITY	Steady state, pre-steady state kinetic experiments, and site-directed mutagenesis have been used to dissect the catalytic mechanism of human glutathione transferase T2-2 with 1-menaphthyl sulfate as co-substrate, This enzyme is close to the ancestral precursor of the more recently evolved glutathione transferases belonging to Alpha, Pi, and Mu classes. The enzyme displays a random kinetic mechanism with very low k(cat) and k(cat)/ K-m(GSH) values and with a rate-limiting step identified as the product release. The chemical step, which is fast and causes product accumulation before the steady state catalysis, strictly depends on the deprotonation of the bound GSH. Replacement of Arg-107 with Ala dramatically affects the fast phase, indicating that this residue is crucial both in the activation and orientation of GSH in the ternary complex. All pre-steady state and steady state kinetic data were convincingly fit to a kinetic mechanism that reflects a quite primordial catalytic efficiency of this enzyme. It involves two slowly interconverting or not interconverting enzyme populations (or active sites of the dimeric enzyme) both able to bind and activate GSH and strongly inhibited by the product. Only one population or subunit is catalytically competent. The proposed mechanism accounts for the apparent half-site behavior of this enzyme and for the apparent negative cooperativity observed under steady state conditions. These findings also suggest some evolutionary strategies in the glutathione transferase family that have been adopted for the optimization of the catalytic activity, which are mainly based on an increased flexibility of critical protein segments and on an optimal orientation of the substrate.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Aquila, Dept Basic & Appl Biol, I-67010 Coppito, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia; St Vincents Inst Med Res, Ian Potter Fdn Prot Crystallog Lab, Fitzroy, Vic 3065, Australia; Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Childrens Hosp IRCCS Bambin Gesu, I-00165 Rome, Italy	University of Rome Tor Vergata; University of L'Aquila; Sapienza University Rome; Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research; University of Rome Tor Vergata; IRCCS Bambino Gesu	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Biol, Viale Ric Sci, I-00133 Rome, Italy.	riccig@uniroma2.it	Parker, Michael W/F-9069-2013; CACCURI, ANNA MARIA/AFU-2643-2022; Paolesse, Roberto/AAI-3182-2020; Paolesse, Roberto/B-8966-2013	Parker, Michael W/0000-0002-3101-1138; Paolesse, Roberto/0000-0002-2380-1404; CACCURI, ANNA MARIA/0000-0002-3756-4163; Antonini, Giovanni/0000-0002-2115-8961; Ricci, Giorgio/0000-0002-7108-2846				Antonini G, 1996, BIOCHEM J, V314, P533, DOI 10.1042/bj3140533; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Board PG, 1997, BIOCHEM J, V328, P929; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 1998, BIOCHEMISTRY-US, V37, P3028, DOI 10.1021/bi971903g; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; CHENG DJ, 1988, MRL B RES DEV, V2, P27; CLAPP JJ, 1970, BIOCHEM J, V118, P765, DOI 10.1042/bj1180765; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Flanagan JU, 1999, PROTEIN SCI, V8, P2205, DOI 10.1110/ps.8.10.2205; HENDLER RW, 1994, J BIOCHEM BIOPH METH, V28, P1, DOI 10.1016/0165-022X(94)90061-2; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; IVANETICH KM, 1990, BIOCHEM PHARMACOL, V39, P1999, DOI 10.1016/0006-2952(90)90621-Q; Jemth P, 1999, BIOCHEMISTRY-US, V38, P9982, DOI 10.1021/bi983065b; Jemth P, 2000, J BIOL CHEM, V275, P8618, DOI 10.1074/jbc.275.12.8618; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Mendes P, 1998, BIOINFORMATICS, V14, P869, DOI 10.1093/bioinformatics/14.10.869; Nieslanik BS, 1999, BIOCHEMISTRY-US, V38, P6971, DOI 10.1021/bi9829130; Parsons JF, 1998, BIOCHEMISTRY-US, V37, P6286, DOI 10.1021/bi980219e; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; Salinas AE, 1999, CURR MED CHEM, V6, P279; Stella L, 1998, J BIOL CHEM, V273, P23267, DOI 10.1074/jbc.273.36.23267; Stella L, 1999, PROTEINS, V37, P10, DOI 10.1002/(SICI)1097-0134(19991001)37:1<10::AID-PROT2>3.0.CO;2-0; Stella L, 1999, PROTEINS, V37, P1; Tan KL, 1996, BIOCHEM J, V319, P315, DOI 10.1042/bj3190315; Widersten M, 1996, BIOCHEMISTRY-US, V35, P7731, DOI 10.1021/bi9601619; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	32	10	10	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5432	5437		10.1074/jbc.M002818200	http://dx.doi.org/10.1074/jbc.M002818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11044441	hybrid			2022-12-27	WOS:000167115100005
J	Augustine, JG; de la Calle, A; Knarr, G; Buchner, J; Frederick, CA				Augustine, JG; de la Calle, A; Knarr, G; Buchner, J; Frederick, CA			The crystal structure of the Fab fragment of the monoclonal antibody MAK33 - Implications for folding and interaction with the chaperone BiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; HEAVY-CHAIN; PEPTIDE-BINDING; ASSOCIATION; SPECIFICITY; COMPLEX; DOMAIN; SEQUENCES; MOLTEN; STATE	The Feb fragment of the murine monoclonal antibody, MAK33, directed against human creatine kinase of the muscle-type, was crystallized and the three-dimensional structure was determined to 2.9 Angstrom. The antigen-binding surface of MAK33 shows a convex overall shape typical for immunoglobulins binding large antigens, The structure allows us to analyze the environment of cis-prolylpeptide bonds whose isomerization is of key importance in the folding process. These residues seem to be involved with not only domain stability but also seem to play a role in the association of heavy and light chains, reinforcing the importance of beta -strand recognition in antibody assembly. The structure also allows the localization of segments of primary sequence postulated to represent binding sites for the ER-specific chaperone BiP within the context of the entire Feb fragment. These sequences are found primarily in beta -strands that are necessary for interactions between the individual domains.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Technical University of Munich	Frederick, CA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, SM1036,44 Binney St, Boston, MA 02115 USA.	caf@red.dfci.harvard.edu	Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				ATHERTON E, 1978, J CHEM SOC CHEM COMM, P537, DOI 10.1039/c39780000537; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESCAR J, 1995, J BIOL CHEM, V270, P18067, DOI 10.1074/jbc.270.30.18067; LILIE H, 1995, FEBS LETT, V362, P43, DOI 10.1016/0014-5793(95)00203-L; LILIE H, 1994, J BIOL CHEM, V269, P14290; LILIE H, 1993, PROTEIN SCI, V2, P1490, DOI 10.1002/pro.5560020913; LILIE H, 1995, J MOL BIOL, V248, P190, DOI 10.1006/jmbi.1995.0211; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1993, DAT COLL PROC P CCP4; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Ptitsyn O, 1996, NAT STRUCT BIOL, V3, P488, DOI 10.1038/nsb0696-488; PTITSYN OB, 1994, FEBS LETT, V341, P15, DOI 10.1016/0014-5793(94)80231-9; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; Skowronek MH, 1998, P NATL ACAD SCI USA, V95, P1574, DOI 10.1073/pnas.95.4.1574; Thies MJW, 1999, J MOL BIOL, V293, P67, DOI 10.1006/jmbi.1999.3128; WIECH H, 1993, J BIOL CHEM, V268, P7414; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	43	25	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3287	3294		10.1074/jbc.M005221200	http://dx.doi.org/10.1074/jbc.M005221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11036070	hybrid			2022-12-27	WOS:000166784900041
J	Kotenko, SV; Izotova, LS; Mirochnitchenko, OV; Esterova, E; Dickensheets, H; Donnelly, RP; Pestka, S				Kotenko, SV; Izotova, LS; Mirochnitchenko, OV; Esterova, E; Dickensheets, H; Donnelly, RP; Pestka, S			Identification of the functional interleukin-22 (IL-22) receptor complex - The IL-10R2 chain (IL-10R beta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-ASSOCIATED GENE; HUMAN-MELANOMA DIFFERENTIATION; INTERFERON-GAMMA RECEPTOR; TRANSGENIC MICE; CANDIDATE GENE; PROTEIN-KINASE; ASTHMA; EXPRESSION; LINKAGE; HYPERRESPONSIVENESS	Interleukin-10 (IL-10)-related T cell-derived inducible factor (IL-TIF; provisionally designated IL-22) is a cytokine with limited homology to IL-10, We report here the identification of a functional IL-TIF receptor complex that consists of two receptor chains, the orphan CRF2-9 and IL-10R2, the second chain of the IL-10 receptor complex. Expression of the CRF2-9 chain in monkey COS cells renders them sensitive to IL-TIF, However, in hamster cells both chains, CRF2-9 and IL-10R2, must be expressed to assemble the functional IL-TIF receptor complex. The CRF2-9 chain (or the IL-TIF-R1 chain) is responsible for Stat recruitment. Substitution of the CRF2-9 intracellular domain with the IFN-gamma R1 intracellular domain changes the pattern of IL-TIF-induced Stat activation. The CRF2-9 gene is expressed in normal liver and kidney, suggesting a possible role for IL-TIF in regulating gene expression in these tissues. Each chain, CRF2-9 and IL-10R2, is capable of binding IL-TIF independently and can be cross-linked to the radiolabeled IL-TIF, However, binding of IL-TIF to the receptor complex is greater than binding to either receptor chain alone. Sharing of the common IL-10R2 chain between the IL-10 and IL-TIF receptor complexes is the first such case for receptor complexes with chains belonging to the class II cytokine receptor family, establishing a novel paradigm for IL-10-related ligands similar to the shared use of the gamma common chain (gamma (c)) by several cytokines, including IL-2, IL-4, IL-7, IL-9, and IL-15,	Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; US FDA, Ctr Biol Evaluat & Res, Div Therapeut Prot, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; US Food & Drug Administration (FDA)	Kotenko, SV (corresponding author), Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA.		Donnelly, Raymond P./AFT-8600-2022	Donnelly, Raymond P./0000-0002-0695-5276	NATIONAL CANCER INSTITUTE [R01CA046465, P30CA072720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043369, R01AI036450] Funding Source: NIH RePORTER; NCI NIH HHS [1P30-CA72720, R01-CA46465] Funding Source: Medline; NIAID NIH HHS [R01-AI43369, R01-AI36450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Barnes KC, 1999, J ALLERGY CLIN IMMUN, V104, P485, DOI 10.1016/S0091-6749(99)70398-2; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bernabei P., 1999, Journal of Interferon and Cytokine Research, V19, pS87; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Hayden C, 1997, CLIN EXP ALLERGY, V27, P1412, DOI 10.1111/j.1365-2222.1997.tb02985.x; Jiang HP, 1995, ONCOGENE, V11, P2477; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Kotenko SV, 1999, P NATL ACAD SCI USA, V96, P5007, DOI 10.1073/pnas.96.9.5007; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kotenko SV, 2000, P NATL ACAD SCI USA, V97, P1695, DOI 10.1073/pnas.97.4.1695; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Krause CD, 1998, EUR CYTOKINE NETW, V9, P456; Levitt RC, 1999, J ALLERGY CLIN IMMUN, V103, pS485, DOI 10.1016/S0091-6749(99)70165-X; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LIU Y, 1994, J IMMUNOL, V152, P1821; Lockridge KM, 2000, VIROLOGY, V268, P272, DOI 10.1006/viro.2000.0195; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Pestka S, 1999, PROTEIN EXPRES PURIF, V17, P203, DOI 10.1006/prep.1999.1118; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; Soo C, 1999, J CELL BIOCHEM, V74, P1; Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; Wilkinson J, 1999, INT ARCH ALLERGY IMM, V118, P265, DOI 10.1159/000024095; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Zdanov A, 1997, J MOL BIOL, V268, P460, DOI 10.1006/jmbi.1997.0990; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	41	324	370	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2725	2732		10.1074/jbc.M007837200	http://dx.doi.org/10.1074/jbc.M007837200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11035029	hybrid			2022-12-27	WOS:000166784800059
J	Latunde-Dada, AO; Cabello-Hurtado, F; Czittrich, N; Didierjean, L; Schopfer, C; Hertkorn, N; Werck-Reichhart, D; Ebel, J				Latunde-Dada, AO; Cabello-Hurtado, F; Czittrich, N; Didierjean, L; Schopfer, C; Hertkorn, N; Werck-Reichhart, D; Ebel, J			Flavonoid 6-hydroxylase from soybean (Glycine max L.), a novel plant P-450 monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCYRRHIZA-ECHINATA L.; FUNCTIONAL EXPRESSION; CYTOCHROME-P450 CDNA; POLYHYDROXYLATED ISOFLAVONES; MOLECULAR CHARACTERIZATION; LIVER-MICROSOMES; YEAST EXPRESSION; SYNTHASE-II; BIOSYNTHESIS; CLONING	Cytochrome P-450-dependent hydroxylases are typical enzymes for the modification of basic flavonoid skeletons. We show in this study that CYP71D9 cDNA, previously isolated from elicitor-induced soybean (Glycine max L.) cells, codes for a protein with a novel hydroxylase activity. When heterologously expressed in yeast, this protein bound various flavonoids with high affinity (1.6 to 52 muM) and showed typical type I absorption spectra. These flavonoids were hydroxylated at position 6 of both resorcinol- and phloroglucinol-based A-rings. Flavonoid 6-hydroxylase (CYP71D9) catalyzed the conversion of flavanones more efficiently than flavones. Isoflavones were hardly hydroxylated. As soybean produces isoflavonoid constituents possessing 6,7-dihydroxy substitution patterns on ring A, the biosynthetic relationship of flavonoid B-hydroxylase to isoflavonoid biosynthesis was investigated. Recombinant 8-hydroxyisoflavanone synthase (CYP93C1v2) efficiently used 6,7,4'-trihydroxyflavanone as substrate. For its structural identification, the chemically labile reaction product was converted to 6,7,4'-trihydroxyisoflavone by acid treatment. The structures of the final reaction products for both enzymes were confirmed by MMR and mass spectrometry. Our results strongly support the conclusion that, in soybean, the B-hydroxylation of the A-ring occurs before the 1,2-aryl migration of the flavonoid B-ring during isoflavanone formation. This is the first identification of a flavonoid B-hydroxylase cDNA from any plant species.	Univ Munich, Inst Bot, D-80638 Munich, Germany; CNRS, Inst Plant Mol Biol, Dept Stress Responses, FRE 2161, F-67083 Strasbourg, France; GSF Forschungszentrum Umwelt & Gesundheit, Inst Okol Chem, D-85764 Neuherberg, Germany	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Ebel, J (corresponding author), Univ Munich, Inst Bot, Menzinger Str 67, D-80638 Munich, Germany.		Hertkorn, Norbert/AAA-5990-2022; WERCK-REICHHART, Danièle/U-3713-2019	WERCK-REICHHART, Danièle/0000-0003-2869-4262				Agrawal PK., 1989, CARBON 13 NMR FLAVON, P96; Akashi T, 1999, PLANT PHYSIOL, V121, P821, DOI 10.1104/pp.121.3.821; Akashi T, 1998, BIOCHEM BIOPH RES CO, V251, P67, DOI 10.1006/bbrc.1998.9414; Akashi T, 1998, FEBS LETT, V431, P287, DOI 10.1016/S0014-5793(98)00781-9; Akashi T, 1999, PLANT CELL PHYSIOL, V40, P1182, DOI 10.1093/oxfordjournals.pcp.a029505; BRITSCH L, 1990, ARCH BIOCHEM BIOPHYS, V282, P152, DOI 10.1016/0003-9861(90)90099-K; Brugliera F, 1999, PLANT J, V19, P441, DOI 10.1046/j.1365-313X.1999.00539.x; CABALLERO P, 1986, J NAT PROD, V49, P1126, DOI 10.1021/np50048a030; Cabello-Hurtado F, 1998, J BIOL CHEM, V273, P7260, DOI 10.1074/jbc.273.13.7260; DIESPERGER H, 1974, FEBS LETT, V43, P155, DOI 10.1016/0014-5793(74)80990-7; Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; EBEL J, 1988, TRENDS BIOCHEM SCI, V13, P23, DOI 10.1016/0968-0004(88)90014-X; EBEL J, 1976, PLANT PHYSIOL, V57, P775, DOI 10.1104/pp.57.5.775; FORKMANN G, 1994, FLAVONOIDS ADV RES 1, P537; GYORGY PAUL, 1964, NATURE, V203, P870, DOI 10.1038/203870a0; Hakamatsuka T, 1998, PHYTOCHEMISTRY, V49, P497, DOI 10.1016/S0031-9422(98)00266-0; Harborne J.B., 1994, FLAVONOIDS ADV RES 1, P589; HARBORNE JB, 1994, FLAVONOIDS ADV RES 1, P1; HASHIM MF, 1990, FEBS LETT, V271, P219, DOI 10.1016/0014-5793(90)80410-K; Heller W., 1993, ADV RES 1986, P499; HOLTON TA, 1993, NATURE, V366, P276, DOI 10.1038/366276a0; JHA HC, 1990, 2ND AS S NONS SOYB F, P4; Jung W, 2000, NAT BIOTECHNOL, V18, P208, DOI 10.1038/72671; Klus K, 1995, ARCH MICROBIOL, V164, P428, DOI 10.1007/s002030050285; Klus K, 1998, PHYTOCHEMISTRY, V47, P1045, DOI 10.1016/S0031-9422(97)00648-1; KOCHS G, 1986, EUR J BIOCHEM, V155, P311, DOI 10.1111/j.1432-1033.1986.tb09492.x; KUDOU S, 1991, AGR BIOL CHEM TOKYO, V55, P2227, DOI 10.1080/00021369.1991.10870966; Le Bail JC, 1998, CANCER LETT, V133, P101, DOI 10.1016/S0304-3835(98)00211-0; LEE H, 1994, MUTAGENESIS, V9, P101, DOI 10.1093/mutage/9.2.101; LI Y, 1994, DRUG METAB DISPOS, V22, P566; LOIDA PJ, 1993, BIOCHEMISTRY-US, V32, P11530, DOI 10.1021/bi00094a009; Lupien S, 1999, ARCH BIOCHEM BIOPHYS, V368, P181, DOI 10.1006/abbi.1999.1298; MARFENS S, 1999, PLANT J, V20, P611; Middleton E., 1994, FLAVONOIDS ADV RES 1, P619; MITCHELL MJ, 1993, INSECT BIOCHEM MOLEC, V23, P65, DOI 10.1016/0965-1748(93)90083-5; NAIM M, 1974, J AGR FOOD CHEM, V22, P806, DOI 10.1021/jf60195a031; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; Robineau T, 1998, PLANT PHYSIOL, V118, P1049, DOI 10.1104/pp.118.3.1049; Schalk M, 1997, BIOCHEMISTRY-US, V36, P15253, DOI 10.1021/bi971575k; SCHMIDT WE, 1987, P NATL ACAD SCI USA, V84, P4117, DOI 10.1073/pnas.84.12.4117; SCHOPFER C, 1998, THESIS U MUNICH GERM; Schopfer CR, 1998, FEBS LETT, V432, P182, DOI 10.1016/S0014-5793(98)00866-7; Schopfer CR, 1998, MOL GEN GENET, V258, P315, DOI 10.1007/s004380050736; Schroder G, 1999, FEBS LETT, V458, P97, DOI 10.1016/S0014-5793(99)01138-2; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; Steele CL, 1999, ARCH BIOCHEM BIOPHYS, V367, P146, DOI 10.1006/abbi.1999.1238; TRUAN G, 1993, GENE, V125, P49, DOI 10.1016/0378-1119(93)90744-N; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; URBAN P, 1990, BIOCHIMIE, V72, P463, DOI 10.1016/0300-9084(90)90070-W; Urban P, 1997, J BIOL CHEM, V272, P19176, DOI 10.1074/jbc.272.31.19176	53	88	104	3	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1688	1695		10.1074/jbc.M006277200	http://dx.doi.org/10.1074/jbc.M006277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11027686	hybrid			2022-12-27	WOS:000166528000006
J	Fulop, V; Szeltner, Z; Renner, V; Polgar, L				Fulop, V; Szeltner, Z; Renner, V; Polgar, L			Structures of prolyl oligopeptidase substrate/inhibitor complexes - Use of inhibitor binding for titration of the catalytic histidine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEPTIDASE; PEPTIDASES; IDENTIFICATION; ENZYME; MAPS; SITE	Structure determination of the inactive S554A variant of prolyl oligopeptidase complexed with an octapeptide has shown that substrate binding is restricted to the P4-P2' region. In addition, it has revealed a hydrogen bond network of potential catalytic importance not detected in other serine peptidases, This involves a unique intramolecular hydrogen bond between the P1' amide and P2 carbonyl groups and another between the P2' amide and N epsilon2 of the catalytic histidine 680 residue. It is argued that both hydrogen bonds promote proton transfer from the imidazolium ion to the leaving group. Another complex formed with the product-like inhibitor benzyloxycarbonyl-glycyl-proline, indicating that the carboxyl group of the inhibitor forms a hydrogen bond with the N epsilon2 of HiS(680). Because a protonated histidine makes a stronger interaction with the carboxyl group, it offers a possibility of the determination of the real pK(alpha) of the catalytic histidine residue. This was found to be 6,25, lower than that of the well studied serine proteases. The new titration method gave a single pK(alpha) for prolyl oligopeptidase, whose reaction exhibited a complex pH dependence for k(cat)/K-m, and indicated that the observed pK(alpha) values are apparent. The procedure presented may be applicable for other serine peptidases.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest 112, Hungary; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; University of Warwick	Polgar, L (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest 112, Hungary.	polgar@enzim.hu	Fulop, Vilmos/AAZ-7720-2021					ATACK JR, 1991, EUR J PHARMACOL, V205, P157, DOI 10.1016/0014-2999(91)90814-7; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fulop V, 2000, EMBO REP, V1, P277, DOI 10.1093/embo-reports/kvd048; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leatherbarrow R. J, 1998, GRAFIT VERSION 4; MAES M, 1994, BIOL PSYCHIAT, V35, P545, DOI 10.1016/0006-3223(94)90101-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Polg?r L., 1987, NEW COMPREHENSIVE BI, V16, P159; POLGAR L, 1993, FEBS LETT, V322, P227, DOI 10.1016/0014-5793(93)81575-K; POLGAR L, 1995, BIOCHEM J, V312, P267, DOI 10.1042/bj3120267; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; POLGAR L, 1991, EUR J BIOCHEM, V197, P441, DOI 10.1111/j.1432-1033.1991.tb15930.x; POLGAR L, 1994, METHOD ENZYMOL, V244, P188; POLGAR L, 1989, MECHANISMS PROTEASE, P87; Portevin B, 1996, J MED CHEM, V39, P2379, DOI 10.1021/jm950858c; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; Szeltner Z, 2000, J BIOL CHEM, V275, P15000, DOI 10.1074/jbc.M000942200; Szeltner Z, 2000, PROTEIN SCI, V9, P353; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; YOSHIMOTO T, 1987, J PHARMACOBIO-DYNAM, V10, P730, DOI 10.1248/bpb1978.10.730	31	76	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1262	1266		10.1074/jbc.M007003200	http://dx.doi.org/10.1074/jbc.M007003200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11031266	hybrid			2022-12-27	WOS:000166430900055
J	Gentzsch, M; Riordan, JR				Gentzsch, M; Riordan, JR			Localization of sequences within the C-terminal domain of the cystic fibrosis transmembrane conductance regulator which impact maturation and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-F508 CFTR; PDZ DOMAINS; CONFORMATIONAL MATURATION; CHLORIDE CHANNEL; P-GLYCOPROTEIN; PROTEIN; GENE; DEGRADATION; PROTEASOME; REQUIRES	Some disease-associated truncations within the 100-residue domain C-terminal of the second nucleotide-binding domain destabilize the mature protein (Haardt, M,, Benharouga, M,, Lechardeur, D,, Kartner, N,, and Lukacs, G;. L, (1999) J, Biol. Chem, 274, 21873-21877), We now have identified three short oligopeptide regions in the C-terminal domain which impact cystic fibrosis transmembrane conductance regulator (CFTR) maturation and stability in different ways, A highly conserved hydrophobic patch (region I) formed by residues 1413-1416 (FLVI) was found to be crucial for the stability of the mature protein. Nascent chain stability was severely decreased by shortening the protein by 81 amino acids (1400X). This accelerated degradation was sensitive to proteasome inhibitors but not influenced by brefeldin A, indicating that it occurred at the endoplasmic reticulum. The five residues at positions 1400 to 1404 (region II) normally maintain nascent CFTR stability in a positional rather than a sequence-specific manner. A third modulating region (III) constituted by residues 1390 to 1394 destabilizes the protein. Hence the nascent form regains stability on further truncation back to residues 1390 or 1380, permitting some degree of maturation and a low level of cyclic AMP-stimulated chloride channel activity at the cell surface. Thus while not absolutely essential, the C-terminal domain strongly modulates the biogenesis and maturation of CFTR.	Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Mayo Fdn, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Riordan, JR (corresponding author), Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Mayo Fdn, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.		Gentzsch, Martina/AAY-1815-2021	Lechardeur, Delphine/0000-0002-5331-4607	NIDDK NIH HHS [DK54076] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054076] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; Chen EYJ, 2000, BIOCHEMISTRY-US, V39, P3797, DOI 10.1021/bi992620m; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gadsby David C., 1999, Physiological Reviews, V79, pS77; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Harlow E., 1988, ANTIBODIES LAB MANUA; Huang P, 2000, AM J PHYSIOL-CELL PH, V278, pC417, DOI 10.1152/ajpcell.2000.278.2.C417; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Luo JX, 1998, AM J PHYSIOL-CELL PH, V274, pC1397, DOI 10.1152/ajpcell.1998.274.5.C1397; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Seibert FS, 1997, J BIOENERG BIOMEMBR, V29, P429, DOI 10.1023/A:1022478822214; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zhang L, 1998, P NATL ACAD SCI USA, V95, P10158, DOI 10.1073/pnas.95.17.10158	43	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1291	1298		10.1074/jbc.M003672200	http://dx.doi.org/10.1074/jbc.M003672200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11022033	hybrid			2022-12-27	WOS:000166430900059
J	Mitchell, LW; Volin, M; Martins, J; Jaffe, EK				Mitchell, LW; Volin, M; Martins, J; Jaffe, EK			Mechanistic implications of mutations to the active site lysine of porphobilinogen syntheses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-AMINOLEVULINIC ACID DEHYDRATASE; X-RAY-STRUCTURE; ESCHERICHIA-COLI; BINDING SITES; SYNTHASE; ENZYME; PURIFICATION; GENE	Porphobilinogen synthase (PBGS) is a homo-octameric protein that catalyzes the complex asymmetric condensation of two molecules of B-aminolevulinic acid (ALA). The only characterized intermediate in the PBGS-catalyzed reaction is a Schiff base that forms between the first ALA that binds and a conserved lysine, which in Escherichia coli PBGS is Lys-246 and in human PBGS is Lys-252, In this study, E. coli PBGS mutants K246H, K246M, K246W, K246N, and K246G and human PBGS mutant K252G were characterized. Alterations to this lysine result in a disabled but not totally inactive protein suggesting an alternate mechanism in which proximity and orientation are major catalytic devices. C-13 NMR studies of [3,5-C-13]porphobilinogen bound at the active sites of the E. coli PBGS and the mutants show only minor chemical shift differences, i.e. environmental alterations. Mammalian PBGS is established to have four functional active sites, whereas the crystal structure of E. coli PBGS shows eight spatially distinct and structurally equivalent subunits, Biochemical data for E. coli PBGS have been interpreted to support both four and eight active sites. A unifying hypothesis is that formation of the Schiff base between this lysine and ALA triggers a conformational change that results in asymmetry. Product binding studies with wild-type E, coli PBGS and K246G demonstrate that both bind porphobilinogen at four per octamer although the latter cannot form the Schiff base from substrate. Thus, formation of the lysine to ALA Schiff base is not required to initiate the asymmetry that results in half-site reactivity.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Jaffe, EK (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	EK_Jaffe@fccc.edu	Volin, Michael/U-4115-2019		NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003654] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline; NIEHS NIH HHS [ES03654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEVAN DR, 1980, J BIOL CHEM, V255, P2030; DENT AJ, 1990, BIOCHEMISTRY-US, V29, P7822, DOI 10.1021/bi00486a007; ECHELARD Y, 1988, MOL GEN GENET, V214, P503, DOI 10.1007/BF00330487; Erskine PT, 2000, ACTA CRYSTALLOGR D, V56, P421, DOI 10.1107/S0907444900000597; Erskine PT, 1999, BIOCHEMISTRY-US, V38, P4266, DOI 10.1021/bi982137w; Erskine PT, 1999, PROTEIN SCI, V8, P1250, DOI 10.1110/ps.8.6.1250; Erskine PT, 1997, NAT STRUCT BIOL, V4, P1025, DOI 10.1038/nsb1297-1025; EVANS JNS, 1985, MAGN RESON CHEM, V23, P939, DOI 10.1002/mrc.1260231112; Frankenberg N, 1999, J MOL BIOL, V289, P591, DOI 10.1006/jmbi.1999.2808; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13968, DOI 10.1021/bi9906468; JAFFE EK, 1995, BIOCHEMISTRY-US, V34, P244, DOI 10.1021/bi00001a029; JAFFE EK, 1990, BIOCHEMISTRY-US, V29, P8345, DOI 10.1021/bi00488a021; JAFFE EK, 1986, J BIOL CHEM, V261, P9348; JAFFE EK, 1987, BIOCHEMISTRY-US, V26, P4258, DOI 10.1021/bi00388a012; Jaffe EK, 2000, ACTA CRYSTALLOGR D, V56, P115, DOI 10.1107/S0907444999014894; JAFFE EK, 1984, J BIOL CHEM, V259, P5032; JAFFE EK, 1992, BIOCHEMISTRY-US, V31, P2113, DOI 10.1021/bi00122a032; Jaffe EK, 2000, J BIOL CHEM, V275, P2619, DOI 10.1074/jbc.275.4.2619; JORDAN PM, 1985, BIOCHEM J, V227, P1015, DOI 10.1042/bj2271015; LI JM, 1989, GENE, V75, P177, DOI 10.1016/0378-1119(89)90394-6; MITCHELL LW, 1995, J BIOL CHEM, V270, P24054, DOI 10.1074/jbc.270.41.24054; MITCHELL LW, 1993, ARCH BIOCHEM BIOPHYS, V300, P169, DOI 10.1006/abbi.1993.1024; NANDI DL, 1968, J BIOL CHEM, V243, P1236; Petrovich RM, 1996, J BIOL CHEM, V271, P8692, DOI 10.1074/jbc.271.15.8692; ROESSNER CA, 1995, PROTEIN EXPRES PURIF, V6, P155, DOI 10.1006/prep.1995.1019; SEEHRA JS, 1981, EUR J BIOCHEM, V113, P435, DOI 10.1111/j.1432-1033.1981.tb05083.x; Senior NM, 1996, BIOCHEM J, V320, P401; SHEMIN D, 1976, PHILOS T ROY SOC B, V273, P109, DOI 10.1098/rstb.1976.0004; SPENCER P, 1993, BIOCHEM J, V290, P279, DOI 10.1042/bj2900279; SPENCER P, 1995, BIOCHEM J, V305, P151, DOI 10.1042/bj3050151; SPENCER P, 1994, BIOCHEM J, V300, P373, DOI 10.1042/bj3000373; UMANOFF H, 1988, J BACTERIOL, V170, P4969, DOI 10.1128/jb.170.10.4969-4971.1988	32	4	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1538	1544		10.1074/jbc.M008505200	http://dx.doi.org/10.1074/jbc.M008505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032841	hybrid			2022-12-27	WOS:000166430900091
J	Yahalom, A; Kim, TH; Winter, E; Karniol, B; von Arnim, AG; Chamovitz, DA				Yahalom, A; Kim, TH; Winter, E; Karniol, B; von Arnim, AG; Chamovitz, DA			Arabidopsis eIF3e (INT-6) associates with both eIF3c and the COP9 signalosome subunit CSN7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION-FACTOR-3 EIF3; PROTEASOME REGULATORY COMPLEX; SACCHAROMYCES-CEREVISIAE; PROTEIN COMPLEX; MAMMALIAN-CELLS; LIGHT CONTROL; PRT1 PROTEIN; RNA-BINDING; YEAST; INTERACTS	The Arabidopsis COP9 signalosome is a multisubunit repressor of photomorphogenesis that is conserved among eukaryotes, This complex may have a general role in development. As a step in dissecting the biochemical mode of action of the COP9 signalosome, we determined the sequence of proteins that copurify with this complex. Here we describe the association between components of the COP9 signalosome (CSN1, CSN7, and CSN8) and two subunits of eukaryotic translation initiation factor 3 (eIF3), eIF3e (p48, known also as INT-6) and eIF3e (p105), To obtain a biochemical marker for Arabidopsis eIF3, we cloned the Arabidopsis ortholog of the eIF3 subunit eIF3b (PRT1), eIF3e coimmunoprecipitated with CSN7, and eIF3c coimmunoprecipitated with eIF3e, eIF3b, CSN8, and CSN1, eIF3e directly interacted with CSN7 and eIF3c, However, eIF3e and eIF3b cofractionated by gel filtration chromatography in a complex that was larger than the COP9 signalosome, Whereas eIF3, as detected through eIF3b, localized solely to the cytoplasm, eIF3e, like CSN7, was also found in the nucleus. This suggests that eIF3e and eIF3c are probably components of multiple complexes and that eIF3e and eIF3c associate with subunits of the COP9 signalosome, even though they are not components of the COP9 signalosome core complex. This interaction may allow for translational control by the COP9 signalosome.	Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Univ Tennessee, Dept Bot, Knoxville, TN 37996 USA	Tel Aviv University; University of Tennessee System; University of Tennessee Knoxville	Chamovitz, DA (corresponding author), Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel.		Chamovitz, Daniel/S-5021-2019	Chamovitz, Daniel/0000-0002-2815-2909; von Arnim, Albrecht/0000-0003-3472-3357				Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; Brent R, 1997, ANNU REV GENET, V31, P663, DOI 10.1146/annurev.genet.31.1.663; BURKS EA, 2001, IN PRESS J BIOL CHEM, V276; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Desbois C, 1999, J CELL SCI, V112, P3331; Dickey LF, 1998, PLANT CELL, V10, P475, DOI 10.1105/tpc.10.3.475; FINLEY RL, 1989, MOL CELL BIOL, V9, P4282, DOI 10.1128/MCB.9.10.4282; Gallie DR, 1998, PLANT J, V14, P715, DOI 10.1046/j.1365-313x.1998.00175.x; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Karniol B, 1998, FEBS LETT, V439, P173, DOI 10.1016/S0014-5793(98)01367-2; Karniol B, 1999, PLANT CELL, V11, P839, DOI 10.1105/tpc.11.5.839; Karniol B, 2000, CURR OPIN PLANT BIOL, V3, P387, DOI 10.1016/S1369-5266(00)00101-1; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kwok SF, 1999, J MOL BIOL, V285, P85, DOI 10.1006/jmbi.1998.2315; Kwok SF, 1998, PLANT CELL, V10, P1779, DOI 10.1105/tpc.10.11.1779; LAUER SJ, 1985, BIOCHEMISTRY-US, V24, P2924, DOI 10.1021/bi00333a016; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MATSUI M, 1995, P NATL ACAD SCI USA, V92, P4239, DOI 10.1073/pnas.92.10.4239; MCNELLIS TW, 1994, PLANT CELL, V6, P1391, DOI 10.1105/tpc.6.10.1391; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Vierstra RD, 1996, PLANT MOL BIOL, V32, P275, DOI 10.1007/BF00039386; von Arnim AG, 1998, GENE, V221, P35, DOI 10.1016/S0378-1119(98)00433-8; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7	44	67	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					334	340		10.1074/jbc.M006721200	http://dx.doi.org/10.1074/jbc.M006721200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11029466	hybrid			2022-12-27	WOS:000166280700046
J	Jayaraman, L; Massague, J				Jayaraman, L; Massague, J			Distinct oligomeric states of SMAD proteins in the transforming growth factor-beta pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; SMAD4/DPC4; GENE; PROMOTER; DNA; COACTIVATORS; ONCOPROTEIN; CBP/P300; RECEPTOR	Protein interactions are critical for the function of SMADs as mediators of transforming growth factor-beta (TGF-beta) signals. TGF-beta receptor phosphorylation of SMAD2 or SMAD3 causes their association with SMAD4 and accumulation in the nucleus where the SMAD complex binds cofactors that determine the choice of target genes. We provide evidence that in the basal state, SMADs 2, 3, and 4 form separate, strikingly different complexes. SMAD2 is found mostly as monomer, whereas the closely related SMAD3 exists in multiple oligomeric states. This difference is due to a unique structural element in the MH1 domain of SMAD2 that inhibits protein-protein interactions in the basal state. In contrast to SMAD2 and SMAD3, SMAD4 in the basal state is found mostly as a homo-oligomer, most likely a trimer. Upon cell stimulation with TGF-beta, SMAD proteins become engaged in a multitude of complexes ranging in size from SMAD2-SMAD4 heterodimers to assemblies of >650 kDa, The latter display the highest DNA binding affinity for the TGF-beta -response elements of JUNB and collagen 7. These observations, all validated with endogenous SMAD proteins, modify previous models regarding the assembly and activity of SMAD complexes in the TGF-beta pathway.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 116, New York, NY 10021 USA.			Massague, Joan/0000-0001-9324-8408				Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Germain S, 2000, GENE DEV, V14, P435; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Takenoshita S, 1998, GENOMICS, V48, P1, DOI 10.1006/geno.1997.5149; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	33	95	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40710	40717		10.1074/jbc.M005799200	http://dx.doi.org/10.1074/jbc.M005799200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018029	hybrid			2022-12-27	WOS:000166114600009
J	Yamakura, T; Borghese, C; Harris, RA				Yamakura, T; Borghese, C; Harris, RA			A transmembrane site determines sensitivity of neuronal nicotinic acetylcholine receptors to general anesthetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; GLYCINE RECEPTORS; XENOPUS OOCYTES; BETA-SUBUNIT; M2 SEGMENT; IDENTIFICATION; CONTRIBUTE; ISOFLURANE; DIVERSITY; REGIONS	Neuronal nicotinic acetylcholine receptors (nAChRs) are potential targets for a wide variety of general anesthetics. We recently showed that alpha (4)beta (2) nAChRS are more sensitive than alpha (4)beta (4) receptors to the gaseous anesthetics nitrous oxide and xenon. The present study examines chimeric and point mutant rat nAChRs expressed in Xenopus oocytes and identifies a single amino acid residue (beta (2)-Val(253) or beta (4)-Phe(255)) near the middle of the second transmembrane segment (TM2) that determines gaseous anesthetic sensitivity. Mutations of this residue in beta subunits and the homologous residue of alpha (4) subunits (alpha (4)-Val(254)) showed that this position also determines sensitivities of nAChRs to acetylcholine, isoflurane, pentobarbital, and hexanol, In contrast, these mutations did not affect actions of ketamine, The positively charged sulfhydryl-specific reagent methanethiosulfonate ethylammonium reacted with a cysteine introduced at alpha (4)-Val(254) or beta (2)-Val(258), and irreversibly reduced anesthetic sensitivities of nAChRs, Propyl methanethiosulfonate is an anesthetic analog that covalently binds to a TM2 site of gamma -aminobutyric acid, and glycine receptors and irreversibly enhances receptor function. However, propyl methanethiosulfonate reversibly inhibited cysteine-substitution mutants at alpha (4)-Val(254) or beta (2)-Val(253) of nAChRs, and did not affect anesthetic sensitivity. Thus, residues alpha (4)-Val(254) and beta (2)-Val(253) alter channel gating and determine anesthetic sensitivity of nAChRs, but are not likely to be anesthetic-binding sites.	Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA; Univ Texas, Waggoner Ctr Alcohol & Addict Res, Austin, TX 78712 USA; Niigata Univ, Sch Med, Dept Anesthesiol, Niigata 9518510, Japan	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Niigata University	Harris, RA (corresponding author), Univ Texas, Inst Cellular & Mol Biol, 2500 Speedway,MBB 1-124, Austin, TX 78712 USA.			Borghese, Cecilia/0000-0002-1028-8277	NIAAA NIH HHS [AA06399] Funding Source: Medline; NIGMS NIH HHS [GM47818] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006399, R01AA006399] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; ALIFIMOFF JK, 1989, BRIT J PHARMACOL, V96, P9, DOI 10.1111/j.1476-5381.1989.tb11777.x; Cardoso RA, 1999, ANESTHESIOLOGY, V91, P1370, DOI 10.1097/00000542-199911000-00029; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; DildyMayfield JE, 1996, J PHARMACOL EXP THER, V276, P1058; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; FIGL A, 1992, FEBS LETT, V308, P245, DOI 10.1016/0014-5793(92)81284-S; FIRESTONE LL, 1986, MOL CELLULAR MECH AN, P455; Flood P, 1997, ANESTHESIOLOGY, V86, P859, DOI 10.1097/00000542-199704000-00016; Forman SA, 1997, BIOPHYS J, V72, P2170, DOI 10.1016/S0006-3495(97)78860-X; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; Francis MM, 2000, MOL PHARMACOL, V58, P109, DOI 10.1124/mol.58.1.109; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GALZI JL, 1995, NEUROPHARMACOLOGY, V34, P563, DOI 10.1016/0028-3908(95)00034-4; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; Gotti C, 1997, PROG NEUROBIOL, V53, P199, DOI 10.1016/S0301-0082(97)00034-8; Husain SS, 1999, J MED CHEM, V42, P3300, DOI 10.1021/jm9806300; Koltchine VV, 1999, MOL PHARMACOL, V56, P1087, DOI 10.1124/mol.56.5.1087; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Pratt MB, 2000, J BIOL CHEM, V275, P29441, DOI 10.1074/jbc.M004710200; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; Stafford GA, 1998, J PHARMACOL EXP THER, V286, P619; Violet JM, 1997, ANESTHESIOLOGY, V86, P866, DOI 10.1097/00000542-199704000-00017; Yamakura T, 2000, ANESTHESIOLOGY, V92, P1144, DOI 10.1097/00000542-200004000-00033; Yamakura T, 1999, J BIOL CHEM, V274, P23006, DOI 10.1074/jbc.274.33.23006; Yamakura T, 2000, ANESTHESIOLOGY, V93, P1095, DOI 10.1097/00000542-200010000-00034; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m; Zhang L, 1997, BRIT J PHARMACOL, V120, P353, DOI 10.1038/sj.bjp.0700934; Zoli M, 1998, J NEUROSCI, V18, P4461	33	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40879	40886		10.1074/jbc.M005771200	http://dx.doi.org/10.1074/jbc.M005771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11020384	hybrid			2022-12-27	WOS:000166114600030
J	Al-Mehdi, AB; Song, C; Tozawa, K; Fisher, AB				Al-Mehdi, AB; Song, C; Tozawa, K; Fisher, AB			Ca2+- and phosphatidylinositol 3-kinase-dependent nitric oxide generation in lung endothelial cells in situ with ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHEAR-STRESS; IN-SITU; FLOW; SYNTHASE; CALCIUM; MECHANOTRANSDUCTION; PHOSPHORYLATION; ACTIVATION; EXPRESSION; CALMODULIN	Endothelial cells generate nitric oxide (NO) in response to agonist stimulation or increased shear stress. In this study, we evaluated the effects of abrupt cessation of shear stress on pulmonary endothelial NO generation and its relationship to changes in intracellular Ca2+. In situ endothelial generation of NO and changes in intracellular Ca2+ in isolated, intact rat lungs were evaluated using fluorescence microscopy with diamino-fluorescein diacetate, an NO probe, and Fluo-3, a Ca2+ probe. The onset of increased NO generation in endothelial cells of subpleural microvessels in situ occurred between 30 and 90 s after onset of ischemia and was preceded by an increase in intracellular Ca2+ due to both influx of extracellular Ca2+ and release from intracellular stores, Flow cessation-induced NO generation in endothelial cells in situ was Ca2+-, calmodulin-, and PI3-kinase-dependent. The similarity of endothelial cell response (increased NO generation) to either increased flow or cessation of flow suggests that cells respond to an imposed alteration from a state of adaptation. This response to flow cessation may constitute a compensatory vasodilatatory mechanism and may play a role in signaling for cell proliferation and vascular remodeling.	Univ Penn, Med Ctr, Inst Environm Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Fisher, AB (corresponding author), Univ Penn, Med Ctr, Inst Environm Med, 1 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.		Al-Mehdi, Abu-Bakr/A-8636-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060290] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50HL60290] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; ALMEHDI AB, 1997, AM J RESP CELL MOL B, V18, P653; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; BOSSU JL, 1989, FEBS LETT, V255, P377, DOI 10.1016/0014-5793(89)81126-3; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Dahm P, 1997, CRIT CARE MED, V25, P280, DOI 10.1097/00003246-199702000-00015; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1984, J CLIN INVEST, V73, P1121, DOI 10.1172/JCI111298; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fisslthaler B, 2000, ACTA PHYSIOL SCAND, V168, P81; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fouty B, 1998, AM J PHYSIOL-HEART C, V274, pH672, DOI 10.1152/ajpheart.1998.274.2.H672; Fukaya Y, 1996, AM J PHYSIOL-HEART C, V270, pH99, DOI 10.1152/ajpheart.1996.270.1.H99; Hsieh HJ, 1998, J CELL PHYSIOL, V175, P156, DOI 10.1002/(SICI)1097-4652(199805)175:2<156::AID-JCP5>3.0.CO;2-N; JAMES NL, 1995, FASEB J, V9, P968, DOI 10.1096/fasebj.9.10.7615166; KORENAGA R, 1994, BIOCHEM BIOPH RES CO, V198, P213, DOI 10.1006/bbrc.1994.1030; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Martin E, 2000, SEMIN PERINATOL, V24, P2, DOI 10.1016/S0146-0005(00)80045-2; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Tozawa K, 1999, ANTIOXID REDOX SIGN, V1, P145, DOI 10.1089/ars.1999.1.2-145; Wei ZH, 1999, CIRC RES, V85, P682, DOI 10.1161/01.RES.85.8.682	25	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39807	39810		10.1074/jbc.C000702200	http://dx.doi.org/10.1074/jbc.C000702200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11042195	hybrid			2022-12-27	WOS:000166039500002
J	Foryst-Ludwig, A; Naumann, M				Foryst-Ludwig, A; Naumann, M			p21-activated kinase 1 activates the nuclear factor kappa B (NF-kappa B)-inducing kinase-I kappa B kinases NF-kappa B pathway and proinflammatory cytokines in Helicobacter pylori infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL-CELLS; PATHOGENICITY ISLAND; CAGA PROTEIN; IKK-GAMMA; INDUCTION; ALPHA; PAK; PHOSPHORYLATION; COSTIMULATION; TRANSLOCATION	Helicobacter pylori, the causative agent of several human gastric diseases, induces activation of the immediate early response transcription factor nuclear factor kappaB (NF-kappaB), which subsequently triggers release of proinflammatory cytokines in colonized epithelial cells. Here we report that in H. pylori infection p21-activated kinase 1 (PAK1) activates NF-kappaB. Activated PAK1 associates with NF-kappaB-inducing kinase, which upon activation directs the activity of I kappaB kinases to I kappaB alpha. Our results indicate that in epithelial cells PAK1 participates in a unique pathway that links H. pylori dependent effector molecules to the activation of NF-kappaB and the induction of the innate immune response.	Max Planck Inst Infektionsbiol, Mol Biol Abt, D-10117 Berlin, Germany	Max Planck Society	Naumann, M (corresponding author), Max Planck Inst Infektionsbiol, Mol Biol Abt, Schumannstr 21-22, D-10117 Berlin, Germany.	naumann@mpiib-berlin.mpg.de	Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BLASER MJ, 1987, GASTROENTEROLOGY, V93, P371, DOI 10.1016/0016-5085(87)91028-6; Bodger K, 1998, BRIT MED BULL, V54, P139; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Garceau N, 2000, J EXP MED, V191, P381, DOI 10.1084/jem.191.2.381; Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Naumann M, 2000, BIOCHEM PHARMACOL, V60, P1109, DOI 10.1016/S0006-2952(00)00390-7; Naumann M, 1997, J EXP MED, V186, P247, DOI 10.1084/jem.186.2.247; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	50	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39779	39785		10.1074/jbc.M007617200	http://dx.doi.org/10.1074/jbc.M007617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11016939	hybrid			2022-12-27	WOS:000165953100110
J	Xiong, JP; Li, R; Essafi, M; Stehle, T; Arnaout, MA				Xiong, JP; Li, R; Essafi, M; Stehle, T; Arnaout, MA			An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; FUNCTION-ASSOCIATED ANTIGEN-1; NEUTROPHIL INHIBITORY FACTOR; LIGAND-BINDING SITE; I-DOMAIN; CRYSTAL-STRUCTURE; DIVALENT-CATION; ALPHA-SUBUNIT; ACTIVATION; ALPHA(M)BETA(2)	In response to cell activation signals, integrins switch from a low to a high affinity state. Physiologic ligands bind to integrins through a von Willebrand Factor A-type domain. Crystallographic studies revealed two conformations of this domain, "closed" and "open." The latter crystallizes in complex with a pseudoligand or ligand, suggesting that it represents the high affinity state; data linking structure and activity are lacking however. In this communication, we expressed stable low and high affinity forms of integrin CD11b A-domain and determined their binding isotherms and crystal structures. The low affinity form, generated by deleting an N-terminal extension extrinsic to the domain, did not bind to physiologic ligands, and crystallized in the closed conformation. The high affinity form was generated by either deleting or substituting an invariable C-terminal Ile(316), wedged into a hydrophobic socket in the closed form, but displaced from it in the open structure. Both mutants crystallized in the open conformation, and the Ile316 --> Gly-modified integrin displayed high affinity. Structural differences between the low and high affinity forms were detected in solution. These data establish the structure-function correlates for the CD11b A-domain, and define a ligand-independent isoleucine-based allosteric switch intrinsic to this domain that controls its conformation and affinity.	Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Arnaout, MA (corresponding author), Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, 149 13th St, Charlestown, MA 02129 USA.		Essafi, Makram/V-8411-2019		NHLBI NIH HHS [HL54227] Funding Source: Medline; NIDDK NIH HHS [DK48549] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048549] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; Baldwin ET, 1998, STRUCTURE, V6, P923, DOI 10.1016/S0969-2126(98)00093-8; Bock CW, 1999, J AM CHEM SOC, V121, P7360, DOI 10.1021/ja9906960; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Edwards CP, 1998, J BIOL CHEM, V273, P28937, DOI 10.1074/jbc.273.44.28937; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Feng Y, 1998, J BIOL CHEM, V273, P5625, DOI 10.1074/jbc.273.10.5625; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KARLSSON R, 1993, J IMMUNOL METHODS, V166, P75, DOI 10.1016/0022-1759(93)90330-A; Katz AK, 1996, J AM CHEM SOC, V118, P5752, DOI 10.1021/ja953943i; KERN A, 1994, J BIOL CHEM, V269, P22811; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Legge GB, 2000, J MOL BIOL, V295, P1251, DOI 10.1006/jmbi.1999.3409; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; McDowall A, 1998, J BIOL CHEM, V273, P27396, DOI 10.1074/jbc.273.42.27396; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; SMITH JW, 1988, J BIOL CHEM, V263, P18726; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1996, J BIOL CHEM, V271, P29953, DOI 10.1074/jbc.271.47.29953; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558	37	122	128	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38762	38767		10.1074/jbc.C000563200	http://dx.doi.org/10.1074/jbc.C000563200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11034990	hybrid			2022-12-27	WOS:000165739800085
J	Dorowski, A; Hofmann, A; Steegborn, C; Boicu, M; Huber, R				Dorowski, A; Hofmann, A; Steegborn, C; Boicu, M; Huber, R			Crystal structure of paprika ferredoxin-NADP(+) reductase - Implications for the electron transfer pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHTHALATE DIOXYGENASE REDUCTASE; ANABAENA SP PCC-7119; AMINO-ACID-RESIDUES; X-RAY-STRUCTURE; NADP+ REDUCTASE; ANGSTROM RESOLUTION; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; BINDING; COMPLEX	cDNA of Capsicum annuum Yolo Wonder (paprika) has been prepared from total cellular RNA, and the complete gene encoding paprika ferredoxin-NADP(+) reductase (pFNR) precursor was sequenced and cloned from this cDNA. Fusion to a T7 promoter allowed expression in Escherichia coli. Both native and recombinant pFNR were purified to homogeneity and crystallized. The crystal structure of pFNR has been solved by Patterson search techniques using the structure of spinach ferredoxin-NADP+ reductase as search model. The structure was refined at 2.5-Angstrom resolution to a crystallographic R-factor of 19.8% (R-free = 26.5%). The overall structure of pFNR is similar to other members of the ferredoxin-NADP(+) reductase family, the major differences concern a long loop (residues 167-177) that forms part of the FAD binding site and some of the variable loops in surface regions. The different orientation of the FAD binding loop leads to a tighter interaction between pFNR and the adenine moiety of FAD. The physiological redox partners [2Fe-2S]-ferredoxin I and NADP(+) were modeled into the native structure of pFNR. The complexes reveal a protein-protein interaction site that is consistent with existing biochemical data and imply possible orientations for the side chain of tyrosine 362, which has to be displaced by the nicotinamide moiety of NADP(+) upon binding. A reasonable electron transfer pathway could be deduced from the modeled structures of the complexes.	Max Planck Inst Biochem, Abt Struktforsch, D-82152 Planegg Martinsried, Germany; Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Planegg Martinsried, Germany; NCI, Macromol Struct Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Max Planck Society; Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Dorowski, A (corresponding author), Max Planck Inst Biochem, Abt Struktforsch, Klopferspitz 18A, D-82152 Planegg Martinsried, Germany.	anja.dorowski@gmx.de	Hofmann, Andreas/B-9515-2008; Hofmann, Andreas/M-9870-2019	Hofmann, Andreas/0000-0003-4408-5467; Hofmann, Andreas/0000-0003-4408-5467				ALIVERTI A, 1994, FEBS LETT, V343, P247, DOI 10.1016/0014-5793(94)80565-2; ALIVERTI A, 1990, EUR J BIOCHEM, V191, P551, DOI 10.1111/j.1432-1033.1990.tb19156.x; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Binda C, 1998, ACTA CRYSTALLOGR D, V54, P1353, DOI 10.1107/S0907444998005137; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; Carrillo N, 1987, TOPICS PHOTOSYNTHESI, V8, P527; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; DEPASCALIS AR, 1993, PROTEIN SCI, V2, P1126, DOI 10.1002/pro.5560020707; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FOUST GP, 1969, J BIOL CHEM, V244, P964; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Hurley JK, 1999, PROTEIN SCI, V8, P1614, DOI 10.1110/ps.8.8.1614; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; JELESAROV I, 1993, EUR J BIOCHEM, V216, P57, DOI 10.1111/j.1432-1033.1993.tb18116.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, O MANUAL; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, RECENT CHANGES MOSFL; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEDINA M, 1992, FEBS LETT, V298, P25, DOI 10.1016/0014-5793(92)80014-8; MEDINA M, 1992, ARCH BIOCHEM BIOPHYS, V299, P281, DOI 10.1016/0003-9861(92)90276-3; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISHIDA H, 1995, BIOCHEMISTRY-US, V34, P2763, DOI 10.1021/bi00009a004; PLATO M, 1989, FEBS LETT, V249, P70, DOI 10.1016/0014-5793(89)80018-3; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmitz S, 1998, BBA-BIOENERGETICS, V1363, P85, DOI 10.1016/S0005-2728(97)00085-6; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TURK D, 1992, THESIS TU MUNICH; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; ZANETTI G, 1988, BIOCHEMISTRY-US, V27, P3753, DOI 10.1021/bi00410a035; ZANETTI G, 1984, J BIOL CHEM, V259, P6153	57	35	36	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9253	9263		10.1074/jbc.M004576200	http://dx.doi.org/10.1074/jbc.M004576200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11053431	hybrid			2022-12-27	WOS:000167607700085
J	Conrath, KE; Lauwereys, M; Wyns, L; Muyldermans, S				Conrath, KE; Lauwereys, M; Wyns, L; Muyldermans, S			Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE DISPLAY; FRAGMENTS; ENZYME	Single-domain antibodies against various antigens are isolated from the unique heavy-chain antibodies of immunized camels and llamas. These minimal sized binders:are very robust and bind the antigen with high affinity in a monomeric state. We evaluated the feasibility to produce soluble, functional bispecific and bivalent antibodies in Escherichia coli with camel single-domain antibody fragments as building blocks. Two single-domain antibody: fragments were tethered by the structural upper hinge of a natural antibody to generate bispecific molecules. This linker was chosen for its protease resistance in serum and its natural flexibility to reorient the upstream and downstream located domains. The expression levels, ease of purification, and the solubility of the recombinant proteins were comparable with those of the constituent monomers. The individual moieties fully retain the binding capacity and the binding characteristics within the recombinant bispecific constructs. The easy generation steps and the biophysical properties of these bispecific and bivalent constructs based on camel single-domain antibody fragments makes them particularly attractive for use in therapeutic dr diagnostic programs.	Free Univ Brussels VIB, Dept Ultrastruct, B-1640 Rhode St Genese, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Conrath, KE (corresponding author), Free Univ Brussels VIB, Dept Ultrastruct, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	kconrath@vub.ac.be	Muyldermans, Serge/AAC-7374-2019; Muyldermans, Serge V/C-6418-2016	Muyldermans, Serge/0000-0002-3678-3575; Muyldermans, Serge V/0000-0002-3678-3575				BOHLEN H, 1993, CANCER RES, V53, P4310; BRINKMANN U, 1995, J IMMUNOL METHODS, V182, P41, DOI 10.1016/0022-1759(95)00016-4; Colcher D, 1998, Q J NUCL MED, V42, P225; De Jonge J, 1998, J IMMUNOL, V161, P1454; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; Frenken LGJ, 2000, J BIOTECHNOL, V78, P11, DOI 10.1016/S0168-1656(99)00228-X; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Lawrence LJ, 1998, FEBS LETT, V425, P479, DOI 10.1016/S0014-5793(98)00292-0; MILSTEIN C, 1983, NATURE, V305, P537, DOI 10.1038/305537a0; Muller KM, 1998, FEBS LETT, V432, P45, DOI 10.1016/S0014-5793(98)00829-1; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Riechmann L, 1999, J IMMUNOL METHODS, V231, P25, DOI 10.1016/S0022-1759(99)00138-6; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; Roux KH, 1998, J IMMUNOL, V161, P4083; SCHUHMACHER J, 1995, CANCER RES, V55, P115; Segal DM, 1999, CURR OPIN IMMUNOL, V11, P558, DOI 10.1016/S0952-7915(99)00015-1; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Transue TR, 1998, PROTEINS, V32, P515, DOI 10.1002/(SICI)1097-0134(19980901)32:4<515::AID-PROT9>3.0.CO;2-E; van der Linden R, 2000, J IMMUNOL METHODS, V240, P185, DOI 10.1016/S0022-1759(00)00188-5; Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6; Zhu ZP, 1997, PROTEIN SCI, V6, P781	27	222	371	0	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7346	7350		10.1074/jbc.M007734200	http://dx.doi.org/10.1074/jbc.M007734200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11053416				2022-12-27	WOS:000167442900067
J	Tomas-Zuber, M; Mary, JL; Lamour, F; Bur, D; Lesslauer, W				Tomas-Zuber, M; Mary, JL; Lamour, F; Bur, D; Lesslauer, W			C-terminal elements control location, activation threshold, and p38 docking of ribosomal S6 kinase B (RSKB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PROTEIN-KINASE; MAP KINASE; PHOSPHORYLATION SITES; FORCE-FIELD; IDENTIFICATION; P90(RSK); RSK; AUTOPHOSPHORYLATION; TRANSDUCTION	RSKB, a p90 ribosomal S6 protein kinase with two catalytic domains, is activated by p38- and extracellular signal-regulated kinase mitogen-activated protein kinase pathways. The sequences between the two catalytic domains and of the C-terminal extension contain elements that control RSKB activity. The C-terminal extension of RSRB presents a putative bipartite (713)KRX(14)KRRKQKLRS(737) nuclear location signal. The distinct cytoplasmic and nuclear locations of various C-terminal truncation mutants supported the hypothesis that the nuclear location signal was essential to direct RSKB to the nuclear compartment;. The (725)APLA-KRRKQKLRS(737) sequence also was essential for the intermolecular association of RSKB with p38. The activation of RSKB through p38 could be dissociated from p38 docking, because RSRB truncated at Ser(681) strongly responded to p38 pathway activity. Interestingly, Delta (725-772)-RSKB was nearly nonresponsive to p38. Sequence alignment with the autoinhibitory C-terminal extension of Ca+2/calmodulin-dependent protein kinase I predicted a conserved regulatory (708)AFN(710) motif. Alanine mutation of the key Phe(709) residue resulted in strongly elevated basal level RSKB activity. A regulatory role also was assigned to Thr(687), which is located in a mitogen-activated protein kinase phosphorylation consensus site. These findings support that the RSKB C-terminal extension contains elements that control activation threshold, subcellular location, and p38 docking.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; F Hoffmann La Roche & Co Ltd, Dept Cent Nervous Syst Dis, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Dept Vasc & Metab Dis, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Dept Discovery Chem, CH-4070 Basel, Switzerland	Yale University; Yale University; Roche Holding; Roche Holding; Roche Holding	Lesslauer, W (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, POB 208034, New Haven, CT 06520 USA.	werner.lesslauer@yale.edu						Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gavin AC, 1999, MOL BIOL CELL, V10, P2971, DOI 10.1091/mbc.10.9.2971; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Gerber PR, 1998, J COMPUT AID MOL DES, V12, P37, DOI 10.1023/A:1007902804814; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Merienne K, 1999, NAT GENET, V22, P13, DOI 10.1038/8719; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Pende M, 1997, J NEUROSCI, V17, P1291; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tomas-Zuber M, 2000, J BIOL CHEM, V275, P23549, DOI 10.1074/jbc.M002586200; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199; Yntema HG, 1999, GENOMICS, V62, P332, DOI 10.1006/geno.1999.6004; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zhu SG, 1998, HUM GENET, V103, P674, DOI 10.1007/s004390050890	48	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5892	5899		10.1074/jbc.M005822200	http://dx.doi.org/10.1074/jbc.M005822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11035004	hybrid			2022-12-27	WOS:000167115100066
J	Jones, RB; Wang, F; Luo, YD; Yu, CD; Jin, CL; Suzuki, T; Kan, M; McKeehan, WL				Jones, RB; Wang, F; Luo, YD; Yu, CD; Jin, CL; Suzuki, T; Kan, M; McKeehan, WL			The nonsense-mediated decay pathway and mutually exclusive expression of alternatively spliced FGFR2IIIb and -IIIc mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-2; PROSTATE EPITHELIAL-CELLS; MESSENGER-RNA; FIBROBLAST; EXON; TRANSLATION; SEQUENCE; SURVEILLANCE; COMPLEX; INTRON	Exons IIIb and me of the FGFR2 gene are alternatively spliced in a mutually exclusive manner in different cell types. A switch from expression of FGFR2IIIb to FGFR2IIIc accompanies the transition of nonmalignant rat prostate tumor epithelial cells (DTE) to cells comprising malignant AT3 tumors. Here we used transfection of minigenes with and without alterations in reading frame and with and without introns to examine how translation affects observed FGFR2 splice products. We observed that nonsense mutations in other than the last exon led to a dramatic reduction in mRNA that is abrogated by removal of downstream introns in both DTE and AT3 cells. The mRNA, devoid of both IIIb and me exons (C1-C2), is a major splice product from minigenes lacking an intron downstream of the second common exon C2. From these observations, we suggest that repression of exon me and activation of exon mb inclusion in DTE cells lead to the generation of both IIIb-C2 and C1-C2 products. However, the C1-C2 product hom the native gene is degraded due to a frameshift and a premature termination codon caused by splicing C1 and C2 together. Derepression of exon me and repression of exon IIIb lead to the generation of both C1-IIIc-C2 and C1-C2 products in AT3 cells, but the C1-C2 product is degraded. The C1-IIIb-IIIc-C2 mRNA containing a premature termination codon in exon me was present, but at apparently trace levels in both cell types. The nonsense-mediated mRNA decay pathway and cell type-dependent rates of inclusion of exons IIIb and me result in the mutually exclusive expression of FGFR2IIIb and IIIc.	Texas A&M Univ Syst, Inst Biosci & Technol, Hlth Sci Ctr, Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station	McKeehan, WL (corresponding author), Texas A&M Univ Syst, Inst Biosci & Technol, Hlth Sci Ctr, Ctr Canc Biol & Nutr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040732, R01DK035310] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK40732, DK35310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; Feng SJ, 1997, CANCER RES, V57, P5369; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; Li SL, 1997, J EXP MED, V185, P985, DOI 10.1084/jem.185.6.985; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; Maquat LE, 1996, AM J HUM GENET, V59, P279; MAQUAT LE, 1995, RNA, V1, P453; Matsubara A, 1998, CANCER RES, V58, P1509; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; SHI E, 1991, J BIOL CHEM, V266, P5774; Valentine CR, 1997, RNA, V3, P660; Valentine CR, 1998, MUTAT RES-REV MUTAT, V411, P87, DOI 10.1016/S1383-5742(98)00010-6; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; Wang F, 1997, J BIOL CHEM, V272, P23887, DOI 10.1074/jbc.272.38.23887; Wang F, 1999, BIOCHEMISTRY-US, V38, P160, DOI 10.1021/bi981758m; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272; Zhang J, 1997, EMBO J, V16, P826, DOI 10.1093/emboj/16.4.826	34	46	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4158	4167		10.1074/jbc.M006151200	http://dx.doi.org/10.1074/jbc.M006151200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11042206	hybrid			2022-12-27	WOS:000166921200058
J	Rudders, S; Gaspar, J; Madore, R; Voland, C; Grall, F; Patel, A; Pellacani, A; Perrella, MK; Libermann, TA; Oettgen, P				Rudders, S; Gaspar, J; Madore, R; Voland, C; Grall, F; Patel, A; Pellacani, A; Perrella, MK; Libermann, TA; Oettgen, P			ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-kappa B to regulate the inducible nitric-oxide synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MOBILITY GROUP-I(Y) PROTEIN; INTERFERON-GAMMA; ETS FAMILY; T-CELLS; EXPRESSION; INDUCTION; PROMOTER; BINDING; INTERLEUKIN-1-BETA	Inflammation is a hallmark of several vascular diseases. The nuclear factor kappaB (NF-kappaB) transcription factors are dimeric proteins involved in the activation of a large number of genes in response to inflammatory stimuli. We report the involvement of a novel member of the ETS transcription factor, ESE-1, in mediating vascular inflammation. ESE-1 is induced in response to inflammatory cytokines and lipopolysaccharide in vascular smooth muscle cells, endothelial cells, and cells of the monocyte-macrophage lineage. This induction occurs within hours of stimulation and is mediated by NF-kappaB transactivation of the ESE-1 promoter. We have identified the inducible form of nitric-oxide synthase (NOS2) as a putative target for ESE-1, ESE-1 can bind to the p50 subunit of NF-kappaB, and cotransfection of ESE-1 with the p50 and p65 subunits of NF-kappaB synergistically enhances transactivation of the NOS2 promoter by ESE-1, An ESE-1-binding site within the NOS2 promoter has been identified, the site-directed mutagenesis of which completely abolishes the ability of ESE-1 to transactivate the NOS2 promoter. Finally, in a mouse model of endotoxemia, associated with acute vascular inflammation, ESE-1 is strongly expressed in vascular endothelium and smooth muscle cells. In summary, ESE-1 represents a novel mediator of vascular inflammation.	Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Oettgen, P (corresponding author), Harvard Univ, Sch Med, Inst Med, 4 Blackfan Circle, Boston, MA 02115 USA.	joettgen@caregroup.harvard.edu	Libermann, Towia/F-9866-2010; Oettgen, Peter/AAF-5026-2021	Libermann, Towia/0000-0002-4006-8179	NATIONAL CANCER INSTITUTE [R01CA076323, K08CA071429] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788, R01HL063008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NCI NIH HHS [R01/CA76323, KO8/CA71429] Funding Source: Medline; NHLBI NIH HHS [R01/HL63008, HL60788] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambs S, 1998, CANCER RES, V58, P334; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Buttery LDK, 1996, LAB INVEST, V75, P77; CONCA W, 1991, J BIOL CHEM, V266, P16265; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Esaki T, 1997, ATHEROSCLEROSIS, V128, P39, DOI 10.1016/S0021-9150(96)05976-X; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; Fu SD, 1999, GASTROENTEROLOGY, V116, P1319, DOI 10.1016/S0016-5085(99)70496-8; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ikeda U, 1998, CLIN CARDIOL, V21, P473, DOI 10.1002/clc.4960210705; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P490, DOI 10.1161/01.ATV.17.3.490; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KRAMER B, 1995, J BIOL CHEM, V270, P6577; LafondWalker A, 1997, AM J PATHOL, V151, P919; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Naito S, 1998, AM J PHYSIOL-CELL PH, V274, pC472, DOI 10.1152/ajpcell.1998.274.2.C472; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; Oettgen P, 1997, GENOMICS, V45, P456, DOI 10.1006/geno.1997.4974; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; Pellacani A, 1999, J BIOL CHEM, V274, P1525, DOI 10.1074/jbc.274.3.1525; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; Rife TK, 2000, MOL BRAIN RES, V75, P225, DOI 10.1016/S0169-328X(99)00293-4; Rikitake Y, 1998, ATHEROSCLEROSIS, V136, P51, DOI 10.1016/S0021-9150(97)00186-X; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sherman TS, 1999, AM J PHYSIOL-LUNG C, V276, pL383, DOI 10.1152/ajplung.1999.276.2.L383; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xu R, 1999, LIFE SCI, V64, P2451, DOI 10.1016/S0024-3205(99)00202-7; Zhang XM, 1999, J BIOL CHEM, V274, P20235, DOI 10.1074/jbc.274.29.20235	53	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3302	3309		10.1074/jbc.M006507200	http://dx.doi.org/10.1074/jbc.M006507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11036073	hybrid			2022-12-27	WOS:000166784900043
J	Azam, N; Vairapandi, M; Zhang, W; Hoffman, B; Liebermann, DA				Azam, N; Vairapandi, M; Zhang, W; Hoffman, B; Liebermann, DA			Interaction of CR6 (GADD45 gamma) with proliferating cell nuclear antigen impedes negative growth control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; RESPONSE GENE MYD118; DNA-REPLICATION; TERMINAL KINASE; PCNA; PROTEIN; DIFFERENTIATION; ACTIVATION; APOPTOSIS; TRANSCRIPTION	GADD45, MyDII8, and CR6 (also termed GADD45 alpha, beta, and gamma) comprise a family of genes that encode for related proteins playing important roles in negative growth control, including growth suppression. Data accumulated suggest that MyD118/GADD45/CR6 serve similar but not identical functions along different apoptotic and growth suppressive pathways. It is also apparent that individual members of the MyD118/GADD45/CR6 family are differentially induced by a variety of genetic and environmental stress agents. The MyD118, CR6, and GADD45 proteins were shown to predominantly localize within the cell nucleus. Recently, we have shown that both MyD118 and GADD45 interact with proliferating cell nuclear antigen (PCNA), a protein that plays a central role in DNA replication, DNA repair, and cell cycle progression, as well as with the universal cyclin-dependent kinase inhibitor p21, In this work we show that also CR6 interacts with PCNA and p21, Moreover, it is shown that CR6 interacts with PCNA via a domain that also mediates interaction of both GADD45 and MyD118 with PCNA. Importantly, evidence has been obtained that interaction of CR6 with PCNA impedes the function of this protein in negative growth control, similar to observations reported for MyD118 and GADD45 (1).	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Hoffman, B (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@unix.temple.edu			NCI NIH HHS [1RO1CA43618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GRANA X, 1995, ONCOGENE, V11, P211; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALL PA, 1995, ONCOGENE, V10, P2427; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; Muschel RJ, 1998, ONCOGENE, V17, P3359, DOI 10.1038/sj.onc.1202580; Nakayama K, 1999, J BIOL CHEM, V274, P24766, DOI 10.1074/jbc.274.35.24766; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	54	75	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2766	2774		10.1074/jbc.M005626200	http://dx.doi.org/10.1074/jbc.M005626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11022036	hybrid			2022-12-27	WOS:000166784800064
J	Sato, N; Imaizumi, K; Manabe, T; Taniguchi, M; Hitomi, J; Katayama, T; Yoneda, T; Morihara, T; Yasuda, Y; Takagi, T; Kudo, T; Tsuda, T; Itoyama, Y; Makifuchi, T; Fraser, PE; St George-Hyslop, P; Tohyama, M				Sato, N; Imaizumi, K; Manabe, T; Taniguchi, M; Hitomi, J; Katayama, T; Yoneda, T; Morihara, T; Yasuda, Y; Takagi, T; Kudo, T; Tsuda, T; Itoyama, Y; Makifuchi, T; Fraser, PE; St George-Hyslop, P; Tohyama, M			Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; UNFOLDED-PROTEIN RESPONSE; PRECURSOR PROTEIN; MISSENSE MUTATIONS; SIGNALING PATHWAY; GENE	An alternative spliced form of the presinilin 2 (PS2) gene (PS2V) lacking exon 5 has previously been reported to be expressed in human brains in sporadic Alzheimer's disease (AD). PS2V encodes the amino-terminal portion of PS2, which contains residues Met(1)-Leu(119) and 5 additional amino acid residues (SSMAG) at its carboxyl terminus. Here we report that PS2V protein impaired the signaling pathway of the unfolded protein response, similarly to familial AD-linked PS1 mutants and caused significant increases in the production of both amyloid beta (40) and beta (42). Interestingly, PS2V-encoding protein was expressed in neuropathologically affected neurons of the hippocampal CA1 region and temporal cortex in AD patients. These findings suggest that the aberrant splicing of the PS2 gene may be implicated in the neuropathology of sporadic AD.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Clin Neurosci, Suita, Osaka 5650871, Japan; Tohoku Univ, Sch Med, Dept Neurol, Sendai, Miyagi 9808574, Japan; Saigata Natl Hosp, Dept Clin Res, Niigata 9493193, Japan; Univ Toronto, Dept Med Neurol, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 1A8, Canada; Japan Sci & Techol Corp, CREST, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Tohoku University; University of Toronto; Japan Science & Technology Agency (JST)	Imaizumi, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Morihara, Takashi/AAK-2709-2021					Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; JONGHE CD, 1999, HUM MOL GENET, V8, P1529; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; OKADA AA, 1995, BIOCHEMISTRY-US, V34, P10272; PerezTur J, 1995, NEUROREPORT, V7, P297; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sato N, 1999, J NEUROCHEM, V72, P2498, DOI 10.1046/j.1471-4159.1999.0722498.x; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tysoe C, 1998, AM J HUM GENET, V62, P70, DOI 10.1086/301672; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Welihinda AA, 1999, GENE EXPRESSION, V7, P293; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552	23	105	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2108	2114		10.1074/jbc.M006886200	http://dx.doi.org/10.1074/jbc.M006886200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11031265	hybrid			2022-12-27	WOS:000166528000063
J	Daily, D; Vlamis-Gardikas, A; Offen, D; Mittelman, L; Melamed, E; Holmgren, A; Barzilai, A				Daily, D; Vlamis-Gardikas, A; Offen, D; Mittelman, L; Melamed, E; Holmgren, A; Barzilai, A			Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI GLUTAREDOXIN; CELL-DEATH; TRANSCRIPTION FACTOR; REDOX REGULATION; ENDONUCLEASE EXPRESSION; THIOREDOXIN REDUCTASE; NUCLEAR TRANSLOCATION; DISULFIDE-ISOMERASE	The neurotransmitter dopamine (DA) induces apoptosis via its oxidative metabolites. This study shows that glutaredoxin 2 (Grx2) from Escherichia coli and human glutaredoxin could protect cerebellar granule neurons from DA-induced apoptosis, E. coli Grx2, which catalyzes glutathione-disulfide oxidoreduction via its -Cys-Pro-Tyr-Cys- active site, penetrates into cerebellar granule neurons and exerts its activity via NF-kappaB activation. Analysis of single and double cysteine to serine substitutions in the active site of Grx2 showed that both cysteine residues were essential for activity. Although DA significantly reduced NF-kappaB binding activity, Grx2 could stimulate the binding of NF-kappaB to DNA by: (i) translocating NF-kappaB from the cytoplasm to the nucleus after promoting the phosphorylation and degradation of I-kappaB alpha, and (ii) activating the binding of pre existing nuclear NF-kappaB. The DNA binding activity of NF-kappaB itself was essential for neuronal survival. Overexpression of I-kappaB dominant negative gene (I-kappaB-DeltaN) in granule neurons significantly reduced their viability, irrespective of the presence of Grx2. Ref-1 expression was down-regulated by DA but up-regulated by Grx2, while treatment of neurons with Ref-1 antisense oligonucleotide reduced the ability of Grx2 to activate NF-kappaB binding activity. These results show that Grx2 exerts its anti apoptotic activity through the activation of Ref-1, which then activates NF-kappaB.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Karolinska Inst, Med Nobel Inst Biochem, Dept Biochem & Biophys, S-17177 Stockholm, Sweden; Tel Aviv Univ, Rabin Med Ctr, Dept Neurol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Rabin Med Ctr, Felsenstein Med Res Inst, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Interdept Core Facil, IL-69978 Tel Aviv, Israel	Tel Aviv University; Karolinska Institutet; Rabin Medical Center; Tel Aviv University; Rabin Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Barzilai, A (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	barzilai@post.tau.ac.il	Vlamis, Alexios/AAF-5152-2020	Vlamis, Alexios/0000-0001-5068-6459				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AHN BY, 1992, P NATL ACAD SCI USA, V89, P7060, DOI 10.1073/pnas.89.15.7060; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENSHACHAR D, 1995, J NEUROCHEM, V64, P718, DOI 10.1046/j.1471-4159.1995.64020718.x; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Chen F, 1999, J BIOL CHEM, V274, P20307, DOI 10.1074/jbc.274.29.20307; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DRAGUNOW M, 1995, NEUROSCI LETT, V191, P189, DOI 10.1016/0304-3940(95)11589-O; DUGUID JR, 1995, CANCER RES, V55, P6097; FILLOUX F, 1993, EXP NEUROL, V119, P79, DOI 10.1006/exnr.1993.1008; Fire E, 1997, J BIOL CHEM, V272, P29538, DOI 10.1074/jbc.272.47.29538; GAN ZR, 1990, BIOCHEM BIOPH RES CO, V168, P944, DOI 10.1016/0006-291X(90)91120-H; GAN ZR, 1987, J BIOL CHEM, V262, P6699; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GRILLI M, 1993, INT REV CYTOL, V143, P1; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Harlow E., 1988, ANTIBODIES LAB MANUA; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1983, EUR J BIOCHEM, V136, P223, DOI 10.1111/j.1432-1033.1983.tb07730.x; HOPPER S, 1989, J BIOL CHEM, V264, P20438; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kawase M, 1999, STROKE, V30, P441, DOI 10.1161/01.STR.30.2.441; KLINTROT IM, 1984, EUR J BIOCHEM, V144, P417, DOI 10.1111/j.1432-1033.1984.tb08481.x; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; LASHER RS, 1972, BRAIN RES, V41, P482, DOI 10.1016/0006-8993(72)90521-5; Legrand-Poels S, 1998, J PHOTOCH PHOTOBIO B, V45, P1, DOI 10.1016/S1011-1344(98)00118-3; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lundstrom-Ljung J, 1999, FEBS LETT, V443, P85, DOI 10.1016/S0014-5793(98)01698-6; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; McLaughlin BA, 1998, J NEUROCHEM, V70, P2406; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; MINAKUCHI K, 1994, FEBS LETT, V337, P157, DOI 10.1016/0014-5793(94)80264-5; Moulder KL, 1999, J NEUROSCI, V19, P705; MYTILINEOU C, 1993, J NEUROCHEM, V61, P1470, DOI 10.1111/j.1471-4159.1993.tb13642.x; Nakamura H, 1998, FREE RADICAL BIO MED, V24, P1176, DOI 10.1016/S0891-5849(97)00429-2; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; OKUNO H, 1993, ONCOGENE, V8, P695; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; POWIS G, 1994, ONCOL RES, V6, P539; PRASAD AV, 1994, NEUROSCI LETT, V170, P145, DOI 10.1016/0304-3940(94)90260-7; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; Rong YQ, 1996, J NEUROCHEM, V67, P662; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Sandvig Kirsten, 1994, Trends in Cell Biology, V4, P275, DOI 10.1016/0962-8924(94)90211-9; SCHRAMM M, 1990, P NATL ACAD SCI USA, V87, P1193, DOI 10.1073/pnas.87.3.1193; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; TANAKA M, 1991, J NEUROL SCI, V101, P198, DOI 10.1016/0022-510X(91)90046-A; Terai K, 1996, BRAIN RES, V735, P159; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; Walton M, 1997, MOL BRAIN RES, V44, P167, DOI 10.1016/S0169-328X(96)00291-4; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; ZilkhaFalb R, 1997, CELL MOL NEUROBIOL, V17, P101, DOI 10.1023/A:1026333222008; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	83	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1335	1344		10.1074/jbc.M008121200	http://dx.doi.org/10.1074/jbc.M008121200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035035	hybrid			2022-12-27	WOS:000166430900065
J	Groth, G; Pohl, E				Groth, G; Pohl, E			The structure of the chloroplast F-1-ATPase at 3.2 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; NUCLEOTIDE BINDING-SITES; ATP-SYNTHASE; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; GAMMA-SUBUNIT; F1-ATPASE; TENTOXIN; CATALYSIS; ROTATION	The structure of the F-1-ATPase from spinach chloroplasts was determined to 3.2 A resolution by molecular replacement based on the homologous structure of the bovine mitochondrial enzyme. The crystallized complex contains four different subunits in a stoichiometry of alpha (3)beta (3)gamma epsilon. Subunit delta was removed before crystallization to improve the diffraction of the crystals. The overall structure of the noncatalytic alpha -subunits and the catalytic beta -subunits is highly similar to those of the mitochondrial and thermophilic subunits. However, in the crystal structure of the chloroplast enzyme, all alpha- and beta -subunits adopt a closed conformation and appear to contain no bound adenine nucleotides. The superimposed crystallographic symmetry in the space group R32 impaired an exact tracing of the gamma- and epsilon -subunits in the complex. However, clear electron density was present at the core of the alpha (3),beta (3)-subcomplex, which probably represents the C-terminal domain of the gamma -subunit, The structure of the spinach chloroplast F-1 has a potential binding site for the phytotoxin, tentoxin, at the cup-interface near beta Asp(83) and an insertion from beta Gly(56)-Asn(60) in the N-terminal beta -barrel domain probably increases the thermal stability of the complex. The structure probably represents an inactive latent state of the ATPase, which is unique to chloroplast and cyanobacterial enzymes.	Univ Dusseldorf, D-40225 Dusseldorf, Germany; EMBL, D-22603 Hamburg, Germany	Heinrich Heine University Dusseldorf; European Molecular Biology Laboratory (EMBL)	Groth, G (corresponding author), Univ Dusseldorf, Univ Str 1, D-40225 Dusseldorf, Germany.		Pohl, Ehmke/I-2408-2012	Pohl, Ehmke/0000-0002-9949-4471				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AKEY CW, 1983, EMBO J, V2, P1409, DOI 10.1002/j.1460-2075.1983.tb01599.x; AVNI A, 1992, SCIENCE, V257, P1245, DOI 10.1126/science.1387730; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BOEKEMA EJ, 1988, Z NATURFORSCH C, V43, P219; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Digel JG, 1998, BIOCHEMISTRY-US, V37, P17209, DOI 10.1021/bi982027p; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FEIERABEND B, 1988, BIOCHIM BIOPHYS ACTA, V932, P146, DOI 10.1016/0005-2728(88)90149-1; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIRAULT G, 1982, EUR J BIOCHEM, V128, P405; Groth G, 1999, PHYSIOL PLANTARUM, V106, P142, DOI 10.1034/j.1399-3054.1999.106120.x; Groth G, 1999, EUR J BIOCHEM, V260, P15, DOI 10.1046/j.1432-1327.1999.00101.x; Guex, 1996, PROTEIN DATA BANK Q, V77, P7; Gunther S, 2000, EUR J BIOCHEM, V267, P541, DOI 10.1046/j.1432-1327.2000.01029.x; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HISABORI T, 1993, J BIOCHEM-TOKYO, V114, P808, DOI 10.1093/oxfordjournals.jbchem.a124260; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; Hu DL, 1997, J BIOL CHEM, V272, P5457, DOI 10.1074/jbc.272.9.5457; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIEBERMANN B, 1983, Z ALLG MIKROBIOL, V23, P503, DOI 10.1002/jobm.3630230810; LIEN S, 1971, METHOD ENZYMOL, V23, P574; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; Mochimaru M, 1997, FEBS LETT, V419, P23, DOI 10.1016/S0014-5793(97)01421-X; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATRIE WJ, 1984, J BIOL CHEM, V259, P1121; Richter ML, 2000, BBA-BIOENERGETICS, V1458, P326, DOI 10.1016/S0005-2728(00)00084-0; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Santolini J, 1999, J BIOL CHEM, V274, P849, DOI 10.1074/jbc.274.2.849; SHAPIRO AB, 1990, J BIOL CHEM, V265, P4340; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; SHAPIRO AB, 1988, J BIOL CHEM, V263, P14160; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Sokolov M, 1999, J BIOL CHEM, V274, P13824, DOI 10.1074/jbc.274.20.13824	47	102	111	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1345	1352		10.1074/jbc.M008015200	http://dx.doi.org/10.1074/jbc.M008015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11032839	hybrid			2022-12-27	WOS:000166430900066
J	Nika, J; Rippel, S; Hannig, EM				Nika, J; Rippel, S; Hannig, EM			Biochemical analysis of the eIF2 beta gamma complex reveals a structural function for eIF2 alpha in catalyzed nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; EUKARYOTIC PROTEIN-SYNTHESIS; TRANSLATION INITIATION; SACCHAROMYCES-CEREVISIAE; GAMMA-SUBUNIT; FACTOR EIF-2; TERNARY COMPLEXES; CHAIN INITIATION; ALPHA-SUBUNIT; BETA-SUBUNIT	Eukaryotic translation initiation factor eIF2 is a heterotrimer that binds and delivers Met-tRNA(i)(Met) to the 40 S ribosomal subunit in a GTP-dependent manner. Initiation requires hydrolysis of eIF2-bound GTP, which releases an eIF2 GDP complex that is recycled to the GTP form by the nucleotide exchange factor eIF2B. The ru-subunit of eIF2 plays a critical role in regulating nucleotide exchange via phosphorylation at serine 51, which converts eIF2 into a competitive inhibitor of the eIF2B-catalyzed exchange reaction. We purified a form of eIF2 (eIF2 beta gamma) completely devoid of the alpha -subunit to further study the role of eIF2 alpha in eIF2 function. These studies utilized a yeast strain genetically altered to bypass a deletion of the normally essential eIF2 alpha structural gene (SU12), Removal of the alpha -subunit did not appear to significantly alter binding of guanine nucleotide or Met-tRN(i)(Met) ligands by eIF2 in vifro. Qualitative assays to detect 43 S initiation complex formation and eIF5-dependent GTP hydrolysis revealed no differences between eIF2 beta gamma and the wild-type eIF2 heterotrimer. However, steady-state kinetic analysis of eIF2B-catalyzed nucleotide exchange revealed that the absence of the a-subunit increased K-m for eIF2 beta gamma (.)GDP by an order of magnitude, with a smaller increase in V-max. These data indicate that eIF2 alpha is required for structural interactions between eIF2 and eIF2B that promote wild-type rates of nucleotide exchange, We suggest that this function contributes to the ability of the alpha -subunit to control the rate of nucleotide exchange through reversible phosphorylation.	Univ Texas, Dept Mol & Cell Biol, Mail Stn FO31, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	Hannig, EM (corresponding author), Univ Texas, Dept Mol & Cell Biol, Mail Stn FO31, POB 830688, Richardson, TX 75083 USA.			Hannig, Ernest/0000-0002-2260-3342				AHMAD MF, 1985, J BIOL CHEM, V260, P6960; ANTHONY DD, 1990, ARCH BIOCHEM BIOPHYS, V281, P157, DOI 10.1016/0003-9861(90)90426-Y; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; BARRIEUX A, 1977, J BIOL CHEM, V252, P3843; BOMMER UA, 1991, BIOCHIM BIOPHYS ACTA, V1079, P308, DOI 10.1016/0167-4838(91)90074-A; BOMMER UA, 1989, FEBS LETT, V244, P323, DOI 10.1016/0014-5793(89)80555-1; CASTILHOVALAVICIUS B, 1990, GENETICS, V124, P483; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; COOPER HL, 1981, J BIOL CHEM, V256, P7461; Das S, 2000, MOL CELL BIOL, V20, P3942, DOI 10.1128/MCB.20.11.3942-3950.2000; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DORRIS DR, 1995, EMBO J, V14, P2239, DOI 10.1002/j.1460-2075.1995.tb07218.x; Erickson FL, 1997, MOL GEN GENET, V253, P711; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; FLYNN A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P117, DOI 10.1016/0167-4781(93)90105-M; GASPAR NJ, 1994, J BIOL CHEM, V269, P3415; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; GRIBSKOV M, 1992, GENE, V119, P107, DOI 10.1016/0378-1119(92)90073-X; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, P627; Keeling PJ, 1998, J MOL EVOL, V47, P649, DOI 10.1007/PL00006422; Kimball SR, 1998, J BIOL CHEM, V273, P3039, DOI 10.1074/jbc.273.5.3039; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; MANCHESTER KL, 1989, BIOCHEM INT, V18, P1279; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Mouat MF, 1998, MOL CELL BIOCHEM, V183, P69, DOI 10.1023/A:1006829615464; NARANDA T, 1995, FEBS LETT, V372, P249, DOI 10.1016/0014-5793(95)00993-J; Nika J, 2000, J BIOL CHEM, V275, P26011, DOI 10.1074/jbc.M003718200; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PANNIERS R, 1994, BIOCHIMIE, V76, P737, DOI 10.1016/0300-9084(94)90078-7; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; PETRYSHYN R, 1983, METHOD ENZYMOL, V99, P346; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; SAFER B, 1981, BIOCHIMIE, V63, P709, DOI 10.1016/S0300-9084(81)80219-2; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WESTERMANN P, 1980, NUCLEIC ACIDS RES, V8, P3065, DOI 10.1093/nar/8.14.3065; Yang WM, 1996, MOL CELL BIOL, V16, P6603	57	50	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1051	1056		10.1074/jbc.M007398200	http://dx.doi.org/10.1074/jbc.M007398200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042214	hybrid			2022-12-27	WOS:000166430900027
J	Cannon, W; Gallegos, MT; Buck, M				Cannon, W; Gallegos, MT; Buck, M			DNA melting within a binary sigma(54)-promoter DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; SIGMA(70) SUBUNIT; ENHANCER RESPONSIVENESS; TERMINAL SEQUENCES; MECHANISM INVIVO; REGION-I; PROMOTER; BINDING; TRANSCRIPTION	The sigma 54 subunit of the bacterial RNA polymerase requires the action of specialized enhancer-binding activators to initiate transcription. Here we show that sigma (54) is able to melt promoter DNA when it is bound to a DNA structure representing the initial nucleation of DNA opening found in closed complexes. Melting occurs in response to activator in a nucleotide-hydrolyzing reaction and appears to spread downstream from the nucleation point toward the transcription start site. We show that sigma (54) contains some weak determinants for DNA melting that are masked by the Region I sequences and some strong ones that require Region I. It seems that sigma (54) binds to DNA in a self-inhibited state, and one function of the activator is therefore to promote a conformational change in sigma (54) to reveal its DNA-melting activity. Results with the holoenzyme bound to early melted DNA suggest an ordered series of events in which changes in core to sigma (54) interactions and sigma (54)-DNA interactions occur in response to activator to allow sigma (54) isomerization and the holoenzyme to progress from the closed complex to the open complex.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England; CSIC, Dept Bioquim Biol Mol & Celular Plantas, Estac Expt Zaidin, E-18008 Granada, Spain	Imperial College London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ)	Buck, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Sir Alexander Fleming Bldg, London SW7 2AZ, England.		Gallegos, María-Trinidad M.T./K-6501-2014	Gallegos, María-Trinidad M.T./0000-0001-7633-8807				Brodolin K, 2000, J BIOL CHEM, V275, P3661, DOI 10.1074/jbc.275.5.3661; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Cannon WV, 1997, P NATL ACAD SCI USA, V94, P5006, DOI 10.1073/pnas.94.10.5006; Casaz P, 1999, J MOL BIOL, V292, P229, DOI 10.1006/jmbi.1999.3076; Casaz P, 1999, J MOL BIOL, V285, P507, DOI 10.1006/jmbi.1998.2328; Chaney M, 1999, MOL MICROBIOL, V33, P1200, DOI 10.1046/j.1365-2958.1999.01566.x; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gallegos MT, 2000, J MOL BIOL, V297, P849, DOI 10.1006/jmbi.2000.3608; Gallegos MT, 1999, J BIOL CHEM, V274, P25285, DOI 10.1074/jbc.274.36.25285; Gallegos MT, 1999, J MOL BIOL, V288, P539, DOI 10.1006/jmbi.1999.2704; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Jovanovic G, 1999, J MOL BIOL, V285, P469, DOI 10.1006/jmbi.1998.2263; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MORRIS L, 1994, J BIOL CHEM, V269, P11563; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; Syed A, 1997, MOL MICROBIOL, V23, P987, DOI 10.1046/j.1365-2958.1997.2851651.x; Syed A, 1998, J BACTERIOL, V180, P5619, DOI 10.1128/JB.180.21.5619-5625.1998; TINTUT Y, 1995, GENE DEV, V9, P2305, DOI 10.1101/gad.9.18.2305; Wang JT, 1996, J BIOL CHEM, V271, P32707, DOI 10.1074/jbc.271.51.32707; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; Wang JT, 1997, P NATL ACAD SCI USA, V94, P9538, DOI 10.1073/pnas.94.18.9538; Wang L, 1999, J BACTERIOL, V181, P7558, DOI 10.1128/JB.181.24.7558-7565.1999; Wang L, 1998, J BACTERIOL, V180, P5626, DOI 10.1128/JB.180.21.5626-5631.1998; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; Wigneshweraraj SR, 2000, EMBO J, V19, P3038, DOI 10.1093/emboj/19.12.3038	41	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					386	394		10.1074/jbc.M007779200	http://dx.doi.org/10.1074/jbc.M007779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11036081	Green Published, hybrid			2022-12-27	WOS:000166280700053
J	Coleman, ST; Fang, TK; Rovinsky, SA; Turano, FJ; Moye-Rowley, WS				Coleman, ST; Fang, TK; Rovinsky, SA; Turano, FJ; Moye-Rowley, WS			Expression of a glutamate decarboxylase homologue is required for normal oxidative stress tolerance in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINIC SEMIALDEHYDE DEHYDROGENASE; CALMODULIN-BINDING; ESCHERICHIA-COLI; SHUTTLE VECTORS; YEAST; PROTEIN; GENE; TRANSFORMATION; GLUTATHIONE; SEQUENCE	The action of gamma -aminobutyrate (GABA) as an intercellular signaling molecule has been intensively studied, but the role of this amino acid metabolite in intracellular metabolism is poorly understood. In this work, we identify a Saccharomyces cerevisiae homologue of the GABA-producing enzyme glutamate decarboxylase (GAD) that is required for normal oxidative stress tolerance. A high copy number plasmid bearing the glutamate decarboxylase gene (GAD1) increases resistance to two different oxidants, H2O2 and diamide, in cells that contain an intact glutamate catabolic pathway. Structural similarity of the S. cerevisiae GAD to previously studied plant enzymes was demonstrated by the crossreaction of the yeast enzyme to a antiserum directed against the plant GAD. The yeast GAD also bound to calmodulin as did the plant enzyme, suggesting a conservation of calcium regulation of this protein. Loss of either gene encoding the downstream steps in the conversion of glutamate to succinate reduced oxidative stress tolerance in normal cells and was epistatic to high copy number GAD1. The gene encoding succinate semialdehyde dehydrogenase (UGA5) was identified and found to be induced by H2O2 exposure. Together, these data strongly suggest that increases in activity of the glutamate catabolic pathway can act to buffer redox changes in the cell.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; USDA ARS, Climate Stress Lab, Beltsville, MD 20705 USA	University of Iowa; United States Department of Agriculture (USDA)	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-612 Bowen Sci Bldg, Iowa City, IA 52242 USA.	moyerowl@blue.weeg.uiowa.edu	Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIGMS NIH HHS [GM49825] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderlund M, 1999, APPL ENVIRON MICROB, V65, P2333; ANDRE B, 1993, MOL GEN GENET, V237, P17; ANDRE B, 1990, NUCLEIC ACIDS RES, V18, P3049, DOI 10.1093/nar/18.10.3049; BAUM G, 1993, J BIOL CHEM, V268, P19610; Baum G, 1996, EMBO J, V15, P2988, DOI 10.1002/j.1460-2075.1996.tb00662.x; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Busch KB, 1999, PLANT PHYSIOL, V121, P589, DOI 10.1104/pp.121.2.589; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Castanie-Cornet MP, 1999, J BACTERIOL, V181, P3525, DOI 10.1128/JB.181.11.3525-3535.1999; CUNNINGHAM TS, 1994, J BACTERIOL, V176, P4718, DOI 10.1128/JB.176.15.4718-4725.1994; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; GALLEGO PP, 1995, PLANT MOL BIOL, V27, P1143, DOI 10.1007/BF00020887; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HEARL WG, 1984, J BIOL CHEM, V259, P1459; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Juhnke H, 1996, MOL GEN GENET, V252, P456, DOI 10.1007/BF02173011; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LING V, 1994, PLANT CELL, V6, P1135, DOI 10.1105/tpc.6.8.1135; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; Nisbet AP, 1996, NEUROSCIENCE, V75, P389, DOI 10.1016/0306-4522(96)00299-0; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; Pearl PL, 2006, FUTUR NEUROL, V1, P631, DOI 10.2217/14796708.1.5.631; RAMOS F, 1985, EUR J BIOCHEM, V149, P401, DOI 10.1111/j.1432-1033.1985.tb08939.x; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Satin LS, 1998, ENDOCRINE, V8, P213, DOI 10.1385/ENDO:8:3:213; Shelp BJ, 1999, TRENDS PLANT SCI, V4, P446, DOI 10.1016/S1360-1385(99)01486-7; Sherman F, 1979, METHODS YEAST GENETI; Sherwin AL, 1999, NEUROCHEM RES, V24, P1385, DOI 10.1023/A:1022580506443; SIKORSKI RS, 1989, GENETICS, V122, P19; Snedden WA, 1996, J BIOL CHEM, V271, P4148; TALIBI D, 1995, NUCLEIC ACIDS RES, V23, P550, DOI 10.1093/nar/23.4.550; Tramonti A, 1998, J BIOL CHEM, V273, P1939, DOI 10.1074/jbc.273.4.1939; Turano FJ, 1998, PLANT PHYSIOL, V117, P1411, DOI 10.1104/pp.117.4.1411; VISSERS S, 1990, EUR J BIOCHEM, V187, P611, DOI 10.1111/j.1432-1033.1990.tb15344.x; WU AL, 1993, J BIOL CHEM, V268, P18850; Yuan T, 1998, J BIOL CHEM, V273, P30328, DOI 10.1074/jbc.273.46.30328; Zik M, 1998, PLANT MOL BIOL, V37, P967, DOI 10.1023/A:1006047623263	46	164	199	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					244	250		10.1074/jbc.M007103200	http://dx.doi.org/10.1074/jbc.M007103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11031268	hybrid			2022-12-27	WOS:000166280700034
J	Mamelak, D; Lingwood, C				Mamelak, D; Lingwood, C			The ATPase domain of hsp70 possesses a unique binding specificity for 3 '-sulfogalactolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; GLYCOLIPID RECEPTOR FUNCTION; MOLECULAR CHAPERONE DNAK; IMMOBILIZING PROTEIN; NUCLEOTIDE EXCHANGE; HELICOBACTER-PYLORI; HYDROLYTIC ACTIVITY; ESCHERICHIA-COLI; STRUCTURAL BASIS; SULFATIDE	The region(s) of hsp70 critical for sulfogalactolipid (SGL) recognition has been defined through deletion analysis and site-directed mutagenesis. Truncated polymerase chain reaction products of hsp70 generated N-terminal fragments of 43, 35, 29, and 22 kDa. The C terminus substrate-binding domain (28 kDa) was also expressed. The N-terminal ATPase domain (rP43) shared the binding specificity of hsp70, because only sulfogalactosyl ceramide and sulfogalactosyl glycerolipid were recognized by both TLC overlay and RELISA. The C-terminal domain showed no binding. SGL binding of rP29 and rP22 was severely reduced. The loss of SGL binding for rP35 by RELISA but not TLC overlay was considered as a function of receptor presentation. The truncation of rP43 to rP35 demonstrates that residues 318-387 (the base of the ATP binding cleft) are critical for high affinity SGL binding. Mutagenesis showed that Arg(342) and Phe(198) are crucial for this process. SGL binding, mediated by these conserved residues within the ATPase domain of hsp70, implies that this binding specificity is evolutionarily conserved.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Hosp Sick Children, Res Inst, Div Infect Immun Injury & Repair, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Lingwood, C (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 100 Coll St, Toronto, ON M5G 1L5, Canada.							Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BHAT S, 1993, AIDS RES HUM RETROV, V9, P175, DOI 10.1089/aid.1993.9.175; Botzler C, 1998, CELL STRESS CHAPERON, V3, P6, DOI 10.1379/1466-1268(1998)003<0006:DOELEO>2.3.CO;2; BOULANGER J, 1995, J CELL PHYSIOL, V165, P7, DOI 10.1002/jcp.1041650103; BOYD B, 1994, EUR J BIOCHEM, V223, P873, DOI 10.1111/j.1432-1033.1994.tb19064.x; BUKAU B, 1993, J GEN MICROBIOL, V139, P95, DOI 10.1099/00221287-139-1-95; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURKART T, 1981, DEV BIOL, V83, P42, DOI 10.1016/S0012-1606(81)80006-1; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; Choi BK, 1999, INFECT IMMUN, V67, P5755, DOI 10.1128/IAI.67.11.5755-5761.1999; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; HANSEN LK, 1995, BBA-PROTEIN STRUCT M, V1252, P135, DOI 10.1016/0167-4838(95)00113-9; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hartmann E, 1997, INFECT IMMUN, V65, P1729, DOI 10.1128/IAI.65.5.1729-1733.1997; HOLT GD, 1990, J BIOL CHEM, V265, P2852; Huesca M, 1998, INFECT IMMUN, V66, P4061; Huesca M, 1996, INFECT IMMUN, V64, P2643, DOI 10.1128/IAI.64.7.2643-2648.1996; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; ISHIZUKA I, 1978, J BIOL CHEM, V253, P898; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P220; KUBUSHIRO K, 1989, ARCH BIOCHEM BIOPHYS, V268, P129, DOI 10.1016/0003-9861(89)90573-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW H, 1988, J CELL PHYSIOL, V137, P462, DOI 10.1002/jcp.1041370310; LEVINE M, 1976, BIOCHIM BIOPHYS ACTA, V441, P134, DOI 10.1016/0005-2760(76)90288-5; LINGWOOD C, 1981, CAN J BIOCHEM CELL B, V59, P556, DOI 10.1139/o81-077; LINGWOOD C, 1991, J CELL PHYSIOL, V146, P258, DOI 10.1002/jcp.1041460210; Lingwood CA, 1996, GLYCOCONJUGATE J, V13, P495, DOI 10.1007/BF00731435; LINGWOOD CA, 1980, J IMMUNOL, V124, P769; LINGWOOD CA, 1985, CAN J BIOCHEM CELL B, V63, P1077, DOI 10.1139/o85-134; Macellaro A, 1998, INFECT IMMUN, V66, P5882, DOI 10.1128/IAI.66.12.5882-5888.1998; Mamelak D, 1997, GLYCOCONJUGATE J, V14, P715, DOI 10.1023/A:1018569417218; MILLER D, 1992, HUM REPROD, V7, P637, DOI 10.1093/oxfordjournals.humrep.a137711; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Multhoff G, 1997, J IMMUNOL, V158, P4341; Murry R. K., 1980, ACS SYM SER, V128, P105; NATOMI H, 1993, LIPIDS, V28, P737, DOI 10.1007/BF02535996; NATOMI H, 1988, BIOCHIM BIOPHYS ACTA, V961, P213; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PELLIZZARI A, 1992, BIOCHEMISTRY-US, V31, P1363, DOI 10.1021/bi00120a011; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; RAULSTON JE, 1993, J BIOL CHEM, V268, P23139; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; ROBERTS DD, 1986, CHEM PHYS LIPIDS, V42, P173, DOI 10.1016/0009-3084(86)90051-4; SCORPIO A, 1994, J BACTERIOL, V176, P6449, DOI 10.1128/JB.176.21.6449-6456.1994; TANPHAICHITR N, 1993, DEV BIOL, V156, P164, DOI 10.1006/dbio.1993.1067; TANPHAICHITR N, 1992, MOL REPROD DEV, V32, P17, DOI 10.1002/mrd.1080320104; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893	57	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					449	456		10.1074/jbc.M006732200	http://dx.doi.org/10.1074/jbc.M006732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024054	hybrid			2022-12-27	WOS:000166280700061
J	Qiu, ZY; Nicoll, DA; Philipson, KD				Qiu, ZY; Nicoll, DA; Philipson, KD			Helix packing of functionally important regions of the cardiac Na+-Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE CROSS-LINKING; NA-CA EXCHANGER; TRANSMEMBRANE SEGMENTS; EXPRESSION; TOPOLOGY; DOMAIN	In a revised topological model of the cardiac Na+-Ca2+ exchanger, there are nine transmembrane segments (TMSs) and two possible re-entrant loops (Nicoll, D, A., Ottolia, M., Lu, Y., Lu, L., and Philipson, K. D. (1999) J. Biol Chem. 274, 910-917; Iwamoto, T., Nakamura, T. Y., Pan, Y., Uehara, A, Imanaga, I., and Shigekawa, M. (1999) FEES Lett. 446, 264-268). The TMSs form two clusters separated by a large intracellular loop between TMS5 and TMS6. We have combined cysteine mutagenesis and oxidative cross-linking to study proximity relationships of TMSs in the exchanger. Pairs of cysteines were reintroduced into a cysteine-less exchanger, one in a TMS in the NH2-terminal cluster (TMSs 1-5) and the other in a TMS in the COOP-terminal cluster (TMSs 6-9). The mutant exchanger proteins were expressed in HEK293 cells, and disulfide bond formation between introduced cysteines was analyzed by gel mobility shifts. Western blots showed that S117C/V804C, A122C/Y892C, A151C/T815C, and A151C/A821C mutant proteins migrated at 120 kDa under reducing conditions and displayed a partial mobility shift to 160 kDa under nonreducing conditions. This shift indicates the formation of a disulfide bond between these paired cysteine residues. Copper phenanthroline and the cross-linker N',N'-o-phenylenedimaleimide enhanced the mobility shift to 160 kDa. Our data suggest that TMS7 is close to TMS3 near the intracellular side of the membrane and is in the vicinity of TMS2 near the extracellular surface. Also, TMS2 must adjoin TMS8. This initial packing model of the exchanger brings two functionally important domains in the exchanger, the alpha1 and alpha2 repeats, close to each other.	Univ Calif Los Angeles, Cardiovasc Res Labs, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Philipson, KD (corresponding author), Univ Calif Los Angeles, Cardiovasc Res Labs, Sch Med, MRL 3-645, Los Angeles, CA 90095 USA.	Kphilipson@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49101] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cook O, 1998, BBA-BIOMEMBRANES, V1371, P40, DOI 10.1016/S0005-2736(97)00272-1; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; LEE SL, 1994, J BIOL CHEM, V269, P14849; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; REEVES JP, 1984, J BIOL CHEM, V259, P7733; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; SAHINTOTH M, 1995, BIOCHEM BIOPH RES CO, V212, P968, DOI 10.1006/bbrc.1995.2064; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099	23	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					194	199		10.1074/jbc.M005571200	http://dx.doi.org/10.1074/jbc.M005571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035002	hybrid			2022-12-27	WOS:000166280700028
J	Sweeney, HL; Chen, LQ; Trybus, KM				Sweeney, HL; Chen, LQ; Trybus, KM			Regulation of asymmetric smooth muscle myosin II molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT REGULATION; LIGHT CHAIN PHOSPHORYLATION; 2 HEADS; ADP RELEASE; CONFORMATIONAL STATES; SKELETAL-MUSCLE; CROSS-LINKING; HEAVY-CHAIN; ACTIN; BINDING	The emerging view of smooth/nonmuscle myosin regulation suggests that the attainment of the completely inhibited state requires numerous weak interactions between components of the two heads and the myosin rod. To further examine the nature of the structural requirements for regulation, we engineered smooth muscle heavy meromyosin molecules that contained one complete head and truncations of the second head. These truncations eliminated the motor domain but retained two, one, or no light chains. All constructs contained 37 heptads of rod sequence. None of the truncated constructs displayed complete regulation of both ATPase and motility, reinforcing the idea that interactions between motor domains are necessary for complete regulation. Surprisingly, the rate of ADP release was slowed by regulatory light chain dephosphorylation of the truncated construct that contained all four light chains and one motor domain, These data suggest that there is a second step (ADP release) in the smooth muscle myosin-actin-activated ATPase cycle that is modulated by regulatory light chain phosphorylation. This may be part of the mechanism underlying "latch" in smooth muscle.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Vermont, Dept Physiol & Biophys, Burlington, VT 05405 USA	University of Pennsylvania; University of Vermont	Sweeney, HL (corresponding author), Univ Penn, Sch Med, Dept Physiol, 3700 Hamilton Walk, Philadelphia, PA 19104 USA.		Sweeney, H Lee/F-1862-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038113, R29HL038113, P01HL015835] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38113, HL15835] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; BURNS CG, 1995, P NATL ACAD SCI USA, V92, P8244, DOI 10.1073/pnas.92.18.8244; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; Ellison PA, 2000, J BIOL CHEM, V275, P15142, DOI 10.1074/jbc.275.20.15142; Gollub J, 1996, NAT STRUCT BIOL, V3, P796, DOI 10.1038/nsb0996-796; Hai C.M., 1988, AM J PHYSIOL, V254, P99; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; Ito K, 1999, BIOPHYS J, V76, P985, DOI 10.1016/S0006-3495(99)77262-0; KATOH T, 1995, EUR J BIOCHEM, V233, P123, DOI 10.1111/j.1432-1033.1995.123_1.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; Malmqvist U, 1997, P NATL ACAD SCI USA, V94, P7655, DOI 10.1073/pnas.94.14.7655; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; PERRIE WT, 1973, BIOCHEM J, V135, P151, DOI 10.1042/bj1350151; POLLARD TD, 1982, METHOD ENZYMOL, V85, P698; Rosenfeld SS, 1998, J BIOL CHEM, V273, P28682, DOI 10.1074/jbc.273.44.28682; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; Trybus KM, 1998, J BIOL CHEM, V273, P18423, DOI 10.1074/jbc.273.29.18423; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; VYAS TB, 1992, AM J PHYSIOL, V263, pC210, DOI 10.1152/ajpcell.1992.263.1.C210; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	33	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41273	41277		10.1074/jbc.M008310200	http://dx.doi.org/10.1074/jbc.M008310200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11018047	hybrid			2022-12-27	WOS:000166114600082
J	Gelb, MH; Valentin, E; Ghomashchi, F; Lazdunski, M; Lambeau, G				Gelb, MH; Valentin, E; Ghomashchi, F; Lazdunski, M; Lambeau, G			Cloning and recombinant expression of a structurally novel human secreted phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFACIAL CATALYSIS; MOUSE; MECHANISM; FAMILY; CELLS; VENOM; IIA	Mammals contain a diverse set of secreted phospholipases A(2) (sPLA(2)s) that liberate arachidonic acid from phospholipids for the production of eicosanoids and exert a variety of physiological and pathological effects. We report the cloning, recombinant expression, and kinetic properties of a novel human sPLA(2) that defines a new structural class of sPLA(2)s called group XII. The human group XII (hGXII) cDNA contains a putative signal peptide of 22 residues followed by a mature protein of 167 amino acids that displays homology to all known sPLA(2)s only over a short stretch of amino acids in the active site region. Northern blot and reverse transcription-polymerase chain reaction analyses show that the tissue distribution of hGXII is distinct from the other human sPLA(2)s with strong expression in heart, skeletal muscle, kidney, and pancreas and weaker expression in brain, liver, small intestine, lung, placenta, ovaries, testis, and prostate. Catalytically active hGXII was produced in Escherichia coli and shown to be Ca2+-dependent despite the fact that it is predicted to have an unusual Ca2+-binding loop. Similar to the previously characterized mouse group IIE sPLA(2)s, the specific activity of hGXII is low in comparison to that of other mammalian sPLA(2), suggesting that hGXII could have novel functions that are independent of its phospholipase A(2) activity.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.		Lambeau, Gerard/GRJ-5624-2022	gelb, michael/0000-0001-7000-5219; Lambeau, Gerard/0000-0002-9239-518X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036235] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL036235, HL36236] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARITA H, 1993, J LIPID MEDIATOR, V6, P217; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BEKKERS ACAPA, 1991, BIOCHIM BIOPHYS ACTA, V1076, P374, DOI 10.1016/0167-4838(91)90479-J; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; Hanasaki K, 1999, ARCH BIOCHEM BIOPHYS, V372, P215, DOI 10.1006/abbi.1999.1511; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; Kim JY, 1999, BBA-GENE STRUCT EXPR, V1489, P389, DOI 10.1016/S0167-4781(99)00193-1; Kundu GC, 1997, J BIOL CHEM, V272, P2346; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LIU CS, 1990, TOXICON, V28, P1457, DOI 10.1016/0041-0101(90)90159-5; MCINTOSH JM, 1995, J BIOL CHEM, V270, P3518, DOI 10.1074/jbc.270.8.3518; Mounier CM, 2000, EUR J BIOCHEM, V267, P4960, DOI 10.1046/j.1432-1327.2000.01523.x; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PRUZANSKI W, 1993, J LIPID MEDIATOR, V8, P161; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Rae D., 1996, SCAND J GASTROENTE S, V219, P24; Sartipy P, 1998, ARTERIOSCL THROM VAS, V18, P1934, DOI 10.1161/01.ATV.18.12.1934; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; Stahl U, 1998, PLANT PHYSIOL, V117, P197, DOI 10.1104/pp.117.1.197; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; VALENTIN E, 2000, IN PRESS BIOCH BIOPH; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; Yuan CH, 1999, BBA-MOL CELL BIOL L, V1441, P215, DOI 10.1016/S1388-1981(99)00156-0	37	135	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39823	39826		10.1074/jbc.C000671200	http://dx.doi.org/10.1074/jbc.C000671200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11031251	Green Accepted, hybrid			2022-12-27	WOS:000166039500006
J	Browne, KA; Johnstone, RW; Jans, DA; Trapani, JA				Browne, KA; Johnstone, RW; Jans, DA; Trapani, JA			Filamin (280-kDa actin-binding protein) is a caspase substrate and is also cleaved directly by the cytotoxic T lymphocyte protease granzyme B during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; CYTOSOLIC DELIVERY; DNA FRAGMENTATION; TARGET-CELLS; PERFORIN; GELSOLIN; FAMILY; GENE; DEPENDENCE; ABP-280	We used yeast two-hybrid screening to identify the cytoskeletal protein filamin as a ligand for the proapoptotic protease granzyme B, produced by cytotoxic T lymphocytes. Filamin was directly cleaved by granzyme B when target cells were exposed to granzyme B and the lytic protein perforin, but it was also cleaved in a caspase-dependent manner following the ligation of Fas receptors. A similar pattern of filamin cleavage to polypeptides of similar to 110 and 95 kDa was observed in Jurkat cells killed by either mechanism. However, filamin cleavage in response to granzyme B was not inhibited by the caspase inhibitor z-Val-Ala-Asp-fluoromethylketone at concentrations that abolished DNA fragmentation. Filamin staining was redistributed from the cell membrane into the cytoplasm of Jurkat cells exposed to granzyme B and perforin and following Ligation of Fas receptors, coincident with the morphological changes of apoptosis. Filamin-deficient human melanoma cells were significantly (although not completely) protected from granzyme B-mediated death compared with isogenic filamin-expressing cells, both in clonogenic survival and Cr-51 release assays, whereas death from multiple other stimuli was not affected by filamin deficiency. Thus, filamin is a functionally important substrate for granzyme B, as its cleavage may account at least partly for caspase-independent cell death mediated by the granzyme.	Peter MacCallum Canc Inst, Canc Immunol Lab, Melbourne, Vic 8006, Australia; Australian Natl Univ, John Curtin Sch Med Res, Dept Biochem & Mol Biol, Nucl Signaling Lab, Canberra, ACT 2601, Australia	Peter Maccallum Cancer Center; Australian National University; John Curtin School of Medical Research	Trapani, JA (corresponding author), Peter MacCallum Canc Inst, Canc Immunol Lab, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.		Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Trapani, Joseph/0000-0003-0983-1532				Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Beresford PJ, 1999, IMMUNITY, V10, P585, DOI 10.1016/S1074-7613(00)80058-8; Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; BOLDIN MP, 1996, CELL, V85, P813; Browne KA, 1999, MOL CELL BIOL, V19, P8604; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V229, P44, DOI 10.1006/bbrc.1996.1755; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Jans DA, 1998, J CELL SCI, V111, P2645; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; KAGI D, 1994, EUR J IMMUNOL, V24, P3068, DOI 10.1002/eji.1830241223; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; Posey SC, 2000, BLOOD, V95, P3483, DOI 10.1182/blood.V95.11.3483.011k05_3483_3488; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Sarin A, 1998, J IMMUNOL, V161, P2810; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Trapani JA, 1998, SPRINGER SEMIN IMMUN, V19, P323, DOI 10.1007/BF00787229; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 1999, IMMUNOL TODAY, V20, P351, DOI 10.1016/S0167-5699(99)01488-7; Trapani JA, 1998, CELL DEATH DIFFER, V5, P488, DOI 10.1038/sj.cdd.4400373; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278	43	68	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39262	39266		10.1074/jbc.C000622200	http://dx.doi.org/10.1074/jbc.C000622200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	11050075	hybrid			2022-12-27	WOS:000165953100044
J	Hooks, SB; Santos, WL; Im, DS; Heise, CE; Macdonald, TL; Lynch, KR				Hooks, SB; Santos, WL; Im, DS; Heise, CE; Macdonald, TL; Lynch, KR			Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE RECEPTOR; PLATELET-AGGREGATION; MOLECULAR-CLONING; ACTIVATING-FACTOR; PHOSPHORIC-ACIDS; XENOPUS OOCYTES; CELLS; IDENTIFICATION; INHIBITION	Lysophosphatidic acid (LPA) is an extracellular signaling mediator with a broad range of cellular responses. Three G-protein-coupled receptors (Edg-2, -4, and -7) have been identified as receptors for LPA. In this study, the ectophosphatase lipid phosphate phosphatase 1 (LPP1) has been shown to down-regulate LPA-mediated mitogenesis. Furthermore, using degradation-resistant phosphonate analogs of LPA and stereoselective agonists of the Edg receptors we have demonstrated that the mitogenic and platelet aggregation responses to LPA are independent of Edg-2, -4, and -7. Specifically, we found that LPA degradation is insufficient to account for the decrease in LPA potency in mitogenic assays, and the stereoselectivity observed at the Edg receptors is not reflected in mitogenesis. Additionally, RH7777 cells, which are devoid of Edg-2, -4, and -7 receptor mRNA, have a mitogenic response to LPA and LPA analogs. Finally, we have determined that the ligand selectivity of the platelet aggregation response is consistent with that of mitogenesis, but not with Edg-2, -4, and -7.	Univ Virginia, Hlth Sci Ctr, Dept Biochem, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Chem, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Hooks, SB (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biochem, Jordan Hall,Box 440,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.			Hooks, Shelley/0000-0003-4702-0490; IM, DONG-SOON/0000-0001-8054-8946; Santos, Webster/0000-0002-4731-8548	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA005927] Funding Source: NIH RePORTER; NIDA NIH HHS [F31-DA05927] Funding Source: Medline; NIGMS NIH HHS [R01-GM52722] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard J, 1998, EUR J NEUROSCI, V10, P1045, DOI 10.1046/j.1460-9568.1998.00117.x; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Dillon DA, 1997, J BIOL CHEM, V272, P10361; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Gueguen G, 1999, BIOCHEMISTRY-US, V38, P8440, DOI 10.1021/bi9816756; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hooks SB, 1998, FEBS LETT, V427, P188, DOI 10.1016/S0014-5793(98)00421-9; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; Hopper DW, 1999, J MED CHEM, V42, P963, DOI 10.1021/jm970809v; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; JALINK K, 1990, J BIOL CHEM, V265, P12232; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kanoh H, 1999, CHEM PHYS LIPIDS, V98, P119, DOI 10.1016/S0009-3084(99)00024-9; KANOH H, 1992, J BIOL CHEM, V267, P25309; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Liliom K, 1996, MOL PHARMACOL, V50, P616; Lynch KR, 1997, MOL PHARMACOL, V52, P75, DOI 10.1124/mol.52.1.75; Moller T, 1999, NEUROREPORT, V10, P2929; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; PROLL MA, 1985, MOL PHARMACOL, V28, P331; PROLL MA, 1991, MOL PHARMACOL, V39, P740; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; SIMON MF, 1982, BIOCHEM BIOPH RES CO, V108, P1743, DOI 10.1016/S0006-291X(82)80113-7; SMYTH SS, 1992, J BIOL CHEM, V267, P15568; SUGIURA T, 1994, ARCH BIOCHEM BIOPHYS, V311, P358, DOI 10.1006/abbi.1994.1249; Svetlov SI, 1996, ARCH BIOCHEM BIOPHYS, V336, P59, DOI 10.1006/abbi.1996.0532; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TOKUMURA A, 1981, BIOCHEM BIOPH RES CO, V99, P391, DOI 10.1016/0006-291X(81)91758-7; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; Van Brocklyn JR, 2000, BLOOD, V95, P2624; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WALSH JP, 1990, J BIOL CHEM, V265, P4374; Weiner JA, 1998, J COMP NEUROL, V398, P587; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Xu J, 2000, J BIOL CHEM, V275, P27520; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	58	123	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4611	4621		10.1074/jbc.M007782200	http://dx.doi.org/10.1074/jbc.M007782200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11042183	hybrid			2022-12-27	WOS:000168484300014
J	Berg, BJV; Beard, WA; Wilson, SH				Berg, BJV; Beard, WA; Wilson, SH			DNA structure and aspartate 276 influence nucleotide binding to human DNA polymerase beta - Implication for the identity of the rate-limiting conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; BASE-EXCISION-REPAIR; DEPENDENT RNA-POLYMERASE; HEPATITIS-C VIRUS; CRYSTAL-STRUCTURE; KLENOW FRAGMENT; GAPPED DNA; REPLICATION FIDELITY; SECONDARY STRUCTURE; TERNARY COMPLEXES	Structures of DNA polymerase (pol) beta bound to single-nucleotide gapped DNA had revealed that the lyase and pol domains form a "doughnut-shaped" structure altering the dNTP binding pocket in a fashion that is not observed when bound to non-gapped DNA, We have investigated dNTP binding to pol beta -DNA complexes employing steady-state and pre-steady-state kinetics. Although po beta has a kinetic scheme similar to other DNA polymerases, polymerization by pol beta is limited by at least two partially rate-limiting steps: a conformational change after dNTP ground-state binding and product release. The equilibrium binding constant, K-d(dNTP) decreased and the insertion efficiency increased with a one-nucleotide gapped DNA substrate, as compared with non-gapped DNA. Valine substitution for Asp(276), which interacts with the base of the incoming nucleotide, increased the binding affinity for the incoming nucleotide indicating that the negative charge contributed by Asp(276) weakens binding and that an interaction between residue 276 with the incoming nucleotide occurs during ground-state binding. Since the interaction between Asp276 and the nascent base pair is observed only in the "closed" conformation of pol beta, the increased free energy in ground-state binding for the mutant suggests that the subsequent rate-limiting conformational change is not the "open" to "closed" structural transition, but instead is triggered in the closed pol conformation.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BEARD WA, 1994, J BIOL CHEM, V269, P28091; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; BEARD WA, 1995, PRACTICAL APPROACH, V2, P15; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; DONLIN MJ, 1994, BIOCHEMISTRY-US, V33, P14908, DOI 10.1021/bi00253a030; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JAJU M, 1995, J BIOL CHEM, V270, P9740, DOI 10.1074/jbc.270.17.9740; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHISTAEDT LA, 1992, SCIENCE, V256, P1783; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUMAR A, 1990, J BIOL CHEM, V265, P2124; Lavrik OI, 1996, J BIOL CHEM, V271, P21891, DOI 10.1074/jbc.271.36.21891; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lewis DA, 1999, J BIOL CHEM, V274, P32924, DOI 10.1074/jbc.274.46.32924; Li Y, 1998, PROTEIN SCI, V7, P1116, DOI 10.1002/pro.5560070505; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oliveros M, 1997, J BIOL CHEM, V272, P30899, DOI 10.1074/jbc.272.49.30899; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1998, J BIOL CHEM, V273, P27259, DOI 10.1074/jbc.273.42.27259; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; Wade RC, 1998, P NATL ACAD SCI USA, V95, P5942, DOI 10.1073/pnas.95.11.5942; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; WHARTON CW, 1981, MOL ENZYMOLOGY, P204; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	62	139	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3408	3416		10.1074/jbc.M002884200	http://dx.doi.org/10.1074/jbc.M002884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11024043	hybrid			2022-12-27	WOS:000166784900056
J	Blahos, J; Fischer, T; Brabet, I; Stauffer, D; Rovelli, G; Bockaert, J; Pin, JP				Blahos, J; Fischer, T; Brabet, I; Stauffer, D; Rovelli, G; Bockaert, J; Pin, JP			A novel site on the G alpha-protein that recognizes heptahelical receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; CHEMOKINE RECEPTORS; INOSITOL PHOSPHATES; CRYSTAL-STRUCTURE; AMINO-ACIDS; BETA-GAMMA; SUBUNIT; ACTIVATION	Specific domains of the G-protein a subunit have been shown to control coupling to heptahelical receptors, The extreme N and C termini and a region between alpha4 and alpha5 helices of the G-protein alpha subunit are known to determine selective interaction with the receptors, The metabotropic glutamate receptor 2 activated both mouse G alpha (15) and its human homologue G alpha (16), whereas metabotropic glutamate receptor 8 activated G alpha (15) only. The extreme C-terminal 20 amino acid residues are identical between the G alpha (15) and G alpha (16) and are therefore unlikely to be involved in coupling selectivity, Our data reveal two regions on G alpha (16) that inhibit its coupling to metabotropic glutamate receptor 8, On a three-dimensional model, both regions are found in a close proximity to the extreme C terminus of G alpha (16). One module comprises alpha4 helix, alpha4-beta6 loop (L9 Loop), beta6 sheet, and alpha5 helix. The other, not described previously, is located within the loop that links the N-terminal alpha helix to the beta1 strand of the Res-like domain of the alpha subunit, Coupling of G alpha (16) protein to the metabotropic glutamate receptor 8 is partially modulated by each module alone, whereas both modules are needed to eliminate the coupling fully.	CNRS, UPR9023, CCIPE, F-34094 Montpellier, France; Acad Sci Czech Republ, Inst Physiol, Prague 2, Czech Republic; Charles Univ, Fac Med 3, Dept Physiol, Lab Mol Physiol, Prague, Czech Republic; Univ Montpellier 2, INSERM, U431, F-34095 Montpellier, France; Novartis Pharma Res, CH-4002 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Charles University Prague; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Novartis	Blahos, J (corresponding author), CNRS, UPR9023, CCIPE, 141 Rue Cardonille, F-34094 Montpellier 5, France.		Blahos, Jaroslav/G-4397-2014; Pin, Jean-Philippe/Y-6668-2019; Blahos, Jaroslav/G-8325-2017	Pin, Jean-Philippe/0000-0002-1423-345X; Fischer, Thierry/0000-0002-9542-322X; Blahos, Jaroslav/0000-0003-3355-1469; Blahos, Jaroslav/0000-0001-9803-0061				AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Bae H, 1999, J BIOL CHEM, V274, P14963, DOI 10.1074/jbc.274.21.14963; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Blahos J, 1998, J BIOL CHEM, V273, P25765, DOI 10.1074/jbc.273.40.25765; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BONE EA, 1984, BIOCHEM J, V221, P803, DOI 10.1042/bj2210803; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Coleman DE, 1998, BIOCHEMISTRY-US, V37, P14376, DOI 10.1021/bi9810306; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; De Colle C, 2000, EUR J PHARMACOL, V394, P17, DOI 10.1016/S0014-2999(00)00113-8; Gomeza J, 1996, MOL PHARMACOL, V50, P923; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1998, J BIOL CHEM, V273, P17886, DOI 10.1074/jbc.273.28.17886; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; Milligan G, 1996, TRENDS PHARMACOL SCI, V17, P235, DOI 10.1016/0165-6147(96)10026-2; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008	42	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3262	3269		10.1074/jbc.M004880200	http://dx.doi.org/10.1074/jbc.M004880200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11027680	hybrid			2022-12-27	WOS:000166784900038
J	Das, A; Chendil, D; Dey, S; Mohiuddin, M; Mohiuddin, M; Milbrandt, J; Rangnekar, VM; Ahmed, MM				Das, A; Chendil, D; Dey, S; Mohiuddin, M; Mohiuddin, M; Milbrandt, J; Rangnekar, VM; Ahmed, MM			Ionizing radiation down-regulates p53 protein in primary Egr-1(-/-) mouse embryonic fibroblast cells causing enhanced resistance to apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; WILMS-TUMOR GENE; TRANSCRIPTION FACTOR EGR-1; IRRADIATED MURINE TUMORS; A-CHAIN GENE; NF-KAPPA-B; GROWTH-FACTOR; DNA-BINDING; NGFI-A; PROMOTER	In this study, we sought to investigate the mechanism of the proapoptotic function of Egr-1 in relation to p53 status in normal isogenic cell backgrounds by using primary MEF cells established from homozygous (Egr-1(-/-)) and heterozygous (Egr-1(+/-)) Egr-1 knock-out mice. Ionizing radiation caused significantly enhanced apoptosis in Egr-1(+/-) cells (22.8%; p < 0.0001) when compared with Egr-1(-/-) cells (3.5%). Radiation elevated p53 protein in Egr-1(+/-) cells in 3-6 h, However, in Egr-1(-/-) cells, the p53 protein was down-regulated 1 h after radiation and was completely degraded at the later time points. Radiation elevated the p53-CAT activity in Egr-1(+/-) cells but not in Egr-1(-/-) cells. Interestingly, transient overexpression of EGR-1 in p53(-/-) MEF cells caused marginal induction of radiation-induced apoptosis when compared with p53(+/+) MEF cells. Together, these results indicate that Egr-1 may transregulate p53, and both EGR-1 and p53 functions are essential to mediate radiation-induced apoptosis, Rb, an Egr-1 target gene, forms a trimeric complex with p53 and MDM2 to prevent MDM2-mediated p53 degradation. Low levels of Rb including hypophosphorylated forms were observed in Egr-1(-/-) MEF cells before and after radiation when compared with the levels observed in Egr-1(+/-) cells. Elevated amounts of the p53-MDM2 complex and low amounts of Rb-MDM-2 complex were observed in Egr-1(-/-) cells after radiation. Because of a reduction in Rb binding to MDM2 and an increase in MDM2 binding with p53, p53 is directly degraded by MDM2, and this leads to inactivation of the p53-mediated apoptotic pathway in Egr-1(-/-) MEF cells. Thus, the proapoptotic function of Egr-1 may involve the mediation of Rb protein that is essential tot overcome the antiapoptotic function of MDM2 on p53.	Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; Washington Univ, Dept Pathol, St Louis, MO 63130 USA	University of Kentucky; University of Kentucky; Washington University (WUSTL)	Ahmed, MM (corresponding author), Univ Kentucky, Dept Radiat Med, 800 Rose St, Lexington, KY 40536 USA.		Ahmed, Mansoor/AAK-5988-2020; Das, Anindita/K-8003-2013	Das, Anindita/0000-0003-4422-7277; Milbrandt, Jeffrey/0000-0002-5477-7689				ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DAY ML, 1993, CANCER RES, V53, P5597; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; HUANG RP, 1995, CANCER RES, V55, P5054; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; MIYASHITA T, 1995, CELL, V80, P293; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STEPHENS LC, 1993, RADIAT RES, V135, P75, DOI 10.2307/3578399; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WANG ZY, 1992, BIOCHEM BIOPH RES CO, V188, P433, DOI 10.1016/0006-291X(92)92403-K; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WU HY, 1994, J BIOL CHEM, V269, P20067	49	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3279	3286		10.1074/jbc.M008454200	http://dx.doi.org/10.1074/jbc.M008454200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11035041	hybrid			2022-12-27	WOS:000166784900040
J	Lykidis, A; Wang, J; Karim, MA; Jackowski, S				Lykidis, A; Wang, J; Karim, MA; Jackowski, S			Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINE KINASE; RAT-LIVER; PHOSPHATIDYLETHANOLAMINE BIOSYNTHESIS; MOLECULAR-CLONING; HAMSTER HEART; PURIFICATION; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; PRECURSOR; MUTATION	Ethanolamine kinase (EKI) is the first committed step in phosphatidylethanolamine (PtdEtn) biosynthesis via the CDP-ethanolamine pathway. We identify a human cDNA encoding an ethanolamine-specific kinase EKI1 and the structure of the EKI1 gene located on chromosome 12. EKI1 overexpression in COS-7 cells results in a 170-fold increase in ethanolamine kinase-specific activity and accelerates the rate of [H-3]ethanolamine incorporation into PtdEtn as a function of the ethanolamine concentration in the culture medium. Acceleration of the CDP-ethanolamine pathway does not result in elevated cellular PtdEtn levels, but rather the excess PtdEtn is degraded to glycerophosphoethanolamine. EKI1 has negligible choline kinase activity in vitro and does not influence phosphatidylcholine biosynthesis. Acceleration of the CDP-ethanolamine pathway also does not change the rate of PtdEtn formation via the decarboxylation of phosphatidylserine. The data demonstrate the existence of separate ethanolamine and choline kinases in mammals and show that ethanolamine kinase can be a rate-controlling step in PtdEtn biosynthesis.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.		Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoyama C, 1998, BBA-LIPID LIPID MET, V1393, P179, DOI 10.1016/S0005-2760(98)00062-9; ARTHUR G, 1991, BIOCHEM J, V273, P121, DOI 10.1042/bj2730121; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; Bladergroen BA, 1997, BBA-LIPID LIPID MET, V1348, P91, DOI 10.1016/S0005-2760(97)00113-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROPHY PJ, 1977, EUR J BIOCHEM, V78, P491, DOI 10.1111/j.1432-1033.1977.tb11761.x; DRAUS E, 1990, BIOCHIM BIOPHYS ACTA, V1045, P195, DOI 10.1016/0005-2760(90)90120-M; HOSAKA K, 1992, FEBS LETT, V304, P229, DOI 10.1016/0014-5793(92)80625-Q; HOUWELING M, 1992, BIOCHEM J, V283, P55, DOI 10.1042/bj2830055; INFANTE JP, 1977, BIOCHEM J, V167, P847, DOI 10.1042/bj1670847; ISHIDATE K, 1985, BIOCHIM BIOPHYS ACTA, V836, P119; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCMASTER CR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P13, DOI 10.1016/0005-2760(92)90119-G; MILLER MA, 1986, J BIOL CHEM, V261, P9753; PAVLIDIS P, 1994, CELL, V79, P23, DOI 10.1016/0092-8674(94)90397-2; PORTER TJ, 1990, J BIOL CHEM, V265, P414; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; UCHIDA T, 1994, J BIOCHEM-TOKYO, V116, P508, DOI 10.1093/oxfordjournals.jbchem.a124554; UCHIDA T, 1990, BIOCHIM BIOPHYS ACTA, V1043, P281, DOI 10.1016/0005-2760(90)90028-V; Uchida T, 1997, BBA-LIPID LIPID MET, V1349, P13, DOI 10.1016/S0005-2760(97)00059-3; UPRETI RK, 1976, ARCH BIOCHEM BIOPHYS, V174, P658, DOI 10.1016/0003-9861(76)90396-9; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5135, DOI 10.1021/bi00722a013; XU ZL, 1991, J BIOL CHEM, V266, P2143; ZELINSKI TA, 1982, CAN J BIOCHEM CELL B, V60, P817, DOI 10.1139/o82-102	30	78	81	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2174	2179		10.1074/jbc.M008794200	http://dx.doi.org/10.1074/jbc.M008794200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11044454	hybrid			2022-12-27	WOS:000166528000071
J	Somani, AK; Yuen, K; Xu, FH; Zhang, JY; Branch, DR; Siminovitch, KA				Somani, AK; Yuen, K; Xu, FH; Zhang, JY; Branch, DR; Siminovitch, KA			The SH2 domain containing tyrosine phosphatase-1 down-regulates activation of Lyn and Lyn-induced tyrosine phosphorylation of the CD19 receptor in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC ACTIVITY; KINASE-ACTIVITY; LINEAGE CELLS; CO-LIGATION; MOTH-EATEN; PROTEIN; SHP-1	SHP-1 is a cytosolic tyrosine phosphatase implicated in down-regulation of B cell antigen receptor signaling. SHP-1 effects on the antigen receptor reflect its capacity to dephosphorylate this receptor as well as several inhibitory comodulators. In view of our observation that antigen receptor-induced CD19 tyrosine phosphorylation is constitutively increased in B cells from SHP-1-deficient motheaten mice, we investigated the possibility that CD19, a positive modulator of antigen receptor signaling, represents another substrate for SHP-1. However, analysis of CD19 coimmunoprecipitable tyrosine phosphatase activity in CD19 immunoprecipitates from SHP-1-deficient and wild-type B cells revealed that SHP-1 accounts for only a minor portion of CD19-associated tyrosine phosphatase activity. As CD19 tyrosine phosphorylation is modulated by the Lyn protein-tyrosine kinase, Lyn activity was evaluated in wild-type and motheaten B cells. The results revealed both Lyn as well as CD19-associated Lyn kinase activity to be constitutively and inducibly increased in SHP-1-deficient compared with wild-type B cells. The data also demonstrated SHP-1 to be associated with Lyn in stimulated but not in resting B cells and indicated this interaction to be mediated via Lyn binding to the SHP-1 N terminal SH2 domain. These findings, together with cyanogen bromide cleavage data revealing that SHP-1 dephosphorylates the Lyn autophosphorylation site, identify Lyn deactivation/dephosphorylation as a likely mechanism whereby SHP-1 exerts its influence on CD19 tyrosine phosphorylation and, by extension, its inhibitory effect on B cell antigen receptor signaling.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Immunol & Med Genet, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Hlth Network Res Inst, Dept Oncol Res, Toronto, ON M5G 2M1, Canada; Canadian Blood Serv, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; Canadian Blood Services	Siminovitch, KA (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Rm 656A,600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Somani, ally-khan/AAA-9656-2020; Siminovitch, Katherine/K-1475-2013	Somani, Ally-Khan/0000-0003-2166-4896				ARNOLD LW, 1983, J IMMUNOL, V131, P2064; Blasioli J, 1999, J BIOL CHEM, V274, P2303, DOI 10.1074/jbc.274.4.2303; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BURG DL, 1994, J BIOL CHEM, V269, P28136; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Dustin LB, 1999, J IMMUNOL, V162, P2717; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; Fujimoto M, 1999, IMMUNITY, V11, P191, DOI 10.1016/S1074-7613(00)80094-1; Fujimoto M, 1999, J IMMUNOL, V162, P7088; GOLD MR, 1994, J IMMUNOL, V152, P42; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; Justement LB, 2000, CURR TOP MICROBIOL, V245, P1; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; Krop I, 1996, EUR J IMMUNOL, V26, P238, DOI 10.1002/eji.1830260137; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; MYERS DE, 1995, P NATL ACAD SCI USA, V92, P9575, DOI 10.1073/pnas.92.21.9575; Nadler MJS, 1997, J BIOL CHEM, V272, P20038, DOI 10.1074/jbc.272.32.20038; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; Nomura T, 1996, INT IMMUNOL, V8, P867, DOI 10.1093/intimm/8.6.867; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1997, J EXP MED, V186, P581, DOI 10.1084/jem.186.4.581; Pao LI, 1997, J IMMUNOL, V158, P2663; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Sato S, 1996, J IMMUNOL, V157, P4371; SAXTON TM, 1994, J IMMUNOL, V153, P623; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Smith KGC, 2000, CURR TOP MICROBIOL, V245, P195; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Tedder TF, 1998, SEMIN IMMUNOL, V10, P259, DOI 10.1006/smim.1998.0118; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; WENG WK, 1994, J BIOL CHEM, V269, P32514; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; Yang WT, 1998, EXP HEMATOL, V26, P1126; Yoshida K, 1999, J BIOL CHEM, V274, P34663, DOI 10.1074/jbc.274.49.34663	63	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1938	1944		10.1074/jbc.M006820200	http://dx.doi.org/10.1074/jbc.M006820200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11042209	hybrid			2022-12-27	WOS:000166528000041
J	Adak, S; Santolini, J; Tikunova, S; Wang, Q; Johnson, JD; Stuehr, DJ				Adak, S; Santolini, J; Tikunova, S; Wang, Q; Johnson, JD; Stuehr, DJ			Neuronal nitric-oxide synthase mutant (Ser-1412 -> Asp) demonstrates surprising connections between heme reduction, NO complex formation, and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; CONTROL ELEMENT; CALMODULIN; ISOFORMS; DOMAIN; BINDING; AKT	Rat neuronal NO synthase (nNOS) contains an Akt-dependent phosphorylation motif in its reductase domain. We mutated a target residue in that site (Ser-1412 to Asp) to mimic phosphorylation and then characterized the mutant using conventional and stopped-flow spectroscopies. Compared with wild-type, S1412D nNOS catalyzed faster cytochrome c and ferricyanide reduction but displayed slower steady-state NO synthesis with greater uncoupling of NADPH oxidation, Paradoxically, the mutant had faster heme reduction, faster heme-NO complex formation, and greater heme-NO complex accumulation at steady state. To understand how these behaviors related to flavin and heme reduction rates, we utilized three soybean calmodulins (CaMs) that supported a range of slower flavin and heme reduction rates in mutant and wild-type nNOS, Reductase activity and two catalytic parameters (speed and amount of heme-NO complex formation) related directly to the speed of flavin and heme reduction. In contrast, steady-state NO synthesis increased, reached a plateau, and then fell at the highest rate of heme reduction that was obtained with S1412D nNOS + CaM. Substituting with soybean CaM slowed heme reduction and increased steady-state NO synthesis by the mutant. We conclude the following. 1) The S1412D mutation speeds electron transfer out of the reductase domain. 2) Faster heme reduction speeds intrinsic NO synthesis but diminishes NO release in the steady state. 3) Heme reduction displays an optimum regarding NO release during steady state. The unique behavior of S1412D nNOS reveals the importance of heme reduction rate in controlling steady-state activity and suggests that nNOS already has a near-optimal rate of heme reduction.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA	Cleveland Clinic Foundation; University System of Ohio; Ohio State University	Adak, S (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Immunol NB-3,9500 Euclid Ave, Cleveland, OH 44195 USA.			Santolini, Jerome/0000-0001-8919-112X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33727] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Cho MJ, 1998, BIOCHEMISTRY-US, V37, P15593, DOI 10.1021/bi981497g; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; KLATT P, 1992, J BIOL CHEM, V267, P11374; Kondo R, 1999, J BIOL CHEM, V274, P36213, DOI 10.1074/jbc.274.51.36213; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MICHEL T, 1997, J CLIN INVEST, V100, P2417; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Richards MK, 1996, BIOCHEMISTRY-US, V35, P7772, DOI 10.1021/bi952582g; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Scheele JS, 1999, J BIOL CHEM, V274, P13105, DOI 10.1074/jbc.274.19.13105; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X	31	100	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1244	1252		10.1074/jbc.M006857200	http://dx.doi.org/10.1074/jbc.M006857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038355	hybrid			2022-12-27	WOS:000166430900053
J	Bagowski, CP; Xiong, W; Ferrell, JE				Bagowski, CP; Xiong, W; Ferrell, JE			c-jun N-terminal kinase activation in Xenopus laevis eggs and embryos - A possible non-genomic role for the JNK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR DEVELOPMENTAL TRANSITION; CYTOPLASMIC RETENTION SIGNAL; SPINDLE ASSEMBLY CHECKPOINT; PROTEIN-KINASE; OOCYTE MATURATION; MAP KINASE; CELL-CYCLE; APOPTOSIS; DROSOPHILA; MOS	The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase family that play critical roles in stress responses and apoptosis, We have discovered that JNK is present in Xenopus oocytes, an experimental system that offers a variety of powerful experimental approaches to questions of protein function and regulation. Like ERK2/p42 MAPK, JNK is activated just prior to germinal vesicle breakdown during Xenopus oocyte maturation and remains active throughout meiosis I and II. However, unlike p42 MAPK which is inactivated about 30 min after eggs are fertilized or parthenogenetically activated, JNK stays constitutively active until the early gastrula stage of embryogenesis, These findings suggest that the JNK pathway may play a role in oocyte maturation and embryogenesis, JNK was activated by microinjection of Mos, by activation of an estrogen-inducible form of Raf, and by a constitutively active MEK-1 (MEK R4F), indicating that the p42 MAPK cascade can trigger JNK activation. However, the MEK inhibitor U0126 blocked progesterone-induced p42 MAPK activation but not progesterone-induced JNK activation, Thus, progesterone can stimulate JNK activation both through the MEK/p42 MAPK pathway and through MEK/p42 MAPK-independent pathways. Many of the key substrates of JNKs identified to date are transcriptional regulators. However, since transcription is not required for germinal vesicle breakdown in progesterone-treated oocytes or for the early embryonic cell cycles, our findings suggest that in these contexts the JNK pathway exerts nongenomic effects.	Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Dept Mol Pharmacol, 269 W Campus Dr, Stanford, CA 94305 USA.				NIGMS NIH HHS [GM46383] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JA, 1997, MOL BIOL CELL, V8, P1195, DOI 10.1091/mbc.8.7.1195; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; BAULIEU EE, 1978, NATURE, V275, P593, DOI 10.1038/275593a0; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Ferrell JE, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P; Fisher DL, 1999, DEVELOPMENT, V126, P4537; Goberdhan DCI, 1998, BIOESSAYS, V20, P1009, DOI 10.1002/(SICI)1521-1878(199812)20:12<1009::AID-BIES7>3.0.CO;2-D; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hensey C, 1997, MECH DEVELOP, V69, P183, DOI 10.1016/S0925-4773(97)00191-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roy LM, 1996, ONCOGENE, V12, P2203; Sible JC, 1997, DEV BIOL, V189, P335, DOI 10.1006/dbio.1997.8683; Stack JH, 1997, DEVELOPMENT, V124, P3185; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Yoshitome S, 1998, BIOL CELL, V90, P509, DOI 10.1016/S0248-4900(99)80009-4; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	51	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1459	1465		10.1074/jbc.M008050200	http://dx.doi.org/10.1074/jbc.M008050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11029471	hybrid			2022-12-27	WOS:000166430900080
J	Folcher, M; Morris, RP; Dale, G; Salah-Bey-Hocini, K; Viollier, PH; Thompson, CJ				Folcher, M; Morris, RP; Dale, G; Salah-Bey-Hocini, K; Viollier, PH; Thompson, CJ			A transcriptional regulator of a pristinamycin resistance gene in Streptomyces coelicolor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; EXPRESSION; PRISTINAESPIRALIS; BIOSYNTHESIS; BINDING; CLUSTER; IDENTIFICATION; SEQUENCE; COMPLEX	Pip is a pristinamycin-induced transcriptional regulator protein detected in many Streptomyces species by its ability to specifically bind sequence motifs within the promoter of a Streptomyces pristinaespiralis multidrug resistance gene (ptr). To investigate the possible role of Pip in regulating multidrug resistance, it was purified from a genetically characterized species, Streptomyces coelicolor, utilizing an affinity matrix of the ptr promoter conjugated to magnetic beads. Reverse genetics identified the corresponding locus and confirmed that it encoded Pip, a protein belonging to the TetR family of procaryotic transcriptional repressors. Pip binding motifs were located upstream of the adjacent gene pep, encoding a major facilitator antiporter homologous to ptr. bz vivo analysis of antibiotic susceptibility profiles demonstrated that pep conferred elevated levels of resistance only to pristinamycin I (PI), a streptogramin B antibiotic having clinical importance. Purified recombinant Pip was a dimer tin the presence or absence of PI) and displayed a high affinity for its palindromic binding motifs within the ptr promoter and the upstream region of pep, The Pip/ptr promoter complex was dissociated by PI but not by any of the other nonstreptogramin antibiotics that were described previously as transcriptional inducers. These procaryotic regulatory elements served as the basis for the development of systems allowing repression or induction of cloned genes in mammalian and plant cells in response to streptogramin antibiotics (including pristinamycin, virginiamycin, and Synercid(R).	Univ Basel, Biozentrum, Dept Microbiol, CH-4056 Basel, Switzerland	University of Basel	Thompson, CJ (corresponding author), Univ Basel, Biozentrum, Dept Microbiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Viollier, Patrick/AAD-9405-2021; Morris, Rowan/HGU-9105-2022	Viollier, Patrick/0000-0002-5249-9910				ARIZA RR, 1995, J BACTERIOL, V177, P1655, DOI 10.1128/jb.177.7.1655-1661.1995; August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; Bamas-Jacques N, 1999, J APPL MICROBIOL, V87, P939, DOI 10.1046/j.1365-2672.1999.00955.x; BARRIERE JC, 1994, EXPERT OPIN INV DRUG, V3, P115; Blanc V, 1997, MOL MICROBIOL, V23, P191, DOI 10.1046/j.1365-2958.1997.2031574.x; BLANC V, 1995, MOL MICROBIOL, V17, P989, DOI 10.1111/j.1365-2958.1995.mmi_17050989.x; Blau HM, 1999, P NATL ACAD SCI USA, V96, P797, DOI 10.1073/pnas.96.3.797; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; FERNANDEZMORENO MA, 1991, CELL, V66, P769, DOI 10.1016/0092-8674(91)90120-N; Fussenegger M, 2000, NAT BIOTECHNOL, V18, P1203, DOI 10.1038/81208; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; GUILFOILE PG, 1992, J BACTERIOL, V174, P3651, DOI 10.1128/JB.174.11.3651-3658.1992; GUILFOILE PG, 1992, J BACTERIOL, V174, P3659, DOI 10.1128/JB.174.11.3659-3666.1992; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P343; Hopwood D.A., 1985, GENETIC MANIPULATION; Lee CK, 1999, J BACTERIOL, V181, P3293, DOI 10.1128/JB.181.10.3293-3297.1999; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; PREUDHOM.J, 1968, B SOC CHIM FR, P585; Rouquette C, 1999, MOL MICROBIOL, V33, P651, DOI 10.1046/j.1365-2958.1999.01517.x; SALAHBEY K, 1995, MOL MICROBIOL, V17, P1109, DOI 10.1111/j.1365-2958.1995.mmi_17061109.x; SALAHBEY K, 1995, MOL MICROBIOL, V17, P1001, DOI 10.1111/j.1365-2958.1995.mmi_17051001.x; Sambrook J., 1989, MOL CLONING, pA1; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; TAKAHASHI M, 1986, J MOL BIOL, V187, P341, DOI 10.1016/0022-2836(86)90437-7; THOMPSON CJ, 1983, P NATL ACAD SCI-BIOL, V80, P5190, DOI 10.1073/pnas.80.17.5190; Westrich L, 1999, FEMS MICROBIOL LETT, V170, P381, DOI 10.1111/j.1574-6968.1999.tb13398.x; White DG, 1997, J BACTERIOL, V179, P6122, DOI 10.1128/jb.179.19.6122-6126.1997; Wu SW, 1996, J BACTERIOL, V178, P6036, DOI 10.1128/jb.178.20.6036-6042.1996; ZHOU YN, 1988, J BACTERIOL, V170, P3640, DOI 10.1128/jb.170.8.3640-3649.1988	33	49	51	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1479	1485		10.1074/jbc.M007690200	http://dx.doi.org/10.1074/jbc.M007690200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050092	hybrid			2022-12-27	WOS:000166430900083
J	Moore, ML; Wang, GL; Belaguli, NS; Schwartz, RJ; McMillin, JB				Moore, ML; Wang, GL; Belaguli, NS; Schwartz, RJ; McMillin, JB			GATA-4 and serum response factor regulate transcription of the muscle-specific carnitine palmitoyltransferase I beta in rat heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; ACTIN GENE-TRANSCRIPTION; CARDIAC TRANSCRIPTION; DNA-BINDING; PPAR-ALPHA; CPT-I; EXPRESSION; PROTEIN; ORGANIZATION; NKX-2.5	Transcriptional regulation of nuclear encoded mitochondrial proteins is dependent on nuclear transcription factors that act on genes encoding key components of mitochondrial transcription, replication, and heme biosynthetic machinery. Cellular factors that target expression of proteins to the heart have been well characterized with respect to excitation-contraction coupling. No information currently exists that examines whether parallel transcriptional mechanisms regulate nuclear encoded expression of heart-specific mitochondrial isoforms. The muscle CPT-I beta isoform in heart is a TATAless gene that uses Sp-1 proteins to support basal expression. The rat cardiac fatty acid response element (-301/-289), previously characterized in the human gene, is responsive to oleic acid following serum deprivation, Deletion and mutational analysis of the 5'-flanking sequence of the carnitine palmitoyltransferase I beta (CPT-I beta) gene defines regulatory regions in the -391/+80 promoter luciferase construct. When deleted or mutated constructs were individually transfected into cardiac myocytes, CPT-I/luciferase reporter gene expression was significantly depressed at sites involving a putative MEF2 sequence downstream from the fatty acid response element and a cluster of heart-specific regulatory regions flanked by two Sp1 elements. Each site demonstrated binding to cardiac nuclear proteins and competition specificity (or supershifts) with oligonucleotides and antibodies. Individual expression vectors for Nkx2,5, serum response factor (SRF), and GATA4 enhanced CPT-I reporter gene expression 4-36-fold in CV-1 cells. Although cotransfection of Nkx and SRF produced additive luciferase expression, the combination of SRF and GATA-4 cotransfection resulted in synergistic activation of CPT-I beta, The results demonstrate that SRF and the tissue-restricted isoform, GATA-4, drive robust gene transcription of a mitochondrial protein highly expressed in heart.	Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Sch Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine	McMillin, JB (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Sch Med, 6431 Fannin, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038863, P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL49953, R01 HL38863] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Bhavsar PK, 2000, J MOL CELL CARDIOL, V32, P95, DOI 10.1006/jmcc.1999.1058; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Browning CL, 1998, DEV BIOL, V194, P18, DOI 10.1006/dbio.1997.8808; Charron F, 1999, MOL CELL BIOL, V19, P4355; Chen CY, 1996, MOL CELL BIOL, V16, P6372; COOK GA, 1984, J BIOL CHEM, V259, P2030; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Djouadi F, 1999, PROSTAG LEUKOTR ESS, V60, P339, DOI 10.1016/S0952-3278(99)80009-X; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Durocher D, 1998, DEV GENET, V22, P250, DOI 10.1002/(SICI)1520-6408(1998)22:3<250::AID-DVG7>3.0.CO;2-5; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; MCMILLIN JB, 1993, METHODS TOXICOL, V2, P301; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; MYNATT RL, 1992, BIOCHIM BIOPHYS ACTA, V1128, P105, DOI 10.1016/0005-2760(92)90263-U; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; Nicholas SB, 1999, AM J PHYSIOL-HEART C, V277, pH324, DOI 10.1152/ajpheart.1999.277.1.H324; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Steffen ML, 1999, BIOCHEM J, V340, P425, DOI 10.1042/0264-6021:3400425; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Wang DC, 1998, GENOMICS, V48, P314, DOI 10.1006/geno.1997.5184; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Xiao QX, 1998, J MOL CELL CARDIOL, V30, P87, DOI 10.1006/jmcc.1997.0574; Zhao JL, 2000, J BIOL CHEM, V275, P8903, DOI 10.1074/jbc.275.12.8903	36	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1026	1033		10.1074/jbc.M009352200	http://dx.doi.org/10.1074/jbc.M009352200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11038368	hybrid			2022-12-27	WOS:000166430900024
J	Oosterom, J; Garner, KM; den Dekker, WK; Nijenhuiss, WAJ; Gispen, WH; Burbach, JPH; Barsh, GS; Adan, RAH				Oosterom, J; Garner, KM; den Dekker, WK; Nijenhuiss, WAJ; Gispen, WH; Burbach, JPH; Barsh, GS; Adan, RAH			Common requirements for melanocortin-4 receptor selectivity of structurally unrelated melanocortin agonist and endogenous antagonist, Agouti protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; HYPOTHALAMUS; BINDING; MC4; EXPRESSION; PEPTIDES; OBESITY; CLONING; MICE; FORM	The activity of melanocortin receptors (MCR) is regulated by melanocortin peptide agonists and by the endogenous antagonists, Agouti protein and AgRP (Agouti-related protein). To understand how the selectivity for these structurally unrelated agonists and antagonist is achieved, chimeric and mutants MC3R and MC4R were expressed in cell lines and pharmacologically analyzed. A region containing the third extracellular loop, EC3, of MC4R was essential for selective Agouti protein antagonism. In addition, this part of MC4R, when introduced in MC3R, conferred Agouti protein antagonism. Further mutational analysis of this region of MC4R demonstrated that Tyr(268) was required for the selective interaction with Agouti protein, because a profound loss of the ability of Agouti protein to inhibit I-125-labeled [Nle(4),D-Phe(7)] alpha -melanocyte-stimulating hormone (MSH) binding was observed by the single mutation of Tyr(268) to Ile, This same residue conferred selectivity for the MC4R selective agonist, [D-Tyr(4)]MT-II, whereas it inhibited interaction with the MC3R-selective agonist, [Nle(4)]Lys-gamma (2)-MSH. Conversely, mutation of Ile(265) in MC3 (the corresponding residue of Tyr(268)) to Tyr displayed a gain of affinity for [D-Tyr(4)]MT-II, but not for Agouti protein, and a loss of affinity for [Me-4]Lys-gamma (2)-MSH as compared with wild-type MC3R. This single amino acid mutation thus confers the selectivity of MC3R toward a pharmacological profile like that observed for MC4R agonists but not for the antagonist, Agouti protein. Thus, selectivity for structurally unrelated ligands with opposite activities is achieved in a similar manner for MC4R but not for MC3R.	Univ Utrecht, Ctr Med, Dept Med Pharmacol, Rudolf Magnus Inst Neurosci, NL-3508 AB Utrecht, Netherlands; Stanford Univ, Sch Med, Howard Hughes Med Inst, Beckman Ctr B271A, Stanford, CA 94305 USA	Utrecht University; Utrecht University Medical Center; Howard Hughes Medical Institute; Stanford University	Adan, RAH (corresponding author), Univ Utrecht, Ctr Med, Dept Med Pharmacol, Rudolf Magnus Inst Neurosci, POB 85060, NL-3508 AB Utrecht, Netherlands.	r.a.h.adan@med.uu.nl						Bray GA, 2000, NATURE, V404, P672, DOI 10.1038/35007544; Broberger C, 1998, J COMP NEUROL, V402, P460; Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; GANTZ I, 1993, J BIOL CHEM, V268, P15174; Haskell-Luevano C, 1999, ENDOCRINOLOGY, V140, P1408, DOI 10.1210/en.140.3.1408; Huang QH, 1999, AM J PHYSIOL-REG I, V276, pR864, DOI 10.1152/ajpregu.1999.276.3.R864; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kiefer LL, 1998, BIOCHEMISTRY-US, V37, P991, DOI 10.1021/bi971913h; Kiefer LL, 1997, BIOCHEMISTRY-US, V36, P2084, DOI 10.1021/bi962647v; Kistler-Heer V, 1998, J NEUROENDOCRINOL, V10, P133; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Miltenberger RJ, 1997, J NUTR, V127, pS1902, DOI 10.1093/jn/127.9.1902S; Mountjoy KG, 1999, ENDOCRINOLOGY, V140, P2167, DOI 10.1210/en.140.5.2167; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Oosterom J, 1999, J BIOL CHEM, V274, P16853, DOI 10.1074/jbc.274.24.16853; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schaaper WMM, 1998, LETT PEPT SCI, V5, P205, DOI 10.1023/A:1008877507882; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Vergoni AV, 1999, EUR J PHARMACOL, V369, P11, DOI 10.1016/S0014-2999(99)00045-X; WOLFF GL, 1986, J HERED, V77, P151, DOI 10.1093/oxfordjournals.jhered.a110206; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; Yang YK, 1999, MOL ENDOCRINOL, V13, P148, DOI 10.1210/me.13.1.148	27	33	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					931	936		10.1074/jbc.M007261200	http://dx.doi.org/10.1074/jbc.M007261200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11024027	hybrid			2022-12-27	WOS:000166430900011
J	Sheng, SH; Li, JQ; McNulty, KA; Kieber-Emmons, T; Kleyman, TR				Sheng, SH; Li, JQ; McNulty, KA; Kieber-Emmons, T; Kleyman, TR			Epithelial sodium channel pore region - Structure and role in gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; CAENORHABDITIS-ELEGANS; CYSTEINE MUTAGENESIS; POTASSIUM CHANNEL; K+-CHANNEL; MEMBRANE TOPOLOGY; MOLECULAR-BASIS; ION PERMEATION; ALPHA-SUBUNIT; SELECTIVITY	Epithelial sodium channels (ENaC) have a crucial role in the regulation of extracellular fluid volume and blood pressure. To study the structure of the pore region of ENaC, the susceptibility of introduced cysteine residues to sulfhydryl-reactive methanethiosulfonate derivatives ((a-aminoethyl)methanethiosulfonate hydrobromide (MTSEA) and [(2-(trimethylammonium)ethyl]methanethiosulfonate bromide (MTSET)) and to Cd2+ was determined. Selected mutants within the amino-terminal portion (alpha Val(569)-alpha Trp(582)) of the pore region responded to MTSEA, MTSET, or Cd2+ with stimulation or inhibition of whole cell Na+ current. The reactive residues were not contiguous but were separated by 23 residues where substituted cysteine residues did not respond to the reagents and line one face of an cu-helix. The activation of (alpha S580C beta gamma mENaC by MTSET was associated with a large increase in channel open probability. Within the carboxyl-terminal portion (alpha Ser(583)-alpha Ser(592)) of the pore region, only one mutation (alpha S583C) conferred a rapid, nearly complete block by MTSEA, MTSET, and Cd2+, whereas several other mutant channels were partially blocked by MTSEA or Cd2+ but not by MTSET. Our data suggest that the outer pore of ENaC is formed by an cr-helix, followed by an extended region that forms a selectivity filter. Furthermore, our data suggest that the pore region participates in ENaC gating.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Kleyman, TR (corresponding author), Div Renal, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15213 USA.	kleyman@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354, P01DK050268] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50268, DK54354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Becchetti A, 2000, PFLUG ARCH EUR J PHY, V440, P556, DOI 10.1007/s004240050006; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Dart C, 1998, J PHYSIOL-LONDON, V511, P25, DOI 10.1111/j.1469-7793.1998.025bi.x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fyfe GK, 1999, J BIOL CHEM, V274, P36415, DOI 10.1074/jbc.274.51.36415; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; HILLE B, 1992, IONIC CHANNELS EXCIT, P276; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Khakh BS, 1999, NEURON, V23, P653, DOI 10.1016/S0896-6273(01)80025-8; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Kubo Y, 1998, FEBS LETT, V435, P69, DOI 10.1016/S0014-5793(98)01038-2; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Melander O, 1998, HYPERTENSION, V31, P1118, DOI 10.1161/01.HYP.31.5.1118; PALMER LG, 1990, RENAL PHYSIOL BIOCH, V13, P51; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; RENARD S, 1994, J BIOL CHEM, V269, P12981; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Schneggenburger R, 1997, NEURON, V18, P167, DOI 10.1016/S0896-6273(01)80055-6; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Sun ZP, 1996, NEURON, V16, P141, DOI 10.1016/S0896-6273(00)80031-8; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; Tsushima RG, 1997, J GEN PHYSIOL, V110, P59, DOI 10.1085/jgp.110.1.59; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3	45	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1326	1334		10.1074/jbc.M008117200	http://dx.doi.org/10.1074/jbc.M008117200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11022046	hybrid			2022-12-27	WOS:000166430900064
J	Bertrand, C; Chatonnet, A; Takke, C; Yan, YL; Postlethwait, J; Toutant, JP; Cousin, X				Bertrand, C; Chatonnet, A; Takke, C; Yan, YL; Postlethwait, J; Toutant, JP; Cousin, X			Zebrafish acetylcholinesterase is encoded by a single gene localized on linkage group 7 - Gene structure and polymorphism; Molecular forms and expression pattern during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE GENOME EVOLUTION; C-TERMINAL DOMAINS; TRANSPOSABLE ELEMENTS; EMBRYONIC ZEBRAFISH; BUNGARUS-FASCIATUS; MESSENGER-RNA; MUSCLE; BUTYRYLCHOLINESTERASE; PROMOTER; BRAIN	We cloned and sequenced the acetylcholinesterase gene and cDNA of zebrafish, Danio rerio. We found a single gene (ache) located on linkage group LG7. The relative organization of ache, eng2, and shh genes is conserved between zebrafish and mammals and defines a synteny. Restriction fragment length polymorphism analysis was allowed to identify several allelic variations. We also identified two transposable elements in non-coding regions of the gene. Compared with other vertebrate acetylcholinesterase genes, ache gene contains no alternative splicing at 5' or 3' ends where only a T exon is present. The translated sequence is 60-80% identical to acetylcholinesterases of the vertebrates and exhibits an extra loop specific to teleosts. Analysis of molecular forms showed a transition, at the time of hatching, from the globular G4 form to asymmetric A12 form that becomes prominent in adults. In situ hybridization and enzymatic activity detection on whole embryos confirmed early expression of the acetylcholinesterase gene in nervous and muscular tissues. We found no butyrylcholinesterase gene or activity in Danio. These findings make zebrafish a promising model to study function of acetylcholinesterase during development and regulation of molecular forms assembly in vivo.	INRA, F-34060 Montpellier, France; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	INRAE; University of Oregon	Cousin, X (corresponding author), INRA, 2 Pl Viala, F-34060 Montpellier, France.	cousin@ensam.inra.fr	Yan, Yi/GSO-3046-2022; BERTRAND-GADAY, Christelle/ABA-8619-2021; Cousin, Xavier/E-2542-2013; Chatonnet, Arnaud/AAM-5569-2021; Chatonnet, Arnaud/E-2190-2017	BERTRAND-GADAY, Christelle/0000-0003-0461-2402; Cousin, Xavier/0000-0002-8520-3610; Chatonnet, Arnaud/0000-0002-4057-3896	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NICHD NIH HHS [P01HD22486] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Atanasova E, 1999, J BIOL CHEM, V274, P21078, DOI 10.1074/jbc.274.30.21078; BIGBEE JW, 2000, PHARMACOL THERAPEUT, V86, P29; Brimijoin S, 1999, ENVIRON HEALTH PERSP, V107, P59, DOI 10.2307/3434472; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; CHATONNET A, 1991, CELL MOL NEUROBIOL, V11, P119, DOI 10.1007/BF00712804; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; Cousin X, 1998, J BIOL CHEM, V273, P9812, DOI 10.1074/jbc.273.16.9812; Durbin L, 2000, DEVELOPMENT, V127, P1703; Durliat M, 2000, EUR J BIOCHEM, V267, P549, DOI 10.1046/j.1432-1327.2000.01033.x; EKKER M, 1992, DEVELOPMENT, V116, P1001; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; Grauso M, 1998, FEBS LETT, V424, P279, DOI 10.1016/S0014-5793(98)00191-4; GREENSPAN RJ, 1980, J COMP NEUROL, V189, P741, DOI 10.1002/cne.901890409; Hallbook F, 1999, CURR OPIN NEUROBIOL, V9, P616, DOI 10.1016/S0959-4388(99)00011-2; HANNEMAN E, 1989, J COMP NEUROL, V284, P350, DOI 10.1002/cne.902840303; HANNEMAN E, 1988, DEVELOPMENT, V103, P49; HANNEMAN EH, 1992, J EXP ZOOL, V263, P41, DOI 10.1002/jez.1402630106; HEIERHORST J, 1992, P NATL ACAD SCI USA, V89, P6798, DOI 10.1073/pnas.89.15.6798; Ivics Z, 1996, P NATL ACAD SCI USA, V93, P5008, DOI 10.1073/pnas.93.10.5008; Izsvak Z, 1996, P NATL ACAD SCI USA, V93, P1077, DOI 10.1073/pnas.93.3.1077; Izsvak Z, 1999, J MOL EVOL, V48, P13, DOI 10.1007/PL00006440; JBILO O, 1994, J BIOL CHEM, V269, P20829; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KIMMEL CB, 1991, DEVELOPMENT, P47; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Krejci E, 1999, J NEUROSCI, V19, P10672, DOI 10.1523/JNEUROSCI.19-24-10672.1999; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LAYER PG, 1988, DEVELOPMENT, V102, P387; LAYER PG, 1990, BIOESSAYS, V12, P415, DOI 10.1002/bies.950120904; LEIBEL WS, 1988, J EXP ZOOL, V247, P209, DOI 10.1002/jez.1402470304; LIU DWC, 1992, J NEUROSCI, V12, P1859; Luo ZD, 1998, J BIOL CHEM, V273, P28486, DOI 10.1074/jbc.273.43.28486; Massoulie J, 1998, J PHYSIOLOGY-PARIS, V92, P183, DOI 10.1016/S0928-4257(98)80007-7; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; MUSSET F, 1987, BIOCHIMIE, V69, P147, DOI 10.1016/0300-9084(87)90247-1; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; Nornes S, 1998, MECH DEVELOP, V77, P185, DOI 10.1016/S0925-4773(98)00156-7; Pezzementi L, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P105; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; RANDALL WR, 1994, BBA-GENE STRUCT EXPR, V1218, P453, DOI 10.1016/0167-4781(94)90204-6; REINHARD E, 1994, DEVELOPMENT, V120, P1767; ROSS LS, 1992, J NEUROSCI, V12, P467; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sawada A, 2000, DEVELOPMENT, V127, P1691; Shimoda N, 1999, GENOMICS, V58, P219, DOI 10.1006/geno.1999.5824; Simon S, 1997, J BIOL CHEM, V272, P33045, DOI 10.1074/jbc.272.52.33045; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; STIEGER S, 1989, EUR J BIOCHEM, V181, P633, DOI 10.1111/j.1432-1033.1989.tb14770.x; TOUTANT JP, 1985, J NEUROCHEM, V44, P580, DOI 10.1111/j.1471-4159.1985.tb05452.x; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; Venters SJ, 1999, DEV DYNAM, V216, P219, DOI 10.1002/(SICI)1097-0177(199911)216:3<219::AID-DVDY1>3.0.CO;2-J; WESTERFIELD M, 1995, ZEBRAFISH BOOK; WILSON SW, 1990, DEVELOPMENT, V108, P121; Xie WH, 2000, J PHARMACOL EXP THER, V293, P896	60	78	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					464	474		10.1074/jbc.M006308200	http://dx.doi.org/10.1074/jbc.M006308200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016933	hybrid, Green Published			2022-12-27	WOS:000166280700063
J	Dixon, TM; Daniel, KW; Farmer, SR; Collins, S				Dixon, TM; Daniel, KW; Farmer, SR; Collins, S			CCAAT/enhancer-binding protein alpha is required for transcription of the beta(3)-adrenergic receptor gene during adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIET-INDUCED OBESITY; PPAR-GAMMA; ADIPOSE-TISSUE; C/EBP-ALPHA; ADIPOCYTE DIFFERENTIATION; ADRENERGIC-RECEPTOR; ECTOPIC EXPRESSION; BROWN ADIPOCYTES; MESSENGER-RNA; BETA	The beta (3)-adrenergic receptor (beta (3)AR) is expressed predominantly in adipocytes, and it plays a major role in regulating lipolysis and adaptive thermogenesis, Its expression in a variety of adipocyte cell models is preceded by the appearance of CCAAT/enhancer-binding protein alpha (C/EBP alpha), which has been shown to regulate a number of other adipocyte-specific genes. Importantly, it has been demonstrated that several adipocyte cell lines that fail to express C/EBP alpha exhibit reduced insulin sensitivity, despite an apparent adipogenic phenotype, Here we show that transcription and function of the beta (3)AR correlates with C/EBP alpha expression in these adipocyte models. A 5.13-kilobase pair fragment of the mouse beta (3)AR promoter was isolated and sequenced. This fragment conferred a 50-fold increase in luciferase reporter gene expression in adipocytes, Two putative C/EBP binding sites exist at -3306 to -3298 and at -1462 to -1454, but only the more distal site is functional. Oligo nucleotides corresponding to both the wild-type and mutated -3306 element were inserted upstream of a thymidine kinase luciferase construct. When cotransfected in fibroblasts with a C/EBP alpha expression vector, reporter gene expression increased 3-fold only in the wild-type constructs, The same mutation, when placed into the intact 5.13-kilobase pair promoter, reduced promoter activity in adipocytes from 50-fold to <10-fold. Electrophoretic mobility shift analysis demonstrated that the site at -3306 generated a specific protein-oligonucleotide complex that was supershifted by C/EBP<alpha> antibody, while a probe corresponding to a putative site at -1462 did not. These results define C/EBP alpha as a key transcriptional regulator of the mouse beta (3)AR gene during adipogenesis.	Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Duke University; Duke University; Boston University	Collins, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol, Box 3557, Durham, NC 27710 USA.	colli008@mc.duke.edu		Farmer, Stephen/0000-0003-2483-2795	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053092] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK46793, R01DK53092] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Cannon B, 1996, BIOCHEM SOC T, V24, P407, DOI 10.1042/bst0240407; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Collins S., 2000, Adipocyte biology and hormone signaling., P51; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Collins S, 1996, J BIOL CHEM, V271, P9437, DOI 10.1074/jbc.271.16.9437; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; Collins S, 1999, INT J OBESITY, V23, P669, DOI 10.1038/sj.ijo.0800894; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Elberg G, 2000, J BIOL CHEM, V275, P27815; FEVE B, 1991, J BIOL CHEM, V266, P20329; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GETTYS TW, 1991, J BIOL CHEM, V266, P15949; GORMAN CM, 1984, PHILOS T ROY SOC B, V307, P343, DOI 10.1098/rstb.1984.0137; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LARGIS EE, 1994, DRUG DEVELOP RES, V32, P69, DOI 10.1002/ddr.430320203; LAUDAT MH, 1975, EUR J BIOCHEM, V56, P583, DOI 10.1111/j.1432-1033.1975.tb02265.x; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Sasaki N, 1998, J VET MED SCI, V60, P465, DOI 10.1292/jvms.60.465; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; SHEPHERD RE, 1977, J BIOL CHEM, V252, P7243; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	47	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					722	728		10.1074/jbc.M008440200	http://dx.doi.org/10.1074/jbc.M008440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024036	hybrid			2022-12-27	WOS:000166280700097
J	Franek, WR; Horowitz, S; Stansberry, L; Kazzaz, JA; Koo, HC; Li, YC; Arita, Y; Davis, JM; Mantell, AS; Scott, W; Mantell, LL				Franek, WR; Horowitz, S; Stansberry, L; Kazzaz, JA; Koo, HC; Li, YC; Arita, Y; Davis, JM; Mantell, AS; Scott, W; Mantell, LL			Hyperoxia inhibits oxidant-induced apoptosis in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; SUPEROXIDE-DISMUTASE; HEME OXYGENASE-1; OXIDATIVE STRESS; GENE-EXPRESSION; TNF-ALPHA; IN-VIVO; DEATH; BCL-2	It has previously been shown that hyperoxia induces non-apoptotic cell death in cultured lung epithelial cells, whereas hydrogen peroxide (H2O2) and paraquat cause apoptosis, To test whether pathways leading to oxidative apoptosis in epithelial cells are sensitive to molecular O-2, A549 cells were exposed to 95% O-2, prior to exposure to lethal concentrations of H2O2. The extent of H2O2-induced apoptosis was significantly reduced in cells preexposed to hyperoxia compared with room-air controls. Preexposure of the hyperoxia-resistant HeLa-80 cell line to 80% O-2 also inhibited oxidant-induced apoptosis, suggesting that this inhibition is not due to O-2, toxicity. Because hyperoxia generates reactive oxygen species and activates the redox-sensitive transcription factor nuclear factor kappaB (NF-kappaB), the role of antioxidant enzymes and NF-kappaB were examined in this inhibitory process. The onset of inhibition appeared to be directly related to the degradation of I kappaB and subsequent activation of NF-kappaB (either by hyperoxia or TNF-alpha), whereas no significant up-regulation of endogenous antioxidant enzyme activities was found. In addition, suppression of NF-kappaB activities by transfecting A549 cells with a dominant-negative mutant construct of I kappaB significantly augmented the extent of H2O2-induced apoptosis. These data suggest that hyperoxia inhibits oxidant-induced apoptosis and that this inhibition is mediated by NF-kappaB.	SUNY Stony Brook, Winthrop Univ Hosp, CardioPulm Res Inst, Mineola, NY 11501 USA; SUNY Stony Brook, Winthrop Univ Hosp, Dept Med, Mineola, NY 11501 USA; SUNY Stony Brook, Winthrop Univ Hosp, Dept Pediat, Mineola, NY 11501 USA; SUNY Stony Brook, Winthrop Univ Hosp, Dept Cardiovasc Thorac Surg, Mineola, NY 11501 USA; Hofstra Univ, Hempstead, NY 11549 USA; Univ Louisville, Dept Med, Jewish Hosp Heart & Lung Inst, Louisville, KY 40202 USA; Univ Louisville, Dept Pharmacol & Toxicol, Jewish Hosp Heart & Lung Inst, Louisville, KY 40202 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; Hofstra University; University of Louisville; University of Louisville	Mantell, LL (corresponding author), SUNY Stony Brook, Winthrop Univ Hosp, CardioPulm Res Inst, Mineola, NY 11501 USA.	lmantell@winthrop.org						Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEERS RF, 1952, J BIOL CHEM, V195, P133; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Capellier G, 1999, Minerva Anestesiol, V65, P388; Cappelletti G, 1998, CELL BIOL INT, V22, P671, DOI 10.1006/cbir.1998.0305; CHOI AMK, 1995, AM J RESP CELL MOL, V13, P74, DOI 10.1165/ajrcmb.13.1.7598940; CLERCH LB, 1993, J CLIN INVEST, V91, P499, DOI 10.1172/JCI116228; Crapo J D, 1978, Methods Enzymol, V53, P382; CRAPO JD, 1974, AM J PHYSIOL, V226, P1401, DOI 10.1152/ajplegacy.1974.226.6.1401; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Fabisiak JP, 1997, AM J PHYSIOL-CELL PH, V272, pC675, DOI 10.1152/ajpcell.1997.272.2.C675; FREEMAN BA, 1986, EXP LUNG RES, V10, P203, DOI 10.3109/01902148609061493; Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200; Hampton MB, 1998, TOXICOL LETT, V103, P355, DOI 10.1016/S0378-4274(98)00333-6; JOENJE H, 1985, LAB INVEST, V52, P420; JOENJE H, 1997, OXYGEN EXPRESSION CE, P67; Jyonouchi H, 1998, AM J RESP CELL MOL, V19, P426, DOI 10.1165/ajrcmb.19.3.2862m; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Lavrovsky Y, 2000, MECH AGEING DEV, V114, P49, DOI 10.1016/S0047-6374(00)00087-7; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lee PJ, 1996, AM J RESP CELL MOL, V14, P556, DOI 10.1165/ajrcmb.14.6.8652184; Li YC, 1997, J BIOL CHEM, V272, P20646, DOI 10.1074/jbc.272.33.20646; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mantell LL, 1997, CELL DEATH DIFFER, V4, P600, DOI 10.1038/sj.cdd.4400278; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; NAKATA T, 1993, INT J CANCER, V55, P646, DOI 10.1002/ijc.2910550422; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pietarinen-Runtti P, 1998, AM J RESP CELL MOL, V19, P286, DOI 10.1165/ajrcmb.19.2.2836; POGREBNIAK HW, 1991, J THORAC CARDIOV SUR, V102, P904, DOI 10.1016/S0022-5223(19)33941-8; Pyatt DW, 1999, BLOOD, V93, P3302, DOI 10.1182/blood.V93.10.3302.410a38_3302_3308; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Shea LM, 1996, J IMMUNOL, V157, P3902; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; YOO JH, 1994, J CLIN INVEST, V93, P297, DOI 10.1172/JCI116959; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009	41	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					569	575		10.1074/jbc.M004716200	http://dx.doi.org/10.1074/jbc.M004716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11034997	hybrid			2022-12-27	WOS:000166280700077
J	Primm, TP; Gilbert, HF				Primm, TP; Gilbert, HF			Hormone binding by protein disulfide isomerase, a high capacity hormone reservoir of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CHAPERONE ACTIVITY; PEPTIDE BINDING; PROLYL 4-HYDROXYLASE; RIBONUCLEASE-A; BETA-SUBUNIT; SITE; PURIFICATION; BACITRACIN; CATALYSIS; DOMAIN	Protein disulfide isomerase (PDI) is a folding assistant of the eukaryotic endoplasmic reticulum, but it also binds the hormones, estradiol, and 3,3',5-triiodo-L-thyronine (T-3), Hormone binding could be at discrete hormone binding sites, or it could be a nonphysiological consequence of binding site(s) that are involved in the interaction PDI with its peptide and protein substrates, Equilibrium dialysis, fluorescent hydrophobic probe binding (4,4'-dianilino-1,1 '-binaphthyl-5,5'-disulfonic acid (bis-ANS)), competition binding, and enzyme activity assays reveal that the hormone binding sites are distinct from the peptide/protein binding sites. PDI has one estradiol binding site with modest affinity (2.1 +/- 0.5 muM). There are two binding sites with comparable affinity for T-3 (4.3 +/- 1.4 muM), One of these overlaps the estradiol site, whereas the other binds the hydrophobic probe, bis-ANS, Neither estradiol nor T-3 inhibit the catalytic or chaperone activity of PDI, Although the affinity of PDI for the hormones estradiol and T-3 is modest, the high local concentration of PDI in the endoplasmic reticulum (>200 muM) would drive hormone binding and result in the association of a substantial fraction (>90%) of the hormones in the cell with PDI, High capacity, low affinity hormone sites may function to buffer hormone concentration in the cell and allow tight, specific binding to the true receptor while preserving a reasonable number of hormone molecules in the very small volume of the cellular environment.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine	Gilbert, HF (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA.	hgilbert@bcm.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BUTLER J, 1988, ANN CLIN BIOCHEM, P25536; CANNON DJ, 1969, BIOCHEM BIOPH RES CO, V35, P403, DOI 10.1016/0006-291X(69)90513-0; Dai Y, 1997, J BIOL CHEM, V272, P27572, DOI 10.1074/jbc.272.44.27572; DANEL L, 1982, CANCER RES, V42, P4701; ERICKSON GF, 1986, SEMIN REPROD ENDOCR, V4, P233, DOI 10.1055/s-2007-1022504; FARRIS FJ, 1978, J AM CHEM SOC, V100, P4469, DOI 10.1021/ja00482a026; FERREIRO B, 1990, ACTA ENDOCRINOL-COP, V123, P95, DOI 10.1530/acta.0.1230095; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gabrielsson J, 1996, Acta Obstet Gynecol Scand Suppl, V163, P26; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GILBERT HF, 1994, PROLYL HYDROXYLASE, P341; Guthapfel R, 1996, EUR J BIOCHEM, V242, P315, DOI 10.1111/j.1432-1033.1996.0315r.x; HORIUCHI R, 1989, EUR J BIOCHEM, V183, P529, DOI 10.1111/j.1432-1033.1989.tb21081.x; IKAI Y, 1995, J ANTIBIOT, V48, P233, DOI 10.7164/antibiotics.48.233; KEMMINK J, 1995, PROTEIN SCI, V4, P2587, DOI 10.1002/pro.5560041216; KITAGAWA S, 1987, J BIOL CHEM, V262, P3903; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; KOIVU J, 1987, J BIOL CHEM, V262, P6447; Korchev YE, 2000, BIOPHYS J, V78, P451, DOI 10.1016/S0006-3495(00)76607-0; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LEBECHE D, 1994, BIOCHEM BIOPH RES CO, V202, P556, DOI 10.1006/bbrc.1994.1964; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MEDINA V, 1993, BIOCHEM MED METAB B, V49, P255, DOI 10.1006/bmmb.1993.1027; MIZUNAGA T, 1990, J BIOCHEM, V108, P846, DOI 10.1093/oxfordjournals.jbchem.a123291; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NACHTIGALL L, 1968, AM J OBSTET GYNECOL, V101, P638, DOI 10.1016/0002-9378(68)90301-3; NEFF S, 1994, MOL ENDOCRINOL, V8, P1215, DOI 10.1210/me.8.9.1215; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1991, J BIOL CHEM, V266, P19645; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; OBATA T, 1988, J BIOL CHEM, V263, P782; Primm TP, 1996, J BIOL CHEM, V271, P33664, DOI 10.1074/jbc.271.52.33664; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; ROTH RA, 1981, BIOCHEM BIOPH RES CO, V98, P431, DOI 10.1016/0006-291X(81)90858-5; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; SIEGEL MM, 1994, BIOL MASS SPECTROM, V23, P186, DOI 10.1002/bms.1200230403; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; TSIBRIS JCM, 1989, J BIOL CHEM, V264, P13967; WALENT JH, 1990, ENDOCRINOLOGY, V126, P2383, DOI 10.1210/endo-126-5-2383; Walker KW, 1997, J BIOL CHEM, V272, P8845; WALKER KW, 1997, STRUCTURE FUNCTION M, P331; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; Westphal V, 1998, J BIOL CHEM, V273, P24992, DOI 10.1074/jbc.273.39.24992; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	55	90	92	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					281	286		10.1074/jbc.M007670200	http://dx.doi.org/10.1074/jbc.M007670200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11035025	hybrid			2022-12-27	WOS:000166280700039
J	Sumi, T; Matsumoto, K; Nakamura, T				Sumi, T; Matsumoto, K; Nakamura, T			Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a rho-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CYTOSKELETON; CLEAVAGE FURROW; ZINC-FINGER; GENOMIC ORGANIZATION; FOCAL ADHESIONS; CELL LOCOMOTION; CDNA CLONING; IN-VIVO; BINDING; CYTOKINESIS	LIM-kinase 1 (LIMK1) and LIM-kinase 2 (LIMK2) regulate actin cytoskeletal reorganization via cofilin phosphorylation downstream of distinct Rho family GTPases, We report our findings that ROCK, a downstream protein kinase of Rho, specifically activates LIMK2 but not LIMK1 downstream of RhoA LIMK1 and LIMH2 activities toward cofilin phosphorylation were stimulated by co-expression with the active form of ROCK (ROCKL-Delta3), whereas full-length ROCK selectively activates LIMH2 but not LIMK1. Activation of LIMX2 by RhoA was inhibited by Y-27632, a specific inhibitor of ROCK, but Rad-mediated activation of LIMK1 was not. ROCK directly phosphorylated the threonine 505 residue within the activation segment of LIMK2 and markedly stimulated LIMK2 activity. A LIMK2 mutant with replacement of threonine 505 by valine abolished LIMK2 activities for cofilin phosphorylation and actin cytoskeletal changes, whereas replacement by glutamate enhanced the protein kinase activity and stress fiber formation by LIMK2. These results indicate that ROCK directly phosphorylates threonine 505 and activates LIMK2 downstream of RhoA and that this phosphorylation is essential for LIMK2 to induce actin cytoskeletal reorganization. Together with the finding that LIMK1 is regulated by Pak1, LIMK1 and LIMK2 are regulated by different protein kinases downstream of distinct Rho family GTPases.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Oncol,Div Biochem, Suita, Osaka 5650871, Japan	Osaka University	Nakamura, T (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Oncol,Div Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	nakamura@onbich.med.osaka-u.ac.jp	MATSUMOTO, Kunio/D-8441-2015	MATSUMOTO, Kunio/0000-0002-6532-4482				AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ikebe C, 1997, GENOMICS, V46, P504, DOI 10.1006/geno.1997.5060; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Kosako H, 1997, J BIOL CHEM, V272, P10333; Koshimizu U, 1997, BIOCHEM BIOPH RES CO, V241, P243, DOI 10.1006/bbrc.1997.7795; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIZUNO K, 1994, ONCOGENE, V9, P1605; Mori T, 1997, MOL BRAIN RES, V45, P247, DOI 10.1016/S0169-328X(96)00257-4; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NUNOUE K, 1995, ONCOGENE, V11, P701; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Takahashi H, 1998, BIOCHEM BIOPH RES CO, V249, P138, DOI 10.1006/bbrc.1998.9094; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	47	238	245	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					670	676		10.1074/jbc.M007074200	http://dx.doi.org/10.1074/jbc.M007074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11018042	hybrid			2022-12-27	WOS:000166280700090
J	Yarov-Yarovoy, V; Brown, J; Sharp, EM; Clare, JJ; Scheuer, T; Catterall, WA				Yarov-Yarovoy, V; Brown, J; Sharp, EM; Clare, JJ; Scheuer, T; Catterall, WA			Molecular determinants of voltage-dependent gating and binding of pore-blocking drugs in transmembrane segment IIIS6 of the Na+ channel alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HIPPOCAMPAL-NEURONS; LOCAL-ANESTHETIC RECEPTOR; SODIUM-CHANNELS; K+-CHANNEL; ANTIARRHYTHMIC DRUGS; MEMBRANE-PROTEINS; FAST INACTIVATION; BRAIN; LAMOTRIGINE; STATE	Mutations of amino acid residues in the inner two-thirds of the S6 segment in domain III of the rat brain type IIA Na+ channel (G1460A to I1473A) caused periodic positive and negative shifts in the voltage dependence of activation, consistent with an cu-helix having one face on which mutations to alanine oppose activation. Mutations in the outer one-third of the IIIS6 segment all favored activation. Mutations in the inner half of IIIS6 had strong effects on the voltage dependence of inactivation from closed states without effect on open-state inactivation. Only three mutations had strong effects on block by local anesthetics and anticonvulsants. Mutations L1465A and I1469A decreased affinity of inactivated Na+ channels up to 8-fold for the anticonvulsant lamotrigine and its congeners 227c89, 4030w92, and 619c89 as well as for the local anesthetic etidocaine. N1466A decreased affinity of inactivated Na+ channels for the anticonvulsant 4030w92 and etidocaine by 3- and 8-fold, respectively, but had no effect on affinity of the other tested compounds. Leu-1465, Asn-1466, and Ile-1469 are located on one side of the IIISG helix, and mutation of each caused a positive shift in the voltage dependence of activation. Evidently, these amino acid residues face the lumen of the pore, contribute to formation of the high-affinity receptor site for pore-blocking drugs, and are involved in voltage-dependent activation and coupling to closed-state inactivation.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Glaxo Wellcome Ltd, Dept Mol Pharmacol, Stevenage, Herts, England	University of Washington; University of Washington Seattle; GlaxoSmithKline	Catterall, WA (corresponding author), Univ Washington, Dept Pharmacol, Mail Stop 357280, Seattle, WA 98195 USA.		Yarov-Yarovoy, Vladimir/ABE-5454-2020	Yarov-Yarovoy, Vladimir/0000-0002-2325-4834	NINDS NIH HHS [NS15751] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BRODIE MJ, 1994, EPILEPSIA, V35, pS41, DOI 10.1111/j.1528-1157.1994.tb05966.x; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; Carter AJ, 2000, P NATL ACAD SCI USA, V97, P4944, DOI 10.1073/pnas.040577097; CATTERALL WA, 1987, TRENDS PHARMACOL SCI, V8, P57, DOI 10.1016/0165-6147(87)90011-3; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; Cohen S A, 1993, Int Rev Cytol, V137C, P55; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; GOA KL, 1993, DRUGS, V46, P152, DOI 10.2165/00003495-199346010-00009; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; HONDEGHEM LM, 1984, ANNU REV PHARMACOL, V24, P387, DOI 10.1146/annurev.pa.24.040184.002131; HONDEGHEM LM, 1977, BIOCHIM BIOPHYS ACTA, V472, P373, DOI 10.1016/0304-4157(77)90003-X; Hong KH, 2000, J GEN PHYSIOL, V115, P51, DOI 10.1085/jgp.115.1.51; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KOMIYA H, 1988, P NATL ACAD SCI USA, V85, P9012, DOI 10.1073/pnas.85.23.9012; KUO CC, 1994, MOL PHARMACOL, V46, P716; Li HL, 1999, MOL PHARMACOL, V55, P134, DOI 10.1124/mol.55.1.134; Li-Smerin YY, 2000, NEURON, V25, P411, DOI 10.1016/S0896-6273(00)80904-6; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; Liu GY, 1998, BIOPHYS J, V74, pA399; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Marban E, 1998, J PHYSIOL-LONDON, V508, P647, DOI 10.1111/j.1469-7793.1998.647bp.x; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; QU YS, 1995, P NATL ACAD SCI USA, V92, P11839, DOI 10.1073/pnas.92.25.11839; Ragsdale DS, 1996, P NATL ACAD SCI USA, V93, P9270, DOI 10.1073/pnas.93.17.9270; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; Tatulian SA, 1998, FEBS LETT, V423, P205, DOI 10.1016/S0014-5793(98)00091-X; Wang GK, 1998, MOL PHARMACOL, V54, P389, DOI 10.1124/mol.54.2.389; Wang GK, 1998, PFLUG ARCH EUR J PHY, V435, P293; Weiser T, 1999, MOL PHARMACOL, V56, P1238, DOI 10.1124/mol.56.6.1238; Wright SN, 1998, MOL PHARMACOL, V54, P733; Xie XM, 1996, NEUROSCIENCE, V73, P951, DOI 10.1016/0306-4522(96)00092-9; XIE XM, 1995, PFLUG ARCH EUR J PHY, V430, P437, DOI 10.1007/BF00373920	46	188	196	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					20	27		10.1074/jbc.M006992200	http://dx.doi.org/10.1074/jbc.M006992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024055	hybrid			2022-12-27	WOS:000166280700004
J	Lechner, T; Carrozza, MJ; Yu, YX; Grant, PA; Eberharter, A; Vannier, D; Brosch, G; Stillman, DJ; Shore, D; Workman, JL				Lechner, T; Carrozza, MJ; Yu, YX; Grant, PA; Eberharter, A; Vannier, D; Brosch, G; Stillman, DJ; Shore, D; Workman, JL			Sds3 (suppressor of defective silencing 3) is an integral component of the yeast Sin3 center dot Rpd3 histone deacetylase complex and is required for histone deacetylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; ACETYLTRANSFERASE COMPLEXES; SACCHAROMYCES-CEREVISIAE; NUCLEOSOMAL ARRAYS; GENE ACTIVATION; MAIZE EMBRYOS; ADA-COMPLEX; N-COR; RPD3; ACETYLATION	SDS3 (suppressor of defective silencing 3) was originally identified in a screen for mutations that cause increased silencing of a crippled HMR silencer in a rap1 mutant background, In addition, sds3 mutants have phenotypes very similar to those seen in sind and rpd3 mutants, suggesting that it functions in the same genetic pathway. In this manuscript we demonstrate that Sds3p is an integral subunit of a previously identified high molecular weight Rpd3p.Sin3p containing yeast histone deacetylase complex. By analyzing an sds3 Delta strain we show that, in the absence of Sds3p, Sin3p can be chromatographically separated from Rpd3p, indicating that Sds3p promotes the integrity of the complex. Moreover, the remaining Rpd3p complex in the sds3 Delta strain had little or no histone deacetylase activity. Thus, Sds3p plays important roles in the integrity and catalytic activity of the Rpd3p.Sin3p complex.	Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, University Pk, PA 16802 USA; Univ Utah, Hlth Sci Ctr, Dept Oncol Sci, Div Mol Biol & Genet, Salt Lake City, UT 84132 USA; Columbia Univ, Dept Microbiol, New York, NY 10032 USA; Univ Innsbruck, Sch Med, Dept Microbiol, A-6020 Innsbruck, Austria; Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Utah System of Higher Education; University of Utah; Columbia University; University of Innsbruck; University of Geneva	Workman, JL (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, University Pk, PA 16802 USA.	jlw10@psu.edu	Shore, David/F-6240-2015	Shore, David/0000-0002-9859-143X; VANNIER, DAVID/0000-0002-8753-2418; Stillman, David/0000-0002-5268-2416				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Brosch G, 1996, FEBS LETT, V393, P287, DOI 10.1016/0014-5793(96)00909-X; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Dorland S, 2000, GENETICS, V154, P573; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Ikeda K, 1999, MOL CELL BIOL, V19, P855; John S, 2000, GENE DEV, V14, P1196; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KASTEN MM, 1997, MOL CELL BIOL, V17, P4215; Kolle D, 1998, METHODS, V15, P323, DOI 10.1006/meth.1998.0636; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lechner T, 2000, BIOCHEMISTRY-US, V39, P1683, DOI 10.1021/bi9918184; LOIDL P, 1994, CHROMOSOMA, V103, P441; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Rossi V, 1998, MOL GEN GENET, V258, P288, DOI 10.1007/s004380050733; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sendra R, 2000, J BIOL CHEM, V275, P24928, DOI 10.1074/jbc.M003783200; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; STILLMAN DJ, 1994, GENETICS, V136, P781; SUSSEL L, 1995, GENETICS, V141, P873; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vannier D, 1996, GENETICS, V144, P1343; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	40	75	77	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40961	40966		10.1074/jbc.M005730200	http://dx.doi.org/10.1074/jbc.M005730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024051	Green Published			2022-12-27	WOS:000166114600041
J	Jung, K; Veen, M; Altendorf, K				Jung, K; Veen, M; Altendorf, K			K+ and ionic strength directly influence the autophosphorylation activity of the putative turgor sensor KdpD of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; KINASE KDPD; OPERON EXPRESSION; OSMOTIC-STRESS; ATP CHANNELS; TRANSPORT; SYSTEM; POTASSIUM; RECONSTITUTION; OSMOSENSOR	The membrane-bound histidine kinase KdpD is a putative turgor sensor that regulates, together with the response regulator KdpE, the expression of the Kdp-FABC operon coding for the high affinity K+-uptake system KdpFABC of Escherichia coli. To elucidate the nature of the primary stimulus for KdpD, we developed an in vitro assay based on right-side-out membrane vesicles. Conditions were varied inside and outside of the vesicles, and KdpD autophosphorylation activity was tested. It was shown that an increase of the ionic strength inside the vesicles was accompanied by an increase of the autophosphorylation activity of KdpD with ATP. However, K+ at concentrations higher than 1 mM inhibited KdpD autophosphorylation activity. This KC specific effect was not observed with KdpD-Arg-511 --> Gln, a KdpD derivative, which causes K+-independent kdpFABC expression. When the osmolality outside the vesicles was increased, autophosphorylation activity of KdpD was stimulated, whereby salts were more effective than sugars. Treatment of the vesicles with amphipathic compounds did not affect KdpD autophosphorylation activity. Based on these results it is proposed that changes of intracellular parameters elicited by K+ limitation or osmotic upshock directly influence KdpD autophosphorylation activity, whereby K+ has an inhibitory and ionic strength a stimulatory effect.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany; Tech Univ Berlin, Inst Biotechnol, Fachgebiet Mikrobiol & Genet, D-13355 Berlin, Germany	University Osnabruck; Technical University of Berlin	Jung, K (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.	jung_k@biologie.uni-osnabrueck.de						ALTENDORF K, 1996, BIOMEMBR, V5, P403; ASHA H, 1993, J BACTERIOL, V175, P4528, DOI 10.1128/JB.175.14.4528-4537.1993; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; Frymier JS, 1997, J BACTERIOL, V179, P3061, DOI 10.1128/jb.179.9.3061-3063.1997; Heermann R, 2000, J BIOL CHEM, V275, P17080, DOI 10.1074/jbc.M000093200; HUGENHOLTZ J, 1981, P NATL ACAD SCI-BIOL, V78, P3446, DOI 10.1073/pnas.78.6.3446; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 1998, J BIOL CHEM, V273, P26415, DOI 10.1074/jbc.273.41.26415; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Malli R, 1998, J BACTERIOL, V180, P5102, DOI 10.1128/JB.180.19.5102-5108.1998; MILNER JL, 1988, J BIOL CHEM, V263, P14900; NAKASHIMA K, 1993, J BIOCHEM-TOKYO, V114, P615, DOI 10.1093/oxfordjournals.jbchem.a124226; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLAREK JW, 1992, J BACTERIOL, V174, P2145, DOI 10.1128/JB.174.7.2145-2151.1992; RAMOS S, 1976, P NATL ACAD SCI USA, V73, P1892, DOI 10.1073/pnas.73.6.1892; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; Roe AJ, 2000, MOL MICROBIOL, V35, P1235, DOI 10.1046/j.1365-2958.2000.01793.x; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Stallkamp I, 1999, ARCH MICROBIOL, V172, P295, DOI 10.1007/s002030050783; SUGIURA A, 1992, MOL MICROBIOL, V6, P1769, DOI 10.1111/j.1365-2958.1992.tb01349.x; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986; Tjaden J, 1998, J BIOL CHEM, V273, P9630, DOI 10.1074/jbc.273.16.9630; VOELKNER P, 1993, EUR J BIOCHEM, V217, P1019, DOI 10.1111/j.1432-1033.1993.tb18333.x; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	33	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40142	40147		10.1074/jbc.M008917200	http://dx.doi.org/10.1074/jbc.M008917200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11016946	hybrid			2022-12-27	WOS:000166039500048
J	Miyake, T; Hu, YF; Yu, DS; Li, R				Miyake, T; Hu, YF; Yu, DS; Li, R			A functional comparison of BRCA1 C-terminal domains in transcription activation and chromatin remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL DNA-REPLICATION; CELL-CYCLE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; CANCER SUSCEPTIBILITY; BINDING-PROTEIN; IN-VIVO; DAMAGE; REPAIR; YEAST; INTERACTS	The BRCA1 C-terminal (BRCT) domain is present in a number of proteins that are involved in various aspects of chromosomal events. The BRCT domain of BRCA1 is important for its function in DNA repair and transcriptional activation. When tethered to chromosomal DNA, this region of BRCA1 is capable of inducing changes in chromatin structure. Despite the sequence homology and functional proximity shared by the BRCT-containing proteins, it is not clear whether different BRCT domains confer a common biochemical activity. Much less is known about the functional significance of the characteristic amino acid residues in the BRCT motif. Here, we show that chromatin remodeling and transcription activation is not a common feature of BRCT domains. However, the BRCT domain of the multi-functional repressor-activator protein 1 (RAP1) can activate transcription and remodel chromatin in a manner similar to that shown for the BRCA1 BRCT domain. Most of the conserved amino acid residues in the second BRCA1 BRCT domain are essential for its function in transcriptional activation. In contrast, mutations of many analogous amino acid residues in the RAP1 BRCT domain greatly elevate the transcriptional activity. These data indicate that the conserved residues in these two BRCT domains may play different roles in transcriptional activation.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Li, R (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [R21CA083990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057893] Funding Source: NIH RePORTER; NCI NIH HHS [R21CA83990] Funding Source: Medline; NIGMS NIH HHS [R01GM57893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams Alison, 1997, P123; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Graham IR, 1999, MOL CELL BIOL, V19, P7481; Hayes F, 2000, CANCER RES, V60, P2411; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Taylor RM, 1998, CURR BIOL, V8, P877, DOI 10.1016/S0960-9822(07)00350-8; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	36	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40169	40173		10.1074/jbc.M007138200	http://dx.doi.org/10.1074/jbc.M007138200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11016938	hybrid			2022-12-27	WOS:000166039500052
J	Bouton, C; Demple, B				Bouton, C; Demple, B			Nitric oxide-inducible expression of heme oxygenase-1 in human cells - Translation-independent stabilization of the mRNA and evidence for direct action of nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; SMOOTH-MUSCLE CELLS; HAMSTER OVARY CELLS; MESSENGER-RNAS; TRANSFERRIN RECEPTOR; PROVIDES PROTECTION; OXIDATIVE STRESS; LUNG INJURY; RAT-BRAIN; INDUCTION	Expression of heme oxygenase-l (HO-1) in mammalian cells contributes to resistance to various types of free radical damage. Nitric oxide (NO) induces HO-1 in many cell types, but the specific contribution of transcriptional or post-transcriptional effects to this induction have remained unresolved. Here we show that the extent of HO-1 mRNA expression in IMR-90 and HeLa cells depends on the rate of NO delivery, and that the induction occurs more slowly in HeLa than in human fibroblast (IMR-90) cells. We used a specific NO scavenger (2-(4-carboxylphenyl)-4,4,5,5-tetramethylimidazolin-1 1-oxyl 3-oxide) that completely prevented the inducible expression of HO-1 by NO, pointing to direct signaling action of NO in this induction. By inhibiting transcription during the NO exposure, we have confirmed that NO treatment activates a mechanism that stabilizes HO-1 mRNA The increase in the HO-1 mRNA half-life in IMR-90 cells was directly correlated with increasing rates of NO release. We also show here that the stabilization of the HO-1 message does not require de novo protein synthesis. Collectively, these results show that stabilization of HO-1 mRNA can be finely tuned to the NO exposure, and that the effect in human fibroblasts is mediated by a pre-existing protein.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.		Bouton, Cecile/J-8663-2013		NCI NIH HHS [CA82737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; AGARWAL A, 1995, KIDNEY INT, V48, P1298, DOI 10.1038/ki.1995.414; AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Bishop A, 1999, FREE RADICAL BIO MED, V26, P978, DOI 10.1016/S0891-5849(98)00284-6; Bouton C, 1999, CELL MOL LIFE SCI, V55, P1043, DOI 10.1007/s000180050355; CASEY JL, 1988, P NATL ACAD SCI USA, V85, P1787, DOI 10.1073/pnas.85.6.1787; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CRUSE I, 1988, J BIOL CHEM, V263, P3348; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Hara E, 1999, BIOCHEM PHARMACOL, V58, P227, DOI 10.1016/S0006-2952(99)00097-0; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; Keefer LK, 1998, CHEMTECH, V28, P30; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; Kitamura Y, 1998, LIFE SCI, V62, P1717, DOI 10.1016/S0024-3205(98)00134-9; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Marquis JC, 1998, CANCER RES, V58, P3435; Motterlini R, 1996, AM J PHYSIOL-HEART C, V270, pH107, DOI 10.1152/ajpheart.1996.270.1.H107; MURPHY BJ, 1991, BRIT J CANCER, V64, P69, DOI 10.1038/bjc.1991.241; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Panahian N, 1999, J NEUROCHEM, V72, P1187; PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415; SAUNDERS EL, 1991, ARCH BIOCHEM BIOPHYS, V288, P368, DOI 10.1016/0003-9861(91)90208-Z; SHIBAHARA S, 1978, ARCH BIOCHEM BIOPHYS, V188, P243, DOI 10.1016/S0003-9861(78)80006-X; SRIVASTAVA KK, 1993, EUR J BIOCHEM, V213, P909, DOI 10.1111/j.1432-1033.1993.tb17835.x; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUN Y, 1990, J BIOL CHEM, V265, P8212; Takahashi K, 1997, J BIOCHEM-TOKYO, V121, P1162; Takahashi K, 1996, J NEUROCHEM, V67, P482; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Thom SR, 2000, P NATL ACAD SCI USA, V97, P1305, DOI 10.1073/pnas.97.3.1305; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VILE GF, 1993, J BIOL CHEM, V268, P14678; Visner GA, 1996, AM J PHYSIOL-LUNG C, V270, pL517, DOI 10.1152/ajplung.1996.270.4.L517; WILLIS D, 1995, BIOCHEM BIOPH RES CO, V214, P1152, DOI 10.1006/bbrc.1995.2406; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; YOSHIDA K, 1993, INFECT IMMUN, V61, P3552, DOI 10.1128/IAI.61.8.3552-3555.1993	49	121	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32688	32693		10.1074/jbc.275.42.32688	http://dx.doi.org/10.1074/jbc.275.42.32688			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	11032845	hybrid			2022-12-27	WOS:000090003800044
J	Ehret, GB; Reichenbach, P; Schindler, U; Horvath, CM; Fritz, S; Nabholz, M; Bucher, P				Ehret, GB; Reichenbach, P; Schindler, U; Horvath, CM; Fritz, S; Nabholz, M; Bucher, P			DNA binding specificity of different STAT proteins - Comparison of in vitro specificity with natural target sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							INTERCELLULAR-ADHESION MOLECULE-1; CLASS-II TRANSACTIVATOR; RECEPTOR-ALPHA GENE; NF-KAPPA-B; ACUTE-PHASE RESPONSE; 3A10/LITHOCHOLIC ACID 6-BETA-HYDROXYLASE; INDOLEAMINE 2,3-DIOXYGENASE GENE; INTERFERON REGULATORY FACTOR-1; SEXUALLY DIMORPHIC REGULATION; COLONY-STIMULATING FACTOR	STAT transcription factors are expressed in many cell types and bind to similar sequences. However, different STAT gene knock-outs show very distinct phenotypes. To determine whether differences between the binding specificities of STAT proteins account for these effects, we compared the sequences bound by STAT1, STAT5A, STAT5B, and STAT6. One sequence set was selected from random oligonucleotides by recombinant STAT1, STAT5A, or STAT6. For another set including many weak binding sites, we quantified the relative affinities to STAT1, STAT5A, STAT5B, and STAT6. We compared the results to the binding sites in natural STAT target genes identified by others. The experiments confirmed the similar specificity of different STAT proteins. Detailed analysis indicated that STAT5A specificity is more similar to that of STAT6 than that of STAT1, as expected from the evolutionary relationships. The preference of STAT6 for sites in which the half-palindromes (TTC) are separated by four nucleotides (N-4) was confirmed, but analysis of weak binding sites showed that STAT6 binds fairly well to N-3 sites. As previously reported, STAT1 and STAT5 prefer N-3 sites; however, STAT5A, but not STAT1, weakly binds N-4 sites. None of the STATs bound to half-palindromes. There were no specificity differences between STAT5A and STAT5B.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Tularik Inc, S San Francisco, CA 94080 USA; Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; Univ Erlangen Nurnberg, Inst Microbiol Biochem & Genet, D-91058 Erlangen, Germany	Swiss Institute Experimental Cancer Research; Icahn School of Medicine at Mount Sinai; University of Erlangen Nuremberg	Ehret, GB (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		EHRET, Georg B/A-9532-2009	EHRET, Georg B/0000-0002-5730-0675; Horvath, Curt/0000-0003-2449-225X				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALBRECHT B, 1994, INT IMMUNOL, V6, P1143, DOI 10.1093/intimm/6.8.1143; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Barbulescu K, 1998, J IMMUNOL, V160, P3642; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; BERTON MT, 1995, J IMMUNOL, V154, P4513; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CARDON LR, 1992, J MOL BIOL, V223, P159, DOI 10.1016/0022-2836(92)90723-W; Chatterjee-Kishore M, 1998, J BIOL CHEM, V273, P16177, DOI 10.1074/jbc.273.26.16177; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chon SY, 1996, J BIOL CHEM, V271, P17247, DOI 10.1074/jbc.271.29.17247; CHON SY, 1995, J INTERF CYTOK RES, V15, P517, DOI 10.1089/jir.1995.15.517; COFFER P, 1995, ONCOGENE, V10, P985; Conrad DJ, 2000, AM J RESP CELL MOL, V22, P226, DOI 10.1165/ajrcmb.22.2.3786; DAMELL JE, 1997, SCIENCE, V277, P1630; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Demoulin JB, 1999, EUR CYTOKINE NETW, V10, P49; Dong YS, 1999, J IMMUNOL, V162, P4731; Dreier B, 1997, J BIOL CHEM, V272, P22118, DOI 10.1074/jbc.272.35.22118; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Durbin R., 1998, BIOL SEQUENCE ANAL P; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Feltus FA, 1999, MOL ENDOCRINOL, V13, P1084, DOI 10.1210/me.13.7.1084; FENGHAO X, 1995, J CLIN INVEST, V96, P907, DOI 10.1172/JCI118138; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Fukuzawa J, 2000, HYPERTENSION, V35, P1191, DOI 10.1161/01.HYP.35.6.1191; Gaffen SL, 1999, BLOOD, V94, P74, DOI 10.1182/blood.V94.1.74.413k36_74_86; Galon J, 1999, J IMMUNOL, V162, P7256; Galsgaard ED, 1999, J BIOL CHEM, V274, P18686, DOI 10.1074/jbc.274.26.18686; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Grigorieva I, 2000, J BIOL CHEM, V275, P7343, DOI 10.1074/jbc.275.10.7343; Gustafson KS, 1996, J BIOL CHEM, V271, P20035, DOI 10.1074/jbc.271.33.20035; GUYER NB, 1995, J IMMUNOL, V155, P3472; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; Hill S, 1999, AM J RESP CELL MOL, V21, P728, DOI 10.1165/ajrcmb.21.6.3709; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; Hutt JA, 2000, J BIOL CHEM, V275, P29123, DOI 10.1074/jbc.M004476200; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JANKOVIC DL, 1989, J IMMUNOL, V142, P3113; John S, 1999, MOL CELL BIOL, V19, P1910; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; Jolivet G, 1996, FEBS LETT, V389, P257, DOI 10.1016/0014-5793(96)00598-4; Kang CJ, 1998, IMMUNITY, V8, P285, DOI 10.1016/S1074-7613(00)80534-8; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; Khew-Goodall Y, 1999, ARTERIOSCL THROM VAS, V19, P1421, DOI 10.1161/01.ATV.19.6.1421; Kieslinger M, 2000, GENE DEV, V14, P232; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; Kojima H, 1996, ONCOGENE, V12, P547; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; KORDULA T, 1995, BIOCHEM J, V309, P63, DOI 10.1042/bj3090063; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Lahuna O, 2000, MOL ENDOCRINOL, V14, P285, DOI 10.1210/me.14.2.285; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Le Stunff C, 1998, ENDOCRINOLOGY, V139, P859, DOI 10.1210/en.139.3.859; LECAM A, 1994, J BIOL CHEM, V269, P21532; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Lee YJ, 1996, J IMMUNOL, V157, P1559; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Li JF, 2000, HUM IMMUNOL, V61, P486, DOI 10.1016/S0198-8859(00)00099-9; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Linehan LA, 1998, J IMMUNOL, V161, P302; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Lu LR, 1998, EUR J IMMUNOL, V28, P805, DOI 10.1002/(SICI)1521-4141(199803)28:03<805::AID-IMMU805>3.0.CO;2-G; Ma YS, 1999, NUCLEIC ACIDS RES, V27, P4649, DOI 10.1093/nar/27.23.4649; Mascareno E, 1998, P NATL ACAD SCI USA, V95, P5590, DOI 10.1073/pnas.95.10.5590; Matsukura S, 1999, J IMMUNOL, V163, P6876; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Min W, 1996, J IMMUNOL, V156, P3174; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Naik SM, 1997, J BIOL CHEM, V272, P1283, DOI 10.1074/jbc.272.2.1283; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; Ohmori Y, 1996, J IMMUNOL, V157, P2058; Ohmori Y, 1998, J BIOL CHEM, V273, P29202, DOI 10.1074/jbc.273.44.29202; Ooi GT, 1998, MOL ENDOCRINOL, V12, P675, DOI 10.1210/me.12.5.675; Pan Q, 2000, EUR J IMMUNOL, V30, P1019, DOI 10.1002/(SICI)1521-4141(200004)30:4<1019::AID-IMMU1019>3.0.CO;2-W; Park HJ, 1998, MOL IMMUNOL, V35, P239, DOI 10.1016/S0161-5890(98)00022-4; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Piskurich JF, 1998, J IMMUNOL, V160, P233; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; REIN T, 1994, NUCLEIC ACIDS RES, V22, P3033, DOI 10.1093/nar/22.15.3033; Richards ML, 1997, J IMMUNOL, V158, P263; Ripperger J, 1995, ANN NY ACAD SCI, V762, P252; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; Rusterholz C, 1999, MOL CELL BIOL, V19, P2681; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki Y, 1999, J BIOL CHEM, V274, P37117, DOI 10.1074/jbc.274.52.37117; Schaffer A, 1999, J IMMUNOL, V162, P5327; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1992, EMBO J, V11, P1275, DOI 10.1002/j.1460-2075.1992.tb05171.x; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; Schumann RR, 1996, MOL CELL BIOL, V16, P3490; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Sepp T, 1997, J VIROL, V71, P771, DOI 10.1128/JVI.71.1.771-777.1997; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Subramanian A, 1998, NUCLEIC ACIDS RES, V26, P2173, DOI 10.1093/nar/26.9.2173; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SYMES AJ, 1995, J NEUROCHEM, V65, P1926; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tessitore A, 1998, EUR J BIOCHEM, V258, P968, DOI 10.1046/j.1432-1327.1998.2580968.x; Tinnell SB, 1998, INT IMMUNOL, V10, P1529, DOI 10.1093/intimm/10.10.1529; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Valente AJ, 1998, J IMMUNOL, V161, P3719; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1992, J BIOL CHEM, V267, P16365; Walter MJ, 1997, J BIOL CHEM, V272, P28582, DOI 10.1074/jbc.272.45.28582; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang YF, 1997, MOL ENDOCRINOL, V11, P1353, DOI 10.1210/me.11.9.1353; Wang YF, 1996, MOL CELL ENDOCRINOL, V121, P19, DOI 10.1016/0303-7207(96)03840-3; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Worm MM, 1998, EUR J IMMUNOL, V28, P901, DOI 10.1002/(SICI)1521-4141(199803)28:03<901::AID-IMMU901>3.0.CO;2-S; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; Ye SK, 1999, IMMUNITY, V11, P213, DOI 10.1016/S1074-7613(00)80096-5; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Yu CR, 1999, J IMMUNOL, V162, P2785; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; Zhang J, 1999, J EXP MED, V190, P1297, DOI 10.1084/jem.190.9.1297; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; ZHAO Y, 1995, J BIOL CHEM, V270, P16449, DOI 10.1074/jbc.270.27.16449	169	307	310	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6675	6688		10.1074/jbc.M001748200	http://dx.doi.org/10.1074/jbc.M001748200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11053426	hybrid			2022-12-27	WOS:000167261000079
J	Vanhoutte, P; Nissen, JL; Brugg, B; Della Gaspera, B; Besson, MJ; Hipskind, RA; Caboche, J				Vanhoutte, P; Nissen, JL; Brugg, B; Della Gaspera, B; Besson, MJ; Hipskind, RA; Caboche, J			Opposing roles of Elk-1 and its brain-specific isoform, short Elk-1, in nerve growth factor-induced PC12 differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; TERNARY COMPLEX FACTORS; SERUM RESPONSE ELEMENT; TRANSCRIPTION FACTOR ELK-1; C-FOS PROMOTER; MESSENGER-RNA; SIGNALING PATHWAYS; NEURITE OUTGROWTH; GENE-EXPRESSION; FACTOR P62TCF	The ternary complex factor Elk-1, a major nuclear target of extracellular signal-regulated kinases, is a strong transactivator of serum-responsive element (SRE) driven gene expression. We report here that mature brain neurons and nerve growth factor (NGF)-differentiated PC12 cells also express a second, smaller isoform of Elk-1, short Elk-1 (sElk-1). sElk-1 arises from an internal translation start site in the Elk-1 sequence, which generates a protein lacking the first 54 amino acids of the DNA-binding domain. This deletion severely compromises the ability of sElk-1 to form complexes with serum response factor on the SRE in vitro and to activate SRE reporter genes in the presence of activated Ras. Instead, sElk, but not a mutant that cannot be phosphorylated, inhibits transactivation driven by Elk-1. More pertinent to the neuronal-specific expression of sElk-1, we show it plays an opposite role to Elk-1 in potentiating NGF-driven PC12 neuronal differentiation. Overexpression of sElk-1 but not Elk-1 increases neurite extension, an effect critically linked to its phosphorylation. interestingly, in the presence of sElk-1, Elk-1 loses its strictly nuclear localization to resemble the nuclear/cytoplasm pattern observed in the mature brain. This is blocked by mutating a normally cryptic nuclear export signal in Elk-1. These data provide new insights into molecular events underlying neuronal differentiation of PC12 cells mediated by the NGF-ERK signaling cascade.	Univ Paris 06, Inst Neurosci, Lab Neurochim Anat, CNRS,UMR 7624, F-75005 Paris, France; Univ Paris 06, Inst Neurosci, Lab Dev & Vieillissement SNC, CNRS,UMR 7624, F-75005 Paris, France; Univ Paris 06, Inst Neurosci, Mol Neurogenet Lab, CNRS,UMR 7624, F-75005 Paris, France; CNRS, IFR 24, UMR 5535, Inst Genet Mol, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Caboche, J (corresponding author), Univ Paris 06, Inst Neurosci, Lab Neurochim Anat, CNRS,UMR 7624, F-75005 Paris, France.			della gaspera, bruno/0000-0002-0652-1822				ALTIN JG, 1992, MOL BIOL CELL, V3, P323, DOI 10.1091/mbc.3.3.323; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Ducret C, 1999, MOL CELL BIOL, V19, P7076; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Grevin D, 1996, GENE, V174, P185, DOI 10.1016/0378-1119(96)00357-5; GYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P30; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Janknecht R, 1996, ONCOGENE, V12, P1961; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Johnson CM, 1997, J NEUROSCI, V17, P6189; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Ling Y, 1997, EMBO J, V16, P2431, DOI 10.1093/emboj/16.9.2431; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; Nozaki M, 1996, DNA CELL BIOL, V15, P855, DOI 10.1089/dna.1996.15.855; O'Donovan KJ, 1999, MOL CELL BIOL, V19, P4711; ORTIZ J, 1995, J NEUROSCI, V15, P1285; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sgambato V, 1998, J NEUROSCI, V18, P8814; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	57	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5189	5196		10.1074/jbc.M006678200	http://dx.doi.org/10.1074/jbc.M006678200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11050086	Green Published, hybrid			2022-12-27	WOS:000168484300088
J	Affar, EB; Germain, M; Winstall, E; Vodenicharov, M; Shah, RG; Salvesen, GS; Poirier, GG				Affar, EB; Germain, M; Winstall, E; Vodenicharov, M; Shah, RG; Salvesen, GS; Poirier, GG			Caspase-3-mediated processing of poly(ADP-ribose) glycohydrolase during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LIVER; KINASE-C-DELTA; (ADP-RIBOSE)N GLYCOHYDROLASE; PROTEOLYTIC ACTIVATION; MAMMALIAN-CELLS; DNA-DAMAGE; IN-VIVO; POLYMERASE; CLEAVAGE; CASPASES	Poly(ADP-ribose) glycohydrolase (PARG) is responsible for the catabolism of poly(ADP-ribose) synthesized by poly(ADP-ribose) polymerase (PARP-1) and other PARP-1-like enzymes. In this work, we report that PARG is cleaved during etoposide-, staurosporine-, and Fas-induced apoptosis in human cells. This cleavage is concomitant with PARP-1 processing and generates two C-terminal fragments of 85 and 74 kDa. In vitro cleavage assays using apoptotic cell extracts showed that a protease of the caspase family is responsible for PARG processing. A complete inhibition of this cleavage was achieved at nanomolar concentrations of the caspase inhibitor acetyl-Asp-Glu-Val-Asp-aldehyde, suggesting the involvement of caspase-3-like proteases. Consistently, recombinant caspase-3 efficiently cleaved PARG in vitro, suggesting the involvement of this protease in PARG processing in vivo, Furthermore, caspase-3-deficient MCF-7 cells did not show any PARG cleavage in response to staurosporine treatment. The cleavage sites identified by site-directed mutagenesis are DEID256 down arrow V and the unconventional site MDVD307 down arrow N. Kinetic studies have shown similar maximal velocity (V-max) and affinity (K-m) for both full-length PARG and its apoptotic fragments, suggesting that caspase-3 may affect PARG function without altering its enzymatic activity. The early cleavage of both PARP-1 and PARG by caspases during apoptosis suggests an important function for poly(ADP-ribose) metabolism regulation during this cell death process.	Univ Laval, CHU Laval, Med Res Ctr, Hlth & Environm Unit, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada; Burnham Inst, La Jolla, CA 92037 USA	Laval University; Laval University; Sanford Burnham Prebys Medical Discovery Institute	Poirier, GG (corresponding author), CHU Laval, Ctr Rech, Unite Sante & Environm, 2705 Blvd Laurier,Local 9700, Quebec City, PQ G1V 4G2, Canada.	guy.poirier@crchul.ulaval.ca		Vodenicharov, Momchil/0000-0002-5509-9891; Poirier, Guy/0000-0002-4869-1424				Affar EB, 1998, ANAL BIOCHEM, V259, P280, DOI 10.1006/abio.1998.2664; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCHU G, 1994, ANAL BIOCHEM, V218, P265, DOI 10.1006/abio.1994.1177; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Duriez PJ, 1997, BBA-GEN SUBJECTS, V1334, P65, DOI 10.1016/S0304-4165(96)00077-3; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; HATAKEYAMA K, 1986, J BIOL CHEM, V261, P4902; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; JONSSON GG, 1988, CANCER RES, V48, P4240; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lin WS, 1997, J BIOL CHEM, V272, P11895, DOI 10.1074/jbc.272.18.11895; MALANGA M, 1994, J BIOL CHEM, V269, P17691; MARUTA H, 1991, BIOCHEMISTRY-US, V30, P5907, DOI 10.1021/bi00238a014; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Negri C, 1997, EXP CELL RES, V234, P174, DOI 10.1006/excr.1997.3591; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TANUMA S, 1990, EUR J BIOCHEM, V191, P57, DOI 10.1111/j.1432-1033.1990.tb19093.x; TANUMA SI, 1986, J BIOL CHEM, V261, P965; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMASSIN H, 1990, NUCLEIC ACIDS RES, V18, P4691, DOI 10.1093/nar/18.16.4691; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; UCHIDA K, 1993, J BIOL CHEM, V268, P3194; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Winstall E, 1999, EXP CELL RES, V246, P395, DOI 10.1006/excr.1998.4321; Winstall E, 1999, EXP CELL RES, V251, P372, DOI 10.1006/excr.1999.4594; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	53	101	103	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2935	2942		10.1074/jbc.M007269200	http://dx.doi.org/10.1074/jbc.M007269200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11053413	hybrid			2022-12-27	WOS:000166784800086
J	Fotiadis, D; Jeno, P; Mini, T; Wirtz, S; Muller, SA; Fraysse, L; Kjellbom, P; Engel, A				Fotiadis, D; Jeno, P; Mini, T; Wirtz, S; Muller, SA; Fraysse, L; Kjellbom, P; Engel, A			Structural characterization of two aquaporins isolated from native spinach leaf plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC PROTEIN MIP; WATER CHANNELS; MASS-SPECTROMETRY; XENOPUS-OOCYTES; RECONSTITUTION; IMAGES; FAMILY; CHIP; PHOSPHORYLATION; MICROSCOPY	Two members of the aquaporin family, PM28A and a new one, PM28C, were isolated and shown to be the major constituents of spinach leaf plasma membranes. These two isoforms were identified and characterized by matrix-assisted laser desorption ionization-mass spectrometry, Edman degradation yielded the amino acid sequence of two domains belonging to the new isoform. PM28B, a previously described isoform, was not found in our preparations. Scanning transmission electron microscopy mass analysis revealed both PM28 isoforms to be tetrameric, Two types of particles, a larger and a smaller one, were found by transmission electron microscopy of negatively stained solubilized proteins and by atomic force microscopy of PM28 two-dimensional crystals. The ratio of larger to smaller particles observed by transmission electron microscopy and single particle analysis correlated with the ratio of PM28A to PM28C determined by matrix-assisted laser desorption ionization-mass spectrometry, The absence of PM28B and the ratio of PM28A to PM28C indicate that these plasma membrane intrinsic proteins are differentially-expressed in spinach leaves. These findings suggest that differential expression of the various aquaporin isoforms may regulate the water flux across the plasma membrane, in addition to the known mechanism of regulation by phosphorylation.	Univ Basel, Biozentrum, ME Muller Inst Microscopy, CH-4056 Basel, Switzerland; Univ Basel, Biozentrum, Div Biochem, CH-4056 Basel, Switzerland; Lund Univ, Dept Plant Biochem, S-22100 Lund, Sweden	University of Basel; University of Basel; Lund University	Engel, A (corresponding author), Univ Basel, Biozentrum, ME Muller Inst Microscopy, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Andreas.Engel@unibas.ch						Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Braun T, 2000, EMBO REP, V1, P183, DOI 10.1093/embo-reports/kvd022; BRETAUDIERE JP, 1986, J MICROSC-OXFORD, V144, P1, DOI 10.1111/j.1365-2818.1986.tb04669.x; Chaumont F, 2000, PLANT PHYSIOL, V122, P1025, DOI 10.1104/pp.122.4.1025; DENKER BM, 1988, J BIOL CHEM, V263, P15634; Engel A, 2000, EMBO J, V19, P800, DOI 10.1093/emboj/19.5.800; Fotiadis D, 2000, J MOL BIOL, V300, P779, DOI 10.1006/jmbi.2000.3920; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; Ghaim JB, 1997, BBA-BIOMEMBRANES, V1330, P113, DOI 10.1016/S0005-2736(97)00127-2; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; Hasler L, 1998, J MOL BIOL, V279, P855, DOI 10.1006/jmbi.1998.1796; Heymann JB, 1999, NEWS PHYSIOL SCI, V14, P187; Heymann JB, 2000, J MOL BIOL, V295, P1039, DOI 10.1006/jmbi.1999.3413; Johansson I, 2000, BBA-BIOMEMBRANES, V1465, P324, DOI 10.1016/S0005-2736(00)00147-4; Johansson I, 1998, PLANT CELL, V10, P451, DOI 10.1105/tpc.10.3.451; Johansson I, 1996, PLANT CELL, V8, P1181, DOI 10.1105/tpc.8.7.1181; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KAMMERLOHER W, 1994, PLANT J, V6, P187, DOI 10.1046/j.1365-313X.1994.6020187.x; KISTLER J, 1994, J CELL BIOL, V126, P1047, DOI 10.1083/jcb.126.4.1047; KJELLBOM P, 1984, PHYSIOL PLANTARUM, V62, P501, DOI 10.1111/j.1399-3054.1984.tb02791.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; le Coutre J, 2000, BIOCHEMISTRY-US, V39, P4237, DOI 10.1021/bi000150m; MAUREL C, 1995, EMBO J, V14, P3028, DOI 10.1002/j.1460-2075.1995.tb07305.x; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; Muller DJ, 1999, BIOPHYS J, V76, P1101, DOI 10.1016/S0006-3495(99)77275-9; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; Ringler P, 1999, J MOL BIOL, V291, P1181, DOI 10.1006/jmbi.1999.3031; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Santoni V, 2000, CURR OPIN PLANT BIOL, V3, P476, DOI 10.1016/S1369-5266(00)00116-3; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SCHABERT FA, 1994, BIOPHYS J, V67, P2394, DOI 10.1016/S0006-3495(94)80726-X; Scheuring S, 1999, EMBO J, V18, P4981, DOI 10.1093/emboj/18.18.4981; SCHEY KL, 1992, BIOPHYS J, V63, P1240, DOI 10.1016/S0006-3495(92)81699-5; SIDEL VW, 1957, J GEN PHYSIOL, V41, P243, DOI 10.1085/jgp.41.2.243; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; ThumanCommike PA, 1996, J STRUCT BIOL, V116, P41, DOI 10.1006/jsbi.1996.0008; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; VANHEEL M, 1984, ULTRAMICROSCOPY, V13, P165, DOI 10.1016/0304-3991(84)90066-4; WALZ T, 1994, EMBO J, V13, P2985, DOI 10.1002/j.1460-2075.1994.tb06597.x; Zhuang JP, 1999, J STRUCT BIOL, V125, P63, DOI 10.1006/jsbi.1998.4059	48	67	82	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1707	1714		10.1074/jbc.M009383200	http://dx.doi.org/10.1074/jbc.M009383200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11050104	hybrid			2022-12-27	WOS:000166528000009
J	Shi, XY; Potvin, B; Huang, TM; Hilgard, P; Spray, DC; Suadicani, SO; Wolkoff, AW; Stanley, P; Stockert, RJ				Shi, XY; Potvin, B; Huang, TM; Hilgard, P; Spray, DC; Suadicani, SO; Wolkoff, AW; Stanley, P; Stockert, RJ			A novel casein kinase 2 alpha-subunit regulates membrane protein traffic in the human hepatoma cell line HuH-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; LOW-DENSITY-LIPOPROTEIN; TRANS-GOLGI NETWORK; ASIALOGLYCOPROTEIN RECEPTOR; CYTOPLASMIC DOMAIN; GENE CSNK2A1; II ACTIVITY; PHOSPHORYLATION; EXPRESSION; MUTANT	A previously isolated endocytic trafficking mutant (TRF1) isolated from HuH-7 cells is defective in the distribution of subpopulations of cell-surface receptors for asialoorosomucoid (asialoglycoprotein receptor (ASGR)), transferrin, and mannose-terminating glycoproteins. The pleiotropic phenotype of TRF1 also includes an increased sensitivity to Pseudomonas toxin and deficient assembly and function of gap junctions. HuH-7xTRF1 hybrids exhibited a normal subcellular distribution of ASGR, consistent with the TRF1 mutation being recessive, A cDNA expression library derived from HuH-7 mRNA was transfected into TRF1 cells, which were subsequently selected for resistance to Pseudomonas toxin. Sequence analysis of a recovered cDNA revealed a unique isoform of casein kinase 2 (CK2), CK2 alpha ", Western blot analysis of TRF1 proteins revealed a 60% reduction in total CK2 alpha expression. Consistent with this finding, the hybrids HuH-7xHuH-7 and HuH-7xTRF1 expressed equivalent amounts of total CK2 alpha. Immunoblots using antibodies against peptides unique to the previously described CK2 isoforms CK2 alpha and CK2 alpha' and the novel CK2 alpha " isoform showed that, although TRF1 and parental HuH-7 cells expressed comparable amounts of CK2 alpha and CK2 alpha', the mutant did not express CK2 alpha " Eased on the genomic DNA sequence, RNA transcripts encoding CK2 alpha " apparently originate from alternative splicing of a primary transcript. Protein overexpression following transfection of TRF1 cells with cDNAs encoding either CK2 alpha or the newly cloned CK2 alpha " restored the parental HuH-7 phenotype, including Pseudomonas toxin resistance, cell-surface ASGR binding activity, phosphorylation, and the assembly of gap junctions. This study suggests that HuH-7 cells express at least three CK2 alpha isoforms and that the pleiotropic TRF1 phenotype is a consequence of a reduction in total CK2 expression.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Univ Sao Judas Tadeu, BR-03166000 Sao Paulo, Brazil	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Universidade Sao Judas Tadeu	Stockert, RJ (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Ullmann 517,1300 Morris Pk Ave, Bronx, NY 10461 USA.			Spray, David/0000-0001-8368-5073; Stanley, Pamela/0000-0001-5704-3747	NIDDK NIH HHS [DK-41918, DK-32972] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032972, P01DK041918] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; Brosius J, 1999, GENE, V238, P115, DOI 10.1016/S0378-1119(99)00227-9; BUCCI M, 1994, SOMAT CELL MOLEC GEN, V20, P47, DOI 10.1007/BF02257485; Cotlin LF, 1999, J BIOL CHEM, V274, P30550, DOI 10.1074/jbc.274.43.30550; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; HAYNES PA, 1994, J BIOL CHEM, V269, P33152; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KRIEGER M, 1983, P NATL ACAD SCI-BIOL, V80, P5607, DOI 10.1073/pnas.80.18.5607; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; MALMSTROM K, 1991, J BIOL CHEM, V266, P24025; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; MELLMAN I, 1996, ANNU REV CELL DEV BI, V12, P675; Mighell AJ, 2000, FEBS LETT, V468, P109, DOI 10.1016/S0014-5793(00)01199-6; MOSTOV KE, 1995, HISTOL HISTOPATHOL, V10, P423; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; Penner CG, 1997, J CELL BIOCHEM, V64, P525; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; STOCKERT RJ, 1995, J BIOL CHEM, V270, P16107, DOI 10.1074/jbc.270.27.16107; Stockert RJ, 1999, HEPATOLOGY, V30, P740, DOI 10.1002/hep.510300304; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Weigel P H, 1993, Subcell Biochem, V19, P125; Weigel PH, 1998, BIOCHEM BIOPH RES CO, V246, P563, DOI 10.1006/bbrc.1998.8491; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; Wirkner U, 1999, MOL CELL BIOCHEM, V191, P59, DOI 10.1023/A:1006848814894; Wirkner U, 1998, GENOMICS, V48, P71, DOI 10.1006/geno.1997.5136; WIRKNER U, 1994, GENOMICS, V19, P257, DOI 10.1006/geno.1994.1056; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; YANGFENG TL, 1994, GENOMICS, V19, P173, DOI 10.1006/geno.1994.1032; Yin XY, 2000, J BIOL CHEM, V275, P6850, DOI 10.1074/jbc.275.10.6850	36	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2075	2082		10.1074/jbc.M008583200	http://dx.doi.org/10.1074/jbc.M008583200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038365	hybrid			2022-12-27	WOS:000166528000059
J	Xia, ZP; Zhou, Q; Lin, JL; Liu, YC				Xia, ZP; Zhou, Q; Lin, JL; Liu, YC			Stable SNARE complex prior to evoked synaptic vesicle fusion revealed by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; T-SNARE; SNAP-25; SYNTAXIN; PROTEIN; CORE; SYNAPTOTAGMIN; EXOCYTOSIS; DOMAIN; CA2+	Although it is clear that soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor (SNARE) complex plays an essential role in synaptic vesicle fusion, the dynamics of SNARE assembly during vesicle fusion remain to be determined. In this report, we employ fluorescence resonance energy transfer technique to study the formation of SNARE complexes. Donor/acceptor pair variants of green fluorescent protein (GFP), cyan fluorescent protein (CFP), and yellow fluorescent protein (YFP) are fused with the N termini of SNAP-25 and synaptobrevin, respectively. lit vitro assembly of SNARE core complex in the presence of syntaxin shows strong fluorescence resonance energy transfer (FRET) between the CFP-SNAP-25 and YFP-synaptobrevin. Under the same conditions, CFP fused to the C terminus of SNAP-25, and YFP- synaptobrevin have no FRET, Adenovirus-mediated gene transfer is used to express the fusion proteins in PC12 cells and cultured rat cerebellar granule cells. Strong FRET is associated with neurite membranes and vesicular structures in PC12 cells co expressing CFP-SNAP-25 and YFP-synaptobrevin, In cultured rat cerebellar granule cells, FRET between CFP-SNAP-25 and YFP-synaptobrevin is mostly associated with sites presumed to be synaptic junctions, Neurosecretion in PC12 cells initiated by KCl depolarization leads to an increase in the extent of FRET. These results demonstrate that significant amounts of stable SNARE complex exist prior to evoked synaptic vesicle fusion and that the assembly of SNARE complex occurs during vesicle docking/priming stage. Moreover, it demonstrates that FRET can be used as an effective tool for investigating dynamic SNARE interactions during synaptic vesicle fusion.	Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Liu, YC (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, POB 26901, Oklahoma City, OK 73190 USA.				NINDS NIH HHS [NS35167] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035167] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hua SY, 1999, NAT NEUROSCI, V2, P1078, DOI 10.1038/16005; Jacob JM, 2000, J NEUROSCI RES, V61, P61, DOI 10.1002/1097-4547(20000701)61:1<61::AID-JNR7>3.0.CO;2-S; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Lane SR, 1997, J NEUROCHEM, V69, P1864; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; MARINI AM, 1992, P NATL ACAD SCI USA, V89, P6555, DOI 10.1073/pnas.89.14.6555; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Sanders JD, 1998, J NEUROSCI RES, V53, P670, DOI 10.1002/(SICI)1097-4547(19980915)53:6<670::AID-JNR5>3.3.CO;2-H; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Vanderklish PW, 2000, P NATL ACAD SCI USA, V97, P2253, DOI 10.1073/pnas.040565597; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Yang YZ, 2000, J BIOL CHEM, V275, P29482, DOI 10.1074/jbc.M003237200; Zhou Q, 2000, J NEUROSCI RES, V61, P321, DOI 10.1002/1097-4547(20000801)61:3<321::AID-JNR10>3.0.CO;2-L	38	46	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1766	1771		10.1074/jbc.M008741200	http://dx.doi.org/10.1074/jbc.M008741200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11035043	hybrid			2022-12-27	WOS:000166528000017
J	Dans, M; Gagnoux-Palacios, L; Blaikie, P; Klein, S; Mariotti, A; Giancotti, FG				Dans, M; Gagnoux-Palacios, L; Blaikie, P; Klein, S; Mariotti, A; Giancotti, FG			Tyrosine phosphorylation of the beta(4) integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE INTERACTION DOMAIN; BULLOUS PEMPHIGOID ANTIGEN-180; GROWTH-FACTOR RECEPTOR; ALPHA(6)BETA(4) INTEGRIN; ADAPTER PROTEIN; CARCINOMA-CELLS; SUBUNIT; TRANSDUCTION; ADHESION; BINDING	Ligation of the alpha (6)beta (4) integrin induces tyrosine phosphorylation of the beta (4) cytoplasmic domain, followed by recruitment of the adaptor protein She and activation of mitogen-activated protein kinase cascades. We have used Far Western analysis and phosphopeptide competition assays to map the sites in the cytoplasmic domain of a, that are required for interaction with She. Our results indicate that, upon phosphorylation, Tyr(1440), or secondarily Tyr(1422), interacts with the SH2 domain of She, whereas Tyr(1526), Or secondarily Tyr(1642), interacts with its phosphotyrosine binding (PTB) domain. An inactivating mutation in the PTB domain of She, but not one in its SM2 domain, suppresses the activation of She by alpha (6)beta (4) In addition, mutation of beta (4) Tyr(1526) which binds to the PTB domain of She, but not of Tyr(1422) and Tyr(1440) which interact with its SH2 domain, abolishes the activation of ERK by alpha (6)beta (4). Phenylalanine substitution of the beta (4) tyrosines able to interact with the SH2 or PTB domain of She does not affect incorporation of alpha (6)beta (4) in the hemidesmosomes of 804G cells. Exposure to the tyrosine phosphatase inhibitor orthovanadate increases tyrosine phosphorylation of beta (4) and disrupts the hemidesmosomes of 804G cells expressing recombinant wild type beta (4). This treatment, however, exerts a decreasing degree of inhibition on the hemidesmosomes of cells expressing versions of beta (4) containing phenylalanine substitutions at Tyr(1422) and Tyr(1440), at Tyr(1526) and Tyr(1642), or at all four tyrosine phosphorylation sites. These results suggest that beta (4) Tyr(1526) interacts in a phosphorylation-dependent manner with the PTB domain of She. This event is required for subsequent tyrosine phosphorylation of She and signaling to ERK but not formation of hemidesmosomes.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Giancotti, FG (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, Box 216,1275 York Ave, New York, NY 10021 USA.		Gagnoux, Laurent/O-9990-2016; Gagnoux, Laurent/O-9954-2016	Mariotti, Agnese/0000-0002-3704-7908	NATIONAL CANCER INSTITUTE [R01CA058976, F32CA079516, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58976, F32-CA79516, P30-CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; Borradori L, 1997, J CELL BIOL, V136, P1333, DOI 10.1083/jcb.136.6.1333; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Giancotti FG, 1996, J CELL SCI, V109, P1165; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUYRE RG, 1997, J BIOL CHEM, V272, P843; IZUMI K, 1981, CANCER RES, V41, P405; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LI NX, 1994, ONCOGENE, V9, P3457; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Niessen CM, 1997, J CELL SCI, V110, P1705; Nievers MG, 1998, J CELL SCI, V111, P1659; PELICCI G, 1995, ONCOGENE, V10, P1631; Pulkkinen L, 1999, MATRIX BIOL, V18, P29, DOI 10.1016/S0945-053X(98)00005-5; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; RIDDELLE KS, 1992, J CELL SCI, V103, P475; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	42	110	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1494	1502		10.1074/jbc.M008663200	http://dx.doi.org/10.1074/jbc.M008663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11044453	hybrid			2022-12-27	WOS:000166430900085
J	Okamoto, T; Toyooka, K; Minamikawa, T				Okamoto, T; Toyooka, K; Minamikawa, T			Identification of a membrane-associated cysteine protease with possible dual roles in the endoplasmic reticulum and protein storage vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEPTIDASE SH-EP; VIGNA-MUNGO SEEDS; HUMAN PROCATHEPSIN-L; HUMAN CATHEPSIN-L; ASPARAGINYL ENDOPEPTIDASE; SULFHYDRYL-ENDOPEPTIDASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; PAPAIN PRECURSOR; THIOL PROTEASES	SH-EP is a vacuolar cysteine proteinase from germinated seeds of Vigna mungo, The enzyme has a C-terminal propeptide of 1 kDa that contains an endoplasmic reticulum (ER) retention signal, KDEL, The KDEL-tail has been suggested to function to store SH-EP as a transient zymogen in the lumen of the ER, and the C-terminal propeptide was thought to be removed within the ER or immediately after exit from the ER, In the present study, a protease that may be involved in the post-translational processing of the C-terminal propeptide of SH-EP was isolated from the microsomes of cotyledons of V. muno seedlings. cDNA sequence for the protease indicated that the enzyme is a member of the papain superfamily, Immunocytochemistry and subcellular fractionation of cotyledon cells suggested that the protease was localized in both the ER and protein storage vacuoles as enzymatically active mature form. In addition, protein fractionations of the cotyledonary microsome and Sf9 cells expressing the recombinant protease indicated that the enzyme associates with the microsomal membrane on the luminal side. The protease was named membrane-associated cysteine protease, MCP, The possibility that a papain-type enzyme, MCP, exists as mature enzyme in both ER and protein storage vacuoles will be discussed.	Tokyo Metropolitan Univ, Dept Sci Biol, Hachioji, Tokyo 1920397, Japan	Tokyo Metropolitan University	Okamoto, T (corresponding author), Tokyo Metropolitan Univ, Dept Sci Biol, Minami Osawa 1-1, Hachioji, Tokyo 1920397, Japan.	okamoto-takashi@c.metro-u.ac.jp	Toyooka, Kiminori/B-5027-2011					AKASOFU H, 1989, NUCLEIC ACIDS RES, V17, P6733, DOI 10.1093/nar/17.16.6733; BECKER C, 1995, EUR J BIOCHEM, V228, P456, DOI 10.1111/j.1432-1033.1995.tb20284.x; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Cercos M, 1999, PLANT PHYSIOL, V119, P1341, DOI 10.1104/pp.119.4.1341; CHRISPEELS MJ, 1992, CELL, V68, P613, DOI 10.1016/0092-8674(92)90134-X; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; DENECKE J, 1992, EMBO J, V11, P2345, DOI 10.1002/j.1460-2075.1992.tb05294.x; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Galili G, 1998, PLANT MOL BIOL, V38, P1, DOI 10.1023/A:1006011919671; Guerrero C, 1998, PLANT MOL BIOL, V36, P565, DOI 10.1023/A:1005952005739; Hara-Nishimura I, 1998, PLANT CELL, V10, P825, DOI 10.1105/tpc.10.5.825; HERMAN EM, 1990, PLANTA, V182, P305, DOI 10.1007/BF00197126; HERMAN EM, 1990, PLANT PHYSIOL, V94, P341, DOI 10.1104/pp.94.1.341; HIRANO H, 1992, J BIOCHEM-TOKYO, V111, P754, DOI 10.1093/oxfordjournals.jbchem.a123831; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; Jerala R, 1998, J BIOL CHEM, V273, P11498, DOI 10.1074/jbc.273.19.11498; KALINSKI A, 1992, J BIOL CHEM, V267, P12068; KALINSKI A, 1990, J BIOL CHEM, V265, P13843; KALINSKI A, 1995, PLANTA, V195, P611, DOI 10.1007/BF00195722; LEE HI, 1993, P NATL ACAD SCI USA, V90, P11433, DOI 10.1073/pnas.90.23.11433; MACH L, 1994, J BIOL CHEM, V269, P13030; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; MITSUHASHI W, 1986, PLANT PHYSIOL, V80, P628, DOI 10.1104/pp.80.3.628; MITSUHASHI W, 1989, PLANT PHYSIOL, V89, P274, DOI 10.1104/pp.89.1.274; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAPIER RM, 1992, J CELL SCI, V102, P261; Nomura T, 1997, BIOCHEM BIOPH RES CO, V230, P143, DOI 10.1006/bbrc.1996.5905; OKAMOTO T, 1994, FEBS LETT, V351, P31, DOI 10.1016/0014-5793(94)00809-4; Okamoto T, 1999, EUR J BIOCHEM, V264, P223, DOI 10.1046/j.1432-1327.1999.00618.x; Okamoto T, 1999, PLANT MOL BIOL, V39, P63, DOI 10.1023/A:1006170518002; Okita TW, 1996, ANNU REV PLANT PHYS, V47, P327, DOI 10.1146/annurev.arplant.47.1.327; Okomoto T, 1999, J BIOL CHEM, V274, P11390, DOI 10.1074/jbc.274.16.11390; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schmid M, 1998, PLANTA, V206, P466, DOI 10.1007/s004250050423; SMITH SM, 1989, J BIOL CHEM, V264, P20487; SUZUKI Y, 1985, PLANT PHYSIOL, V79, P327, DOI 10.1104/pp.79.2.327; TANAKA T, 1991, PLANT MOL BIOL, V16, P1083, DOI 10.1007/BF00016081; TOMURA H, 1981, PLANT PHYSIOL, V79, P935; Toyooka K, 2000, J CELL BIOL, V148, P453, DOI 10.1083/jcb.148.3.453; VALPUESTA V, 1995, PLANT MOL BIOL, V28, P575, DOI 10.1007/BF00020403; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; Vitale A, 1999, PLANT CELL, V11, P615, DOI 10.1105/tpc.11.4.615; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YU WJ, 1994, J EXP BOT, V45, P261, DOI 10.1093/jxb/45.2.261; YU WJ, 1996, PLANT PHYSL PGR, V112, P862	48	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					742	751		10.1074/jbc.M003078200	http://dx.doi.org/10.1074/jbc.M003078200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11022031	hybrid			2022-12-27	WOS:000166280700100
J	Bertin, J; Guo, Y; Wang, L; Srinivasula, SM; Jacobson, MD; Poyet, JL; Merriam, S; Du, MQ; Dyer, MJS; Robison, KE; DiStefano, PS; Alnemri, ES				Bertin, J; Guo, Y; Wang, L; Srinivasula, SM; Jacobson, MD; Poyet, JL; Merriam, S; Du, MQ; Dyer, MJS; Robison, KE; DiStefano, PS; Alnemri, ES			CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED COILS; RECEPTOR; PATHWAY; GENE; RIP	BCL10/CLAP is an activator of apoptosis and NF-kappaB signaling pathways and has been implicated in B cell lymphomas of mucosa-associated lymphoid tissue. Although its role in apoptosis remains to be determined, BCL10 likely activates NF-kappaB through the IKK complex in response to upstream stimuli. The N-terminal caspase recruitment domain (CARD) of BCL10 has been proposed to function as an activation domain that mediates hemophilic interactions with an upstream CARD-containing NF-kappaB activator. To identify upstream signaling partners of BCL10, we performed a mammalian two-hybrid analysis and identified CARDS as a novel CARD-containing protein that interacts selectively with the CARD activation domain of BCL10. When expressed in cells, CARDS binds to BCL10 and activates NF-kappaB. Furthermore, endogenous CARDS is found associated with BCL10 suggesting that both proteins form a pre-existing signaling complex within cells. CARDS also self-associates and contains extensive coiled-coil motifs that may function as oligomerization domains. We propose here that CARDS is an upstream activator of BCL10 and NF-kappaB signaling.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA; Thomas Jefferson Univ, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; UCL Royal Free & Univ Coll Med Sch, Dept Histopathol, London, England; Inst Canc Res, Acad Dept Haematol & Cytogenet, Sutton, Surrey, England	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Jefferson University; Jefferson University; University of London; University College London; UCL Medical School; University of London; Institute of Cancer Research - UK	Bertin, J (corresponding author), Millennium Pharmaceut Inc, 640 Memorial Dr, Cambridge, MA 02139 USA.	bertin@mpi.com; E_Alnemri@lac.jci.tju.edu	Alnemri, Emad S/B-4526-2010; Poyet, Jean-Luc/G-7114-2017; Dyer, Martin/F-2691-2014	Poyet, Jean-Luc/0000-0002-3747-255X; Du, Ming-Qing/0000-0002-1017-5045; Dyer, Martin/0000-0002-5033-2236	NATIONAL CANCER INSTITUTE [R01CA085421] Funding Source: NIH RePORTER; NCI NIH HHS [CA85421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad M, 1997, CANCER RES, V57, P615; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; Guiet C, 2000, J CELL BIOL, V148, P1131, DOI 10.1083/jcb.148.6.1131; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Pawson T, 2000, GENE DEV, V14, P1027; POYET JL, 2000, IN PRESS J BIOL CHEM; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Ye HT, 2000, AM J PATHOL, V157, P1147, DOI 10.1016/S0002-9440(10)64630-5; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	21	182	200	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41082	41086		10.1074/jbc.C000726200	http://dx.doi.org/10.1074/jbc.C000726200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11053425	hybrid			2022-12-27	WOS:000166114600057
J	Carlotti, F; Dower, SK; Qwarnstrom, EE				Carlotti, F; Dower, SK; Qwarnstrom, EE			Dynamic shuttling of nuclear factor kappa B between the nucleus and cytoplasm as a consequence of inhibitor dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; DNA-BINDING; FACTOR-ALPHA; ACTIVATION; PHOSPHORYLATION; INTERLEUKIN-1; DEGRADATION; PROTEINS; ASSOCIATION	Activation of the nuclear factor kappaB (NF kappaB) transcription factor is intimately associated with its translocation from the cytoplasm to the nucleus. Using the nuclear export inhibitor leptomycin B, we demonstrate shuttling of the RELA subunit of NF kappaB and the inhibitory subunit I kappaB alpha between these two compartments in unstimulated cells. Determination of the kinetics of nuclear entry shows marked differences for the two components; the entry of I kappaB alpha occurs more rapidly than RELA. The shuttling is suggested to be a consequence of the cytoplasmic dissociation of the NF kappaB.I kappaB complex rather than its direct nuclear import or degradation and resynthesis of I kappaB alpha. Using previously published kinetic data, this proposition is born out by the deduction that 17% of NF kappaB is not complexed to I kappaB alpha in a resting cell. A numerical model is presented to validate the proposed regulation of NF kappaB subcellular localization consequent in part on the:nuclear export function and in part on the cytoplasmic retention function of I kappaB alpha. We suggest that the non-saturated interaction of NF kappaB with the inhibitor may enhance the specificity of action of I kappaB proteins on different NF kappaB dimers and allow additional modes of regulation of I kappaB function.	Univ Sheffield, Royal Hallamshire Hosp, Div Mol & Genet Med, Funct Genom Grp, Sheffield S10 2JF, S Yorkshire, England; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Sheffield; University of Washington; University of Washington Seattle	Qwarnstrom, EE (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Mol & Genet Med, Funct Genom Grp, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.			Qwarnstrom, Eva/0000-0003-4417-8663; dower, steve/0000-0002-4675-4225				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Carlotti F, 1999, J BIOL CHEM, V274, P37941, DOI 10.1074/jbc.274.53.37941; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang DM, 1998, LINEAR ALGEBRA APPL, V273, P1; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	27	123	126	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41028	41034		10.1074/jbc.M006179200	http://dx.doi.org/10.1074/jbc.M006179200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11024020	hybrid			2022-12-27	WOS:000166114600051
J	West, AP; Bennett, MJ; Sellers, VM; Andrews, NC; Enns, CA; Bjorkman, PJ				West, AP; Bennett, MJ; Sellers, VM; Andrews, NC; Enns, CA; Bjorkman, PJ			Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; IRON UPTAKE; HELA-CELLS; BINDING; GENE	The transferrin receptor (TfR) interacts with two proteins important for iron metabolism, transferrin (Tf) and HFE, the protein mutated in hereditary hemochromatosis. A second receptor for Tf, TfR2, was recently identified and found to be functional for iron uptake in transfected cells (Kawabata, H., Germain, R. S., Vuong, P. T., Nakamaki, T,, Said, J. W., and Koeffler, H. P. (2000) J. Biol. Chem. 275, 16618-16625), TfR2 has a pattern of expression and regulation that is distinct from TfR, and mutations in TfR2 have been recognized as the cause of a non-HFE linked form of hemochromatosis (Camaschella, C., Roetto, A., Cali, A., De Gobbi, M., Garozzo, G., Carella, M., Majorano, N., Totaro, A., and Gasparini, P. (2000) Not. Genet. 25, 14-15). To investigate the relationship between TfR, TfR2, Tf, and HFE, we performed a series of binding experiments using soluble forms of these proteins. We find no detectable binding between TfR2 and HFE by co-immunoprecipitation or using a surface plasmon resonance-based assay. The affinity of TfR2 for iron-loaded Tf was determined to be 27 NM 25-fold lower than the affinity of TfR for Tf. These results imply that HFE regulates Tf-mediated iron uptake only from the classical TfR and that TfR2 does not compete for HFE binding in cells expressing both forms TfR.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Childrens Hosp, Div Hematol Oncol, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Oregon Health & Science University	Bjorkman, PJ (corresponding author), CALTECH, Div Biol, 156-29, Pasadena, CA 91125 USA.			Andrews, Nancy/0000-0003-0243-4462	NIDDK NIH HHS [DK54488] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054488, R37DK054488] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534; Corsi B, 1999, FEBS LETT, V460, P149, DOI 10.1016/S0014-5793(99)01330-7; Cullen LM, 1999, ANNU REV MED, V50, P87; Dubljevic V, 1999, BIOCHEM J, V341, P11, DOI 10.1042/0264-6021:3410011; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming RE, 2000, P NATL ACAD SCI USA, V97, P2214, DOI 10.1073/pnas.040548097; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Kawabata H, 2000, J BIOL CHEM, V275, P16618, DOI 10.1074/jbc.M908846199; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lebron JA, 1999, J MOL BIOL, V294, P239, DOI 10.1006/jmbi.1999.3252; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; RAMALINGAM TS, 2000, IN PRESS NAT CELL BI; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Riedel HD, 1999, BLOOD, V94, P3915, DOI 10.1182/blood.V94.11.3915.423k27_3915_3921; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022	24	188	193	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38135	38138		10.1074/jbc.C000664200	http://dx.doi.org/10.1074/jbc.C000664200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11027676	hybrid, Green Accepted			2022-12-27	WOS:000165739800003
J	Rangan, A; Fedoroff, OY; Hurley, LH				Rangan, A; Fedoroff, OY; Hurley, LH			Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEASE-HYPERSENSITIVE ELEMENT; UNUSUAL DNA STRUCTURES; TELOMERIC DNA; GENE; TRANSCRIPTION; BINDING; INHIBITION; CHROMATIN; RIBONUCLEOPROTEIN; REGULATORS	A major control element of the human c-myc oncogene is the nuclease-hypersensitive purine/pyrimidine-rich sequence. This double-stranded DNA fragment, corresponding to the 27-base pair segment in the nuclease-hypersensitive element of the c-myc promoter region, forms a stable Watson-Crick double helix under physiological conditions. However, this duplex DNA can be effectively converted to G-quadruplex DNA by a small molecular weight ligand. Both intermolecular and intramolecular G-quadruplex forms can be induced by this ligand. Similar transitional changes are also observed with the duplex telomeric sequence from the Oxytricha species. These results provide additional support to the idea that G-quadruplex structures may play structural roles in vivo and also provide insight into novel methodologies for rational drug design. These structurally altered DNA elements might serve as regulatory signals in gene expression or in telomere dynamics and hence are promising targets for drug action.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA; Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Texas System; University of Texas Austin	Hurley, LH (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.		Fedorov, Oleg Y./B-6412-2014	Fedorov, Oleg Y./0000-0001-9004-1815; Rangan, Anupama/0000-0001-7462-8309	NATIONAL CANCER INSTITUTE [R01CA049751, R35CA049751] Funding Source: NIH RePORTER; NCI NIH HHS [CA49751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERBERICH SJ, 1995, ONCOGENE, V10, P2343; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; BOUFFLER S, 1993, BIOESSAYS, V15, P409, DOI 10.1002/bies.950150607; BRAHMACHARI SK, 1995, ELECTROPHORESIS, V16, P1705, DOI 10.1002/elps.11501601283; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chan PP, 1997, J MOL MED, V75, P267, DOI 10.1007/s001090050112; Chen Q, 1996, P NATL ACAD SCI USA, V93, P2635, DOI 10.1073/pnas.93.7.2635; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; Fedoroff OY, 2000, BIOCHEMISTRY-US, V39, P15083, DOI 10.1021/bi001528j; Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n; Giovannangeli C, 1997, ANTISENSE NUCLEIC A, V7, P413, DOI 10.1089/oli.1.1997.7.413; Han FXG, 1999, J AM CHEM SOC, V121, P3561, DOI 10.1021/ja984153m; Han HY, 1999, BIOCHEMISTRY-US, V38, P6981, DOI 10.1021/bi9905922; Han HY, 2000, BIOCHEMISTRY-US, V39, P9311, DOI 10.1021/bi000482r; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HORWITZ MSZ, 1989, NUCLEIC ACIDS RES, V17, P5537, DOI 10.1093/nar/17.14.5537; KINNIBURGH AJ, 1994, GENE, V149, P93, DOI 10.1016/0378-1119(94)90416-2; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; Simonsson T, 2000, BIOCHEM BIOPH RES CO, V278, P158, DOI 10.1006/bbrc.2000.3783; Simonsson T, 1998, NUCLEIC ACIDS RES, V26, P1167, DOI 10.1093/nar/26.5.1167; Spiro C, 1997, J BIOL CHEM, V272, P33145, DOI 10.1074/jbc.272.52.33145; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WELLS RD, 1988, J BIOL CHEM, V263, P1095; Wemmer DE, 1997, CURR OPIN STRUC BIOL, V7, P355, DOI 10.1016/S0959-440X(97)80051-6; YANIV M, 1986, CRIT REV BIOCHEM MOL, V21, P1, DOI 10.3109/10409238609113607	34	180	185	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4640	4646		10.1074/jbc.M005962200	http://dx.doi.org/10.1074/jbc.M005962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11035006	hybrid			2022-12-27	WOS:000168484300017
J	Webb, JH; Villoutreix, BO; Dahlback, B; Blom, AM				Webb, JH; Villoutreix, BO; Dahlback, B; Blom, AM			Localization of a hydrophobic binding site for anticoagulant protein S on the beta-chain of complement regulator C4b-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4-BINDING PROTEIN; C4B BINDING; AFFINITY; MODULE; PROTEOLYSIS; COMPONENT; HOMOLOGY; CHIMERAS; DOMAINS; CD46	C4b-binding protein (C4BP) is a plasma glycoprotein involved in regulation of the complement system. C4BP consists of seven alpha -chains and one unique beta -chain, all constructed of repeating complement control protein (CCP) modules. The beta -chain, made up of three CCPs, binds tightly to vitamin K-dependent protein S, a cofactor to anticoagulant activated protein C. When bound to C4BP, protein S loses its activated protein C cofactor function. In this study, we have mutated potentially important amino acids located at the surface of CCP1 of the beta -chain to probe the protein S-C4BP interaction. The substitutions were designed after analysis of a homology-based three-dimensional structure of the beta -chain and were L2T/F45Q, I16SN18S, V31T/I33N, I16S/V18S/V31T/I33N, L38S/V39S, and K41E/K42E. The mutants were expressed in a prokaryotic system, purified using an N-terminal His-tag, refolded using an oxido-shuffling system, and tested in several assays for their ability to bind protein S. Our data define Ile(16), Val(18), Val(31), and Ile(33) as crucial for protein S binding, with secondary effects from Leu(38) and Val(39). In addition, Lys(41) and Lys(42) contribute slightly to the interaction. Our results further confirm that surface hydrophobicity analysis may be used to identify ligand recognition sites.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Clin Chem, S-20502 Malmo, Sweden; Univ Paris 05, INSERM U428, F-75006 Paris, France	Lund University; Skane University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dahlback, B (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Clin Chem, S-20502 Malmo, Sweden.	Bjorn.Dahlback@klkemi.mas.lu.se	Blom, Anna/AFS-7369-2022; Villoutreix, Bruno/I-4565-2015; Blom, Anna/B-9607-2009	Villoutreix, Bruno/0000-0002-6456-7730; Blom, Anna/0000-0002-1348-1734; Dahlback, Bjorn/0000-0003-1546-0328				Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237; Blom AM, 1998, BBA-PROTEIN STRUCT M, V1388, P181, DOI 10.1016/S0167-4838(98)00178-2; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cordes MHJ, 1999, PROTEIN SCI, V8, P318; DAHLBACK B, 1995, THROMB RES, V77, P1, DOI 10.1016/0049-3848(94)00138-4; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; Evenas P, 1999, EUR J BIOCHEM, V266, P935, DOI 10.1046/j.1432-1327.1999.00928.x; FERNANDEZ JA, 1994, J BIOL CHEM, V269, P2535; FERNANDEZ JA, 1994, BIOCHEMISTRY-US, V33, P11073, DOI 10.1021/bi00203a003; Freund C, 1999, NAT STRUCT BIOL, V6, P656, DOI 10.1038/10712; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; FURMANIAKKAZMIERCZAK E, 1993, BLOOD, V81, P405; GRIFFIN JH, 1992, BLOOD, V79, P3203; Hardig Y, 1996, J BIOL CHEM, V271, P20861, DOI 10.1074/jbc.271.34.20861; HARDIG Y, 1993, J BIOL CHEM, V268, P3033; He XH, 1997, BIOCHEMISTRY-US, V36, P3745, DOI 10.1021/bi962315q; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; HILLARP A, 1988, J BIOL CHEM, V263, P12759; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; Jonsson AP, 1999, RAPID COMMUN MASS SP, V13, P1782, DOI 10.1002/(SICI)1097-0231(19990930)13:18<1782::AID-RCM714>3.0.CO;2-W; Lijnzaad P, 1996, PROTEINS, V25, P389, DOI 10.1002/(SICI)1097-0134(199607)25:3<389::AID-PROT10>3.3.CO;2-S; Lum K, 1999, J PHYS CHEM B, V103, P4570, DOI 10.1021/jp984327m; Maisner A, 1996, J VIROL, V70, P4973, DOI 10.1128/JVI.70.8.4973-4977.1996; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Qasba PK, 2000, CARBOHYD POLYM, V41, P293, DOI 10.1016/S0144-8617(99)00148-4; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SCHWALBE R, 1990, J BIOL CHEM, V265, P16074; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; Stenberg Y, 1999, J MOL BIOL, V293, P653, DOI 10.1006/jmbi.1999.3139; van de Poel RHL, 1999, J BIOL CHEM, V274, P15144, DOI 10.1074/jbc.274.21.15144; van de Poel RHL, 1999, BLOOD CELL MOL DIS, V25, P279, DOI 10.1006/bcmd.1999.0255; Villoutreix BO, 1995, PROTEIN ENG, V8, P1253, DOI 10.1093/protein/8.12.1253; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; YOUNG L, 1994, PROTEIN SCI, V3, P717; ZOLLER B, 1995, BLOOD, V85, P3524, DOI 10.1182/blood.V85.12.3524.bloodjournal85123524	41	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4330	4337		10.1074/jbc.M006541200	http://dx.doi.org/10.1074/jbc.M006541200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11050085	hybrid			2022-12-27	WOS:000166921200080
J	Witting, PK; Douglas, DJ; Mauk, AG				Witting, PK; Douglas, DJ; Mauk, AG			Reaction of human myoglobin and nitric oxide - Heme iron or protein sulfhydryl (S) nitrosation dependence on the absence or presence of oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; HUMAN SKELETAL-MUSCLE; RELAXING FACTOR; VASCULAR TONE; SMOOTH-MUSCLE; HEMOGLOBIN; NITROSOTHIOLS; METMYOGLOBIN; GLUTATHIONE; OXIDATION	The amino acid sequence of human myoglobin (Mb) is similar to other mammalian Mb except for a unique cysteine residue at position 110 (Cys(110)). Anaerobic treatment of ferrous forms of wild-type human Rib, the C110A variant of human Mb or horse heart Mb, with either authentic NO or chemically derived NO in vitro yields heme-NO complexes as detected by electron paramagnetic resonance spectroscopy (EPR). By contrast, no EPR-detectable heme-NO complex was observed from the aerobic reactions of NO and either the ferric or oxy-Mb forms of wild-type human or horse heart myoglobins, Mass analyses of wild-type human Mb treated aerobically with NO indicated a mass increase of similar to 30 atomic mass units (i.e,, NO/Mb = 1 mol/mol), Mass analyses of the corresponding apoprotein after heme removal showed that NO was associated with the apoprotein fraction. New electronic maxima were detected at A(333) nm (epsilon = 3665 +/- 90 mol(-1) cm(-1); mean +/- S.D.) and A(545) nm (epsilon = 44 +/- 3 mol(-1) cm(-1)) in solutions of S-nitrosated wild-type human Mb (similar to S-nitrosoglutathione), Importantly, the sulfhydryl S-H stretch vibration for Cys(110) measured by Fourier transform infrared (nu similar to 2552 cm(-1)) was absent for both holo- and apo- forms of the wild-type human protein after aerobic treatment of the protein with NO. Together, these data indicate that the reaction of wild-type human Mb and NO yields either heme-NO or a novel S-nitrosated protein dependent on the oxidation state of the heme iron and the presence or absence of dioxygen.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	University of British Columbia; University of British Columbia	Mauk, AG (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.		Witting, Paul/ABD-2053-2020; Witting, Paul/L-9786-2019	Witting, Paul/0000-0003-2237-7004; 				ALBEN JO, 1974, NATURE, V252, P736, DOI 10.1038/252736a0; AMEZCUA JL, 1989, BRIT J PHARMACOL, V97, P1119, DOI 10.1111/j.1476-5381.1989.tb12569.x; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P40; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GAREL MC, 1982, EUR J BIOCHEM, V123, P513; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Gross SS, 1999, P NATL ACAD SCI USA, V96, P9967, DOI 10.1073/pnas.96.18.9967; HAGLER L, 1979, J BIOL CHEM, V254, P6505; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Holzhutter HG, 1997, EUR J BIOCHEM, V245, P608, DOI 10.1111/j.1432-1033.1997.00608.x; HUBBARD SR, 1990, J MOL BIOL, V213, P215, DOI 10.1016/S0022-2836(05)80181-0; Hunter CL, 1997, BIOCHEMISTRY-US, V36, P1018, DOI 10.1021/bi961993+; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Kalyanaraman B, 1996, METHODS ENZYMOL, V268, P168; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KOBAYASHI K, 1982, BIOCHEMISTRY-US, V21, P729, DOI 10.1021/bi00533a022; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LUI Z, 1998, J PHARMACOL EXP THER, V284, P526; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Masuda K, 1999, EUR J APPL PHYSIOL O, V79, P347, DOI 10.1007/s004210050519; McMahon TJ, 1999, METHOD ENZYMOL, V301, P99; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEITES L, 1948, ANAL CHEM, V20, P984, DOI 10.1021/ac60022a044; MOLLER P, 1981, SCAND J CLIN LAB INV, V41, P479, DOI 10.3109/00365518109090486; MONEADA S, 1991, PHARMACOL REV, V43, P109; MORSE RH, 1980, J BIOL CHEM, V255, P7876; Mutus B, 1999, FEBS LETT, V449, P79, DOI 10.1016/S0014-5793(99)00311-7; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; Osipov AN, 1996, METHOD ENZYMOL, V268, P193; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; PERKOFF GT, 1958, METABOLISM, V7, P751; Qiu Y, 1998, J BIOL CHEM, V273, P23426, DOI 10.1074/jbc.273.36.23426; RAGAVAN V, 1985, P NATL ACAD SCI USA, V82, P5681; REDDY D, 1983, SCIENCE, V221, P769, DOI 10.1126/science.6308761; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; SHARMA VS, 1983, BIOCHEMISTRY-US, V22, P3897, DOI 10.1021/bi00285a026; Silvester JA, 1998, FREE RADICAL BIO MED, V24, P754, DOI 10.1016/S0891-5849(97)00327-4; SINGH RJ, 1995, FEBS LETT, V360, P47, DOI 10.1016/0014-5793(95)00065-H; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TSAI AL, 1994, FEBS LETT, V341, P141, DOI 10.1016/0014-5793(94)80445-1; WHERLAND S, 1975, J AM CHEM SOC, V97, P5260, DOI 10.1021/ja00851a040; Williams DLH, 1999, ACCOUNTS CHEM RES, V32, P869, DOI 10.1021/ar9800439; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200	58	53	53	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3991	3998		10.1074/jbc.M005758200	http://dx.doi.org/10.1074/jbc.M005758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11053410	hybrid			2022-12-27	WOS:000166921200038
J	Ichida, M; Finkel, T				Ichida, M; Finkel, T			Ras regulates NFAT3 activity in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COUPLED RECEPTOR AGONISTS; MUSCLE CELL HYPERTROPHY; NUCLEAR FACTOR; T-CELLS; VENTRICULAR MYOCYTES; GENE-EXPRESSION; ALPHA(1)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; EFFECTOR PATHWAYS	Multiple distinct signal transduction pathways have been implicated in the development of cardiac myocyte hypertrophy. These hypertrophic pathways include those regulated by the Ras superfamily of small GTPases and a separate calcineurin-regulated pathway that culminates in the activation of the transcription factor NFAT3, In this report, we demonstrate a functional interaction between Ras-regulated and calcineurin-regulated pathways. In particular, expression in neonatal myocytes of a constitutively active form of Res (V12ras), but not activating mutants of Rad, RhoA, or Cdc42, results in an increase in NFAT activity. Similarly, expression of an activated Ras, but not other small GTPases, results in the nuclear translocation of an NFAT3 fusion protein. Expression of a dominant negative ras gene product blocks phenylephrine-stimulated NEAT transcriptional activity and the ligand-stimulated NFAT3 nuclear localization. Res proteins appear to function upstream of calcineurin, because cyclosporin A blocks the ability of V12ras to stimulate NFAT-dependent transcription and nuclear localization. Similarly, expression of a dominant negative ras gene inhibits phenylephrine-stimulated calcineurin activity. Pharmacological inhibition of MEK1 or expression of a dominant negative form of c-Raf or ERK2 inhibits phenylephrine-stimulated NFAT3 activation Conversely, NEAT activity was stimulated by expression of constitutively active forms of c-Raf or MEK1, Taken together, these results imply that, in cardiac myocytes, a Res-regulated pathway involving stimulation of mitogen-activated protein kinase regulates NFAT3 activity.	NHLBI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Finkel, T (corresponding author), NHLBI, Mol Biol Lab, NIH, Bldg 10,10-6N-240,10 Ctr Dr, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005012, ZIAHL005012] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Cacace AM, 1996, ONCOGENE, V13, P2517; Cachero TG, 1998, CELL, V93, P1077, DOI 10.1016/S0092-8674(00)81212-X; CANTRELL D, 1994, ADV EXP MED BIOL, V365, P73; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Ding B, 1999, CIRC RES, V84, P729, DOI 10.1161/01.RES.84.6.729; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Hines WA, 1998, J MOL CELL CARDIOL, V30, P485, DOI 10.1006/jmcc.1997.0613; Ho PD, 1998, J BIOL CHEM, V273, P21730, DOI 10.1074/jbc.273.34.21730; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Sussman MA, 2000, J CLIN INVEST, V105, P875, DOI 10.1172/JCI8497; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; THORBURN A, 1993, J BIOL CHEM, V268, P2244; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Turner H, 1998, J EXP MED, V188, P527, DOI 10.1084/jem.188.3.527; Turner H, 1997, J EXP MED, V185, P43, DOI 10.1084/jem.185.1.43; VAN AL, 1997, GENE DEV, V11, P2295; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722	46	81	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3524	3530		10.1074/jbc.M004275200	http://dx.doi.org/10.1074/jbc.M004275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11044444	hybrid			2022-12-27	WOS:000166784900070
J	Sattler, M; Verma, S; Pride, YB; Salgia, R; Rohrschneider, LR; Griffin, JD				Sattler, M; Verma, S; Pride, YB; Salgia, R; Rohrschneider, LR; Griffin, JD			SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; INOSITOL PHOSPHATASE SHIP; POLYPHOSPHATE 5-PHOSPHATASE SHIP; PHOSPHOTYROSINE BINDING DOMAIN; MULTIPLE CYTOKINES; INSULIN-RECEPTOR; ADAPTER PROTEINS; KINASE-ACTIVITY; CELL-MIGRATION; GROWTH-FACTORS	SHIP1 is an SH2 domain containing inositol-5-phosphatase that appears to be a negative regulator of hematopoiesis, The tyrosine kinase oncogene BCR/ABL drastically reduces expression of SHIP1. The major effect of re-expressing SHIP1 in BCR/ABL-transformed cells is reduction of hypermotility, To investigate the potential signaling pathways involving SHIP1 in hematopoietic cells, we overexpressed SHIP1 in a murine BCR/ABL-transformed Ba/F3 cell line and identified SHIP1-associated proteins. SHIP1 was found to form a novel signaling complex with BCR/ABL that includes DOK1 (p62(DOK)), phosphatidylinositol 3-kinase (PI3K), and CRKL, each of which has been previously shown to regulate migration in diverse cell types. We found that DOK1 binds directly through its PTB domain to SHIP1. Direct interaction of SHIP1 with CRKL was mediated through the CRKL-SH2 domain. Go-precipitation experiments suggest that Tyr(917) and Tyr(1020) in SHIP1 are likely to mediate interactions with DOK1, In contrast to wild type SHIP1, expression of tyrosine mutant SHIP1 by transient transfection did not alter migration. PI3K was likely linked to this complex by CRKL, Thus, this complex may serve to generate a very specific set of phosphoinositol products, possibly involved in regulating migration. Overall, these data suggest that proteins that interact with SHIP1 through Tyr(917) and Tr-1020, such as DOK1 and SHC, are likely to be involved in the regulation of SHIP1 dependent migration.	Harvard Univ, Sch Med, Dept Adult Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Fred Hutchinson Cancer Center	Sattler, M (corresponding author), Harvard Univ, Sch Med, Dept Adult Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.			Pride, Yuri/0000-0002-5884-0964	NCI NIH HHS [CA78348, CA82499] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Chacko GW, 1996, J IMMUNOL, V157, P2234; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Dunant NM, 2000, CELL SIGNAL, V12, P317, DOI 10.1016/S0898-6568(00)00073-5; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; HEJNA JA, 1995, GENOMICS, V29, P285, DOI 10.1006/geno.1995.1247; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Hunter MG, 1998, J IMMUNOL, V160, P4979; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kim CH, 1999, J CLIN INVEST, V104, P1751, DOI 10.1172/JCI7310; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Lee T, 1996, DEVELOPMENT, V122, P409; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P10998; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; Lucas DM, 1999, BLOOD, V93, P1922, DOI 10.1182/blood.V93.6.1922.406k21_1922_1933; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; NICHOLS GL, 1994, BLOOD, V84, P2912; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; ODA T, 1994, J BIOL CHEM, V269, P22925; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Park RK, 1999, BLOOD, V94, P2112; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; REYNOLDS FH, 1980, J VIROL, V36, P374, DOI 10.1128/JVI.36.2.374-386.1980; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Siegel J, 1999, ONCOGENE, V18, P7135, DOI 10.1038/sj.onc.1203212; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; TENHOEVE J, 1994, BLOOD, V84, P1731; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Ueoka Y, 2000, BRIT J CANCER, V82, P891, DOI 10.1054/bjoc.1999.1016; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; Wisniewski D, 1996, LEUKEMIA, V10, P229; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	60	48	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2451	2458		10.1074/jbc.M006250200	http://dx.doi.org/10.1074/jbc.M006250200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11031258	hybrid			2022-12-27	WOS:000166784800022
J	Baouz, S; Jacquet, E; Accorsi, K; Hountondji, C; Balestrin, M; Zippel, R; Sturani, E; Parmeggiani, A				Baouz, S; Jacquet, E; Accorsi, K; Hountondji, C; Balestrin, M; Zippel, R; Sturani, E; Parmeggiani, A			Sites of phosphorylation by protein kinase a in CDC25Mm/GRF1, a guanine nucleotide exchange factor for Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM-MEMORY; DEPENDENT ACTIVATION; SIGNALING PATHWAY; CATALYTIC DOMAIN; STRUCTURAL BASIS; FACTOR CDC25(MM); CALCIUM; GRF; SOS; MODULATION	Activation of the neuronal Ras GDP/GTP exchange factor (GEF) CDC25Mm/GRF1 is known to be associated with phosphorylation of serine/threonine. To increase our knowledge of the mechanism involved, we have analyzed the ability of several serine/threonine kinases to phosphorylate CDC25Mm in vivo and in vitro. We could demonstrate the involvement of cAMP-dependent protein kinase (PKA) in the phosphorylation of CDC25Mm in fibroblasts overexpressing this RasGEF as well as in mouse brain synaptosomal membranes. In vitro, PKA was found to phosphorylate multiple sites on purified CDC25Mm, in contrast to protein kinase C, calmodulin kinase II, and casein kinase II, which were virtually inactive. Eight phosphorylated serines and one threonine were identified by mass spectrometry and Edman degradation. Most of them were clustered around the Ras exchanger motif/PEST motifs situated in the C-terminal moiety (residues 631-978) preceding the catalytic domain. Ser(745) and Ser(822) were the most heavily phosphorylated residues and the only ones coinciding with PKA consensus sequences. Substitutions S745D and S822D showed that the latter mutation strongly inhibited the exchange activity of CDC25Mm on Ha-Ras. The multiple PKA-dependent phosphorylation sites on CDC25Mm suggest a complex regulatory picture of this RasGEF. The results are discussed in the light of structural and/or functional similarities with other members of this RasGEF family.	Ecole Polytech, Grp Biophys, Equipe 2, F-91128 Palaiseau, France; Ecole Polytech, CNRS, UMR 7654, Biochim Lab, F-91128 Palaiseau, France; Univ Milan, Dipartimento Fisiol & Biochim Gen, I-20133 Milan, Italy	Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris; University of Milan	Parmeggiani, A (corresponding author), Ecole Polytech, Grp Biophys, Equipe 2, F-91128 Palaiseau, France.			JACQUET, Eric/0000-0001-6366-8436; Hountondji, Codjo/0000-0003-0683-4439				Ambrosini A, 2000, MOL BRAIN RES, V75, P54, DOI 10.1016/S0169-328X(99)00294-6; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Carrera V, 1998, FEBS LETT, V440, P291, DOI 10.1016/S0014-5793(98)01481-1; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; de Hoog CL, 2000, MOL CELL BIOL, V20, P2727, DOI 10.1128/MCB.20.8.2727-2733.2000; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; Innocenti M, 1999, FEBS LETT, V460, P357, DOI 10.1016/S0014-5793(99)01374-5; Itier JM, 1998, NATURE, V393, P125, DOI 10.1038/30120; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; KAPLON T, 1995, J BIOL CHEM, V270, P20742, DOI 10.1074/jbc.270.35.20742; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Mattingly RR, 1999, J BIOL CHEM, V274, P37379, DOI 10.1074/jbc.274.52.37379; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Orban PC, 1999, TRENDS NEUROSCI, V22, P38, DOI 10.1016/S0166-2236(98)01306-X; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Schlessinger J, 1993, Harvey Lect, V89, P105; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Zippel R, 1996, ONCOGENE, V12, P2697; Zippel R, 2000, EXP CELL RES, V258, P403, DOI 10.1006/excr.2000.4937	36	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1742	1749		10.1074/jbc.M005770200	http://dx.doi.org/10.1074/jbc.M005770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11018028	hybrid			2022-12-27	WOS:000166528000014
J	Wiedemann, I; Breukink, E; van Kraaij, C; Kuipers, OP; Bierbaum, G; de Kruijff, B; Sahl, HG				Wiedemann, I; Breukink, E; van Kraaij, C; Kuipers, OP; Bierbaum, G; de Kruijff, B; Sahl, HG			Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; C-TERMINAL PART; LANTIBIOTIC MERSACIDIN; LACTOCOCCUS-LACTIS; ANTIMICROBIAL PEPTIDE; MEMBRANE; VESICLES; DODECYLPHOSPHOCHOLINE; ORIENTATION; MECHANISM	Unlike numerous pore-forming amphiphilic peptide antibiotics, the lantibiotic nisin is active in nanomolar concentrations, which results from its ability to use the Lipid-bound cell wall precursor lipid II as a docking molecule for subsequent pore formation. Here we use genetically engineered nisin variants to identify the structural requirements for the interaction of the peptide with lipid II. Mutations affecting the conformation of the N-terminal part of nisin comprising rings A through C, e.g. [S3T]nisin, led to reduced binding and increased the peptide concentration necessary for pore formation, The binding constant for the S3T mutant was 0.043 x 10(7) M-1 compared with 2 x 10(7) M-1 for the wildtype peptide, and the minimum concentration for pore formation increased from the 1 nM to the 50 nM range. In contrast, peptides mutated in the flexible hinge region, e,g, [Delta N20/Delta M21]nisin, were completely inactive in the pore formation assay, but were reduced to some extent in their in vivo activity. We found the remaining in vivo activity to result from the unaltered capacity of the mutated peptide to bind to lipid II and thus to inhibit its incorporation into the peptidoglycan network, Therefore, through interaction with the membrane-bound cell wall precursor lipid II, nisin inhibits peptidoglycan synthesis and forms highly specific pores. The combination of two killing mechanisms in one molecule potentiates antibiotic activity and results in nanomolar MIC values, a strategy that may well be worth considering for the construction of novel antibiotics.	Univ Bonn, Inst Med Mikrobiol & Immunol, D-53105 Bonn, Germany; Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Dept Biochem & Membranes, NL-3584 CH Utrecht, Netherlands; NIZO Food Res, Microbial Ingredients Sect, NL-6710 BA Ede, Netherlands	University of Bonn; Utrecht University; NIZO Food Research	Sahl, HG (corresponding author), Univ Groningen, Inst Biomol Sci & Biotechnol, POB 14, NL-9750 AA Haren, Netherlands.	sahl@mibi03.meb.uni-bonn.de	Kuipers, Oscar/B-6752-2009; Breukink, Eefjan/I-3039-2016	Kuipers, Oscar/0000-0001-5596-7735; Breukink, Eefjan/0000-0002-7311-0660				Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Breukink E, 1998, BIOCHEMISTRY-US, V37, P8153, DOI 10.1021/bi972797l; Breukink E, 1997, BIOCHEMISTRY-US, V36, P6968, DOI 10.1021/bi970008u; Brotz H, 2000, J ANTIMICROB CHEMOTH, V46, P1, DOI 10.1093/jac/46.1.1; BROTZ H, 1995, ANTIMICROB AGENTS CH, V39, P714, DOI 10.1128/AAC.39.3.714; Brotz H, 1998, MOL MICROBIOL, V30, P317, DOI 10.1046/j.1365-2958.1998.01065.x; Brotz H, 1997, EUR J BIOCHEM, V246, P193, DOI 10.1111/j.1432-1033.1997.t01-1-00193.x; Brotz H, 1998, ANTIMICROB AGENTS CH, V42, P154, DOI 10.1128/AAC.42.1.154; Chan WC, 1996, FEBS LETT, V390, P129, DOI 10.1016/0014-5793(96)00638-2; CHAN WC, 1989, FEBS LETT, V252, P29, DOI 10.1016/0014-5793(89)80884-1; DEVOS WM, 1993, APPL ENVIRON MICROB, V59, P213, DOI 10.1128/AEM.59.1.213-218.1993; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; DRIESSEN AJM, 1995, BIOCHEMISTRY-US, V34, P1606, DOI 10.1021/bi00005a017; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hurst A., 1981, ADV APPL MICROBIOL, V27, P85, DOI [10.1016/s0065-2164(08)70342-3, DOI 10.1016/S0065-2164(08)70342-3, 10.1016/S0065-2164(08)70342-3]; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; KUIPERS OP, 1993, FEBS LETT, V330, P23, DOI 10.1016/0014-5793(93)80911-D; Kuipers OP, 1996, ANTON LEEUW INT J G, V69, P161, DOI 10.1007/BF00399421; KUIPERS OP, 1991, NISIN NOVEL LANTIBIO, P250; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P12553, DOI 10.1021/bi00039a009; Mattick ATR, 1944, NATURE, V154, P551, DOI 10.1038/154551a0; Moll GN, 1996, ANTON LEEUW INT J G, V69, P185, DOI 10.1007/BF00399423; OTTENWALDER B, 1995, APPL ENVIRON MICROB, V61, P3894; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; RALSTON E, 1981, BIOCHIM BIOPHYS ACTA, V649, P133, DOI 10.1016/0005-2736(81)90019-5; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; RUHR E, 1985, ANTIMICROB AGENTS CH, V27, P841, DOI 10.1128/AAC.27.5.841; SAHL HG, 1987, ARCH MICROBIOL, V149, P120, DOI 10.1007/BF00425076; SAHL HG, 1985, ANTIMICROB AGENTS CH, V27, P836, DOI 10.1128/AAC.27.5.836; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; van Kraaij C, 1998, BIOCHEMISTRY-US, V37, P16033, DOI 10.1021/bi980931b; van Kraaij C, 2000, EUR J BIOCHEM, V267, P901, DOI 10.1046/j.1432-1327.2000.01075.x; vandenHooven HW, 1996, EUR J BIOCHEM, V235, P382, DOI 10.1111/j.1432-1033.1996.00382.x; vandenHooven HW, 1996, EUR J BIOCHEM, V235, P394, DOI 10.1111/j.1432-1033.1996.00394.x; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; VanKraaij C, 1997, EUR J BIOCHEM, V247, P114; Verheul A, 1997, APPL ENVIRON MICROB, V63, P3451, DOI 10.1128/AEM.63.9.3451-3457.1997; WADE D, 1992, INT J PEPT PROT RES, V40, P429	39	551	570	1	90	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1772	1779		10.1074/jbc.M006770200	http://dx.doi.org/10.1074/jbc.M006770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11038353	hybrid, Green Published			2022-12-27	WOS:000166528000018
J	Casarosa, P; Bakker, RA; Verzijl, D; Navis, M; Timmerman, H; Leurs, R; Smit, MJ				Casarosa, P; Bakker, RA; Verzijl, D; Navis, M; Timmerman, H; Leurs, R; Smit, MJ			Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; FACTOR-KAPPA-B; G-BETA-GAMMA; KAPOSIS-SARCOMA; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; ACTIVATION; SUBUNITS; ALPHA	Previously it was shown that the HHV-8-encoded chemokine receptor ORF74 shows considerable agonist-independent, constitutive activity giving rise to oncogenic transformation (Arvanitakis, L., Geras-Raaka, E., Varma, A., Grershengorn, M. C., and Cesarman, E. (1997) Nature 385, 347-350), In this study we report that a second viral-encoded chemokine receptor, the human cytomegalovirus-encoded US28, also efficiently signals in an agonist-independent manner. Transient expression of US28 in COS-7 cells leads to the constitutive activation of phospholipase C and NF-kappaB signaling via G(q/11) protein-dependent pathways. Whereas phospholipase C activation is mediated via G alpha (q/11) subunits, the activation of NF-KB strongly depends on py subunits with a preference for the beta (2)gamma (1) dimer. The CC chemokines RANTES (regulated on activation, normal T cell expressed and secreted) and MCP-1 (monocyte chemotactic protein-1) act as neutral antagonists at US28, whereas the CX,C chemokine fractalkine acts as a partial inverse agonist with IC50 values of 1-5 nM. Our data suggest that a high level of constitutive activity might be a more general characteristic of viral G protein-coupled receptors and that human cytomegalovirus might exploit this G protein-coupled receptor property to modulate the homeostasis of infected cells via the early gene product US28.	Vrije Univ Amsterdam, Leiden Amsterdam Ctr Drug Res, Div Med Chem, Fac Chem, NL-1081 HV Amsterdam, Netherlands	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Leurs, R (corresponding author), Vrije Univ Amsterdam, Leiden Amsterdam Ctr Drug Res, Div Med Chem, Fac Chem, De Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.	leurs@chem.vu.nl	Leurs, Rob/AAC-8508-2022; Leurs, Rob/ABB-4299-2021	Leurs, Rob/0000-0003-1354-2848; Verzijl, Dennis/0000-0002-7716-9838; Smit, Martine/0000-0003-2713-0238				Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; Chen F, 1999, CLIN CHEM, V45, P7; DavisPoynter NJ, 1996, IMMUNOL CELL BIOL, V74, P513, DOI 10.1038/icb.1996.84; Diviani D, 1996, J BIOL CHEM, V271, P5049; Epstein SE, 1999, AM HEART J, V138, pS476, DOI 10.1016/S0002-8703(99)70279-6; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; GAO JL, 1994, J BIOL CHEM, V269, P28539; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; Isegawa Y, 1998, J VIROL, V72, P6104, DOI 10.1128/JVI.72.7.6104-6112.1998; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Lalani AS, 2000, IMMUNOL TODAY, V21, P100, DOI 10.1016/S0167-5699(99)01556-X; LEE SB, 1993, J BIOL CHEM, V268, P25952; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Milligan G, 1996, TRENDS PHARMACOL SCI, V17, P235, DOI 10.1016/0165-6147(96)10026-2; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 1997, NATURE, V385, P296, DOI 10.1038/385296a0; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; Pleskoff O, 1998, J VIROL, V72, P6389, DOI 10.1128/JVI.72.8.6389-6397.1998; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Vieira J, 1998, J VIROL, V72, P8158, DOI 10.1128/JVI.72.10.8158-8165.1998; Wilson SH, 2000, ATHEROSCLEROSIS, V148, P23, DOI 10.1016/S0021-9150(99)00211-7; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827; Zou P, 1999, J VIROL, V73, P5926, DOI 10.1128/JVI.73.7.5926-5933.1999	49	201	209	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1133	1137		10.1074/jbc.M008965200	http://dx.doi.org/10.1074/jbc.M008965200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11050102	Green Published, hybrid			2022-12-27	WOS:000166430900039
J	Cieslik, K; Abrams, CS; Wu, KK				Cieslik, K; Abrams, CS; Wu, KK			Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase gamma/Janus kinase 2/MEK-1-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PROTEIN-COUPLED RECEPTORS; LYMPHOCYTE-T ACTIVATION; SMOOTH-MUSCLE CELLS; II AT(1) RECEPTOR; MAP KINASE; PHOSPHOINOSITIDE 3-KINASE-GAMMA; SIGNALING PATHWAY; HUMAN-MONOCYTES; CYTOSKELETAL REORGANIZATION	Our recent study indicates that lysophosphatidylcholine (LPC) enhances Spl binding and Spl-dependent endothelial nitric oxide synthase (eNOS) promoter activity via the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1 (MEK-1) signaling pathway (Cieslik, K,, Lee, C.-M, Tang, J,-L., and Wu, K, K, (1999) J, Biol, Chem. 274, 84669-94675). To identify upstream signaling molecules, we transfected human endothelial cells with dominant negative and active mutants of Bas and evaluated their effects on eNOS promoter activity. Neither mutant altered the basal or LPC-induced eNOS promoter function. By contrast, a dominant negative mutant of phosphatidylinositol 3-kinase gamma (PI-3K gamma) blocked the promoter activity induced by LPC, Wortmannin and LY 294002 had a similar effect. AG-490, a selective inhibitor of Janus kinase 2 (Jak2), also reduced the LPC-induced Spl binding and eNOS promoter activity to the basal level. LPC induced Jak2 phosphorylation, which was abolished by LY 294002 and the dominant negative mutant of PI-3K gamma. LY 294002 and AG-490 abrogated MEK-1 phosphorylation induced by LPC but had no effect on Raf-l. These results indicate that PI-SKy and Jak2 are essential for LPC-induced eNOS promoter activity. This signaling pathway was sensitive to pertussis toxin, suggesting the involvement of a Gi protein in PI-SK gamma activation. These results indicate that LPC enhances Sp1-dependent eNOS promoter activity by a pertussis toxin-sensitive, Res-independent novel pathway, PI-3K gamma /Jak2/MEK-1/ERK1/2.	Univ Texas, Sch Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Div Hematol, Houston, TX 77030 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Texas System; University of Texas System; University of Pennsylvania	Wu, KK (corresponding author), Univ Texas, Sch Med, Vasc Biol Res Ctr, 6431 Fannin,MSB 5-016, Houston, TX 77030 USA.		Wu, Kenneth Kun-Yu/B-1070-2010; Cieslik, Katarzyna/AAO-1982-2021	Cieslik, Katarzyna/0000-0002-2167-7921	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL50675] Funding Source: Medline; NINDS NIH HHS [P50 NS23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Al-Shami A, 1999, J BIOL CHEM, V274, P5333, DOI 10.1074/jbc.274.9.5333; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; Cieslik K, 1999, J BIOL CHEM, V274, P34669, DOI 10.1074/jbc.274.49.34669; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; Engelmann B, 1999, ARTERIOSCL THROM VAS, V19, P47, DOI 10.1161/01.ATV.19.1.47; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; INOUE N, 1995, ARTERIOSCL THROM VAS, V15, P1255, DOI 10.1161/01.ATV.15.8.1255; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Ma AD, 1999, J BIOL CHEM, V274, P28730, DOI 10.1074/jbc.274.40.28730; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MOHANDAS N, 1982, J BIOL CHEM, V257, P6537; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nadaud S, 1996, CIRC RES, V79, P857, DOI 10.1161/01.RES.79.4.857; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; Nishioka H, 1998, FEBS LETT, V441, P63, DOI 10.1016/S0014-5793(98)01526-9; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Rikitake Y, 2000, ARTERIOSCL THROM VAS, V20, P1006, DOI 10.1161/01.ATV.20.4.1006; RODRIGUEZLINARES B, 1994, FEBS LETT, V352, P335, DOI 10.1016/0014-5793(94)00983-X; SAKAI M, 1994, J BIOL CHEM, V269, P31430; Santibanez JF, 2000, BIOCHEM BIOPH RES CO, V273, P521, DOI 10.1006/bbrc.2000.2946; Sato N, 1998, THROMB HAEMOSTASIS, V79, P217; Sato N, 1998, J BIOCHEM-TOKYO, V123, P1119; SESSA WC, 1994, CIRC RES, V74, P3349; SHINGU T, 1994, J BIOL CHEM, V269, P32551; Storz P, 1999, FEBS LETT, V464, P159, DOI 10.1016/S0014-5793(99)01689-0; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; TANG JL, 1995, BIOCHEM BIOPH RES CO, V213, P673, DOI 10.1006/bbrc.1995.2184; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Ueno Y, 1999, FEBS LETT, V457, P241, DOI 10.1016/S0014-5793(99)01049-2; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wong JT, 1998, J BIOL CHEM, V273, P6830, DOI 10.1074/jbc.273.12.6830; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; Wu KK, 1998, P ASSOC AM PHYSICIAN, V110, P163; Yamakawa T, 1998, HYPERTENSION, V31, P248, DOI 10.1161/01.HYP.31.1.248; Yamamoto H, 1999, EUR J BIOCHEM, V264, P110, DOI 10.1046/j.1432-1327.1999.00584.x; Yuan YP, 1996, J BIOL CHEM, V271, P27090, DOI 10.1074/jbc.271.43.27090; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Zhu Y, 1997, BBA-LIPID LIPID MET, V1345, P93, DOI 10.1016/S0005-2760(96)00169-5	59	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1211	1219		10.1074/jbc.M005305200	http://dx.doi.org/10.1074/jbc.M005305200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042169	hybrid			2022-12-27	WOS:000166430900049
J	Panisko, EA; McAlister-Henn, L				Panisko, EA; McAlister-Henn, L			Subunit interactions of yeast NAD(+)-specific isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; KINETIC-ANALYSIS; PHOSPHORYLATION; PURIFICATION; BINDING; GENE; EXPRESSION; MECHANISM; CLONING	Yeast mitochondrial NAD(+)-specific isocitrate dehydrogenase is an octamer composed of four each of two nonidentical but related subunits designated IDH1 and IDH2, IDH2 was previously shown to contain the catalytic site, whereas IDH1 contributes regulatory properties including cooperativity with respect to isocitrate and allosteric activation by AMP, In this study, interactions between IDH1 and IDH2 were detected using the yeast two-hybrid system, but interactions between identical subunit polypeptides were not detected with this or other methods. A model for heterodimeric interactions between the subunits is therefore proposed for this enzyme. A corollary of this model, based on the three-dimensional structure of the homologous enzyme from Escherichia coli, is that some interactions between subunits occur at isocitrate binding sites. Based on this model, two residues (Lys-183 and Asp-217) in the regulatory IDH1 subunit were predicted to be important in the catalytic site of IDH2, We found that individually replacing these residues with alanine results in mutant enzymes that exhibit a drastic reduction in catalysis both in vitro and in vivo. Also based on this model, the two analogous residues (Lys-189 and Asp-222) of the catalytic IDH2 subunit were predicted to contribute to the regulatory site of IDH1. A K189A substitution in IDH2 was found to produce a decrease in activation of the enzyme by AMP and a loss of cooperativity with respect to isocitrate, A D222A substitution in IDH2 produces similar regulatory defects and a substantial reduction in V-max in the absence of AMP. Collectively, these results suggest that the basic structural/functional unit of yeast isocitrate dehydrogenase is a heterodimer of IDH1 and IDH2 subunits and that each subunit contributes to the isocitrate binding site of the other.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	McAlister-Henn, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	henn@uthscsa.edu			NIGMS NIH HHS [GM51265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BOTSTEIN D, 1979, GENE, V9, P12; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DEAN AM, 1989, J BIOL CHEM, V264, P20482; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; HASSELBECK RJ, 1991, J BIOL CHEM, V266, P2339; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; HUANG YC, 1989, J BIOL CHEM, V264, P12208; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8670; ILLINGWORTH JA, 1972, BIOCHEM J, V129, P1119, DOI 10.1042/bj1291119; JAMES P, 1996, GENETICS, V144, P1423; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KUEHN GD, 1971, BIOCHEMISTRY-US, V10, P3945, DOI 10.1021/bi00797a023; LEE ME, 1995, BIOCHEMISTRY-US, V34, P378, DOI 10.1021/bi00001a046; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; NIMMO HG, 1986, BIOCHEM J, V234, P317, DOI 10.1042/bj2340317; SAMBROOK J, 1989, MOL CLONING LAB MANU, P348; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; Zhao WN, 1997, J BIOL CHEM, V272, P21811, DOI 10.1074/jbc.272.35.21811	25	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1204	1210		10.1074/jbc.M005056200	http://dx.doi.org/10.1074/jbc.M005056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11042198	hybrid			2022-12-27	WOS:000166430900048
J	Toulokhonov, II; Shulgina, I; Hernandez, VJ				Toulokhonov, II; Shulgina, I; Hernandez, VJ			Binding of the transcription effector ppGpp to Escherichia coli RNA polymerase is allosteric, modular, and occurs near the N terminus of the beta '-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANOSINE TETRAPHOSPHATE; ELONGATION COMPLEX; RIBOSOMAL-RNA; STRINGENT CONTROL; MESSENGER-RNA; BETA-SUBUNIT; PURIFICATION; SITES; ORGANIZATION; PROMOTERS	Among the prokaryotae, the nucleotide ppGpp is a second messenger of physiological stress and starvation. The target of ppGpp is RNA polymerase, where it putatively binds and alters the enzyme's activity. Previous data had implicated the beta -subunit of Escherichia coli RNA polymerase as containing a single ppGpp binding site. In this study, a photocross-linkable derivative of ppGpp, 6-thioguanosine-3',5'-(bis)pyrophosphate (6-thio-ppGpp), was used to localize the ppGpp binding site. In in vitro transcription assays, 6-thio-ppGpp inhibited transcription from the argT promoter identically to bona fide ppGpp, The thio group of 6-thio-ppGpp is directly photoactivatable and is thus a zero-length crosslinker, Cross-linking of RNA polymerase was directed primarily to the beta'-subunit and could be competed efficiently by native ppGpp but not by GTP or GDP, Cyanogen bromide digestion analysis of the cross-linked beta'-subunit was consistent with an extreme N-terminal cross-link. To assess allosteric consequences of ppGpp binding to RNA polymerase, high level trypsin resistance in the presence and absence of ppGpp was monitored. Trypsin digestion of RNA polymerase bound to ppGpp leads to protection of an N-terminal fragment of the beta'-subunit and a C-terminal fragment of the beta -subunit. We propose that the N terminus of beta' together with the C terminus of beta constitute a modular ppGpp binding site.	SUNY Buffalo, Sch Med, Ctr Microbial Pathogenesis, Dept Microbiol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Hernandez, VJ (corresponding author), SUNY Buffalo, Sch Med, Ctr Microbial Pathogenesis, Dept Microbiol, Buffalo, NY 14214 USA.	vjh@buffalo.edu			NIGMS NIH HHS [GM57189] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057189] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CASHEL M, 1974, ANAL BIOCHEM, V57, P100, DOI 10.1016/0003-2697(74)90056-6; CASHEL M, 1970, J BIOL CHEM, V245, P2309; Cashel M., 1994, METH MOL G, V3, P341; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CHASHEL M, 1969, NATURE, V221, P838, DOI 10.1038/221838a0; Chatterji D, 1998, GENES CELLS, V3, P279, DOI 10.1046/j.1365-2443.1998.00190.x; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; Gourse RL, 1998, COLD SPRING HARB SYM, V63, P131, DOI 10.1101/sqb.1998.63.131; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; Hsu LM, 1996, METHOD ENZYMOL, V273, P59; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; LITTLE R, 1983, J BACTERIOL, V154, P787, DOI 10.1128/JB.154.2.787-792.1983; LITTLE R, 1983, J BACTERIOL, V155, P1162, DOI 10.1128/JB.155.3.1162-1170.1983; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; McMahan SA, 1999, BIOCHEMISTRY-US, V38, P12424, DOI 10.1021/bi990824x; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; ROWLEY KB, 1993, J BACTERIOL, V175, P1309, DOI 10.1128/JB.175.5.1309-1315.1993; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; Sergiev PV, 1997, RNA, V3, P464; TEDIN K, 1992, J BIOL CHEM, V267, P2337; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335; Vogel U, 1997, J BIOL CHEM, V272, P12265, DOI 10.1074/jbc.272.19.12265; VOGEL U, 1994, J BIOL CHEM, V269, P16236; Wang DG, 1997, P NATL ACAD SCI USA, V94, P8433, DOI 10.1073/pnas.94.16.8433; WELLINGTON SR, 1991, BIOCHEM BIOPH RES CO, V179, P1107, DOI 10.1016/0006-291X(91)91934-5; WOODY AYM, 1987, BIOCHIM BIOPHYS ACTA, V909, P115, DOI 10.1016/0167-4781(87)90033-9; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	40	88	94	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1220	1225		10.1074/jbc.M007184200	http://dx.doi.org/10.1074/jbc.M007184200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11035017	hybrid			2022-12-27	WOS:000166430900050
J	Barry, R; Moore, S; Alonso, A; Ausio, J; Buckley, JT				Barry, R; Moore, S; Alonso, A; Ausio, J; Buckley, JT			The channel-forming protein proaerolysin remains a dimer at low concentrations in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN AEROLYSIN; RECEPTOR-BINDING; MEMBRANE-CHANNEL	Proaerolysin, the preform of the channel-forming protein aerolysin, is secreted as a dimer by Aeromonas sp, The protein also exists as a dimer in the crystal, as well as in solution, at least at concentrations in the region of 500 mug/ml. Recently it has been argued that proaerolysin becomes monomeric at concentrations below 100 mug/ml and that only the monomeric form of the protoxin can bind to cell surface receptors (Fivaz, M,, Velluz, DI,-C,, and van der Goot, F. G. (1999) J. Biol. Chem. 274, 37705-37708), Here we show, using non-denaturing polyacrylamide electrophoresis, chemical cross-linking, and analytical ultracentrifugation, that proaerolysin remains dimeric at the lowest concentrations of the protein that we measured (less than 5 mug/ml) and that the dimeric protoxin is quite capable of receptor binding.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Buckley, JT (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.		Alonso, Alicia/E-5310-2012	Alonso, Alicia/0000-0002-2730-7470				BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; BUCKLEY JT, 1999, COMPREHENSIVE SOURCE, P362; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; Fivaz M, 1999, J BIOL CHEM, V274, P37705, DOI 10.1074/jbc.274.53.37705; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; HARDIE KR, 1995, MOL MICROBIOL, V14, P1093; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacKenzie CR, 1999, J BIOL CHEM, V274, P22604, DOI 10.1074/jbc.274.32.22604; McRorie D. K., 1993, SELF ASSOCIATING SYS; Moniatte M, 1996, FEBS LETT, V384, P269, DOI 10.1016/0014-5793(96)00328-6; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Rossjohn J, 1997, EMBO J, V16, P3426, DOI 10.1093/emboj/16.12.3426; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x	18	15	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					551	554		10.1074/jbc.M008097200	http://dx.doi.org/10.1074/jbc.M008097200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11016941	hybrid			2022-12-27	WOS:000166280700074
J	Gerlach, VL; Feaver, WJ; Fischhaber, PL; Friedberg, EC				Gerlach, VL; Feaver, WJ; Fischhaber, PL; Friedberg, EC			Purification and characterization of pol kappa, a DNA polymerase encoded by the human DINB1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; MUTAGENESIS; PROTEIN; DELTA; IV; REQUIREMENT	The Escherichia coli dinB gene encodes DNA polymerase (pol) IV, a protein involved in increasing spontaneous mutations in vivo. The protein-coding region of DINB1, the human ortholog of DNA pol IV was fused to glutathione S-transferase and expressed in insect cells. The purified fusion protein was shown to be a template-directed DNA polymerase that we propose to designate pol kappa, Human pol kappa lacks detectable 3' --> 5' proofreading exonuclease activity and is not stimulated by recombinant human proliferating cell nuclear antigen in vitro, Between pH 6.5 and 8.5, human pol kappa possesses optimal activity at 37 degreesC over the pH range 6.5-7.5, and is insensitive to inhibition by aphidicolin, dideoxynucleotides, or NaCl up to 50 mM. Either Mg2+ or Mn2+ can satisfy a metal cofactor requirement for pol kappa activity, with Mg2+ being preferred, Human pol kappa is unable to bypass a cisplatin adduct in the template. However, pol kappa shows limited bypass of an 2-acetylaminofluorene lesion and can incorporate dCTP or dTTP across from this lesion, suggesting that the bypass is potentially mutagenic. These results are consistent with a model in which pol kappa acts as a specialized DNA polymerase whose possible role is to facilitate the replication of templates containing abnormal bases, or possessing structurally aberrant replication forks that inhibit normal DNA synthesis.	Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Friedberg, EC (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA.	friedberg.errol@pathology.swmed.edu			NCI NIH HHS [CA83314, CA69029, CA75733] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA083314, F32CA075733, R01CA069029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biggerstaff M, 1999, METH MOL B, V113, P357; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; Fischhaber PL, 1997, NUCLEOS NUCLEOT, V16, P365, DOI 10.1080/07328319708001356; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Hatahet Z, 1998, CONT CANC RES, P229; Hindges R, 1997, BIOL CHEM, V378, P345; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; KENYON CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2819, DOI 10.1073/pnas.77.5.2819; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; KRIEK E, 1971, CHEM-BIOL INTERACT, V3, P397, DOI 10.1016/0009-2797(71)90019-6; KRIEK E, 1969, Chemico-Biological Interactions, V1, P3, DOI 10.1016/0009-2797(69)90015-5; KRIEK E, 1967, BIOCHEMISTRY-US, V6, P177, DOI 10.1021/bi00853a029; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McConnell M, 1996, BIOCHEMISTRY-US, V35, P8268, DOI 10.1021/bi9530649; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; OHASHI E, 2000, IN PRESS J BIOL CHEM, V275; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Schumacher SB, 2000, NUCLEIC ACIDS RES, V28, P620, DOI 10.1093/nar/28.2.620; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wang TSF, 1999, PRACT APPROACH SER, V199, P67; WEISSBACH A, 1975, SCIENCE, V190, P401, DOI 10.1126/science.1179222	31	112	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					92	98		10.1074/jbc.M004413200	http://dx.doi.org/10.1074/jbc.M004413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11024016	hybrid			2022-12-27	WOS:000166280700014
J	Podust, LM; Krezel, AM; Kim, Y				Podust, LM; Krezel, AM; Kim, Y			Crystal structure of the CCAAT box/enhancer-binding protein beta activating transcription factor-4 basic leucine zipper heterodimer in the absence of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; NMR-SPECTRA; JUN; COMPLEX; C/EBP; CREB; GCN4; FOS; EXPRESSION; SPECTROSCOPY	dThe crystal structure of the heterodimer formed by the basic leucine zipper (bZIP) domains of activating transcription factor-4 (ATF4) and CCAAT box/enhancer-binding protein beta (C/EBP beta), from two different bZIP transcription factor families, has been determined and refined to 2.6 A. The structure shows that the heterodimer forms an asymmetric coiled-coil. Even in the absence of DNA, the basic region of ATF4 forms a continuous a-helix, but the basic region of C/EBP beta is disordered. Proteolysis, electrophoretic mobility shift assay, circular dichroism, and NMR analyses indicated that (i) the bZIP domain of ATF4 is a disordered monomer and forms a homodimer upon binding to the DNA target; (ii) the bZIP domain of ATF4 forms a heterodimer with the bZIP domain of C/EBP beta that binds the cAMP response element, but not CCAAT box DNA, with high affinity; and (iii) the basic region of ATF4 has a higher alpha -helical propensity than that of C/EBP beta. These results suggest that the degree of ordering of the basic region and the fork and the dimerization properties of the leucine zipper combine to distinguish the structurally similar bZIP domains of ATF I: and C/EBP beta with respect to DNA target sequence. This study provides insight into the mechanism by which dimeric bZIP transcription factors discriminate between closely related but distinct DNA targets.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Kim, Y (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.		Podust, Larissa/ABB-7940-2020	Podust, Larissa/0000-0002-8537-8760; Kim, Youngchang/0000-0002-1610-4889	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [P60 DK20593, DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bracken C, 1999, J MOL BIOL, V285, P2133, DOI 10.1006/jmbi.1998.2429; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHATTON B, 1994, ONCOGENE, V9, P375; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; KIM J, 1995, NUCLEIC ACIDS RES, V23, P2531, DOI 10.1093/nar/23.13.2531; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; Osada S, 1996, J BIOL CHEM, V271, P3891; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SANTIAGORIVERA ZI, 1993, PROTEIN SCI, V2, P1461, DOI 10.1002/pro.5560020910; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; Woody R. W., 1992, ADV BIOPHYS CHEM, V2, P37; Wuthrich K, 1986, NMR PROTEINS NUCL AC	42	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					505	513		10.1074/jbc.M005594200	http://dx.doi.org/10.1074/jbc.M005594200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11018027	hybrid			2022-12-27	WOS:000166280700068
